FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Lataillade, M
   Lalezari, JP
   Kozal, M
   Aberg, JA
   Pialoux, G
   Cahn, P
   Thompson, M
   Molina, JM
   Moreno, S
   Grinsztejn, B
   Diaz, RS
   Castagna, A
   Kumar, PN
   Latiff, GH
   De Jesus, E
   Wang, M
   Chabria, S
   Gartland, M
   Pierce, A
   Ackerman, P
   Llamoso, C
AF Lataillade, Max
   Lalezari, Jacob P.
   Kozal, Michael
   Aberg, Judith A.
   Pialoux, Gilles
   Cahn, Pedro
   Thompson, Melanie
   Molina, Jean-Michel
   Moreno, Santiago
   Grinsztejn, Beatriz
   Diaz, Ricardo S.
   Castagna, Antonella
   Kumar, Princy N.
   Latiff, Gulam H.
   De Jesus, Edwin
   Wang, Marcia
   Chabria, Shiven
   Gartland, Margaret
   Pierce, Amy
   Ackerman, Peter
   Llamoso, Cyril
TI Safety and efficacy of the HIV-1 attachment inhibitor prodrug
   fostemsavir in heavily treatment-experienced individuals: week 96
   results of the phase 3 BRIGHTE study
SO LANCET HIV
LA English
DT Article
ID OPTIMIZED BACKGROUND THERAPY; ACTIVE COMPONENT; RESISTANT; RALTEGRAVIR;
   BMS-663068; BMS-626529; BENCHMRK; ENVELOPE; 2B
AB Background Fostemsavir, a prodrug of the first-in-class attachment inhibitor, temsavir, is indicated for heavily treatment-experienced individuals with multidrug-resistant HIV-1. We previously reported superior efficacy of fostemsavir versus placebo in the randomised cohort of the BRIGHTE study after 8-day functional monotherapy (primary endpoint); here we report planned interim analyses through week 96.
   Methods BRIGHTE (NCT02362503) is an ongoing multicentre, two-cohort, phase 3 trial, done at 108 centres in 22 countries. We enrolled heavily treatment-experienced adults (>= 18 years) failing antiretroviral therapy (HIV-1 RNA >= 400 copies per mL) into two cohorts: the randomised cohort, in which patients with one or two fully active antiretrovirals remaining received oral fostemsavir (600 mg twice a day) or placebo in combination with their failing regimen for 8 days, followed by fostemsavir plus optimised background therapy; or the non-randomised cohort, in which patients with no remaining antiretroviral options received oral fostemsavir (600 mg twice a day) plus optimised background therapy from day 1. Endpoints for the week 96 interim analyses included the proportions of participants with plasma HIV-1 RNA of less than 40 copies per mL, changes from baseline in CD4 cell counts, and the frequency of adverse events, adverse events leading to discontinuation, and deaths. The intention-to-treat exposed population and the safety population both included all participants who received at least one dose of study treatment. The response rates (proportion of participants with HIV-1 RNA <40 copies per mL) in the intention-to-treat exposed population were calculated via snapshot analysis at weeks 24, 48, and 96.
   Findings Between Feb 23, 2015, and Aug 11, 2016, 371 participants were enrolled and treated, of which 272 participants were in the randomised cohort and 99 in the non-randomised cohort. 320 (86%) of 371 reported a history of AIDS. In the randomised cohort, rates of virological suppression (HIV-1 RNA <40 copies per mu L) increased from 53% (144 of 272) at week 24 to 60% (163 of 272) at week 96. Response rates in the non-randomised cohort were 37% (37 of 99) at week 24 and week 96. Mean increases in CD4 counts from baseline at week 96 were 205 cells per mu L (SD 191) in the randomised cohort and 119 cells per pL (202) in the non-randomised cohort. Mean CD4/CD8 ratio increased from 0.20 at baseline to 0.44 at week 96 in the randomised cohort. Few adverse events led to discontinuation (26 [7%1 of 371). 12 (4%) of 272 people in the randomised cohort and 17 (17%) of 99 in the non-randomised cohort died; the median baseline CD4 count for participants who died was 11 cells per mu L.
   Interpretation In heavily treatment-experienced individuals with advanced HIV-1 disease and limited treatment options, fostemsavir-based antiretroviral regimens were generally well tolerated and showed a distinctive trend of increasing virological and immunological response rates through 96 weeks; these findings support fostemsavir as a treatment option for this vulnerable population.Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Lataillade, Max; Chabria, Shiven; Ackerman, Peter; Llamoso, Cyril] ViiV Healthcare, Branford, CT 06405 USA.
   [Lalezari, Jacob P.] Quest Clin Res, San Francisco, CA USA.
   [Kozal, Michael] Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT 06510 USA.
   [Aberg, Judith A.] Icahn Sch Med Mt Sinai, Div Infect Dis, New York, NY 10029 USA.
   [Pialoux, Gilles] Hop Tenon, AP HP, Dept Infect & Trop Dis, Paris, France.
   [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Thompson, Melanie] AIDS Res Consortium Atlanta, Atlanta, GA USA.
   [Molina, Jean-Michel] Hop St Louis, AP HP, Dept Infect Dis, Paris, France.
   [Moreno, Santiago] Alcala Univ, Hosp Univ Ramon y Cajal, Dept Infect Dis, Madrid, Spain.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas FIOCRUZ, STD & AIDS Clin Res Lab, Infect Dis, Rio De Janeiro, Brazil.
   [Diaz, Ricardo S.] Univ Fed Sao Paulo, Paulista Sch Med, Infect Dis Div, Sao Paulo, Brazil.
   [Castagna, Antonella] Univ Vita Salute San Raffaele, Clin Infect Dis, Milan, Italy.
   [Kumar, Princy N.] Georgetown Univ, Med Ctr, Dept Med & Microbiol, Washington, DC 20007 USA.
   [Latiff, Gulam H.] Maxwell Ctr, Durban, South Africa.
   [De Jesus, Edwin] Orlando Immunol Ctr, Orlando, FL USA.
   [Wang, Marcia] GlaxoSmithKline, Upper Providence Townshi, PA USA.
   [Gartland, Margaret; Pierce, Amy] ViiV Healthcare, Res Triangle Pk, NC USA.
RP Lataillade, M (corresponding author), ViiV Healthcare, Branford, CT 06405 USA.
EM max.x.lataillade@viivhealthcare.com
FU ViiV Healthcare
FX ViiV Healthcare.
CR Aki I B, 2015, ANTIVIR THER, V20, P343
   Alvarez RA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.88226
   Castagna A, 2014, J INFECT DIS, V210, P354, DOI 10.1093/infdis/jiu051
   Cella DF, 1996, QUAL LIFE RES, V5, P450, DOI 10.1007/BF00449920
   Department of Health and Human Services, 2019, GUID US ANT AG AD AD
   Emu B, 2018, NEW ENGL J MED, V379, P645, DOI 10.1056/NEJMoa1711460
   Eron JJ, 2013, LANCET INFECT DIS, V13, P587, DOI 10.1016/S1473-3099(13)70093-8
   Et troQol, 2015, EQ 5D 3L US GUID
   Hardy WD, 2010, JAIDS-J ACQ IMM DEF, V55, P558, DOI 10.1097/QAI.0b013e3181ee3d82
   Katlama C, 2010, ANTIVIR THER, V15, P1045, DOI 10.3851/IMP1662
   Klatt NR, 2013, IMMUNOL REV, V254, P326, DOI 10.1111/imr.12065
   Kozal M, 2020, NEW ENGL J MED, V382, P1232, DOI 10.1056/NEJMoa1902493
   Lalezari JP, 2015, LANCET HIV, V2, pE427, DOI 10.1016/S2352-3018(15)00177-0
   Lataillade M, 2017, 16 EUR AIDS C MIL IT
   Lataillade M, 2018, JAIDS-J ACQ IMM DEF, V77, P299, DOI [10.1097/QAI.0000000000001602, 10.1097/qai.0000000000001602]
   Li ZF, 2013, ANTIMICROB AGENTS CH, V57, P4172, DOI 10.1128/AAC.00513-13
   Munro JB, 2014, SCIENCE, V346, P759, DOI 10.1126/science.1254426
   Mussini C, 2015, LANCET HIV, V2, pE98, DOI 10.1016/S2352-3018(15)00006-5
   Nowicka-Sans B, 2012, ANTIMICROB AGENTS CH, V56, P3498, DOI 10.1128/AAC.00426-12
   Pancera M, 2017, NAT CHEM BIOL, V13, P1115, DOI [10.1038/NCHEMBIO.2460, 10.1038/nchembio.2460]
   Proudfoot C, 2018, OPEN FORUM INFECT S1, V5, P5203
   Sant AJ, 2012, J EXP MED, V209, P1391, DOI 10.1084/jem.20121517
   Steigbigel RT, 2008, NEW ENGL J MED, V359, P339, DOI 10.1056/NEJMoa0708975
   Steigbigel RT, 2010, CLIN INFECT DIS, V50, P605, DOI 10.1086/650002
   US Food and Drug Administration, 2018, HUM IMM VIR 1 INF DE
   Vavro C, 2014, REV ANTIVIR THER INF, V2, P13
   Viala-Danten M, 2010, QUAL LIFE RES, V19, P1215, DOI 10.1007/s11136-010-9674-9
   Zeluf-Andersson G, 2019, AIDS CARE, V31, P403, DOI 10.1080/09540121.2018.1545990
   Zhou N, 2011, J ANTIMICROB CHEMOTH, V69, P57381
   Zhou NN, 2011, ANTIMICROB AGENTS CH, V55, P729, DOI 10.1128/AAC.01173-10
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD NOV
PY 2020
VL 7
IS 11
BP E740
EP E751
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA OJ0ZX
UT WOS:000583698300008
PM 33128903
DA 2020-11-24
ER

PT J
AU Barrocas, JBP
   Pereira, GH
   Guimaraes, L
   Duarte, J
   Victor, LB
   Baldin, C
   Inacio, C
   Silva, R
   Chaves, U
   Portela, E
   Grinsztejn, B
   Veloso, V
   Fernandes, FF
   Perazzo, H
AF Barrocas, Juliana Baptista Piedade
   Pereira, Gustavo Henrique
   Guimaraes, Livia
   Duarte, Joana
   Victor, Livia B.
   Baldin, Caroline
   Inacio, Cintia
   Silva, Ricardo
   Chaves, Ursula
   Portela, Estevao
   Grinsztejn, Beatriz
   Veloso, Valdilea
   Fernandes, Flavia Ferreira
   Perazzo, Hugo
TI REGRESSION OF LIVER STIFFNESS MEASUREMENT AFTER SUSTAINED VIROLOGICAL
   RESPONSE BY DIRECT-ACTING ANTIVIRALS DECREASES THE RISK OF CLINICAL
   OUTCOMES
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Liver Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 13-16, 2020
CL ELECTR NETWORK
SP Amer Assoc Study Liver Dis
C1 [Barrocas, Juliana Baptista Piedade; Inacio, Cintia; Silva, Ricardo] Fiocruz MS, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Pereira, Gustavo Henrique; Guimaraes, Livia; Duarte, Joana; Victor, Livia B.; Baldin, Caroline; Fernandes, Flavia Ferreira] Bonsucesso Fed Hosp, Gastroenterol & Hepatol Unit, Rio De Janeiro, Brazil.
   [Chaves, Ursula; Portela, Estevao; Grinsztejn, Beatriz; Veloso, Valdilea; Perazzo, Hugo] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Lab Clin Res HIV AIDS LAPCLIN AIDS, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD NOV
PY 2020
VL 72
SU 1
MA 986
BP 603A
EP 603A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NV0MH
UT WOS:000574027002123
DA 2020-11-24
ER

PT J
AU Luz, PM
   Torres, TS
   Almeida-Brasil, CC
   Marins, LMS
   Bezerra, DRB
   Veloso, VG
   Grinsztejn, B
   Harel, D
   Thombs, BD
AF Luz, Paula M.
   Torres, Thiago S.
   Almeida-Brasil, Celline C.
   Marins, Luana M. S.
   Bezerra, Daniel R. B.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Harel, Daphna
   Thombs, Brett D.
TI Translation and validation of the Short HIV Stigma scale in Brazilian
   Portuguese
SO HEALTH AND QUALITY OF LIFE OUTCOMES
LA English
DT Article
DE HIV-related stigma; HIV; AIDS; Validation; Psychometric properties;
   Portuguese; Brazil
ID CONFIRMATORY FACTOR-ANALYSIS; PSYCHOMETRIC ASSESSMENT; HIV/AIDS STIGMA;
   DISCRIMINATION; CRITERIA; PEOPLE; OLDER; SELF; MEN
AB BackgroundHIV-related stigma, or the degree to which people living with HIV endorse negative stereotypes associated with HIV, is associated with poor continuum of care outcomes. We translated the 12-item Short HIV Stigma scale and evaluated its psychometric properties in a Brazilian context with regard to construct validity and reliability.MethodsThe first step included translation, back-translation, evaluation, peer review, and pre-testing of the Short HIV Sigma scale developed by Reinius et al. (Health Qual Life Outcomes 15(1):115, 2017). The second step involved piloting the scale in three convenience samples of adults recruited online through advertisements on different platforms: Grindr (October/2019) and Hornet (February-March/2020), geospatial network apps for sexual encounters for gay, bisexuals and other men who have sex with men, and social media apps (Facebook and WhatsApp, October/2019). The psychometric evaluation included confirmatory factor analysis, differential item functioning using the Multiple-Indicator Multiple-Cause model, and correlations between subscale scores and antiretroviral treatment use and adherence. Reliability was assessed using Cronbach's alpha, and ordinal alpha and omega from the polychoric correlation matrix.ResultsIn total, 114, 164, and 1824 participants completed the measure items through Grindr, social media, and Hornet, respectively. We confirmed a 4-factor structure with factors for personalized stigma (3 items), disclosure concerns (3 items), concerns with public attitudes (3 items), and negative self-image (3 items). Small differential item functioning with respect to sample was found for one item ("I feel guilty because I have HIV"), which did not substantively influence estimates of latent factor scores. Grindr and Hornet's participants scored significantly higher than social media participants on all factors except personalized stigma. Higher subscale scores correlated with antiretroviral treatment use among participants from Hornet and with lower treatment adherence in participants from Grindr and Hornet. Reliability as measured by Cronbach's alpha, ordinal alpha and omega were 0.83, 0.88 and 0.93 for the entire scale.DiscussionThe Brazilian Portuguese version of the Short HIV Stigma scale had satisfactory psychometric properties with present results suggesting that scores from different samples may be compared without concern that measurement differences substantively influence results though further studies with greater representation of women and heterosexual men are warranted.
C1 [Luz, Paula M.; Torres, Thiago S.; Marins, Luana M. S.; Bezerra, Daniel R. B.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
   [Almeida-Brasil, Celline C.] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada.
   [Harel, Daphna] NYU, Dept Appl Stat Social Sci & Humanities, New York, NY USA.
   [Harel, Daphna] NYU, Ctr Practice & Res, New York, NY USA.
   [Harel, Daphna] NYU, Intersect Informat Soc & Methodol, New York, NY USA.
   [Thombs, Brett D.] Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ, Canada.
   [Thombs, Brett D.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada.
   [Thombs, Brett D.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
   [Thombs, Brett D.] McGill Univ, Dept Med, Montreal, PQ, Canada.
   [Thombs, Brett D.] McGill Univ, Dept Psychol, Montreal, PQ, Canada.
   [Thombs, Brett D.] McGill Univ, Dept Educ & Counselling Psychol, Montreal, PQ, Canada.
   [Thombs, Brett D.] McGill Univ, Biomed Eth Unit, Montreal, PQ, Canada.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
EM paula.luz@ini.fiocruz.br
FU Programa Inova FIOCRUZ; Edital Geracao do Conhecimento/VPPCB; Programa
   PrInt, Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)/FIOCRUZCAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq) [28/2018]; Fonds de recherche du Quebec Sante
   Distinguished Scholar Award
FX Dr. Luz was supported by Programa Inova FIOCRUZ, Edital Geracao do
   Conhecimento/VPPCB, and Programa PrInt, Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES)/FIOCRUZ. Dr. Torres was supported
   by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   #28/2018). Dr. Thombs was supported by a Fonds de recherche du Quebec
   Sante Distinguished Scholar Award.
CR de Sousa AIA, 2016, EPIDEMIOL SERV SAUDE, V25, P467, DOI [10.5123/S1679-49742016000300003, 10.5123/s1679-49742016000300003]
   Andersson GZ, 2020, LANCET HIV, V7, pE129, DOI 10.1016/S2352-3018(19)30343-1
   [Anonymous], 2019, B EP DST AIDS
   [Anonymous], 2020, INDICE ESTIGMA RELAC
   Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014
   BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238
   Benzaken AS, 2018, MEDICINE, V97, pS1, DOI 10.1097/MD.0000000000010109
   Berger BE, 2001, RES NURS HEALTH, V24, P518, DOI 10.1002/nur.10011
   Costa JD, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25066
   Almeida Maria Rita de Cassia Barreto de, 2007, Ciênc. saúde coletiva, V12, P263
   Delisle VC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102897
   Earnshaw VA, 2009, AIDS BEHAV, V13, P1160, DOI 10.1007/s10461-009-9593-3
   Emlet CA, 2006, AIDS PATIENT CARE ST, V20, P350, DOI 10.1089/apc.2006.20.350
   Fife BL, 2000, J HEALTH SOC BEHAV, V41, P50, DOI 10.2307/2676360
   Fitzgerald-Husek A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188393
   Franke MF, 2010, AIDS BEHAV, V14, P189, DOI 10.1007/s10461-008-9474-1
   Gadermann A, 2012, PARE, V17, P13
   Gesesew HA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173928
   Hatzenbuehler ML, 2016, AM PSYCHOL, V71, P742, DOI 10.1037/amp0000068
   Holzemer WL, 2007, AIDS CARE, V19, P1002, DOI 10.1080/09540120701245999
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Jackson DL, 2009, PSYCHOL METHODS, V14, P6, DOI 10.1037/a0014694
   Jeyaseelan L, 2013, AIDS BEHAV, V17, P434, DOI 10.1007/s10461-011-0128-3
   Kalichman SC, 2009, AIDS CARE, V21, P87, DOI 10.1080/09540120802032627
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Kerrigan D, 2017, GLOB PUBLIC HEALTH, V12, P185, DOI 10.1080/17441692.2015.1064459
   Kwakkenbos L, 2015, J RHEUMATOL, V42, P1156, DOI 10.3899/jrheum.141421
   Kwakkenbos L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053923
   Lewis TT, 2012, AM J EPIDEMIOL, V175, P391, DOI 10.1093/aje/kwr287
   Lindberg MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114867
   MacCarthy S, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1313
   Macinko J, 2012, INT J EQUITY HEALTH, V11, DOI 10.1186/1475-9276-11-80
   Massignam FM, 2015, EPIDEMIOL SERV SAUDE, V24, P541, DOI 10.5123/S1679-49742015000300020
   McDonald RP, 2002, PSYCHOL METHODS, V7, P64, DOI 10.1037//1082-989X.7.1.64
   Muthen LK, 2017, MPLUS USERS GUIDE
   Ojikutu BO, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153600
   Pascom ARP, 2018, MEDICINE, V97, pS69, DOI [10.1097/MD.0000000000009857, 10.1097/md.0000000000009857]
   Pinho AD, 2018, ARCH SEX BEHAV, V47, P1983, DOI 10.1007/s10508-017-1110-6
   R Core Team, 2019, R LANG ENV STAT COMP
   Reinius M, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0691-z
   REISE SP, 1993, PSYCHOL BULL, V114, P552, DOI 10.1037/0033-2909.114.3.552
   Rendina H Jonathon, 2019, J Int Assoc Provid AIDS Care, V18, p2325958219888462, DOI 10.1177/2325958219888462
   Rueda S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011453
   Sabido M, 2015, AIDS BEHAV, V19, P1630, DOI 10.1007/s10461-015-1016-z
   Sayles JN, 2008, AIDS BEHAV, V12, P748, DOI 10.1007/s10461-008-9375-3
   Slater LZ, 2015, J ASSOC NURSE AIDS C, V26, P24, DOI 10.1016/j.jana.2014.06.007
   STEIGER JH, 1990, MULTIVAR BEHAV RES, V25, P173, DOI 10.1207/s15327906mbr2502_4
   Taber KS, 2018, RES SCI EDUC, V48, P1273, DOI 10.1007/s11165-016-9602-2
   TUCKER LR, 1973, PSYCHOMETRIKA, V38, P1, DOI 10.1007/bf02291170
   Vale FC, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052000337, 10.11606/s1518-8787.2018052000337]
   Van Rie A, 2008, TROP MED INT HEALTH, V13, P21, DOI 10.1111/j.1365-3156.2007.01971.x
   Yu CH, 2019, INT J NURS PRACT, V25, DOI 10.1111/ijn.12708
NR 52
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7525
J9 HEALTH QUAL LIFE OUT
JI Health Qual. Life Outcomes
PD OCT 2
PY 2020
VL 18
IS 1
AR 322
DI 10.1186/s12955-020-01571-1
PG 12
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA NZ2OA
UT WOS:000576934200001
PM 33008400
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Luz, PM
   Torres, TS
   Almeida-Brasil, CC
   Marins, LMS
   Veloso, VG
   Grinsztejn, B
   Cox, J
   Moodie, EEM
AF Luz, Paula M.
   Torres, Thiago S.
   Almeida-Brasil, Celline C.
   Marins, Luana M. S.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Cox, Joseph
   Moodie, Erica E. M.
TI High-Risk Sexual Behavior, Binge Drinking and Use of Stimulants are Key
   Experiences on the Pathway to High Perceived HIV Risk Among Men Who Have
   Sex with Men in Brazil
SO AIDS AND BEHAVIOR
LA English
DT Article; Early Access
DE Perceived HIV risk; Sexual behavior; Binge drinking; Stimulant use; HIV;
   Gay; Bisexual and other men who have sex with men (GBM)
ID HEALTH; MSM; DISCRIMINATION; PERSPECTIVES; PREVENTION; WOMEN; MODEL
AB In Brazil, pre-exposure prophylaxis (PrEP) is currently available for gay, bisexual, and other men who have sex with men. As PrEP use depends on an individual's perceived risk, we explored pathways by which potentially modifiable behaviors lead to high perceived HIV risk. Using online surveys (N = 16,667), we conducted a path analysis on the basis of ordered sequences of multivariate logistic regressions. High perceived HIV risk was low (26.3%) compared to condomless receptive anal sex (41.4%). While younger age increased the odds of binge drinking and of condomless receptive anal sex, it was associated with decreased odds of high perceived HIV risk. In contrast, use of stimulants increased the odds of condomless receptive anal sex and of high perceived HIV risk. Our results suggest that binge drinking and use of stimulants are key points in different pathways to high-risk sexual behavior and may lead to different perceptions of HIV risk.
C1 [Luz, Paula M.; Torres, Thiago S.; Marins, Luana M. S.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
   [Almeida-Brasil, Celline C.; Cox, Joseph] McGill Univ, Hlth Ctr, Res Inst, Montreal, PQ, Canada.
   [Cox, Joseph; Moodie, Erica E. M.] McGill Univ, Fac Med, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
EM paula.luz@ini.fiocruz.br; thiago.torres@ini.fiocruz.br;
   celline.cardoso@gmail.com; luana.marins@ini.fiocruz.br;
   valdilea.veloso@ini.fiocruz.br; beatriz.grinsztejn@gmail.com;
   joseph.cox@mcgill.ca; erica.moodie@mcgill.ca
FU Coordenacao de Aperfeicoamento Pessoal de Nivel Superior (CAPES)CAPES;
   Programa de Internacionalizacao da Fundacao Oswaldo Cruz
   (PrInt-FIOCRUZCAPES); Fonds de recherche du Quebec-SanteFonds de la
   Recherche en Sante du Quebec
FX PML acknowledges funding from Coordenacao de Aperfeicoamento Pessoal de
   Nivel Superior (CAPES) and Programa de Internacionalizacao da Fundacao
   Oswaldo Cruz (PrInt-FIOCRUZCAPES). EEMM acknowledges receipt of a
   chercheur boursier career award from the Fonds de recherche du
   Quebec-Sante.
CR Almeida-Brasil CC, 2018, AIDS, V32, P1323, DOI [10.1097/QAD.0000000000001822, 10.1097/qad.0000000000001822]
   Andersson GZ, 2020, LANCET HIV, V7, pE129, DOI 10.1016/S2352-3018(19)30343-1
   Baral S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-482
   Bavinton BR, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-917
   Becker C, 2013, ROBUSTNESS COMPLEX D
   Blumenthal J, 2019, JAIDS-J ACQ IMM DEF, V80, pE23, DOI 10.1097/QAI.0000000000001888
   Blumenthal-Barby JS, 2015, MED DECIS MAKING, V35, P539, DOI 10.1177/0272989X14547740
   CATANIA JA, 1990, HEALTH EDUC QUART, V17, P53, DOI 10.1177/109019819001700107
   CGIBR, 2018, TIC DOM US INT IND A
   Chandler J, 2016, ANNU REV CLIN PSYCHO, V12, P53, DOI 10.1146/annurev-clinpsy-021815-093623
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Cox DR, 1998, MULTIVARIATE DEPENDE
   Guimaraes MDC, 2018, MEDICINE, V97, pS62, DOI 10.1097/MD.0000000000009079
   CUMMINGS KM, 1978, HEALTH EDUC QUART, V6, P394, DOI 10.1177/109019818700600406
   Ferrer RA, 2016, ANN BEHAV MED, V50, P653, DOI 10.1007/s12160-016-9790-z
   Fitzgerald-Husek A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188393
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Grucza RA, 2018, ALCOHOL CLIN EXP RES, V42, P1939, DOI 10.1111/acer.13859
   Guimarães Mark Drew Crosland, 2019, Rev. bras. epidemiol., V22, pe190005, DOI 10.1590/1980-549720190005.supl.1
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   KAHNEMAN D, 1984, AM PSYCHOL, V39, P341, DOI 10.1037/0003-066X.39.4.341
   Kahneman D, 2013, THINKING FAST SLOW
   Kerr L, 2018, MEDICINE, V97, pS9, DOI [10.1097/MD.0000000000010573, 10.1097/md.0000000000010573]
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Khawcharoenporn T, 2019, AIDS RES THER, V16, DOI 10.1186/s12981-019-0229-z
   Lambert G, 2011, AIDS BEHAV, V15, P584, DOI 10.1007/s10461-009-9605-3
   Laranjeira R, 2007, ADDICTION, V102, P1502, DOI 10.1111/j.1360-0443.2007.01964.x
   Laranjeira R, 2010, REV BRAS PSIQUIATR, V32, P231, DOI 10.1590/S1516-44462009005000012
   Latalova K, 2014, NEUROPSYCH DIS TREAT, V10, P1399, DOI 10.2147/NDT.S54081
   Luz PM, 2019, CURR OPIN HIV AIDS, V14, P366, DOI 10.1097/COH.0000000000000564
   Macinko J, 2012, INT J EQUITY HEALTH, V11, DOI 10.1186/1475-9276-11-80
   MacKellar DA, 2005, JAIDS-J ACQ IMM DEF, V38, P603, DOI 10.1097/01.qai.0000141481.48348.7e
   Massignam FM, 2015, EPIDEMIOL SERV SAUDE, V24, P541, DOI 10.5123/S1679-49742015000300020
   Ministerio da Saude, 2018, B EP AIDA DST
   MS, 2018, B EP DST AIDS
   MS, 2018, PROT CLIN DIR TER PR
   MS, 2019, B EP DST AIDS
   Napper LE, 2012, AIDS BEHAV, V16, P1075, DOI 10.1007/s10461-011-0003-2
   Pascoe EA, 2009, PSYCHOL BULL, V135, P531, DOI 10.1037/a0016059
   Plotzker R, 2017, JAIDS-J ACQ IMM DEF, V76, P473, DOI [10.1097/qai.0000000000001536, 10.1097/QAI.0000000000001536]
   Prestage G, 2012, SEX TRANSM DIS, V39, P167, DOI 10.1097/OLQ.0b013e31823e67a9
   Rehm J, 2012, ADDICTION, V107, P51, DOI 10.1111/j.1360-0443.2011.03621.x
   Rodger AJ, 2019, LANCET, V393, P2428, DOI 10.1016/S0140-6736(19)30418-0
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203
   Sabido M, 2015, AIDS BEHAV, V19, P1630, DOI 10.1007/s10461-015-1016-z
   Seekaew P, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25430
   Sharma A, 2018, AM J MENS HEALTH, V12, P1824, DOI 10.1177/1557988318790875
   Sharot T, 2011, CURR BIOL, V21, pR941, DOI 10.1016/j.cub.2011.10.030
   Skagerlund K, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00970
   Slovic P, 2007, EUR J OPER RES, V177, P1333, DOI 10.1016/j.ejor.2005.04.006
   Smolen JR, 2017, CIENC SAUDE COLETIVA, V22, P4021, DOI 10.1590/1413-812320172212.19782016
   Torres TS, 2020, DRUG ALCOHOL DEPEN, V209, DOI 10.1016/j.drugalcdep.2020.107908
   Torres TS, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4704-x
   Torres TS, 2019, AIDS CARE, V31, P1193, DOI 10.1080/09540121.2019.1619665
   Torres TS, 2019, JMIR PUBLIC HLTH SUR, V5, P177, DOI 10.2196/13771
   Torres TS, 2018, JMIR PUBLIC HLTH SUR, V4, P147, DOI 10.2196/publichealth.8997
   Wang LW, 2020, AM J EPIDEMIOL, V189, P44, DOI 10.1093/aje/kwz231
   Warren EA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198680
   Wilton J, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20777
NR 60
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
DI 10.1007/s10461-020-03035-5
EA SEP 2020
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA NQ9QM
UT WOS:000571200900002
PM 32940826
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Piedade, J
   Castro, R
   Pinto, L
   Veloso, VG
   Grinsztejn, B
   Pereira, G
   Fernandes, FF
AF Perazzo, Hugo
   Piedade, Juliana
   Castro, Rodolfo
   Pinto, Laura
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Pereira, Gustavo
   Fernandes, Flavia F.
TI COVID-19: An Overview of Worldwide Recommendations for Management of
   Patients With Liver Diseases or Liver Transplantation
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Letter
C1 [Perazzo, Hugo] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, FIOCRUZ, Rio De Janeiro, Brazil.
   [Piedade, Juliana; Pinto, Laura; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Castro, Rodolfo] Fundacao Oswaldo Cruz, Sergio Arouca Natl Sch Publ Hlth, Rio De Janeiro, Brazil.
   [Castro, Rodolfo] Fed Univ State Rio Janeiro, Inst Collect Hlth, Rio De Janeiro, Brazil.
   [Pereira, Gustavo; Fernandes, Flavia F.] Bonsucesso Fed Hosp, Gastroentrol & Hepatol Dept, Rio De Janeiro, Brazil.
RP Perazzo, H (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, FIOCRUZ, Rio De Janeiro, Brazil.
RI ; Castro, Rodolfo/D-4231-2013
OI Perazzo, Hugo/0000-0003-0931-6418; Piedade, Juliana/0000-0002-0718-2033;
   Castro, Rodolfo/0000-0002-0701-2528
FU Programa de Incentivo a Jovens Pesquisadores (Evandro Chagas National
   Institute of Infectious Diseases Oswaldo Cruz Foundation)
   [INI-003-FIO-19-2-5]; University Estacio de Sa Programa Pesquisa e
   Produtividade
FX This work was supported by funding from the Programa de Incentivo a
   Jovens Pesquisadores (Evandro Chagas National Institute of Infectious
   Diseases Oswaldo Cruz Foundation) grant INI-003-FIO-19-2-5 (H.P.), and
   from the University Estacio de Sa Programa Pesquisa e Produtividade
   (G.P.). The funders had no role in the study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], 2020, COMBINED DATA SECURE
   Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Donato MF, 2020, CLIN GASTROENTEROL H, V18, P2131, DOI 10.1016/j.cgh.2020.04.041
   Fix OK, 2020, HEPATOLOGY, V72, P287, DOI 10.1002/hep.31281
   Lleo A, 2020, J HEPATOL, V73, P453, DOI 10.1016/j.jhep.2020.04.002
   Marcoux Rita M, 2016, P T, V41, P567
   Meyer T, 2020, ILCA GUIDANCE MANAGE
   Serper M, 2020, HEPATOLOGY, V72, P723, DOI 10.1002/hep.31276
NR 8
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD SEP
PY 2020
VL 18
IS 10
BP 2381
EP +
DI 10.1016/j.cgh.2020.04.074
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ND6EB
UT WOS:000561992000043
PM 32407967
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Castro, EC
   Piedade, J
   Castro, R
   Luz, PM
   Fernandes, F
   Grinsztejn, B
   Veloso, VG
   Pereira, GH
   Perazzo, H
AF Castro Filho, Elio C.
   Piedade, Juliana
   Castro, Rodolfo
   Luz, Paula M.
   Fernandes, Flavia
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Pereira, Gustavo Henrique
   Perazzo, Hugo
TI Effectiveness of direct-acting agents for chronic hepatitis C treatment
   in South America: A systematic review and meta-analysis
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Review
DE HCV therapy; hepatitis C; interferon-free regimens; South America
ID VIRUS-INFECTION; REAL-WORLD; ANTIVIRALS; MULTICENTER; EXPERIENCE;
   REGIMENS; THERAPY; SAFETY; LIVER
AB The effectiveness of direct-acting agents (DAAs) for hepatitis C treatment in limited-resource settings remains unclear. We estimated the pooled sustained virological response rates of DAA therapy in South America. We searched online databases for studies that reported 12-week sustained virological response (SVR12) to hepatitis C virus (HCV) treatment in individuals living in South America. Pooled SVR12 in intention-to-treat (ITT) and per-protocol were estimated. Additionally, using all studies with available data, the pooled relative risk (RR) of SVR12 using a random-effects model (DerSimonian-Laird) was estimated to compare effectiveness of DAAs in patients with or without cirrhosis, HIV co-infection or previous HCV therapy. Heterogeneity was assessed using theI(2)statistics. We identified 20 studies [14 manuscripts and 6 conference abstracts] comprising 7393 individuals from five countries [Brazil (n = 11), Argentina (n = 4), Chile (n = 1), Colombia (n = 1) and Peru (n = 1)] and two South-American collaborations. The pooled overall SVR12 rates [95% confidence interval (CI)] were 92.6% [90.2-94.7] and 95.5% [94.3-96.6] by ITT (11 studies; n = 4,153;I-2 = 84.2%) and per-protocol analysis (15 studies; n = 4,833;I-2 = 64.5%), respectively. The RR of SVR12 was similar in patients with or without HIV co-infection [4 studies; RR = 1.03 (0.99-1.07)] and those naive compared with treatment experimented-individuals [9 studies; RR = 1.01 (1.00-1.03)], but significantly higher in patients without cirrhosis compared with those with cirrhosis [11 studies; RR = 1.04 (1.02-1.05),P < .001]. DAAs are highly effective for HCV treatment in South America. The use of DAAs should be considered in limited-resource settings to decrease the burden of liver disease in HCV-infected patients. PROSPERO[CRD 42019134603].
C1 [Castro Filho, Elio C.; Piedade, Juliana; Luz, Paula M.; Grinsztejn, Beatriz; Veloso, Valdilea G.; Perazzo, Hugo] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Rio De Janeiro, Brazil.
   [Piedade, Juliana; Fernandes, Flavia; Pereira, Gustavo Henrique] Hosp Fed Bonsucesso, Dept Gastroenterol & Hepatol, Rio De Janeiro, Brazil.
   [Castro, Rodolfo] Fundacao Oswaldo Cruz FIOCRUZ, Escola Nacl Saude Publ ENSP, Rio De Janeiro, Brazil.
   [Castro, Rodolfo] Univ Fed Estado Rio de Janeiro UNIRIO, Inst Saude Colet ISC, Rio De Janeiro, Brazil.
RP Perazzo, H (corresponding author), Fundacao Oswaldo Cruz, Lab Pesquisa Clin DST & AIDS, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM perazzohugo@gmail.com
RI Castro, Rodolfo/D-4231-2013
OI Castro, Rodolfo/0000-0002-0701-2528; Goncalves Veloso dos Santos,
   Valdilea/0000-0002-6622-3165
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCAPES [001];
   Fundacao Oswaldo Cruz [PJP INI-003-FIO-19-2-5]; University Estacio de Sa
FX Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Grant/Award
   Number: Finance Code 001; Fundacao Oswaldo Cruz, Grant/Award Number: PJP
   INI-003-FIO-19-2-5; University Estacio de Sa
CR [Anonymous], 2019, PROTOCOLO CLIN DIRET
   [Anonymous], 2015, GUIA CLIN MANEJO INF
   [Anonymous], 2018, GUIA PRACTICA CLIN L
   Cheinquer HH, 2017, J HEPATOL, V66, pS508, DOI 10.1016/S0168-8278(17)31417-4
   Cooke GS, 2019, LANCET GASTROENTEROL, V4, P135, DOI 10.1016/S2468-1253(18)30270-X
   Costa VD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216327
   da Fonseca EM, 2019, NEW ENGL J MED, V380, P605, DOI 10.1056/NEJMp1812959
   Davalos Moscol Milagros, 2019, Rev. gastroenterol. Perú, V39, P45
   Diaz ACMB, 2018, BR J INFECT DIS, V22, P61
   Douglass CH, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1162-z
   Falade-Nwulia O, 2017, ANN INTERN MED, V166, P637, DOI [10.7326/M16-2575, 10.7326/m16-2575]
   Fernandes FF, 2019, J GASTROEN HEPATOL, V34, P2187, DOI 10.1111/jgh.14707
   Ferrarese A, 2018, WORLD J GASTROENTERO, V24, P4403, DOI 10.3748/wjg.v24.i38.4403
   Ferreira VL, 2018, BRAZ J INFECT DIS, V22, P186, DOI 10.1016/j.bjid.2018.04.003
   Gadano A, 2017, HEPATOL INT, V11, pS1036
   Gualano G, 2017, HEPATOLOGY, V66, p605A
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Harris RJ, 2008, STATA J, V8, P3, DOI 10.1177/1536867X0800800102
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holzmann I, 2018, BRAZ J INFECT DIS, V22, P317, DOI 10.1016/j.bjid.2018.06.004
   Vargas JI, 2017, REV MED CHILE, V145, P1235, DOI 10.4067/S0034-98872017001001235
   Jakobsen JC, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012143.pub2
   Ji F, 2018, ALIMENT PHARM THER, V47, P550, DOI 10.1111/apt.14507
   Kershenobich D, 2011, LIVER INT, V31, P18, DOI 10.1111/j.1478-3231.2011.02538.x
   Marciano S, 2018, REV GASTROENTEROL ME, V83, P208, DOI 10.1016/j.rgmx.2018.02.009
   Marciano S, 2018, J MED VIROL, V90, P951, DOI 10.1002/jmv.25033
   Mendizabal M, 2017, J MED VIROL, V89, P1590, DOI 10.1002/jmv.24816
   Mesquita F, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3784-4
   Miotto N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199941
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Molina RJ, 2018, BR J INFECT DIS, V22, P58
   Nahon P, 2017, GASTROENTEROLOGY, V152, P142, DOI 10.1053/j.gastro.2016.09.009
   Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39
   Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
   Perazzo H, 2020, B WORLD HEALTH ORGAN, V98, P188, DOI 10.2471/BLT.19.231522
   Pessoa MG, 2018, ANN HEPATOL, V17, P959, DOI 10.5604/01.3001.0012.2244
   Pott H, 2019, CLIN MICROBIOL INFEC, V25, P365, DOI 10.1016/j.cmi.2018.06.007
   Ridruejo E, 2018, J HEPATOL, V68, pS280, DOI 10.1016/S0168-8278(18)30777-3
   Ridruejo E, 2018, GUIDELINE TREATMENT
   Ridruejo E, 2019, J VIRAL HEPATITIS, V26, P1200, DOI 10.1111/jvh.13148
   Sette H, 2017, ANN HEPATOL, V16, P727, DOI 10.5604/01.3001.0010.2717
   Spearman CW, 2019, LANCET, V394, P1451, DOI 10.1016/S0140-6736(19)32320-7
   Varon A, 2019, MEDICINA-BUENOS AIRE, V79, P29
   World Health Organization, COMB HEP B C REACH E
   World Health Organization, 2019, CONS STRAT INF GUID
NR 45
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD DEC
PY 2020
VL 27
IS 12
BP 1396
EP 1407
DI 10.1111/jvh.13364
EA AUG 2020
PG 12
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA OJ9ST
UT WOS:000555765600001
PM 32706518
DA 2020-11-24
ER

PT J
AU Smeaton, LM
   Kileel, EM
   Grinsztejn, B
   Gardner, EM
   Starr, K
   Murry, ML
   Desvigne-Nickens, P
   Alston-Smith, B
   Waclawiw, MA
   Cooper-Arnold, K
   Madruga, JV
   Sangle, S
   Fitch, KV
   Zanni, MV
   Douglas, PS
   Ribaudo, HJ
   Grinspoon, SK
   Klingman, KL
AF Smeaton, Laura M.
   Kileel, Emma M.
   Grinsztejn, Beatriz
   Gardner, Edward M.
   Starr, Kate
   Murry, Melissa L.
   Desvigne-Nickens, Patrice
   Alston-Smith, Beverly
   Waclawiw, Myron A.
   Cooper-Arnold, Katharine
   Madruga, Jose, V
   Sangle, Shashi
   Fitch, Kathleen, V
   Zanni, Markella, V
   Douglas, Pamela S.
   Ribaudo, Heather J.
   Grinspoon, Steven K.
   Klingman, Karin L.
TI Characteristics of REPRIEVE Trial Participants Identifying Across the
   Transgender Spectrum
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE cardiovascular; gender-affirming hormone treatment; gender identity;
   HIV; transgender spectrum
ID CARDIOVASCULAR-DISEASE; HORMONE-THERAPY; HIV PREVENTION; PEOPLE; WOMEN;
   POPULATIONS; PREVALENCE; BURDEN
AB Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >10(2) cm (compared with <= 25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS.
C1 [Smeaton, Laura M.; Ribaudo, Heather J.] Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, 651 Huntington Ave,FXB 511, Boston, MA 02115 USA.
   [Kileel, Emma M.; Fitch, Kathleen, V; Zanni, Markella, V; Grinspoon, Steven K.] Massachusetts Gen Hosp, Metab Unit, Boston, MA 02114 USA.
   [Kileel, Emma M.; Fitch, Kathleen, V; Zanni, Markella, V; Grinspoon, Steven K.] Harvard Med Sch, Boston, MA 02115 USA.
   [Grinsztejn, Beatriz] Funda Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas INI Fiocruz, Rio De Janeiro, Brazil.
   [Gardner, Edward M.] Denver Publ Hlth, Denver, CO USA.
   [Starr, Kate] Ohio State Univ, Columbus, OH 43210 USA.
   [Murry, Melissa L.] Houston Cross Network Community Advisory Board, Houston, TX USA.
   [Desvigne-Nickens, Patrice; Waclawiw, Myron A.; Cooper-Arnold, Katharine] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Alston-Smith, Beverly; Klingman, Karin L.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Madruga, Jose, V] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Sangle, Shashi] BJ Med Coll, Dept Med, Pune, Maharashtra, India.
   [Douglas, Pamela S.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
RP Smeaton, LM (corresponding author), Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, 651 Huntington Ave,FXB 511, Boston, MA 02115 USA.
EM smeaton@sdac.harvard.edu
OI Smeaton, Laura/0000-0001-7243-4703
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [U01 HL123336, U01
   HL123339]; National Institute of Allergy and Infectious Diseases
   (NIAID)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1 AI068636, UM1 AI106701]
FX This work was funded by the National Heart, Lung, and Blood Institute
   (Grant Numbers U01 HL123336 and U01 HL123339) with additional support
   from the National Institute of Allergy and Infectious Diseases (NIAID)
   (UM1 AI068636, UM1 AI106701).
CR AIDSinfo, TRANSG PEOPL HIV CON
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Bares SH, 2018, J WOMENS HEALTH, V27, P1162, DOI 10.1089/jwh.2017.6717
   Becasen JS, 2019, AM J PUBLIC HEALTH, V109, pE1, DOI 10.2105/AJPH.2018.304727
   Curno MJ, 2016, JAIDS-J ACQ IMM DEF, V71, P181, DOI 10.1097/QAI.0000000000000842
   Daniels J, 2019, AIDS BEHAV, V23, P2849, DOI 10.1007/s10461-019-02628-z
   Division of AIDS Cross-Network Transgender Working Group, 2019, GUID US GEND INCL II
   Estimated HIV, 2010, ESTIMATED HIV INCIDE
   Flores AR, MANY ADULTS IDENTIFY
   Gandhi M, 2019, JAIDS-J ACQ IMM DEF, V81, pE158, DOI 10.1097/QAI.0000000000002073
   Gogia S, 2018, JAIDS-J ACQ IMM DEF, V79, pE39, DOI 10.1097/QAI.0000000000001767
   Grinspoon SK, 2019, AM HEART J, V212, P23, DOI 10.1016/j.ahj.2018.12.016
   Hare C, 2019, CROI
   Irwig MS, 2018, REV ENDOCR METAB DIS, V19, P243, DOI 10.1007/s11154-018-9454-3
   King WM, 2019, J INTERPERS VIOLENCE, DOI 10.1177/0886260519876024
   Lake JE, 2019, AIDS, V33, P363, DOI 10.1097/QAD.0000000000002095
   Mayer KH, 2016, JAIDS-J ACQ IMM DEF, V72, pS207, DOI 10.1097/QAI.0000000000001086
   National Institute of Allergy and Infectious Diseases, 2020, NIAID DIV AIDS LANG
   Overton ET, 2020, J INFECT DIS, V222, pS41, DOI 10.1093/infdis/jiaa222
   Peltzer K, 2019, HIV AIDS-RES PALLIAT, V11, P275, DOI 10.2147/HIV.S229285
   Poteat T, 2020, CLIN INFECT DIS, V70, P1131, DOI 10.1093/cid/ciz322
   Poteat TC, 2020, AIDS CARE, V32, P310, DOI 10.1080/09540121.2019.1668526
   Reisner SL, 2016, LANCET, V388, P412, DOI 10.1016/S0140-6736(16)00684-X
   Scully EP, 2018, CURR HIV-AIDS REP, V15, P136, DOI 10.1007/s11904-018-0383-2
   Siskind RL, 2016, JAIDS-J ACQ IMM DEF, V72, pS243, DOI 10.1097/QAI.0000000000001085
   Smeaton LM, 2020, CLIN INFECT DIS, V71, P1300, DOI 10.1093/cid/ciz959
   Squires K, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofw047
   Streed CG, 2017, ANN INTERN MED, V167, P256, DOI 10.7326/M17-0577
   Tracy LA, 2018, J ASSOC NURSE AIDS C, V29, P371, DOI 10.1016/j.jana.2018.01.004
   Fontanari AMV, 2019, SOC SCI MED, V230, P280, DOI 10.1016/j.socscimed.2019.03.016
   Wansom T, 2016, J VIRUS ERAD, V2, P87
   Westbury CF, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00192
   WHO- HIV-2017, HIV PREV DIAGN TREAT
   Wierckx K, 2013, EUR J ENDOCRINOL, V169, P471, DOI 10.1530/EJE-13-0493
   Williams Institute of the UCLA School of Law, 2016, DAT COLL METH SEX OR
NR 35
TC 1
Z9 1
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 1
PY 2020
VL 222
SU 1
BP S31
EP S40
DI 10.1093/infdis/jiaa213
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA MY9DC
UT WOS:000558718300004
PM 32645160
DA 2020-11-24
ER

PT J
AU Torres, TS
   Hoagland, B
   Bezerra, DRB
   Garner, A
   Jalil, EM
   Coelho, LE
   Benedetti, M
   Pimenta, C
   Grinsztejn, B
   Veloso, VG
AF Torres, Thiago S.
   Hoagland, Brenda
   Bezerra, Daniel R. B.
   Garner, Alex
   Jalil, Emilia M.
   Coelho, Lara E.
   Benedetti, Marcos
   Pimenta, Cristina
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
TI Impact of COVID-19 Pandemic on Sexual Minority Populations in Brazil: An
   Analysis of Social/Racial Disparities in Maintaining Social Distancing
   and a Description of Sexual Behavior
SO AIDS AND BEHAVIOR
LA English
DT Article; Early Access
DE MSM; Transgender people; PrEP; Covid-19; Brazil
ID TRANSGENDER WOMEN; LATIN-AMERICA; HIV; PREP; MEN
AB We conducted a web-based survey to understand the impact of social distancing measures on Brazilian MSM and transgender/non-binary lives. A total of 3486 respondents were included in this analysis and the great majority were cismen (98%). The median age was 32 years (IQR: 27-40), 44% non-white, 36% low schooling and 38% low income. Most of participants reported HIV negative/unknown status (77%). Participants on-PrEP reported more condomless anal sex than those off-PrEP. Conversely, 24% off-PrEP were at substantial HIV-risk. PrEP/ART continuation were reported by the majority, despite reports of impediments to medication refill. Transgender/non-binary reported more mental health problems and challenges to access health care. Social and racial disparities were associated with unattainability of maintaining social distancing. Tailored social and economic support policies during COVID-19 pandemic should be made available to these populations. Challenges for PrEP/ART access will demand the implementation of innovative solutions to avoid the expansion of the HIV epidemic.
C1 [Torres, Thiago S.; Hoagland, Brenda; Bezerra, Daniel R. B.; Jalil, Emilia M.; Coelho, Lara E.; Benedetti, Marcos; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, STD AIDS Clin Res Lab, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365, BR-21040900 Manguinho, RJ, Brazil.
   [Garner, Alex] Hornet INC, Los Angeles, CA USA.
   [Pimenta, Cristina] Brazilian Minist Hlth, Brasilia, DF, Brazil.
RP Torres, TS (corresponding author), Fundacao Oswaldo Cruz, STD AIDS Clin Res Lab, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365, BR-21040900 Manguinho, RJ, Brazil.
EM thiago.torres@ini.fiocruz.br
FU Unitaid's; National Council of Technological (CNPq) [28/2018]; National
   Council of Technological and Scientific DevelopmentNational Council for
   Scientific and Technological Development (CNPq); Research Funding Agency
   of the State of Rio de Janeiro (Programa Cientista do Nosso Estado)
FX This project was made possible, thanks to Unitaid's funding and support.
   Unitaid accelerates access to innovative health products and lays the
   foundations for their scale-up by countries and partners. Unitaid is a
   hosted partnership of the WHO. TST acknowledges funding from the
   National Council of Technological (CNPq, #28/2018). BG acknowledges
   funding from the National Council of Technological and Scientific
   Development and the Research Funding Agency of the State of Rio de
   Janeiro (Programa Cientista do Nosso Estado; Edital No. 03/2018). This
   work has been presentated as late breaker in a Poster Session at the
   23rd International AIDS Conference (AIDS 2020: Virtual), held on 6-10
   July 2020.
CR Anadolu Agency, 2020, COVID 19 TRIGG MASS
   [Anonymous], 2020, LANCET, V395, P1461, DOI 10.1016/S0140-6736(20)31095-3
   [Anonymous], WHO TIM COVID 19
   Baqui P, 2020, LANCET GLOB HEALTH, V8, P1018, DOI 10.1016/S2214-109X(20)30285-0
   Barney A, 2020, J ADOLESCENT HEALTH, V67, P164, DOI 10.1016/j.jadohealth.2020.05.006
   Benevides BG, 2020, DOSSIE ASSASSINATOS
   Bilal U, 2019, LANCET PLANET HEALTH, V3, pE503, DOI 10.1016/S2542-5196(19)30235-9
   Brasil, 2020, PAINEL CORONAVIRUS
   Brasil. Ministerio da Saude, 2018, PROT CLIN DIR TER PR
   Coelho LE, 2019, LANCET HIV, V6, pE788, DOI 10.1016/S2352-3018(19)30238-3
   Comite Gestor da Internet no Brasil (CGIBR), 2020, J2 IND QUE POSS TEL
   Comite Gestor da Internet no Brasil (CGIBR), 2019, C2A USUARIOS INT IND
   Costa JD, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25066
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Dourado I, 2020, AIDS BEHAV, V24, P1994, DOI 10.1007/s10461-020-02927-w
   Ferreira Ana Cristina Garcia, 2019, Transgend Health, V4, P107, DOI 10.1089/trgh.2018.0063
   Galea JT, 2018, LANCET HIV, V5, pE110, DOI 10.1016/S2352-3018(18)30011-0
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Heerwegh D, 2009, INT J PUBLIC OPIN R, V21, P111, DOI 10.1093/ijpor/edn054
   Hoagland B, 2020, BRAZ J INFECT DIS, V24, P360, DOI 10.1016/j.bjid.2020.05.004
   Hoagland B, 2017, AIDS BEHAV, V21, P1278, DOI 10.1007/s10461-016-1516-5
   Instituto Brasileiro de Geografia e Estatisticas-IBGE, 2020, PESQ NAC AM DOM CONT
   Jalil EM, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21873
   Jiang HB, 2020, LANCET HIV, V7, pE308, DOI 10.1016/S2352-3018(20)30105-3
   Kerr L, 2018, MEDICINE, V97, pS9, DOI [10.1097/MD.0000000000010573, 10.1097/md.0000000000010573]
   Luz PM, 2019, CURR OPIN HIV AIDS, V14, P366, DOI 10.1097/COH.0000000000000564
   National Institute on Alcohol Abuse and Alcoholism (NIAAA) Abuse and Alcoholism (NIAAA), 2004, NIAAA APPR DEF BING
   Rezende LFM, 2020, REV SAUDE PUBL, V54, DOI 10.11606/s1518-8787.2020054002596
   Safer JD, 2016, CURR OPIN ENDOCRINOL, V23, P168, DOI 10.1097/MED.0000000000000227
   Torres TS, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4704-x
   Torres TS, 2019, AIDS CARE, V31, P1193, DOI 10.1080/09540121.2019.1619665
   Torres TS, 2019, JMIR PUBLIC HLTH SUR, V5, P68, DOI 10.2196/15504
   Torres TS, 2018, JMIR PUBLIC HLTH SUR, V4, P147, DOI 10.2196/publichealth.8997
   UNAIDS, 2019, UNAIDS DAT 2019
   United Nations, RAC DISCR MISC EXP B
   UNITED NATIONS ECONOMIC COMMISSION FOR LATIN AMERICA AND THE CARIBBEAN, 2020, SOC PAN LAT AM 2019
   WHO, 2017, BRAZ BEG PREP ROLL O
   Wilson EC, 2019, GLOB PUBLIC HEALTH, V14, P300, DOI 10.1080/17441692.2018.1505933
   World Health Organization, WHATS 2 1 1 EV DRIV
NR 39
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
DI 10.1007/s10461-020-02984-1
EA JUL 2020
PG 12
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA MZ8DO
UT WOS:000559355900002
PM 32737817
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU de Azevedo, SSD
   Ribeiro-Alves, M
   Cortes, FH
   Delatorre, E
   Spangenberg, L
   Naya, H
   Seito, LN
   Hoagland, B
   Grinsztejn, B
   Veloso, VG
   Morgado, MG
   Souza, TML
   Bello, G
AF de Azevedo, Suwellen S. D.
   Ribeiro-Alves, Marcelo
   Cortes, Fernanda H.
   Delatorre, Edson
   Spangenberg, Lucia
   Naya, Hugo
   Seito, Leonardo N.
   Hoagland, Brenda
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Morgado, Mariza G.
   Souza, Thiago Moreno L.
   Bello, Gonzalo
TI Increased expression of CDKN1A/p21 in HIV-1 controllers is correlated
   with upregulation of ZC3H12A/MCPIP1
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1 controllers; Restriction factors; MCPIP1; p21; Immune activation
ID CD4(+) T-CELLS; VIRUS TYPE-1 INFECTION; RESTRICTION FACTORS; INHIBITOR
   P21; RNA-BINDING; KAPPA-B; MCPIP1; PROLIFERATION; TRANSCRIPTION;
   ACTIVATION
AB Background Some multifunctional cellular proteins, as the monocyte chemotactic protein-induced protein 1 (ZC3H12A/MCPIP1) and the cyclin-dependent kinase inhibitor CDKN1A/p21, are able to modulate the cellular susceptibility to the human immunodeficiency virus type 1 (HIV-1). Several studies showed that CDKN1A/p21 is expressed at high levels ex vivo in cells from individuals who naturally control HIV-1 replication (HIC) and a recent study supports a coordinate regulation of ZC3H12A/MCPIP1 and CDKN1A/p21 transcripts in a model of renal carcinoma cells. Here, we explored the potential associations between mRNA expression of ZC3H12A/MCPIP1 and CDKN1A/p21 in HIC sustaining undetectable (elite controllers-EC) or low (viremic controllers-VC) viral loads. Results We found a selective upregulation of ZC3H12A/MCPIP1 and CDKN1A/p21 mRNA levels in PBMC from HIC compared with both ART-suppressed and HIV-negative control groups (P <= 0.02) and higher MCPIP1 and p21 proteins levels in HIC than in HIV-1 negative subjects. There was a moderate positive correlation (r >= 0.57; P <= 0.014) between expressions of both transcripts in HIC and in HIC combined with control groups. We found positive correlations between the mRNA level of CDKN1A/p21 with activated CD4(+)T cells levels in HIC (r >= 0.53; P <= 0.017) and between the mRNA levels of both CDKN1A/p21 (r = 0.74; P = 0.005) and ZC3H12A/MCPIP1 (r = 0.58; P = 0.040) with plasmatic levels of sCD14 in EC. Reanalysis of published transcriptomic data confirmed the positive association between ZC3H12A/MCPIP1 and CDKN1A/p21 mRNA levels in CD4(+)T cells and monocytes from disparate cohorts of HIC and other HIV-positive control groups. Conclusions These data show for the first time the simultaneous upregulation of ZC3H12A/MCPIP1 and CDKN1A/p21 transcripts in the setting of natural suppression of HIV-1 replication in vivo and the positive correlation of the expression of these cellular factors in disparate cohorts of HIV-positive individuals. The existence of a common regulatory pathway connecting ZC3H12A/MCPIP1 and CDKN1A/p21 could have a synergistic effect on HIV-1 replication control and pharmacological manipulation of these multifunctional host factors may open novel therapeutic perspectives to prevent HIV-1 replication and disease progression.
C1 [de Azevedo, Suwellen S. D.; Cortes, Fernanda H.; Morgado, Mariza G.; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz IOC, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Ribeiro-Alves, Marcelo; Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin DST AIDS, Rio De Janeiro, Brazil.
   [Delatorre, Edson] Univ Fed Espirito Santo, Ctr Ciencias Exatas Nat & Saude, Dept Biol, Alegre, Brazil.
   [Spangenberg, Lucia; Naya, Hugo] Inst Pasteur Montevideo, Unidad Bioinformat, Montevideo, Uruguay.
   [Spangenberg, Lucia] Univ Catolica Uruguay, Fac Ingn & Tecnol, Dept Informat & Ciencias Comp, Montevideo, Uruguay.
   [Naya, Hugo] Univ Republica, Fac Agron, Dept Prod Anim & Pasturas, Montevideo, Uruguay.
   [Seito, Leonardo N.] Fiocruz MS, Inst Tecnol Farmacos Farmanguinhos, Lab Farmacol Aplicada, Rio De Janeiro, Brazil.
   [Souza, Thiago Moreno L.] Fiocruz MS, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Dis Neglected Pop, Rio De Janeiro, Brazil.
   [Souza, Thiago Moreno L.] Fiocruz MS, Oswaldo Cruz IOC, Lab Imunofarmacol, Rio De Janeiro, Brazil.
RP de Azevedo, SSD (corresponding author), Fiocruz MS, Inst Oswaldo Cruz IOC, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM suwellen@ioc.fiocruz.br
RI Delatorre, Edson/J-8330-2015
OI Delatorre, Edson/0000-0002-5746-0820
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro-FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ) [E-26/110.123/2014]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico-CNPqNational Council for
   Scientific and Technological Development (CNPq) [401220/2016-8];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); "Pos-Doutorado Nota 10 (PDR 10)" by Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro-FAPERJ; "Pos-Doutorado Junior
   (PDJ)" by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq)
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro-FAPERJ (Grant number E-26/110.123/2014) and the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq
   (Grant Number 401220/2016-8). SSDA had her PhD funded by Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Fundacao
   de Amparo a Pesquisa do Estado do Rio de Janeiro-FAPERJ. Currently, SSDA
   is financed by Postdoctoral fellowship from the "Pos-Doutorado Nota 10
   (PDR 10)" by Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro-FAPERJ, but during the execution of this work she also was
   financed by the "Pos-Doutorado Junior (PDJ)" by Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq).
CR Abdel-Mohsen M, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-106
   Allouch A, 2013, P NATL ACAD SCI USA, V110, pE3997, DOI 10.1073/pnas.1306719110
   Arias CF, 2007, J IMMUNOL, V178, P2296, DOI 10.4049/jimmunol.178.4.2296
   Arpa L, 2009, EUR J IMMUNOL, V39, P514, DOI 10.1002/eji.200838283
   Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272
   Basso D., 2009, NONPARAMETRIC ONE WA, P105, DOI 10.1007/978-0-387-85956-9_5
   Bergamaschi A, 2009, J VIROL, V83, P12253, DOI 10.1128/JVI.01395-09
   Brenchley JM, 2006, J VIROL, V80, P6801, DOI 10.1128/JVI.00070-06
   Buchanan EL, 2015, J ANTIMICROB CHEMOTH, V70, P954, DOI 10.1093/jac/dku428
   Canoui E, 2017, JAIDS-J ACQ IMM DEF, V74, pE56, DOI 10.1097/QAI.0000000000001166
   Chen HB, 2011, J CLIN INVEST, V121, P1549, DOI 10.1172/JCI44539
   Colomer-Lluch M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02876
   Cortes FH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01576
   de Azevedo SSD, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0354-5
   de Pablo A, 2016, AIDS RES HUM RETROV, V32, P232, DOI [10.1089/aid.2015.0137, 10.1089/AID.2015.0137]
   Diamond MS, 2013, NAT REV IMMUNOL, V13, P46, DOI 10.1038/nri3344
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Doyle T, 2015, NAT REV MICROBIOL, V13, P403, DOI 10.1038/nrmicro3449
   Elahi S, 2016, AIDS, V30, P171, DOI 10.1097/QAD.0000000000000917
   Elahi S, 2012, BLOOD, V119, P4192, DOI 10.1182/blood-2011-11-389585
   Farberov L, 2015, J CELL SCI, V128, P1607, DOI 10.1242/jcs.167817
   Feinberg MW, 2007, EMBO J, V26, P4138, DOI 10.1038/sj.emboj.7601824
   Feinberg MW, 2005, J BIOL CHEM, V280, P38247, DOI 10.1074/jbc.M509378200
   Fernandez S, 2011, J INFECT DIS, V204, P1927, DOI 10.1093/infdis/jir659
   Fu MG, 2017, NAT REV IMMUNOL, V17, P130, DOI 10.1038/nri.2016.129
   Garg A, 2015, BLOOD CELL MOL DIS, V55, P248, DOI 10.1016/j.bcmd.2015.07.009
   Happel C, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000998
   Hardy GAD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056527
   Harris RS, 2012, J BIOL CHEM, V287, P40875, DOI 10.1074/jbc.R112.416925
   Hyrcza MD, 2007, J VIROL, V81, P3477, DOI 10.1128/JVI.01552-06
   Jeltsch KM, 2014, NAT IMMUNOL, V15, P1079, DOI 10.1038/ni.3008
   Jura J, 2012, BBA-MOL CELL RES, V1823, P1905, DOI 10.1016/j.bbamcr.2012.06.029
   Kapoor N, 2015, J IMMUNOL, V194, P6011, DOI 10.4049/jimmunol.1402797
   Khanna AK, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-22
   Khanna AK, 2005, J IMMUNOL, V174, P7610, DOI 10.4049/jimmunol.174.12.7610
   Krishnan S, 2014, J INFECT DIS, V209, P931, DOI 10.1093/infdis/jit581
   Kumari N, 2014, ANTIMICROB AGENTS CH, V58, P6558, DOI 10.1128/AAC.02918-14
   Leng J, 2014, CELL HOST MICROBE, V15, P717, DOI 10.1016/j.chom.2014.05.011
   Li M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049841
   Li Y, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.66
   Liang J, 2008, J BIOL CHEM, V283, P6337, DOI 10.1074/jbc.M707861200
   Liang JA, 2010, J EXP MED, V207, P2959, DOI 10.1084/jem.20092641
   Liang J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002880
   Lichawska-Cieslar Agata, 2018, Oncotarget, V9, P8597, DOI 10.18632/oncotarget.24269
   Lin RJ, 2014, J IMMUNOL, V193, P4159, DOI 10.4049/jimmunol.1400337
   Lin RJ, 2013, NUCLEIC ACIDS RES, V41, P3314, DOI 10.1093/nar/gkt019
   Liu SF, 2013, P NATL ACAD SCI USA, V110, P19083, DOI 10.1073/pnas.1316208110
   Madlala P, 2018, J VIRUS ERAD, V4, P170
   Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924
   Moosa Y, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2961-8
   Morou A, 2019, NAT IMMUNOL, V20, P1059, DOI 10.1038/s41590-019-0418-x
   Pauls E, 2014, P NATL ACAD SCI USA, V111, pE1322, DOI 10.1073/pnas.1322059111
   R Core Team, 2018, R LANG ENV STAT COMP
   Rempel H, 2010, AIDS, V24, P1415, DOI 10.1097/QAD.0b013e32833ac623
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Riveira-Munoz E, 2014, J ANTIMICROB CHEMOTH, V69, P3057, DOI 10.1093/jac/dku276
   Rotger M, 2011, J CLIN INVEST, V121, P2391, DOI 10.1172/JCI45235
   Rotger M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000781
   Saez-Cirion A, 2011, BLOOD, V118, P955, DOI 10.1182/blood-2010-12-327106
   Santiago-Raber ML, 2001, J IMMUNOL, V167, P4067, DOI 10.4049/jimmunol.167.7.4067
   Scatizzi JC, 2009, EUR J IMMUNOL, V39, P820, DOI 10.1002/eji.200838683
   Sedaghat AR, 2008, J VIROL, V82, P1870, DOI 10.1128/JVI.02228-07
   Skalniak L, 2009, FEBS J, V276, P5892, DOI 10.1111/j.1742-4658.2009.07273.x
   Suzuki HI, 2011, MOL CELL, V44, P424, DOI 10.1016/j.molcel.2011.09.012
   Trakala M, 2009, EUR J IMMUNOL, V39, P810, DOI 10.1002/eji.200838676
   Uehata T, 2017, J INTERF CYTOK RES, V37, P220, DOI 10.1089/jir.2017.0001
   Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034
   Valle-Casuso JC, 2017, J VIROL, V91, DOI 10.1128/JVI.01324-17
   Van Hecke C, 2019, EBIOMEDICINE, V41, P1
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Vigneault F, 2011, J VIROL, V85, P3015, DOI 10.1128/JVI.01846-10
   Walker BD, 2013, NAT REV IMMUNOL, V13, P487, DOI 10.1038/nri3478
   Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266-7279.2001
   Wu JQ, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-361
   Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200
   Zhang JL, 2007, J CLIN INVEST, V117, P473, DOI 10.1172/JCI28971
   Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200
NR 77
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD JUL 2
PY 2020
VL 17
IS 1
AR 18
DI 10.1186/s12977-020-00522-4
PG 14
WC Virology
SC Virology
GA MM3NI
UT WOS:000550066300002
PM 32615986
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Hoagland, B
   Torres, TS
   Bezerra, DRB
   Geraldo, K
   Pimenta, C
   Veloso, VG
   Grinsztejn, B
AF Hoagland, Brenda
   Torres, Thiago S.
   Bezerra, Daniel R. B.
   Geraldo, Kim
   Pimenta, Cristina
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI Telemedicine as a tool for PrEP delivery during the COVID-19 pandemic in
   a large HIV prevention service in Rio de Janeiro-Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Telemedicine; PrEP; COVID-19; Brazil
AB COVID-19 public health responses such as social distancing and community containment measures protocols are critical to preventing and containing the spread of coronavirus. Brazil accounts for almost half of Latin American HIV cases and Rio de Janeiro is the city with the second largest number of AIDS. Clinical appointments and pharmacy antiretroviral refills may be impaired due to restricted traffic and possible lockdowns, preventing people living with HIV and those using PrEP from accessing needed antiretrovirals. We hereby describe the telemedicine procedures implemented in a large PrEP delivery service in Rio de janeiro in the context of the COVID-19 pandemic. At the initial teleconsultation, individuals under-goe HIV rapid testing and are assessed by phone for PrEP related procedures. Individuals receive a digital prescription to retrieve a 120-day PrEP supply plus two HIV self-test kits. Subsequent follow-up teleconsultations will be performed remotely by phone call, including instructions for the HIV self-test performance, which results are to be sent using a digital picture. Participants will attend the service only for PrEP refill. The use of telemedicine procedures is being effective to avoid PrEP shortage and reduce the time PrEP users spend at the service during the COVID-19 pandemic and social distancing recommendations. (C) 2020 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Hoagland, Brenda; Torres, Thiago S.; Bezerra, Daniel R. B.; Geraldo, Kim; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz INI Fiocruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Pimenta, Cristina] Brazilian Minist Hlth, Brasilia, DF, Brazil.
RP Hoagland, B (corresponding author), Fundacao Oswaldo Cruz INI Fiocruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
EM brenda.hoagland@ini.fiocruz.br; thiago.torres@ini.fiocruz.br;
   daniel.bezerra@ini.fiocruz.br; kim.geraldo@ini.fiocruz.br;
   cristina.pimenta@aids.gov.br; valdilea.veloso@ini.fiocruz.br;
   gbeatriz@ini.fiocruz.br
OI Geraldo, Kim/0000-0001-7788-405X; Goncalves Veloso dos Santos,
   Valdilea/0000-0002-6622-3165; Pimenta de Oliveira, Maria
   Cristina/0000-0002-4205-9786
FU ImPrEP project
FX The ImPrEP project was made possible, thanks to Unitaid's funding and
   support. Unitaid accelerates access to innovative health products and
   lays the foundations for their scale -up by countries and partners.
   Unitaid is a hosted partnership of the WHO.
CR [Anonymous], 2019, TIC DOMICILIOS 2018
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Jiang HB, 2020, LANCET HIV, V7, pE308, DOI 10.1016/S2352-3018(20)30105-3
   Kerr L, 2018, MEDICINE, V97, pS9, DOI [10.1097/MD.0000000000010573, 10.1097/md.0000000000010573]
   Luz PM, 2019, CURR OPIN HIV AIDS, V14, P366, DOI 10.1097/COH.0000000000000564
   Tones TS, 2019, CROI C
   Torres TS, 2019, AIDS CARE, V31, P1193, DOI 10.1080/09540121.2019.1619665
   Torres TS, 2019, JMIR PUBLIC HLTH SUR, V5, P177, DOI 10.2196/13771
   UNAIDS, UNAIDS DAT 2019
   Veloso V, 2019, J INT AIDS SOC, V22, DOI [10.1007/jia7.75377, DOI 10.1007/JIAS.25327]
   WHO, 2017, BRAZ BEGINS PREP ROL
NR 12
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUL-AUG
PY 2020
VL 24
IS 4
BP 360
EP 364
DI 10.1016/j.bjid.2020.05.004
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA NW2JT
UT WOS:000574836900014
PM 32504552
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Nunez-Saavedra, I
   Crabtree-Ramirez, B
   Shepherd, BE
   Sterling, TR
   Cahn, P
   Grinsztejn, B
   Cortes, CP
   Padgett, D
   Sierra-Madero, J
   McGowan, C
   Person, AK
   Caro-Vega, Y
AF Nunez-Saavedra, I.
   Crabtree-Ramirez, B.
   Shepherd, B. E.
   Sterling, T. R.
   Cahn, P.
   Grinsztejn, B.
   Cortes, C. P.
   Padgett, D.
   Sierra-Madero, J.
   McGowan, C.
   Person, A. K.
   Caro-Vega, Y.
CA Cent South Amer Network HIV Epidem
TI Late-onset opportunistic infections while on ART in Latin America
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Nunez-Saavedra, I.; Crabtree-Ramirez, B.; Sierra-Madero, J.; Caro-Vega, Y.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [Shepherd, B. E.; Sterling, T. R.; McGowan, C.; Person, A. K.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Cahn, P.] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Grinsztejn, B.] Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Cortes, C. P.] Fdn Arriaran, Santiago, Chile.
   [Padgett, D.] Hosp Escuela Univ, Tegucigalpa, Honduras.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
SU 4
SI SI
MA OAB0202
BP 13
EP 14
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MP1RO
UT WOS:000551988900028
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Marcy, O
   De Castro, N
   Chazallon, C
   Messou, E
   Eholie, S
   Bhatt, N
   Khosa, C
   Laureillard, D
   Do Chau, G
   Veloso, V
   Delaugerre, C
   Anglaret, X
   Grinsztejn, B
   Molina, JM
AF Marcy, O.
   De Castro, N.
   Chazallon, C.
   Messou, E.
   Eholie, S.
   Bhatt, N.
   Khosa, C.
   Laureillard, D.
   Do Chau, G.
   Veloso, V.
   Delaugerre, C.
   Anglaret, X.
   Grinsztejn, B.
   Molina, J. -M.
CA ANRS 12300 Reflate TB2 Study Grp
TI Adherence and factors associated with virologic success in HIV-1
   infected adults with tuberculosis receiving raltegravir or efavirenz in
   the ANRS 12300 Reflate TB2 trial
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Marcy, O.; Chazallon, C.; Anglaret, X.] Univ Bordeaux, Bordeaux Populat Hlth Ctr, INSERM, U1219, Bordeaux, France.
   [De Castro, N.; Delaugerre, C.; Molina, J. -M.] Hop St Louis, AP HP, Paris, France.
   [Messou, E.] CEPREF, Abidjan, Cote Ivoire.
   [Eholie, S.] CHU Treichville, SMIT, Abidjan, Cote Ivoire.
   [Bhatt, N.; Khosa, C.] Inst Nacl Saude, Maputo, Mozambique.
   [Laureillard, D.] CHU Nimes, Nimes, France.
   [Do Chau, G.] Pham Ngoc Thach Hosp, Ho Chi Minh City, Vietnam.
   [Veloso, V.; Grinsztejn, B.] Fiocruz MS, IPEC, Rio De Janeiro, Brazil.
RI Anglaret, Xavier/T-2757-2019
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
SU 4
SI SI
MA OAB0303
BP 16
EP 16
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MP1RO
UT WOS:000551988900033
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Veloso, VG
   Vega-Ramirez, EH
   Hoagland, B
   Konda, KA
   Bautista-Arredondo, S
   Guanira, JV
   Torres, T
   Oliveira, MCP
   Vernandere, H
   Farias, A
   Lacerda, MVG
   Benedetti, M
   Diaz, S
   Luz, PM
   Moreira, RI
   Moreira, J
   Leite, ID
   Grinsztejn, B
   Caceres, C
AF Veloso, V. G.
   Vega-Ramirez, E. H.
   Hoagland, B.
   Konda, K. A.
   Bautista-Arredondo, S.
   Guanira, J. V.
   Torres, T.
   Oliveira, M. C. P.
   Vernandere, H.
   Farias, A.
   Lacerda, M. V. G.
   Benedetti, M.
   Diaz, S.
   Luz, P. M.
   Moreira, R. I.
   Moreira, J.
   Leite, I. d. C.
   Grinsztejn, B.
   Caceres, C.
CA ImPrEP Study Team
TI Factors associated with early continuation (EC) of pre-exposure
   prophylaxis (PrEP) among young MSM (YMSM) in Brazil, Peru and Mexico:
   The ImPrEP Study
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Veloso, V. G.; Hoagland, B.; Torres, T.; Benedetti, M.; Luz, P. M.; Moreira, R. I.; Leite, I. d. C.; Grinsztejn, B.] INI Fiocruz, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Vega-Ramirez, E. H.] Natl Inst Psychiat Ramon de la Fuente Muniz, Mexico City, DF, Mexico.
   [Konda, K. A.; Caceres, C.] Univ Peruana Cayetano Heredia, Ctr Invest Interdisciplinaria Sexualidad Sida & S, Lima, Peru.
   [Bautista-Arredondo, S.; Vernandere, H.] Natl Inst Publ Hlth, Mexico City, DF, Mexico.
   [Guanira, J. V.] Invest Med Salud, Lima, Peru.
   [Oliveira, M. C. P.] Minist Hlth, Dept Chron Condit & STIs, Brasilia, DF, Brazil.
   [Farias, A.] Secretaria Estadual Saude, Ctr Estadual Especializado Diagnost Assistencia &, Salvador, BA, Brazil.
   [Lacerda, M. V. G.] Fundacao Med Trop Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Diaz, S.] United Nations Populat Fund, Mexico City, DF, Mexico.
   [Moreira, J.] Grp Arco Iris Cidadania LGBTI, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
SU 4
SI SI
MA OAC0505
BP 44
EP 44
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MP1RO
UT WOS:000551988900079
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Wilson, EC
   Jalil, EM
   Fernandez, NM
   Ferreira, AL
   Castro, CV
   Jalil, CM
   Kamel, L
   Moura, I
   Souza, C
   Bezerra, D
   Monteiro, L
   Veloso, VG
   Grinsztejn, B
AF Wilson, E. C.
   Jalil, E. M.
   Martinez Fernandez, N.
   Ferreira, A. L.
   Castro, C. V.
   Jalil, C. M.
   Kamel, L.
   Moura, I.
   Souza, C.
   Bezerra, D.
   Monteiro, L.
   Veloso, V. G.
   Grinsztejn, B.
TI Symbolic violence in healthcare as a barrier to HIV prevention and care
   for young trans women in Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Wilson, E. C.] Univ Calif San Francisco, San Francisco Dept Publ Hlth, Trans Res Unit Equ Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Jalil, E. M.; Martinez Fernandez, N.; Ferreira, A. L.; Castro, C. V.; Jalil, C. M.; Kamel, L.; Moura, I.; Souza, C.; Bezerra, D.; Monteiro, L.; Veloso, V. G.; Grinsztejn, B.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
SU 4
SI SI
MA OAD0105
BP 54
EP 54
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MP1RO
UT WOS:000551988900100
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Torres, TS
   Marins, LMS
   Bezerra, DRB
   Veloso, VG
   Grinsztejn, B
   Luz, PM
AF Torres, T. S.
   Marins, L. M. S.
   Bezerra, D. R. B.
   Veloso, V. G.
   Grinsztejn, B.
   Luz, P. M.
TI A call to improve understanding of Undetectable equals Untransmissible
   (U=U) slogan in Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Torres, T. S.; Marins, L. M. S.; Bezerra, D. R. B.; Veloso, V. G.; Grinsztejn, B.; Luz, P. M.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
SU 4
SI SI
MA PDD0507
BP 147
EP 148
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MP1RO
UT WOS:000551988900286
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Donnell, D
   Clement, M
   Hanscom, B
   Cottle, L
   Coelho, L
   Cabello, R
   Chariyalestak, S
   Dunne, E
   Frank, I
   Gaur, A
   Gonzalez, P
   Ha, TV
   Hinojosa, J
   Kallas, E
   Kelley, C
   Losso, M
   Madruga, JV
   Middelkoop, K
   Phanuphak, N
   Gallardo, J
   Santos, B
   Sued, O
   Huanami, JV
   Hucks-Ortiz, C
   Cardozo, N
   Monteiro, L
   Promjantuek, K
   Mvula, X
   Jones, D
   Eshleman, S
   Blanchette, C
   Lucas, J
   Scott, H
   Fields, S
   Gomez-Feliciano, K
   Jennings, A
   Rooney, J
   Spreen, W
   Margolis, D
   Rinehart, A
   Adeyeye, A
   Cohen, M
   McCauley, M
   Landovitz, R
   Vela, C
AF Grinsztejn, B.
   Donnell, D.
   Clement, M.
   Hanscom, B.
   Cottle, L.
   Coelho, L.
   Cabello, R.
   Chariyalestak, S.
   Dunne, E.
   Frank, I.
   Gaur, A.
   Gonzalez, P.
   Ha, T. V.
   Hinojosa, J.
   Kallas, E.
   Kelley, C.
   Losso, M.
   Madruga, J. Valdez
   Middelkoop, K.
   Phanuphak, N.
   Gallardo, J.
   Santos, B.
   Sued, O.
   Huanami, J. Valencia
   Hucks-Ortiz, C.
   Cardozo, N.
   Monteiro, L.
   Promjantuek, K.
   Mvula, X.
   Jones, D.
   Eshleman, S.
   Blanchette, C.
   Lucas, J.
   Scott, H.
   Fields, S.
   Gomez-Feliciano, K.
   Jennings, A.
   Rooney, J.
   Spreen, W.
   Margolis, D.
   Rinehart, A.
   Adeyeye, A.
   Cohen, M.
   McCauley, M.
   Landovitz, R.
   Vela, C.
CA HPTN 083 Study Team
TI HPTN 083 interim results: Efficacy of pre-exposure prophylaxis (PrEP)
   containing long-acting injectable cabotegravir (CAB-LA) is maintained
   across regions and key populations
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Grinsztejn, B.] Inst Nacl Infectol Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Donnell, D.; Hanscom, B.; Cottle, L.] Fred Hutchinson Canc Inst, Seattle, WA USA.
   [Clement, M.] Louisiana State Univ, Baton Rouge, LA 70803 USA.
   [Coelho, L.] Inst Pesquisa Clin Evandro Changas Fiocruz, Rio De Janeiro, Brazil.
   [Cabello, R.] Via Libre Clin Res Ctr, Lima, Peru.
   [Chariyalestak, S.] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Dunne, E.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Dunne, E.] Silom Clin, Bangkok, Thailand.
   [Frank, I.] Univ Penn, Philadelphia, PA 19104 USA.
   [Gaur, A.; Jones, D.] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Gonzalez, P.] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Ha, T. V.] Hlth Ctr Pho Yen, Pho Yen, Vietnam.
   [Hinojosa, J.; Vela, C.] Asociaci Civil Selva Amazon, Iquitos, Peru.
   [Kallas, E.] Univ Sao Paulo, Sao Paulo, SP, Brazil.
   [Kelley, C.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Losso, M.] Hosp Gen Agudos JM Ramos Mejia, Buenos Aires, DF, Argentina.
   [Madruga, J. Valdez] Sao Paulo DST AIDS CRS, Sao Paulo, Brazil.
   [Middelkoop, K.] Groote Schuur Hosp, Cape Town, South Africa.
   [Phanuphak, N.; Promjantuek, K.] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand.
   [Gallardo, J.] CITBM CRS, Lima, Peru.
   [Santos, B.] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Sued, O.; Cardozo, N.] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Huanami, J. Valencia] Barranco CRS, Lima, Peru.
   [Hucks-Ortiz, C.] JWCH Inst, Los Angeles, CA USA.
   [Monteiro, L.] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Mvula, X.] Univ Cape Town, Desmond Tutu HIV Ctr, Cape Town, South Africa.
   [Eshleman, S.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Blanchette, C.; Lucas, J.; Gomez-Feliciano, K.; Jennings, A.; McCauley, M.] FHI 360, Durham, NC USA.
   [Scott, H.] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Fields, S.] New York Inst Technol, Old Westbury, NY 11568 USA.
   [Rooney, J.] Gilead Sci, Foster City, CA USA.
   [Spreen, W.; Margolis, D.; Rinehart, A.] ViiV Healthcare, Durham, NC USA.
   [Adeyeye, A.] NIAID, Div AIDS, NIH, Clin Prevent Res Branch, Rockville, MD USA.
   [Cohen, M.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27515 USA.
   [Landovitz, R.] Univ Calif Los Angeles, UCLA Ctr Clin AIDS Res & Educ, Los Angeles, CA USA.
NR 0
TC 1
Z9 1
U1 2
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
SU 4
SI SI
MA OACLB0101
BP 174
EP 175
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MP1RO
UT WOS:000551988900334
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Landovitz, RJ
   Donnell, D
   Clement, M
   Hanscom, B
   Cottle, L
   Coelho, L
   Cabello, R
   Chariyalestak, S
   Dunne, E
   Frank, I
   Gallardo, J
   Gaur, A
   Gonzalez, P
   Ha, V
   Hinojosa, J
   Kallas, E
   Kelley, C
   Losso, M
   Madruga, JV
   Middelkoop, K
   Phanuphak, N
   Santos, B
   Sued, O
   Huanami, JV
   Overton, ET
   Swaminathan, S
   del Rio, C
   Gulick, R
   Richardson, P
   Sullivan, P
   Piwowar-Manning, E
   Marzinke, M
   Marrazzo, J
   Daar, E
   Asmelash, A
   Anderson, P
   Eshleman, S
   Blanchette, C
   Lucas, J
   Psaros, C
   Safren, S
   Sugarman, J
   Scott, H
   Eron, J
   Fields, S
   Gomez-Feliciano, K
   Jennings, A
   Shin, K
   Rooney, J
   Spreen, W
   Margolis, D
   Rinehart, A
   Adeyeye, A
   Cohen, M
   McCauley, M
   Grinsztejn, B
AF Landovitz, R. J.
   Donnell, D.
   Clement, M.
   Hanscom, B.
   Cottle, L.
   Coelho, L.
   Cabello, R.
   Chariyalestak, S.
   Dunne, E.
   Frank, I.
   Gallardo, J.
   Gaur, A.
   Gonzalez, P.
   Ha, V.
   Hinojosa, J.
   Kallas, E.
   Kelley, C.
   Losso, M.
   Valdez Madruga, J.
   Middelkoop, K.
   Phanuphak, N.
   Santos, B.
   Sued, O.
   Valencia Huanami, J.
   Overton, E. T.
   Swaminathan, S.
   Rio, C. del
   Gulick, R.
   Richardson, P.
   Sullivan, P.
   Piwowar-Manning, E.
   Marzinke, M.
   Marrazzo, J.
   Daar, E.
   Asmelash, A.
   Anderson, P.
   Eshleman, S.
   Blanchette, C.
   Lucas, J.
   Psaros, C.
   Safren, S.
   Sugarman, J.
   Scott, H.
   Eron, J.
   Fields, S.
   Gomez-Feliciano, K.
   Jennings, A.
   Shin, K.
   Rooney, J.
   Spreen, W.
   Margolis, D.
   Rinehart, A.
   Adeyeye, A.
   Cohen, M.
   McCauley, M.
   Grinsztejn, B.
CA HPTN 083 Study Team
TI HPTN083 interim results: Pre-exposure prophylaxis (PrEP) containing
   long-acting injectable cabotegravir (CAB-LA) is safe and highly
   effective for cisgender men and transgender women who have sex with men
   (MSM,TGW)
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Landovitz, R. J.] Univ Calif Los Angeles, UCLA Ctr Clin AIDS Res & Educ, Los Angeles, CA USA.
   [Donnell, D.; Hanscom, B.; Cottle, L.] Fred Hutchinson Canc Inst, Seattle, WA USA.
   [Clement, M.] Louisiana State Univ, Baton Rouge, LA 70803 USA.
   [Coelho, L.; Grinsztejn, B.] Inst Pesquisa Clin Evandro Changas Fiocruz, Rio De Janeiro, Brazil.
   [Cabello, R.] Via Libre Clin Res Ctr, Lima, Peru.
   [Chariyalestak, S.] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Dunne, E.] Ctr Dis Control & Prevent, Silom Clin Bangkok Thailand, Atlanta, GA USA.
   [Frank, I.] Univ Penn, Philadelphia, PA 19104 USA.
   [Gallardo, J.] CITBM CRS, Lima, Peru.
   [Gaur, A.] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Gonzalez, P.] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Ha, V.] Yen Hoa Clin, Hanoi, Vietnam.
   [Hinojosa, J.] Asociaci Civil Selva Amazon, Iquitos, Peru.
   [Kallas, E.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Kelley, C.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Losso, M.] Hosp Gen Agudos JM Ramos Mejia, Buenos Aires, DF, Argentina.
   [Valdez Madruga, J.] Sao Paulo DST AIDS CRS, Sao Paulo, Brazil.
   [Middelkoop, K.] Groote Schuur Hosp, Cape Town, South Africa.
   [Phanuphak, N.] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand.
   [Santos, B.] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Sued, O.] Fundac Huesped, Buenos Aires, DF, Argentina.
   [Valencia Huanami, J.] Barranco CRS, Lima, Peru.
   [Overton, E. T.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Swaminathan, S.] Rutgers New Jersey Med Sch, Newark, NJ USA.
   [Rio, C. del] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Gulick, R.] Cornell Univ, Div Infect Dis, Weill Med Coll, New York, NY USA.
   [Richardson, P.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA.
   [Sullivan, P.; Piwowar-Manning, E.; Marzinke, M.] Johns Hopkins Univ, Baltimore, MD USA.
   [Marrazzo, J.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
   [Daar, E.] Harbor UCLA Med Ctr, Lundquist Inst, Los Angeles, CA USA.
   [Asmelash, A.; Blanchette, C.; Lucas, J.; Gomez-Feliciano, K.; Jennings, A.; McCauley, M.] FHI 360, Washington, DC USA.
   [Anderson, P.] Univ Colorado, Anschutz Campus, Aurora, CO USA.
   [Eshleman, S.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Psaros, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Safren, S.] Univ Miami, Miami, FL USA.
   [Sugarman, J.] Johns Hopkins Berman Inst Bioeth, Baltimore, MD USA.
   [Scott, H.] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Eron, J.] Univ N Carolina, Div Infect Dis, Chapel Hill, NC 27515 USA.
   [Fields, S.] New York Inst Technol, Old Westbury, NY 11568 USA.
   [Shin, K.] Pharmaceut Affairs Branch, Div AIDS, Rockville, MD USA.
   [Rooney, J.] Gilead Sci, Foster City, CA USA.
   [Spreen, W.; Margolis, D.; Rinehart, A.] ViiV Healthcare, Durham, NC USA.
   [Adeyeye, A.] NIAID, Div AIDS, NIH, Clin Prevent Res Branch, Rockville, MD USA.
   [Cohen, M.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27515 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
SU 4
SI SI
MA OAXLB0101
BP 183
EP 183
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MP1RO
UT WOS:000551988900349
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Landovitz, RJ
   Li, S
   Eron, JJ
   Grinsztejn, B
   Dawood, H
   Liu, AY
   Magnus, M
   Hosseinipour, MC
   Panchia, R
   Cottle, L
   Chau, G
   Richardson, P
   Marzinke, MA
   Eshleman, SH
   Kofron, R
   Adeyeye, A
   Burns, D
   Rinehart, AR
   Margolis, D
   Cohen, MS
   McCauley, M
   Hendrix, CW
AF Landovitz, Raphael J.
   Li, Sue
   Eron Jr, Joseph J.
   Grinsztejn, Beatriz
   Dawood, Halima
   Liu, Albert Y.
   Magnus, Manya
   Hosseinipour, Mina C.
   Panchia, Ravindre
   Cottle, Leslie
   Chau, Gordon
   Richardson, Paul
   Marzinke, Mark A.
   Eshleman, Susan H.
   Kofron, Ryan
   Adeyeye, Adeola
   Burns, David
   Rinehart, Alex R.
   Margolis, David
   Cohen, Myron S.
   McCauley, Marybeth
   Hendrix, Craig W.
TI Tail-phase safety, tolerability, and pharmacokinetics of long-acting
   injectable cabotegravir in HIV-uninfected adults: a secondary analysis
   of the HPTN 077 trial
SO LANCET HIV
LA English
DT Article
ID PREEXPOSURE PROPHYLAXIS; INFECTION; MEN
AB Background Long-acting injectable cabotegravir is a novel integrase inhibitor currently in advanced clinical development for HIV prevention and treatment. We aimed to assess the terminal phase pharmacokinetics and safety of long-acting injectable cabotegravir in participants included in the HPTN 077 trial. Methods HPTN 077 was a multicentre, double-blind, randomised, placebo-controlled phase 2a trial done at eight sites in Brazil, Malawi, South Africa, and the USA. Participants (aged 18-65 years), who were HIV-uninfected and at low-risk for HIV, were randomly assigned (3:1) to long-acting injectable cabotegravir (800 mg given three times at 12 week intervals or 600 mg given five times, administered at one 4 week interval, and every 8 weeks thereafter) or placebo. Participants were followed up to 76 weeks after final injection. In a prespecified analysis of secondary and exploratory outcomes, we assessed the safety, measured by the proportion of participants with grade 2 or worse adverse events, and pharmacokinetics, measured by apparent terminal phase half-life (t(1/2app)) and estimated time to lower limit of quantification (LLOQ) of long-acting injectable cabotegravir during the injection phase (defined as the time between first injection and 12 weeks or 8 weeks after the last injection in cohort 1 or cohort 2 respectively) and tail phase (defined as the time between final injection and 52-76 weeks post-final injection). Safety was analysed in all participants who received at least one injection. Pharmacokinetic analyses included all participants who had received at least one injection and had at least three cabotegravir measurements higher than the LLOQ after the final injection. Pharmacokinetic outcomes were estimated using non-compartmental methods. The trial is completed, and was registered with ClinicalTrials.gov, NCT02178800. Findings Between Feb 9, 2015, and May 27, 2016, 177 participants (134 participants in the cabotegravir group [74 participants in cohort 1; 60 participants in cohort 2] and 43 participants in the placebo group [25 participants in cohort 1; 18 participants in cohort 2) were enrolled and received at least one injection and thus were included in the safety analysis. The incidence of grade 2 or worse adverse events was significantly lower during the tail phase than the injection phase (p<0.0001). At 52-60 weeks after final injection, nine (23%) of 40 male participants had detectable cabotegravir concentrations and at week 76, four (13%) of 30 male participants had detectable cabotegravir concentrations compared with 52 (63%) of 82 female participants and 27 (42%) of 64 female participants at the same timepoints. The median time from the last injection to the time when cabotegravir concentration decreased below the LLOQ was 43.7 weeks (IQR 31.1-66.6; range 20.4-152.5) for male participants and 67.3 weeks (29.1-89.6; 17.7-225.5) for female participants (p=0.0003). t(1/2app) was longer for female participants than male participants (geometric mean fold-change 1.33, 95% CI 1.06-1.68; p=0.014), and longer for participants with a high body-mass index (BMI) than those with a low BMI (1.31, 1.06-1.63; p=0.015). Interpretation The clinical significance of the long pharmacokinetic tail of cabotegravir observed in female participants compared with male participants, and those with higher BMI compared with a lower BMI, need to be addressed in future trials.
C1 [Landovitz, Raphael J.; Kofron, Ryan] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Ctr Clin AIDS Res & Educ, Los Angeles, CA 90025 USA.
   [Li, Sue; Cottle, Leslie; Chau, Gordon] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, 1124 Columbia St, Seattle, WA 98104 USA.
   [Eron Jr, Joseph J.; Cohen, Myron S.] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Dawood, Halima] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Durban, South Africa.
   [Liu, Albert Y.] San Francisco Dept Hlth, Bridge HIV, Populat Hlth Div, San Francisco, CA USA.
   [Magnus, Manya] George Washington Univ, Sch Publ Hlth, Milken Inst, Dept Epidemiol, Washington, DC USA.
   [Hosseinipour, Mina C.] Univ North Carolina Project Malawi, Lilongwe, Malawi.
   [Panchia, Ravindre] Chris Hani Baragwanath Hosp, Perinatal HIV Res Unit, Soweto, South Africa.
   [Richardson, Paul; Marzinke, Mark A.; Eshleman, Susan H.; Hendrix, Craig W.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Adeyeye, Adeola; Burns, David] NIAID, Div Aids, NIH, Rockville, MD USA.
   [Rinehart, Alex R.; Margolis, David] ViiV Healthcare, Durham, NC USA.
   [McCauley, Marybeth] FHI 360, Washington, DC USA.
RP Landovitz, RJ (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Ctr Clin AIDS Res & Educ, Los Angeles, CA 90025 USA.
EM rlandovitz@mednet.ucla.edu
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
FX National Institute of Allergy and Infectious Diseases.
CR Andrews CD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010298
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Babor T.F., 1992, ALCOHOL USE DISORDER
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Center for Drug Evaluation and Research Center for Veterinary Medicine, 2001, GUID IND BIOAN METH
   Cohen SE, 2019, LANCET HIV, V6, pE43, DOI 10.1016/S2352-3018(18)30288-1
   Colby DJ, 2018, CLIN INFECT DIS, V67, P962, DOI 10.1093/cid/ciy321
   DiFrancesco R, 2013, CLIN PHARMACOL THER, V93, P479, DOI 10.1038/clpt.2013.62
   Division of AIDS National Institute of Allergy and Infectious Diseases National Institutes of Health US Department of Health and Human Services, 2014, DIV AIDS DAIDS TABL
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hoornenborg E, 2017, LANCET HIV, V4, pE522, DOI 10.1016/S2352-3018(17)30132-7
   Knox DC, 2017, NEW ENGL J MED, V376, P501, DOI 10.1056/NEJMc1611639
   Landovitz RJ, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002690
   Margolis DA, 2017, LANCET, V390, P1499, DOI 10.1016/S0140-6736(17)31917-7
   MARKOWITZ M, 2017, J ACQ IMMUN DEF SYND, V76, pE10
   Markowitz M, 2017, LANCET HIV, V4, pE331, DOI 10.1016/S2352-3018(17)30068-1
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Radzio J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010297
   Spreen W, 2015, C RETR OPP INF SEATT
   Thaden JT, 2018, AIDS, V32, pF1, DOI 10.1097/QAD.0000000000001825
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Villard PH, 1998, PHARMACOL TOXICOL, V82, P74, DOI 10.1111/j.1600-0773.1998.tb01401.x
NR 23
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD JUL
PY 2020
VL 7
IS 7
BP E472
EP E481
DI 10.1016/S2352-3018(20)30106-5
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MG0BF
UT WOS:000545700100012
PM 32497491
DA 2020-11-24
ER

PT J
AU Godfrey, C
   Hughes, MD
   Ritz, J
   Coelho, L
   Gross, R
   Salata, R
   Mngqibisa, R
   Wallis, CL
   Mumbi, ME
   Matoga, M
   Poongulali, S
   Van Schalkwyk, M
   Hogg, E
   Fletcher, CV
   Grinsztejn, B
   Collier, AC
AF Godfrey, Catherine
   Hughes, Michael D.
   Ritz, Justin
   Coelho, Lara
   Gross, Robert
   Salata, Robert
   Mngqibisa, Rosie
   Wallis, Carole L.
   Mumbi, Makanga. E.
   Matoga, Mitch
   Poongulali, Selvamuthu
   Van Schalkwyk, Marije
   Hogg, Evelyn
   Fletcher, Courtney V.
   Grinsztejn, Beatriz
   Collier, Ann C.
CA A5288 Team
TI Brief Report: Sex Differences in Outcomes for Individuals Presenting for
   Third-Line Antiretroviral Therapy
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE women; LMIC; sex differences; third-line ART; HIV; women with HIV
ID RITONAVIR; GENDER; PHARMACOKINETICS
AB Background: Sex differences in studies of antiretroviral (ART) drug exposure and treatment outcomes support the hypothesis that some ART combinations may not be well tolerated in women. We evaluated disparities in outcomes between men and women participating in ACTG A5288, an interventional strategy trial for individuals failing a protease inhibitor-based second-line ART regimen in low- and middle-income countries. Methods: Participants were assigned to one of 4 cohorts (A-D) based on resistance profiles and ART history. Cohort A had no lopinavir/ritonavir (LPV/r) resistance and stayed on their second-line regimen, and cohorts B, C, and D had increasing resistance and accessed novel ART regimens. In this secondary analysis, we evaluated sex differences in the primary endpoint, HIV-1 RNA <= 200 copies/mL at week 48; confirmed virologic failure >= 1000 copies/mL (VF); and clinical outcomes and adverse events (intent-to-treat). Results: Women made up 258/545 (47%) of the study population. More women than men were assigned to cohort A. Median follow-up was 72 weeks. Fewer women than men had HIV-1 RNA <= 200 copies/mL at week 48: 39% vs. 49% in cohort A and 83% vs. 89% in cohorts B, C, and D combined. More women experienced VF, grade >= 3 signs and symptoms, but similar grade >= 3 diagnoses or laboratory abnormalities. Conclusions: More women than men entered the study with a resistance profile suggesting that their second-line regimen could have been effective in maintaining virologic suppression. The more frequent occurrence of grade >= 3 signs and symptoms in women suggests that tolerability issues were under recognized in women on protease inhibitor-based therapy.
C1 [Godfrey, Catherine] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA.
   [Hughes, Michael D.; Ritz, Justin] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
   [Coelho, Lara; Grinsztejn, Beatriz] Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Gross, Robert] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Salata, Robert] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Mngqibisa, Rosie] Durban Int CRS, Enhancing Care Fdn, Durban, South Africa.
   [Wallis, Carole L.] Lancet Labs, Johannesburg, South Africa.
   [Wallis, Carole L.] BARC SA, Johannesburg, South Africa.
   [Mumbi, Makanga. E.] KEMRI Ctr Global Hlth Res, Kisumu, Kenya.
   [Matoga, Mitch] UNC Project, Lilongwe, Malawi.
   [Poongulali, Selvamuthu] Voluntary Hlth Serv, CART Clin Res Site, Chennai, Tamil Nadu, India.
   [Van Schalkwyk, Marije] Stellenbosch Univ, CRS, FAM CRU, Cape Town, South Africa.
   [Hogg, Evelyn] Social & Sci Syst, Silver Spring, MD USA.
   [Fletcher, Courtney V.] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Collier, Ann C.] Univ Washington, Sch Med, Seattle, WA USA.
RP Godfrey, C (corresponding author), US Dept State, Off Global AIDS Coordinator, S GAC, 1800 G St,NW, Washington, DC 20003 USA.
EM qea0@cdc.gov
OI Wallis, Carole/0000-0001-8408-8772
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1 AI068634, UM1 AI068636,
   UM1 AI106701]
FX Supported by the National Institute of Allergy and Infectious Diseases
   of the National Institutes of Health under Award Number UM1 AI068634,
   UM1 AI068636, and UM1 AI106701. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the National Institutes of Health.
CR Currier J, 2010, ANN INTERN MED, V153, P349, DOI 10.7326/0003-4819-153-6-201009210-00002
   Fletcher CV, 2004, J INFECT DIS, V189, P1176, DOI 10.1086/382754
   Grinsztejn B, 2019, LANCET HIV, V6, pE588, DOI 10.1016/S2352-3018(19)30146-8
   Krecic-Shepard ME, 2000, J CLIN PHARMACOL, V40, P219, DOI 10.1177/00912700022008883
   Levison JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032144
   Mazhude C, 2002, AIDS, V16, P1566, DOI 10.1097/00002030-200207260-00020
   Ofotokun I, 2007, GENDER MED, V4, P106, DOI 10.1016/S1550-8579(07)80025-8
   Pillay P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068995
   Smith KY, 2014, CLIN INFECT DIS, V58, P555, DOI 10.1093/cid/cit747
   Squires KE, 2011, J ANTIMICROB CHEMOTH, V66, P363, DOI 10.1093/jac/dkq457
   Sundaram M, 2009, J INFECTION, V58, P255, DOI 10.1016/j.jinf.2009.01.003
   Thunander S. L., 2012, PHARM PRACT, V10, P207, DOI DOI 10.4321/S1886-36552012000400005
   Umeh OC, 2011, J CLIN PHARMACOL, V51, P1665, DOI 10.1177/0091270010388650
   WHO, 2019, HIV DRUG RES REP 201
NR 14
TC 0
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN 1
PY 2020
VL 84
IS 2
BP 203
EP 207
DI 10.1097/QAI.0000000000002324
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA NP6AC
UT WOS:000570256000010
PM 32049773
DA 2020-11-24
ER

PT J
AU Belaunzaran-Zamudio, PF
   Caro-Vega, YN
   Shepherd, BE
   Rebeiro, PF
   Crabtree-Ramirez, BE
   Cortes, CP
   Grinsztejn, B
   Gotuzzo, E
   Mejia, F
   Padgett, D
   Pape, JW
   Rouzier, V
   Veloso, V
   Cardoso, SW
   McGowan, CC
   Sierra-Madero, JG
AF Belaunzaran-Zamudio, Pablo F.
   Caro-Vega, Yanink N.
   Shepherd, Bryan E.
   Rebeiro, Peter F.
   Crabtree-Ramirez, Brenda E.
   Cortes, Claudia P.
   Grinsztejn, Beatriz
   Gotuzzo, Eduardo
   Mejia, Fernando
   Padgett, Denis
   Pape, Jean W.
   Rouzier, Vanessa
   Veloso, Valdilea
   Wagner Cardoso, Sandra
   McGowan, Catherine C.
   Sierra-Madero, Juan G.
CA Caribbean Cent South Amer Network
TI The Population Impact of Late Presentation With Advanced HIV Disease and
   Delayed Antiretroviral Therapy in Adults Receiving HIV Care in Latin
   America
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE acquired immune deficiency syndrome; adult; early diagnosis; HIV
   infection; Latin America; retrospective studies
ID ATTRIBUTABLE RISK; BRITISH-COLUMBIA; UNIVERSAL ACCESS; MORTALITY;
   INITIATION; HAART; RETENTION; CANADA; MEXICO; BRAZIL
AB Late presentation to care and antiretroviral therapy (ART) initiation with advanced human immunodeficiency virus (HIV) disease are common in Latin America. We estimated the impact of these conditions on mortality in the region. We included adults enrolled during 2001-2014 at HIV care clinics. We estimated the adjusted attributable risk (AR) and population attributable fraction (PAF) for all-cause mortality of presentation to care with advanced HIV disease (advanced LP), ART initiation with advanced HIV disease, and not initiating ART. Advanced HIV disease was defined as CD4 of <200 cells/mu L or acquired immune deficiency syndrome. AR and PAF were derived using marginal structural models. Of 9,229 patients, 56% presented with advanced HIV disease. ARs of death for advanced LP were 86%, 71%, and 58%, and PAFs were 78%, 58%, and 43% at 1, 5, and 10 years after enrollment. Among people without advanced LP, ARs of death for delaying ART were 39%, 32%, and 37% at 1, 5, and 10 years post-enrollment and PAFs were 20%, 14%, and 15%. Among people with advanced LP, ART decreased the hazard of death by 63% in the first year after enrollment, but 93% of these started ART; thus universal ART among them would reduce mortality by only 10%. Earlier presentation to care and earlier ART initiation would prevent most HIV deaths in Latin America.
C1 [Belaunzaran-Zamudio, Pablo F.; Caro-Vega, Yanink N.; Crabtree-Ramirez, Brenda E.; Sierra-Madero, Juan G.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Calle Vasco de Quiroga 15,Secc 16, Mexico City 14080, DF, Mexico.
   [Shepherd, Bryan E.; Rebeiro, Peter F.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.
   [Rebeiro, Peter F.; McGowan, Catherine C.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN USA.
   [Cortes, Claudia P.] Univ Chile, Fdn Arriaran, Santiago, Chile.
   [Grinsztejn, Beatriz; Veloso, Valdilea; Wagner Cardoso, Sandra] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Gotuzzo, Eduardo; Mejia, Fernando] Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Padgett, Denis] Inst Hondureno Seguridad Social & Hosp Escuela, Tegucigalpa, Honduras.
   [Pape, Jean W.; Rouzier, Vanessa] Grp Haitien Etud Sarcome Kaposi & Infect Opportun, Port Au Prince, Haiti.
RP Caro-Vega, YN (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Calle Vasco de Quiroga 15,Secc 16, Mexico City 14080, DF, Mexico.
EM yanink.caro@infecto.mx
OI Crabtree-Ramirez, Brenda/0000-0002-2587-1123
FU NIH-funded Caribbean, Central and South America network for HIV
   epidemiology (CCASAnet), a member cohort of the International
   Epidemiologic Databases to Evaluate AIDS (leDEA)United States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [U01AI069923]; Eunice Kennedy Shriver National Institute of Child Health
   and Human Development, National Cancer Institute, National Institute of
   Allergy and Infectious Diseases, National Institute of Mental Health;
   Office of the Director, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923] Funding Source: NIH RePORTER
FX This work was supported by the NIH-funded Caribbean, Central and South
   America network for HIV epidemiology (CCASAnet), a member cohort of the
   International Epidemiologic Databases to Evaluate AIDS (leDEA) (grant
   U01AI069923). This award is funded by the following institutes: Eunice
   Kennedy Shriver National Institute of Child Health and Human
   Development, National Cancer Institute, National Institute of Allergy
   and Infectious Diseases, National Institute of Mental Health, and the
   Office of the Director, National Institutes of Health.
CR Antinori A, 2011, HIV MED, V12, P61, DOI 10.1111/j.1468-1293.2010.00857.x
   Belaunzaran-Zamudio P, 2019, HIV HEP AM 2019 BOG
   Bigogo G, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-376
   Braitstein P, 2006, LANCET, V367, P817
   Cain LE, 2010, INT J BIOSTAT, V6, DOI 10.2202/1557-4679.1212
   Carriquiry G, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20016
   Chen YQ, 2006, BIOSTATISTICS, V7, P515, DOI 10.1093/biostatistics/kxj023
   Cheung CC, 2016, HIV MED, V17, P694, DOI 10.1111/hiv.12379
   Cox C, 2006, STAT METHODS MED RES, V15, P611, DOI 10.1177/0962280206071930
   Crabtree-Ramirez B, 2012, SALUD PUBLICA MEXICO, V54, P506, DOI 10.1590/S0036-36342012000500007
   Crabtree-Ramirez B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020272
   da Silva DST, 2017, AIDS CARE, V29, P263, DOI 10.1080/09540121.2016.1211610
   Govindasamy D, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19032
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Haneuse S, 2019, JAMA-J AM MED ASSOC, V321, P602, DOI 10.1001/jama.2018.21554
   Harrell Jr FE, 2015, REGRESSION MODELING
   Hernan MA, 2006, BASIC CLIN PHARMACOL, V98, P237, DOI 10.1111/j.1742-7843.2006.pto_329.x
   Hernan MA, 2000, EPIDEMIOLOGY, V11
   Hernandez-Avila JE, 2015, JAIDS-J ACQ IMM DEF, V69, pe100, DOI 10.1097/QAI.0000000000000645
   Jani IV, 2011, LANCET, V378, P1572, DOI 10.1016/S0140-6736(11)61052-0
   Joint United Nations Programme on HIV/AIDS, 2019, IND AIDS REL DEATHS
   Joint United Nations Programme on HIV/AIDS, AIDSINFO GLOB AIDS M
   Joint United Nations Programme on HIV/AIDS, 2014, GAP REP 2014
   Magis-Rodriguez CL, 2015, SALUD PUBLICA MEXICO, V57, pS127
   Lima VD, 2015, LANCET HIV, V2, pE92, DOI 10.1016/S2352-3018(15)00017-X
   Lin H, 2013, AM J PUB HLTH, V103
   Luz PM, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-278
   MacPherson P, 2014, JAMA-J AM MED ASSOC, V312, P372, DOI 10.1001/jama.2014.6493
   Martin-Onraet A, 2015, SALUD PUBLICA MEXICO, V57, pS163
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617
   Ministerio de Salud y Desarrollo Social, 2019, B EP VIH SID ITS ARG, V31
   Ministerio de Salud y Proteccion Social Republica de Colombia, 2014, INF GARPR 2014
   Mocroft A, 2015, EURO SURVEILL, V20
   Morgenstern H, 1982, J Community Health, V7, P292, DOI 10.1007/BF01318961
   Mosqueda JL, 2015, J INT AIDS SOC, V18
   Op de Cou ELM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009688
   Pai NP, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001414
   Ruiz G, 2016, SPAN J PSYCHOL, V19, P1, DOI 10.1017/sjp.2016.73
   Suthar AB, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001496
   Valentini MB, 2015, BRAZ J INFECT DIS, V19, P253, DOI 10.1016/j.bjid.2015.01.005
   WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268
   Warley E, 2012, MEDICINA-BUENOS AIRE, V72, P367
   World Health Organization, CONS GUID US ANT DRU
NR 44
TC 2
Z9 2
U1 2
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN
PY 2020
VL 189
IS 6
BP 564
EP 572
DI 10.1093/aje/kwz252
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NO3DC
UT WOS:000569363500012
PM 31667488
DA 2020-11-24
ER

PT J
AU Castro, R
   De Boni, RB
   Perazzo, H
   Grinsztejn, B
   Veloso, VG
   Ribeiro-Alves, M
AF Castro, Rodolfo
   De Boni, Raquel B.
   Perazzo, Hugo
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Ribeiro-Alves, Marcelo
TI Development of algorithms to estimate EQ-5D and derive health utilities
   from WHOQOL-HIV Bref: a mapping study
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Health-related quality of life; Algorithms; Cost-utility analysis;
   Health economics
ID QUALITY-OF-LIFE; OUTCOME MEASURES; EUROQOL; QUESTIONNAIRE; VALIDITY;
   PEOPLE; SCORES; VALUES
AB Purpose
   This study aimed to develop and evaluate different families of applicable models available for utility mapping between World Health Organization Quality of Life for HIV-abbreviated version (WHOQOL-HIV Bref) and EQ-5D-3L and to propose an optimised algorithm to estimate health utilities of people living with HIV. Methods Estimation dataset was collected between July 2014 and September 2016 in a cross-sectional study including 1526 people living with HIV/Aids (PLWH) under care at the Instituto Nacional de Infectologia Evandro Chagas-FIOCRUZ, in Brazil. Data of WHOQOL-HIV Bref and EQ-5D-3L questionnaires were collected. Fisher's exact tests were used for testing WHOQOL-HIV Bref response frequencies among groups of responses to each of the five EQ-5D-3L domains. Multiple correspondence analyses (MCA) were used to inspect the relationships between both instrument responses. Different families of applicable models available for utility mapping between WHOQOL-HIV Bref and EQ-5D-3L were adjusted for the prediction of disutility. Results Candidate models' performances using mean absolute error (MAE), mean squared error (MSE), and root mean squared error (RMSE) were similarly good, which was evidenced by the overlapping of its 95% confidence intervals of the mean tenfold cross-validation or estimated generalisation errors. However, the Hurdle Logistic-Log-Normal model was better on average according to generalisation errors both in the prediction of Brazilian utility values (MAE = 0.1037, MSE = 0.0178, and RMSE = 0.1332) and for those of the UK (MAE = 0.1476, MSE = 0.0443, and RMSE = 0.2099). Conclusions Mapping EQ-5D-3L responses or deriving health utilities directly from WHOQOL-HIV Bref responses can be a valid alternative for settings with no preference-based health utility data.
C1 [Castro, Rodolfo] Fundacao Oswaldo Cruz, FIOCRUZ, Escola Nacl Saude Publ Sergio Arouca, Rua Leopoldo Bulhoes 1480, BR-21041210 Rio De Janeiro, RJ, Brazil.
   [Castro, Rodolfo] Univ Fed Estado Rio de Janeiro, UNIRIO, Inst Saude Colet, Rio De Janeiro, RJ, Brazil.
   [De Boni, Raquel B.; Perazzo, Hugo; Grinsztejn, Beatriz; Veloso, Valdilea G.; Ribeiro-Alves, Marcelo] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
RP Castro, R (corresponding author), Fundacao Oswaldo Cruz, FIOCRUZ, Escola Nacl Saude Publ Sergio Arouca, Rua Leopoldo Bulhoes 1480, BR-21041210 Rio De Janeiro, RJ, Brazil.; Castro, R (corresponding author), Univ Fed Estado Rio de Janeiro, UNIRIO, Inst Saude Colet, Rio De Janeiro, RJ, Brazil.
EM rodolfo.castro@fiocruz.br
RI Castro, Rodolfo/D-4231-2013; DE BONI, RAQUEL BRANDINI/D-4212-2013
OI Castro, Rodolfo/0000-0002-0701-2528; DE BONI, RAQUEL
   BRANDINI/0000-0002-2455-5997; Goncalves Veloso dos Santos,
   Valdilea/0000-0002-6622-3165; Ribeiro-Alves,
   Marcelo/0000-0002-8663-3364; Perazzo, Hugo/0000-0003-0931-6418
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [476024/2013-7, 476333/2013-0]; Fundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); Newton Fund RCUK-CONFAP Research Partnerships call
   [E-26/170.021/2015]
FX This study was funded by Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq)-Grant Numbers: 476024/2013-7, 476333/2013-0; and
   Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ), Newton Fund RCUK-CONFAP Research Partnerships call,
   Grant Number: E-26/170.021/2015. These funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ali FM, 2017, QUAL LIFE RES, V26, P3025, DOI 10.1007/s11136-017-1607-4
   [Anonymous], 2018, R LANG ENV STAT COMP
   Benzaken AS, 2019, AIDS RES THER, V16, DOI 10.1186/s12981-019-0234-2
   Castro R, 2019, QUAL LIFE RES, V28, P1035, DOI 10.1007/s11136-018-2044-8
   Collado-Mateo D, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0690-0
   Cooper V, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0778-6
   Crott R, 2018, PHARMACOECON-OPEN, V2, P165, DOI 10.1007/s41669-017-0049-9
   Dakin H, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0857-3
   Dakin H, 2013, QUAL LIFE RES, V22, P683, DOI 10.1007/s11136-012-0189-4
   de Noordhout CM, 2017, ARCH PUBLIC HEALTH, V75, DOI 10.1186/s13690-017-0174-z
   Dessie ZG, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-04972-1
   Dunn PK, 2008, STAT COMPUT, V18, P73, DOI 10.1007/s11222-007-9039-6
   Dunn PK, 2005, STAT COMPUT, V15, P267, DOI 10.1007/s11222-005-4070-y
   Engelhard EAN, 2018, AIDS, V32, P103, DOI [10.1097/QAD.0000000000001672, 10.1097/qad.0000000000001672]
   Feng Y, 2014, QUAL LIFE RES, V23, P977, DOI 10.1007/s11136-013-0537-z
   Gabbe BJ, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0047-z
   Gray AM, 2006, MED DECIS MAKING, V26, P18, DOI 10.1177/0272989X05284108
   Gueler A, 2017, AIDS, V31, P427, DOI 10.1097/QAD.0000000000001335
   Hua AY, 2018, KNEE SURG SPORT TR A, V26, P3083, DOI 10.1007/s00167-018-4954-y
   Joyce Vilija R, 2017, MDM Policy Pract, V2, p2381468317716440, DOI 10.1177/2381468317716440
   Kent S, 2015, MED DECIS MAKING, V35, P902, DOI 10.1177/0272989X15584921
   Kiadaliri AA, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0547-y
   Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01
   Maheswaran H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192991
   Mpundu-Kaambwa C, 2017, PHARMACOECONOMICS, V35, P453, DOI 10.1007/s40273-016-0476-y
   Mukuria C, 2019, APPL HEALTH ECON HEA, V17, P295, DOI 10.1007/s40258-019-00467-6
   National Institute for Health and Care Excellence United Kingdom, 2013, GUID METH TECHN APPR
   O'Connell KA, 2012, AIDS BEHAV, V16, P452, DOI 10.1007/s10461-010-9863-0
   Parsons TD, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-11
   Petrou S, 2016, QUAL LIFE RES, V25, P275, DOI 10.1007/s11136-015-1082-8
   Petrou S, 2015, PHARMACOECONOMICS, V33, P993, DOI 10.1007/s40273-015-0312-9
   Poudel A, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-016-1191-0
   Rencz F, 2016, QUAL LIFE RES, V25, P2693, DOI 10.1007/s11136-016-1375-6
   Round J, 2017, PHARMACOECON-OPEN, V1, P233, DOI 10.1007/s41669-017-0027-2
   Santos M, 2016, MED DECIS MAKING, V36, P253, DOI 10.1177/0272989X15613521
   Sassi F, 2006, HEALTH POLICY PLANN, V21, P402, DOI 10.1093/heapol/czl018
   Shi Y, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1135-8
   Therneau T, 2000, MODELING SURVIVAL DA
   Wee HL, 2018, MED DECIS MAKING, V38, P319, DOI 10.1177/0272989X18756890
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Wong CKH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175847
NR 41
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD SEP
PY 2020
VL 29
IS 9
BP 2497
EP 2508
DI 10.1007/s11136-020-02534-1
EA MAY 2020
PG 12
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA ND3BB
UT WOS:000535430800002
PM 32451983
DA 2020-11-24
ER

PT J
AU Boettiger, DC
   Escuder, MM
   Law, MG
   Veloso, V
   Souza, RA
   Ikeda, MLR
   de Alencastro, PR
   Tupinambas, U
   Brites, C
   Grinsztejn, B
   Ggomes, JO
   Ribeiro, S
   McGowan, CC
   Jayathilake, K
   Castilho, JL
   Grangeiro, A
AF Boettiger, David C.
   Escuder, Maria Mercedes
   Law, Matthew G.
   Veloso, Valdilea
   Souza, Rosa A.
   Ikeda, Maria L. R.
   de Alencastro, Paulo R.
   Tupinambas, Unai
   Brites, Carlos
   Grinsztejn, Beatriz
   Ggomes, Jackeline O.
   Ribeiro, Sayonara
   McGowan, Catherine C.
   Jayathilake, Karu
   Castilho, Jessica L.
   Grangeiro, Alexandre
CA HIV-Brazil Cohort Study
TI Cardiovascular disease among people living with HIV in Brazil
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE HIV; cardiovascular disease; mortality; Brazil; antiretroviral therapy
ID ACUTE MYOCARDIAL-INFARCTION; LONG-TERM SURVIVAL; NATIONAL-HEALTH SURVEY;
   ABACAVIR USE; ANTIRETROVIRAL THERAPIES; INCREASED RISK; POPULATION;
   MORTALITY; EVENTS; INDIVIDUALS
AB Objectives There is a paucity of data on cardiovascular disease (CVD) among people living with HIV (PLHIV) in resource-limited countries. We assessed factors associated with CVD and the impact of prevalent CVD on all-cause mortality in PLHIV on antiretroviral therapy in Brazil.
   Methods Competing risk regression to assess factors associated with CVD and all-cause mortality in the HIV-Brazil Cohort Study between 2003 and 2014.
   Results Among 5614 patients, the rate of CVD was 3.5 (95% confidence interval [95% CI] 2.9-4.3) per 1000 person-years. CVD was associated with older age (adjusted hazard ratio [aHR] 6.4 for >= 55 years vs. <35 years, 95% CI: 2.5-16.3, P < 0.01), black race (aHR 1.8 vs. white race, 95% CI: 1.0-3.1, P = 0.04), past CVD (aHR 3.0 vs. no past CVD, 95% CI: 1.4-6.2, P < 0.01), hypertension (aHR 1.8 vs. no hypertension, 95% CI: 1.0-3.1, P = 0.04), high-grade dyslipidemia (aHR 9.3 vs. no high-grade dyslipidemia, 95% CI: 6.0-14.6, P < 0.01), ever smoking (aHR 2.4 vs. never, 95% CI: 1.2-5.0, P = 0.02) and low nadir CD4 cell count (aHR 1.8 for 100-250 cells/mm(3) vs. >250 cells/mm(3), 95% CI: 1.0-3.2, P = 0.05). The rate of death was 16.6 (95% CI: 15.1-18.3) per 1000 person-years. Death was strongly associated with having had a past CVD event (aHR 1.7 vs. no past CVD event, 95% CI: 1.1-2.7, P = 0.01).
   Conclusions Traditional and HIV-specific factors associated with CVD among PLHIV in Brazil are similar to those identified among PLHIV in high-income countries. PLHIV in Brazil with a history of CVD have a high risk of death. CVD care and treatment remain priorities for PLHIV in Brazil as this population ages and antiretroviral therapy use expands.
C1 [Boettiger, David C.] Univ Calif San Francisco, Inst Hlth Policy Studies, 3333 Calif St, San Francisco, CA 94143 USA.
   [Boettiger, David C.; Law, Matthew G.] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Escuder, Maria Mercedes; Ggomes, Jackeline O.] Inst Hlth, Sao Paulo State Dept Hlth, Sao Paulo, Brazil.
   [Veloso, Valdilea; Grinsztejn, Beatriz; Ribeiro, Sayonara] Fundacao Oswaldo Cruz, Natl Inst Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Souza, Rosa A.] AIDS Reference & Training Ctr, Sao Paulo State Dept Hlth, Sao Paulo, Brazil.
   [Ikeda, Maria L. R.] Univ Vale Rio dos Sinos, Sch Hlth, Porto Alegre, RS, Brazil.
   [de Alencastro, Paulo R.] Hosp Sanatorio Partenon, Rio Grande Sul State Dept Hlth, Care & Treatment Clin, Porto Alegre, RS, Brazil.
   [Tupinambas, Unai] Univ Fed Minas Gerais, Med Sch, Belo Horizonte, MG, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Edgar Santos Univ Hosp Complex, Salvador, BA, Brazil.
   [McGowan, Catherine C.; Jayathilake, Karu; Castilho, Jessica L.] Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN USA.
   [Grangeiro, Alexandre] Univ Sao Paulo, Dept Prevent Med, Sch Med, Sao Paulo, Brazil.
RP Boettiger, DC (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, 3333 Calif St, San Francisco, CA 94143 USA.
EM dboettiger@kirby.unsw.edu.au
FU Brazilian National Council for Scientific & Technological Development;
   Brazilian National Ministry of Health; Pan American Health Organization;
   U.S. National Institutes of Health (NIH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [K23AI1120875, P30AI110527]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [U01AI069923];
   Eunice Kennedy Shriver National Institute Of Child Health & Human
   Development (NICHD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD);
   National Cancer Institute (NCI)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI); National Institute Of Allergy And Infectious
   Diseases (NIAID)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); National Institute Of Mental
   Health (NIMH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH); Office Of The Director, National Institutes Of Health (OD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA
FX The HIV-Brazil Cohort Study was supported by the Brazilian National
   Council for Scientific & Technological Development, Brazilian National
   Ministry of Health, and Pan American Health Organization. The study was
   supported in part by the U.S. National Institutes of Health (NIH)
   (K23AI1120875 and P30AI110527) and the NIH-funded Caribbean, Central and
   South America network for HIV epidemiology (CCASAnet), a member cohort
   of the International epidemiology Databases to Evaluate AIDS (leDEA)
   (U01AI069923). This award is funded by the following institutes: Eunice
   Kennedy Shriver National Institute Of Child Health & Human Development
   (NICHD), National Cancer Institute (NCI), National Institute Of Allergy
   And Infectious Diseases (NIAID), National Institute Of Mental Health
   (NIMH), and the Office Of The Director, National Institutes Of Health
   (OD).
CR Bedimo RJ, 2011, CLIN INFECT DIS, V53, P84, DOI 10.1093/cid/cir269
   Bijker R, 2019, HIV MED, V20, P183, DOI 10.1111/hiv.12687
   Bronnum-Hansen H, 2001, STROKE, V32, P2131, DOI 10.1161/hs0901.094253
   Brothers CH, 2009, JAIDS-J ACQ IMM DEF, V51, P20, DOI 10.1097/QAI.0b013e31819ff0e6
   Brouwer ES, 2014, EPIDEMIOLOGY, V25, P406, DOI 10.1097/EDE.0000000000000041
   Castilho JL, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25233
   Choi AI, 2011, AIDS, V25, P1289, DOI 10.1097/QAD.0b013e328347fa16
   Cruciani M, 2011, AIDS, V25, P1993, DOI 10.1097/QAD.0b013e328349c6ee
   Desai M, 2015, CLIN INFECT DIS, V61, P445, DOI 10.1093/cid/civ316
   Diaz CM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1735-4
   Ding X, 2012, JAIDS-J ACQ IMM DEF, V61, P441, DOI 10.1097/QAI.0b013e31826f993c
   Drozd DR, 2017, JAIDS-J ACQ IMM DEF, V75, P568, DOI [10.1097/QAI.0000000000001450, 10.1097/qai.0000000000001450]
   Duncan Bruce Bartholow, 2017, Rev. bras. epidemiol., V20, P90, DOI 10.1590/1980-5497201700050008
   Elion RA, 2018, JAIDS-J ACQ IMM DEF, V78, P62, DOI [10.1097/QAI.0000000000001642, 10.1097/qai.0000000000001642]
   Friis-Moller N, 2016, EUR J PREV CARDIOL, V23, P214, DOI 10.1177/2047487315579291
   Grangeiro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095673
   Gupta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022730
   Lorgis L, 2013, CIRCULATION, V127, P1767, DOI 10.1161/CIRCULATIONAHA.113.001874
   Mahajan AP, 2008, AIDS, V22, pS67, DOI 10.1097/01.aids.0000327438.13291.62
   Malta DC, 2016, SAO PAULO MED J, V134, P163, DOI 10.1590/1516-3180.2015.02090911
   Malta DC, 2015, SAO PAULO MED J, V133, P286, DOI 10.1590/1516-3180.2015.13340308
   Nauta ST, 2012, DIABETES CARE, V35, P2043, DOI 10.2337/dc11-2462
   Obel N, 2010, HIV MED, V11, P130, DOI 10.1111/j.1468-1293.2009.00751.x
   Sabin CA, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0588-4
   Schmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9
   Schmidt M, 2016, CIRC-CARDIOVASC QUAL, V9, P523, DOI 10.1161/CIRCOUTCOMES.115.002661
   Schmidt M, 2014, NEUROLOGY, V82, P340, DOI 10.1212/WNL.0000000000000062
   Shah ASV, 2018, CIRCULATION, V138, P1100, DOI 10.1161/CIRCULATIONAHA.117.033369
   Smolina K, 2012, CIRC-CARDIOVASC QUAL, V5, P532, DOI 10.1161/CIRCOUTCOMES.111.964700
   Walker RW, 2013, LANCET GLOB HEALTH, V1, pE282, DOI 10.1016/S2214-109X(13)70068-8
   Zanni MV, 2012, CURR HIV-AIDS REP, V9, P200, DOI 10.1007/s11904-012-0123-y
NR 31
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUL
PY 2020
VL 25
IS 7
BP 886
EP 896
DI 10.1111/tmi.13405
EA MAY 2020
PG 11
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA MF1NP
UT WOS:000531433900001
PM 32306480
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Birse, KD
   Kratzer, K
   Zuend, CF
   Mutch, S
   Noel-Romas, L
   Lamont, A
   Abou, M
   Jalil, E
   Veloso, V
   Grinsztejn, B
   Friedman, RK
   Broliden, K
   Bradley, F
   Poliquin, V
   Li, F
   Yanavich, C
   Burgener, A
   Aldrovandi, G
AF Birse, Kenzie D.
   Kratzer, Kateryna
   Zuend, Christina Farr
   Mutch, Sarah
   Noel-Romas, Laura
   Lamont, Alana
   Abou, Max
   Jalil, Emilia
   Veloso, Valdilea
   Grinsztejn, Beatriz
   Friedman, Ruth Khalili
   Broliden, Kristina
   Bradley, Frideborg
   Poliquin, Vanessa
   Li, Fan
   Yanavich, Carolyn
   Burgener, Adam
   Aldrovandi, Grace
TI The neovaginal microbiome of transgender women post-gender reassignment
   surgery
SO MICROBIOME
LA English
DT Article
DE Transgender women; Neovagina; Gender reassignment surgery; Microbiome;
   Metaproteomics
ID SEQUENCE DATA; HIV; INFLAMMATION; BACTERIA; QUALITY; SUSCEPTIBILITY;
   MICROFLORA; CELLS; SEX
AB Background Gender reassignment surgery is a procedure some transgender women (TW) undergo for gender-affirming purposes. This often includes the construction of a neovagina using existing penile and scrotal tissue and/or a sigmoid colon graft. There are limited data regarding the composition and function of the neovaginal microbiome representing a major gap in knowledge in neovaginal health. Results Metaproteomics was performed on secretions collected from the neovaginas (n = 5) and rectums (n = 7) of TW surgically reassigned via penile inversion/scrotal graft with (n = 1) or without (n = 4) a sigmoid colon graft extension and compared with secretions from cis vaginas (n = 32). We identified 541 unique bacterial proteins from 38 taxa. The most abundant taxa in the neovaginas were Porphyromonas (30.2%), Peptostreptococcus (9.2%), Prevotella (9.0%), Mobiluncus (8.0%), and Jonquetella (7.2%), while cis vaginas were primarily Lactobacillus and Gardnerella. Rectal samples were mainly composed of Prevotella and Roseburia. Neovaginas (median Shannon's H index = 1.33) had higher alpha diversity compared to cis vaginas (Shannon's H = 0.35) (p = 7.2E-3, Mann-Whitney U test) and were more similar to the non-Lactobacillus dominant/polymicrobial cis vaginas based on beta diversity (perMANOVA, p = 0.001, r(2) = 0.342). In comparison to cis vaginas, toll-like receptor response, amino acid, and short-chain fatty acid metabolic pathways were increased (p < 0.01), while keratinization and cornification proteins were decreased (p < 0.001) in the neovaginal proteome. Conclusions Penile skin-lined neovaginas have diverse, polymicrobial communities that show similarities in composition to uncircumcised penises and host responses to cis vaginas with bacterial vaginosis (BV) including increased immune activation pathways and decreased epithelial barrier function. Developing a better understanding of microbiome-associated inflammation in the neovaginal environment will be important for improving our knowledge of neovaginal health.
C1 [Birse, Kenzie D.; Kratzer, Kateryna; Zuend, Christina Farr; Mutch, Sarah; Noel-Romas, Laura; Lamont, Alana; Abou, Max; Burgener, Adam] Publ Hlth Agcy Canada, JC Wilt Infect Dis Res Ctr, Natl HIV & Retrovirol Labs, 745 Logan Ave, Winnipeg, MB R3E 3L5, Canada.
   [Birse, Kenzie D.; Kratzer, Kateryna; Zuend, Christina Farr; Mutch, Sarah; Noel-Romas, Laura; Lamont, Alana; Burgener, Adam] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada.
   [Birse, Kenzie D.; Kratzer, Kateryna; Zuend, Christina Farr; Mutch, Sarah; Noel-Romas, Laura; Lamont, Alana; Burgener, Adam] Univ Manitoba, Dept Infect Dis, Winnipeg, MB, Canada.
   [Jalil, Emilia; Veloso, Valdilea; Grinsztejn, Beatriz; Friedman, Ruth Khalili] Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Broliden, Kristina; Bradley, Frideborg; Burgener, Adam] Karolinska Inst, Karolinska Univ Hosp, Ctr Mol Med, Dept Med Solna,Unit Infect Dis, Stockholm, Sweden.
   [Poliquin, Vanessa; Burgener, Adam] Univ Manitoba, Dept Obstet & Gynecol, Winnipeg, MB, Canada.
   [Li, Fan; Yanavich, Carolyn; Aldrovandi, Grace] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
RP Burgener, A (corresponding author), Publ Hlth Agcy Canada, JC Wilt Infect Dis Res Ctr, Natl HIV & Retrovirol Labs, 745 Logan Ave, Winnipeg, MB R3E 3L5, Canada.; Burgener, A (corresponding author), Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada.; Burgener, A (corresponding author), Univ Manitoba, Dept Infect Dis, Winnipeg, MB, Canada.; Burgener, A (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Ctr Mol Med, Dept Med Solna,Unit Infect Dis, Stockholm, Sweden.; Burgener, A (corresponding author), Univ Manitoba, Dept Obstet & Gynecol, Winnipeg, MB, Canada.; Aldrovandi, G (corresponding author), Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
EM adam.burgener@umanitoba.ca; GAldrovandi@mednet.ucla.edu
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [TMI-138658]; Fiocruz PMA (Programa de Politicas
   Publicas e Modelos de Atencao a Saude); National Institutes of Health:
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [5RO1AI128796]; National Institute of Allergy and Infectious Diseases
   (NIAID) of the National Institutes of Health (NIH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI068632, UM1AI068616, UM1AI106716]; Eunice Kennedy Shriver National
   Institute of Child Health and Human Development (NICHD)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD); National Institute of Mental Health
   (NIMH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH)
FX Funding for this project was provided by the Canadian Institutes of
   Health Research (A.B. TMI-138658), Fiocruz PMA (Programa de Politicas
   Publicas e Modelos de Atencao a Saude), and the National Institutes of
   Health: National Institute of Allergy and Infectious Diseases (grant no:
   5RO1AI128796). Overall support for the International Maternal Pediatric
   Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the
   National Institute of Allergy and Infectious Diseases (NIAID) of the
   National Institutes of Health (NIH) under award numbers UM1AI068632
   (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC), and UM1AI106716 (IMPAACT LC),
   with co-funding from the Eunice Kennedy Shriver National Institute of
   Child Health and Human Development (NICHD) and the National Institute of
   Mental Health (NIMH). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   NIH.
CR Ahmad M M, 1987, IPPF Med Bull, V21, P3
   Anahtar MN, 2015, IMMUNITY, V42, P965, DOI 10.1016/j.immuni.2015.04.019
   Bandurska K, 2015, BIOFACTORS, V41, P289, DOI 10.1002/biof.1225
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Basic A, 2018, J ORAL MICROBIOL, V10, DOI 10.1080/20002297.2018.1527655
   Birse K, 2015, J VIROL, V89, P8793, DOI 10.1128/JVI.00756-15
   Borgdorff H, 2016, MUCOSAL IMMUNOL, V9, P621, DOI 10.1038/mi.2015.86
   Bradley F, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.12863
   Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]
   Camelo-Castillo A, 2015, J CLIN PERIODONTOL, V42, P1074, DOI 10.1111/jcpe.12470
   Charles CA, 2008, J AM ACAD DERMATOL, V59, P758, DOI 10.1016/j.jaad.2008.07.018
   Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879
   Dang AT, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126955
   Delva E, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002543
   Dreher PC, 2018, CLIN ANAT, V31, P191, DOI 10.1002/ca.23001
   Eastment MC, 2018, AIDS, V32, P687, DOI 10.1097/QAD.0000000000001768
   Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
   Gholizadeh P, 2016, BIOMED PHARMACOTHER, V84, P552, DOI 10.1016/j.biopha.2016.09.082
   Gosmann C, 2017, IMMUNITY, V46, P29, DOI 10.1016/j.immuni.2016.12.013
   Gu C, 2019, CURR PROTEIN PEPT SC
   Haaland RE, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25199
   Illumina, 2013, PREP 16S RIB RNA GEN
   Jumas-Bilak E, 2007, INT J SYST EVOL MICR, V57, P2743, DOI 10.1099/ijs.0.65213-0
   Kaufmann U, 2014, EUR J OBSTET GYN R B, V172, P102, DOI 10.1016/j.ejogrb.2013.10.019
   Klatt NR, 2017, SCIENCE, V356, P938, DOI 10.1126/science.aai9383
   Kleiner M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01544-x
   Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808
   Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13
   Li S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29423-5
   Liu CM, 2017, MBIO, V8, DOI [10.1128/mBio.00996-17, 10.1128/mbio.00996-17]
   Liu CM, 2015, MBIO, V6, DOI 10.1128/mBio.00589-15
   Liu CM, 2013, MBIO, V4, DOI 10.1128/mBio.00076-13
   Marchandin H, 2010, RES MICROBIOL, V161, P91, DOI 10.1016/j.resmic.2009.12.008
   Mills RH, 2019, MSYSTEMS, V4, DOI 10.1128/mSystems.00337-18
   Miyagawaa S, 2015, P NATL ACAD SCI USA, V112, P12986, DOI 10.1073/pnas.1513550112
   Moschen AR, 2016, CELL HOST MICROBE, V19, P455, DOI 10.1016/j.chom.2016.03.007
   Pask AJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002308
   Pescatore NA, 2018, AIDS RES HUM RETROV, V34, P277, DOI [10.1089/aid.2017.0206, 10.1089/AID.2017.0206]
   Petricevic L, 2014, J SEX MED, V11, P2738, DOI 10.1111/jsm.12671
   Petrina MAB, 2017, ANAEROBE, V47, P115, DOI 10.1016/j.anaerobe.2017.05.005
   PM MS, 2018, HIV RES PREVENTION
   Price LB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008422
   Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864
   Qian BJ, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2197975
   Qiao L, 2012, J UROLOGY, V187, P1427, DOI 10.1016/j.juro.2011.12.008
   Ravindran R, 2016, NATURE, V531, P523, DOI 10.1038/nature17186
   Reed HM, 2015, AESTHET PLAST SURG, V39, P733, DOI 10.1007/s00266-015-0523-7
   Rotzer V, 2016, J INVEST DERMATOL, V136, P301, DOI 10.1038/JID.2015.380
   Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09
   Siqueira JF, 2003, J ENDODONT, V29, P735, DOI 10.1097/00004770-200311000-00012
   Smith Benjamin C., 2016, Yale Journal of Biology and Medicine, V89, P277
   Srinivasan S, 2015, MBIO, V6, DOI 10.1128/mBio.00204-15
   Stieh DJ, 2016, CELL HOST MICROBE, V19, P529, DOI 10.1016/j.chom.2016.03.005
   Takeda M, 2018, J DERMATOL, V45, P1463, DOI 10.1111/1346-8138.14675
   Tobin NH, 2018, JOVE-J VIS EXP, DOI 10.3791/56974
   Ueland PM, 2017, MOL ASPECTS MED, V53, P10, DOI 10.1016/j.mam.2016.08.001
   Vielkind P, 2015, INT J MED MICROBIOL, V305, P682, DOI 10.1016/j.ijmm.2015.08.018
   Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07
   Weinforth G, 2019, DTSCH ARZTEBL INT, V116, P253, DOI 10.3238/arztebl.2019.0253
   Weyers S, 2010, CYTOPATHOLOGY, V21, P111, DOI 10.1111/j.1365-2303.2009.00663.x
   Weyers S, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-102
   Zevin AS, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005889
   Zhou H, 2018, ANIM SCI J, V89, P3, DOI 10.1111/asj.12937
   Zhou J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.289
NR 64
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2049-2618
J9 MICROBIOME
JI Microbiome
PD MAY 5
PY 2020
VL 8
IS 1
AR 61
DI 10.1186/s40168-020-00804-1
PG 13
WC Microbiology
SC Microbiology
GA LL5YU
UT WOS:000531635500001
PM 32370783
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Torres, TS
   Bastos, LS
   Kamel, L
   Bezerra, DRB
   Fernandes, NM
   Moreira, RI
   Garner, A
   Veloso, VG
   Grinsztejn, B
   De Boni, RB
AF Torres, Thiago S.
   Bastos, Leonardo S.
   Kamel, Luciana
   Bezerra, Daniel R. B.
   Fernandes, Nilo M.
   Moreira, Ronaldo I.
   Garner, Alex
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   De Boni, Raquel B.
TI Do men who have sex with men who report alcohol and illicit drug use
   before/during sex (chemsex) present moderate/high risk for substance use
   disorders?
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Sexualized drug use; Chemsex; Men who have sex with men (MSM); Substance
   use disorders; HIV/AIDS; Brazil
ID TRANSGENDER WOMEN; HIV-INFECTION; PREEXPOSURE PROPHYLAXIS; PREVALENCE;
   BEHAVIORS; BRAZIL; MSM; EPIDEMIOLOGY; ADHERENCE; DRINKING
AB Background: We evaluated the prevalence of sexualized drug use (Chemsex) and its association with moderate/high risk for substance use disorders and HIV sexual risk behavior among men who have sex with men (MSM).
   Methods: We conducted a cross-sectional web-based survey among MSM from Rio de Janeiro (Brazil). The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) was used to screen people at moderate/high-risk for substance use disorders. Individuals found to be using substances in the prior three months were asked if they used before/during sex. Sexualized drug use was classified into: no sexualized drug use, sex using only alcohol (alcohol-sex), sex using only illicit drugs (drug-sex) and sex using alcohol and illicit drugs (alcohol-drug-sex). The questionnaire included questions about sociodemographic, HIV status/prevention and risk behavior. A multinomial regression model was performed to assess the factors associated with sexualized drug use.
   Results: Overall, 1048 MSM completed the questionnaire; median age was 29 years. Prevalence of alcohol and illicit drug use in previous 3 months was 89 % and 49 %, respectively. Most MSM (64 %) reported sexualized drug use: 28 % alcohol-sex, 9 % drug-sex and 27 % alcohol-drug-sex. Median ASSIST scores were higher among those reporting sexualized drug use compared to no use. All HIV sexual risk behavior variables presented increasing prevalence across the outcome categories. In the adjusted multivariate model, having moderate/high-risk for substance use disorders were associated with sexualized drug use.
   Conclusions: MSM reporting sexualized drug use should receive brief intervention for substance use disorders and be evaluated for combination HIV prevention strategies including PrEP.
C1 [Torres, Thiago S.; Kamel, Luciana; Bezerra, Daniel R. B.; Fernandes, Nilo M.; Moreira, Ronaldo I.; Veloso, Valdilea G.; Grinsztejn, Beatriz; De Boni, Raquel B.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
   [Bastos, Leonardo S.] Fiocruz MS, Programa Computacao Cient, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
   [Bastos, Leonardo S.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Garner, Alex] Hornet INC, 3962 Ince Blvd, Culver City, CA 90232 USA.
RP Torres, TS (corresponding author), INI Evandro Chagas, LapClin DST AIDS, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM thiago.torres@ini.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Bastos, Leonardo
   Soares/AAD-5335-2019
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Bastos, Leonardo
   Soares/0000-0002-1406-0122
FU National Council for Scientific and Technological Development -
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [310541/2017-4]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro - FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/203.154/2017]
FX RBDB acknowledges the National Council for Scientific and Technological
   Development - CNPq (grant #310541/2017-4) and Fundacao Carlos Chagas
   Filho de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJ (grant
   #E-26/203.154/2017).
CR Allen JL, 2016, DRUG ALCOHOL DEPEN, V161, P323, DOI 10.1016/j.drugalcdep.2016.02.025
   Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339
   Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6
   Boyd CJ, 2019, LGBT HEALTH, V6, P15, DOI 10.1089/lgbt.2018.0122
   Brasil Ministerio da Saude, 2018, B EP HIV AIDS
   Cunha CB, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2002-0
   Cunha CB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-379
   Davis SLM, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21386
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   De Boni RB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194228
   De Boni RB, 2016, DRUG ALCOHOL DEPEN, V159, P174, DOI 10.1016/j.drugalcdep.2015.12.013
   De Cock KM, 2012, AIDS, V26, P1205, DOI 10.1097/QAD.0b013e328354622a
   Dean A, 2014, OPENEPI OPEN SOURCE
   Deiss RG, 2013, DRUG ALCOHOL DEPEN, V132, P134, DOI 10.1016/j.drugalcdep.2013.01.011
   Delgado JR, 2017, DRUG ALCOHOL DEPEN, V170, P17, DOI 10.1016/j.drugalcdep.2016.10.033
   Edmundson C, 2018, INT J DRUG POLICY, V55, P131, DOI 10.1016/j.drugpo.2018.02.002
   Evans-Polce RJ, 2020, SOC PSYCH PSYCH EPID, V55, P101, DOI 10.1007/s00127-019-01694-x
   Fritz K, 2010, LANCET, V376, P398, DOI 10.1016/S0140-6736(10)60884-7
   Galea JT, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017338
   Glynn RW, 2018, INT J DRUG POLICY, V52, P9, DOI 10.1016/j.drugpo.2017.10.008
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Henrique Iara Ferraz Silva, 2004, Rev. Assoc. Med. Bras., V50, P199, DOI 10.1590/S0104-42302004000200039
   Hoagland B, 2017, AIDS BEHAV, V21, P1278, DOI 10.1007/s10461-016-1516-5
   Kenyon C, 2018, AIDS RES THER, V15, DOI 10.1186/s12981-018-0201-3
   Kerr L, 2018, MEDICINE, V97, pS9, DOI [10.1097/MD.0000000000010573, 10.1097/md.0000000000010573]
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Kerridge BT, 2017, DRUG ALCOHOL DEPEN, V170, P82, DOI 10.1016/j.drugalcdep.2016.10.038
   Luz PM, 2019, CURR OPIN HIV AIDS, V14, P366, DOI 10.1097/COH.0000000000000564
   Machado IK, 2017, INT J STD AIDS, V28, P1175, DOI 10.1177/0956462417692278
   Maxwell S, 2019, INT J DRUG POLICY, V63, P74, DOI 10.1016/j.drugpo.2018.11.014
   McCabe SE, 2019, ALCOHOL CLIN EXP RES, V43, P497, DOI 10.1111/acer.13960
   Patel P, 2014, AIDS, V28, P1509, DOI 10.1097/QAD.0000000000000298
   Patel V, 2018, LANCET, V392, P1553, DOI 10.1016/S0140-6736(18)31612-X
   Pascom ARP, 2018, MEDICINE, V97, pS69, DOI [10.1097/MD.0000000000009857, 10.1097/md.0000000000009857]
   Pighinelli L, 2018, SPR SER POLYM COMPOS, P97, DOI 10.1007/978-3-319-66417-0_4
   Pufall EL, 2018, HIV MED, V19, P261, DOI 10.1111/hiv.12574
   R Core Team, 2019, R PROJECT STAT COMPU
   Rosinska M, 2018, INT J DRUG POLICY, V55, P231, DOI 10.1016/j.drugpo.2018.01.002
   Sewell J, 2017, INT J DRUG POLICY, V43, P33, DOI 10.1016/j.drugpo.2017.01.001
   Smith DK, 2012, JAIDS-J ACQ IMM DEF, V60, P421, DOI 10.1097/QAI.0b013e318256b2f6
   Tomkins A, 2019, PERSPECT PUBLIC HEAL, V139, P23, DOI 10.1177/1757913918778872
   Torres TS, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4704-x
   Torres TS, 2019, AIDS CARE, V31, P1193, DOI 10.1080/09540121.2019.1619665
   Torres TS, 2019, JMIR PUBLIC HLTH SUR, V5, P177, DOI 10.2196/13771
   Torres TS, 2018, JMIR PUBLIC HLTH SUR, V4, P147, DOI 10.2196/publichealth.8997
   UNAIDS, 2019, UNAIDS DAT 2019
   Weatherburn P, 2017, SEX TRANSM INFECT, V93, DOI 10.1136/sextrans-2016-052695
   WHO, 2018, GLOB STAT REP ALC HL
   WHO, 2016, WHO ASS V3 0
   Young SD, 2016, AIDS CARE, V28, P112, DOI 10.1080/09540121.2015.1069789
NR 50
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD APR 1
PY 2020
VL 209
AR 107908
DI 10.1016/j.drugalcdep.2020.107908
PG 8
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA LG2DI
UT WOS:000527917700029
PM 32078972
DA 2020-11-24
ER

PT J
AU Kozal, M
   Aberg, J
   Pialoux, G
   Cahn, P
   Thompson, M
   Molina, JM
   Grinsztejn, B
   Diaz, R
   Castagna, A
   Kumar, P
   Latiff, G
   DeJesus, E
   Gummel, M
   Gartland, M
   Pierce, A
   Ackerman, P
   Llamoso, C
   Lataillade, M
AF Kozal, Michael
   Aberg, Judith
   Pialoux, Gilles
   Cahn, Pedro
   Thompson, Melanie
   Molina, Jean-Michel
   Grinsztejn, Beatriz
   Diaz, Ricardo
   Castagna, Antonella
   Kumar, Princy
   Latiff, Gulam
   DeJesus, Edwin
   Gummel, Mark
   Gartland, Margaret
   Pierce, Amy
   Ackerman, Peter
   Llamoso, Cyril
   Lataillade, Max
CA BRIGHTE Trial Team
TI Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ATTACHMENT INHIBITOR BMS-626529; PRODRUG BMS-663068; ACTIVE COMPONENT;
   PHASE 2B; EFFICACY; DOLUTEGRAVIR; AI438011; SAFETY; TRIAL
AB BackgroundAmong some patients with human immunodeficiency virus type 1 (HIV-1) infection who have undergone multiple antiretroviral therapies and have limited options for treatment, new classes of antiretroviral drugs with novel mechanisms of action are needed. Fostemsavir is the prodrug of temsavir, a first-in-class investigational HIV-1 attachment inhibitor.
   MethodsIn this ongoing phase 3 trial in 23 countries, we enrolled patients with multidrug-resistant HIV-1 infection in two cohorts, according to their remaining treatment options. In the first cohort, we assigned (in a 3:1 ratio) patients who had the option of using at least one fully active, approved antiretroviral drug in at least one but no more than two antiretroviral classes to add either fostemsavir (at a dose of 600 mg twice daily) or placebo to their failing regimen for 8 days, followed by open-label fostemsavir plus optimized background therapy (randomized cohort). In the second cohort, patients who had no remaining antiretroviral options were started on open-label fostemsavir plus optimized background therapy on day 1 (nonrandomized cohort). The primary end point was the mean change in the HIV-1 RNA level from day 1 through day 8 in the randomized cohort.
   ResultsA total of 371 patients were treated, including 272 in the randomized cohort and 99 in the nonrandomized cohort. At day 8, the mean decrease in the HIV-1 RNA level was 0.79 log(10) copies per milliliter in the fostemsavir group and 0.17 log(10) copies in the placebo group (P<0.001). At week 48, a virologic response (HIV-1 RNA level, <40 copies per milliliter) had occurred in 54% of the patients in the randomized cohort and in 38% of those in the nonrandomized cohort; the mean increase in the CD4+ T-cell count was 139 cells per cubic millimeter and 64 cells per cubic millimeter, respectively. Adverse events led to the discontinuation of fostemsavir in 7% of the patients. In the randomized cohort, glycoprotein 120 (gp120) substitutions were found in 20 of 47 patients (43%) with virologic failure.
   ConclusionsIn patients with multidrug-resistant HIV-1 infection with limited therapy options, those who received fostemsavir had a significantly greater decrease in the HIV-1 RNA level than those who received placebo during the first 8 days. Efficacy was sustained through 48 weeks. (Funded by Bristol-Myers Squibb and GSK/ViiV Healthcare; BRIGHTE ClinicalTrials.gov number, NCT02362503.)
   In this international trial involving 371 patients with highly drug-resistant HIV-1 infection, fostemsavir reduced the HIV-1 RNA level by 0.79 log(10) copies per milliliter during the first 8 days of treatment. At week 48, more than half the patients treated with fostemsavir and an optimized background regimen had a virologic response.
C1 [Kozal, Michael] Yale Univ, Sch Med, New Haven, CT USA.
   [Kozal, Michael] Vet Affairs Connecticut Healthcare Syst, New Haven, CT USA.
   [Ackerman, Peter; Llamoso, Cyril; Lataillade, Max] ViiV Healthcare, 36 E Ind Rd, Branford, CT 06405 USA.
   [Aberg, Judith] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Pialoux, Gilles] Hop Tenon, AP HP, Paris, France.
   [Molina, Jean-Michel] Hop St Louis, AP HP, Paris, France.
   [Molina, Jean-Michel] Univ Paris Diderot Paris 7, Paris, France.
   [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Thompson, Melanie] AIDS Res Consortium Atlanta, Atlanta, GA USA.
   [Grinsztejn, Beatriz] Fundacao Oswald Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Diaz, Ricardo] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Castagna, Antonella] Ist Sci San Raffaele, Milan, Italy.
   [Kumar, Princy] Georgetown Univ Hosp, Washington, DC 20007 USA.
   [Latiff, Gulam] Maxwell Ctr, Durban, South Africa.
   [DeJesus, Edwin] Orlando Immunol Ctr, Orlando, FL USA.
   [Gummel, Mark] GlaxoSmithKline, Upper Providence, PA USA.
   [Gartland, Margaret; Pierce, Amy] ViiV Healthcare, Res Triangle Pk, NC USA.
RP Lataillade, M (corresponding author), ViiV Healthcare, 36 E Ind Rd, Branford, CT 06405 USA.
EM max.x.lataillade@viivhealthcare.com
OI Belaunzaran, Pablo/0000-0003-4775-4734; Orofino,
   Giancarlo/0000-0003-3115-9674
FU Bristol-Myers SquibbBristol-Myers Squibb; GSK/ViiV Healthcare
FX Funded by Bristol-Myers Squibb and GSK/ViiV Healthcare; BRIGHTE
   ClinicalTrials.gov number, NCT02362503.
CR Akil B, 2015, ANTIVIR THER, V20, P343, DOI 10.3851/IMP2878
   [Anonymous], 2015, HUM IMM VIR 1 INF DE
   Brown J, 2013, J PHARM SCI-US, V102, P1742, DOI 10.1002/jps.23476
   Castagna A, 2014, J INFECT DIS, V210, P354, DOI 10.1093/infdis/jiu051
   Emu B, 2018, NEW ENGL J MED, V379, P645, DOI 10.1056/NEJMoa1711460
   Hruska M, 2013, 14 INT WORKSH CLIN P
   Hsu R, 2018, 22 INT AIDS C AMST J
   Lalezari JP, 2015, LANCET HIV, V2, pE427, DOI 10.1016/S2352-3018(15)00177-0
   Langley DR, 2015, PROTEINS, V83, P331, DOI 10.1002/prot.24726
   Lataillade M, 2017, 16 EUR AIDS C MIL OC
   Lataillade M, 2018, JAIDS-J ACQ IMM DEF, V77, P299, DOI [10.1097/QAI.0000000000001602, 10.1097/qai.0000000000001602]
   Li ZF, 2013, ANTIMICROB AGENTS CH, V57, P4172, DOI 10.1128/AAC.00513-13
   Mani N, 2012, AIDS, V26, P899, DOI 10.1097/QAD.0b013e3283519371
   Murray JS, 1999, AIDS, V13, P797, DOI 10.1097/00002030-199905070-00008
   Nowicka-Sans B, 2012, ANTIMICROB AGENTS CH, V56, P3498, DOI 10.1128/AAC.00426-12
   Pancera M, 2017, NAT CHEM BIOL, V13, P1115, DOI [10.1038/NCHEMBIO.2460, 10.1038/nchembio.2460]
   Ray N, 2013, JAIDS-J ACQ IMM DEF, V64, P7, DOI 10.1097/QAI.0b013e31829726f3
   Stolbach A, 2015, J MED TOXICOL, V11, P326, DOI 10.1007/s13181-015-0465-0
   Thompson M, 2017, ANTIVIR THER, V22, P215, DOI 10.3851/IMP3112
   Thompson S, 2019, INT J EVID BASED COA, P4, DOI 10.24384/86ee-ps25
   Wensing AM, 2017, TOP ANTIVIR MED, V24, P132
   Zhou NN, 2014, J ANTIMICROB CHEMOTH, V69, P573, DOI 10.1093/jac/dkt412
   Zhu L, 2015, ANTIMICROB AGENTS CH, V59, P3816, DOI 10.1128/AAC.04914-14
NR 23
TC 7
Z9 7
U1 1
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAR 26
PY 2020
VL 382
IS 13
BP 1232
EP 1243
DI 10.1056/NEJMoa1902493
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA KY1UO
UT WOS:000522357300010
PM 32212519
DA 2020-11-24
ER

PT J
AU Castro, R
   Luz, PM
   Wakimoto, MD
   Veloso, VG
   Grinsztejn, B
   Perazzo, H
AF Castro, Rodolfo
   Luz, Paula M.
   Wakimoto, Mayumi D.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Perazzo, Hugo
TI COVID-19: a meta-analysis of diagnostic test accuracy of commercial
   assays registered in Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE SARS-CoV-2; Coronavirus; Diagnostic accuracy
AB The accuracy of commercially available tests for COVID-19 in Brazil remains unclear. We aimed to perform a meta-analysis to describe the accuracy of available tests to detect COVID-19 in Brazil. We searched at the Brazilian Health Regulatory Agency (ANVISA) online platform to describe the pooled sensitivity (Se), specificity (Sp), diagnostic odds ratio (DOR) and summary receiver operating characteristic curves (SROC) for detection of IgM/IgG antibodies and for tests using naso/oropharyngeal swabs in the random-effects models. We identified 16 tests registered, mostly rapid-tests. Pooled diagnostic accuracy measures [95%CI] were: (i) for IgM antibodies Se = 82% [76-87]; Sp = 97% [96-98]; DOR = 168 [92-305] and SROC = 0.98 [0.96-0.99]; (ii) for IgG antibodies Se = 97% [90-99]; Sp = 98% [97-99]; DOR = 1994 [385-10334] and SROC = 0.99 [0.98-1.00]; and (iii) for detection of SARS-CoV-2 by antigen or molecular assays in naso/oropharyngeal swabs Se = 97% [85-99]; Sp = 99% [77-100]; DOR = 2649 [30-233056] and SROC = 0.99 [0.98-1.00]. These tests can be helpful for emergency testing during the COVID-19 pandemic in Brazil. However, it is important to highlight the high rate of false negative results from tests which detect SARS-CoV-2 IgM antibodies in the initial course of the disease and the scarce evidence-based validation results published in Brazil. Future studies addressing the diagnostic performance of tests for COVID-19 in the Brazilian population are urgently needed. (C) 2020 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Castro, Rodolfo] Fundacao Oswaldo Cruz FIOCRUZ, Escola Nacl Saude Publ Sergio Arouca ENSP, Rio De Janeiro, RJ, Brazil.
   [Castro, Rodolfo] Univ Fed Estado Rio de Janeiro UNIRIO, Inst Saude Colet ISC, Rio De Janeiro, RJ, Brazil.
   [Luz, Paula M.; Wakimoto, Mayumi D.; Veloso, Valdilea G.; Grinsztejn, Beatriz; Perazzo, Hugo] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Rio De Janeiro, RJ, Brazil.
RP Perazzo, H (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Rio De Janeiro, RJ, Brazil.
EM hugo.perazzo@ini.fiocruz.br
RI Castro, Rodolfo/D-4231-2013
OI Castro, Rodolfo/0000-0002-0701-2528; Perazzo, Hugo/0000-0003-0931-6418
CR [Anonymous], 2020, COVID 19 BRAZIL UPDA
   Dwamena B, 2007, MIDAS STATA MODULE M
   European Centre for Disease Prevention and Control, 2020, NOV COR DIS 2019 COV
   Imperial College London, 2020, GLOB IMP COVID 19 ST
   Li Z, 2020, J MED VIROL, DOI [10.1002/jmv.75777, DOI 10.1002/JMV.75777]
   Petherick A, 2020, LANCET, V395, P1101, DOI 10.1016/S0140-6736(20)30788-1
   Pfefferle S, 2020, EUROSURVEILLANCE, V25, P18, DOI 10.2807/1560-7917.ES.2020.25.9.2000152
   Salathe M, 2020, SWISS MED WEEKLY, V150
   Walker P, 2020, GLOBAL IMPACT COVID, DOI [10.25561/77735, DOI 10.25561/77735]
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
NR 10
TC 18
Z9 19
U1 1
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAR-APR
PY 2020
VL 24
IS 2
BP 180
EP 187
DI 10.1016/j.bjid.2020.04.003
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA LU0IQ
UT WOS:000537447600012
PM 32330437
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Crabtree-Ramirez, B
   Belaunzaran-Zamudio, PF
   Cortes, CP
   Morales, M
   Sued, O
   Sierra-Madero, J
   Cahn, P
   Pozniak, A
   Grinsztejn, B
AF Crabtree-Ramirez, Brenda
   Belaunzaran-Zamudio, Pablo F.
   Cortes, Claudia P.
   Morales, Miguel
   Sued, Omar
   Sierra-Madero, Juan
   Cahn, Pedro
   Pozniak, Anton
   Grinsztejn, Beatriz
TI The HIV epidemic in Latin America: a time to reflect on the history of
   success and the challenges ahead
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Review
DE Latin America; HIV epidemic; migration; HIV; PrEP in Latin America; ART;
   HIV testing
ID INJECT DRUGS; PEOPLE
C1 [Crabtree-Ramirez, Brenda; Belaunzaran-Zamudio, Pablo F.; Sierra-Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Vasco de Quiroga 15, Salvador Zubiran 14080, Tlalpan, Mexico.
   [Cortes, Claudia P.] Univ Chile, Fdn Arriaran, Santiago, Chile.
   [Morales, Miguel] Taller Venezolano VIH, Caracas, Venezuela.
   [Sued, Omar; Cahn, Pedro] Fdn Huesped, Invest Clin, Buenos Aires, DF, Argentina.
   [Pozniak, Anton] Chelsea & Westminster Hosp NHS Fdn Trust, London, England.
   [Pozniak, Anton] Imperial Coll London, London, England.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
RP Crabtree-Ramirez, B (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Vasco de Quiroga 15, Salvador Zubiran 14080, Tlalpan, Mexico.
EM brenda.crabtree@infecto.mx
OI Belaunzaran, Pablo/0000-0003-4775-4734; Crabtree-Ramirez,
   Brenda/0000-0002-2587-1123
CR Angulo-Arreola Iliana Alexandra, 2017, J Int Assoc Provid AIDS Care, V16, P56, DOI 10.1177/1545109711417408
   [Anonymous], 2014, GLOBAL UPDATE HLTH S
   Aran-Matero D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022373
   Balzer C, 2016, TRANS MURDER MONITOR
   Barre-Sinoussi F, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25161
   Belaunzaran-Zamudio PF, 2020, AM J EPIDEMIOL, V189, P564, DOI 10.1093/aje/kwz252
   Belaunzaran-Zamudio PF, 2015, B WORLD HEALTH ORGAN, V93, P529, DOI 10.2471/BLT.14.147447
   Caffe S, 2016, SEX TRANSM DIS, V43, P733, DOI 10.1097/OLQ.0000000000000528
   Carriquiry G, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20016
   Cesar C, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20684
   Corrales J, 2020, OXFORD HDB GLOBAL LG, P185, DOI [10.1093/oxfordhb/9780190673741.013.14, DOI 10.1093/OXFORDHB/9780190673741.013.14]
   Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3
   Goldenberg S, 2020, HIV VULNERABILITY MI
   Grulich AE, 2018, LANCET HIV, V5, pE629, DOI 10.1016/S2352-3018(18)30215-7
   Hayes R, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002292
   IOM/UN Migration, 2019, MIGR REF VEN CRIS IO
   Jalil EM, 2019, J INT AIDS SOC, V22
   Joint United Nationes Programme on HIV/AIDS (UNAIDS), 2017, COUNTR FACTSH VEN BO
   Joint United Nations Programme on HIV/AIDS (UNAIDS), GAP REP TRANSG PEOPL
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2019, TAK ACT HIV MES STOC
   Joint United Nations Programme on HIV/AIDS (UNAIDS), REG FACTSH CAR 2017
   Marins LMS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221281
   Marukutira T, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25090
   Mathers BM, 2010, LANCET, V375, P1014, DOI 10.1016/S0140-6736(10)60232-2
   National Conference of State Legislatures, 2019, SNAPSH US IMM 2019
   Pan American Health Organization [PAHO] John Snow Inc World Professional Association for Transgender Health, 2014, BLUEPR PROV COMPR CA
   Pineirua A, 2015, LANCET INFECT DIS, V15, P833, DOI 10.1016/S1473-3099(15)00108-5
   Rebeiro PF, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20636
   Silva-Santisteban A, 2016, J INT AIDS SOC, V19, P65, DOI 10.7448/IAS.19.3.20799
   Simoes M, 2018, BRAZILS POLARIZING N
   Stover J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154893
   UNAIDS, UNAIDS DAT 2019
   World Health Organization, 2019, GLOB HLTH OBS GHO DA
NR 33
TC 0
Z9 0
U1 1
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD MAR
PY 2020
VL 23
IS 3
AR e25468
DI 10.1002/jia2.25468
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA KY3BX
UT WOS:000522447100013
PM 32115884
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Castro, R
   Luz, PM
   Banholi, M
   Goldenzon, RV
   Cardoso, SW
   Grinsztejn, B
   Veloso, VG
AF Perazzo, Hugo
   Castro, Rodolfo
   Luz, Paula M.
   Banholi, Mariana
   Goldenzon, Rafaela, V
   Cardoso, Sandra W.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
TI Effectiveness of generic direct-acting agents for the treatment of
   hepatitis C: systematic review and meta-analysis
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Review
ID VIRUS-INFECTION; LIVER-TRANSPLANTATION; VIROLOGICAL RESPONSE; PLUS
   SOFOSBUVIR; ANTIVIRALS; DACLATASVIR; RIBAVIRIN; CIRRHOSIS; EFFICACY
AB Objective To compare the efficacy of generic direct-acting agents and brand-name medicines for treating hepatitis C virus (HCV) infection by conducting a systematic review and meta-analysis.
   Methods We searched online databases for studies that reported sustained virological responses 12 weeks after the end of HCV treatment with generic direct-acting agents. We derived pooled proportions of treated patients with a sustained virological response from intention-to-treat and per-protocol analyses. In addition, we calculated the pooled relative risk (RR) of a sustained virological response brand-name versus generic direct-acting agents using a random-effects model (DerSimonian-Laird) from the data available. Between-study heterogeneity was assessed using the I-2 statistic.
   Findings We identified 19 studies involving a total of 57 433 individuals from eight territories or regions. The pooled overall proportions of patients with a sustained virological response were 98% (95% confidence interval, CI: 97-99; 18 studies; I-2 = 94.1%) in per-protocol analyses and 96% (95% CI: 93-98; 8 studies; I-2 = 68.1%) in intention-to-treat analyses. The likelihood of a sustained virological response with brand-name medicines was similar to that with generic direct-acting agents (RR: 1.00; 95% CI: 0.98-1.02; I-2 = 0.0%). The likelihood of a sustained virological response was significantly higher in patients without than with cirrhosis (RR:1.03; 95% CI: 1.01-1.06; 7 studies) but was not significantly affected by either previous treatment (3 studies) or human immunodeficiency virus coinfection (3 studies).
   Conclusion Generic direct-acting agents are highly effective for treating hepatitis C. Generic agents should be considered in resource-constrained settings for decreasing the burden of liver disease in HCV-infected patients.
C1 [Perazzo, Hugo; Castro, Rodolfo; Luz, Paula M.; Banholi, Mariana; Goldenzon, Rafaela, V; Cardoso, Sandra W.; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
RP Perazzo, H (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM hugo.perazzo@ini.fiocruz.br
RI Castro, Rodolfo/D-4231-2013
OI Castro, Rodolfo/0000-0002-0701-2528; Perazzo, Hugo/0000-0003-0931-6418
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ, Bolsa de Iniciacao Cientifica)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
   [2017/2, 235083]; PIBIC-FIOCRUZ (Programa Institucional de Bolsa de
   Iniciacao Cientifica 2018); INI-FIOCRUZ (Programa de Incentivo a Jovens
   Pesquisadores do INI) [INI-003-19-2-5]
FX This work was supported by the Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ, Bolsa de Iniciacao
   Cientifica 2017/2, grant number 235083 for authors HP and RVG), by
   PIBIC-FIOCRUZ (Programa Institucional de Bolsa de Iniciacao Cientifica
   2018, for HP, RC and MB] and by INI-FIOCRUZ (Programa de Incentivo a
   Jovens Pesquisadores do INI, grant number INI-003-19-2-5 for HP).
CR Abozeid M, 2018, INT J INFECT DIS, V75, P109, DOI 10.1016/j.ijid.2018.07.025
   Adam R, 2012, J HEPATOL, V57, P675, DOI 10.1016/j.jhep.2012.04.015
   Aggarwal R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176503
   [Anonymous], 2018, GIL SUBS LAUNCH AUTH
   [Anonymous], 2019, LIST ANTI PHARM PROD
   [Anonymous], 2016, COMB HEP B C REACH E
   [Anonymous], 2019, STUD QUAL ASS TOOLS
   Blach S, 2017, LANCET GASTROENTEROL, V2, P161, DOI 10.1016/S2468-1253(16)30181-9
   Cattaneo D, 2017, AIDS REV, V19, P167, DOI 10.24875/AIDSRev.M17000002
   Cipriano Lauren E, 2018, MDM Policy Pract, V3, p2381468318776634, DOI 10.1177/2381468318776634
   da Fonseca EM, 2019, NEW ENGL J MED, V380, P605, DOI 10.1056/NEJMp1812959
   El-Nahaas SM, 2018, EUR J GASTROEN HEPAT, V30, P1194, DOI 10.1097/MEG.0000000000001228
   Elsharkawy A, 2018, J HEPATOL, V68, P691, DOI 10.1016/j.jhep.2017.11.034
   Falade-Nwulia O, 2017, ANN INTERN MED, V166, P637, DOI [10.7326/M16-2575, 10.7326/m16-2575]
   Ferrarese A, 2018, WORLD J GASTROENTERO, V24, P4403, DOI 10.3748/wjg.v24.i38.4403
   Goel A, 2018, J GASTROEN HEPATOL, V33, P2029, DOI 10.1111/jgh.14301
   Gupta S, 2018, J VIRAL HEPATITIS, V25, P771, DOI 10.1111/jvh.12870
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Harris RJ, 2008, STATA J, V8, P3, DOI 10.1177/1536867X0800800102
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hill A, 2018, J VIRUS ERAD, V4, P128
   Hill A, 2017, J VIRUS ERAD, V3, P200
   Vargas JI, 2017, REV MED CHILE, V145, P1235, DOI 10.4067/S0034-98872017001001235
   Iyengar S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002032
   Kumar M, 2018, LIVER INT, V38, P2137, DOI 10.1111/liv.13863
   Li YY, 2018, HEPATOL INT, V12, P465, DOI 10.1007/s12072-018-9891-9
   Liu CH, 2018, ALIMENT PHARM THER, V47, P1690, DOI 10.1111/apt.14647
   Liu CH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32060-7
   Lombardi A, 2019, LIVER INT, V39, P416, DOI 10.1111/liv.14011
   Marciano S, 2018, J MED VIROL, V90, P951, DOI 10.1002/jmv.25033
   Merat S, 2017, HEPAT MON, V17, DOI 10.5812/hepatmon.44564
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Myers Samantha, 2018, J Pharm Pharm Sci, V21, p271s, DOI 10.18433/jpps30220
   Nagral A, 2017, J CLIN EXP HEPATOL, V7, P172, DOI 10.1016/j.jceh.2017.08.002
   Nahon P, 2017, GASTROENTEROLOGY, V152, P142, DOI 10.1053/j.gastro.2016.09.009
   National Institute of Health Research, 2019, PROSPERO INT PROSPEC
   Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39
   Omar H, 2018, ALIMENT PHARM THER, V47, P421, DOI 10.1111/apt.14428
   Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
   Pearce JA, 2006, LONG RANGE PLANN, V39, P71, DOI 10.1016/j.lrp.2005.04.006
   Perazzo H, 2019, SUPPLEMENTARY MAT EF, DOI [10.5281/zenodo.3476933, DOI 10.5281/ZENODO.3476933]
   Perazzo H, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0676-8
   Pol S, 2017, J HEPATOL, V66, P39, DOI 10.1016/j.jhep.2016.08.021
   Sharafi H, 2017, HEPAT MON, V17, DOI 10.5812/hepatmon.12216
   Shousha HI, 2018, HEPAT MON, V18, DOI 10.5812/hepatmon.78777
   Siqueira FM, 2018, REV INST MED TROP SP, V60, DOI [10.1590/S1678-9946201860072, 10.1590/s1678-9946201860072]
   Sulkowski MS, 2016, GASTROENTEROLOGY, V150, P419, DOI 10.1053/j.gastro.2015.10.013
   Reggiardo MV, 2012, ANN HEPATOL, V11, P658
   Ward T, 2016, PUBLIC HEALTH, V141, P42, DOI 10.1016/j.puhe.2016.08.002
   Yakoot M, 2017, EBIOMEDICINE, V21, P182, DOI 10.1016/j.ebiom.2017.05.011
   Yakoot M, 2016, DRUG DES DEV THER, V10, P2659, DOI 10.2147/DDDT.S111496
   Zeng QL, 2017, J HEPATOL, V66, P1123, DOI 10.1016/j.jhep.2017.01.025
NR 52
TC 1
Z9 1
U1 0
U2 2
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
EI 1564-0604
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD MAR
PY 2020
VL 98
IS 3
BP 188
EP +
DI 10.2471/BLT.19.231522
PG 20
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA KS5XW
UT WOS:000518382600017
PM 32132753
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Castro, R
   Perazzo, H
   de Araujo, LAMM
   Gutierres, IG
   Grinsztejn, B
   Veloso, VG
AF Castro, Rodolfo
   Perazzo, Hugo
   Artilles Mello Mendonca de Araujo, Leticia
   Gutierres, Isabella Goncalves
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
TI Effectiveness of implementing a decentralized delivery of hepatitis C
   virus treatment with direct-acting antivirals: A systematic review with
   meta-analysis
SO PLOS ONE
LA English
DT Review
ID REAL-WORLD; CARE; SOFOSBUVIR; SAFETY; REGIMENS; THERAPY; PROGRAM
AB Direct-acting agents (DAAs) for hepatitis C virus (HCV) treatment are safe and highly effective. Few studies described the sustained virologic response rates of treatment conducted by non-specialists. We performed a systematic review and meta-analysis to evaluate the effectiveness of decentralized strategies of HCV treatment with DAAs. PubMed, Embase, Scopus and LILACS were searched until March-2019. Studies were screened by two researchers according to the following inclusion criteria: HCV treatment using DAAs on real-life cohort studies or clinical trials conducted by non-specialized health personnel. The primary endpoint was the sustained virologic response rate at week 12 after the end-of-treatment (SVR12), which is binary at the patient level. Data were extracted in duplicate using electronic-forms and quality appraisal was performed with the NIH Quality Assessment Tool. Heterogeneity was assessed by I-2 statistics. Random-effects meta-analysis models were used for pooling SVR12 rates. Publication bias was assessed using funnel plots. Among the 130 selected studies, nine papers were included for quantitative synthesis. The quality-appraisal was good for two, fair for three and poor for four studies. The pooled relative risk (RR) of SVR12 was not statistically different between decentralized strategy and treatment by specialists [RR = 1.05; 95% confidence interval (95% CI): 0.98-1.1; I-2 = 45% (95% CI: 0-84%), p = 0.145]. SVR12 rate for decentralized HCV treatment was 81% [SVR12 95% CI: 72-89%; I-2 = 93% (95% CI: 88-96%)] and 95% [SVR12 95%CI: 92-98%; I-2 = 77% (95% CI: 52-89%)] with intention to treat analysis and per-protocol analysis, respectively. SVR12 rates using DAAs managed by non-specialized health personnel were satisfactory and similar to those obtained by specialists. This new delivery strategy can improve access to HCV treatment, especially in resource-limited settings.
C1 [Castro, Rodolfo; Artilles Mello Mendonca de Araujo, Leticia; Gutierres, Isabella Goncalves] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, RJ, Brazil.
   [Castro, Rodolfo] Univ Fed Estado Rio de Janeiro, Inst Saude Colet, Rio De Janeiro, RJ, Brazil.
   [Perazzo, Hugo; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
RP Castro, R (corresponding author), Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, RJ, Brazil.; Castro, R (corresponding author), Univ Fed Estado Rio de Janeiro, Inst Saude Colet, Rio De Janeiro, RJ, Brazil.
EM rodolfoalcastro@gmail.com
RI Castro, Rodolfo/D-4231-2013
OI Castro, Rodolfo/0000-0002-0701-2528; Perazzo, Hugo/0000-0003-0931-6418
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -CNPq
   through Programa Institucional de Bolsas de Iniciacao Cientifica -
   PIBIC/CNPqNational Council for Scientific and Technological Development
   (CNPq); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   -CNPq through Programa Institucional de Bolsas de Iniciacao em
   Desenvolvimento Tecnologico e Inovacao - PIBITI/CNPq at Fundacao Oswaldo
   Cruz (FIOCRUZ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico -CNPq through Programa de Incentivo a Jovens Pesquisadores
   at Instituto Nacional de Infectologia Evandro Chagas - INI/FIOCRUZ
FX This study was funded by Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico -CNPq (http://cnpq.br/) through these research grants:
   Programa Institucional de Bolsas de Iniciacao Cientifica - PIBIC/CNPq
   (http://cnpq.br/pibic) [RC, LAMMA], Programa Institucional de Bolsas de
   Iniciacao em Desenvolvimento Tecnologico e Inovacao - PIBITI/CNPq
   (http://cnpq.br/pibiti) [RC,IGG] at Fundacao Oswaldo Cruz (FIOCRUZ), and
   Programa de Incentivo a Jovens Pesquisadores at Instituto Nacional de
   Infectologia Evandro Chagas - INI/FIOCRUZ (https://www.ini.fiocruz.br/)
   [HP]. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aghemo A, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25076
   Andreone P, 2019, DIGEST LIVER DIS, V51, P915, DOI 10.1016/j.dld.2019.03.033
   Baker D, 2018, MED J AUSTRALIA, V208, P190, DOI 10.5694/mja17.00733
   Beste LA, 2017, AM J MED, V130, P432, DOI 10.1016/j.amjmed.2016.11.019
   Butt AA, 2019, CLIN INFECT DIS, V68, P857, DOI 10.1093/cid/ciy697
   Capileno YA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175562
   Carrat F, 2019, LANCET, V393, P1453, DOI 10.1016/S0140-6736(18)32111-1
   Christensen S, 2018, ADDICTION, V113, P868, DOI 10.1111/add.14128
   Chun HS, 2020, EUR J GASTROEN HEPAT, V32, P378, DOI 10.1097/MEG.0000000000001512
   Fehily SR, 2019, SEMIN LIVER DIS, V39, P341, DOI 10.1055/s-0039-1685538
   Fernandes FF, 2019, J GASTROEN HEPATOL, V34, P2187, DOI 10.1111/jgh.14707
   Ford N, 2014, J HEPATOL, V61, pS132, DOI 10.1016/j.jhep.2014.09.019
   Gupta N, 2019, LANCET GASTROENTEROL, V4, P119, DOI 10.1016/S2468-1253(18)30382-0
   Hajarizadeh B, 2018, J VIRAL HEPATITIS, V25, P640, DOI 10.1111/jvh.12852
   Haridy J, 2018, J VIRAL HEPATITIS, V25, P1287, DOI 10.1111/jvh.12943
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Harris RJ, 2008, STATA J, V8, P3, DOI 10.1177/1536867X0800800102
   Hong CM, 2020, J MICROBIOL IMMUNOL, V53, P569, DOI 10.1016/j.jmii.2018.09.005
   Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80
   Ioannou GN, 2016, GASTROENTEROLOGY, V151, P457, DOI 10.1053/j.gastro.2016.05.049
   Jayasekera CR, 2015, DIGEST DIS SCI, V60, P3552, DOI 10.1007/s10620-015-3911-6
   Jonathan S., 2003, METAFUNNEL STATA MOD
   Kattakuzhy S, 2017, ANN INTERN MED, V167, P311, DOI [10.7326/M17-0118, 10.7326/m17-0118]
   Kontopantelis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069930
   Kontopantelis E, 2010, STATA J, V10, P395, DOI 10.1177/1536867X1001000307
   Kracht P A M, 2018, Hepatol Med Policy, V3, P12, DOI 10.1186/s41124-018-0040-9
   Lasser KE, 2017, ANN FAM MED, V15, P258, DOI 10.1370/afm.2069
   Lee A, 2018, J VIRUS ERAD, V4, P160
   Calleja JL, 2017, J HEPATOL, V66, P1138, DOI 10.1016/j.jhep.2017.01.028
   Marciano S, 2018, J MED VIROL, V90, P951, DOI 10.1002/jmv.25033
   Nicola O, 2005, HETEROGI STATA MODUL
   Nouch S, 2018, INT J DRUG POLICY, V59, P76, DOI 10.1016/j.drugpo.2018.06.019
   Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39
   Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
   Razavi H, 2017, LANCET GASTROENTEROL, V2, P325, DOI 10.1016/S2468-1253(17)30045-6
   Read P, 2017, INT J DRUG POLICY, V47, P209, DOI 10.1016/j.drugpo.2017.05.032
   Robert MH, 2000, METABIAS STATA MODUL
   Rumi MG, 2018, SEMIN LIVER DIS, V38, P112, DOI 10.1055/s-0038-1655774
   Schroeder SE, 2019, LIVER INT, V39, P1818, DOI 10.1111/liv.14222
   Siederdissen CHZ, 2018, UNITED EUR GASTROENT, V6, P213, DOI 10.1177/2050640617716607
   Sikavi C, 2018, DIGEST DIS SCI, V63, P2829, DOI 10.1007/s10620-018-5215-0
   Takaguchi K, 2019, J GASTROENTEROL, V54, P742, DOI 10.1007/s00535-019-01568-8
   Wade AJ, 2018, J VIRAL HEPATITIS, V25, P1089, DOI 10.1111/jvh.12910
   Wehmeyer MH, 2018, J MED VIROL, V90, P304, DOI 10.1002/jmv.24903
   Welzel TM, 2017, GUT, V66, P1844, DOI 10.1136/gutjnl-2016-311609
   World Health Organization, 2016, COMB HEP B C REACH E
   World Health Organization, 2017, GLOB HEP REP 2017
   Yek C, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0969-3
NR 48
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2020
VL 15
IS 2
AR e0229143
DI 10.1371/journal.pone.0229143
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LQ8DJ
UT WOS:000535227900061
PM 32084187
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Dooley, KE
   Kaplan, R
   Mwelase, N
   Grinsztejn, B
   Ticona, E
   Lacerda, M
   Sued, O
   Belonosova, E
   Ait-Khaled, M
   Angelis, K
   Brown, D
   Singh, R
   Talarico, CL
   Tenorio, AR
   Keegan, MR
   Aboud, M
AF Dooley, Kelly E.
   Kaplan, Richard
   Mwelase, Noluthando
   Grinsztejn, Beatriz
   Ticona, Eduardo
   Lacerda, Marcus
   Sued, Omar
   Belonosova, Elena
   Ait-Khaled, Mounir
   Angelis, Konstantinos
   Brown, Dannae
   Singh, Rajendra
   Talarico, Christine L.
   Tenorio, Allan R.
   Keegan, Michael R.
   Aboud, Michael
CA Int Study Patients HIV Rifampicin
TI Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With
   Tuberculosis and Human Immunodeficiency Virus: A Multicenter,
   Noncomparative, Open-label, Randomized Trial
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV; tuberculosis; dolutegravir; efavirenz; immune reconstitution
   inflammatory syndrome
ID DRUG-INTERACTIONS; HIV; RIFAMPIN; NEVIRAPINE; EFAVIRENZ; ADULTS
AB Background: The concurrent treatment of tuberculosis and human immunodeficiency virus (HIV) is challenging, owing to drug interactions, overlapping toxicities, and immune reconstitution inflammatory syndrome (IRIS). The efficacy and safety of dolutegravir (DTG) were assessed in adults with HIV and drug-susceptible tuberculosis.
   Methods: International Study of Patients with HIV on Rifampicin ING is a noncomparative, active-control, randomized, open-label study in HIV-1-infected antiretroviral therapy-naive adults (CD4+ >= 50 cells/mm(3)). Participants on rifampicin-based tuberculosis treatment <= 8 weeks were randomized (3:2) to receive DTG (50 mg twice daily both during and 2 weeks after tuberculosis therapy, then 50 mg once daily) or efavirenz (EFV; 600 mg daily) with 2 nucleoside reverse transcriptase inhibitors for 52 weeks. The primary endpoint was the proportion of DTG-arm participants with plasma HIV-1-RNA <50 copies/mL (responders) by the Food and Drug Administration Snapshot algorithm (intent-to-treat exposed population) at Week 48. The study was not powered to compare arms.
   Results: For DTG (n = 69), the baseline HIV-1 RNA was >100 000 copies/mL in 64% of participants, with a median CD4+ count of 208 cells/mm(3); for EFV (n = 44), 55% of participants had HIV-1 RNA >100 000 copies/mL, with a median CD4+ count of 202 cells/mm(3). The Week 48 response rates were 75% (52/69, 95% confidence interval [CI] 65-86%) for DTG and 82% (36/44, 95% CI 70-93%) for EFV. The DTG nonresponses were driven by non-treatment related discontinuations (n = 10 lost to follow-up). There were no deaths or study drug switches. There were 2 discontinuations for toxicity (EFV). There were 3 protocol-defined virological failures (2 DTG, no acquired resistance; 1 EFV, emergent resistance to nucleoside reverse transcriptase inhibitors and nonnucleoside reverse transcriptase inhibitors). The tuberculosis treatment success rate was high. Tuberculosis-associated IRIS was uncommon (4/arm), with no discontinuations for IRIS.
   Conclusions: Among adults with HIV receiving rifampicin-based tuberculosis treatment, twice-daily DTG was effective and well tolerated.
C1 [Dooley, Kelly E.] Johns Hopkins Univ, Sch Med, Ctr TB Res, Baltimore, MD USA.
   [Kaplan, Richard] Desmond Tutu Human Immunodeficiency Virus HIV Fdn, Cape Town, South Africa.
   [Mwelase, Noluthando] Clin HIV Res Unit, Johannesburg, South Africa.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Ticona, Eduardo] Univ Nacl Mayor San Marcos, Hosp Nacl Mayo, Lima, Peru.
   [Lacerda, Marcus] Trop Med Fdn Dr Heitor Vieira Dourado, FIOCRUZ, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
   [Sued, Omar] Fdn Hasped, Buenos Aires, DF, Argentina.
   [Belonosova, Elena] Reg Ctr Prevent & Treatment Acquired Immunodefici, Oryol, Russia.
   [Ait-Khaled, Mounir; Keegan, Michael R.; Aboud, Michael] ViiV Healthcare Ltd, Brentford, England.
   [Angelis, Konstantinos] GlaxeSmithKfine, Uxbridge, Middx, England.
   [Brown, Dannae] ViiV Healthcare Ltd, Melbourne, Vic, Australia.
   [Singh, Rajendra] GlaxoSmithKline, Collegeville, PA USA.
   [Talarico, Christine L.; Tenorio, Allan R.] ViiV Healthcare, Res Triangle Pk, NC USA.
RP Dooley, KE (corresponding author), Johns Hopkins Univ, Sch Med, 600 N Wolfe St,Osler 527, Baltimore, MD 21218 USA.
EM kdooley1@jhmi.edu
FU ViiV Healthcare
FX This work was supported by ViiV Healthcare.
CR [Anonymous], 2016, CONGUID UANT DRU
   Atwine D, 2018, BRIT J CLIN PHARMACO, V84, P1641, DOI 10.1111/bcp.13600
   Baciewicz AM, 2013, CURR MED RES OPIN, V29, P1, DOI 10.1185/03007995.2012.747952
   Bhatt NB, 2015, J ANTIMICROB CHEMOTH, V70, P225, DOI 10.1093/jac/dku348
   Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911
   Bonnet M, 2013, LANCET INFECT DIS, V13, P303, DOI 10.1016/S1473-3099(13)70007-0
   Cottrell ML, 2013, CLIN PHARMACOKINET, V52, P981, DOI 10.1007/s40262-013-0093-2
   Custodio JM, 2018, C RETR OPP INF
   Decloedt EH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032173
   DICKINSON JM, 1981, AM REV RESPIR DIS, V123, P367
   Dooley K, 2012, INT ADV EDU-GLOB, P3
   Dooley KE, 2008, J INFECT DIS, V198, P948, DOI 10.1086/591459
   Emmelkamp JM, 2007, EUR J MED RES, V12, P409
   Gibb D, 2018, P C RETR OPP INF BOS
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P459, DOI 10.1016/S1473-3099(14)70711-X
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   Hill AM, 2018, CURR OPIN HIV AIDS, V13, P102, DOI [10.1097/coh.0000000000000445, 10.1097/COH.0000000000000445]
   Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181
   Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848
   Manosuthi W, 2016, AIDS RES THER, V13, DOI 10.1186/s12981-016-0106-y
   Manosuthi W, 2009, CLIN INFECT DIS, V48, P1752, DOI 10.1086/599114
   McIlleron H, 2007, J INFECT DIS, V196, pS63, DOI 10.1086/518655
   Psichogiou M, 2017, CURR HIV RES, V15, P405, DOI 10.2174/1570162X15666171122155708
   Rabie H, 2017, EXPERT OPIN PHARMACO, V18, P589, DOI 10.1080/14656566.2017.1309023
   Raizes E, 2017, J INFECT DIS, V216, pS805, DOI 10.1093/infdis/jix432
   Sinha S, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2864-0
   Nguyen T, 2016, AIDS REV, V18, P101
   van Lunzen J, 2012, LANCET INFECT DIS, V12, P111, DOI 10.1016/S1473-3099(11)70290-0
   Wang X, 2018, PHARMACOKINETICS DOL
   WEHRLI W, 1983, REV INFECT DIS, V5, pS407
   WHO, 2017, GUID TREATM DRUG SUS
   WHO, 2017, HIV DRUG RES REP 201
   World Health Organization, 2018, WHOCDSTB201820
   World Health Organization, 2018, UPD ANT REG TREAT PR
NR 34
TC 12
Z9 12
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD FEB 15
PY 2020
VL 70
IS 4
BP 549
EP 556
DI 10.1093/cid/ciz256
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA KS8AZ
UT WOS:000518529000001
PM 30918967
OA Other Gold
DA 2020-11-24
ER

PT J
AU Tolley, EE
   Zangeneh, SZ
   Chau, G
   Eron, J
   Grinsztejn, B
   Humphries, H
   Liu, A
   Siegel, M
   Bertha, M
   Panchia, R
   Li, S
   Cottle, L
   Rinehart, A
   Margolis, D
   Jennings, A
   McCauley, M
   Landovitz, RJ
AF Tolley, Elizabeth E.
   Zangeneh, Sahar Z.
   Chau, Gordon
   Eron, Joe
   Grinsztejn, Beatriz
   Humphries, Hilton
   Liu, Albert
   Siegel, Marc
   Bertha, Maseko
   Panchia, Ravindre
   Li, Sue
   Cottle, Leslie
   Rinehart, Alex
   Margolis, David
   Jennings, Andrea
   McCauley, Marybeth
   Landovitz, Raphael J.
TI Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in
   HIV-Uninfected Individuals: HPTN 077
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV prevention; Clinical trial; Acceptability; PrEP; Injectable;
   Females; Males
ID PREEXPOSURE PROPHYLAXIS PREP; ADHERENCE; WOMEN; PREVENTION; INFECTION;
   SAFETY; RISK
AB Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninfected males and females in sequentially-enrolled cohorts of two dosing strategies. We compared acceptability of product attributes, prevention preferences and future interest in injectable PrEP (FIIP) by region, sex-at-birth, arm and cohort and used multivariable analysis to identify FIIP determinants. Baseline injectable PrEP preferences were higher in non-U.S. sites and increased in both regions over time. In multivariable models, FIIP was most strongly associated with acceptability of product attributes, was higher in non-U.S. sites and more altruistic participants. Treatment arm and report of pain were not associated with FIIP. Injectable acceptability was highest in non-U.S. sites. Preferences for injectable versus other PrEP methods were higher among U.S. males than females, but higher among males and females in non-U.S. settings.
C1 [Tolley, Elizabeth E.] Behav Epidemiol & Behav Sci, FHI 360,359 Blackwell St, Durham, NC 27701 USA.
   [Zangeneh, Sahar Z.; Chau, Gordon; Li, Sue; Cottle, Leslie] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Eron, Joe] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Humphries, Hilton] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Durban, South Africa.
   [Liu, Albert] San Francisco Dept Publ Hlth, Bridge HIV Populat Hlth Div, San Francisco, CA USA.
   [Siegel, Marc] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA.
   [Bertha, Maseko] UNC Project Malawi, Lilongwe, Malawi.
   [Panchia, Ravindre] Chris Hani Baragwanath Hosp, Perinatal HIV Res Unit, Soweto, South Africa.
   [Rinehart, Alex; Margolis, David] ViiV Healthcare, Durham, NC USA.
   [Jennings, Andrea] Sci Facilitat, FHI 360, Durham, NC USA.
   [McCauley, Marybeth] Sci Facilitat, FHI 360, Washington, DC USA.
   [Landovitz, Raphael J.] UCLA Ctr Clin AIDS Res & Educ, Los Angeles, CA USA.
RP Tolley, EE (corresponding author), Behav Epidemiol & Behav Sci, FHI 360,359 Blackwell St, Durham, NC 27701 USA.
EM btolley@fhi360.org
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI068619, UM1AI068617]; District of Columbia Developmental Center
   for AIDS Research [AI117970]
FX Funding was provided by National Institute of Allergy and Infectious
   Diseases (Grant Nos. UM1AI068619 and UM1AI068617) and District of
   Columbia Developmental Center for AIDS Research (Grant No. AI117970).
CR Aaron E, 2018, AIDS PATIENT CARE ST, V32, P16, DOI 10.1089/apc.2017.0201
   Amico KR, 2014, JAIDS-J ACQ IMM DEF, V66, P530, DOI 10.1097/QAI.0000000000000216
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bekker L-G, 2017, C RETR OPP INF CROI
   Benitez-Gutierrez L, 2018, EXPERT REV CLIN PHAR, V11, P507, DOI 10.1080/17512433.2018.1453805
   Calabrese SK, 2017, AM J PUBLIC HEALTH, V107, P1883, DOI 10.2105/AJPH.2017.304061
   Calabrese SK, 2017, AIDS PATIENT CARE ST, V31, P196, DOI 10.1089/apc.2017.0002
   CDC, 2019, EST HIV INC PREV US, V24
   Corneli A, 2014, JAIDS-J ACQ IMM DEF, V67, P555, DOI 10.1097/QAI.0000000000000362
   Delany-Moretlwe S, 2016, CURR OPIN HIV AIDS, V11, P87, DOI 10.1097/COH.0000000000000221
   Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4
   Eakle R, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0408-3
   Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hodder SL, 2010, JAIDS-J ACQ IMM DEF, V55, pS69, DOI 10.1097/QAI.0b013e3181fbbdf9
   Hosek SG, 2017, JAIDS-J ACQ IMM DEF, V74, P21, DOI 10.1097/QAI.0000000000001179
   Huang YLA, 2018, MMWR-MORBID MORTAL W, V67, P1147, DOI 10.15585/mmwr.mm6741a3
   Kerrigan D, 2018, AIDS BEHAV, V22, P3540, DOI 10.1007/s10461-017-2017-x
   Lambert CC, 2018, J ASSOC NURSE AIDS C, V29, P835, DOI 10.1016/j.jana.2018.03.005
   Landovitz RJ, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002690
   Landovitz RJ, 2016, CURR OPIN HIV AIDS, V11, P122, DOI 10.1097/COH.0000000000000219
   MacQueen KM, 2016, AIDS BEHAV, V20, P2682, DOI 10.1007/s10461-016-1339-4
   Markowitz M, 2017, LANCET HIV, V4, pE331, DOI 10.1016/S2352-3018(17)30068-1
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Meyers K, 2018, AIDS BEHAV, V22, P1209, DOI 10.1007/s10461-017-1871-x
   Mugo NR, 2016, CURR OPIN HIV AIDS, V11, P80, DOI 10.1097/COH.0000000000000224
   Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174
   PEPE MS, 1994, COMMUN STAT SIMULAT, V23, P939, DOI 10.1080/03610919408813210
   Roberts ST, 2016, JAIDS-J ACQ IMM DEF, V73, P313, DOI 10.1097/QAI.0000000000001093
   Sidebottom D, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3463-4
   Tolley EE, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25408
   Tsui AO, 2017, POPUL DEV REV, V43, P166, DOI 10.1111/padr.12051
   UN Women, 2018, FACTS FIG HIV AIDS
   UNAIDS, 2019, UNAIDS DAT 2019
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   van der Straten A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089118
   Venter WDF, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00188
   World Health Organization, 2018, HIV AIDS, V19, P2018
NR 38
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD SEP
PY 2020
VL 24
IS 9
BP 2520
EP 2531
DI 10.1007/s10461-020-02808-2
EA FEB 2020
PG 12
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA MZ5QI
UT WOS:000513030600001
PM 32052214
OA Green Published, Other Gold
DA 2020-11-24
ER

PT J
AU Caetano, DG
   de Paula, HHS
   Bello, G
   Hoagland, B
   Villela, LM
   Grinsztejn, B
   Veloso, VG
   Morgado, MG
   Guimaraes, ML
   Cortes, FH
AF Caetano, Diogo G.
   de Paula, Hury H. S.
   Bello, Gonzalo
   Hoagland, Brenda
   Villela, Larissa M.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Morgado, Mariza G.
   Guimaraes, Monick L.
   Cortes, Fernanda H.
TI HIV-1 elite controllers present a high frequency of activated regulatory
   T and Th17 cells
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE ACTIVATION; DISEASE PROGRESSION;
   ANTIRETROVIRAL THERAPY; VIRAL REPLICATION; LYMPHOID-TISSUE; NEUTROPHIL
   RECRUITMENT; INFECTED PATIENTS; CUTTING EDGE; RNA LEVELS
AB HIV-1 infection is characterized by generalized deregulation of the immune system, resulting in increased chronic immune activation. However, some individuals called HIV controllers (HICs) present spontaneous control of viral replication and have a more preserved immune system. Among HICs, discordant results have been observed regarding immune activation and the frequency of different T cell subsets, including Treg and Th17 cells. We evaluated T cell immune activation, differentiation and regulatory profiles in two groups of HICs-elite controllers (ECs) and viremic controllers (VCs)-and compared them to those of cART-treated individuals (cART) and HIV-1-negative (HIV-neg) individuals. ECs demonstrated similar levels of activated CD4(+) and CD8(+) T cells in comparison to HIV-neg, while cART and VCs showed elevated T cell activation. CD4(+) T cell subset analyses showed differences only for transitional memory T cell frequency between the EC and HIVneg groups. However, VC individuals showed higher frequencies of terminally differentiated, naive, and stem cell memory T cells and lower frequencies of transitional memory and central memory T cells compared to the HIV-neg group. Among CD8(+) T cell subsets, ECs presented higher frequencies of stem cell memory T cells, while VCs presented higher frequencies of terminally differentiated T cells compared to the HIV-neg group. HICs showed lower frequencies of total Treg cells compared to the HIV-neg and cART groups. ECs also presented higher frequencies of activated and a lower frequency of resting Treg cells than the HIV-neg and cART groups. Furthermore, we observed a high frequency of Th17 cells in ECs and high Th17/Treg ratios in both HIC groups. Our data showed that ECs had low levels of activated T cells and a high frequency of activated Treg and Th17 cells, which could restrict chronic immune activation and be indicative of a preserved mucosal response in these individuals.
C1 [Caetano, Diogo G.; de Paula, Hury H. S.; Bello, Gonzalo; Morgado, Mariza G.; Guimaraes, Monick L.; Cortes, Fernanda H.] Fiocruz MS, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz IOC, Rio De Janeiro, Brazil.
   [Hoagland, Brenda; Villela, Larissa M.; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Rio De Janeiro, Brazil.
RP Cortes, FH (corresponding author), Fiocruz MS, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz IOC, Rio De Janeiro, Brazil.
EM fheloise@ioc.fiocruz.br
FU PrInt Fiocruz-CAPES Program; Fundacao de Amparo a Pesquisa do Estado do
   Rio de Janeiro -FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico -CNPqNational Council for
   Scientific and Technological Development (CNPq); Fiocruz; CNPqNational
   Council for Scientific and Technological Development (CNPq); FIOCRUZ
   PDTIS Flow Cytometry Platform [RPT08A]
FX This work was supported by the PrInt Fiocruz-CAPES Program, the Fundacao
   de Amparo a Pesquisa do Estado do Rio de Janeiro -FAPERJ and the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -CNPq and
   Fiocruz. MLG, GB, and MGM are recipients of a CNPq Fellowship. A CNPq
   Ph.D. fellowship funds DGC. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.; We thank the patients, nurses, and clinicians who
   participated in the study. We also thank Egydio Sampaio for support in
   the recruitment of patients and all INI staff from the blood collection
   sector. Finally, we thank CD4+ T cell counts and HIV-1 viral load
   clinical services from the Brazilian Ministry of Health National
   Network, and the FIOCRUZ PDTIS Flow Cytometry Platform (RPT08A).
CR Aandahl EM, 2004, J VIROL, V78, P2454, DOI 10.1128/JVI.78.5.2454-2459.2004
   Almeida CAM, 2002, AIDS RES HUM RETROV, V18, P1351, DOI 10.1089/088922202320935429
   Anderson AM, 2017, J INFECT DIS, V215, P105, DOI 10.1093/infdis/jiw505
   Andersson J, 2005, J IMMUNOL, V174, P3143, DOI 10.4049/jimmunol.174.6.3143
   Angin M, 2012, J INFECT DIS, V205, P1495, DOI 10.1093/infdis/jis236
   Baker CAR, 2007, CLIN EXP IMMUNOL, V147, P533, DOI 10.1111/j.1365-2249.2006.03319.x
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Bi X, 2009, EUR J IMMUNOL, V39, P301, DOI 10.1002/eji.200838667
   Biancotto A, 2007, BLOOD, V109, P4272, DOI 10.1182/blood-2006-11-055764
   Boffito M, 2020, AIDS RES HUM RETROV, V36, P13, DOI [10.1089/aid.2019.0171, 10.1089/AID.2019.0171]
   Brandt L, 2011, JAIDS-J ACQ IMM DEF, V57, P101, DOI 10.1097/QAI.0b013e318215a991
   Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874
   Breton G, 2013, J IMMUNOL, V191, P2194, DOI 10.4049/jimmunol.1200646
   Burgers WA, 2009, J IMMUNOL, V182, P4751, DOI 10.4049/jimmunol.0803801
   Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445
   Caetano DG, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0444-z
   Card CM, 2012, JAIDS-J ACQ IMM DEF, V59, P427, DOI 10.1097/QAI.0b013e3182454fcd
   Cecchinato V, 2008, MUCOSAL IMMUNOL, V1, P279, DOI 10.1038/mi.2008.14
   Chase AJ, 2008, J VIROL, V82, P8307, DOI 10.1128/JVI.00520-08
   Chevalier MF, 2013, BLOOD, V121, P29, DOI 10.1182/blood-2012-07-409755
   Christensen-Quick A, 2019, J VIROL, V93, DOI 10.1128/JVI.00179-19
   Chun TW, 2008, J INFECT DIS, V197, P714, DOI 10.1086/527324
   Ciccone EJ, 2011, J VIROL, V85, P5880, DOI 10.1128/JVI.02643-10
   Cohen J, 2011, SCIENCE, V334, P1614, DOI 10.1126/science.334.6063.1614
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463
   Cortes FH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01576
   Cortes FH, 2015, JAIDS-J ACQ IMM DEF, V68, P377, DOI 10.1097/QAI.0000000000000500
   Dandekar S, 2010, CURR OPIN HIV AIDS, V5, P173, DOI 10.1097/COH.0b013e328335eda3
   de Azevedo SSD, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0354-5
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Doisne JM, 2004, J IMMUNOL, V173, P2410, DOI 10.4049/jimmunol.173.4.2410
   Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053
   Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407
   Elrefaei M, 2004, J IMMUNOL, V173, P2184, DOI 10.4049/jimmunol.173.3.2184
   Falivene J, 2015, SCI REP-UK, V5, DOI 10.1038/srep11511
   Favre D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000295
   Flannigan KL, 2017, MUCOSAL IMMUNOL, V10, P673, DOI 10.1038/mi.2016.80
   French MA, 2009, J INFECT DIS, V200, P1212, DOI 10.1086/605890
   Gaardbo JC, 2014, JAIDS-J ACQ IMM DEF, V65, P10, DOI 10.1097/QAI.0b013e3182a7c932
   Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446
   Ghiglione Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104235
   GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Griffin GK, 2012, J IMMUNOL, V188, P6287, DOI 10.4049/jimmunol.1200385
   Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380
   Hasenkrug KJ, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006776
   He T, 2016, J IMMUNOL, V197, P4535, DOI 10.4049/jimmunol.1601539
   Hryniewicz A, 2006, BLOOD, V108, P3834, DOI 10.1182/blood-2006-04-010637
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Hunt PW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015924
   Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786
   Jenabian MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078146
   Jiang W, 2014, J VIROL, V88, P5369, DOI 10.1128/JVI.00017-14
   Jiao YM, 2009, IMMUNOLOGY, V128, pe366, DOI 10.1111/j.1365-2567.2008.02978.x
   Kinter A, 2007, P NATL ACAD SCI USA, V104, P3390, DOI 10.1073/pnas.0611423104
   Klatt NR, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004345
   Krishnan S, 2014, J INFECT DIS, V209, P931, DOI 10.1093/infdis/jit581
   Kulpa DA, 2019, J VIROL, V93, DOI 10.1128/JVI.00969-19
   Lederman MM, 2011, J INFECT DIS, V204, P1217, DOI 10.1093/infdis/jir507
   Li GM, 2017, J INFECT DIS, V216, P1579, DOI 10.1093/infdis/jix547
   Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308
   Lima VD, 2007, AIDS, V21, P685, DOI 10.1097/QAD.0b013e32802ef30c
   Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003
   Luo ZW, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0646-1
   Macal M, 2008, MUCOSAL IMMUNOL, V1, P475, DOI 10.1038/mi.2008.35
   Mens H, 2010, J VIROL, V84, P12971, DOI 10.1128/JVI.00387-10
   Mildvan D, 2005, CLIN INFECT DIS, V40, P853, DOI 10.1086/427877
   Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0
   Moir S, 2011, ANNU REV PATHOL-MECH, V6, P223, DOI 10.1146/annurev-pathol-011110-130254
   Montes M, 2011, J INFECT DIS, V203, P496, DOI 10.1093/infdis/jiq073
   Ndhlovu LC, 2008, AIDS, V22, P990, DOI 10.1097/QAD.0b013e3282ff884e
   Nikolova M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002110
   Nilsson J, 2006, BLOOD, V108, P3808, DOI 10.1182/blood-2006-05-021576
   Okulicz J F., 2012, J AIDS CLIN RES, V03, DOI [10.4172/2155-6113.1000139, DOI 10.4172/2155-6113.1000139]
   Owen RE, 2010, AIDS, V24, P1095, DOI 10.1097/QAD.0b013e3283377a1e
   Pereyra F, 2012, AIDS, V26, P2409, DOI 10.1097/QAD.0b013e32835a9950
   Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683
   Piconi S, 2010, AIDS, V24, P1991, DOI 10.1097/QAD.0b013e32833c93ce
   Popovic M, 2005, P NATL ACAD SCI USA, V102, P14807, DOI 10.1073/pnas.0506857102
   Potter SJ, 2007, J VIROL, V81, P13904, DOI 10.1128/JVI.01401-07
   Prendergast A, 2010, AIDS, V24, P491, DOI 10.1097/QAD.0b013e3283344895
   RABIN RL, 1995, J CLIN INVEST, V95, P2054, DOI 10.1172/JCI117891
   Raffatellu M, 2008, NAT MED, V14, P421, DOI 10.1038/nm1743
   Ribeiro SP, 2014, J VIROL, V88, P13836, DOI 10.1128/JVI.01948-14
   Rodger AJ, 2019, LANCET, V393, P2428, DOI 10.1016/S0140-6736(19)30418-0
   ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892
   Saez-Cirion A, 2013, IMMUNOL REV, V254, P281, DOI 10.1111/imr.12076
   Salgado M, 2011, CLIN IMMUNOL, V139, P110, DOI 10.1016/j.clim.2011.02.008
   Shaw JM, 2011, J VIROL, V85, P11422, DOI 10.1128/JVI.05608-11
   Simonetta F, 2012, J INFECT DIS, V205, P1510, DOI 10.1093/infdis/jis235
   Sokoya T, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/6825493
   Suchard MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011762
   Teeraananchai S, 2017, HIV MED, V18, P256, DOI 10.1111/hiv.12421
   Tsunemi S, 2005, AIDS, V19, P879, DOI 10.1097/01.aids.0000171401.23243.56
   Valverde-Villegas JM, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/647916
   Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427
   Younas M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02185
   Zangerle R, 1998, INT ARCH ALLERGY IMM, V116, P228, DOI 10.1159/000023949
   Zelinskyy G, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000406
   zur Wiesch JS, 2011, J VIROL, V85, P1287, DOI 10.1128/JVI.01758-10
NR 103
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 5
PY 2020
VL 15
IS 2
AR e0228745
DI 10.1371/journal.pone.0228745
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LP9FN
UT WOS:000534621500066
PM 32023301
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Delagreverie, HM
   Bauduin, C
   De Castro, N
   Grinsztejn, B
   Chevrier, M
   Jouenne, F
   Mourah, S
   Kalidi, I
   Pilotto, JH
   Brites, C
   Barcellos, NT
   Amara, A
   Wittkop, L
   Molina, JM
   Delaugerre, C
AF Delagreverie, Heloise M.
   Bauduin, Claire
   De Castro, Nathalie
   Grinsztejn, Beatriz
   Chevrier, Marc
   Jouenne, Fanelie
   Mourah, Samia
   Kalidi, Issa
   Pilotto, Jose Henrique
   Brites, Carlos
   Barcellos, Nemora Tregnago
   Amara, Ali
   Wittkop, Linda
   Molina, Jean-Michel
   Delaugerre, Constance
TI Impact of Raltegravir or Efavirenz on Cell-Associated Human
   Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic
   Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating
   Antiretroviral Therapy
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1 DNA; HIV integrase inhibitors; inflammation; raltegravir;
   tuberculosis
ID IMMUNE ACTIVATION; PREDICT MORTALITY; DECAY DYNAMICS; REPEAT CIRCLES;
   DNA; PHARMACOKINETICS; INTENSIFICATION; INFECTION; RESERVOIR; BLOOD
AB Background. In view of the fast viremia decline obtained with integrase inhibitors, we studied the respective effects of initiating efavirenz (EFV) or raltegravir (RAL)-based antiretroviral therapy (ART) regimens on human immunodeficiency virus (HIV)-1 deoxyribonucleic acid (DNA) levels and inflammation biomarkers in the highly inflammatory setting of advanced HIV-1 disease with tuberculosis (TB) coinfection.
   Methods. We followed cell-associated HIV-1 DNA, high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), soluble CD14 and D-Dimer levels for 48 weeks after ART initiation in the participants to the ANRS12-180 REFLATE-TB study. This phase II open-label randomized study included ART-naive people with HIV and TB treated with rifampicin to receive RAL 400 mg twice daily (RAL400), RAL 800 mg twice daily (RAL800) or EFV 600 mg QD with tenofovir and lamivudine.
   Results. In 146 participants, the median (interquartile range [IQR]) week (W)0 HIV-1 DNA level was 4.7 (IQR, 4.3-5.1) log(10) copies/10(6) CD4(+), and the reduction by W48 was -0.8 log(10) copies/10(6) CD4(+) on EFV, -0.9 on RAL400, and -1.0 on RAL800 (P = .74). Baseline median (IQR) hsCRP, IL-6, sCD14, and D-Dimer levels were 6.9 (IQR, 3.3-15.6) mg/L, 7.3 (IQR, 3.5-12.3) pg/mL, 3221 (IQR, 2383-4130) ng/mL, and 975 (IQR, 535-1970) ng/mL. All biomarker levels decreased over the study: the overall W0-W48 mean (95% confidence interval) fold-change on ART was 0.37 (IQR, 0.28-0.48) for hsCRP, 0.42 (IQR, 0.35-0.51) for IL-6, 0.51 (IQR, 0.47-0.56) for sCD14, and 0.39 (IQR, 0.32-0.47) for D-Dimers. There were no differences in biomarker reduction across treatment arms.
   Conclusions. In participants with HIV and TB, EFV, RAL400, or RAL800 effectively and equally reduced inflammation and HIV-1 DNA levels.
C1 [Delagreverie, Heloise M.; Delaugerre, Constance] Hop St Louis, AP HP, Lab Virol, Paris, France.
   [Delagreverie, Heloise M.; Amara, Ali; Molina, Jean-Michel; Delaugerre, Constance] Univ Paris, INSERM, U944, Paris, France.
   [Bauduin, Claire; Wittkop, Linda] Bordeaux Univ, Bordeaux Populat Hlth Res Ctr, Team MORPH3EUS, ISPED,Inserm,UMR 1219,CIC,EC 1401, Bordeaux, France.
   [De Castro, Nathalie; Molina, Jean-Michel] Hop St Louis, AP HP, Malad Infect & Trop, Paris, France.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Clin Res Inst, STD AIDS Clin Res Lab, Rio De Janeiro, Brazil.
   [Chevrier, Marc] Hop St Louis, AP HP, Lab Biochim, Paris, France.
   [Jouenne, Fanelie; Mourah, Samia] Hop St Louis, AP HP, Lab Pharmacol, Paris, France.
   [Kalidi, Issa] Hop St Louis, AP HP, Lab Hematol, Paris, France.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Dept DST AIDS, Rio De Janeiro, Brazil.
   [Brites, Carlos] Hosp Univ Profesor Edgar Santos, Lab Pesquisa Doencas Infecciosas, Salvador, BA, Brazil.
   [Barcellos, Nemora Tregnago] Hosp Sanatorio Partenon, Hlth State Secretariat RS, Porto Alegre, RS, Brazil.
   [Wittkop, Linda] CHU Bordeaux, Serv Informat Med, Pole Sante Publ, Bordeaux, France.
RP Delaugerre, C (corresponding author), Hop St Louis, Lab Virol, 1 Ave Claude Vellefaux, F-75010 Paris, France.
EM constance.delaugerre@aphp.fr
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; AMARA,
   Ali/0000-0002-0283-1815
FU French National Agency for Research on AIDS and Viral Hepatitis
   (ANRS)ANRSFrench National Research Agency (ANR); Brazilian National
   STD/AIDS Program of the Ministry of Health; MERCKMerck & Company [IISP
   50621]
FX This work was funded by the French National Agency for Research on AIDS
   and Viral Hepatitis (ANRS), the Brazilian National STD/AIDS Program of
   the Ministry of Health, and MERCK (Investigator Initiated Studies
   Program; IISP 50621).
CR Achhra AC, 2015, HIV MED, V16, P449, DOI 10.1111/hiv.12258
   Alteri C, 2019, J CLIN VIROL, V117, P61, DOI 10.1016/j.jcv.2019.06.004
   De Castro N, 2019, IAS 2019
   Avettand-Fenoel V, 2016, CLIN MICROBIOL REV, V29, P859, DOI 10.1128/CMR.00015-16
   Avettand-Fenol V, 2009, J MED VIROL, V81, P217, DOI 10.1002/jmv.21390
   Baker JV, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx262
   Besson GJ, 2014, CLIN INFECT DIS, V59, P1312, DOI 10.1093/cid/ciu585
   Buzon MJ, 2010, NAT MED, V16, P460, DOI 10.1038/nm.2111
   Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972
   Delaugerre C, 2010, AIDS, V24, P2391, DOI 10.1097/QAD.0b013e32833d214c
   Dooley KE, AIDS C 2018 AMST NET
   Dutertre M, 2017, INITIATION ART BASED
   Funderburg NT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083514
   Gandhi RT, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006285
   Ghislain M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144317
   Gibb D, CROI 2018
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P459, DOI 10.1016/S1473-3099(14)70711-X
   Hatano H, 2013, J INFECT DIS, V208, P1436, DOI 10.1093/infdis/jit453
   Hileman CO, 2015, J INFECT DIS, V212, P345, DOI 10.1093/infdis/jiv004
   Hunt PW, 2014, J INFECT DIS, V210, P1228, DOI 10.1093/infdis/jiu238
   Kelesidis T, 2015, CLIN INFECT DIS, V61, P651, DOI 10.1093/cid/civ327
   Khoury G, 2017, J INFECT DIS, V215, P911, DOI 10.1093/infdis/jix039
   Koelsch KK, 2011, AIDS, V25, P2069, DOI 10.1097/QAD.0b013e32834b9658
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lam YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034233
   Lee S, 2017, J INFECT DIS, V215, P1270, DOI 10.1093/infdis/jix113
   Lelievre JD, CROI C 2018 BOST MA
   Manosuthi W, 2016, AIDS RES THER, V13, DOI 10.1186/s12981-016-0106-y
   Massanella M, 2016, CURR OPIN HIV AIDS, V11, P234, DOI 10.1097/COH.0000000000000230
   Olsson O, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz015
   Parisi SG, 2012, J CLIN MICROBIOL, V50, P258, DOI 10.1128/JCM.06022-11
   Reynolds HE, 2015, J ANTIMICROB CHEMOTH, V70, P550, DOI 10.1093/jac/dku376
   Rossetti B, 2017, J CLIN VIROL, V91, P18, DOI 10.1016/j.jcv.2017.03.018
   Sasindran SJ, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00002
   Sullivan ZA, 2015, EBIOMEDICINE, V2, P334, DOI 10.1016/j.ebiom.2015.03.005
   Taburet AM, 2015, CLIN INFECT DIS, V61, P1328, DOI 10.1093/cid/civ477
   Uprety P, 2015, CLIN INFECT DIS, V61, P1862, DOI 10.1093/cid/civ688
   Vallejo A, 2012, AIDS, V26, P1885, DOI 10.1097/QAD.0b013e3283584521
   Wada NI, 2016, CLIN INFECT DIS, V63, P984, DOI 10.1093/cid/ciw409
   Wenning LA, 2009, ANTIMICROB AGENTS CH, V53, P2852, DOI 10.1128/AAC.01468-08
   Wijting I, 2017, INTEGRASE INHIBITORS
NR 41
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD FEB
PY 2020
VL 7
IS 2
AR ofz549
DI 10.1093/ofid/ofz549
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA KY9BQ
UT WOS:000522870200029
PM 32083147
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Fernandez, LG
   Casas, EC
   Singh, S
   Churchyard, GJ
   Brigden, G
   Gotuzzo, E
   Vandevelde, W
   Sahu, S
   Ahmedov, S
   Kamarulzaman, A
   Ponce-de-Leon, A
   Grinsztejn, B
   Swindells, S
AF Fernandez, Lucia Gonzalez
   Casas, Esther C.
   Singh, Satvinder
   Churchyard, Gavin J.
   Brigden, Grania
   Gotuzzo, Eduardo
   Vandevelde, Wim
   Sahu, Suvanand
   Ahmedov, Sevim
   Kamarulzaman, Adeeba
   Ponce-de-Leon, Alfredo
   Grinsztejn, Beatriz
   Swindells, Susan
TI New opportunities in tuberculosis prevention: implications for people
   living with HIV (vol 23, e25438, 2020)
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Correction
CR Fernandez LG, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25438
   GONZALEZ FL, 2020, J INTERN AIDS SOC, V23
NR 2
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD FEB
PY 2020
VL 23
IS 2
DI 10.1002/jia2.25464
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA KS8YS
UT WOS:000518595100008
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Landovitz, RJ
   Zangeneh, SZ
   Chau, G
   Grinsztejn, B
   Eron, JJ
   Dawood, H
   Magnus, M
   Liu, AY
   Panchia, R
   Hosseinipour, MC
   Kofron, R
   Margolis, DA
   Rinehart, A
   Adeyeye, A
   Burns, D
   McCauley, M
   Cohen, MS
   Currier, JS
AF Landovitz, Raphael J.
   Zangeneh, Sahar Z.
   Chau, Gordon
   Grinsztejn, Beatriz
   Eron, Joseph J.
   Dawood, Halima
   Magnus, Manya
   Liu, Albert Y.
   Panchia, Ravindre
   Hosseinipour, Mina C.
   Kofron, Ryan
   Margolis, David A.
   Rinehart, Alex
   Adeyeye, Adeola
   Burns, David
   McCauley, Marybeth
   Cohen, Myron S.
   Currier, Judith S.
TI Cabotegravir Is Not Associated With Weight Gain in Human
   Immunodeficiency Virus-uninfected Individuals in HPTN 077
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
DE cabotegravir; CAB; weight gain; HIV uninfected
ID DOLUTEGRAVIR; THERAPY; ADULTS
AB Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
C1 [Landovitz, Raphael J.; Kofron, Ryan; Currier, Judith S.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr AIDS Res & Educ, Dept Med,Div Infect Dis, Los Angeles, CA 90095 USA.
   [Landovitz, Raphael J.; Kofron, Ryan; Currier, Judith S.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr HIV Prevent, Los Angeles, CA 90095 USA.
   [Zangeneh, Sahar Z.; Chau, Gordon] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab HIV, Rio De Janeiro, Brazil.
   [Eron, Joseph J.; Cohen, Myron S.] Univ N Carolina, Div Infect Dis, Chapel Hill, NC 27515 USA.
   [Dawood, Halima] Univ KwaZulu Natal, Dept Med, Durban, South Africa.
   [Magnus, Manya] George Washington Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Milken Inst, Washington, DC USA.
   [Liu, Albert Y.] San Francisco Dept Publ Hlth, Populat Hlth Div, Bridge HIV, San Francisco, CA USA.
   [Panchia, Ravindre] Univ Witwatersrand, Perinatal HIV Res Unit, Chris Hani Baragwanath Acad Hosp, Soweto, South Africa.
   [Hosseinipour, Mina C.] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC 27515 USA.
   [Margolis, David A.; Rinehart, Alex] ViiV Healthcare, Res Triangle Pk, Durham, NC USA.
   [Adeyeye, Adeola; Burns, David] NIAID, Div AIDS, NIH, Rockville, MD USA.
   [McCauley, Marybeth] FHI 360, Sci Facilitat Dept, FHI 360, Washington, DC USA.
RP Landovitz, RJ (corresponding author), Univ Calif Los Angeles, Ctr Clin AIDS Res Educ, 11075 Santa Monica Blvd,Suite 100, Los Angeles, CA 90025 USA.
EM rlandovitz@mednet.ucla.edu
RI Dawood, Halima/AAO-6963-2020; Dawood, Halima/AAF-6045-2020
OI Dawood, Halima/0000-0001-8180-6791; 
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI068619, UM1AI068613,
   UM1AI068617]
FX This work was supported by National Institute of Allergy and Infectious
   Diseases of the National Institutes of Health (NIH; grants UM1AI068619,
   UM1AI068613, and UM1AI068617). ViiV Healthcare provided study products
   for the conduct of HPTN 077.
CR Bakal DR, 2018, J ANTIMICROB CHEMOTH, V73, P2177, DOI 10.1093/jac/dky145
   Bourgi K, 2019, C RETR OPP INF SEATT
   Di Angelantonio E, 2016, LANCET, V388, P776, DOI 10.1016/S0140-6736(16)30175-1
   Gatell JM, 2017, AIDS, V31, P2503, DOI 10.1097/QAD.0000000000001675
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hill A, 2019, J VIRUS ERAD, V5, P41
   Koethe JR, 2016, AIDS RES HUM RETROV, V32, P50, DOI 10.1089/aid.2015.0147
   Landovitz RJ, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002690
   Sax PE, 2017, LANCET, V390, P2073, DOI [10.1016/S0140-6736(17)32340-1, 10.1016/s0140-6736(17)32340-1]
   Sculier D, 2018, HIV MED, V19, P572, DOI 10.1111/hiv.12626
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   van Lunzen J, 2012, LANCET INFECT DIS, V12, P111, DOI 10.1016/S1473-3099(11)70290-0
NR 12
TC 7
Z9 7
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JAN 15
PY 2020
VL 70
IS 2
BP 319
EP 322
DI 10.1093/cid/ciz439
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA KB9IY
UT WOS:000506801400024
PM 31125395
OA Green Published
DA 2020-11-24
ER

PT J
AU Domingues, RMSM
   da Silva, CMFP
   Grinsztejn, BGJ
   Moreira, RI
   Derrico, M
   Andrade, AC
   Friedman, RK
   Luz, PM
   Coelho, LE
   Veloso, VG
AF Soares Madeira Domingues, Rosa Maria
   Furtado Passos da Silva, Cosme Marcelo
   Jegerhorn Grinsztejn, Beatriz Gilda
   Moreira, Ronaldo Ismerio
   Derrico, Monica
   Andrade, Angela Cristina
   Friedman, Ruth Khalili
   Luz, Paula M.
   Coelho, Lara Esteves
   Veloso, Valdilea G.
TI Prevalence of induced abortion and associated factors in a cohort of
   women living with HIV/AIDS, Rio de Janeiro, Brazil, 1996-2016
SO CADERNOS DE SAUDE PUBLICA
LA English
DT Article
DE Induced Abortion; HIV Infections; Cohort Studies
ID UNSAFE ABORTION; PREGNANCY; VULNERABILITY; VIOLENCE; HEALTH; TRENDS
AB The aim of this study was to verify the prevalence of induced abortion and associated factors at the time of inclusion in a cohort of women living with HIV/AIDS in the city of Rio de Janeiro, Brazil, from 1996 to 2016. Eligibility criteria for inclusion in the cohort were female sex at birth, age 18 years and older, and confirmed HIV infection. At the baseline visit, data on sexual, reproductive, and behavioral aspects and HIV infection were obtained through a face-to-face interview with the attending physician. Lifetime prevalence of induced abortion was calculated, and factors associated with induced abortion were verified by multiple logistic regression for all the women and for those with previous pregnancy. In the entire cohort of women, 30.4% reported a history of induced abortion, compared to 33.5% in women with previous pregnancy. Frequency of reported induced abortion showed a significant reduction during the period (41.7% in 1996-2000 versus 22.5% in 2011-2016, p < 0.001). Factors associated with induced abortion, both for the entire cohort and for the women with previous pregnancy, were age, schooling, >= 5 lifetime sexual partners, teenage pregnancy, lifetime use of any illicit drug, and inclusion in the cohort after the year 2005. Changes in the socioeconomic, sexual, reproductive, and HIV infection profile are possible explanations for the reduction in abortions during the period. Studies that use direct methods to measure abortion should be conducted in other populations to confirm the downward trend in induced abortion and its determinants in Brazil.
C1 [Soares Madeira Domingues, Rosa Maria; Jegerhorn Grinsztejn, Beatriz Gilda; Moreira, Ronaldo Ismerio; Derrico, Monica; Andrade, Angela Cristina; Friedman, Ruth Khalili; Luz, Paula M.; Coelho, Lara Esteves; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Furtado Passos da Silva, Cosme Marcelo] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, Brazil.
RP Domingues, RMSM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM rosa.domingues@ini.fiocruz.br
RI Domingues, Rosa/AAS-3606-2020
OI Domingues, Rosa/0000-0001-5722-8127; Goncalves Veloso dos Santos,
   Valdilea/0000-0002-6622-3165; Ismerio Moreira,
   Ronaldo/0000-0003-2680-4317; DERRICO, MONICA/0000-0003-3552-3584
CR Barbosa RM, 2009, CIENC SAUDE COLETIVA, V14, P1085, DOI 10.1590/S1413-81232009000400015
   Berquó Elza, 2008, Rev. Saúde Pública, V42, P34, DOI [10.1590/S0034-89102008000800006, 10.1590/s0034-89102008000800006]
   Bongain A, 2002, EUR J OBSTET GYN R B, V104, P124, DOI 10.1016/S0301-2115(02)00103-3
   Camargo RS, 2011, INT J GYNECOL OBSTET, V112, P88, DOI 10.1016/j.ijgo.2010.08.013
   Cecatti JG, 2010, REV BRAS GINECOL OBS, V32, P105, DOI 10.1590/S0100-72032010000300002
   Centro Brasileiro de Analise e Planejamento Ministerio da Saude, 2009, PESQ NAC DEM SAUD CR
   Dalgaard P, 2008, STAT COMPUT SER, P1, DOI 10.1007/978-0-387-79054-1_1
   Departamento de Acoes Programaticas e Es- trategicas Secretaria de Atencao a Saude Mi- nisterio da Saude, 2017, PROT CUID SAUD AD AT
   Departamento de DST AIDS e Hepatites Vi- rais Secretaria de Vigilancia em Saude Minis- terio da Saude, PESQ CONH AT PRAT PO
   Diniz D, 2017, CIENC SAUDE COLETIVA, V22, P653, DOI 10.1590/1413-81232017222.23812016
   Diniz D, 2010, CIENC SAUDE COLETIVA, V15, P959, DOI 10.1590/S1413-81232010000700002
   Friedman RK, 2011, REV SAUDE PUBL, V45, P373, DOI 10.1590/S0034-89102011000200016
   Fusco CLB, 2012, CAD SAUDE PUBLICA, V28, P709, DOI 10.1590/S0102-311X2012000400010
   Gomez-Suarez M, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25273
   Kaye DK, 2006, TROP MED INT HEALTH, V11, P90, DOI 10.1111/j.1365-3156.2005.01531.x
   Machado Carla Jorge, 2013, Rev. bras. epidemiol., V16, P18, DOI 10.1590/S1415-790X2013000100002
   Martins I R, 1991, Cad Saude Publica, V7, P251
   Martins-MeloI FR, 2014, REV SAUDE PUBL, V48, P508, DOI 10.1590/S0034-8910.2014048004878
   Medeiros M, 2012, CIENC SAUDE COLETIVA, V17, P1721, DOI 10.1590/S1413-81232012000700010
   Menezes Greice M. S., 2006, Cad. Saúde Pública, V22, P1431, DOI 10.1590/S0102-311X2006000700008
   Menezes GMS, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00197918, 10.1590/0102-311x00197918]
   Monteiro MFG, 2015, REPROD CLIM, V30, P11
   Olinto MTA, 2004, REV PANAM SALUD PUBL, V15, P331, DOI 10.1590/S1020-49892004000500008
   Pallitto CC, 2013, INT J GYNECOL OBSTET, V120, P3, DOI 10.1016/j.ijgo.2012.07.003
   Pilecco FB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095570
   Pilecco FB, 2011, CAD SAUDE PUBLICA, V27, P427, DOI 10.1590/S0102-311X2011000300004
   Pinho AD, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00057916, 10.1590/0102-311x00057916]
   Santos NJS, 2009, CAD SAUDE PUBLICA, V25, pS321, DOI 10.1590/S0102-311X2009001400014
   Secretaria de Vigilancia em Saude Ministerio da Saude, 2017, B EP HIV AIDS
   Singh S, 2001, FAM PLANN PERSPECT, V33, P251, DOI 10.2307/3030192
   Domingues RMSM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192985
   Souza Milena Goulart, 2014, Rev. bras. epidemiol., V17, P297, DOI 10.1590/1809-4503201400020002ENG
   Stockl H, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-12
   van Benthem BHB, 2000, AIDS, V14, P2171, DOI 10.1097/00002030-200009290-00014
   Zachek CM, 2019, AIDS BEHAV, V23, P1541, DOI 10.1007/s10461-019-02395-x
NR 35
TC 0
Z9 0
U1 0
U2 0
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
EI 1678-4464
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PY 2020
VL 36
SU 1
AR e00201318
DI 10.1590/0102-311X00201318
PG 16
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA KM4XI
UT WOS:000514134300015
PM 32049128
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Scott, H
   Vittinghoff, E
   Irvin, R
   Liu, AB
   Nelson, L
   Del Rio, C
   Magnus, M
   Mannheimer, S
   Fields, S
   Tieu, HV
   Kuo, IR
   Shoptaw, S
   Grinsztejn, B
   Sanchez, J
   Wakefield, S
   Fuchs, JD
   Wheeler, D
   Mayer, KH
   Koblin, BA
   Buchbinder, S
AF Scott, Hyman
   Vittinghoff, Eric
   Irvin, Risha
   Liu, Albert
   Nelson, LaRon
   Del Rio, Carlos
   Magnus, Manya
   Mannheimer, Sharon
   Fields, Sheldon
   Van Tieu, Hong
   Kuo, Irene
   Shoptaw, Steve
   Grinsztejn, Beatriz
   Sanchez, Jorge
   Wakefield, Steven
   Fuchs, Jonathan D.
   Wheeler, Darrell
   Mayer, Kenneth H.
   Koblin, Beryl A.
   Buchbinder, Susan
TI Development and Validation of the Personalized Sexual Health Promotion
   (SexPro) HIV Risk Prediction Model for Men Who Have Sex with Men in the
   United States
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV risk assessment; MSM; HIV prevention
ID EFFICACY TRIAL; LIFETIME RISK; WHITE MEN; BLACK MSM; INFECTION;
   DISPARITIES; INTERVENTION; ACQUISITION; PREVENTION
AB Accurate HIV risk assessment among men who have sex with men (MSM) is important to help providers assess risk, and target HIV prevention interventions. We sought to develop an evidence-based HIV risk assessment tool for US MSM that is inclusive of Black MSM. Data from four large longitudinal cohorts of MSM were used to develop (EXPLORE), and validate (VAX004, HPTN061, and HVTN505). These data included visits in which participants self-reported HIV risk behavior and underwent HIV testing. We developed a pooled logistic model for incident HIV infection based on self-reported risk behaviors during the 6 months before each study visit. A total of 4069 MSM were used for the development cohort, and 8047 MSM in the three validation cohorts through 2013. The final model includes age (< 35, >= 35); Black race and Latino ethnicity; numbers of HIV-negative anal sex partners; number of insertive or receptive anal intercourse episodes; having 1 HIV-negative partner only; self-reported substance use; and bacterial sexually transmitted infection diagnosis. The model showed good discrimination in internal validation (C-statistic = 79.5). The external validation cohorts also showed good discrimination, with C-statistics of 73.1, 71.0, 71.9 in VAX004, HPTN061, and HVTN505 respectively, and acceptable calibration. We developed and validated an HIV risk assessment tool for MSM, which showed good predictive ability, including among the largest cohort of HIV-uninfected Black MSM in the US. This tool is available online (mysexpro.org) and can be used by providers to support targeting of HIV prevention interventions such as pre-exposure prophylaxis for MSM.
C1 [Scott, Hyman; Liu, Albert; Buchbinder, Susan] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA 94102 USA.
   [Vittinghoff, Eric] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Irvin, Risha] Johns Hopkins Sch Med, Baltimore, MD USA.
   [Nelson, LaRon] Yale Sch Nursing, New Haven, CT USA.
   [Del Rio, Carlos] Emory Univ, Atlanta, GA 30322 USA.
   [Magnus, Manya; Kuo, Irene] George Washington Univ, Columbia, DC USA.
   [Mannheimer, Sharon] Columbia Univ, New York, NY USA.
   [Fields, Sheldon] New York Inst Technol, Old Westbury, NY 11568 USA.
   [Van Tieu, Hong; Koblin, Beryl A.] New York Blood Ctr, New York, NY 10021 USA.
   [Shoptaw, Steve] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas IPEC, Rio De Janeiro, Brazil.
   [Sanchez, Jorge] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Wakefield, Steven] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Fuchs, Jonathan D.] San Francisco Dept Publ Hlth, Ctr Learning Innovat, San Francisco, CA USA.
   [Wheeler, Darrell] SUNY Albany, Albany, NY 12222 USA.
   [Mayer, Kenneth H.] Fenway Hlth, Boston, MA USA.
RP Scott, H (corresponding author), San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA 94102 USA.
EM hyman.scott@sfdph.org; Eric.Vittinghoff@ucsf.edu; rirvin1@jhmi.edu;
   albert.liu@sfdph.org; laron.nelson@yale.edu; cdelrio@emory.edu;
   manyadm@gwu.edu; sbm20@columbia.edu; sheldon.fields@nyit.edu;
   htieu@nybc.org; ikuo@gwu.edu; sshoptaw@mednet.ucla.edu;
   gbeatriz@ipec.fiocruz.br; jsanchez@impactaperu.org;
   swakefield@fhcrc.org; jonathan.fuchs@sfdph.org; dwheeler@albany.edu;
   khmayer@gmail.com; BKoblin@nybc.org; susan.buchbinder@sfdph.org
RI del Rio, Carlos/B-3763-2012
OI del Rio, Carlos/0000-0002-0153-3517; Nelson, LaRon/0000-0002-2630-602X
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR001863] Funding Source: Medline;
   NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI104309, R01 AI083060] Funding Source:
   Medline; NICHD NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [R25 HD045810] Funding Source: Medline; NIMH NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [K23MH104116, K23
   MH104116, P30 MH058107] Funding Source: Medline
CR [Anonymous], 2017, US CDC NEWS     0927
   Baral S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-482
   Bartholow BN, 2006, JAIDS-J ACQ IMM DEF, V43, P594
   Buchbinder SP, 2005, JAIDS-J ACQ IMM DEF, V39, P82, DOI 10.1097/01.qai.0000134740.41585.f4
   CDC, 2014, PREEXP PROPH PREV HI
   Centers for Disease Control and Prevention, 2014, 26 CTR DIS CONTR PRE
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Gallagher KM, 2012, ANN BEHAV MED, V43, P101, DOI 10.1007/s12160-011-9308-7
   Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566
   Hess KL, 2017, ANN EPIDEMIOL, V27, P238, DOI 10.1016/j.annepidem.2017.02.003
   Hoenigl M, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001242
   Irvin R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118281
   Koblin B, 2004, LANCET, V364, P41, DOI 10.1016/S0140-6736(04)16588-4
   Koblin BA, 2006, AIDS, V20, P731, DOI 10.1097/01.aids.0000216374.61442.55
   Koblin BA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070413
   Lancki N, 2018, AIDS, V32, P383, DOI 10.1097/QAD.0000000000001710
   Lieb S, 2011, PUBLIC HEALTH REP, V126, P60, DOI 10.1177/003335491112600110
   MacKellar DA, 2007, AIDS BEHAV, V11, P263, DOI 10.1007/s10461-006-9136-0
   MacKellar DA, 2011, SEX TRANSM DIS, V38, P419, DOI 10.1097/OLQ.0b013e31820369dd
   Maulsby C, 2014, AIDS BEHAV, V18, P10, DOI 10.1007/s10461-013-0476-2
   Mayer KH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087298
   Menza TW, 2009, SEX TRANSM DIS, V36, P547, DOI 10.1097/OLQ.0b013e3181a9cc41
   Millett GA, 2007, AIDS, V21, P2083, DOI 10.1097/QAD.0b013e3282e9a64b
   Mimiaga MJ, 2009, J URBAN HEALTH, V86, P602, DOI 10.1007/s11524-009-9363-6
   Poundstone KE, 2004, EPIDEMIOL REV, V26, P22, DOI 10.1093/epirev/mxh005
   Rodger AJ, 2019, LANCET, V393, P2428, DOI 10.1016/S0140-6736(19)30418-0
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   Rothman AJ, 2000, HEALTH PSYCHOL, V19, P64, DOI 10.1037/0278-6133.19.Suppl1.64
   Scott HM, 2014, JAIDS-J ACQ IMM DEF, V65, P115, DOI 10.1097/QAI.0b013e3182a98bae
   Smith DK, 2012, JAIDS-J ACQ IMM DEF, V60, P421, DOI 10.1097/QAI.0b013e318256b2f6
   Sullivan PS, 2015, ANN EPIDEMIOL, V25, P445, DOI 10.1016/j.annepidem.2015.03.006
   Sullivan PS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090514
   Wejnert C, 2016, J INFECT DIS, V213, P776, DOI 10.1093/infdis/jiv500
   Woody GE, 1999, DRUG ALCOHOL DEPEN, V53, P197, DOI 10.1016/S0376-8716(98)00134-3
NR 34
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JAN
PY 2020
VL 24
IS 1
BP 274
EP 283
DI 10.1007/s10461-019-02616-3
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA KJ4YJ
UT WOS:000512065500023
PM 31352633
DA 2020-11-24
ER

PT J
AU Fernandez, LG
   Casas, EC
   Singh, S
   Churchyard, GJ
   Brigden, G
   Gotuzzo, E
   Vandevelde, W
   Sahu, S
   Ahmedov, S
   Kamarulzaman, A
   Ponce-de-Leon, A
   Grinsztejn, B
   Swindells, S
AF Fernandez, Lucia Gonzalez
   Casas, Esther C.
   Singh, Satvinder
   Churchyard, Gavin J.
   Brigden, Grania
   Gotuzzo, Eduardo
   Vandevelde, Wim
   Sahu, Suvanand
   Ahmedov, Sevim
   Kamarulzaman, Adeeba
   Ponce-de-Leon, Alfredo
   Grinsztejn, Beatriz
   Swindells, Susan
TI New opportunities in tuberculosis prevention: implications for people
   living with HIV
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Editorial Material
DE TB; HV care continuum; differentiated care; public health; co-infection;
   treatment
ID PLUS ANTIRETROVIRAL THERAPY; LATENT TUBERCULOSIS; INFECTED ADULTS;
   MYCOBACTERIUM-TUBERCULOSIS; SOUTH-AFRICA; RIFAPENTINE; RISK;
   PHARMACOKINETICS; PROPHYLAXIS; RIFAMPIN
AB Introduction Tuberculosis (TB) is a leading cause of mortality among people living with HIV (PLHIV). An invigorated global END TB Strategy seeks to increase efforts in scaling up TB preventive therapy (TPT) as a central intervention for HIV programmes in an effort to contribute to a 90% reduction in TB incidence and 95% reduction in mortality by 2035. TPT in PLHIV should be part of a comprehensive approach to reduce TB transmission, illness and death that also includes TB active case-finding and prompt, effective and timely initiation of anti-TB therapy among PLHIV. However, the use and implementation of preventive strategies has remained deplorably inadequate and today TB prevention among PLHIV has become an urgent priority globally. Discussion We present a summary of the current and novel TPT regimens, including current evidence of use with antiretroviral regimens (ART). We review challenges and opportunities to scale-up TB prevention within HIV programmes, including the use of differentiated care approaches and demand creation for effective TB/HIV services delivery. TB preventive vaccines and diagnostics, including optimal algorithms, while important topics, are outside of the focus of this commentary. Conclusions A number of new tools and strategies to make TPT a standard of care in HIV programmes have become available. The new TPT regimens are safe and effective and can be used with current ART, with attention being paid to potential drug-drug interactions between rifamycins and some classes of antiretrovirals. More research and development is needed to optimize TPT for small children, pregnant women and drug-resistant TB (DR-TB). Effective programmatic scale-up can be supported through context-adapted demand creation strategies and the inclusion of TPT in client-centred services, such as differentiated service delivery (DSD) models. Robust collaboration between the HIV and TB programmes represents a unique opportunity to ensure that TB, a preventable and curable condition, is no longer the number one cause of death in PLHIV.
C1 [Fernandez, Lucia Gonzalez] Int AIDS Soc, HIV Coinfect & Comorbid, Geneva, Switzerland.
   [Casas, Esther C.] Med Sans Frontieres, Southern Africa Med Unit, Cape Town, South Africa.
   [Singh, Satvinder] WHO, HIV Dept, Geneva, Switzerland.
   [Churchyard, Gavin J.] Aurum Inst, Parktown, South Africa.
   [Churchyard, Gavin J.] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa.
   [Churchyard, Gavin J.] South African Med Res Council, Advancing Care & Treatment TB HIV, Parktown, South Africa.
   [Brigden, Grania] Int Union TB & Lung Dis, Dept TB, Geneva, Switzerland.
   [Gotuzzo, Eduardo] Peruvian Univ Cayetano Heredia, Dept Med, Lima, Peru.
   [Gotuzzo, Eduardo] Peruvian Univ Cayetano Heredia, Alexander von Humboldt Inst Trop Med & Infect Dis, Lima, Peru.
   [Vandevelde, Wim] Global Network People Living HIV GNP, Cape Town, South Africa.
   [Sahu, Suvanand] Stop TB Partnership, Geneva, Switzerland.
   [Ahmedov, Sevim] USAID, TB Div, Bur Global Hlth Infect Dis, Washington, DC USA.
   [Kamarulzaman, Adeeba] Univ Malaya, Dept Med, Kuala Lumpur, Malaysia.
   [Ponce-de-Leon, Alfredo] Inst Nacl Ciencias Med Nutr Salvador Zubiran, Infect Dis Dept, Mexico City, DF, Mexico.
   [Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Swindells, Susan] Univ Nebraska Med Ctr, Omaha, NE USA.
RP Fernandez, LG (corresponding author), Ave France 23, CH-1202 Geneva, Switzerland.
EM lucia.gonzalez.work@gmail.com
FU United States Agency for International Development (USAID)United States
   Agency for International Development (USAID)
FX The authors thank Kelly Dooley at Johns Hopkins University, for her
   contribution to the section about the use of TPT and ART in children.
   Financial support was provided by the United States Agency for
   International Development (USAID). The author's views expressed in this
   publication do not necessarily reflect the views of USAID.
CR Adjetey V, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-3878-7
   Akolo C, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000171.pub3
   [Anonymous], 084 HPTN
   Badje A, 2017, LANCET GLOB HEALTH, V5, pE1080, DOI 10.1016/S2214-109X(17)30372-8
   Barry CE, 2009, NAT REV MICROBIOL, V7, P845, DOI 10.1038/nrmicro2236
   Briggs MA, 2015, JAIDS-J ACQ IMM DEF, V68, pS297, DOI 10.1097/QAI.0000000000000497
   Cawley C, 2016, 6 MONTHLY APPOINTMEN
   Cerrone M, 2019, J ANTIMICROB CHEMOTH, V74, P1670, DOI 10.1093/jac/dkz068
   Charan J, 2018, PEDIATR INFECT DIS J, V37, P773, DOI 10.1097/INF.0000000000001879
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Decroo T, 2014, TROP MED INT HEALTH, V19, P514, DOI 10.1111/tmi.12278
   Den Boon S, 2016, AIDS, V30, P797, DOI 10.1097/QAD.0000000000000985
   Denholm JT, 2014, DRUG HEALTHC PATIENT, V6, P145, DOI 10.2147/DHPS.S68837
   Denti P, 2016, ANTIMICROB AGENTS CH, V60, P1234, DOI 10.1128/AAC.02051-15
   Dooley KE, 2019, SAFETY PK WEEKLY RIF
   Dooley KE, 2020, CLIN INFECT DIS, V70, P549, DOI 10.1093/cid/ciz256
   Ernst JD, 2012, NAT REV IMMUNOL, V12, P581, DOI 10.1038/nri3259
   Farenc C, 2014, CROI 2014
   Fox GJ, 2017, INT J INFECT DIS, V56, P68, DOI 10.1016/j.ijid.2016.11.006
   Getahun H, 2015, NEW ENGL J MED, V372, P2127, DOI 10.1056/NEJMra1405427
   Gold E, CREATING DEMAND VMMC
   Golub JE, 2015, CLIN INFECT DIS, V60, P639, DOI 10.1093/cid/ciu849
   Golub JE, 2009, AIDS, V23, P631, DOI 10.1097/QAD.0b013e328327964f
   GRIMSRUD A, 2017, J INT AIDS SOC S4, V20, DOI DOI 10.7448/IAS.20.5.22024
   Grimsrud A, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21484
   Gupta A, 2019, NEW ENGL J MED, V381, P1333, DOI 10.1056/NEJMoa1813060
   Gupta A, 2011, J INFECT DIS, V203, P358, DOI [10.1093/infdis/jiq064, 10.1093/jinfdis/jiq064]
   Hakim J, 2017, NEW ENGL J MED, V377, P233, DOI 10.1056/NEJMoa1615822
   Harries AD, 2019, INT J TUBERC LUNG D, V23, P241, DOI 10.5588/ijtld.18.0207
   Harries AD, 2015, LANCET INFECT DIS, V15, P1492, DOI 10.1016/S1473-3099(15)00242-X
   Hausler HP, 2006, B WORLD HEALTH ORGAN, V84, P528, DOI 10.2471/BLT.04.018606
   HPTN, 083 HPTN
   International Aids Society, 2017, KEY CONS DIFF ANT TH
   Johnson KT, 2018, CLIN INFECT DIS, V67, P1072, DOI 10.1093/cid/ciy230
   Knight GM, 2019, LANCET INFECT DIS, V19, P903, DOI 10.1016/S1473-3099(19)30307-X
   Landovitz RJ, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002690
   Lapadula G, 2012, EUR RESPIR J, V39, P1064, DOI 10.1183/09031936.00116611
   Luetkemeyer AF, 2013, CLIN INFECT DIS, V57, P586, DOI 10.1093/cid/cit246
   Manabe YC, 2009, J INFECT DIS, V199, P437, DOI 10.1086/595985
   Mathad JS, 2012, CLIN INFECT DIS, V55, P1532, DOI 10.1093/cid/cis732
   Menzies D, 2018, NEW ENGL J MED, V379, P440, DOI 10.1056/NEJMoa1714283
   Mills HL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005260
   Moro RN, 2016, B107 TUBERCULOSIS IS, pA7859
   Njie GJ, 2018, AM J PREV MED, V55, P244, DOI 10.1016/j.amepre.2018.04.030
   Pathmanathan I, 2018, INT J TUBERC LUNG D, V22, P596, DOI 10.5588/ijtld.17.0758
   Pathmanathan I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196831
   Pawlowski A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002464
   PEPFAR, VOL MED MAL CIRC DEM
   Peters JS, 2019, LANCET INFECT DIS, V19, pE65, DOI 10.1016/S1473-3099(18)30477-8
   Pillay T, 2004, INT J TUBERC LUNG D, V8, P59
   Podany AT, 2015, CLIN INFECT DIS, V61, P1322, DOI 10.1093/cid/civ464
   Rangaka MX, 2014, LANCET, V384, P682, DOI 10.1016/S0140-6736(14)60162-8
   Reid MJA, 2019, LANCET, V393, P1331, DOI 10.1016/S0140-6736(19)30024-8
   Rhines AS, 2018, AIDS, V32, P2129, DOI 10.1097/QAD.0000000000001959
   Samandari T, 2015, AIDS, V29, P351, DOI 10.1097/QAD.0000000000000535
   Shrestha RK, 2007, INT J TUBERC LUNG D, V11, P747
   Society I. A, 2016, DIFF CAR HIV DEC FRA
   Sterling TR, 2016, AIDS, V30, P1607, DOI 10.1097/QAD.0000000000001098
   Suthar AB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001270
   Swindells S, 2019, NEW ENGL J MED, V380, P1001, DOI 10.1056/NEJMoa1806808
   Swindells S, 2018, INT J TUBERC LUNG D, V22, P125, DOI 10.5588/ijtld.17.0486
   Swindells S, 2019, CROI C
   Taburet AM, 2015, CLIN INFECT DIS, V61, P1328, DOI 10.1093/cid/civ477
   TB Working Group, LEAP
   UNAIDS, 2018, MIL GO
   United Nations, 2019, SUST DEV GOALS
   USAID TB DIAH DIA and CH, TB DAT HUB ENH DAT E
   Weiner M, 2014, J ANTIMICROB CHEMOTH, V69, P1079, DOI 10.1093/jac/dkt483
   Weld ED, 2018, CLIN PHARMACOL THER, V104, P1098, DOI 10.1002/cpt.1221
   WHO, 2016, CONS GUID US ANT DRU
   Wilkinson L, 2016, TROP MED INT HEALTH, V21, P743, DOI 10.1111/tmi.12699
   World Health Organisation, 2011, DEV IMPR NAT TOLL FR
   World Health Organisation (WHO), LAT TUB INF 2018 UPD
   World Health Organization, 2018, GLOB TUB REP 2018
   World Health Organization, 2017, GUID MAN ADV HIV DIS
   World Health Organization, 2012, WHOHTMTB20121, P1, DOI DOI 10.1016/S0140-6736(12)61766-8
   World Health Organization, 2015, END TB STRAT
   World Health Organization (WHO), 2018, UN HIGH LEV M FIGHT
   Yirdaw KD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104557
   Zumla A, 2000, POSTGRAD MED J, V76, P259, DOI 10.1136/pmj.76.895.259
   Zunza M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006418.pub3
NR 81
TC 3
Z9 3
U1 1
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JAN
PY 2020
VL 23
IS 1
AR e25438
DI 10.1002/jia2.25438
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA KH6KA
UT WOS:000510759100008
PM 31913556
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Torres, TS
   Marins, LMS
   Veloso, VG
   Grinsztejn, B
   Luz, PM
AF Torres, Thiago S.
   Marins, Luana M. S.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Luz, Paula M.
TI How heterogeneous are MSM from Brazilian cities? An analysis of sexual
   behavior and perceived risk and a description of trends in awareness and
   willingness to use pre-exposure prophylaxis
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE MSM; HIV risk behavior; HIV perceived risk; Web-based survey; PrEP;
   Brazil; Latin America
ID HIV TESTING BEHAVIORS; YOUNG MEN; TRANSGENDER WOMEN; PERCEPTIONS;
   PREVENTION; INFECTION; PREP; EPIDEMIOLOGY; HIV/AIDS
AB Background: Brazil has the largest population of individuals living with HIV/AIDS in Latin America, with a disproportional prevalence of infection among gays, bisexuals and other men who have sex with men (MSM). Of relevance to prevention and treatment efforts, Brazilian MSM from different regions may differ in behaviors and risk perception related to HIV.
   Methods: We report on MSM living in 29 different cities: 26 Brazilian state capitals, the Federal District and two large cities in Sao Paulo state assessed in three web-based surveys (2016-2018) advertised on Grindr, Hornet and Facebook. Using logistic regression models, we assessed the association of risk behavior with HIV perceived risk as well as factors associated with high-risk behavior.
   Results: A total of 16,667 MSM completed the survey. Overall, MSM from the North and Northeast were younger, more black/mixed-black, of lower income and lower education compared to MSM from the South, Southeast and Central-west. Though 17% had never tested for HIV (with higher percentages in the North and Northeast), condomless receptive anal sex (previous 6 months) and high-risk behavior as per HIV Incidence Risk scale for MSM were observed for 41 and 64%, respectively. Sexual behavior and HIV perceived risk had low variability by city and high-risk behavior was strongly associated with high HIV perceived risk. Younger age, being gay/homosexual, having a steady partner, binge drinking, report of sexually transmitted infection (STI) and ever testing for HIV were associated with increased odds of high-risk behavior. Awareness and willingness to use PrEP increased from 2016 to 2018 in most cities.
   Conclusions: Overall, MSM socio-demographic characteristics were heterogeneous among Brazilian cities, but similarities were noted among the cities from the same administrative region with a marked exception of the Federal District not following the patterns for the Central-West. Combination HIV prevention is most needed among young men who self-identify as gay/homosexual, report binge drinking or prior STI.
C1 [Torres, Thiago S.; Marins, Luana M. S.; Veloso, Valdilea G.; Grinsztejn, Beatriz; Luz, Paula M.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
RP Torres, TS (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
EM thiago.torres@ini.fiocruz.br
RI TORRES, THIAGO SILVA/D-6548-2014
OI TORRES, THIAGO SILVA/0000-0002-2557-601X
FU Unitaid's
FX Gilead Sciences covered the costs related to advertisement of the survey
   on 2016 and 2017. The 2018 survey was made possible thanks to Unitaid's
   funding and support. Unitaid accelerates access to innovative health
   products and lays the foundations for their scale-up by countries and
   partners. Gilead and Unitaid played no role in the study design,
   collection, analysis, or interpretation of data, the writing of the
   manuscript, or the decision to submit this manuscript for publication.
CR Bavinton BR, 2018, LANCET HIV, V5, pE438, DOI 10.1016/S2352-3018(18)30132-2
   Blumenthal J, 2019, J ACQ IMMUN DEF SYND, V80, P7
   Brasil Ministerio da Saude, 2016, PROT CLIN DIR TER AT
   Calabrese SK, 2019, LANCET HIV, V6, pE211, DOI 10.1016/S2352-3018(19)30030-X
   Centers for Disease Control (CDC), 2018, TEST HIV BAS HIV AID
   Chan PA, 2016, SEX TRANSM DIS, V43, P717, DOI 10.1097/OLQ.0000000000000514
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Comite Gestor da Internet no Brasil (CGIBR), 2017, TIC DOM C16 USUARIOS
   Comite Gestor da Internet no Brasil (CGIBR), 2017, TIC DOM J2 INDIVIDUO
   Comite Gestor da Internet no Brasil (CGIBR), 2017, TIC DOM C2A USUARIOS
   Damacena Giseli Nogueira, 2019, Rev. bras. epidemiol., V22, pe190009, DOI 10.1590/1980-549720190009.supl.1
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Gomes RRDM, 2014, REV SAUDE PUBL, V48, P206, DOI 10.1590/S0034-8910.2014048004911
   Feinstein BA, 2019, ARCH SEX BEHAV, V48, P261, DOI 10.1007/s10508-018-1148-0
   Gallagher T, 2014, LGBT HEALTH, V1, P218, DOI 10.1089/lgbt.2013.0046
   Goedel WC, 2016, J ASSOC NURSE AIDS C, V27, P133, DOI 10.1016/j.jana.2015.11.005
   Golub SA, 2014, AIDS BEHAV, V18, P1686, DOI 10.1007/s10461-014-0770-7
   Golub SA, 2013, AIDS PATIENT CARE ST, V27, P621, DOI 10.1089/apc.2013.0245
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Guimarães Mark Drew Crosland, 2019, Rev. bras. epidemiol., V22, pe190005, DOI 10.1590/1980-549720190005.supl.1
   Heerwegh D, 2009, INT J PUBLIC OPIN R, V21, P111, DOI 10.1093/ijpor/edn054
   Hoagland B, 2017, AIDS BEHAV, V21, P1278, DOI 10.1007/s10461-016-1516-5
   Huebner DM, 2004, JAIDS-J ACQ IMM DEF, V37, P1514, DOI 10.1097/01.qai.0000127027.55052.22
   Instituto Brasileiro de Geografia e Estatistica (IBGE), 2010, TAB 3175 POP RES COR
   Kahle EM, 2018, AM J MENS HEALTH, V12, P676, DOI 10.1177/1557988318776581
   Kerr L, 2018, MEDICINE, V97, pS9, DOI [10.1097/MD.0000000000010573, 10.1097/md.0000000000010573]
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Khawcharoenporn T, 2019, AIDS RES THER, V16, DOI 10.1186/s12981-019-0229-z
   Klein H, 2012, AM J MENS HEALTH, V6, P280, DOI 10.1177/1557988311434825
   Krueger EA, 2016, AIDS CARE, V28, P1301, DOI 10.1080/09540121.2016.1178699
   Lapinski MK, 2009, J HEALTH PSYCHOL, V14, P251, DOI 10.1177/1359105308100209
   Laranjeira RR, 2007, BRIT MED J, V335, P735, DOI 10.1136/bmj.39360.432940.BE
   Liu C, 2017, SEX HEALTH, V15, P39
   Ludford KT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069966
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Luz PM, 2019, CURR OPIN HIV AIDS, V14, P366, DOI 10.1097/COH.0000000000000564
   MacKellar DA, 2005, JAIDS-J ACQ IMM DEF, V38, P603, DOI 10.1097/01.qai.0000141481.48348.7e
   MacKellar DA, 2007, AIDS BEHAV, V11, P263, DOI 10.1007/s10461-006-9136-0
   Magno L, 2019, GLOB PUBLIC HEALTH, V14, P1098, DOI 10.1080/17441692.2019.1571090
   Mimiaga MJ, 2015, JAIDS-J ACQ IMM DEF, V68, P329, DOI 10.1097/QAI.0000000000000475
   Morrison SA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197998
   Mustanski B, 2013, AIDS BEHAV, V17, P2999, DOI 10.1007/s10461-013-0507-z
   Newcomb ME, 2014, HEALTH PSYCHOL, V33, P690, DOI 10.1037/hea0000010
   Sharma A, 2018, AM J MENS HEALTH, V12, P1824, DOI 10.1177/1557988318790875
   Smith DK, 2012, JAIDS-J ACQ IMM DEF, V60, P421, DOI 10.1097/QAI.0b013e318256b2f6
   Stephenson R, 2015, AIDS BEHAV, V19, P553, DOI 10.1007/s10461-014-0862-4
   Stockman JK, 2004, JAIDS-J ACQ IMM DEF, V35, P432, DOI 10.1097/00126334-200404010-00016
   Stueve A, 2002, AIDS EDUC PREV, V14, P482, DOI 10.1521/aeap.14.8.482.24108
   Torres TS, 2018, JMIR PUBLIC HLTH SUR, V4, P147, DOI 10.2196/publichealth.8997
   Torres TS, 2019, AIDS CARE, V23, P1
   Torres TS, 2019, WILLINGNESS USE HIV
   TORRES TS, 2019, JMIR PUBLIC HLTH SUR, V5
   Venturi G, 2017, TEMPO SOC, V29, P159, DOI 10.11606/0103-2070.ts.2017.126682
   Warren EA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198680
   Wilton J, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20777
   World Health Organization (WHO), WHO BRAZ BEG PREP RO
NR 56
TC 3
Z9 3
U1 2
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 19
PY 2019
VL 19
IS 1
AR 1067
DI 10.1186/s12879-019-4704-x
PG 16
WC Infectious Diseases
SC Infectious Diseases
GA KI2EL
UT WOS:000511160000004
PM 31856746
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Fernandes, FF
   Piedade, J
   Guimaraes, L
   Nunes, EP
   Chaves, U
   Goldenzon, RV
   Cardoso, SW
   Duarte, J
   Grinsztejn, B
   Veloso, VG
   Pereira, G
   Perazzo, H
AF Fernandes, Flavia F.
   Piedade, Juliana
   Guimaraes, Livia
   Nunes, Estevao P.
   Chaves, Ursula
   Goldenzon, Rafaela V.
   Cardoso, Sandra W.
   Duarte, Joana
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Pereira, Gustavo
   Perazzo, Hugo
TI Effectiveness of direct-acting agents for hepatitis C and liver
   stiffness changing after sustained virological response
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE fibrosis; hepatitis C; liver stiffness; treatment
ID ANTIVIRAL THERAPY; TRANSIENT ELASTOGRAPHY; VIRUS-INFECTION; FOLLOW-UP;
   FIBROSIS; REGRESSION; ERADICATION; RISK; IMPROVEMENT; DIAGNOSIS
AB Background and Aim Few studies have evaluated sustained virological response (SVR) rates by direct-acting agents (DAAs) and liver stiffness measurement (LSM) changing post-SVR in limited-resource settings. We aimed to describe the effectiveness of DAAs for hepatitis C virus treatment and to assess the changing of LSM post-SVR. Methods This retrospective study analyzed data of consecutive hepatitis C virus-infected patients treated by DAAs from 2015 to 2017 in two tertiary centers in Brazil. SVR rates were reported by intention-to-treat and per-protocol analyses. LSM by transient elastography performed before treatment and post-SVR was compared, and logistic regression models were performed. Results Six hundred seventy-one patients (63% female, 62 years [55-68], 89% genotype 1, 8% HIV co-infected, and 64% with cirrhosis) were included. Most patients were treated by sofosbuvir/daclatasvir +/- ribavirin (74%) and sofosbuvir/simeprevir +/- ribavirin (21%). SVR rates (95% confidence interval [CI]) were 94.6% (92.7-96.1) and 97.8% (96.4-98.7) for intention-to-treat and per-protocol analyses, respectively. The leading adverse event was anemia (9.6% [95% CI 7.6-12.1]). Pretreatment and post-SVR12 LSM were available in 400 patients. LSM had significantly decreased after SVR (13.6 kPa [interquartile range, 10.0-21.6] vs 10.2 kPa [7.0-17.6], P < 0.001). A total of 167 patients (42%) decreased at least 30% of LSM post-SVR. The absence of type 2 diabetes (odds ratio = 1.52 [95% CI 1.05-2.21], P = 0.028) and presence of platelet count >= 150 x 10(9)/mm(3) (odds ratio = 1.75 [1.23-2.50], P = 0.002) were independently associated with a significant LSM regression (>= 30%) post-SVR. Conclusion DAAs were highly effective and safe, and LSM significantly decreased after SVR in a real-life cohort in Brazil. The absence of type 2 diabetes and presence of high platelet count were independently associated with LSM decrease post-SVR.
C1 [Fernandes, Flavia F.; Piedade, Juliana; Guimaraes, Livia; Duarte, Joana; Pereira, Gustavo] Bonsucesso Fed Hosp, Gastroenterol & Hepatol Dept, Rio De Janeiro, Brazil.
   [Piedade, Juliana; Nunes, Estevao P.; Chaves, Ursula; Goldenzon, Rafaela V.; Cardoso, Sandra W.; Grinsztejn, Beatriz; Veloso, Valdilea G.; Perazzo, Hugo] Oswaldo Cruz Fdn FIOCRUZ, Evandro Chagas Natl Inst Infect Dis INI, Lab Clin Res STD AIDS, Av Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
   [Pereira, Gustavo] Univ Estacio Sa, Sch Med, Rio De Janeiro, Brazil.
RP Perazzo, H (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Evandro Chagas Natl Inst Infect Dis INI, Lab Clin Res STD AIDS, Av Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM perazzohugo@gmail.com
OI Piedade, Juliana/0000-0002-0718-2033; Perazzo, Hugo/0000-0003-0931-6418
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [405211/2016-3] Funding Source: Medline; Fundacao Carlos Chagas
   Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ) [Bolsa de Iniciacao Cientifica - 2017/2, 235083]
   Funding Source: Medline; Fundacao Oswaldo Cruz [06.19, Programa de
   Incentivo a Jovens Pesquisadores INI] Funding Source: Medline;
   Universidade Estacio de Sa (UNESA) [Programa Pesquisa e Produtividade]
   Funding Source: Medline
CR Afdhal N, 2017, J VIRAL HEPATITIS, V24, P823, DOI 10.1111/jvh.12706
   Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
   [Anonymous], 2018, GUIDELINE MANAGEMENT
   Bachofner JA, 2017, LIVER INT, V37, P369, DOI 10.1111/liv.13256
   Castera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018
   Castro R, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0515-9
   Chan J, 2018, DIGEST DIS SCI, V63, P486, DOI 10.1007/s10620-017-4749-x
   Chen SH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190455
   D'Ambrosio R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155967
   de Franchis R, 2015, J HEPATOL, V63, P743, DOI 10.1016/j.jhep.2015.05.022
   Dolmazashvili E, 2017, EUR J GASTROEN HEPAT, V29, P1223, DOI 10.1097/MEG.0000000000000964
   Fabbri G, 2018, HIV MED, V19, P578, DOI 10.1111/hiv.12632
   Fagundes C, 2013, J HEPATOL, V59, P474, DOI 10.1016/j.jhep.2013.04.036
   Falade-Nwulia O, 2017, ANN INTERN MED, V166, P637, DOI [10.7326/M16-2575, 10.7326/m16-2575]
   Ferreira VL, 2018, BRAZ J INFECT DIS, V22, P186, DOI 10.1016/j.bjid.2018.04.003
   George SL, 2009, HEPATOLOGY, V49, P729, DOI 10.1002/hep.22694
   Iacob S, 2018, J GASTROINTEST LIVER, V27, P139, DOI 10.15403/jgld.2014.1121.272.100
   Jakobsen JC, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012143.pub2
   Lens S, 2017, GASTROENTEROLOGY, V153, P1273, DOI 10.1053/j.gastro.2017.07.016
   Li J, 2019, ALIMENT PHARM THER, V49, P599, DOI 10.1111/apt.15102
   Malin JJ, 2019, HIV MED, V20, P230, DOI 10.1111/hiv.12705
   Mandorfer M, 2016, J HEPATOL, V65, P692, DOI 10.1016/j.jhep.2016.05.027
   Miotto N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199941
   Nahon P, 2017, GASTROENTEROLOGY, V152, P142, DOI 10.1053/j.gastro.2016.09.009
   Ogasawara N, 2018, J MED VIROL, V90, P313, DOI 10.1002/jmv.24950
   Pons M, 2017, THER ADV GASTROENTER, V10, P619, DOI 10.1177/1756283X17715198
   Poynard T, 2013, J HEPATOL, V59, P675, DOI 10.1016/j.jhep.2013.05.015
   Sebastiani G, 2014, WORLD J GASTROENTERO, V20, P11033, DOI 10.3748/wjg.v20.i32.11033
   Serfaty L, 2016, LIVER INT, V36, P67, DOI 10.1111/liv.13016
   Sette H, 2017, ANN HEPATOL, V16, P727, DOI 10.5604/01.3001.0010.2717
   Singh S, 2018, CLIN GASTROENTEROL H, V16, P27, DOI 10.1016/j.cgh.2017.04.038
   Sulkowski MS, 2016, GASTROENTEROLOGY, V150, P419, DOI 10.1053/j.gastro.2015.10.013
   Tachi Y, 2016, ALIMENT PHARM THER, V44, P346, DOI 10.1111/apt.13695
   Tachi Y, 2017, JGH OPEN, V1, P44, DOI 10.1002/jgh3.12007
   Tachi Y, 2018, EUR J GASTROEN HEPAT, V30, P1066, DOI [10.1097/MEG.0000000000001159, 10.1097/meg.0000000000001159]
   Tachi Y, 2018, LIVER INT, V38, P59, DOI 10.1111/liv.13486
   Tachi Y, 2016, J GASTROEN HEPATOL, V31, P1001, DOI 10.1111/jgh.13245
   Tada T, 2018, ALIMENT PHARM THER, V47, P1012, DOI 10.1111/apt.14554
   Tag-Adeen M, 2017, HEPATIC MED-EVID RES, V9, P45, DOI 10.2147/HMER.S142600
   Telo GH, 2016, DIABETOL METAB SYNDR, V8, DOI 10.1186/s13098-016-0181-1
   van Katwyk S, 2017, LIVER INT, V37, P851, DOI 10.1111/liv.13260
   Vergniol J, 2011, GASTROENTEROLOGY, V140, P1970, DOI 10.1053/j.gastro.2011.02.058
NR 42
TC 3
Z9 3
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD DEC
PY 2019
VL 34
IS 12
BP 2187
EP 2195
DI 10.1111/jgh.14707
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA JZ7ED
UT WOS:000505270000024
PM 31062880
DA 2020-11-24
ER

PT J
AU Moreira, R
   Ferreira, ACG
   Coelho, LE
   Jalil, EM
   Bensenor, I
   Friedman, RK
   Monteiro, L
   Eksterman, LF
   Moreira, RI
   Cardoso, SW
   Veloso, VG
   Chor, D
   Grinsztejn, B
   Pacheco, AG
AF Moreira, R.
   Ferreira, A. C. G.
   Coelho, L. E.
   Jalil, E. M.
   Bensenor, I.
   Friedman, R. K.
   Monteiro, L.
   Eksterman, L. F.
   Moreira, R. I.
   Cardoso, S. W.
   Veloso, V. G.
   Chor, D.
   Grinsztejn, B.
   Pacheco, A. G.
TI Association of current Estradiol use with carotid intimal media
   thickness among transgender women: a cross-sectional study
SO HIV MEDICINE
LA English
DT Meeting Abstract
C1 [Moreira, R.] Fiocruz MS, Rio De Janeiro, Brazil.
   [Ferreira, A. C. G.; Coelho, L. E.; Jalil, E. M.; Friedman, R. K.; Monteiro, L.; Eksterman, L. F.; Moreira, R. I.; Cardoso, S. W.; Veloso, V. G.; Grinsztejn, B.] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Bensenor, I.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Chor, D.] Fundacao Oswaldo Cruz, Dept Epidemiol, Natl Sch Publ Hlth, Rio De Janeiro, Brazil.
   [Pacheco, A. G.] Fundacao Oswaldo Cruz, Sci Comp Program, Rio De Janeiro, Brazil.
RI Pacheco, Antonio Guilherme/E-6378-2013
OI Pacheco, Antonio Guilherme/0000-0003-3095-1774
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD NOV
PY 2019
VL 20
SU 9
SI SI
MA PE11/9
BP 161
EP 161
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA JK2QA
UT WOS:000494690300342
DA 2020-11-24
ER

PT J
AU Singh, R
   Chandasana, H
   Dooley, KE
   Kaplan, R
   Mwelase, N
   Grinsztejn, B
   Ticona, E
   Lacerda, M
   Sued, O
   Belonosova, E
   Ait-Khaled, M
   Angelis, K
   Brown, D
   Talarico, CL
   Tenorio, AR
   Keegan, MR
   Aboud, M
AF Singh, R.
   Chandasana, H.
   Dooley, K. E.
   Kaplan, R.
   Mwelase, N.
   Grinsztejn, B.
   Ticona, E.
   Lacerda, M.
   Sued, O.
   Belonosova, E.
   Ait-Khaled, M.
   Angelis, K.
   Brown, D.
   Talarico, C. L.
   Tenorio, A. R.
   Keegan, M. R.
   Aboud, M.
CA Inspiring Study Grp
TI Population pharmacokinetic analysis of dolutegravir in HIV/TB
   co-infected people with and without rifampicin
SO HIV MEDICINE
LA English
DT Meeting Abstract
C1 [Singh, R.; Chandasana, H.] GlaxoSmithKline, Clin Pharmacol Modeling Simulat, Collegeville, PA USA.
   [Dooley, K. E.] Johns Hopkins Univ, Sch Med, Ctr TB Res, Baltimore, MD USA.
   [Kaplan, R.] Desmond Tutu HIV Fdn HIV Fdn, Cape Town, South Africa.
   [Mwelase, N.] Clin HIV Res Unit, Johannesburg, South Africa.
   [Grinsztejn, B.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Ticona, E.] Univ Nacl Mayor San Marcos, Hosp Nacl Mayo, Lima, Peru.
   [Lacerda, M.] Trop Med Fdn Dr Heitor Vieira Dourado, Inst Leonidas & Maria Deane Fiocruz, Manaus, Amazonas, Brazil.
   [Sued, O.] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Belonosova, E.] Reg Ctr Prevent & Treatment AIDS & Infect Dis, Oryol, Russia.
   [Ait-Khaled, M.; Keegan, M. R.; Aboud, M.] ViiV Healthcare, Brentford, England.
   [Angelis, K.] GlaxoSmithKline, Uxbridge, Middx, England.
   [Brown, D.] ViiV Healthcare, Melbourne, Vic, Australia.
   [Talarico, C. L.; Tenorio, A. R.] ViiV Healthcare, Res Triangle Pk, NC USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD NOV
PY 2019
VL 20
SU 9
SI SI
MA PE35/9
BP 287
EP 287
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA JK2QA
UT WOS:000494690300658
DA 2020-11-24
ER

PT J
AU Coelho, LE
   Torres, TS
   Veloso, VG
   Landovitz, RJ
   Grinsztejn, B
AF Coelho, Lara Esteves
   Torres, Thiago Silva
   Veloso, Valdilea Goncalves
   Landovitz, Raphael J.
   Grinsztejn, Beatriz
TI Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline
SO LANCET HIV
LA English
DT Review
ID LONG-ACTING RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE; HIV-INFECTION;
   DOUBLE-BLIND; ANTIBODY VRC01; SAFETY; PHARMACOKINETICS; PREVENTION;
   PHASE-1; TRIAL
AB Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was adopted by WHO as a strategy to reduce HIV incidence. Although shown to be highly effective in reducing HIV acquisition, the protective efficacy of oral tenofovir disoproxil fumarate and emtricitabine relies on optimal adherence, which poses a challenge for a key portion of the most at-risk populations (women, young individuals [15-24 years], racial and ethnic minority men who have sex with men, and transgender women). New PrEP agents in clinical development include novel oral agents (eg, tenofovir alafenamide and islatravir [also known as MK-8591]), long-acting injectables (eg, cabotegravir), vaginal rings, broadly neutralising monoclonal antibodies, topical products (including gels, films, and enemas), and multipurpose technologies. In addition, new drug delivery systems, such as implants and transdermal devices, are promising strategies that are being developed for HIV prevention. The ultimate goal of this new PrEP research agenda is to expand the available PrEP regimens and offer preventive technologies that will appeal to a wide variety of individuals with different needs over the course of their sexually active lifespan.
C1 [Coelho, Lara Esteves; Torres, Thiago Silva; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Natl Inst Infect Dis Evandro Chagas, BR-21040036 Rio De Janeiro, Brazil.
   [Landovitz, Raphael J.] Univ Calif Los Angeles, UCLA Ctr Clin AIDS Res & Educ, Los Angeles, CA USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Natl Inst Infect Dis Evandro Chagas, BR-21040036 Rio De Janeiro, Brazil.
EM gbeatriz@ini.fiocruz.br
RI TORRES, THIAGO SILVA/D-6548-2014
OI TORRES, THIAGO SILVA/0000-0002-2557-601X
CR Achilles SL, 2018, HIV RES PREVENTION
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Baeten J, 2019, INT AIDS C MEX CIT M
   Baeten JM, 2016, NEW ENGL J MED, V375, P2121, DOI 10.1056/NEJMoa1506110
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bar KJ, 2016, NEW ENGL J MED, V375, P2037, DOI 10.1056/NEJMoa1608243
   Barrett SE, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01058-18
   Bavinton BR, 2018, LANCET HIV, V5, pE438, DOI 10.1016/S2352-3018(18)30132-2
   Bekker L-G, 2019, C RETR OPP INF SEATT
   Benhabour SR, 2018, HIV RES PREVENTION
   Blair CS, 2019, C RETR OPP INF SEATT
   Brown E, 2016, INT AIDS C DURB S AF
   Bunge KE, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25156
   Bunge KE, 2016, JAIDS-J ACQ IMM DEF, V71, P498, DOI 10.1097/QAI.0000000000000897
   Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268
   Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411
   Chen BA, 2019, CLIN INFECT DIS, V68, P1144, DOI 10.1093/cid/ciy654
   Chen BA, 2015, JAIDS-J ACQ IMM DEF, V70, P242, DOI 10.1097/QAI.0000000000000702
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Cohen YZ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219142
   Cottrell ML, 2017, J ANTIMICROB CHEMOTH, V72, P1731, DOI 10.1093/jac/dkx064
   Cranage M, 2008, PLOS MED, V5, P1238, DOI 10.1371/journal.pmed.0050157
   Cranston RD, 2017, CLIN INFECT DIS, V64, P614, DOI 10.1093/cid/ciw832
   Delany-Moretlwe S, 2018, LANCET INFECT DIS, V18, P1241, DOI 10.1016/s1473-3099(18)30428-6
   Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4
   Donnell D, 2014, JAIDS-J ACQ IMM DEF, V66, P340, DOI 10.1097/QAI.0000000000000172
   EDCTP, 2017, STRAT ACT SUPP LARG
   Flexner C, 2018, CURR OPIN HIV AIDS, V13, P374, DOI 10.1097/COH.0000000000000470
   Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145
   Ford SL, 2019, ANTIVIR THER, V24, P301, DOI 10.3851/IMP3306
   Friedland BA, 2016, JAIDS-J ACQ IMM DEF, V73, P489, DOI 10.1097/QAI.0000000000001136
   Gallant JE, 2016, LANCET HIV, V3, pE158, DOI 10.1016/S2352-3018(16)00024-2
   Gardner MR, 2015, NATURE, V519, P87, DOI 10.1038/nature14264
   Gatto G, 2018, C RETR OPP INF BOST
   Gaudinski MR, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002493
   Gaudinski MR, 2018, C RETR OPP INF BOST
   Gilbert PB, 2017, STAT COMMUN INFECT D, DOI [10.1515/said-201600p1, DOI 10.1515/SAID-201600P1]
   Grinsztejn B, 2018, LANCET HIV
   Grulich AE, 2018, LANCET HIV, V5, pE629, DOI 10.1016/S2352-3018(18)30215-7
   Gulick RM, 2017, ANN INTERN MED, V167, P384, DOI 10.7326/M17-0520
   Gulick RM, 2017, J INFECT DIS, V215, P238, DOI 10.1093/infdis/jiw525
   Gunawardana M, 2015, ANTIMICROB AGENTS CH, V59, P3913, DOI 10.1128/AAC.00656-15
   Hare CB, 2019, C RETR OPP INF SEATT
   Holt BY, 2018, EUR J CONTRACEP REPR, V23, P326, DOI 10.1080/13625187.2018.1508650
   Hosek SG, 2017, JAIDS-J ACQ IMM DEF, V74, P21, DOI 10.1097/QAI.0000000000001179
   Hraber P, 2014, AIDS, V28, P163, DOI 10.1097/QAD.0000000000000106
   Hua CK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01655
   Huang YX, 2016, CELL, V165, P1621, DOI 10.1016/j.cell.2016.05.024
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Jaworski JP, 2018, LANCET HIV, V5, pE723, DOI 10.1016/S2352-3018(18)30174-7
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Keller M, 2019, LANCET HIV, V6, pE498, DOI 10.1016/S2352-3018(19)30145-6
   Keller MJ, 2016, AIDS, V30, P743, DOI 10.1097/QAD.0000000000000979
   Klatt NR, 2017, SCIENCE, V356, P938, DOI 10.1126/science.aai9383
   Koup RA, 2018, SATELLITE SESSIONS S
   Landovitz RJ, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002690
   Ledgerwood JE, 2015, CLIN EXP IMMUNOL, V182, P289, DOI 10.1111/cei.12692
   Liu AY, 2019, CLIN INFECT DIS, V68, P1129, DOI 10.1093/cid/ciy652
   Lykins WR, 2017, DRUG DELIV TRANSL RE, V7, P805, DOI 10.1007/s13346-017-0391-6
   Lynch RM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad5752
   Markowitz M, 2020, J INFECT DIS, V221, P1398, DOI 10.1093/infdis/jiz271
   Markowitz M, 2018, CURR OPIN HIV AIDS, V13, P294, DOI 10.1097/COH.0000000000000467
   Markowitz M, 2017, LANCET HIV, V4, pE331, DOI 10.1016/S2352-3018(17)30068-1
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Matthews RP, 2019, 10 IAS C HIV SCI MEX
   Mayer KH, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002435
   Mcgowan I, 2015, PLOS ONE, V10
   McGowan I, 2018, C RETR OPP INF BOST
   McGowan I, 2016, LANCET HIV, V3, pE569, DOI 10.1016/S2352-3018(16)30113-8
   Mcgowan I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060147
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Nabeta H, 2018, C RETR OPP INF BOST
   Nel A, 2016, NEW ENGL J MED, V375, P2133, DOI 10.1056/NEJMoa1602046
   Northwestern Medicine News Center, 2015, NW REC 17 MILL GRANT
   Notario-Perez F, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11030137
   Orkin C, 2019, C RETR OPP INF SEATT
   Parikh UM, 2009, J VIROL, V83, P10358, DOI 10.1128/JVI.01073-09
   Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174
   Penrose KJ, 2016, J INFECT DIS, V213, P1013, DOI 10.1093/infdis/jiv528
   PEPFAR, 2018, MAPS PREP DISS MICR
   Pilkington V, 2018, J VIRUS ERAD, V4, P215
   Pons-Faudoa FP, 2019, J CONTROL RELEASE, V306, P89, DOI 10.1016/j.jconrel.2019.05.037
   Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   Safety Nel A., 2019, 9 SA AIDS C DURB S A
   San Francisco Department of Public Health Population Health Division, 2017, HIV EP ANN REP
   Scheer S, 2018, CLIN INFECT DIS, V66, P1027, DOI 10.1093/cid/cix940
   Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929
   Schwartz J, 2018, HIV RES PREVENTION
   Sloan DD, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005233
   Spinner CD, 2019, 10 IAS C HIV SCI MEX
   Swindells S, 2019, C RETR OPP INF SEATT
   Thurman AR, 2018, PLOS ONE
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P337, DOI 10.1128/AAC.48.1.337-339.2004
   Vincent KL, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002655
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
   WHO, 2016, CONS GUID US ANT DRU
   Williams PE, 2015, CURR OPIN HIV AIDS, V10, P233, DOI 10.1097/COH.0000000000000164
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Xu L, 2017, SCIENCE, V358, P85, DOI 10.1126/science.aan8630
NR 101
TC 9
Z9 9
U1 2
U2 5
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD NOV
PY 2019
VL 6
IS 11
BP E788
EP E799
DI 10.1016/S2352-3018(19)30238-3
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA JJ1GO
UT WOS:000493909100014
PM 31558423
DA 2020-11-24
ER

PT J
AU Rose, R
   Hall, M
   Redd, AD
   Lamers, S
   Barbier, AE
   Porcella, SF
   Hudelson, SE
   Piwowar-Manning, E
   McCauley, M
   Gamble, T
   Wilson, EA
   Kumwenda, J
   Hosseinipour, MC
   Hakim, JG
   Kumarasamy, N
   Chariyalertsak, S
   Pilotto, JH
   Grinsztejn, B
   Mills, LA
   Makhema, J
   Santos, BR
   Chen, YQ
   Quinn, TC
   Fraser, C
   Cohen, MS
   Eshleman, SH
   Laeyendecker, O
AF Rose, Rebecca
   Hall, Matthew
   Redd, Andrew D.
   Lamers, Susanna
   Barbier, Andrew E.
   Porcella, Stephen F.
   Hudelson, Sarah E.
   Piwowar-Manning, Estelle
   McCauley, Marybeth
   Gamble, Theresa
   Wilson, Ethan A.
   Kumwenda, Johnstone
   Hosseinipour, Mina C.
   Hakim, James G.
   Kumarasamy, Nagalingeswaran
   Chariyalertsak, Suwat
   Pilotto, Jose H.
   Grinsztejn, Beatriz
   Mills, Lisa A.
   Makhema, Joseph
   Santos, Breno R.
   Chen, Ying Q.
   Quinn, Thomas C.
   Fraser, Christophe
   Cohen, Myron S.
   Eshleman, Susan H.
   Laeyendecker, Oliver
TI Phylogenetic Methods Inconsistently Predict the Direction of HIV
   Transmission Among Heterosexual Pairs in the HPTN 052 Cohort
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Networks; epidemiology; viral dynamics
ID PREVENTION; NETWORK; IDENTIFICATION; INFECTION; CLUSTERS; TOOL
AB Background. We evaluated use of phylogenetic methods to predict the direction of human immunodeficiency virus (HIV) transmission.
   Methods. For 33 pairs of HIV-infected patients (hereafter, "index patients") and their partners who acquired genetically linked HIV infection during the study, samples were collected from partners and index patients close to the time when the partner seroconverted (hereafter, "SC samples"); for 31 pairs, samples collected from the index patient at an earlier time point (hereafter, "early index samples") were also available. Phylogenies were inferred using env next-generation sequences (1 tree per pair/subtype). The direction of transmission (DoT) predicted from each tree was classified as correct or incorrect on the basis of which sequences (those from the index patient or the partner) were closest to the root. DoT was also assessed using maximum parsimony to infer ancestral node states for 100 bootstrap trees.
   Results. DoT was predicted correctly for both single-pair and subtype-specific trees in 22 pairs (67%) by using SC samples and in 23 pairs (74%) by using early index samples. DoT was predicted incorrectly for 4 pairs (15%) by using SC or early index samples. In the bootstrap analysis, DoT was predicted correctly for 18 pairs (55%) by using SC samples and for 24 pairs (73%) by using early index samples. DoT was predicted incorrectly for 7 pairs (21%) by using SC samples and for 4 pairs (13%) by using early index samples.
   Conclusions. Phylogenetic methods based solely on the tree topology of HIV env sequences, particularly without consideration of phylogenetic uncertainty, may be insufficient for determining DoT.
C1 [Rose, Rebecca; Lamers, Susanna; Barbier, Andrew E.] BioInfoExperts, Thibodaux, LA USA.
   [Hall, Matthew; Fraser, Christophe] Univ Oxford, Big Data Inst, Oxford, England.
   [Redd, Andrew D.; Quinn, Thomas C.; Laeyendecker, Oliver] NIAID, Lab Immunoregulat, Div Intramural Res, NIH, Baltimore, MD 21205 USA.
   [Redd, Andrew D.; Quinn, Thomas C.; Laeyendecker, Oliver] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Porcella, Stephen F.] NIAID, Genom Unit, Res Technol Sect, Rocky Mt Labs,Div Intramural Res,NIH, Hamilton, MT USA.
   [Hudelson, Sarah E.; Piwowar-Manning, Estelle; Eshleman, Susan H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [McCauley, Marybeth; Gamble, Theresa] FHI360, Sci Facilitat Dept, Chapel Hill, NC USA.
   [Wilson, Ethan A.; Chen, Ying Q.] Fred Hutchinson Canc Res Inst, Vaccine & Infect Dis Sci Div, Seattle, WA USA.
   [Kumwenda, Johnstone] Johns Hopkins Project, Coll Med, Blantyre, Malawi.
   [Hosseinipour, Mina C.; Cohen, Myron S.] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA.
   [Hakim, James G.] Univ Zimbabwe, Harare, Zimbabwe.
   [Kumarasamy, Nagalingeswaran] YRGCARE Med Ctr, Chennai, Tamil Nadu, India.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Pilotto, Jose H.] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, Jose H.] Fiocruz MS, Lab AIDS & Imunol Mol, IOC, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Rio De Janeiro, Brazil.
   [Mills, Lisa A.] Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, KEMRI CDC Res & Publ Hlth Collaborat HIV Res Bran, Kisumu, Kenya.
   [Makhema, Joseph] Botswana Harvard AIDS Inst, Gaborone, Botswana.
   [Santos, Breno R.] Hosp Nossa Senhora Conceicao GHC, Serv Infectol, Porto Alegre, RS, Brazil.
   [Quinn, Thomas C.; Laeyendecker, Oliver] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
RP Laeyendecker, O (corresponding author), NIAID, Lab Immunoregulat, NIH, 855 N Wolfe St,Rangos Bldg,Rm 538A, Baltimore, MD 21205 USA.
EM olaeyen1@jhmi.edu
RI Fraser, Christophe/A-8109-2008; Pilotto, Jose Henrique/AAD-9773-2019
OI Fraser, Christophe/0000-0003-2399-9657; Pilotto, Jose
   Henrique/0000-0003-0521-8597
FU HIV Prevention Trials Network (HPTN) - National Institute of Allergy and
   Infectious Diseases [NIAID]; HIV Prevention Trials Network (HPTN) -
   National Institute on Drug Abuse; HIV Prevention Trials Network (HPTN) -
   National Institute of Mental Health; HIV Prevention Trials Network
   (HPTN) - Office of AIDS Research, National Institutes of Health [NIH],
   Department of Health and Human ServicesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [UM1AI068613, UM1AI068617, UM1AI068619]; Division of Intramural
   Research, NIAID, NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); National Cancer Institute,
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [HHSN261200800001E]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069423, UM1AI068617, UM1AI069476,
   UM1AI068613, UM1AI068613, ZIAAI001040, ZIAAI001040, ZIAAI000361,
   UM1AI068613, ZIAAI000361, UM1AI068613, UM1AI069518, UM1AI069518,
   UM1AI069423, UM1AI068613, ZIAAI000361, UM1AI069423, UM1AI069476,
   UM1AI069518, UM1AI069518, UM1AI068617, UM1AI068617, UM1AI068617,
   ZIAAI000361, UM1AI069476, UM1AI068617, ZIAAI001040, UM1AI069423,
   UM1AI069423] Funding Source: NIH RePORTER
FX This work was supported by the HIV Prevention Trials Network (HPTN;
   sponsored by the National Institute of Allergy and Infectious Diseases
   [NIAID], the National Institute on Drug Abuse, the National Institute of
   Mental Health, and the Office of AIDS Research, National Institutes of
   Health [NIH], Department of Health and Human Services, under grants
   UM1AI068613 [to the HPTN Network Laboratory, S. H. E., principal
   investigator], UM1AI068617 [to the HPTN Statistical and Data Management
   Center, Deborah Donnell, principal investigator), and UM1AI068619 (to
   the HPTN Core and Operations Center, Wafaa El-Sadr, principal
   investigator]); the Division of Intramural Research, NIAID, NIH; and the
   National Cancer Institute, NIH (contract HHSN261200800001E).
CR Abecasis AB, 2018, AIDS, V32, P543, DOI 10.1097/QAD.0000000000001728
   Abecasis AB, 2011, LANCET INFECT DIS, V11, P78, DOI 10.1016/S1473-3099(10)70283-8
   Bernard EJ, 2007, HIV MED, V8, P382, DOI 10.1111/j.1468-1293.2007.00486.x
   Brown AJL, 2011, J INFECT DIS, V204, P1463, DOI 10.1093/infdis/jir550
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Drummond AJ, 2003, TRENDS ECOL EVOL, V18, P481, DOI 10.1016/S0169-5347(03)00216-7
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Eshleman SH, 2017, JAIDS-J ACQ IMM DEF, V74, P112, DOI 10.1097/QAI.0000000000001158
   Eshleman SH, 2011, J INFECT DIS, V204, P1918, DOI 10.1093/infdis/jir651
   Guindon S, 2009, METHODS MOL BIOL, V537, P113, DOI 10.1007/978-1-59745-251-9_6
   Hassan AS, 2017, AIDS, V31, P1211, DOI 10.1097/QAD.0000000000001470
   Hughes GJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000590
   Jacka B, 2016, J HEPATOL, V64, P1247, DOI 10.1016/j.jhep.2016.02.031
   Kouyos RD, 2011, CLIN INFECT DIS, V52, P532, DOI 10.1093/cid/ciq164
   Larsson A, 2014, BIOINFORMATICS, V30, P3276, DOI 10.1093/bioinformatics/btu531
   Le Vu S, 2018, EPIDEMICS-NETH, V23, P1, DOI 10.1016/j.epidem.2017.10.001
   Leitner T, 2000, AIDS REV, V2, P241
   Leitner T, 2018, NAT MICROBIOL, V3, P983, DOI 10.1038/s41564-018-0204-9
   Lemey P, 2005, J VIROL, V79, P11981, DOI 10.1128/JVI.79.18.11981-11989.2005
   Lemey P, 2006, AIDS REV, V8, P125
   Lewis F, 2008, PLOS MED, V5, P392, DOI 10.1371/journal.pmed.0050050
   McCloskey RM, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew029
   Pond SLK, 2018, MOL BIOL EVOL, V35, P1812, DOI 10.1093/molbev/msy016
   Prosperi MCF, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1325
   Puller V, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005775
   Ragonnet-Cronin M, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-317
   Romero-Severson EO, 2017, GENETICS, V207, P1089, DOI 10.1534/genetics.117.300284
   Romero-Severson EO, 2016, P NATL ACAD SCI USA, V113, P2690, DOI 10.1073/pnas.1522930113
   Rose R, 2017, AIDS RES HUM RETROV, V33, P211, DOI [10.1089/aid.2016.0205, 10.1089/AID.2016.0205]
   Scaduto DI, 2010, P NATL ACAD SCI USA, V107, P21242, DOI 10.1073/pnas.1015673107
   Siljic M, 2017, FORENSIC SCI INT-GEN, V27, P100, DOI 10.1016/j.fsigen.2016.12.006
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Vrancken B, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003505
   Wertheim JO, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006000
   Wertheim JO, 2016, AIDS RES HUM RETROV, V32, P1046, DOI 10.1089/aid.2015.0272
   Wertheim JO, 2014, J INFECT DIS, V209, P304, DOI 10.1093/infdis/jit524
   Wertheim JO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027775
   Wymant C, 2018, MOL BIOL EVOL, V35, P719, DOI 10.1093/molbev/msx304
NR 39
TC 6
Z9 6
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2019
VL 220
IS 9
BP 1406
EP 1413
DI 10.1093/infdis/jiy734
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA JE9EU
UT WOS:000490992100004
PM 30590741
OA Bronze, Green Published
DA 2020-11-24
ER

PT J
AU Luz, PM
   Veloso, VG
   Grinsztejn, B
AF Luz, Paula M.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI The HIV epidemic in Latin America: accomplishments and challenges on
   treatment and prevention
SO CURRENT OPINION IN HIV AND AIDS
LA English
DT Review
DE epidemiology; HIV/AIDS; Latin America; preexposure prophylaxis;
   treatment as prevention
ID PREEXPOSURE PROPHYLAXIS; ANTIRETROVIRAL THERAPY; TRANSGENDER WOMEN;
   BRAZIL; SEX; MEN; PREVALENCE; CARE; BEHAVIORS; RISK
AB Purpose of review
   To describe how countries in Latin America and the Caribbean are (or are not) meeting 2016 WHO guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, that is, their progress on the adoption of 'Treat All' and of preexposure prophylaxis (PrEP) as an additional prevention tool for people at substantial risk of HIV infection.
   Recent findings
   The HIV epidemic in the region continues largely concentrated in vulnerable populations with MSM and transgender women (TGW) suffering the highest burden. On treatment, the challenges of late initiation as well as suboptimal adherence persist. On prevention, recent studies on PrEP willingness in key populations show promising results, meanwhile PrEP implementation projects as well as actual PrEP adoption by national health systems is expanding. A glimpse of real-world PrEP uptake is shown through Brazil's first-year experience of offering PrEP in multiple cities in all regions of the country.
   Summary
   In conclusion, accomplishments have been made though challenges for fully addressing the HIV epidemic persist. The impact of both treatment and PrEP will be limited by the availability and prompt use of all services, including HIV testing.
C1 [Luz, Paula M.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM gbeatriz@ini.fiocruz.br
OI Luz, Paula/0000-0001-9746-719X
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do
   Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX P.M.L. and B.G. acknowledge funding from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) and Fundacao Carlos
   Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ).
CR Almeida-Brasil CC, 2018, AIDS, V32, P1323, DOI [10.1097/QAD.0000000000001822, 10.1097/qad.0000000000001822]
   Colchero MA, 2015, SALUD PUBLICA MEXICO, V57, pS99
   Assasf R, 2019, CROI 2017
   Avila D, 2014, JAIDS-J ACQ IMM DEF, V65, pE8, DOI 10.1097/QAI.0b013e3182a39979
   Bastos FI, 2008, INT J EPIDEMIOL, V37, P729, DOI 10.1093/ije/dyn127
   Bautista-Arredondo S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072616
   Belaunzaran-Zamudio PF, 2015, B WORLD HEALTH ORGAN, V93, P529, DOI 10.2471/BLT.14.147447
   Beyrer C, 2013, AIDS, V27, P2665, DOI 10.1097/01.aids.0000432449.30239.fe
   Bezabhe WM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003361
   Borquez A, 2019, LANCET PUBLIC HEALTH, V4, pE127, DOI 10.1016/S2468-2667(18)30236-6
   Brito AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130445
   Buchbinder SP, 2014, LANCET INFECT DIS, V14, P468, DOI 10.1016/S1473-3099(14)70025-8
   Caceres CF, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.7.21108
   Calabrese SK, 2019, LANCET HIV, V6, pE211, DOI 10.1016/S2352-3018(19)30030-X
   Carnegie NB, 2015, JAIDS-J ACQ IMM DEF, V69, P119, DOI 10.1097/QAI.0000000000000555
   Caro-Vega Y, 2018, EPIDEMIOL INFECT, V146, P1308, DOI [10.1017/s0950268818001346, 10.1017/S0950268818001346]
   Carriquiry G, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20016
   Costa JD, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25066
   Costa JD, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052000399, 10.11606/s1518-8787.2018052000399]
   Guimaraes MDC, 2018, MEDICINE, V97, pS62, DOI 10.1097/MD.0000000000009079
   De Boni RB, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25116
   Ferreira OD, 2018, MEDICINE, V97, pS3, DOI 10.1097/MD.0000000000009218
   Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145
   Ford N, 2015, CLIN INFECT DIS, V60, P1128, DOI 10.1093/cid/ciu1138
   Gaspar PC, 2018, MEDICINE, V97, pS32, DOI [10.1097/MD.0000000000010125, 10.1097/md.0000000000010125]
   Gomez GB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001323
   Grangeiro A, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-99
   Grangeiro A, 2010, REV SAUDE PUBL, V44, P430, DOI 10.1590/s0034-89102010005000013
   Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   IBGE, IND DEM SAUD INF SOC
   Garcia JI, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022632
   Jalil EM, 2016, HIV RES PREVENTION 2
   Jalil EM, 2019, PREP UPTAKE EARLY AD
   Salas-Espinoza KJ, 2017, AIDS BEHAV, V21, P3271, DOI 10.1007/s10461-017-1931-2
   Katz IT, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.3.18640
   Kerr L, 2018, MEDICINE, V97, pS9, DOI [10.1097/MD.0000000000010573, 10.1097/md.0000000000010573]
   Kojima N, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2332-x
   Luz PM, 2018, MEDICINE, V97, pS75, DOI [10.1097/MD.0000000000010602, 10.1097/md.0000000000010602]
   Luz PM, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25096
   Mangal TD, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3844-3
   Ministerio da Saude, 2013, PESQ CONH AT PRAT PO
   Pascom ARP, 2018, MEDICINE, V97, pS69, DOI [10.1097/MD.0000000000009857, 10.1097/md.0000000000009857]
   Pilkington V, 2018, J VIRUS ERAD, V4, P215
   Ravasi G, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.7.21113
   Santos MA, 2018, MEDICINE, V97, pS38, DOI [10.1097/md.0000000000009015, 10.1097/MD.0000000000009015]
   Sperhacke RD, 2018, MEDICINE, V97, pS25, DOI [10.1097/MD.0000000000009014, 10.1097/md.0000000000009014]
   Torres TS, 2018, JMIR PUBLIC HLTH SUR, V4, P147, DOI 10.2196/publichealth.8997
   Veloso VG, 2018, HIVR4P MADR
   Volk JE, 2016, INT J STD AIDS, V27, P531, DOI 10.1177/0956462415586676
   Wolff MJ, 2018, INT J STD AIDS, V29, P4, DOI 10.1177/0956462417714094
   World Health Organization, 2018, WHO HIV POL AD IMPL
   Zalazar Virginia, 2016, Transgend Health, V1, P266, DOI 10.1089/trgh.2016.0033
NR 58
TC 8
Z9 8
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1746-630X
EI 1746-6318
J9 CURR OPIN HIV AIDS
JI Curr. Opin. HIV AIDS
PD SEP
PY 2019
VL 14
IS 5
BP 366
EP 373
DI 10.1097/COH.0000000000000564
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA JL7RJ
UT WOS:000495725900004
PM 31219888
OA Green Published
DA 2020-11-24
ER

PT J
AU Zurcher, K
   Ballif, M
   Kiertiburanakul, S
   Chenal, H
   Yotebieng, M
   Grinsztejn, B
   Michael, D
   Sterling, TR
   Ngonyani, KM
   Mandalakas, AM
   Egger, M
   Pettit, AC
   Fenner, L
   Veloso, V
   Luz, P
   de Boni, R
   Wagner, SC
   Friedman, R
   Moreira, R
   Padgett, D
   Madero, JS
   Ramirez, BC
   Belaunzaran, P
   Vega, YC
   Gotuzzo, E
   Mejia, F
   Carriquiry, G
   McGowan, CC
   Shepherd, BE
   Sterling, T
   Jayathilake, K
   Person, AK
   Rebeiro, PF
   Giganti, M
   Castilho, J
   Duda, SN
   Maruri, F
   Vansell, H
   Ditangco, R
   Uy, E
   Bantique, R
   Avihingsanon, A
   Gatechompol, S
   Phanuphak, P
   Phadungphon, C
   Kiertiburanakul, S
   Phuphuakrat, A
   Chumla, L
   Sanmeema, N
   Nguyen, KV
   Bui, HV
   Nguyen, DTH
   Nguyen, DT
   Cuong, DD
   An, NV
   Luan, NT
   Sohn, AH
   Ross, JL
   Petersen, B
   Law, MG
   Jiamsakul, A
   Boettiger, DC
   Diero, L
   Ayaya, S
   Sang, E
   Ssali, J
   Ssemakadde, M
   Ngonyani, K
   Lwali, J
   Urassa, M
   Machemba, R
   Wools-Kaloustian, K
   Yiannoutscs, C
   Vreeman, R
   Musick, B
   Elul, B
   Syvertsen, J
   Kantor, R
   Martin, J
   Wenger, M
   Cohen, C
   Kulzer, J
   Braitstein, P
   Zannou, DM
   Ahouada, C
   Akakpo, J
   Ahomadegbe, C
   Bashi, J
   Gougounon-Houeto, A
   Azon-Kouanou, A
   Houngbe, F
   Sehonou, J
   Hawerlander, D
   Soppi, F
   Traore, HA
   Minta, D
   Cisse, T
   Dembele, M
   Doumbia, M
   Fomba, M
   Kaya, AS
   Traore, AM
   Traore, H
   Toure, AA
   Seydi, M
   Sow, PS
   Diop, B
   Manga, NM
   Tine, JM
   Bassabi, CC
   Dabis, F
   Bissagnene, E
   Arrive, E
   Coffie, P
   Ekouevi, D
   Jaquet, A
   Leroy, V
   Lewden, C
   Sasco, AJ
   Amani, D
   Azani, JC
   Balestre, E
   Bessekon, S
   Bohossou, F
   Gilbert, C
   Karcher, S
   Gonsan, JM
   Le Carrou, J
   Lenaud, S
   Nchot, C
   Malateste, K
   Yao, AR
   Siloue, B
   Clouet, G
   Doss, M
   Doring, A
   Kouakou, A
   Rabourdin, E
   Rivenc, J
   Anglaret, X
   Ba, B
   Essanin, JB
   Ciaranello, A
   Datte, S
   Desmonde, S
   Diby, JSE
   Gottlieb, GS
   Horo, AG
   Kangah, SN
   Malvy, D
   Meless, D
   Mounkaila-Harouna, A
   Ndondoki, C
   Shiboski, C
   Tchounga, B
   Thiebaut, R
   Wanderer, G
   Dusingize, JC
   Mutimura, E
   Anastos, K
   Tatwangire, J
   Izabelle, I
   Niyongabo, T
   Twizere, C
   Baramperanye, E
   Edmonds, A
   Ayangma, IAL
   Anderegg, N
   Bartels, L
   Bohlius, J
   Chammartin, F
   Christ, B
   Ostinelli, CH
   von Groote, P
   Haas, A
   Katayoun, T
   Rohner, E
   Smith, L
   Sporri, A
   Wandeler, G
   Zaniewski, E
   Boulle, A
   Cornell, M
   Davies, MA
   Lyun, V
   Johnson, L
   Kubjane, M
   Maxwell, N
   Nembandona, T
   Nyakato, P
   Mokotoane, E
   Patten, G
   Schomaker, M
   Tsondai, P
   de Waal, R
AF Zurcher, Kathrin
   Ballif, Marie
   Kiertiburanakul, Sasisopin
   Chenal, Henri
   Yotebieng, Marcel
   Grinsztejn, Beatriz
   Michael, Denna
   Sterling, Timothy R.
   Ngonyani, Kapella M.
   Mandalakas, Anna M.
   Egger, Matthias
   Pettit, April C.
   Fenner, Lukas
   Veloso, Valdilea
   Luz, Paula
   de Boni, Raquel
   Wagner, Sandra Cardoso
   Friedman, Ruth
   Moreira, Ronaldo
   Padgett, Denis
   Sierra Madero, Juan
   Crabtree Ramirez, Brenda
   Belaunzaran, Paco
   Caro Vega, Yanink
   Gotuzzo, Eduardo
   Mejia, Fernando
   Carriquiry, Gabriela
   McGowan, Catherine C.
   Shepherd, Bryan E.
   Sterling, Timothy
   Jayathilake, Karu
   Person, Anna K.
   Rebeiro, Peter F.
   Giganti, Mark
   Castilho, Jessica
   Duda, Stephany N.
   Maruri, Fernanda
   Vansell, Hilary
   Ditangco, R.
   Uy, E.
   Bantique, R.
   Avihingsanon, A.
   Gatechompol, S.
   Phanuphak, P.
   Phadungphon, C.
   Kiertiburanakul, S.
   Phuphuakrat, A.
   Chumla, L.
   Sanmeema, N.
   Nguyen, K., V
   Bui, H., V
   Nguyen, D. T. H.
   Nguyen, D. T.
   Cuong, D. D.
   An, N., V
   Luan, N. T.
   Sohn, A. H.
   Ross, J. L.
   Petersen, B.
   Law, M. G.
   Jiamsakul, A.
   Boettiger, D. C.
   Diero, L.
   Ayaya, S.
   Sang, E.
   Ssali, John
   Ssemakadde, Mathew
   Ngonyani, Kapella
   Lwali, Jerome
   Urassa, Mark
   Machemba, Richard
   Wools-Kaloustian, Kara
   Yiannoutscs, Constantin
   Vreeman, Rachel
   Musick, Beverly
   Elul, Batya
   Syvertsen, Jennifer
   Kantor, Rami
   Martin, Jeffrey
   Wenger, Megan
   Cohen, Craig
   Kulzer, Jayne
   Braitstein, Paula
   Zannou, Djimon Marcel
   Ahouada, Carin
   Akakpo, Jocelyn
   Ahomadegbe, Christelle
   Bashi, Jules
   Gougounon-Houeto, Alice
   Azon-Kouanou, Angele
   Houngbe, Fabien
   Sehonou, Jean
   Hawerlander, Denise
   Soppi, Franck
   Traore, Hamar Alassane
   Minta, Daouda
   Cisse, Tidiani
   Dembele, Mamadou
   Doumbia, Mohammed
   Fomba, Mahamadou
   Kaya, Assetou Soukho
   Traore, Abdoulaye M.
   Traore, Hamady
   Toure, Amadeu Abathina
   Seydi, Moussa
   Sow, Papa Salif
   Diop, Bernard
   Manga, Noel Magloire
   Tine, Judicael Malick
   Bassabi, Coumba Cisse
   Dabis, Francois
   Bissagnene, Emmanuel
   Arrive, Elise
   Coffie, Patrick
   Ekouevi, Didier
   Jaquet, Antoine
   Leroy, Valerian
   Lewden, Charlotte
   Sasco, Annie J.
   Amani, Dieudonne
   Azani, Jean-Claude
   Balestre, Eric
   Bessekon, Serge
   Bohossou, Franck
   Gilbert, Camille
   Karcher, Sophie
   Gonsan, Jules Mahan
   Le Carrou, Jerome
   Lenaud, Severin
   Nchot, Celestin
   Malateste, Karen
   Yao, Amon Roseamonde
   Siloue, Bertine
   Clouet, Gwenaelle
   Doss, Madikona
   Doring, Alexandra
   Kouakou, Adrienne
   Rabourdin, Elodie
   Rivenc, Jean
   Anglaret, Xavier
   Ba, Boubacar
   Essanin, Jean Bosco
   Ciaranello, Andrea
   Datte, Sebastien
   Desmonde, Sophie
   Diby, Jean-Serge Elvis
   Gottlieb, Geoffrey S.
   Horo, Apollinaire Gninlgninrin
   Kangah, Serge N'zore
   Malvy, Denis
   Meless, David
   Mounkaila-Harouna, Aida
   Ndondoki, Camille
   Shiboski, Caroline
   Tchounga, Boris
   Thiebaut, Rodolphe
   Wanderer, Gilles
   Dusingize, Jean Claude
   Mutimura, Eugene
   Anastos, Kathryn
   Tatwangire, Judy
   Izabelle, Izimukwiye
   Niyongabo, Theodore
   Twizere, Christelle
   Baramperanye, Evelyne
   Edmonds, Andrew
   Ayangma, Innocent Azinyue Liliane
   Anderegg, Nina
   Bartels, Lina
   Bohlius, Julia
   Chammartin, Frederique
   Christ, Benedikt
   Ostinelli, Cam Ha Dao
   von Groote, Per
   Haas, Andreas
   Katayoun, Taghavi
   Rohner, Eliane
   Smith, Lilian
   Sporri, Adrian
   Wandeler, Gilles
   Zaniewski, Elizabeth
   Boulle, Andrew
   Cornell, Morna
   Davies, Mary-Ann
   Lyun, Victoria
   Johnson, Leigh
   Kubjane, Mmamapudi
   Maxwell, Nicola
   Nembandona, Tshabakwane
   Nyakato, Patience
   Mokotoane, Ernest
   Patten, Gem
   Schomaker, Michael
   Tsondai, Priscilla
   de Waal, Renee
CA Int Epidemiology Databases Evaluat
TI Diagnosis and clinical outcomes of extrapulmonary tuberculosis in
   antiretroviral therapy programmes in low- and middle-income countries: a
   multicohort study
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE extrapulmonary tuberculosis; pulmonary tuberculosis; tuberculosis;
   HIV-positive patients; low- and middle-income countries; diagnostics;
   mortality; lost to follow-up
ID EVALUATE AIDS IEDEA; CAPE-TOWN; SMEAR; DATABASES; CHILDREN; ADULTS;
   IMPACT
AB Introduction Extrapulmonary tuberculosis (EPTB) is difficult to confirm bacteriologically and requires specific diagnostic capacities. Diagnosis can be especially challenging in under-resourced settings. We studied diagnostic modalities and clinical outcomes of EPTB compared to pulmonary tuberculosis (PTB) among HIV-positive adults in antiretroviral therapy (ART) programmes in low- and middle-income countries (LMIC). Methods We collected data from HIV-positive TB patients (>= 16 years) in 22 ART programmes participating in the International Epidemiology Databases to Evaluate AIDS (IeDEA) consortium in sub-Saharan Africa, Asia-Pacific, and Caribbean, Central and South America regions between 2012 and 2014. We categorized TB as PTB or EPTB (EPTB included mixed PTB/EPTB). We used multivariable logistic regression to assess associations with clinical outcomes. Results and Discussion We analysed 2695 HIV-positive TB patients. Median age was 36 years (interquartile range (IQR) 30 to 43), 1102 were female (41%), and the median CD4 count at TB treatment start was 114 cells/mu L (IQR 40 to 248). Overall, 1930 had PTB (72%), and 765 EPTB (28%). Among EPTB patients, the most frequently involved sites were the lymph nodes (24%), pleura (15%), abdomen (11%) and meninges (6%). The majority of PTB (1123 of 1930, 58%) and EPTB (582 of 765, 76%) patients were diagnosed based on clinical criteria. Bacteriological confirmation (using positive smear microscopy, culture, Xpert MTB/RIF, or other nucleic acid amplification tests result) was obtained in 897 of 1557 PTB (52%) and 183 of 438 EPTB (42%) patients. EPTB was not associated with higher mortality compared to PTB (adjusted odd ratio (aOR) 1.0, 95% CI 0.8 to 1.3), but TB meningitis was (aOR 1.9, 95% CI 1.0 to 3.1). Bacteriological confirmation was associated with reduced mortality among PTB patients (aOR 0.7, 95% CI 0.6 to 0.8) and EPTB patients (aOR 0.3 95% CI 0.1 to 0.8) compared to TB patients with a negative test result. Conclusions Diagnosis of EPTB and PTB at ART programmes in LMIC was mainly based on clinical criteria. Greater availability and usage of TB diagnostic tests would improve the diagnosis and clinical outcomes of both EPTB and PTB.
C1 [Zurcher, Kathrin; Ballif, Marie; Egger, Matthias; Fenner, Lukas; Anderegg, Nina; Bartels, Lina; Bohlius, Julia; Chammartin, Frederique; Christ, Benedikt; Ostinelli, Cam Ha Dao; von Groote, Per; Haas, Andreas; Katayoun, Taghavi; Rohner, Eliane; Smith, Lilian; Sporri, Adrian; Wandeler, Gilles; Zaniewski, Elizabeth] Univ Bern, ISPM, Bern, Switzerland.
   [Kiertiburanakul, Sasisopin; Kiertiburanakul, S.; Phuphuakrat, A.; Chumla, L.; Sanmeema, N.] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok, Thailand.
   [Chenal, Henri; Hawerlander, Denise; Soppi, Franck] CIRBA, Abidjan, Cote Ivoire.
   [Yotebieng, Marcel] Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA.
   [Grinsztejn, Beatriz] Fundacao Oswald Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Michael, Denna] Kisesa HDSS, Natl Inst Med Res, Mwanza, Tanzania.
   [Sterling, Timothy R.; Pettit, April C.] Vanderbilt TB Ctr, Nashville, TN USA.
   [Sterling, Timothy R.; Pettit, April C.] Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN USA.
   [Ngonyani, Kapella M.] Tumbi Special Hosp, CTC, Kibaha Town, Tanzania.
   [Mandalakas, Anna M.] Texas Childrens Hosp, Global TB Program, Houston, TX 77030 USA.
   [Mandalakas, Anna M.] Baylor Coll Med, Houston, TX 77030 USA.
   [Egger, Matthias; Clouet, Gwenaelle] Univ Cape Town, Sch Publ Hlth & Family Med, Ctr Infect Dis Epidemiol & Res, Rondebosch, South Africa.
   [Grinsztejn, Beatriz; Veloso, Valdilea; Luz, Paula; de Boni, Raquel; Wagner, Sandra Cardoso; Friedman, Ruth; Moreira, Ronaldo] Fiocruz MS, Inst Nacl Infectol, Rio De Janeiro, Brazil.
   [Padgett, Denis] Inst Hondureno Seguridad Social, La Ceiba, Honduras.
   [Sierra Madero, Juan; Crabtree Ramirez, Brenda; Belaunzaran, Paco; Caro Vega, Yanink] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [Gotuzzo, Eduardo; Mejia, Fernando; Carriquiry, Gabriela] Inst Med Trop Alexander von Humboldt, San Martin De Porres, Peru.
   [McGowan, Catherine C.; Shepherd, Bryan E.; Sterling, Timothy; Jayathilake, Karu; Person, Anna K.; Rebeiro, Peter F.; Giganti, Mark; Castilho, Jessica; Duda, Stephany N.; Maruri, Fernanda; Vansell, Hilary] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Ditangco, R.; Uy, E.; Bantique, R.] Res Inst Trop Med, Manila, Philippines.
   [Avihingsanon, A.; Gatechompol, S.; Phanuphak, P.; Phadungphon, C.] HIVNAT Thai Red Cross AIDS Res Ctr, Bangkok, Thailand.
   [Nguyen, K., V; Bui, H., V; Nguyen, D. T. H.; Nguyen, D. T.] Natl Hosp Trop Dis, Hanoi, Vietnam.
   [Cuong, D. D.; An, N., V; Luan, N. T.] Bach Mai Hosp, Hanoi, Vietnam.
   [Sohn, A. H.; Ross, J. L.; Petersen, B.] AmfAR Fdn AIDS Res, TREAT Asia, Bangkok, Thailand.
   [Law, M. G.; Jiamsakul, A.; Boettiger, D. C.] UNSW Australia, Kirby Inst, Sydney, NSW, Australia.
   [Diero, L.; Ayaya, S.; Sang, E.] MOI Univ, AMPATH Plus, Eldoret, Kenya.
   [Ssali, John; Ssemakadde, Mathew] Masaka Reg Referral Hosp, Masaka, Uganda.
   [Ngonyani, Kapella; Lwali, Jerome] Tumbi Reg Hosp, Pwani, Tanzania.
   [Michael, Denna; Urassa, Mark; Machemba, Richard] Kisesa HDSS, NIMR, Mwanza, Tanzania.
   [Wools-Kaloustian, Kara; Yiannoutscs, Constantin; Vreeman, Rachel; Musick, Beverly] Indiana Univ, Indiana Univ Sch Med, Indianapolis, IN 46204 USA.
   [Elul, Batya] Columbia Univ, New York, NY USA.
   [Syvertsen, Jennifer] Ohio State Univ, Columbus, OH 43210 USA.
   [Kantor, Rami] Brown Univ, Miriam Hosp, Providence, RI USA.
   [Martin, Jeffrey; Wenger, Megan; Cohen, Craig; Kulzer, Jayne] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Braitstein, Paula] Univ Toronto, Toronto, ON, Canada.
   [Zannou, Djimon Marcel; Ahouada, Carin; Akakpo, Jocelyn; Ahomadegbe, Christelle; Bashi, Jules; Gougounon-Houeto, Alice; Azon-Kouanou, Angele; Houngbe, Fabien; Sehonou, Jean] CNHU Hubert Maga, Cotonou, Benin.
   [Traore, Hamar Alassane; Cisse, Tidiani; Dembele, Mamadou; Doumbia, Mohammed; Fomba, Mahamadou; Kaya, Assetou Soukho; Traore, Abdoulaye M.; Traore, Hamady; Toure, Amadeu Abathina] CH Point G, Bamako, Mali.
   [Seydi, Moussa; Sow, Papa Salif; Diop, Bernard; Manga, Noel Magloire; Tine, Judicael Malick; Bassabi, Coumba Cisse] CHU Fann, SMIT, Dakar, Senegal.
   Univ Bordeaux Segalen, Coordinating Ctr ISPED, Bordeaux, France.
   [Coffie, Patrick; Ekouevi, Didier; Amani, Dieudonne; Azani, Jean-Claude; Bessekon, Serge; Bohossou, Franck; Gonsan, Jules Mahan; Lenaud, Severin; Nchot, Celestin; Yao, Amon Roseamonde; Siloue, Bertine; Kouakou, Adrienne; Datte, Sebastien; Diby, Jean-Serge Elvis; Horo, Apollinaire Gninlgninrin; Kangah, Serge N'zore; Meless, David; Tchounga, Boris] Reg Off PAC CI, Abidjan, Cote Ivoire.
   MEREVA, Bordeaux, France.
   [Azani, Jean-Claude; Mutimura, Eugene] Andre Gitembagara Womens Equ Access Care & Treat, Kigali, Rwanda.
   [Anastos, Kathryn] Albert Einstein Coll Med, New York, NY USA.
   [Anastos, Kathryn] Montefiore Med Ctr, New York, NY USA.
   [Tatwangire, Judy; Izabelle, Izimukwiye] Rwanda Mil Hosp, Kigali, Rwanda.
   [Niyongabo, Theodore; Twizere, Christelle] Ctr Hosp Univ Kamenge, Bujumbura, Burundi.
   [Baramperanye, Evelyne] Ctr Natl Reference Matiere VIH, Bujumbura, Burundi.
   [Yotebieng, Marcel; Edmonds, Andrew] Kalembelembe Pediat Hosp, Kinshasa, DEM REP CONGO.
   [Ayangma, Innocent Azinyue Liliane] Mil Hosp Yaounde, Yaounde, Cameroon.
   [Boulle, Andrew; Cornell, Morna; Davies, Mary-Ann; Lyun, Victoria; Johnson, Leigh; Kubjane, Mmamapudi; Maxwell, Nicola; Nembandona, Tshabakwane; Nyakato, Patience; Mokotoane, Ernest; Patten, Gem; Schomaker, Michael; Tsondai, Priscilla; de Waal, Renee] Univ Cape Town, Sch Publ Hlth & Family Med, Rondebosch, South Africa.
RP Zurcher, K (corresponding author), Univ Bern, ISPM, Bern, Switzerland.
EM kathrin.zurecher@ispm.unibe.ch
RI Belaunzaran-Zamudio, Pablo Francisco/T-4085-2019; Phuphuakrat,
   Angsana/AAI-2492-2019; Wandeler, Gilles/ABB-2961-2020; DE BONI, RAQUEL
   BRANDINI/D-4212-2013; Anglaret, Xavier/T-2757-2019; Leroy,
   Valeriane/AAO-5175-2020; Desmonde, Sophie/AAC-3850-2019; Yotebieng,
   Marcel/L-2083-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Leroy,
   Valeriane/0000-0003-3542-8616; Desmonde, Sophie/0000-0001-9372-2819;
   Yotebieng, Marcel/0000-0003-2110-2631; Zurcher,
   Kathrin/0000-0002-7915-3194; Michael, Denna/0000-0001-6883-1431
FU U.S. National Institutes of Health's National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); Eunice Kennedy Shriver
   National Institute of Child Health and Human DevelopmentUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD); National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI); National Institute of Mental
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH); National Institute on Drug Abuse: Asia-Pacific [U01AI069907];
   National Institute on Drug Abuse: CCASAnet [U01AI069923]; National
   Institute on Drug Abuse: Central Africa [U01AI096299]; National
   Institute on Drug Abuse: East Africa [U01AI069911]; National Institute
   on Drug Abuse: NA-ACCORD [U01AI069918]; National Institute on Drug
   Abuse: Southern Africa [U01AI069924]; National Institute on Drug Abuse:
   West Africa [U01AI069919]; National Institute on Drug Abuse: Pettit [K08
   AI104352]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000445, UL1TR000445] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01AI069923, U01AI069924, U01AI096299, U01AI069907,
   U01AI069918, U01AI069923, U01AI069923, U01AI069911, U01AI069918,
   U01AI069918, U01AI069923, U01AI069907, U01AI069924, U01AI069919,
   U01AI069911, K08AI104352, U01AI069918, U01AI069918, U01AI069919,
   U01AI069911, U01AI096299, U01AI069923, U01AI069911, U01AI069907,
   U01AI069924, U01AI069919, U01AI069907, U01AI069907, U01AI096299,
   U01AI069907, U01AI069923, U01AI069919, U01AI096299, U01AI096299,
   U01AI069918, U01AI069919, U01AI069924, U01AI096299, U01AI069924] Funding
   Source: NIH RePORTER
FX The International Epidemiology Databases to Evaluate AIDS (IeDEA) is
   supported by the U.S. National Institutes of Health's National Institute
   of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National
   Institute of Child Health and Human Development, the National Cancer
   Institute, the National Institute of Mental Health, and the National
   Institute on Drug Abuse: Asia-Pacific, U01AI069907; CCASAnet,
   U01AI069923; Central Africa, U01AI096299; East Africa, U01AI069911;
   NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa,
   U01AI069919; Pettit K08 AI104352. This work is solely the responsibility
   of the authors and does not necessarily represent the official views of
   any of the institutions mentioned above.
CR [Anonymous], 2017, IEEE T POWER SYSTEMS, VPP, P1, DOI DOI 10.1109/IEEESTD.2017.7920364
   BRINDLE RJ, 1993, AM REV RESPIR DIS, V147, P958, DOI 10.1164/ajrccm/147.4.958
   Carlucci JG, 2017, JAIDS-J ACQ IMM DEF, V75, P156, DOI 10.1097/qai.0000000000001335
   Chakravorty S, 2005, J CLIN MICROBIOL, V43, P4357, DOI 10.1128/JCM.43.9.4357-4362.2005
   Clouse K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171384
   Denkinger CM, 2014, EUR RESPIR J, V44, P435, DOI 10.1183/09031936.00007814
   Dorman SE, 2018, LANCET INFECT DIS, V18, P76, DOI [10.1016/S1473-3099(17)30691-6, 10.1016/s1473-3099(17)30691-6]
   Egger M, 2012, INT J EPIDEMIOL, V41, P1256, DOI 10.1093/ije/dyr080
   Enane LA, 2016, INT J TUBERC LUNG D, V20, P1320, DOI 10.5588/ijtld.16.0060
   Fanning A, 1999, CAN MED ASSOC J, V160, P1597
   Fenner L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077697
   Gupta RK, 2013, INT J TUBERC LUNG D, V17, P1014, DOI 10.5588/ijtld.13.0032
   Gupta RK, 2015, AIDS, V29, P1987, DOI 10.1097/QAD.0000000000000802
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hermans S, 2017, B WORLD HEALTH ORGAN, V95, P554, DOI 10.2471/BLT.16.185314
   Ifebunandu Ngozi A, 2012, J Infect Public Health, V5, P340, DOI 10.1016/j.jiph.2012.06.002
   Kang'ombe C, 2000, T ROY SOC TROP MED H, V94, P305, DOI 10.1016/S0035-9203(00)90335-3
   Karstaedt AS, 2014, SAMJ S AFR MED J, V104, P22, DOI [10.7196/SAMJ.6374, 10.7196/samj.6374]
   Kendall EA, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002472
   Kulchavenya E, 2014, THER ADV INFECT DIS, V2, P61, DOI 10.1177/2049936114528173
   Leeds IL, 2012, CLIN INFECT DIS, V55, P75, DOI 10.1093/cid/cis303
   Marx Grace E, 2011, Tuberc Res Treat, V2011, P798764, DOI 10.1155/2011/798764
   Naing C, 2013, LUNG, V191, P27, DOI 10.1007/s00408-012-9440-6
   Norbis L, 2014, EXPERT REV ANTI-INFE, V12, P633, DOI 10.1586/14787210.2014.899900
   RIEDER HL, 1990, AM REV RESPIR DIS, V141, P347, DOI 10.1164/ajrccm/141.2.347
   Sharma SK, 2004, INDIAN J MED RES, V120, P316
   Steingart KR, 2006, LANCET INFECT DIS, V6, P664, DOI 10.1016/S1473-3099(06)70602-8
   Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393
   Telzak EE, 1997, CLIN INFECT DIS, V25, P666, DOI 10.1086/513772
   Waitt CJ, 2016, INT J TUBERC LUNG D, V20, P1320
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   World Health Organisation (WHO), 2013, CONS GUID US ANT DRU, P1, DOI DOI 10.1017/CBO9781107415324.004
   World Health Organization, 2014, DEF REP FRAM TUB 201
   World Health Organization, 2006, IMPR DIAGN TREATM SM
   World Health Organization, 2013, WHOHTMTB201316197
   Yang ZH, 2004, CLIN INFECT DIS, V38, P199, DOI 10.1086/380644
NR 36
TC 2
Z9 2
U1 0
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD SEP
PY 2019
VL 22
IS 9
AR e25392
DI 10.1002/jia2.25392
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA JB3WC
UT WOS:000488486400013
PM 31507083
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Hughes, MD
   Ritz, J
   Salata, R
   Mugyenyi, P
   Hogg, E
   Wieclaw, L
   Gross, R
   Godfrey, C
   Cardoso, SW
   Bukuru, A
   Makanga, M
   Faesen, S
   Mave, V
   Ndege, BW
   Fontain, SN
   Samaneka, W
   Secours, R
   van Schalkwyk, M
   Mngqibisa, R
   Mohapi, L
   Valencia, J
   Sugandhavesa, P
   Montalban, E
   Avihingsanon, A
   Santos, BR
   Kumarasamy, N
   Kanyama, C
   Schooley, RT
   Mellors, JW
   Wallis, CL
   Collier, AC
AF Grinsztejn, Beatriz
   Hughes, Michael D.
   Ritz, Justin
   Salata, Robert
   Mugyenyi, Peter
   Hogg, Evelyn
   Wieclaw, Linda
   Gross, Robert
   Godfrey, Catherine
   Cardoso, Sandra W.
   Bukuru, Aggrey
   Makanga, Mumbi
   Faesen, Sharlaa
   Mave, Vidya
   Ndege, Beatrice Wangari
   Fontain, Sandy Nerette
   Samaneka, Wadzanai
   Secours, Rode
   van Schalkwyk, Marije
   Mngqibisa, Rosie
   Mohapi, Lerato
   Valencia, Javier
   Sugandhavesa, Patcharaphan
   Montalban, Esmelda
   Avihingsanon, Anchalee
   Santos, Breno R.
   Kumarasamy, Nagalingeswaran
   Kanyama, Cecilia
   Schooley, Robert T.
   Mellors, John W.
   Wallis, Carole L.
   Collier, Ann C.
CA A5288 Team
TI Third-line antiretroviral therapy in low-income and middle-income
   countries (ACTG A5288): a prospective strategy study
SO LANCET HIV
LA English
DT Article
ID RESISTANCE PROFILE; DRUG-RESISTANCE; HIV-1; DOLUTEGRAVIR; RALTEGRAVIR;
   INHIBITORS; DARUNAVIR; EFFICACY
AB Background Antiretroviral therapy (ART) management is challenging for individuals in resource-limited settings presenting for third-line treatment because of complex resistance patterns, partly due to reduced access to viral load monitoring. We aimed to evaluate use of newer antiretroviral drugs and contemporary management approaches, including population-based sequencing, to select appropriate antiretrovirals, plasma viral load monitoring, and interventions to improve adherence in individuals presenting with second-line viral failure.
   Methods A5288 was a phase 4, third-line ART strategy study done at 19 urban sites in ten countries that enrolled adult participants with confirmed plasma HIV-1 RNA (viral load) of 1000 copies per mL or more after more than 24 weeks of protease inhibitor-based second-line ART. The primary objective was to use antiretrovirals (raltegravir, etravirine, and ritonavir-boosted darunavir) and diagnostic monitoring technologies, including viral load, genotyping, and adherence support to achieve viral load suppression (defined as <= 200 copies per mL) in 65% or more of participants. ART history and real-time drug resistance genotypes were used to assign participants to one of four cohorts: cohort A (no lopinavir resistance) stayed on second-line ART and cohorts B (B1, best available nucleoside reverse transcriptase inhibitors [NRTIs] plus ritonavir-boosted darunavir plus raltegravir; B2, ritonavir-boosted darunavir plus raltegravir plus etravirine; B3, ritonavir-boosted darunavir, raltegravir, and either tenofovir plus emtricitabine or tenofovir plus lamivudine), C (ritonavir-boosted darunavir plus raltegravir plus tenofovir-emtricitabine or tenofovir plus lamivudine), and D (best available NRTIs plus ritonavir-boosted darunavir plus raltegravir) were defined by increasing levels of resistance and received appropriate regimens, including new antiretrovirals. Participants in Cohort B without detectable hepatitis B surface antigen were assigned by blocked randomisation to cohorts B1 and B2, and those with detectable hepatitis B surface antigen were assigned to cohort B3. The trial is registered with ClinicalTrials.gov , number NCT01641367.
   Findings From Jan 10, 2013, to Sept 10, 2015, 545 participants were enrolled. 287 (53%) were assigned to cohort A, 74 (14%) to B1, 72 (13%) to B2, eight (1%) to B3, 70 (13%) to C, and 34 (6%) to D. Overall, 349 (64%, 95% CI 60-68) participants achieved viral suppression at week 48, with proportions varying from 125 (44%) of 287 in cohort A to 65 (88%) of 74 in cohort B1, 63 (88%) of 72 in B2, eight (100%) of eight in B3, 63 (90%) of 70 in C, and 25 (74%) of 34 in D. Participants in cohort A remained on their second-line protease inhibitor, and had the most participants with grade 3 or higher adverse events (147 [51%]).
   Interpretation Targeted real-time genotyping to select third-line ART can appropriately allocate more costly antiretrovirals to those with greater levels of HIV drug resistance. Copyright (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Grinsztejn, Beatriz; Cardoso, Sandra W.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Hughes, Michael D.; Ritz, Justin] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
   [Salata, Robert] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
   [Mugyenyi, Peter; Bukuru, Aggrey] Joint Clin Res Ctr, Kampala, Uganda.
   [Hogg, Evelyn] Social & Sci Syst Inc, Silver Spring, MD USA.
   [Wieclaw, Linda] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA.
   [Gross, Robert] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   [Godfrey, Catherine] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA.
   [Makanga, Mumbi] Kenya Govt Med Res Ctr, Kisumu, Kenya.
   [Makanga, Mumbi] Ctr Dis Control, Kisumu, Kenya.
   [Faesen, Sharlaa] Wits HIV Clin Res Site, Johannesburg, South Africa.
   [Mave, Vidya] BJ Med Coll Clin Res Site, Pune, Maharashtra, India.
   [Ndege, Beatrice Wangari] Moi Univ Teaching Hosp Eldoret Clin Res Site, AMPATH, Eldoret, Kenya.
   [Fontain, Sandy Nerette; Secours, Rode] Les Ctr GHESKIO Clin Res Site, Port Au Prince, Haiti.
   [Samaneka, Wadzanai] Univ Zimbabwe, Coll Hlth Sci, Clin Trials Res Ctr, Harare, Zimbabwe.
   [van Schalkwyk, Marije] Stellenbosch Univ, Family Clin Res Unit Clin Res Site, Cape Town, South Africa.
   [Mngqibisa, Rosie] Enhancing Care Fdn, Durban Adult HIV Clin Res Site, Durban, South Africa.
   [Mohapi, Lerato] Univ Witwatersrand, Soweto AIDS Clin Trials Grp Clin Res Site, Johannesburg, South Africa.
   [Valencia, Javier] Barranco Clin Res Site, Lima, Peru.
   [Sugandhavesa, Patcharaphan] Chiang Mai Univ, Ctr AIDS & STDs, Chiang Mai, Thailand.
   [Montalban, Esmelda] San Miguel Clin Res Site, Lima, Peru.
   [Avihingsanon, Anchalee] Thai Red Cross AIDS Res Ctr Treatment Clin Res Si, Bangkok, Thailand.
   [Santos, Breno R.] Grp Hosp Conceicao, Hosp Nossa Senhora Conceicao, Serv Infectol, Porto Alegre, RS, Brazil.
   [Kumarasamy, Nagalingeswaran] Chennai Antiviral Res & Treatment Clin Res Site, Chennai, Tamil Nadu, India.
   [Kanyama, Cecilia] Kamuzu Cent Hosp, Univ North Carolina Project, Lilongwe, Malawi.
   [Schooley, Robert T.] Univ Calif San Diego, Div Infect Dis, San Diego, CA 92103 USA.
   [Mellors, John W.] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA.
   [Wallis, Carole L.] Lancet Labs, Bio Analyt Res Corp South Africa, Johannesburg, South Africa.
   [Collier, Ann C.] Univ Washington, Sch Med, Seattle, WA USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
EM beatriz.grinsztejn@gmail.com
OI MONTALBAN, ESMELDA/0000-0002-7613-2857; Wallis,
   Carole/0000-0001-8408-8772
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069424,
   UM1AI069399, UM1AI069432, UM1AI069501, UM1AI068634, UM1AI068636,
   UM1AI069463, UM1AI069463, UM1AI069481, UM1AI108568, UM1AI069418,
   UM1AI069423, UM1AI069424, UM1AI069521, UM1AI069534, UM1AI069501,
   UM1AI069481, UM1AI069453, UM1AI068636, UM1AI069432, UM1AI069421,
   UM1AI069418, UM1AI069521, UM1AI069399, UM1AI069421, UM1AI069534,
   UM1AI069521, UM1AI069481, UM1AI069436, UM1AI069436, UM1AI069432,
   UM1AI069521, UM1AI069534, UM1AI069453, UM1AI068634, UM1AI069436,
   UM1AI069436, UM1AI069421, UM1AI069424, UM1AI068636, UM1AI069534,
   UM1AI069399, UM1AI069432, UM1AI068634, UM1AI069432, UM1AI069424,
   UM1AI069423, UM1AI069463, UM1AI068634, UM1AI069399, UM1AI069481,
   UM1AI069481, UM1AI069534, UM1AI069424, UM1AI108568, UM1AI068634,
   UM1AI069501, UM1AI069432, UM1AI069423, UM1AI069534, UM1AI069423,
   UM1AI069423, UM1AI069453, UM1AI069481, UM1AI069418, UM1AI068636,
   UM1AI069463, UM1AI068636, UM1AI069399, UM1AI069436, UM1AI069421,
   UM1AI069501] Funding Source: NIH RePORTER
FX National Institutes of Health.
CR Aboud M, 2019, LANCET INFECT DIS, V19, P253, DOI 10.1016/S1473-3099(19)30036-2
   Arathoon E, 2014, J INT AIDS SOC, V17, P177, DOI 10.7448/IAS.17.4.19783
   Cahn P, 2013, LANCET, V382, P700, DOI 10.1016/S0140-6736(13)61221-0
   Cambiano V, 2014, AIDS, V28, pS15, DOI 10.1097/QAD.0000000000000082
   Castagna A, 2014, J INFECT DIS, V210, P354, DOI 10.1093/infdis/jiu051
   Chimbetete C, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy005
   Cohen K, 2019, JAIDS-J ACQ IMM DEF, V80, P325, DOI 10.1097/QAI.0000000000001923
   de Meyer S, 2008, AIDS RES HUM RETROV, V24, P379, DOI 10.1089/aid.2007.0173
   Fox MP, 2016, TROP MED INT HEALTH, V21, P1131, DOI 10.1111/tmi.12741
   Gregson J, 2016, LANCET INFECT DIS, V16, P565, DOI 10.1016/S1473-3099(15)00536-8
   Gross R, 2019, LANCET DIGIT HEALTH, V1, pE26, DOI 10.1016/S2589-7500(19)30006-8
   Gupta A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164619
   Inzaule SC, 2017, AIDS, V31, P1495, DOI 10.1097/QAD.0000000000001500
   Kuritzkes DR, 2018, J INFECT DIS, V218, P673, DOI 10.1093/infdis/jiy186
   Lorenzana SB, 2012, AIDS, V26, P1083, DOI 10.1097/QAD.0b013e32835221eb
   Meintjes G, 2015, AIDS RES THER, V12, DOI 10.1186/s12981-015-0081-8
   Meloni ST, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0184-5
   Moh R, 2017, 9 IAS C HIV SCI PAR
   Moorhouse M, 2019, JAIDS-J ACQ IMM DEF, V80, P73, DOI 10.1097/QAI.0000000000001883
   Parikh UM, 2006, J VIROL, V80, P4971, DOI 10.1128/JVI.80.10.4971-4977.2006
   Sawadogo S, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy014
   Scherrer AU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050307
   Squires KE, 2011, J ANTIMICROB CHEMOTH, V66, P363, DOI 10.1093/jac/dkq457
   Tashima KT, 2015, ANN INTERN MED, V163, P908, DOI 10.7326/M15-0949
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
   Vingerhoets J, 2015, HIV MED, V16, P297, DOI 10.1111/hiv.12218
   Vingerhoets J, 2010, AIDS, V24, P503, DOI 10.1097/QAD.0b013e32833677ac
   Wallis C. L., 2011, AIDS Research and Treatment, V2011, P769627, DOI 10.1155/2011/769627
   WHO, 2015, ANT MED LOW AND MIDD
   World Health Organisation (WHO), 2013, CONS ARV GUID
NR 30
TC 8
Z9 8
U1 0
U2 2
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD SEP
PY 2019
VL 6
IS 9
BP E588
EP E600
DI 10.1016/S2352-3018(19)30146-8
PG 13
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA IV0HJ
UT WOS:000483959800012
PM 31371262
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Marins, LMS
   Torres, TS
   Leite, ID
   Moreira, RI
   Luz, PM
   Hoagland, B
   Kallas, EG
   Madruga, JV
   Liu, AY
   Anderson, PL
   Grinsztejn, B
   Veloso, VG
AF Marins, Luana M. S.
   Torres, Thiago S.
   Leite, Iuri da C.
   Moreira, Ronaldo I.
   Luz, Paula M.
   Hoagland, Brenda
   Kallas, Esper G.
   Madruga, Jose Valdez
   Liu, Albert Y.
   Anderson, Peter L.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
TI Performance of HIV pre-exposure prophylaxis indirect adherence measures
   among men who have sex with men and transgender women: Results from the
   PrEP Brasil Study
SO PLOS ONE
LA English
DT Article
ID SERODISCORDANT COUPLES; CLINICAL-TRIAL; PREVENTION; INFECTION;
   CONCORDANCE; SYSTEM; RISK
AB Introduction
   Efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP is strongly dependent on the adherence. We examined the concordance between indirect adherence measures and protective drug levels among participants retained through 48 weeks in the PrEP Brasil Study.
   Methods
   PrEP Brasil was a prospective, multicenter, open-label demonstration project evaluating PrEP provision for men who have sex with men (MSM) and transgender women (TGW) at higher risk for HIV infection within the setting of Brazilian Public Health System. Three indirect adherence measures were obtained at week 48: medication possession ratio (MPR), pill count and self-report (30-days recall). Tenofovir diphosphate (TFV-DP) concentration in Dried Blood Spot (DBS) was measured at week 48. Areas under (AUC) the receiver operating characteristics (ROC) curve were used to evaluate the concordance between achieving protective drug levels (TFV-DP >= 700fmol/punch) and the indirect adherence measures. Youden's index and distance to corner were used to determine the optimal cutoff points for each indirect adherence measure. We calculated sensitivity, specificity, negative (NPV) and positive (PPV) predictive values for the found cutoff points. Finally, Delong test was used to compare AUCs.
   Results and discussion
   From April, 2014 to July, 2016, 450 participants initiated PrEP, 375(83.3%) were retained through 48 weeks. Of these, 74% (277/375) had TFV-DP >= 700fmol/punch. All adherence measures discriminated between participants with and without protective drug levels (AUC>0.5). High indirect adherence measure was predictive of protective drug levels (PPV>0.8) while low indirect adherence measure was not predictive of lack of protective drug levels (NPV<0.5). No significant differences were found between the adherence methods (p = 0.44).
   Conclusions
   Low-burden measurements such as MPR and self-report can be used to predict PrEP adherence in a public health context in Brazil for MSM and TGW retained through 48 weeks.
C1 [Marins, Luana M. S.; Torres, Thiago S.; Moreira, Ronaldo I.; Luz, Paula M.; Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea G.] Inst Nacl Infectol Evandro Chagas INI Fiocruz, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Leite, Iuri da C.] Escola Nacl Saude Publ ENSP Fiocruz, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Escola Med, Sao Paulo, Brazil.
   [Madruga, Jose Valdez] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [Anderson, Peter L.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA.
RP Marins, LMS (corresponding author), Inst Nacl Infectol Evandro Chagas INI Fiocruz, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
EM luana.marins@ini.fiocruz.br
RI TORRES, THIAGO SILVA/D-6548-2014
OI TORRES, THIAGO SILVA/0000-0002-2557-601X; Marins,
   Luana/0000-0003-0045-6764; Kallas, Esper/0000-0003-2026-6925
FU Brazilian Ministry of Health (Brasilia, Brazil) [01/2013 BRA/K57];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [402004/2012-4, 454931/2014-0]; Secretaria de Vigilancia em Saude
   (SVS) [281/2013]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/110.261/2014]; Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2012/51743-0]; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ);
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Secretaria de Vigilancia Sanitaria; Gilead SciencesGilead Sciences;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476]
   Funding Source: NIH RePORTER
FX This study was sponsored by the Brazilian Ministry of Health (Brasilia,
   Brazil; #01/2013 BRA/K57), Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq; #402004/2012-4, #454931/2014-0),
   Secretaria de Vigilancia em Saude (SVS; #281/2013), Fundacao Carlos
   Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ;
   #E-26/110.261/2014), and Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP; #2012/51743-0). BG and PML are funded by the CNPq and
   FAPERJ. EGK is funded by FAPESP. Gilead Sciences donated the study drug
   and covered costs related to drug concentration assessment but had no
   role in study design, collection, analysis and interpretation of data,
   writing of the manuscript, or the decision to submit the manuscript for
   publication.; The authors would like to thank the following: the study
   participants; the PrEP Brasil Study Team; and the University of Colorado
   Antiviral Pharmacology Laboratory. The authors also acknowledge the
   support of our funders: CNPq; Secretaria de Vigilancia Sanitaria;
   FAPERJ; FAPESP; and Gilead Sciences.
CR Abaasa A, 2018, AIDS BEHAV, V22, P1165, DOI 10.1007/s10461-017-1951-y
   Agot K, 2015, AIDS BEHAV, V19, P743, DOI 10.1007/s10461-014-0859-z
   Amico KR, 2016, AIDS BEHAV, V20, P1535, DOI 10.1007/s10461-016-1360-7
   Amico KR, 2014, JAIDS-J ACQ IMM DEF, V66, P530, DOI 10.1097/QAI.0000000000000216
   Amico KR, 2012, CURR OPIN HIV AIDS, V7, P542, DOI 10.1097/COH.0b013e3283582d4a
   Anderson PL, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01710-17
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   [Anonymous], 2018, J Int AIDS Soc, V21 Suppl 6, pe25148, DOI 10.1002/jia2.25148
   [Anonymous], SIST CONTR LOG MED S
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Baker Z, 2018, AIDS BEHAV, V22, P1174, DOI 10.1007/s10461-017-1958-4
   Baxi SM, 2015, JAIDS-J ACQ IMM DEF, V68, P13, DOI 10.1097/QAI.0000000000000386
   Berg KM, 2006, JAIDS-J ACQ IMM DEF, V43, pS79, DOI 10.1097/01.qai.0000248337.97814.66
   Castillo-Mancilla JR, 2018, CURR HIV-AIDS REP, V15, P49, DOI 10.1007/s11904-018-0377-0
   Castillo-Mancilla JR, 2012, AIDS RES HUM RETROV
   Cohen SE, 2015, JAIDS-J ACQ IMM DEF, V68, P439, DOI 10.1097/QAI.0000000000000479
   Corneli AL, 2014, JAIDS-J ACQ IMM DEF, V66, P324, DOI 10.1097/QAI.0000000000000158
   D'Alessandro A, 2010, BLOOD TRANSFUS-ITALY, V8, P82, DOI 10.2450/2009.0122-09
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135
   Food and Drug Administration, 2012, TRUV PREP FACT SHEET
   Galea JT, 2018, LANCET HIV, V5, pE110, DOI 10.1016/S2352-3018(18)30011-0
   Grangeiro A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009021
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Haberer JE, 2016, CURR OPIN HIV AIDS, V11, P10, DOI 10.1097/COH.0000000000000220
   Haberer JE, 2015, AIDS, V29, P1277, DOI 10.1097/QAD.0000000000000647
   Haberer JE, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001511
   Hajian-Tilaki K, 2018, STAT METHODS MED RES, V27, P2374, DOI 10.1177/0962280216680383
   Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   Kabore Lassane, 2015, J Int Assoc Provid AIDS Care, V14, P156, DOI 10.1177/2325957414557263
   Kebaabetswe PM, 2015, AIDS BEHAV, V19, P758, DOI 10.1007/s10461-014-0891-z
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
   Liu AY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083736
   Luz PM, 2018, MEDICINE, V97, pS75, DOI [10.1097/MD.0000000000010602, 10.1097/md.0000000000010602]
   Marcus JL, 2016, JAIDS-J ACQ IMM DEF, V73, P540, DOI 10.1097/QAI.0000000000001129
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Montgomery MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157742
   Musinguzi N, 2016, AIDS, V30, P1121, DOI 10.1097/QAD.0000000000001024
   PAHO/ WHO, BRAZ IN IMPL PREP PR
   PrEP-O ESTADO DE IMPLEMENTACAO DA PREP NO BRASIL, 2019, B VAC ANT HIV AIDS, V32
   Psaros C, 2014, JAIDS-J ACQ IMM DEF, V66, P522, DOI 10.1097/QAI.0000000000000212
   Seifert SM, 2015, CLIN INFECT DIS, V60, P804, DOI 10.1093/cid/ciu916
   Spinner CD, 2016, INFECTION, V44, P151, DOI 10.1007/s15010-015-0850-2
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Torres T. S., 2018, AIDS 2018
   Torres TS, 2019, JMIR PUBLIC HLTH SUR
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   WHO, 2017, BRAZ BEG PREP ROLL O
   Williams AB, 2013, AIDS BEHAV, V17, P284, DOI 10.1007/s10461-012-0172-7
   World Health Organization, 2014, CONS PREEXP PROPH PR
   Zheng JH, 2016, J PHARMACEUT BIOMED, V122, P16, DOI 10.1016/j.jpba.2016.01.038
NR 55
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 20
PY 2019
VL 14
IS 8
AR e0221281
DI 10.1371/journal.pone.0221281
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IW5OC
UT WOS:000485026800040
PM 31430318
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Rose, R
   Redd, AD
   Lamers, S
   Porcella, SF
   Hudelson, SE
   Piwowar-Manning, E
   McCauley, M
   Gamble, T
   Wilson, EA
   Kumwenda, J
   Hosseinipour, MC
   Hakim, JG
   Kumarasamy, N
   Chariyalertsak, S
   Pilotto, JH
   Grinsztejn, B
   Mills, LA
   Makhema, J
   Santos, BR
   Chen, YQ
   Quinn, TC
   Cohen, MS
   Eshleman, SH
   Laeyendecker, O
AF Rose, R.
   Redd, A. D.
   Lamers, S.
   Porcella, S. F.
   Hudelson, S. E.
   Piwowar-Manning, E.
   McCauley, M.
   Gamble, T.
   Wilson, E. A.
   Kumwenda, J.
   Hosseinipour, M. C.
   Hakim, J. G.
   Kumarasamy, N.
   Chariyalertsak, S.
   Pilotto, J. H.
   Grinsztejn, B.
   Mills, L. A.
   Makhema, J.
   Santos, B. R.
   Chen, Y. Q.
   Quinn, T. C.
   Cohen, M. S.
   Eshleman, S. H.
   Laeyendecker, O.
TI Evaluation of phylogenetic inference methods to determine direction of
   HIV transmission
SO VIRUS EVOLUTION
LA English
DT Meeting Abstract
C1 [Rose, R.; Lamers, S.] BioInfoExperts LLC, Thibodaux, LA USA.
   [Redd, A. D.; Porcella, S. F.; Quinn, T. C.; Laeyendecker, O.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Hudelson, S. E.; Piwowar-Manning, E.; Eshleman, S. H.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
   [McCauley, M.; Gamble, T.] FHI 360, Durham, NC USA.
   [Wilson, E. A.; Chen, Y. Q.] Fred Hutchinson Canc Res Inst, Vaccine & Infect Dis Sci Div, Seattle, WA USA.
   [Kumwenda, J.] Johns Hopkins Project, Coll Med, Blantyre, Malawi.
   [Hosseinipour, M. C.; Cohen, M. S.] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA.
   [Hakim, J. G.] Univ Zimbabwe, Harare, Zimbabwe.
   [Kumarasamy, N.] YRGCARE Med Ctr, Chennai, Tamil Nadu, India.
   [Chariyalertsak, S.] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Pilotto, J. H.] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, J. H.] Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Grinsztejn, B.] Inst Nacl Infectol Evandro Chagas INI Fiocruz, Rio De Janeiro, Brazil.
   [Mills, L. A.] KEMRI CDC Res & Publ Hlth Collaborat, CDC Div HIV AIDS Prevent, HIV Res Branch, Kisumu, Kenya.
   [Makhema, J.] Botswana Harvard Aids Inst, Gaborone, Botswana.
   [Santos, B. R.] Hosp Nossa Senhora Conceicao GHC, Serv Infectol, Porto Alegre, Brazil.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
EI 2057-1577
J9 VIRUS EVOL
JI Virus Evol.
PD AUG
PY 2019
VL 5
SU 1
MA A11
BP S4
EP S4
DI 10.1093/ve/vez002.010
PG 1
WC Virology
SC Virology
GA JX6ZN
UT WOS:000503880600012
OA DOAJ Gold, Green Accepted
DA 2020-11-24
ER

PT J
AU Lin, CQ
   Slama, J
   Gonzalez, P
   Goodman, MT
   Xia, NS
   Kreimer, AR
   Wu, T
   Hessol, NA
   Shvetsov, Y
   Ortiz, AP
   Grinsztejn, B
   Moscicki, AB
   Heard, I
   Losa, MDG
   Kojic, EM
   van der Loeff, MFS
   Wei, FX
   Longatto-Filho, A
   Mbulawa, ZA
   Palefsky, JM
   Sohn, AH
   Hernandez, BY
   Robison, K
   Simpson, S
   Conley, LJ
   de Pokomandy, A
   van der Sande, MAB
   Mandishora, RSD
   Volpini, LPB
   Pierangeli, A
   Romero, B
   Wilkin, T
   Franceschi, S
   Hidalgo-Tenorio, C
   Ramautarsing, RA
   Park, IU
   Tso, FK
   Godbole, S
   D'Hauwers, KWM
   Sehnal, B
   Menezes, LJ
   Heraclio, SA
   Clifford, GM
AF Lin, Chunqing
   Slama, Jiri
   Gonzalez, Paula
   Goodman, Marc T.
   Xia, Ningshao
   Kreimer, Aimee R.
   Wu, Ting
   Hessol, Nancy A.
   Shvetsov, Yurii
   Ortiz, Ana P.
   Grinsztejn, Beatriz
   Moscicki, Anna-Barbara
   Heard, Isabelle
   Losa, Maria del Refugio Gonzalez
   Kojic, Erna M.
   Schim van der Loeff, Maarten F.
   Wei, Feixue
   Longatto-Filho, Adhemar
   Mbulawa, Zizipho A.
   Palefsky, Joel M.
   Sohn, Annette H.
   Hernandez, Brenda Y.
   Robison, Katina
   Simpson, Steve, Jr.
   Conley, Lois J.
   de Pokomandy, Alexandra
   van der Sande, Marianne A. B.
   Dube Mandishora, Racheal S.
   Volpini, Lays P. B.
   Pierangeli, Alessandra
   Romero, Byron
   Wilkin, Timothy
   Franceschi, Silvia
   Hidalgo-Tenorio, Carmen
   Ramautarsing, Reshmie A.
   Park, Ina U.
   Tso, Fernanda K.
   Godbole, Sheela
   D'Hauwers, Kathleen W. M.
   Sehnal, Borek
   Menezes, Lynette J.
   Heraclio, Sandra A.
   Clifford, Gary M.
TI Cervical determinants of anal HPV infection and high-grade anal lesions
   in women: a collaborative pooled analysis
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-PAPILLOMAVIRUS INFECTION; RISK HUMAN-PAPILLOMAVIRUS;
   INTRAEPITHELIAL NEOPLASIA; HIV; PREVALENCE; CANCER; CYTOLOGY; ANUS; SEX;
   MEN
AB Background Cervical cancer screening might contribute to the prevention of anal cancer in women. We aimed to investigate if routine cervical cancer screening results-namely high-risk human papillomavirus (HPV) infection and cytohistopathology-predict anal HPV16 infection, anal high-grade squamous intraepithelial lesions (HSIL) and, hence, anal cancer.
   Methods We did a systematic review of MEDLINE, Embase, and the Cochrane library for studies of cervical determinants of anal HPV and HSIL published up to Aug 31, 2018. We centrally reanalysed individual-level data from 13 427 women with paired cervical and anal samples from 36 studies. We compared anal high-risk HPV prevalence by HIV status, cervical high-risk HPV, cervical cytohistopathology, age, and their combinations, using prevalence ratios (PR) and 95% CIs. Among 3255 women with anal cytohistopathology results, PRs were similarly calculated for all anal HSIL and HPV16-positive anal HSIL.
   Findings Cervical and anal HPV infections were highly correlated. In HIV-negative women, anal HPV16 prevalence was 41% (447/1097) in cervical HPV16-positive versus 2% (214/8663) in cervical HPV16-negative women (PR 16.5, 95% CI 14.2-19.2, p<0.0001); these values were 46% (125/273) versus 11% (272/2588) in HIV-positive women (4.4, 3.7-5.3, p<0.0001). Anal HPV16 was also associated with cervical cytohistopathology, with a prevalence of 44% [101/228] for cervical cancer in HIV-negative women (PR vs normal cytology 14.1, 11.1-17.9, p<0.0001). Anal HSIL was associated with cervical high-risk HPV, both in HIV-negative women (from 2% [11/527] in cervical high-risk HPV-negative women up to 24% [33/138] in cervical HPV16-positive women; PR 12.9, 95% CI 6.7-24.8, p<0.0001) and HIV-positive women (from 8% [84/1094] to 17% [31/186]; 2.3, 1.6-3.4, p<0.0001). Anal HSIL was also associated with cervical cytohistopathology, both in HIV-negative women (from 1% [5/498] in normal cytology up to 22% [59/273] in cervical HSIL; PR 23.1, 9.4-57.0, p<0.0001) and HIV-positive women (from 7% [105/1421] to 25% [25/101]; 3.6, 2.5-5.3, p<0.0001). Prevalence of HPV16-positive anal HSIL was 23-25% in cervical HPV16-positive women older than 45 years (5/20 in HIV-negative women, 12/52 in HIV-positive women).
   Interpretation HPV-based cervical cancer screening programmes might help to stratify anal cancer risk, irrespective of HIV status. For targeted secondary anal cancer prevention in high-risk groups, HIV-negative women with cervical HPV16, especially those older than 45 years, have a similar anal cancer risk profile to that of HIV-positive women. Copyright Copyright (C) 2019 International Agency for Research on Cancer; licensee Elsevier.
C1 [Lin, Chunqing; Clifford, Gary M.] Int Agcy Res Canc, Lyon, France.
   [Lin, Chunqing] Chinese Acad Med Sci, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China.
   [Lin, Chunqing] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China.
   [Lin, Chunqing] Peking Union Med Coll, Beijing, Peoples R China.
   [Slama, Jiri; Sehnal, Borek] Charles Univ Prague, Gen Univ Hosp, Dept Gynecol & Obstet, Prague, Czech Republic.
   [Slama, Jiri; Sehnal, Borek] Charles Univ Prague, Fac Med 1, Prague, Czech Republic.
   [Gonzalez, Paula; Romero, Byron] Fdn INCIENSA, Proyecto Epidemiol Guanacaste, San Jose, Costa Rica.
   [Goodman, Marc T.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.
   [Xia, Ningshao; Wu, Ting; Wei, Feixue] Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Sch Publ Hlth, Xiamen, Fujian, Peoples R China.
   [Kreimer, Aimee R.] NCI, NIH, Bethesda, MD 20892 USA.
   [Hessol, Nancy A.; Palefsky, Joel M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Shvetsov, Yurii; Hernandez, Brenda Y.] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA.
   [Ortiz, Ana P.] Univ Puerto Rico, Dept Biostat & Epidemiol, Grad Sch Publ Hlth, Comprehens Canc Ctr,UPR, San Juan, PR 00936 USA.
   [Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Moscicki, Anna-Barbara] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Heard, Isabelle] Grp Hosp Pitie Salpetriere, AP HP, Dept Endocrinol & Reprod Med, IE3M, Paris, France.
   [Losa, Maria del Refugio Gonzalez] Autonomous Univ Yucatan, Dr Hideyo Noguchy Ctr Reg Invest, Merida, Yucatan, Mexico.
   [Kojic, Erna M.] Mt Sinai West Hosp, New York, NY USA.
   [Kojic, Erna M.] St Lukes Hosp, New York, NY USA.
   [Schim van der Loeff, Maarten F.] GGD Amsterdam, Dept Infect Dis Infect Dis Res & Prevent, Amsterdam, Netherlands.
   [Longatto-Filho, Adhemar] Univ Minho, Sch Med, Res Inst Life & Hlth Sci, Braga, Portugal.
   [Longatto-Filho, Adhemar] Portugal Govt Associate Lab, 3Bs Biomat Biodegradables & Biomimet Res Grp, Braga, Portugal.
   [Longatto-Filho, Adhemar] Univ Sao Paulo, Dept Pathol, Lab Med Invest 14, Fac Med, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Barretos Canc Hosp Pio XII Fdn, Teaching & Res Inst, Mol Oncol Res Ctr, Barretos, Brazil.
   [Mbulawa, Zizipho A.] Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa.
   [Mbulawa, Zizipho A.] Univ Cape Town, Div Med Virol, Dept Pathol, Cape Town, South Africa.
   [Mbulawa, Zizipho A.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr HIV & STIs, Johannesburg, South Africa.
   [Mbulawa, Zizipho A.] Univ Cape Town, South African Med Res Council Gynaecol Canc Res C, Cape Town, South Africa.
   [Sohn, Annette H.] Thai Red Cross AIDS Res Ctr, TREAT Asia AmfAR Fdn AIDS Res, Bangkok, Thailand.
   [Robison, Katina] Brown Univ, Warren Alpert Med Sch, Obstet & Gynecol & Med, Providence, RI 02912 USA.
   [Simpson, Steve, Jr.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.
   [Conley, Lois J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Epidemiol Res Team, Atlanta, GA USA.
   [de Pokomandy, Alexandra] McGill Univ, Ctr Hlth, Chron Viral Illness Serv, Montreal, PQ, Canada.
   [de Pokomandy, Alexandra] McGill Univ, Dept Family Med, Montreal, PQ, Canada.
   [van der Sande, Marianne A. B.] Inst Trop Med, Dept Publ Hlth, Publ Hlth Epidemiol, Antwerp, Belgium.
   [Dube Mandishora, Racheal S.] Univ Zimbabwe, Coll Hlth Sci, Parirenyatwa Hosp Premises, Dept Med Microbiol, Harare, Zimbabwe.
   [Volpini, Lays P. B.] Univ Fed Espirito Santo, Hlth Sci Ctr, Vitoria, Brazil.
   [Pierangeli, Alessandra] Sapienza Univ Rome, Dept Mol Med, Rome, Italy.
   [Wilkin, Timothy] Weill Cornell Med, New York, NY USA.
   [Franceschi, Silvia] Aviano Canc Ctr, Aviano, Italy.
   [Hidalgo-Tenorio, Carmen] Univ Hosp Virgen de las Nieves, Infect Dis Serv, Granada, Spain.
   [Ramautarsing, Reshmie A.] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand.
   [Park, Ina U.] Univ Calif San Francisco, Sch Med, Dept Family & Community Med, San Francisco, CA USA.
   [Tso, Fernanda K.] Univ Fed Sao Paulo, Dept Gynecol, Sao Paulo, Brazil.
   [Godbole, Sheela] Indian Council Med Res, ICMR Natl AIDS Res Inst, Div Epidemiol & Biostat, Pune, Maharashtra, India.
   [D'Hauwers, Kathleen W. M.] Radboud Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands.
   [Menezes, Lynette J.] Univ S Florida, Div Infect Dis, Tampa, FL USA.
   [Heraclio, Sandra A.] Inst Med Integral Prof Fernando Figueira, Womens Healthcare Ctr, Recife, PE, Brazil.
   [Heraclio, Sandra A.] Publ Hlth Lab State Pernambuco, Cytopathol Div, Recife, PE, Brazil.
RP Clifford, GM (corresponding author), Int Agcy Res Canc, Lyon, France.
EM cliffordg@iarc.fr
RI Longatto-Filho, Adhemar/N-3397-2019; d'Hauwers, K W M/L-4353-2015;
   Shvetsov, Yurii/ABA-3196-2020; Tso, Fernanda Kesselring/AAR-1767-2020;
   franceschi, silvia/M-2452-2014
OI Longatto-Filho, Adhemar/0000-0002-5779-9752; Xia,
   Ningshao/0000-0003-0179-5266; franceschi, silvia/0000-0003-4181-8071;
   van der Sande, Marianne AB/0000-0002-4778-6739
FU International Agency for Research on Cancer; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [R01HD073972] Funding Source: NIH RePORTER;
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA071789, P30CA071789, P30CA071789, P30CA071789,
   P30CA071789, P30CA071789, P30CA071789, P30CA071789, P30CA071789,
   P30CA071789, P30CA071789, P30CA071789, P30CA071789, ZIACP010217,
   P30CA071789, P30CA071789, P30CA071789, P30CA071789, P30CA071789,
   P30CA071789, P30CA071789, P30CA071789, P30CA071789, P30CA071789,
   P30CA071789, P30CA071789, ZIACP010217, ZIACP010217, P30CA071789,
   P30CA071789, P30CA071789, P30CA071789, P30CA071789, P30CA071789,
   P30CA071789, P30CA071789, P30CA071789, P30CA071789, P30CA071789,
   P30CA071789, ZIACP010217, P30CA071789] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476]
   Funding Source: NIH RePORTER
FX International Agency for Research on Cancer.
CR Acevedo-Fontanez AI, 2018, J LOW GENIT TRACT DI, V22, P225, DOI 10.1097/LGT.0000000000000395
   Bertisch B, 2013, AM J EPIDEMIOL, V178, P877, DOI 10.1093/aje/kwt153
   Volpini LPB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176422
   Cambou MC, 2015, AIDS PATIENT CARE ST, V29, P4, DOI 10.1089/apc.2014.0166
   Castro FA, 2012, J INFECT DIS, V206, P1103, DOI 10.1093/infdis/jis458
   Chaturvedi AK, 2009, JNCI-J NATL CANCER I, V101, P1120, DOI 10.1093/jnci/djp205
   Clifford GM, 2018, AIDS, V32, P2363, DOI 10.1097/QAD.0000000000001947
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Combes JD, 2018, J INFECT DIS, V217, P1535, DOI 10.1093/infdis/jiy059
   Cranston RD, 2018, SEX TRANSM DIS, V45, P266, DOI 10.1097/OLQ.0000000000000745
   D'Hauwers KWM, 2012, EUR J OBSTET GYN R B, V164, P69, DOI 10.1016/j.ejogrb.2012.05.014
   Daling JR, 2004, CANCER-AM CANCER SOC, V101, P270, DOI 10.1002/cncr.20365
   Darragh TM, 2013, INT J GYNECOL PATHOL, V32, P76, DOI 10.1097/PGP.0b013e31826916c7
   de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
   de Pokomandy A, 2017, J INFECT DIS, V216, P447, DOI 10.1093/infdis/jix273
   de Pokomandy A, 2011, CLIN INFECT DIS, V52, P1174, DOI 10.1093/cid/cir064
   Gonzalez-Losa MD, 2018, ENFERM INFEC MICR CL, V36, P209, DOI 10.1016/j.eimc.2016.11.010
   Ebisch RMF, 2017, J CLIN ONCOL, V35, P2542, DOI 10.1200/JCO.2016.71.4543
   Edgren G, 2007, LANCET ONCOL, V8, P311, DOI 10.1016/S1470-2045(07)70043-8
   European AIDS Clinical Society, 2018, EACS GUID VERS 9 1
   Godbole SV, 2014, JAIDS-J ACQ IMM DEF, V67, pE111, DOI 10.1097/QAI.0000000000000328
   Goeieman BJ, 2017, JAIDS-J ACQ IMM DEF, V75, pE59, DOI 10.1097/QAI.0000000000001300
   Goncalves Maria Alice G, 2008, Infect Agent Cancer, V3, P5, DOI 10.1186/1750-9378-3-5
   Goodman MT, 2010, J INFECT DIS, V201, P1331, DOI 10.1086/651620
   Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485
   Heard I, 2016, J INFECT DIS, V213, P1455, DOI 10.1093/infdis/jiv751
   Hemminki K, 2000, EPIDEMIOLOGY, V11, P457, DOI 10.1097/00001648-200007000-00016
   Heraclio SD, 2011, ACTA CYTOL, V55, P218, DOI 10.1159/000320922
   Hernandez BY, 2013, ASIA-PAC J PUBLIC HE, V25, P19, DOI 10.1177/1010539511410867
   Hernandez BY, 2005, CANCER EPIDEM BIOMAR, V14, P2550, DOI 10.1158/1055-9965.EPI-05-0460
   Hessol NA, 2013, AIDS, V27, P1743, DOI 10.1097/QAD.0b013e3283601b09
   Hidalgo-Tenorio C, 2018, ENFERM INFEC MICR CL, V36, P555, DOI 10.1016/j.eimc.2017.10.014
   IARC, BIOL AGENTS B, V100
   Islami F, 2017, INT J EPIDEMIOL, V46, P924, DOI 10.1093/ije/dyw276
   Kojic EM, 2014, CLIN INFECT DIS, V59, P127, DOI 10.1093/cid/ciu238
   Kojic EM, 2011, SEX TRANSM DIS, V38, P253, DOI 10.1097/OLQ.0b013e3181f70253
   Lin CQ, 2018, LANCET INFECT DIS, V18, P198, DOI [10.1016/S1473-3099(17)30653-9, 10.1016/s1473-3099(17)30653-9]
   Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3
   Mandishora RSD, 2017, J MED VIROL, V89, P1671, DOI 10.1002/jmv.24825
   Marra E, 2018, J INFECTION, V76, P393, DOI 10.1016/j.jinf.2017.12.011
   Marra E, 2019, J INFECT DIS, V219, P590, DOI 10.1093/infdis/jiy556
   Menezes LJ, 2016, INT J STD AIDS, V27, P543, DOI 10.1177/0956462415587226
   Morlat P., 2017, PRISE CHARGE MED PER
   Moscicki AB, 2003, AIDS, V17, P311, DOI 10.1097/00002030-200302140-00004
   Ortiz AP, 2016, PAPILLOMAVIRUS RES, V2, P89, DOI 10.1016/j.pvr.2016.04.002
   Ortiz AP, 2013, J LOW GENIT TRACT DI, V17, P210, DOI 10.1097/LGT.0b013e318260e312
   Palefsky JM, 2001, J INFECT DIS, V183, P383, DOI 10.1086/318071
   Park IU, 2009, GYNECOL ONCOL, V114, P399, DOI 10.1016/j.ygyno.2009.05.008
   Pierangeli A, 2012, J INFECTION, V65, P255, DOI 10.1016/j.jinf.2012.05.004
   Ramautarsing RA, 2015, J VIRUS ERAD, V1, P96
   Robison K, 2015, OBSTET GYNECOL, V126, P1294, DOI 10.1097/AOG.0000000000001135
   Shiels MS, 2012, JNCI-J NATL CANCER I, V104, P1591, DOI 10.1093/jnci/djs371
   Silverberg MJ, 2012, CLIN INFECT DIS, V54, P1026, DOI 10.1093/cid/cir1012
   Simpson S, 2016, CANCER EPIDEMIOL, V42, P124, DOI 10.1016/j.canep.2016.04.001
   Slama J, 2015, NEOPLASMA, V62, P308, DOI 10.4149/neo_2015_037
   Sohn AH, 2018, CLIN INFECT DIS, V67, P606, DOI 10.1093/cid/ciy144
   Stewart DB, 2018, DIS COLON RECTUM
   Teng CJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001803
   Tomassi MJ, 2019, INT J COLORECTAL DIS, V34, P47, DOI 10.1007/s00384-018-3167-7
   Tso FK, 2015, GENET MOL RES, V14, P17630, DOI 10.4238/2015.December.21.36
   Veo CAR, 2015, TUMOR BIOL, V36, P5399, DOI 10.1007/s13277-015-3205-9
   Vriend HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060696
   Wei FX, 2018, INT J CANCER, V142, P1244, DOI 10.1002/ijc.31128
NR 63
TC 12
Z9 12
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD AUG
PY 2019
VL 19
IS 8
BP 880
EP 891
DI 10.1016/S1473-3099(19)30164-1
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA IK8SC
UT WOS:000476864600048
PM 31204304
OA Green Published, Green Accepted, Bronze
DA 2020-11-24
ER

PT J
AU De Boni, RB
   Veloso, VG
   Fernandes, NM
   Lessa, F
   Correa, RG
   Lima, RD
   Cruz, M
   Oliveira, J
   Nogueira, SM
   de Jesus, B
   Reis, T
   Lentini, N
   Miranda, RL
   Bingham, T
   Johnson, CC
   Barbosa, AB
   Grinsztejn, B
AF De Boni, Raquel Brandini
   Veloso, Valdilea Goncalves
   Fernandes, Nilo Martinez
   Lessa, Flavia
   Correa, Renato Girade
   Lima, Renato De Souza
   Cruz, Marly
   Oliveira, Julian
   Nogueira, Simone Muniz
   de Jesus, Beto
   Reis, Toni
   Lentini, Nena
   Miranda, Raquel Lima
   Bingham, Trista
   Johnson, Cheryl C.
   Barbosa Junior, Aristides
   Grinsztejn, Beatriz
TI An Internet-Based HIV Self-Testing Program to Increase HIV Testing
   Uptake Among Men Who Have Sex With Men in Brazil: Descriptive
   Cross-Sectional Analysis
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE HIV/AIDS; HIV self-testing; key populations; mobile health; men
ID TRANSGENDER WOMEN; PREEXPOSURE PROPHYLAXIS; ACCEPTABILITY; BEHAVIORS;
   INFECTION; EPIDEMIOLOGY; FEASIBILITY; SEEKING; PREP; MSM
AB Background: Approximately 30% of people living with HIV worldwide are estimated to be unaware of their infection. HIV self-testing (HIVST) is a strategy recommended by the World Health Organization to increase access to and uptake of testing among key populations who are at high risk for HIV infection.
   Objective: This study aimed to describe the development and feasibility of a free, anonymous, internet-based HIVST strategy designed for men who have sex with men in Curitiba, Brazil (electronic testing [e-testing]).
   Methods: The project was developed under the scope of the "A Hora e Agora" (The Time is Now) program. Individuals aiming to request an HIVST package (two tests each) answered an anonymous 5-minute questionnaire regarding inclusion criteria and sexual risk behavior. Eligible individuals could receive one package every 6 months for free. Website analytics, response to online questionnaires, package distribution, and return of test results were monitored via a platform-integrated system.
   Results: Between February 2015 and January 2016, the website documented 17,786 unique visitors and 3218 completed online questionnaires Most individuals self-reported being white (77.0%), young (median age: 25 years, interquartile range: 22-31 years), educated (87.3% completed secondary education or more), and previously tested for HIV (62.5%). Overall, 2526 HIVST packages were delivered; of those, 542 (21.4%) reported a result online or by mail (23 reactive and 11 invalid). During the study period, 37 individuals who reported using e-testing visited the prespecified health facility for confirmatory testing (30 positive, 7 negative).
   Conclusions: E-testing proved highly feasible and acceptable in this study, thus supporting scale-up to additional centers for men who have sex with men in Brazil.
C1 [De Boni, Raquel Brandini; Veloso, Valdilea Goncalves; Fernandes, Nilo Martinez; Lessa, Flavia] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365, BR-20530360 Rio De Janeiro, Brazil.
   [Correa, Renato Girade; Lima, Renato De Souza] Minist Hlth, Natl Dept STI Aids & Viral Hepatitis, Brailia, Brazil.
   [Cruz, Marly; de Jesus, Beto] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil.
   [Oliveira, Julian; Nogueira, Simone Muniz] Secretaria Municipal Saude Curitiba, Curitiba, Parana, Brazil.
   [Reis, Toni] Grp Dignidade, Curitiba, Parana, Brazil.
   [Lentini, Nena; Miranda, Raquel Lima; Barbosa Junior, Aristides] Ctr Dis Control & Prevent Brazil, Brasilia, DF, Brazil.
   [Bingham, Trista] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV & TB, Atlanta, GA USA.
   [Johnson, Cheryl C.] WHO, HIV Dept, Geneva, Switzerland.
   [Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
RP De Boni, RB (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365, BR-20530360 Rio De Janeiro, Brazil.
EM raqueldeboni@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; DE SOUZA LIMA,
   RENATO/0000-0003-4540-1054; Cruz, Marly/0000-0002-4061-474X; Goncalves
   Veloso dos Santos, Valdilea/0000-0002-6622-3165; Lessa,
   Flavia/0000-0003-4200-5734
FU President's Emergency Plan for AIDS Relief (PEPFAR) through the CDC
   under the terms of the Key Population Implementation Science (KPIS)
   initiative [NU2GGH01152]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476] Funding Source: NIH RePORTER
FX This project was supported (in part) by the President's Emergency Plan
   for AIDS Relief (PEPFAR) through the CDC under the terms of the Key
   Population Implementation Science (KPIS) initiative (Grant number:
   NU2GGH01152). The findings and conclusions in this report are those of
   the authors and do not necessarily represent the official position of
   the funding agencies.
CR Ackers ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034972
   Anand T, 2015, J VIRUS ERAD, V1, P111
   [Anonymous], 2013, MAT REG RIC, P74
   [Anonymous], 2016, GUID HIV SELF TEST P
   Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6
   Bottorff JL, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5076
   Bull SS, 2001, AM J PUBLIC HEALTH, V91, P988, DOI 10.2105/AJPH.91.6.988
   Carey J., 2017, 9 INT AIDS SOC PAR
   Carpe BC, 2014, REV ESP SALUD PUBLIC, V88, P327, DOI 10.4321/S1135-57272014000300003
   Castro R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157309
   Centers of Disease Control and Prevention, 2014, PREEXP PROPH PREV HI
   Guimaraes MDC, 2018, MEDICINE, V97, pS62, DOI 10.1097/MD.0000000000009079
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   De Boni RB, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25116
   Devi R, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009386.pub2
   Estem KS, 2016, CURR HIV-AIDS REP, V13, P107, DOI 10.1007/s11904-016-0307-y
   Figueroa C, 2015, AIDS BEHAV, V19, P1949, DOI 10.1007/s10461-015-1097-8
   Fisher M, 2010, AIDS, V24, P1739, DOI 10.1097/QAD.0b013e32833ac9e6
   Garofalo R, 2007, AM J PUBLIC HEALTH, V97, P1113, DOI 10.2105/AJPH.2005.075630
   Golub SA, 2013, AIDS PATIENT CARE ST, V27, P621, DOI 10.1089/apc.2013.0245
   Goncalves VF, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00049015
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Hoagland B, 2017, AIDS BEHAV, V21, P1278, DOI 10.1007/s10461-016-1516-5
   James C., 2017, 9 INT AIDS SOC PAR
   Johnson CC, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21594
   Kerr L, 2018, MEDICINE, V97, pS9, DOI [10.1097/MD.0000000000010573, 10.1097/md.0000000000010573]
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Krska J, 2015, J PUBLIC HEALTH-UK, V37, P210, DOI 10.1093/pubmed/fdu054
   LeGrand S, 2017, CURR OPIN HIV AIDS, V12, P425, DOI 10.1097/COH.0000000000000400
   Liau A, 2006, SEX TRANSM DIS, V33, P576, DOI 10.1097/01.olq.0000204710.35332.c5
   Lippman SA, 2018, JAIDS-J ACQ IMM DEF, V77, P279, DOI [10.1097/qai.0000000000001601, 10.1097/QAI.0000000000001601]
   Lippman SA, 2014, CAD SAUDE PUBLICA, V30, P724, DOI 10.1590/0102-311X00008913
   MacGowan R., 2017, IMPACT HIV SELF TEST
   Meyerson B, 2014, AIDS PATIENT CARE ST, V28, P22, DOI 10.1089/apc.2013.0238
   Mocroft A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001510
   Mustanski B, 2011, ARCH SEX BEHAV, V40, P289, DOI 10.1007/s10508-009-9596-1
   Nota Sjoerd P F T, 2014, Hand (N Y), V9, P504, DOI 10.1007/s11552-014-9618-x
   Oldenburg CE, 2017, INT J STD AIDS, V28, P242, DOI 10.1177/0956462416641556
   Rosengren AL, 2016, SEX HEALTH, V13, P389, DOI 10.1071/SH15236
   Rutstein SE, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21579
   Sharma M, 2015, NATURE, V528, pS77, DOI 10.1038/nature16044
   Smith DK, 2012, JAIDS-J ACQ IMM DEF, V60, P421, DOI 10.1097/QAI.0b013e318256b2f6
   Szwarcwald CL, 2018, AIDS CARE, V30, P56, DOI 10.1080/09540121.2017.1363370
   Torres TS, 2018, JMIR PUBLIC HLTH SUR, V4, P147, DOI 10.2196/publichealth.8997
   UNAIDS, 2017, END AIDS PROGR 90 90
   UNAIDS, 2014, 90 90 90 AMB TREATM
   Volk JE, 2016, INT J STD AIDS, V27, P531, DOI 10.1177/0956462415586676
   Yarris LM, 2014, J EMERG MED, V47, P702, DOI 10.1016/j.jemermed.2014.06.057
   Zhong F, 2017, HIV MED, V18, P376, DOI 10.1111/hiv.12437
   Zou HC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051919
NR 50
TC 3
Z9 3
U1 2
U2 2
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD AUG 1
PY 2019
VL 21
IS 8
AR e14145
DI 10.2196/14145
PG 15
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA IN4OQ
UT WOS:000478654900001
PM 31373276
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU Caetano, DG
   Cortes, FH
   Bello, G
   de Azevedo, SSD
   Hoagland, B
   Villela, LM
   Grinsztejn, B
   Veloso, VG
   Guimaraes, ML
   Morgado, MG
AF Caetano, Diogo Gama
   Cortes, Fernanda Heloise
   Bello, Gonzalo
   Dias de Azevedo, Suwellen Sardinha
   Hoagland, Brenda
   Villela, Larissa Melo
   Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
   Guimaraes, Monick Lindenmeyer
   Morgado, Mariza Goncalves
TI A case report of HIV-1 superinfection in an HIV controller leading to
   loss of viremia control: a retrospective of 10 years of follow-up
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; HIV-controllers; LTNP; Superinfection; Dual infection
ID IMMUNODEFICIENCY-VIRUS TYPE-1; LONG-TERM; DUAL INFECTION; DISEASE
   PROGRESSION; MEN; TROPISM; NEF; SEX; PREVALENCE; PREDICTION
AB BackgroundHIV controllers (HICs) are a rare group of HIV-1-infected individuals able to naturally control viral replication. Several studies have identified the occurrence of HIV dual infections in seropositive individuals leading to disease progression. In HICs, however, dual infections with divergent outcomes in pathogenesis have been described.Case presentationHere, we present a case report of a HIC diagnosed in late 1999 who displayed stable CD4(+) T cell levels and low plasmatic viral load across 12years of follow-up. In early 2013, the patient started to present an increase in viral load, reaching a peak of 10,000 copies/ml in early 2014, followed by an oscillation of viremia at moderate levels in the following years. The genetic diversity of env proviral quasispecies from peripheral blood mononuclear cells (PBMCs) was studied by single genome amplification (SGA) at six timepoints across 2009-2017. Phylogenetic analyses of env sequences from 2009 and 2010 samples showed the presence of a single subtype B variant (called B-1). Analyses of sequences from 2011 and after revealed an additional subtype B variant (called B-2) and a subsequent dominance shift in the proviral quasispecies frequencies, with the B-2 variant becoming the most frequent from 2014 onwards. Latent syphilis related to unprotected sexual intercourse was diagnosed a year before the first detection of B-2,B- evidencing risk behavior and supporting the superinfection hypothesis. Immunologic analyses revealed an increase in CD8(+) and CD4(+) T cell immune activation following viremia increase and minor T cell subset alterations during follow-up. HIV-specific T cell responses remained low throughout the follow-up period.ConclusionsAltogether, these results show that loss of viremia control in the HIC was associated with superinfection. These data alert to the negative consequences of reinfection on HIV pathogenesis, even in patients with a long history of viremia control and an absence of disease progression, reinforcing the need for continued use of adequate prevention strategies.
C1 [Caetano, Diogo Gama; Cortes, Fernanda Heloise; Bello, Gonzalo; Dias de Azevedo, Suwellen Sardinha; Guimaraes, Monick Lindenmeyer; Morgado, Mariza Goncalves] Fiocruz MS, IOC, Lab Aids & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Hoagland, Brenda; Villela, Larissa Melo; Grinsztejn, Beatriz; Veloso, Valdilea Goncalves] Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin DST & Aids, Rio De Janeiro, Brazil.
RP Cortes, FH (corresponding author), Fiocruz MS, IOC, Lab Aids & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM fheloise@ioc.fiocruz.br
RI Cortes, Fernanda/AAF-9254-2020; de Azevedo, Suwellen/P-7199-2017
OI de Azevedo, Suwellen/0000-0001-6681-0987; Cortes,
   Fernanda/0000-0003-1416-0657
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPqNational Council for Scientific and Technological
   Development (CNPq); Fundacao Oswaldo Cruz - FIOCRUZ; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH
   RePORTER
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro - FAPERJ; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq; and Fundacao Oswaldo Cruz - FIOCRUZ.
   None of these cited academic research funding institutions had
   participation in the design of the study, collection, analysis, and
   interpretation of data and in writing the manuscript.
CR Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005
   Andreani G, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-392
   Blackard JT, 2004, SEX TRANSM DIS, V31, P201, DOI 10.1097/01.OLQ.0000118082.45312.1F
   Braibant M, 2010, VIROLOGY, V405, P81, DOI 10.1016/j.virol.2010.05.026
   Brener J, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0390-9
   Caetano DG, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0444-z
   Casado C, 2007, J INFECT DIS, V196, P895, DOI 10.1086/520885
   Ceresola ER, 2015, J ANTIMICROB CHEMOTH, V70, P1391, DOI 10.1093/jac/dku573
   Chaillon A, 2013, J VIROL, V87, P12737, DOI 10.1128/JVI.02260-13
   Clerc O, 2010, J CLIN VIROL, V47, P376, DOI 10.1016/j.jcv.2010.01.013
   Cornelissen M, 2012, CLIN INFECT DIS, V54, P539, DOI 10.1093/cid/cir849
   Reis MND, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178578
   de Azevedo SSD, 2019, AIDS, V33, P399, DOI 10.1097/QAD.0000000000002090
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   Estrada-Aguirre JA, 2013, CURR HIV RES, V11, P506, DOI 10.2174/1570162X11666140101120225
   Fang GW, 2004, AIDS, V18, P153, DOI 10.1097/00002030-200401230-00003
   Felsenstein J, 2005, PHYLIP PHYLOGENY INF
   Gottlieb GS, 2004, LANCET, V363, P619, DOI 10.1016/S0140-6736(04)15596-7
   Hendel H, 1999, J IMMUNOL, V162, P6942
   Kagan RM, 2014, AIDS RES HUM RETROV, V30, P151, DOI [10.1089/aid.2013.0123, 10.1089/AID.2013.0123]
   Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405
   Kirchhoff F, 1999, J VIROL, V73, P5497, DOI 10.1128/JVI.73.7.5497-5508.1999
   Koning FA, 2013, AIDS RES HUM RETROV, V29, P963, DOI [10.1089/aid.2013.0009, 10.1089/AID.2013.0009]
   Torres AJL, 2015, BRAZ J INFECT DIS, V19, P163, DOI 10.1016/j.bjid.2014.11.007
   Lengauer T, 2007, NAT BIOTECHNOL, V25, P1407, DOI 10.1038/nbt1371
   Leye N, 2013, INFECT GENET EVOL, V20, P206, DOI 10.1016/j.meegid.2013.09.002
   Luan H, 2017, JAIDS-J ACQ IMM DEF, V75, P480, DOI 10.1097/QAI.0000000000001420
   MICHAEL NL, 1995, J VIROL, V69, P4228, DOI 10.1128/JVI.69.7.4228-4236.1995
   Oh DY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002747
   Okulicz JF, 2012, J AIDS CLIN RES, V3, P139
   Pernas M, 2013, JAIDS-J ACQ IMM DEF, V64, P225, DOI 10.1097/QAI.0b013e31829bdc85
   Pernas M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031928
   Philpott S, 2003, J INFECT DIS, V187, P569, DOI 10.1086/367995
   Rachinger A, 2008, CLIN INFECT DIS, V47, pE86, DOI 10.1086/592978
   Recordon-Pinson P, 2010, ANTIMICROB AGENTS CH, V54, P3335, DOI 10.1128/AAC.00148-10
   Redd AD, 2014, AIDS, V28, P2147, DOI 10.1097/QAD.0000000000000365
   Ritchie AJ, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0069-9
   Rodes B, 2004, AIDS, V18, P1109, DOI [10.1097/01.aids.0000125962.16506.f9, 10.1097/00002030-200405210-00004]
   Rosas-Umbert M, 2019, J VIROL, V93, DOI 10.1128/JVI.01436-18
   Saez-Cirion A, 2013, IMMUNOL REV, V254, P281, DOI 10.1111/imr.12076
   Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Sharkey M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001303
   de Oliveira ACS, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-223
   de Paula HHS, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0458-6
   Trecarichi Enrico M, 2006, AIDS Res Ther, V3, P22, DOI 10.1186/1742-6405-3-22
   van der Kuyl AC, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-67
   Wagner GA, 2014, J INFECT DIS, V209, P1032, DOI 10.1093/infdis/jit633
NR 48
TC 1
Z9 1
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUL 5
PY 2019
VL 19
AR 588
DI 10.1186/s12879-019-4229-3
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA IH5ST
UT WOS:000474554500004
PM 31277590
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Torres, TS
   Konda, KA
   Vega-Ramirez, EH
   Elorreaga, OA
   Diaz-Sosa, D
   Hoagland, B
   Diaz, S
   Pimenta, C
   Benedetti, M
   Lopez-Gatell, H
   Robles-Garcia, R
   Grinsztejn, B
   Caceres, C
   Veloso, VG
AF Torres, Thiago Silva
   Konda, Kelika A.
   Hamid Vega-Ramirez, E.
   Elorreaga, Oliver A.
   Diaz-Sosa, Dulce
   Hoagland, Brenda
   Diaz, Steven
   Pimenta, Cristina
   Benedetti, Marcos
   Lopez-Gatell, Hugo
   Robles-Garcia, Rebeca
   Grinsztejn, Beatriz
   Caceres, Carlos
   Veloso, Valdilea G.
CA ImPrEP Study Grp
TI Factors Associated With Willingness to Use Pre-Exposure Prophylaxis in
   Brazil, Mexico, and Peru: Web-Based Survey Among Men Who Have Sex With
   Men (vol 5, e13771, 2019)
SO JMIR PUBLIC HEALTH AND SURVEILLANCE
LA English
DT Correction
C1 [Torres, Thiago Silva; Hoagland, Brenda; Benedetti, Marcos; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz INI Fiocruz, Inst Nacl Infectol Evandro Chagas, Brasil 4365 Manguinhos, BR-21040900 Rio De Janeiro, Brazil.
   [Konda, Kelika A.; Elorreaga, Oliver A.; Caceres, Carlos] UPCH, Ctr Invest Interdisciplinaria Sexualidad Sida & S, Lima, Peru.
   [Hamid Vega-Ramirez, E.; Diaz-Sosa, Dulce; ImPrEP Study Grp] Condesa & Condesa Iztapalapa Specialized Clin, Mexico City, DF, Mexico.
   [Hamid Vega-Ramirez, E.; Diaz-Sosa, Dulce; Robles-Garcia, Rebeca] Natl Inst Psychiat Ramon Fuente Muniz, Mexico City, DF, Mexico.
   [Diaz, Steven] Ctr Prevent & Comprehens Healthcare HIV AIDS Mexi, Mexico City, DF, Mexico.
   [Pimenta, Cristina] Brazilian Minist Hlth, Brasilia, DF, Brazil.
   [Lopez-Gatell, Hugo] Natl Inst Publ Hlth, Mexico City, DF, Mexico.
RP Torres, TS (corresponding author), Fundacao Oswaldo Cruz INI Fiocruz, Inst Nacl Infectol Evandro Chagas, Brasil 4365 Manguinhos, BR-21040900 Rio De Janeiro, Brazil.
EM thiago.torres@ini.fiocruz.br
RI Elorreaga, Oliver A./AAU-1706-2020
OI Elorreaga, Oliver A./0000-0003-0181-5378; Benedetti, Marcos
   Renato/0000-0001-8283-5025; Vega-Ramirez, E. Hamid/0000-0003-0390-9992;
   Pimenta de Oliveira, Maria Cristina/0000-0002-4205-9786
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1 AI069476] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
CR TORRES TS, 2019, JMIR PUBLIC HLTH SUR, V5
NR 1
TC 1
Z9 1
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2369-2960
J9 JMIR PUBLIC HLTH SUR
JI JMIR Public Health Surveill.
PD JUL-SEP
PY 2019
VL 5
IS 3
BP 68
EP 69
DI 10.2196/15504
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LE6EN
UT WOS:000526816600006
PM 31322130
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU De Castro, N
   Marcy, O
   Chazallon, C
   Messou, E
   Eholie, S
   Bhatt, N
   Khosa, C
   Laureillard, D
   Chau, GD
   Veloso, VG
   Delaugerre, C
   Anglaret, X
   Molina, JM
   Grinsztejn, B
AF De Castro, N.
   Marcy, O.
   Chazallon, C.
   Messou, E.
   Eholie, S.
   Bhatt, N.
   Khosa, C.
   Laureillard, D.
   Chau, G. Do
   Veloso, V. G.
   Delaugerre, C.
   Anglaret, X.
   Molina, J. -M.
   Grinsztejn, B.
CA ANRS 12300 Reflate TB2 Study Grp
TI Virologic efficacy of raltegravir vs. efavirenz-based antiretroviral
   treatment in HIV1-infected adults with tuberculosis: W48 results of the
   ANRS 12300 Reflate TB2 trial
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [De Castro, N.; Delaugerre, C.; Molina, J. -M.] Hop St Louis, AP HP, Paris, France.
   [Marcy, O.; Chazallon, C.; Anglaret, X.; Grinsztejn, B.] Univ Bordeaux, Bordeaux Populat Hlth Ctr, INSERM, U1219, Bordeaux, France.
   [Messou, E.] CEPREF, Abidjan, Cote Ivoire.
   [Eholie, S.] SMIT, Abidjan, Cote Ivoire.
   [Bhatt, N.; Khosa, C.] Inst Nacl Saude, Maracuene, Mozambique.
   [Laureillard, D.] CHU Nimes, Nimes, France.
   [Chau, G. Do] Pham Ngoc Thach Hosp, Ho Chi Minh City, Vietnam.
   [Veloso, V. G.] Oswaldo Cruz Fdn FIOCRUZ, Rio De Janeiro, Brazil.
RI Anglaret, Xavier/T-2757-2019
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2019
VL 22
SU 5
SI SI
MA MOAB0101
BP 1
EP 1
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA IK9BV
UT WOS:000476890500002
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Yanavich, C
   Pacheco, A
   Cardoso, S
   Nunes, E
   Chaves, U
   Santos, R
   Morata, M
   Veloso, VG
   Grinsztejn, B
   Perazzo, H
AF Yanavich, C.
   Pacheco, A.
   Cardoso, S.
   Nunes, E.
   Chaves, U.
   Santos, R.
   Morata, M.
   Veloso, V. G.
   Grinsztejn, B.
   Perazzo, H.
CA GPC-Hepatol
TI Validation of serological biomarkers for detection of non-alcoholic
   fatty liver disease (NAFLD) and/or advanced liver fibrosis in people
   living with HIV
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Yanavich, C.; Cardoso, S.; Nunes, E.; Chaves, U.; Santos, R.; Morata, M.; Veloso, V. G.; Grinsztejn, B.; Perazzo, H.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Yanavich, C.] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Pacheco, A.] Fundacao Oswaldo Cruz, PROCC, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2019
VL 22
SU 5
SI SI
MA MOAB0203
BP 5
EP 6
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA IK9BV
UT WOS:000476890500010
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Ramos, M
   Jalil, E
   Lessa, F
   Castro, C
   Jalil, C
   Carvalheira, E
   Kamel, L
   Moreira, RI
   Pacheco, V
   Veloso, VG
   Grinsztejn, B
   De Boni, RB
AF Ramos, M.
   Jalil, E.
   Lessa, F.
   Castro, C.
   Jalil, C.
   Carvalheira, E.
   Kamel, L.
   Moreira, R. I.
   Pacheco, V.
   Veloso, V. G.
   Grinsztejn, B.
   De Boni, R. B.
TI Evaluation of syndemics in transgender women using pre-exposure
   prophylaxis (PrEP) for HIV prevention: Preliminary findings
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Ramos, M.; Jalil, E.; Lessa, F.; Castro, C.; Jalil, C.; Carvalheira, E.; Kamel, L.; Moreira, R. I.; Pacheco, V.; Veloso, V. G.; Grinsztejn, B.; De Boni, R. B.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, LAPCLIN DST AIDSLAPCLIN DST AIDS, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2019
VL 22
SU 5
SI SI
MA TUAC0103
BP 27
EP 27
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA IK9BV
UT WOS:000476890500054
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Jalil, E
   Torres, T
   Moreira, RI
   Castro, C
   Monteiro, L
   Monteiro, L
   Garcia, AC
   Santos, D
   Leite, I
   Pedrosa, M
   Cattani, V
   Kamel, L
   Jalil, C
   Carvalheira, E
   Luz, PM
   Gomes, M
   Hoagland, B
   Estrela, R
   Anderson, PL
   Liu, AY
   Wagner, S
   Veloso, VG
   Grinsztejn, B
AF Jalil, E.
   Torres, T.
   Moreira, R. I.
   Castro, C.
   Monteiro, L.
   Monteiro, L.
   Garcia, A. C.
   Santos, D.
   Leite, I.
   Pedrosa, M.
   Cattani, V.
   Kamel, L.
   Jalil, C.
   Carvalheira, E.
   Luz, P. M.
   Gomes, M.
   Hoagland, B.
   Estrela, R.
   Anderson, P. L.
   Liu, A. Y.
   Wagner, S.
   Veloso, V. G.
   Grinsztejn, B.
CA PrEParadas Study Team
TI PrEP uptake and early adherence among at HIV risk trans-gender women
   from Rio de Janeiro, Brazil: Results from the PrEParadas dstudy
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Jalil, E.; Torres, T.; Moreira, R. I.; Castro, C.; Monteiro, L.; Monteiro, L.; Garcia, A. C.; Santos, D.; Leite, I.; Pedrosa, M.; Cattani, V.; Kamel, L.; Jalil, C.; Carvalheira, E.; Luz, P. M.; Gomes, M.; Hoagland, B.; Estrela, R.; Wagner, S.; Veloso, V. G.; Grinsztejn, B.] Fiocruz MS, Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Anderson, P. L.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus, Aurora, CO USA.
   [Liu, A. Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2019
VL 22
SU 5
SI SI
MA TUAC0302
BP 31
EP 31
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA IK9BV
UT WOS:000476890500062
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Guanira, JV
   Hoagland, B
   Calvo, GM
   Diaz, S
   Konda, KA
   Grinsztejn, B
   Vega, EH
   Caceres, CF
   Veloso, VG
AF Guanira, J. V.
   Hoagland, B.
   Calvo, G. M.
   Diaz, S.
   Konda, K. A.
   Grinsztejn, B.
   Vega, E. H.
   Caceres, C. F.
   Veloso, V. G.
CA ImPrEP Study Team
TI Acute HIV infection among individuals who start PrEP: The ImPrEP
   experience, a demonstration project in the context of combination
   prevention in Brazil, Mexico and Peru
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Guanira, J. V.] Invest Med Salud, Lima, Peru.
   [Guanira, J. V.; Calvo, G. M.; Konda, K. A.; Caceres, C. F.] Univ Peruana Cayetano Heredia, CIISSS, Lima, Peru.
   [Hoagland, B.; Grinsztejn, B.; Veloso, V. G.] Inst Nacl Infectol Evandro Chagas INI Fiocruz, Rio De Janeiro, Brazil.
   [Diaz, S.] Mexico City HIV Aids Prevent & Comprehens Care Ct, Mexico City, DF, Mexico.
   [Vega, E. H.] Condesa & Condesa Iztapalapa Specialized Clin, Mexico City, DF, Mexico.
   [Vega, E. H.] Natl Inst Psychiat Ramon de la Fuente Muniz, Mexico City, DF, Mexico.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2019
VL 22
SU 5
SI SI
MA WEAC0104
BP 53
EP 53
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA IK9BV
UT WOS:000476890500111
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Pereira, G
   Kim, A
   Jalil, E
   Fonseca, FF
   Shepherd, B
   Veloso, VG
   Rick, FM
   Ribeiro, R
   Beber, A
   Jayathilake, K
   Girade, R
   Lima, R
   Maruri, F
   Caruso, A
   Perini, F
   McGowan, C
   Benzaken, A
   Castilho, J
   Grinsztejn, B
AF Pereira, G.
   Kim, A.
   Jalil, E.
   Fernandes Fonseca, F.
   Shepherd, B.
   Veloso, V. G.
   Rick, F. M.
   Ribeiro, R.
   Beber, A.
   Jayathilake, K.
   Girade, R.
   Lima, R.
   Maruri, F.
   Caruso, A.
   Perini, F.
   McGowan, C.
   Benzaken, A.
   Castilho, J.
   Grinsztejn, B.
CA Natl Cohort Study Dolutegravir
TI No occurrences of neural tube defects among 382 women on dolutegravir at
   pregnancy conception in Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Pereira, G.; Rick, F. M.; Ribeiro, R.; Girade, R.; Lima, R.; Caruso, A.; Perini, F.] Minist Hlth Brazil, Secretariat Hlth Surveillance, Dept STI AIDS Viral Hepatitis, Brasilia, DF, Brazil.
   [Kim, A.; Shepherd, B.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA.
   [Jalil, E.; Veloso, V. G.; Grinsztejn, B.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Fernandes Fonseca, F.; Beber, A.; Benzaken, A.] Minist Hlth Brazil, Dept Surveillance Prevent & Control STIs HIV Aids, Brasilia, DF, Brazil.
   [Jayathilake, K.; Maruri, F.; McGowan, C.; Castilho, J.] Vanderbilt Univ, MOAX0104LB, 221 Kirkland Hall, Nashville, TN 37235 USA.
RI da Cunha, Alessandro Ricardo Caruso/AAG-6448-2019
OI da Cunha, Alessandro Ricardo Caruso/0000-0001-5441-1006
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2019
VL 22
SU 5
SI SI
MA MOAX0104L
BP 93
EP 93
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA IK9BV
UT WOS:000476890500189
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Veloso, VG
   Vega-Ramirez, EH
   Hoagland, B
   Konda, KA
   Bautista-Arredondo, S
   Guanira, JV
   Leyva-Flores, R
   Pimenta, C
   Benedetti, M
   Luz, PM
   Leite, IC
   Moreira, RI
   Grinsztejn, B
   Caceres, CF
AF Veloso, V. G.
   Vega-Ramirez, E. H.
   Hoagland, B.
   Konda, K. A.
   Bautista-Arredondo, S.
   Guanira, J. V.
   Leyva-Flores, R.
   Pimenta, C.
   Benedetti, M.
   Luz, P. M.
   Leite, I. C.
   Moreira, R. I.
   Grinsztejn, B.
   Caceres, C. F.
TI Safety, early continuation and adherence of same day PrEP initiation
   among MSM and TGW in Brazil, Mexico and Peru: the ImPrEP Study
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Veloso, V. G.; Hoagland, B.; Benedetti, M.; Luz, P. M.; Leite, I. C.; Moreira, R. I.; Grinsztejn, B.] Natl Inst Infect Dis Evandro Chagas INI Fiocruz, Rio De Janeiro, Brazil.
   [Vega-Ramirez, E. H.] Natl Inst Psychiat Ramon de la Fuente Muniz, Mexico City, DF, Mexico.
   [Vega-Ramirez, E. H.] Condesa Specialized Clin, Mexico City, DF, Mexico.
   [Konda, K. A.; Caceres, C. F.] Univ Peruana Cayetano Heredia, Ctr Invest Interdisciplinaria Sexualidad Sida & S, Lima, Peru.
   [Bautista-Arredondo, S.; Leyva-Flores, R.] Natl Inst Publ Hlth, Mexico City, DF, Mexico.
   [Guanira, J. V.] Invest Med Salud, Lima, Peru.
   [Pimenta, C.] MoH, Dept Transmissible Dis Chron Condit & Sexually Tr, Brasilia, DF, Brazil.
RI LEYVA, RENE/AAE-9368-2020
OI LEYVA, RENE/0000-0002-5973-4549
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2019
VL 22
SU 5
SI SI
MA TUAC0404LB
BP 99
EP 99
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA IK9BV
UT WOS:000476890500199
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Oliveira, MCP
   Bermudez, XP
   Godoi, AM
   Benedetti, M
   Maksud, I
   Martins, A
   Lopes, B
   Grinsztejn, B
   Veloso, VG
AF Pimenta Oliveira, M. C.
   Bermudez, X. P.
   Godoi, A. M.
   Benedetti, M.
   Maksud, I.
   Martins, A.
   Lopes, B.
   Grinsztejn, B.
   Veloso, V. G.
TI Qualitative evaluation of PrEP implementation in Brazil - ImPREP
   stakeholders study
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Pimenta Oliveira, M. C.] Univ Veiga de Almeida, Sch Nursing, Rio De Janeiro, Brazil.
   [Pimenta Oliveira, M. C.] Minist Hlth Brazil, STI HIV & Viral Hepatitis, Brasilia, DF, Brazil.
   [Bermudez, X. P.; Godoi, A. M.; Martins, A.; Lopes, B.] Univ Brasilia, Lab Antropol Saude LABAS, Brasilia, DF, Brazil.
   [Benedetti, M.; Grinsztejn, B.; Veloso, V. G.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Rio De Janeiro, Brazil.
   [Maksud, I.] Fiocruz MS, IFF, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2019
VL 22
SU 5
SI SI
MA WESY0802LB
BP 104
EP 105
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA IK9BV
UT WOS:000476890500209
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Caniglia, EC
   Robins, JM
   Cain, LE
   Sabin, C
   Logan, R
   Abgrall, S
   Mugavero, MJ
   Hernandez-Diaz, S
   Meyer, L
   Seng, R
   Drozd, DR
   Seage, GR
   Bonnet, F
   Le Marec, F
   Moore, RD
   Reiss, P
   van Sighem, A
   Mathews, WC
   Jarrin, I
   Alejos, B
   Deeks, SG
   Muga, R
   Boswell, SL
   Ferrer, E
   Eron, JJ
   Gill, J
   Pacheco, A
   Grinsztejn, B
   Napravnik, S
   Jose, S
   Phillips, A
   Justice, A
   Tate, J
   Bucher, HC
   Egger, M
   Furrer, H
   Miro, JM
   Casabona, J
   Porter, K
   Touloumi, G
   Crane, H
   Costagliola, D
   Saag, M
   Hernan, MA
AF Caniglia, Ellen C.
   Robins, James M.
   Cain, Lauren E.
   Sabin, Caroline
   Logan, Roger
   Abgrall, Sophie
   Mugavero, Michael J.
   Hernandez-Diaz, Sonia
   Meyer, Laurence
   Seng, Remonie
   Drozd, Daniel R.
   Seage, George R., III
   Bonnet, Fabrice
   Le Marec, Fabien
   Moore, Richard D.
   Reiss, Peter
   van Sighem, Ard
   Mathews, William C.
   Jarrin, Inma
   Alejos, Belen
   Deeks, Steven G.
   Muga, Roberto
   Boswell, Stephen L.
   Ferrer, Elena
   Eron, Joseph J.
   Gill, John
   Pacheco, Antonio
   Grinsztejn, Beatriz
   Napravnik, Sonia
   Jose, Sophie
   Phillips, Andrew
   Justice, Amy
   Tate, Janet
   Bucher, Heiner C.
   Egger, Matthias
   Furrer, Hansjakob
   Miro, Jose M.
   Casabona, Jordi
   Porter, Kholoud
   Touloumi, Giota
   Crane, Heidi
   Costagliola, Dominique
   Saag, Michael
   Hernan, Miguel A.
TI Emulating a trial of joint dynamic strategies: An application to
   monitoring and treatment of HIV-positive individuals
SO STATISTICS IN MEDICINE
LA English
DT Article
DE causal inference; dynamic regime; joint treatment strategies; marginal
   structural model; no direct effect
ID COMBINED ANTIRETROVIRAL THERAPY; AIDS-DEFINING ILLNESS; IMMEDIATE
   INITIATION; TREATMENT REGIMES; REDUCE MORTALITY; COUNTRIES
AB Decisions about when to start or switch a therapy often depend on the frequency with which individuals are monitored or tested. For example, the optimal time to switch antiretroviral therapy depends on the frequency with which HIV-positive individuals have HIV RNA measured. This paper describes an approach to use observational data for the comparison of joint monitoring and treatment strategies and applies the method to a clinically relevant question in HIV research: when can monitoring frequency be decreased and when should individuals switch from a first-line treatment regimen to a new regimen? We outline the target trial that would compare the dynamic strategies of interest and then describe how to emulate it using data from HIV-positive individuals included in the HIV-CAUSAL Collaboration and the Centers for AIDS Research Network of Integrated Clinical Systems. When, as in our example, few individuals follow the dynamic strategies of interest over long periods of follow-up, we describe how to leverage an additional assumption: no direct effect of monitoring on the outcome of interest. We compare our results with and without the "no direct effect" assumption. We found little differences on survival and AIDS-free survival between strategies where monitoring frequency was decreased at a CD4 threshold of 350 cells/mu l compared with 500 cells/mu l and where treatment was switched at an HIV-RNA threshold of 1000 copies/ml compared with 200 copies/ml. The "no direct effect" assumption resulted in efficiency improvements for the risk difference estimates ranging from an 7- to 53-fold increase in the effective sample size.
C1 [Caniglia, Ellen C.; Robins, James M.; Cain, Lauren E.; Logan, Roger; Hernandez-Diaz, Sonia; Seage, George R., III; Hernan, Miguel A.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Caniglia, Ellen C.] NYU, Dept Populat Hlth, Sch Med, 227 East 30th St, New York, NY 10016 USA.
   [Robins, James M.; Hernan, Miguel A.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Sabin, Caroline; Jose, Sophie; Phillips, Andrew; Porter, Kholoud] UCL, London, England.
   [Abgrall, Sophie] Hop Avicenne, AP HP, Bobigny, France.
   [Mugavero, Michael J.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
   [Meyer, Laurence; Seng, Remonie] Univ Paris Sud, Inserm, Orsay, France.
   [Drozd, Daniel R.; Crane, Heidi] Univ Washington, Seattle, WA 98195 USA.
   [Bonnet, Fabrice; Le Marec, Fabien] Ctr Hosp Univ Bordeaux, Bordeaux, France.
   [Moore, Richard D.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Reiss, Peter; van Sighem, Ard] Acad Med Ctr Geneeskunde, Amsterdam, Netherlands.
   [Mathews, William C.] Univ Calif San Diego Hlth, Dept Med, San Diego, CA USA.
   [Jarrin, Inma; Alejos, Belen] Inst Salud Carlos III, Natl Ctr Epidemiol, Madrid, Spain.
   [Deeks, Steven G.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
   [Muga, Roberto] Germans Trias Hosp, Barcelona, Spain.
   [Boswell, Stephen L.] Fenway Hlth, Boston, MA USA.
   [Ferrer, Elena] Hosp Univ Bellvitge, Barcelona, Spain.
   [Eron, Joseph J.; Napravnik, Sonia] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA.
   [Gill, John] Southern Alberta HIV Program, Calgary, AB, Canada.
   [Pacheco, Antonio; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Justice, Amy; Tate, Janet] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
   [Bucher, Heiner C.] Univ Spital Basel, Basel, Switzerland.
   [Egger, Matthias] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.
   [Furrer, Hansjakob] Univ Bern, Div Infect Dis, Bern Univ Hosp, Bern, Switzerland.
   [Miro, Jose M.] Univ Barcelona, Barcelona, Spain.
   [Casabona, Jordi] Inst Catala Oncol, Barcelona, Spain.
   [Touloumi, Giota] Univ Athens, Dept Hyg Epidemiol & Med Stat, Med Sch, Athens, Greece.
   [Costagliola, Dominique] Univ Paris 06, Paris, France.
   [Saag, Michael] Univ Alabama Birmingham, Birmingham, AL USA.
   [Hernan, Miguel A.] Harvard MIT Div Hlth Sci & Technol, Boston, MA USA.
RP Caniglia, EC (corresponding author), NYU, Dept Populat Hlth, Sch Med, 227 East 30th St, New York, NY 10016 USA.
EM caniglia@nyumc.org
RI Costagliola, Dominique/H-5849-2011; Furrer, Hansjakob/G-6768-2013;
   Phillips, Andrew N/B-4427-2008; Pacheco, Antonio Guilherme/E-6378-2013
OI Costagliola, Dominique/0000-0003-0765-0869; Furrer,
   Hansjakob/0000-0002-1375-3146; Phillips, Andrew N/0000-0003-2384-4807;
   Pacheco, Antonio Guilherme/0000-0003-3095-1774; Hernan,
   Miguel/0000-0003-1619-8456; Deeks, Steven/0000-0001-6371-747X
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R37 AI102634];
   National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [T32 AI007433]; Center for AIDS Research Network of
   Integrated Clinical Systems [R24 AI067039]; National Heart, Lung and
   Blood InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI); Institut d'Investigacions Biomediques August
   Pi i Sunyer (IDIBAPS); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR001863, UL1TR001863, UL1TR001863,
   UL1TR001863, UL1TR001863, UL1TR001863, UL1TR001863, UL1TR001863,
   UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P30AI050410, T32AI007433,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, R24AI067039, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, T32AI007433, T32AI007433,
   P30AI050410, T32AI007433, R24AI067039, R01AI127271, R01AI127271,
   R37AI102634, P30AI050410, T32AI007433, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, R24AI067039,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   R01AI127271, R24AI067039, R01AI127271, P30AI050410, P30AI050410,
   T32AI007433, P30AI050410, R24AI067039, P30AI050410, R37AI102634,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410] Funding
   Source: NIH RePORTER
FX National Institutes of Health (NIH), Grant/Award Number: R37 AI102634;
   National Institute of Allergy and Infectious Diseases (NIAID),
   Grant/Award Number: T32 AI007433; Center for AIDS Research Network of
   Integrated Clinical Systems, Grant/Award Number: R24 AI067039; National
   Heart, Lung and Blood Institute; Institut d'Investigacions Biomediques
   August Pi i Sunyer (IDIBAPS), Grant/Award Number: personal 80:20
   research grant
CR [Anonymous], 1992, MMWR Recomm Rep, V41, P1
   Asboe D, 2012, HIV MED, V13, P1, DOI 10.1111/j.1468-1293.2011.00971.x
   Cain LE, 2016, INT J EPIDEMIOL, V45, P2038, DOI 10.1093/ije/dyv295
   Cain LE, 2011, ANN INTERN MED, V154, P509, DOI 10.7326/0003-4819-154-8-201104190-00001
   Cain LE, 2010, INT J BIOSTAT, V6, DOI 10.2202/1557-4679.1212
   Caniglia EC, 2016, JAIDS-J ACQ IMM DEF, V72, P214, DOI 10.1097/QAI.0000000000000956
   European AIDS Clinical Society, 2015, EACS GUID VERS 8 0
   Hernan MA, 2006, BASIC CLIN PHARMACOL, V98, P237, DOI 10.1111/j.1742-7843.2006.pto_329.x
   Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43
   Hernan MA, 2002, STAT MED, V21, P1689, DOI 10.1002/sim.1144
   Hernan MA, 2019, CAUSAL INFERENCE, P73
   Hernan MA, 2017, NEW ENGL J MED, V377, P1391, DOI 10.1056/NEJMsm1605385
   Hernan MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254
   Hernan MA, 2010, EPIDEMIOLOGY, V21, P13, DOI 10.1097/EDE.0b013e3181c1ea43
   Kitahata MM, 2008, INT J EPIDEMIOL, V37, P948, DOI 10.1093/ije/dym231
   Lodi S, 2018, AIDS, V32, P327, DOI 10.1097/QAD.0000000000001692
   Lodi S, 2017, JAIDS-J ACQ IMM DEF, V76, P311, DOI 10.1097/QAI.0000000000001498
   Ray M, 2010, AIDS, V24, P123, DOI 10.1097/QAD.0b013e3283324283
   ROBINS J, 1986, MATH MODELLING, V7, P1393, DOI 10.1016/0270-0255(86)90088-6
   Robins J, 2008, STAT MED, V27, P4678, DOI 10.1002/sim.3301
   Robins JM, 1999, COMPUTATION, CAUSATION, AND DISCOVERY, P349
   Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a
   U. S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, 2016, GUIDELINES USE ANTIR
   WHO, 2016, CONS GUID US ANT DRU
   Young JG, 2011, STAT BIOSCI, V3, P119, DOI 10.1007/s12561-011-9040-7
NR 25
TC 1
Z9 1
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
EI 1097-0258
J9 STAT MED
JI Stat. Med.
PD JUN 15
PY 2019
VL 38
IS 13
BP 2428
EP 2446
DI 10.1002/sim.8120
PG 19
WC Mathematical & Computational Biology; Public, Environmental &
   Occupational Health; Medical Informatics; Medicine, Research &
   Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
   Occupational Health; Medical Informatics; Research & Experimental
   Medicine; Mathematics
GA HW3GQ
UT WOS:000466578800009
PM 30883859
OA Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU Zachek, CM
   Coelho, LE
   Domingues, RMSM
   Clark, JL
   De Boni, RB
   Luz, PM
   Friedman, RK
   de Andrade, ACV
   Veloso, VG
   Lake, JE
   Grinsztejn, B
AF Zachek, Christine M.
   Coelho, Lara E.
   Domingues, Rosa M. S. M.
   Clark, Jesse L.
   De Boni, Raquel B.
   Luz, Paula M.
   Friedman, Ruth K.
   de Andrade, Angela C. Vasconcelos
   Veloso, Valdilea G.
   Lake, Jordan E.
   Grinsztejn, Beatriz
TI The Intersection of HIV, Social Vulnerability, and Reproductive Health:
   Analysis of Women Living with HIV in Rio de Janeiro, Brazil from 1996 to
   2016
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV; Sexual and reproductive health; Women; Disparities; Brazil; VIH;
   Salud sexual y reproductiva; Mujeres; Disparidades; Brasil
ID HPV INFECTION; PREGNANCY; PREVALENCE; ABORTION; TRENDS; RISK;
   POPULATION; SYPHILIS; VIOLENCE; CARE
AB Comprehensive care for sexual and reproductive health (SRH) and social needs for women living with HIV remains limited globally. We aimed to assess trends in baseline sociodemographic, clinical, sexual, and reproductive characteristics among a cohort of HIV-infected women in Rio de Janeiro from 1996 to 2016. Participants were stratified into four time periods based on year of enrollment; we compared cross-sectional data from each period. Of 1361 participants (median age 36), most were black or mixed race (60.1%), unemployed (52.1%), and without secondary education (54%). Adolescent pregnancy was common (51.5%), and 18.3% reported sexual debut at<15years old. Nearly half (45.2%) had<5 lifetime sexual partners, yet prior syphilis and oncogenic human papillomavirus prevalence were 10.9% and 43.1%, respectively. Lifetime prevalence of induced abortion was 30.3%, and 16% used no contraceptive method. Future research should explore interactions between social vulnerability, HIV, and poor SRH outcomes and healthcare models to alleviate these disparities.
C1 [Zachek, Christine M.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.
   [Zachek, Christine M.; Clark, Jesse L.; Lake, Jordan E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, South Amer Program HIV Prevent Res SAPHIR, Los Angeles, CA 90095 USA.
   [Coelho, Lara E.; Domingues, Rosa M. S. M.; De Boni, Raquel B.; Luz, Paula M.; Friedman, Ruth K.; de Andrade, Angela C. Vasconcelos; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Lake, Jordan E.] Univ Texas Hlth Sci Ctr Houston UTHlth, Dept Med, Houston, TX USA.
RP Zachek, CM (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.; Zachek, CM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, South Amer Program HIV Prevent Res SAPHIR, Los Angeles, CA 90095 USA.
EM christine.zachek@ucsf.edu
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Domingues, Rosa/AAS-3606-2020
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Domingues,
   Rosa/0000-0001-5722-8127; Luz, Paula/0000-0001-9746-719X; Zachek,
   Christine/0000-0002-1826-101X
FU Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF);
   US National Institute of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [NIH R25
   MH087222, K23 AI110532]; Research Funding Agency of the State of Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ) [E-26/203.154/2017]; National
   Council of Technological and Scientific Development (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [310541/2017-4]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069476, K23AI110532, K23AI110532,
   UM1AI069476, UM1AI069476, UM1AI069476, K23AI110532, K23AI110532] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, R25MH087222, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107] Funding Source: NIH
   RePORTER
FX This work was supported in part by the Doris Duke Charitable Foundation
   through a grant supporting the Doris Duke International Clinical
   Research Fellows Program at the University of California San Francisco.
   CMZ is a Doris Duke International Clinical Research Fellow. This work
   was also supported by the US National Institute of Health Grants NIH R25
   MH087222 to JLC and K23 AI110532 to JEL. RBDB acknowledges funding from
   the Research Funding Agency of the State of Rio de Janeiro (FAPERJ)
   E-26/203.154/2017 and from the National Council of Technological and
   Scientific Development (CNPq) 310541/2017-4.
CR Adolf R, 2012, AIDS CARE, V24, P252, DOI 10.1080/09540121.2011.597706
   Ally EZ, 2016, REV BRAS PSIQUIATR, V38, P98, DOI 10.1590/1516-4446-2015-1798
   [Anonymous], 2006, 2 LEV DOM US DROG PS
   [Anonymous], 2016, PESQ CONH AT PRAT PO, p166p
   [Anonymous], 2013, B EP DST AIDS
   Barbosa RM, 2009, CIENC SAUDE COLETIVA, V14, P1085, DOI 10.1590/S1413-81232009000400015
   Bekker LG, 2018, LANCET, V392, P312, DOI [10.1016/s0140-6736(18)31070-5, 10.1016/S0140-6736(18)31070-5]
   Bonolo PD, 2013, CLINICS, V68, P612, DOI 10.6061/clinics/2013(05)06
   Cianelli Rosina, 2016, Hisp Health Care Int, V14, P4, DOI 10.1177/1540415316629672
   Cohen CR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172992
   Coser J, 2013, GENET MOL RES, V12, P4276, DOI 10.4238/2013.February.19.3
   Dehlendorf C, 2010, AM J OBSTET GYNECOL, V202, P214, DOI 10.1016/j.ajog.2009.08.022
   Diniz D, 2017, CIENC SAUDE COLETIVA, V22, P653, DOI 10.1590/1413-81232017222.23812016
   Diniz SG, 2015, GLOB PUBLIC HEALTH, V10, P183, DOI 10.1080/17441692.2014.986167
   Fiore S, 2008, HUM REPROD, V23, P2140, DOI 10.1093/humrep/den232
   Fonseca MGP, 2007, CAD SAUDE PUBLICA, V23, pS333, DOI 10.1590/S0102-311X2007001500002
   Fusco CLB, 2012, CAD SAUDE PUBLICA, V28, P709, DOI 10.1590/S0102-311X2012000400010
   Haddad LB, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2016.09.079
   Haley DF, 2017, SEX TRANSM INFECT, V93, P583, DOI 10.1136/sextrans-2016-052889
   Heard I, 2013, BJOG-INT J OBSTET GY, V120, P41, DOI 10.1111/1471-0528.12015
   Heffron R, 2018, AIDS BEHAV, V22, P1758, DOI 10.1007/s10461-017-1902-7
   Hipolito Rodrigo Leite, 2017, Rev. Latino-Am. Enfermagem, V25, pe2874, DOI 10.1590/1518-8345.1258.2874
   Howe CJ, 2017, AIDS BEHAV, V21, P3353, DOI 10.1007/s10461-017-1771-0
   Iyun V, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019979
   Johnson M, 2015, AIDS CARE, V27, P1220, DOI 10.1080/09540121.2015.1046416
   Kapetanovic S, 2014, AIDS BEHAV, V18, P1152, DOI 10.1007/s10461-014-0728-9
   Lippman SA, 2010, INT J STD AIDS, V21, P105, DOI 10.1258/ijsa.2009.008436
   Liu G, 2018, AIDS, V32, P795, DOI [10.1097/QAD.0000000000001765, 10.1097/qad.0000000000001765]
   Loutfy MR, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18509
   MacCarthy S, 2014, CULT HEALTH SEX, V16, P190, DOI 10.1080/13691058.2013.855820
   Meyer Jaimie P., 2016, Yale Journal of Biology and Medicine, V89, P193
   Meyer JP, 2011, J WOMENS HEALTH, V20, P991, DOI 10.1089/jwh.2010.2328
   Ministerio da Saude, 2009, PESQ NAC DEM SAUD CR
   Ministerio da SaUde, 2016, B EP AIDS DST
   Ministerio da Saude, 2017, VIG BRAS 2016 VIG FA
   Ministerio da Saude (BR), 2017, B EP SIF
   Molinatti F, 2015, REV PANAM SALUD PUBL, V37, P279
   Mujica OJ, 2014, B WORLD HEALTH ORGAN, V92, P405, DOI 10.2471/BLT.13.127977
   Ngou J, 2015, JAIDS-J ACQ IMM DEF, V68, P162, DOI 10.1097/QAI.0000000000000428
   Okie S, 2006, NEW ENGL J MED, V354, P1977, DOI 10.1056/NEJMp068069
   Orza L, 2014, BUILDING SAFE HOUSE
   Tejada CAO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171888
   Pilecco FB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095570
   Pinho AD, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00057916, 10.1590/0102-311x00057916]
   Santos NJS, 2009, CAD SAUDE PUBLICA, V25, pS321, DOI 10.1590/S0102-311X2009001400014
   Domingues RMSM, 2014, REV SAUDE PUBL, V48, P766, DOI 10.1590/S0034-8910.2014048005114
   Stewart DE, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1994-9
   Sun MY, 2012, OBSTET GYNECOL, V120, P783, DOI 10.1097/AOG.0b013e318269c8bb
   Tamegao-Lopes BP, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-25
   Teixeira LB, 2013, CAD SAUDE PUBLICA, V29, P609, DOI 10.1590/S0102-311X2013000300018
   Tsuyuki K, 2016, J FAM PLAN REPROD H, V42, P271, DOI 10.1136/jfprhc-2015-101175
   UNAIDS, 2016, PREV GAP REP
   UNAIDS, 2017, UNAIDS DAT 2017
   Vaz RF, 2016, REV ASSOC MED BRAS, V62, P330, DOI 10.1590/1806-9282.62.04.330
   Wellings K, 2006, LANCET, V368, P1706, DOI 10.1016/S0140-6736(06)69479-8
   World Health Organization, 2004, AD PREGN ISS AD HLTH
   World Health Organization, 2017, CONS GUID SEX REPR H
NR 57
TC 2
Z9 2
U1 1
U2 7
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JUN
PY 2019
VL 23
IS 6
BP 1541
EP 1551
DI 10.1007/s10461-019-02395-x
PG 11
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA HZ9PE
UT WOS:000469188400013
PM 30652206
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Torres, TS
   Luz, PM
   De Boni, RB
   de Vasconcellos, MTL
   Hoagland, B
   Garner, A
   Moreira, RI
   Veloso, VG
   Grinsztejn, B
AF Torres, Thiago S.
   Luz, Paula M.
   De Boni, Raquel B.
   de Vasconcellos, Mauricio T. L.
   Hoagland, Brenda
   Garner, Alex
   Moreira, Ronaldo, I
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI Factors associated with PrEP awareness according to age and willingness
   to use HIV prevention technologies: the 2017 online survey among MSM in
   Brazil*
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE HIV; prevention; MSM; PrEP; Latin America; Young MSM
ID PREEXPOSURE PROPHYLAXIS PREP; SEXUAL HEALTH; TRANSGENDER WOMEN;
   DRUG-USE; MEN; RISK; EPIDEMIOLOGY; PREVALENCE; INFECTION
AB Brazil has the largest population of individuals living with HIV/AIDS in Latin America with a disproportional prevalence of infection among men who have sex with men (MSM). This study evaluated PrEP awareness by age (18-24, 25-35, >= 36 years), its associated factors and the willingness to use HIV prevention technologies among MSM using a GSN app in Brazil. Inclusion criteria were >= 18 years-old, cisgender men and HIV-negative serostatus. Of 7242 individuals, 4136 (57%) completed the questionnaire. PrEP awareness was reported by 51% (though lower among MSM aged 18-24 and >= 36 years) and its associated factors were higher family income, most friends with the same sexual orientation, high number of male sexual partners and marijuana use. HIV testing (never vs. at least once) lead to an almost 3-fold increase in the odds of PrEP awareness. High HIV risk perception led to increased PrEP awareness only among MSM aged 18-24 years. A total of 2335 (56%) was willing to use daily oral PrEP. PrEP awareness remains low in Brazil and mobile tools are key strategies to reach MSM and increase awareness of prevention technologies. Community-based interventions could add to online campaigns to reach the most vulnerable, which include young, non-white and lower-income MSM.
C1 [Torres, Thiago S.; Luz, Paula M.; De Boni, Raquel B.; Hoagland, Brenda; Moreira, Ronaldo, I; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [de Vasconcellos, Mauricio T. L.] Escola Nacl Ciencias Estat, Rio De Janeiro, Brazil.
   [Garner, Alex] Hornet INC, Los Angeles, CA USA.
RP Torres, TS (corresponding author), Av Brasil 4365, BR-21040900 Manguinho, RJ, Brazil.
EM thiago.torres@ini.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; TORRES, THIAGO SILVA/D-6548-2014
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; TORRES, THIAGO
   SILVA/0000-0002-2557-601X; Luz, Paula/0000-0001-9746-719X
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
CR Alisson P. D., 1999, LOGISTIC REGRESSION
   Barbosa A, 2009, CAD SAUDE PUBLICA, V25, P727, DOI 10.1590/S0102-311X2009000400003
   Beymer MR, 2014, SEX TRANSM INFECT, V90, P567, DOI 10.1136/sextrans-2013-051494
   Biello KB, 2014, AIDS BEHAV, V18, P1675, DOI 10.1007/s10461-014-0844-6
   Brasil, 2018, B EPIDEMIOLOGICO HIV
   Brazilian Internet Steering Committee, 2017, ICT HOUS 2017 SURV U
   CDC, 2014, PREP PREV HIV INF US
   Guimaraes MDC, 2018, MEDICINE, V97, pS62, DOI 10.1097/MD.0000000000009079
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   De Boni RB, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25116
   De Boni RB, 2018, DRUG ALCOHOL DEPEN, V185, P168, DOI 10.1016/j.drugalcdep.2017.12.016
   Fonseca AM, 2010, CIENC SAUDE COLETIVA, V15, P663, DOI 10.1590/S1413-81232010000300008
   Greene GJ, 2017, AIDS BEHAV, V21, P1336, DOI 10.1007/s10461-016-1565-9
   Grov C, 2016, AIDS EDUC PREV, V28, P378, DOI 10.1521/aeap.2016.28.5.378
   Hall EW, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5713
   Han J, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25242
   Hoagland B, 2017, AIDS BEHAV, V21, P1278, DOI 10.1007/s10461-016-1516-5
   Kerr L, 2018, MEDICINE, V97, pS9, DOI [10.1097/MD.0000000000010573, 10.1097/md.0000000000010573]
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Liu A, 2014, JAIDS-J ACQ IMM DEF, V67, P528, DOI 10.1097/QAI.0000000000000351
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
   Ludford KT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069966
   Mayer KH, 2012, SEX TRANSM DIS, V39, P1, DOI 10.1097/OLQ.0b013e31823b1922
   Meyers K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114700
   National Institute on Alcohol Abuse and Alcoholism (NIAAA), 2004, NIAAA COUNC APPR DEF
   Patrick R, 2017, JAIDS-J ACQ IMM DEF, V75, pS375, DOI [10.1097/QAI.0000000000001414, 10.1097/qai.0000000000001414]
   Smith DK, 2012, JAIDS-J ACQ IMM DEF, V60, P421, DOI 10.1097/QAI.0b013e318256b2f6
   Spyer Juliano, 2017, SOCIAL MEDIA EMERGEN
   Steward WT, 2009, AIDS BEHAV, V13, P1054, DOI 10.1007/s10461-009-9582-6
   Stueve A, 2002, AIDS EDUC PREV, V14, P482, DOI 10.1521/aeap.14.8.482.24108
   Tomkins A, 2018, INT J STD AIDS, V29, P350, DOI 10.1177/0956462417725638
   Torres T. S., 2018, C RETR OPP INF BOST
   Torres TS, 2018, JMIR PUBLIC HLTH SUR, V4, P147, DOI 10.2196/publichealth.8997
   Wang HD, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6092-3
   WHO, 2014, 90 90 90 AMB TREATM
   Yi S, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21580
   Young I, 2014, AIDS BEHAV, V18, P195, DOI 10.1007/s10461-013-0560-7
   Zou HC, 2017, ARCH SEX BEHAV, V46, P885, DOI 10.1007/s10508-016-0709-3
NR 38
TC 5
Z9 5
U1 1
U2 14
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0954-0121
EI 1360-0451
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PD OCT 3
PY 2019
VL 31
IS 10
BP 1193
EP 1202
DI 10.1080/09540121.2019.1619665
EA MAY 2019
PG 10
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychology, Multidisciplinary; Respiratory System; Social Sciences,
   Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychology; Respiratory System; Biomedical Social Sciences
GA IS6JV
UT WOS:000469663600001
PM 31122033
DA 2020-11-24
ER

PT J
AU Sevelius, J
   Murray, LR
   Fernandes, NM
   Veras, MA
   Grinsztejn, B
   Lippman, SA
AF Sevelius, Jae
   Murray, Laura Rebecca
   Fernandes, Nilo Martinez
   Veras, Maria Amelia
   Grinsztejn, Beatriz
   Lippman, Sheri A.
TI Optimising HIV programming for transgender women in Brazil
SO CULTURE HEALTH & SEXUALITY
LA English
DT Article
DE Transgender women; travesti; Brazil; HIV prevention; HIV treatment;
   programme development
ID SEX WORKERS; RISK; FACILITATORS; ENGAGEMENT; BARRIERS; GENDER;
   TRANSSEXUALS; RETENTION; EPIDEMIC; HEALTH
AB In Brazil, little data is available to inform HIV prevention programming for travestis and transgender ('trans') women, despite the existence of a social movement that has gained strength in recent years. We conducted formative research in Rio de Janeiro to gather trans women's perspectives on combination HIV prevention approaches. Framing the analysis within the model of gender affirmation, we found that several social and contextual factors inhibited participants' access to HIV prevention and treatment. Experienced and anticipated gender-related discrimination and HIV stigma were linked to the avoidance of HIV testing, health services and HIV status disclosure. Participants recommended HIV prevention interventions which combined socio-structural interventions, such as peer-based empowerment and social support, with biomedical interventions such as pre-exposure prophylaxis (PrEP). Participants expressed a preference for programmes and interventions that emphasised a gender-affirmative approach, promoted autonomy and aimed to reduce stigma and discrimination in public health services.
C1 [Sevelius, Jae; Lippman, Sheri A.] Univ Calif San Francisco, Dept Med, Div Prevent Sci, San Francisco, CA 94110 USA.
   [Murray, Laura Rebecca] Univ Estado Rio De Janeiro, Inst Social Med, Dept Hlth Policy Planning & Adm, Rio De Janeiro, Brazil.
   [Fernandes, Nilo Martinez; Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Veras, Maria Amelia] Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil.
RP Sevelius, J (corresponding author), Univ Calif San Francisco, Dept Med, Div Prevent Sci, San Francisco, CA 94110 USA.
EM Jae.Sevelius@ucsf.edu
RI Sevelius, Jae/AAG-2404-2020; Veras, Maria S/F-3171-2012
OI Veras, Maria S/0000-0002-1159-5762; Lippman, Sheri/0000-0003-3152-9372
FU US National Institute of Mental HealthUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH); NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246] Funding
   Source: NIH RePORTER
FX US National Institute of Mental Health.
CR Antunes P. P. S., 2010, TRAVESTIS ENVELECEM
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Bockting WO, 2013, AM J PUBLIC HEALTH, V103, P943, DOI 10.2105/AJPH.2013.301241
   Brennan J, 2012, AM J PUBLIC HEALTH, V102, P1751, DOI 10.2105/AJPH.2011.300433
   Carrara Sérgio, 2006, Physis, V16, P233, DOI 10.1590/S0103-73312006000200006
   Cazarre M., 2015, DIREITOS HUMANOS
   Costa AB, 2015, ARCH SEX BEHAV, V44, P521, DOI 10.1007/s10508-014-0386-z
   da Fonseca EM, 2018, INT J HEALTH PLAN M, V33, pE238, DOI 10.1002/hpm.2452
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Farias MSD, 2011, INT J INFECT DIS, V15, pE635, DOI 10.1016/j.ijid.2011.05.007
   Dourado I, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00180415
   Grangeiro A., 2008, CTR TESTAGEM ACONSEL
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Infante C, 2009, CULT HEALTH SEX, V11, P125, DOI 10.1080/13691050802431314
   Kaplan RL, 2016, GLOB PUBLIC HEALTH, V11, P824, DOI 10.1080/17441692.2015.1136346
   Kulick Don, 1998, TRAVESTI SEX GENDER
   Lippman SA, 2016, AIDS BEHAV, V20, P928, DOI 10.1007/s10461-015-1236-2
   [Los Angeles County Commission on HIV Division of HIV and STD Programs], 2013, LOS ANG COUNT 5 YEAR
   Malta M, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18817
   Meier SLC, 2011, J GAY LESBIAN MENT H, V15, P281, DOI 10.1080/19359705.2011.581195
   Melendez RM, 2007, CULT HEALTH SEX, V9, P233, DOI 10.1080/13691050601065909
   Muhr T, 2004, USERS MANUAL ATLAS T
   Nemoto T, 2011, AM J PUBLIC HEALTH, V101, P1980, DOI 10.2105/AJPH.2010.197285
   Nuttbrock L, 2013, AM J PUBLIC HEALTH, V103, P300, DOI 10.2105/AJPH.2011.300568
   Paiva V., 2012, VULNERBILIDADE DIREI
   Paiva V, 2015, REPROD HEALTH MATTER, V23, P96, DOI 10.1016/j.rhm.2015.11.015
   PELuCIO Larissa, 2009, ABJECAO DESEJO ETNOG
   Peters MM, 2016, CULT HEALTH SEX, V18, P84, DOI 10.1080/13691058.2015.1060359
   Pinto TP, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00113316, 10.1590/0102-311x00113316]
   Poteat T, 2016, GLOB PUBLIC HEALTH, V11, P835, DOI 10.1080/17441692.2015.1134615
   Cortez FCP, 2011, ARCH SEX BEHAV, V40, P1223, DOI 10.1007/s10508-011-9776-7
   Rebchook G, 2017, AM J PUBLIC HEALTH, V107, P224, DOI 10.2105/AJPH.2016.303582
   Remien RH, 2015, JAIDS-J ACQ IMM DEF, V69, pS16, DOI 10.1097/QAI.0000000000000577
   Scheffer M., 2014, FOLHA SAO PAULO
   Seffner F., 2016, MYTH VS REALITY EVAL, P22
   Sevelius J, 2013, 8 INT C HIV TREATM P
   Sevelius JM, 2016, GLOB PUBLIC HEALTH, V11, P1060, DOI 10.1080/17441692.2016.1154085
   Sevelius JM, 2014, ANN BEHAV MED, V47, P5, DOI 10.1007/s12160-013-9565-8
   Sevelius JM, 2013, SEX ROLES, V68, P675, DOI 10.1007/s11199-012-0216-5
   Sevelius JM, 2010, J ASSOC NURSE AIDS C, V21, P256, DOI 10.1016/j.jana.2010.01.005
   Silva-Santisteban A, 2012, AIDS BEHAV, V16, P872, DOI 10.1007/s10461-011-0053-5
   Garcia MRV, 2009, CULT HEALTH SEX, V11, P611, DOI 10.1080/13691050902825282
NR 42
TC 6
Z9 6
U1 1
U2 5
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1369-1058
EI 1464-5351
J9 CULT HEALTH SEX
JI Cult. Health Sex
PD MAY 4
PY 2019
VL 21
IS 5
BP 543
EP 557
DI 10.1080/13691058.2018.1496277
PG 15
WC Family Studies; Social Sciences, Biomedical
SC Family Studies; Biomedical Social Sciences
GA HU9RY
UT WOS:000465632800004
PM 30378463
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Gross, R
   Ritz, J
   Hughes, MD
   Salata, R
   Mugyenyi, P
   Hogg, E
   Wieclaw, L
   Godfrey, C
   Wallis, CL
   Mellors, JW
   Mudhune, VO
   Badal-Faesen, S
   Grinsztejn, B
   Collier, AC
AF Gross, Robert
   Ritz, Justin
   Hughes, Michael D.
   Salata, Robert
   Mugyenyi, Peter
   Hogg, Evelyn
   Wieclaw, Linda
   Godfrey, Catherine
   Wallis, Carole L.
   Mellors, John W.
   Mudhune, Victor O.
   Badal-Faesen, Sharlaa
   Grinsztejn, Beatriz
   Collier, Ann C.
TI Two-way mobile phone intervention compared with standard-of-care
   adherence support after second-line antiretroviral therapy failure: a
   multinational, randomised controlled trial
SO LANCET DIGITAL HEALTH
LA English
DT Article
ID VIROLOGICAL FAILURE; RESISTANCE; IMPACT; HIV-1
AB Background Antiretroviral therapy (ART) non-adherence causes HIV treatment failure. Past behaviour might predict future behaviour; failing second-line ART could indicate ongoing risk for subsequent non-adherence. We aimed to find out whether a two-way mobile phone-based communication intervention would increase HIV treatment success by improving medication adherence.
   Methods We did a multinational, randomised controlled trial of patients at 17 sites in nine lower-income and middle income countries in Africa, Asia, and the Americas. Patients aged 18 years and older, with HIV infection, and on second-line protease-inhibitor-based antiretroviral regimens, were randomly assigned (1:1) to either two-way mobile phone intervention plus standard of care (MPI + SOC) adherence support or standard-of-care alone (SOC). Our study was nested within a strategy study of ART after second-line ART failure (the main study, A5288). The main study had four cohorts, which were assigned regimens according to ART history and real-time genotype. Randomisation was stratified by the main study cohort with dynamic institutional balancing. Only the clinical management committee was masked, not the participants or site personnel. Text messages were sent over 48 weeks starting once a day and tapering down to once per week; participants were to respond once to each message if taking ART without issues. Repeated non-response to three messages over a 2-week period for the first 8 weeks, and then two messages over a 2-week period for the remainder of the study, triggered problem-solving counselling by staff. For this study, the primary endpoint was plasma HIV-1 RNA 200 copies per mL or less at 48 weeks and the secondary endpoint was virological failure (two consecutive HIV-1 RNA >= 1000 copies per mL) at 24 or more weeks. Prespecified intention-totreat analyses were adjusted for cohort. Follow-up continued until the last participant had reached 48 weeks, with a median follow-up time of 72 weeks. The trial is registered with ClinicalTrials.gov, number NCT01641367.
   Findings Enrolment began on Feb 22, 2013, and ended on Dec 21, 2015, with the last participant completing follow-up on Feb 13, 2017. Of 545 participants in the main study, 521 (96%) were enrolled and randomly assigned to MPI + SOC (n=257) or SOC alone (n=264). 52% of patients were men and the median HIV-1 RNA 4.4 log(10) copies per mL (IQR 3.5 to 5.2). At week 48, HIV-1 RNA 200 copies per mL or less was reached in 169 (66%) of 257 patients in the MPI + SOC group and 164 (62%) of 264 patients in the SOC group (estimated difference 3.6% [95% CI 4.6% to 11.9%]; p=0.39). The adjusted odds ratio comparing MPI + SOC and SOC was 1.23 (0.82 to 1.84; p=0.32). Virological failure occurred in 66 (26%) patients in the MPI + SOC group and 89 (34%) patients in the SOC group during the median 72 weeks follow-up (adjusted p=0.027). Observed difference in virological failure favoured MPI + SOC in all cohorts. 23 (4%) participants died, 11 (4%) in the MPI + SOC group and 12 (5%) in the SOC group (p=0.89), with none of the deaths ascribed to ART, the MPI, or study procedures.
   Interpretation Two-way MPI did not significantly improve week 48 suppression, but it did modestly affect virological failure. People failing second-line ART might not achieve benefits from phone-based triggers or enhanced adherence support (or both). More effective strategies are needed. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Gross, Robert] Univ Penn, Dept Med Infect Dis, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Gross, Robert] Univ Penn, Dept Epidemiol Biostat & Informat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Ritz, Justin; Hughes, Michael D.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
   [Salata, Robert] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Mugyenyi, Peter] Joint Clin Res Ctr, Kampala, Uganda.
   [Hogg, Evelyn] Social & Sci Syst, Silver Spring, MD USA.
   [Wieclaw, Linda] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA.
   [Godfrey, Catherine] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Wallis, Carole L.] Lancet Labs, Johannesburg, South Africa.
   [Wallis, Carole L.] Bio Analyt Res Corp South Africa, Johannesburg, South Africa.
   [Mellors, John W.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
   [Mudhune, Victor O.] Kenya Govt Med Res Ctr, Dept Med, Kisumu, Kenya.
   [Badal-Faesen, Sharlaa] Univ Witwatersrand, Dept Internal Med, Clin HIV Res Unit, Johannesburg, South Africa.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Collier, Ann C.] Univ Washington, Seattle, WA 98195 USA.
RP Gross, R (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM grossr@pennmedicine.upenn.edu
OI Wallis, Carole/0000-0001-8408-8772
FU AIDS Clinical Trials Group (National Institutes of Health)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; Janssen Pharmaceuticals NV; GileadGilead Sciences; MerckMerck &
   Company; AbbVie; FOGARTY INTERNATIONAL CENTERUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [D43TW009781, D43TW009781] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069501, UM1AI069418, UM1AI069438,
   UM1AI069501, P30AI045008, UM1AI069494, UM1AI069465, UM1AI068634,
   UM1AI068618, P30AI045008, UM1AI069399, P30AI045008, UM1AI069438,
   UM1AI069453, UM1AI069418, P30AI045008, P30AI045008, UM1AI069453,
   P30AI045008, P30AI045008, UM1AI068618, UM1AI069534, P30AI045008,
   UM1AI069424, UM1AI069453, UM1AI069494, UM1AI069423, UM1AI069438,
   UM1AI069424, UM1AI069476, UM1AI108568, UM1AI068634, P30AI045008,
   P30AI045008, UM1AI106716, P30AI045008, P30AI045008, P30AI045008,
   UM1AI069424, UM1AI069534, UM1AI106701, UM1AI068618, UM1AI069494,
   UM1AI069418, UM1AI069423, P30AI045008, P30AI045008, UM1AI069421,
   P30AI045008, UM1AI069423, UM1AI069399, UM1AI068636, P30AI045008,
   UM1AI069534, UM1AI069465, UM1AI069501, UM1AI106716, UM1AI069418,
   UM1AI106716, UM1AI068618, UM1AI068636, UM1AI069432, P30AI045008,
   UM1AI068634, UM1AI069438, UM1AI069424, UM1AI069463, UM1AI068618,
   UM1AI069476, P30AI045008, UM1AI069421, UM1AI106701, P30AI045008,
   P30AI045008, UM1AI069534, P30AI045008, UM1AI069476, UM1AI069432,
   UM1AI108568, P30AI045008, UM1AI069438, UM1AI069432, UM1AI106701,
   UM1AI106701, UM1AI106716, UM1AI069465, P30AI045008, UM1AI069421,
   UM1AI069501, UM1AI069521, UM1AI069476, P30AI045008, UM1AI069521,
   UM1AI069453, UM1AI069453, UM1AI069494, UM1AI069423, P30AI045008,
   UM1AI069432, P30AI045008, UM1AI069463, UM1AI068634, UM1AI108568,
   UM1AI069418, P30AI045008, UM1AI069432, P30AI045008, UM1AI069465,
   P30AI045008, UM1AI069501, UM1AI069521, P30AI045008, UM1AI106716,
   P30AI045008, UM1AI069399, UM1AI069463, UM1AI069424, UM1AI069494,
   P30AI045008, UM1AI068634, UM1AI069534, UM1AI069521, UM1AI069399,
   UM1AI069521, UM1AI069534, P30AI045008] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488] Funding Source: NIH RePORTER
FX AIDS Clinical Trials Group (National Institutes of Health), Gilead,
   Janssen Pharmaceuticals NV, Merck, and AbbVie
CR Aranda-Jan CB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-188
   Bangsberg DR, 2006, AIDS, V20, P223, DOI 10.1097/01.aids.0000199825.34241.49
   Boender TS, 2015, CLIN INFECT DIS, V61, P1453, DOI 10.1093/cid/civ556
   Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Croome N, 2017, AIDS, V31, P995, DOI 10.1097/QAD.0000000000001416
   Gross R, 2013, JAMA INTERN MED, V173, P300, DOI 10.1001/jamainternmed.2013.2152
   Haberer JE, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21371
   Kanters S, 2017, LANCET HIV, V4, pE31, DOI 10.1016/S2352-3018(16)30206-5
   Kuritzkes DR, 2008, J INFECT DIS, V197, P867, DOI 10.1086/528802
   Lee LS, 2006, CLIN INFECT DIS, V43, P1052, DOI 10.1086/507894
   Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6
   Levi J, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2015-000010
   Levison JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032144
   Lima VD, 2008, AIDS, V22, P2371, DOI 10.1097/QAD.0b013e328315cdd3
   Mbuagbaw L, 2015, AIDS PATIENT CARE ST, V29, P248, DOI 10.1089/apc.2014.0308
   Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679
   Nachega JB, 2007, ANN INTERN MED, V146, P564, DOI 10.7326/0003-4819-146-8-200704170-00007
   Pop-Eleches C, 2011, AIDS, V25, P825, DOI 10.1097/QAD.0b013e32834380c1
   Shubber Z, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002183
   Simen BB, 2009, J INFECT DIS, V199, P693, DOI 10.1086/596736
   Stirratt MJ, 2015, TRANSL BEHAV MED, V5, P470, DOI 10.1007/s13142-015-0315-2
   Vujkovic M, 2018, PHARMACOGENOMICS J, V18, P678, DOI 10.1038/s41397-018-0028-2
   Vujkovic M, 2017, JAIDS-J ACQ IMM DEF, V75, P488, DOI 10.1097/QAI.0000000000001442
NR 24
TC 5
Z9 5
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2589-7500
J9 LANCET DIGIT HEALTH
JI Lancet Digit. Health
PD MAY
PY 2019
VL 1
IS 1
BP E26
EP E34
DI 10.1016/S2589-7500(19)30006-8
PG 9
WC Medical Informatics; Medicine, General & Internal
SC Medical Informatics; General & Internal Medicine
GA LD2MN
UT WOS:000525867400010
PM 31528850
OA DOAJ Gold, Green Accepted
DA 2020-11-24
ER

PT J
AU Mesquita, EC
   Coelho, LE
   Amancio, RT
   Veloso, V
   Grinsztejn, B
   Luz, P
   Bozza, FA
AF Mesquita, Emersom Cicilini
   Coelho, Lara Esteves
   Amancio, Rodrigo Teixeira
   Veloso, Valdilea
   Grinsztejn, Beatriz
   Luz, Paula
   Bozza, Fernando Augusto
TI Severe infection increases cardiovascular risk among HIV-infected
   individuals
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Cardiovascular disease; Risk factor; HIV; AIDS; Severe infection; cART;
   CD4+
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE MYOCARDIAL-INFARCTION;
   ANTIRETROVIRAL THERAPY; DISEASE; INFLAMMATION; REPLICATION; PNEUMONIA;
   MORTALITY; STROKE; BRAZIL
AB Background: The identification and management of cardiovascular risk factors became a major clinical issue among HIV-infected individuals in the post-cART era. As in the past decades the link between acute infections and cardiovascular diseases became clear in the general population, we sorted to investigate the role of severe infections on incident cardiovascular diseases (CVDs) among HIV-infected individuals.
   Methods: HIV-infected individuals aged >= 18 years, with no history of CVD were followed from January 2000 to December 2013 until the occurrence of the first CVD event, death or end of study, whichever occurred first. To explore the effect of severe infections on the incidence of CVD we used extended Cox regression models and stratified post-hospitalization follow-up time into three periods: <3months, 3-12months and >12 months post discharge.
   Results: One hundred-eighty four persons from 3384 HIV-infected individuals developed incident CVD events during the follow-up (incidence rate = 11.10/1000 PY (95%CI: 9.60-12.82)). Risk of an incident CVD was 4-fold higher at < 3 months post-hospitalization for severe infections (adjusted hazard ratio [aHR], 4.52; 95% confidence interval [CI] 2.46-8.30), after adjusting for sociodemographic and clinical factors as well as comorbidities. This risk remained significant up to one year (3-12months post hospital discharge aHR 2.39, 95% CI 1.30-4.38). Additionally, non-white race/ethnicity (aHR 1.49, 95% CI 1.10-2.02), age >= 60 years (aHR 2.01, 95% CI 1.01-3.97) and hypertension (aHR 1.90, 95% CI 1.38-2.60) were associated with an increased risk of CVD events. High CD4 (>= 500 cells/mm(3): aHR 0.41, 95% CI 0.27-0.62) and cART use (aHR 0.21, 95% CI 0.14-0.31) reduced the risk of CVD events.
   Conclusions: We provide evidence for a time-dependent association between severe infection and incident cardiovascular disease in HIV-infected individuals. cART use, and high CD4 count were significantly associated with reduced hazards of CVD.
C1 [Mesquita, Emersom Cicilini; Amancio, Rodrigo Teixeira; Bozza, Fernando Augusto] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin Med Intens, Rio De Janeiro, Brazil.
   [Coelho, Lara Esteves; Veloso, Valdilea; Grinsztejn, Beatriz; Luz, Paula] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab HIV, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto] Inst DOr Pesquisa & Ensino IDOR, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin Med Intens, Rio De Janeiro, Brazil.; Bozza, FA (corresponding author), Inst DOr Pesquisa & Ensino IDOR, Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Mesquita,
   Emersom/0000-0002-5132-3315; Luz, Paula/0000-0001-9746-719X
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Programa Estrategico de Apoio a Pesquisa em
   Saude (PAPES)/FiocruzNational Council for Scientific and Technological
   Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476] Funding Source: NIH RePORTER
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ), and Programa Estrategico
   de Apoio a Pesquisa em Saude (PAPES)/Fiocruz.
CR Amancio RT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068730
   [Anonymous], WHO CARD DIS CVDS
   Armah KA, 2012, CLIN INFECT DIS, V55, P126, DOI 10.1093/cid/cis406
   Bakal DR, 2018, J ANTIMICROB CHEMOTH, V73, P2177, DOI 10.1093/jac/dky145
   Baker JV, 2012, JAIDS-J ACQ IMM DEF, V60, P128, DOI 10.1097/QAI.0b013e318252f99f
   Basevi V, 2011, DIABETES CARE, V34, P1887, DOI 10.2337/dc11-s011
   Baylin A, 2007, ANN EPIDEMIOL, V17, P112, DOI 10.1016/j.annepidem.2006.05.004
   Bernal E, 2012, J AIDS CLIN RES, V03, DOI [10.4172/2155-6113.1000164, DOI 10.4172/2155-6113.1000164]
   Butt AA, 2011, ARCH INTERN MED, V171, P737, DOI 10.1001/archinternmed.2011.151
   de Oliveira RDC, 2018, AIDS CARE, V30, P551, DOI 10.1080/09540121.2017.1391984
   Corrales-Medina VF, 2015, JAMA-J AM MED ASSOC, V313, P264, DOI 10.1001/jama.2014.18229
   Corrales-Medina VF, 2010, LANCET INFECT DIS, V10, P83, DOI 10.1016/S1473-3099(09)70331-7
   Crane HM, 2017, JAMA CARDIOL, V2, P260, DOI 10.1001/jamacardio.2016.5139
   Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7
   Diaz CM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1735-4
   Falasca K, 2010, CURR HIV RES, V8, P405, DOI 10.2174/157016210791330365
   Freiberg MS, 2013, JAMA INTERN MED, V173, P614, DOI 10.1001/jamainternmed.2013.3728
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Greenberg JA, 2012, J CRIT CARE, V27, P51, DOI 10.1016/j.jcrc.2011.08.015
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grund B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155100
   Grundy SM, 2019, J AM COLL CARDIOL, V73, pE285, DOI 10.1016/j.jacc.2018.11.003
   Huang L, 2006, NEW ENGL J MED, V355, P173, DOI 10.1056/NEJMra050836
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Kalayjian RC, 2010, J INFECT DIS, V201, P1796, DOI 10.1086/652750
   Lang S, 2012, CLIN INFECT DIS, V55, P600, DOI 10.1093/cid/cis489
   Lu W, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20052
   Ludwig A, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872-015-0095-0
   Mesquita EC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33403-0
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Paisible AL, 2015, JAIDS-J ACQ IMM DEF, V68, P209, DOI 10.1097/QAI.0000000000000419
   Phillips AN, 2008, ANTIVIR THER, V13, P177
   Ramirez J, 2008, CLIN INFECT DIS, V47, P182, DOI 10.1086/589246
   Ribeiro SR, 2014, ANTIVIR THER, V19, P387, DOI 10.3851/IMP2716
   Saves M, 2003, CLIN INFECT DIS, V37, P292, DOI 10.1086/375844
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Sico JJ, 2015, NEUROLOGY, V84, P1933, DOI 10.1212/WNL.0000000000001560
   Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747
   Stein JH, 2012, JAMA-J AM MED ASSOC, V308, P405, DOI 10.1001/jama.2012.8488
   Subramanian S, 2012, JAMA-J AM MED ASSOC, V308, P379, DOI 10.1001/jama.2012.6698
   Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397
   Torriani FJ, 2008, J AM COLL CARDIOL, V52, P569, DOI 10.1016/j.jacc.2008.04.049
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   Tseng ZH, 2012, J AM COLL CARDIOL, V59, P1891, DOI 10.1016/j.jacc.2012.02.024
   Ucciferri C, 2017, AIDS REV, V19, P198
   Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339
   World Health Organization, 2011, US GLYC HAEM HBA1C D
   Yende S, 2008, AM J RESP CRIT CARE, V177, P1242, DOI 10.1164/rccm.200712-1777OC
   Yende S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022847
   Young J, 2015, JAIDS-J ACQ IMM DEF, V69, P413, DOI 10.1097/QAI.0000000000000662
NR 52
TC 1
Z9 1
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD APR 11
PY 2019
VL 19
AR 319
DI 10.1186/s12879-019-3894-6
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA HT8UX
UT WOS:000464841300006
PM 30975092
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU de Azevedo, SSD
   Cortes, FH
   Delatorre, E
   Ribeiro-Alves, M
   Hoagland, B
   Grinsztejn, B
   Veloso, VG
   Morgado, MG
   Bello, G
AF de Azevedo, Suwellen S. D.
   Cortes, Fernanda H.
   Delatorre, Edson
   Ribeiro-Alves, Marcelo
   Hoagland, Brenda
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Morgado, Mariza G.
   Bello, Gonzalo
TI Proviral Quasispecies Diversity Is Not Associated With Virologic
   Breakthrough or CD4(+) T Cell Loss in HIV-1 Elite Controllers
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE elite controllers; HIV proviral diversity; plasma biomarkers; CD4(+) T
   cell loss; breakthrough viremia
ID DISEASE PROGRESSION; ABSENCE; PREDICTORS; ACTIVATION; MECHANISMS; COUNT
AB Elite controllers (EC) are able to control HIV-1 replication to extremely low levels (<50 HIV-1 RNA copies/mL) in the absence of antiretroviral therapy. However, some EC experience CD4(+) T cell loss and/or lose their ability to control HIV-1 over the course of infection. High levels of HIV-1 env proviral diversity, activated T cells and proinflammatory cytokines were pointed out as relevant biomarkers for detection of EC at risk of virologic/immunologic progression. The aim of this study was to assess the importance of proviral diversity as a prognostic marker of virologic and/or immunologic progression in EC. To this end, we analyzed plasma viremia, total HIV DNA levels, T cells dynamics, and activation/inflammatory biomarkers in EC with low (ECLD = 4) and high (ECHD = 6) HIV-1 env diversity. None of ECLD and ECHD subjects displayed evidence of immunologic progression (decrease in absolute and percentage of CD4 C T cells) and only one ECHD subject presented virologic progression (>= 2 consecutive viral loads measurements above the detection limit) 2-5 years after determination of proviral env diversity. Despite differences in proviral genetic diversity, the ECLD and ECHD subgroups displayed comparable levels of total cell-associated HIV DNA, activated CD8(+) T (CD38 C HLA-DR+) cells and plasmatic inflammatory biomarkers (IP-10, IL-18, RANTES, PDGF-AA, and CTACK). These results indicate that the genetic diversity of the HIV-1 proviral reservoir is not a surrogate marker of residual viral replication, immune activation or inflammation, nor an accurate biomarker for the prediction of virologic breakthrough or CD4 C T cells loss in EC.
C1 [de Azevedo, Suwellen S. D.; Cortes, Fernanda H.; Delatorre, Edson; Morgado, Mariza G.; Bello, Gonzalo] Fundacao Oswaldo Cruz, Lab AIDS & Imunol Mol, Inst Oswaido Cruz, Rio De Janeiro, Brazil.
   [Ribeiro-Alves, Marcelo; Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Lab Pesquisa Clin DST & AIDS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Delatorre, Edson] Fundacao Oswald Cruz, Lab Genet Mol Microrganismos, Inst Oswald Cruz, Rio De Janeiro, Brazil.
RP Bello, G (corresponding author), Fundacao Oswaldo Cruz, Lab AIDS & Imunol Mol, Inst Oswaido Cruz, Rio De Janeiro, Brazil.
EM gbellobr@gmail.com
RI Delatorre, Edson/J-8330-2015; Cortes, Fernanda/AAF-9254-2020; de
   Azevedo, Suwellen/P-7199-2017
OI Delatorre, Edson/0000-0002-5746-0820; de Azevedo,
   Suwellen/0000-0001-6681-0987; Ribeiro-Alves, Marcelo/0000-0002-8663-3364
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ) [E-26/110.123/2014]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPqNational Council for
   Scientific and Technological Development (CNPq) [401220/2016-8];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -
   CNPqNational Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro -
   FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior - Brasil (CAPES)CAPES [001]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [302317/2017-1];
   FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/202.896/2018]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro - FAPERJ (Grant No. E-26/110.123/2014) and the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq
   (Grant No. 401220/2016-8). SA was supported by funding from Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq and Fundacao
   de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJ. ED was
   financed by a Postdoctoral fellowship from the "Programa Nacional de
   Pos-Doutorado (PNPD)" by the Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior - Brasil (CAPES) - Finance Code 001. GB was supported
   by fundings from CNPq (Grant No. 302317/2017-1) and FAPERJ (Grant No.
   E-26/202.896/2018).
CR Andrade A, 2008, CLIN INFECT DIS, V46, pE78, DOI 10.1086/529387
   Bello G, 2005, J GEN VIROL, V86, P355, DOI 10.1099/vir.0.80410-0
   Boufassa F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018726
   BURCHAM J, 1991, AIDS, V5, P365, DOI 10.1097/00002030-199104000-00002
   Canoui E, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx064
   Chereau F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173893
   Cortes FH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01576
   Cortes FH, 2015, JAIDS-J ACQ IMM DEF, V68, P377, DOI 10.1097/QAI.0000000000000500
   de Azevedo SSD, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0354-5
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Groves KC, 2012, JAIDS-J ACQ IMM DEF, V61, P407, DOI 10.1097/QAI.0b013e318269c414
   Hulgan T, 2007, J INFECT DIS, V195, P425, DOI 10.1086/510536
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Leon A, 2016, AIDS, V30, P1209, DOI 10.1097/QAD.0000000000001050
   Noel N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131922
   Noel N, 2014, AIDS, V28, P467, DOI 10.1097/QAD.0000000000000174
   Okulicz JF, 2009, J INFECT DIS, V200, P1714, DOI 10.1086/646609
   Olson AD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086719
   Pernas M, 2018, J VIROL, V92, DOI 10.1128/JVI.01805-17
   Platten M, 2016, AIDS RES HUM RETROV, V32, P579, DOI [10.1089/AID.2015.0226, 10.1089/aid.2015.0226]
   Rodriguez-Gallego E, 2019, J INFECT DIS, V219, P867, DOI 10.1093/infdis/jiy599
   Sajadi MM, 2007, AIDS, V21, P517
   Sajadi MM, 2009, JAIDS-J ACQ IMM DEF, V50, P403, DOI 10.1097/QAI.0b013e3181945f1e
   Tarancon-Diez L, 2018, EBIOMEDICINE, V28, P15, DOI 10.1016/j.ebiom.2018.01.013
   Walker BD, 2013, NAT REV IMMUNOL, V13, P487, DOI 10.1038/nri3478
   Yang Y, 2012, AIDS, V26, P701, DOI 10.1097/QAD.0b013e3283519b22
NR 26
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD APR 2
PY 2019
VL 10
AR 673
DI 10.3389/fmicb.2019.00673
PG 7
WC Microbiology
SC Microbiology
GA HR3OQ
UT WOS:000463048900001
PM 31001238
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Bavinton, BR
   Prestage, GP
   Jin, FG
   Phanuphak, N
   Grinsztejn, B
   Fairlev, CK
   Baker, D
   Hoy, J
   Templeton, DJ
   Tee, BK
   Kelleher, A
   Grulich, AE
   Zablotska-Manos, IB
   Cooper, DA
   Emery, S
   Fairley, CK
   Wilson, D
   Koelsch, KK
   Triffitt, K
   Doong, N
   Bloch, M
   McNulty, A
   Pell, C
   Tee, BK
   Moore, R
   Roth, N
   Orth, D
   Pinto, AN
AF Bavinton, Benjamin R.
   Prestage, Garrett P.
   Jin, Fengyi
   Phanuphak, Nittaya
   Grinsztejn, Beatriz
   Fairlev, Christopher K.
   Baker, David
   Hoy, Jennifer
   Templeton, David J.
   Tee, Ban K.
   Kelleher, Anthony
   Grulich, Andrew E.
   Zablotska-Manos, Iryna B.
   Cooper, David A.
   Emery, Sean
   Fairley, Christopher K.
   Wilson, David
   Koelsch, Kersten K.
   Triffitt, Kathy
   Doong, Nicolas
   Bloch, Mark
   McNulty, Anna
   Pell, Catherine
   Tee, Ban Kiem
   Moore, Richard
   Roth, Norm
   Orth, David
   Pinto, Angie N.
CA Opposites Attract Study Grp
TI Strategies used by gay male HIV serodiscordant couples to reduce the
   risk of HIV transmission from anal intercourse in three countries
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE serodiscordant couples; homosexual; gay men; men who have sex with men;
   HIV prevention; risk reduction strategies; sexual behaviour
ID PREEXPOSURE PROPHYLAXIS; BISEXUAL MEN; HOMOSEXUAL-MEN; AUSTRALIAN GAY;
   PREVENTION; SEX; BEHAVIORS; INFECTION; MONOGAMY; PARTNER
AB Introduction: There are few data about the range of strategies used to prevent sexual HIV transmission within gay male serodiscordant couples. We examined HIV prevention strategies used by such couples and compared differences between countries.
   Methods: Opposites Attract was a cohort study of male serodiscordant couples in Australia, Brazil and Thailand, from May 2014 (Australia) or May 2016 (Brazil/Thailand) to December 2016. At visits, HIV-positive partners had viral load (VL) tested; HIV-negative partners reported sexual behaviour and perceptions of their HIV-positive partner's VL results. Within-couple acts of condomless anal intercourse (CLAI) were categorized by strategy: condom-protected, biomedically protected (undetectable VL and/or pre-exposure prophylaxis [PrEP]), or not protected by either (HIV-negative partners engaging in insertive CLAI, receptive CLAI with withdrawal, or receptive CLAI with ejaculation).
   Results: A total of 343 couples were included in this analysis (153 in Australia, 93 in Brazil and 97 in Thailand). Three-quarters of HIV-positive partners were consistently virally suppressed (<200 copies/mL) during follow-up, and HIV-negative partners had correct perceptions of their partner's VL result for 76.5% of tests. One-third of HIV-negative partners used daily PrEP during follow-up. Over follow-up, 73.8% of couples had CLAI. HIV-negative partners reported 31,532 acts of anal intercourse with their HIV-positive partner. Of these, 46.7% were protected by condoms, 48.6% by a biomedical strategy and 4.7% of acts were not protected by these strategies. Australian couples had fewer condom-protected acts and a higher proportion of biomedically protected acts than Brazilian and Thai couples. Of the 1473 CLAI acts where the perceived VL was detectable/unknown and were not protected by PrEP (4.7% of all acts), two-thirds (n = 983) were when the HIV-negative partner was insertive (strategic positioning). Of the 490 acts when the HIV-negative partner was receptive, 261 involved withdrawal and 280 involved ejaculation. Thus, <1% of acts were in the highest risk category of receptive CLAI with ejaculation.
   Conclusions: Couples used condoms, PrEP or perceived undetectable VL for prevention in the majority of anal intercourse acts. Only a very small proportion of events were not protected by these strategies. Variation between countries may reflect differences in access to HIV treatment, education, knowledge and attitudes.
C1 [Bavinton, Benjamin R.; Prestage, Garrett P.; Jin, Fengyi; Templeton, David J.; Kelleher, Anthony; Grulich, Andrew E.] UNSW Sydney, Kirby Inst, Sydney, NSW 2052, Australia.
   [Phanuphak, Nittaya] Thai Red Cross AIDS Res Ctr, PREVENT, Bangkok, Thailand.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Inst Clin Res IPEC, Rio De Janeiro, Brazil.
   [Fairlev, Christopher K.] Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia.
   [Fairlev, Christopher K.; Hoy, Jennifer] Monash Univ, Melbourne, Vic, Australia.
   [Baker, David] East Sydney Doctors, Sydney, NSW, Australia.
   [Hoy, Jennifer] Alfred Hosp, Melbourne, Vic, Australia.
   [Templeton, David J.] RPA Sexual Hlth, Sydney, NSW, Australia.
   [Tee, Ban K.] Ctr Clin, Melbourne, Vic, Australia.
RP Bavinton, BR (corresponding author), UNSW Sydney, Kirby Inst, Sydney, NSW 2052, Australia.
EM bbavinton@kirby.unsw.edu.au
RI Hoy, Jennifer/AAK-7968-2020; Phanuphak, Nittaya/AAA-8579-2019
OI Prestage, Garrett/0000-0003-3917-8992; Bavinton, Benjamin
   Robert/0000-0001-5834-8278; Kelleher, Anthony/0000-0002-0009-3337;
   Templeton, David/0000-0003-2157-9587; Phanuphak,
   Nittaya/0000-0002-0036-3165
FU National Health and Medical Research Council, AustraliaNational Health
   and Medical Research Council of Australia; amfAR, Foundation for AIDS
   Research, USA; ViiV Healthcare, UK; Gilead Sciences, USA
FX Funding for the Opposites Attract Study was received from the National
   Health and Medical Research Council, Australia; amfAR, Foundation for
   AIDS Research, USA; ViiV Healthcare, UK; and Gilead Sciences, USA.
CR Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine, 2015, AUSTR COMM US DEP HL
   Bavinton BR, 2018, LANCET HIV, V5, pE438, DOI 10.1016/S2352-3018(18)30132-2
   Bavinton BR, 2017, SEX HEALTH, V14, P523, DOI [10.1071/sh16198, 10.1071/SH16198]
   Bavinton BR, 2016, AIDS BEHAV, V20, P1777, DOI 10.1007/s10461-016-1354-5
   Bavinton BR, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19884
   Bavinton BR, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-917
   Brazilian Ministry of Health, 2013, GUID COMPR CAR AD CE
   Brooks RA, 2012, AIDS PATIENT CARE ST, V26, P87, DOI 10.1089/apc.2011.0283
   Chakravarty D, 2012, AIDS BEHAV, V16, P1944, DOI 10.1007/s10461-012-0181-6
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Crepaz N, 2015, AIDS CARE, V27, P1361, DOI 10.1080/09540121.2015.1112353
   Guimaraes MDC, 2018, MEDICINE, V97, pS62, DOI 10.1097/MD.0000000000009079
   Davidovich U, 2004, AIDS EDUC PREV, V16, P304, DOI 10.1521/aeap.16.4.304.40398
   DETELS R, 1989, J ACQ IMMUN DEF SYND, V2, P77
   Down I, 2017, AIDS BEHAV, V21, P2543, DOI 10.1007/s10461-017-1747-0
   Duncan D, 2015, J SEX MARITAL THER, V41, P345, DOI 10.1080/0092623X.2014.915902
   Eaton LA, 2009, AIDS BEHAV, V13, P185, DOI 10.1007/s10461-008-9480-3
   El-Bassel N, 2010, JAIDS-J ACQ IMM DEF, V55, pS98, DOI 10.1097/QAI.0b013e3181fbf407
   Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145
   Goodreau SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050522
   Hankins C, 2015, J INT AIDS SOC, V18, P71, DOI 10.7448/IAS.18.4.19973
   Holt M, 2018, LANCET HIV, V5, pE448, DOI 10.1016/S2352-3018(18)30072-9
   Hosking W, 2014, ARCH SEX BEHAV, V43, P823, DOI 10.1007/s10508-013-0197-7
   Jin FY, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00086
   Jin FY, 2009, AIDS, V23, P243, DOI 10.1097/QAD.0b013e32831fb51a
   Johnson WD, 2018, AIDS, V32, P1499, DOI [10.1097/QAD.0000000000001832, 10.1097/qad.0000000000001832]
   Keen P, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25109
   Lasry A, 2014, AIDS, V28, P1521, DOI 10.1097/QAD.0000000000000307
   Medland NA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177634
   Mitchell JW, 2013, AIDS BEHAV, V17, P1557, DOI 10.1007/s10461-012-0388-6
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Muessig KE, 2014, CURR HIV-AIDS REP, V11, P434, DOI 10.1007/s11904-014-0225-9
   Mujugira A, 2016, JAIDS-J ACQ IMM DEF, V72, P579, DOI 10.1097/QAI.0000000000001019
   New South Wales Ministry of Health, 2018, NSW HIV STRAT 2016 2
   Philpot SP, 2018, AIDS BEHAV, V22, P3981, DOI 10.1007/s10461-018-2247-6
   Rodger A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-296
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   Scott HM, 2014, JAIDS-J ACQ IMM DEF, V65, P115, DOI 10.1097/QAI.0b013e3182a98bae
   Smith DK, 2015, JAIDS-J ACQ IMM DEF, V68, P337, DOI 10.1097/QAI.0000000000000461
   Starks TJ, 2014, ARCH SEX BEHAV, V43, P139, DOI 10.1007/s10508-013-0216-8
   Sullivan PS, 2009, AIDS, V23, P1153, DOI 10.1097/QAD.0b013e32832baa34
   Thailand Ministry of Public Health Thai AIDS Society., 2014, THAIL NAT GUID HIV A
   Torres TS, 2018, JMIR PUBLIC HLTH SUR, V4, P147, DOI 10.2196/publichealth.8997
   UNAIDS, 2014, 90 90 90 AMB TREATM
   Van de Ven P, 2002, AIDS CARE, V14, P471, DOI 10.1080/09540120208629666
   Vernazza P, 2008, B MED SUISSES, V89, P165, DOI DOI 10.4414/BMS.2008.13252
   World Health Organization, 2012, GUID OR PREEXP PROPH
   Worth H, 2002, J SOCIOL, V38, P237, DOI 10.1177/144078302128756642
   Xiridou M, 2003, AIDS, V17, P1029, DOI 10.1097/00002030-200305020-00012
NR 50
TC 3
Z9 3
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD APR
PY 2019
VL 22
IS 4
AR e25277
DI 10.1002/jia2.25277
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA HY6TX
UT WOS:000468263900012
PM 30983155
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Castro, R
   De Boni, RB
   Luz, PM
   Velasque, L
   Lopes, LV
   Medina-Lara, A
   Cardoso, SW
   De Oliveira, MS
   Friedman, RK
   Grinsztejn, B
   Veloso, VG
AF Castro, Rodolfo
   De Boni, Raquel B.
   Luz, Paula M.
   Velasque, Luciane
   Lopes, Livia V.
   Medina-Lara, Antonieta
   Cardoso, Sandra W.
   De Oliveira, Marilia S.
   Friedman, Ruth K.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
TI Health-related quality of life assessment among people living with HIV
   in Rio de Janeiro, Brazil: a cross-sectional study
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Quality of life; Gender; Age factors; Educational status; Depression;
   Substance abuse; Viral load, HIV
ID ANTIRETROVIRAL THERAPY; SUBSTANCE USE; INFECTED INDIVIDUALS; HAART USE;
   DEPRESSION; IMPACT; EQ-5D-3L; COHORT; WOMEN; CARE
AB Purpose To assess health-related quality of life (HRQoL) and its associated factors among people living with HIV/AIDS (PLWHA) in Rio de Janeiro, Brazil.
   Methods A cross-sectional study including PLWHA receiving usual HIV-care at Instituto Nacional de Infectologia Evandro Chagas (INI/Fiocruz) was conducted between 2014 and 2016 in Rio de Janeiro, Brazil. The EQ-5D-3L assessed HRQoL; PHQ-2 and ASSIST were used for screening depression and substance use, respectively. Clinical variables were obtained from the INI/Fiocruz cohort database, and structured questions evaluated intimate partner violence, sexual abstinence and relationship status. Data were analysed using multivariable Tobit regression model.
   Results A total of 1480 PLWHA were included: 64.7% were male at birth (38.4% men who have sex with men [MSM], 24.3% heterosexual men and 2% transgender women [TGW]); median age was 43.1 years, and 95.8% were receiving antiretroviral therapy. The median EQ-5D-3L utility score was 0.801. Results showed that the following factors: MSM and women; older age; lower educational level; no engagement in a relationship; depression screening positive; polysubstance use; and, detectable viral load were independently associated with worse HRQoL.
   Conclusions PLWHA under care at INI/Fiocruz presented good HRQoL. Polysubstance use, depression and lower educational level were among the factors negatively associated with HRQoL. This was the first time that the EQ-5D-3L utility scores were calculated for a considerable number of PLWHA in Brazil, which is a fundamental piece of information for future cost-effectiveness analysis.
C1 [Castro, Rodolfo; De Boni, Raquel B.; Luz, Paula M.; Lopes, Livia V.; Cardoso, Sandra W.; De Oliveira, Marilia S.; Friedman, Ruth K.; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil,Rio de Janeiro 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Castro, Rodolfo] Univ Fed Estado Rio de Janeiro, Inst Saude Colet, Rua Prof Gabizo,264,3 Andar, BR-20271062 Rio De Janeiro, RJ, Brazil.
   [Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Ave Pasteur 458, BR-22290240 Rio De Janeiro, RJ, Brazil.
   [Medina-Lara, Antonieta] Univ Exeter, Hlth Econ Grp, St Lukes Campus,Heavitree Rd, Exeter EX1 2LU, Devon, England.
RP Castro, R (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil,Rio de Janeiro 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.; Castro, R (corresponding author), Univ Fed Estado Rio de Janeiro, Inst Saude Colet, Rua Prof Gabizo,264,3 Andar, BR-20271062 Rio De Janeiro, RJ, Brazil.
EM rodolfoalcastro@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Castro, Rodolfo/D-4231-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Castro,
   Rodolfo/0000-0002-0701-2528; Luz, Paula/0000-0001-9746-719X
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [476024/2013-7, 476333/2013-0]; Fundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Newton Fund
   RCUK-CONFAP Research Partnerships callCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/170.021/2015]; Programa Institucional de Bolsas de Iniciacao
   Cientifica (PIBIC/CNPq)National Council for Scientific and Technological
   Development (CNPq)
FX This study was funded by Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq)-Grant Numbers: 476024/2013-7 and 476333/2013-0;
   Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ), Newton Fund RCUK-CONFAP Research Partnerships call,
   Grant Number: E-26/170.021/2015; and, Programa Institucional de Bolsas
   de Iniciacao Cientifica (PIBIC/CNPq). These funders had no role in study
   design, data collection and analysis, decision to publish or preparation
   of the manuscript.
CR Alsayed NS, 2017, QUAL LIFE RES, V26, P655, DOI 10.1007/s11136-016-1482-4
   [Anonymous], 2017, LANCET HIV, V4, pE475, DOI 10.1016/S2352-3018(17)30183-2
   [Anonymous], 2017, STAT STAT SOFTW REL
   Tran BX, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-132
   Bekele T, 2017, AIDS PATIENT CARE ST, V31, P49, DOI 10.1089/apc.2016.0174
   Bernell S, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00159
   Bernier A, 2016, AIDS CARE, V28, P26, DOI 10.1080/09540121.2016.1146208
   Bhatta DN, 2017, AIDS BEHAV, V21, P1620, DOI 10.1007/s10461-016-1546-z
   Boussari O, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/1471-2288-15-10
   Catalan J, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0148-9
   de Medeiros RCDC, 2017, REV SAUDE PUBL, V51, DOI [10.1590/S1518-8787.2017051006266, 10.1590/s1518-8787.2017051006266]
   De Boni RB, 2018, DRUG ALCOHOL DEPEN, V185, P168, DOI 10.1016/j.drugalcdep.2017.12.016
   Degroote S, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-40
   Delany-Moretlwe S, 2015, J INT AIDS SOC, V18, P29, DOI 10.7448/IAS.18.2.19833
   Dickerson JF, 2018, QUAL LIFE RES, V27, P447, DOI 10.1007/s11136-017-1728-9
   Emuren L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178953
   Ezeamama AE, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002525
   Fleming CA, 2004, CLIN INFECT DIS, V38, P572, DOI 10.1086/381263
   Gill CJ, 2002, J ACQ IMMUN DEF SYND, V30, P485, DOI 10.1097/00126334-200208150-00004
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Henrique Iara Ferraz Silva, 2004, Rev. Assoc. Med. Bras., V50, P199, DOI 10.1590/S0104-42302004000200039
   Jia YX, 2014, QUAL LIFE RES, V23, P2355, DOI 10.1007/s11136-014-0670-3
   Kalichman SC, 2001, J PERS ASSESS, V76, P379, DOI 10.1207/S15327752JPA7603_02
   Karimi M, 2016, PHARMACOECONOMICS, V34, P645, DOI 10.1007/s40273-016-0389-9
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C
   Liu CL, 2006, QUAL LIFE RES, V15, P941, DOI 10.1007/s11136-005-5913-x
   Machado IK, 2017, INT J STD AIDS, V28, P1175, DOI 10.1177/0956462417692278
   Mafirakureva N, 2016, AIDS CARE, V28, P904, DOI 10.1080/09540121.2016.1173639
   Majeed Z, 2017, AIDS CARE, V29, P1399, DOI 10.1080/09540121.2017.1300627
   Ramos-Goni JM, 2011, STATA J, V11, P120, DOI 10.1177/1536867X1101100108
   Menezes RD, 2015, QUAL LIFE RES, V24, P2761, DOI 10.1007/s11136-015-0994-7
   Millar BM, 2017, AIDS BEHAV, V21, P1684, DOI 10.1007/s10461-016-1613-5
   Miller P, 2015, J HIV-AIDS SOC SERV, V14, P308, DOI 10.1080/15381501.2014.912180
   Miners A, 2014, LANCET HIV, V1, pE32, DOI 10.1016/S2352-3018(14)70018-9
   Mitchell MM, 2017, AIDS BEHAV, V21, P1580, DOI 10.1007/s10461-016-1589-1
   Nobre N, 2017, AIDS CARE, V29, P1074, DOI 10.1080/09540121.2017.1281879
   O'Connell KA, 2012, AIDS BEHAV, V16, P452, DOI 10.1007/s10461-010-9863-0
   Osorio FD, 2009, PERSPECT PSYCHIATR C, V45, P216, DOI 10.1111/j.1744-6163.2009.00224.x
   Pokhrel KN, 2017, AIDS CARE, V29, P1137, DOI 10.1080/09540121.2017.1332331
   Prasithsirikul W, 2017, AIDS CARE, V29, P299, DOI 10.1080/09540121.2016.1201194
   Preau M, 2007, AIDS, V21, pS19, DOI 10.1097/01.aids.0000255081.24105.d7
   Quatremere G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173338
   Risher K, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.3.18715
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   Rzeszutek M, 2017, QUAL LIFE RES, V26, P2805, DOI 10.1007/s11136-017-1612-7
   Santos M, 2016, MED DECIS MAKING, V36, P253, DOI 10.1177/0272989X15613521
   Scanavino MD, 2016, ARCH SEX BEHAV, V45, P207, DOI 10.1007/s10508-014-0356-5
   Serrano-Villar S, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw097
   Siemieniuk RAC, 2013, JAIDS-J ACQ IMM DEF, V64, P32, DOI 10.1097/QAI.0b013e31829bb007
   Silva MT, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0734-5
   Skevington SM, 2010, AIDS CARE, V22, P614, DOI 10.1080/09540120903311466
   Sullivan KM, 2009, PUBLIC HEALTH REP, V124, P471, DOI 10.1177/003335490912400320
   Venturini A, 2017, AIDS CARE, V29, P1373, DOI 10.1080/09540121.2017.1286286
   Wada N, 2014, AIDS, V28, P257, DOI 10.1097/QAD.0000000000000078
   Wagner GJ, 2012, AIDS BEHAV, V16, P1862, DOI 10.1007/s10461-011-0051-7
   WHO, 2008, MHGAP MENT HLTH GAP
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Xiao ZW, 2017, AIDS CARE, V29, P319, DOI 10.1080/09540121.2016.1224298
   Yeoh HL, 2018, ANTIVIR THER, V23, P117, DOI 10.3851/IMP3185
   Zimpel RR, 2007, AIDS CARE, V19, P923, DOI 10.1080/09540120701213765
   Zimpel RR, 2014, PSYCHOL HEALTH MED, V19, P47, DOI 10.1080/13548506.2013.772302
   2002, ADDICTION, V97, P1183
NR 62
TC 6
Z9 6
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD APR
PY 2019
VL 28
IS 4
BP 1035
EP 1045
DI 10.1007/s11136-018-2044-8
PG 11
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA HS1JU
UT WOS:000463619000018
PM 30415417
DA 2020-11-24
ER

PT J
AU Biello, KB
   Grinsztejn, B
   Fernandes, NM
   Edeza, A
   Kamel, L
   Salhaney, P
   Veloso, V
   Mimiaga, MJ
AF Biello, Katie B.
   Grinsztejn, Beatriz
   Fernandes, Nilo Martinez
   Edeza, Alberto
   Kamel, Luciana
   Salhaney, Peter
   Veloso, Valdilea
   Mimiaga, Matthew J.
TI DEVELOPMENT OF A SOCIAL NETWORK-BASED INTERVENTION TO OVERCOME
   MULTILEVEL BARRIERS TO ART ADHERENCE AMONG ADOLESCENTS IN BRAZIL
SO AIDS EDUCATION AND PREVENTION
LA English
DT Article
DE adolescents; HIV; medication adherence; Brazil; men who have sex with
   men; transgender women
ID MEDICATION ADHERENCE; ANTIRETROVIRAL TREATMENT; BEHAVIORAL INTERVENTION;
   SUPPORT GROUP; HIV; THERAPY; STIGMA; YOUTH; SEX; COMMUNITIES
AB Brazil's comprehensive HIV treatment program does not specifically address ART adherence challenges for adolescents-a group accounting for the largest number of incident HIV infections in Brazil. We conducted three focus groups with 24 adolescents (age 15-24) living with HIV in Rio de Janeiro, separately for cisgender men who have sex with men, heterosexual-identified cisgender men and women, and transgender women of any sexual orientation, and key informant interviews (n = 7) with infectious disease specialists and HIV/AIDS service organization staff. Content analysis identified socioecological barriers and facilitators to adherence, including individual (e.g., low knowledge, side effects, and substance use), interpersonal (e.g., stigma from partners and health care providers) and structural (e.g., transportation and medication access) barriers. Overlapping and unique barriers emerged by sexual/gender identity. A community-informed, theory-driven ART adherence intervention for adolescents that is organized around identity and leverages social networks has the potential to improve HIV treatment and health outcomes for Brazilian adolescents.
C1 [Biello, Katie B.; Edeza, Alberto; Salhaney, Peter; Mimiaga, Matthew J.] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA.
   [Biello, Katie B.; Mimiaga, Matthew J.] Fenway Hlth, Fenway Inst, Boston, MA USA.
   [Grinsztejn, Beatriz; Fernandes, Nilo Martinez; Kamel, Luciana; Veloso, Valdilea] Fiocruz MS, Evandro Chagas Clin Res Inst IPEC, Rio De Janeiro, Brazil.
RP Biello, KB (corresponding author), Brown Univ, Ctr Hlth Equ Res, 121 Main St,Box G-5121-8, Providence, RI 02912 USA.
EM katie_biello@brown.edu
FU Watson Institute for International and Public Affairs at Brown
   University
FX This work was supported by a grant from the Watson Institute for
   International and Public Affairs at Brown University. The authors
   express our gratitude to the study teams in Brazil and Providence, and
   the study participants for their willingness to share their lived
   experiences.
CR Ballard PJ, 2016, J EPIDEMIOL COMMUN H, V70, P202, DOI 10.1136/jech-2015-206110
   Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660
   Bandura A, 1997, AM J HEALTH PROMOT, V12, P8, DOI 10.4278/0890-1171-12.1.8
   Bartlett J. G, 2008, GUIDELINES USE ANTIR, P42
   Bartlett JA, 2002, J ACQ IMMUN DEF SYND, V29, pS2, DOI 10.1097/00126334-200202011-00002
   Berkowitz S., 1997, USER FRIENDLY HDB MI, P91
   Bhatti AB, 2016, CUREUS, V8, DOI 10.7759/cureus.515
   Brazilian Ministry of Health, 2014, PROT CLIN DIR TER MA
   CASCADE Collaboration, 2000, LANCET, V355, P1158
   Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   da Costa TM, 2010, INT J MED INFORM, V79, P65, DOI 10.1016/j.ijmedinf.2009.09.001
   Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068
   Daughters SB, 2010, COGN BEHAV PRACT, V17, P309, DOI 10.1016/j.cbpra.2009.12.003
   DeCuir-Gunby JT, 2011, FIELD METHOD, V23, P136, DOI 10.1177/1525822X10388468
   Department of STD AIDS and Viral Hepatitis/ SVS/ MS., 2012, AIDS BRAZ
   Ernesto AS, 2012, BRAZ J INFECT DIS, V16, P315, DOI 10.1016/j.bjid.2012.06.006
   Funck-Brentano I, 2005, AIDS, V19, P1501, DOI 10.1097/01.aids.0000183124.86335.0a
   Gallagher KM, 2012, ANN BEHAV MED, V43, P101, DOI 10.1007/s12160-011-9308-7
   Ganju D, 2017, CULT HEALTH SEX, V19, P903, DOI 10.1080/13691058.2016.1271141
   Garvie PA, 2010, J ADOLESCENT HEALTH, V47, P504, DOI 10.1016/j.jadohealth.2010.03.013
   Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157
   Henwood R, 2016, AIDS CARE, V28, P898, DOI 10.1080/09540121.2016.1173638
   Hill S, 2012, AIDS CARE, V24, P583, DOI 10.1080/09540121.2011.630354
   Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450
   Ingersoll K, 2004, AIDS CARE, V16, P199, DOI 10.1080/09540120410001641048
   Jeffries WL, 2015, AIDS EDUC PREV, V27, P58, DOI 10.1521/aeap.2015.27.1.58
   Latkin CA, 2013, JAIDS-J ACQ IMM DEF, V63, pS54, DOI 10.1097/QAI.0b013e3182928e2a
   Crozatti MTL, 2013, AIDS CARE, V25, P1462, DOI 10.1080/09540121.2013.774312
   Luz PM, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20623
   MacDonell K, 2013, AIDS BEHAV, V17, P86, DOI 10.1007/s10461-012-0364-1
   Martin DA, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-322
   Mellins CA, 2004, PEDIATR INFECT DIS J, V23, P1035, DOI 10.1097/01.inf.0000143646.15240.ac
   Mo PKH, 2008, CYBERPSYCHOL BEHAV, V11, P371, DOI 10.1089/cpb.2007.0118
   Murphy DA, 2001, AIDS CARE, V13, P27, DOI 10.1080/09540120020018161
   Naar-King S, 2009, ARCH PEDIAT ADOL MED, V163, P1092, DOI 10.1001/archpediatrics.2009.212
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Patton M. Q., 2005, ENCY STAT BEHAV SCI, V3
   Pop-Eleches C, 2011, AIDS, V25, P825, DOI 10.1097/QAD.0b013e32834380c1
   Poudel KC, 2015, INT Q COMMUNITY HEAL, V36, P71, DOI 10.1177/0272684X15614220
   Psaros C, 2014, JAIDS-J ACQ IMM DEF, V66, P522, DOI 10.1097/QAI.0000000000000212
   Rao D, 2012, AIDS BEHAV, V16, P711, DOI 10.1007/s10461-011-9915-0
   Reisner Sari L, 2009, Top HIV Med, V17, P14
   Richardson JL, 2004, AIDS, V18, P1179, DOI 10.1097/00002030-200405210-00011
   RIGER S, 1993, AM J COMMUN PSYCHOL, V21, P279, DOI 10.1007/BF00941504
   Rintamaki LS, 2006, AIDS PATIENT CARE ST, V20, P359, DOI 10.1089/apc.2006.20.359
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   Ryan G. W., 2003, FIELD METHOD, V15, P85, DOI DOI 10.1177/1525822X02239569
   Saffier IP, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2795-9
   Safren SA, 1999, COGN BEHAV PRACT, V6, P332, DOI DOI 10.1016/S1077-7229(99)80052-2
   Safren SA, 2012, J CONSULT CLIN PSYCH, V80, P404, DOI 10.1037/a0028208
   Samji H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081355
   Secord E, 2007, ANN ALLERG ASTHMA IM, V98, P405, DOI 10.1016/S1081-1206(10)60753-3
   Shiu CS, 2013, COGN BEHAV PRACT, V20, P202, DOI 10.1016/j.cbpra.2012.05.005
   Slavin S, 2007, AIDS CARE, V19, P130, DOI 10.1080/09540120600866473
   Speer PW, 2001, HEALTH EDUC BEHAV, V28, P716, DOI 10.1177/109019810102800605
   Taquette SR, 2013, SAUDE SOC-SAO PAULO, V22, P618, DOI 10.1590/S0104-12902013000200029
   Thurston IB, 2014, COGN BEHAV PRACT, V21, P191, DOI 10.1016/j.cbpra.2013.11.001
   Turan B, 2017, AM J PUBLIC HEALTH, V107, P863, DOI 10.2105/AJPH.2017.303744
   Wansink B, 2015, NUTR REV, V73, P4, DOI 10.1093/nutrit/nuu010
NR 60
TC 0
Z9 0
U1 0
U2 4
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA
SN 0899-9546
EI 1943-2755
J9 AIDS EDUC PREV
JI Aids Educ. Prev.
PD APR
PY 2019
VL 31
IS 2
BP 111
EP 126
DI 10.1521/aeap.2019.31.2.111
PG 16
WC Education & Educational Research; Public, Environmental & Occupational
   Health
SC Education & Educational Research; Public, Environmental & Occupational
   Health
GA HQ7KN
UT WOS:000462599100002
PM 30917013
DA 2020-11-24
ER

PT J
AU Torres, TS
   Konda, KA
   Vega-Ramirez, EH
   Elorreaga, OA
   Diaz-Sosa, D
   Hoagland, B
   Diaz, S
   Benedetti, M
   Bennedeti, M
   Lopez-Gatell, H
   Robles-Garcia, R
   Grinsztejn, B
   Caceres, C
   Veloso, VG
AF Torres, Thiago Silva
   Konda, Kelika A.
   Vega-Ramirez, E. Hamid
   Elorreaga, Oliver A.
   Diaz-Sosa, Dulce
   Hoagland, Brenda
   Diaz, Steven
   Benedetti, Marcos
   Bennedeti, Marcos
   Lopez-Gatell, Hugo
   Robles-Garcia, Rebeca
   Grinsztejn, Beatriz
   Caceres, Carlos
   Veloso, Valdilea G.
CA ImPrEP Study Grp
TI Factors Associated With Willingness to Use Pre-Exposure Prophylaxis in
   Brazil, Mexico, and Peru: Web-Based Survey Among Men Who Have Sex With
   Men
SO JMIR PUBLIC HEALTH AND SURVEILLANCE
LA English
DT Article
DE pre-exposure prophylaxis; men who have sex with men; prevention; Latin
   America; surveys and questionnaires
ID TRANSGENDER WOMEN; LATIN-AMERICA; YOUNG MEN; PREP; HIV; ADHERENCE;
   AWARENESS; BARRIERS; RISK
AB Background: HIV disproportionally affects key populations including men who have sex with men (MSM). HIV prevalence among MSM varies from 17% in Brazil and Mexico to 13% in Peru, whereas it is below 0.5% for the general population in each country. Pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir is being implemented in the context of combination HIV prevention. Reports on willingness to use PrEP among MSM have started to emerge over the last few years. Previously reported factors associated with willingness to use PrEP include awareness, higher sexual risk behavior, and previous sexually transmitted infection.
   Objective: This study aimed to evaluate the factors associated with willingness to use daily oral PrEP among MSM in 3 Latin American, middle-income countries (Brazil, Mexico, and Peru).
   Methods: This Web-based, cross-sectional survey was advertised in 2 gay social network apps (Grindr and Hornet) used by MSM to find sexual partners and on Facebook during 2 months in 2018. Inclusion criteria were being 18 years or older, cisgender men, and HIV-negative by self-report. Eligible individuals answered questions on demographics, behavior, and PrEP (awareness, willingness to use, barriers, and facilitators). Multivariable logistic regression modeling was performed to assess the factors associated with willingness to use daily oral PrEP in each country.
   Results: From a total sample of 43,687 individuals, 44.54% of MSM (19,457/43,687) were eligible and completed the Web-based survey-Brazil: 58.42% (11,367/19,457), Mexico: 30.50% (5934/19,457), and Peru: 11.08% (2156/19,457); median age was 28 years (interquartile range: 24-34), and almost half lived in large urban cities. Most participants were recruited on Grindr (69%, 13,349/19,457). Almost 20% (3862/19,352) had never tested for HIV, and condomless receptive anal sex was reported by 40% (7755/19,326) in the previous 6 months. Whereas 67.51% (13,110/19,376) would be eligible for PrEP, only 9.80% (1858/18,959) of participants had high HIV risk perception. PrEP awareness was reported by 64.92% (12,592/19,396); this was lower in Peru (46.60%, 1002/2156). Overall, willingness to use PrEP was reported by 64.23% (12,498/19,457); it was highest in Mexico (70%, 4158/5934) and lowest in Peru (58%, 1241/2156). In multivariate regression models adjusted for age, schooling, and income in each country, willingness to use PrEP was positively associated with PrEP awareness and PrEP facilitators (eg, free PrEP and HIV testing) and negatively associated with behavioral (eg, concerned by daily pill regimen) and belief barriers (eg, sexual partners may expect condomless sex).
   Conclusions: In this first cross-country, Web-based survey in Latin America, willingness to use PrEP was found to be high and directly related to PrEP awareness. Interventions to increase awareness and PrEP knowledge about safety and efficacy are crucial to increase PrEP demand. This study provides important information to support the implementation of PrEP in Brazil, Mexico, and Peru.
C1 [Torres, Thiago Silva; Hoagland, Brenda; Benedetti, Marcos; Bennedeti, Marcos; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz INI Fiocruz, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365 Manguinhos, BR-21040900 Rio De Janeiro, Brazil.
   [Konda, Kelika A.; Elorreaga, Oliver A.; Caceres, Carlos] UPCH, Ctr Invest Interdisciplinaria Sexualidad Sida & S, Lima, Peru.
   [Vega-Ramirez, E. Hamid; Diaz-Sosa, Dulce; ImPrEP Study Grp] Condesa & Condesa Iztapalapa Specialized Clin, Mexico City, DF, Mexico.
   [Vega-Ramirez, E. Hamid; Diaz-Sosa, Dulce; Robles-Garcia, Rebeca] Natl Inst Psychiat Ramon Fuente Muniz, Mexico City, DF, Mexico.
   [Diaz, Steven] Ctr Prevent & Comprehens Healthcare HIV AIDS Mexi, Mexico City, DF, Mexico.
   [Lopez-Gatell, Hugo] Natl Inst Publ Hlth, Mexico City, DF, Mexico.
RP Torres, TS (corresponding author), Fundacao Oswaldo Cruz INI Fiocruz, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365 Manguinhos, BR-21040900 Rio De Janeiro, Brazil.
EM thiago.torres@ini.fiocruz.br
RI Elorreaga, Oliver A./AAU-1706-2020; TORRES, THIAGO SILVA/D-6548-2014
OI Elorreaga, Oliver A./0000-0003-0181-5378; TORRES, THIAGO
   SILVA/0000-0002-2557-601X; Vega-Ramirez, E. Hamid/0000-0003-0390-9992;
   Benedetti, Marcos Renato/0000-0001-8283-5025; Pimenta de Oliveira, Maria
   Cristina/0000-0002-4205-9786; Lopez-Gatell, Hugo/0000-0001-5857-6625
FU Unitaid; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476]
   Funding Source: NIH RePORTER
FX Y This project was made possible, thanks to Unitaid's funding and
   support. Unitaid accelerates access to innovative health products and
   lays the foundations for their scale-up by countries and partners.
   Unitaid is a hosted partnership of the WHO. We would like to thank the
   MoH of Brazil, Mexico, and Peru.
CR AIDS.gov, 2017, PROT CLIN DIR TER PR
   Bauermeister JA, 2014, CURR HIV RES, V11, P520, DOI 10.2174/1570162X12666140129100411
   Bautista-Arredondo S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072616
   Centers of Disease Control and Prevention, 2014, PREEXP PROPH PREV HI
   Cetic.br, 2016, ICT HOUS 2015 SURV U
   Clark JL, 2014, AIDS BEHAV, V18, P2338, DOI 10.1007/s10461-013-0680-0
   Colby DJ, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20966
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Department of Surveillance Prevention and Control of Sexually Transmitted Infections, 2018, HIV AIDS VIR HEP B E
   Golub SA, 2013, AIDS PATIENT CARE ST, V27, P248, DOI 10.1089/apc.2012.0419
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Hoagland B, 2017, AIDS BEHAV, V21, P1278, DOI 10.1007/s10461-016-1516-5
   Hoots BE, 2016, CLIN INFECT DIS, V63, P672, DOI 10.1093/cid/ciw367
   Kerr L, 2018, MEDICINE, V97, pS9, DOI [10.1097/MD.0000000000010573, 10.1097/md.0000000000010573]
   LIBROS, 2018, FIN EV REP MULT STRA
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   National Institute of Alcohol Abuse and Alcoholism, 2004, NIAAA COUNC APPR DEF
   Newcomb ME, 2018, JAIDS-J ACQ IMM DEF, V77, P358, DOI 10.1097/QAI.0000000000001604
   Oldenburg CE, 2018, AIDS BEHAV, V22, P1075, DOI 10.1007/s10461-017-1701-1
   Ormaeche M, 2012, INT J INFECT DIS, V16, pE724, DOI 10.1016/j.ijid.2012.05.1032
   Patrick R, 2017, JAIDS-J ACQ IMM DEF, V75, pS375, DOI [10.1097/QAI.0000000000001414, 10.1097/qai.0000000000001414]
   PROCHASKA JO, 1993, HEALTH PSYCHOL, V12, P399, DOI 10.1037/0278-6133.12.5.399
   Rocha GM, 2020, AIDS BEHAV, V24, P938, DOI 10.1007/s10461-019-02459-y
   Torres TS, 2018, JMIR PUBLIC HLTH SUR, V4, P147, DOI 10.2196/publichealth.8997
   Torres TS, 2019, AIDS CARE, V23, P1
   UNAIDS, 2016, PREV GAP REP
   UNAIDS, 2019, FACTSH PERU 2017
   UNAIDS, 2017, END AIDS PROGR 90 90
   UNAIDS, NAT REP MON COMM EXP
   WHO, 2017, BRAZ BEG PREP ROLL O
   WHO, 2016, CONS GUID US ANT DRU
   World Health Organization, 2017, WHO IMPL TOOL PREEXP
   Yi S, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21580
NR 36
TC 4
Z9 4
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2369-2960
J9 JMIR PUBLIC HLTH SUR
JI JMIR Public Health Surveill.
PD APR-JUN
PY 2019
VL 5
IS 2
BP 177
EP 192
AR UNSP e13771
DI 10.2196/13771
PG 16
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LE6EL
UT WOS:000526816400013
PM 31210143
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU de Azevedo, SSD
   Delatorre, E
   Cortes, FH
   Hoagland, B
   Grinsztejn, B
   Veloso, VG
   Souza, TML
   Morgado, MG
   Bello, G
AF de Azevedo, Suwellen S. D.
   Delatorre, Edson
   Cortes, Fernanda H.
   Hoagland, Brenda
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Souza, Thiago Moreno L.
   Morgado, Mariza G.
   Bello, Gonzalo
TI HIV controllers suppress viral replication and evolution and prevent
   disease progression following intersubtype HIV-1 superinfection
SO AIDS
LA English
DT Article
DE disease progression; HIV controllers; reservoir; superinfection; viral
   load
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZING ANTIBODY-RESPONSE; DUAL
   INFECTION; LONG-TERM; IN-DEPTH; SEX; MEN; RECOMBINATION; SEQUENCES;
   DYNAMICS
AB Objective: The aim of this study was to investigate the impact of intersubtype HIV-1 superinfection on viremia, reservoir reseeding, viral evolution and disease progression in HIV controllers (HIC).
   Design: A longitudinal analysis of two Brazilian HIC individuals (EEC09 and VC32) previously identified as dually infected with subtypes B and F1 viruses.
   Methods: Changes in plasma viremia, total HIV-1 DNA levels, CD4(+) T-cell counts and HIV-1 quasispecies composition were measured over time. HIV-1 env diversity in peripheral blood mononuclear cell (PBMC) and plasma samples was accessed by single genome amplification and next-generation sequencing approaches, respectively. Viral evolution was evaluated by estimating nucleotide diversity and divergence.
   Results: Individual EEC09 was probably initially infected with a CCR5-tropic subtype B strain and sequentially superinfected with a CXCR4-tropic subtype B strain and with a subtype F1 variant. Individual VC32 was infected with a subtype B strain and superinfected with a subtype F1 variant. The intersubtype superinfection events lead to a moderate increase in viremia and extensive turnover of viral population in plasma but exhibited divergent impact on the size and composition of cell-associated HIV DNA population. Both individuals maintained virologic control (<2000 copies/ml) and presented no evidence of viral evolution or immunologic progression for at least 2 years after the intersubtype superinfection event.
   Conclusion: These data revealed that some HIC are able to repeatedly limit replication and evolution of superinfecting viral strains of a different subtype with no signs of disease progression. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
C1 [de Azevedo, Suwellen S. D.; Delatorre, Edson; Cortes, Fernanda H.; Morgado, Mariza G.; Bello, Gonzalo] Fiocruz MS, IOC, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Rio De Janeiro, Brazil.
   [Souza, Thiago Moreno L.] Fiocruz MS, CDTS, Rio De Janeiro, Brazil.
   [Souza, Thiago Moreno L.] Fiocruz MS, IOC, Lab Imunofarmacol, Rio De Janeiro, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, IOC, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM gbello@ioc.fiocruz.br
RI Cortes, Fernanda/AAF-9254-2020; Delatorre, Edson/J-8330-2015; de
   Azevedo, Suwellen/P-7199-2017
OI Delatorre, Edson/0000-0002-5746-0820; de Azevedo,
   Suwellen/0000-0001-6681-0987; Souza, Thiago/0000-0003-2212-3899
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ) [E-26/110.123/2014]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPqNational Council for
   Scientific and Technological Development (CNPq) [401220/2016-8];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro -
   FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); 'Programa Nacional de Pos-Doutorado
   (PNPD)'/CAPES-Brazil
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro - FAPERJ (grant number E-26/110.123/2014) and the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq
   (Grant Number 401220/2016-8). S.S.D.A. was supported by funding from
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and
   Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJ. E.D.
   was supported by a Postdoctoral fellowship from the 'Programa Nacional
   de Pos-Doutorado (PNPD)'/CAPES-Brazil.
CR Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200
   Bailey JR, 2008, J VIROL, V82, P7395, DOI 10.1128/JVI.00800-08
   Bello G, 2005, J GEN VIROL, V86, P355, DOI 10.1099/vir.0.80410-0
   Bello G, 2004, J GEN VIROL, V85, P399, DOI 10.1099/vir.0.19365-0
   Blankson JN, 2007, J VIROL, V81, P2508, DOI 10.1128/JVI.02165-06
   Boritz EA, 2016, CELL, V166, P1004, DOI 10.1016/j.cell.2016.06.039
   Braibant M, 2010, VIROLOGY, V405, P81, DOI 10.1016/j.virol.2010.05.026
   Brener J, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0390-9
   Casado C, 2007, J INFECT DIS, V196, P895, DOI 10.1086/520885
   Chaillon A, 2013, J VIROL, V87, P12737, DOI 10.1128/JVI.02260-13
   Clerc O, 2010, J CLIN VIROL, V47, P376, DOI 10.1016/j.jcv.2010.01.013
   Cornelissen M, 2016, AIDS RES HUM RETROV, V32, P1135, DOI 10.1089/aid.2015.0324
   Cornelissen M, 2012, CLIN INFECT DIS, V54, P539, DOI 10.1093/cid/cir849
   de Azevedo SSD, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0354-5
   Gerhardt M, 2005, J VIROL, V79, P8249, DOI 10.1128/JVI.79.13.8249-8261.2005
   Gottlieb GS, 2007, CLIN INFECT DIS, V45, P501, DOI 10.1086/520024
   Gottlieb GS, 2004, LANCET, V363, P619, DOI 10.1016/S0140-6736(04)15596-7
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Jost S, 2002, NEW ENGL J MED, V347, P731, DOI 10.1056/NEJMoa020263
   Jurriaans S, 2008, JAIDS-J ACQ IMM DEF, V47, P69, DOI 10.1097/QAI.0b013e3181582d6f
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Koelsch KK, 2003, AIDS, V17, pF11, DOI 10.1097/00002030-200305020-00001
   Koning FA, 2013, AIDS RES HUM RETROV, V29, P963, DOI [10.1089/aid.2013.0009, 10.1089/AID.2013.0009]
   Kozaczynska K, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-59
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lamine A, 2007, AIDS, V21, P1043, DOI 10.1097/QAD.0b013e3280d5a7ac
   Lengauer T, 2007, NAT BIOTECHNOL, V25, P1407, DOI 10.1038/nbt1371
   Leye N, 2013, INFECT GENET EVOL, V20, P206, DOI 10.1016/j.meegid.2013.09.002
   Luan H, 2017, JAIDS-J ACQ IMM DEF, V75, P480, DOI 10.1097/QAI.0000000000001420
   McCutchan FE, 2005, J VIROL, V79, P11693, DOI 10.1128/JVI.79.18.11693-11704.2005
   Okulicz JF, 2009, J INFECT DIS, V200, P1714, DOI 10.1086/646609
   Pacold ME, 2012, AIDS, V26, P157, DOI 10.1097/QAD.0b013e32834dcd26
   Pernas M, 2006, JAIDS-J ACQ IMM DEF, V42, P12, DOI 10.1097/01.qai.0000214810.65292.73
   Pernas M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134054
   Pernas M, 2013, JAIDS-J ACQ IMM DEF, V64, P225, DOI 10.1097/QAI.0b013e31829bdc85
   Pernas M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031928
   Philpott SM, 2003, CURR HIV RES, V1, P217, DOI 10.2174/1570162033485357
   Piantadosi A, 2007, PLOS PATHOG, V3, P1745, DOI 10.1371/journal.ppat.0030177
   Rachinger A, 2008, CLIN INFECT DIS, V47, pE86, DOI 10.1086/592978
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Ronen K, 2014, AIDS, V28, P2281, DOI 10.1097/QAD.0000000000000422
   Rose PP, 2000, BIOINFORMATICS, V16, P400, DOI 10.1093/bioinformatics/16.4.400
   Smith D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001473
   Smith DM, 2005, J INFECT DIS, V192, P438, DOI 10.1086/431682
   de Oliveira ACS, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-223
   Ssemwanga D, 2012, AIDS RES HUM RETROV, V28, P357, DOI [10.1089/aid.2011.0024, 10.1089/AID.2011.0024]
   Streeck H, 2008, J EXP MED, V205, P1789, DOI 10.1084/jem.20080281
   Takehisa J, 1998, VIROLOGY, V245, P1, DOI 10.1006/viro.1998.9141
   Templeton AR, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-54
   Topfer A, 2013, J COMPUT BIOL, V20, P113, DOI 10.1089/cmb.2012.0232
NR 50
TC 2
Z9 2
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAR 1
PY 2019
VL 33
IS 3
BP 399
EP 410
DI 10.1097/QAD.0000000000002090
PG 12
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA IQ3YZ
UT WOS:000480689200008
PM 30531316
DA 2020-11-24
ER

PT J
AU Leite, TF
   Delatorre, E
   Cortes, FH
   Ferreira, ACG
   Cardoso, SW
   Grinsztejn, B
   de Andrade, MM
   Veloso, VG
   Morgado, MG
   Guimaraes, ML
AF Leite, Thaysse Ferreira
   Delatorre, Edson
   Cortes, Fernanda Heloise
   Garcia Ferreira, Ana Cristina
   Cardoso, Sandra Wagner
   Grinsztejn, Beatriz
   de Andrade, Michelle Morata
   Veloso, Valdilea Goncalves
   Morgado, Mariza Goncalves
   Guimaraes, Monick Lindenmeyer
TI Reduction of HIV-1 Reservoir Size and Diversity After 1 Year of cART
   Among Brazilian Individuals Starting Treatment During Early Stages of
   Acute Infection
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE HIV-1; reservoir; diversity; early cART; acute infection
ID ANTIRETROVIRAL THERAPY; DRUG-RESISTANCE; VIRUS; DNA; SEROCONVERSION;
   REPLICATION; PERSISTENCE; DYNAMICS; MAINTAINS; GENETICS
AB The aim of early combined antiretroviral therapy (cART) of HIV is to limit the seeding of the viral reservoir during the initial phase of infection and, consequently, decrease intrahost viral diversity. Here, we assessed the effect of early cART on size and complexity of the proviral reservoir. Peripheral blood mononuclear cell (PBMC) and plasma samples were obtained from ten HIV-infected Brazilian individuals diagnosed at the acute phase of infection, before (PREART) and 12 months (M12(ART)) after suppressive cART. HIV proviral reservoir size was determined by quantitative real-time PCR; intrahost viral diversity of the env C2-V3 region was assessed by single genome amplification or next-generation sequencing in PBMC and plasma, respectively. Mean nucleotide diversity (pi) and normalized Shannon entropy (H-SN) were used to infer the complexity of the viral population. Compared to PREART, M12(ART) saw an immunological recovery with a gain of similar to 200 CD4(+) T cells (P = 0.008) and a normalization of the CD4/CD8 ratio [1.0 (IQR: 0.88-1.18), P = 0.016], as well as a significant decrease in HIV-1 RNA (similar to 4 log, P = 0.004) and DNA (similar to 1 log, P = 0.002) levels. The median time to achieve viral suppression was 3 months (IQR: 2.8-5.8 months). The high intermixing between sequences from both visits suggests that the HIV-1 DNA reservoir remained remarkably stable under cART. After 1 year of cART, there was a minor reduction in proviral pi (Pre(ART) = 0.20 vs. M12(ART) = 0.10; P = 0.156) but a significant decrease in H-SN (Pre(ART) = 0.41 vs. M12(ART) = 0.25; P = 0.019). We found no correlation between pi or H-SN at Pre(ART) and the rate of HIV DNA decay, T CD4(+) counts, or CD4/CD8 ratio at M12(ART). Based on a small cohort of Brazilian infected individuals under early cART and analyses of the env region, 1 year of follow-up suggested a reservoir size reduction, allowed a significant decrease of HIV-1 complexity, and achieved immunological restoration regardless of the initial HIV-1 plasma viral load, CD4(+) T cell counts, or HIV-1 subtype. However, further studies in the Brazilian setting aiming a longer follow-up and larger cohort are required in this field.
C1 [Leite, Thaysse Ferreira; Delatorre, Edson; Cortes, Fernanda Heloise; Morgado, Mariza Goncalves; Guimaraes, Monick Lindenmeyer] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Garcia Ferreira, Ana Cristina; Cardoso, Sandra Wagner; Grinsztejn, Beatriz; de Andrade, Michelle Morata; Veloso, Valdilea Goncalves] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin DST & AIDS, Rio De Janeiro, Brazil.
   [Delatorre, Edson] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Genet Mol Microrganismos, Rio De Janeiro, Brazil.
RP Delatorre, E (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.; Delatorre, E (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Genet Mol Microrganismos, Rio De Janeiro, Brazil.
EM delatorre.ioc@gmail.com
RI Cortes, Fernanda/AAF-9254-2020; Delatorre, Edson/J-8330-2015
OI Delatorre, Edson/0000-0002-5746-0820
FU Postdoctoral fellowship from the "Programa Nacional de Pos-Doutorado
   (PNPD)" by the Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior-Brazil [001]; CNPq FellowshipNational Council for Scientific
   and Technological Development (CNPq); CAPES Ph.D. fellowship
FX ED was financed by a Postdoctoral fellowship from the "Programa Nacional
   de Pos-Doutorado (PNPD)" by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior-Brazil (CAPES) - Finance Code 001. MGandMMwere
   recipients of a CNPq Fellowship, and TL was funded by a CAPES Ph.D.
   fellowship.
CR Abrahams MR, 2009, J VIROL, V83, P3556, DOI 10.1128/JVI.02132-08
   Ananworanich J, 2016, EBIOMEDICINE, V11, P68, DOI 10.1016/j.ebiom.2016.07.024
   Archin NM, 2012, P NATL ACAD SCI USA, V109, P9523, DOI 10.1073/pnas.1120248109
   Avettand-Fenoel V, 2016, CLIN MICROBIOL REV, V29, P859, DOI 10.1128/CMR.00015-16
   Bar KJ, 2010, J VIROL, V84, P6241, DOI 10.1128/JVI.00077-10
   Batorsky R, 2011, P NATL ACAD SCI USA, V108, P5661, DOI 10.1073/pnas.1102036108
   Bello G, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/154945
   Brodin J, 2016, ELIFE, V5, DOI 10.7554/eLife.18889
   Buzon MJ, 2014, J VIROL, V88, P10056, DOI 10.1128/JVI.01046-14
   Buzon MJ, 2010, NAT MED, V16, P460, DOI 10.1038/nm.2111
   Carlson JM, 2014, SCIENCE, V345, DOI 10.1126/science.1254031
   Chalmet K, 2012, J INFECT DIS, V205, P174, DOI 10.1093/infdis/jir714
   Cheret A, 2015, LANCET INFECT DIS, V15, P387, DOI 10.1016/S1473-3099(15)70021-6
   Chomont N, 2011, CURR OPIN HIV AIDS, V6, P30, DOI 10.1097/COH.0b013e3283413775
   Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972
   Chun TW, 2002, J INFECT DIS, V185, P1672, DOI 10.1086/340521
   Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193
   Colby DJ, 2018, NAT MED, V24, P923, DOI 10.1038/s41591-018-0026-6
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   de Azevedo SSD, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0354-5
   Delwart E, 2002, AIDS, V16, P189, DOI 10.1097/00002030-200201250-00007
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Ferreira ACG, 2017, BRAZ J INFECT DIS, V21, P396, DOI 10.1016/j.bjid.2017.03.013
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005
   Ghosn J, 2018, LANCET, V392, P685, DOI 10.1016/S0140-6736(18)31311-4
   Gottlieb GS, 2008, J INFECT DIS, V197, P1011, DOI 10.1086/529206
   Gregori J, 2016, VIROLOGY, V493, P227, DOI 10.1016/j.virol.2016.03.017
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hayashida T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177033
   Hecht FM, 2006, J INFECT DIS, V194, P725, DOI 10.1086/506616
   Hocqueloux L, 2013, J ANTIMICROB CHEMOTH, V68, P1169, DOI 10.1093/jac/dks533
   Hoenigl M, 2016, CLIN INFECT DIS, V63, P425, DOI 10.1093/cid/ciw293
   Josefsson L, 2013, P NATL ACAD SCI USA, V110, pE4987, DOI 10.1073/pnas.1308313110
   Kearney M, 2009, J VIROL, V83, P2715, DOI 10.1128/JVI.01960-08
   Kearney MF, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004010
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Kiselinova M, 2015, J ANTIMICROB CHEMOTH, V70, P3311, DOI 10.1093/jac/dkv250
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lengauer T, 2007, NAT BIOTECHNOL, V25, P1407, DOI 10.1038/nbt1371
   Li H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000890
   Lorenzo-Redondo R, 2016, NATURE, V530, P51, DOI 10.1038/nature16933
   Lori F, 1999, J INFECT DIS, V180, P1827, DOI 10.1086/315113
   Marz M, 2014, BIOINFORMATICS, V30, P1793, DOI 10.1093/bioinformatics/btu105
   Ngo-Giang-Huong N, 2001, AIDS, V15, P665, DOI 10.1097/00002030-200104130-00001
   Novitsky V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016714
   Oksanen J, 2017, VEGAN COMMUNITY ECOL
   Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005
   Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105
   Piketty C, 2010, J MED VIROL, V82, P1819, DOI 10.1002/jmv.21907
   Pilcher CD, 2004, J CLIN INVEST, V113, P937, DOI [10.1172/JCI21540, 10.1172/JCI200421540]
   Raymond S, 2010, AIDS, V24, P2305, DOI 10.1097/QAD.0b013e32833e50bb
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Rieder P, 2011, CLIN INFECT DIS, V53, P1271, DOI 10.1093/cid/cir725
   Rose PP, 2000, BIOINFORMATICS, V16, P400, DOI 10.1093/bioinformatics/16.4.400
   Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211
   Schiffer V, 2004, HIV MED, V5, P326, DOI 10.1111/j.1468-1293.2004.00231.x
   Sheppard HW, 2002, J ACQ IMMUN DEF SYND, V29, P307, DOI 10.1097/00126334-200203010-00013
   Strain MC, 2005, J INFECT DIS, V191, P1410, DOI 10.1086/428777
   Van Zyl GU, 2017, J CLIN INVEST, V127, P3827, DOI [10.1172/JCI94582, 10.1172/jci94582]
   von Stockenstrom S, 2015, J INFECT DIS, V212, P596, DOI 10.1093/infdis/jiv092
   Wang ND, 2017, J MED VIROL, V89, P982, DOI 10.1002/jmv.24723
   Yerly S, 2000, AIDS, V14, P243, DOI 10.1097/00002030-200002180-00006
   Yukl SA, 2010, AIDS, V24, P2450, DOI 10.1097/QAD.0b013e32833ef7bb
NR 64
TC 3
Z9 3
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD FEB 11
PY 2019
VL 10
AR 145
DI 10.3389/fmicb.2019.00145
PG 12
WC Microbiology
SC Microbiology
GA HK8JL
UT WOS:000458235600001
PM 30804915
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Tan, DHS
   Raboud, JM
   Szadkowski, L
   Grinsztejn, B
   Madruga, JV
   Figueroa, MI
   Cahn, P
   Barton, SE
   Clarke, A
   Fox, J
   Zubyk, W
   Walmsley, SL
   Brunetta, J
   Cameron, W
   Cohen, J
   Conway, B
   Fortin, C
   Fraser, C
   Kilby, D
   Klein, M
   Logue, K
   Pick, N
   Rachlis, A
   Romanowski, B
   Smaill, F
   Trottier, S
   Winston, A
AF Tan, Darrell H. S.
   Raboud, Janet M.
   Szadkowski, Leah
   Grinsztejn, Beatriz
   Madruga, Jose Valdez
   Figueroa, Maria Ines
   Cahn, Pedro
   Barton, Simon E.
   Clarke, Amanda
   Fox, Julie
   Zubyk, Wendy
   Walmsley, Sharon L.
   Brunetta, Jason
   Cameron, William
   Cohen, Jeff
   Conway, Brian
   Fortin, Claude
   Fraser, Chris
   Kilby, Don
   Klein, Marina
   Logue, Ken
   Pick, Neora
   Rachlis, Anita
   Romanowski, Barbara
   Smaill, Fiona
   Trottier, Sylvie
   Winston, Alan
CA VALIDATE Study Grp
TI Effect of valaciclovir on CD4 count decline in untreated HIV: an
   international randomized controlled trial
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID SIMPLEX-VIRUS TYPE-2; SELF-REPORTED ADHERENCE; VIRAL LOAD; GENITAL
   HERPES; DOUBLE-BLIND; INFECTION; VALACYCLOVIR; ACYCLOVIR; HSV-2; RNA
AB Objectives: To determine the impact of valaciclovir on HIV disease progression in treatment-naive HIV-positive adults.
   Methods: In this fully blind, multicentre, 1:1 randomized placebo-controlled trial, treatment-naive HIV-1-positive adults with CD4 counts 400-900 cells/mm' and not meeting contemporaneous recommendations for combination ART (cART) were randomized to valaciclovir 500 mg or placebo twice daily, and followed quarterly until having two consecutive CD4 counts <= 350 cells/mm(3) or initiating cART for any reason. The primary analysis compared the rate of CD4 count decline by study arm after adjusting for baseline CD4 count and viral load (VL). Secondary analyses compared the rate of [D4 percentage decline, HIV VL, herpes simplex virus (HSV) recurrences and drug-related adverse events. The trial closed after release of the START trial results in August 2015.
   Results: We enrolled 198 participants in Canada, Brazil, Argentina and the UK. Median (IQR) age was 35 (3043) years. Baseline CD4 count was 592 (491-694) cells/mm(3) and VL was 4.04 (3.5-4.5) log(10) copies/mL. Over 276 person-years of follow-up, CD4 counts declined by 49 cells/mm(3)/year in the valaciclovir arm versus 58 cells/mm(3)/yea r in the placebo arm (P = 0.65). No differences were seen in the rate of change in CD4 percentage (-1.2 /0/year versus 1.7/0/year, P = 0.34). VL was 0.27 loglo copies/mL lower in valaciclovir participants overall (P<0,001). Placebo participants had more HSV recurrences (62 versus 21/100 person-years, P < 0.0001) but similar rates of grade >= 2 drug-related adverse events.
   Conclusions: Unlike prior trials using aciclovir, we found that valaciclovir did not slow CD4 count decline in cARTuntreated adults, although power was limited due to premature study discontinuation. Valaciclovir modestly lowered HIV VL.
C1 [Tan, Darrell H. S.] St Michaels Hosp, Div Infect Dis, Toronto, ON, Canada.
   [Tan, Darrell H. S.] St Michaels Hosp, Ctr Urban Hlth Solut, Toronto, ON, Canada.
   [Tan, Darrell H. S.; Walmsley, Sharon L.] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Tan, Darrell H. S.; Walmsley, Sharon L.] Univ Hlth Network, Div Infect Dis, Toronto, ON, Canada.
   [Raboud, Janet M.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Raboud, Janet M.; Walmsley, Sharon L.] Toronto Gen Res Inst, Toronto, ON, Canada.
   [Szadkowski, Leah] Univ Hlth Network, Biostat Res Unit, Toronto, ON, Canada.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, Rio De Janeiro, Brazil.
   [Madruga, Jose Valdez] Ctr Referencia & Treinamento DST AIDS SP, Sao Paulo, Brazil.
   [Figueroa, Maria Ines; Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Barton, Simon E.] Chelsea & Westminster Hosp, London, England.
   [Clarke, Amanda] Brighton & Sussex Univ Hosp NHS Trust, Brighton, E Sussex, England.
   [Fox, Julie] Guys & St Thomas NHS Fdn Trust, London, England.
   [Zubyk, Wendy; Walmsley, Sharon L.] CIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
   [Brunetta, Jason] Maple Leaf Med Clin, Toronto, ON, Canada.
   [Cameron, William] Ottawa Hosp, Ottawa, ON, Canada.
   [Cohen, Jeff] Windsor Reg Hosp, Windsor, ON, Canada.
   [Conway, Brian] Downtown ID Clin, Vancouver, BC, Canada.
   [Fortin, Claude] Ctr Hosp Univ Montreal, Montreal, PQ, Canada.
   [Fraser, Chris] Cool Aid Community Hlth Ctr, Victoria, BC, Canada.
   [Kilby, Don] Univ Ottawa Hlth Serv, Ottawa, ON, Canada.
   [Klein, Marina] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
   [Logue, Ken] St Clair Med Associates, Toronto, ON, Canada.
   [Pick, Neora] Oak Tree Clin, Vancouver, BC, Canada.
   [Rachlis, Anita] Sunnybrook Med Ctr, Toronto, ON, Canada.
   [Romanowski, Barbara] Univ Alberta, Edmonton, AB, Canada.
   [Smaill, Fiona] Hamilton Hlth Sci Ctr, Hamilton, ON, Canada.
   [Trottier, Sylvie] Ctr Hosp Univ Quebec, Quebec City, PQ, Canada.
   [Winston, Alan] St Marys Hosp, London, England.
RP Tan, DHS (corresponding author), 30 Bond St,4CC Room 4-179, Toronto, ON M5B 1W8, Canada.
EM darrell.tan@gmail.com
RI Cameron, Bill/E-9180-2010
OI Cameron, Bill/0000-0002-0090-3539; Walmsley, Sharon/0000-0002-3959-5692
FU Canadian Institutes of Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR) [MCT 94245]; CIHR Canadian HIV Trials
   NetworkCanadian Institutes of Health Research (CIHR); Canadian
   Institutes of Health ResearchCanadian Institutes of Health Research
   (CIHR); Ontario HIV Treatment Network [NEB 136629]
FX This work was supported by a grant from the Canadian Institutes of
   Health Research (CIHR) (grant number MCT 94245) and by the CIHR Canadian
   HIV Trials Network. D. H. S. T. is supported by a New Investigator Award
   from the Canadian Institutes of Health Research and Ontario HIV
   Treatment Network (grant number NEB 136629). J. M. R. and S. L. W.
   received salary support from the Ontario HIV Treatment Network. The
   funding agencies had no role in the design of the trial or writing of
   this manuscript.
CR Ashley-Morrow R, 2004, CLIN MICROBIOL INFEC, V10, P530, DOI 10.1111/j.1469-0691.2004.00836.x
   BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004
   Benedetti JK, 1999, ANN INTERN MED, V131, P14, DOI 10.7326/0003-4819-131-1-199907060-00004
   Biraro S, 2011, SEX TRANSM DIS, V38, P140, DOI 10.1097/OLQ.0b013e3181f0bafb
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891
   Chu K, 2006, INT J STD AIDS, V17, P681, DOI 10.1258/095646206780071108
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cowan FF, 2006, AIDS, V20, P261, DOI 10.1097/01.aids.0000198086.39831.4a
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Diggle P. J., 1994, ANAL LONGITUDINAL DA
   Gray RH, 1999, AIDS, V13, P2113, DOI 10.1097/00002030-199910220-00015
   Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555
   Kasiari M, 2008, J CHROMATOGR B, V864, P78, DOI 10.1016/j.jchromb.2008.01.046
   Le T, 2013, NEW ENGL J MED, V368, P218, DOI 10.1056/NEJMoa1110187
   Lingappa JR, 2010, LANCET, V375, P824, DOI 10.1016/S0140-6736(09)62038-9
   Lisco A, 2008, CELL HOST MICROBE, V4, P260, DOI 10.1016/j.chom.2008.07.008
   Ludema C, 2011, AIDS, V25, P1265, DOI 10.1097/QAD.0b013e328347fa37
   MacDougall C, 2004, J ANTIMICROB CHEMOTH, V53, P899, DOI 10.1093/jac/dkh244
   McMahon MA, 2008, J BIOL CHEM, V283, P31289, DOI 10.1074/jbc.C800188200
   Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003
   Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297
   Nagot N, 2007, NEW ENGL J MED, V356, P790, DOI 10.1056/NEJMoa062607
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   Panel on Antiretroviral Guidelines for Adults and Adolescents, 2009, GUIDELINES USE ANTIR
   PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402
   Ramaswamy M, 2006, SEX TRANSM DIS, V33, P96, DOI 10.1097/01.olq.0000187211.61052.c7
   Reynolds NR, 2007, JAIDS-J ACQ IMM DEF, V46, P402, DOI 10.1097/QAI.0b013e318158a44f
   Reynolds SJ, 2012, LANCET INFECT DIS, V12, P441, DOI 10.1016/S1473-3099(12)70037-3
   Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498
   Romanowski B, 2009, SEX TRANSM DIS, V36, P165, DOI 10.1097/OLQ.0b013e31818d3fb6
   Santos FC, 2006, MEM I OSWALDO CRUZ, V101, P315, DOI 10.1590/S0074-02762006000300016
   Schacker T, 2002, J INFECT DIS, V186, P1718, DOI 10.1086/345771
   Stebbing Justin, 2003, AIDS Rev, V5, P205
   Strick LB, 2006, CLIN INFECT DIS, V43, P347, DOI 10.1086/505496
   Tan DHS, 2015, AIDS RES HUM RETROV, V31, P276, DOI [10.1089/aid.2014.0183, 10.1089/AID.2014.0183]
   Tan DHS, 2013, CLIN INFECT DIS, V57, P448, DOI 10.1093/cid/cit208
   Tan DHS, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-113
   Tan DHS, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-502
   The INSIGHT START Study Group, 2015, NEW ENGL J MED, V20, P20
   Tobian AAR, 2013, J INFECT DIS, V208, P839, DOI 10.1093/infdis/jit252
   Vanpouille C, 2015, CLIN INFECT DIS, V60, P1708, DOI 10.1093/cid/civ172
   VICENZI E, 1994, J LEUKOCYTE BIOL, V56, P328
   Workowski Kimberly A., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Wu AW, 1997, QUAL LIFE RES, V6, P481, DOI 10.1023/A:1018451930750
   Yi TJ, 2013, CLIN INFECT DIS, V57, P1331, DOI 10.1093/cid/cit539
   Zuckerman RA, 2007, J INFECT DIS, V196, P1500, DOI 10.1086/522523
NR 47
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD FEB
PY 2019
VL 74
IS 2
BP 480
EP 488
DI 10.1093/jac/dky433
PG 9
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA HN8UW
UT WOS:000460473100027
PM 30376108
OA Other Gold, Green Published
DA 2020-11-24
ER

PT J
AU Goncalves, J
   Silva, MCA
   Roma, EH
   Grinsztejn, B
   de Lemos, AD
   Moreira, NG
   Cruz, AM
   de Almeida, CF
   Quintana, MDB
   Bonecini-Almeida, MG
   de Brito, PD
AF Goncalves, Juliana
   Amorim Silva, Maria Clara
   Roma, Eric Henrique
   Grinsztejn, Beatriz
   de Lemos, Alberto dos Santos
   Moreira, Nathalia Gorni
   Cruz, Adele Moura
   de Almeida, Cristiane Fonseca
   Borges Quintana, Marcel de Souza
   Bonecini-Almeida, Maria Gloria
   de Brito, Patricia Dias
TI Iron intake is positively associated with viral load in antiretroviral
   naive Brazilian men living with HIV
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE HIV; iron intake; nutrition; ART naive
ID FOOD FREQUENCY QUESTIONNAIRE; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION;
   ANEMIA; SUPPLEMENTATION; VALIDATION; DEFICIENCY; HEPCIDIN; ADULTS
AB BACKGROUND Iron homeostasis contribute for the human immunodeficiency virus (HIV) pathogenesis.
   OBJECTIVES We assessed the iron intake pattern in antiretroviral naive Brazilian men living with HIV correlating with clinical and nutritional parameters.
   METHODS The iron consumption mean was estimated according to a food frequency questionnaire (FFQ), and a 3-day food record (3dFR) submitted to the patients. HIV viral load, CD4(+) T cell counts, scrum iron, haematological and anthropometrics parameters were recorded.
   FINDINGS Fifty-one HIV-infected adult men naive for antiretroviral therapy (ART) were enrolled. The mean age of participants was 35 (SEM +/- 1.28) years old, with mean time of HIV-1 infection of 1.78 (0-16.36, min-max) years. Majority (41.18%) had complete secondary, and 21.57% had tertiary educational level. The income was around 1x (54.90%) to 2x (41.18%) minimum wage. Fifty-four percent showed normal weight, while 40% were overweight. The patients showed normal mean values of haematological parameters, and mean serum iron was 14.40 mu M (SEM +/- 0.83). The FFQ showed moderate correlation with the 3dFR (p = 0.5436, p = 0.0009), and the mean values of iron intake were 10.55(+/- 0.92) mg/day, recorded by FFQ, and 15.75(+/- 1.51) mg/day, recorded by 3dFR. The iron intake, recorded by FFQ, negatively correlated with serum iron (p = -0.3448, p = 0.0132), and did not have influence in the CD4(+) T cell counts [e.B 0.99 (0.97-1.01, 95% confidence interval (CI), p = 0.2]. However, the iron intake showed a positive effect in HIV viral load [e.B 1.12 (1.02-1.25, 95%CI), p < 0.01].
   MAIN CONCLUSIONS This study draws attention for the importance of iron intake nutritional counseling in people living with HIV. However, more studies are required to clarify the association between high iron intake and HIV infection and outcome.
C1 [Goncalves, Juliana; Amorim Silva, Maria Clara; Moreira, Nathalia Gorni; Cruz, Adele Moura; de Almeida, Cristiane Fonseca; de Brito, Patricia Dias] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Serv Nutr, Rio De Janeiro, RJ, Brazil.
   [Amorim Silva, Maria Clara; Roma, Eric Henrique; Bonecini-Almeida, Maria Gloria] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Lab Imunol & Imunogenet Doencas Infeccios, Rio De Janeiro, RJ, Brazil.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin DST & AIDS, Rio De Janeiro, RJ, Brazil.
   [de Lemos, Alberto dos Santos] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Ctr Hosp, Rio De Janeiro, RJ, Brazil.
   [Borges Quintana, Marcel de Souza] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Plataforma Pesquisa Clin, Rio De Janeiro, RJ, Brazil.
RP Roma, EH (corresponding author), Fundacao Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Lab Imunol & Imunogenet Doencas Infeccios, Rio De Janeiro, RJ, Brazil.
EM eric.roma@ini.fiocruz.br
RI de Lemos, Alberto dos Santos/M-4246-2013; Roma, Eric/E-2752-2014
OI de Lemos, Alberto dos Santos/0000-0003-0138-6577; Roma,
   Eric/0000-0001-5265-5277; Bonecini-Almeida, Maria da
   Gloria/0000-0001-6030-5576
FU Instituto Nacional de Infectologia Evandro Chagas (FIOCRUZ); CAPESCAPES;
   FIOCRUZ-CAPESCAPES
FX Instituto Nacional de Infectologia Evandro Chagas (FIOCRUZ).; MCAS
   received a master fellowship from CAPES; JLG received a post-doc
   fellowship from FIOCRUZ-CAPES.
CR Armitage AE, 2014, P NATL ACAD SCI USA, V111, P12187, DOI 10.1073/pnas.1402351111
   Banjoko SO, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-26
   Belperio PS, 2004, AM J MED, V116, P27, DOI 10.1016/j.amjmed.2003.12.010
   Chang HC, 2015, AIDS RES HUM RETROV, V31, P305, DOI 10.1089/aid.2014.0169
   Debebe Z, 2011, MOL PHARMACOL, V79, P185, DOI 10.1124/mol.110.069062
   Denic S, 2007, NUTRITION, V23, P603, DOI 10.1016/j.nut.2007.05.002
   Drakesmith H, 2008, NAT REV MICROBIOL, V6, P541, DOI 10.1038/nrmicro1930
   Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577
   Esan MO, 2012, T ROY SOC TROP MED H, V106, P579, DOI 10.1016/j.trstmh.2012.07.002
   Fields-Gardner C, 2010, J AM DIET ASSOC, V110, P1105, DOI 10.1016/j.jada.2010.05.020
   James P, 2015, BRIT J NUTR, V114, P387, DOI 10.1017/S0007114515001920
   Kent K, 2018, NUTR DIET, V75, P106, DOI 10.1111/1747-0080.12371
   Obirikorang C, 2016, AIDS RES TREAT, V2016, DOI 10.1155/2016/1623094
   Olsen A, 2004, JAIDS-J ACQ IMM DEF, V36, P637, DOI 10.1097/00126334-200405010-00013
   Perreault M, 2016, CAN J DIET PRACT RES, V77, P133, DOI 10.3148/cjdpr-2016-002
   Quiros-Roldan E, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1358-6
   Ribeiro SR, 2014, ANTIVIR THER, V19, P387, DOI 10.3851/IMP2716
   Salhi Y, 1998, J ACQ IMMUN DEF SYND, V18, P473, DOI 10.1097/00042560-199808150-00009
   Savarino A, 1999, CELL BIOCHEM FUNCT, V17, P279, DOI 10.1002/(SICI)1099-0844(199912)17:4<279::AID-CBF833>3.0.CO;2-J
   Semba RD, 2007, INT J TUBERC LUNG D, V11, P854
   Semba RD, 2001, J INVEST MED, V49, P225, DOI 10.2310/6650.2001.33967
   Semba RD, 2007, JAIDS-J ACQ IMM DEF, V45, P298
   Shah KK, 2019, NUTR RES
   Sichieri R, 1998, NUTR RES, V18, P1649, DOI 10.1016/S0271-5317(98)00151-1
   THOMPSON FE, 1994, J NUTR, V124, pS2245, DOI 10.1093/jn/124.suppl_11.2245s
   Traore HN, 2004, J CLIN VIROL, V31, pS92, DOI 10.1016/j.jcv.2004.09.011
   World Health Organization, 2000, OB PREV MAN GLOB EP
   Yang YJ, 2010, NUTR RES PRACT, V4, P142, DOI 10.4162/nrp.2010.4.2.142
NR 28
TC 0
Z9 0
U1 0
U2 0
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2019
VL 114
AR e190350
DI 10.1590/0074-02760190350
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA KJ8RL
UT WOS:000512323300001
PM 32022169
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Castilho, JL
   Escuder, MM
   Veloso, V
   Gomes, JO
   Jayathilake, K
   Ribeiro, S
   Souza, RA
   Ikeda, ML
   de Alencastro, PR
   Tupinanbas, U
   Brites, C
   McGowan, CC
   Grangeiro, A
   Grinsztejn, B
AF Castilho, Jessica L.
   Escuder, Maria M.
   Veloso, Valdilea
   Gomes, Jackeline O.
   Jayathilake, Karu
   Ribeiro, Sayonara
   Souza, Rosa A.
   Ikeda, Maria L.
   de Alencastro, Paulo R.
   Tupinanbas, Unai
   Brites, Carlos
   McGowan, Catherine C.
   Grangeiro, Alexandre
   Grinsztejn, Beatriz
TI Trends and predictors of non-communicable disease multimorbidity among
   adults living with HIV and receiving antiretroviral therapy in Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE HIV; ART; multimorbidity; non-communicable diseases; ageing; Brazil
ID T-CELL-ACTIVATION; NATIONAL-HEALTH SURVEY; CO-MORBIDITIES; AGE;
   COMORBIDITIES; POPULATION; ERA; INFLAMMATION; INDIVIDUALS; PREVALENCE
AB IntroductionPeople living with HIV (PLHIV) on antiretroviral therapy (ART) experience high rates of non-communicable diseases (NCDs). These co-morbidities often accumulate and older adults may suffer from multimorbidity. Multimorbidity has been associated with loss of quality of life, polypharmacy, and increased risk of frailty and mortality. Little is known of the trends or predictors NCD multimorbidity in PLHIV in low- and middle-income countries.
   MethodsWe examined NCD multimorbidity in adult PLHIV initiating ART between 2003 and 2014 using a multi-site, observational cohort in Brazil. NCDs included cardiovascular artery disease, hyperlipidemia (HLD), diabetes, chronic kidney disease, cirrhosis, osteoporosis, osteonecrosis, venous thromboembolism and non-AIDS-defining cancers. Multimorbidity was defined as the incident accumulation of two or more unique NCDs. We used Poisson regression to examine trends and Cox proportional hazard models to examine predictors of multimorbidity.
   ResultsOf the 6206 adults, 332 (5%) developed multimorbidity during the study period. Parallel to the ageing of the cohort, the prevalence of multimorbidity rose from 3% to 11% during the study period. Older age, female sex (adjusted hazard ratio (aHR)=1.30 (95% confidence interval (CI) 1.03 to 1.65)) and low CD4 nadir (<100 vs. 200cells/mm(3) aHR=1.52 (95% CI: 1.15 to 2.01)) at cohort entry were significantly associated with increased risk of multimorbidity. Among patients with incident multimorbidity, the most common NCDs were HLD and diabetes; however, osteoporosis was also frequent in women (16 vs. 35% of men and women with multimorbidity respectively).
   ConclusionsAmong adult PLHIV in Brazil, NCD multimorbidity increased from 2003 to 2014. Females and adults with low CD4 nadir were at increased risk in adjusted analyses. Further studies examining prevention, screening and management of NCDs in PLHIV in low- and middle-income countries are needed.
C1 [Castilho, Jessica L.; Jayathilake, Karu; McGowan, Catherine C.] Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN USA.
   [Escuder, Maria M.; Gomes, Jackeline O.] Inst Hlth, Sao Paulo State Dept Hlth, Sao Paulo, Brazil.
   [Veloso, Valdilea; Ribeiro, Sayonara; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Natl Inst Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Souza, Rosa A.] AIDS Reference & Training Ctr, Sao Paulo State Dept Hlth, Sao Paulo, Brazil.
   [Ikeda, Maria L.] Univ Vale Rio dos Sinos, Sch Hlth, Porto Alegre, RS, Brazil.
   [de Alencastro, Paulo R.] Care & Treatment Clin Partenon Sanat, Rio Grande Do Sul State Dept Hlth, Porto Alegre, RS, Brazil.
   [Tupinanbas, Unai] Univ Fed Minas Gerais, Med Sch, Belo Horizonte, MG, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Edgar Santos Univ Hosp Complex, Salvador, BA, Brazil.
   [Grangeiro, Alexandre] Univ Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil.
RP Castilho, JL (corresponding author), Vanderbilt Univ, Med Ctr, A2200 Med Ctr North,1161 21st Ave South, Nashville, TN 37232 USA.
EM jessica.castilho@vanderbilt.edu
RI Brites, Carlos/D-1353-2013
OI Brites, Carlos/0000-0002-4673-6991
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U01AI69923,
   K23AI1120875, P30AI110527]; Brazilian National Council for Scientific &
   Technological Development; Brazilian National Ministry of Health; Pan
   American Health Organization; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI069923, U01AI069923,
   U01AI069923, U01AI069923] Funding Source: NIH RePORTER
FX National Institutes of Health: U01AI69923 (J.L.C., M.M.E., V.G.V.,
   J.O.G., K.J., C.M., A.G., B.G.), K23AI1120875 (J.L.C.), P30AI110527
   (J.L.C.). Brazilian National Council for Scientific & Technological
   Development. Brazilian National Ministry of Health. Pan American Health
   Organization.
CR Balderson BH, 2013, AIDS CARE, V25, P451, DOI 10.1080/09540121.2012.712669
   Bertoldi AD, 2013, GLOBALIZATION HEALTH, V9, DOI 10.1186/1744-8603-9-62
   Borges AH, 2015, J INFECT DIS, V212, P585, DOI 10.1093/infdis/jiv123
   Crabtree-Ramirez B, 2014, JAIDS-J ACQ IMM DEF, V67, pS96, DOI 10.1097/QAI.0000000000000261
   Duncan Bruce Bartholow, 2017, Rev. bras. epidemiol., V20, P90, DOI 10.1590/1980-5497201700050008
   Goulet JL, 2007, CLIN INFECT DIS, V45, P1593, DOI 10.1086/523577
   Grangeiro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095673
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Hearps AC, 2014, CURR HIV-AIDS REP, V11, P20, DOI 10.1007/s11904-013-0190-8
   Hentzien M, 2016, J NUTR HEALTH AGING, V20, P408, DOI 10.1007/s12603-015-0608-7
   Kaplan RC, 2011, ATHEROSCLEROSIS, V217, P207, DOI 10.1016/j.atherosclerosis.2011.03.011
   Kendall CE, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-161
   Kowal P, 2010, GLOBAL HEALTH ACTION, V3, P11, DOI 10.3402/gha.v3i0.5302
   Longenecker CT, 2013, HIV MED, V14, P385, DOI 10.1111/hiv.12013
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Mallon PWG, 2010, CURR OPIN INFECT DIS, V23, P1, DOI 10.1097/QCO.0b013e328334fe9a
   Malta DC, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0427-4
   Malta DC, 2016, SAO PAULO MED J, V134, P163, DOI 10.1590/1516-3180.2015.02090911
   Malta DC, 2015, SAO PAULO MED J, V133, P286, DOI 10.1590/1516-3180.2015.13340308
   Manner IW, 2013, J CLIN HYPERTENS, V15, P101, DOI 10.1111/jch.12029
   Moran Caitlin A, 2017, Curr Treat Options Infect Dis, V9, P52, DOI 10.1007/s40506-017-0109-9
   Narayan KMV, 2014, JAIDS-J ACQ IMM DEF, V67, pS2, DOI 10.1097/QAI.0000000000000267
   Oursler KK, 2006, AIDS PATIENT CARE ST, V20, P782, DOI 10.1089/apc.2006.20.782
   Pacheco YM, 2015, ANTIVIR RES, V117, P69, DOI 10.1016/j.antiviral.2015.03.002
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636
   Rodriguez-Penney AT, 2013, AIDS PATIENT CARE ST, V27, P5, DOI 10.1089/apc.2012.0329
   Schmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9
   Schouten J, 2014, CLIN INFECT DIS, V59, P1787, DOI 10.1093/cid/ciu701
   Smit M, 2015, LANCET INFECT DIS, V15, P810, DOI 10.1016/S1473-3099(15)00056-0
   Tenorio AR, 2014, J INFECT DIS, V210, P1248, DOI 10.1093/infdis/jiu254
   Torres TS, 2013, BRAZ J INFECT DIS, V17, P324, DOI 10.1016/j.bjid.2012.10.024
   Vance DE, 2014, J NEUROSCI NURS, V46, P292, DOI 10.1097/JNN.0000000000000074
   Wong C, 2018, CLIN INFECT DIS, V66, P1230, DOI 10.1093/cid/cix998
NR 35
TC 5
Z9 5
U1 1
U2 6
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JAN
PY 2019
VL 22
IS 1
AR e25233
DI 10.1002/jia2.25233
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA HK1ZI
UT WOS:000457705500011
PM 30697950
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Wilson, EC
   Jalil, EM
   Castro, C
   Fernandez, NM
   Kamel, L
   Grinsztejn, B
AF Wilson, Erin C.
   Jalil, Emilia M.
   Castro, Cristiane
   Fernandez, Nilo Martinez
   Kamel, Luciana
   Grinsztejn, Beatriz
TI Barriers and facilitators to PrEP for transwomen in Brazil
SO GLOBAL PUBLIC HEALTH
LA English
DT Article
DE Pre exposure prophylaxis; transgender women; HIV prevention; Brazil
ID PREEXPOSURE PROPHYLAXIS PREP; TRANSGENDER WOMEN; RISK COMPENSATION;
   SAN-FRANCISCO; HIV; HEALTH; AWARENESS; MEN; SEX
AB Pre-exposure prophylaxis (PrEP) is an important biomedical intervention that may help reduce the risk of HIV transmission among transwomen. To date, little research is available to inform interventions to increase uptake and adherence to PrEP among transwomen, especially in places outside the U.S. We conducted a qualitative study in 2015 with 34 adult transwomen in Rio de Janeiro, Brazil and assessed awareness, interest, barriers and facilitators to PrEP uptake and adherence for transwomen. Almost one third of participants had heard of PrEP, and most were interested and thought it would be beneficial for transwomen in their community. Barriers to PrEP included fear of being HIV positive resulting in low HIV testing and concerns about the ability to adhere to a daily PrEP regimen. The most prominent barrier to uptake was past experiences of transgender-identity related discrimination in the universal health care system that reduced willingness to seek PrEP or health care in general. Participants recommended technological solutions to PrEP health education information that could address uptake and adherence. This study informs efforts to increase PrEP use among transwomen in Brazil.
C1 [Wilson, Erin C.] San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA.
   [Jalil, Emilia M.; Castro, Cristiane; Fernandez, Nilo Martinez; Kamel, Luciana; Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol INI Evandro Chaga, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Wilson, EC (corresponding author), San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA.
EM erincwilson@gmail.com
OI Wilson, Erin/0000-0002-0237-495X
FU Brazilian Research Council (National Council for Scientific and
   Technological Development) [470056/2014-2]; Division of Intramural
   Research, National Institute of Allergy and Infectious Diseases
   (National Institutes of Health)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069496];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069496, UM1AI069496, UM1AI069496, UM1AI069496, UM1AI069496,
   UM1AI069496, UM1AI069496, UM1AI069496, UM1AI069496, UM1AI069496] Funding
   Source: NIH RePORTER
FX This study was funded by the Brazilian Research Council (National
   Council for Scientific and Technological Development [470056/2014-2])
   and Division of Intramural Research, National Institute of Allergy and
   Infectious Diseases (National Institutes of Health [UM1AI069496]).
CR Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   (CDC) C f D C a P, 2018, PREEXP PROPH PREP
   Cezaretto A, 2016, ANN M INT AIDS SOC D
   Costa AB, 2018, J IMMIGR MINOR HEALT, V20, P115, DOI 10.1007/s10903-016-0527-7
   Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4
   Grant JM, 2010, NATL TRANSGENDER DIS
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Grov C, 2015, AIDS BEHAV, V19, P2234, DOI 10.1007/s10461-015-1030-1
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   Hoagland B, 2017, AIDS BEHAV, V21, P1278, DOI 10.1007/s10461-016-1516-5
   Hojilla JC, 2016, AIDS BEHAV, V20, P1461, DOI 10.1007/s10461-015-1055-5
   Jalil E., 2016, HIV RES PREV 2016 AI
   Krippendorf K., 1980, CONTENT ANAL INTRO I
   Kulick D., 1998, TRAVESTIS
   Marcus JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081997
   Mayer KH, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx214
   Newcomb ME, 2018, JAIDS-J ACQ IMM DEF, V77, P358, DOI 10.1097/QAI.0000000000001604
   Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8
   Peterson Leigh, 2007, PLoS Clin Trials, V2, pe27, DOI 10.1371/journal.pctr.0020027
   Raifman JRG, 2017, AM J PREV MED, V52, P55, DOI 10.1016/j.amepre.2016.07.031
   Rapues J, 2013, AM J PUBLIC HEALTH, V103, P1485, DOI 10.2105/AJPH.2012.301109
   Rocon PC, 2016, CIENC SAUDE COLETIVA, V21, P2517, DOI 10.1590/1413-81232015218.14362015
   Saggese G., 2016, INT AIDS SOC ANN M D
   Sevelius JM, 2016, GLOB PUBLIC HEALTH, V11, P1060, DOI 10.1080/17441692.2016.1154085
   Silva-Santisteban A, 2016, J INT AIDS SOC, V19, P65, DOI 10.7448/IAS.19.3.20799
   UNAIDS, 2014, THE GAP REP
   US Public Health Service, 2014, PREEXP PROPH PREV HI
   Wilson E, 2016, AIDS PATIENT CARE ST, V30, P147, DOI 10.1089/apc.2015.0266
   Wilson EC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128971
NR 29
TC 2
Z9 2
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1744-1692
EI 1744-1706
J9 GLOB PUBLIC HEALTH
JI Glob. Public Health
PY 2019
VL 14
IS 2
BP 300
EP 308
DI 10.1080/17441692.2018.1505933
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA HI3YN
UT WOS:000456387700011
PM 30084305
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Moreira, J
   Paixao, A
   Oliveira, J
   Jalo, W
   Manuel, O
   Rodrigues, R
   Oliveira, A
   Tinoco, L
   Lima, J
   Grinsztejn, B
   Veloso, VG
   Japiassu, AM
   Lamas, CC
AF Moreira, J.
   Paixao, A.
   Oliveira, J.
   Jalo, W.
   Manuel, O.
   Rodrigues, R.
   Oliveira, A.
   Tinoco, L.
   Lima, J.
   Grinsztejn, B.
   Veloso, V. G.
   Japiassu, A. M.
   Lamas, C. C.
TI Accuracy of quick sequential organ failure assessment score to predict
   mortality in hospitalized patients with suspected infection in an
   HIV/AIDS reference centre in Rio de Janeiro, Brazil
SO CLINICAL MICROBIOLOGY AND INFECTION
LA English
DT Article
DE Intensive care unit; Mortality; qSOFA; Sepsis; SIRS
ID SEPSIS
AB Objectives: : To compare the discriminatory capacity of the quick sequential organ failure assessment (qSOFA) vs. the systemic inflammatory response syndrome (SIRS) score for predicting 30-day mortality and intensive care unit (ICU) admission in patients with suspicion of infection at an HIV reference centre.
   Methods: We performed a prospective cohort study including consecutive adult patients who had suspected infection and who were subsequently admitted to the medical ward. Variables related to qSOFA and SIRS were measured at admission. The performance (area under the receiver operating curve, AUROC) of qSOFA (score >= 2) and SIRS (>= 2 criteria) as a predictor of 30-day mortality and ICU admission was evaluated.
   Results: One hundred seventy-three patients (mean +/- standard deviation age, 42.6 +/- 12.4 years) were included in the analysis; 107 (61.8%) were male, and 111 (64.2%) were HIV positive. Respiratory and gastrointestinal infections occurred in 49 (28.3%) and 23 (13.3%), respectively. The 30-day mortality rate was 9 (5.2%) of 173. The prognostic performance of qSOFA was similar compared to SIRS, with an AUROC of 0.68 (95% confidence interval, 0.55-0.81) and 0.69 (95% confidence interval, 0.53-0.86) (p 0.96). Twenty patients (11%) were admitted to the ICU; qSOFA and SIRS had a similar discriminatory capacity for ICU admission (AUROC 0.63 (95% confidence interval, 0.51-0.75) and 0.63 (95% confidence interval, 0.50-0.76)), respectively).
   Conclusions: We found a poor prognostic accuracy of the qSOFA to predict 30-day mortality in hospitalized patients suspected of infection in a setting with a high burden of HIV infection. (C) 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Moreira, J.; Paixao, A.; Oliveira, J.; Jalo, W.; Manuel, O.; Grinsztejn, B.; Veloso, V. G.; Japiassu, A. M.; Lamas, C. C.] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Av Brasil 4365,POB 21040, Rio De Janeiro, Brazil.
   [Moreira, J.; Lamas, C. C.] Inst Nacl Cardiol, Cardiovasc Res Unit, Rio De Janeiro, Brazil.
   [Rodrigues, R.; Oliveira, A.; Tinoco, L.; Lima, J.; Lamas, C. C.] Univ Grande Rio UNIGRANRIO, Fac Med, Rio De Janeiro, Brazil.
RP Moreira, J (corresponding author), Fundacao Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Av Brasil 4365,POB 21040, Rio De Janeiro, Brazil.
EM jose.moreira@ini.fiocruz.br
RI Lamas, Cristiane/AAV-4157-2020
OI Lamas, Cristiane/0000-0002-5561-999X
FU Coordination for the Improvement of Higher Level Personnel
   (CAPES/FIOCRUZ) [001]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476] Funding Source: NIH RePORTER
FX JM is a PhD student supported with a scholarship from the Coordination
   for the Improvement of Higher Level Personnel (CAPES/FIOCRUZ): finance
   code 001. All authors report no conflicts of interest relevant to this
   article.
CR Huson MAM, 2017, INFECTION, V45, P893, DOI 10.1007/s15010-017-1057-5
   Machado FR, 2017, J CRIT CARE, V40, P315, DOI 10.1016/j.jcrc.2017.04.037
   Maitra S, 2018, CLIN MICROBIOL INFEC, V24, P1123, DOI 10.1016/j.cmi.2018.03.032
   Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1198-743X
EI 1469-0691
J9 CLIN MICROBIOL INFEC
JI Clin. Microbiol. Infect.
PD JAN
PY 2019
VL 25
IS 1
AR e3
DI 10.1016/j.cmi.2018.08.003
PG 3
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA HF5BD
UT WOS:000454246700030
PM 30118761
OA Bronze
DA 2020-11-24
ER

PT J
AU de Paula, HHS
   Ferreira, ACG
   Caetano, DG
   Delatorre, E
   Teixeira, SLM
   Coelho, LE
   Joao, EG
   de Andrade, MM
   Cardoso, SW
   Grinsztejn, B
   Veloso, VG
   Morgado, MG
   Guimaraes, ML
   Cortes, FH
AF Souza de Paula, Hury Hellen
   Garcia Ferreira, Ana Cristina
   Caetano, Diogo Gama
   Delatorre, Edson
   Maia Teixeira, Sylvia Lopes
   Coelho, Lara Esteves
   Joao, Eduarda Grinsztejn
   de Andrade, Michelle Morata
   Cardoso, Sandra Wagner
   Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
   Morgado, Mariza Goncalves
   Guimaraes, Monick Lindenmeyer
   Cortes, Fernanda Heloise
TI Reduction of inflammation and T cell activation after 6months of cART
   initiation during acute, but not in early chronic HIV-1 infection
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1 acute infection; Inflammation; cART; Immune activation; IP-10;
   IL-18
ID ANTIRETROVIRAL THERAPY; HIV-1-INFECTED PATIENTS; PREDICT MORTALITY;
   SOLUBLE CD163; CD4/CD8 RATIO; PLASMA-LEVELS; D-DIMER; DEATH; RISK; AIDS
AB ObjectivesTo investigate the impact of early combined antiretroviral therapy (cART) on inflammation biomarkers and immune activation during acute and early chronic HIV-1 infection.MethodsWe included 12 acute (AHI), 11 early chronic (EcHI), and 18 late chronic HIV-1-infected (LcHI) individuals who were treated with cART and 18 HIV-1-uninfected (HIV-neg) individuals. Plasmatic levels of inflammation biomarkers, CD8(+)CD38(+)HLA-DR+ T cell frequencies, CD4 T cell counts, CD4/CD8 ratio, total HIV-1 DNA and plasmatic viral load were evaluated. Mann-Whitney test, Pearson and Spearman correlation, and linear regression models were used for statistical analyses.ResultsIP-10, IL-18, and sCD163 were significantly elevated at pre-ART in the AHI and EcHI groups, showing a significant reduction after 6months of cART in the AHI group, achieving similar levels to the HIV-neg group. For the EcHI group, the IP-10 and sCD163 levels were also significantly reduced on M6-ART; however, IP-10 levels remained higher than in the HIV-neg group, and no significant reduction of IL-18 levels was observed. The CD8(+) T cell activation levels were elevated in the AHI and EcHI groups at pre-ART and showed a significant reduction on M6-ART, but they were similar to levels seen for HIV-neg only after 12months of cART. At pre-ART, IP-10 levels but not IL-18 levels were positively correlated with HIV-1 viral load in the AHI group.ConclusionsEarly initiation of cART in HIV infection can reduce systemic inflammation, but the earlier normalization of the inflammation markers was only observed when cART was initiated in the acute phase of infection. A slower dynamic of reduction was observed for CD8(+) T cell activation.
C1 [Souza de Paula, Hury Hellen; Caetano, Diogo Gama; Delatorre, Edson; Maia Teixeira, Sylvia Lopes; Morgado, Mariza Goncalves; Guimaraes, Monick Lindenmeyer; Cortes, Fernanda Heloise] Fiocruz MS, IOC, Lab Aids & Imunol Mol, Av Brasil,4365,Pavilhao Leonidas Deane,Sala 401, BR-21040360 Rio De Janeiro, Brazil.
   [Garcia Ferreira, Ana Cristina; Coelho, Lara Esteves; Joao, Eduarda Grinsztejn; de Andrade, Michelle Morata; Cardoso, Sandra Wagner; Grinsztejn, Beatriz; Veloso, Valdilea Goncalves] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin DST & Aids, BR-25984220 Rio De Janeiro, Brazil.
RP Cortes, FH (corresponding author), Fiocruz MS, IOC, Lab Aids & Imunol Mol, Av Brasil,4365,Pavilhao Leonidas Deane,Sala 401, BR-21040360 Rio De Janeiro, Brazil.
EM fheloise@ioc.fiocruz.br
RI Cortes, Fernanda/AAF-9254-2020; Delatorre, Edson/J-8330-2015
OI Delatorre, Edson/0000-0002-5746-0820; Joao, Esau/0000-0002-2412-0627
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPqNational Council for Scientific and Technological
   Development (CNPq); Fiocruz
FX Supported by the Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro - FAPERJ; the Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPq; and Fiocruz.
CR Ananworanich J, 2016, J VIRUS ERAD, V2, P43
   Ananworanich J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033948
   Balagopal A, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw118
   Bhaskaran K, 2008, JAMA-J AM MED ASSOC, V300, P51, DOI 10.1001/jama.300.1.51
   Boulware DR, 2011, J INFECT DIS, V203, P1637, DOI 10.1093/infdis/jir134
   Domingues CSB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114661
   Burdo TH, 2011, J INFECT DIS, V204, P1227, DOI 10.1093/infdis/jir520
   Chivero ET, 2017, J NEUROSCI, V37, P3599, DOI 10.1523/JNEUROSCI.3045-16.2017
   Crowell TA, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21163
   Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7
   Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005
   Foley JF, 2005, J IMMUNOL, V174, P4892, DOI 10.4049/jimmunol.174.8.4892
   French MA, 2009, J INFECT DIS, V200, P1212, DOI 10.1086/605890
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Guaraldi G, 2011, CLIN INFECT DIS, V53, P1120, DOI 10.1093/cid/cir627
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hamlyn E, 2014, AIDS, V28, P869, DOI 10.1097/QAD.0000000000000155
   Hernandez JC, 2014, INTERVIROLOGY, V57, P36, DOI 10.1159/000353902
   Hocqueloux L, 2013, J ANTIMICROB CHEMOTH, V68, P1169, DOI 10.1093/jac/dks533
   Hoenigl M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00404
   Hunt PW, 2014, J INFECT DIS, V210, P1228, DOI 10.1093/infdis/jiu238
   Jacquelin B, 2009, J CLIN INVEST, V119, P3544, DOI 10.1172/JCI40093
   Jain V, 2013, J INFECT DIS, V208, P1202, DOI 10.1093/infdis/jit311
   Kahle EM, 2015, J INFECT DIS, V211, P1451, DOI 10.1093/infdis/jiu621
   Knudsen TB, 2016, J INFECT DIS, V214, P1198, DOI 10.1093/infdis/jiw263
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lau B, 2007, JAIDS-J ACQ IMM DEF, V44, P179, DOI 10.1097/01.qai.0000247229.68246.c5
   Ledwaba L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0024243
   Liovat AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046143
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Lundgren JD, 2018, CURR HIV AIDS REP
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Margolick JB, 2006, JAIDS-J ACQ IMM DEF, V42, P620, DOI 10.1097/01.qai.0000223028.55080.9d
   McBride JA, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006624
   Mehraj V, 2016, AIDS, V30, P1617, DOI 10.1097/QAD.0000000000001105
   Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2
   Leite TCNF, 2017, AIDS RES HUM RETROV, V33, P41, DOI [10.1089/aid.2016.0126, 10.1089/AID.2016.0126]
   Paiardini M, 2013, IMMUNOL REV, V254, P78, DOI 10.1111/imr.12079
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pantaleo G, 1996, ANNU REV MICROBIOL, V50, P825, DOI 10.1146/annurev.micro.50.1.825
   Pastor L, 1925, FRONT IMMUNOL, V2017, P8
   Pastor L, 2017, CLIN INFECT DIS, V65, P1670, DOI 10.1093/cid/cix600
   Ploquin MJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005774
   Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211
   Sainz T, 2013, AIDS, V27, P1513, DOI 10.1097/QAD.0b013e32835faa72
   Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118
   Schuetz A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004543
   Sereti I, 2017, CLIN INFECT DIS, V64, P124, DOI 10.1093/cid/ciw683
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Smith CJ, 2014, LANCET, V384, P241, DOI 10.1016/S0140-6736(14)60604-8
   Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08
   Vinikoor MJ, 2013, JAIDS-J ACQ IMM DEF, V62, P505, DOI 10.1097/QAI.0b013e318285cd33
   Zheng L, 2014, JAIDS-J ACQ IMM DEF, V67, P153, DOI 10.1097/QAI.0000000000000286
NR 57
TC 9
Z9 9
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD DEC 12
PY 2018
VL 15
AR 76
DI 10.1186/s12977-018-0458-6
PG 11
WC Virology
SC Virology
GA HE1VU
UT WOS:000453062600001
PM 30541557
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Jalil, EM
   Grinsztejn, B
   Velasque, L
   Makkeda, AR
   Luz, PM
   Moreira, RI
   Kamel, L
   Fernandes, NM
   Ferreira, ACG
   Hoagland, B
   Wagner, S
   Liu, A
   McFarland, W
   Buchbinder, S
   Veloso, VG
   Wilson, E
AF Jalil, Emilia M.
   Grinsztejn, Beatriz
   Velasque, Luciane
   Makkeda, Alessandra Ramos
   Luz, Paula M.
   Moreira, Ronaldo I.
   Kamel, Luciana
   Fernandes, Nilo M.
   Ferreira, Ana Cristina G.
   Hoagland, Brenda
   Wagner, Sandra
   Liu, Albert
   McFarland, Willi
   Buchbinder, Susan
   Veloso, Valdilea G.
   Wilson, Erin
CA Transcender Study Team
TI Awareness, Willingness, and PrEP Eligibility Among Transgender Women in
   Rio de Janeiro, Brazil
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE transgender person; HIV; pre-exposure prophylaxis; HIV
   infections/prevention and control; health knowledge; attitudes; practice
ID PREEXPOSURE PROPHYLAXIS PREP; HEALTH-CARE; BLACK-MEN; HIV; SEX;
   ADHERENCE; ACCESS
AB Background: HIV epidemics disproportionately affect transwomen worldwide. Trans-specific guidance, outreach, and interventions to increase pre-exposure prophylaxis (PrEP) use among transwomen are scarce.
   Setting: Rio de Janeiro, Brazil.
   Methods: We measured awareness and willingness to use PrEP and examined factors associated with those outcomes among transwomen in Rio de Janeiro and estimated how many transwomen would be eligible for PrEP. Data originate from Transcender study, a respondent-driven sampling survey conducted from August 2015 to January 2016. We performed regression models for PrEP awareness and willingness.
   Results: One hundred thirty-one (38.0%) of 345 participants had heard of PrEP. Among transwomen who self-reported as HIV-negative, 162 (76.4%, N = 212 with available data) reported willingness to use it and 163 (66.8%, N = 244) met PrEP behavioral eligibility criteria. Transwomen with health access in the previous 6 months who reported HIV-infected sexual partner and with 8+ years of schooling had increased odds of PrEP awareness. Lower PrEP awareness was associated with condomless anal intercourse and newly diagnosed HIV infection. Younger age and perceiving themselves at risk of HIV infection increased the odds of PrEP willingness. Lower odds of PrEP willingness were associated with concerns about long-term effects of PrEP and with difficulties in getting access to health care due to transphobia.
   Conclusion: Combination of low awareness, high willingness, and substantial PrEP eligibility corroborates transwomen as a key population for HIV prevention. PrEP is a promising and empowering strategy for HIV prevention among transwomen, but trans-specific recommendations are needed to effectively implement PrEP in this population.
C1 [Jalil, Emilia M.; Grinsztejn, Beatriz; Luz, Paula M.; Moreira, Ronaldo I.; Kamel, Luciana; Fernandes, Nilo M.; Ferreira, Ana Cristina G.; Hoagland, Brenda; Wagner, Sandra; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, STD & AIDS Clin Res Lab, Rio De Janeiro, RJ, Brazil.
   [Velasque, Luciane] Fed Univ State Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, RJ, Brazil.
   [Makkeda, Alessandra Ramos] Rio de Janeiro Fed Inst Educ Sci & Technol, Niteroi, RJ, Brazil.
   [Liu, Albert; Buchbinder, Susan; Wilson, Erin] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [McFarland, Willi; Buchbinder, Susan] UCSF, Dept Med, San Francisco, CA USA.
   [McFarland, Willi; Buchbinder, Susan] UCSF, Dept Epidemiol & Biostat, San Francisco, CA USA.
RP Jalil, EM (corresponding author), Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Ave Brasil,4365 Manguinhos, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM emiliajalil@gmail.com
OI Luz, Paula/0000-0001-9746-719X
FU Brazilian Research Council [470056/2014-2]; NIAID-NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069496]; Brazilian Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Scientific Development
   and Research Funding Agency of the State of Rio de Janeiro; CNPqNational
   Council for Scientific and Technological Development (CNPq); National
   Institute of Allergy and Infectious Diseases (NIAID-NIH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069496, UM1AI069496, UM1AI069476, UM1AI069496,
   UM1AI069496, UM1AI069476, UM1AI069496, U01AI069496, U01AI069496,
   U01AI069496, U01AI069496, UM1AI069496, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069496, UM1AI069496, U01AI069496, U01AI069496,
   UM1AI069496, UM1AI069476, U01AI069496, UM1AI069476] Funding Source: NIH
   RePORTER
FX Supported in part by Brazilian Research Council (470056/2014-2) and
   NIAID-NIH (UM1AI069496). B.G. and P.M.L. acknowledge funding from
   Brazilian Research Council (CNPq) and Scientific Development and
   Research Funding Agency of the State of Rio de Janeiro. The authors
   acknowledge the CNPq and the National Institute of Allergy and
   Infectious Diseases (NIAID-NIH) for funding this study.
CR Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Bradford J, 2013, AM J PUBLIC HEALTH, V103, P1820, DOI 10.2105/AJPH.2012.300796
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Prevencao e Controle das Infeccoes Sexualmente Transmissiveis do HIV/Aids e das Hepatites Virais, 2017, DEP VIG PREV CONTR I
   Calabrese SK, 2017, AM J PUBLIC HEALTH, V107, P1883, DOI 10.2105/AJPH.2017.304061
   Centers for Disease Control and Prevention, 2014, PREEXP PROPH PREV HI
   Cruz TM, 2014, SOC SCI MED, V110, P65, DOI 10.1016/j.socscimed.2014.03.032
   Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4
   Draper BL, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21885
   Eaton LA, 2017, PREV SCI, V18, P505, DOI 10.1007/s11121-017-0756-6
   Fabris B, 2015, J ENDOCRINOL INVEST, V38, P269, DOI 10.1007/s40618-014-0186-2
   Costa EMF, 2014, ARQ BRAS ENDOCRINOL, V58, P188, DOI 10.1590/0004-2730000003091
   Garnett M, 2018, AIDS CARE, V30, P9, DOI 10.1080/09540121.2017.1363364
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Kuhns LM, 2016, AIDS BEHAV, V20, P1470, DOI 10.1007/s10461-015-1182-z
   Ministerio da Sande, 2013, DEP DST AIDS HEP VIR
   Oldenburg CE, 2016, AIDS BEHAV, V20, pS365, DOI 10.1007/s10461-016-1483-x
   Pinto TP, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00113316, 10.1590/0102-311x00113316]
   Poteat T, 2016, JAIDS-J ACQ IMM DEF, V72, pS210, DOI 10.1097/QAI.0000000000001087
   Poteat T, 2015, LANCET, V385, P274, DOI 10.1016/S0140-6736(14)60833-3
   Poteat T, 2013, SOC SCI MED, V84, P22, DOI 10.1016/j.socscimed.2013.02.019
   Raymond HF, 2017, AM J PUBLIC HEALTH, V107, pE12, DOI 10.2105/AJPH.2017.303964
   Sevelius JM, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.7.21105
   Veloso VG, 2015, J INT AIDS SOC, V18, P48, DOI 10.7448/IAS.18.4.20010
   Wang ZX, 2017, AIDS BEHAV, V21, P3287, DOI 10.1007/s10461-017-1869-4
   Ware NC, 2012, JAIDS-J ACQ IMM DEF, V59, P463, DOI 10.1097/QAI.0b013e31824a060b
   Wejnert C, 2008, SOCIOL METHOD RES, V37, P105, DOI 10.1177/0049124108318333
   Wilson EC, 2016, LANCET HIV, V3, pE200, DOI 10.1016/S2352-3018(16)30022-4
   Wilson EC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128971
   World Professional Association for Transgender Health Inc., 2012, STAND CAR HLTH TRANS
   Yang DZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054495, 10.1371/journal.pone.0059020]
   Zalazar Virginia, 2016, Transgend Health, V1, P266, DOI 10.1089/trgh.2016.0033
NR 33
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2018
VL 79
IS 4
BP 445
EP 452
DI 10.1097/QAI.0000000000001839
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA HK4GE
UT WOS:000457879400008
PM 30142140
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Cespedes, MS
   Kang, M
   Kojic, EM
   Umbleja, T
   Godfrey, C
   Webster-Cyriaque, JY
   Masih, R
   Firnhaber, C
   Grinsztejn, B
   Saah, A
   Cu-Uvin, S
   Aberg, JA
AF Cespedes, Michelle S.
   Kang, Minhee
   Kojic, Erna Milunka
   Umbleja, Trim
   Godfrey, Catherine
   Webster-Cyriaque, Jennifer Y.
   Masih, Reena
   Firnhaber, Cynthia
   Grinsztejn, Beatriz
   Saah, Alfred
   Cu-Uvin, Susan
   Aberg, Judith A.
TI Anogenital human papillomavirus virus DNA and sustained response to the
   quadrivalent HPV vaccine in women living with HIV-1
SO PAPILLOMAVIRUS RESEARCH
LA English
DT Article
DE HPV; HIV; Anogenital; Quadrivalent; HPV vaccine; Women; Immunogenicity
ID IMMUNODEFICIENCY; CANCER; RISK
AB Objectives: People living with HIV have increased Human Papillomavirus (HPV) related lesions and malignancies. We describe HPV DNA recovered from the cervix and anal canal, explore the effect of vaccination on HPV detection, and examine the durability of vaccine titers in women living with HIV-1 who were vaccinated with the quadrivalent HPV vaccine.
   Methods: AIDS Clinical Trials Group A5240 was a prospective study of the quadrivalent HPV (qHPV) vaccine in 315 HIV-1 infected women in three CD4 strata (A: > 350, B; 201-350, C: <= 200 cells/mm(3)). Vaccine was administered at entry, week 8 and week 24. Cervical and anal HPV DNA specimens were collected at baseline, weeks 28 and 52; serum for antibody testing was obtained at baseline, weeks 28 and 72.
   Results: Vaccine antibody titers decreased across all four HPV types at week 72 compared to week 28. Lower proportions of sustained seropositivity were observed in women with lower CD4 counts for all four vaccine types, with the lowest titers for HPV 18. Despite the decrease, the geometric mean titer levels were above the seroconversion cut-off levels for all types except HPV 18 in the lowest CD4 stratum. Of the 174 participants who had a negative baseline HPV 16 antibody and developed antibody response at week 28, 95%, 88%, and 86% retained seropositivity at week 72 in strata A, B, and C respectively. Lower antibody retention was observed in women with CD4 <= 200 compared to CD4 > 350 (p = 0.016). Anal HPV detection was more prevalent compared to cervical detection at all visits. Among high risk types, type 52, 31, 16, 18 and 51 were the most common in the cervical compartment, while types 16, 35, 18, and 51 were the most prevalent in the anal canal at baseline (listed in the order of prevalence). Later detection of HPV not present at baseline was uncommon in either compartment. Serial recovery of HPV over time was more commonly observed in the anal canal.
   Conclusion: The qHPV vaccine elicits durable titer response above the seroconversion cut-off levels in HIV-infected women. However, the titer levels were substantially lower by Week 72, most noticeably in type 18. HPV DNA was detected more frequently in the anal canal. Detection of non-vaccine high risk HPV suggests a role for the nonavalent vaccine.
C1 [Cespedes, Michelle S.; Aberg, Judith A.] Icahn Sch Med Mt Sinai, Div Infect Dis, New York, NY 10029 USA.
   [Kang, Minhee; Umbleja, Trim] Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA USA.
   [Kojic, Erna Milunka; Cu-Uvin, Susan] Brown Univ, Div Infect Dis, Providence, RI 02912 USA.
   [Godfrey, Catherine] NIAID, HIV Res Branch, TRP, DAIDS,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Webster-Cyriaque, Jennifer Y.] Univ N Carolina, Dept Microbiol, Chapel Hill, NC 27515 USA.
   [Webster-Cyriaque, Jennifer Y.] Univ N Carolina, Dept Immunol, Chapel Hill, NC 27515 USA.
   [Webster-Cyriaque, Jennifer Y.] Univ N Carolina, Dept Dent Ecol, Chapel Hill, NC 27515 USA.
   [Masih, Reena] ACTG Network Coordinating Ctr, Social & Sci Syst, Silver Spring, MD USA.
   [Firnhaber, Cynthia] Univ Witwatersrand, Fac Hlth Sci, Dept Clin Med, Clin HIV Res Unit, Johannesburg, South Africa.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Infect Dis Dept, Rio De Janeiro, Brazil.
   [Saah, Alfred] Merck & Co Inc, Kenilworth, NJ USA.
RP Cespedes, MS (corresponding author), One Gustave L Levy Pl,Box 1090, New York, NY 10029 USA.
EM Michelle.Cespedes@mssm.edu
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [1U01AI068636]; National Institute of Dental and Craniofacial Research
   (NIDCR)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Dental &
   Craniofacial Research (NIDCR); Statistical and Data Management Center of
   the AIDS Clinical Trials Group, under the National Institute of Allergy
   and Infectious Diseases [UM1 AI068634]; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW000004, D43TW000004, D43TW000004, D43TW000004, D43TW000004,
   D43TW000004, D43TW000004, D43TW000004, D43TW000004, D43TW000004,
   D43TW000004, D43TW000004, D43TW000004, D43TW000004, D43TW000004,
   D43TW000004, D43TW000004, D43TW000004, D43TW000004, D43TW000004,
   D43TW000004, D43TW000004, D43TW000004, D43TW000004, D43TW000004,
   D43TW000004, D43TW000004, D43TW000004, D43TW000004, D43TW000004,
   D43TW000004, D43TW000004, D43TW000004, D43TW000004, D43TW000004,
   D43TW000004, D43TW000004, D43TW000004, D43TW000004, D43TW000004,
   D43TW000004, D43TW000004, D43TW000004, D43TW000004, D43TW000004,
   D43TW000004, D43TW000004, D43TW000004, D43TW000004, D43TW000004,
   D43TW000004, D43TW000004, D43TW000004] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI106701, UM1AI069463, UM1AI069432, UM1AI069432, U01AI068634,
   U01AI038855, UM1AI068634, UM1AI069463, UM1AI068636, UM1AI069463,
   UM1AI106701, UM1AI068636, UM1AI106701, U01AI069532, UM1AI068636,
   UM1AI069432, U01AI038855, U01AI068636, UM1AI068636, UM1AI068634,
   UM1AI069476, U01AI069532, UM1AI069432, UM1AI068636, UM1AI106701,
   UM1AI069432, UM1AI069432, UM1AI069476, UM1AI068634, UM1AI068634,
   U01AI038855, U01AI069532, U01AI068636, UM1AI069476, UM1AI069463,
   UM1AI069463, U01AI038855, UM1AI106701, U01AI069532, UM1AI069412,
   UM1AI069532, UM1AI068636, U01AI038855, U01AI038855, UM1AI068636,
   U01AI038855, U01AI068634, UM1AI069412, U01AI038855, UM1AI068636,
   UM1AI069412, U01AI038855, U01AI068636, UM1AI068636, U01AI069532,
   UM1AI069432, U01AI068634, UM1AI069532, UM1AI106701, UM1AI069476,
   UM1AI106701, UM1AI068636, U01AI068636, UM1AI069412, UM1AI069476,
   U01AI068634, UM1AI069432, U01AI038855, UM1AI069463, UM1AI069412,
   UM1AI069476, U01AI068636, UM1AI069432, UM1AI069476, UM1AI068636,
   UM1AI069476, UM1AI068634, U01AI038855, U01AI038855, UM1AI106701,
   UM1AI068634, UM1AI068634, U01AI068634, UM1AI069463, UM1AI068636,
   U01AI068636, UM1AI068634, UM1AI069432, UM1AI068634, UM1AI068634,
   UM1AI106701, UM1AI069463, U01AI068636, UM1AI069532, UM1AI069463,
   UM1AI069476] Funding Source: NIH RePORTER
FX This project was supported by Award Number 1U01AI068636 from the
   National Institute of Allergy and Infectious Diseases and supported by
   the National Institute of Dental and Craniofacial Research (NIDCR). The
   work was also supported by the Statistical and Data Management Center of
   the AIDS Clinical Trials Group, under the National Institute of Allergy
   and Infectious Diseases grant No. UM1 AI068634. Merck & Co. provided the
   study product and the assays to measure antibody response.
CR Volpini LPB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176422
   Brisson M, 2016, LANCET PUBLIC HEALTH, V1, pE8, DOI 10.1016/S2468-2667(16)30001-9
   Clifford GM, 2017, CLIN INFECT DIS, V64, P1228, DOI 10.1093/cid/cix135
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Einstein MH, 2014, HUM VACC IMMUNOTHER, V10, P3435, DOI 10.4161/hv.36121
   Ellsworth G. B., 2018, PAPILLOMAVIRUS RES
   Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487
   Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760
   Godfrey C., 2015, INT J STD AIDS, P543
   Goeieman BJ, 2017, JAIDS-J ACQ IMM DEF, V75, pE59, DOI 10.1097/QAI.0000000000001300
   Heard I, 2016, J INFECT DIS, V213, P1455, DOI 10.1093/infdis/jiv751
   Heard I, 2015, CLIN INFECT DIS, V60, P1559, DOI 10.1093/cid/civ049
   Hidalgo-Tenorio C., 2017, ENFERM INFECC MICROB
   Hleyhel M, 2014, AIDS, V28, P2109, DOI 10.1097/QAD.0000000000000382
   Kavanagh K, 2017, LANCET INFECT DIS, V17, P1293, DOI 10.1016/S1473-3099(17)30468-1
   Kojic EM, 2014, CLIN INFECT DIS, V59, P127, DOI 10.1093/cid/ciu238
   Kojic EM, 2011, SEX TRANSM DIS, V38, P253, DOI 10.1097/OLQ.0b013e3181f70253
   Lehtinen M., 2018, INT J CANC
   Lin CQ, 2018, LANCET INFECT DIS, V18, P198, DOI [10.1016/S1473-3099(17)30653-9, 10.1016/s1473-3099(17)30653-9]
   Liu G, 2018, AIDS, V32, P795, DOI [10.1097/QAD.0000000000001765, 10.1097/qad.0000000000001765]
   Liu G, 2016, J INFECT DIS, V213, P191, DOI 10.1093/infdis/jiv403
   Machalek DA, 2018, J INFECT DIS, V217, P1590, DOI 10.1093/infdis/jiy075
   Massad L.S., 2016, AM J OBSTET GYNECOL, pe1
   MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K
   Menezes LJ, 2016, INT J STD AIDS, V27, P543, DOI 10.1177/0956462415587226
   Naud PS, 2014, HUM VACC IMMUNOTHER, V10, P2147, DOI 10.4161/hv.29532
   Nygard M., 2015, CLIN VACCIN IMMUNOL, P43
   OGUNBIYI OA, 1994, OBSTET GYNECOL, V83, P212
   Palefsky JM, 2001, J INFECT DIS, V183, P383, DOI 10.1086/318071
   Palefsky JM, 2017, CURR OPIN HIV AIDS, V12, P26, DOI 10.1097/COH.0000000000000336
   Patel HS, 2007, INT J COLORECTAL DIS, V22, P1, DOI 10.1007/s00384-005-0023-3
   Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005
   Piketty C, 2003, ANN INTERN MED, V138, P453, DOI 10.7326/0003-4819-138-6-200303180-00008
   Robbins HA, 2014, AIDS, V28, P881, DOI 10.1097/QAD.0000000000000163
   Silverberg MJ, 2012, CLIN INFECT DIS, V54, P1026, DOI 10.1093/cid/cir1012
   Travassos AG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185423
   Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741
   Wilkin T, 2010, J INFECT DIS, V202, P1246, DOI 10.1086/656320
   Wu Xiaocheng, 2012, Morbidity and Mortality Weekly Report, V61, P258
NR 39
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2405-8521
J9 PAPILLOMAVIRUS RES
JI Papillomavirus Res.
PD DEC
PY 2018
VL 6
BP 15
EP 21
DI 10.1016/j.pvr.2018.08.002
PG 7
WC Virology
SC Virology
GA HC8QU
UT WOS:000452069800004
PM 30118852
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Panayidou, K
   Davies, MA
   Anderegg, N
   Egger, M
   Fatti, G
   Vinikoor, M
   Sawry, S
   Ehmer, J
   Eley, B
   Phiri, S
   Technau, KG
   Chimbetete, C
   Rabie, H
   Boulle, A
   Tanser, F
   Wood, R
   Wools-Kaloustian, K
   Vreeman, R
   Oyaro, P
   Ayaya, S
   Nakigozi, G
   Musick, B
   Yiannoutsos, C
   Amorissani-Folquet, M
   Takassi, E
   Sylla, M
   Renner, L
   Malateste, K
   Desmonde, S
   Leroy, V
   Kurniati, N
   Hansudewechakul, R
   Nguyen, LV
   Ly, PS
   Truong, KH
   Kariminia, A
   Sohn, AH
   Edmonds, A
   Yumo, HA
   Dusingize, JC
   Yotebieng, M
   Judd, A
   Rojo, P
   Smit, C
   Grabar, S
   Warszwarski, J
   Chene, G
   Raban, D
   Patel, K
   Seage, GR
   Van Dyke, RB
   Oleske, J
   Williams, PL
   Abzug, MJ
   Succi, R
   Machado, DM
   Pinto, J
   Rouzier, V
   Luque, M
   Mejia, F
   Ly, PS
   Khol, V
   Tucker, J
   Kumarasamy, N
   Saghayam, S
   Chandrasekaran, E
   Wati, DK
   Vedaswari, D
   Malino, IY
   Kurniati, N
   Muktiarti, D
   Fong, SM
   Lim, M
   Daut, F
   Yusoff, NKN
   Mohamad, P
   Mohamed, TJ
   Drawis, MR
   Nallusamy, R
   Chan, KC
   Sudjaritruk, T
   Sirisanthana, V
   Aurpibul, L
   Oberdorfer, P
   Hansudewechakul, R
   Denjanta, S
   Watanaporn, S
   Kongphonoi, A
   Lumbiganon, P
   Kosalaraksa, P
   Tharnprisan, P
   Udomphanit, T
   Jourdain, G
   Puthanakit, T
   Anugulruengkitt, S
   Phadungphon, C
   Chokephaibulkit, K
   Lapphra, K
   Phongsamart, W
   Sricharoenchai, S
   Truong, KH
   Du, QT
   Nguyen, CH
   Do, VC
   Ha, TM
   An, VT
   Nguyen, LV
   Khu, DTK
   Pham, AN
   Nguyen, LT
   Le, ON
   Sohn, AH
   Ross, JL
   Sethaputra, C
   Law, MG
   Kariminia, A
   Cahn, P
   Cesar, C
   Fink, V
   Sued, O
   Dell'Isola, E
   Perez, H
   Valiente, J
   Yamamoto, C
   Grinsztejn, B
   Veloso, V
   Luz, P
   de Boni, R
   Wagner, SC
   Friedman, R
   Moreira, R
   Pinto, J
   Ferreira, F
   Maia, M
   Succi, RCD
   Machado, DM
   Gouvea, ADB
   Wolff, M
   Cortes, C
   Rodriguez, MF
   Allendes, G
   Pape, JW
   Rouzier, V
   Marcelin, A
   Perodin, C
   Luque, MT
   Padgett, D
   Madero, JS
   Ramirez, BC
   Belaunzaran, P
   Vega, YC
   Gotuzzo, E
   Mejia, F
   Carriquiry, G
   McGowan, CC
   Shepherd, BE
   Sterling, T
   Jayathilake, K
   Person, AK
   Rebeiro, PF
   Giganti, M
   Castilho, J
   Duda, SN
   Maruri, F
   Vansell, H
   Pelagie, N
   Gateretse, P
   Munezero, J
   Nitereka, V
   Niyongabo, T
   Twizere, C
   Bukuru, H
   Nahimana, T
   Biziragusenyuka, J
   Manyundo, RS
   Atsu, K
   Mbuh, T
   Ajeh, R
   Benwi, M
   Dzudie, A
   Mbuh, A
   Ngamani, ML
   Nkome, V
   Amadou, D
   Ngassam, E
   Yone, EWP
   Ewanoge, AN
   Fuhngwa, N
   Moki, C
   Akele, C
   Kitetele, F
   Lelo, P
   Tabala, M
   Okitolonda, EW
   Wenzi, L
   Diafouka, M
   Ekat, MH
   Nsonde, DM
   Mafou, A
   Ntarambirwa, F
   Tuyishimire, Y
   Hakizimana, T
   Ayinkamiye, J
   Mukantwali, S
   Kayitesi, H
   Uwamahoro, O
   Habumuremyi, V
   Mukamana, J
   Dusingize, JC
   Kubwimana, G
   Mugenzi, P
   Muhoza, B
   Munyaneza, A
   Ndahiro, E
   Nyiransabimana, D
   Sinayobye, JD
   Sugira, V
   Benekigeri, C
   Mbaraga, G
   Adedimeji, A
   Anastos, K
   Dilorenzo, M
   Murchison, L
   Ross, J
   Addison, D
   Baker, M
   Brazier, E
   Jones, H
   Kelvin, E
   Kulkarni, S
   Nash, D
   Tymejczyk, O
   Elul, B
   Cai, XT
   Hoover, D
   Kim, HY
   Li, CS
   Shi, QH
   Lancaster, K
   Yotebieng, M
   Kuniholm, M
   Edmonds, A
   Parcesepe, A
   Duda, S
   Kimmel, A
   McNairy, M
   Diero, L
   Ayaya, S
   Bukusi, E
   Ssali, J
   Nalugoda, F
   Somi, GR
   Lyamuya, RE
   Ngonyani, K
   Lugina, E
   Urassa, M
   Michael, D
   Zannou, MD
   Poda, A
   Sarfo, FS
   Messou, E
   Chenal, H
   Minga, KA
   Bissagnene, E
   Tanon, A
   Seydi, M
   Patassi, AA
   Koumakpai-Adeothy, SA
   Renner, LA
   N'Gbeche, SM
   Bosse, CA
   Kouakou, K
   Folquet, MA
   Eboua, FT
   Traore, FD
   Sylla, M
   Takassi, E
   Dabis, F
   Arrive, E
   Balestre, E
   Becquet, R
   Bernard, C
   Arikawa, SC
   Doring, A
   Jaquet, A
   Malateste, K
   Rabourdin, E
   Tiendrebeogo, T
   Desmonde, S
   Jesson, J
   Leroy, V
   Ekouevi, DK
   Azani, JC
   Coffie, P
   Gnepa, G
   Kouadio, CGK
   Tchounga, B
   Maartens, G
   von Lettow, M
   Sawry, S
   Tanser, F
   Boulle, A
   Fatti, G
   Phiri, S
   Chimbetete, C
   Technau, KG
   Eley, B
   Muhairwe, J
   Jores, A
   Kamenova, K
   Fox, MP
   Prozesky, H
   Judd, A
   Zangerle, R
   Touloumi, G
   Warszawski, J
   Meyer, L
   Dabis, F
   Krause, MM
   Ghosn, J
   Leport, C
   Wittkop, L
   Reiss, P
   Wit, F
   Prins, M
   Bucher, H
   Gibb, D
   Fatkenheuer, G
   Del Amo, J
   Obel, N
   Thorne, C
   Mocroft, A
   Kirk, O
   Stephan, C
   Perez-Hoyos, S
   Hamouda, O
   Bartmeyer, B
   Chkhartishvili, N
   Noguera-Julian, A
   Antinori, A
   Monforte, AD
   Brockmeyer, N
   Prieto, L
   Conejo, PR
   Soriano-Arandes, A
   Soriano-Arandes, A
   Battegay, M
   Kouyos, R
   Mussini, C
   Tookey, P
   Casabona, J
   Miro, JM
   Castagna, A
   Konopnick, D
   Goetghebuer, T
   Sonnerborg, A
   Torti, C
   Sabin, C
   Teira, R
   Garrido, M
   Haerry, D
   de Wit, S
   Miro, JM
   Costagliola, D
   d'Arminio-Monforte, A
   Castagna, A
   del Amo, J
   Mocroft, A
   Raben, D
   Chene, G
   Judd, A
   Conejo, PR
   Barger, D
   Schwimmer, C
   Termote, M
   Wittkop, L
   Campbell, M
   Frederiksen, CM
   Friis-Moller, N
   Kjaer, J
   Raben, D
   Brandt, RS
   Berenguer, J
   Bohlius, J
   Bouteloup, V
   Bucher, H
   Cozzi-Lepri, A
   Dabis, F
   Monforte, AD
   Davies, MA
   del Amo, J
   Dorrucci, M
   Dunn, D
   Egger, M
   Furrer, H
   Guiguet, M
   Grabar, S
   Judd, A
   Kirk, O
   Lambotte, O
   Leroy, V
   Lodi, S
   Matheron, S
   Meyer, L
   Miro, JM
   Mocroft, A
   Monge, S
   Nakagawa, F
   Paredes, R
   Phillips, A
   Puoti, M
   Rohner, E
   Schomaker, M
   Smit, C
   Sterne, J
   Thiebaut, R
   Thorne, C
   Torti, C
   van der Valk, M
   Wittkop, L
   Abzug, MJ
   Hazra, R
   Heckman, B
   O'gara, E
   Oleske, J
   Patel, K
   Seage, GR
   Van Dyke, RB
   Williams, PL
   Siminski, S
AF Panayidou, Klea
   Davies, Mary-Ann
   Anderegg, Nanina
   Egger, Matthias
   Fatti, Geoffrey
   Vinikoor, Michael
   Sawry, Shobna
   Ehmer, Jochen
   Eley, Brian
   Phiri, Sam
   Technau, Karl-Gunter
   Chimbetete, Cleophas
   Rabie, Helena
   Boulle, Andrew
   Tanser, Frank
   Wood, Robin
   Wools-Kaloustian, Kara
   Vreeman, Rachel
   Oyaro, Patrick
   Ayaya, Samuel
   Nakigozi, Gertrude
   Musick, Beverley
   Yiannoutsos, Constantin
   Amorissani-Folquet, Madeleine
   Takassi, Elom
   Sylla, Mariam
   Renner, Lorna
   Malateste, Karen
   Desmonde, Sophie
   Leroy, Valeriane
   Kurniati, Nia
   Hansudewechakul, Rawiwan
   Lam Van Nguyen
   Ly, Penh Sun
   Khanh Huu Truong
   Kariminia, Azar
   Sohn, Annette H.
   Edmonds, Andrew
   Yumo, Habakkuk Azinyui
   Dusingize, Jean Claude
   Yotebieng, Marcel
   Judd, Ali
   Rojo, Pablo
   Smit, Colette
   Grabar, Sophie
   Warszwarski, Josiane
   Chene, Genevieve
   Raban, Dorthe
   Patel, Kunjal
   Seage, George R., III
   Van Dyke, Russell B.
   Oleske, James
   Williams, Paige L.
   Abzug, Mark J.
   Succi, Regina
   Machado, Daisy M.
   Pinto, Jorge
   Rouzier, Vanessa
   Luque, Marco
   Mejia, Fernando
   Ly, P. S.
   Khol, V.
   Tucker, J.
   Kumarasamy, N.
   Saghayam, S.
   Chandrasekaran, E.
   Wati, D. K.
   Vedaswari, D.
   Malino, I. Y.
   Kurniati, N.
   Muktiarti, D.
   Fong, S. M.
   Lim, M.
   Daut, F.
   Yusoff, N. K. Nik
   Mohamad, P.
   Mohamed, T. J.
   Drawis, M. R.
   Nallusamy, R.
   Chan, K. C.
   Sudjaritruk, T.
   Sirisanthana, V.
   Aurpibul, L.
   Oberdorfer, P.
   Hansudewechakul, R.
   Denjanta, S.
   Watanaporn, S.
   Kongphonoi, A.
   Lumbiganon, P.
   Kosalaraksa, P.
   Tharnprisan, P.
   Udomphanit, T.
   Jourdain, G.
   Puthanakit, T.
   Anugulruengkitt, S.
   Phadungphon, C.
   Chokephaibulkit, K.
   Lapphra, K.
   Phongsamart, W.
   Sricharoenchai, S.
   Truong, K. H.
   Du, Q. T.
   Nguyen, C. H.
   Do, V. C.
   Ha, T. M.
   An, V. T.
   Nguyen, L. V.
   Khu, D. T. K.
   Pham, A. N.
   Nguyen, L. T.
   Le, O. N.
   Sohn, A. H.
   Ross, J. L.
   Sethaputra, C.
   Law, M. G.
   Kariminia, A.
   Cahn, Pedro
   Cesar, Carina
   Fink, Valeria
   Sued, Omar
   Dell'Isola, Emanuel
   Perez, Hector
   Valiente, Jose
   Yamamoto, Cleyton
   Grinsztejn, Beatriz
   Veloso, Valdilea
   Luz, Paula
   de Boni, Raquel
   Wagner, Sandra Cardoso
   Friedman, Ruth
   Moreira, Ronaldo
   Pinto, Jorge
   Ferreira, Flavia
   Maia, Marcelle
   de Menezes Succi, Regina Celia
   Maria Machado, Daisy
   Barbosa Gouvea, Aida de Fatima
   Wolff, Marcelo
   Cortes, Claudia
   Rodriguez, Maria Fernanda
   Allendes, Gladys
   William Pape, Jean
   Rouzier, Vanessa
   Marcelin, Adias
   Perodin, Christian
   Tulio Luque, Marco
   Padgett, Denis
   Sierra Madero, Juan
   Crabtree Ramirez, Brenda
   Belaunzaran, Paco
   Caro Vega, Yanink
   Gotuzzo, Eduardo
   Mejia, Fernando
   Carriquiry, Gabriela
   McGowan, Catherine C.
   Shepherd, Bryan E.
   Sterling, Timothy
   Jayathilake, Karu
   Person, Anna K.
   Rebeiro, Peter F.
   Giganti, Mark
   Castilho, Jessica
   Duda, Stephany N.
   Maruri, Fernanda
   Vansell, Hilary
   Pelagie, Nimbona
   Gateretse, Patrick
   Munezero, Jeanine
   Nitereka, Valentin
   Niyongabo, Theodore
   Twizere, Christelle
   Bukuru, Helene
   Nahimana, Thierry
   Biziragusenyuka, Jeremie
   Manyundo, Risase Scholastique
   Atsu, Kien
   Mbuh, Tabeyang
   Ajeh, Rogers
   Benwi, Mark
   Dzudie, Anastase
   Mbuh, Akindeh
   Ngamani, Marc Lionel
   Nkome, Victorine
   Amadou, Djenabou
   Ngassam, Eric
   Yone, Eric Walter Pefura
   Ewanoge, Alice Ndelle
   Fuhngwa, Norbert
   Moki, Chris
   Akele, Catherine
   Kitetele, Faustin
   Lelo, Patricia
   Tabala, Martine
   Okitolonda, Emile Wemakoy
   Wenzi, Landry
   Diafouka, Merlin
   Ekat, Martin Herbas
   Nsonde, Dominique Mahambou
   Mafou, Adolphe
   Ntarambirwa, Fidele
   Tuyishimire, Yvonne
   Hakizimana, Theogene
   Ayinkamiye, Josephine
   Mukantwali, Sandrine
   Kayitesi, Henriette
   Uwamahoro, Olive
   Habumuremyi, Viateur
   Mukamana, Joyce
   Dusingize, Jean Claude
   Kubwimana, Gallican
   Mugenzi, Pacifique
   Muhoza, Benjamin
   Munyaneza, Athanase
   Ndahiro, Emmanuel
   Nyiransabimana, Diane
   Sinayobye, Jean d'Amour
   Sugira, Vincent
   Benekigeri, Chantal
   Mbaraga, Gilbert
   Adedimeji, Adebola
   Anastos, Kathryn
   Dilorenzo, Madeline
   Murchison, Lynn
   Ross, Jonathan
   Addison, Diane
   Baker, Meg
   Brazier, Ellen
   Jones, Heidi
   Kelvin, Elizabeth
   Kulkarni, Sarah
   Nash, Denis
   Tymejczyk, Olga
   Elul, Batya
   Cai, Xiatao
   Hoover, Don
   Kim, Hae-Young
   Li, Chunshan
   Shi, Qiuhu
   Lancaster, Kathryn
   Yotebieng, Marcel
   Kuniholm, Mark
   Edmonds, Andrew
   Parcesepe, Angela
   Duda, Stephany
   Kimmel, April
   McNairy, Margaret
   Diero, Lameck
   Ayaya, Samuel
   Bukusi, Elizabeth
   Ssali, John
   Nalugoda, Fred
   Somi, G. R.
   Lyamuya, Rita Elias
   Ngonyani, Kapella
   Lugina, Emanuel
   Urassa, Mark
   Michael, Denna
   Zannou, Marcel Djimon
   Poda, Armel
   Sarfo, Fred Stephen
   Messou, Eugene
   Chenal, Henri
   Minga, Kla Albert
   Bissagnene, Emmanuel
   Tanon, Aristophane
   Seydi, Moussa
   Patassi, Akessiwe Akouda
   Koumakpai-Adeothy, Sikiratou Adouni
   Renner, Lorna Awo
   N'Gbeche, Sylvie Marie
   Bosse, Clarisse Amani
   Kouakou, Kouadio
   Folquet, Madeleine Amorissani
   Eboua, Francois Tanoh
   Traore, Fatoumata Dicko
   Sylla, Mariam
   Takassi, Elom
   Dabis, Francois
   Arrive, Elise
   Balestre, Eric
   Becquet, Renaud
   Bernard, Charlotte
   Arikawa, Shino Chassagne
   Doring, Alexandra
   Jaquet, Antoine
   Malateste, Karen
   Rabourdin, Elodie
   Tiendrebeogo, Thierry
   Desmonde, Sophie
   Jesson, Julie
   Leroy, Valeriane
   Ekouevi, Didier Koumavi
   Azani, Jean-Claude
   Coffie, Patrick
   Gnepa, Guy
   Kouadio, Christian Gerard Kaugbouh
   Tchounga, Boris
   Maartens, Gary
   von Lettow, Monique
   Sawry, Shobna
   Tanser, Frank
   Boulle, Andrew
   Fatti, Geoffrey
   Phiri, Sam
   Chimbetete, Cleophas
   Technau, Karl-Gunther
   Eley, Brian
   Muhairwe, Josephine
   Jores, Anna
   Kamenova, Kamelia
   Fox, Matthew P.
   Prozesky, Hans
   Judd, Ali
   Zangerle, Robert
   Touloumi, Giota
   Warszawski, Josiane
   Meyer, Laurence
   Dabis, Francois
   Krause, Murielle Mary
   Ghosn, Jade
   Leport, Catherine
   Wittkop, Linda
   Reiss, Peter
   Wit, Ferdinand
   Prins, Maria
   Bucher, Heiner
   Gibb, Diana
   Faetkenheuer, Gerd
   Del Amo, Julia
   Obel, Niels
   Thorne, Claire
   Mocroft, Amanda
   Kirk, Ole
   Stephan, Christoph
   Perez-Hoyos, Santiago
   Hamouda, Osamah
   Bartmeyer, Barbara
   Chkhartishvili, Nikoloz
   Noguera-Julian, Antoni
   Antinori, Andrea
   Monforte, Antonella d'Arminio
   Brockmeyer, Norbert
   Prieto, Luis
   Rojo Conejo, Pablo
   Soriano-Arandes, Antoni
   Soriano-Arandes, Antoni
   Battegay, Manuel
   Kouyos, Roger
   Mussini, Cristina
   Tookey, Pat
   Casabona, Jordi
   Miro, Jose M.
   Castagna, Antonella
   Konopnick, Deborah
   Goetghebuer, Tessa
   Sonnerborg, Anders
   Torti, Carlo
   Sabin, Caroline
   Teira, Ramon
   Garrido, Myriam
   Haerry, David
   de Wit, Stephane
   Miro, Jose M.
   Costagliola, Dominique
   d'Arminio-Monforte, Antonella
   Castagna, Antonella
   del Amo, Julia
   Mocroft, Amanda
   Raben, Dorthe
   Chene, Genevieve
   Judd, Ali
   Conejo, Pablo Rojo
   Barger, Diana
   Schwimmer, Christine
   Termote, Monique
   Wittkop, Linda
   Campbell, Maria
   Frederiksen, Casper M.
   Friis-Moller, Nina
   Kjaer, Jesper
   Raben, Dorthe
   Brandt, Rikke Salbol
   Berenguer, Juan
   Bohlius, Julia
   Bouteloup, Vincent
   Bucher, Heiner
   Cozzi-Lepri, Alessandro
   Dabis, Francois
   Monforte, Antonella d'Arminio
   Davies, Mary-Ann
   del Amo, Julia
   Dorrucci, Maria
   Dunn, David
   Egger, Matthias
   Furrer, Hansjakob
   Guiguet, Marguerite
   Grabar, Sophie
   Judd, Ali
   Kirk, Ole
   Lambotte, Olivier
   Leroy, Valeriane
   Lodi, Sara
   Matheron, Sophie
   Meyer, Laurence
   Ma Miro, Jose
   Mocroft, Amanda
   Monge, Susana
   Nakagawa, Fumiyo
   Paredes, Roger
   Phillips, Andrew
   Puoti, Massimo
   Rohner, Eliane
   Schomaker, Michael
   Smit, Colette
   Sterne, Jonathan
   Thiebaut, Rodolphe
   Thorne, Claire
   Torti, Carlo
   van der Valk, Marc
   Wittkop, Linda
   Abzug, Mark J.
   Hazra, Rohan
   Heckman, Barbara
   O'gara, Ellen
   Oleske, James
   Patel, Kunjal
   Seage, George R., III
   Van Dyke, Russell B.
   Williams, Paige L.
   Siminski, Suzanne
CA IeDEA
   COHERE
   PHACS
   IMPAACT 219C Collaborations
TI Global temporal changes in the proportion of children with advanced
   disease at the start of combination antiretroviral therapy in an era of
   changing criteria for treatment initiation
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE antiretroviral therapy; advanced HIV disease; CD4 cell count; WHO
   guidelines; sub-Saharan Africa; North America; Caribbean; Central and
   South America; Europe; Asia
ID HIV-INFECTED CHILDREN; HUMAN-IMMUNODEFICIENCY-VIRUS;
   POLYMERASE-CHAIN-REACTION; CHRONIC LUNG-DISEASE; SHORT-TERM RISK;
   HIV-1-INFECTED CHILDREN; MORTALITY; ADOLESCENTS; OUTCOMES; DIAGNOSIS
AB Introduction
   The CD4 cell count and percent at initiation of combination antiretroviral therapy (cART) are measures of advanced HIV disease and thus are important indicators of programme performance for children living with HIV. In particular, World Health Organization (WHO) 2017 guidelines on advanced HIV disease noted that >80% of children aged <5years started cART with WHO Stage 3 or 4 disease or severe immune suppression. We compared temporal trends in CD4 measures at cART start in children from low-, middle- and high-income countries, and examined the effect of WHO treatment initiation guidelines on reducing the proportion of children initiating cART with advanced disease.
   MethodsResultsWe included children aged <16years from the International Epidemiology Databases to Evaluate acquired immunodeficiency syndrome (AIDS) (IeDEA) Collaboration (Caribbean, Central and South America, Asia-Pacific, and West, Central, East and Southern Africa), the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), the North American Pediatric HIV/AIDS Cohort Study (PHACS) and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 219C study. Severe immunodeficiency was defined using WHO guidelines. We used generalized weighted additive mixed effect models to analyse temporal trends in CD4 measurements and piecewise regression to examine the impact of 2006 and 2010 WHO cART initiation guidelines.
   We included 52,153 children from fourteen low-, eight lower middle-, five upper middle- and five high-income countries. From 2004 to 2013, the estimated percentage of children starting cART with severe immunodeficiency declined from 70% to 42% (low-income), 67% to 64% (lower middle-income) and 61% to 43% (upper middle-income countries). In high-income countries, severe immunodeficiency at cART initiation declined from 45% (1996) to 14% (2012). There were annual decreases in the percentage of children with severe immunodeficiency at cART initiation after the WHO guidelines revisions in 2006 (low-, lower middle- and upper middle-income countries) and 2010 (all countries).
   Conclusions By 2013, less than half of children initiating cART had severe immunodeficiency worldwide. WHO treatment initiation guidelines have contributed to reducing the proportion of children and adolescents starting cART with advanced disease. However, considerable global inequity remains, in 2013, >40% of children in low- and middle-income countries started cART with severe immunodeficiency compared to <20% in high-income countries.
C1 [Panayidou, Klea; Anderegg, Nanina; Egger, Matthias] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.
   [Davies, Mary-Ann; Egger, Matthias; Boulle, Andrew] Univ Cape Town, Sch Publ Hlth & Family Med, Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa.
   [Fatti, Geoffrey] KhethImpilo, Cape Town, South Africa.
   [Fatti, Geoffrey] Stellenbosch Univ, Div Epidemiol & Biostat, Dept Global Hlth, Fac Med & Hlth Sci, Stellenbosch, South Africa.
   [Vinikoor, Michael] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA.
   [Vinikoor, Michael] Ctr Infect Dis Res Zambia, Lusaka, Zambia.
   [Vinikoor, Michael] Univ Zambia, Dept Med, Lusaka, Zambia.
   [Sawry, Shobna] Harriet Shezi Childrens Clin, Soweto, South Africa.
   [Sawry, Shobna] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa.
   [Ehmer, Jochen] Swiss Org Hlth Africa, SolidarMed, Luzern, Switzerland.
   [Eley, Brian] Univ Cape Town, Red Cross War Mem Childrens Hosp, Rondebosch, South Africa.
   [Eley, Brian] Univ Cape Town, Dept Paediat & Child Hlth, Rondebosch, South Africa.
   [Phiri, Sam] Lighthouse Trust Clin, Lilongwe, Malawi.
   [Technau, Karl-Gunter] Rahima Moosa Hosp, Empliweni Serv & Res Unit, Johannesburg, South Africa.
   [Technau, Karl-Gunter] Univ Witwatersrand, Johannesburg, South Africa.
   [Chimbetete, Cleophas] Newlands Clin, Harare, Zimbabwe.
   [Rabie, Helena] Univ Stellenbosch, Tygerberg Acad Hosp, Stellenbosch, South Africa.
   [Boulle, Andrew] Medecins San Frontieres, Khayelitsha, South Africa.
   [Boulle, Andrew] Khayelitsha ART Program, Khayelitsha, South Africa.
   [Tanser, Frank] Univ KwaZulu Natal, Africa Hlth Res Inst, Sch Nursing & Publ Hlth, Durban, South Africa.
   [Tanser, Frank] Hlabisa HIV Programme, Hlabisa, South Africa.
   [Wood, Robin] Univ Cape Town, Gugulethu HIV Program, Rondebosch, South Africa.
   [Wood, Robin] Univ Cape Town, Desmond Tutu HIV Ctr, Rondebosch, South Africa.
   [Wools-Kaloustian, Kara] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
   [Vreeman, Rachel] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.
   [Oyaro, Patrick] Family AIDS Care & Educ Serv, Kisumu, Kenya.
   [Ayaya, Samuel] MOI Univ, Dept Child Hlth & Pediat, Eldoret, Kenya.
   [Nakigozi, Gertrude] Rakai Hlth Sci Program, Kalisizo, Uganda.
   [Musick, Beverley; Yiannoutsos, Constantin] Indiana Univ, RM Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA.
   [Musick, Beverley; Yiannoutsos, Constantin] Indiana Sch Med, Dept Biostat, Indianapolis, IN USA.
   [Amorissani-Folquet, Madeleine] CHU Cocody, Abidjan, Cote Ivoire.
   [Takassi, Elom] CHU Sylvanus Olympio, Lome, Togo.
   [Sylla, Mariam] CHU Gabriel Toure, Bamako, Mali.
   [Renner, Lorna] KorleBu Hosp, Accra, Ghana.
   [Malateste, Karen] Univ Bordeaux, INSERM, UMR1219, Bordeaux, France.
   [Desmonde, Sophie; Leroy, Valeriane] Univ Toulouse 3, INSERM, UMR1027, Toulouse, France.
   [Kurniati, Nia] Cipto Mangunkusumo Gen Hosp, Jakarta, Indonesia.
   [Hansudewechakul, Rawiwan] Chiangrai Prachanukroh Hosp, Chiang Mai, Thailand.
   [Lam Van Nguyen] Natl Hosp Pediat, Hanoi, Vietnam.
   [Ly, Penh Sun] Natl Ctr HIV AIDS Dermatol & STDs, Phnom Penh, Cambodia.
   [Khanh Huu Truong] Childrens Hosp 1, Ho Chi Minh City, Vietnam.
   [Kariminia, Azar] UNSW, Kirby Inst, Sydney, NSW, Australia.
   [Sohn, Annette H.; Sohn, A. H.; Ross, J. L.; Sethaputra, C.] TREAT Asia AmfAR, Bangkok, Thailand.
   [Edmonds, Andrew] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
   [Yumo, Habakkuk Azinyui] Res Dev R4D Int, Yaounde, Cameroon.
   [Dusingize, Jean Claude] Rwanda Mil Hosp, Div Res & Clin Educ, Kanombe, Kigali, Rwanda.
   [Yotebieng, Marcel] Ohio State Univ, Div Epidemiol, Coll Publ Hlth, Columbus, OH 43210 USA.
   [Judd, Ali] UCL, MRC, Clin Trials Unit, London, England.
   [Rojo, Pablo] Univ Complutense Madrid, Hosp 12 Octubre, Dept Pediat, Madrid, Spain.
   [Smit, Colette] Stichting HIV Monitoring, Amsterdam, Netherlands.
   [Grabar, Sophie] UPMC Univ Paris 06, Sorbonne Univ, F-75013 Paris, France.
   [Grabar, Sophie] Inst Pierre Louis Epidemiol & Sante Publ, INSERM, UMR S 1136, F-75013 Paris, France.
   [Grabar, Sophie] Univ Paris 05, Paris, France.
   [Grabar, Sophie] Grp Hosp Cochin Hotel Dieu, AP HP, Paris, France.
   [Warszwarski, Josiane] 1018 Inserm, Ctr Rech Epidemiol & Sante Populat, Paris, France.
   [Chene, Genevieve] Univ Bordeaux, ISPED Bordeaux Sch Publ Hlth, Bordeaux Populat Hlth Res Ctr, Inserm,UMR1219, Bordeaux, France.
   [Raban, Dorthe] Univ Copenhagen, Rigshosp, Dept Infect Dis, Copenhagen, Denmark.
   [Patel, Kunjal; Seage, George R., III; Williams, Paige L.] Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Dept Epidemiol, Boston, MA USA.
   [Van Dyke, Russell B.] Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA.
   [Oleske, James] New Jersey Med Sch Rutgers, Div Pediat Allergy Immunol & Infect Dis, Newark, NJ USA.
   [Abzug, Mark J.] Univ Colorado, Sch Med, Dept Pediat Infect Dis, Aurora, CO USA.
   [Abzug, Mark J.] Childrens Hosp Colorado, Aurora, CO USA.
   [Succi, Regina; Machado, Daisy M.] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Rouzier, Vanessa; Wolff, Marcelo; Cortes, Claudia; Rodriguez, Maria Fernanda; Allendes, Gladys] Les Ctr GHESKIO, Port Au Prince, Haiti.
   [Luque, Marco] Hosp Escuela Univ, Tegucigalpa, Honduras.
   [Mejia, Fernando; Sierra Madero, Juan; Crabtree Ramirez, Brenda; Belaunzaran, Paco; Caro Vega, Yanink] Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Ly, P. S.; Khol, V.] Natl Ctr HIV AIDS Dermatol & STDs, Phnom Penh, Cambodia.
   [Tucker, J.] New Hope Cambodian Children, Phnom Penh, Cambodia.
   [Kumarasamy, N.; Saghayam, S.; Chandrasekaran, E.] CART CRS, YRGCARE Med Ctr, Madras, Tamil Nadu, India.
   [Wati, D. K.; Vedaswari, D.; Malino, I. Y.] Udayana Univ, Sanglah Hosp, Bali, Indonesia.
   [Kurniati, N.; Muktiarti, D.] Univ Indonesia, Cipto Mangunkusumo Fac Med, Jakarta, Indonesia.
   [Fong, S. M.; Lim, M.; Daut, F.] Hosp Likas, Kota Kinabalu, Malaysia.
   [Yusoff, N. K. Nik; Mohamad, P.] Hosp Raja Perempuan Zainab II, Kelantan, Malaysia.
   [Mohamed, T. J.; Drawis, M. R.] Hosp Kuala Lumpur, Inst Pediat, Kuala Lumpur, Malaysia.
   [Nallusamy, R.; Chan, K. C.] Penang Hosp, George Town, Malaysia.
   [Sudjaritruk, T.; Sirisanthana, V.; Aurpibul, L.; Oberdorfer, P.] Chiang Mai Univ, Fac Med, Dept Pediat, Chiang Mai, Thailand.
   [Sudjaritruk, T.; Sirisanthana, V.; Aurpibul, L.; Oberdorfer, P.] Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Hansudewechakul, R.; Denjanta, S.; Watanaporn, S.; Kongphonoi, A.] Chiangrai Prachanukroh Hosp, Chiang Rai, Thailand.
   [Lumbiganon, P.; Kosalaraksa, P.; Tharnprisan, P.; Udomphanit, T.] Khon Kaen Univ, Fac Med, Dept Pediat, Div Infect Dis, Khon Kaen, Thailand.
   [Jourdain, G.] IRD, UMI 174, PHPT, Chiang Mai, Thailand.
   [Jourdain, G.] Chiang Mai Univ, Chiang Mai, Thailand.
   [Puthanakit, T.; Anugulruengkitt, S.; Phadungphon, C.] Thai Red Cross AIDS Res Ctr, HIV NAT, Bangkok, Thailand.
   [Chokephaibulkit, K.; Lapphra, K.; Phongsamart, W.; Sricharoenchai, S.] Mahidol Univ, Fac Med, Dept Pediat, Siriraj Hosp, Bangkok, Thailand.
   [Truong, K. H.; Du, Q. T.; Nguyen, C. H.] Childrens Hosp 1, Ho Chi Minh City, Vietnam.
   [Do, V. C.; Ha, T. M.; An, V. T.] Childrens Hosp 2, Ho Chi Minh City, Vietnam.
   [Nguyen, L. V.; Khu, D. T. K.; Pham, A. N.; Nguyen, L. T.] Natl Hosp Pediat, Hanoi, Vietnam.
   [Le, O. N.] Worldwide Orphans Fdn, Ho Chi Minh City, Vietnam.
   [Law, M. G.; Kariminia, A.] UNSW Australia, Kirby Inst, Sydney, NSW, Australia.
   [Cahn, Pedro; Cesar, Carina; Fink, Valeria; Sued, Omar; Dell'Isola, Emanuel; Perez, Hector; Valiente, Jose; Yamamoto, Cleyton] Fiocruz MS, Inst Nacl Infectol, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz; Veloso, Valdilea; Luz, Paula; de Boni, Raquel; Wagner, Sandra Cardoso; Friedman, Ruth; Moreira, Ronaldo] Univ Fed Minas Gerais, Santa Maria, RS, Brazil.
   [Pinto, Jorge; Ferreira, Flavia; Maia, Marcelle] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [de Menezes Succi, Regina Celia; Maria Machado, Daisy; Barbosa Gouvea, Aida de Fatima] Fdn Arriaran, Santiago, Chile.
   [Rouzier, Vanessa; William Pape, Jean; Marcelin, Adias; Perodin, Christian] Hosp Escuela Univ, Tegucigalpa, Honduras.
   [Tulio Luque, Marco] Inst Hondureno Seguridad Social, La Ceiba, Honduras.
   [Padgett, Denis] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [Mejia, Fernando; Gotuzzo, Eduardo; Carriquiry, Gabriela] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Pelagie, Nimbona] ANSS, Bujumbura, Burundi.
   [Gateretse, Patrick; Munezero, Jeanine; Nitereka, Valentin; Niyongabo, Theodore; Twizere, Christelle] Ctr Natl Reference Matiere VIH SIDA, Bujumbura, Burundi.
   [Bukuru, Helene; Nahimana, Thierry] CHUK, Bujumbura, Burundi.
   [Biziragusenyuka, Jeremie; Manyundo, Risase Scholastique] HPRC, Bujumbura, Burundi.
   [Atsu, Kien; Mbuh, Tabeyang] Bamenda Hosp, Bamenda, Cameroon.
   [Ajeh, Rogers; Benwi, Mark; Dzudie, Anastase; Mbuh, Akindeh; Ngamani, Marc Lionel; Nkome, Victorine] CRENC, Yaounde, Cameroon.
   [Ajeh, Rogers; Benwi, Mark; Dzudie, Anastase; Mbuh, Akindeh; Ngamani, Marc Lionel; Nkome, Victorine] Douala Gen Hosp, Douala, Cameroon.
   [Amadou, Djenabou; Ngassam, Eric; Yone, Eric Walter Pefura] Jamot Hosp, Yaounde, Cameroon.
   [Ewanoge, Alice Ndelle; Fuhngwa, Norbert; Moki, Chris] Limbe Reg Hosp, Limbe, Cameroon.
   [Akele, Catherine; Kitetele, Faustin; Lelo, Patricia; Tabala, Martine] Kalembelembe Pediat Hosp, Kinshasa, DEM REP CONGO.
   [Okitolonda, Emile Wemakoy; Wenzi, Landry] Kinshasa Sch Publ Hlth, Kinshasa, DEM REP CONGO.
   [Diafouka, Merlin; Ekat, Martin Herbas; Nsonde, Dominique Mahambou] CTA Brazzaville, Brazzaville, Rep Congo.
   [Mafou, Adolphe] CTA Pointe Noire, Pointe Noire, Rep Congo.
   [Ntarambirwa, Fidele] Bethsaida Hosp, Kigali, Rwanda.
   [Tuyishimire, Yvonne] Busanza Hlth Ctr, Kigali, Rwanda.
   [Hakizimana, Theogene] Gahanga Hlth Ctr, Kigali, Rwanda.
   [Ayinkamiye, Josephine] Gikondo Hlth Ctr, Kigali, Rwanda.
   [Mukantwali, Sandrine] Kabuga Hlth Ctr, Kigali, Rwanda.
   [Kayitesi, Henriette; Uwamahoro, Olive] Kicukiro Hlth Ctr, Kigali, Rwanda.
   [Habumuremyi, Viateur] Masaka Hlth Ctr, Kigali, Rwanda.
   [Mukamana, Joyce] Nyarugunga Hlth Ctr, Kigali, Rwanda.
   [Dusingize, Jean Claude; Kubwimana, Gallican; Mugenzi, Pacifique; Muhoza, Benjamin; Munyaneza, Athanase; Ndahiro, Emmanuel; Nyiransabimana, Diane; Sinayobye, Jean d'Amour; Sugira, Vincent] Rwanda Mil Hosp, Kigali, Rwanda.
   [Benekigeri, Chantal; Mbaraga, Gilbert] WE ACTx Hlth Ctr, Kigali, Rwanda.
   [Benekigeri, Chantal; Mbaraga, Gilbert] Coordinating & Data Ctr, Kigali, Rwanda.
   [Adedimeji, Adebola; Anastos, Kathryn; Dilorenzo, Madeline; Murchison, Lynn; Ross, Jonathan] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Addison, Diane; Baker, Meg; Brazier, Ellen; Jones, Heidi; Kelvin, Elizabeth; Kulkarni, Sarah; Nash, Denis; Tymejczyk, Olga] CUNY, Sch Publ Hlth, New York, NY 10021 USA.
   [Elul, Batya] Columbia Univ, New York, NY 10027 USA.
   [Cai, Xiatao; Hoover, Don; Kim, Hae-Young; Li, Chunshan; Shi, Qiuhu] Data Solut, Wixom, MI USA.
   [Yotebieng, Marcel; Lancaster, Kathryn] Ohio State Univ, Columbus, OH 43210 USA.
   [Kuniholm, Mark] SUNY Albany, Albany, NY 12222 USA.
   [Edmonds, Andrew; Parcesepe, Angela] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Duda, Stephany] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Kimmel, April] Virginia Commonwealth Univ, Sch Med, Richmond, VA 23284 USA.
   [McNairy, Margaret] Weill Cornell Med Ctr, New York, NY USA.
   [Ayaya, Samuel; Diero, Lameck] MOI Univ, AMPATH Plus, Eldoret, Kenya.
   [Bukusi, Elizabeth] Kenya Med Res Inst KEMRI, Kisumu, Kenya.
   [Ssali, John] Masaka Reg Referral Hosp, Masaka, Uganda.
   [Nalugoda, Fred] Rakai Hlth Sci Program, Kalisizo, Uganda.
   [Somi, G. R.] NACP, Dar Es Salaam, Tanzania.
   [Lyamuya, Rita Elias] Morogoro Reg Hosp, Morogoro, Tanzania.
   [Ngonyani, Kapella] Tumbi Reg Hosp, Pwani, Tanzania.
   [Lugina, Emanuel] Ocean Rd Canc Inst, Dar Es Salaam, Tanzania.
   [Urassa, Mark; Michael, Denna] Natl Inst Med Res NIMR Kisesa HDSS, Mwanza, Tanzania.
   [Zannou, Marcel Djimon] CNHU, Cotonou, Benin.
   [Poda, Armel] CHU Souro Sanou, Bobo Dioulasso, Burkina Faso.
   [Sarfo, Fred Stephen] Komfo Anokeye Teaching Hosp, Kumasi, Ghana.
   [Messou, Eugene] ACONDA CePReF, Abidjan, Cote Ivoire.
   [Chenal, Henri] CIRBA, Abidjan, Cote Ivoire.
   [Minga, Kla Albert] CNTS, Abidjan, Cote Ivoire.
   [Bissagnene, Emmanuel; Tanon, Aristophane] CHU Treichville, Abidjan, Cote Ivoire.
   [Seydi, Moussa] CHU Fann, Dakar, Senegal.
   [Patassi, Akessiwe Akouda] CHU Sylvanus Olympio, Lome, Togo.
   [Koumakpai-Adeothy, Sikiratou Adouni] CNHU, Cotonou, Benin.
   [Renner, Lorna Awo] Korle Bu Hosp, Accra, Ghana.
   [N'Gbeche, Sylvie Marie] ACONDA CePReF, Abidjan, Cote Ivoire.
   [Bosse, Clarisse Amani] ACONDA MTCT, Abidjan, Cote Ivoire.
   [Kouakou, Kouadio] CIRBA, Abidjan, Cote Ivoire.
   [Folquet, Madeleine Amorissani] CHU Cocody, Abidjan, Cote Ivoire.
   [Eboua, Francois Tanoh] CHU Yopougon, Abidjan, Cote Ivoire.
   [Sylla, Mariam; Traore, Fatoumata Dicko] Hop Gabriel Toure, Bamako, Mali.
   [Takassi, Elom] CHU Sylvanus Olympio, Lome, Togo.
   [Takassi, Elom] Coordinating & Data Ctr, Lome, Togo.
   [Malateste, Karen; Dabis, Francois; Arrive, Elise; Balestre, Eric; Becquet, Renaud; Bernard, Charlotte; Arikawa, Shino Chassagne; Doring, Alexandra; Jaquet, Antoine; Rabourdin, Elodie; Tiendrebeogo, Thierry] Isped, ADERA, Bordeaux, France.
   [Malateste, Karen; Dabis, Francois; Arrive, Elise; Balestre, Eric; Becquet, Renaud; Bernard, Charlotte; Arikawa, Shino Chassagne; Doring, Alexandra; Jaquet, Antoine; Rabourdin, Elodie; Tiendrebeogo, Thierry] INSERM, U1219, Bordeaux, France.
   [Desmonde, Sophie; Jesson, Julie; Leroy, Valeriane] INSERM, U1027, Toulouse, France.
   [Ekouevi, Didier Koumavi; Azani, Jean-Claude; Coffie, Patrick; Gnepa, Guy; Kouadio, Christian Gerard Kaugbouh; Tchounga, Boris] CHU Treichville, PACCI, Abidjan, Cote Ivoire.
   [Maartens, Gary] Aid AIDS, Pretoria, South Africa.
   [Vinikoor, Michael] Ctr Infect Dis Res Zambia CIDRZ, Lusaka, Zambia.
   [von Lettow, Monique] Dignitas, Zomba, Malawi.
   [Wood, Robin] Gugulethu ART Programme, Pretoria, South Africa.
   [Sawry, Shobna] Harriet Shezi Childrens Clin, Johannesburg, South Africa.
   [Tanser, Frank] Africa Hlth Res Inst Hlabisa, Hlabisa, South Africa.
   [Tanser, Frank] Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Durban, South Africa.
   [Boulle, Andrew] Khayelitsha ART Programme, Cape Town, South Africa.
   [Fatti, Geoffrey] KhethImpilo, Pietermaritzburg, South Africa.
   [Phiri, Sam] Lighthouse Clin, Lilongwe, Malawi.
   [Chimbetete, Cleophas] Newlands Clin, Harare, Zimbabwe.
   [Technau, Karl-Gunther] Rahima Moosa Mother & Child Hosp, Johannesburg, South Africa.
   [Eley, Brian] Red Cross Childrens Hosp, Cape Town, South Africa.
   [Muhairwe, Josephine] SolidarMed Lesotho, Maseru, Lesotho.
   [Jores, Anna] SolidarMed Mozambique, Maputo, Mozambique.
   [Kamenova, Kamelia] SolidarMed Zimbabwe, Masvingo, Zimbabwe.
   [Fox, Matthew P.] Themba Lethu Clin, George, South Africa.
   [Prozesky, Hans] Tygerberg Acad Hosp, Tygerberg, South Africa.
   [Touloumi, Giota] AMACS, Houston, TX USA.
   [Obel, Niels] Danish HIV Cohort, Copenhagen, Denmark.
   [Prieto, Luis] Madrid PMTCT Cohort, Madrid, Spain.
   [Rojo Conejo, Pablo] CORISPES Madrid, Madrid, Spain.
   [Mussini, Cristina] Modena Cohort, Modena, Italy.
   [Torti, Carlo] Italian Master Cohort, Milan, Italy.
   [Haerry, David] European AIDS Treatment Grp, Brussels, Belgium.
   [de Wit, Stephane] St Pierre Univ Hosp, Brussels, Belgium.
   [Raben, Dorthe] Copenhagen Reg Coordinating Ctr, Copenhagen, Denmark.
   [Chene, Genevieve] Bordeaux Reg Coordinating Ctr, Bordeaux, France.
   [Judd, Ali; Conejo, Pablo Rojo] Bordeaux RCC, Reg Coordinating Ctr, Bordeaux, France.
   [Wittkop, Linda; Barger, Diana; Schwimmer, Christine; Termote, Monique] Copenhagen RCC, Copenhagen, Denmark.
RP Davies, MA (corresponding author), Univ Cape Town, Fac Hlth Sci, Falmouth Bldg,Anzio Rd, ZA-7925 Cape Town, South Africa.
EM mary-ann.davies@uct.ac.za
RI Puoti, Massimo/AAA-6580-2020; Nallusamy, Revathy/V-3443-2019; Berenguer,
   Juan/A-1347-2009; Desmonde, Sophie/E-4748-2019; Jourdain,
   Gonzague/F-9117-2017; Jesson, Julie/X-3007-2019; Furrer,
   Hansjakob/G-6768-2013; Wittkop, Linda/E-3319-2014; Arandes, Antonio
   Soriano/Q-3348-2016; Arriv\\xc3\\xa9, Elise/T-9126-2019; DABIS,
   FRANCOIS/S-9298-2019; Prozesky, Hans/ABE-6956-2020; van der valk,
   marc/AAQ-9026-2020; Stephan, Christoph J/D-1305-2014; Becquet,
   Renaud/F-4837-2013; Sterne, Jonathan/Z-3106-2019; Sonnerborg,
   Anders/W-2011-2019; , Leroy/F-8129-2013; PEREZ, HECTOR M./S-9366-2019;
   Pinto, Jorge A/D-1743-2014; DE BONI, RAQUEL BRANDINI/D-4212-2013;
   Soriano-Arandes, Antoni/G-6851-2013; Desmonde, Sophie/AAC-3850-2019;
   Cortes, Claudia/AAF-7326-2020; Guiguet, Marguerite/L-8480-2018; Leroy,
   Valeriane/AAO-5175-2020; Wit, Ferdinand/AAC-3803-2019; EKOUEVI, Didier
   K/E-7960-2014; Fatti, Geoffrey/AAA-9217-2019; Grabar,
   Sophie/AAM-9857-2020; Thiebaut, Rodolphe/T-6803-2019; Thorne,
   Claire/C-5943-2008
OI Berenguer, Juan/0000-0001-8541-8200; Desmonde,
   Sophie/0000-0001-9372-2819; Jourdain, Gonzague/0000-0002-3365-7020;
   Furrer, Hansjakob/0000-0002-1375-3146; Wittkop,
   Linda/0000-0003-2403-0960; Arandes, Antonio Soriano/0000-0001-9613-7228;
   DABIS, FRANCOIS/0000-0002-1614-8857; Prozesky, Hans/0000-0001-9715-3449;
   Stephan, Christoph J/0000-0003-3777-9006; Becquet,
   Renaud/0000-0003-3277-0985; Sterne, Jonathan/0000-0001-8496-6053;
   Sonnerborg, Anders/0000-0001-8928-3374; , Leroy/0000-0003-3542-8616;
   Pinto, Jorge A/0000-0003-2987-3238; DE BONI, RAQUEL
   BRANDINI/0000-0002-2455-5997; Desmonde, Sophie/0000-0001-9372-2819;
   Cortes, Claudia/0000-0001-9101-9783; Leroy,
   Valeriane/0000-0003-3542-8616; Fatti, Geoffrey/0000-0002-6467-662X;
   Thorne, Claire/0000-0003-0389-1956; Egger, Matthias/0000-0001-7462-5132;
   Rabie, Helena/0000-0001-6336-2963; Puoti, Massimo/0000-0003-3278-7138;
   Anderegg, Nanina/0000-0002-8238-8832
FU National Institute of Allergy And Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child
   Health and Human Development (NICHD)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD); National Cancer Institute (NCI)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI); National Institute of Mental Health
   (NIMH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH); National Institute on Drug Abuse (NIDA)United States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [U01AI069907, U01AI069923,
   U01AI096299, U01AI069911, U01AI069924, U01AI069919]; Australian
   Government Department of Health and AgeingAustralian
   GovernmentDepartment of Health & Ageing; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA;
   NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [N01-HD-3-3345,
   N01-HD-8-0001]; Agence Nationale de Recherches sur le SIDA et les
   Hepatites Virales (ANRS), FranceANRS; Augustinus Foundation, Denmark;
   Dutch Ministry of Health, Welfare and Sport through the Centre for
   Infectious Disease Control of the National Institute for Public Health
   and the Environment, The Netherlands; European UnionEuropean Union (EU)
   [260694]; NICHDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD);
   National Institute Of Dental & Craniofacial Research (NIDCR)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Dental & Craniofacial
   Research (NIDCR); NIAIDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); National Institute Of
   Neurological Disorders And Stroke (NINDS)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Neurological Disorders & Stroke (NINDS); National
   Institute On Deafness And Other Communication Disorders (NIDCD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Deafness & Other
   Communication Disorders (NIDCD); Office of AIDS Research (OAR)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA; NIMHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH); National Institute On Drug Abuse (NIDA)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); National
   Institute On Alcohol Abuse And Alcoholism (NIAAA)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA);
   Harvard T.H. Chan School of Public Health [HD052102]; Tulane University
   School of Medicine [HD052104]; NIAIDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01AI068632]; NICHD
   International and Domestic Pediatric and Maternal HIV Clinical Trials
   Network - NICHDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [N01-3-3345, HHSN267200800001C]; Statistical and Data Analysis Center at
   Harvard School of Public Health, under NIAIDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI41110]; Pediatric AIDS Clinical Trials Group (PACTG); IMPAACT
   Group [U01AI068616]; Swiss National Science FoundationSwiss National
   Science Foundation (SNSF) [174281]; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [U01HD052102, U01HD052102, U01HD052102, U01HD052102,
   U01HD052104, U01HD052102, U01HD052102, U01HD052102, U01HD052104,
   U01HD052102, U01HD052104, U01HD052104] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI069919, U01AI069923, U01AI069919, U01AI096299, U01AI069907,
   U01AI069924, U01AI096299, U01AI069911, U01AI069924, U01AI069911,
   U01AI069907, U01AI069924, U01AI069911, U01AI069911, U01AI069907,
   U01AI069911, U01AI069919, U01AI096299, U01AI096299, UM1AI068616,
   U01AI069919, UM1AI068616, U01AI069924, U01AI069919, U01AI069924,
   UM1AI068616, U01AI069911, U01AI069923, U01AI096299, UM1AI068616,
   U01AI069923, U01AI069907] Funding Source: NIH RePORTER
FX The International Epidemiology Databases to Evaluate AIDS (IeDEA)
   collaboration is supported by the core regional IeDEA grants through the
   National Institute of Allergy And Infectious Diseases (NIAID), the
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD), the National Cancer Institute (NCI), the National
   Institute of Mental Health (NIMH) and the National Institute on Drug
   Abuse (NIDA): U01AI069907 (Asia-Pacific), U01AI069923 (CCASAnet),
   U01AI096299 (Central Africa), U01AI069911 (East Africa), U01AI069924
   (Southern Africa), U01AI069919 (West Africa). The Kirby Institute is
   funded by the Australian Government Department of Health and Ageing, and
   is affiliated with the Faculty of Medicine, University of New South
   Wales. The NICHD Site Development Initiative (NISDI) was funded by the
   NIH and NICHD (contracts N01-HD-3-3345 and N01-HD-8-0001). The COHERE
   study group has received unrestricted funding from: Agence Nationale de
   Recherches sur le SIDA et les Hepatites Virales (ANRS), France and the
   Augustinus Foundation, Denmark. The Netherlands ATHENA database is
   maintained by Stichting HIV Monitoring and supported by a grant from the
   Dutch Ministry of Health, Welfare and Sport through the Centre for
   Infectious Disease Control of the National Institute for Public Health
   and the Environment, The Netherlands. The research leading to these
   results has received funding from the European Union Seventh Framework
   Programme (FP7/2007-2013) under EuroCoord grant agreement no. 260694. A
   list of the funders of the participating cohorts can be found at
   www.COHERE.org.The Pediatric HIV/AIDS Cohort Study (PHACS) was supported
   by NICHD with co-funding from the National Institute Of Dental &
   Craniofacial Research (NIDCR), NIAID, the National Institute Of
   Neurological Disorders And Stroke (NINDS), the National Institute On
   Deafness And Other Communication Disorders (NIDCD), Office of AIDS
   Research (OAR), NIMH, the National Institute On Drug Abuse (NIDA) and
   the National Institute On Alcohol Abuse And Alcoholism (NIAAA), through
   cooperative agreements with the Harvard T.H. Chan School of Public
   Health (HD052102) and the Tulane University School of Medicine
   (HD052104). Overall support for the International Maternal Pediatric
   Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by NIAID
   [U01AI068632] and the NICHD International and Domestic Pediatric and
   Maternal HIV Clinical Trials Network supported by NICHD [contract
   N01-3-3345 and HHSN267200800001C]. This work was supported by the
   Statistical and Data Analysis Center at Harvard School of Public Health,
   under NIAID cooperative agreement U01AI41110 with the Pediatric AIDS
   Clinical Trials Group (PACTG) and U01AI068616 with the IMPAACT Group.
   This study was also supported by special project funding (Grant No.
   174281) from the Swiss National Science Foundation.
CR Abrams EJ, 2015, J INT AIDS SOC, V18, P7, DOI 10.7448/IAS.18.7.20296
   Anaky MF, 2010, B WORLD HEALTH ORGAN, V88, P490, DOI 10.2471/BLT.09.068015
   Attia EF, 2017, CURR OPIN INFECT DIS, V30, P21, DOI 10.1097/QCO.0000000000000325
   Brady MT, 2010, JAIDS-J ACQ IMM DEF, V53, P86, DOI 10.1097/QAI.0b013e3181b9869f
   Chatterjee A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-553
   Chene G, 2017, INT J EPIDEMIOL, V46, P797, DOI 10.1093/ije/dyw211
   Cohen S, 2015, JAIDS-J ACQ IMM DEF, V68, P178, DOI 10.1097/QAI.0000000000000431
   Creek T, 2008, PEDIATR INFECT DIS J, V27, P22, DOI 10.1097/INF.0b013e3181469050
   Davies MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081037
   Desai SR, 2018, CLIN INFECT DIS, V66, P274, DOI 10.1093/cid/cix778
   Dunn D, 2008, J INFECT DIS, V197, P398, DOI 10.1086/524686
   Dunn DT, 2003, LANCET, V362, P1605
   Edmonds A, 2012, JAIDS-J ACQ IMM DEF, V61, P90, DOI 10.1097/QAI.0b013e31825bd9b7
   Ferrand R, 2010, B WORLD HEALTH ORGAN, V88, P428, DOI 10.2471/BLT.09.066126
   Ferrand RA, 2010, CLIN INFECT DIS, V51, P844, DOI 10.1086/656361
   Gibb DM, 2008, AIDS, V22, P97
   IeDEA Pediatric Working Group, 2013, J Int AIDS Soc, V16, P17998, DOI 10.7448/IAS.16.1.17998
   de Jose MI, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-2
   Judd A, 2007, CLIN INFECT DIS, V45, P918, DOI 10.1086/521167
   Koller M, 2015, JAIDS-J ACQ IMM DEF, V68, P62, DOI 10.1097/QAI.0000000000000380
   Krogstad P, 2015, AIDS, V29, P683, DOI 10.1097/QAD.0000000000000598
   Laughton B, 2012, AIDS, V26, P1685, DOI 10.1097/QAD.0b013e328355d0ce
   Leroy V, 2013, JAIDS-J ACQ IMM DEF, V62, P208, DOI 10.1097/QAI.0b013e31827b70bf
   Musoke P, 2015, AIDS, V29, P1623, DOI [10.1097/QAD.0000000000000749, 10.1097/QAD.0000000000000590]
   Nuwagaba-Biribonwoha H, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-44
   Patel K, 2008, CLIN INFECT DIS, V46, P1751, DOI 10.1086/587900
   Puthanakit T, 2012, LANCET INFECT DIS, V12, P933, DOI 10.1016/S1473-3099(12)70242-6
   Rubin DB, 1987, MUTIPLE IMPUTATION N
   Rylance J, 2016, AIDS, V30, P2795, DOI 10.1097/QAD.0000000000001249
   Schomaker M, 2016, EPIDEMIOLOGY, V27, P237, DOI 10.1097/EDE.0000000000000412
   Sherman GG, 2005, PEDIATR INFECT DIS J, V24, P993, DOI 10.1097/01.inf.0000187036.73539.8d
   UNAIDS, 2017, AIDSINFO ONL DAT
   UNAIDS, 2014, 90 90 90 AMB TREATM
   Van Dyke RB, 2011, JAIDS-J ACQ IMM DEF, V57, P165, DOI 10.1097/QAI.0b013e318215c7b1
   Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971
   Williams PL, 2008, AM J EPIDEMIOL, V167, P1375, DOI 10.1093/aje/kwn072
   Williams PL, 2013, AIDS, V27, P1959, DOI 10.1097/QAD.0b013e328361195b
   World Bank, 2013, CHANG COUNTR CLASS
   World Health Organization, 2015, GUID START ANT THER
NR 39
TC 1
Z9 1
U1 0
U2 16
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD NOV 22
PY 2018
VL 21
IS 11
AR e25200
DI 10.1002/jia2.25200
PG 16
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA HC5HX
UT WOS:000451835200001
PM 30614622
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Cardoso, SW
   Yanavich, C
   Nunes, EP
   Morata, M
   Gorni, N
   da Silva, PS
   Cardoso, C
   Almeida, C
   Luz, P
   Veloso, VG
   Grinsztejn, B
AF Perazzo, Hugo
   Cardoso, Sandra W.
   Yanavich, Carolyn
   Nunes, Estevao P.
   Morata, Michelle
   Gorni, Nathalia
   da Silva, Paula Simplicio
   Cardoso, Claudia
   Almeida, Cristiane
   Luz, Paula
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI Predictive factors associated with liver fibrosis and steatosis by
   transient elastography in patients with HIV mono-infection under
   long-term combined antiretroviral therapy
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE liver disease; hepatic fibrosis; fatty liver; HIV infection; HIV care
   continuum
ID CONTROLLED ATTENUATION PARAMETER; FATTY LIVER; METABOLIC SYNDROME;
   HEPATIC-FIBROSIS; PREVALENCE; DIAGNOSIS; DISEASE; ADULTS;
   STEATOHEPATITIS; VARIABILITY
AB Introduction
   Non-alcoholic fatty liver disease is characterized by the presence of hepatic steatosis and can be associated with fibrosis progression, development of cirrhosis and liver-related complications. Data on the prevalence of liver fibrosis and steatosis in HIV patients remain contradictory in resource-limited settings. We aimed to describe the prevalence and factors associated with liver fibrosis and steatosis in patients with HIV mono-infection under long-term antiretroviral therapy (ART) in Rio de Janeiro, Brazil.
   MethodsResultsClinical assessment, fasting blood collection and liver stiffness measurement (LSM)/controlled attenuation parameter (CAP) by transient elastography were performed on the same day for this cross-sectional study (PROSPEC-HIV study; NCT02542020). Patients with viral hepatitis co-infection, ART-naive or missing data were excluded. Liver fibrosis and steatosis were defined by LSM8.0kPa and CAP248dB/m respectively. HIV history, cumulative and current ART regimens were evaluated. Multivariate logistic regression models adjusted for age and gender were performed.
   In total, 395 patients (60% female; median age of 45 (IQR, 35 to 52) years, body mass index=25.7 (23.2 to 29.4) kg/m(2), alanine aminotransferase=30 (23 to 42) IU/L, duration of ART for 7 (4 to 14) years) were included. LSM and CAP were reliable in 93% (n=367) and 87% (n=344) respectively. The prevalence of fibrosis and steatosis were 9% (95% confidence interval (CI), 7 to 13) and 35% (95% CI, 30 to 40) respectively. The following factors were associated with fibrosis (odds ratio (OR) (95% CI)): older age (per 10years; 1.80 (1.27 to 2.55); p=0.001) and CD4+ count <200cells/mm(3) (7.80 (2.09 to 29.09), p=0.002). Type 2 diabetes had a trend towards the presence of liver fibrosis (2.67 (0.96 to 7.46), p=0.061). Central obesity (10.74 (4.40 to 26.20), p<0.001), type 2 diabetes (9.74 (3.15 to 30.10), p<0.001), dyslipidaemia (2.61 (1.35 to 5.05), p=0.003) and metabolic syndrome (4.28 (2.45 to 7.46), p<0.001) were associated with steatosis. A dominant backbone ART regimen of zidovudine (AZT), d4T, ddI or ddC was associated with steatosis (1.90 (1.07 to 3.38), p=0.028) independently of metabolic features.
   ConclusionIntegrated strategies for preventing non-communicable diseases in people with HIV mono-infection are necessary to decrease the burden of liver diseases. Clinical Trial Number: NCT02542020.
C1 [Perazzo, Hugo; Cardoso, Sandra W.; Yanavich, Carolyn; Nunes, Estevao P.; Morata, Michelle; Luz, Paula; Veloso, Valdilea G.; Grinsztejn, Beatriz] Evandro Chagas Oswaldo Cruz Fdn INI FIOCRUZ, Natl Inst Infect Dis, Lab Clin Res STI AIDS LAPCLIN, Rio De Janeiro, Brazil.
   [Morata, Michelle] Evandro Chagas Oswaldo Cruz Fdn INI FIOCRUZ, Natl Inst Infect Dis, Plataform Clin Res, Rio De Janeiro, Brazil.
   [Gorni, Nathalia; da Silva, Paula Simplicio; Cardoso, Claudia; Almeida, Cristiane] Evandro Chagas Oswaldo Cruz Fdn INI FIOCRUZ, Natl Inst Infect Dis, Dept Nutr, Rio De Janeiro, Brazil.
RP Perazzo, H (corresponding author), INI FIOCRUZ, LAPCLIN AIDS, Av Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM perazzohugo@gmail.com
OI Simplicio da Silva, Paula/0000-0002-7414-9698; Luz,
   Paula/0000-0001-9746-719X; Perazzo, Hugo/0000-0003-0931-6418
FU International Society for Infectious Diseases (ISID Research Grant
   2016); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do
   Rio de JaneiroCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ) [E-26/110.268/2014]; Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq) - Universal
   2016National Council for Scientific and Technological Development (CNPq)
   [405.211/2016-3]; Programa Ciencias Sem Fronteiras -Bolsa Jovens
   Talentos/CNPq [407.410/2013-9, 301.520/2014-3]
FX This study was supported by the International Society for Infectious
   Diseases (ISID Research Grant 2016 to HP); Fundacao Carlos Chagas Filho
   de Amparo a Pesquisa do Estado do Rio de Janeiro (E-26/110.268/2014 to
   VGV); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq) - Universal 2016 (405.211/2016-3 to HP) and Programa Ciencias Sem
   Fronteiras -Bolsa Jovens Talentos/CNPq (407.410/2013-9 to BG and
   301.520/2014-3 to HP). The funders had no role in study design, data
   collection and analysis, decision to publish or preparation of the
   manuscript.
CR Akinwande M. O., 2015, OPEN J STAT, V5, P754, DOI [10.4236/ojs.2015.57075, DOI 10.4236/OJS.2015.57075]
   Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
   [Anonymous], 2017, GUID MAN TREATM HIV
   Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022
   Bellentani S, 2017, LIVER INT, V37, P81, DOI 10.1111/liv.13299
   Bota S, 2013, LIVER INT, V33, P1138, DOI 10.1111/liv.12240
   Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706
   Caron-Debarle M, 2010, CURR PHARM DESIGN, V16, P3352, DOI 10.2174/138161210793563446
   Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367
   Coghlan ME, 2001, CLIN INFECT DIS, V33, P1914, DOI 10.1086/323783
   de Ledinghen V, 2008, GASTROEN CLIN BIOL, V32, P58, DOI 10.1016/S0399-8320(08)73994-0
   Diehl AM, 2017, NEW ENGL J MED, V377, P2063, DOI 10.1056/NEJMra1503519
   Fernandes FF, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8252980
   Franzeck FC, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-90
   Glassner A, 2013, J HEPATOL, V59, P427, DOI 10.1016/j.jhep.2013.04.029
   Grattagliano I, 2012, CLIN BIOCHEM, V45, P610, DOI 10.1016/j.clinbiochem.2012.03.024
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Karlas T, 2017, J HEPATOL, V66, P1022, DOI 10.1016/j.jhep.2016.12.022
   Koehler EM, 2016, HEPATOLOGY, V63, P138, DOI 10.1002/hep.27981
   Koethe JR, 2016, AIDS RES HUM RETROV, V32, P50, DOI 10.1089/aid.2015.0147
   Lemoine M, 2017, AIDS, V31, P1955, DOI 10.1097/QAD.0000000000001587
   Lombardi R, 2016, DIGEST LIVER DIS, V48, P1471, DOI 10.1016/j.dld.2016.08.117
   Loomba R, 2018, J HEPATOL, V68, P296, DOI 10.1016/j.jhep.2017.11.028
   Lui G, 2016, ALIMENT PHARM THER, V44, P411, DOI 10.1111/apt.13702
   Macias J, 2016, HIV MED, V17, P766, DOI 10.1111/hiv.12384
   Macias J, 2017, CLIN INFECT DIS, V65, P1012, DOI 10.1093/cid/cix467
   Maurice JB, 2017, AIDS, V31, P1621, DOI 10.1097/QAD.0000000000001504
   Mohr R, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002127
   Morse CG, 2015, AIDS, V29, P2297, DOI 10.1097/QAD.0000000000000841
   Morse CG, 2015, CLIN INFECT DIS, V60, P1569, DOI 10.1093/cid/civ101
   Pembroke T, 2017, J HEPATOL, V67, P801, DOI 10.1016/j.jhep.2017.05.011
   Perazzo H, 2015, INT J HEPATOL, V2015, DOI 10.1155/2015/624596
   Perazzo H, 2015, LIVER INT, V35, P1533, DOI 10.1111/liv.12551
   Platt L, 2016, LANCET INFECT DIS, V16, P797, DOI 10.1016/S1473-3099(15)00485-5
   Poynard T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003857
   Price JC, 2017, AIDS, V31, P2119, DOI 10.1097/QAD.0000000000001601
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Tsai E, 2018, CLIN LIVER DIS, V22, P73, DOI 10.1016/j.cld.2017.08.004
   Wong VWS, 2017, J HEPATOL, V67, P577, DOI 10.1016/j.jhep.2017.05.005
   World Health Organization, 2011, PROGR REP 2011 GLOB
NR 40
TC 11
Z9 11
U1 1
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD NOV 5
PY 2018
VL 21
IS 11
AR e25201
DI 10.1002/jia2.25201
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA HC5HY
UT WOS:000451835300001
PM 30394678
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Landovitz, RJ
   Li, S
   Grinsztejn, B
   Dawood, H
   Liu, AY
   Magnus, M
   Hosseinipour, MC
   Panchia, R
   Cottle, L
   Chau, G
   Richardson, P
   Marzinke, MA
   Hendrix, CW
   Eshleman, SH
   Zhang, YF
   Tolley, E
   Sugarman, J
   Kofron, R
   Adeyeye, A
   Burns, D
   Rinehart, AR
   Margolis, D
   Spreen, WR
   Cohen, MS
   McCauley, M
   Eron, JJ
AF Landovitz, Raphael J.
   Li, Sue
   Grinsztejn, Beatriz
   Dawood, Halima
   Liu, Albert Y.
   Magnus, Manya
   Hosseinipour, Mina C.
   Panchia, Ravindre
   Cottle, Leslie
   Chau, Gordon
   Richardson, Paul
   Marzinke, Mark A.
   Hendrix, Craig W.
   Eshleman, Susan H.
   Zhang, Yinfeng
   Tolley, Elizabeth
   Sugarman, Jeremy
   Kofron, Ryan
   Adeyeye, Adeola
   Burns, David
   Rinehart, Alex R.
   Margolis, David
   Spreen, William R.
   Cohen, Myron S.
   McCauley, Marybeth
   Eron, Joseph J.
TI Safety, tolerability, and pharmacokinetics of long-acting injectable
   cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase
   2a randomized controlled trial
SO PLOS MEDICINE
LA English
DT Article
ID PREEXPOSURE PROPHYLAXIS; PROTECTS MACAQUES; PREVENTION; MEN;
   RILPIVIRINE; ADULTS; 2B
AB Background
   Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States.
   Methods and findings
   HPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age 18-65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those without safety concerns in the oral phase continued and received injections in the injection phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2 injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary outcomes included pharmacokinetics and events occurring during the oral and injection phases. Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant population characteristics were as follows: 66% female at birth; median age 31 years; 27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/ other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants discontinued the oral study product; 6 of these were for clinical or laboratory adverse events (AEs). Of those who received at least 1 CAB LA injection, 80% of Cohort 1 and 92% of Cohort 2 participants completed all injections; injection course completion rates were not different from those in the PBO arm. Injection site reactions (ISRs) were common (92% of Cohort 1 and 88% of Cohort 2 participants who received CAB LA reported any ISR). ISRs were mostly Grade 1 (mild) to Grade 2 (moderate), and 1 ISR event (Cohort 1) led to product discontinuation. Grade 2 or higher ISRs were the only AEs reported more commonly among CAB LA recipients than PBO recipients. Two Grade 3 (severe) ISRs occurred in CAB recipients, 1 in each cohort, but did not lead to product discontinuation in either case. Seven incident sexually transmitted infections were diagnosed in 6 participants. One HIV infection occurred in a participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test. Participants in Cohort 2 (unlike Cohort 1) consistently met prespecified pharmacokinetic targets of at least 95% of participants maintaining CAB trough concentrations above PA-IC90, and 80% maintaining trough concentrations above 4x PA-IC90. Study limitations include a modest sample size, a short course of injections, and a low-risk study population.
   Conclusions
   In this study, CAB LA was well tolerated at the doses and dosing intervals used. ISRs were common, but infrequently led to product discontinuation. CAB LA 600 mg every 8 weeks met pharmacokinetic targets for both male and female study participants. The safety and pharmacokinetic results observed support the further development of CAB LA, and efficacy studies of CAB LA for HIV treatment and prevention are in progress.
C1 [Landovitz, Raphael J.; Kofron, Ryan] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA USA.
   [Li, Sue; Cottle, Leslie; Chau, Gordon] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, 1124 Columbia St, Seattle, WA 98104 USA.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Dawood, Halima] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Durban, South Africa.
   [Liu, Albert Y.] San Francisco Dept Hlth, Populat Hlth Div, Bridge HIV, San Francisco, CA USA.
   [Magnus, Manya] George Washington Univ, Dept Epidemiol & Biostat, Milken Inst Sch Publ Hlth, Washington, DC USA.
   [Hosseinipour, Mina C.] UNC Project Malawi, Lilongwe, Malawi.
   [Panchia, Ravindre] Chris Hani Baragwanath Hosp, Perinatal HIV Res Unit, Soweto, South Africa.
   [Richardson, Paul; Marzinke, Mark A.; Hendrix, Craig W.; Eshleman, Susan H.; Zhang, Yinfeng; Sugarman, Jeremy] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Tolley, Elizabeth; McCauley, Marybeth] FHI360, Durham, NC USA.
   [Sugarman, Jeremy] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD USA.
   [Adeyeye, Adeola; Burns, David] NIAID, Div Aids, NIH, Rockville, MD USA.
   [Rinehart, Alex R.; Margolis, David; Spreen, William R.] ViiV Healthcare, Durham, NC USA.
   [Cohen, Myron S.; Eron, Joseph J.] Univ N Carolina, Chapel Hill, NC 27515 USA.
RP Landovitz, RJ (corresponding author), Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA USA.
EM rlandovitz@mednet.ucla.edu
RI Dawood, Halima/AAF-6045-2020; Dawood, Halima/AAO-6963-2020
OI Dawood, Halima/0000-0001-8180-6791; Sugarman,
   Jeremy/0000-0001-7022-8332; Landovitz, Raphael/0000-0002-1442-714X;
   Zhang, Yinfeng/0000-0003-3989-6820
FU National Institute Of Allergy And Infectious Diseases of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI068619, UM1AI068613,
   UM1AI068617]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI050410, P30AI050410, P30AI094189,
   UM1AI069423, UM1AI069453, UM1AI068619, P30AI094189, P30AI050410,
   UM1AI068619, P30AI094189, UM1AI068617, UM1AI069453, UM1AI068613,
   P30AI050410, P30AI094189, P30AI050410, P30AI094189, UM1AI069530,
   P30AI050410, P30AI050410, P30AI050410, P30AI094189, UM1AI068613,
   P30AI050410, UM1AI068617, P30AI094189, P30AI050410, P30AI094189,
   UM1AI068613, P30AI094189, UM1AI069423, P30AI094189, P30AI094189,
   P30AI050410, P30AI094189, P30AI050410, UM1AI068617, UM1AI069469,
   P30AI094189, UM1AI069453, UM1AI069453, P30AI094189, P30AI094189,
   P30AI050410, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI050410, UM1AI069469, P30AI050410, P30AI094189, UM1AI068619,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069423, P30AI050410,
   P30AI094189, P30AI050410, P30AI094189, P30AI050410, P30AI094189,
   P30AI050410, P30AI094189, P30AI050410, P30AI094189, P30AI094189,
   UM1AI068619, P30AI094189, P30AI050410, P30AI050410, P30AI094189,
   P30AI094189, UM1AI068619, P30AI050410, UM1AI069423, P30AI094189,
   P30AI050410, P30AI050410, UM1AI069423, P30AI094189, UM1AI068619,
   UM1AI069530, P30AI050410, UM1AI068617, P30AI094189, P30AI050410,
   UM1AI068617, P30AI094189, UM1AI069530, P30AI094189, UM1AI069530,
   P30AI094189, P30AI050410, P30AI094189, P30AI094189, P30AI050410,
   P30AI050410, P30AI050410, P30AI094189, P30AI050410, P30AI094189,
   P30AI050410, P30AI050410, P30AI094189, P30AI050410, P30AI050410,
   P30AI050410, UM1AI068613, UM1AI069469, P30AI094189] Funding Source: NIH
   RePORTER
FX Research reported in this publication was supported by the National
   Institute Of Allergy And Infectious Diseases of the National Institutes
   of Health under Award Numbers UM1AI068619, UM1AI068613, and UM1AI068617.
   The funders assisted in the study design, preparation and review of this
   manuscript.
CR Andrews C, 2013, 20 C RETR OPP INF MA
   Andrews CD, 2017, AIDS, V31, P461, DOI 10.1097/QAD.0000000000001343
   Andrews CD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010298
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Babor T, 2001, AUDIT ALCOHOL USE DI
   Baeten JM, 2016, NEW ENGL J MED, V375, P2121, DOI 10.1056/NEJMoa1506110
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bekker L-G, 2017, 24 C RETR OPP INF FE
   Cohen MS, 2017, SCIENCE, V358, P46, DOI 10.1126/science.aap8131
   Dobard C, 2018, 25 C RETR OPP INF MA
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gunawardana M, 2015, ANTIMICROB AGENTS CH, V59, P3913, DOI 10.1128/AAC.00656-15
   Haberer JE, 2015, AIDS, V29, P1277, DOI 10.1097/QAD.0000000000000647
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
   Margolis DA, 2017, LANCET, V390, P1499, DOI 10.1016/S0140-6736(17)31917-7
   Margolis DA, 2015, LANCET INFECT DIS, V15, P1145, DOI 10.1016/S1473-3099(15)00152-8
   Markowitz M, 2017, LANCET HIV, V4, pE331, DOI 10.1016/S2352-3018(17)30068-1
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Muller RH, 2011, EUR J PHARM BIOPHARM, V78, P1, DOI 10.1016/j.ejpb.2011.01.007
   National Institute of Allergy and Infectious Diseases, 2014, DIV AIDS DAIDS TABL
   Nel A, 2016, NEW ENGL J MED, V375, P2133, DOI 10.1056/NEJMoa1602046
   Radzio J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010297
   Schivone GB, 2017, CURR OPIN OBSTET GYN, V29, P443, DOI 10.1097/GCO.0000000000000408
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Yoshinaga T, 2012, 52 INT C ANT AG CHEM
NR 28
TC 35
Z9 35
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD NOV
PY 2018
VL 15
IS 11
AR e1002690
DI 10.1371/journal.pmed.1002690
PG 22
WC Medicine, General & Internal
SC General & Internal Medicine
GA HC5FB
UT WOS:000451827800007
PM 30408115
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Mesquita, EC
   Hottz, ED
   Amancio, RT
   Carneiro, AB
   Palhinha, L
   Coelho, LE
   Grinsztejn, B
   Zimmerman, GA
   Rondina, MT
   Weyrich, AS
   Bozza, PT
   Bozza, FA
AF Mesquita, Emersom C.
   Hottz, Eugenio D.
   Amancio, Rodrigo T.
   Carneiro, Alan B.
   Palhinha, Lohanna
   Coelho, Lara E.
   Grinsztejn, Beatriz
   Zimmerman, Guy A.
   Rondina, Matthew T.
   Weyrich, Andrew S.
   Bozza, Patricia T.
   Bozza, Fernando A.
TI Persistent platelet activation and apoptosis in virologically suppressed
   HIV-infected individuals
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMBINATION ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION; P-SELECTIN;
   MICROBIAL TRANSLOCATION; HIV-1-INFECTED PATIENTS; MONONUCLEAR-CELLS;
   RISK-FACTOR; IN-VIVO; DC-SIGN; MORTALITY
AB Cardiovascular diseases and thrombotic events became major clinical problems in the combined antiretroviral therapy (cART) era. Although the precise mechanisms behind these clinical problems have not been fully elucidated, a persistent pro-inflammatory state plays a central role. As platelets play important roles on both, thrombus formation and inflammatory/immune response, we aimed at investigating platelet function in HIV-infected subjects virologically controlled through cART. We evaluate parameters of activation, mitochondrial function and activation of apoptosis pathways in platelets from 30 HIV-infected individuals under stable cART and 36 healthy volunteers. Despite viral control achieved through cART, HIV-infected individuals exhibited increased platelet activation as indicated by P-selectin expression and platelet spreading when adhered on fibrinogen-coated surfaces. Platelets from HIV-infected subjects also exhibited mitochondrial dysfunction and activation of apoptosis pathways. Finally, thrombin stimuli induced lower levels of P-selectin translocation and RANTES secretion, but not TXA(2) synthesis, in platelets from HIV-infected individuals compared to control; and labeling of platelet alpha granules showed reduced granule content in platelets from HIV-infected individuals when compared to healthy subjects. In summary, platelets derived from HIV-infected individuals under stable cART exhibit a phenotype of increased activation, activation of the intrinsic pathway of apoptosis and undermined granule secretion in response to thrombin.
C1 [Mesquita, Emersom C.; Amancio, Rodrigo T.; Bozza, Fernando A.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Med Intens, Rio De Janeiro, Brazil.
   [Coelho, Lara E.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab HIV, Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.; Carneiro, Alan B.; Palhinha, Lohanna; Bozza, Patricia T.] Fundacao Oswaldo Cruz FIOCRUZ, IOC, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.] Univ Fed Juiz de Fora UFJF, Inst Ciencias Biol, Dept Bioquim, Juiz De Fora, MG, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Zimmerman, Guy A.; Rondina, Matthew T.; Weyrich, Andrew S.] Univ Utah, Mol Med Program, Salt Lake City, UT USA.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Med Intens, Rio De Janeiro, Brazil.; Bozza, FA (corresponding author), DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
EM fernando.bozza@ini.fiocruz.br
RI Hottz, Eugenio D/I-9850-2014; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Weyrich,
   Andrew/0000-0001-9622-4647; Bozza, Patricia/0000-0001-8349-9529;
   Palhinha, Lohanna/0000-0003-0163-3574; Zimmerman,
   Guy/0000-0003-1731-7074; Mesquita, Emersom/0000-0002-5132-3315; Rondina,
   Matthew/0000-0003-3455-3730
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq); Fundacao de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ) [E-26/200.839/2017]; Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior-Brasil (CAPES)CAPES [001]; Programa Estrategico de
   Apoio a Pesquisa em Saude (PAPES)/Fiocruz; National Institute of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; National Institute of Allergy and
   Infectious Diseases (NHLBI) [5R37 HL044525, NHLBI R01 HL126547, NIA R01
   AG048022]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL126547,
   R01HL126547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   AGINGUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [R01AG048022, R01AG048022] Funding Source: NIH RePORTER
FX We thank Joseph Aslan for critical discussion of the study and Edson
   Fernandes de Assis for technical assistance. This work was supported by
   grants from Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (PTB and FAB are scholars from CNPq), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ Grant: E-26/200.839/2017),
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil
   (CAPES) - Finance Code 001, Programa Estrategico de Apoio a Pesquisa em
   Saude (PAPES)/Fiocruz; and National Institute of Health and National
   Institute of Allergy and Infectious Diseases (NHLBI Merit Award 5R37
   HL044525 to G. A. Z and NHLBI R01 HL126547 and NIA R01 AG048022 to A. S.
   W and M. T. R).
CR Alonzo MTG, 2012, J INFECT DIS, V205, P1321, DOI 10.1093/infdis/jis180
   Andonegui G, 2005, BLOOD, V106, P2417, DOI 10.1182/blood-2005-03-0916
   Bociaga-Jasik M, 2013, CURR HIV RES, V11, P263, DOI 10.2174/1570162X113116660055
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Casper C, 2011, ANNU REV MED, V62, P157, DOI 10.1146/annurev-med-050409-103711
   Chaipan C, 2006, J VIROL, V80, P8951, DOI 10.1128/JVI.00136-06
   Choudhury A, 2008, CHEST, V134, P574, DOI 10.1378/chest.07-2745
   Dore GJ, 2002, J ACQ IMMUN DEF SYND, V29, P388, DOI 10.1097/00126334-200204010-00010
   Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978-94-007-2869-1_7
   Falcinelli E, 2013, THROMB HAEMOSTASIS, V110, P349, DOI 10.1160/TH12-07-0504
   Fraietta JA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003658
   Goehringer F, 2017, AIDS RES HUM RETROV, V33, P187, DOI [10.1089/aid.2016.0222, 10.1089/AID.2016.0222]
   Grundler K, 2014, CRIT CARE, V18, DOI 10.1186/cc13724
   Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2
   HAMBURGER SA, 1990, BLOOD, V75, P550
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Holme PA, 1998, FASEB J, V12, P79
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Hottz ED, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00121
   Hottz ED, 2014, J IMMUNOL, V193, P1864, DOI 10.4049/jimmunol.1400091
   Jirouskova M, 2007, BLOOD, V109, P5260, DOI 10.1182/blood-2006-10-054015
   Jobe SM, 2008, BLOOD, V111, P1257, DOI 10.1182/blood-2007-05-092684
   Kelesidis T, 2015, AIDS REV, V17, P191
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lang S, 2012, CLIN INFECT DIS, V55, P600, DOI 10.1093/cid/cis489
   Lazar R., 2013, CLIN INFECT DIS
   Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72
   Leytin V, 2006, J THROMB HAEMOST, V4, P2656, DOI 10.1111/j.1538-7836.2006.02200.x
   Lichtenstein KA, 2010, CLIN INFECT DIS, V51, P435, DOI 10.1086/655144
   Marcantoni Emanuela, 2018, JACC Basic Transl Sci, V3, P9, DOI 10.1016/j.jacbts.2017.10.005
   Marin B, 2009, AIDS, V23, P1743, DOI 10.1097/QAD.0b013e32832e9b78
   Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037
   Mayne E, 2012, JAIDS-J ACQ IMM DEF, V59, P340, DOI 10.1097/QAI.0b013e3182439355
   McDonald B, 2013, AIDS RES HUM RETROV, V29, P993, DOI [10.1089/aid.2012.0309, 10.1089/AID.2012.0309]
   Monforte AD, 2004, AIDS, V18, P1811
   Nkambule BB, 2014, PLATELETS, P1
   Nkambule BB, 2015, THROMB RES, V135, P1131, DOI 10.1016/j.thromres.2015.01.031
   O'Brien M, 2013, JAIDS-J ACQ IMM DEF, V63, P280, DOI 10.1097/QAI.0b013e31828a292c
   O'Halloran JA, 2015, HIV MED, V16, P608, DOI 10.1111/hiv.12270
   Papakonstantinou VD, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-90
   Piconi S, 2010, AIDS, V24, P1991, DOI 10.1097/QAD.0b013e32833c93ce
   Pinto LMD, 2002, BLOOD, V99, P1666, DOI 10.1182/blood.V99.5.1666
   Pinto LMD, 2002, AIDS, V16, P329, DOI 10.1097/00002030-200202150-00003
   Rajasuriar R, 2010, J INFECT DIS, V202, P1254, DOI 10.1086/656369
   Satchell CS, 2011, J INFECT DIS, V204, P1202, DOI 10.1093/infdis/jir509
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shashkin PN, 2008, J IMMUNOL, V181, P3495, DOI 10.4049/jimmunol.181.5.3495
   Sternfeld T, 2009, HIV MED, V10, P512, DOI 10.1111/j.1468-1293.2009.00723.x
   Tien PC, 2010, JAIDS-J ACQ IMM DEF, V55, P316, DOI 10.1097/QAI.0b013e3181e66216
   Trevillyan JM, 2017, PLATELETS, V28, P301, DOI 10.1080/09537104.2016.1237627
   Tsoupras AB, 2012, ANGIOLOGY, V63, P343, DOI 10.1177/0003319711420608
   Tunjungputri RN, 2014, AIDS, V28, P2091, DOI 10.1097/QAD.0000000000000415
   van Lelyveld SFL, 2012, AIDS, V26, P465, DOI 10.1097/QAD.0b013e32834f32f8
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   von Hentig N, 2008, J ANTIMICROB CHEMOTH, V62, P1118, DOI 10.1093/jac/dkn333
   WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921
NR 56
TC 11
Z9 11
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 9
PY 2018
VL 8
AR 14999
DI 10.1038/s41598-018-33403-0
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GW3LB
UT WOS:000446802800005
PM 30301959
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Adachi, K
   Xu, JH
   Ank, B
   Watts, DH
   Camarca, M
   Mofenson, LM
   Pilotto, JH
   Joao, E
   Gray, G
   Theron, G
   Santos, B
   Fonseca, R
   Kreitchmann, R
   Pinto, J
   Mussi-Pinhata, MM
   Machado, DM
   Ceriotto, M
   Morgado, MG
   Bryson, YJ
   Veloso, VG
   Grinsztejn, B
   Mirochnick, M
   Moye, J
   Nielsen-Saines, K
AF Adachi, Kristina
   Xu, Jiahong
   Ank, Bonnie
   Watts, D. Heather
   Camarca, Margaret
   Mofenson, Lynne M.
   Pilotto, Jose Henrique
   Joao, Esau
   Gray, Glenda
   Theron, Gerhard
   Santos, Breno
   Fonseca, Rosana
   Kreitchmann, Regis
   Pinto, Jorge
   Mussi-Pinhata, Marisa M.
   Machado, Daisy Maria
   Ceriotto, Mariana
   Morgado, Mariza G.
   Bryson, Yvonne J.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Mirochnick, Mark
   Moye, Jack
   Nielsen-Saines, Karin
CA MPH NICHD HPTN 040 Study Team
TI Congenital Cytomegalovirus and HIV Perinatal Transmission
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE congenital CMV; HIV MTCT; HIV perinatal transmission
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TO-CHILD TRANSMISSION; BIRTH PREVALENCE;
   NEWBORN-INFANTS; REFERRAL CENTER; INFECTION; MOTHERS; EXPRESSION; BORN;
   ENHANCEMENT
AB Background: Congenital cytomegalovirus (CMV) infection (cCMV) is an important cause of hearing loss and cognitive impairment. Prior studies suggest that HIV-exposed children are at higher risk of acquiring cCMV. We assessed the presence, magnitude and risk factors associated with cCMV among infants born to HIV-infected women, who were not receiving antiretrovirals during pregnancy.
   Methods: cCMV and urinary CMV load were determined in a cohort of infants born to HIV-infected women not receiving antiretrovirals during pregnancy. Neonatal urines obtained at birth were tested for CMV DNA by qualitative and reflex quantitative real-time polymerase chain reaction.
   Results: Urine specimens were available for 992 (58.9%) of 1684 infants; 64 (6.5%) were CMV-positive. Mean CMV load (VL) was 470,276 copies/ml (range: < 200-2,000,000 copies/ml). Among 89 HIV-infected infants, 16 (18%) had cCMV versus 42 (4.9%) of 858 HIV-exposed, uninfected infants (P < 0.0001). cCMV was present in 23.2% of infants with in utero and 9.1% infants with intrapartum HIV infection (P < 0.0001). Rates of cCMV among HIV-infected infants were 4-fold greater (adjusted OR, 4.4; 95% CI: 2.3-8.2) and 6-fold greater among HIV in utero-infected infants (adjusted OR, 6; 95% CI: 3-12.1) compared with HIV-exposed, uninfected infants. cCMV was not associated with mode of delivery, gestational age, Apgar scores, 6-month infant mortality, maternal age, race/ethnicity, HIV viral load or CD4 count. Primary cCMV risk factors included infant HIV-infection, particularly in utero infection.
   Conclusion: High rates of cCMV with high urinary CMV VL were observed in HIV-exposed infants. In utero HIV infection appears to be a major risk factor for cCMV in infants whose mothers have not received combination antiretroviral therapy in pregnancy.
C1 [Adachi, Kristina; Ank, Bonnie; Bryson, Yvonne J.; Nielsen-Saines, Karin] David Geffen UCLA Sch Med, Los Angeles, CA USA.
   [Xu, Jiahong; Camarca, Margaret] Westat Corp, Rockville, MD USA.
   [Watts, D. Heather] US Dept State, Off Global AIDS Coordinator, Washington, DC 20520 USA.
   [Watts, D. Heather; Mofenson, Lynne M.; Moye, Jack] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Nova Iguacu, RJ, Brazil.
   [Joao, Esau] Hosp Fed Servidores Estado, Rio De Janeiro, RJ, Brazil.
   [Gray, Glenda] Univ Witwatersrand, SAMRC, Cape Town, South Africa.
   [Gray, Glenda] Univ Witwatersrand, Perinatal HIV Res Unit, Cape Town, South Africa.
   [Theron, Gerhard] Stellenbosch Univ, Tygerberg Hosp, Cape Town, South Africa.
   [Santos, Breno] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Fonseca, Rosana] Hosp Femina, Porto Alegre, RS, Brazil.
   [Kreitchmann, Regis] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Ceriotto, Mariana] Univ Sao Paulo, Ribeirao Preto Med Sch, Sao Paulo, SP, Brazil.
   [Machado, Daisy Maria] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Ceriotto, Mariana] Fdn Maternal & Infant Hlth FUNDASAMIN, Buenos Aires, DF, Argentina.
   [Morgado, Mariza G.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, RJ, Brazil.
   [Mirochnick, Mark] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Mofenson, Lynne M.] Elizabeth Glaser Pediat AIDS Fdn, Washington, DC USA.
RP Adachi, K (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, 10833 Le Conte Ave,MDCC 22-442, Los Angeles, CA 90095 USA.
EM kadachi@mednet.ucla.edu
RI Pinto, Jorge A/D-1743-2014; Pilotto, Jose Henrique/AAD-9773-2019;
   Mofenson, Lynne/P-9631-2019
OI Pinto, Jorge A/0000-0003-2987-3238; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Mofenson, Lynne/0000-0002-2818-9808; Joao,
   Esau/0000-0002-2412-0627; Kreitchmann, Regis/0000-0002-1146-0497;
   Machado, Daisy/0000-0003-1993-6442
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [HHSN267200800001C, N01-HD-8-0001]; NIAID/ NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [U01
   AI047986]; National Institute of Allergy and Infectious Diseases
   (NIAID)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01 AI068632, UM1AI068632, UM1AI068616,
   UM1AI106716]; Eunice Kennedy Shriver National Institute of Child Health
   and Human Development (NICHD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD);
   National Institute of Mental Health (NIMH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [AI068632]; Boehringer
   Ingelheim Pharmaceuticals Inc.Boehringer Ingelheim;
   GlaxoSmithKlineGlaxoSmithKline; UCLA Children's Discovery and Innovation
   Institute through the Harry Winston Fellowship Award; UCLA AIDS
   Institute; UCLA Center for AIDS Research (CFAR) NIH/ NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI02869, AI28697]; UCLA Pediatric AIDS Coalition; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI047986,
   UM1AI069476, P30AI028697, P30AI028697, P30AI028697, UM1AI106716,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI068632, UM1AI069453,
   P30AI028697, P30AI028697, P30AI028697, U01AI068632, UM1AI069424,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068616, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI047986,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI047986, P30AI028697, P30AI028697, UM1AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   U01AI068632, P30AI028697, UM1AI069476, U01AI068632, P30AI028697,
   UM1AI068632, P30AI028697, P30AI028697, UM1AI069424, P30AI028697,
   U01AI047986, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, UM1AI069476, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068616, P30AI028697, P30AI028697, P30AI028697, UM1AI106716,
   P30AI028697, P30AI028697, P30AI028697, UM1AI068632, P30AI028697,
   UM1AI069476, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069424, P30AI028697, UM1AI106716, U01AI068632, P30AI028697,
   P30AI028697, UM1AI068632, P30AI028697, U01AI068632, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, UM1AI069476, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, UM1AI069453, P30AI028697, P30AI028697,
   U01AI047986, P30AI028697, UM1AI068632, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI069424,
   UM1AI069453, P30AI028697, U01AI047986, UM1AI068616, P30AI028697,
   UM1AI069476, P30AI028697, UM1AI106716, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, P30AI028697, P30AI028697, UM1AI106716, U01AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI106716,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI047986,
   U01AI047986, U01AI068632, UM1AI069453, P30AI028697, UM1AI069476,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068616, UM1AI069476, P30AI028697, UM1AI068616, P30AI028697,
   P30AI028697, UM1AI068616, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI106716, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069453, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI106716, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, U01AI068632, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068632, U01AI068632, P30AI028697, P30AI028697] Funding Source: NIH
   RePORTER
FX The NICHD HPTN 040 study was supported by NICHD Contract #
   HHSN267200800001C (NICHD Control # N01-HD-8-0001) and U01 AI047986
   (Brazilian AIDS Prevention Trials International Network), NIAID/ NIH.
   Overall support for the International Maternal Pediatric Adolescent AIDS
   Clinical Trials Group (IMPAACT) was provided by the National Institute
   of Allergy and Infectious Diseases (NIAID) U01 AI068632, UM1AI068632
   (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC),
   with co-funding from the Eunice Kennedy Shriver National Institute of
   Child Health and Human Development (NICHD) and the National Institute of
   Mental Health (NIMH) AI068632. The original parent study was supported
   in part by Boehringer Ingelheim Pharmaceuticals Inc. and
   GlaxoSmithKline, on behalf of ViiV Healthcare. Support was also provided
   by the UCLA Children's Discovery and Innovation Institute through the
   Harry Winston Fellowship Award, the UCLA AIDS Institute, the UCLA Center
   for AIDS Research (CFAR) NIH/ NIAID AI02869 and AI28697, and the UCLA
   Pediatric AIDS Coalition.
CR Barbi M, 2006, PEDIATR INFECT DIS J, V25, P156, DOI 10.1097/01.inf.0000199261.98769.29
   Barbi M, 2006, J CLIN VIROL, V35, P206, DOI 10.1016/j.jcv.2005.08.010
   BELLO C, 1991, J CLIN PATHOL, V44, P366, DOI 10.1136/jcp.44.5.366
   BOPPANA SB, 1992, PEDIATR INFECT DIS J, V11, P93, DOI 10.1097/00006454-199202000-00007
   Boppana SB, 2013, CLIN INFECT DIS, V57, pS178, DOI 10.1093/cid/cit629
   Chandwani S, 1996, PEDIATR INFECT DIS J, V15, P310, DOI 10.1097/00006454-199604000-00006
   DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642
   Delicio AM, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-35
   DEMMLER GJ, 1991, REV INFECT DIS, V13, P315, DOI 10.1093/clinids/13.2.315
   Dollard SC, 2007, REV MED VIROL, V17, P355, DOI 10.1002/rmv.544
   Doyle M, 1996, PEDIATR INFECT DIS J, V15, P1102, DOI 10.1097/00006454-199612000-00010
   DUDDING L, 1989, J IMMUNOL, V143, P3343
   Duryea EL, 2010, PEDIATR INFECT DIS J, V29, P915, DOI 10.1097/INF.0b013e3181e0ce05
   Ellington SR, 2016, J INFECT DIS, V213, P891, DOI 10.1093/infdis/jiv549
   Frederick T, 2012, CLIN INFECT DIS, V55, P877, DOI 10.1093/cid/cis535
   Gantt S, 2016, J MED VIROL, V88, P1051, DOI 10.1002/jmv.24420
   Guibert G, 2009, CLIN INFECT DIS, V48, P1516, DOI 10.1086/598934
   HO WZ, 1990, J GEN VIROL, V71, P97, DOI 10.1099/0022-1317-71-1-97
   Kaye S, 2008, J INFECT DIS, V197, P1307, DOI 10.1086/586715
   Khamduang W, 2011, JAIDS-J ACQ IMM DEF, V58, P188, DOI [10.1097/QAI.0B013E31822D0433, 10.1097/QAI.0b013e31822d0433]
   King CC, 2013, CURR HIV RES, V11, P10
   Kovacs A, 1999, NEW ENGL J MED, V341, P77, DOI 10.1056/NEJM199907083410203
   LATHEY JL, 1994, VIROLOGY, V199, P98, DOI 10.1006/viro.1994.1101
   Manicklal S, 2014, CLIN INFECT DIS, V58, P1467, DOI 10.1093/cid/ciu096
   Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12
   Marin Gabriel M A, 2005, An Pediatr (Barc), V62, P38
   MCKEATING JA, 1990, NATURE, V343, P659, DOI 10.1038/343659a0
   MITCHELL CD, 1990, PEDIATR INFECT DIS J, V9, P512, DOI 10.1097/00006454-199007000-00012
   Mussi-Pinhata MM, 2009, CLIN INFECT DIS, V49, P522, DOI 10.1086/600882
   Mussi-Pinhata MM, 1998, J PEDIATR-US, V132, P285, DOI 10.1016/S0022-3476(98)70446-9
   Mwaanza N, 2014, CLIN INFECT DIS, V58, P728, DOI 10.1093/cid/cit766
   Nielsen-Saines K, 2012, NEW ENGL J MED, V366, P2368, DOI 10.1056/NEJMoa1108275
   Olusanya BO, 2015, PEDIATR INFECT DIS J, V34, P322, DOI 10.1097/INF.0000000000000555
   Reitter A, 2016, MED MICROBIOL IMMUN, V205, P63, DOI 10.1007/s00430-015-0427-9
   RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134
   Robbins JR, 2012, CURR OPIN MICROBIOL, V15, P36, DOI 10.1016/j.mib.2011.11.006
   Ross Shannon A, 2005, Semin Pediatr Infect Dis, V16, P44, DOI 10.1053/j.spid.2004.09.011
   Roxby AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087855
   SCHOPFER K, 1978, ARCH DIS CHILD, V53, P536, DOI 10.1136/adc.53.7.536
   SKOLNIK PR, 1988, J INFECT DIS, V157, P508, DOI 10.1093/infdis/157.3.508
   Slyker JA, 2009, AIDS, V23, P2173, DOI 10.1097/QAD.0b013e32833016e8
   Spinillo A, 2014, EARLY HUM DEV, V90, pS7, DOI 10.1016/S0378-3782(14)70003-9
   van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000492
   Yamamoto AY, 2001, PEDIATR INFECT DIS J, V20, P188, DOI 10.1097/00006454-200102000-00014
   Yeganeh N, 2015, PEDIATR INFECT DIS J, V34, pE52, DOI 10.1097/INF.0000000000000578
NR 45
TC 3
Z9 3
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 2018
VL 37
IS 10
BP 1016
EP 1021
DI 10.1097/INF.0000000000001975
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA HF0GQ
UT WOS:000453838400019
PM 30216294
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Veloso, VG
   Torres, TS
   Moreira, RI
   Leite, IC
   Kallas, EG
   Cerqueira, NB
   Madruga, JV
   Goulart, SP
   Fernandes, NM
   Santos, TA
   Freitas, JS
   Monteiro, L
   Lacerda, MV
   Alencastro, P
   Marins, LMS
   Nazer, S
   Cardoso, SW
   Luz, PM
   Hoagland, B
   Grinsztejn, B
AF Veloso, Valdilea G.
   Torres, Thiago Silva
   Moreira, Ronaldo I.
   Leite, Iuri C.
   Kallas, Esper G.
   Cerqueira, Natalia B.
   Madruga, Jose V.
   Goulart, Silvia P.
   Fernandes, Nilo M.
   Santos, Tony A.
   Freitas, Josias S.
   Monteiro, Laylla
   Lacerda, Marcus V.
   Alencastro, Paulo
   Marins, Luana M. S.
   Nazer, Sandro
   Cardoso, Sandra Wagner
   Luz, Paula Mendes
   Hoagland, Brenda
   Grinsztejn, Beatriz
CA PrEP Brasil Study Team
TI Retention and Persistance on PrEP for MSM and TGW: 96-week Results of
   the PrEP Brazil Demonstration Study
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide
   and ARV-Based Prevention Science
CY OCT 21-25, 2018
CL Madrid, SPAIN
C1 [Veloso, Valdilea G.; Torres, Thiago Silva; Moreira, Ronaldo I.; Leite, Iuri C.; Fernandes, Nilo M.; Santos, Tony A.; Freitas, Josias S.; Monteiro, Laylla; Marins, Luana M. S.; Nazer, Sandro; Cardoso, Sandra Wagner; Luz, Paula Mendes; Hoagland, Brenda; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Kallas, Esper G.; Cerqueira, Natalia B.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Madruga, Jose V.; Goulart, Silvia P.] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Lacerda, Marcus V.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Alencastro, Paulo] Hosp Sanat Partenon, Porto Alegre, RS, Brazil.
RI TORRES, THIAGO SILVA/D-6548-2014
OI TORRES, THIAGO SILVA/0000-0002-2557-601X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2018
VL 34
SU 1
MA P25.18
BP 373
EP 373
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GY2KM
UT WOS:000448371600692
DA 2020-11-24
ER

PT J
AU Tolley, EE
   Zangeneh, S
   Chau, G
   Eron, J
   Grinsztejn, B
   Dawood, H
   Liu, A
   Magnus, M
   Hosseinipour, M
   Panchia, R
   Li, S
   Cottle, L
   Rinehart, A
   Margolis, D
   McCauley, M
   Landovitz, RJ
AF Tolley, Elizabeth Ellen
   Zangeneh, Sahar
   Chau, Gordon
   Eron, Joe
   Grinsztejn, Beatriz
   Dawood, Halima
   Liu, Albert
   Magnus, Manya
   Hosseinipour, Mina
   Panchia, Ravindre
   Li, Sue
   Cottle, Leslie
   Rinehart, Alex
   Margolis, David
   McCauley, Marybeth
   Landovitz, Raphael J.
TI Acceptability of Long-acting Injectable Cabotegravir (CAB LA) in
   HIV-uninfected Individuals: HPTN 077
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide
   and ARV-Based Prevention Science
CY OCT 21-25, 2018
CL Madrid, SPAIN
C1 [Tolley, Elizabeth Ellen; McCauley, Marybeth] FHI 360, Durham, NC USA.
   [Zangeneh, Sahar; Chau, Gordon; Li, Sue; Cottle, Leslie] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Eron, Joe] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Grinsztejn, Beatriz] Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Dawood, Halima] CAPRISA, Durban, South Africa.
   [Dawood, Halima] Univ KwaZulu Natal, Durban, South Africa.
   [Liu, Albert] San Francisco Dept Hlth, San Francisco, CA USA.
   [Magnus, Manya] George Washington Univ, Washington, DC 20052 USA.
   [Hosseinipour, Mina] UNC Project Malawi, Lilongwe, Malawi.
   [Panchia, Ravindre] Chris Hani Baragwanath Hosp, Soweto, South Africa.
   [Rinehart, Alex; Margolis, David] ViiV Healthcare, Res Triangle Pk, NC USA.
   [Landovitz, Raphael J.] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA 90024 USA.
RI Dawood, Halima/AAF-6045-2020; Dawood, Halima/AAO-6963-2020
OI Dawood, Halima/0000-0001-8180-6791
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2018
VL 34
SU 1
MA OA05.01
BP 25
EP 25
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GY2KM
UT WOS:000448371600026
DA 2020-11-24
ER

PT J
AU Wilson, EC
   Jalil, EM
   Veloso, VV
   Wagner, SC
   Moreira, RI
   Velasque, L
   Ferreira, ACG
   Grinsztejn, E
   Castro, CV
   Ramos, A
   McFarland, W
   Liu, A
   Buchbinder, S
   Grinsztejn, B
AF Wilson, Erin C.
   Jalil, Emilia M.
   Veloso, Valdilea V.
   Wagner, Sandra C.
   Moreira, Ronaldo I.
   Velasque, Luciane
   Ferreira, Ana Cristina G.
   Grinsztejn, Eduarda
   Castro, Cristiane V.
   Ramos, Alessandra
   McFarland, Willi
   Liu, Albert
   Buchbinder, Susan
   Grinsztejn, Beatriz
TI Young Transwomen in Brazil Have High HIV Risk and Low Prevention Use
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide
   and ARV-Based Prevention Science
CY OCT 21-25, 2018
CL Madrid, SPAIN
C1 [Wilson, Erin C.; McFarland, Willi; Liu, Albert; Buchbinder, Susan] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Jalil, Emilia M.; Veloso, Valdilea V.; Wagner, Sandra C.; Moreira, Ronaldo I.; Velasque, Luciane; Ferreira, Ana Cristina G.; Grinsztejn, Eduarda; Castro, Cristiane V.; Grinsztejn, Beatriz] INI Oswaldo Cruz Fdn FIOCRUZ, Rio De Janeiro, Brazil.
   [Ramos, Alessandra] Rio de Janeiro Fed Inst Educ Sci & Technol, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2018
VL 34
SU 1
MA OA10.05
BP 42
EP 42
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GY2KM
UT WOS:000448371600060
DA 2020-11-24
ER

PT J
AU Landovitz, RJ
   Li, S
   Eron, JJ
   Grinsztejn, B
   Dawood, H
   Liu, AY
   Magnus, M
   Hosseinipour, MC
   Panchia, R
   Cottle, L
   Richardson, P
   Marzinke, MA
   Eshleman, SH
   Kofron, R
   Adeyeye, A
   Burns, D
   Rinehart, AR
   Margolis, D
   McCauley, M
   Hendrix, CW
AF Landovitz, Raphael J.
   Li, Sue
   Eron, Joseph J.
   Grinsztejn, Beatriz
   Dawood, Halima
   Liu, Albert Y.
   Magnus, Manya
   Hosseinipour, Mina C.
   Panchia, Ravindre
   Cottle, Leslie
   Richardson, Paul
   Marzinke, Mark A.
   Eshleman, Susan H.
   Kofron, Ryan
   Adeyeye, Adeola
   Burns, David
   Rinehart, Alex R.
   Margolis, David
   McCauley, Marybeth
   Hendrix, Craig W.
TI Tail-phase Safety, Tolerability and Pharmacokinetics of Long-acting
   Injectable Cabotegravir in HIV-uninfected Individuals: HPTN 077 Final
   Results
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide
   and ARV-Based Prevention Science
CY OCT 21-25, 2018
CL Madrid, SPAIN
C1 [Landovitz, Raphael J.; Kofron, Ryan] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA 90024 USA.
   [Li, Sue; Cottle, Leslie] Stat Ctr HIV AIDS Res & Prevent, Seattle, WA USA.
   [Eron, Joseph J.] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Grinsztejn, Beatriz] Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Dawood, Halima] Univ KwaZulu Natal, CAPRISA, Durban, South Africa.
   [Liu, Albert Y.] San Francisco Dept Hlth, San Francisco, CA USA.
   [Magnus, Manya] George Washington Univ, Milken Inst Sch Publ Hlth, Washington, DC 20052 USA.
   [Hosseinipour, Mina C.] UNC Project Malawi, Lilongwe, Malawi.
   [Panchia, Ravindre] Chris Hani Baragwanath Hosp, Johannesburg, South Africa.
   [Richardson, Paul; Marzinke, Mark A.; Eshleman, Susan H.; Hendrix, Craig W.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
   [Adeyeye, Adeola; Burns, David] NIAID, DAIDS, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Rinehart, Alex R.; Margolis, David] ViiV Healthcare, Res Triangle Pk, NC USA.
   [McCauley, Marybeth] FHI 360, Durham, NC USA.
RI Dawood, Halima/AAF-6045-2020; Dawood, Halima/AAO-6963-2020
OI Dawood, Halima/0000-0001-8180-6791
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2018
VL 34
SU 1
MA OA15.06LB
BP 57
EP 57
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GY2KM
UT WOS:000448371600091
DA 2020-11-24
ER

PT J
AU Baeten, J
   Grant, R
   McCormack, S
   Bekker, LG
   Grinsztejn, B
   Smith, L
   Hawkins, T
   Das, M
   Mera, R
   Magnuson, D
AF Baeten, Jared
   Grant, Robert
   McCormack, Sheena
   Bekker, Linda-Gail
   Grinsztejn, Beatriz
   Smith, Lindsey
   Hawkins, Trevor
   Das, Moupali
   Mera, Robertino
   Magnuson, David
TI HIV Incidence in Persons Using Truvada (FTC/TDF) for HIV Pre-exposure
   Prophylaxis (PrEP): Worldwide Experience From 46 Studies
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide
   and ARV-Based Prevention Science
CY OCT 21-25, 2018
CL Madrid, SPAIN
C1 [Baeten, Jared] Univ Washington, Seattle, WA 98195 USA.
   [Grant, Robert] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [McCormack, Sheena] UCL, London, England.
   [Bekker, Linda-Gail] Desmond Tutu HIV Ctr, Cape Town, South Africa.
   [Grinsztejn, Beatriz] Fiocruz MS, Rio De Janeiro, Brazil.
   [Smith, Lindsey; Hawkins, Trevor; Das, Moupali; Mera, Robertino; Magnuson, David] Gilead Sci, Foster City, CA USA.
RI Bekker, Linda-Gail/AAZ-8929-2020
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2018
VL 34
SU 1
MA OA23.01
BP 79
EP 79
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GY2KM
UT WOS:000448371600134
DA 2020-11-24
ER

PT J
AU Torres, TS
   Luz, PM
   De Vasconcellos, MTL
   Konda, K
   Garner, A
   Moreira, RI
   Hoagland, B
   Cardoso, SW
   Veloso, VG
   Grinsztejn, B
AF Torres, Thiago Silva
   Luz, Paula Mendes
   De Vasconcellos, Mauricio T. L.
   Konda, Kelika
   Garner, Alex
   Moreira, Ronaldo I.
   Hoagland, Brenda
   Cardoso, Sandra Wagner
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI Awareness, Willingness and Barriers to HIV Self-testing (HIVST) Among
   Men Who Have Sex With Men (MSM) in Brazil: A Cross-sectional Online
   Study
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide
   and ARV-Based Prevention Science
CY OCT 21-25, 2018
CL Madrid, SPAIN
C1 [Torres, Thiago Silva; Luz, Paula Mendes; Moreira, Ronaldo I.; Hoagland, Brenda; Cardoso, Sandra Wagner; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Rio De Janeiro, RJ, Brazil.
   [De Vasconcellos, Mauricio T. L.] Escola Nacl Ciencias Estat, Rio De Janeiro, RJ, Brazil.
   [Konda, Kelika] Univ Peruana Cayetano Heredia, Lima, Peru.
   [Garner, Alex] Hornet Networks, San Francisco, CA USA.
RI TORRES, THIAGO SILVA/D-6548-2014
OI TORRES, THIAGO SILVA/0000-0002-2557-601X
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2018
VL 34
SU 1
MA PD02.02
BP 85
EP 85
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GY2KM
UT WOS:000448371600145
DA 2020-11-24
ER

PT J
AU Caracas, C
   Jalil, EM
   Garcia, ACF
   Nazer, SC
   de Oliveira, LP
   Veloso, V
   Moreira, RI
   Castro, CV
   Wilson, EC
   Grinsztejn, B
   Velasque, L
AF Caracas, Carolina
   Jalil, Emilia Moreira
   Ferreira Garcia, Ana Cristina
   Nazer, Sandro C.
   de Oliveira, Lais Pacheco
   Veloso, Valdilea
   Moreira, Ronaldo I.
   Castro, Cristiane V.
   Wilson, Erin C.
   Grinsztejn, Beatriz
   Velasque, Luciane
TI High Chlamydia and Gonorrhea Prevalences and Low Performance of
   Syndromic Management Among Brazilian Transwomen
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide
   and ARV-Based Prevention Science
CY OCT 21-25, 2018
CL Madrid, SPAIN
C1 [Caracas, Carolina; Velasque, Luciane] Fed Univ State Rio de Janeiro, Rio De Janeiro, Brazil.
   [Jalil, Emilia Moreira; Ferreira Garcia, Ana Cristina; Nazer, Sandro C.; Veloso, Valdilea; Moreira, Ronaldo I.; Castro, Cristiane V.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [de Oliveira, Lais Pacheco] Souza Marques Tech Educ Insititut, Rio De Janeiro, Brazil.
   [Wilson, Erin C.] San Francisco Dept Publ Hlth, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2018
VL 34
SU 1
MA P11.17
BP 240
EP 240
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GY2KM
UT WOS:000448371600434
DA 2020-11-24
ER

PT J
AU Caetano, DG
   Cortes, FH
   Bello, G
   Teixeira, SLM
   Hoagland, B
   Grinsztejn, B
   Veloso, VG
   Guimaraes, ML
   Morgado, MG
AF Caetano, Diogo Gama
   Cortes, Fernanda Heloise
   Bello, Gonzalo
   Maia Teixeira, Sylvia Lopes
   Hoagland, Brenda
   Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
   Guimaraes, Monick Lindenmeyer
   Morgado, Mariza Goncalves
TI Next-generation sequencing analyses of the emergence and maintenance of
   mutations in CTL epitopes in HIV controllers with differential viremia
   control
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1; HIV controller; CTL epitope; Single-nucleotide polymorphism;
   Escape mutant; Next-generation sequencing
ID HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHOCYTE ESCAPE MUTATIONS; VIRAL
   REPLICATION CAPACITY; LONG-TERM NONPROGRESSORS; LOW-LEVEL VIREMIA;
   T-CELL RESPONSES; ELITE SUPPRESSORS; POPULATION-LEVEL; GAG; EVOLUTION
AB Background: Despite the low level of viral replication in HIV controllers (HICs), studies have reported viral mutations related to escape from cytotoxic T-lymphocyte (CTL) response in HIV-1 plasma sequences. Thus, evaluating the dynamics of the emergence of CTL-escape mutants in HICs reservoirs is important for understanding viremia control. To analyze the HIV-1 mutational profile and dynamics of CTL-escape mutants in HICs, we selected 11 long-term non-progressor individuals and divided them into the following groups: (1) viremic controllers (VCs; n = 5) and (2) elite controllers (ECs; n = 6). For each individual, we used HIV-1 proviral DNA from PBMCs related to earliest (V-E) and latest (V-L) visits to obtain gag and nef sequences using the Illumina HiSeq system. The consensus of each mapped gene was used to assess viral divergence, and next-generation sequencing data were employed to identify SNPs and variations within and flanking CTL epitopes.
   Results: Divergence analysis showed higher values for nef compared to gag among the HICs. EC and VC groups showed similar divergence rates for both genes. Analysis of the number of SNPs showed that VCs present more variability in both genes. Synonymous/non-synonymous mutation ratios were < 1 for gag among ECs and for nef among ECs and VCs, exhibiting a predominance of non-synonymous mutations. Such mutations were observed in regions encoding CTL-restricted epitopes in all individuals. All ECs presented non-synonymous mutations in CTL epitopes but generally at low frequency (< 1%); all VCs showed a high number of mutations, with significant frequency changes between V-E and V-L visits. A higher frequency of internal mutations was observed for gag epitopes, with significant changes across visits compared to Nef epitopes, indicating a pattern associated with differential genetic pressure.
   Conclusions: The high genetic conservation of HIV-1 gag and nef among ECs indicates that the higher level of viremia control restricts the evolution of both genes. Although viral replication levels in HICs are low or undetectable, all individuals exhibited CTL epitope mutations in proviral gag and nef variants, indicating that potential CTL escape mutants are present in HIC reservoirs and that situations leading to a disequilibrium of the host-virus relationship can result in the spread of CTL-escape variants.
C1 [Caetano, Diogo Gama; Cortes, Fernanda Heloise; Bello, Gonzalo; Maia Teixeira, Sylvia Lopes; Guimaraes, Monick Lindenmeyer; Morgado, Mariza Goncalves] Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea Goncalves] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin DST & Aids, Rio De Janeiro, Brazil.
RP Morgado, MG (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Cortes, Fernanda/AAF-9254-2020
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPqNational Council for Scientific and Technological
   Development (CNPq); Fiocruz; NATIONAL EYE INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Eye Institute (NEI) [R01EY026103, R01EY026103,
   R01EY026103, R01EY026103] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro - FAPERJ and the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq and Fiocruz.
CR Dilernia DA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003429
   Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005
   [Anonymous], 2015, FASTQC QUAL CONTR TO
   Assone T, 2016, VIRUSES-BASEL, V8, DOI [10.1016/J.VIROL.2012.09.028, 10.3390/v8020038]
   Bailey JR, 2007, J INFECT DIS, V196, P50, DOI 10.1086/518515
   Bailey JR, 2006, J EXP MED, V203, P1357, DOI 10.1084/jem.20052319
   Bailey JR, 2009, J VIROL, V83, P88, DOI 10.1128/JVI.01958-08
   Bello G, 2005, J GEN VIROL, V86, P355, DOI 10.1099/vir.0.80410-0
   Bello G, 2007, AIDS RES HUM RETROV, V23, P1242, DOI 10.1089/aid.2007.0074
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Boutwell CL, 2009, J VIROL, V83, P2460, DOI 10.1128/JVI.01970-08
   Brumme ZL, 2008, J VIROL, V82, P9216, DOI 10.1128/JVI.01041-08
   Cale EM, 2011, J VIROL, V85, P3746, DOI 10.1128/JVI.02420-10
   Carlson JM, 2008, MICROBES INFECT, V10, P455, DOI 10.1016/j.micinf.2008.01.013
   Carlson JM, 2015, TRENDS MICROBIOL, V23, P212, DOI 10.1016/j.tim.2014.12.008
   Carlson JM, 2012, J VIROL, V86, P13202, DOI 10.1128/JVI.01998-12
   Casadella M, 2015, AIDS, V29, P1493, DOI 10.1097/QAD.0000000000000748
   Chen RX, 2004, CURR PHARM DESIGN, V10, P4065, DOI 10.2174/1381612043382404
   Cortes FH, 2015, JAIDS-J ACQ IMM DEF, V68, P377, DOI 10.1097/QAI.0000000000000500
   Cortes FH, 2013, VACCINE, V31, P1106, DOI 10.1016/j.vaccine.2012.12.023
   Cozzi-Lepri A, 2015, J ANTIMICROB CHEMOTH, V70, P930, DOI 10.1093/jac/dku426
   Dalmau J, 2014, AIDS, V28, P1261, DOI 10.1097/QAD.0000000000000293
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   de Azevedo SSD, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0354-5
   Deng K, 2015, NATURE, V517, P381, DOI 10.1038/nature14053
   Erdmann N, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005111
   Feeney ME, 2004, J VIROL, V78, P8927, DOI 10.1128/JVI.78.16.8927-8930.2004
   Fischer W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012303
   Fryer HR, 2012, J VIROL, V86, P8568, DOI 10.1128/JVI.07020-11
   Gaardbo JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063744
   Gijsbers EF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081235
   Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Gounder K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119886
   Hatano H, 2009, J VIROL, V83, P329, DOI 10.1128/JVI.01763-08
   Hayat T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179576
   Henn MR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002529
   Hughes AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047818
   Immonen TT, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0081-0
   Joshi NA, 2011, SICKLE SLIDING WINDO
   Juarez-Molina CI, 2014, J VIROL, V88, P10392, DOI 10.1128/JVI.01162-14
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330
   Torres AJL, 2013, REV INST MED TROP SP, V55, P323, DOI 10.1590/S0036-46652013000500005
   Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992
   Lewis GK, 2017, IMMUNOL REV, V275, P271, DOI 10.1111/imr.12510
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Los Alamos National Laboratory, 2015, LOS AL IMM DAT
   Martin E, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0064-1
   Mens H, 2010, J VIROL, V84, P12971, DOI 10.1128/JVI.00387-10
   Metzner KJ, 2014, AIDS, V28, P2231, DOI 10.1097/QAD.0000000000000397
   Migueles SA, 2003, J VIROL, V77, P6889, DOI 10.1128/JVI.77.12.6889-6898.2003
   Miura T, 2009, J VIROL, V83, P2743, DOI 10.1128/JVI.02265-08
   Mothe B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029717
   Mudd PA, 2012, J IMMUNOL, V188, P3364, DOI 10.4049/jimmunol.1102470
   O'Connell KA, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-63
   O'Connell KA, 2010, J VIROL, V84, P7018, DOI 10.1128/JVI.00548-10
   Okulicz JF, 2012, J AIDS CLIN RES, VS8, P005
   Ouyang YB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05594-5
   Pantaleo G, 1996, ANNU REV MICROBIOL, V50, P825, DOI 10.1146/annurev.micro.50.1.825
   Pereyra F, 2009, J INFECT DIS, V200, P984, DOI 10.1086/605446
   Perreau M, 2013, CURR OPIN HIV AIDS, V8, P333, DOI 10.1097/COH.0b013e328361faf4
   Pohlmeyer CW, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-152
   Radebe M, 2015, AIDS, V29, P23, DOI 10.1097/QAD.0000000000000508
   Roberts HE, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004914
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Saez-Cirion A, 2013, IMMUNOL REV, V254, P281, DOI 10.1111/imr.12076
   Saez-Cirion A, 2009, J IMMUNOL, V182, P7828, DOI 10.4049/jimmunol.0803928
   Salgado M, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-94
   Setiawan LC, 2015, J GEN VIROL, V96, P2372, DOI 10.1099/vir.0.000148
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Sharkey M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001303
   STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6
   Sun JP, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004429
   Sunshine JE, 2015, J VIROL, V89, P10303, DOI 10.1128/JVI.01876-15
   Swenson LC, 2012, CURR OPIN HIV AIDS, V7, P478, DOI 10.1097/COH.0b013e328356e9da
   Teixeira SLM, 2014, GENES IMMUN, V15, P256, DOI 10.1038/gene.2014.14
   TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989
   Yebra G, 2015, 22 HIV DYN EVOL WORK
   Zaunders J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00095
NR 80
TC 3
Z9 3
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD SEP 10
PY 2018
VL 15
AR 62
DI 10.1186/s12977-018-0444-z
PG 13
WC Virology
SC Virology
GA GT5CG
UT WOS:000444522900001
PM 30201008
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Coelho, L
   Rebeiro, PF
   Castilho, JL
   Caro-Vega, Y
   Mejia, FA
   Cesar, C
   Cortes, CP
   Padgett, D
   McGowan, CC
   Veloso, VG
   Sterling, TR
   Grinsztejn, B
   Shepherd, BE
   Luz, PM
AF Coelho, Lara
   Rebeiro, Peter F.
   Castilho, Jessica L.
   Caro-Vega, Yanink
   Mejia, Fernando A.
   Cesar, Carina
   Cortes, Claudia P.
   Padgett, Denis
   McGowan, Catherine C.
   Veloso, Valdilea G.
   Sterling, Timothy R.
   Grinsztejn, Beatriz
   Shepherd, Bryan E.
   Luz, Paula M.
TI Early Retention in Care Neither Mediates Nor Modifies the Effect of Sex
   and Sexual Mode of HIV Acquisition on HIV Survival in the Americas (vol
   32, pg 306, 2018)
SO AIDS PATIENT CARE AND STDS
LA English
DT Correction
RI Cortes, Claudia/AAF-7326-2020
OI Cortes, Claudia/0000-0001-9101-9783
CR Coelho L, 2018, AIDS PATIENT CARE ST, V32, P306, DOI 10.1089/apc.2018.0028
NR 1
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD SEP
PY 2018
VL 32
IS 9
BP 379
EP 379
DI 10.1089/apc.2018.0028.correx
PG 1
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA GT2FR
UT WOS:000444301000006
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Bakal, DR
   Coelho, LE
   Luz, PM
   Clark, JL
   De Boni, RB
   Cardoso, SW
   Veloso, VG
   Lake, JE
   Grinsztejn, B
AF Bakal, David R.
   Coelho, Lara E.
   Luz, Paula M.
   Clark, Jesse L.
   De Boni, Raquel B.
   Cardoso, Sandra W.
   Veloso, Valdilea G.
   Lake, Jordan E.
   Grinsztejn, Beatriz
TI Obesity following ART initiation is common and influenced by both
   traditional and HIV-/ART-specific risk factors
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS-INFECTION; ACUTE MYOCARDIAL-INFARCTION;
   ANTIRETROVIRAL THERAPY; WEIGHT-GAIN; CARDIOVASCULAR RISK; UNITED-STATES;
   RALTEGRAVIR; DISEASE; PREVALENCE; OVERWEIGHT
AB Background: Obesity rates are increasing among HIV-infected individuals, but risk factors for obesity development on ART remain unclear.
   Objectives: In a cohort of HIV-infected adults in Rio de Janeiro, Brazil, we aimed to determine obesity rates before and after ART initiation and to analyse risk factors for obesity on ART.
   Methods: We retrospectively analysed data from individuals initiating ART between 2000 and 2015. BMI was calculated at baseline (time of ART initiation). Participants who were non-obese at baseline and had >90 days of ART exposure were followed until the development of obesity or the end of follow-up. Obesity incidence rates were estimated using Poisson regression models and risk factors were assessed using Cox regression models.
   Results: Of participants analysed at baseline (n = 1794), 61.3% were male, 48.3% were white and 7.9% were obese. Among participants followed longitudinally (n = 1567), 66.2% primarily used an NNRTI, 32.9% a PI and 0.9% an integrase strand transfer inhibitor (INSTI); 18.3% developed obesity and obesity incidence was 37.4 per 1000 person-years. In multivariable analysis, the greatest risk factor for developing obesity was the use of an INSTI as the primary ART core drug (adjusted HR 7.12, P< 0.0001); other risk factors included younger age, female sex, higher baseline BMI, lower baseline CD4+ T lymphocyte count, higher baseline HIV-1 RNA, hypertension and diabetes mellitus.
   Conclusions: Obesity following ART initiation is frequent among HIV-infected adults. Key risk factors include female sex, HIV disease severity and INSTI use. Further research regarding the association between INSTIs and the development of obesity is needed.
C1 [Bakal, David R.; Clark, Jesse L.; Lake, Jordan E.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
   [Coelho, Lara E.; Luz, Paula M.; De Boni, Raquel B.; Cardoso, Sandra W.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Av Brasil,4365 Manguinhos, Rio De Janeiro, Brazil.
   [Lake, Jordan E.] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Dept Med, 6431 Fannin St, Houston, TX 77030 USA.
RP Bakal, DR (corresponding author), Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM dbakal89@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Luz,
   Paula/0000-0001-9746-719X
FU South American Program in HIV Prevention Research, National Institutes
   of Health/National Institute of Mental Health [R25 H087222]; National
   Institute of Allergy and Infectious DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [K23
   AI110532]; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [R25
   MH087222]; National Institutes of Health - Caribbean, Central and South
   America network for HIV epidemiology (CCASAnet), a member cohort of the
   International Epidemiologic Databases to Evaluate AIDS (leDEA)
   [U01AI069923]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01AI069923, UM1AI069476, U01AI069923,
   U01AI069923, U01AI069923, K23AI110532, K23AI110532, U01AI069923,
   UM1AI069476, U01AI069923, K23AI110532, U01AI069923, U01AI069923,
   U01AI069923, UM1AI069476, U01AI069923, UM1AI069476, UM1AI069476,
   U01AI069923, UM1AI069476, UM1AI069476, K23AI110532, K23AI110532,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, K23AI110532, U01AI069923, U01AI069923, U01AI069923,
   UM1AI069476, UM1AI069476, U01AI069923, U01AI069923] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, R25MH087222, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107] Funding Source: NIH RePORTER
FX This work was supported by the South American Program in HIV Prevention
   Research, National Institutes of Health/National Institute of Mental
   Health (R25 H087222 to D. R. B.); the National Institute of Allergy and
   Infectious Diseases (K23 AI110532 to J. E. L.); the National Institutes
   of Health (R25 MH087222 to J. L. C.); and the National Institutes of
   Health-funded Caribbean, Central and South America network for HIV
   epidemiology (CCASAnet), a member cohort of the International
   Epidemiologic Databases to Evaluate AIDS (leDEA) (U01AI069923).
CR Amorosa V, 2005, JAIDS-J ACQ IMM DEF, V39, P557
   [Anonymous], 1992, MMWR Recomm Rep, V41, P1
   Berrahmoune H, 2008, INT J OBESITY, V32, P1279, DOI 10.1038/ijo.2008.94
   Boyd MA, 2009, CURR OPIN HIV AIDS, V4, P194, DOI 10.1097/COH.0b013e328329fc8d
   Crum-Cianflone N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010106
   Crum-Cianflone N, 2009, JAIDS-J ACQ IMM DEF, V50, P464, DOI 10.1097/QAI.0b013e318198a88a
   Ezechi LO, 2016, CEYLON MED J, V61, P56, DOI 10.4038/cmj.v61i2.8300
   Gomes A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160797
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Guehi C, 2016, AIDS RES THER, V13, DOI 10.1186/s12981-016-0094-y
   Guh DP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-88
   Koethe JR, 2016, AIDS RES HUM RETROV, V32, P50, DOI 10.1089/aid.2015.0147
   Lake JE, 2017, CLIN INFECT DIS, V64, P1422, DOI 10.1093/cid/cix178
   Lakey W, 2013, AIDS RES HUM RETROV, V29, P435, DOI [10.1089/aid.2012.0234, 10.1089/AID.2012.0234]
   Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1
   McComsey GA, 2016, CLIN INFECT DIS, V62, P853, DOI 10.1093/cid/ciw017
   Menard A, 2017, AIDS, V31, P1499, DOI 10.1097/QAD.0000000000001495
   Minesterio da Saude, 2014, VIG BARS 2014 VIG FA
   Mulligan K, 1997, NEW ENGL J MED, V336, P70, DOI 10.1056/NEJM199701023360115
   Norwood J, 2017, JAIDS-J ACQ IMM DEF, V76, P527, DOI [10.1097/QAI.0000000000001525, 10.1097/qai.0000000000001525]
   Paisible AL, 2015, JAIDS-J ACQ IMM DEF, V68, P209, DOI 10.1097/QAI.0000000000000419
   Patterson KB, 2013, AIDS, V27, P1413, DOI 10.1097/QAD.0b013e32835f2b49
   Poirier Paul, 2002, Curr Atheroscler Rep, V4, P448, DOI 10.1007/s11883-002-0049-8
   Rodger AJ, 2013, AIDS, V27, P973, DOI 10.1097/QAD.0b013e32835cae9c
   Samji H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081355
   Shepherd BE, 2017, JAIDS-J ACQ IMM DEF, V74, pE60, DOI 10.1097/QAI.0000000000001221
   Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961
   Torres TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115900
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   WHO, 2013, CLIN GUID ACR CONT C
   Wilson PWF, 2002, ARCH INTERN MED, V162, P1867, DOI 10.1001/archinte.162.16.1867
   World Health Organization, 2014, ATT 9 GLOB NONC DIS
NR 32
TC 36
Z9 36
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD AUG
PY 2018
VL 73
IS 8
BP 2177
EP 2185
DI 10.1093/jac/dky145
PG 9
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA GP5WX
UT WOS:000440948600023
PM 29722811
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Bavinton, BR
   Pinto, AN
   Phanuphak, N
   Grinsztejn, B
   Prestage, GP
   Zablotska-Manos, IB
   Jin, FY
   Fairley, CK
   Moore, R
   Roth, N
   Bloch, M
   Pell, C
   McNulty, AM
   Baker, D
   Hoy, J
   Tee, BK
   Templeton, DJ
   Cooper, DA
   Emery, S
   Kelleher, A
   Grulich, AE
AF Bavinton, Benjamin R.
   Pinto, Angie N.
   Phanuphak, Nittaya
   Grinsztejn, Beatriz
   Prestage, Garrett P.
   Zablotska-Manos, Iryna B.
   Jin, Fengyi
   Fairley, Christopher K.
   Moore, Richard
   Roth, Norman
   Bloch, Mark
   Pell, Catherine
   McNulty, Anna M.
   Baker, David
   Hoy, Jennifer
   Tee, Ban Kiem
   Templeton, David J.
   Cooper, David A.
   Emery, Sean
   Kelleher, Anthony
   Grulich, Andrew E.
CA Opposites Attract Study Grp
TI Viral suppression and HIV transmission in serodiscordant male couples:
   an international, prospective, observational, cohort study
SO LANCET HIV
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; HOMOSEXUAL-MEN; INFECTION; HEALTH; PREVENTION;
   GUIDELINES; RISK
AB Background Evidence on viral load and HIV transmission risk in HIV-serodiscordant male homosexual couples is limited to one published study. We calculated transmission rates in couples reporting condomless anal intercourse (CLAI), when HIV-positive partners were virally suppressed, and daily pre-exposure prophylaxis (PrEP) was not used by HIV-negative partners.
   Methods In the Opposites Attract observational cohort study, serodiscordant male homosexual couples were recruited from 13 clinics in Australia, one in Brazil, and one in Thailand. At study visits, HIV-negative partners provided information on sexual behaviour and were tested for HIV and sexually transmitted infections; HIV-positive partners had HIV viral load tests, CD4 cell count, and sexually transmitted infection tests done. Viral suppression was defined as less than 200 copies per mL. Linked within-couple HIV transmissions were identified with phylogenetic analysis. Incidence was calculated per couple-year of follow-up, focusing on periods with CLAI, no use of daily PrEP, and viral suppression. One-sided upper 95% CI limits for HIV transmission rates were calculated with exact Poisson methods.
   Findings From May 8, 2012, to March 31, 2016, in Australia, and May 7, 2014, to March 31, 2016, in Brazil and Thailand, 358 couples were enrolled. 343 couples had at least one follow-up visit and were followed up for 588 . 4 couple-years. 258 (75%) of 343 HIV-positive partners had viral loads consistently less than 200 copies per mL and 115 (34%) of 343 HIV-negative partners used daily PrEP during follow-up. 253 (74%) of 343 couples reported within-couple CLAI during follow-up, with a total of 16 800 CLAI acts. Three new HIV infections occurred but none were phylogenetically linked. There were 232 . 2 couple-years of follow-up and 12 447 CLAI acts in periods when CLAI was reported, HIV-positive partners were virally suppressed, and HIV-negative partners did not use daily PrEP, resulting in an upper CI limit of 1 . 59 per 100 couple-years of follow-up for transmission rate.
   Interpretation HIV treatment as prevention is effective in men who have sex with men. Increasing HIV testing and linking to immediate treatment is an important strategy in HIV prevention in homosexual men. Copyright (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Bavinton, Benjamin R.; Pinto, Angie N.; Prestage, Garrett P.; Templeton, David J.; Cooper, David A.; Emery, Sean; Grulich, Andrew E.] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Bavinton, Benjamin R.; Pinto, Angie N.; Prestage, Garrett P.; Templeton, David J.; Cooper, David A.; Emery, Sean; Grulich, Andrew E.] Univ New South Wales, Sydney, NSW, Australia.
   [Phanuphak, Nittaya] AIDS Res Ctr, Prevent, Thai Red Cross, Bangkok, Thailand.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Inst Clin Res, Rio De Janeiro, Brazil.
   [Zablotska-Manos, Iryna B.] Westmead Univ Sydney, Sydney Med School, Sydney, NSW, Australia.
   [Fairley, Christopher K.; Hoy, Jennifer] Monash Univ, Melbourne, Vic, Australia.
   [Fairley, Christopher K.] Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia.
   [Moore, Richard] Northside Clin, Melbourne, Vic, Australia.
   [Moore, Richard; Hoy, Jennifer] Alfred Hosp, Melbourne, Vic, Australia.
   [Roth, Norman] Prahran Market Clin, Melbourne, Vic, Australia.
   [Bloch, Mark] Holdsworth House Med Practice, Sydney, NSW, Australia.
   [Pell, Catherine] Taylor Sq Private Clin, Sydney, NSW, Australia.
   [McNulty, Anna M.] Sydney Sexual Hlth Ctr, Sydney, NSW, Australia.
   [Baker, David] East Sydney Doctors, Sydney, NSW, Australia.
   [Tee, Ban Kiem] Ctr Clin, Melbourne, Vic, Australia.
   [Templeton, David J.] RPA Sexual Hlth, Sydney, NSW, Australia.
   [Cooper, David A.] St Vincents Hosp, Immunol B Ambulatory Clin, Sydney, NSW, Australia.
   [Emery, Sean] Univ Queensland, Fac Med, Brisbane, Qld, Australia.
RP Bavinton, BR (corresponding author), Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.; Bavinton, BR (corresponding author), Univ New South Wales, Sydney, NSW, Australia.
EM bbavinton@kirby.unsw.edu.au
RI Emery, Sean/O-9122-2019; Hoy, Jennifer/AAK-7968-2020; Phanuphak,
   Nittaya/AAA-8579-2019
OI Emery, Sean/0000-0001-6072-8309; Prestage, Garrett/0000-0003-3917-8992;
   Christopher, Fairley/0000-0001-9081-1664; Hoy,
   Jennifer/0000-0002-6948-7086; Kelleher, Anthony/0000-0002-0009-3337;
   Templeton, David/0000-0003-2157-9587; Bavinton, Benjamin
   Robert/0000-0001-5834-8278
FU National Health and Medical Research CouncilNational Health and Medical
   Research Council of Australia; amfAR, The Foundation for AIDS Research;
   ViiV Healthcare; Gilead SciencesGilead Sciences
FX National Health and Medical Research Council; amfAR, The Foundation for
   AIDS Research; ViiV Healthcare; and Gilead Sciences.
CR [Anonymous], 2016, CONGUID UANT DRU
   Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca
   Bavinton BR, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19884
   Bavinton BR, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-917
   Campbell MS, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016986, 10.1371/journal.pone.0018283]
   Cohen MS, 2016, N ENGL J MED
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grulich AE, 2015, C RETR OPP INF SEATT
   Jin FJ, 2008, SEX HEALTH, V5, P109, DOI 10.1071/SH07073
   Jin FY, 2010, JAIDS-J ACQ IMM DEF, V53, P144, DOI 10.1097/QAI.0b013e3181b48f33
   Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Mujugira A, 2016, JAIDS-J ACQ IMM DEF, V72, P579, DOI 10.1097/QAI.0000000000001019
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   Templeton DJ, 2014, SEX HEALTH, V11, P217, DOI 10.1071/SH14003
   ULM K, 1990, AM J EPIDEMIOL, V131, P373, DOI 10.1093/oxfordjournals.aje.a115507
   Vernazza P, 2008, B MED SUISSES, V89, P165, DOI DOI 10.4414/BMS.2008.13252
   WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001
   World Health Organization, 2015, GUID START ANT THER
   Wright E, 2017, J VIRUS ERAD, V3, P168
NR 22
TC 121
Z9 122
U1 2
U2 13
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD AUG
PY 2018
VL 5
IS 8
BP E438
EP E447
DI 10.1016/S2352-3018(18)30132-2
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GP4EO
UT WOS:000440811500012
PM 30025681
DA 2020-11-24
ER

PT J
AU Coelho, L
   Rebeiro, PF
   Castilho, JL
   Caro-Veja, Y
   Mejia, FA
   Cesar, C
   Cortes, CP
   Padgett, D
   McGowan, CC
   Veloso, VG
   Sterling, TR
   Grinsztejn, B
   Shepherd, BE
   Luz, PM
AF Coelho, Lara
   Rebeiro, Peter F.
   Castilho, Jessica L.
   Caro-Veja, Yanink
   Mejia, Fernando A.
   Cesar, Carina
   Cortes, Claudia P.
   Padgett, Denis
   McGowan, Catherine C.
   Veloso, Valdilea G.
   Sterling, Timothy R.
   Grinsztejn, Beatriz
   Shepherd, Bryan E.
   Luz, Paula M.
CA CCASAnet
TI Early Retention in Care Neither Mediates Nor Modifies the Effect of Sex
   and Sexual Mode of HIV Acquisition on HIV Survival in the Americas
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
DE retention in care; mortality; sex disparities; HIV; Americas
ID ACTIVE ANTIRETROVIRAL THERAPY; FOLLOW-UP; GENDER-DIFFERENCES; INFECTED
   PERSONS; LATIN-AMERICA; UNITED-STATES; MORTALITY; COHORT; RISK; PROGRAM
AB Early retention in care, sex, and sexual mode of HIV acquisition has been associated with mortality risk among persons living with HIV (PLWH). We assessed whether early retention in care mediates or modifies the association between mortality and sex and sexual mode of HIV acquisition among PLWH on antiretroviral therapy (ART) in the Americas. ART-naive, adult PLWH (18 years) enrolling at Caribbean, Central and South America network for HIV epidemiology (CCASAnet) and Vanderbilt Comprehensive Care Clinic sites 2000-2015, starting ART, and with 1 visit after ART-start were included. Early retention in care was defined as 2 HIV care visits/labs 90 days apart in the first year of ART. Cox models assessed the association between early retention in care, sex, and sexual mode of HIV acquisition [i.e., women, heterosexual men and men who have sex with men (MSM)], and mortality. Associations were estimated separately by site and pooled. Among 11,721 included PLWH (median follow-up, 4.3 years; interquartile range, 2.0-7.6), 647 died (rate=10.9/1000 person-years) and 1985 were lost to follow-up (rate=33.6/1000 person-years). After adjustment for confounders, early retention in care was associated with lower mortality during subsequent years (pooled hazard ratio=0.47; 95% confidence interval=0.39-0.57). MSM had lower and heterosexual men had comparable mortality risk to women; risks were similar when adjusting for early retention in care. Additionally, no evidence of an interaction between early retention in care and sex and sexual mode of HIV acquisition on mortality was observed (p>0.05). Early retention in care substantially reduced mortality but does not mediate or modify the association between sex and sexual mode of HIV acquisition and mortality in our population.
C1 [Coelho, Lara; Veloso, Valdilea G.; Grinsztejn, Beatriz; Luz, Paula M.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-22040 Rio De Janeiro, Brazil.
   [Rebeiro, Peter F.; Castilho, Jessica L.; McGowan, Catherine C.; Sterling, Timothy R.; Shepherd, Bryan E.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Caro-Veja, Yanink] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [Mejia, Fernando A.] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Cesar, Carina] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Cortes, Claudia P.] Univ Chile, Sch Med, Fdn Arriaran, Santiago, Chile.
   [Padgett, Denis] Inst Hondureno Seguridad Social, Tegucigalpa, Honduras.
   [Padgett, Denis] Hosp Escuela Univ, Tegucigalpa, Honduras.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-22040 Rio De Janeiro, Brazil.
EM paula.luz@ini.fiocruz.br
RI Cesar, Carina/H-2831-2019; Cortes, Claudia/AAF-7326-2020
OI Cortes, Claudia/0000-0001-9101-9783; mejia,
   fernando/0000-0001-8429-8833; Luz, Paula/0000-0001-9746-719X
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01-AI069923]; Eunice Kennedy Shriver
   National Institute of Child Health & Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); National Cancer Institute
   (NCI)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI);
   National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); National Institute of Mental Health (NIMH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH); Office
   of the Director, National Institutes of Health (OD)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [K01AI131895, UM1AI069476, UM1AI069476, K23AI120875,
   K23AI120875, UM1AI069476, K23AI120875, UM1AI069476, UM1AI069476,
   K23AI120875, K01AI131895, UM1AI069476, UM1AI069476, UM1AI069476] Funding
   Source: NIH RePORTER
FX This work was supported by the NIH-funded Caribbean, Central and South
   America network for HIV epidemiology (CCASAnet), a member cohort of the
   International Epidemiologic Databases to Evaluate AIDS (leDEA)
   (U01-AI069923). This award is funded by the following institutes: Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD), National Cancer Institute (NCI), National Institute of Allergy
   and Infectious Diseases (NIAID), National Institute of Mental Health
   (NIMH), and the Office of the Director, National Institutes of Health
   (OD).
CR Beckham SW, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21106
   Bowman AS, 2017, AIDS PATIENT CARE ST, V31, P407, DOI 10.1089/apc.2017.0118
   Cargill Victoria A, 2013, Top Antivir Med, V21, P133
   Carriquiry G, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20016
   Castilho JL, 2014, AIDS RES HUM RETROV, V30, P446, DOI [10.1089/aid.2013.0208, 10.1089/AID.2013.0208]
   Coelho L, 2016, LANCET HIV, V3, pE490, DOI 10.1016/S2352-3018(16)30052-2
   da Silva DST, 2017, AIDS CARE, V29, P263, DOI 10.1080/09540121.2016.1211610
   Ezzati M, 2013, NEW ENGL J MED, V369, P954, DOI 10.1056/NEJMra1203528
   Giganti MJ, 2015, AIDS RES HUM RETROV, V31, P496, DOI [10.1089/aid.2014.0241, 10.1089/AID.2014.0241]
   Giordano TP, 2007, CLIN INFECT DIS, V44, P1493, DOI 10.1086/516778
   Grangeiro A, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-99
   Higa DH, 2012, CURR HIV-AIDS REP, V9, P313, DOI 10.1007/s11904-012-0136-6
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Horberg MA, 2013, AIDS PATIENT CARE ST, V27, P442, DOI 10.1089/apc.2013.0073
   Kronfli N, 2017, AIDS PATIENT CARE ST, V31, P428, DOI 10.1089/apc.2017.0115
   Maskew M, 2013, J WOMENS HEALTH, V22, P113, DOI 10.1089/jwh.2012.3585
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   McGowan CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018462
   Mugavero MJ, 2009, CLIN INFECT DIS, V48, P248, DOI 10.1086/595705
   Ochieng-Ooko V, 2010, B WORLD HEALTH ORGAN, V88, P681, DOI 10.2471/BLT.09.064329
   Park WB, 2007, J INTERN MED, V261, P268, DOI 10.1111/j.1365-2796.2006.01762.x
   Rebeiro P, 2013, JAIDS-J ACQ IMM DEF, V62, P356, DOI 10.1097/QAI.0b013e31827f578a
   Rebeiro PF, 2017, AIDS PATIENT CARE ST, V31, P129, DOI 10.1089/apc.2016.0178
   Sabin CA, 2017, AIDS, V31, P653, DOI 10.1097/QAD.0000000000001373
   Shepherd BE, 2013, AM J EPIDEMIOL, V178, P819, DOI 10.1093/aje/kwt030
   Sobrino-Vegas P, 2016, J INFECTION, V72, P587, DOI 10.1016/j.jinf.2016.01.017
   Taylor-Smith K, 2010, MALAWI MED J, V22, P49
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
NR 28
TC 1
Z9 1
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD AUG
PY 2018
VL 32
IS 8
BP 306
EP 313
DI 10.1089/apc.2018.0028
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA GO9LN
UT WOS:000440428900002
PM 30067405
OA Green Published
DA 2020-11-24
ER

PT J
AU Glidden, DV
   Mulligan, K
   McMahan, V
   Anderson, PL
   Guanira, J
   Chariyalertsak, S
   Buchbinder, SP
   Bekker, LG
   Schechter, M
   Grinsztejn, B
   Grant, RM
AF Glidden, David, V
   Mulligan, Kathleen
   McMahan, Vanessa
   Anderson, Peter L.
   Guanira, Juan
   Chariyalertsak, Suwat
   Buchbinder, Susan P.
   Bekker, Linda-Gail
   Schechter, Mauro
   Grinsztejn, Beatriz
   Grant, Robert M.
TI Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir
   Disoproxil Fumarate and Emtricitabine
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE lipids; lipodystrophy; tenofovir/emtricitabine; PrEP; body composition
ID RANDOMIZED COMPARATIVE TRIAL; PLACEBO-CONTROLLED TRIAL; HIV-INFECTED
   ADULTS; DOUBLE-BLIND; ANTIRETROVIRAL PROPHYLAXIS; TRANSGENDER WOMEN;
   NON-INFERIORITY; WEIGHT CHANGE; OPEN-LABEL; PHASE-3
AB Background. Antiretroviral drugs have been associated with changes in lipids, fat mass and dat distribution. Tenofovir disoproxil fumarate (TDF) has been shown lo have a more favorable metabolic profile than other drugs in its class. However, the metabolic effects of TDF in preexposure prophylaxis (PrEP) are unknown.
   Methods. We evaluated the effects of TDF/emtricitabine (FTC) on lipids and body composition in a blinded, placebo-controlled PrEP trial. Participants enrolled in a metabolic subcohort (N = 251, TDF/FTC; N = 247, placebo) consented to fasting lipid panels, dual-energy X-ray absorptiometry scans for body composition, and pharmacologic testing of drug metabolites at baseline and every 24 weeks thereafter.
   Results. Lean body mass was stable and unaffected by TDF/FTC. Body weight increased in both groups but was lower on TDF/FTC through week 72. This difference was explained by lower fat accumulation on TDF/FTC. The net median percent difference (standard error, P value) for TDF/FTC vs placebo at week 24 was -0.8% (0.4%, P=.02), +0.3% (0.4%, P =.46), and -3.8% (1.4%, P=.009) for total, lean, and fat mass, respectively. There was no apparent differential regional fat accumulation on TDF/FTC. Decreases in cholesterol, but not triglycerides, were seen in TDF/FTC participants, with detectable drug levels compared to placebo.
   Conclusions. TDF/FTC for PrEP showed cholesterol reductions and appeared to transiently suppress the accumulation of weight and body fat compared to placebo. There was no evidence of altered fat distribution or lipodystrophy during daily oral TDF/FTC PrEP. Clinical Trials Registration. NCT00458393.
C1 [Glidden, David, V; Mulligan, Kathleen; Buchbinder, Susan P.; Bekker, Linda-Gail] Univ Calif San Francisco, San Francisco, CA 94158 USA.
   [McMahan, Vanessa] Univ Washington, Seattle, WA 98195 USA.
   [Anderson, Peter L.] Univ Colorado Denver, Aurora, CO USA.
   [Guanira, Juan] Invest Med Salud, Lima, Peru.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Buchbinder, Susan P.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [Bekker, Linda-Gail] Desmond Tutu HIV Fdn, Cape Town, South Africa.
   [Schechter, Mauro] Hosp Escola Sao Francisco Assis, Projeto Praca Onze, Rio De Janeiro, Brazil.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Grant, Robert M.] Gladstone Inst Virol, San Francisco, CA USA.
   [Grant, Robert M.] San Francisco AIDS Fdn, San Francisco, CA USA.
RP Glidden, DV (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 550 16th St, San Francisco, CA 94158 USA.
EM david.glidden@ucsf.edu
RI Glidden, David/AAD-4730-2020; Bekker, Linda-Gail/AAZ-8929-2020;
   Schechter, Mauro/AAG-7445-2020
OI BEKKER, LINDA-GAIL/0000-0002-0755-4386; Glidden,
   David/0000-0001-5888-1419
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01 AI106499, UM1 AI068619, U01 AI064002,
   R03 AI120819, R03 AI122908]; NIH/National Academy for Advancing
   Translational Science [UL1 TR000004]; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA; Bill
   and Melinda Gates FoundationBill & Melinda Gates Foundation; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI118575, UM1AI069496, U01AI069496, UM1AI069496, R03AI120819,
   R03AI120819, UM1AI069496, UM1AI069496, UM1AI068619, U01AI069496,
   UM1AI069476, UM1AI069496, U01AI069496, UM1AI069496, U01AI069496,
   UM1AI069496, UM1AI069496, R01AI118575, R01AI118575, UM1AI069496,
   U01AI069496, UM1AI069476, U01AI069496, UM1AI069476, UM1AI068619,
   UM1AI069476, R03AI122908, UM1AI069476, UM1AI068619, R01AI118575,
   U01AI069496, UM1AI068619, R03AI122908, UM1AI069496, R01AI118575,
   R01AI118575, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding
   Source: NIH RePORTER
FX This work was supported by the NIAID (U01 AI106499, UM1 AI068619, U01
   AI064002, R03 AI120819, R03 AI122908). Some infrastructure support at
   the University of California, San Francisco, was provided by an award
   from the NIH/National Academy for Advancing Translational Science (UL1
   TR000004). The iPrEx studies were sponsored by the NIH with cofunding
   from the Bill and Melinda Gates Foundation. Gilead Sciences supported
   travel expenses for non-US investigators to attend study meetings.
CR Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Fisher M, 2009, JAIDS-J ACQ IMM DEF, V51, P562, DOI 10.1097/QAI.0b013e3181ae2eb9
   Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Golub SA, 2013, AIDS PATIENT CARE ST, V27, P248, DOI 10.1089/apc.2012.0419
   Gordon-Larsen P, 2009, AM J CLIN NUTR, V89, P19, DOI 10.3945/ajcn.2008.26147
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinspoon S, 2005, NEW ENGL J MED, V352, P48, DOI 10.1056/NEJMra041811
   Hosek SG, 2017, JAIDS-J ACQ IMM DEF, V74, P21, DOI 10.1097/QAI.0000000000001179
   Koechlin FM, 2017, AIDS BEHAV, V21, P1325, DOI 10.1007/s10461-016-1627-z
   Koenker R., 2005, QUANTILE REGRESSION
   Lal L, 2017, AIDS, V31, P1709, DOI [10.1097/QAD.0000000000001519, 10.1097/qad.0000000000001519]
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
   Madruga JVR, 2007, HIV CLIN TRIALS, V8, P381, DOI 10.1310/hct0806-381
   Mallewa JE, 2008, J ANTIMICROB CHEMOTH, V62, P648, DOI 10.1093/jac/dkn251
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Milinkovic A, 2007, ANTIVIR THER, V12, P407
   Mills A, 2016, LANCET INFECT DIS, V16, P43, DOI 10.1016/S1473-3099(15)00348-5
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Moyle GJ, 2006, AIDS, V20, P2043, DOI 10.1097/01.aids.0000247574.33998.03
   Mulligan K, 2015, CLIN INFECT DIS, V61, P572, DOI 10.1093/cid/civ324
   Post FA, 2017, JAIDS-J ACQ IMM DEF, V74, P180, DOI 10.1097/QAI.0000000000001186
   Randell PA, 2010, ANTIVIR THER, V15, P227, DOI 10.3851/IMP1518
   Ribera E, 2008, HIV CLIN TRIALS, V9, P407, DOI 10.1310/hct0906-407
   Santos JR, 2015, CLIN INFECT DIS, V61, P403, DOI 10.1093/cid/civ296
   Sax PE, 2015, LANCET, V385, P2606, DOI 10.1016/S0140-6736(15)60616-X
   Sheehan TJ, 2003, INT J OBESITY, V27, P498, DOI 10.1038/sj.ijo.0802263
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Tungsiripat M, 2010, AIDS, V24, P1781, DOI 10.1097/QAD.0b013e32833ad8b4
   Vittinghoff E., 2012, REGRESSION METHODS B
   Volk JE, 2015, CLIN INFECT DIS, V61, P1601, DOI 10.1093/cid/civ778
NR 33
TC 7
Z9 7
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2018
VL 67
IS 3
BP 411
EP 419
DI 10.1093/cid/ciy083
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA GO2TZ
UT WOS:000439832200018
PM 29415175
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Barre-Sinoussi, F
   Karim, SSA
   Albert, J
   Bekker, LG
   Beyrer, C
   Cahn, P
   Calmy, A
   Grinsztejn, B
   Grulich, A
   Kamarulzaman, A
   Kumarasamy, N
   Loutfy, MR
   El Filali, KM
   Mboup, S
   Montaner, JSG
   Munderi, P
   Pokrovsky, V
   Vandamme, AM
   Young, B
   Godfrey-Faussett, P
AF Barre-Sinoussi, Francoise
   Karim, Salim S. Abdool
   Albert, Jan
   Bekker, Linda-Gail
   Beyrer, Chris
   Cahn, Pedro
   Calmy, Alexandra
   Grinsztejn, Beatriz
   Grulich, Andrew
   Kamarulzaman, Adeeba
   Kumarasamy, Nagalingeswaran
   Loutfy, Mona R.
   El Filali, Kamal M.
   Mboup, Souleymane
   Montaner, Julio S. G.
   Munderi, Paula
   Pokrovsky, Vadim
   Vandamme, Anne-Mieke
   Young, Benjamin
   Godfrey-Faussett, Peter
TI Expert consensus statement on the science of HIV in the context of
   criminal law
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE human rights; law and policy; risk factors; policy; criminalization;
   criminal law; prosecution
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY;
   NONOCCUPATIONAL POSTEXPOSURE PROPHYLAXIS; UNPROTECTED ANAL INTERCOURSE;
   HEALTH-CARE WORKERS; LIFE EXPECTANCY; HETEROSEXUAL TRANSMISSION;
   INFECTED PATIENTS; VIRAL LOAD; OCCUPATIONAL TRANSMISSION
AB INTRODUCTION: Globally, prosecutions for non-disclosure, exposure or transmission of HIV frequently relate to sexual activity, biting, or spitting. This includes instances in which no harm was intended, HIV transmission did not occur, and HIV transmission was extremely unlikely or not possible. This suggests prosecutions are not always guided by the best available scientific and medical evidence.
   DISCUSSION: Twenty scientists from regions across the world developed this Expert Consensus Statement to address the use of HIV science by the criminal justice system. A detailed analysis of the best available scientific and medical research data on HIV transmission, treatment effectiveness and forensic phylogenetic evidence was performed and described so it may be better understood in criminal law contexts. Description of the possibility of HIV transmission was limited to acts most often at issue in criminal cases. The possibility of HIV transmission during a single, specific act was positioned along a continuum of risk, noting that the possibility of HIV transmission varies according to a range of intersecting factors including viral load, condom use, and other risk reduction practices. Current evidence suggests the possibility of HIV transmission during a single episode of sex, biting or spitting ranges from no possibility to low possibility. Further research considered the positive health impact of modern antiretroviral therapies that have improved the life expectancy of most people living with HIV to a point similar to their HIV-negative counterparts, transforming HIV infection into a chronic, manageable health condition. Lastly, consideration of the use of scientific evidence in court found that phylogenetic analysis alone cannot prove beyond reasonable doubt that one person infected another although it can be used to exonerate a defendant.
   CONCLUSIONS: The application of up-to-date scientific evidence in criminal cases has the potential to limit unjust prosecutions and convictions. The authors recommend that caution be exercised when considering prosecution, and encourage governments and those working in legal and judicial systems to pay close attention to the significant advances in HIV science that have occurred over the last three decades to ensure current scientific knowledge informs application of the law in cases related to HIV.
C1 [Barre-Sinoussi, Francoise] Pasteur Inst, Paris, France.
   [Karim, Salim S. Abdool] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
   [Karim, Salim S. Abdool] Univ KwaZulu Natal, Ctr AIDS Program Res South Africa, Durban, South Africa.
   [Karim, Salim S. Abdool] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
   [Albert, Jan] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.
   [Bekker, Linda-Gail] Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa.
   [Beyrer, Chris] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Ctr AIDS Res, Baltimore, MD USA.
   [Beyrer, Chris] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Baltimore, MD USA.
   [Cahn, Pedro] Juan A Fernandez Hosp Buenos Aires, Infect Dis Unit, Caba, Argentina.
   [Cahn, Pedro] Buenos Aires Univ Med Sch, Buenos Aires, DF, Argentina.
   [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Calmy, Alexandra] Geneva Univ Hosp, Infect Dis, Geneva, Switzerland.
   [Grinsztejn, Beatriz] Inst Nacl Infectol Evandro Chagas Fiocruz, Fiocruz, RJ, Brazil.
   [Grulich, Andrew] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Kamarulzaman, Adeeba] Univ Malaya, Facu Med, Kuala Lumpur, Malaysia.
   [Kumarasamy, Nagalingeswaran] Voluntary Hlth Serv, YRGCARE Med Ctr, Madras, Tamil Nadu, India.
   [Loutfy, Mona R.] Womens Coll Res Inst, Toronto, ON, Canada.
   [Loutfy, Mona R.] Womens Coll Hosp, Toronto, ON, Canada.
   [Loutfy, Mona R.] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [El Filali, Kamal M.] Ibn Rochd Univ Hosp, Infect Dis Unit, Casablanca, Morocco.
   [Mboup, Souleymane] Inst Rech Sante Surveillance Epidemiol & Format, Dakar, Senegal.
   [Montaner, Julio S. G.] Univ British Columbia, Fac Med, Vancouver, BC, Canada.
   [Montaner, Julio S. G.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
   [Munderi, Paula] Int Assoc Providers AIDS Care, Kampala, Uganda.
   [Pokrovsky, Vadim] Russian Peoples Friendship Univ, RUDN Univ, Moscow, Russia.
   [Pokrovsky, Vadim] Cent Res Inst Epidemiol, Fed Serv Customers Rights Protect & Human Wellbei, Moscow, Russia.
   [Vandamme, Anne-Mieke] Katholieke Univ Leuven, Dept Microbiol & Immunol, Rega Inst Med Res Clin & Epidemiol Virol, Leuven, Belgium.
   [Vandamme, Anne-Mieke] Univ Nova Lisboa, Ctr Global Hlth & Trop Med, Inst Higiene & Med Trop, Unidade Microbiol, Lisbon, Portugal.
   [Young, Benjamin] Int Assoc Providers AIDS Care, Washington, DC USA.
   [Godfrey-Faussett, Peter] UNAIDS, Ave Appia 20, CH-1211 Geneva, Switzerland.
   [Godfrey-Faussett, Peter] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London, England.
RP Godfrey-Faussett, P (corresponding author), UNAIDS, Ave Appia 20, CH-1211 Geneva, Switzerland.
EM godfreyp@unaids.org
RI Pokrovsky, Vadim/AAH-7554-2020; Karim, Salim Abdool/P-3117-2019;
   Vandamme, Anne-Mieke/I-4127-2012; Karim, Salim Abdool/AAE-7118-2019;
   Bekker, Linda-Gail/AAZ-8929-2020
OI Karim, Salim Abdool/0000-0002-4986-2133; Vandamme,
   Anne-Mieke/0000-0002-6594-2766; BEKKER, LINDA-GAIL/0000-0002-0755-4386;
   Pokrovsky, Vadim/0000-0002-9514-7288
FU International AIDS Society (IAS); International Association of Providers
   of AIDS Care (IAPAC); Robert Carr Fund for Civil Society Networks;
   UNAIDS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH
   RePORTER
FX Funding for this work was provided by the International AIDS Society
   (IAS), the International Association of Providers of AIDS Care (IAPAC),
   the Robert Carr Fund for Civil Society Networks, and UNAIDS.
CR Abecasis A, 2017, AIDS, V26, P2017
   Abecasis AB, 2011, LANCET INFECT DIS, V11, P78, DOI 10.1016/S1473-3099(10)70283-8
   Albert J, 2014, SCAND J INFECT DIS, V46, P673, DOI 10.3109/00365548.2014.926565
   Anglemyer A, 2013, JAMA-J AM MED ASSOC, V310, P1619, DOI 10.1001/jama.2013.278328
   [Anonymous], 1992, BMJ, V304, P809
   ARCHIBALD DW, 1990, AIDS RES HUM RETROV, V6, P1425, DOI 10.1089/aid.1990.6.1425
   Asiki G, 2016, AIDS, V30, P487, DOI 10.1097/QAD.0000000000000930
   Baggaley RF, 2010, INT J EPIDEMIOL, V39, P1048, DOI 10.1093/ije/dyq057
   Baggaley RF, 2008, INT J EPIDEMIOL, V37, P1255, DOI 10.1093/ije/dyn151
   Baggaley RF, 2006, AIDS, V20, P805, DOI 10.1097/01.aids.0000218543.46963.6d
   Bavinton B, 2017, 9 INT AIDS SOC C HIV
   Beltrami EM, 2002, INFECT CONT HOSP EP, V23, P345, DOI 10.1086/502065
   Bernard E, 2011, HIV FORENSICS 2 ESTI
   Bernard EJ, 2007, HIV MED, V8, P382, DOI 10.1111/j.1468-1293.2007.00486.x
   Bernard EJ, 2016, ADV HIV JUSTICE 2 BU
   BERTHIER A, 1986, LANCET, V2, P598
   Bloomfield GS, 2014, JAIDS-J ACQ IMM DEF, V67, pS40, DOI 10.1097/QAI.0000000000000257
   Boily MC, 2009, LANCET INFECT DIS, V9, P118, DOI 10.1016/S1473-3099(09)70021-0
   Boyd M, 2016, MED J AUSTRALIA, V205, P409, DOI 10.5694/mja16.00934
   BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014
   Campo J, 2006, ORAL DIS, V12, P219, DOI 10.1111/j.1601-0825.2005.01187.x
   Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101
   Centers for Disease Control and Prevention, 2017, CDC INF UND VIR LOAD
   Centers for Disease Control and Prevention, 2009, OR SEX HIV RISK CDC
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Courville TM, 1998, CLIN PEDIATR, V37, P175, DOI 10.1177/000992289803700303
   Crepaz N, 2009, AIDS, V23, P1617, DOI 10.1097/QAD.0b013e32832effae
   Cresswell FV, 2018, HIV MED, V19, P532, DOI 10.1111/hiv.12625
   Crosby RA, 2012, SEX HEALTH, V9, P10, DOI 10.1071/SH11036
   Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16
   DEBRY RW, 1993, NATURE, V361, P691, DOI 10.1038/361691a0
   Deeks SG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3172
   DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X
   del Romero J, 2002, AIDS, V16, P1296, DOI 10.1097/00002030-200206140-00017
   Donnell D, 2010, AIDS BEHAV, V14, P1182, DOI 10.1007/s10461-010-9712-1
   DRUMMOND JA, 1986, JAMA-J AM MED ASSOC, V256, P2342, DOI 10.1001/jama.1986.03380170058010
   Fideli OS, 2001, AIDS RES HUM RETROV, V17, P901, DOI 10.1089/088922201750290023
   FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640
   Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145
   Foster R, 2015, CLIN INFECT DIS, V61, P1336, DOI 10.1093/cid/civ511
   FRIEDLAND G, 1990, AIDS, V4, P639, DOI 10.1097/00002030-199007000-00005
   Furuya-Kanamori L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078403
   Gilbart V L, 1998, Commun Dis Public Health, V1, P108
   Goedhals D, 2012, LANCET, V380, P702, DOI 10.1016/S0140-6736(12)60957-X
   Gonzalez-Candelas F, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-76
   GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344
   Grant RM, 2015, AIDS, V29, P331, DOI 10.1097/QAD.0000000000000556
   Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2
   Griffith WF, 2010, OBSTET GYNECOL INT, V2010, DOI 10.1155/2010/196963
   Grulich A, 2015, 2015 C RETR OPP INF
   Gueler A, 2017, AIDS, V31, P427, DOI 10.1097/QAD.0000000000001335
   Halperin DT, 2002, 14 INT AIDS C BARC S
   Hawkins DA, 2001, J INFECTION, V43, P12, DOI [10.1016/S0163-4453(01)90811-4, 10.1039/jinf.2001.0811]
   Helleberg M, 2013, CLIN INFECT DIS, V56, P727, DOI 10.1093/cid/cis933
   HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740
   HUELSENBECK JP, 1993, SYST BIOL, V42, P247, DOI 10.2307/2992463
   Hughes JP, 2012, J INFECT DIS, V205, P358, DOI 10.1093/infdis/jir747
   JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169
   Jain S, 2015, AIDS PATIENT CARE ST, V29, P20, DOI 10.1089/apc.2014.0154
   Jin FY, 2010, AIDS, V24, P907, DOI 10.1097/QAD.0b013e3283372d90
   Jin FY, 2009, AIDS, V23, P243, DOI 10.1097/QAD.0b013e32831fb51a
   Jochimsen Elise M., 1997, American Journal of Medicine, V102, P52, DOI 10.1016/S0002-9343(97)00062-4
   Johnson LF, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001418
   Joint United Nations Programme on HIV/ AIDS (UNAIDS), 2013, UNAIDS GUID NOT END
   Kojic EM, 2007, J WOMENS HEALTH, V16, P1402, DOI 10.1089/jwh.2007.0345
   Lavoie E, 2008, SEX TRANSM DIS, V35, P25, DOI 10.1097/OLQ.0b013e31814fb113
   Learmont JC, 1999, NEW ENGL J MED, V340, P1715, DOI 10.1056/NEJM199906033402203
   Lee FJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097482
   Lemey P, 2005, AIDS, V19, P1649, DOI 10.1097/01.aids.0000187904.02261.1a
   Leynaert B, 1998, AM J EPIDEMIOL, V148, P88, DOI 10.1093/oxfordjournals.aje.a009564
   Linden JA, 2005, ACAD EMERG MED, V12, P640, DOI 10.1197/j.aem.2005.01.015
   Lohse N, 2016, ANN INTERN MED, V165, P749, DOI 10.7326/L16-0091
   Lot F, 1999, B EPID HEBDO, V18, P69
   Loutfy M, 2014, CAN J INFECT DIS MED, V25, P135, DOI 10.1155/2014/498459
   Loutfy MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048168
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Lunding S, 2010, SEX TRANSM DIS, V37, P49, DOI 10.1097/OLQ.0b013e3181b6f284
   LUSHER JM, 1991, PEDIATRICS, V88, P242
   Lytle CD, 1997, SEX TRANSM DIS, V24, P161, DOI 10.1097/00007435-199703000-00007
   Macdonald N, 2007, SEX TRANSM INFECT, V84, P8, DOI 10.1136/sti.2007.027946
   Madec Y, 2009, JAIDS-J ACQ IMM DEF, V50, P19, DOI 10.1097/QAI.0b013e31818ce709
   MALAMUD D, 1993, CRIT REV ORAL BIOL M, V4, P461, DOI 10.1177/10454411930040032901
   Manfredi R, 2004, AGEING RES REV, V3, P31, DOI 10.1016/j.arr.2003.07.001
   Manfredi R, 2002, DRUG AGING, V19, P647, DOI 10.2165/00002512-200219090-00003
   Marcus JL, 2016, JAIDS-J ACQ IMM DEF, V73, P39, DOI 10.1097/QAI.0000000000001014
   Mastro T D, 1996, AIDS, V10 Suppl A, pS75, DOI 10.1097/00002030-199601001-00011
   May MT, 2014, AIDS, V28, P1193, DOI 10.1097/QAD.0000000000000243
   McAllister J, 2014, HIV MED, V15, P13, DOI 10.1111/hiv.12075
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   McManus H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048839
   Millett GA, 2009, JAMA-J AM MED ASSOC, V301, P1126
   Millett GA, 2008, JAMA-J AM MED ASSOC, V300, P1674, DOI 10.1001/jama.300.14.1674
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Montaner JSG, 2006, LANCET, V368, P531, DOI 10.1016/S0140-6736(06)69162-9
   Morrow Gavin, 2007, Curr HIV/AIDS Rep, V4, P29, DOI 10.1007/s11904-007-0005-x
   Narayan KMV, 2014, JAIDS-J ACQ IMM DEF, V67, pS2, DOI 10.1097/QAI.0000000000000267
   Nglazi MD, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-676
   Nsanzimana S, 2015, LANCET GLOB HEALTH, V3, pE169, DOI 10.1016/S2214-109X(14)70364-X
   Okulicz JF, 2009, J INFECT DIS, V200, P1714, DOI 10.1086/646609
   Olshen E, 2006, ARCH PEDIAT ADOL MED, V160, P674, DOI 10.1001/archpedi.160.7.674
   OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Paraschiv S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185866
   Patel P, 2014, AIDS, V28, P1509, DOI 10.1097/QAD.0000000000000298
   Patterson S, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0969-x
   Pinkerton SD, 2004, ARCH INTERN MED, V164, P46, DOI 10.1001/archinte.164.1.46
   Poropatich K, 2011, J GEN VIROL, V92, P247, DOI 10.1099/vir.0.027102-0
   Powers KA, 2008, LANCET INFECT DIS, V8, P553, DOI 10.1016/S1473-3099(08)70156-7
   Poynten IM, 2007, HIV MED, V8, P374, DOI 10.1111/j.1468-1293.2007.00483.x
   Price AJ, 2017, INT J EPIDEMIOL, V46, P479, DOI 10.1093/ije/dyw208
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   RAITERI R, 1994, LANCET, V344, P270, DOI 10.1016/S0140-6736(94)93037-6
   Rambaut A, 2004, NAT REV GENET, V5, P52, DOI 10.1038/nrg1246
   Reniers G, 2017, LANCET HIV, V4, pE113, DOI 10.1016/S2352-3018(16)30225-9
   Rhodes DI, 2000, J VIROL, V74, P10581, DOI 10.1128/JVI.74.22.10581-10588.2000
   Richman KM, 1993, J ACQ IMMUN DEF SYND, V64, P40
   Rodger A, 2014, CROI MAR 3 6 BOST US
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498
   ROGERS MF, 1990, PEDIATRICS, V85, P210
   ROMEA S, 1995, EUR J EPIDEMIOL, V11, P225, DOI 10.1007/BF01719493
   Romero-Severson E, 2014, MOL BIOL EVOL, V31, P2472, DOI 10.1093/molbev/msu179
   Romero-Severson EO, 2016, P NATL ACAD SCI USA, V113, P2690, DOI 10.1073/pnas.1522930113
   Sabin CA, 2013, CURR OPIN HIV AIDS, V8, P311, DOI 10.1097/COH.0b013e328361fa66
   Samji H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081355
   Schechter M, 2004, JAIDS-J ACQ IMM DEF, V35, P519, DOI 10.1097/00126334-200404150-00010
   Scott HM, 2014, JAIDS-J ACQ IMM DEF, V65, P115, DOI 10.1097/QAI.0b013e3182a98bae
   Serrano-Villar S, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw097
   Sexton J, 2005, SEX TRANSM DIS, V32, P351, DOI 10.1097/01.olq.0000154504.54686.d1
   Shine N, 1997, J DENT RES, V76, P634, DOI 10.1177/00220345970760020301
   SHIRLEY LR, 1989, J PEDIATR-US, V114, P425, DOI 10.1016/S0022-3476(89)80563-3
   Shugars DC, 1998, J AM DENT ASSOC, V129, P851, DOI 10.14219/jada.archive.1998.0349
   Shugars DC, 1998, J DENT RES, V77, P285
   Siddiqi AEA, 2016, JAIDS-J ACQ IMM DEF, V72, P230, DOI 10.1097/QAI.0000000000000960
   Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2
   Smith DK, 2015, JAIDS-J ACQ IMM DEF, V68, P337, DOI 10.1097/QAI.0000000000000461
   SMITH TF, 1992, SCIENCE, V256, P1155, DOI 10.1126/science.256.5060.1155
   Sonder GJB, 2010, SEX TRANSM DIS, V37, P681, DOI 10.1097/OLQ.0b013e3181e2f999
   Sorstedt E, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1628-6
   Stephan C, 2013, HIV MED, V14, P284, DOI 10.1111/hiv.12004
   Supervie V, 2014, CLIN INFECT DIS, V59, P115, DOI 10.1093/cid/ciu223
   Teeraananchai S, 2017, HIV MED, V18, P256, DOI 10.1111/hiv.12421
   Teeraananchai S, 2017, ANTIVIR THER, V22, P393, DOI 10.3851/IMP3121
   Teira R, 2017, HIV MED, V18, P196, DOI 10.1111/hiv.12413
   Tereskerz PM, 1996, LANCET, V348, P1512, DOI 10.1016/S0140-6736(05)65921-1
   Tovanabutra S, 2002, J ACQ IMMUN DEF SYND, V29, P275, DOI 10.1097/00126334-200203010-00008
   Trickey A, 2017, LANCET HIV, V4, pE349, DOI 10.1016/S2352-3018(17)30066-8
   TSOUKAS CM, 1988, J ACQ IMMUN DEF SYND, V1, P505
   UNDP, 2012, GLOB COMM HIV LAW RI
   Van de Ven P, 2002, AIDS CARE, V14, P471, DOI 10.1080/09540120208629666
   van Sighem A, 2008, JAIDS-J ACQ IMM DEF, V48, P104, DOI 10.1097/QAI.0b013e31816a1d4f
   van Sighem A, 2010, AIDS, V24, P1527, DOI 10.1097/QAD.0b013e32833a3946
   Vandamme AM, 1999, EUR J CLIN INVEST, V29, P445
   Vernazza P, 2008, B MED SUISSES, V89, P165, DOI DOI 10.4414/BMS.2008.13252
   VERRUSIO AC, 1989, J AM DENT ASSOC, V118, P339, DOI 10.14219/jada.archive.1989.0108
   Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003
   Wandeler G, 2016, CURR OPIN HIV AIDS, V11, P492, DOI 10.1097/COH.0000000000000298
   Weller S, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003255
   Weller S, 2001, CONDOM EFFECTIVENESS
   Wertheim JO, 2010, SYST BIOL, V59, P1, DOI 10.1093/sysbio/syp072
   World Health Organization, 2015, SEX HLTH HUM RIGHTS
   Wulfsohn A, 2003, P 10 C RETR OPP INF
   YEH CK, 1992, J ACQ IMMUN DEF SYND, V5, P898
   YEUNG SCH, 1993, J INFECT DIS, V167, P803, DOI 10.1093/infdis/167.4.803
   Young J, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1120-8
   Zhu H, 2013, JAIDS-J ACQ IMM DEF, V63, pE150, DOI 10.1097/QAI.0b013e3182948d82
NR 167
TC 30
Z9 30
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL 25
PY 2018
VL 21
IS 7
AR e25161
DI 10.1002/jia2.25161
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GO5OM
UT WOS:000440072800001
PM 30044059
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Cortes, FH
   de Paula, HHS
   Bello, G
   Ribeiro-Alves, M
   de Azevedo, SSD
   Caetano, DG
   Teixeira, SLM
   Hoagland, B
   Grinsztejn, B
   Veloso, VG
   Guimaraes, ML
   Morgado, MG
AF Cortes, Fernanda H.
   de Paula, Hury H. S.
   Bello, Gonzalo
   Ribeiro-Alves, Marcelo
   de Azevedo, Suwellen S. D.
   Caetano, Diogo G.
   Teixeira, Sylvia L. M.
   Hoagland, Brenda
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Guimaraes, Monick L.
   Morgado, Mariza G.
TI Plasmatic Levels of IL-18, IP-10, and Activated CD8(+) T Cells Are
   Potential Biomarkers to Identify HIV-1 Elite Controllers With a True
   Functional Cure Profile
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE HIV-1; inflammation; immune activation; elite controller; IP-10; IL-18
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE ACTIVATION; CD4/CD8 RATIO;
   INDIVIDUALS; ABSENCE; INFECTION; LONG; HETEROGENEITY; SUPPRESSION;
   DEPLETION
AB Elite controllers (ECs) are rare individuals able to naturally control HIV-1 replication below the detection limit of viral load (VL) commercial assays. It is unclear, however, whether ECs might be considered a natural model of a functional cure because some studies have noted CD4(+) T cell depletion and disease progression associated with abnormally high levels of immune activation and/or inflammation in this group. Here, we propose the use of immunological parameters to identify HIV-1 ECs that could represent the best model of a functional cure. We compared plasma levels of six inflammatory biomarkers (IP-10, IL-18, sCD163, sCD14, CRP, and IL-6) and percentages of activated CD8(+) T cells (CD38(+)HLA-DR+) between 15 ECs [8 with persistent undetectable viremia (persistent elite controllers) and 7 with occasional viral blips (ebbing elite controllers)], 13 viremic controllers (VCs-plasma VL between 51 and 2,000 RNA copies/mL), and 18 HIV-1 infected patients in combined antiretroviral therapy, with suppressed viremia, and 18 HIV-uninfected controls (HIV-neg). The two groups of ECs presented inflammation and activation profiles similar to HIV-neg individuals, and there was no evidence of CD4(+) T cell decline over time. VCs, by contrast, had higher levels of IL-18, IP-10, and CRP and a lower CD4/CD8 ratio than that of HIV-neg (P < 0.05). Plasma levels of IL-18 and IP-10 correlated positively with CD8(+) T cell activation and negatively with both CD4/CD8 and CD4% in HIV-1 controllers. These results suggest that most ECs, defined using stringent criteria in relation to the cutoff level of viremia (<= 50 copies/mL) and a minimum follow-up time of >5 years, show no evidence of persistent inflammation or immune activation. This study further suggests that plasmatic levels of IL-18/IP-10 combined with the frequency of CD8(+) CD38(+) HLA-DR+T cells can be important biomarkers to identify models of a functional cure among HIV-1 ECs.
C1 [Cortes, Fernanda H.; de Paula, Hury H. S.; Bello, Gonzalo; de Azevedo, Suwellen S. D.; Caetano, Diogo G.; Teixeira, Sylvia L. M.; Guimaraes, Monick L.; Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Rio De Janeiro, Brazil.
   [Ribeiro-Alves, Marcelo; Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin DST Aids, Rio De Janeiro, Brazil.
RP Cortes, FH (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Rio De Janeiro, Brazil.
EM fheloise@ioc.fiocruz.br
RI Cortes, Fernanda/AAF-9254-2020; Bello, Gonzalo/E-6842-2013; de Azevedo,
   Suwellen/P-7199-2017
OI de Azevedo, Suwellen/0000-0001-6681-0987; Ribeiro-Alves,
   Marcelo/0000-0002-8663-3364
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPqNational Council for Scientific and Technological
   Development (CNPq); Fiocruz; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro - FAPERJ; the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq; and Fiocruz.
CR Ahmad R, 2002, J VIROL, V76, P12448, DOI 10.1128/JVI.76.24.12448-12456.2002
   Andrade A, 2008, CLIN INFECT DIS, V46, pE78, DOI 10.1086/529387
   Autran B, 2011, CURR OPIN HIV AIDS, V6, P181, DOI 10.1097/COH.0b013e328345a328
   Bansal A, 2015, AIDS, V29, P2245, DOI 10.1097/QAD.0000000000000860
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Bello G, 2009, J MED VIROL, V81, P1681, DOI 10.1002/jmv.21565
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Canoui E, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx064
   Castley A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115226
   Chereau F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173893
   Chun TW, 2013, J INFECT DIS, V208, P1443, DOI 10.1093/infdis/jit306
   Cortes FH, 2015, JAIDS-J ACQ IMM DEF, V68, P377, DOI 10.1097/QAI.0000000000000500
   de Azevedo SSD, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0354-5
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Giorgi JV, 2002, J ACQ IMMUN DEF SYND, V29, P346, DOI 10.1097/00126334-200204010-00004
   Gurdasani D, 2014, AIDS, V28, P149, DOI 10.1097/QAD.0000000000000049
   Hatano H, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003691
   Hatano H, 2009, J VIROL, V83, P329, DOI 10.1128/JVI.01763-08
   Helleberg M, 2015, J INFECT DIS, V211, P1726, DOI 10.1093/infdis/jiu669
   HOLM S, 1979, SCAND J STAT, V6, P65
   Hua S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101920
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Iannello A, 2017, CYTOKINE, V90, P96, DOI 10.1016/j.cyto.2016.10.018
   Kamya P, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-20
   Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d
   Leon A, 2016, AIDS, V30, P1209, DOI 10.1097/QAD.0000000000001050
   Margolick JB, 2006, JAIDS-J ACQ IMM DEF, V42, P620, DOI 10.1097/01.qai.0000223028.55080.9d
   Noel N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131922
   Noel N, 2014, AIDS, V28, P467, DOI 10.1097/QAD.0000000000000174
   Pastor L, 2017, CLIN INFECT DIS, V65, P1670, DOI 10.1093/cid/cix600
   Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786
   Pereyra F, 2009, J INFECT DIS, V200, P984, DOI 10.1086/605446
   Pirzada Yasmin, 2006, AIDS Res Ther, V3, P20, DOI 10.1186/1742-6405-3-20
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Saez-Cirion A, 2009, J IMMUNOL, V182, P7828, DOI 10.4049/jimmunol.0803928
   SATTERTHWAITE FE, 1946, BIOMETRICS BULL, V2, P110, DOI 10.2307/3002019
   Sedaghat AR, 2009, CLIN INFECT DIS, V49, P1763, DOI 10.1086/648081
   Serrano-Villar S, 2013, J INFECTION, V66, P57, DOI 10.1016/j.jinf.2012.09.013
   Sousa AE, 2002, J IMMUNOL, V169, P3400, DOI 10.4049/jimmunol.169.6.3400
   Veenhuis RT, 2017, CLIN INFECT DIS, V64, P589, DOI 10.1093/cid/ciw771
   Wada NI, 2015, AIDS, V29, P463, DOI 10.1097/QAD.0000000000000545
   Walker-Sperling VE, 2017, EBIOMEDICINE, V16, P141, DOI 10.1016/j.ebiom.2017.01.034
   Wiercinska-Drapalo A, 2004, MICROBES INFECT, V6, P1273, DOI 10.1016/j.micinf.2004.07.009
   Yandell BS, 1997, CHAPMAN HALL CRC TEX
NR 45
TC 10
Z9 10
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 11
PY 2018
VL 9
AR 1576
DI 10.3389/fimmu.2018.01576
PG 11
WC Immunology
SC Immunology
GA GM6TK
UT WOS:000438306900001
PM 30050532
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Dooley, K
   Kaplan, R
   Mwelase, T
   Grinsztejn, B
   Ticona, E
   Lacerda, M
   Sued, O
   Belonosova, E
   Ait-Khaled, M
   Angelis, K
   Brown, D
   Singh, R
   Talarico, C
   Tenorio, A
   Keegan, M
   Aboud, M
AF Dooley, K.
   Kaplan, R.
   Mwelase, T.
   Grinsztejn, B.
   Ticona, E.
   Lacerda, M.
   Sued, O.
   Belonosova, E.
   Ait-Khaled, M.
   Angelis, K.
   Brown, D.
   Singh, R.
   Talarico, C.
   Tenorio, A.
   Keegan, M.
   Aboud, M.
TI Safety and efficacy of dolutegravir-based ART in TB/HIV co-infected
   adults at week 48
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Dooley, K.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Kaplan, R.] Desmond Tutu HIV Fdn, Cape Town, South Africa.
   [Mwelase, T.] Clin HIV Res Unit, Johannesburg, South Africa.
   [Grinsztejn, B.] 4Inst Pesquisa Clin Evandro Chagas FIOCRUZ, Rio De Janeiro, Brazil.
   [Ticona, E.] Hosp Dos de Mayo, Lima, Peru.
   [Lacerda, M.] Fiocruz Trop Med Fdn Dr Heitor, Manaus, Amazonas, Brazil.
   [Sued, O.] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Belonosova, E.] Reg Ctr Prevent & Treatment AIDS & Infect Dis, Moscow, Russia.
   [Ait-Khaled, M.; Keegan, M.; Aboud, M.] ViiV Healthcare, Brentford, England.
   [Angelis, K.] GlaxoSmithKline, Stockley Pk, England.
   [Brown, D.] ViiV Healthcare, Melbourne, Vic, Australia.
   [Singh, R.] GlaxoSmithKline, Upper Merion, PA USA.
   [Talarico, C.; Tenorio, A.] ViiV Healthcare, Res Triangle Pk, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2018
VL 21
SU 6
SI SI
MA TUAB0206
BP 10
EP 10
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GO4RZ
UT WOS:000440002700019
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Marins, LMS
   Torres, TS
   Leite, IC
   Moreira, RI
   Hoagland, B
   Kallas, EG
   Madruga, JV
   Anderson, PL
   Liu, AY
   Grinsztejn, B
   Veloso, V
AF Marins, L. M. S.
   Torres, T. S.
   Costa Leite, I.
   Moreira, R. I.
   Hoagland, B.
   Kallas, E. G.
   Madruga, J. V.
   Anderson, P. L.
   Liu, A. Y.
   Grinsztejn, B.
   Veloso, V.
CA PrEP Brasil Study Team
TI Comparison of measures of adherence to HIV pre-exposure prophylaxis
   (PrEP) among men who have sex with men (MSM) and transgender women
   (TGW): results from the PrEP Brasil study
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Marins, L. M. S.; Torres, T. S.; Moreira, R. I.; Hoagland, B.; Grinsztejn, B.; Veloso, V.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Costa Leite, I.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil.
   [Kallas, E. G.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Madruga, J. V.] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Anderson, P. L.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Denver, CO 80202 USA.
   [Liu, A. Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2018
VL 21
SU 6
SI SI
MA TUAC0303
BP 16
EP 17
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GO4RZ
UT WOS:000440002700032
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Pacheco, A
   Perazzo, H
   Cardoso, S
   Fonseca, MJ
   Griep, R
   Lotufo, P
   Bensenor, I
   Mill, J
   Moreira, R
   Moreira, R
   Friedman, R
   Santini-Oliveira, M
   Veloso, V
   Chor, D
   Grinsztejn, B
AF Pacheco, A.
   Perazzo, H.
   Cardoso, S.
   Fonseca, M. J.
   Griep, R.
   Lotufo, P.
   Bensenor, I.
   Mill, J.
   Moreira, R.
   Moreira, R.
   Friedman, R.
   Santini-Oliveira, M.
   Veloso, V.
   Chor, D.
   Grinsztejn, B.
TI HIV infection is an independent risk factor for liver steatosis: a study
   in HIV mono-infected patients compared to uninfected paired controls and
   associated risk factors
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Pacheco, A.; Moreira, R.] Fundacao Oswaldo Cruz FIOCRUZ, PROCC, Rio De Janeiro, Brazil.
   [Perazzo, H.; Cardoso, S.; Moreira, R.; Moreira, R.; Friedman, R.; Santini-Oliveira, M.; Veloso, V.; Grinsztejn, B.] Fundacao Oswaldo Cruz FIOCRUZ, LAPCLIN AIDS, Rio De Janeiro, Brazil.
   [Fonseca, M. J.; Chor, D.] Fundacao Oswaldo Cruz FIOCRUZ, Dept Epidemiol & Metodos Quantitat Saude, Rio De Janeiro, Brazil.
   [Griep, R.] Fundacao Oswaldo Cruz FIOCRUZ, Lab Hlth & Environm Educ, Rio De Janeiro, Brazil.
   [Lotufo, P.; Bensenor, I.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Mill, J.] Univ Fed Espirito Santo, Dept Ciencias Fisiol, Vitoria, Brazil.
RI Pacheco, Antonio Guilherme/E-6378-2013
OI Pacheco, Antonio Guilherme/0000-0003-3095-1774
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2018
VL 21
SU 6
SI SI
MA THAB0205
BP 66
EP 67
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GO4RZ
UT WOS:000440002700140
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Caro-Vega, Y
   Belaunzaran-Zamudio, PF
   Crabtree-Ramirez, B
   Shepherd, BE
   Mejia, F
   Giganti, MJ
   Patterson, P
   Grinsztejn, B
   Wolff, M
   Pape, JW
   Padgett, D
   Castilho, JL
   McGowan, C
   Sierra-Madero, JG
AF Caro-Vega, Y.
   Belaunzaran-Zamudio, P. F.
   Crabtree-Ramirez, B.
   Shepherd, B. E.
   Mejia, F.
   Giganti, M. J.
   Patterson, P.
   Grinsztejn, B.
   Wolff, M.
   Pape, J. W.
   Padgett, D.
   Castilho, J. L.
   McGowan, C.
   Sierra-Madero, J. G.
TI Trends in proportion of older HIV-infected people in care in Latin
   America and the Caribbean: a growing challenge
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Aging; Caribbean; HIV; AIDS; Latin America; older
ID AGING POPULATION; EPIDEMIOLOGY; VALIDATION
AB We aimed to quantify the proportion of people receiving care for HIV-infection that are 50 years or older (older HIV patients) in Latin America and the Caribbean between 2000 and 2015 and to estimate the contribution to the growth of this population of people enrolled before (<50yo) and after 50 years old (yo) (>= 50yo). We used a series of repeated, cross-sectional measurements over time in the Caribbean, Central and South American network (CCASAnet) cohort. We estimated the percentage of patients retained in care each year that were older HIV patients. For every calendar year, we divided patients into two groups: those who enrolled before age 50 and after age 50. We used logistic regression models to estimate the change in the proportion of older HIV patients between 2000 and 2015. The percentage of CCASAnet HIV patients over 50 years had a threefold increase (8% to 24%) between 2000 and 2015. Most of the growth of this population can be explained by the increasing proportion of people that enrolled before 50 years and aged in care. These changes will impact needs of care for people living with HIV, due to multiple comorbidities and high risk of disability associated with aging.
C1 [Caro-Vega, Y.; Belaunzaran-Zamudio, P. F.; Crabtree-Ramirez, B.; Sierra-Madero, J. G.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Mexico City, DF, Mexico.
   [Shepherd, B. E.; Giganti, M. J.] Vanderbilt Univ, Dept Biostat, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Mejia, F.] Univ Peruana Cayetano Heredia, Infect Dis Clin, Lima, Peru.
   [Patterson, P.] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Grinsztejn, B.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Wolff, M.] Fdn Arriaran, Dept Infect Dis, Santiago, Chile.
   [Pape, J. W.] Ctre GHESKIO, Integrated Care Ctr & Res Inst, Port Au Prince, Haiti.
   [Padgett, D.] Hosp Escuela Univ, Dept Infect Dis, Tegucigalpa, Honduras.
   [Castilho, J. L.; McGowan, C.] Vanderbilt Univ, Dept Med, Nashville, TN USA.
RP Belaunzaran-Zamudio, PF (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Mexico City, DF, Mexico.
EM p.belaunz@infecto.mx
RI Belaunzaran-Zamudio, Pablo F./T-4218-2019; Belaunzaran-Zamudio, Pablo
   Francisco/T-4085-2019; PATTERSON, PATRICIA/AAA-1668-2019
OI Belaunzaran, Pablo/0000-0003-4775-4734; Crabtree-Ramirez,
   Brenda/0000-0002-2587-1123; mejia, fernando/0000-0001-8429-8833
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01AI069923]; Eunice Kennedy Shriver
   National Institute of Child Health & Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); National Cancer Institute
   (NCI)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI);
   National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); National Institute of Mental Health (NIMH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH); Office
   of The Director, National Institutes of Health (OD)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069421, U01AI069923, U01AI069923, UM1AI069476,
   UM1AI069421, U01AI069923, UM1AI069476, K23AI120875, U01AI069923,
   UM1AI069476, U01AI069923, K23AI120875, K23AI120875, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, UM1AI069421, K23AI120875, UM1AI069421, U01AI069923,
   U01AI069923, UM1AI069476, UM1AI069476, U01AI069923, UM1AI069476,
   U01AI069923, U01AI069923, U01AI069923, UM1AI069476, UM1AI069421,
   UM1AI069476, UM1AI069421, U01AI069923, U01AI069923, UM1AI069476,
   U01AI069923, UM1AI069421, UM1AI069421, U01AI069923, UM1AI069421,
   K23AI120875, U01AI069923] Funding Source: NIH RePORTER
FX This work was supported by the NIH-funded Caribbean, Central and South
   America network for HIV epidemiology (CCASAnet), a member cohort of the
   International Epidemiologic Databases to Evaluate AIDS (leDEA)
   (U01AI069923). This award is funded by the following institutes: Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD), National Cancer Institute (NCI), National Institute of Allergy
   and Infectious Diseases (NIAID), National Institute of Mental Health
   (NIMH) and the Office of The Director, National Institutes of Health
   (OD).
CR Avila-Funes JA, 2016, AIDS RES HUM RETROV, V32, P155, DOI [10.1089/AID.2015.0171, 10.1089/aid.2015.0171]
   Belaunzaran-Zamudio PF, 2015, B WORLD HEALTH ORGAN, V93, P529, DOI 10.2471/BLT.14.147447
   Belaunzaran-Zamudio PF, 2017, J INT AIDS SOC S2, V20, P3
   Eaton JW, 2015, LANCET GLOB HEALTH, V3, pE598, DOI 10.1016/S2214-109X(15)00080-7
   Guaraldi G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118531
   Joint United Nations Programme on HIV/AIDS, 2014, GAP REP 2014 PEOPL A
   Joint United Nations Programme on HIV/AIDS, 2013, HIV AG SPEC SUPPL UN
   Kirk JB, 2009, J AM GERIATR SOC, V57, P2129, DOI 10.1111/j.1532-5415.2009.02494.x
   Martin CP, 2008, AM J MED, V121, P1032, DOI 10.1016/j.amjmed.2008.08.009
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   Michael D, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.21783
   Sabin CA, 2017, AIDS, V31, pS121, DOI [10.1097/QAD.0000000000001374, 10.1097/qad.0000000000001374]
   Silhol R, 2017, AIDS, V31, pS41, DOI 10.1097/QAD.0000000000001418
   Smit M, 2015, LANCET INFECT DIS, V15, P810, DOI 10.1016/S1473-3099(15)00056-0
NR 14
TC 5
Z9 5
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD JUL
PY 2018
VL 146
IS 10
BP 1308
EP 1311
DI 10.1017/S0950268818001346
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA GO3YN
UT WOS:000439936400016
PM 29843838
OA Bronze, Green Accepted
DA 2020-11-24
ER

PT J
AU De Boni, RB
   Lentini, N
   Santelli, ACFS
   Barbosa, A
   Cruz, M
   Bingham, T
   Cota, V
   Correa, RG
   Veloso, VG
   Grinsztejn, B
AF De Boni, Raquel B.
   Lentini, Nena
   Santelli, Ana C. F. S.
   Barbosa, Aristides, Jr.
   Cruz, Marly
   Bingham, Trista
   Cota, Vanda
   Correa, Renato Girade
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI Self-testing, communication and information technology to promote HIV
   diagnosis among young gay and other men who have sex with men (MSM) in
   Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Editorial Material
DE men who have sex with men; key and vulnerable populations; self-testing;
   HIV; mobile applications; Brazil
C1 [De Boni, Raquel B.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Oswaldo Cruz Fdn Fiocruz, Evandro Chagas Natl Inst Infectol INI, Rio De Janeiro, Brazil.
   [Lentini, Nena; Santelli, Ana C. F. S.; Barbosa, Aristides, Jr.] Country Off Brasilia, Ctr Dis Control & Prevent CDC, Div Global HIV & TB DGHT, Brasilia, DF, Brazil.
   [Cruz, Marly; Cota, Vanda] Oswaldo Cruz Fdn Fiocruz, Sergio Arouca Natl Sch Publ Hlth ENSP, Rio De Janeiro, Brazil.
   [Bingham, Trista] Ctr Dis Control & Prevent CDC, Div Global HIV & TB DGHT, Atlanta, GA USA.
   [Correa, Renato Girade] Minist Hlth Brazil, HIV AIDS & Viral Hepatitis Dept DIAHV, IST, Brasilia, DF, Brazil.
RP De Boni, RB (corresponding author), Fiocruz MS, LAPCLIN DST AIDS INI Evandro Chagas, Ave Brasil 4365, BR-21040360 Manguinho, RJ, Brazil.
EM raqueldeboni@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997
FU United States President's Emergency Plan for AIDS Relief (PEPFAR)
   through Centers for Disease Control and Prevention (CDC);  [NU2G
   GH001152]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding
   Source: NIH RePORTER
FX This publication was supported by the Cooperative Agreement Number NU2G
   GH001152, funded by the United States President's Emergency Plan for
   AIDS Relief (PEPFAR) through the Centers for Disease Control and
   Prevention (CDC). Its contents are solely the responsibility of the
   authors and do not necessarily represent the official position of the
   funding agencies.
CR Brazil Ministry of Health Health Surveillance Secretariat Department of Surveillance Prevention and Control of STIs HIV/AIDS and Viral Hepatitis, 2017, AIDS EP B, P3
   Davis SLM, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21386
   De Boni R, 2017, HORA E AGORA TIME IS
   De Boni RB, 2017, ONLINE HIV SELF TEST
   Figueroa C, 2015, AIDS BEHAV, V19, P1949, DOI 10.1007/s10461-015-1097-8
   Figueroa Carmen, 2018, LANCET HIV, P30044, DOI 10.1016/s2352-3018(18)
   Logie CH, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21385
   Macdonald V, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.5.21658
   Patton GC, 2016, LANCET, V387, P2423, DOI 10.1016/S0140-6736(16)00579-1
   Stevens DR, 2018, AIDS BEHAV, V22, P497, DOI 10.1007/s10461-017-1707-8
   World Health Organization, 2016, POL BRIEF HIV TEST S
NR 11
TC 6
Z9 6
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2018
VL 21
SU 5
SI SI
AR e25116
DI 10.1002/jia2.25116
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GO2RS
UT WOS:000439824900001
PM 30033612
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Fink, VI
   Jenkins, CA
   Castilho, JL
   Person, AK
   Shepherd, BE
   Grinsztejn, B
   Netto, J
   Crabtree-Ramirez, B
   Cortes, CP
   Padgett, D
   Jayathilake, K
   McGowan, C
   Cahn, P
AF Fink, Valeria, I
   Jenkins, Cathy A.
   Castilho, Jessica L.
   Person, Anna K.
   Shepherd, Bryan E.
   Grinsztejn, Beatriz
   Netto, Juliana
   Crabtree-Ramirez, Brenda
   Cortes, Claudia P.
   Padgett, Denis
   Jayathilake, Karu
   McGowan, Catherine
   Cahn, Pedro
CA CCASAnet
TI Survival after cancer diagnosis in a cohort of HIV-positive individuals
   in Latin America
SO INFECTIOUS AGENTS AND CANCER
LA English
DT Article
DE Cohort studies; HIV; Cancer; Survival; Latin America; AIDS defining
   cancer; Non AIDS defining cancer
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; INFECTED PATIENTS;
   AIDS; MORTALITY; HIV/AIDS; PEOPLE; TRENDS; MALIGNANCIES; HAART
AB Background: This study aimed to evaluate trends and predictors of survival after cancer diagnosis in persons living with HIV in the Caribbean, Central, and South America network for HIV epidemiology cohort.
   Methods: Demographic, cancer, and HIV-related data from HIV-positive adults diagnosed with cancer <= 1 year before or any time after HIV diagnosis from January 1, 2000-June 30, 2015 were retrospectively collected. Cancer cases were classified as AIDS-defining cancers (ADC) and non-AIDS-defining cancers (NADC). The association of mortality with cancer-and HIV-related factors was assessed using Kaplan-Meier curves and Cox proportional hazards models stratified by clinic site and cancer type.
   Results: Among 15,869 patients, 783 had an eligible cancer diagnosis; 82% were male and median age at cancer diagnosis was 39 years (interquartile range [IQR]: 32-47). Patients were from Brazil (36.5%), Argentina (19.9%), Chile (19.7%), Mexico (19.3%), and Honduras (4.6%). A total of 564 ADC and 219 NADC were diagnosed. Patients with NADC had similar survival probabilities as those with ADC at one year (81% vs. 79%) but lower survival at five years (60% vs. 69%). In the adjusted analysis, risk of mortality increased with detectable viral load (adjusted hazard ratio [aHR] = 1.63, p = 0.02), age (aHR = 1.02 per year, p = 0.002) and time between HIV and cancer diagnoses (aHR = 1.03 per year, p = 0.01).
   Conclusion: ADC remain the most frequent cancers in the region. Overall mortality was related to detectable viral load and age. Longer-term survival was lower after diagnosis of NADC than for ADC, which may be due to factors unrelated to HIV.
C1 [Fink, Valeria, I; Cahn, Pedro] Fdn Huesped, Pasaje Gianantonio 3932,C1202ABB Buenos Aires, Buenos Aires, DF, Argentina.
   [Jenkins, Cathy A.; Castilho, Jessica L.; Person, Anna K.; Shepherd, Bryan E.; Jayathilake, Karu; McGowan, Catherine] Vanderbilt Univ, Sch Med, 1161 21st Ave S A2200 Med Ctr North, Nashville, TN 37232 USA.
   [Grinsztejn, Beatriz; Netto, Juliana] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365, BR-21040900 Rio De Janeiro, RI, Brazil.
   [Crabtree-Ramirez, Brenda] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, UPA, 5to Piso Vasco de Quiroga 15 Col Secc 16 Delegac, Mexico City 14000, DF, Mexico.
   [Cortes, Claudia P.] Fdn Arriaran, Santa Elvira 629, Santiago, Chile.
   [Padgett, Denis] Hosp Escuela Univ, Inst Hondureno Seguridad Social, Av Salud, Tegucigalpa, Honduras.
RP Fink, VI (corresponding author), Fdn Huesped, Pasaje Gianantonio 3932,C1202ABB Buenos Aires, Buenos Aires, DF, Argentina.
EM valeria.fink@huesped.org.ar
RI Cortes, Claudia/AAF-7326-2020
OI Cortes, Claudia/0000-0001-9101-9783; Crabtree-Ramirez,
   Brenda/0000-0002-2587-1123
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01AI069923]; Eunice Kennedy Shriver
   National Institute Of Child Health & Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); Office Of The Director, National
   Institutes Of Health (OD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Institute Of
   Allergy And Infectious Diseases (NIAID)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID); National
   Cancer Institute (NCI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); National Institute Of Mental Health (NIMH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH); NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   K23AI120875, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, K23AI120875, UM1AI069476, K23AI120875, UM1AI069476,
   K23AI120875, UM1AI069476, K23AI120875] Funding Source: NIH RePORTER
FX This work was funded by the NIH-funded Caribbean, Central and South
   America network for HIV epidemiology (CCASAnet), a member cohort of the
   International Epidemiologic Databases to Evaluate AIDS (leDEA)
   (U01AI069923). This award is funded by the following institutes: Eunice
   Kennedy Shriver National Institute Of Child Health & Human Development
   (NICHD), Office Of The Director, National Institutes Of Health (OD),
   National Institute Of Allergy And Infectious Diseases (NIAID), National
   Cancer Institute (NCI), and the National Institute Of Mental Health
   (NIMH).
CR Achenbach CJ, 2011, AIDS, V25, P691, DOI 10.1097/QAD.0b013e3283437f77
   Barillari G, 1999, BLOOD, V94, P663
   Bohlius J, 2017, CLIN INFECT DIS, V65, P1316
   Bonnet F, 2009, CLIN INFECT DIS, V48, P633, DOI 10.1086/596766
   Brickman C, 2015, CURR HIV-AIDS REP, V12, P388, DOI 10.1007/s11904-015-0283-7
   Carriquiry G, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20016
   Castilho JL, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/1750-9378-10-4
   Chen M, 2014, JAIDS-J ACQ IMM DEF, V65, P463, DOI 10.1097/QAI.0000000000000065
   Cheung MC, 2005, ONCOLOGIST, V10, P412, DOI 10.1634/theoncologist.10-6-412
   Chiu CG, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3229-1
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Coghill AE, 2015, CANCER EPIDEM BIOMAR, V24, P1165, DOI 10.1158/1055-9965.EPI-15-0454
   Crum-Cianflone N, 2009, AIDS, V23, P41, DOI 10.1097/QAD.0b013e328317cc2d
   Dryden-Peterson S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135602
   Duda SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033908
   Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487
   Ensoli B, 2000, SEMIN CANCER BIOL, V10, P367, DOI 10.1006/scbi.2000.0329
   Fazito E, 2013, CAD SAUDE PUBLICA, V29, P1644, DOI [10.1590/0102-311X00128912, 10.1590/S0102-311X2013001200016]
   Fink VI, 2011, JAIDS-J ACQ IMM DEF, V56, P467, DOI 10.1097/QAI.0b013e31820bb1c3
   Franceschi S, 2010, BRIT J CANCER, V103, P416, DOI 10.1038/sj.bjc.6605756
   Gopal S, 2013, AIDS, V27, P2365, DOI 10.1097/QAD.0b013e3283635232
   Gopal S, 2013, JNCI-J NATL CANCER I, V105, P1221, DOI 10.1093/jnci/djt158
   Gotti D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094768
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Hleyhel M, 2015, INT J CANCER, V137, P2443, DOI 10.1002/ijc.29603
   Impola U, 2003, BRIT J DERMATOL, V149, P905, DOI 10.1046/j.1365-2133.2003.05561.x
   International Agency for Research on Cancer WHO, 2017, GLOBOCAN 2012 EST CA
   Laurido M, 2007, MEDICINA-BUENOS AIRE, V67, P243
   Lewden C, 2005, INT J EPIDEMIOL, V34, P121, DOI 10.1093/ije/dyh307
   Luz PM, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-278
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   Narayan KMV, 2014, JAIDS-J ACQ IMM DEF, V67, pS2, DOI 10.1097/QAI.0000000000000267
   Cobucci RNO, 2015, J INFECT PUBLIC HEAL, V8, P1, DOI 10.1016/j.jiph.2014.08.003
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005
   Patel P, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu012
   Powles T, 2009, J CLIN ONCOL, V27, P884, DOI 10.1200/JCO.2008.19.6626
   Raffetti E, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1565-0
   Riedel DJ, 2017, AIDS RES HUM RETROV, V33, P482, DOI [10.1089/aid.2016.0181, 10.1089/AID.2016.0181]
   Rohner E, 2016, INT J CANCER, V138, P45, DOI 10.1002/ijc.29687
   Sachdeva RK, 2016, INDIAN J MED RES, V143, P129, DOI 10.4103/0971-5916.191813
   Selik RM, 2014, MMWR RECOMM REP, V63
   Shiels MS, 2011, J NATL CANCER I, V103, P753, DOI 10.1093/jnci/djr076
   Sigel K, 2013, BRIT J CANCER, V109, P1974, DOI 10.1038/bjc.2013.545
   Silverberg MJ, 2015, ANN INTERN MED, V163, P507, DOI 10.7326/M14-2768
   Silverberg MJ, 2009, AIDS, V23, P2337, DOI 10.1097/QAD.0b013e3283319184
   Simard EP, 2010, CLIN INFECT DIS, V51, P957, DOI 10.1086/656416
   Spano JP, 2004, MED ONCOL, V21, P109, DOI 10.1385/MO:21:2:109
   Suneja G, 2015, J ONCOL PRACT, V11, pE380, DOI 10.1200/JOP.2014.002709
   Tanaka LF, 2017, EUR J CANCER PREV, V00, P000
   Vandenhende MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129550
   Weller I, 2009, AIDS, V23, P2029, DOI 10.1097/QAD.0b013e32832e531c
   Worm SW, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-471
   Yang J, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1416-3
   Zohar M, 2015, AIDS RES HUM RETROV, V31, P873, DOI [10.1089/aid.2015.0022, 10.1089/AID.2015.0022]
NR 55
TC 2
Z9 2
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1750-9378
J9 INFECT AGENTS CANCER
JI Infect. Agents Cancer
PD MAY 8
PY 2018
VL 13
AR 16
DI 10.1186/s13027-018-0188-3
PG 11
WC Oncology; Immunology
SC Oncology; Immunology
GA GF3ER
UT WOS:000431828900001
PM 29760767
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Luz, PM
   Benzaken, A
   de Alencar, TM
   Pimenta, C
   Veloso, VG
   Grinsztejn, B
AF Luz, Paula M.
   Benzaken, Adele
   de Alencar, Tatianna M.
   Pimenta, Cristina
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI PrEP adopted by the brazilian national health system: What is the size
   of the demand?
SO MEDICINE
LA English
DT Article
DE Brazil; HIV; AIDS; PrEP
ID HIV; MEN; SEX; MSM
AB Background:Brazil's response to the HIV epidemic now includes free access to preexposure prophylaxis (PrEP) to populations at substantial risk for HIV infection including men who have sex with men (MSM). We used nationally representative demographic, epidemiologic, and surveillance data to offer estimates for the number of MSM at substantial risk for HIV infection who might be eligible and willing to use PrEP in Brazil.Methods:Starting from the age/sex-stratified population, we calculated the number of men aged 15 to 64 years, in 5-year age groups, and the proportion of those who report sex with other men during their lifetime. We focused on 11 cities (representing all regions) that are responsible for a significant fraction of the HIV burden of the country and used city-specific HIV prevalence estimates to infer the fraction of MSM who are HIV-negative. We then derived the proportion of HIV-negative MSM under substantial risk for HIV infection defined as having unprotected receptive anal intercourse in the 6 months before study participation. Finally, PrEP uptake among the eligible was inferred from the PrEP Brazil study.Results:Our results show that PrEP demand in these 11 cities is of 66,120 men aged 15 to 64 years. When we consider the lower and upper bounds for the available parameters, we find that PrEP demand in these 11 cities might vary from 33,378 to 97,962 men. If PrEP is restricted to those aged 15 to 49 years, demand drops by 20%. PrEP demand varies considerably by city, mostly because of the differences in population size and city-specific HIV prevalence.Discussion:We have shed light on the probable size of PrEP demand in Brazil certain that the incorporation of PrEP as part of Brazil's combination prevention for populations at substantial risk for HIV infection is a necessary challenge. PrEP will not only prevent HIV infections, it will also expand testing among the most vulnerable with the added benefit of offering combination prevention for the uninfected and immediate treatment for those already infected. As such, expected added benefits of PrEP will be earlier linkage to care, prompt treatment initiation leading to health benefits and decreased transmission.
C1 [Luz, Paula M.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-22461 Rio De Janeiro, Brazil.
   [Benzaken, Adele; de Alencar, Tatianna M.; Pimenta, Cristina] Minist Hlth, Dept Surveillance Prevent & Control STI HIV AIDS, Brasilia, DF, Brazil.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-22461 Rio De Janeiro, Brazil.
EM paula.luz@ini.fiocruz.br
OI Luz, Paula/0000-0001-9746-719X
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH
   RePORTER; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1 AI069476] Funding Source:
   Medline
CR [Anonymous], 2016, B EP DST AIDS
   Veras MADM, 2015, AIDS BEHAV, V19, P1589, DOI 10.1007/s10461-014-0944-3
   Grangeiro Alexandre, 2015, Rev. bras. epidemiol., V18, P43, DOI 10.1590/1809-4503201500050005
   Grangeiro A, 2010, REV SAUDE PUBL, V44, P430, DOI 10.1590/s0034-89102010005000013
   Grinsztejn B, 2017, 9 IAS C HIV SCI IAS
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   Hoagland B, 2017, AIDS BEHAV, V21, P1278, DOI 10.1007/s10461-016-1516-5
   IBGE, 2016, IND DEM SAUD INF SOC
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Landmann-Szwarcwald C, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0462-1
   McCormack SM, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.7.21103
   Ministerio da Saude, 2013, PESQ CONH AT PRAT PO
   Pachankis JE, 2015, AIDS, V29, P1239, DOI 10.1097/QAD.0000000000000724
   Rocha GM, 2013, AIDS BEHAV, V17, P1288, DOI 10.1007/s10461-012-0398-4
   Veloso VG, 2015, J INT AIDS SOC, V18, P48, DOI 10.7448/IAS.18.4.20010
NR 15
TC 6
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY
PY 2018
VL 97
SU 1
BP S75
EP S77
AR e10602
DI 10.1097/MD.0000000000010602
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA GI3XW
UT WOS:000434306400012
PM 29794605
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Moreira, RC
   Mill, JG
   Grinsztejn, B
   Veloso, V
   Fonseca, MD
   Griep, RH
   Bensenor, I
   Cardoso, SW
   Lotufo, P
   Chor, D
   Pacheco, AG
AF Moreira, Rodrigo C.
   Mill, Jose G.
   Grinsztejn, Beatriz
   Veloso, Valdilea
   Fonseca, Maria de Jesus
   Griep, Rosane H.
   Bensenor, Isabela
   Cardoso, Sandra W.
   Lotufo, Paulo
   Chor, Dora
   Pacheco, Antonio G.
CA INI ELSA BRASIL
TI HIV Infection Is Not Associated With Aortic Stiffness. Traditional
   Cardiovascular Risk Factors Are the Main Determinants-Cross-sectional
   Results of INI-ELSA-BRASIL
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE people living with HIV; cardiovascular risk factors; arterial stiffness
ID INCREASED ARTERIAL STIFFNESS; PULSE-WAVE VELOCITY; ANTIRETROVIRAL
   THERAPY; MYOCARDIAL-INFARCTION; ALL-CAUSE; IMMUNODEFICIENCY;
   INDIVIDUALS; MORTALITY; EVENTS; HEALTH
AB Introduction: Aortic stiffness measured by carotid-femoral pulse wave velocity (cf-PWV) is a marker of subclinical atherosclerosis. We propose to assess whether HIV infection is associated with arterial stiffness and their determinants in HIV-infected subjects.
   Methods: We compared data from an HIV cohort (644 patients, HIV+) in Rio de Janeiro with 2 groups: 105 HIV-negative (HIV-) individuals and 14,873 participants of the ELSA-Brasil study. We used multivariable linear regression to investigate factors associated with cf-PWV and whether HIV was independently associated with aortic stiffness and propensity score weighting to control for imbalances between groups.
   Results: From 15,860 participants, cf-PWV was obtained in 15,622 (98.5%). Median age was 51 (interquartile range 45-58), 44.41 (35.73, 54.72), and 43.60 (36.01, 50.79) years (P < 0.001), and median cf-PWV (m/s; interquartile range) was 9.0 (8.10, 10.20), 8.70 (7.90, 10.20), and 8.48 (7.66, 9.40) for ELSA-Brasil, HIV- and HIV+, respectively (P < 0.001). In the final weighted multivariable models, HIV group was not associated with cf-PWV when compared either with ELSA-Brasil [beta = -0.05; 95% confidence interval (CI) = -0.23; P = 0.12; P = 0.52] or with the HIV- groups (beta = 0.10; 95% CI = -0.10; 0, 31; P = 0.32). Traditional risk factors were associated with higher cf-PWV levels in the HIV+ group, particularly waist-tohip ratio (beta = 0.20; 95% CI = 0.10; 0.30; P < 0.001, result per one SD change).
   Conclusions: HIV infection was not associated with higher aortic stiffness according to our study. In HIV-infected subjects, the stiffness of large arteries is mainly associated with traditional risk factors and not to the HIV infection per se.
C1 [Moreira, Rodrigo C.; Grinsztejn, Beatriz; Veloso, Valdilea; Cardoso, Sandra W.] Inst Nacl Infectol Evandro Chagas, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Moreira, Rodrigo C.; Pacheco, Antonio G.] Fundacao Oswaldo Cruz, Programa Computacao Cient, Rio De Janeiro, Brazil.
   [Mill, Jose G.] Univ Fed Espirito Santo, Dept Ciencias Fisiol, Vitoria, Brazil.
   [Fonseca, Maria de Jesus; Chor, Dora] Fundacao Oswaldo Cruz, Dept Epidemiol & Metodos Quantitat Saude, Rio De Janeiro, Brazil.
   [Griep, Rosane H.] Fundacao Oswaldo Cruz, Lab Hlth & Environm Educ, Rio De Janeiro, Brazil.
   [Bensenor, Isabela; Lotufo, Paulo] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RP Pacheco, AG (corresponding author), Fiocruz MS, Programa Computacao Cient, Ave 4365, Rio De Janeiro, Brazil.
EM antgui@gmail.com
RI Griep, Rosane Harter/ABB-4509-2020; Pacheco, Antonio
   Guilherme/E-6378-2013
OI Pacheco, Antonio Guilherme/0000-0003-3095-1774
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   JaneiroCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/102398/2009, E-26/201.471/2014];
   Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq) [01 06
   0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01 06
   0115.00 SP, 01 06 0071.00 RJ, 407446/2012-5, 304614/2012-2]; Programa
   Estrategico de Apoio a Pesquisa em Saude [407446/2012-5]
FX Supported by the Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro [E-26/102398/2009 to DC and E-26/201.471/2014
   to AP]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   [grant numbers 01 06 0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01
   06 0278.00 MG, 01 06 0115.00 SP, 01 06 0071.00 RJ, 407446/2012-5 to AP
   and 304614/2012-2 to AP]; Programa Estrategico de Apoio a Pesquisa em
   Saude [407446/2012-5 to AP].
CR Adler NE, 2002, HEALTH AFFAIR, V21, P60, DOI 10.1377/hlthaff.21.2.60
   Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
   Baena CP, 2015, AM J HYPERTENS, V28, P966, DOI 10.1093/ajh/hpu298
   Baker JV, 2009, JAIDS-J ACQ IMM DEF, V52, P25, DOI 10.1097/QAI.0b013e3181b02e6a
   Baldo MP, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005477
   Bensenor IM, 2013, REV SAUDE PUBL, V47, P37, DOI 10.1590/S0034-8910.2013047003780
   Braitstein P, 2006, LANCET, V367, P817
   Brasil. Ministerio da Saude, 2014, B EP HIV AIDS
   Brito Ana Maria de, 2005, Braz J Infect Dis, V9, P9, DOI 10.1590/S1413-86702005000100004
   Calcagno CdM V, 2010, J STAT SOFTW, V34
   Charakida M, 2009, ANTIVIR THER, V14, P1075, DOI 10.3851/IMP1437
   D'Ascenzo F, 2012, EUR HEART J, V33, P875, DOI 10.1093/eurheartj/ehr456
   de Koning L, 2007, EUR HEART J, V28, P850, DOI 10.1093/eurheartj/ehm026
   Echeverria P, 2014, JAIDS-J ACQ IMM DEF, V65, P50, DOI 10.1097/QAI.0b013e3182a97c17
   Eira M, 2012, ARQ BRAS CARDIOL, V99, P1100, DOI 10.1590/S0066-782X2012005000110
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   Ferdinand KC, 2006, AM J CARDIOL, V97, p12A, DOI 10.1016/j.amjcard.2005.11.011
   Freiberg MS, 2013, JAMA INTERN MED, V173, P614, DOI 10.1001/jamainternmed.2013.3728
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Ho D, 2017, MATCHIT NONPARAMETRI
   Ho JE, 2010, AIDS, V24, P1897, DOI 10.1097/QAD.0b013e32833bee44
   Klein DB, 2015, CLIN INFECT DIS, V60, P1278, DOI 10.1093/cid/civ014
   Kooij KW, 2016, JAIDS-J ACQ IMM DEF, V73, P55, DOI 10.1097/QAI.0000000000001024
   Laurent S, 2001, HYPERTENSION, V37, P1236, DOI 10.1161/01.HYP.37.5.1236
   Ledergerber B, 2007, CLIN INFECT DIS, V45, P111, DOI 10.1086/518619
   Lekakis J, 2009, AM J HYPERTENS, V22, P828, DOI 10.1038/ajh.2009.90
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Leite LHM, 2017, ARCH CARDIOVASC DIS, V110, P495, DOI 10.1016/j.acvd.2017.03.001
   Maia-Leite LH, 2016, J HYPERTENS, V34, P1338, DOI 10.1097/HJH.0000000000000957
   McCaffrey DF, 2013, STAT MED, V32, P3388, DOI 10.1002/sim.5753
   Monteiro P, 2012, BRAZ J MED BIOL RES, V45, P818, DOI 10.1590/S0100-879X2012007500116
   Morris AA, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.002154
   Mugavero MJ, 2011, CLIN INFECT DIS, V53, P927, DOI 10.1093/cid/cir526
   Nou E, 2016, AIDS, V30, P1495, DOI 10.1097/QAD.0000000000001109
   Pacheco AG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158999
   Pacheco AG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117461
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636
   de Miranda EJFP, 2017, AM J HYPERTENS, V30, P81, DOI 10.1093/ajh/hpw117
   Petoumenos K, 2011, HIV MED, V12, P412, DOI 10.1111/j.1468-1293.2010.00901.x
   Quiros-Roldan E, 2016, AIDS CARE, V28, P1551, DOI 10.1080/09540121.2016.1198750
   Schmidt MI, 2015, INT J EPIDEMIOL, V44, P68, DOI 10.1093/ije/dyu027
   Sevastianova K, 2005, ANTIVIR THER, V10, P925
   Team RC, 2015, R LANG ENV STAT COMP
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   Usach I, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18567
   Vlachopoulos C, 2010, J AM COLL CARDIOL, V55, P1318, DOI 10.1016/j.jacc.2009.10.061
   Wilson DP, 2013, HIV MED, V14, P193, DOI 10.1111/hiv.12006
   Zeng Y, 2010, CHINESE MED J-PEKING, V123, P3396, DOI 10.3760/cma.j.issn.0366-6999.2010.23.004
NR 50
TC 2
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAY 1
PY 2018
VL 78
IS 1
BP 73
EP 81
DI 10.1097/QAI.0000000000001646
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GT6NP
UT WOS:000444631200012
PM 29624545
DA 2020-11-24
ER

PT J
AU Palumbo, PJ
   Fogel, JM
   Hudelson, SE
   Wilson, EA
   Hart, S
   Hovind, L
   Piwowar-Manning, E
   Wallis, C
   Papathanasopoulos, MA
   Morgado, MG
   Saravanan, S
   Tripathy, S
   Eron, JJ
   Gallant, JE
   McCauley, M
   Gamble, T
   Hosseinipour, MC
   Kumarasamy, N
   Hakim, JG
   Pilotto, JH
   Kumwenda, J
   Akelo, V
   Godbole, SV
   Santos, BR
   Grinsztejn, B
   Panchia, R
   Chariyalertsak, S
   Makhema, J
   Badal-Faesen, S
   Chen, YQ
   Cohen, MS
   Eshleman, SH
AF Palumbo, Philip J.
   Fogel, Jessica M.
   Hudelson, Sarah E.
   Wilson, Ethan A.
   Hart, Stephen
   Hovind, Laura
   Piwowar-Manning, Estelle
   Wallis, Carole
   Papathanasopoulos, Maria A.
   Morgado, Mariza G.
   Saravanan, Shanmugam
   Tripathy, Srikanth
   Eron, Joseph J.
   Gallant, Joel E.
   McCauley, Marybeth
   Gamble, Theresa
   Hosseinipour, Mina C.
   Kumarasamy, Nagalingeswaran
   Hakim, James G.
   Pilotto, Jose H.
   Kumwenda, Johnstone
   Akelo, Victor
   Godbole, Sheela V.
   Santos, Breno R.
   Grinsztejn, Beatriz
   Panchia, Ravindre
   Chariyalertsak, Suwat
   Makhema, Joseph
   Badal-Faesen, Sharlaa
   Chen, Ying Q.
   Cohen, Myron S.
   Eshleman, Susan H.
TI HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral
   Therapy: HPTN 052
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; HPTN 052; early ART; virologic failure; resistance
ID VIROLOGICAL FAILURE; CELL COUNTS; PREVENTION; INITIATION; MUTATIONS;
   TRIAL; ART; INFECTION; NAIVE; ACCUMULATION
AB Introduction: We evaluated HIV drug resistance in adults who received early vs. delayed antiretroviral therapy (ART) in a multinational trial [HIV Prevention Trials Network (HPTN) 052, enrollment 2005-2010]. In HPTN 052, 1763 index participants were randomized to start ART at a CD4 cell count of 350-550 cells/mm(3) (early ART arm) or <250 cells/mm(3) (delayed ART arm). In May 2011, interim study results showed benefit of early ART, and all participants were offered ART regardless of CD4 cell count; the study ended in 2015.
   Methods: Virologic failure was defined as 2 consecutive viral loads >1000 copies/mL >24 weeks after ART initiation. Drug resistance testing was performed for pretreatment (baseline) and failure samples from participants with virologic failure.
   Results: HIV genotyping results were obtained for 211/249 participants (128 early ART arm and 83 delayed ART arm) with virologic failure. Drug resistance was detected in 4.7% of participants at baseline; 35.5% had new resistance at failure. In univariate analysis, the frequency of new resistance at failure was lower among participants in the early ART arm (compared with delayed ART arm, P = 0.06; compared with delayed ART arm with ART initiation before May 2011, P = 0.032). In multivariate analysis, higher baseline viral load (P = 0.0008) and ART regimen (efavirenz/lamivudine/zidovudine compared with other regimens, P = 0.024) were independently associated with higher risk of new resistance at failure.
   Conclusions: In HPTN 052, the frequency of new drug resistance at virologic failure was lower in adults with early ART initiation. The main factor associated with reduced drug resistance with early ART was lower baseline viral load.
C1 [Palumbo, Philip J.; Fogel, Jessica M.; Hudelson, Sarah E.; Piwowar-Manning, Estelle; Eshleman, Susan H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Wilson, Ethan A.; Chen, Ying Q.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Hart, Stephen; Hovind, Laura] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA.
   [Wallis, Carole] Lancet Labs, Specialty Mol Div, Johannesburg, South Africa.
   [Wallis, Carole] BARC SA, Johannesburg, South Africa.
   [Papathanasopoulos, Maria A.] Univ Witwatersrand, Fac Hlth Sci, HIV Pathogenesis Res Unit, Johannesburg, South Africa.
   [Morgado, Mariza G.] Oswaldo Cruz Inst, Lab AIDS & Mol Immunol, Rio De Janeiro, Brazil.
   [Saravanan, Shanmugam] YR Gaitonde Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
   [Tripathy, Srikanth] Natl Inst Res TB, Madras, Tamil Nadu, India.
   [Eron, Joseph J.; Cohen, Myron S.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
   [Gallant, Joel E.] Southwest CARE Ctr, Dept Specialty Serv, Santa Fe, NM USA.
   [McCauley, Marybeth] HPTN Leadership & Operat Ctr, FHI 360, Washington, DC USA.
   [Gamble, Theresa] HPTN Leadership & Operat Ctr, FHI 360, Durham, NC USA.
   [Hosseinipour, Mina C.] Univ N Carolina, Div Infect Dis, Chapel Hill, NC USA.
   [Hosseinipour, Mina C.] UNC Project Malawi, Inst Global Hlth & Infect Dis, Lilongwe, Malawi.
   [Kumarasamy, Nagalingeswaran] YRGCARE Med Ctr, VHS, CART CRS, Madras, Tamil Nadu, India.
   [Hakim, James G.] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
   [Pilotto, Jose H.] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, Jose H.] Lab AIDS & Imunol Mol IOC Fiocruz, Rio De Janeiro, Brazil.
   [Kumwenda, Johnstone] Johns Hopkins Project, Coll Med, Blantyre, Malawi.
   [Akelo, Victor] Kenya Med Res Inst KEMRI, CDC, Kisumu, Kenya.
   [Godbole, Sheela V.] Natl AIDS Res Inst ICMR, Dept Epidemiol & Biostat, Pune, Maharashtra, India.
   [Santos, Breno R.] Hosp Nossa Senhora Conceicao, Dept Infect Dis, Porto Alegre, RS, Brazil.
   [Grinsztejn, Beatriz] Inst Nacl Infectol Evandro Chagas INI Fiocruz, Rio De Janeiro, Brazil.
   [Panchia, Ravindre] Univ Witwatersrand, Soweto HPTN CRS, Perinatal HIV Res Unit, Soweto, South Africa.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Makhema, Joseph] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana.
   [Badal-Faesen, Sharlaa] Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Dept Internal Med,Clin HIV Res Unit, Johannesburg, South Africa.
RP Eshleman, SH (corresponding author), Johns Hopkins Med Inst, Dept Pathol, Ross Bldg,Room 646,720 Rutland Ave, Baltimore, MD 21205 USA.
EM seshlem@jhmi.edu
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Palumbo,
   Philip/0000-0002-6394-6878; Wallis, Carole/0000-0001-8408-8772
FU Division of AIDS of the U.S. National Institute of Allergy and
   Infectious Diseases (NIAID); Office of AIDS Research of the U.S.
   National Institutes of Health (NIH) [UM1-AI068613, UM1-AI068617,
   UM1-AI068619]; AbbVieAbbott Laboratories; Bristol-Myers
   SquibbBristol-Myers Squibb; Gilead SciencesGilead Sciences; Janssen
   Therapeutics; Merck Co.Merck & Company; Sangamo BioSciences; ViiV
   Healthcare; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI068617, UM1AI068613, UM1AI069432, UM1AI069518,
   UM1AI068619, UM1AI068617, UM1AI069476, UM1AI069518, UM1AI069423,
   UM1AI069518, UM1AI069518, UM1AI069456, UM1AI069436, UM1AI069436,
   UM1AI068613, UM1AI069476, UM1AI069423, UM1AI069463, UM1AI068617,
   UM1AI069453, UM1AI068619, UM1AI069436, UM1AI069463, UM1AI069432,
   UM1AI069399, UM1AI069463, UM1AI069476, UM1AI069399, UM1AI068613,
   UM1AI069399, UM1AI069456, UM1AI068613, UM1AI069423, UM1AI069456,
   UM1AI068613, UM1AI068613, UM1AI069436, UM1AI069432, UM1AI069423,
   UM1AI068619, UM1AI069453, UM1AI068617, UM1AI069456, UM1AI069476,
   UM1AI069436, UM1AI069423, UM1AI069436, UM1AI068619, UM1AI069432,
   UM1AI069476, UM1AI069432, UM1AI069453, UM1AI068617, UM1AI069423,
   UM1AI068619, UM1AI069432, UM1AI069456, UM1AI068619, UM1AI069432,
   UM1AI068617, UM1AI069399, UM1AI069423, UM1AI069476, UM1AI069456,
   UM1AI069518, UM1AI068617, UM1AI068617, UM1AI069432, UM1AI069399,
   UM1AI069399, UM1AI068619, UM1AI068619, UM1AI068617, UM1AI068617,
   UM1AI069476, UM1AI068613, UM1AI068613, UM1AI069432, UM1AI069399,
   UM1AI069436, UM1AI068613, UM1AI069399, UM1AI069518, UM1AI069423,
   UM1AI069518, UM1AI069476, UM1AI069463, UM1AI069436, UM1AI069423,
   UM1AI069463, UM1AI069463, UM1AI068613, UM1AI069463, UM1AI069432,
   UM1AI068619, UM1AI069453, UM1AI069399, UM1AI068613, UM1AI069476,
   UM1AI069456, UM1AI069456, UM1AI069436, UM1AI069423, UM1AI068617,
   UM1AI068619, UM1AI068613, UM1AI069463, UM1AI068619, UM1AI069518] Funding
   Source: NIH RePORTER
FX Supported by grants from the Division of AIDS of the U.S. National
   Institute of Allergy and Infectious Diseases (NIAID); and by the Office
   of AIDS Research of the U.S. National Institutes of Health (NIH)
   [UM1-AI068613 (S.H.E); UM1-AI068617 (Donnell); and UM1-AI068619
   (El-Sadr)]. Study drugs used in HPTN 052 were donated by Abbott
   Laboratories, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers
   Squibb, Gilead Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, and
   Merck & Co., Inc.; C.W. served as a consultant for Celera for
   development of software updates related to the HIV drug resistance
   algorithm used with the ViroSeq HIV-1 Genotyping System. J.J.E. receives
   honoraria for advisory board membership from Bristol-Myers Squibb,
   Gilead Sciences, Janssen Therapeutics, Merck & Co., and ViiV Healthcare
   and research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences,
   Janssen Therapeutics, Merck & Co., Sangamo BioSciences, and ViiV
   Healthcare through contracts to the University of North Carolina. J.E.G.
   receives honoraria for advisory board membership from Bristol-Myers
   Squibb, Gilead Sciences, Theratechnologies, Merck & Co., and ViiV
   Healthcare. JEG's organization receives research support from AbbVie,
   Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck &
   Co., Sangamo BioSciences, and ViiV Healthcare. M.C.H. has received
   honoraria for advisory board membership from ViiV healthcare. M.S.C.
   receives honoraria for advisory board membership from Janssen Global
   Services, Roche Molecular Systems, and Merck Research. S.H.E. has
   collaborated with investigators from Abbott Diagnostics on research
   studies. For the remaining authors have no funding or conflicts of
   interest to disclose. Author contributions are moved to Acknowledgments
   section.
CR Algburi A, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00650-17
   Boender TS, 2016, J ANTIMICROB CHEMOTH, V71, P2918, DOI 10.1093/jac/dkw218
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cozzi-Lepri A, 2012, HIV MED, V13, P62, DOI 10.1111/j.1468-1293.2011.00943.x
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Dinesha TR, 2016, AIDS RES HUM RETROV, V32, P1234, DOI 10.1089/aid.2016.0110
   Eshleman SH, 2017, HIV CLIN TRIALS, V18, P100, DOI 10.1080/15284336.2017.1311056
   Fogel JM, 2016, JAIDS-J ACQ IMM DEF, V72, P304, DOI 10.1097/QAI.0000000000000951
   Fogel JM, 2013, J INFECT DIS, V208, P1624, DOI 10.1093/infdis/jit390
   Fogel JM, 2015, P 8 IAS C HIV PATH T
   Gonsalez CR, 2007, VIRUS RES, V129, P87, DOI 10.1016/j.virusres.2007.06.021
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Hamers RL, 2012, CLIN INFECT DIS, V54, P1660, DOI 10.1093/cid/cis254
   Hamers RL, 2012, LANCET INFECT DIS, V12, P307, DOI 10.1016/S1473-3099(11)70255-9
   Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9
   Harrigan PR, 2005, J INFECT DIS, V191, P339, DOI 10.1086/427192
   Kantor R, 2015, CLIN INFECT DIS, V60, P1541, DOI 10.1093/cid/civ102
   Kityo C, 2017, JAIDS-J ACQ IMM DEF, V75, pE45, DOI [10.1097/QAI.0000000000001285, 10.1097/qai.0000000000001285]
   Lifson AR, 2017, AIDS, V31, P953, DOI 10.1097/QAD.0000000000001417
   Lima VD, 2015, AIDS, V29, P1871, DOI 10.1097/QAD.0000000000000790
   Luber Andrew D, 2005, MedGenMed, V7, P69, DOI 10.1186/1758-2652-7-3-69
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Marconi VC, 2008, CLIN INFECT DIS, V46, P1589, DOI 10.1086/587109
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Toledo PV, 2010, BRAZ J INFECT DIS, V14, P360, DOI 10.1590/S1413-86702010000400009
   Montgomery ET, 2017, AIDS BEHAV, V21, P481, DOI 10.1007/s10461-016-1609-1
   Mudhune V, 2017, AIDS BEHAV
   Mungati More, 2016, BMC Res Notes, V9, P302, DOI 10.1186/s13104-016-2101-8
   Rhee SY, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001810
   Safren SA, 2015, JAIDS-J ACQ IMM DEF, V69, P234, DOI 10.1097/QAI.0000000000000593
   Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370
   Sigaloff KCE, 2012, AIDS RES HUM RETROV, V28, P171, DOI 10.1089/aid.2011.0136
   Steegen K, 2017, J ANTIMICROB CHEMOTH, V72, P210, DOI 10.1093/jac/dkw358
   Uy J, 2009, JAIDS-J ACQ IMM DEF, V51, P450, DOI 10.1097/QAI.0b013e3181acb630
   Wallis CL, 2014, CLIN INFECT DIS, V59, P706, DOI 10.1093/cid/ciu314
   Zhang FD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0165110
NR 37
TC 1
Z9 2
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 15
PY 2018
VL 77
IS 5
BP 484
EP 491
DI 10.1097/QAI.0000000000001623
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GT6NL
UT WOS:000444630800011
PM 29293156
OA Green Accepted
DA 2020-11-24
ER

PT J
AU De Boni, RB
   Machado, IK
   De Vasconcellos, MTL
   Hoagland, B
   Kallas, EG
   Madruga, JV
   Fernandes, NM
   Cerqueira, NB
   Moreira, RI
   Goulart, SP
   Veloso, VG
   Grinsztejn, B
   Luz, PM
AF De Boni, Raquel B.
   Machado, Iona K.
   De Vasconcellos, Mauricio T. L.
   Hoagland, Brenda
   Kallas, Esper G.
   Madruga, Jose Valdez
   Fernandes, Nilo M.
   Cerqueira, Natalia B.
   Moreira, Ronaldo I.
   Goulart, Silvia P.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Luz, Paula M.
TI Syndemics among individuals enrolled in the PrEP Brasil Study
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE HIV infection; Pre-exposure prophylaxis; MSM; Transgender; Binge
   drinking; Polysubstance use
ID COST-EFFECTIVENESS ANALYSIS; PSYCHOSOCIAL HEALTH-PROBLEMS; PREEXPOSURE
   PROPHYLAXIS; HIV RISK; TRANSGENDER WOMEN; SEXUAL COMPULSIVITY; SENSATION
   SEEKING; ANAL INTERCOURSE; BISEXUAL MEN; SAMPLE
AB Background: Concurrent psychosocial problems may synergistically increase the risk of HIV infection (syndemics), representing a challenge for prevention. We aimed to evaluate the prevalence and associated factors of syndemics among men who have sex with men (MSM) and transgender women (TGW) enrolled in the Brazilian pre-exposure prophylaxis demonstration study (PrEP Brasil Study).
   Methods: Secondary cross-sectional analysis of the PrEP Brasil Study was performed. Of 450 HIV-seronegative MSM/TGW enrolled in the PrEP Brasil Study- conducted at Rio de Janeiro and Sao Paulo, Brazil- 421 participants with complete data were included in the present analysis. Syndemics was defined as occurrence of 2 of the following conditions: polysubstance (2) use, binge drinking, positive depression screen, compulsive sexual behavior, and intimate partner violence (IPV).
   Results: The prevalence of recent polysubstance use was 22.8%, binge drinking 51.1%, positive depression screening 5.2%, compulsive sexual behavior 7.1%, and IPV 7.3%. Syndemics prevalence was 24.2%, and associated factors were younger age (adjusted Odds Ratio (aOR) 0.95, 95% Confidence Interval (95% CI) 0.92-0.98 per year increase), TGW vs. MSM (aOR 3.09, 95% CI: 1.2-8.0), some college education or more vs. less than college (aOR 2.49, 95% CI: 1.31-4.75), and multiple male sexual partners in prior 3 months (aOR 1.69, 95% CI: 0.92-3.14).
   Conclusion: Given the high prevalence of syndemics, particularly of polysubstance use and binge drinking, PrEP delivery offers an opportunity to diagnose and intervene in mental and social well-being.
C1 [De Boni, Raquel B.; Hoagland, Brenda; Fernandes, Nilo M.; Moreira, Ronaldo I.; Veloso, Valdilea G.; Grinsztejn, Beatriz; Luz, Paula M.] Fiocruz MS, Natl Inst Infectol Evandro Chagas, Lapclin STD AIDS, Ave Brasil 4-365, Rio De Janeiro, Brazil.
   [Machado, Iona K.] Columbia Coll Phys & Surg, 630 W 168 St, New York, NY USA.
   [De Vasconcellos, Mauricio T. L.] IBGE, Natl Sch Stat Sci, Rua Andre Cavalcanti,106 Ctr, Rio De Janeiro, Brazil.
   [Kallas, Esper G.; Cerqueira, Natalia B.; Goulart, Silvia P.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Madruga, Jose Valdez] Ctr Referencia & Treinamento DST AIDS, 81 Vila Mariana, Sao Paulo, Brazil.
RP De Boni, RB (corresponding author), Fiocruz MS, Natl Inst Infectol Evandro Chagas, Lapclin STD AIDS, Ave Brasil 4350, BR-21040360 Rio De Janeiro, Brazil.
EM raqueldeboni@gmail.com; raqueldeboni@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Kallas,
   Esper/0000-0003-2026-6925; Luz, Paula/0000-0001-9746-719X
FU Brazilian Ministry of Health [01/2013 BRA/650 K57]; CNPqNational Council
   for Scientific and Technological Development (CNPq) [476333/2013-0,
   402004/2012-4, 454931/2014-0, 476024/2013-7]; SVS [281/2013];
   FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E- 26/110.261/2014, 2012/51743]; National
   Council of Technological and Scientific DevelopmentNational Council for
   Scientific and Technological Development (CNPq); Research Funding Agency
   the State of Rio de Janeiro; Sao Paulo State Funding Agency; Gilead
   SciencesGilead Sciences
FX The authors acknowledge funding from the Brazilian Ministry of Health
   (#01/2013 BRA/650 K57), CNPq ((#476333/2013-0, #402004/2012-4, #
   454931/2014-0, # 476024/2013-7) SVS (#281/2013), FAPERJ (#E-
   26/110.261/2014) and FAPESP (< gn4 > #2012/51743- </gn4 > 0). PML and BG
   acknowledge funding from the National Council of Technological and
   Scientific Development and the Research Funding Agency the State of Rio
   de Janeiro. EGK acknowledges funding from the Sao Paulo State Funding
   Agency. Gilead Sciences donated the study drug and covered the costs
   related to drug level assessment in the PrEP Brasil Study.
CR Abdalla RR, 2014, ADDICT BEHAV, V39, P297, DOI 10.1016/j.addbeh.2013.10.019
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Biello K. B., 2016, AIDS CARE, V121, P1
   Biello KB, 2014, AIDS BEHAV, V18, P1264, DOI 10.1007/s10461-013-0632-8
   Blashill AJ, 2015, AIDS BEHAV, V19, P981, DOI 10.1007/s10461-014-0925-6
   Caceres CF, 2015, J INT AIDS SOC, V18
   CDC, 2014, PREEXP PROPH PREV HI
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Defechereux PA, 2016, AIDS BEHAV, V20, P1478, DOI 10.1007/s10461-015-1082-2
   Drabo EF, 2016, CLIN INFECT DIS, V63, P1495, DOI 10.1093/cid/ciw578
   Dyer TP, 2012, J URBAN HEALTH, V89, P697, DOI 10.1007/s11524-012-9674-x
   Ferlatte O, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1961-5
   Ferlatte O, 2014, AIDS BEHAV, V18, P1256, DOI 10.1007/s10461-013-0639-1
   Friedman MR, 2015, AIDS, V29, P1087, DOI 10.1097/QAD.0000000000000657
   Gonzalez-Guarda RM, 2011, PUBLIC HEALTH NURS, V28, P366, DOI 10.1111/j.1525-1446.2010.00928.x
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Guadamuz TE, 2014, AIDS BEHAV, V18, P2089, DOI 10.1007/s10461-014-0826-8
   Halkitis PN, 2015, AIDS BEHAV, V19, P970, DOI 10.1007/s10461-014-0892-y
   Halkitis PN, 2013, AM PSYCHOL, V68, P261, DOI 10.1037/a0032746
   Henrique Iara Ferraz Silva, 2004, Rev. Assoc. Med. Bras., V50, P199, DOI 10.1590/S0104-42302004000200039
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   Institute for Health and Metrics Evaluation (IHME), 2016, GLOB BURD DIS COUNTR
   KALICHMAN SC, 1994, J PERS ASSESS, V62, P385, DOI 10.1207/s15327752jpa6203_1
   KALICHMAN SC, 1995, J PERS ASSESS, V65, P586, DOI 10.1207/s15327752jpa6503_16
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C
   Liu A, 2014, JAIDS-J ACQ IMM DEF, V67, P528, DOI 10.1097/QAI.0000000000000351
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
   Martinez O, 2016, DRUG ALCOHOL DEPEN, V166, P258, DOI 10.1016/j.drugalcdep.2016.06.033
   Mayer KH, 2012, SEX TRANSM DIS, V39, P1, DOI 10.1097/OLQ.0b013e31823b1922
   Mimiaga MJ, 2015, ARCH SEX BEHAV, V44, P1869, DOI 10.1007/s10508-015-0488-2
   Mimiaga MJ, 2015, JAIDS-J ACQ IMM DEF, V68, P329, DOI 10.1097/QAI.0000000000000475
   NIAAA, 2004, NIAAA COUNC APPR DEF, V3
   Nichols BE, 2016, LANCET INFECT DIS, V16, P1423, DOI 10.1016/S1473-3099(16)30311-5
   Operario D, 2010, JAIDS-J ACQ IMM DEF, V55, pS91, DOI 10.1097/QAI.0b013e3181fbc9ec
   Osorio FD, 2009, PERSPECT PSYCHIATR C, V45, P216, DOI 10.1111/j.1744-6163.2009.00224.x
   Parsons JT, 2012, AM J PUBLIC HEALTH, V102, P156, DOI 10.2105/AJPH.2011.300284
   Rocha GM, 2013, AIDS BEHAV, V17, P1288, DOI 10.1007/s10461-012-0398-4
   Santos GM, 2014, SEX TRANSM INFECT, V90, P250, DOI 10.1136/sextrans-2013-051318
   Scanavino MD, 2016, ARCH SEX BEHAV, V45, P207, DOI 10.1007/s10508-014-0356-5
   Schneider K, 2014, CLIN INFECT DIS, V58, P1027, DOI 10.1093/cid/cit946
   SINGER M, 1994, SOC SCI MED, V39, P931, DOI 10.1016/0277-9536(94)90205-4
   Singer M, 2017, LANCET, V389, P941, DOI 10.1016/S0140-6736(17)30003-X
   Stall R, 2003, AM J PUBLIC HEALTH, V93, P939, DOI 10.2105/AJPH.93.6.939
   Tsai AC, 2017, LANCET, V389, P978, DOI 10.1016/S0140-6736(17)30403-8
   Tsai AC, 2016, AIDS BEHAV, V20, P423, DOI 10.1007/s10461-015-1260-2
   United Nations Office on Drugs and Crime, 2016, WORLD DRUG REP
   Wang Y, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2132-8
   Wei CY, 2012, DRUG ALCOHOL DEPEN, V120, P246, DOI 10.1016/j.drugalcdep.2011.07.016
   Wu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032312
NR 51
TC 6
Z9 5
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD APR 1
PY 2018
VL 185
BP 168
EP 172
DI 10.1016/j.drugalcdep.2017.12.016
PG 5
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA GD8TD
UT WOS:000430784100021
PM 29454927
DA 2020-11-24
ER

PT J
AU Moreira, J
   Castro, R
   Lamas, C
   Ribeiro, S
   Grinsztejn, B
   Veloso, VG
AF Moreira, Jose
   Castro, Rodolfo
   Lamas, Cristiane
   Ribeiro, Sayonara
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
TI Hyperglycemia during tuberculosis treatment increases morbidity and
   mortality in a contemporary cohort of HIV-infected patients in Rio de
   Janeiro, Brazil
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Hyperglycemia; Diabetes mellitus; Tuberculosis; Mortality; Brazil
ID CRITICALLY-ILL PATIENTS; PULMONARY TUBERCULOSIS; STRESS HYPERGLYCEMIA;
   GLUCOSE-INTOLERANCE; HOSPITAL MORTALITY; DIABETES-MELLITUS; ASSOCIATION;
   SEPSIS; POPULATION; MANAGEMENT
AB Background: Hyperglycemia occurs in tuberculosis (TB), but the long-term impact is unknown. We estimated the prevalence of hyperglycemia and compared the TB treatment outcomes and 1-year mortality rate according to the glycemic status noted during TB treatment.
   Methods: We conducted a retrospective cohort analysis of adult patients who had TB and HIV coinfection and started receiving TB treatment at the Instituto Nacional de Infectologia Evandro Chagas, Brazil, between 2010-2015. Diabetes Mellitus (DM) and hyperglycemia were defined according to the American Diabetes Association. After excluding for known DM at baseline, the proportion of participants who developed new-onset DM after TB treatment was assessed. TB outcome was classified as successful or adverse (i.e., treatment failure, abandonment, and death). Kaplan-Meier survival curves were compared by the log-rank test based on the glycemic status of patients. Multivariate Cox regression models were used to assess the association between hyperglycemia and 1-year mortality. Two-sided p values < 0.05 were considered statistically significant.
   Results: We identified 414 euglycemic patients (87.5%), 49 hyperglycemic patients (10.3%), and 10 patients with known DM (2.1%). Diabetic patients were older compared to the euglycemic and hyperglycemic patients (47.9 vs. 37 vs. 39.7 years, respectively, p = 0.001). Diabetic patients frequently had cavitation on chest image compared to hyperglycemic and euglycemic patients (50% vs. 23.4% vs. 15.3%, p = 0.007, respectively). Hyperglycemic patients had more new-onset DM at follow-up compared to euglycemic (22 vs. 1; p < 0001). Hyperglycemia was associated with adverse outcomes (71.4% vs. 24.6%, p < 0.0001) compared to euglycemia. Crude 1-year mortality was significantly higher in patients with hyperglycemia compared with euglycemia (48.9% vs. 7.9%; unadjusted HR: 5.79 (3.74-8.96)). In the adjusted Cox models, hyperglycemia remained a significant factor for increased 1-year mortality (adjusted HR: 3.72 (2.17-6.38)].
   Conclusions: Hyperglycemia frequently occurs in HIV-infected patients who commence TB treatment, and it increases the risks of adverse TB outcomes and 1-year mortality. Glucose testing during TB treatment detects patients at risk of adverse outcomes. (C) 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Moreira, Jose; Castro, Rodolfo; Lamas, Cristiane; Ribeiro, Sayonara; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365,POB 21040-360, Rio De Janeiro, Brazil.
   [Moreira, Jose; Lamas, Cristiane] Inst Nacl Cardiol, Rio De Janeiro, Brazil.
   [Castro, Rodolfo] Univ Fed Estado Rio de Janeiro UNIRIO, Inst Saude Colet, Rio De Janeiro, Brazil.
   [Lamas, Cristiane] Univ Grande Rio Unigranrio, Rio De Janeiro, Brazil.
RP Moreira, J (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365,POB 21040-360, Rio De Janeiro, Brazil.
EM jose.moreira@ini.fiocruz.br
RI Castro, Rodolfo/D-4231-2013; Lamas, Cristiane/AAV-4157-2020
OI Castro, Rodolfo/0000-0002-0701-2528; Lamas,
   Cristiane/0000-0002-5561-999X
FU Programa de Estudantes-Convenio de Pos-graduacao (PEC-PG, CAPES/CNPQ);
   National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)
FX Jose Moreira is supported by a scholarship from Programa de
   Estudantes-Convenio de Pos-graduacao (PEC-PG, CAPES/CNPQ).; Beatriz
   Grinsztejn acknowledges the funding from the National Council of
   Technological and Scientific Development (CNPq) and the Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ).
CR [Anonymous], 2016, GLOB TUB REP
   Bailey SL, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2066-1
   Baker MA, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-81
   Basoglu O K, 1999, Monaldi Arch Chest Dis, V54, P307
   BLOOM JD, 1969, AM REV RESPIR DIS, V100, P38
   Boillat-Blanco N, 2016, J INFECT DIS, V213, P1163, DOI 10.1093/infdis/jiv568
   Brasil, 2011, MANUAL RECOMENDACOES
   Brasil MrdSd, 2015, PROTOCOLO CLIN DIRET
   Brazil (Ministerio da Saude), 2008, MAN NAC VIG LAB TUB
   Chamberlain JJ, 2016, ANN INTERN MED, V164, P542, DOI 10.7326/M15-3016
   Degner NR, 2017, CLIN INFECT DIS
   Dungan KM, 2009, LANCET, V373, P1798, DOI 10.1016/S0140-6736(09)60553-5
   Fandinho FCO, 1997, B WORLD HEALTH ORGAN, V75, P361
   Faurholt-Jepsen D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024215
   Girardi E, 2017, INT J INFECT DIS, V56, P45, DOI 10.1016/j.ijid.2017.01.018
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Jawad Fatema, 1995, JPMA (Journal of the Pakistan Medical Association), V45, P237
   Jeon CY, 2008, PLOS MED, V5, P1091, DOI 10.1371/journal.pmed.0050152
   Kibirige D, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-122
   Krinsley JS, 2003, MAYO CLIN PROC, V78, P1471, DOI 10.4065/78.12.1471
   Leonidou L, 2007, J INFECTION, V55, P340, DOI 10.1016/j.jinf.2007.05.177
   McAlister FA, 2005, DIABETES CARE, V28, P810, DOI 10.2337/diacare.28.4.810
   Moreno-Martinez A, 2015, INT J TUBERC LUNG D, V19, P1507, DOI 10.5588/ijtld.15.0102
   Ogbera AO, 2015, BMJ OPEN DIAB RES CA, V3, DOI 10.1136/bmjdrc-2015-000112
   OLUBOYO PO, 1990, TUBERCLE, V71, P135, DOI 10.1016/0041-3879(90)90010-6
   Oni T, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00004-2017
   Restrepo BI, 2016, TUBERCULOSIS, V101, pS69, DOI 10.1016/j.tube.2016.09.008
   Schuetz P, 2012, AM J MED, V125, P670, DOI 10.1016/j.amjmed.2012.03.001
   SETH SC, 1982, HORM METAB RES, V14, P50, DOI 10.1055/s-2007-1018917
   Sharma T N, 1986, J Assoc Physicians India, V34, P131
   Singhal A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009885
   Strevel EL, 2006, LANCET INFECT DIS, V6, P178, DOI 10.1016/S1473-3099(06)70414-5
   Tabarsi P, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/s40200-014-0123-0
   TAKASU N, 1982, AM REV RESPIR DIS, V125, P23
   Tiruvoipati R, 2012, J CRIT CARE, V27, P153, DOI 10.1016/j.jcrc.2011.06.011
   Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300
   van Vught LA, 2016, CRIT CARE MED, V44, P1338, DOI 10.1097/CCM.0000000000001650
   Workneh MH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147621
NR 38
TC 4
Z9 5
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD APR
PY 2018
VL 69
BP 11
EP 19
DI 10.1016/j.ijid.2017.12.014
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA GD0DE
UT WOS:000430169000003
PM 29253707
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Kozal, M
   Aberg, J
   Pialoux, G
   Cahn, P
   Thompson, M
   Molina, JM
   Grinsztejn, B
   Diaz, R
   Lazzarin, A
   Gummel, M
   Pierce, A
   Ackerman, P
   Llamoso, C
   Lataillade, M
AF Kozal, M.
   Aberg, J.
   Pialoux, G.
   Cahn, P.
   Thompson, M.
   Molina, J-M
   Grinsztejn, B.
   Diaz, R.
   Lazzarin, A.
   Gummel, M.
   Pierce, A.
   Ackerman, P.
   Llamoso, C.
   Lataillade, M.
TI Week-24 safety of fostemsavir in heavily treatment-experienced
   participants with HIV-1 (Study 205888, formerly AI438-047)
SO HIV MEDICINE
LA English
DT Meeting Abstract
C1 [Kozal, M.] Yale Univ, Sch Med, New Haven, CT USA.
   [Aberg, J.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Pialoux, G.] Hop Tenon, Paris, France.
   [Cahn, P.] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Thompson, M.] AIDS Res Consortium Atlanta, Atlanta, GA USA.
   [Molina, J-M] Hop St Louis, Paris, France.
   [Grinsztejn, B.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Diaz, R.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Lazzarin, A.] Osped San Raffaele, Milan, Italy.
   [Gummel, M.] GlaxoSmithKline, Upper Providence, PA USA.
   [Pierce, A.] ViiV Healthcare, Res Triangle Pk, NC USA.
   [Ackerman, P.; Llamoso, C.; Lataillade, M.] ViiV Healthcare, Branford, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD APR
PY 2018
VL 19
SU 2
SI SI
MA P31
BP S31
EP S32
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA GD0FD
UT WOS:000430174700077
DA 2020-11-24
ER

PT J
AU Kozal, M
   Aberg, J
   Pialoux, G
   Cahn, P
   Thompson, M
   Molina, JM
   Grinsztejn, B
   Diaz, R
   Lazzarin, A
   Gummel, M
   Pierce, A
   Ackerman, P
   Llamoso, C
   Lataillade, M
AF Kozal, M.
   Aberg, J.
   Pialoux, G.
   Cahn, P.
   Thompson, M.
   Molina, J-M
   Grinsztejn, B.
   Diaz, R.
   Lazzarin, A.
   Gummel, M.
   Pierce, A.
   Ackerman, P.
   Llamoso, C.
   Lataillade, M.
TI Phase 3 study of fostemsavir in heavily treatment experienced HIV-1
   infected subjects: day 8 and week 24 primary efficacy and safety results
   (Study 205888, formerly AI438-047)
SO HIV MEDICINE
LA English
DT Meeting Abstract
C1 [Kozal, M.] Yale Univ, Sch Med, New Haven, CT USA.
   [Aberg, J.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Pialoux, G.] Hop Tenon, Paris, France.
   [Cahn, P.] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Thompson, M.] AIDS Res Consortium Atlanta, Atlanta, GA USA.
   [Molina, J-M] Hop St Louis, Paris, France.
   [Grinsztejn, B.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Diaz, R.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Lazzarin, A.] Osped San Raffaele, Milan, Italy.
   [Gummel, M.] GlaxoSmithKline, Upper Providence, PA USA.
   [Pierce, A.] ViiV Healthcare, Res Triangle Pk, NC USA.
   [Ackerman, P.; Llamoso, C.; Lataillade, M.] ViiV Healthcare, Branford, CT USA.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD APR
PY 2018
VL 19
SU 2
SI SI
MA P18
BP S27
EP S27
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA GD0FD
UT WOS:000430174700064
DA 2020-11-24
ER

PT J
AU Carriquiry, G
   Giganti, MJ
   Castilho, JL
   Jayathilake, K
   Cahn, P
   Grinsztejn, B
   Cortes, C
   Pape, JW
   Padgett, D
   Sierra-Madero, J
   McGowan, CC
   Shepherd, BE
   Gotuzzo, E
AF Carriquiry, Gabriela
   Giganti, Mark J.
   Castilho, Jessica L.
   Jayathilake, Karu
   Cahn, Pedro
   Grinsztejn, Beatriz
   Cortes, Claudia
   Pape, Jean W.
   Padgett, Denis
   Sierra-Madero, Juan
   McGowan, Catherine C.
   Shepherd, Bryan E.
   Gotuzzo, Eduardo
TI Virologic failure and mortality in older ART initiators in a multisite
   Latin American and Caribbean Cohort
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE HIV; Ageing; Over 50; Latin America; Caribbean; ART outcomes; Virologic
   failure
ID COMBINATION ANTIRETROVIRAL THERAPY; OBSERVATIONAL COHORT; INFECTED
   PATIENTS; RISK-FACTORS; 1ST YEAR; HIV; AGE; ADULTS; INDIVIDUALS;
   PREDICTORS
AB Introduction: The "greying" of the HIV epidemic necessitates a better understanding of the healthcare needs of older HIV-positive adults. As these individuals age, it is unclear whether comorbidities and their associated therapies or the ageing process itself alter the response to antiretroviral therapy (ART). In this study, HIV treatment outcomes and corresponding risk factors were compared between older ART initiators and those who were younger using data from the Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet).
   Methods: HIV-positive adults (>= 18 years) initiating ART at nine sites in Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru were included. Patients were classified as older (>= 50 years) or younger (<50 years) based on age at ART initiation. ART effectiveness was measured using three outcomes: death, virologic failure and ART treatment modification. Cox regression models for each outcome compared risk between older and younger patients, adjusting for other covariates.
   Results: Among 26,311 patients initiating ART between 1996 and 2016, 3389 (13%) were >= 50 years. The majority of patients in both >= 50 and <50 age groups received a non-nucleoside reverse transcriptase inhibitor-based regimen (89% vs. 87%), did not have AIDS at baseline (63% vs. 62%), and were male (59% vs. 58%). Older patients had a higher risk of death (adjusted hazard ratio (aHR) 1.64; 95% confidence intervals (CI): 1.48 to 1.83) and a lower risk of virologic failure (aHR: 0.73; 95% CI: 0.63 to 0.84). There was no difference in risk of ART modification (aHR: 1.00; 95% CI: 0.94 to 1.06). Risk factors for death, virologic failure and treatment modification were similar for each group.
   Conclusions: Older age at ART initiation was associated with increased mortality and decreased risk of virologic failure in our cohort of more than 26,000 ART initiators in Latin America and the Caribbean. To the best of our knowledge this is the first study from the region to evaluate ART outcomes in this growing and important population. Given the complexity of issues related to ageing with HIV, a greater understanding is needed in order to properly respond to this shifting epidemic.
C1 [Carriquiry, Gabriela; Gotuzzo, Eduardo] Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Giganti, Mark J.; Castilho, Jessica L.; Jayathilake, Karu; McGowan, Catherine C.; Shepherd, Bryan E.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Cortes, Claudia] Fdn Arriaran, Santiago, Chile.
   [Pape, Jean W.] Grp Haitien Etud Sarcome Kaposi & Infect Opportun, Port Au Prince, Haiti.
   [Pape, Jean W.] Weill Cornell Med Coll, New York, NY USA.
   [Padgett, Denis] Inst Hondureno Seguridad Social, Tegucigalpa, Honduras.
   [Padgett, Denis] Hosp Escuela Univ, Tegucigalpa, Honduras.
   [Sierra-Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
RP Carriquiry, G; Giganti, MJ (corresponding author), Av Angamos Oeste, Lima 11, Peru.
EM gabriela.carriquiry@yahoo.com; mark.giganti@vanderbilt.edu
RI Cortes, Claudia/AAF-7326-2020
OI Cortes, Claudia/0000-0001-9101-9783
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01AI069923]; Eunice Kennedy Shriver
   National Institute of Child Health & Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); Office of The Director, National
   Institutes of Health (OD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Institute of
   Allergy and Infectious Diseases (NIAID)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID); National
   Cancer Institute (NCI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); National Institute of Mental Health (NIMH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH); NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069421,
   UM1AI069476, UM1AI069421, K23AI120875, UM1AI069476, K23AI120875,
   U01AI069923, UM1AI069421, UM1AI069421, K23AI120875, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, UM1AI069421, U01AI069923,
   K23AI120875, U01AI069923, U01AI069923, U01AI069923, UM1AI069476,
   K23AI120875, U01AI069923, UM1AI069421, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, UM1AI069476, UM1AI069421,
   U01AI069923, U01AI069923, UM1AI069476, UM1AI069421, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, UM1AI069476, UM1AI069421,
   U01AI069923, U01AI069923, UM1AI069476, UM1AI069476] Funding Source: NIH
   RePORTER
FX This work was supported by the NIH-funded Caribbean, Central and South
   America network for HIV epidemiology (CCASAnet), a member cohort of the
   International Epidemiologic Databases to Evaluate AIDS (leDEA)
   (U01AI069923). This award is funded by the following institutes: Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD), Office of The Director, National Institutes of Health (OD),
   National Institute of Allergy and Infectious Diseases (NIAID), National
   Cancer Institute (NCI), and the National Institute of Mental Health
   (NIMH).
CR Akers A, 2007, J WOMENS HEALTH, V16, P842, DOI 10.1089/jwh.2006.0028
   Althoff KN, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-45
   Althoff KN, 2010, AIDS, V24, P2467, DOI 10.1097/QAD.0b013e32833e6d14
   Balestre E, 2012, AIDS, V26, P951, DOI 10.1097/QAD.0b013e3283528ad4
   Barclay TR, 2007, HEALTH PSYCHOL, V26, P40, DOI 10.1037/0278-6133.26.1.40
   CDC, HIV PEOPL AG 50
   Centers for Disease Control and Prevention, 2016, HIV SURV SUPPL REP 2, V21
   Cesar C, 2015, LANCET HIV, V2, pE492, DOI 10.1016/S2352-3018(15)00183-6
   Cooperman NA, 2007, AIDS EDUC PREV, V19, P321, DOI 10.1521/aeap.2007.19.4.321
   Cornell M, 2015, LANCET HIV, V2, pE368, DOI 10.1016/S2352-3018(15)00113-7
   Duda SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033908
   Durvasula R, 2014, BEHAV MED, V40, P85, DOI 10.1080/08964289.2014.893983
   Edwards JK, 2015, CLIN INFECT DIS, V61, P1189, DOI 10.1093/cid/civ463
   Fatti G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100273
   Ghidei L, 2013, DRUG AGING, V30, P809, DOI 10.1007/s40266-013-0107-7
   Giganti MJ, 2015, AIDS RES HUM RETROV, V31, P496, DOI [10.1089/aid.2014.0241, 10.1089/AID.2014.0241]
   GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
   Harawa NT, 2011, SEX TRANSM DIS, V38, P1110, DOI 10.1097/OLQ.0b013e31822e614b
   High KP, 2012, JAIDS-J ACQ IMM DEF, V60, pS1, DOI 10.1097/QAI.0b013e31825a3668
   Hughes AK, 2011, AIDS PATIENT CARE ST, V25, P539, DOI 10.1089/apc.2011.0026
   Kowalska JD, 2016, AIDS RES THER, V13, DOI 10.1186/s12981-015-0084-5
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   Lok JJ, 2010, AIDS, V24, P1867, DOI 10.1097/QAD.0b013e32833adbcf
   Lumley T, 2013, BIOMETRIKA, V100, P831, DOI 10.1093/biomet/ast027
   Luz PM, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv079
   Maskew Mhairi, 2012, J Int Assoc Physicians AIDS Care (Chic), V11, P57, DOI 10.1177/1545109711421641
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   Mutevedzi PC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021795
   Ordunez P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141685
   Pan American Health Organization/World Health Organization Communicable Diseases and Health Analysis/Health Information and Analysis, 2017, COMM DIS HLTH AN HLT
   Pirrone V, 2013, FUTURE VIROL, V8, P81, DOI 10.2217/FVL.12.127
   Prosperi MCF, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-296
   Schick V, 2010, J SEX MED, V7, P315, DOI 10.1111/j.1743-6109.2010.02013.x
   Schouten J, 2014, CLIN INFECT DIS, V59, P1787, DOI 10.1093/cid/ciu701
   Smit M, 2015, LANCET INFECT DIS, V15, P810, DOI 10.1016/S1473-3099(15)00056-0
   Su YS, 2011, J STAT SOFTW, V45, P1
   Torres TS, 2014, BRAZ J INFECT DIS, V18, P34, DOI 10.1016/j.bjid.2013.04.005
   UNAIDS, 2015, AIDS NUMB 2015
   UNAIDS, 2013, SPEC SUPPL UNAIDS RE
   Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678
   Webber L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039589
NR 41
TC 4
Z9 4
U1 1
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD MAR 22
PY 2018
VL 21
IS 3
AR e25088
DI 10.1002/jia2.25088
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GA6XT
UT WOS:000428478700001
PM 29569354
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU De Boni, RB
   Peratikos, MB
   Shepherd, BE
   Grinsztejn, B
   Cortes, C
   Padgett, D
   Gotuzzo, E
   Belaunzaran-Zamudio, PF
   Rebeiro, PF
   Duda, SN
   McGowan, CC
AF De Boni, Raquel B.
   Peratikos, Meridith B.
   Shepherd, Bryan E.
   Grinsztejn, Beatriz
   Cortes, Claudia
   Padgett, Denis
   Gotuzzo, Eduardo
   Belaunzaran-Zamudio, Pablo F.
   Rebeiro, Peter F.
   Duda, Stephany N.
   McGowan, Catherine C.
CA CCASAnet
TI Is substance use associated with HIV cascade outcomes in Latin America?
SO PLOS ONE
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; FOLLOW-UP; INFECTED PEOPLE; DRUG-USE; CARE;
   ALCOHOL; HEALTH; COHORT; SYNDEMICS; RETENTION
AB Background
   The HIV care cascade has improved in Latin America over the last decade. However, the influence of alcohol and noninjected drug use (NIDU) on cascade outcomes is mostly unknown. This study estimated the association of alcohol and NIDU with retention in care, loss to follow up (LTFU), and virologic failure (VF).
   Methods
   Individuals >18 years attending routine HIV clinic visits and completing the Rapid Screening Tool (RST; evaluating NIDU and ART adherence in 7-day recall period) during 2012-13 were followed up to 2015 in the Caribbean, Central and South America network for HIV epidemiology. Adjusted odds ratios (aOR) were calculated for the association of alcohol consumption and NIDU with retention in care by logistic regression; adjusted hazard ratios (aHR) were estimated for the associations with LTFU and VF by Cox regression.
   Results
   Among 3604 individuals, the proportions retained in care for one year were 84%, 79%, 72%, and 69% for patients reporting non-use, alcohol use, NIDU, and both alcohol and NIDU, respectively. For the same patient groups, the proportions LTFU over 18 months were 6%, 8%, 12%, and 13%, respectively. There were 1901 patients (53%) with HIV RNA results; VF proportions were similar between users and nonusers (ranging from 14-16%). After controlling for age, sex, study site, HIV transmission mode, time on ART, AIDS status, and CD4 count, neither alcohol use (aOR =1.1, CI = 0.9-1.4; aHR = 1.0, CI = 0.8-1.3) nor NIDU (aOR = 1.3, CI = 0.9-1.8; aHR = 1.4, CI = 0.9-2.1) were significantly associated with retention or VF, respectively. However, both alcohol use (aHR = 1.2, CI = 1.02-1.4) and NIDU (aHR = 1.3, CI = 1.00-1.8) were associated with increased LTFU.
   Conclusion
   Alcohol use and NIDU in a 7-day recall period increased the risk of being LTFU during the next 18 months, highlighting the need for routine screening and targeted interventions to keep these individuals in care and on ART.
C1 [De Boni, Raquel B.; Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Peratikos, Meridith B.; Shepherd, Bryan E.; Rebeiro, Peter F.; Duda, Stephany N.; McGowan, Catherine C.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Cortes, Claudia] Univ Chile, Fac Med, Fdn Arriaran, Santiago, Chile.
   [Padgett, Denis] Inst Hondureno Seguridad Social & Hosp Escuela, Tegucigalpa, Honduras.
   [Gotuzzo, Eduardo] Univ Peruana Cayetano Heredia, Lima, Peru.
   [Belaunzaran-Zamudio, Pablo F.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Mexico City, DF, Mexico.
RP De Boni, RB (corresponding author), Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
EM raqueldeboni@gmail.com
RI Belaunzaran-Zamudio, Pablo Francisco/T-4085-2019; Cortes,
   Claudia/AAF-7326-2020; DE BONI, RAQUEL BRANDINI/D-4212-2013;
   Belaunzaran-Zamudio, Pablo F./T-4218-2019
OI Cortes, Claudia/0000-0001-9101-9783; DE BONI, RAQUEL
   BRANDINI/0000-0002-2455-5997; Rebeiro, Peter/0000-0003-1951-9104;
   Belaunzaran, Pablo/0000-0003-4775-4734
FU NIH-funded Caribbean, Central and South America network for HIV
   epidemiology (CCASAnet), a member cohort of the International
   epidemiology Databases to Evaluate AIDS (IeDEA) [U01-AI069923]; Eunice
   Kennedy Shriver National Institute Of Child Health & Human Development
   (NICHD)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD); National Cancer
   Institute (NCI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); National Institute Of Allergy And Infectious Diseases
   (NIAID)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); National Institute Of Mental Health
   (NIMH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH); Office Of The Director, National Institutes Of Health (OD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA; Division de Investigacion de la Facultad de
   Medicina, Universidad Nacional Autonoma de Mexico, Mexico City; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI069923, UM1AI069476, U01AI069923, UM1AI069476, U01AI069923,
   U01AI069923, K01AI131895, K01AI131895, U01AI069923, U01AI069923,
   U01AI069923, UM1AI069476, U01AI069923, UM1AI069476, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, K01AI131895, U01AI069923, UM1AI069476, U01AI069923,
   K01AI131895, U01AI069923, U01AI069923, UM1AI069476, UM1AI069476,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, UM1AI069476] Funding
   Source: NIH RePORTER
FX This work was supported by the NIH-funded Caribbean, Central and South
   America network for HIV epidemiology (CCASAnet), a member cohort of the
   International epidemiology Databases to Evaluate AIDS (IeDEA)
   (U01-AI069923). This award is funded by the following institutes: Eunice
   Kennedy Shriver National Institute Of Child Health & Human Development
   (NICHD), National Cancer Institute (NCI), National Institute Of Allergy
   And Infectious Diseases (NIAID), National Institute Of Mental Health
   (NIMH), and the Office Of The Director, National Institutes Of Health
   (OD). The work of Pablo F Belaunzaran Zamudio is supported by the
   Division de Investigacion de la Facultad de Medicina, Universidad
   Nacional Autonoma de Mexico, Mexico City. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Belaunzaran-Zamudio PF, 2015, B WORLD HEALTH ORGAN, V93, P529, DOI 10.2471/BLT.14.147447
   Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790
   Carriquiry G, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20016
   Cesar C, 2015, LANCET HIV, V2, pE492, DOI 10.1016/S2352-3018(15)00183-6
   Cohen E, 2007, DRUG ALCOHOL DEPEN, V86, P214, DOI 10.1016/j.drugalcdep.2006.06.008
   Colasanti J, 2017, J ACQ IMMUN DEF SYND, V74, p113 
   Connor JP, 2016, LANCET, V387, P988, DOI 10.1016/S0140-6736(15)00122-1
   Cunningham CO, 2014, JAIDS-J ACQ IMM DEF, V66, P419, DOI 10.1097/QAI.0000000000000171
   de Almeida MC, 2014, AIDS BEHAV, V18, P2387, DOI 10.1007/s10461-014-0812-1
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   De Boni RB, 2016, AIDS BEHAV, V20, P2692, DOI 10.1007/s10461-016-1398-6
   De Boni RB, 2016, DRUG ALCOHOL DEPEN, V159, P174, DOI 10.1016/j.drugalcdep.2015.12.013
   De la Mata NL, 2017, JAIDS-J ACQ IMM DEF, V74, P555, DOI 10.1097/QAI.0000000000001293
   Dennis Michael, 2007, Addict Sci Clin Pract, V4, P45
   Dombrowski JC, 2013, JAIDS-J ACQ IMM DEF, V63, P299, DOI 10.1097/QAI.0b013e3182945bc7
   Duda SN, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19045
   Fairbairn NS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166539
   Ford MA, 2012, MONITORING HIV CARE
   Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243
   Haber N, 2016, CURR OPIN HIV AIDS, V11, P102, DOI 10.1097/COH.0000000000000212
   Hart L, 2017, LANCET, V389, P888, DOI 10.1016/S0140-6736(17)30599-8
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2014, 90 90 90 AMB TREATM, V40
   Justice AC, 2016, DRUG ALCOHOL DEPEN, V161, P95, DOI 10.1016/j.drugalcdep.2016.01.017
   Kipp AM, 2011, J SUBST ABUSE TREAT, V40, P386, DOI 10.1016/j.jsat.2011.01.001
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   Meyer JP, 2013, CLIN INFECT DIS, V57, P1309, DOI 10.1093/cid/cit427
   Milloy MJS, 2012, AIDS, V26, P1049, DOI 10.1097/QAD.0b013e32835221cc
   Mitchell AJ, 2012, BRIT J PSYCHIAT, V201, P93, DOI 10.1192/bjp.bp.110.091199
   Monroe AK, 2016, JAIDS-J ACQ IMM DEF, V73, P419, DOI 10.1097/QAI.0000000000001083
   National Institute on Alcohol Abuse and Alcohlism (NIAAA), 2004, NIAAA NEWSLETTER
   NIDA, 2012, PRINC DRUG ADD TREAT, P1
   NIDA (National Institute on Drug Abuse), 2014, DRUGS BRAINS BEH SCI
   Nishijima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073639
   P. L. S, 2016, PLOS ONE, V11
   Pecoraro A, 2015, AIDS CARE, V27, P86, DOI 10.1080/09540121.2014.959464
   Petoumenos K, 2016, CURR OPIN HIV AIDS, V11, P514, DOI 10.1097/COH.0000000000000306
   Powers KA, 2015, JAIDS-J ACQ IMM DEF, V69, P341, DOI 10.1097/QAI.0000000000000611
   Rasbach DA, 2013, AIDS CARE, V25, P109, DOI 10.1080/09540121.2012.687814
   Rebeiro PF, 2016, J INT AIDS SOC, V19
   Tamara-Ramirez JR, 2016, BIOMEDICA, V36, P265, DOI 10.7705/biomedica.v36i2.2939
   Singer M, 2003, MED ANTHROPOL Q, V17, P423, DOI 10.1525/maq.2003.17.4.423
   SINGER M, 1994, SOC SCI MED, V39, P931, DOI 10.1016/0277-9536(94)90205-4
   Singer M, 2017, LANCET, V389, P941, DOI 10.1016/S0140-6736(17)30003-X
   UNAIDS, 2016, GET FAST TRACK
   UNAIDS, DATA2017
   UNODC, 2016, WORLD DRUG REP
   Volkow ND, 2011, HEALTH AFFAIR, V30, P1411, DOI 10.1377/hlthaff.2011.0663
   Weber R, 2015, HIV MED, V16, P137, DOI 10.1111/hiv.12184
   WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1
   Yehia BR, 2015, AIDS BEHAV, V19, P1491, DOI 10.1007/s10461-015-1080-4
NR 50
TC 4
Z9 4
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 15
PY 2018
VL 13
IS 3
AR e0194228
DI 10.1371/journal.pone.0194228
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FZ3GA
UT WOS:000427473500058
PM 29543857
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Luz, PM
   Osher, B
   Grinsztejn, B
   Maclean, RL
   Losina, E
   Stern, ME
   Struchiner, CJ
   Parker, RA
   Freedberg, KA
   Mesquita, F
   Walensky, RP
   Veloso, VG
   Paltiel, AD
AF Luz, Paula M.
   Osher, Benjamin
   Grinsztejn, Beatriz
   Maclean, Rachel L.
   Losina, Elena
   Stern, Madeline E.
   Struchiner, Claudio J.
   Parker, Robert A.
   Freedberg, Kenneth A.
   Mesquita, Fabio
   Walensky, Rochelle P.
   Veloso, Valdilea G.
   Paltiel, A. David
TI The cost-effectiveness of HIV pre-exposure prophylaxis in men who have
   sex with men and transgender women at high risk of HIV infection in
   Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE HIV; pre-exposure prophylaxis; men who have sex with men; Brazil;
   cost-effectiveness
ID TENOFOVIR DISOPROXIL FUMARATE; RIO-DE-JANEIRO; UNITED-STATES; NAIVE
   PATIENTS; EMTRICITABINE; EFAVIRENZ; PREP; ZIDOVUDINE/LAMIVUDINE;
   PREVENTION; RESISTANCE
AB Introduction: Men who have sex with men (MSM) and transgender women (TGW) in Brazil experience high rates of HIV infection. We examined the clinical and economic outcomes of implementing a pre-exposure prophylaxis (PrEP) programme in these populations.
   Methods: We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International model of HIV prevention and treatment to evaluate two strategies: the current standard of care (SOC) in Brazil, including universal ART access (No PrEP strategy); and the current SOC plus daily tenofovir/emtracitabine PrEP (PrEP strategy) until age 50. Mean age (31 years, SD 8.4 years), age-stratified annual HIV incidence (age <= 40 years: 4.3/100 PY; age > 40 years: 1.0/100 PY), PrEP effectiveness (43% HIV incidence reduction) and PrEP drug costs ($23/month) were from Brazil-based sources. The analysis focused on direct medical costs of HIV care. We measured the comparative value of PrEP in 2015 United States dollars (USD) per year of life saved (YLS). Willingness-to-pay threshold was based on Brazil's annual per capita gross domestic product (GDP; 2015: $8540 USD).
   Results: Lifetime HIV infection risk among high-risk MSM and TGW was 50.5% with No PrEP and decreased to 40.1% with PrEP. PrEP increased per-person undiscounted (discounted) life expectancy from 36.8 (20.7) years to 41.0 (22.4) years and lifetime discounted HIV-related medical costs from $4100 to $8420, which led to an incremental cost-effectiveness ratio (ICER) of $2530/YLS. PrEP remained cost-effective (<1x GDP) under plausible variation in key parameters, including PrEP effectiveness and cost, initial cohort age and HIV testing frequency on/off PrEP.
   Conclusion: Daily tenofovir/emtracitabine PrEP among MSM and TGW at high risk of HIV infection in Brazil would increase life expectancy and be highly cost-effective.
C1 [Luz, Paula M.; Grinsztejn, Beatriz; Struchiner, Claudio J.; Mesquita, Fabio; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
   [Osher, Benjamin; Maclean, Rachel L.; Losina, Elena; Stern, Madeline E.; Parker, Robert A.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
   [Osher, Benjamin; Maclean, Rachel L.; Stern, Madeline E.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
   [Losina, Elena; Parker, Robert A.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Harvard Univ, Ctr AIDS Res, Harvard Med Sch, Boston, MA 02115 USA.
   [Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA.
   [Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Parker, Robert A.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
   [Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Freedberg, Kenneth A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
   [Freedberg, Kenneth A.] Harvard Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
   [Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA.
   [Paltiel, A. David] Yale Sch Publ Hlth, New Haven, CT USA.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM luzpaulamendes@gmail.com
RI Mesquita, Fabio/AAZ-7021-2020; Struchiner, Claudio J/M-9360-2013
OI Struchiner, Claudio J/0000-0003-2114-847X; Luz,
   Paula/0000-0001-9746-719X
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI058736, R37AI093269]; National Institute of Mental HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH)
   [R01MH105203]; National Institute on Drug AbuseUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [R01DA015612]; National Council
   of Technological and Scientific Development (CNPq)National Council for
   Scientific and Technological Development (CNPq); Research Funding Agency
   of the State of Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ);
   Massachusetts General Hospital Steve and Deborah Gorlin Research Scholar
   Award; French National Research Agency (ANR)French National Research
   Agency (ANR) [ANR11LABX0091, ANR 11 IDEX000502]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R37AI058736,
   R01AI058736, UM1AI069476, UM1AI069476, UM1AI069476, R01AI058736,
   R37AI093269, R01AI058736, R01AI058736, R01AI058736, R01AI058736,
   R01AI058736, R01AI058736, R01AI058736, R01AI058736, R01AI058736,
   UM1AI069476, UM1AI069476, R37AI058736, R01AI058736, R37AI093269,
   R37AI058736, R01AI058736, R01AI058736, UM1AI069476, R01AI058736,
   UM1AI069476, R01AI058736, R37AI093269, R37AI093269, R01AI058736,
   R37AI093269, R01AI058736, UM1AI069476, UM1AI069476, R01AI058736] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [R01MH105203,
   R01MH105203, R01MH105203, R01MH105203, R01MH105203] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [R01DA015612, R01DA015612,
   R01DA015612, R01DA015612, R01DA015612, R01DA015612, R01DA015612,
   R01DA015612, R01DA015612, R01DA015612, R01DA015612, R01DA015612,
   R01DA015612, R01DA015612, R37DA015612, R01DA015612, R01DA015612] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (R01AI058736; R37AI093269), National Institute of
   Mental Health (R01MH105203), and National Institute on Drug Abuse
   (R01DA015612). The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the National
   Institutes of Health. PML, BG, and CJS acknowledge funding from the
   National Council of Technological and Scientific Development (CNPq) and
   the Research Funding Agency of the State of Rio de Janeiro (FAPERJ). RPW
   also acknowledges the support of the Massachusetts General Hospital
   Steve and Deborah Gorlin Research Scholar Award. ADP acknowledges the
   support of a sabbatical leave from the Yale School of Public Health and
   a visiting appointment - supported by a public grant overseen by the
   French National Research Agency (ANR) as part of the "Investissements
   d'Avenir" program within the framework of the Laboratory for
   Interdisciplinary Evaluation of Public Policies (LIEPP) center of
   excellence (ANR11LABX0091, ANR 11 IDEX000502) - at SciencesPo, Paris.
CR Anderson P, 2017, TFV DP DRIED BLOOD S
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   [Anonymous], 2014, 2014 ESP PREV AT HUM
   Arribas JR, 2008, JAIDS-J ACQ IMM DEF, V47, P74, DOI 10.1097/QAI.0b013e31815acab8
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Beyrer C, 2013, AIDS, V27, P2665, DOI 10.1097/01.aids.0000432449.30239.fe
   Brasil Departamento de DST, 2010, AIDS HEP VIR REC TER
   Brazilian Ministry of Health, 2016, 2016 HIV AIDS EP B
   Buchbinder SP, 2014, LANCET INFECT DIS, V14, P468, DOI 10.1016/S1473-3099(14)70025-8
   Carnegie NB, 2015, JAIDS-J ACQ IMM DEF, V69, P119, DOI 10.1097/QAI.0000000000000555
   Castro R, 2015, 10 INT C HIV TREATM
   Chirwa LI, 2014, AIDS, V28, P223, DOI 10.1097/QAD.0000000000000102
   Coelho L, 2016, LANCET HIV, V3, pE490, DOI 10.1016/S2352-3018(16)30052-2
   DATASUS, SIST GER TAB PROC SI
   Department of STDs AaVH, RESP DAT REQ DEP STD
   Desai K, 2008, AIDS, V22, P1829, DOI 10.1097/QAD.0b013e32830e00f5
   Elsesser SA, 2016, AIDS BEHAV, V20, P1400, DOI 10.1007/s10461-015-1238-0
   Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145
   Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108
   Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871
   Gandhi M, 2016, LANCET HIV, V3, pE521, DOI 10.1016/S2352-3018(16)30153-9
   Gomez GB, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001401
   Gomez GB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001323
   Government of Brazil  Ministry of Health (Ministerio da Saude), 2017, CLIN PROT THER GUID
   Grant RM, 2016, LANCET, V387, P1507, DOI 10.1016/S0140-6736(16)30125-8
   Grant RM, 2016, CURR OPIN HIV AIDS, V11, P3, DOI 10.1097/COH.0000000000000216
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Health BMo, RESP SIST INF CONS P
   Hoagland B, 2015, PREEXPOSURE PROPHYLA
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   Hoagland B, 2017, AIDS BEHAV, V21, P1278, DOI 10.1007/s10461-016-1516-5
   Juusola JL, 2012, ANN INTERN MED, V156, P541, DOI [10.7326/0003-4819-156-8-201204170-00001, 10.7326/0003-4819-156-8-201204170-00004]
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Laeyendecker O, 2015, J INFECT DIS, V212, P754, DOI 10.1093/infdis/jiv110
   Luz PM, 2015, JAIDS-J ACQ IMM DEF, V68, P152, DOI 10.1097/QAI.0000000000000426
   Ministerio da Saude, 2017, 1402017 MIN SAUD
   Mulligan K, 2015, CLIN INFECT DIS, V61, P572, DOI 10.1093/cid/civ324
   Neumann PJ, 2017, COST EFFECTIVENESS H, P496
   Pozniak AL, 2006, JAIDS-J ACQ IMM DEF, V43, P535
   Santos M, 2016, MED DECIS MAKING, V36, P253, DOI 10.1177/0272989X15613521
   Schackman BR, 2012, CURR OPIN HIV AIDS, V7, P587, DOI 10.1097/COH.0b013e3283582c8b
   Walensky RP, 2016, ANN INTERN MED, V165, P325, DOI 10.7326/M16-0799
   Walensky RP, 2013, NEW ENGL J MED, V369, P1715, DOI 10.1056/NEJMsa1214720
   World Health Organization, 2015, GUID START ANT THER
   World Health Organization, 2001, MACR HLTH INV HLTH E
NR 48
TC 6
Z9 6
U1 0
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD MAR
PY 2018
VL 21
IS 3
AR e25096
DI 10.1002/jia2.25096
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GB4BU
UT WOS:000429006000011
PM 29603888
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Caro-Vega, Y
   Belaunzaran-Zamudio, PF
   Crabtree-Ramirez, BE
   Shepherd, BE
   Grinsztejn, B
   Wolff, M
   Pape, JW
   Padgett, D
   Gotuzzo, E
   McGowan, CC
   Sierra-Madero, JG
AF Caro-Vega, Yanink
   Belaunzaran-Zamudio, Pablo F.
   Crabtree-Ramirez, Brenda E.
   Shepherd, Bryan E.
   Grinsztejn, Beatriz
   Wolff, Marcelo
   Pape, Jean W.
   Padgett, Denis
   Gotuzzo, Eduardo
   McGowan, Catherine C.
   Sierra-Madero, Juan G.
TI Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based
   Regimens in Antiretroviral-Naive Patients in the Caribbean and Central
   and South America
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE antiretroviral therapy; durability; HIV; Latin America; nonnucleoside
   reverse transcriptase inhibitor; protease inhibitor
ID INITIAL TREATMENT; LATIN-AMERICA; 7 SITES; THERAPY; OUTCOMES; INFECTION;
   MEXICO; LOPINAVIR/RITONAVIR; MORTALITY; RITONAVIR
AB Background. Efavirenz (EFV) and boosted protease inhibitors (bPIs) are still the preferred options for firstline antiretroviral regimens (firstline ART) in Latin America and have comparable short-term efficacy. We assessed the long-term durability and outcomes of patients receiving EFV or bPIs as firstline ART in the Caribbean, Central and South America network for HIV epidemiology (CCASAnet).
   Methods. We included ART-naive, HIV-positive adults on EFV or bPIs as firstline ART in CCASAnet between 2000 and 2016. We investigated the time from starting until ending firstline ART according to changes of third component for any reason, including toxicity and treatment failure, death, and/or loss to follow-up. Use of a third-line regimen was a secondary outcome. Kaplan-Meier estimators of composite end points were generated. Crude cumulative incidence of events and adjusted hazard ratios (aHRs) were estimated accounting for competing risk events.
   Results. We included 14 519 patients: 12 898 (89%) started EFV and 1621 (11%) bPIs. The adjusted median years on firstline ART were 4.6 (95% confidence interval [CI], 4.4-4.7) on EFV and 3.8 (95% CI, 3.8-4.0) on bPI (P<.001). Cumulative incidence of firstline ART ending at 10 years of follow-up was 32% (95% CI, 31-33) on EFV and 44% (95% CI, 39-48) on bPI (aHR, 0.88; 95% CI, 0.78-0.97). The cumulative incidence rates of third-line initiation in the bPI-based group were 6% (95% CI, 2.4-9.6) and 2% (95% CI, 1.4-2.2) among the EFV-based group (P<.01).
   Conclusions. Durability of firstline ART was longer with EFV than with bPIs. EFV-based regimens may continue to be the preferred firstline regimen for our region in the near future due to their high efficacy, relatively low toxicity (especially at lower doses), existence of generic formulations, and affordability for national programs.
C1 [Caro-Vega, Yanink; Belaunzaran-Zamudio, Pablo F.; Crabtree-Ramirez, Brenda E.; Sierra-Madero, Juan G.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Mexico City, DF, Mexico.
   [Shepherd, Bryan E.; McGowan, Catherine C.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Wolff, Marcelo] Univ Chile, Fdn Arriaran, Sch Med, Santiago, Chile.
   [Pape, Jean W.] Les Ctr GHESKIO, Port Au Prince, Haiti.
   [Pape, Jean W.] Weill Cornell Med Coll, New York, NY USA.
   [Padgett, Denis] Inst Hondureno Seguridad Social, Tegucigalpa, Honduras.
   [Gotuzzo, Eduardo] Inst Med Trop Alexander von Humboldt, Lima, Peru.
RP Sierra-Madero, JG (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Vasco de Quiroga 15, Cdmx 14080, Mexico.
EM jsmadero@yahoo.com
RI Belaunzaran-Zamudio, Pablo F./T-4218-2019; Belaunzaran-Zamudio, Pablo
   Francisco/T-4085-2019
OI Belaunzaran, Pablo/0000-0003-4775-4734; Crabtree-Ramirez,
   Brenda/0000-0002-2587-1123
FU National Institutes of Heatlh [U01AI069923]; Eunice Kennedy Shriver
   National Institute of Child Health and Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); Office of The Director (OD),
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Institute of
   Allergy and Infectious Diseases (NIAID)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID); National
   Cancer Institute (NCI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); National Institute of Mental Health (NIMH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH); NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069421,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, UM1AI069421, UM1AI069421, UM1AI069476,
   U01AI069923, U01AI069923, UM1AI069476, UM1AI069421, U01AI069923,
   U01AI069923, UM1AI069421, U01AI069923, UM1AI069476, UM1AI069476,
   U01AI069923, U01AI069923, UM1AI069421, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, UM1AI069421, U01AI069923, UM1AI069421,
   U01AI069923, U01AI069923, UM1AI069476, UM1AI069476, UM1AI069476,
   U01AI069923, UM1AI069476, UM1AI069421, U01AI069923, UM1AI069476] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institutes of Heatlh-funded
   Caribbean, Central and South America network for HIV epidemiology
   (CCASAnet), a member cohort of the International Epidemiologic Databases
   to Evaluate AIDS (leDEA; U01AI069923). This award is funded by the
   following institutes: Eunice Kennedy Shriver National Institute of Child
   Health and Human Development (NICHD), Office of The Director (OD),
   National Institutes of Health, National Institute of Allergy and
   Infectious Diseases (NIAID), National Cancer Institute (NCI), and the
   National Institute of Mental Health (NIMH).
CR Amin J, 2015, LANCET INFECT DIS, V15, P793, DOI 10.1016/S1473-3099(15)70060-5
   Angriman F, 2016, INT J STD AIDS, V27, P118, DOI 10.1177/0956462415575621
   Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607
   Borges AH, 2016, CLIN INFECT DIS, V63, P268, DOI 10.1093/cid/ciw236
   Caro JJ, 2001, PHARMACOECONOMICS, V19, P95, DOI 10.2165/00019053-200119010-00007
   Celi AP, 2016, J INT AIDS SOC S, V19, P35
   CENSIDA, GUIA MAN ANT PERS CO
   Cesar C, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20684
   Cesar C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106887
   Cesar C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010490
   Crabtree-Ramirez B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020272
   Daar ES, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00316
   Echeverria P, 2010, ANTIVIR RES, V85, P403, DOI 10.1016/j.antiviral.2009.11.008
   Esposito A, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-341
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Hernan MA, 2012, CLIN TRIALS, V9, P48, DOI 10.1177/1740774511420743
   Juday T, 2011, AIDS CARE, V23, P1154, DOI 10.1080/09540121.2010.543884
   Magis-Rodriguez CL, 2015, SALUD PUBLICA MEXICO, V57, pS127
   Lopez-Martinez A, 2012, JAIDS-J ACQ IMM DEF, V59, P155, DOI 10.1097/QAI.0b013e31823ff035
   Ministerio da Saude, REC TER ANT AD INF P
   Ministerio de Salud, NORM TECN TRAT ANT G
   Ministerio de Salud, MAN PAC AD CON INF V
   MINSAL, GUIA CLIN SINDR INM
   Miro JM, 2010, AIDS RES HUM RETROV, V26, P747, DOI 10.1089/aid.2009.0105
   MSPP, MAN NORM PRIS CHARG
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   SADI, CONS ARG TER ANT 201
   Sierra-Madero J, 2010, JAIDS-J ACQ IMM DEF, V53, P582, DOI 10.1097/QAI.0b013e3181cae4a1
   Tuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
   WHO, TRANS NEW ANT HIV PR
   WHO, US ANT DRUGS TREAT P
   Wolff M, 2016, JAIDS-J ACQ IMM DEF, V71, P102, DOI 10.1097/QAI.0000000000000817
NR 34
TC 4
Z9 4
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD MAR
PY 2018
VL 5
IS 3
AR UNSP ofy004
DI 10.1093/ofid/ofy004
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA GC0EN
UT WOS:000429449800001
PM 29527539
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Hoagland, B
   Moreira, RI
   Kallas, EG
   Madruga, JV
   Goulart, S
   Leite, IC
   Freitas, L
   Martins, LMS
   Torres, TS
   Vasconcelos, R
   De Boni, RB
   Anderson, PL
   Liu, A
   Luz, PM
   Veloso, VG
AF Grinsztejn, Beatriz
   Hoagland, Brenda
   Moreira, Ronaldo I.
   Kallas, Esper G.
   Madruga, Jose V.
   Goulart, Silvia
   Leite, Iuri C.
   Freitas, Lucilene
   Martins, Luana M. S.
   Torres, Thiago S.
   Vasconcelos, Ricardo
   De Boni, Raquel B.
   Anderson, Peter L.
   Liu, Albert
   Luz, Paula M.
   Veloso, Valdilea G.
CA PrEP Brasil Study Team
TI Retention, engagement, and adherence to pre-exposure prophylaxis for men
   who have sex with men and transgender women in PrEP Brasil: 48 week
   results of a demonstration study
SO LANCET HIV
LA English
DT Article
ID DRIED BLOOD SPOTS; TENOFOVIR-DIPHOSPHATE; HIV-INFECTION; EMTRICITABINE;
   VALIDITY; RISK
AB Background PrEP Brasil was a demonstration study to assess feasibility of daily oral tenofovir diphosphate disoproxil fumarate plus emtricitabine provided at no cost to men who have sex with men (MSM) and transgender women at high risk for HIV within the Brazilian public health system. We report week 48 pre-exposure prophylaxis (PrEP) retention, engagement, and adherence, trends in sexual behaviour, and incidence of HIV and sexually transmitted infections in this study cohort.
   Methods PrEP Brasil was a 48 week, open-label, demonstration study that assessed PrEP delivery at three referral centres for HIV prevention and care in Rio de Janeiro, Brazil (Fundacao Oswaldo Cruz), and Sao Paulo, Brazil (Universidade de Sao Paulo and Centro de Referencia e Treinamento em DST e AIDS). Eligible participants were MSM and transgender women who were HIV negative, aged at least 18 years, resident in Rio de Janeiro or Sao Paulo, and reported one or more sexual risk criteria in the previous 12 months (eg, condomless anal sex with two or more partners, two or more episodes of anal sex with an HIV-infected partner, or history of sexually transmitted infection [STI] diagnosis). Participants were seen at weeks 4, 12, 24, 36, and 48 for PrEP provision, clinical and laboratory evaluation, and HIV testing. Computer-assisted self-interviews were also done at study visits 12, 24, 36, and 48, and assessed sexual behaviour and drug use. PrEP retention was defined by attendance at the week 48 visit, PrEP engagement was an ordinal five-level variable combining presence at the study visit and drug concentrations, and PrEP adherence was evaluated by measuring tenofovir diphosphate concentrations in dried blood spots. Logistic regression models were used to quantify the association of variables with high adherence (>= 4 doses per week). The study is registered with ClinicalTrials. gov, number NCT01989611.
   Findings Between April 1, 2014, and July 8, 2016, 450 participants initiated PrEP, 375 (83%) of whom were retained until week 48. At week 48, 277 (74%) of 375 participants had protective drug concentrations consistent with at least four doses per week: 183 (82%) of 222 participants from Sao Paulo compared with 94 (63%) of 150 participants from Rio de Janeiro (adjusted odds ratio 1.88, 95% CI 1.06-3.34); 119 (80%) of 148 participants who reported sex with HIV-infected partners compared with 158 (70%) of 227 participants who did not (1.78, 1.03-3.08); 67 (87%) of 77 participants who used stimulants compared with 210 (71%) of 298 participants who did not (2.23, 1.02-4.92); and 232 (80%) of 289 participants who had protective concentrations of tenofovir disphosphate at week 4 compared with 42 (54%) of 78 participants who did not (3.28, 1.85-5.80). Overall, receptive anal sex with the last three partners increased from 45% at enrolment to 49% at week 48 (p=0.17), and the mean number of sexual partners in the previous 3 months decreased from 11.4 (SD 28.94) at enrolment to 8.3 (19.55) at week 48 (p<0.0013). Two individuals seroconverted during follow-up (HIV incidence 0.51 per 100 person-years, 95% CI 0.13-2.06); both of these patients had undetectable tenofovir concentrations at seroconversion.
   Interpretation Our results support the effectiveness and feasibility of PrEP in a real-world setting. Offering PrEP at public health-care clinics in a middle-income setting can retain high numbers of participants and achieve high levels of adherence without risk compensation in the investigated populations.
C1 [Grinsztejn, Beatriz; Hoagland, Brenda; Moreira, Ronaldo I.; Freitas, Lucilene; Martins, Luana M. S.; Torres, Thiago S.; De Boni, Raquel B.; Luz, Paula M.; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, BR-22461 Rio De Janeiro, Brazil.
   [Kallas, Esper G.; Vasconcelos, Ricardo] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Madruga, Jose V.; Goulart, Silvia] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Leite, Iuri C.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil.
   [Anderson, Peter L.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus, Aurora, CO USA.
   [Liu, Albert] Bridge HIV, San Francisco Dept Publ Hlth, San Francisco, CA USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, BR-22461 Rio De Janeiro, Brazil.
EM beatriz.grinsztejn@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Vasconcelos,
   Ricardo/AAL-4634-2020; TORRES, THIAGO SILVA/D-6548-2014
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Vasconcelos,
   Ricardo/0000-0002-9753-0563; TORRES, THIAGO SILVA/0000-0002-2557-601X;
   Moreira, Carlos Henrique Valente/0000-0002-4187-5482; Luz,
   Paula/0000-0001-9746-719X; Kallas, Esper/0000-0003-2026-6925; PRADO,
   GLADYS/0000-0001-8833-3368
FU Brazilian Ministry of Health; Conselho Nacional de Desenvolvimento
   Cientifico e TecnologicoNational Council for Scientific and
   Technological Development (CNPq); Secretaria de Vigilancia em Saude;
   Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   JaneiroCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX Brazilian Ministry of Health, Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Secretaria de Vigilancia em Saude, Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro,
   and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo.
CR Allison P. D., 2012, LOGISTIC REGRESSION
   Anderson P, 2017, C RETR OPP INF 2017
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Barbosa A, 2009, CAD SAUDE PUBLICA, V25, P727, DOI 10.1590/S0102-311X2009000400003
   Brasil. Ministerio da Saude (MS), 2016, B EP HIV AIDS
   Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/AID.2012.0089, 10.1089/aid.2012.0089]
   Curran K, 2013, AIDS BEHAV, V17, P2977, DOI 10.1007/s10461-013-0510-4
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4
   Division of AIDS National Institute of Allergy and Infectious Diseases, 2004, DIVISION AIDS TABLE
   Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   Hosek SG, 2017, JAIDS-J ACQ IMM DEF, V74, P21, DOI 10.1097/QAI.0000000000001179
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C
   Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6
   Liu A, 2017, ADHERENCE 2017
   Liu A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001613
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
   Luz PM, 2016, 21 INT AIDS C DURB S
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Osorio FD, 2009, PERSPECT PSYCHIATR C, V45, P216, DOI 10.1111/j.1744-6163.2009.00224.x
   Tangmunkongvorakul A, 2013, AIDS CARE, V25, P961, DOI 10.1080/09540121.2012.748871
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
   Zheng JH, 2016, J PHARMACEUT BIOMED, V122, P16, DOI 10.1016/j.jpba.2016.01.038
NR 29
TC 37
Z9 37
U1 2
U2 17
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD MAR
PY 2018
VL 5
IS 3
BP E136
EP E145
DI 10.1016/S2352-3018(18)30008-0
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FZ2PK
UT WOS:000427422000009
PM 29467098
DA 2020-11-24
ER

PT J
AU Adachi, K
   Xu, JH
   Yeganeh, N
   Camarca, M
   Morgado, MG
   Watts, DH
   Mofenson, LM
   Veloso, VG
   Pilotto, JH
   Joao, E
   Gray, G
   Theron, G
   Santos, B
   Fonseca, R
   Kreitchmann, R
   Pinto, J
   Mussi-Pinhata, MM
   Ceriotto, M
   Machado, DM
   Bryson, YJ
   Grinsztejn, B
   Moye, J
   Klausner, JD
   Bristow, CC
   Dickover, R
   Mirochnick, M
   Nielsen-Saines, K
AF Adachi, Kristina
   Xu, Jiahong
   Yeganeh, Nava
   Camarca, Margaret
   Morgado, Mariza G.
   Watts, D. Heather
   Mofenson, Lynne M.
   Veloso, Valdilea G.
   Pilotto, Jose Henrique
   Joao, Esau
   Gray, Glenda
   Theron, Gerhard
   Santos, Breno
   Fonseca, Rosana
   Kreitchmann, Regis
   Pinto, Jorge
   Mussi-Pinhata, Marisa M.
   Ceriotto, Mariana
   Machado, Daisy Maria
   Bryson, Yvonne J.
   Grinsztejn, Beatriz
   Moye, Jack
   Klausner, Jeffrey D.
   Bristow, Claire C.
   Dickover, Ruth
   Mirochnick, Mark
   Nielsen-Saines, Karin
CA NICHD HPTN 040 Study Team
TI Combined evaluation of sexually transmitted infections in HIV-infected
   pregnant women and infant HIV transmission
SO PLOS ONE
LA English
DT Article
ID CONGENITAL CYTOMEGALOVIRUS-INFECTION; HUMAN-IMMUNODEFICIENCY-VIRUS;
   CHLAMYDIA-TRACHOMATIS INFECTION; GENITAL-TRACT INFECTIONS; TO-CHILD
   TRANSMISSION; PERINATAL TRANSMISSION; RISK; SYPHILIS; DISEASES;
   CHORIOAMNIONITIS
AB Background
   Sexually transmitted infections (STIs) including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Treponema pallidum (TP), and cytomegalovirus (CMV) may lead to adverse pregnancy and infant outcomes. The role of combined maternal STIs in HIV mother-to-child transmission (MTCT) was evaluated in mother-infant pairs from NICHD HPTN 040.
   Methodology
   Urine samples from HIV-infected pregnant women during labor were tested by polymerase chain reaction (PCR) for CT, NG, and CMV. Infant HIV infection was determined by serial HIV DNA PCR testing. Maternal syphilis was tested by VDRL and confirmatory treponemal antibodies.
   Results
   A total of 899 mother-infant pairs were evaluated. Over 30% had at least one of the following infections (TP, CT, NG, and/or CMV) detected at the time of delivery. High rates of TP (8.7%), CT (17.8%), NG (4%), and CMV (6.3%) were observed. HIV MTCT was 9.1% (n = 82 infants). HIV MTCT was 12.5%, 10.3%, 11.1%, and 26.3% among infants born to women with CT, TP, NG or CMV respectively. Forty-two percent of HIV-infected infants were born to women with at least one of these 4 infections. Women with these infections were nearly twice as likely to have an HIV-infected infant (aOR 1.9, 95% CI 1.1-3.0), particularly those with 2 STIs (aOR 3.4, 95% CI 1.5-7.7). Individually, maternal CMV (aOR 4.4 1.5-13.0) and infant congenital CMV (OR 4.1, 95% CI 2.2-7.8) but not other STIs (TP, CT, or NG) were associated with an increased risk of HIV MTCT.
   Conclusion
   HIV-infected pregnant women identified during labor are at high risk for STIs. Co-infection with STIs including CMV nearly doubles HIV MTCT risk. CMV infection appears to confer the largest risk of HIV MTCT.
C1 [Adachi, Kristina; Yeganeh, Nava; Bryson, Yvonne J.; Klausner, Jeffrey D.; Nielsen-Saines, Karin] David Geffen UCLA Sch Med, Los Angeles, CA 90095 USA.
   [Xu, Jiahong; Camarca, Margaret] Westat Corp, Rockville, MD USA.
   [Morgado, Mariza G.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, RJ, Brazil.
   [Watts, D. Heather] US Dept State, Off Global AIDS Coordinator, Washington, DC 20520 USA.
   [Mofenson, Lynne M.] Elizabeth Glaser Pediat AIDS Fdn, Washington, DC USA.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Nova Iguacu, RJ, Brazil.
   [Joao, Esau] Hosp Fed Servidores Estado, Rio De Janeiro, RJ, Brazil.
   [Gray, Glenda] Univ Witwatersrand, SAMRC & Perinatal HIV Res Unit, Johannesburg, South Africa.
   [Theron, Gerhard] Stellenbosch Univ, Tygerberg Hosp, Cape Town, South Africa.
   [Santos, Breno] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Fonseca, Rosana] Hosp Femina, Porto Alegre, RS, Brazil.
   [Kreitchmann, Regis] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Sao Paulo, Brazil.
   [Ceriotto, Mariana] Fdn Maternal & Infant Hlth FUNDASAMIN, Buenos Aires, DF, Argentina.
   [Machado, Daisy Maria] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Moye, Jack] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
   [Klausner, Jeffrey D.] UCLA, Fielding Sch Publ Hlth, Los Angeles, CA USA.
   [Bristow, Claire C.] UCSD Sch Med, La Jolla, CA USA.
   [Dickover, Ruth] UC Davis Sch Med, Davis, CA USA.
   [Mirochnick, Mark] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Adachi, K (corresponding author), David Geffen UCLA Sch Med, Los Angeles, CA 90095 USA.
EM kadachi@mednet.ucla.edu
RI Pinto, Jorge A/D-1743-2014; Mofenson, Lynne/P-9631-2019; Pilotto, Jose
   Henrique/AAD-9773-2019; Mussi-Pinhata, Marisa M/G-6568-2012
OI Pinto, Jorge A/0000-0003-2987-3238; Mofenson, Lynne/0000-0002-2818-9808;
   Pilotto, Jose Henrique/0000-0003-0521-8597; Mussi-Pinhata, Marisa
   M/0000-0001-8985-1570; Kreitchmann, Regis/0000-0002-1146-0497; Joao,
   Esau/0000-0002-2412-0627; Machado, Daisy/0000-0003-1993-6442
FU NICHD (NICHD) [HHSN267200800001C, N01-HD-8-0001]; (Brazilian AIDS
   Prevention Trials International Network), NIAID/ NIH [U01 AI047986];
   National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01 AI068632, UM1AI068632, UM1AI068616, UM1AI106716];
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD);
   National Institute of Mental Health (NIMH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [AI068632]; Boehringer
   Ingelheim Pharmaceuticals Inc. (BIPI)Boehringer Ingelheim;
   GlaxoSmithKline, on behalf of ViiV Healthcare; Cepheid for the testing
   of CT; NG in a prior HPTN [040]; UCLA Children's Discovery and
   Innovation Institute (CDI) through the Harry Winston Fellowship Award;
   UCLA AIDS Institute; UCLA Center for AIDS Research (CFAR) NIH/
   NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI02869, AI28697]; UCLA Pediatric AIDS
   Coalition, and Westat; NIH/NICHDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [HHSN275201300003C]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [K23AI118584, UM1AI068632,
   UM1AI068632, K23AI118584, UM1AI069476, UM1AI068632, K23AI118584,
   UM1AI069476, UM1AI068632, UM1AI069476, UM1AI068632, UM1AI069476,
   UM1AI069453, K23AI118584, UM1AI069476, K23AI118584, UM1AI068632,
   UM1AI069476, UM1AI069453, UM1AI068632, UM1AI069476, UM1AI069476,
   UM1AI068632, UM1AI068632, UM1AI069453, UM1AI069476, UM1AI068632,
   UM1AI069453] Funding Source: NIH RePORTER
FX The NICHD HPTN 040 study was supported by NICHD Contract
   #HHSN267200800001C (NICHD Control # N01-HD-8-0001) and U01 AI047986
   (Brazilian AIDS Prevention Trials International Network), NIAID/ NIH.
   Overall support for the International Maternal Pediatric Adolescent AIDS
   Clinical Trials Group (IMPAACT) was provided by the National Institute
   of Allergy and Infectious Diseases (NIAID) U01 AI068632, UM1AI068632
   (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC),
   with co-funding from the Eunice Kennedy Shriver National Institute of
   Child Health and Human Development (NICHD) and the National Institute of
   Mental Health (NIMH) AI068632. The original parent study was supported
   in part by Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), and
   GlaxoSmithKline, on behalf of ViiV Healthcare and support was also
   received from Cepheid for the testing of CT and NG in a prior HPTN 040
   sub-study. Support was also provided by the UCLA Childrens Discovery and
   Innovation Institute (CDI) through the Harry Winston Fellowship Award,
   the UCLA AIDS Institute, the UCLA Center for AIDS Research (CFAR)
   NIH/NIAID AI02869 and AI28697, the UCLA Pediatric AIDS Coalition, and
   Westat contract with NIH/NICHD HHSN275201300003C. The content,
   conclusions and opinions expressed in this article are those of the
   authors and do not necessarily represent those of the National
   Institutes of Health, the U.S. Department of Health and Human Services,
   or the U.S. Department of State, affiliated universities, programs or
   companies. Co-authors Margaret Camarca and Jiahong Xu were employed by
   Westat. Westat provided support in the form of salary for the co-authors
   MC and JX but did not have any additional role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The authors, themselves, did play a role in the study
   design, data collection, analysis, preparation of the manuscript. The
   specific roles of these authors to the study are articulated in the
   author contributions section.
CR Adachi K, 2017, CLIN INFECT DIS, V65, P405, DOI 10.1093/cid/cix222
   Adachi K, 2015, SEX TRANSM DIS, V42, P554, DOI 10.1097/OLQ.0000000000000340
   Adler SP, 2007, SEMIN PERINATOL, V31, P10, DOI 10.1053/j.semperi.2007.01.002
   Cannon MJ, 2011, REV MED VIROL, V21, P240, DOI 10.1002/rmv.695
   Chaisilwattana P, 1997, SEX TRANSM DIS, V24, P495, DOI 10.1097/00007435-199710000-00001
   Chen KT, 2005, OBSTET GYNECOL, V106, P1341, DOI 10.1097/01.AOG.0000185917.90004.7c
   Chi BH, 2006, AM J OBSTET GYNECOL, V194, P174, DOI 10.1016/j.ajog.2005.06.081
   CONBOY TJ, 1987, J PEDIATR-US, V111, P343, DOI 10.1016/S0022-3476(87)80451-1
   Drake AL, 2007, OBSTET GYNECOL, V109, P403, DOI 10.1097/01.AOG.0000251511.27725.5c
   Ellington SR, 2016, J INFECT DIS, V213, P891, DOI 10.1093/infdis/jiv549
   Fawzi W, 2001, AIDS, V15, P1157, DOI 10.1097/00002030-200106150-00011
   Ghys PD, 1997, AIDS, V11, pF85, DOI 10.1097/00002030-199712000-00001
   Glasier A, 2006, LANCET, V368, P1595, DOI 10.1016/S0140-6736(06)69478-6
   Goldenberg RL, 1998, LANCET, V352, P1927, DOI 10.1016/S0140-6736(98)04453-5
   Goldenberg RL, 2006, AM J OBSTET GYNECOL, V195, P1065, DOI 10.1016/j.ajog.2006.05.046
   Gray RH, 2001, AM J OBSTET GYNECOL, V185, P1209, DOI 10.1067/mob.2001.118158
   Hammerschlag MR, 2011, CLIN INFECT DIS, V53, pS99, DOI 10.1093/cid/cir699
   ISTAS AS, 1995, CLIN INFECT DIS, V20, P665, DOI 10.1093/clinids/20.3.665
   Ivarsson SA, 2003, J PEDIATR ENDOCR MET, V16, P1233
   Johnson EL, 2016, CURR OPIN INFECT DIS, V29, P248, DOI 10.1097/QCO.0000000000000267
   Johnson EL, 2015, J INFECT DIS, V211, P187, DOI 10.1093/infdis/jiu424
   Johnson LF, 2008, SEX TRANSM DIS, V35, P946, DOI 10.1097/OLQ.0b013e3181812d15
   Kaul R, 2008, J REPROD IMMUNOL, V77, P32, DOI 10.1016/j.jri.2007.02.002
   Khamduang W, 2011, JAIDS-J ACQ IMM DEF, V58, P188, DOI [10.1097/QAI.0B013E31822D0433, 10.1097/QAI.0b013e31822d0433]
   King CC, 2013, CURR HIV RES, V11, P10
   LeFevre ML, 2014, ANN INTERNAL MED
   Lurain NS, 2004, J INFECT DIS, V190, P619, DOI 10.1086/422533
   Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12
   Maupin R Jr, 2004, J Matern Fetal Neonatal Med, V16, P45
   Mayaud P, 2004, SEX TRANSM INFECT, V80, P174, DOI 10.1136/sti.2002.004101
   McClelland RS, 2001, AIDS, V15, P105, DOI 10.1097/00002030-200101050-00015
   Mwaanza N, 2013, CLIN INFECT DIS OFFI
   Mwanyumba F, 2002, J ACQ IMMUN DEF SYND, V29, P262, DOI 10.1097/00126334-200203010-00006
   Nielsen-Saines K, 2013, INCREASED CMV COINFE
   Nielsen-Saines K, 2012, NEW ENGL J MED, V366, P2368, DOI 10.1056/NEJMoa1108275
   Rotchford K, 2000, SEX TRANSM DIS, V27, P243, DOI 10.1097/00007435-200005000-00001
   Silveira MF, 2010, INT J STD AIDS, V21, P367, DOI 10.1258/ijsa.2010.009559
   Silveira MF, 2009, INT J STD AIDS, V20, P465, DOI 10.1258/ijsa.2008.008388
   Sullivan EA, 2004, INT J STD AIDS, V15, P116, DOI 10.1258/095646204322764316
   Taha TE, 2006, AIDS, V20, P1313, DOI 10.1097/01.aids.0000232240.05545.08
   Taha TE, 2000, ANN NY ACAD SCI, V918, P84
   Wabwire-Mangen F, 1999, J ACQ IMMUN DEF SYND, V22, P379
   Walker DG, 2002, LANCET INFECT DIS, V2, P432, DOI 10.1016/S1473-3099(02)00319-5
   Walker GJA, 2007, SEMIN FETAL NEONAT M, V12, P198, DOI 10.1016/j.siny.2007.01.019
   Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3
   WHO, 2012, GLOB INC PREV SEL CU
   Woods Charles R, 2005, Semin Pediatr Infect Dis, V16, P258, DOI 10.1053/j.spid.2005.06.006
   Woods Charles R, 2005, Semin Pediatr Infect Dis, V16, P245
   Woods CR, 2009, PEDIATR INFECT DIS J, V28, P536, DOI 10.1097/INF.0b013e3181ac8a69
   Workowski Kimberly A., 2010, Morbidity and Mortality Weekly Report, V59, P1
   World Health Organization, 2006, GLOB STRAT PREV CONT
   Yamamoto AY, 2013, EPIDEMIOL INFECT, V141, P2187, DOI 10.1017/S0950268812002695
   Yeganeh N, 2015, PEDIATR INFECT DIS J, V34, pE52, DOI 10.1097/INF.0000000000000578
NR 53
TC 11
Z9 13
U1 2
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 5
PY 2018
VL 13
IS 1
AR e0189851
DI 10.1371/journal.pone.0189851
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FR9OU
UT WOS:000419403800025
PM 29304083
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU de Oliveira, RDC
   Shimakura, SE
   Campos, DP
   Hokerberg, YHM
   Victoriano, FP
   Ribeiro, S
   Veloso, VG
   Grinsztejn, B
   Carvalho, MS
AF Carvalhaes de Oliveira, Raquel de Vasconcellos
   Shimakura, Silvia Emiko
   Campos, Dayse Pereira
   Marques Hokerberg, Yara Hahr
   Victoriano, Flaviana Pavan
   Ribeiro, Sayonara
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Carvalho, Marilia Sa
TI Effects of antiretroviral treatment and nadir CD4 count in progression
   to cardiovascular events and related comorbidities in a HIV Brazilian
   cohort: a multi-stage approach
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE Cardiovascular events; progression; HIV/AIDS; multi-stage model; cohort
   study
ID ACUTE MYOCARDIAL-INFARCTION; COMPETING RISKS; DISEASE; INFECTION;
   MODELS; THERAPY; INDIVIDUALS; POPULATION; INHIBITORS; SURVIVAL
AB The use of highly active antiretroviral therapy has resulted in changes of comorbidity profile in people living with HIV (PLHIV), increasing non-AIDS-related events. The occurrence of cardiovascular events is greater in PLHIV, but the mechanism responsible for it is still controversial. This article aimed to investigate factors associated with the progression to cardiovascular events in PLHIV using HAART. A 15-years cohort study with 1135 PLHIV was conducted in Rio de Janeiro-Brazil. Clinical progression was stratified in five states: No comorbidities (s(1)), arterial hypertension (s(2)), lipid abnormalities (s(3)), hypertension and lipid abnormalities (s(4)) and major cardiovascular events (stroke, coronary artery disease, thrombosis or death) (s(5)). Semi-Markov models evaluated the effects of cardiovascular traditional factors, treatment and clinical covariates on transitions between these states. Hazard Ratios (HR) and 95% confidence intervals (CI) were provided. In addition to traditional factors (age, sex, educational level and skin color), the development of one comorbidity (lipid abnormalities or hypertension) increased in patients with low nadir CD4 (<50 cells/mm(3)), (HR=1.59, CI 1.11-2.28 and 1.36, CI 1.11-1.66, respectively). The risk to experience a second comorbidity (s(3)s(4)) increased 75% with low nadir CD4. Age was the only factor that increased the risk of major cardiovascular events once having lipid abnormalities with or without hypertension (s(3),s(4)s(5)). The prolonged use of certain antiretroviral drugs (abacavir, didanosine, ritonavir, lopinavir, amprenavir and fosamprenavir) increased the risk of direct transition (s(1)s(5)) to major cardiovascular events (HR=5.29, CI 1.16-24.05). This analysis suggests that prolonged use of certain antiretroviral drugs led directly to major cardiovascular events, while low nadir CD4 only affected the occurrence of lipid abnormalities and hypertension. Management strategies, including rational use of complex exams (such as, computed-tomography angiography), statins and antihypertensives, should be developed based on the distinct roles of antiretroviral use and of HIV infection itself on the progression to cardiovascular events.
C1 [Carvalhaes de Oliveira, Raquel de Vasconcellos; Campos, Dayse Pereira; Marques Hokerberg, Yara Hahr; Victoriano, Flaviana Pavan; Ribeiro, Sayonara; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Shimakura, Silvia Emiko] Univ Fed Parana, Setor Ciencias Exatas, Curitiba, Parana, Brazil.
   [Carvalho, Marilia Sa] Fundacao Oswaldo Cruz, Programa Comp Cient, Rio De Janeiro, RJ, Brazil.
RP de Oliveira, RDC (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Lab Epidemiol Clin, Ave Brasil 4365, Rio De Janeiro, RJ, Brazil.
EM raquel.vasconcellos@ini.fiocruz.br
RI CARVALHO, MARILIA/AAD-8283-2020; hokerberg, yara/K-2880-2016; Oliveira,
   Raquel de V C de/S-7443-2016
OI CARVALHO, MARILIA/0000-0002-9566-0284; hokerberg,
   yara/0000-0001-7140-7172; Shimakura, Silvia/0000-0002-5468-2516;
   Oliveira, Raquel de V C de/0000-0001-9387-8645
CR Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2
   Andersen PK, 2002, STAT METHODS MED RES, V11, P203, DOI 10.1191/0962280202sm281ra
   Arildsen H, 2013, HIV MED, V14, P1, DOI 10.1111/j.1468-1293.2012.01027.x
   Brasil. Ministerio da Saude, 2008, REC TER ANT AD INF P
   Brignol S, 2015, CAD SAUDE PUBLICA, V31, P1035, DOI 10.1590/0102-311X00178313
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   de Oliveira RDC, 2013, CAD SAUDE PUBLICA, V29, P801, DOI 10.1590/S0102-311X2013000400017
   Core Team R, 2015, R LANG ENV STAT COMP
   de Wreede LC, 2011, J STAT SOFTW, V38, P1
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   Feinstein MJ, 2016, AM J CARDIOL, V117, P214, DOI 10.1016/j.amjcard.2015.10.030
   Foucher Y, 2005, BIOMETRICAL J, V47, P825, DOI 10.1002/bimj.200410170
   Gomo ZAR, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-32
   Albuquerque VMG, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-274
   Huzurbazar AV, 2005, FLOWGRAPH MODELS MUL
   Islam FM, 2012, HIV MED, V13, P453, DOI 10.1111/j.1468-1293.2012.00996.x
   Josephson F, 2010, J INTERN MED, V268, P530, DOI 10.1111/j.1365-2796.2010.02301.x
   Kousignian I, 2003, JAIDS-J ACQ IMM DEF, V34, P50, DOI 10.1097/00126334-200309010-00007
   Lawless JF, 2015, LIFETIME DATA ANAL, V21, P160, DOI 10.1007/s10985-014-9310-z
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Malta M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1530-y
   Martin-Iguacel R, 2015, CURR HIV-AIDS REP, V12, P375, DOI 10.1007/s11904-015-0284-6
   Mathieu E, 2007, METHODOL COMPUT APPL, V9, P389, DOI 10.1007/s11009-007-9033-7
   Nam S, 2016, J CLIN HYPERTENS, V18, P572, DOI 10.1111/jch.12714
   Negredo E, 2010, CLIN INFECT DIS, V50, P1300, DOI 10.1086/651689
   Paisible AL, 2015, JAIDS-J ACQ IMM DEF, V68, P209, DOI 10.1097/QAI.0000000000000419
   Reyskens KMSE, 2014, BBA-MOL BASIS DIS, V1842, P256, DOI 10.1016/j.bbadis.2013.11.019
   Sabin CA, 2008, LANCET, V371, P1417, DOI 10.1016/S0140-6736(08)60423-7
   Santos IS, 2015, ARTERIOSCL THROM VAS, V35, P2054, DOI 10.1161/ATVBAHA.115.305765
   Titman AC, 2010, STAT METHODS MED RES, V19, P621, DOI 10.1177/0962280209105541
   Trevillyan JM, 2015, AIDS, V29, P2309, DOI 10.1097/QAD.0000000000000848
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   Triant VA, 2012, J INFECT DIS, V205, pS355, DOI 10.1093/infdis/jis195
   Wang SA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017326
   World Health Organization, 2006, ANT THER HIV INF AD
   Zanni MV, 2014, AIDS, V28, P2061, DOI 10.1097/QAD.0000000000000360
NR 36
TC 3
Z9 3
U1 0
U2 3
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0954-0121
EI 1360-0451
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PY 2018
VL 30
IS 5
BP 551
EP 559
DI 10.1080/09540121.2017.1391984
PG 9
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychology, Multidisciplinary; Respiratory System; Social Sciences,
   Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychology; Respiratory System; Biomedical Social Sciences
GA GA1QZ
UT WOS:000428093200003
PM 29058481
DA 2020-11-24
ER

PT J
AU Jalil, EM
   Luz, PM
   Quintana, M
   Friedman, RK
   Madeira, RMDS
   Andrade, AC
   Chicarino, J
   Moreira, RI
   Derrico, M
   Levi, JE
   Russomano, F
   Veloso, VG
   Grinsztejn, B
AF Jalil, Emilia Moreira
   Luz, Paula M.
   Quintana, Marcel
   Friedman, Ruth Khalili
   Madeira, Rosa M. Domingues S.
   Andrade, Angela Cristina
   Chicarino, Janice
   Moreira, Ronaldo Isrnerio
   Derrico, Monica
   Levi, Jose Eduardo
   Russomano, Fabio
   Veloso, Valdilea Goncalves
   Grinsztejn, Beatriz
TI Hybrid capture as a tool for cervical lesions screening in HIV-infected
   women: insights from a Brazilian cohort
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HPV; HIV; Women; Cohort; Incidence
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SQUAMOUS INTRAEPITHELIAL LESIONS;
   HUMAN-PAPILLOMAVIRUS INFECTION; SEROPOSITIVE WOMEN; RISK-FACTORS;
   CYTOLOGY; PREVALENCE; ACCURACY; PERFORMANCE; PROGRESSION
AB Introduction: Cervical cancer remains an important burden for HIV-infected women in the era of combination antiretroviral therapy. Recommendations for cervical screening in these women diverge and may include high-risk HPV (HRHPV) testing. We aimed to evaluate the clinical usefulness of a single HRHPV testing for cervical screening of HIV-infected women.
   Methods: 723 HIV-infected women from a Brazilian prospective cohort were included between 1996 and 2012. Inclusion criteria were: normal cervical cytology at baseline and having a HRHPV-test at baseline. We calculated incidence rates of any squamous intraepithelial lesion (SIL) and high grade SIL+ (HSIL+) and negative predictive values (NPV) within 12 and 36 months. Hazard Ratios were obtained using Cox proportional hazards regression models.
   Results: Incidence rate for both outcomes was low (9.9 cases per 100 PY [95% CI 8.8-11.0] for any SIL and 1.3 cases per 100 PY [95% IC 0.9-1.8] for HSIL+). Women with a HRHPV positive status at baseline had 1.7-fold (95% CI 1.3-2.2) and 3.2-fold (95% CI 1.5-7.1) increased risk of presenting any SIL and HSIL+, respectively, during follow-up. Negative-HRHPV test presented high NPV for both periods and outcomes (any SIL: 92.4% [95% CI 89.7-94.6] for 12 months and 80.9% [95% CI 77.2-84.3] for 36 months; and HSIL+: 99.8% [95% CI 98.9-100.0] for 12 months and 99.0 [95% CI 97.6-99.7] for 36 months).
   Conclusions: Incidence of any and high grade cytological abnormality was significantly higher among HIV-infected women with positive-HRHPV test. A single negative-HRHPV test helped reassure follow-up free of cytological abnormalities through three years of follow-up in HIV-infected women with negative cytology. (C) 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license.
C1 [Jalil, Emilia Moreira; Luz, Paula M.; Quintana, Marcel; Friedman, Ruth Khalili; Madeira, Rosa M. Domingues S.; Andrade, Angela Cristina; Chicarino, Janice; Moreira, Ronaldo Isrnerio; Derrico, Monica; Russomano, Fabio; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas INI Evandro Cha, Rio De Janeiro, RJ, Brazil.
   [Quintana, Marcel; Levi, Jose Eduardo] Univ Sao Paulo, Sao Paulo, SP, Brazil.
RP Jalil, EM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas INI Evandro Cha, Rio De Janeiro, RJ, Brazil.
EM emjalil@hotmail.com
OI Luz, Paula/0000-0001-9746-719X
FU Scientific Development and Research Funding Agency of the State of Rio
   de Janeiro (FAPERJ); Brazilian Research Council (CNPq)National Council
   for Scientific and Technological Development (CNPq); FIOCRUZ
FX The authors acknowledge Scientific Development and Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ), the Brazilian Research
   Council (CNPq), and FIOCRUZ for funding this study.
CR Allison P.D., 1995, SURVIVAL ANAL USING
   Anderson JR, 2006, CLIN INFECT DIS, V42, P562, DOI 10.1086/499357
   [Anonymous], 2016, Obstet Gynecol, V127, pe1, DOI 10.1097/AOG.0000000000001263
   [Anonymous], 2016, DIRETRIZES BRASILEIR
   [Anonymous], 2014, COMPR CERV CANC CONT
   Boldrini NT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102169
   Castle PE, 2002, CANCER EPIDEM BIOMAR, V11, P1394
   Chaturvedi AK, 2009, JNCI-J NATL CANCER I, V101, P1120, DOI 10.1093/jnci/djp205
   COX DR, 1972, J R STAT SOC B, V34, P187
   Denny L, 2008, OBSTET GYNECOL, V111, P1380, DOI 10.1097/AOG.0b013e3181743327
   Denslow SA, 2014, INT J STD AIDS, V25, P163, DOI 10.1177/0956462413491735
   Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031
   Goodman A, 2000, INT J GYNECOL CANCER, V10, P27, DOI 10.1046/j.1525-1438.2000.00001.x
   GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Harris TG, 2005, JAMA-J AM MED ASSOC, V293, P1471, DOI 10.1001/jama.293.12.1471
   Jamieson DJ, 2002, AM J OBSTET GYNECOL, V186, P21, DOI 10.1067/mob.2002.119776
   Keller MJ, 2015, CLIN INFECT DIS, V61, P1573, DOI 10.1093/cid/civ569
   Keller MJ, 2012, JAMA-J AM MED ASSOC, V308, P362, DOI 10.1001/jama.2012.5664
   Kojic EM, 2011, SEX TRANSM DIS, V38, P253, DOI 10.1097/OLQ.0b013e3181f70253
   Koliopoulos G, 2007, GYNECOL ONCOL, V104, P232, DOI 10.1016/j.ygyno.2006.08.053
   KORN AP, 1994, OBSTET GYNECOL, V83, P401
   Kreitchmann R, 2013, ARCH GYNECOL OBSTET, V288, P1107, DOI 10.1007/s00404-013-2871-3
   Levi JE, 2002, J CLIN MICROBIOL, V40, P3341, DOI 10.1128/JCM.40.9.3341-3345.2002
   MAIMAN M, 1991, OBSTET GYNECOL, V78, P84
   Maiman M, 1998, GYNECOL ONCOL, V68, P233, DOI 10.1006/gyno.1998.4938
   Massad LS, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.12.003
   Massad LS, 2013, J LOW GENIT TRACT DI, V17, pS1, DOI 10.1097/LGT.0b013e318287d329
   Cobucci RNO, 2015, J INFECT PUBLIC HEAL, V8, P1, DOI 10.1016/j.jiph.2014.08.003
   Palefsky Joel, 2007, Top HIV Med, V15, P130
   Palefsky J, 2009, CURR OPIN HIV AIDS, V4, P52, DOI 10.1097/COH.0b013e32831a7246
   Palmer TJ, 2016, BRIT J CANCER, V114, P582, DOI 10.1038/bjc.2015.474
   Peyton CL, 1998, J CLIN MICROBIOL, V36, P3248, DOI 10.1128/JCM.36.11.3248-3254.1998
   Raposo LM, 2011, CAD SAUDE PUBLICA, V27, P1281, DOI 10.1590/S0102-311X2011000700004
   Singh DK, 2009, J INFECT DIS, V199, P1851, DOI 10.1086/599123
   Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114
   Spinillo A, 1998, GYNECOL ONCOL, V69, P109, DOI 10.1006/gyno.1998.4985
   van Buuren S, 2000, MULTIVARIATE IMPUTAT
   Vanni T, 2012, INT J CANCER, V131, pE96, DOI 10.1002/ijc.26472
   WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591
NR 41
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JAN-FEB
PY 2018
VL 22
IS 1
BP 16
EP 23
DI 10.1016/j.bjid.2017.10.007
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA GG4ET
UT WOS:000432647100003
PM 29207280
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Hoagland, B
   Moreira, RI
   De Boni, RB
   Kallas, EG
   Madruga, JV
   Vasconcelos, R
   Goulart, S
   Torres, TS
   Marins, LMS
   Anderson, PL
   Luz, PM
   Leite, ID
   Liu, AY
   Veloso, VG
   Grinsztejn, B
AF Hoagland, Brenda
   Moreira, Ronaldo I.
   De Boni, Raquel B.
   Kallas, Esper G.
   Madruga, Jose Valdez
   Vasconcelos, Ricardo
   Goulart, Silvia
   Torres, Thiago S.
   Marins, Luana M. S.
   Anderson, Peter L.
   Luz, Paula M.
   Leite, Iuri da Costa
   Liu, Albert Y.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
CA PrEP Brasil Study Team
TI High pre-exposure prophylaxis uptake and early adherence among men who
   have sex with men and trans-gender women at risk for HIV Infection: the
   PrEP Brasil demonstration project (vol 20, 21472, 2017)
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Correction
RI Vasconcelos, Ricardo/AAL-4634-2020
OI Vasconcelos, Ricardo/0000-0002-9753-0563
CR Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
NR 1
TC 0
Z9 0
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JAN
PY 2018
VL 21
AR e25069
DI 10.1002/jia2.25069
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FU4FO
UT WOS:000423809100012
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Jalil, EM
   Wilson, EC
   Luz, PM
   Velasque, L
   Moreira, RI
   Castro, CV
   Monteiro, L
   Garcia, ACF
   Cardoso, SW
   Coelho, LE
   McFarland, W
   Liu, AY
   Veloso, VG
   Buchbinder, S
   Grinsztejn, B
AF Jalil, Emilia M.
   Wilson, Erin C.
   Luz, Paula M.
   Velasque, Luciane
   Moreira, Ronaldo I.
   Castro, Cristiane V.
   Monteiro, Laylla
   Garcia, Ana Cristina F.
   Cardoso, Sandra W.
   Coelho, Lara E.
   McFarland, Willi
   Liu, Albert Y.
   Veloso, Valdilea G.
   Buchbinder, Susan
   Grinsztejn, Beatriz
TI HIV testing and the care continuum among transgender women: population
   estimates from Rio de Janeiro, Brazil (vol 20, 21873, 2017)
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Correction
CR Jalil EM, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21873
NR 1
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JAN
PY 2018
VL 21
AR e25047
DI 10.1002/jia2.25047
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FU4FO
UT WOS:000423809100004
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Wolff, MJ
   Cortes, CP
   Mejia, FA
   Padgett, D
   Belaunzaran-Zamudio, P
   Grinsztejn, B
   Giganti, MJ
   McGowan, CC
   Rebeiro, PF
AF Wolff, Marcelo J.
   Cortes, Claudia P.
   Mejia, Fernando A.
   Padgett, Denis
   Belaunzaran-Zamudio, Pablo
   Grinsztejn, Beatriz
   Giganti, Mark J.
   McGowan, Catherine C.
   Rebeiro, Peter F.
CA Caribbean Central South Amer
TI Evaluating the care cascade after antiretroviral therapy initiation in
   Latin America
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE HIV; AIDS; Epidemiology; ART; HIV; homosexual; South America
ID HIV CARE; DRUG-USE; RETENTION; STRATEGIES; AGE
AB Accelerating antiretroviral therapy (ART) administration, improving retention, and achieving viral suppression in low- and middle-income countries must be prioritized. We evaluated trends and disparities in these milestones in a large Latin American cohort. Adults starting ART (ART(start)) from 2003 to 2014 at Caribbean, Central, and South America network for HIV epidemiology sites were assessed for care cascade outcomes: CD4 cell count >200cells/mm(3) at ART(start); retention (1 visit at one year after ART(start)); viral suppression (1 HIV-1 RNA <200 copies/ml at one year after ART(start)). Modified Poisson regression provided adjusted prevalence ratios by age, gender, and HIV transmission risk, accounting for site and year of ART(start). Proportions achieving ART(start) and suppression improved over time (p<0.05). Older age was associated with better retention and viral suppression, but not ART(start) at CD4 cell count >200cells/mm(3). Females and men who have sex with men (MSM) were more likely to have CD4 cell count >200cells/mm(3) at ART(start). Injection drug users (IDUs) were less likely to be retained while MSM were more likely to achieve viral suppression (all p<0.05). Despite improvements in these outcomes over the course of a decade in this cohort, significant disparities existed, disadvantaging younger patients, men, and IDUs. These gaps indicate continued progress in providing early diagnosis and ART(start) remain critical.
C1 [Wolff, Marcelo J.; Cortes, Claudia P.] Univ Chile, Sch Med, Fdn Arriaran, Santiago, Chile.
   [Mejia, Fernando A.] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Padgett, Denis] Inst Hondureno Seguridad Social, Tegucigalpa, Honduras.
   [Padgett, Denis] Hosp Escuela Univ, Tegucigalpa, Honduras.
   [Belaunzaran-Zamudio, Pablo] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [Belaunzaran-Zamudio, Pablo] Univ Nacl Autonoma Mexico, Div Invest, Fac Med, Mexico City, DF, Mexico.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Giganti, Mark J.; McGowan, Catherine C.; Rebeiro, Peter F.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
RP Rebeiro, PF (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, 1161 21st Ave S,A-2200 MCN, Nashville, TN 37232 USA.
EM p.rebeiro@vanderbilt.edu
RI Belaunzaran-Zamudio, Pablo F./T-4218-2019; Cortes,
   Claudia/AAF-7326-2020; Belaunzaran-Zamudio, Pablo Francisco/T-4085-2019
OI Cortes, Claudia/0000-0001-9101-9783; Rebeiro, Peter/0000-0003-1951-9104;
   Belaunzaran, Pablo/0000-0003-4775-4734; mejia,
   fernando/0000-0001-8429-8833
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01AI069923]; National Cancer
   Institute (NCI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); National Institute of Allergy and Infectious Diseases
   (NIAID)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute
   of Child Health & Human Development (NICHD)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD); National Institute on Drug Abuse (NIDA)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); National
   Institute of Mental Health (NIMH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH); Office of the Director, National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, K01AI131895, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   K01AI131895, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, K01AI131895, U01AI069923, U01AI069923, K01AI131895,
   U01AI069923] Funding Source: NIH RePORTER
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the NIH-funded Caribbean, Central and South America network
   for HIV epidemiology (CCASAnet), a member cohort of the International
   Epidemiologic Databases to Evaluate AIDS (leDEA) (U01AI069923). This
   award is funded by the following institutes: National Cancer Institute
   (NCI), National Institute of Allergy and Infectious Diseases (NIAID),
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD), the National Institute on Drug Abuse (NIDA), the
   National Institute of Mental Health (NIMH), and Office of the Director,
   National Institutes of Health (OD).
CR Alonso-Gonzalez M., 2013, ANTIRETROVIRAL TREAT, P52
   Altice FL, 2010, LANCET, V376, P367, DOI 10.1016/S0140-6736(10)60829-X
   Avila D, 2014, JAIDS-J ACQ IMM DEF, V65, pE8, DOI 10.1097/QAI.0b013e3182a39979
   Braitstein P, 2008, J WOMENS HEALTH, V17, P47, DOI 10.1089/jwh.2007.0353
   Crabtree-Ramirez B, 2012, SALUD PUBLICA MEXICO, V54, P506, DOI 10.1590/S0036-36342012000500007
   Crabtree-Ramirez B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020272
   De Boni RB, 2016, AIDS BEHAV, V20, P2692, DOI 10.1007/s10461-016-1398-6
   Degenhardt L, 2013, LANCET, V382, P1564, DOI 10.1016/S0140-6736(13)61530-5
   Ford MA, 2012, MONITORING HIV CARE
   Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243
   Harrell F, 2001, REGRESSION MODELING
   Hirnschall G, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18757
   Maquera-Afaray J, 2016, REV CHIL INFECTOL, V33, pS20, DOI 10.4067/S0716-10182016000700003
   Martin-Onraet A, 2017, AIDS BEHAV, V21, P505, DOI 10.1007/s10461-016-1560-1
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   Rebeiro P, 2013, JAIDS-J ACQ IMM DEF, V62, P356, DOI 10.1097/QAI.0b013e31827f578a
   Rebeiro PF, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20636
   Rodriguez CM, 2002, AIDS, V16, pS34, DOI 10.1097/00002030-200212003-00006
   Tassie JM, 2010, JAIDS-J ACQ IMM DEF, V54, P437, DOI 10.1097/QAI.0b013e3181d73e1b
   UNAIDS, 2016, GLOB AIDS UPD 2016
   UNAIDS, 2018, AIDSINFO DAT
   Valdiserri Ronald O, 2013, Public Health Rep, V128, P354
   Vega WA, 2002, DRUG ALCOHOL DEPEN, V68, P285, DOI 10.1016/S0376-8716(02)00224-7
   Yehia BR, 2015, JAIDS-J ACQ IMM DEF, V68, P413, DOI 10.1097/QAI.0000000000000489
   Yiannoutsos CT, 2012, SEX TRANSM INFECT, V88, pI33, DOI 10.1136/sextrans-2012-050658
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 26
TC 5
Z9 5
U1 0
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD JAN
PY 2018
VL 29
IS 1
BP 4
EP 12
DI 10.1177/0956462417714094
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FQ8KB
UT WOS:000418610600001
PM 28618980
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Torres, TS
   De Boni, RB
   de Vasconcellos, MTL
   Luz, PM
   Hoagland, B
   Moreira, RI
   Veloso, VG
   Grinsztejn, B
AF Torres, Thiago Silva
   De Boni, Raquel Brandini
   de Vasconcellos, Mauricio T. L.
   Luz, Paula Mendes
   Hoagland, Brenda
   Moreira, Ronaldo Ismerio
   Veloso, Valdilea Goncalves
   Grinsztejn, Beatriz
TI Awareness of Prevention Strategies and Willingness to Use Preexposure
   Prophylaxis in Brazilian Men Who Have Sex With Men Using Apps for Sexual
   Encounters: Online Cross-Sectional Study
SO JMIR PUBLIC HEALTH AND SURVEILLANCE
LA English
DT Article
DE HIV; prevention; MSM; app; internet; PrEP; Brazil; Latin America
AB Background: Geosocial networking (GSN) smartphone apps are becoming the main venue for sexual encounters among Brazilian men who have sex with men (MSM). To address the increased HIV incidence in this population, preexposure prophylaxis (PrEP) was recently implemented in the Brazilian public health system in the context of combined HIV prevention.
   Objective: This study aimed to describe the characteristics of MSM using GSN apps for sexual encounters, their awareness of prevention strategies, and willingness to use PrEP.
   Methods: This study was an online cross-sectional study conducted in 10 Brazilian state capitals from July 1 to July 31, 2016. The questionnaire was programmed on SurveyGizmo and advertised in two GSN apps used by MSM to find sexual partners (Hornet and Grindr). Inclusion criteria were >18 years of age, cisgender men, with an HIV-negative status. Eligible individuals answered questions on: demographics; behavior; and knowledge, preferences, and willingness to use PrEP, nonoccupational postexposure prophylaxis (nPEP), HIV self-testing (HIVST), and condoms. Logistic regression modeling was performed to assess the factors associated with daily oral PrEP willingness.
   Results: During the study period, 8885 individuals provided consent and started the questionnaire. Of these, 23.05% (2048/8885) were ineligible, 6837 (6837/8885, 76.94%) initiated, and 5065 (5065/8885, 57.00%) completed the entire questionnaire and were included in the present analysis. Median age was 30 years (interquartile range: 25-36), most self-declared as MSM (4991/5065, 98.54%), white (3194/5065, 63.06%), middle income (2148/5065, 42.41%), and had 12 or more years of schooling (3106/5062, 61.36%). The majority of MSM (3363/5064, 66.41%) scored >10 points (high risk) on The HIV Incidence Risk for MSM Scale, but only 21.39% (1083/5064) had a low perceived likelihood of getting HIV in the next year. Daily use of apps for sex was reported by 35.58% (1798/5054). Most MSM (4327/5065, 85.43%) reported testing for HIV at least once in their lifetime and 9.16% (464/5065) used nPEP in the previous year. PrEP, nPEP, and HIVST awareness was reported by 57.89% (2932/5065), 57.39% (2907/5065), and 26.57% (1346/5065) of participants, respectively. Half of all respondents (2653/5065, 52.38%) were willing to use daily oral PrEP, and this finding was associated with higher numbers of male sexual partners (adjusted odds ratio [AOR] 1.26, 95% CI 1.09-1.47), condomless receptive anal intercourse (AOR 1.27, 95% CI 1.12-1.44), sex with HIV-positive partner versus no HIV-positive partner (one HIV-positive partner: AOR 1.36, 95% CI 1.11-1.67), daily use of apps for sexual encounters (AOR 1.48, 95% CI 1.17-1.87), high and unknown perceived likelihood of getting HIV in the next year (AOR 1.72, 95% CI 1.47-2.02 and AOR 1.39, 95% CI 1.13-1.70), sexually transmitted infection diagnosis (AOR 1.25, 95% CI 1.03-1.51), stimulant use (AOR 1.24, 95% CI 1.07-1.43), PrEP awareness (AOR 1.48, 95% CI 1.30-1.70), and unwillingness to use condoms (AOR 1.16, 95% CI 1.00-1.33).
   Conclusions: Our results evidenced high-risk scores in the studied population, suggesting the importance of PrEP use. Those individuals presenting risky sexual behaviors were more willing to use PrEP. Nonetheless, only 58% (2932/5065) of individuals had heard about this prevention strategy. Efforts to increase awareness of new prevention strategies are needed, and mobile health tools are a promising strategy to reach MSM.
C1 [Torres, Thiago Silva; De Boni, Raquel Brandini; Luz, Paula Mendes; Hoagland, Brenda; Moreira, Ronaldo Ismerio; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365 Manguinhos, BR-21040360 Rio De Janeiro, Brazil.
   [de Vasconcellos, Mauricio T. L.] Escola Nacl Ciencias Estat, Rio De Janeiro, Brazil.
RP Torres, TS (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365 Manguinhos, BR-21040360 Rio De Janeiro, Brazil.
EM thiago.torres@ini.fiocruz.br
RI TORRES, THIAGO SILVA/D-6548-2014; DE BONI, RAQUEL BRANDINI/D-4212-2013;
   Teixeira Leite de Vasconcellos, Mauricio/I-4335-2017
OI TORRES, THIAGO SILVA/0000-0002-2557-601X; DE BONI, RAQUEL
   BRANDINI/0000-0002-2455-5997; Luz, Paula/0000-0001-9746-719X; Goncalves
   Veloso dos Santos, Valdilea/0000-0002-6622-3165; Teixeira Leite de
   Vasconcellos, Mauricio/0000-0003-1658-2589; Ismerio Moreira,
   Ronaldo/0000-0003-2680-4317
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH
   RePORTER; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1 AI069476] Funding Source:
   Medline
CR Aghaizu A, 2013, SEX TRANSM INFECT, V89, P207, DOI 10.1136/sextrans-2012-050648
   Allison P. D., 2012, LOGISTIC REGRESSION
   Barash EA, 2010, AIDS PATIENT CARE ST, V24, P689, DOI 10.1089/apc.2010.0173
   Barbosa A, 2009, CAD SAUDE PUBLICA, V25, P727, DOI 10.1590/S0102-311X2009000400003
   Biello KB, 2014, AIDS BEHAV, V18, P1675, DOI 10.1007/s10461-014-0844-6
   Biello KB, 2014, AIDS BEHAV, V18, P1264, DOI 10.1007/s10461-013-0632-8
   Bil JP, 2015, AIDS, V29, P955, DOI 10.1097/QAD.0000000000000639
   Brazilian Internet Steering Committee, 2015, ICT HOUS 2015 SURV U
   Brito AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130445
   Burrell ER, 2012, AIDS BEHAV, V16, P1816, DOI 10.1007/s10461-012-0277-z
   Celentano DD, 2006, SEX TRANSM DIS, V33, P265, DOI 10.1097/01.olq.0000187207.10992.4e
   Centers for Disease Control and Prevention, 2008, MMWR-MORBID MORTAL W, V59, P1201
   Centers for Disease Control and Prevention, 2014, PREEXP PROPH PREV HI
   Chard AN, 2018, SUBST USE MISUSE, V53, P42, DOI 10.1080/10826084.2017.1322985
   Chomchey N, 2017, J VIRUS ERAD, V3, P128
   De Baetselier Irith, 2017, JMIR Res Protoc, V6, pe11, DOI 10.2196/resprot.6767
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   De Boni RB, 2017, 2017 JUL 23 INT AIDS
   DiNenno EA, 2017, MMWR-MORBID MORTAL W, V66, P830, DOI 10.15585/mmwr.mm6631a3
   Draper BL, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21885
   Eisingerich AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028238
   Fallin A, 2015, PREV MED, V74, P123, DOI 10.1016/j.ypmed.2014.11.026
   Ferrer L, 2016, AIDS BEHAV, V20, P1423, DOI 10.1007/s10461-016-1379-9
   Figueroa C, 2015, AIDS BEHAV, V19, P1949, DOI 10.1007/s10461-015-1097-8
   Flores SA, 2009, SEX TRANSM DIS, V36, P325, DOI 10.1097/OLQ.0b013e3181924201
   Fonseca AM, 2010, CIENC SAUDE COLETIVA, V15, P663, DOI 10.1590/S1413-81232010000300008
   Gandhi M, 2017, AIDS, V31, P2245, DOI [10.1097/qad.0000000000001615, 10.1097/QAD.0000000000001615]
   Goedel William C, 2015, JMIR Public Health Surveill, V1, pe4, DOI 10.2196/publichealth.4353
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Greene GJ, 2017, AIDS BEHAV, V21, P1336, DOI 10.1007/s10461-016-1565-9
   Grosskopf NA, 2014, AM J MENS HEALTH, V8, P510, DOI 10.1177/1557988314527311
   Grov C, 2016, AIDS BEHAV, V20, P1989, DOI 10.1007/s10461-015-1284-7
   Grov C, 2015, AIDS BEHAV, V19, P2234, DOI 10.1007/s10461-015-1030-1
   Hall EW, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5713
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   Hoagland B, 2017, AIDS BEHAV, V21, P1278, DOI 10.1007/s10461-016-1516-5
   Holloway IW, 2015, AIDS BEHAV, V19, pS112, DOI 10.1007/s10461-014-0989-3
   Holloway IW, 2014, AIDS BEHAV, V18, P285, DOI 10.1007/s10461-013-0671-1
   Holt M, 2017, SEX TRANSM INFECT, V93, P438, DOI 10.1136/sextrans-2016-052774
   Holt M, 2012, SEX TRANSM INFECT, V88, P258, DOI 10.1136/sextrans-2011-050312
   Tieu HV, 2013, JAIDS-J ACQ IMM DEF, V64, P121, DOI 10.1097/QAI.0b013e318299cede
   Hoots BE, 2016, CLIN INFECT DIS, V63, P672, DOI 10.1093/cid/ciw367
   Hosmer WH, 2000, APPL LOGISTIC REGRES
   Huang E, 2016, AIDS EDUC PREV, V28, P341, DOI 10.1521/aeap.2016.28.4.341
   Karuga RN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151716
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Krakower DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033119
   Lal L, 2017, AIDS, V31, P1709, DOI [10.1097/QAD.0000000000001519, 10.1097/qad.0000000000001519]
   Landovitz RJ, 2013, J URBAN HEALTH, V90, P729, DOI 10.1007/s11524-012-9766-7
   Lebouche B, 2016, HIV MED, V17, P152, DOI 10.1111/hiv.12286
   Ludford KT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069966
   MANSERGH G, 2015, J ACQ IMMUN DEF SYND, V70, pE15, DOI DOI 10.1097/QAI.0000000000000810]
   Marcus U, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-826
   Markowitz M, 2017, LANCET HIV, V4, pE331, DOI 10.1016/S2352-3018(17)30068-1
   Marks G, 2010, SEX TRANSM DIS, V37, P325, DOI 10.1097/OLQ.0b013e3181c95dac
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   McDougal SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105030
   McFarlane M, 2000, JAMA-J AM MED ASSOC, V284, P443, DOI 10.1001/jama.284.4.443
   Meyers K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114700
   Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P77, DOI 10.1097/QAI.0b013e31818d5a27
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Molina JM, 2017, LANCET HIV, V4, pE402, DOI 10.1016/S2352-3018(17)30089-9
   Newcomb ME, 2016, JAIDS-J ACQ IMM DEF, V71, P200, DOI 10.1097/QAI.0000000000000819
   Patrick R, 2017, JAIDS-J ACQ IMM DEF, V75, pS375, DOI [10.1097/QAI.0000000000001414, 10.1097/qai.0000000000001414]
   Phillips G, 2014, AIDS BEHAV, V18, P1630, DOI 10.1007/s10461-014-0760-9
   Rendina HJ, 2014, AIDS BEHAV, V18, P41, DOI 10.1007/s10461-013-0573-2
   Rosengren AL, 2016, SEX HEALTH, V13, P389, DOI 10.1071/SH15236
   Ross J, 2013, GLOB HEALTH-SCI PRAC, V1, P203, DOI 10.9745/GHSP-D-13-00010
   Sineath R Craig, 2013, J Int Assoc Provid AIDS Care, V12, P227, DOI 10.1177/2325957413488184
   Smith DK, 2012, JAIDS-J ACQ IMM DEF, V60, P421, DOI 10.1097/QAI.0b013e318256b2f6
   Steward WT, 2009, AIDS BEHAV, V13, P1054, DOI 10.1007/s10461-009-9582-6
   Stueve A, 2002, AIDS EDUC PREV, V14, P482, DOI 10.1521/aeap.14.8.482.24108
   Tomkins A, 2018, INT J STD AIDS, V29, P350, DOI 10.1177/0956462417725638
   Volk JE, 2016, INT J STD AIDS, V27, P531, DOI 10.1177/0956462415586676
   Wheelock A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054288
   Winetrobe H, 2014, AIDS CARE, V26, P1303, DOI 10.1080/09540121.2014.911811
   Yi S, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21580
   Young I, 2014, AIDS BEHAV, V18, P195, DOI 10.1007/s10461-013-0560-7
   Young SD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062271
   Zhang XY, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3905-0
   Zou HC, 2017, ARCH SEX BEHAV, V46, P885, DOI 10.1007/s10508-016-0709-3
NR 82
TC 16
Z9 16
U1 0
U2 1
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2369-2960
J9 JMIR PUBLIC HLTH SUR
JI JMIR Public Health Surveill.
PD JAN-MAR
PY 2018
VL 4
IS 1
BP 147
EP 161
DI 10.2196/publichealth.8997
PG 15
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA VJ0RN
UT WOS:000526815300013
PM 29358160
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Greer, AE
   Ou, SS
   Wilson, E
   Piwowar-Manning, E
   Forman, MS
   McCauley, M
   Gamble, T
   Ruangyuttikarn, C
   Hosseinipour, MC
   Kumarasamy, N
   Nyirenda, M
   Grinsztejn, B
   Pilotto, JH
   Kosashunhanan, N
   de Melo, MG
   Makhema, J
   Akelo, V
   Panchia, R
   Badal-Faesen, S
   Chen, YQ
   Cohen, MS
   Eshleman, SH
   Thio, CL
   Valsamakis, A
AF Greer, Amy E.
   Ou, San-San
   Wilson, Ethan
   Piwowar-Manning, Estelle
   Forman, Michael S.
   McCauley, Marybeth
   Gamble, Theresa
   Ruangyuttikarn, Cholticha
   Hosseinipour, Mina C.
   Kumarasamy, Nagalingeswaran
   Nyirenda, Mulinda
   Grinsztejn, Beatriz
   Pilotto, Jose Henrique
   Kosashunhanan, Natthapol
   de Melo, Marineide Goncalves
   Makhema, Joseph
   Akelo, Victor
   Panchia, Ravindre
   Badal-Faesen, Sharlaa
   Chen, Ying Q.
   Cohen, Myron S.
   Eshleman, Susan H.
   Thio, Chloe L.
   Valsamakis, Alexandra
TI Comparison of Hepatitis B Virus Infection in HIV-Infected and
   HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial:
   HPTN 052
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; HBV; CD4(+) cell count; chronic HBV infection; endemic HBV;
   prevalence of HBV infection; HIV/HBV co-infection
ID C VIRUS; CORE ANTIBODY; RISK-FACTORS; ANTIRETROVIRAL THERAPY;
   COINFECTION; PREVALENCE; ANTIGEN; IMPACT; PREVENTION; COHORT
AB Objective: Data comparing hepatitis B virus (HBV) infection in HIV-infected [HIV(+)], and HIV-uninfected [HIV(-)] individuals recruited into the same study are limited. HBV infection status and chronic hepatitis B (cHB) were characterized in a multinational clinical trial: HIV Prevention Trials Network (HPTN 052).
   Method: HBV infection status at enrollment was compared between HIV(+) (N = 1241) and HIV(-) (N = 1232) from 7 HBV-endemic countries. Hepatitis B e antigen and plasma HBV DNA were determined in cHB. Median CD4, median plasma HIV RNA, and prevalence of transaminase elevation were compared in HIV(+) with and without cHB. Significance was assessed with chi(2), Fisher exact, and median tests.
   Results: Among all participants, 33.6% had HBV exposure without cHB (8.9% isolated HBV core antibody, "HBcAb"; 24.7% HBcAb and anti-HB surface antibody positive, "recovered"), 4.3% had cHB, 8.9% were vaccinated, and 53.5% were uninfected. Data were similar among HIV(+) and HIV(-) except for isolated HBcAb, which was more prevalent in HIV(+) than HIV(-) [10.1% vs. 7.7%, P = 0.046]. Median HBV DNA trended higher in HIV(+) than in HIV(-). In HIV (+) with cHB versus those without cHB, transaminase elevations were more prevalent (alanine aminotransferase <= grade 2, 12% vs. 5.2%, P = 0.037; aspartate aminotransferase <= grade 2, 26% vs. 6.0%, P < 0.001), CD4 trended lower, and HIV RNA was similar.
   Conclusions: HBV infection status did not differ by HIV infection status. HIV co-infection was associated with isolated HBcAb and a trend of increased HBV DNA. In HIV, cHB was associated with mild transaminase elevations and a trend toward lower CD4.
C1 [Greer, Amy E.; Forman, Michael S.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA.
   [Ou, San-San; Wilson, Ethan; Chen, Ying Q.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Piwowar-Manning, Estelle; Eshleman, Susan H.; Valsamakis, Alexandra] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [McCauley, Marybeth] FHI 360, Washington, DC USA.
   [Gamble, Theresa] FHI 360, Durham, NC USA.
   [Ruangyuttikarn, Cholticha; Kosashunhanan, Natthapol] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Hosseinipour, Mina C.] Univ N Carolina, Chapel Hill, NC USA.
   [Hosseinipour, Mina C.] UNC Project Malawi, Inst Global Hlth & Infect Dis, Lilongwe, Malawi.
   [Kumarasamy, Nagalingeswaran] VHS, YRGCARE Med Ctr, Madras, Tamil Nadu, India.
   [Nyirenda, Mulinda] Johns Hopkins Project, Coll Med, Blantyre, Malawi.
   [Grinsztejn, Beatriz] Inst Nacl Infectol Evandro Chagas INI Fiocruz, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Lab AIDS & Imunol Mol IOC Fiocruz, Rio De Janeiro, Brazil.
   [de Melo, Marineide Goncalves] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Makhema, Joseph] Botswana Harvard AIDS Inst, Gaborone, Botswana.
   [Akelo, Victor] Kenya Govt Med Res Ctr, Kisumu, Kenya.
   [Akelo, Victor] Ctr Dis Control, Kisumu, Kenya.
   [Panchia, Ravindre] Univ Witwatersrand, Perinatal HIV Res Unit, Soweto HPTN CRS, Soweto, South Africa.
   [Badal-Faesen, Sharlaa] Univ Witwatersrand, Johannesburg, South Africa.
   [Cohen, Myron S.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
   [Thio, Chloe L.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
RP Valsamakis, A (corresponding author), Johns Hopkins Univ Hosp, Meyer B1-193,600 North Wolfe St, Baltimore, MD 21287 USA.
EM avalsam1@jhmi.edu
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
FU Division of AIDS of the U.S. National Institute of Allergy and
   Infectious Diseases (NIAID); Office of AIDS Research of the U.S.
   National Institutes of Health (NIH) [U01-AI068613/UM1-AI068613,
   U01-AI068617/UM1-AI068617, U01AI068619/UM1-AI068619]; Gilead
   SciencesGilead Sciences;  [U01-AI018136]; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI068613, UM1AI069432,
   UM1AI069423, UM1AI068617, UM1AI068617, UM1AI068613, UM1AI069424,
   UM1AI069453, UM1AI069424, UM1AI069518, UM1AI069453, UM1AI068619,
   U01AI068617, UM1AI069518, UM1AI068617, UM1AI069432, UM1AI068634,
   UM1AI068636, UM1AI068634, UM1AI069423, UM1AI068617, UM1AI069423,
   U01AI068613, UM1AI069456, UM1AI069456, UM1AI069456, UM1AI069456,
   UM1AI068619, UM1AI068617, UM1AI068613, UM1AI069432, UM1AI069518,
   UM1AI069463, UM1AI069453, UM1AI069399, UM1AI069463, UM1AI069453,
   UM1AI069432, UM1AI069518, UM1AI069518, U01AI068617, UM1AI069399,
   UM1AI068617, UM1AI069518, UM1AI069423, UM1AI069518, UM1AI068619,
   UM1AI069463, UM1AI069424, UM1AI068634, U01AI068636, UM1AI068619,
   UM1AI069456, UM1AI068617, UM1AI068619, UM1AI068636, UM1AI069456,
   UM1AI069399, UM1AI068619, UM1AI068613, UM1AI068634, UM1AI068636,
   UM1AI068636, UM1AI069453, UM1AI068613, UM1AI069432, UM1AI068619,
   UM1AI069424, U01AI068613, UM1AI068613, UM1AI069453, U01AI068636,
   U01AI068636, UM1AI069432, UM1AI068617, UM1AI069518, UM1AI069423,
   UM1AI068636, U01AI068613, UM1AI069423, UM1AI068636, UM1AI068613,
   UM1AI069423, UM1AI069463, U01AI068636, UM1AI069399, UM1AI069399,
   UM1AI068636, UM1AI068613, U01AI068617, UM1AI069432, UM1AI068613,
   UM1AI069463, UM1AI068619, UM1AI068617, UM1AI069399, UM1AI069399,
   UM1AI068636, UM1AI069453, UM1AI068613, UM1AI068636, UM1AI069424,
   UM1AI069456, UM1AI068619, U01AI068617, U01AI068636, UM1AI069463,
   UM1AI069456, UM1AI069432, UM1AI069456, UM1AI068619, UM1AI068617,
   UM1AI069453, U01AI068636, UM1AI069423, U01AI068617, UM1AI069463,
   UM1AI069432, UM1AI069399, UM1AI069453, UM1AI068617, UM1AI068613,
   UM1AI069432, UM1AI069518, U01AI068636, U01AI068613, UM1AI068636,
   UM1AI068613, UM1AI068619, UM1AI069399, UM1AI069423, UM1AI069463,
   UM1AI069463, UM1AI068636, UM1AI068636] Funding Source: NIH RePORTER
FX Supported by the grants from the Division of AIDS of the U.S. National
   Institute of Allergy and Infectious Diseases (NIAID); and by the Office
   of AIDS Research of the U.S. National Institutes of Health (NIH)
   [U01-AI068613/UM1-AI068613 (S.H.E.); U01-AI068617/UM1-AI068617
   (Donnell); and U01AI068619/UM1-AI068619 (M.S.C./El-Sadr)]. The HPTN 052
   trial also received funding through U01-AI018136.r M.C.H. has received
   honoraria for advisory board membership from ViiV healthcare. M.S.C.
   receives honoraria for advisory board membership from Janssen Global
   Services, Roche Molecular Systems, and Merck Research. A.V. has received
   study support and honoraria for advisory board membership from Roche
   Molecular Systems. C.L.T. has received a research grant from Gilead
   Sciences. The remaining authors have no conflicts of interest to
   disclose.
CR Andersson MI, 2015, SAMJ S AFR MED J, V105, P281, DOI [10.7196/SAMJ.8907, 10.7196/samj.8907]
   [Anonymous], 2016, PANEL ON ANTIRETROVI
   Attia KA, 2012, WORLD J HEPATOL, V4, P218, DOI 10.4254/wjh.v4.i7.218
   Bartholomeusz A, 2004, REV MED VIROL, V14, P3, DOI 10.1002/rmv.400
   Bihl F, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0308-0
   Chandra N, 2013, INDIAN J MED RES, V138, P950
   Chun HM, 2012, J INFECT DIS, V205, P185, DOI 10.1093/infdis/jir720
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Colin JF, 1999, HEPATOLOGY, V29, P1306, DOI 10.1002/hep.510290447
   DallaPiazza M, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-116
   Dao DY, 2011, J MED VIROL, V83, P1551, DOI 10.1002/jmv.22160
   European AIDS Clinical Society, 2015, EUR AIDS CLIN SOC GU
   European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021
   French AL, 2007, J INFECT DIS, V195, P1437, DOI 10.1086/515578
   French AL, 2009, CLIN INFECT DIS, V49, P148, DOI 10.1086/599610
   Hoffmann CJ, 2007, LANCET INFECT DIS, V7, P402, DOI 10.1016/S1473-3099(07)70135-4
   Khamduang W, 2013, CLIN INFECT DIS, V56, P1704, DOI 10.1093/cid/cit166
   Kilongosi MW, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1060-3
   Liang SH, 2010, JAIDS-J ACQ IMM DEF, V54, P122, DOI 10.1097/QAI.0b013e3181daafd5
   Lok ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513
   Martins S, 2014, REV SOC BRAS MED TRO, V47, P552, DOI 10.1590/0037-8682-0109-2014
   Matthews PC, 2014, J CLIN VIROL, V61, P20, DOI 10.1016/j.jcv.2014.05.018
   Peters Philip James, 2013, J Int Assoc Provid AIDS Care, V12, P349, DOI 10.1177/2325957413488201
   Phuangchoei Prapinpa, 2015, Journal of the Medical Association of Thailand, V98, P226
   Price JC, 2016, JAIDS-J ACQ IMM DEF, V72, P319, DOI 10.1097/QAI.0000000000000981
   Price JC, 2012, J INFECT DIS, V205, P1005, DOI 10.1093/infdis/jir885
   Rodriguez-Mendez ML, 2000, AM J GASTROENTEROL, V95, P1316, DOI 10.1111/j.1572-0241.2000.01981.x
   Saha D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073613
   Saravanan S, 2007, WORLD J GASTROENTERO, V13, P5015, DOI 10.3748/wjg.v13.i37.5015
   Siegel S, 1988, NONPARAMETRIC STAT, P124
   Stabinski L, 2015, JAIDS-J ACQ IMM DEF, V68, pS274, DOI 10.1097/QAI.0000000000000496
   Sungkanuparph Somnuek, 2004, Journal of the Medical Association of Thailand, V87, P1349
   Thio CL, 2013, AIDS, V27, P191, DOI 10.1097/QAD.0b013e32835a9984
   Thio CL, 2002, LANCET, V360, P1921, DOI 10.1016/S0140-6736(02)11913-1
   Tsai MS, 2013, J INFECT DIS, V208, P1184, DOI 10.1093/infdis/jit299
   van der Kuyl AC, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-540
   Vinikoor MJ, 2016, TROP MED INT HEALTH, V6, P12764
   Wandeler G, 2016, INT J INFECT DIS, V3, P31155
   Witt MD, 2013, CLIN INFECT DIS, V56, P606, DOI 10.1093/cid/cis908
   Yim HJ, 2006, HEPATOLOGY, V43, pS173, DOI 10.1002/hep.20956
NR 41
TC 6
Z9 6
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2017
VL 76
IS 4
BP 388
EP 393
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FT6TQ
UT WOS:000423287100011
PM 28749822
OA Green Accepted, Green Published
DA 2020-11-24
ER

PT J
AU Lamas, CC
   Coelho, LE
   Grinsztejn, BJ
   Veloso, VG
AF Lamas, Cristiane C.
   Coelho, Lara E.
   Grinsztejn, Beatriz J.
   Veloso, Valdilea G.
TI Community-acquired lower respiratory tract infections in HIV-infected
   patients on antiretroviral therapy: predictors in a contemporary cohort
   study
SO INFECTION
LA English
DT Article
DE Community-acquired pneumonia; HIV; AIDS; Antiretroviral therapy;
   Vaccination
ID BACTERIAL PNEUMONIA; RISK-FACTORS; SOCIOECONOMIC-STATUS;
   HOSPITALIZATION; COCAINE; ADULTS; DISEASE
AB Community-acquired pneumonia represents the most frequent bacterial infection in patients with HIV/AIDS.
   We aimed to assess variables associated with lower respiratory tract infection (LRTI) among HIV-infected adults using ART.
   A cohort study of HIV-infected patients aged >= 18 years, enrolled from 2000 to 2015, on ART for at least 60 days, with primary outcome as the 1st episode of LRTI during follow-up. The independent variables included were sex at birth, age, race/skin color, educational level, tobacco smoking, alcohol use, cocaine use, diabetes mellitus, CD4 count, HIV viral load, influenza and pneumococcal vaccination. Extended Cox proportional hazards models accounting for time-updated variables were fitted to assess LRTI predictors.
   2669 patients were included; median follow-up was 3.9 years per patient. LRTI was diagnosed in 384 patients; incidence rate was 30.7/1000 PY. In the unadjusted Cox extended models, non-white race [crude hazard ratio (cHR) 1.28, p = 0.020], cocaine use (cHR 2.01, p < 0.001), tobacco smoking (cHR 1.34, p value 0.007), and HIV viral load >= 400 copies/mL (cHR 3.40, p < 0.001) increased the risk of LRTI. Lower risk of LRTI was seen with higher educational level (cHR 0.61, p < 0.001), rise in CD4 counts (cHR 0.81, p < 0.001, per 100 cells/mm(3) increase), influenza (cHR 0.60, p = 0.002) and pneumococcal vaccination (cHR 0.57, p < 0.001). In the adjusted model, aHR for CD4 count was 0.86, for cocaine use 1.47 and for viral load >= 400 copies 2.20.
   LRTI has a high incidence in HIV-infected adults using ART. Higher CD4 counts and undetectable viral loads were protective, as were pneumococcal and influenza vaccines.
C1 [Lamas, Cristiane C.; Coelho, Lara E.; Grinsztejn, Beatriz J.; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365 Manguinhos, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Lamas, Cristiane C.] Univ Grande Rio, Rio De Janeiro, Brazil.
RP Lamas, CC (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365 Manguinhos, BR-21040900 Rio De Janeiro, RJ, Brazil.; Lamas, CC (corresponding author), Univ Grande Rio, Rio De Janeiro, Brazil.
EM cristianelamas@gmail.com
RI Lamas, Cristiane/AAV-4157-2020
OI Lamas, Cristiane/0000-0002-5561-999X
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01AI069923]; Eunice Kennedy Shriver
   National Institute of Child Health & Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); National Cancer Institute
   (NCI)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI);
   National Institute Of Allergy And Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); National Institute Of Mental Health (NIMH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH); Office
   Of The Director, National Institutes Of Health (OD)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069476, UM1AI069476, U01AI069923, UM1AI069476,
   U01AI069923, U01AI069923, UM1AI069476, UM1AI069476, U01AI069923,
   UM1AI069476, UM1AI069476, UM1AI069476, U01AI069923, UM1AI069476,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923] Funding Source: NIH RePORTER
FX We thank Dr. Michael Bruce Macrae for his assistance with language
   editing. This work was supported in part by the NIH-funded Caribbean,
   Central and South America network for HIV epidemiology (CCASAnet), a
   member cohort of the International Epidemiologic Databases to Evaluate
   AIDS (leDEA) (U01AI069923). This award is funded by the following
   institutes: Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD), National Cancer Institute (NCI), National
   Institute Of Allergy And Infectious Diseases (NIAID), National Institute
   Of Mental Health (NIMH), and the Office Of The Director, National
   Institutes Of Health (OD).".
CR Baez-Saldana R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138115
   Baldwin GC, 1997, AM J RESP CRIT CARE, V156, P1606, DOI 10.1164/ajrccm.156.5.9704146
   Barry PM, 2006, AIDS, V20, P437, DOI 10.1097/01.aids.0000206507.54901.84
   Beck CR, 2012, J INFECT DIS, V206, P1250, DOI 10.1093/infdis/jis487
   Benard A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008896
   BRASIL. Ministerio da Saude/Secretaria de Vigilancia em Saude. Departamento de DST Aids e Hepatites Virais, 2013, PROTOCOLO CLINICO E
   CAIAFFA WT, 1994, AM J RESP CRIT CARE, V150, P1493, DOI 10.1164/ajrccm.150.6.7952605
   *CDC, 1989, MMWR-MORBID MORTAL W, V38, P73
   Coelho L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098666
   Cook JA, 2011, LIFE SCI, V88, P931, DOI 10.1016/j.lfs.2011.01.003
   Crothers K, 2011, AM J RESP CRIT CARE, V183, P388, DOI 10.1164/rccm.201006-0836OC
   Curran A, 2008, HIV MED, V9, P609, DOI 10.1111/j.1468-1293.2008.00603.x
   Feikin DR, 2004, LANCET INFECT DIS, V4, P445, DOI 10.1016/S1473-3099(04)01060-6
   Ford N, 2015, LANCET HIV, V2, pE438, DOI 10.1016/S2352-3018(15)00137-X
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Izquierdo C, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-421
   Jasti H, 2008, CLIN INFECT DIS, V46, P550, DOI 10.1086/526526
   Kim JH, 2013, INFECTION, V41, P545, DOI 10.1007/s15010-012-0386-7
   Kohli R, 2006, CLIN INFECT DIS, V43, P90, DOI 10.1086/504871
   Kornum JB, 2012, EUR RESPIR J, V39, P149, DOI 10.1183/09031936.00000611
   Lewden C, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18797
   Lima VD, 2015, LANCET HIV, V2, pE92, DOI 10.1016/S2352-3018(15)00017-X
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Mullerova H, 2012, RESP MED, V106, P1124, DOI 10.1016/j.rmed.2012.04.008
   Nacher M, 2009, AIDS, V23, P2223, DOI 10.1097/QAD.0b013e32833147c2
   Pedersen RH, 2011, HIV MED, V12, P323, DOI 10.1111/j.1468-1293.2010.00892.x
   Ribeiro SR, 2014, ANTIVIR THER, V19, P387, DOI 10.3851/IMP2716
   Schwarcz L, 2013, AIDS, V27, P597, DOI 10.1097/QAD.0b013e32835b0fa2
   Sogaard OS, 2013, J INFECTION, V66, P439, DOI 10.1016/j.jinf.2012.12.012
   Sogaard OS, 2008, CLIN INFECT DIS, V47, P1345, DOI 10.1086/592692
   Stelianides S, 1999, EUR J CLIN MICROBIOL, V18, P704, DOI 10.1007/s100960050382
   Torres A, 2013, THORAX, V68, P1057, DOI 10.1136/thoraxjnl-2013-204282
   Tyagi M, 2016, J NEUROVIROL, V22, P261, DOI 10.1007/s13365-015-0398-z
NR 33
TC 12
Z9 12
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
PD DEC
PY 2017
VL 45
IS 6
BP 801
EP 809
DI 10.1007/s15010-017-1041-0
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA FN6IN
UT WOS:000416117700006
PM 28660356
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Lodi, S
   Costagliola, D
   Sabin, C
   del Amo, J
   Logan, R
   Abgrall, S
   Reiss, P
   van Sighem, A
   Jose, S
   Blanco, JR
   Hernando, V
   Bucher, HC
   Kovari, H
   Segura, F
   Ambrosioni, J
   Gogos, CA
   Pantazis, N
   Dabis, F
   Vandenhende, MA
   Meyer, L
   Seng, R
   Gill, MJ
   Krentz, H
   Phillips, AN
   Porter, K
   Grinsztejn, B
   Pacheco, AG
   Muga, R
   Tate, J
   Justice, A
   Hernan, MA
AF Lodi, Sara
   Costagliola, Dominique
   Sabin, Caroline
   del Amo, Julia
   Logan, Roger
   Abgrall, Sophie
   Reiss, Peter
   van Sighem, Ard
   Jose, Sophie
   Blanco, Jose-Ramon
   Hernando, Victoria
   Bucher, Heiner C.
   Kovari, Helen
   Segura, Ferran
   Ambrosioni, Juan
   Gogos, Charalambos A.
   Pantazis, Nikos
   Dabis, Francois
   Vandenhende, Marie-Anne
   Meyer, Laurence
   Seng, Remonie
   Gill, M. John
   Krentz, Hartmut
   Phillips, Andrew N.
   Porter, Kholoud
   Grinsztejn, Beatriz
   Pacheco, Antonio G.
   Muga, Roberto
   Tate, Janet
   Justice, Amy
   Hernan, Miguel A.
TI Effect of Immediate Initiation of Antiretroviral Treatment in
   HIV-Positive Individuals Aged 50 Years or Older
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT Conference on Retroviruses and Opportunistic Infections (CROI)
CY FEB 22-25, 2016
CL Boston, MA
SP CROI Fdn, Int Antiviral Soc
DE aging; when to start; antiretroviral treatment; CD4 cell count; causal
   inference; parametric g-formula; comparative effectiveness
ID PARAMETRIC G-FORMULA; RISK-FACTORS; THERAPY; COHORT; INFECTION;
   MORTALITY; EUROPE
AB Background: Clinical guidelines recommend immediate initiation of combined antiretroviral therapy for all HV-positive individuals. However, those guidelines are based on trials of relatively young participants.
   Methods: We included HIV-positive antiretroviral therapy-naive, AIDS-free individuals aged 50-70 years after 2004 in the HIV-CAUSAL Collaboration. We used the parametric g-formula to estimate the 5-year risk of all-cause and non-AIDS mortality under (1) immediate initiation at baseline and initiation at CD4 count, (2) <500 cells/mm(3), and (3) <350 cells/mm(3).
   Results were presented separately for the general HIV population and for a US Veterans cohort with high mortality. Results: The study included 9596 individuals (28% US Veterans) with median (interquantile range) age of 55 (52-60) years and CD4 count of 336 (182-513) at baseline. The 5-year risk of all-cause mortality was 0.40% (95% confidence interval (CI): 0.10 to 0.71) lower for the general HIV population and 1.61% (95% CI: 0.79 to 2.67) lower for US Veterans when comparing immediate initiation vs initiation at CD4 <350 cells/mm(3). The 5-year risk of non-AIDS mortality was 0.17% (95% CI: 20.07 to 0.43) lower for the general HIV population and 1% (95% CI: 0.31 to 2.00) lower for US Veterans when comparing immediate initiation vs initiation at CD4 <350 cells/mm(3).
   Conclusions: Immediate initiation seems to reduce all-cause and non-AIDS mortality in patients aged 50-70 years.
C1 [Lodi, Sara; Logan, Roger; Hernan, Miguel A.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Costagliola, Dominique; Abgrall, Sophie] UPMC, Sorbonne Univ, Univ Paris 06, INSERM,Inst Pierre Louis Epidemiol & Sante Publ I, Paris, France.
   [Sabin, Caroline; Jose, Sophie] UCL, Inst Global Hlth, London, England.
   [del Amo, Julia; Hernando, Victoria; Phillips, Andrew N.; Porter, Kholoud] Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid, Spain.
   [del Amo, Julia; Hernando, Victoria] Inst Salud Carlos III, CIBERESP, Madrid, Spain.
   [Abgrall, Sophie] Hop Antoine Beclere, AP HP, Serv Med Interne, Clamart, France.
   [Reiss, Peter; van Sighem, Ard] Stichting HIV Monitoring, Amsterdam, Netherlands.
   [Reiss, Peter] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, Amsterdam, Netherlands.
   [Reiss, Peter] Univ Amsterdam, Div Infect Dis, Amsterdam, Netherlands.
   [Reiss, Peter] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands.
   [Blanco, Jose-Ramon] Hosp San Pedro CIBIR, Logrono, Spain.
   [Bucher, Heiner C.] Univ Basel, Univ Basel Hosp, Basel Inst Clin Epidemiol & Biostat, Basel, Switzerland.
   [Kovari, Helen] Univ Zurich, Div Infect Dis, Zurich, Switzerland.
   [Kovari, Helen] Univ Zurich, Univ Zurich Hosp, Hosp Epidemiol, Zurich, Switzerland.
   [Segura, Ferran] Hosp Parc Tauli, Infect Dis Dept, Sabadell, Spain.
   [Ambrosioni, Juan] Hosp Clin IDIBAPS, Barcelona, Spain.
   [Gogos, Charalambos A.] Patras Univ Hosp, Div Infect Dis, Patras, Greece.
   [Pantazis, Nikos] Univ Athens, Fac Med, Dept Hyg Epidemiol & Med Stat, Athens, Greece.
   [Dabis, Francois; Vandenhende, Marie-Anne] Univ Bordeaux, ISPED, Ctr INSERM U Epidemiol & Biostat 1219, Bordeaux, France.
   [Dabis, Francois; Vandenhende, Marie-Anne] Univ Bordeaux, Ctr INSERM U Epidemiol & Biostat 1219, Bordeaux, France.
   [Vandenhende, Marie-Anne] Bordeaux Univ Hosp, Dept Internal Med, Bordeaux, France.
   [Meyer, Laurence] Univ Paris Sud, UMR 1018, Paris, France.
   [Meyer, Laurence; Seng, Remonie] INSERM, UMR 1018, Paris, France.
   [Meyer, Laurence; Seng, Remonie] Hop Bicetre, AP HP, Serv Sante Publ, Paris, France.
   [Gill, M. John; Krentz, Hartmut] Southem Alberta Clin, Calgary, AB, Canada.
   [Gill, M. John; Krentz, Hartmut] Univ Calgary, Dept Med, Calgary, AB, Canada.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Pacheco, Antonio G.] Fundacao Oswaldo Cruz, Programa Computacao Cientif, Rio De Janeiro, Brazil.
   [Muga, Roberto] Hosp Badalona Germans Trias & Pujol, Badalona, Spain.
   [Tate, Janet; Justice, Amy] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
   [Justice, Amy] VA Connecticut Healthcare Syst, West Haven, CT USA.
   [Hernan, Miguel A.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Hernan, Miguel A.] Harvard MET Div Hlth Sci & Technol, Boston, MA USA.
RP Lodi, S (corresponding author), Harvard TH Chan Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA.
EM slodi@hsph.harvard.edu
RI Vandenhende, Marie-Anne/T-6625-2019; Phillips, Andrew N/B-4427-2008;
   Dodsley, Maria/G-7083-2016; DEL AMO VALERO, JULIA/M-7020-2015; DABIS,
   FRANCOIS/S-9298-2019; Blanco, Jose-Ramon/L-6768-2018; Sabin,
   Caroline/C-2464-2008; Pacheco, Antonio Guilherme/E-6378-2013;
   Costagliola, Dominique/H-5849-2011; Gill, Michael John/G-7083-2016;
   HERNANDO, VICTORIA/E-1740-2015
OI Phillips, Andrew N/0000-0003-2384-4807; Dodsley,
   Maria/0000-0001-7587-558X; DEL AMO VALERO, JULIA/0000-0002-3104-540X;
   DABIS, FRANCOIS/0000-0002-1614-8857; Blanco,
   Jose-Ramon/0000-0002-4268-0150; Sabin, Caroline/0000-0001-5173-2760;
   Pacheco, Antonio Guilherme/0000-0003-3095-1774; Costagliola,
   Dominique/0000-0003-0765-0869; Hernan, Miguel/0000-0003-1619-8456; Gill,
   Michael John/0000-0002-8546-8790; Porter, Kholoud/0000-0002-9226-6206;
   HERNANDO, VICTORIA/0000-0003-2762-4924
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 AI102634]; UK Medical Research
   CouncilMedical Research Council UK (MRC) [G0000199, G0600337, 60900274,
   M004236]; Gilead SciencesGilead Sciences; BMSBristol-Myers Squibb; Viiv
   Healthcare; JanssenJohnson & Johnson USAJanssen Biotech Inc;
   AbbvieAbbott Laboratories; MSD; Bristol-Myers SquibbBristol-Myers
   Squibb; MerckMerck & Company; GileadGilead Sciences;
   Janssen-CilagJohnson & Johnson USAJanssen Biotech Inc; Dutch Ministry of
   Health, Welfare and Sport; Medical Research CouncilMedical Research
   Council UK (MRC) [MR/M004236/1, G0600337, MC_UU_12023/15, G0900274]
   Funding Source: researchfish; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR001863, UL1TR001863,
   UL1TR001863, UL1TR001863, UL1TR001863, UL1TR001863, UL1TR001863,
   UL1TR001863, UL1TR001863] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI102634, R01AI102634, R01AI102634, R01AI102634, R01AI102634]
   Funding Source: NIH RePORTER
FX The HIV-CAUSAL Collaboration is funded by NIH Grant R01 AI102634. UK
   CHIC is funded by the UK Medical Research Council (Grant numbers
   G0000199, G0600337, 60900274, and M004236). The views expressed in this
   manuscript are those of the researchers and not necessarily those of the
   Medical Research Council.; H.C.B. or his institution has received
   honorarium, support to attend conferences or unrestricted research
   grants from Gilead Sciences, BMS, Viiv Healthcare, Janssen, Abbvie, MSD
   in the last 3 years preceding the submission date of this manuscript.
   J.-R.B. has carried out consulting work for Abbvie, Bristol-Myers
   Squibb, Gilead Sciences, Janssen, Merck, and ViiV Healthcare; has
   received compensation for lectures from Abbvie, Bristol-Myers Squibb,
   Gilead Sciences, Janssen, Merck, and ViiV Healthcare, as well as grants
   and payments for the development of educational presentations for Gilead
   Sciences, Bristol-Myers Squibb, and VIIV Healthcare. A N.P. has received
   payment for invited presentations from Gilead Sciences. S.J. received
   speakers fees from Gilead. C.S. received funding from Gilead Sciences,
   ViiV Healthcare and Janssen-Cilag for the membership of Data Safety and
   Monitoring Boards, Advisory Boards, Speaker Panels and for the
   preparation of educational materials. A.v.S. reports grants from Dutch
   Ministry of Health, Welfare and Sport, during the conduct of the study;
   grants from European Centre for Disease Prevention and Control, personal
   fees from ViiV Healthcare, personal fees from Gilead Sciences, personal
   fees from Janssen-Cilag, outside the submitted work. M.-A.V. received
   travel/meeting expenses from Gilead and Jansen-Cilag during the 36
   months prior to submission. J.A. received travel Grants from Gilead,
   ViiV and Janssen, symposium honoraria from Gilead and Janssen and
   research Grants from ViiV and is part of the advisory boards for
   Janssen. K.P. received personal fees from ViiV healthcare. J.d.A. has
   received research grants awarded to her team from Companies BMS, MSD,
   Gilead, ViiV. J.d.A. has received teaching fees from Companies MSD,
   Gilead, ViiV. M.J.G. has been on National HIV advisory boards to Gilead
   ViiV and Merck. D.C. reports grants from Merck-Sharp & Dohme-Chibret
   (2014-2016), ViiV (2015), and Janssen (current), personal fees from
   Janssen-Cilag (2016), and Merck-Sharp & Dohme-Chibret (2015) for
   lectures, personal fees from ViiV (2015), for
   travel/accomodations/meeting expenses, personal fees from Gilead France
   from July 2011 until December 2015 for being a member of the French HIV
   board, personal fees from Innavirvax (in 2015 and in 2016) for
   consultancy, outside the submitted work.
CR Althoff KN, 2010, CLIN INFECT DIS, V50, P1512, DOI 10.1086/652650
   ANCELLEPARK R, 1993, LANCET, V341, P441, DOI 10.1016/0140-6736(93)93040-8
   Babiker AG, 2001, J CLIN EPIDEMIOL, V54, pS16, DOI 10.1016/S0895-4356(01)00456-5
   Centers for Disease Control and Prevention, 2015, HIV SURV REP, V25
   Centers for Disease Control and Prevention, 2016, HIV SURVEILLANCE S
   Centers for Disease Control and Prevention, 2015, HIV SURV REP, V26
   Costagliola D, 2014, CURR OPIN HIV AIDS, V9, P294, DOI 10.1097/COH.0000000000000076
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Edwards JK, 2015, CLIN INFECT DIS, V61, P1189, DOI 10.1093/cid/civ463
   European AIDS clinical society (EACS), 2016, EUR GUID TREATM HIV
   European Centre for Disease Prevention and Control WHO Regional Office for Europe, 2013, HIV AIDS SURV EUR 20
   Grabar S, 2004, AIDS, V18, P2029, DOI 10.1097/00002030-200410210-00007
   Greene M, 2013, JAMA-J AM MED ASSOC, V309, P1397, DOI 10.1001/jama.2013.2963
   Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43
   Hernando V, 2012, AIDS, V26, P1829, DOI 10.1097/QAD.0b013e328352ada4
   Kaufmann GR, 2005, CLIN INFECT DIS, V41, P361, DOI 10.1086/431484
   Kramarow E. A, 2012, HLTH MALE VETERANS N
   Krentz HB, 2016, AIDS PATIENT CARE ST, V30, P11, DOI 10.1089/apc.2015.0199
   Lodi S, 2015, LANCET HIV, V2, pE335, DOI 10.1016/S2352-3018(15)00108-3
   Lodi S, 2014, AIDS, V28, P2297, DOI 10.1097/QAD.0000000000000410
   Lodi S, 2011, CLIN INFECT DIS, V53, P817, DOI 10.1093/cid/cir494
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   May MT, 2012, INT J EPIDEMIOL, V41, P1807, DOI 10.1093/ije/dys164
   Mocroft A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001510
   Molina JM, 2016, S AFR 21 INT AIDS C
   Panel on Antiretroviral Guidelines for Adults and Adolescents, 2016, GUIDELINES USE ANTIR
   ROBINS J, 1986, MATH MODELLING, V7, P1393, DOI 10.1016/0270-0255(86)90088-6
   Robins JM, 2009, CH CRC HANDB MOD STA, P553
   Sabin CA, 2008, AIDS, V22, P1463
   Schouten J, 2014, CLIN INFECT DIS, V59, P1787, DOI 10.1093/cid/ciu701
   Taubman SL, 2009, INT J EPIDEMIOL, V38, P1599, DOI 10.1093/ije/dyp192
   vourli G, 2017, HEPHIV C 2017 JAN 31
   World Health Organization, 2016, CONS GUID HIV PREV D
   Young JG, 2011, STAT BIOSCI, V3, P119, DOI 10.1007/s12561-011-9040-7
NR 34
TC 5
Z9 6
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD NOV 1
PY 2017
VL 76
IS 3
BP 311
EP 318
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FO3IP
UT WOS:000416721800018
PM 28746165
OA Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU Glidden, DV
   Mulligan, K
   McMahan, V
   Anderson, PL
   Guanira, J
   Chariyalertsak, S
   Buchbinder, SP
   Bekker, LG
   Schechter, M
   Grinsztejn, B
   Grant, RM
AF Glidden, David V.
   Mulligan, Kathleen
   McMahan, Vanessa
   Anderson, Peter L.
   Guanira, Juan
   Chariyalertsak, Suwat
   Buchbinder, Susan P.
   Bekker, Linda Gail
   Schechter, Mauro
   Grinsztejn, Beatriz
   Grant, Robert M.
TI Recovery of Bone Mineral Density After Discontinuation of
   Tenofovir-Based HIV Pre-exposure Prophylaxis
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE pre-exposure prophylaxis; tenofovir/emtricitabine; PrEP; bone mineral
   density; DXA scan
ID DOUBLE-BLIND; ANTIRETROVIRAL PROPHYLAXIS; DISOPROXIL FUMARATE;
   TRANSGENDER WOMEN; TRIAL; MEN; EMTRICITABINE/TENOFOVIR; INFECTION;
   EXPOSURE; FRACTURE
AB Background: Oral tenofovir disoproxil fumarate (TDF) for HIV prevention and treatment is associated with decreases in bone mineral density (BMD). Previous reports suggest that these changes may be reversible after discontinuation of TDF.
   Setting: A metabolic substudy of 498 participants in a randomized, placebo-controlled HIV prevention trial of oral coformulated TDF with emtricitabine (TDF/FTC, Truvada) for HIV pre-exposure prophylaxis (PrEP) enrolling a global sample of men who have sex with men and trans women.
   Methods: Participants underwent dual X-ray absorptiometry to quantify bone mineral density (BMD) in the hip and spine during PrEP and at 2 visits after stopping (median of 23 and 79 weeks post-PrEP, respectively). Results are stratified by pharmacologic measure of TDF/FTC adherence.
   Results: There was no significant difference in change in hip/spine BMD at any time point between placebo and those with low adherence. Adherent participants had a mean (standard error) BMD change at TDF/FTC discontinuation of -1.02% (0.24) in the hip and -1.84% (0.36) in the spine. After stop, annualized BMD increases of 1.13% per year (0.27) in hip and 1.81% per year (0.36) in spine BMD were observed in adherent participants compared with 0.19% (0.16) and 0.74% (0.21) in the placebo group, respectively (P = 0.003, both comparisons). On average, BMD returned to baseline levels by 1 year after PrEP stop. Recovery was consistent across age, baseline BMD z-score, and treatment duration.
   Conclusions: Mean BMD returns to baseline levels within 12-18 months after TDF-based PrEP discontinuation in both hip and spine with consistency across participant subgroups.
C1 [Glidden, David V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, 550 16th St, San Francisco, CA 94158 USA.
   [Mulligan, Kathleen] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [McMahan, Vanessa] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
   [Anderson, Peter L.] Univ Colorado, Dept Pharmaceut Sci, Denver, CO 80202 USA.
   [Guanira, Juan] Invest Med Salud, Lima, Peru.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Buchbinder, Susan P.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [Bekker, Linda Gail] Desmond Tutu HIV Fdn, Dept Med, Cape Town, South Africa.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, Hosp Escola Sao Francisco Assis, Projeto Praca Onze, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Evandro Chagas Natl Inst Infect Dis Fiocruz, Rio De Janeiro, Brazil.
   [Grant, Robert M.] Gladstone Inst Virol, San Francisco, CA USA.
   [Grant, Robert M.] San Francisco AIDS Fdn, San Francisco, CA USA.
RP Glidden, DV (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 550 16th St, San Francisco, CA 94158 USA.
EM david.glidden@ucsf.edu
RI Bekker, Linda-Gail/AAZ-8929-2020; Glidden, David/AAD-4730-2020;
   Schechter, Mauro/AAG-7445-2020
OI Grant, Robert/0000-0002-0851-7085; Glidden, David/0000-0001-5888-1419;
   BEKKER, LINDA-GAIL/0000-0002-0755-4386
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01 AI106499, UM1 AI068619, U01 AI064002, R03 AI120819, R03 AI122908];
   US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA; ViiV; Gilead
   SciencesGilead Sciences; Bill and Melinda Gates FoundationBill & Melinda
   Gates Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01AI069496, UM1AI069496, U01AI106499,
   U01AI069496, UM1AI069496, U01AI064002, U01AI064002, UM1AI068619,
   UM1AI069496, UM1AI068619, UM1AI069476, UM1AI069496, UM1AI069476,
   UM1AI069496, R01AI118575, UM1AI068619, UM1AI069476, UM1AI068619,
   UM1AI068619, UM1AI068619, R03AI122908, U01AI064002, UM1AI069476,
   U01AI106499, UM1AI069496, UM1AI068619, R01AI118575, U01AI064002,
   U01AI064002, U01AI069496, R01AI118575, UM1AI069476, UM1AI069476,
   R01AI118575, U01AI064002, UM1AI068619, U01AI106499, UM1AI069476,
   U01AI069496, R01AI118575, U01AI064002, U01AI064002, UM1AI069496,
   U01AI069496, R03AI122908, R03AI120819, U01AI106499, UM1AI069496,
   UM1AI068619, UM1AI069496, UM1AI068619, UM1AI069476, R01AI118575,
   U01AI064002, UM1AI068619, U01AI069496, UM1AI069476, R03AI120819,
   UM1AI069496, U01AI069496] Funding Source: NIH RePORTER
FX Supported by the National Institute of Allergy and Infectious Diseases
   (U01 AI106499, UM1 AI068619, U01 AI064002, R03 AI120819, R03 AI122908).
   Study medication was donated by Gilead Sciences.; The iPrEx studies were
   sponsored by the US National Institutes of Health with cofunding from
   the Bill and Melinda Gates Foundation; study medication was donated by
   Gilead Sciences, which also supported travel expenses for non-US
   investigators to attend study meetings. R.M.G. and D.V.G. have received
   fees from and R.M.G. has received a research grant from ViiV, a
   manufacturer of an investigational compound being investigated for use
   as PrEP. P.L.A. receives study drug and contract work from Gilead
   Sciences. All other authors have no conflicts to declare. The remaining
   authors have no conflicts of interest to disclose.
CR Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bedimo R, 2012, AIDS, V26, P825, DOI 10.1097/QAD.0b013e32835192ae
   Bianco C, 2014, J INT AIDS SOC, V17, P198, DOI [10.7448/IAS.17.4.19816, 10.7448/IAS.17.4.19818]
   Carpenter J. R., 2012, MULTIPLE IMPUTATION
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4
   Diggle PJ, ANAL LONGITUDINAL DA, P81
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grigsby IF, 2010, THER CLIN RISK MANAG, V6, P41
   Horizon AA, 2011, HIV AIDS-RES PALLIAT, V3, P53, DOI 10.2147/HIV.S15588
   Kasonde M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090111
   Liu AY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023688
   Mary-Krause M, 2012, J CLIN DENSITOM, V15, P422, DOI 10.1016/j.jocd.2012.04.001
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Mirembe BG, 2016, JAIDS-J ACQ IMM DEF, V71, P287, DOI 10.1097/QAI.0000000000000858
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Mulligan K, 2015, CLIN INFECT DIS, V61, P572, DOI 10.1093/cid/civ324
   Mundy LM, 2012, AIDS, V26, P1073, DOI 10.1097/QAD.0b013e328351997f
   Negredo E, 2014, J ANTIMICROB CHEMOTH, V69, P3368, DOI 10.1093/jac/dku300
   Sax PE, 2015, LANCET, V385, P2606, DOI 10.1016/S0140-6736(15)60616-X
   Solomon MM, 2014, AIDS, V28, P851, DOI 10.1097/QAD.0000000000000156
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Yong MK, 2011, JAIDS-J ACQ IMM DEF, V57, P205, DOI 10.1097/QAI.0b013e31821ecf4c
NR 25
TC 12
Z9 12
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2017
VL 76
IS 2
BP 177
EP 182
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FN6NV
UT WOS:000416133000016
PM 28639995
OA Green Accepted, Green Published
DA 2020-11-24
ER

PT J
AU Ramirez, BC
   Vega, YC
   Shepherd, BE
   Le, C
   Turner, M
   Frola, C
   Grinsztejn, B
   Cortes, C
   Padgett, D
   Sterling, TR
   McGowan, CC
   Person, A
AF Crabtree Ramirez, B.
   Caro Vega, Y.
   Shepherd, B. E.
   Le, C.
   Turner, M.
   Frola, C.
   Grinsztejn, B.
   Cortes, C.
   Padgett, D.
   Sterling, T. R.
   McGowan, C. C.
   Person, A.
TI Outcomes of HIV-positive patients with cryptococcal meningitis in the
   Americas
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Cryptococcal meningitis; AIDS defining events; HIV; AIDS; Latin America;
   Opportunistic Infections in HIV
ID ANTIRETROVIRAL THERAPY
AB Background: Cryptococcal meningitis (CM) is associated with substantial mortality in HIV-infected patients. Optimal timing of antiretroviral therapy (ART) in persons with CM represents a clinical challenge, and the burden of CM in Latin America has not been well described. Studies suggest that early ART initiation is associated with higher mortality, but data from the Americas are scarce.
   Methods: HIV-infected adults in care between 1985-2014 at participating sites in the Latin America (the Caribbean, Central and South America network (CCASAnet)) and the Vanderbilt Comprehensive Care Clinic (VCCC) and who had CM were included. Survival probabilities were estimated. Risk of death when initiating ART within the first 2 weeks after CM diagnosis versus initiating between 2-8 weeks was assessed using dynamic marginal structural models adjusting for site, age, sex, year of CM, CD4 count, and route of HIV transmission.
   Findings: 340 patients were included (Argentina 58, Brazil 138, Chile 28, Honduras 27, Mexico 34, VCCC 55) and 142 (42%) died during the observation period. Among 151 patients with CM prior to ART 56 (37%) patients died compared to 86 (45%) of 189 with CM after ART initiation (p = 0.14). Patients diagnosed with CM after ART had a higher risk of death (p = 0.03, log-rank test). The probability of survival was not statistically different between patients who started ART within 2 weeks of CM (7/24, 29%) vs. those initiating between 2-8 weeks (14/53, 26%) (p = 0.96), potentially due to lack of power.
   Interpretation: In this large Latin-American cohort, patients with CM had very high mortality rates, especially those diagnosed after ART initiation. This study reflects the overwhelming burden of CM in HIV-infected patients in Latin America. (C) 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Crabtree Ramirez, B.; Caro Vega, Y.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [Shepherd, B. E.; Le, C.; Turner, M.; Sterling, T. R.; McGowan, C. C.; Person, A.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Frola, C.] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Grinsztejn, B.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Cortes, C.] Univ Chile, Fdn Arriaran, Santiago, Chile.
   [Padgett, D.] Inst Hondureno Seguridad Social & Hosp Escuela, Tegucigalpa, Honduras.
RP Ramirez, BC (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
EM brenda.crabtree@infecto.mx
RI Cortes, Claudia/AAF-7326-2020
OI Cortes, Claudia/0000-0001-9101-9783; Crabtree-Ramirez,
   Brenda/0000-0002-2587-1123
FU NIH-funded CaribbeanUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Central and South
   America network for HIV epidemiology (CCASAnet); cohort of the
   International Epidemiologic Databases [U01AI069923]; Eunice Kennedy
   Shriver National Institute Of Child Health & Human Development
   (NICHD)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD); National Cancer
   Institute (NCI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); National Institute Of Allergy And Infectious Diseases
   (NIAID)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); National Institute Of Mental Health
   (NIMH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH); Office Of The DirectorNational Science Foundation (NSF)NSF -
   Office of the Director (OD); National Institutes Of Health (OD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA; NIH-funded Tennessee Center for AIDS ResearchUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [P30 AI110527]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P30AI110527, U01AI069923,
   P30AI110527, P30AI110527, P30AI110527, P30AI110527, U01AI069923,
   P30AI110527, P30AI110527, P30AI110527, P30AI110527, U01AI069923,
   P30AI110527, U01AI069923, U01AI069923, P30AI110527, P30AI110527,
   U01AI069923, P30AI110527, P30AI110527, P30AI110527, P30AI110527,
   P30AI110527, U01AI069923, U01AI069923, P30AI110527, U01AI069923,
   U01AI069923, P30AI110527, U01AI069923, U01AI069923, P30AI110527,
   P30AI110527, P30AI110527, P30AI110527, U01AI069923, P30AI110527,
   U01AI069923, U01AI069923, P30AI110527, P30AI110527, U01AI069923,
   U01AI069923, P30AI110527, P30AI110527, P30AI110527, P30AI110527,
   P30AI110527, P30AI110527, P30AI110527, P30AI110527, P30AI110527,
   U01AI069923, P30AI110527, P30AI110527, U01AI069923, P30AI110527,
   U01AI069923, P30AI110527, P30AI110527, U01AI069923, P30AI110527,
   U01AI069923, U01AI069923] Funding Source: NIH RePORTER
FX This work was supported in part by the NIH-funded Caribbean, Central and
   South America network for HIV epidemiology (CCASAnet), a member cohort
   of the International Epidemiologic Databases to Evaluate AIDS (leDEA)
   (U01AI069923). This award is funded by the following institutes: Eunice
   Kennedy Shriver National Institute Of Child Health & Human Development
   (NICHD), National Cancer Institute (NCI), National Institute Of Allergy
   And Infectious Diseases (NIAID), National Institute Of Mental Health
   (NIMH), and Office Of The Director, National Institutes Of Health (OD).
   This work was also supported in part by the NIH-funded Tennessee Center
   for AIDS Research (P30 AI110527).`
CR Anekthananon T, 2011, INT J STD AIDS, V22, P665, DOI 10.1258/ijsa.2011.010538
   Bamba S, 2012, AIDS, V26, P1039, DOI 10.1097/QAD.0b013e328352d1d8
   Bisson GP, 2013, CLIN INFECT DIS, V56, P1165, DOI 10.1093/cid/cit019
   Boulware DR, 2014, NEW ENGL J MED, V370, P2487, DOI 10.1056/NEJMoa1312884
   Cain LE, 2016, INT J EPIDEMIOL, V45, P2038, DOI 10.1093/ije/dyv295
   Department of Health and Human Services, 2016, GUID US ANT AG HIV 1
   Ingle SM, 2015, CROI IN PRESS
   Jarvis JN, 2007, AIDS, V21, P2119, DOI 10.1097/QAD.0b013e3282a4a64d
   Makadzange AT, 2010, CLIN INFECT DIS, V50, P1532, DOI 10.1086/652652
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   Njei B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009012.pub2
   Park BJ, 2009, AIDS, V23, P525, DOI 10.1097/QAD.0b013e328322ffac
   Perfect JR, 2010, CLIN INFECT DIS, V50, P291, DOI 10.1086/649858
   Ramirez B Crabtree, 2011, PLOS ONE, V6
   Shepherd BE, 2016, STAT MED, V35, P4335, DOI 10.1002/sim.7007
   Tshepo BL, 2017, CROI IN PRESS
   Vidal JE, 2013, BRAZ J INFECT DIS, V17, P353, DOI 10.1016/j.bjid.2012.10.020
   WHO, 2011, AD CHILDR
NR 18
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD OCT
PY 2017
VL 63
BP 57
EP 63
DI 10.1016/j.ijid.2017.08.004
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA FI1PH
UT WOS:000411705700010
PM 28807740
OA DOAJ Gold, Green Accepted
DA 2020-11-24
ER

PT J
AU Machado, IK
   Luz, PM
   Lake, JE
   Castro, R
   Velasque, L
   Clark, JL
   Veloso, VG
   Grinsztejn, B
   De Boni, RB
AF Machado, Iona K.
   Luz, Paula M.
   Lake, Jordan E.
   Castro, Rodolfo
   Velasque, Luciane
   Clark, Jesse L.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   De Boni, Raquel B.
TI Self-rated health and substance use among individuals in HIV care in Rio
   de Janeiro, Brazil: a cross-sectional study
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE Self-rated health; substance use; HIV/AIDS; self-assessment
ID ALCOHOL-CONSUMPTION; UNITED-STATES; OLDER-ADULTS; MORTALITY; DISEASE;
   INFECTION; DRINKING; PEOPLE
AB Self-rated health (SRH) is associated with morbidity and mortality in HIV-uninfected populations but is understudied in HIV. Substance use may affect SRH in addition to its deleterious effect on HIV disease. This analysis aimed to estimate SRH and substance use prevalence and evaluate factors associated with poor SRH among individuals in HIV care in Rio de Janeiro, Brazil. A convenience sample of HIV-infected adults completed one item of SRH, the Alcohol, Smoking and Substance Involvement Screening Test, and the Patient Health Questionnaire-2 (PHQ-2). Logistic regression models identified factors associated with poor SRH. Participants' (n = 1029) median age was 42.9 years, 64.2% were male, and 54.5% were nonwhite. Poor SRH was reported by 19.5% and the use of alcohol, tobacco, marijuana, and crack/cocaine by 30.1, 19.5, 3.9, and 3.5%, respectively. Less than high school education (adjusted odds ratio [aOR] 1.54, 95% confidence interval [CI]: 1.08-2.20), lack of sexual activity in previous 12 months (aOR 1.53, 95% CI: 1.01-2.30), crack/cocaine use (aOR 3.82, 95% CI: 1.80-8.09), positive PHQ-2 screen (aOR 3.43, 95% CI: 2.09-5.62), and HIV-1 RNA >= 40 c/ml (aOR 2.51, 95% CI: 1.57-4.02) were significantly associated with poor SRH as identified by logistic regression analyses. Alcohol, marijuana, and sedative use were not significantly associated with poor SRH. These results emphasize the need for substance use and mental health screening and treatment in this population. Further research may elucidate the consequences of poor SRH on treatment adherence, morbidity, and mortality in HIV-infected individuals.
C1 [Machado, Iona K.; Lake, Jordan E.; Clark, Jesse L.] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Machado, Iona K.] Columbia Coll Phys & Surg, New York, NY USA.
   [Luz, Paula M.; Castro, Rodolfo; Veloso, Valdilea G.; Grinsztejn, Beatriz; De Boni, Raquel B.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Castro, Rodolfo; Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Rio De Janeiro, Brazil.
RP Machado, IK (corresponding author), 630 W 168th St, New York, NY 10032 USA.
EM ikm2105@columbia.edu
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Castro, Rodolfo/D-4231-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Castro,
   Rodolfo/0000-0002-0701-2528; Luz, Paula/0000-0001-9746-719X; Clark,
   Jesse/0000-0001-5862-6530
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R25 MH087222];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [476024/2013-7]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [K23 AI110532]; leDEA
   [U01AI069923]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [K23AI110532, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, UM1AI069476, U01AI069923, UM1AI069476,
   U01AI069923, U01AI069923, U01AI069923, K23AI110532, U01AI069923,
   UM1AI069476, UM1AI069476, UM1AI069476, K23AI110532, U01AI069923,
   U01AI069923, UM1AI069476, K23AI110532, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   UM1AI069476, UM1AI069476, K23AI110532, U01AI069923, U01AI069923,
   K23AI110532, U01AI069923, UM1AI069476, U01AI069923, U01AI069923] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107] Funding Source: NIH RePORTER
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   funded by the National Institutes of Health grants R25 MH087222 (South
   American Program in HIV Research) and K23 AI110532 in addition to the
   NIH-funded Caribbean, Central and South America network for HIV
   epidemiology (CCASAnet), a member cohort of the International
   Epidemiologic Databases to Evaluate AIDS (leDEA, U01AI069923), and the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   476024/2013-7).
CR Basson R, 2010, J SEX MED, V7, P374, DOI 10.1111/j.1743-6109.2009.01621.x
   Bell C, 2010, JAIDS-J ACQ IMM DEF, V54, P376, DOI 10.1097/QAI.0b013e3181d01d31
   Benyamini Y, 2011, PSYCHOL HEALTH, V26, P1407, DOI 10.1080/08870446.2011.621703
   Blanco JR, 2012, AIDS RES HUM RETROV, V28, P800, DOI [10.1089/aid.2011.0377, 10.1089/AID.2011.0377]
   Blazer DG, 2009, AM J GERIAT PSYCHIAT, V17, P237, DOI 10.1097/JGP.0b013e318190b8ef
   de Souza PRB, 2011, CAD SAUDE PUBLICA, V27, pS56, DOI 10.1590/S0102-311X2011001300007
   Brasil MDS, PESQ CONH AT PRAT PO
   Brasil MDS, PROT CLIN DIR TER UT
   Cagney KA, 2005, J GERONTOL B-PSYCHOL, V60, pS181, DOI 10.1093/geronb/60.4.S181
   Centers for Disease Control and Prevention, 1993, MMWR RECOMM REP, V41, P1
   Cott CA, 1999, J EPIDEMIOL COMMUN H, V53, P731, DOI 10.1136/jech.53.11.731
   Dageid W, 2015, J HEALTH PSYCHOL, V20, P1463, DOI 10.1177/1359105313513623
   De Boni RB, 2016, AIDS BEHAV, V20, P2692, DOI 10.1007/s10461-016-1398-6
   DeSalvo KB, 2006, J GEN INTERN MED, V21, P267, DOI 10.1111/j.1525-1497.2005.00291.x
   Dowd JB, 2007, INT J EPIDEMIOL, V36, P1214, DOI 10.1093/ije/dym214
   Falck RS, 2000, ADDICT BEHAV, V25, P579, DOI 10.1016/S0306-4603(99)00040-4
   Fleishman JA, 1998, MED CARE, V36, P533, DOI 10.1097/00005650-199804000-00009
   Franks P, 2003, SOC SCI MED, V56, P2505, DOI 10.1016/S0277-9536(02)00281-2
   Frisher M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1993-x
   Galvan FH, 2002, J STUD ALCOHOL, V63, P179, DOI 10.15288/jsa.2002.63.179
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Henrique Iara Ferraz Silva, 2004, Rev. Assoc. Med. Bras., V50, P199, DOI 10.1590/S0104-42302004000200039
   Huang CQ, 2010, AGE AGEING, V39, P23, DOI 10.1093/ageing/afp187
   IBGE IB de G e, 2013, PESQ NAC SAU 2013 PE
   Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359
   Jylha M, 2006, J CLIN EPIDEMIOL, V59, P465, DOI 10.1016/j.jclinepi.2005.12.004
   Jylha M, 2009, SOC SCI MED, V69, P307, DOI 10.1016/j.socscimed.2009.05.013
   Kawachi I, 1999, AM J PUBLIC HEALTH, V89, P1187, DOI 10.2105/AJPH.89.8.1187
   Kondo N, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4471
   Krumpal I, 2013, QUAL QUANT, V47, P2025, DOI 10.1007/s11135-011-9640-9
   Leserman J, 2008, PSYCHOSOM MED, V70, P539, DOI 10.1097/PSY.0b013e3181777a5f
   Lorraine Phillips J, 2005, Prev Chronic Dis, V2, pA12
   MATICKA-TYNDALE E., 2002, CANADIAN J HUMAN SEX, V11, P33
   Mimiaga MJ, 2013, AM J PUBLIC HEALTH, V103, P1457, DOI 10.2105/AJPH.2012.301162
   Mrus JM, 2006, QUAL LIFE RES, V15, P503, DOI 10.1007/s11136-005-1946-4
   Nahvi S, 2009, AIDS EDUC PREV, V21, P14, DOI 10.1521/aeap.2009.21.3_supp.14
   Osorio FD, 2009, PERSPECT PSYCHIATR C, V45, P216, DOI 10.1111/j.1744-6163.2009.00224.x
   Pinquart M, 2001, PSYCHOL AGING, V16, P414, DOI 10.1037//0882-7974.16.3.414
   Rosenbloom MJ, 2007, J STUD ALCOHOL DRUGS, V68, P115, DOI 10.15288/jsad.2007.68.115
   Singer M, 2003, MED ANTHROPOL Q, V17, P423, DOI 10.1525/maq.2003.17.4.423
   Sun W, 2014, INT J INFECT DIS, V28, P147, DOI 10.1016/j.ijid.2014.07.010
   Szwarcwald Célia Landmann, 2005, Cad. Saúde Pública, V21, pS54, DOI 10.1590/S0102-311X2005000700007
   Tobias CR, 2007, AIDS PATIENT CARE ST, V21, P426, DOI 10.1089/apc.2006.0138
   Torres TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115900
   Valencia-Martin JL, 2009, ALCOHOL CLIN EXP RES, V33, P240, DOI 10.1111/j.1530-0277.2008.00826.x
   Wu S, 2013, BMC PUBLIC HEALTH, V13, P9
NR 46
TC 4
Z9 4
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD OCT
PY 2017
VL 28
IS 12
BP 1175
EP 1183
DI 10.1177/0956462417692278
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FH9BE
UT WOS:000411500500003
PM 28152664
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Vieira, VA
   Avelino-Silva, VI
   Cerqueira, NB
   Costa, DA
   Costa, PR
   Vasconcelos, RP
   Madruga, VR
   Moreira, RI
   Hoagland, B
   Veloso, VG
   Grinsztejn, B
   Kallas, EG
AF Vieira, Vinicius A.
   Avelino-Silva, Vivian I.
   Cerqueira, Natalia B.
   Costa, Dayane A.
   Costa, Priscilla R.
   Vasconcelos, Ricardo P.
   Madruga, Valdez R.
   Moreira, Ronaldo I.
   Hoagland, Brenda
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Kallas, Esper G.
CA PrEP Brasil Study Team
TI Asymptomatic anorectal Chlamydia trachomatis and Neisseria gonorrhoeae
   infections are associated with systemic CD8(+) T-cell activation
SO AIDS
LA English
DT Article
DE cellular immunity; Chlamydia trachomatis; HIV; immune activation;
   Neisseria gonorrhoeae; preexposure prophylaxis; T lymphocyte
ID HIV PREEXPOSURE PROPHYLAXIS; SEXUALLY-TRANSMITTED INFECTIONS; IMMUNE
   ACTIVATION; HIGH-RISK; TRANSGENDER WOMEN; RECTAL GONORRHEA;
   GENITAL-TRACT; UNITED-STATES; MEN; SEX
AB Background: Oral preexposure prophylaxis (PrEP) has been established as a pivotal strategy in HIV prevention. However, bacterial sexually transmitted infections (STIs), such as Chlamydia trachomatis and Neisseria gonorrhoeae, are also highly prevalent. Although the presence of STI-related mucosal lesions is a known risk factor for HIV acquisition, the potential increase in risk associated with asymptomatic STIs is not completely understood. Recent data demonstrated higher T-cell activation is a risk factor for sexually acquired HIV-1 infection. We examined the effect of asymptomatic C. trachomatis and N. gonorrhoeae anorectal infection on systemic immune activation, potentially increasing the risk of HIV acquisition.
   Methods: We analyzed samples from participants of PrEP Brasil, a demonstration study of daily oral emtricitabine/tenofovir disoproxil fumarate HIV PrEP among healthy MSM, for T-cell activation by flow cytometry. We included 34 asymptomatic participants with anorectal swab for C. trachomatis and/or N. gonorrhoeae infection, whereas negative for other STIs, and 35 controls.
   Results: We found a higher frequency of human leukocyte antigen DR(+)CD3(+)CD8(+)T cells (1.5 vs. 0.9%, P<0.005) and with memory phenotype in the group with asymptomatic C. trachomatis and/or N. gonorrhoeae infection. Exhaustion and senescence markers were also significant higher in this group. No difference was observed in the soluble CD14 levels.
   Conclusion: Our findings suggest asymptomatic anorectal C. trachomatis and/or N. gonorrhoeae increase systemic immune activation, potentially increasing the risk of HIV acquisition. Regular screening and treatment of asymptomatic STIs should be explored as adjuvant tools for HIV prevention. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Vieira, Vinicius A.; Cerqueira, Natalia B.; Costa, Dayane A.; Costa, Priscilla R.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Vasconcelos, Ricardo P.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, SP, Brazil.
   [Avelino-Silva, Vivian I.] Hosp Sirio Libanes, Inst Ensino & Pesquisa, Sao Paulo, SP, Brazil.
   [Madruga, Valdez R.] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, SP, Brazil.
   [Moreira, Ronaldo I.; Hoagland, Brenda; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
EM esper.kallas@usp.br
RI Vasconcelos, Ricardo/AAL-4634-2020; Avelino-Silva, Vivian I/L-2640-2013
OI Vasconcelos, Ricardo/0000-0002-9753-0563; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Kallas, Esper/0000-0003-2026-6925
FU Brazilian Ministry of Health [01/2013 BRA/K57]; National Counsel of
   Technological and Scientific Development - CNPqNational Council for
   Scientific and Technological Development (CNPq) [402004/2012-4,
   454931/2014-0]; SVS [281/2013]; Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro - FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ) [E-26/110.261/2014];
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/51743-0];
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Programa de Excelencia Academica - PROEX Program, Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - CAPES
FX The current work and PrEP Brasil study was supported by the Brazilian
   Ministry of Health (#01/2013 BRA/K57), National Counsel of Technological
   and Scientific Development - CNPq (#402004/2012-4, #454931/2014-0) SVS
   (#281/2013), Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro -
   FAPERJ (#E-26/110.261/2014) and Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo - FAPESP (#2012/51743-0). Gilead Sciences donated the study
   drug and covered the costs related to drug level assessment. D.A.C.'s
   scholarship was funded by FAPESP; P.R.C.'s scholarship was funded by
   Programa de Excelencia Academica - PROEX Program, Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - CAPES.
CR Avelino-Silva VI, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005219
   Baker J, 2009, AIDS PATIENT CARE ST, V23, P585, DOI 10.1089/apc.2008.0277
   Begaud E, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-35
   Bernstein KT, 2010, JAIDS-J ACQ IMM DEF, V53, P537, DOI 10.1097/QAI.0b013e3181c3ef29
   Blumenthal Jill, 2014, Virtual Mentor, V16, P909, DOI 10.1001/virtualmentor.2014.16.11.stas1-1411
   Buchbinder SP, 2014, LANCET INFECT DIS, V14, P468, DOI 10.1016/S1473-3099(14)70025-8
   Card CM, 2009, J INFECT DIS, V199, P1318, DOI 10.1086/597801
   Centers for Disease Control and Prevention, SEX TRANSM DIS SURV
   Cohen MS, 1998, LANCET, V351, P5
   Cohen Myron S, 2004, Top HIV Med, V12, P104
   CRAIB KJP, 1995, GENITOURIN MED, V71, P150, DOI 10.1136/sti.71.3.150
   Cunha CB, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2002-0
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Fichorova RN, 2001, INFECT IMMUN, V69, P5840, DOI 10.1128/IAI.69.9.5840-5848.2001
   Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145
   Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   HAHN T, 1989, CLIN IMMUNOL IMMUNOP, V50, P53, DOI 10.1016/0090-1229(89)90221-3
   Horton RE, 2010, J INFECT DIS, V202, pS377, DOI 10.1086/655971
   Hunt PW, 2012, CURR HIV-AIDS REP, V9, P139, DOI 10.1007/s11904-012-0118-8
   Kaech SM, 2001, NAT IMMUNOL, V2, P415
   Kahle EM, 2015, J INFECT DIS, V211, P1451, DOI 10.1093/infdis/jiu621
   Koning FA, 2005, J IMMUNOL, V175, P6117, DOI 10.4049/jimmunol.175.9.6117
   Kuebler PJ, 2016, J INFECT DIS, V213, P569, DOI 10.1093/infdis/jiv425
   Lee HSW, 2008, J IMMUNOL, V180, P6827, DOI 10.4049/jimmunol.180.10.6827
   Liu AY, 2013, JAIDS-J ACQ IMM DEF, V64, P87, DOI 10.1097/QAI.0b013e31828f097a
   Masson L, 2015, CLIN INFECT DIS, V61, P260, DOI 10.1093/cid/civ298
   Masson L, 2014, SEX TRANSM INFECT, V90, P580, DOI 10.1136/sextrans-2014-051601
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   McLaren PJ, 2010, J INFECT DIS, V202, pS339, DOI 10.1086/655968
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Murali-Krishna K, 2000, J IMMUNOL, V165, P1733, DOI 10.4049/jimmunol.165.4.1733
   Pathela P, 2015, CLIN INFECT DIS, V61, P281, DOI 10.1093/cid/civ289
   Pathela P, 2013, CLIN INFECT DIS, V57, P1203, DOI 10.1093/cid/cit437
   Pattacini L, 2016, JAIDS-J ACQ IMM DEF, V72, P119, DOI 10.1097/QAI.0000000000000919
   Reddy BS, 2004, CLIN EXP IMMUNOL, V137, P552, DOI 10.1111/j.1365-2249.2004.02564.x
   Redgrove KA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00534
   Restrepo C, 2010, J IMMUNOL, V185, P982, DOI 10.4049/jimmunol.1000221
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   Scott HM, 2016, AIDS RES THER, V13, DOI 10.1186/s12981-016-0089-8
   Sheth PM, 2008, J INFECT DIS, V197, P1394, DOI 10.1086/587697
   Solomon MM, 2014, CLIN INFECT DIS, V59, P1020, DOI 10.1093/cid/ciu450
   Tao GY, 2016, CLIN INFECT DIS, V63, P1325, DOI 10.1093/cid/ciw594
   Volk JE, 2015, CLIN INFECT DIS, V61, P1601, DOI 10.1093/cid/civ778
   Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862
NR 45
TC 1
Z9 1
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD SEP 24
PY 2017
VL 31
IS 15
BP 2069
EP 2076
DI 10.1097/QAD.0000000000001580
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA FG8ZM
UT WOS:000410727600004
PM 28692536
DA 2020-11-24
ER

PT J
AU Jalil, EM
   Wilson, EC
   Luz, PM
   Velasque, L
   Moreira, RI
   Castro, CV
   Monteiro, L
   Garcia, ACF
   Cardoso, SW
   Coelho, LE
   McFarland, W
   Liu, AY
   Veloso, VG
   Buchbinder, S
   Grinsztejn, B
AF Jalil, Emilia M.
   Wilson, Erin C.
   Luz, Paula M.
   Velasque, Luciane
   Moreira, Ronaldo I.
   Castro, Cristiane V.
   Monteiro, Laylla
   Garcia, Ana Cristina F.
   Cardoso, Sandra W.
   Coelho, Lara E.
   McFarland, Willi
   Liu, Albert Y.
   Veloso, Valdilea G.
   Buchbinder, Susan
   Grinsztejn, Beatriz
TI HIV testing and the care continuum among transgender women: population
   estimates from Rio de Janeiro, Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE HIV; antiretroviral therapy; care continuum; transgender women; HIV
   testing; Brazil
ID MENTAL-HEALTH; PREVENTION; INFECTION; SEX; METAANALYSIS; OUTCOMES;
   THERAPY
AB Introduction: Evidence suggests that, of all affected populations, transgender women (transwomen) may have the heaviest HIV burden worldwide. Little is known about HIV linkage and care outcomes for transwomen. We aimed to estimate population-level indicators of the HIV cascade of care continuum, and to evaluate factors associated with viral suppression among transwomen in Rio de Janeiro, Brazil.
   Methods: We conducted a respondent-driven sampling (RDS) study of transwomen from August 2015 to January 2016 in Rio de Janeiro, Brazil and collected data on linkage and access to care, antiretroviral treatment and performed HIV viral load testing. We derived population-based estimates of cascade indicators using sampling weights and conducted RDS-weighted logistic regression analyses to evaluate correlates of viral suppression (viral load <= 50 copies/mL).
   Results: Of the 345 transwomen included in the study, 89.2% (95% CI 55-100%) had been previously tested for HIV, 77.5% (95% CI 48.7-100%) had been previously diagnosed with HIV, 67.2% (95% CI 39.2-95.2) reported linkage to care, 62.2% (95% CI 35.4-88.9) were currently on ART and 35.4% (95% CI 9.5-61.4%) had an undetectable viral load. The final adjusted RDS-weighted logistic regression model for viral suppression indicated that those who self-identified as black (adjusted odds ratio [aOR] 0.06, 95% CI 0.01-0.53, p < 0.01), reported earning <= U$160/month (aOR 0.11, 95% CI 0.16-0.87, p = 0.04) or reported unstable housing (aOR 0.08, 95% CI 0.01-0.43, p < 0.01) had significantly lower odds of viral suppression.
   Conclusions: Our cascade indicators for transwomen showed modest ART use and low viral suppression rates. Multi-level efforts including gender affirming care provision are urgently needed to decrease disparities in HIV clinical outcomes among transwomen and reduce secondary HIV transmission to their partners.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Beatriz Grinsztejn Inst Nacl Infectol Evandro Cha, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM gbeatriz@ini.fiocruz.br
OI Luz, Paula/0000-0001-9746-719X
FU Brazilian Research Council (National Council for Scientific and
   Technological Development) [470056/2014-2]; National Institute of
   Allergy and Infectious Diseases (National Institutes of Health)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069496]; Brazilian Research Council (National
   Council for Scientific and Technological Development); Carlos Chagas
   Filho Research Support Foundation of the state of Rio de Janeiro;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069496, UM1AI069496, UM1AI069496, UM1AI069496, UM1AI069496,
   UM1AI069496, UM1AI069496, UM1AI069496, UM1AI069496] Funding Source: NIH
   RePORTER
FX This study was funded by the Brazilian Research Council (National
   Council for Scientific and Technological Development [470056/2014-2])
   and National Institute of Allergy and Infectious Diseases (National
   Institutes of Health [UM1AI069496]). BG and PML have received funding
   from the Brazilian Research Council (National Council for Scientific and
   Technological Development) and Carlos Chagas Filho Research Support
   Foundation of the state of Rio de Janeiro.
CR Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Castro R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157309
   Chow JY, 2016, INT J STD AIDS, V27, P1039, DOI 10.1177/0956462416645727
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068
   Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7
   Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Handcock MS, 2014, RDS ANALYST SOFTWARE
   Houston Area Ryan White Planning Council, 2013, ACC HIV CAR TRANSG G
   Logie CH, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17392
   Meier SLC, 2011, J GAY LESBIAN MENT H, V15, P281, DOI 10.1080/19359705.2011.581195
   Melendez RM, 2009, J ASSOC NURSE AIDS C, V20, P387, DOI 10.1016/j.jana.2009.06.002
   Ministerio da Saude, 2015, B EP HIV AIDS 2015
   Ministerio da Saude, 2013, AIDS HEP VIR BRAS MA
   Murad MH, 2010, CLIN ENDOCRINOL, V72, P214, DOI 10.1111/j.1365-2265.2009.03625.x
   Nemoto T, 1999, AIDS CARE, V11, P297, DOI 10.1080/09540129947938
   Santos GM, 2014, SEX TRANSM INFECT, V90, P430, DOI 10.1136/sextrans-2013-051342
   SFDPH, 2014, HIV EP ANN REP
   Stone VE, 2004, CLIN INFECT DIS, V38, P400, DOI 10.1086/380969
   Wejnert C, 2008, SOCIOL METHODS RES
   Wiewel EW, 2016, AM J PUBLIC HEALTH, V106, P497, DOI 10.2105/AJPH.2015.302974
   Wilson EC, 2013, INT J TRANSGENDERISM, V14, P182, DOI 10.1080/15532739.2014.890090
   Wilson EC, 2015, J URBAN HEALTH, V92, P182, DOI 10.1007/s11524-014-9921-4
   Yehia BR, 2013, CLIN INFECT DIS, V57, P774, DOI 10.1093/cid/cit363
NR 25
TC 11
Z9 12
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD SEP 19
PY 2017
VL 20
AR 21873
DI 10.7448/IAS.20.1.21873
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FH4VJ
UT WOS:000411160000001
PM 28953323
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Machado, IK
   Luz, PM
   Lake, JE
   Castro, R
   Velasque, L
   Clark, JL
   Veloso, VG
   Grinsztejn, B
   De Boni, RB
AF Machado, Iona K.
   Luz, Paula M.
   Lake, Jordan E.
   Castro, Rodolfo
   Velasque, Luciane
   Clark, Jesse L.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   De Boni, Raquel B.
TI Substance use among HIV-infected patients in Rio de Janeiro, Brazil:
   Agreement between medical records and the ASSIST questionnaire
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Substance use; HIV/AIDS; Concordance; Medical record; Questionnaire
ID DISEASE PROGRESSION; ALCOHOL-USE; ANTIRETROVIRAL THERAPY; CLINICAL CARE;
   CRACK-COCAINE; UNITED-STATES; MORTALITY; COHORT; INDIVIDUALS;
   CONSUMPTION
AB Background: Substance use assessment is a challenge in busy clinical settings that may adversely affect HIV-infected persons. This study aimed to evaluate agreement between the medical chart and a standardized substance use screening questionnaire.
   Methods: Of adults (n = 1050) in HIV care in Rio de Janeiro who completed the World Health Organization's Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST), we randomly selected 200 participants for medical chart review. Lifetime use of tobacco, alcohol, marijuana, and cocaine agreement between the medical record and ASSIST was evaluated using Kappa statistics. Sensitivity and specificity of chart information were also calculated.
   Results: The median age was 42.4 years, 60.3% were male and 49.5% were white. Prevalence of lifetime use reported in ASSIST was 55.3% (tobacco), 79.4% (alcohol), 23.1% (marijuana), and 20.7% (cocaine). Any information on lifetime use was found in the medical chart for tobacco (n = 180, 90.5%), alcohol (n = 183, 92.0%), marijuana (n = 143, 71.8%), and cocaine (n = 151, 75.9%). The Kappa statistic, sensitivity and specificity of the medical chart accurately identifying lifetime substance users per ASSIST were respectively 0.60, 0.71, and 0.91 for tobacco; 0.22, 0.75, and 0.51 for alcohol; 0.58, 0.51, and 0.98 for marijuana; and 0.73, 0.75, and 0.96 for cocaine.
   Conclusion: Considering inaccuracies in the medical chart, the implementation of brief, standardized substance use screening is recommended in HIV care settings.
C1 [Machado, Iona K.; Lake, Jordan E.; Clark, Jesse L.] Univ Calif Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
   [Machado, Iona K.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.
   [Luz, Paula M.; Castro, Rodolfo; Veloso, Valdilea G.; Grinsztejn, Beatriz; De Boni, Raquel B.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, Manguinhos Rio De Janeir, RJ, Brazil.
   [Castro, Rodolfo; Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Ave Pasteur 296, Urca Rio De Janeiro, RJ, Brazil.
RP Machado, IK (corresponding author), 251 Ft Washington Ave,Apt 51, New York, NY 10032 USA.
EM ionak.machado@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Castro, Rodolfo/D-4231-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Castro,
   Rodolfo/0000-0002-0701-2528; Luz, Paula/0000-0001-9746-719X; Clark,
   Jesse/0000-0001-5862-6530
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R25MH087222, K23AI110532,
   U01AI069923]; Columbia University; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq) [476024/2013-7]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [K23AI110532,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, K23AI110532, K23AI110532, K23AI110532,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, K23AI110532, U01AI069923,
   U01AI069923, K23AI110532, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, R25MH087222, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107] Funding Source: NIH RePORTER
FX We would like to thank the participants enrolled in the INI HIV/AIDS
   program and the dedicated staff at INI. IKM gratefully acknowledges
   funding from NIH R25MH087222 (South American Program in HIV Research)
   and from Columbia University. JEL has received research grants provided
   by the NIH K23AI110532. Support for RD, PL, RC, and BG was provided by
   the NIH-funded Caribbean, Central and South America network for HIV
   epidemiology (CCASAnet), a member cohort of the International
   Epidemiologic Databases to Evaluate AIDS (leDEA, U01AI069923), and the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   476024/2013-7).
CR Azar MM, 2010, DRUG ALCOHOL DEPEN, V112, P178, DOI 10.1016/j.drugalcdep.2010.06.014
   Bai JR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-50
   Baum MK, 2010, AIDS RES HUM RETROV, V26, P511, DOI 10.1089/aid.2009.0211
   Baum MK, 2009, JAIDS-J ACQ IMM DEF, V50, P93, DOI 10.1097/QAI.0b013e3181900129
   Bonn-Miller MO, 2014, J BEHAV MED, V37, P1, DOI 10.1007/s10865-012-9458-5
   Braithwaite RS, 2007, AIDS CARE, V19, P459, DOI 10.1080/09540120601095734
   Cook JA, 2008, AIDS, V22, P1355, DOI 10.1097/QAD.0b013e32830507f2
   Gonzalez Adam, 2011, Curr HIV/AIDS Rep, V8, P223, DOI 10.1007/s11904-011-0093-5
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   Helleberg M, 2013, CLIN INFECT DIS, V56, P727, DOI 10.1093/cid/cis933
   Henrique Iara Ferraz Silva, 2004, Rev. Assoc. Med. Bras., V50, P199, DOI 10.1590/S0104-42302004000200039
   INPAD, 2014, LEV NAC ALC DROG LEN
   Instituto Brasileiro de Geografia e Estatistica (IBGE), 2014, PESQ NAC SAUD 2013 P
   Korthuis PT, 2011, AIDS BEHAV, V15, P832, DOI 10.1007/s10461-010-9779-8
   Korthuis PT, 2008, J SUBST ABUSE TREAT, V35, P294, DOI 10.1016/j.jsat.2007.11.005
   Machado I. K., 2017, INT J STD AIDS
   Metsch LR, 2008, DRUG ALCOHOL DEPEN, V95, P37, DOI 10.1016/j.drugalcdep.2007.12.006
   Mitchell AJ, 2012, BRIT J PSYCHIAT, V201, P93, DOI 10.1192/bjp.bp.110.091199
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Reddy KP, 2016, J INFECT DIS, V214, P1672, DOI 10.1093/infdis/jiw430
   Rehm J, 2010, ADDICTION, V105, P817, DOI 10.1111/j.1360-0443.2010.02899.x
   Torres TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115900
   World Health Organization, 2016, WHO ASSIST V3 0
NR 24
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD SEP 1
PY 2017
VL 178
BP 115
EP 118
DI 10.1016/j.drugalcdep.2017.04.033
PG 4
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA FF6UK
UT WOS:000409152300019
PM 28646713
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Badal-Faesen, S
   Firnhaber, C
   Kendall, MA
   Wu, XY
   Grinsztejn, B
   Escada, ROD
   Fernandez, M
   Hogg, E
   Sanne, I
   Johnson, P
   Alland, D
   Mazurek, GH
   Benator, DA
   Luetkemeyer, AF
AF Badal-Faesen, Sharlaa
   Firnhaber, Cynthia
   Kendall, Michelle A.
   Wu, Xingye
   Grinsztejn, Beatriz
   da Silva Escada, Rodrigo Otavio
   Fernandez, Michel
   Hogg, Evelyn
   Sanne, Ian
   Johnson, Pamela
   Alland, David
   Mazurek, Gerald H.
   Benator, Debra A.
   Luetkemeyer, Anne F.
CA AIDS Clinical Trials Grp A5295
TI Impact of Larger Sputum Volume on Xpert((R)) MTB/RIF Assay Detection of
   Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected
   Tuberculosis
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE larger volume sputum; Xpert MTB; RIF; smear-negative suspects
AB As a strategy to improve the sensitivity of nucleic acid-based testing in acid-fast bacilli (AFB) negative samples, larger volumes of sputum (5-10 mL) were tested with Xpert((R)) MTB/RIF from 176 individuals with smear-negative sputum undergoing tuberculosis evaluation. Despite larger volumes, this strategy had a suboptimal sensitivity of 50% (4/8).
C1 [Badal-Faesen, Sharlaa; Firnhaber, Cynthia; Sanne, Ian] Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Dept Internal Med,Clin HIV Res Unit, ZA-2092 Johannesburg, South Africa.
   [Kendall, Michelle A.; Wu, Xingye] Harvard TH Chan Sch Publ Hlth Boston, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [Grinsztejn, Beatriz; da Silva Escada, Rodrigo Otavio] INI Fiocruz, Inst Nacl Infectol Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Fernandez, Michel] Baylor Scott & White Hosp, Pulm & Crit Care Dept, Temple, TX 76508 USA.
   [Hogg, Evelyn] Social & Sci Syst Inc, Silver Spring, MD 20910 USA.
   [Johnson, Pamela] Cepheid Inc, Sunnyvale, CA 94089 USA.
   [Alland, David] Rutgers New Jersey Med Sch, Div Infect Dis, 185 South Orange Ave, Newark, NJ 07103 USA.
   [Mazurek, Gerald H.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA.
   [Benator, Debra A.] George Washington Univ, Vet Affairs Med Ctr, Washington, DC 20422 USA.
   [Luetkemeyer, Anne F.] Univ Calif San Francisco, Zuckerberg San Francisco Gen, Div HIV Infect Dis & Global Med, San Francisco, CA 94110 USA.
RP Badal-Faesen, S (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Dept Internal Med,Clin HIV Res Unit, ZA-2092 Johannesburg, South Africa.; Luetkemeyer, AF (corresponding author), Univ Calif San Francisco, Zuckerberg San Francisco Gen, Div HIV Infect Dis & Global Med, San Francisco, CA 94110 USA.
EM sfaesen@witshealth.co.za; csfirnhaber@gmail.com;
   kendall@sdac.harvard.edu; xwu@sdac.harvard.edu; gbeatriz@ini.fiocruz.br;
   rodrigo.escada@ini.fiocruz.br; michel_6815@yahoo.com; ehogg@s-3.com;
   isanne@witshealth.co.za; pamela.johnson@cepheid.com;
   allandda@njms.rutgers.edu; gym6@cdc.gov; debra.benator@va.gov;
   annie.luetkemeyer@ucsf.edu
RI Kendall, Michelle A/B-7665-2016
OI Kendall, Michelle A/0000-0001-9160-4544
FU Cepheid; National Institute of Allergy and Infectious Diseases through
   ACTG grant [AI068634, U01AI068636, UM1 AI106701]; CDC through TBTC;
   Division of Tuberculosis Elimination; National Center for HIV; Viral
   Hepatitis; STD; TB Prevention; National Institute of Mental HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH);
   National Institute of Dental and Craniofacial ResearchUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Dental & Craniofacial Research (NIDCR);
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI068634, UM1AI069419, UM1AI106701, UM1AI069476, UM1AI106701,
   UM1AI069463, UM1AI069419, UM1AI106701, UM1AI069432, UM1AI069419,
   UM1AI068634, UM1AI069432, UM1AI068634, UM1AI068636, UM1AI106701,
   UM1AI068636, UM1AI106701, UM1AI069419, UM1AI069419, UM1AI069419,
   UM1AI069496, UM1AI069496, UM1AI069432, UM1AI069496, UM1AI068634,
   UM1AI069496, UM1AI069463, UM1AI069432, UM1AI069432, UM1AI069476,
   UM1AI106701, UM1AI069476, UM1AI068636, UM1AI068636, UM1AI069496,
   UM1AI068636, UM1AI069432, UM1AI068634] Funding Source: NIH RePORTER
FX The AIDS Clinical Trials Group (ACTG) and the Tuberculosis Trials
   Consortium (TBTC) were responsible for design and conduct of the study
   and preparation, review, and approval of the manuscript. Cepheid
   contributed to study design, provided material support (Xpert
   cartridges, Gene pert machines, technical support, and funding for
   specimen shipping and some laboratory activities), and conducted a
   review of the study manuscript. References in this manuscript to any
   specific commercial products, process, service, manufacturer, or company
   do not constitute its endorsement or recommendation by the US
   government. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of any US government
   agency. This work was supported by the National Institute of Allergy and
   Infectious Diseases through the ACTG (grant numbers AI068634,
   U01AI068636, and UM1 AI106701); the CDC through the TBTC and the
   Division of Tuberculosis Elimination, National Center for HIV, Viral
   Hepatitis, STD, and TB Prevention; the National Institute of Mental
   Health, and the National Institute of Dental and Craniofacial Research.
   No funds were received to cover the cost to publish in open access.
CR Alisjahbana B, 2005, INT J TUBERC LUNG D, V9, P814
   Alland D., 2015, P C RETR OPP INF SEA
   Boehme CC, 2011, LANCET, V377, P1495, DOI 10.1016/S0140-6736(11)60438-8
   Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847
   Kent P.T., 1985, PUBLIC HLTH MYCOBACT
   Luetkemeyer AF, 2016, CLIN INFECT DIS, V62, P1081, DOI 10.1093/cid/ciw035
   Mpagama Stellah G, 2012, Tuberc Res Treat, V2012, P128057, DOI 10.1155/2012/128057
   Steingart KR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009593.pub3
   Warren JR, 2000, AM J RESP CRIT CARE, V161, P1559, DOI 10.1164/ajrccm.161.5.9908063
   World Health Organization, GLOB TUB REP 2015
NR 10
TC 3
Z9 3
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2017
VL 6
IS 8
AR 78
DI 10.3390/jcm6080078
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA FF4CG
UT WOS:000408875600003
PM 28783093
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Coelho, LE
   Ribeiro, SR
   Japiassu, AM
   Moreira, RI
   Lara, PC
   Veloso, VG
   Grinsztejn, B
   Luz, PM
AF Coelho, Lara E.
   Ribeiro, Sayonara R.
   Japiassu, Andre M.
   Moreira, Ronaldo I.
   Lara, Priscila C.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Luz, Paula M.
TI Thirty-day Readmission Rates in an HIV-infected Cohort From Rio de
   Janeiro, Brazil
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; hospitalization; readmission; health care utilization; length of
   stay; antiretroviral therapy
ID LENGTH-OF-STAY; HOSPITAL READMISSION; MEDICAL ADVICE; HEART-FAILURE;
   UNITED-STATES; MORTALITY; CARE; REHOSPITALIZATION; ADULTS; BENEFICIARIES
AB Background: The 30-day readmission rate is an indicator of the quality of hospital care and transition to the outpatient setting. Recent studies suggest HIV infection might increase the risk of readmission although estimates of 30-day readmission rates are unavailable among HIV-infected individuals living in middle/low-income settings. Additionally, factors that may increase readmission risk in HIV-infected populations are poorly understood.
   Methods: Thirty-day readmission rates were estimated for HIV-infected adults from the Instituto Nacional de Infectologia Evandro Chagas/Fiocruz cohort in Rio de Janeiro, Brazil, from January 2007 to December 2013. Cox regression models were used to evaluate factors associated with the risk of 30-day readmission.
   Results: Between January 2007 and December 2013, 3991 patients were followed and 1861 hospitalizations were observed. The estimated 30-day readmission rate was 14% (95% confidence interval: 12.3 to 15.9). Attending a medical visit within 30 days after discharge (adjusted hazard ratio [aHR] = 0.73, P = 0.048) and being hospitalized in more recent calendar years (aHR = 0.89, P = 0.002) reduced the risk of 30-day readmission. In contrast, low CD4 counts (51-200 cells/mm(3) : aHR = 1.70, P = 0.024 and <= 50 cells/mm 3 : aHR = 2.05, P = 0.003), time since HIV infection diagnosis >= 10 years (aHR = 1.58, P = 0.058), and leaving hospital against medical advice (aHR = 2.67, P = 0.004) increased the risk of 30-day readmission.
   Conclusions: Patients with advanced HIV/AIDS are most at risk of readmission and should be targeted with prevention strategies to reduce this risk. Efforts to reduce discharge against medical advice and to promote early postdischarge medical visit would likely reduce 30-day readmission rates in our population.
C1 [Coelho, Lara E.; Ribeiro, Sayonara R.; Japiassu, Andre M.; Moreira, Ronaldo I.; Lara, Priscila C.; Veloso, Valdilea G.; Grinsztejn, Beatriz; Luz, Paula M.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
RP Coelho, LE (corresponding author), Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM lara.coelho@ini.fiocruz.br
OI Luz, Paula/0000-0001-9746-719X
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01AI069923]; National Council of
   Technological and Scientific Development (CNPq)National Council for
   Scientific and Technological Development (CNPq); Research Funding Agency
   of the State of Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ); NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, UM1AI069476, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   UM1AI069476, UM1AI069476, U01AI069923, UM1AI069476, U01AI069923,
   U01AI069923, U01AI069923, UM1AI069476, U01AI069923, U01AI069923,
   U01AI069923, UM1AI069476, U01AI069923, UM1AI069476, UM1AI069476,
   UM1AI069476, U01AI069923] Funding Source: NIH RePORTER
FX Supported in part by the NIH-funded Caribbean, Central and South America
   Network for HIV epidemiology (CCASAnet), a member cohort of the
   International Epidemiologic Databases to Evaluate AIDS (leDEA)
   (U01AI069923).; P.M.L. and B.G. acknowledge funding from the National
   Council of Technological and Scientific Development (CNPq) and the
   Research Funding Agency of the State of Rio de Janeiro (FAPERJ).
CR Alfandre D, 2017, J ASSOC NURSE AIDS C, V28, P95, DOI 10.1016/j.jana.2016.10.002
   Anis AH, 2002, CAN MED ASSOC J, V167, P633
   Arbaje AI, 2008, GERONTOLOGIST, V48, P495, DOI 10.1093/geront/48.4.495
   Barret ML, 2015, AGENCY HLTH RES QUAL, P199
   Berry SA, 2016, HIV MED, V17, P167, DOI 10.1111/hiv.12287
   Berry SA, 2013, AIDS, V27, P2059, DOI 10.1097/QAD.0b013e3283623d5f
   Berry SA, 2012, JAIDS-J ACQ IMM DEF, V59, P368, DOI 10.1097/QAI.0b013e318246b862
   Brasil. Agencia Nacional de Saude Suplementar-ANS, 2015, 34DIDES ANS
   Castilho JL, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/1750-9378-10-4
   Catumbela E, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0801-8
   Chen HY, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002291
   Chew KW, 2011, AIDS PATIENT CARE ST, V25, P273, DOI 10.1089/apc.2010.0365
   Coelho LE, 2017, BRAZ J INFECT DIS, V21, P190, DOI 10.1016/j.bjid.2016.10.007
   Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822
   Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7
   Desai AS, 2012, CIRCULATION, V126, P501, DOI 10.1161/CIRCULATIONAHA.112.125435
   Dharmarajan K, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6571
   Erlandson KM, 2015, J INFECT DIS, V212, P339, DOI 10.1093/infdis/jiv007
   Feller DJ, 2016, JAIDS-J ACQ IMM DEF, V71, P407, DOI 10.1097/QAI.0000000000000876
   Glasgow JM, 2010, J GEN INTERN MED, V25, P926, DOI 10.1007/s11606-010-1371-4
   Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882
   Greysen SR, 2015, JAMA INTERN MED, V175, P559, DOI 10.1001/jamainternmed.2014.7756
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008
   Hsieh YH, 2008, JAIDS-J ACQ IMM DEF, V49, P398, DOI 10.1097/QAI.0b013e318183ac84
   Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563
   Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598
   Kaboli PJ, 2012, ANN INTERN MED, V157, P837, DOI 10.7326/0003-4819-157-12-201212180-00003
   Kim JH, 2013, INFECTION, V41, P545, DOI 10.1007/s15010-012-0386-7
   Krentz HB, 2006, HIV MED, V7, P457, DOI 10.1111/j.1468-1293.2006.00408.x
   Mannino DM, 2015, CHEST, V147, P1199, DOI 10.1378/chest.15-0380
   Martin RB, 2000, REV CLIN ESP, V200, P252
   Ministerio da Saude, SIST INF HOSP SUS SI
   Nijhawan AE, 2015, AIDS PATIENT CARE ST, V29, P465, DOI 10.1089/apc.2015.0096
   Nijhawan AE, 2012, JAIDS-J ACQ IMM DEF, V61, P349, DOI 10.1097/QAI.0b013e31826ebc83
   Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126
   Ribeiro SR, 2014, ANTIVIR THER, V19, P387, DOI 10.3851/IMP2716
   Ross JS, 2008, ARCH INTERN MED, V168, P1371, DOI 10.1001/archinte.168.13.1371
   Sharma G, 2010, ARCH INTERN MED, V170, P1664, DOI 10.1001/archinternmed.2010.345
   Shih SL, 2015, J GEN INTERN MED, V30, P1688, DOI 10.1007/s11606-015-3350-2
   van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860
NR 43
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2017
VL 75
IS 4
BP E90
EP E98
DI 10.1097/QAI.0000000000001352
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FA6LK
UT WOS:000405554600016
PM 28291051
OA Green Accepted, Green Published
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Pacheco, AG
   Luz, PM
   Castro, R
   Hyde, C
   Fittipaldi, J
   Rigolon, C
   Cardoso, SW
   Grinsztejn, B
   Veloso, VG
AF Perazzo, Hugo
   Pacheco, Antonio G.
   Luz, Paula M.
   Castro, Rodolfo
   Hyde, Chris
   Fittipaldi, Juliana
   Rigolon, Caroline
   Cardoso, Sandra W.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
TI Age-standardized mortality rates related to viral hepatitis in Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Liver disease; Hepatitis; Death rates; Age-standardized mortality
ID ILL-DEFINED CAUSES; RIO-DE-JANEIRO; C VIRUS; DISEASE; PREVALENCE;
   INFECTION; BURDEN; DEATH; COVERAGE; SYSTEM
AB Background: Liver-related mortality has been increasing worldwide. We aimed to estimate the age-standardized mortality rates from viral hepatitis in Brazil.
   Methods: The Brazilian National Death Registry was analyzed from 2008 to 2014. Viral hepatitis deaths were defined by the following ICD-10 codes in the death certificate: hepatitis A [B15.0; B15.9]; hepatitis B [B16.2; B16.9; B18.1]; hepatitis C [B17.1; B18.2]; hepatitis Delta [B16.0; B16.1; B18.0; B17.0] and other viral hepatitis [B17.2; B17.8; B18.8; B18. 9; B19.0; B19.9]. Crude mortality rates were calculated by the ratio between total number of deaths and estimated population. Mortality rates were age-standardized by the direct method using the WHO standard population.
   Results: Thirty four thousand, nine hundred seventy eight deaths had viral hepatitis mentioned in their death certificate [65% male, aged 58 years, 73% associated with hepatitis C]. Age-standardized mortality rate (95% CI) due to viral hepatitis was 2.695 (2.667-2.724) deaths per 100,000 inhabitants: South region had the higher rates [3.997 (3.911-4.085)]. Mortality rates associated with hepatitis A and Delta were 0.032 (0.029-0.035) and 0.028 (0.025-0.031), respectively. Hepatitis C mortality rates were 4-fold higher than those associated with hepatitis B [1.964 (1.940-1.989) vs 0.500 (0.488-0.512)]. South region had the higher rates for hepatitis C [3.163 (3.087-3.241)] and North had the higher rates for hepatitis A [0.066 (0.049-0.087)], B [0.986 (0.918-1.058)] and Delta [0.220 (0.190-0.253)].
   Conclusion: Viral hepatitis remains a major public health issue in Brazil. Mortality rates were not homogeneous across the country, suggesting that health policies should be customized according to geographical location.
C1 [Perazzo, Hugo; Luz, Paula M.; Castro, Rodolfo; Fittipaldi, Juliana; Rigolon, Caroline; Cardoso, Sandra W.; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin DST & AIDS LAPCLIN AIDS, Rio De Janeiro, Brazil.
   [Pacheco, Antonio G.] Fundacao Oswaldo Cruz FIOCRUZ, Programa Comp Cient PROCC, Rio De Janeiro, Brazil.
   [Hyde, Chris] Univ Exeter, Peninsula Technol Assessment Grp PenTAG, Evidence Synth & Modelling Hlth Improvement ESMI, Inst Hlth Res,Med Sch, Exeter, Devon, England.
RP Perazzo, H (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin DST & AIDS LAPCLIN AIDS, Rio De Janeiro, Brazil.
EM perazzohugo@gmail.com
RI Pacheco, Antonio Guilherme/E-6378-2013; Castro, Rodolfo/D-4231-2013
OI Pacheco, Antonio Guilherme/0000-0003-3095-1774; Castro,
   Rodolfo/0000-0002-0701-2528; Perazzo, Hugo/0000-0003-0931-6418; Luz,
   Paula/0000-0001-9746-719X
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) /
   Bolsa Jovem Talento (BJT) - Programa Ciencias Sem FronteirasNational
   Council for Scientific and Technological Development (CNPq)
   [301,520/2014-3]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); Newton Fund
   RCUK CONFAP; FAPERJ (Brazil)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ) [E-26/170.021/2015];
   Medical Research Council (MRC) (UK)Medical Research Council UK (MRC)
   [MR/M026515/1]; Medical Research CouncilMedical Research Council UK
   (MRC) [MR/M026515/1] Funding Source: researchfish; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX This work was supported by funding from: Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) / Bolsa Jovem Talento
   (BJT) - Programa Ciencias Sem Fronteiras under grant 301,520/2014-3;
   from Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio
   de Janeiro (FAPERJ) and Newton Fund RCUK CONFAP Research Partnerships
   call, FAPERJ under grant E-26/170.021/2015 (Brazil) and Medical Research
   Council (MRC) grant reference MR/M026515/1 (UK).
CR Ferreira PRA, 2015, BRAZ J INFECT DIS, V19, P363, DOI 10.1016/j.bjid.2015.04.004
   Aggarwal R, 2015, CURR OPIN INFECT DIS, V28, P488, DOI 10.1097/QCO.0000000000000188
   Oliveira MDA, 2009, J CLIN VIROL, V44, P200, DOI 10.1016/j.jcv.2008.12.008
   [Anonymous], 2001, GUID INF CAUS DEATH
   [Anonymous], 2015, B EP HEP VIR
   [Anonymous], 2014, GUID MAN TREATM CHRO
   [Anonymous], 2015, ROL HEP EL LIV FIBR
   [Anonymous], 2015, GUID MAN TREATM CHRO
   Barata RB, 2012, J EPIDEMIOL COMMUN H, V66, P934, DOI 10.1136/jech-2011-200341
   Blasco-Perrin H, 2016, LIVER INT, V36, P130, DOI 10.1111/liv.13014
   de Lima EEC, 2014, CAD SAUDE PUBLICA, V30, P1721, DOI 10.1590/0102-311X00131113
   Castro R, 2015, INT J HEPATOL, V2015, DOI 10.1155/2015/852968
   Couto I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174453
   Cruz HM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1249-5
   da Rosa L, 2013, HEPAT MON, V13, DOI 10.5812/hepatmon.12274
   Souto FJD, 2016, REV SOC BRAS MED TRO, V49, P11, DOI 10.1590/0037-8682-0176-2015
   Crispim MAE, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-94
   Ferrarese A, 2016, WORLD J GASTROENTERO, V22, P1570, DOI 10.3748/wjg.v22.i4.1570
   Franca EB, 2014, REV BRAS EPIDEMIOL, V17, P119, DOI [10.1590/1415-790X201400010010, DOI 10.1590/1415-790X201400010010ENG]
   Franca E, 2008, INT J EPIDEMIOL, V37, P891, DOI 10.1093/ije/dyn121
   Franca E, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-39
   Hanus JS, 2015, REV SOC BRAS MED TRO, V48, P665, DOI 10.1590/0037-8682-0230-2015
   Institute for Health Metrics and Evaluation, GLOB BURD DIS COMP
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Ly KN, 2012, ANN INTERN MED, V156, P271, DOI 10.7326/0003-4819-156-4-201202210-00004
   Mendez-Sanchez Nahum, 2005, Ann Hepatol, V4, P52
   Mesquita F, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3784-4
   Braga WSM, 2014, J HEPATOL, V61, P1205, DOI 10.1016/j.jhep.2014.05.041
   Nader LA, 2014, LIVER INT, V34, P844, DOI 10.1111/liv.12470
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
   Naing N N, 2000, Malays J Med Sci, V7, P10
   Perazzo H, 2017, ANN HEPATOL, V16, P269, DOI 10.5604/16652681.1231586
   Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
   Pinto FPD, 2015, ANN HEPATOL, V14, P815, DOI 10.5604/16652681.1171756
   Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X
   Viana S, 2005, AM J TROP MED HYG, V73, P808, DOI 10.4269/ajtmh.2005.73.808
   Victora CG, 2011, LANCET, V377, P2042, DOI 10.1016/S0140-6736(11)60055-X
   Vitral CL, 2006, MEM I OSWALDO CRUZ, V101, P119, DOI 10.1590/S0074-02762006000200001
   Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4
   Younossi ZM, 2015, J VIRAL HEPATITIS, V22, P137, DOI 10.1111/jvh.12262
   Zago-Gomes MP, 2005, REV SOC BRAS MED TRO, V38, P285, DOI 10.1590/S0037-86822005000400001
NR 41
TC 3
Z9 3
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUL 31
PY 2017
VL 17
AR 527
DI 10.1186/s12879-017-2619-y
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA FC1SB
UT WOS:000406616600001
PM 28760138
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Coelho, LE
   Luz, PM
   Veloso, VG
AF Grinsztejn, Beatriz
   Coelho, Lara E.
   Luz, Paula M.
   Veloso, Valdilea G.
TI Towards an ideal antiretroviral regimen for the global HIV epidemic
SO JOURNAL OF VIRUS ERADICATION
LA English
DT Review
ID VIROLOGICALLY SUPPRESSED ADULTS; TENOFOVIR DISOPROXIL FUMARATE;
   DOUBLE-BLIND; INFECTION; THERAPY; TRIAL; EFFICACY; CARE; ALAFENAMIDE;
   SAFETY
AB Currently, immediate initiation of antiretroviral therapy (ART) is recommended for all individuals with HIV infection. However, among the 37 million people estimated to be living with HIV/AIDS, only 17 million are actively on treatment. Optimal use of ART among HIV-infected and at-risk individuals reduces morbidity, mortality, transmission and acquisition of HIV infection. ART regimen choices are affected by factors such as economic differences between resource-rich and low-and middle-income countries (LIMC), drug availability, and considerations for use in special populations. Ideal ART regimens combine high efficacy, high tolerability, low toxicity, low pill burden, affordability and global availability. Here, we highlight five aspects to be considered when thinking of an ideal global ART regimen: (1) the co-administration with other medications especially tuberculosis treatment; (2) treatment for specific populations such as women, children, adolescents, older people and acutely infected individuals; (3) efficacy; (4) safety, tolerability and convenience; and (5) affordability and global access for all PLWH.
C1 [Grinsztejn, Beatriz; Coelho, Lara E.; Luz, Paula M.; Veloso, Valdilea G.] Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM gbeatriz@ini.fiocruz.br
OI Luz, Paula/0000-0001-9746-719X
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH
   RePORTER; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1 AI069476] Funding Source:
   Medline
CR Ananworanich J, 2016, EBIOMEDICINE, V11, P68, DOI 10.1016/j.ebiom.2016.07.024
   Andany N, 2016, J VIRUS ERAD, V2, P67
   [Anonymous], 2016, GUIDELINES USE ANTIR
   Brooks K., 2017, C RETR OPP INF FEBR
   Cahn P RM, 2016, INT AIDS C JUL 2016
   Clark Rebecca A, 2005, Expert Rev Anti Infect Ther, V3, P213, DOI 10.1586/14787210.3.2.213
   Clayden P, 2016, DRUGS DIAGNOSTICS VA
   Clinton Health Access Initiative, ARV MARK REP STAT AN
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cowan FM, 2017, JAIDS-J ACQ IMM DEF, V74, P375, DOI [10.1097/QAI.0000000000001255, 10.1097/qai.0000000000001255]
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Derache AIC, 2017, C RETR OPP INF FEBR
   Dutertre M, 2017, C RETR OPP INF FEBR
   European AIDS Clinical Society, EACS TREATM GUID 8 1
   Foster C, 2017, HIV MED, V18, P133, DOI 10.1111/hiv.12399
   Gallant JE, 2016, LANCET HIV, V3, pE158, DOI 10.1016/S2352-3018(16)00024-2
   Grobler J, 2016, C RETR OPP INF FEBR
   Gunthard HF, 2016, JAMA-J AM MED ASSOC, V316, P191, DOI 10.1001/jama.2016.8900
   Hoffmann C, 2017, HIV MED, V18, P56, DOI 10.1111/hiv.12468
   Hsu R, 2017, C RETR OPP INF FEBR
   Jalil EM, 2016, AIDS RES HUM RETROV, V32, P50
   Jiamsakul A, 2016, AUSTR HIV AIDS C NOV
   Joly V, 2017, C RETR OPP INF FEBR
   Kanters S, 2016, LANCET HIV, V3, pE510, DOI 10.1016/S2352-3018(16)30091-1
   Kim SH, 2014, AIDS, V28, P1945, DOI 10.1097/QAD.0000000000000316
   Lee FJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097482
   Lewis S, 2017, C RETR OPP INF FEBR
   Llibre JM, 2017, C RETR OPP INF FEBR
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Margolis D, 2016, INT AIDS C JUL 2016
   Mehta SH, 2015, CLIN INFECT DIS, V61, P1732, DOI 10.1093/cid/civ669
   Ministerio da Saude, 2015, PROT CLIN DIR TER MA
   Odone A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112017
   Pham QD, 2014, AIDS, V28, P2751, DOI 10.1097/QAD.0000000000000494
   Philips A, 2017, C RETR OPP INF FEBR
   Puls RL, 2014, LANCET, V383, P1474, DOI 10.1016/S0140-6736(13)62187-X
   Raffi F, 2017, JAIDS-J ACQ IMM DEF, V75, P226, DOI [10.1097/QAI.0000000000001344, 10.1097/qai.0000000000001344]
   Sawyer SM, 2007, LANCET, V369, P1481, DOI 10.1016/S0140-6736(07)60370-5
   Sax PE, 2017, LANCET HIV, V4, pE154, DOI 10.1016/S2352-3018(17)30016-4
   Smit M, 2015, LANCET INFECT DIS, V15, P810, DOI 10.1016/S1473-3099(15)00056-0
   Thompson M, 2016, ANTIVIR THER
   Tse WC, 2017, C RETR OPP INF FEBR
   UNAIDS, AIDS BY THE NUMB
   UNAIDS, 2015, 2016 2021 STRAT FAST
   UNAIDS, PREV GAP REP
   Vreeman Rachel C, 2014, J Int AIDS Soc, V17, P19227, DOI 10.7448/IAS.17.1.19227
   Wallis CGB, 2016, C RETR OPP INF FEBR
   WHO, 2016, CONS GUID US ANT DRU
   Wijting I, 2017, C RETR OPP INF FEBR
   Wirtz AL, 2016, SEX TRANSM INFECT, V92, P161, DOI 10.1136/sextrans-2015-052076
   World Health Organization, 2016, GLOB TUB REP
   World Health Organization, 2016, PROGR REP 2016 PREV
NR 52
TC 2
Z9 2
U1 0
U2 1
PU MEDISCRIPT LTD
PI LONDON
PA 1 MOUNTVIEW CT, 310 FRIERN BARNET LN, LONDON, N20 0LD, ENGLAND
SN 2055-6640
EI 2055-6659
J9 J VIRUS ERAD
JI J. Virus Erad.
PD JUL
PY 2017
VL 3
IS 3
BP 111
EP 116
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA FR6XU
UT WOS:000419211600001
PM 28758017
DA 2020-11-24
ER

PT J
AU Ferreira, ACG
   Coelho, LE
   Grinsztejn, E
   de Jesus, CS
   Guimaraes, ML
   Veloso, VG
   Grinsztejn, B
   Cardoso, SW
AF Ferreira, Ana Cristina G.
   Coelho, Lara E.
   Grinsztejn, Eduarda
   de Jesus, Carlos S.
   Guimaraes, Monick L.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Cardoso, Sandra W.
TI Transmitted drug resistance in patients with acute/recent HIV infection
   in Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Infection; Transmission; Primary resistance; Antiretroviral therapy
ID ANTIRETROVIRAL THERAPY; NAIVE PATIENTS; TRANSMISSION; EPIDEMIOLOGY;
   INDIVIDUALS; PREVENTION; OUTCOMES; IMPACT; SEX; MEN
AB Introduction: The widespread use of antiretroviral therapy increased the transmission of antiretroviral resistant HIV strains. Antiretroviral therapy initiation during acute/recent HIV infection limits HIV reservoirs and improves immune response in HIV infected individuals. Transmitted drug resistance may jeopardize the early goals of early antiretroviral treatment among acute/recent HIV infected patients.
   Methods: Patients with acute/recent HIV infection who underwent resistance test before antiretroviral treatment initiation were included in this analysis. HIV-1 sequences were obtained using an in house protease/reverse transcriptase genotyping assay. Transmitted drug resistance was identified according to the Stanford HIV Database for Transmitted Drug Resistance Mutations, based on WHO 2009 surveillance list, and HIV-1 subtyping according to Rega HIV-1 subtyping tool. Comparison between patients with and without transmitted drug resistance was made using Kruskal-Wallis and Chi-square tests.
   Results: Forty-three patients were included, 13 with acute HIV infection and 30 with recent HIV infection. The overall transmitted drug resistance prevalence was 16.3% (95% confidence interval [CI]: 8.1-30.0%). The highest prevalence of resistance (11.6%, 95% CI: 8.1-24.5) was against non-nucleoside reverse transcriptase inhibitors, and K103N was the most frequently identified mutation.
   Conclusions: The high prevalence of nonnucleoside reverse transcriptase inhibitors resistance indicates that efavirenz-based regimen without prior resistance testing is not ideal for acutely/recently HIV-infected individuals in our setting. In this context, the recent proposal of including integrase inhibitors as a first line regimen in Brazil could be an advantage for the treatment of newly HIV infected individuals. However, it also poses a new challenge, since integrase resistance test is not routinely performed for antiretroviral naive individuals. Further studies on transmitted drug resistance among acutely/recently HIV-infected are needed to inform the predictors of transmitted resistance and the antiretroviral therapy outcomes among these population. (C) 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.
C1 [Ferreira, Ana Cristina G.; Coelho, Lara E.; Grinsztejn, Eduarda; Veloso, Valdilea G.; Grinsztejn, Beatriz; Cardoso, Sandra W.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [de Jesus, Carlos S.; Guimaraes, Monick L.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Rio De Janeiro, RJ, Brazil.
RP Cardoso, SW (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
EM sandra.wagner@ini.fiocruz.br
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)
FX Beatriz Grinsztejn acknowledges the funding from the National Council of
   Technological and Scientific Development (CNPq) and the Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ).
CR Ambrosioni J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125837
   Ananworanich J, 2015, JAIDS-J ACQ IMM DEF, V68, P481, DOI 10.1097/QAI.0000000000000502
   Avila-Rios S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158560
   Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724
   Boletim EpidemiolOgico HIV/Aids, 2015, AIDS HEPATITES VIRAI
   Brenner B, 2013, AIDS, V27, P1045, DOI 10.1097/QAD.0b013e32835cffd9
   Brenner BG, 2007, J INFECT DIS, V195, P951, DOI 10.1086/512088
   Carlson JM, 2014, SCIENCE, V345, DOI 10.1126/science.1254031
   Castor D, 2012, JAIDS-J ACQ IMM DEF, V61, P1, DOI 10.1097/QAI.0b013e31825a289b
   Celum C, 2013, J INFECT DIS, V208, P189, DOI 10.1093/infdis/jit154
   Cohen MS, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001232
   Dai LL, 2014, VIRAL IMMUNOL, V27, P392, DOI 10.1089/vim.2014.0025
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   de Medeiros LB, 2006, MEM I OSWALDO CRUZ, V101, P845, DOI 10.1590/S0074-02762006000800004
   Delatorre E, 2016, AIDS RES HUM RETROVI
   Frentz D, 2012, AIDS REV, V14, P17
   Gifford RJ, 2009, BIOINFORMATICS, V25, P1197, DOI 10.1093/bioinformatics/btp134
   Graf T, 2011, J CLIN VIROL, V51, P186, DOI 10.1016/j.jcv.2011.04.011
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Hollingsworth TD, 2008, J INFECT DIS, V198, P687, DOI 10.1086/590501
   Hurt CB, 2009, ANTIVIR THER, V14, P673
   Jain S, 2015, JAIDS-J ACQ IMM DEF, V68, P97, DOI 10.1097/QAI.0000000000000403
   Jain V, 2011, J INFECT DIS, V203, P1174, DOI 10.1093/infdis/jiq167
   Jain V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015510
   Alcantara LCJ, 2009, NUCLEIC ACIDS RES, V37, pW634, DOI 10.1093/nar/gkp455
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Laanani M, 2015, CLIN INFECT DIS, V60, P1715, DOI 10.1093/cid/civ171
   Lewis F, 2008, PLOS MED, V5, P392, DOI 10.1371/journal.pmed.0050050
   Liegler T, 2014, J INFECT DIS, V710, P1717
   Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552
   Luz PM, 2015, JAIDS-J ACQ IMM DEF, V68, P152, DOI 10.1097/QAI.0000000000000426
   Myers JE, 2012, AIDS RES HUM RETROV, V28, P667, DOI [10.1089/aid.2010.0355, 10.1089/AID.2010.0355]
   Okulicz JF, 2015, JAMA INTERN MED, V175, P88, DOI 10.1001/jamainternmed.2014.4010
   Panichsillapakit T, 2016, J ACQ IMMUN DEF SYND, V71, P228
   Phanuphak P, 2014, JAIDS-J ACQ IMM DEF, V66, P74, DOI 10.1097/QAI.0000000000000108
   Pilcher CD, 2007, AIDS, V21, P1723, DOI 10.1097/QAD.0b013e3281532c82
   Pillay D, 2006, AIDS LOND ENGL, V70, P21
   Pineda-Pena AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101738
   Taniguchi T, 2012, AIDS RES HUM RETROV, V28, P259, DOI 10.1089/aid.2011.0022
   Truong HHM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025281
   Velasco-de-Castro CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087622
   Volz EM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001568
   Wittkop L, 2011, LANCET INFECT DIS, V11, P363, DOI 10.1016/S1473-3099(11)70032-9
NR 43
TC 6
Z9 7
U1 0
U2 5
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUL-AUG
PY 2017
VL 21
IS 4
BP 396
EP 401
DI 10.1016/j.bjid.2017.03.013
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA FB2TG
UT WOS:000405995500005
PM 28539254
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Barbosa, HPP
   Cardoso, S
   Yanavich, C
   Soares, JC
   Fittipaldi, J
   Morata, M
   Cardoso, C
   Simplicio, P
   De Almeida, C
   Veloso, V
   Grinsztejn, B
AF Perazzo Pedroso Barbosa, H.
   Cardoso, S.
   Yanavich, C.
   Soares, J. C.
   Fittipaldi, J.
   Morata, M.
   Cardoso, C.
   Simplicio, P.
   De Almeida, C.
   Veloso, V.
   Grinsztejn, B.
TI Predictor factors associated with liver fibrosis and steatosis by
   transient elastography in HIV-monoinfected patients under long-term
   combined antiretroviral therapy: the PROSPEC-HIV study
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Perazzo Pedroso Barbosa, H.; Cardoso, S.; Yanavich, C.; Soares, J. C.; Fittipaldi, J.; Morata, M.; Cardoso, C.; Simplicio, P.; De Almeida, C.; Veloso, V.; Grinsztejn, B.] Fundacao Oswaldo Cruz, LAPCLIN AIDS, Rio De Janeiro, Brazil.
EM perazzohugo@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2017
VL 20
SU 5
MA MOAB0305
BP 15
EP 15
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FB8ZQ
UT WOS:000406429800027
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Castilho, J
   Escuder, MM
   Veloso, V
   Gomes, JO
   Jayathilake, K
   Ribeiro, S
   Souza, RA
   Ikeda, ML
   de Alencastro, PR
   Tupinanba, U
   Brites, C
   McGowan, C
   Grangeiro, A
   Grinsztejn, B
AF Castilho, J.
   Escuder, M. M.
   Veloso, V.
   Gomes, J. O.
   Jayathilake, K.
   Ribeiro, S.
   Souza, R. A.
   Ikeda, M. L.
   de Alencastro, P. R.
   Tupinanba, U.
   Brites, C.
   McGowan, C.
   Grangeiro, A.
   Grinsztejn, B.
TI Trends and predictors of non-communicable disease multi-morbidity among
   HIV-infected adults initiating ART in Brazil, 2003-2014
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Castilho, J.; Jayathilake, K.; McGowan, C.] Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN USA.
   [Escuder, M. M.; Gomes, J. O.] Sao Paulo State Dept Hlth, Hlth Inst, Sao Paulo, Brazil.
   [Veloso, V.; Ribeiro, S.; Grinsztejn, B.] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   [Souza, R. A.] Sao Paulo State Dept Hlth, AIDS Reference & Training Ctr, Sao Paulo, Brazil.
   [Ikeda, M. L.; de Alencastro, P. R.] Rio Grande do Sul State Dept Hlth, Care & Treatment Clin Partenon Sanatorium, Porto Alegre, RS, Brazil.
   [Tupinanba, U.] Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, Brazil.
   [Brites, C.] 7Federal Univ Bahia, Edgar Santos Univ Hosp Complex, Salvador, BA, Brazil.
   [Grangeiro, A.] Univ Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil.
EM jessica.castilho@vanderbilt.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2017
VL 20
SU 5
MA WEAB0101
BP 52
EP 53
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FB8ZQ
UT WOS:000406429800104
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Landovitz, R
   Li, S
   Grinsztejn, B
   Dawood, H
   Liu, A
   Magnus, M
   Hosseinipour, M
   Panchia, R
   Cottle, L
   Chau, G
   Richardson, P
   Marzinke, M
   Hendrix, C
   Tolley, B
   Adeyeye, A
   Burns, D
   Rinehart, A
   Margolis, D
   McCauley, M
   Eron, J
AF Landovitz, R.
   Li, S.
   Grinsztejn, B.
   Dawood, H.
   Liu, A.
   Magnus, M.
   Hosseinipour, M.
   Panchia, R.
   Cottle, L.
   Chau, G.
   Richardson, P.
   Marzinke, M.
   Hendrix, C.
   Tolley, B.
   Adeyeye, A.
   Burns, D.
   Rinehart, A.
   Margolis, D.
   McCauley, M.
   Eron, J.
TI Safety, tolerability and pharmacokinetics of long-acting injectable
   cabotegravir in low-risk HIV-uninfected women and men: HPTN 077
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Landovitz, R.] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA USA.
   [Li, S.; Cottle, L.; Chau, G.] SCHARP, Seattle, WA USA.
   [Grinsztejn, B.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Dawood, H.] Univ Kwazulu Natal, CAPRISA, Vulindlela, South Africa.
   [Liu, A.] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Magnus, M.] George Washington Univ, Washington, DC USA.
   [Hosseinipour, M.] UNC Malawi Project, Lilongwe, Malawi.
   [Panchia, R.] Chris Hani Baragwanath Hosp, PHRU, Johannesburg, South Africa.
   [Richardson, P.; Marzinke, M.; Hendrix, C.] Johns Hopkins Univ, Baltimore, MD USA.
   [Tolley, B.] FHI360, Durham, NC USA.
   [Adeyeye, A.; Burns, D.] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA.
   [Rinehart, A.; Margolis, D.] ViiV Healthcare, Durham, NC USA.
   [McCauley, M.] FHI360, Washington, DC USA.
   [Eron, J.] Univ N Carolina, Chapel Hill, NC USA.
EM rlandovitz@mednet.ucla.edu
RI Dawood, Halima/AAO-6963-2020; Dawood, Halima/AAF-6045-2020
OI Dawood, Halima/0000-0001-8180-6791; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2017
VL 20
SU 5
MA TUAC0106LB
BP 113
EP 114
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FB8ZQ
UT WOS:000406429800212
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Bavinton, B
   Grinsztejn, B
   Phanuphak, N
   Jin, F
   Zablotska, I
   Prestage, G
   Kelleher, A
   Pinto, A
   Cooper, D
   Grulich, A
AF Bavinton, B.
   Grinsztejn, B.
   Phanuphak, N.
   Jin, F.
   Zablotska, I.
   Prestage, G.
   Kelleher, A.
   Pinto, A.
   Cooper, D.
   Grulich, A.
CA Opposites Attract Study Grp
TI HIV treatment prevents HIV transmission in male serodiscordant couples
   in Australia, Thailand and Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Bavinton, B.; Jin, F.; Zablotska, I.; Prestage, G.; Kelleher, A.; Pinto, A.; Cooper, D.; Grulich, A.] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Grinsztejn, B.] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Phanuphak, N.] Thai Red Cross, AIDS Res Ctr, Bangkok, Thailand.
EM agrulich@kirby.unsw.edu.au
RI Phanuphak, Nittaya/AAA-8579-2019
NR 0
TC 4
Z9 4
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2017
VL 20
SU 5
MA TUAC0506LB
BP 115
EP 115
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FB8ZQ
UT WOS:000406429800213
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Hoagland, B
   Moreira, R
   Kallas, E
   Madruga, J
   Leite, I
   de Boni, R
   Anderson, P
   Liu, A
   Luz, P
   Veloso, V
AF Grinsztejn, B.
   Hoagland, B.
   Moreira, R.
   Kallas, E.
   Madruga, J.
   Leite, I.
   de Boni, R.
   Anderson, P.
   Liu, A.
   Luz, P.
   Veloso, V.
CA PrEP Brasil Study Grp
TI High level of retention and adherence at Week 48 for MSM and TGW
   enrolled in the PrEP Brasil demonstration study
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Grinsztejn, B.; Hoagland, B.; Moreira, R.; de Boni, R.; Luz, P.; Veloso, V.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Kallas, E.; Madruga, J.] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Leite, I.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil.
   [Anderson, P.] Univ Colorado, Anschutz Med Campus, Denver, CO 80202 USA.
   [Liu, A.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
EM gbeatriz@ini.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2017
VL 20
SU 5
MA TUPD
BP 125
EP 125
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FB8ZQ
UT WOS:000406429800231
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Wolff, MJ
   Giganti, MJ
   Cortes, CP
   Cahn, P
   Grinsztejn, B
   Pape, JW
   Padgett, D
   Sierra-Madero, J
   Gotuzzo, E
   Duda, SN
   McGowan, CC
   Shepherd, BE
AF Wolff, Marcelo J.
   Giganti, Mark J.
   Cortes, Claudia P.
   Cahn, Pedro
   Grinsztejn, Beatriz
   Pape, Jean W.
   Padgett, Denis
   Sierra-Madero, Juan
   Gotuzzo, Eduardo
   Duda, Stephany N.
   McGowan, Catherine C.
   Shepherd, Bryan E.
CA Caribbean Cent S Amer Network HIV
TI A decade of HAART in Latin America: Long term outcomes among the first
   wave of HIV patients to receive combination therapy
SO PLOS ONE
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; FOLLOW-UP; EARLY MORTALITY; CD4 COUNT; 7
   SITES; INFECTION; SURVIVAL; ACCESS; COHORT; ADULTS
AB Background
   In Latin America, the first wave of HIV-infected patients initiated highly active antiretroviral therapy (HAART) 10 or more years ago. Characterizing their treatment experience and corresponding outcomes across a decade of HAART may yield insights relevant to the ongoing care of such patients and those initiating HAART more recently in similar clinical settings.
   Methods
   This retrospective study included adults initiating HAART before 2004 at 8 sites in Argentina, Brazil, Chile, Haiti, Honduras, and Mexico. Patient status (in care, dead, or lost to follow-up [LTFU]) was assessed at 6-month intervals for 10 years, along with CD4 count and HIV-1 viral load (VL) for patients in care.
   Results
   4,975 patients (66% male) started HAART prior to 2004; 45% were not antiretroviral-naive. At 1, 5, and 10 years, rates of mortality were 4.2%, 9.0%, and 13.6% respectively. LTFU rates for the same periods were 2.4%, 10.9%, and 24.2%. Among patients remaining in care at 10 years, 84.4% were estimated to have VL <= 400 copies/mL (Haiti excluded) and median baseline CD4 increased from 158 to 525 cells/mm(3). Only 11.4% of all patients remained on their first regimen, 12.6% were on their second, 11.5% were on their third, and 23.0% were on their fourth or subsequent regimen. Outcomes were generally better for patients who were not antiretroviral-naive, except for viral suppression. Heterogeneity among sites was substantial.
   Conclusions
   Despite advanced disease and predominant use of older antiretrovirals, a large percentage of early HAART initiators in this Latin American cohort were alive and in care with sustained virologic suppression and progressive immune recovery after 10 years.
C1 [Wolff, Marcelo J.; Cortes, Claudia P.] Univ Chile, Fdn Arriaran, Fac Med, Santiago, Chile.
   [Giganti, Mark J.; Shepherd, Bryan E.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.
   [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Grinsztejn, Beatriz] Inst Nacl Infectol Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Pape, Jean W.] Grp Haitien Etud Sarcome Kaposi & Infect Opportun, Port Au Prince, Haiti.
   [Padgett, Denis] Inst Hondureno Seguridad Social Hosp Especialidad, Tegucigalpa, Honduras.
   [Sierra-Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Talplan, Mexico.
   [Gotuzzo, Eduardo] Univ Peruana Cayetano Heredia, Hosp Nacl Cayetano Heredia, Lima, Peru.
   [Duda, Stephany N.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA.
   [McGowan, Catherine C.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.
RP Wolff, MJ (corresponding author), Univ Chile, Fdn Arriaran, Fac Med, Santiago, Chile.
EM marcewolff@yahoo.com
RI Cortes, Claudia/AAF-7326-2020
OI Cortes, Claudia/0000-0001-9101-9783; Wolff, Marcelo/0000-0002-9956-8872
FU National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); National Cancer Institute (NCI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI); Eunice Kennedy Shriver
   National Institute of Child Health and Human Development (NICHD) as part
   of the International epidemiologic Databases to Evaluate AIDS (IeDEA)
   [U01 Al069923]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, UM1AI069476, UM1AI069421, U01AI069923,
   U01AI069923, UM1AI069421, U01AI069923, U01AI069923, UM1AI069421,
   U01AI069923, UM1AI069421, UM1AI069476, U01AI069923, UM1AI069476,
   U01AI069923, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069421,
   U01AI069923, UM1AI069421, UM1AI069476, U01AI069923, UM1AI069421,
   U01AI069923, UM1AI069421, U01AI069923, U01AI069923, UM1AI069476,
   U01AI069923, U01AI069923, UM1AI069476, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923] Funding Source: NIH RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (NIAID), the National Cancer Institute (NCI) and the
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD) as part of the International epidemiologic Databases
   to Evaluate AIDS (IeDEA): U01 Al069923.
CR [Anonymous], 2014, HIV MED, V15, P1
   Ballif M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008275
   Belloso WH, 2010, HIV MED, V11, P554, DOI 10.1111/j.1468-1293.2010.00824.x
   Cesar C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010490
   Chequer P, 2002, AIDS, V16, pS50, DOI 10.1097/00002030-200212003-00008
   Cicconi P, 2010, HIV MED, V11, P104, DOI 10.1111/j.1468-1293.2009.00750.x
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Crabtree-Ramirez B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020272
   Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents, 2013, GUIDELINES USE ANTIR
   DHHS, 2014, GUIDELINES USE ANTIR
   Duda SN, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19045
   Garcia F, 2004, JAIDS-J ACQ IMM DEF, V36, P702, DOI 10.1097/00126334-200406010-00007
   Girard PM, 2000, CLIN INFECT DIS, V31, P987, DOI 10.1086/318154
   Grimsrud A, 2014, JAIDS-J ACQ IMM DEF, V67, pE55, DOI 10.1097/QAI.0000000000000268
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Gupta A, PLOS ONE, V6
   Hicks C, 2004, AIDS, V18, P775, DOI 10.1097/00002030-200403260-00008
   Koenig SP, 2012, JAIDS-J ACQ IMM DEF, V59, pE60, DOI 10.1097/QAI.0b013e318245d3c1
   Kumarasamy N, 2013, CURR OPIN HIV AIDS, V8, P586, DOI 10.1097/COH.0000000000000004
   Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd
   Lesko CR, 2016, AIDS
   Lok JJ, 2010, AIDS, V24, P1867, DOI 10.1097/QAD.0b013e32833adbcf
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   May MT, 2016, CLIN INFECT DIS, V62, P1571, DOI 10.1093/cid/ciw183
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   Mocroft A, 2013, CLIN INFECT DIS, V57, P1038, DOI 10.1093/cid/cit423
   Mouala C, 2008, Sante, V18, P89, DOI 10.1684/san.2008.0117
   Pan American Health Organization, 2013, PUBL HLTH AN LAT AM
   Patel K, 2008, CLIN INFECT DIS, V46, P507, DOI 10.1086/526524
   Pierre S, 2016, NEW ENGL J MED, V374, P397, DOI 10.1056/NEJMc1508934
   Sabin CA, 2001, J ACQ IMMUN DEF SYND, V26, P462, DOI 10.1097/00126334-200104150-00009
   Segeral O, 2011, AIDS RES HUM RETROV, V27, P597, DOI [10.1089/aid.2010.0125, 10.1089/AID.2010.0125]
   Stoszek SK, 2013, INT J GYNECOL OBSTET, V122, P37, DOI 10.1016/j.ijgo.2012.12.021
   The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups, 2006, LANCET
   Tuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a
   UNAIDS, 2014, GAP REP
   Wolff M, 2016, JAIDS-J ACQ IMM DEF, V71, P102, DOI 10.1097/QAI.0000000000000817
   Wolff MJ, 2010, JAIDS-J ACQ IMM DEF, V55, P368, DOI 10.1097/QAI.0b013e3181eb4fb9
   World Health Organization, 2015, WORLD HLTH ORG GUIDE
   World Health Organization. AIDS Medicines and diagnostic service, 2014, ANT MED LOW MIDDL IN
   Wright S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064902
NR 41
TC 9
Z9 10
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 26
PY 2017
VL 12
IS 6
AR e0179769
DI 10.1371/journal.pone.0179769
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EZ2KD
UT WOS:000404537300020
PM 28651014
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Martin, D
   Luz, PM
   Lake, JE
   Clark, JL
   Campos, DP
   Veloso, VG
   Moreira, RI
   Cardoso, SW
   Klausner, JD
   Grinsztejn, B
AF Martin, David
   Luz, Paula M.
   Lake, Jordan E.
   Clark, Jesse L.
   Campos, Dayse P.
   Veloso, Valdilea G.
   Moreira, Ronaldo I.
   Cardoso, Sandra W.
   Klausner, Jeffrey D.
   Grinsztejn, Beatriz
TI Pharmacy refill data can be used to predict virologic failure for
   patients on antiretroviral therapy in Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE adherence; antiretroviral therapy; pharmacy refill; cohort studies;
   Brazil; viral load
ID VIRAL LOAD; ADHERENCE; OUTCOMES; TIME; LONG
AB Introduction: Pharmacy adherence measures such as pharmacy dispensing ratios (PDRs) have previously been shown to be predictive of virologic outcomes. We aimed to determine the optimal interval of PDR assessment for predicting virologic failure for HIV-infected patients on antiretroviral therapy (ART).
   Methods: Using national Brazilian ART pharmacy refill data, we examined PDRs for patients >= 18 years of age with at least one HIV RNA level >= 180 days after ART initiation on or after 1 January 2011. Patients with a documented ART change <= 270 days prior to viral load test date were excluded. Logistic regression models were used to describe associations between virologic failure, defined as an HIV RNA level >= 400 copies/mL and PDRs, defined as the number of days index drug dispensed (non-nucleoside reverse-transcriptase inhibitor or protease inhibitor) per 180- and 90-day, interval preceding viral load testing, adjusting for sex, age, race, time since ART initiation and index drug. Backward elimination of insignificant variables was performed after adjusting for PDR. A predictive probability of virologic failure was calculated using the corresponding odds ratios for the PDR and any other significant variables. The diagnostic performance of the PDR interval was assessed by calculating the area under the receiver operating characteristic curve (AUROC) for the predictive probability with respect to virologic failure.
   Results and Discussion: A total of 1,025 patients were included (68% were male, median age 40 years, median time on ART 3.4 years). The PDR was found to be significantly associated with virologic failure for all of the PDR intervals (p < 0.001). There was an increased risk of virologic failure for all PDRs < 0.95. The 90-180 days interval had a AUROC of 0.842, compared to 0.841 and 0.829 for the 0-180 days and 0-90 days intervals, respectively. The PDR performed well as a predictive tool to identify patients in virologic failure with the 90-180-days interval prior to viral load testing being marginally more predictive.
   Conclusions: The validation and use of the pharmacy dispensing ratio using public pharmacy refill data could aid in early identification of patients with poor adherence and prevent development of treatment failure and drug resistance in Brazil.
C1 [Martin, David] Highland Hosp, Dept Emergency Med, Oakland, CA USA.
   [Luz, Paula M.; Campos, Dayse P.; Veloso, Valdilea G.; Moreira, Ronaldo I.; Cardoso, Sandra W.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, INI, Rio De Janeiro, Brazil.
   [Lake, Jordan E.; Clark, Jesse L.; Klausner, Jeffrey D.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
RP Martin, D (corresponding author), 2032 McAllister St,Apt 3, San Francisco, CA 94118 USA.
EM dmartin@post.harvard.edu
OI Luz, Paula/0000-0001-9746-719X; Clark, Jesse/0000-0001-5862-6530
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R25 MH087222];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [K23AI110532, UM1AI069476, K23AI110532, UM1AI069476, UM1AI069476,
   K23AI110532, UM1AI069476, UM1AI069476, K23AI110532, UM1AI069476,
   UM1AI069476, K23AI110532, K23AI110532, UM1AI069476] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [R25MH087222, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, R25MH087222, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107] Funding
   Source: NIH RePORTER
FX Support provided by the National Institutes of Health R25 MH087222
   (South American Program in HIV Prevention Research).
CR Acri TL, 2010, JAIDS-J ACQ IMM DEF, V54, pE16, DOI 10.1097/QAI.0b013e3181ed1626
   Bangsberg DR, 2008, J INFECT DIS, V197, pS272, DOI 10.1086/533415
   Cain LE, 2015, CLIN INFECT DIS, V60, P1262, DOI 10.1093/cid/ciu1167
   Cardoso SW, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-29
   Court R, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0664-3
   Gross R, 2001, AIDS, V15, P2109, DOI 10.1097/00002030-200111090-00006
   Gross R, 2006, J INFECT DIS, V194, P1108, DOI 10.1086/507680
   Grossberg R, 2004, J CLIN EPIDEMIOL, V57, P1107, DOI 10.1016/j.jclinepi.2004.04.002
   Lima VD, 2009, JAIDS-J ACQ IMM DEF, V50, P529, DOI 10.1097/QAI.0b013e31819675e9
   Martin DA, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-322
   Martin M, 2008, AIDS RES HUM RETROV, V24, P1263, DOI 10.1089/aid.2008.0141
   McMahon JH, 2011, CLIN INFECT DIS, V52, P493, DOI 10.1093/cid/ciq167
   Ministerio da Saude, 2008, REC TER ANT AD INF P
   Molina JM, 2010, JAIDS-J ACQ IMM DEF, V53, P323, DOI 10.1097/QAI.0b013e3181c990bf
   Murphy RA, 2012, JAIDS-J ACQ IMM DEF, V61, P158, DOI 10.1097/QAI.0b013e3182615ad1
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301
   World Health Organization, 2006, PAT MON GUID HIV CAR
NR 18
TC 5
Z9 5
U1 0
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUN 5
PY 2017
VL 20
AR 21405
DI 10.7448/IAS.20.1.21405
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EW6SL
UT WOS:000402640500001
PM 28605172
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Escada, ROD
   Velasque, L
   Ribeiro, SR
   Cardoso, SW
   Marins, LMS
   Grinsztejn, E
   Lourenco, MCD
   Grinsztejn, B
   Veloso, VG
AF da Silva Escada, Rodrigo Otavio
   Velasque, Luciane
   Ribeiro, Sayonara Rocha
   Cardoso, Sandra Wagner
   Spindola Marins, Luana Monteiro
   Grinsztejn, Eduarda
   da Silva Lourenco, Maria Cristina
   Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
TI Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de
   Janeiro, Brazil - associated factors and causes of death
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Tuberculosis; Mortality; CoDe; Bacterial disease; Tuberculosis;
   HIV/Aids; Cohort study; Brazil
ID ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; PULMONARY TUBERCULOSIS;
   IMMUNE RECONSTITUTION; DETERMINANTS; PROPHYLAXIS; INITIATION; DIAGNOSIS;
   SURVIVAL; AMERICA
AB Background: Tuberculosis is the most frequent opportunistic infection and the leading cause of death among persons living with HIV in several low and middle-income countries. Mortality rates during tuberculosis treatment and death causes among HIV-1/TB co-infected patients may differ based on the immunosuppression severity, timing of diagnosis and prompt initiation of tuberculosis and antiretroviral therapy.
   Methods: This was a retrospective observational study conducted in the clinical cohort of patients with HIV-1/Aids of the National Institute of Infectious Diseases Evandro Chagas, Rio de Janeiro, Brazil. All HIV-1 infected patients who started combination antiretroviral therapy up to 30 days before or within 180 days after the start of tuberculosis treatment from 2000 to 2010 were eligible. Causes of death were categorized according to the "Coding Causes of Death in HIV" (CoDe) protocol. The Cox model was used to estimate the hazard ratio (HR) of selected mortality variables.
   Results: A total of 310 patients were included. Sixty-four patients died during the study period. Mortality rate following tuberculosis treatment initiation was 44 per 100 person-years within the first 30 days, 28.1 per 100 person-years within 31 and 90 days, 6 per 100 person-years within 91 and 365 days and 1.6 per 100 person-years after 365 days. Death probability within one year from tuberculosis treatment initiation was approximately 13%. In the adjusted analysis the associated factors with mortality were: CD4 <= 50 cells/mm(3) (HR: 3.10; 95% CI: 1.720 to 5.580; p = 0.00); mechanical ventilation (HR: 2.81; 95% CI: 1.170 to 6.760; p = 0.02); and disseminated tuberculosis (HR: 3.70; 95% CI: 1.290 to 10.590, p = 0.01). Invasive bacterial disease was the main immediate cause of death (46.9%).
   Conclusion: Our results evidence the high morbidity and mortality among patients co-infected with HIV-1 and tuberculosis in Rio de Janeiro, Brazil. During the first year following tuberculosis diagnosis, mortality was the highest within the first 3 months, being invasive bacterial infection the major cause of death. In order to successfully intervene in this scenario, it is utterly necessary to address the social determinants of health contributing to the inequitable health care access faced by this population.
C1 [da Silva Escada, Rodrigo Otavio; Velasque, Luciane; Ribeiro, Sayonara Rocha; Cardoso, Sandra Wagner; Spindola Marins, Luana Monteiro; Grinsztejn, Eduarda; da Silva Lourenco, Maria Cristina; Grinsztejn, Beatriz; Veloso, Valdilea Goncalves] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil.
RP Veloso, VG (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
EM valdilea.veloso@ini.fiocruz.br
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01AI069923]; Eunice Kennedy Shriver
   National Institute of Child Health & Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); Office of the Director, National
   Institutes of Health (OD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Institute of
   Allergy and Infectious Diseases (NIAID)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID); National
   Cancer Institute (NCI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); National Institute of Mental Health (NIMH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH); NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01AI069923,
   UM1AI069476, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, UM1AI069476, U01AI069923, U01AI069923,
   UM1AI069476, U01AI069923, U01AI069923, UM1AI069476, U01AI069923,
   U01AI069923, UM1AI069476, U01AI069923, U01AI069923, UM1AI069476,
   U01AI069923, UM1AI069476, U01AI069923, UM1AI069476] Funding Source: NIH
   RePORTER
FX This work was supported by the NIH-funded Caribbean, Central and South
   America network for HIV epidemiology (CCASAnet), a member cohort of the
   International Epidemiologic Databases to Evaluate AIDS (leDEA)
   (U01AI069923). This award is funded by the following institutes: Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD), Office of the Director, National Institutes of Health (OD),
   National Institute of Allergy and Infectious Diseases (NIAID), National
   Cancer Institute (NCI), and the National Institute of Mental Health
   (NIMH).
CR Boehme CC, 2011, LANCET, V377, P1495, DOI 10.1016/S0140-6736(11)60438-8
   Buehler M., 1990, MMWR RECOMM REP
   Cain KP, 2009, EMERG INFECT DIS, V15, P258, DOI 10.3201/eid1502.080942
   Castelnuovo B, 2009, CLIN INFECT DIS, V49, P965, DOI 10.1086/605500
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   de Oliveira GP, 2013, BRAZ J INFECT DIS, V17, P218, DOI 10.1016/j.bjid.2013.01.005
   de Pinho AMF, 2001, AIDS, V15, P2129, DOI 10.1097/00002030-200111090-00008
   Field N, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0679-9
   Golub JE, 2007, AIDS, V21, P1441, DOI 10.1097/QAD.0b013e328216f441
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Guimaraes RM, 2012, J BRAS PNEUMOL, V38, P511, DOI 10.1590/S1806-37132012000400014
   Gutierrez EB, 2002, PATHOL RES PRACT, V198, P339, DOI 10.1078/0344-0338-00264
   Harries AD, 2009, INT J TUBERC LUNG D, V13, P6
   Harries AD, 2001, INT J TUBERC LUNG D, V5, P1000
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   Instituto Brasileiro de Geografia e Estatistica. IBGE. Ministerio do Planejamento Orcamento e Gestao, 2011, CENS DEM 2010 CAR PO
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Kantipong P, 2012, HIVAIDS RES PALLIAT, V159
   Kleinbaum D. G., 1996, SURVIVAL ANAL
   Kowalska JD, 2011, EPIDEMIOLOGY, V22, P516, DOI 10.1097/EDE.0b013e31821b5332
   Kwara A, 2005, INT J TUBERC LUNG D, V9, P485
   Lawn SD, 2005, AIDS
   Lawn SD, 2008, AM J RESP CRIT CARE, V177, P680, DOI 10.1164/rccm.200709-1311PP
   Lawn SD, 2012, AIDS, V26, P2121, DOI 10.1097/QAD.0b013e3283565dd1
   Levy Mitchell M, 2003, Intensive Care Med, V29, P530
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Maior MD, 2012, J BRAS PNEUMOL, V38, P202, DOI 10.1590/S1806-37132012000200009
   Marcy O, 2014, CLIN INFECT DIS, V59, P435, DOI 10.1093/cid/ciu283
   Martinson NA, 2007, AIDS, V21, P2043, DOI 10.1097/QAD.0b013e3282eea47f
   Ministerio da Saude (Brasil) Secretaria de Vigilancia em Saude Programa Nacional de Controle da Tuberculose, 2011, MAN REC CONTR TUB BR
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Nunn AJ, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a257
   Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8
   Podlekareva DN, 2016, LANCET HIV, V3, pE120, DOI 10.1016/S2352-3018(15)00252-0
   Podlekareva DN, 2009, AIDS, V23, P2485, DOI 10.1097/QAD.0b013e3283326879
   Sharma SK, 2004, INDIAN J MED RES, V120, P316
   Schmaltz CAS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045704
   Schmaltz CAS, 2009, JAIDS-J ACQ IMM DEF, V52, P623, DOI 10.1097/QAI.0b013e3181b31e56
   Storla DG, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-15
   Therneau T. M., 2014, PACKAGE SURVIVAL ANA
   Wang JY, 2007, MEDICINE, V86, P39, DOI 10.1097/MD.0b013e318030b605
   Whalen C, 1997, AIDS, V11, P455, DOI 10.1097/00002030-199704000-00008
   WHO, 2010, TREATMENT OF TUBERCULOSIS: GUIDELINES, FOURTH EDITION, P1
   Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0
   Wong EB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047542
   World Health Organization, 2014, GLOB TUB REP 2014
NR 48
TC 9
Z9 10
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAY 30
PY 2017
VL 17
AR 373
DI 10.1186/s12879-017-2473-y
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA EW5UE
UT WOS:000402571200005
PM 28558689
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Palumbo, PJ
   Wilson, EA
   Piwowar-Manning, E
   McCauley, M
   Gamble, T
   Kumwenda, N
   Makhema, J
   Kumarasamy, N
   Chariyalertsak, S
   Hakim, JG
   Hosseinipour, MC
   Melo, MG
   Godbole, SV
   Pilotto, JH
   Grinsztejn, B
   Panchia, R
   Chen, YQ
   Cohen, MS
   Eshleman, SH
   Fogel, JM
AF Palumbo, Philip J.
   Wilson, Ethan A.
   Piwowar-Manning, Estelle
   McCauley, Marybeth
   Gamble, Theresa
   Kumwenda, Newton
   Makhema, Joseph
   Kumarasamy, Nagalingeswaran
   Chariyalertsak, Suwat
   Hakim, James G.
   Hosseinipour, Mina C.
   Melo, Marineide G.
   Godbole, Sheela V.
   Pilotto, Jose H.
   Grinsztejn, Beatriz
   Panchia, Ravindre
   Chen, Ying Q.
   Cohen, Myron S.
   Eshleman, Susan H.
   Fogel, Jessica M.
TI Association of HIV diversity and virologic outcomes in early
   antiretroviral treatment: HPTN 052
SO PLOS ONE
LA English
DT Article
ID RESOLUTION MELTING ASSAY; DISEASE PROGRESSION; ENV GENE; INFECTION;
   EVOLUTION; PREVENTION; CHILDREN; THERAPY; RATES
AB Higher HIV diversity has been associated with virologic outcomes in children on antiretroviral treatment (ART). We examined the association of HIV diversity with virologic outcomes in adults from the HPTN 052 trial who initiated ART at CD4 cell counts of 350-550 cells/mm(3). A high resolution melting (HRM) assay was used to analyze baseline (pre-treatment) HIV diversity in six regions in the HIV genome (two in gag, one in pol, and three in env) from 95 participants who failed ART. We analyzed the association of HIV diversity in each genomic region with baseline (pre-treatment) factors and three clinical outcomes: time to virologic suppression after ART initiation, time to ART failure, and emergence of HIV drug resistance at ART failure. After correcting for multiple comparisons, we did not find any association of baseline HIV diversity with demographic, laboratory, or clinical characteristics. For the 18 analyses performed for clinical outcomes evaluated, there was only one significant association: higher baseline HIV diversity in one of the three HIV env regions was associated with longer time to ART failure (p = 0.008). The HRM diversity assay may be useful in future studies exploring the relationship between HIV diversity and clinical outcomes in individuals with HIV infection.
C1 [Palumbo, Philip J.; Piwowar-Manning, Estelle; Eshleman, Susan H.; Fogel, Jessica M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Wilson, Ethan A.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [McCauley, Marybeth] FHI 360, Sci Facilitat Dept, Washington, DC USA.
   [Gamble, Theresa] FHI 360, Sci Facilitat Dept, Durham, NC USA.
   [Kumwenda, Newton] Johns Hopkins Project, Coll Med, Blantyre, Malawi.
   [Makhema, Joseph] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana.
   [Kumarasamy, Nagalingeswaran] VHS, YRGCARE Med Ctr, CART CRS, Madras, Tamil Nadu, India.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Hakim, James G.] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
   [Hosseinipour, Mina C.] Univ North Carolina Chapel Hill, Div Infect Dis, Chapel Hill, NC USA.
   [Hosseinipour, Mina C.] UNC Project Malawi, Inst Global Hlth & Infect Dis, Lilongwe, Malawi.
   [Melo, Marineide G.] Hosp Nossa Senhora Conceicao, Serv Infectol, Porto Alegre, RS, Brazil.
   [Godbole, Sheela V.] Natl AIDS Res Inst ICMR, Pune, Maharashtra, India.
   [Pilotto, Jose H.] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, Jose H.] Fiocruz MS, Lab AIDS Imunol Mol IOC, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Rio De Janeiro, Brazil.
   [Panchia, Ravindre] Univ Witwatersrand, Perinatal HIV Res Unit, Soweto HPTN CRS, Soweto, South Africa.
   [Chen, Ying Q.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Cohen, Myron S.] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA.
RP Eshleman, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
EM seshlem@jhmi.edu
RI Pilotto, Jose Henrique/AAD-9773-2019; Godbole, Sheela/K-4177-2017
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Palumbo,
   Philip/0000-0002-6394-6878; Kumwenda, Newton/0000-0003-2622-4339
FU Division of AIDS of the U.S. National Institute of Allergy and
   Infectious Diseases (NIAID); Office of AIDS Research of the U.S.
   National Institutes of Health (NIH) [UM1-AI068613, UM1-AI068617,
   UM1-AI068619]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069423, UM1AI069456, UM1AI069436,
   UM1AI069423, UM1AI069436, UM1AI069476, UM1AI069432, UM1AI069456,
   UM1AI069423, UM1AI069399, UM1AI069432, UM1AI068613, UM1AI068613,
   UM1AI069436, UM1AI069476, UM1AI069456, UM1AI069423, UM1AI069476,
   UM1AI069476, UM1AI068613, UM1AI068613, UM1AI069399, UM1AI069453,
   UM1AI069399, UM1AI068613, UM1AI069399, UM1AI069456, UM1AI069399,
   UM1AI069456, UM1AI069436, UM1AI069453, UM1AI069432, UM1AI069476,
   UM1AI069436, UM1AI069423, UM1AI069432, UM1AI069453, UM1AI069432,
   UM1AI069453, UM1AI069432, UM1AI068613, UM1AI069399, UM1AI069476,
   UM1AI069476, UM1AI068613, UM1AI069432, UM1AI068613, UM1AI069456,
   UM1AI069399, UM1AI069476, UM1AI068613, UM1AI069436, UM1AI069453,
   UM1AI069423, UM1AI069453, UM1AI069436, UM1AI069399, UM1AI069456,
   UM1AI069453, UM1AI069423, UM1AI069423, UM1AI068613, UM1AI069432,
   UM1AI069453, UM1AI069453, UM1AI069456, UM1AI068613, UM1AI069399,
   UM1AI069432, UM1AI069456, UM1AI069476, UM1AI069436, UM1AI069432,
   UM1AI069423] Funding Source: NIH RePORTER
FX This work was supported by the grants from the Division of AIDS of the
   U.S. National Institute of Allergy and Infectious Diseases (NIAID); and
   by the Office of AIDS Research of the U.S. National Institutes of Health
   (NIH) [UM1-AI068613 (Eshleman); UM1-AI068617 (Donnell); and UM1-AI068619
   (Cohen/El-Sadr)]. Study drugs used in HPTN 052 were donated by Abbott
   Laboratories, Boehringer-Ingelheim Pharmaceuticals, Inc, Bristol-Myers
   Squibb, Gilead Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, and
   Merck & Co., Inc. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Chen I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081213
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cousins MM, 2013, J MOL DIAGN, V15, P130, DOI 10.1016/j.jmoldx.2012.08.008
   Cousins MM, 2012, J CLIN MICROBIOL, V50, P3054, DOI 10.1128/JCM.01460-12
   Cousins MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027211
   Eshleman SH, 2007, AIDS, V21, P1165, DOI 10.1097/QAD.0b013e32810fd72e
   Fogel JM, VIROLOGIC OUTC UNPUB
   Ganeshan S, 1997, J VIROL, V71, P663, DOI 10.1128/JVI.71.1.663-677.1997
   James MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057350
   James MM, 2012, PEDIATR INFECT DIS J, V31, pE222, DOI 10.1097/INF.0b013e3182678c3f
   James MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018642
   Joos B, 2005, J VIROL, V79, P9026, DOI 10.1128/JVI.79.14.9026-9037.2005
   Keele BF, 2010, CURR OPIN HIV AIDS, V5, P327, DOI 10.1097/COH.0b013e32833a0b9b
   Kitrinos KM, 2005, J VIROL, V79, P10627, DOI 10.1128/JVI.79.16.10627-10637.2005
   Lemey P, 2007, PLOS COMPUT BIOL, V3, P282, DOI 10.1371/journal.pcbi.0030029
   Mani I, 2002, J VIROL, V76, P10745, DOI 10.1128/JVI.76.21.10745-10755.2002
   Markham RB, 1998, P NATL ACAD SCI USA, V95, P12568, DOI 10.1073/pnas.95.21.12568
   Piantadosi A, 2009, AIDS, V23, P579, DOI 10.1097/QAD.0b013e328328f76e
   Rachinger A, 2012, AIDS, V26, P1517, DOI 10.1097/QAD.0b013e328354f539
   Rambaut A, 2004, NAT REV GENET, V5, P52, DOI 10.1038/nrg1246
   Sagar M, 2003, J VIROL, V77, P12921, DOI 10.1128/JVI.77.23.12921-12926.2003
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Towler WI, 2010, AIDS RES HUM RETROV, V26, P913, DOI 10.1089/aid.2009.0259
   Williamson S, 2003, MOL BIOL EVOL, V20, P1318, DOI 10.1093/molbev/msg144
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
NR 27
TC 2
Z9 2
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 8
PY 2017
VL 12
IS 5
AR e0177281
DI 10.1371/journal.pone.0177281
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EU8UJ
UT WOS:000401313700047
PM 28481902
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU de Azevedo, SSD
   Caetano, DG
   Cortes, FH
   Teixeira, SLM
   Silva, KD
   Hoagland, B
   Grinsztejn, B
   Veloso, VG
   Morgado, MG
   Bello, G
AF de Azevedo, Suwellen S. D.
   Caetano, Diogo Gama
   Cortes, Fernanda H.
   Teixeira, Sylvia L. M.
   Silva, Karina dos Santos
   Hoagland, Brenda
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Morgado, Mariza G.
   Bello, Gonzalo
TI Highly divergent patterns of genetic diversity and evolution in proviral
   quasispecies from HIV controllers
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1; Elite controllers; Viremic controllers; Reservoir; Diversity;
   Evolution; Reseeding
ID IMMUNODEFICIENCY-VIRUS TYPE-1; LONG-TERM NONPROGRESSORS; ELITE
   SUPPRESSORS; ANTIRETROVIRAL THERAPY; NATURAL CONTROL; SEX-DIFFERENCES;
   PLASMA VIRUS; INFECTION; SEQUENCES; REPLICATION
AB Background: Ongoing intra-host HIV-1 evolution has been shown in individuals that naturally suppress the viremia to low levels (HIV controllers) by the analysis of the RNA in plasma compartment. Detection of evolution at the DNA proviral compartment in HIV controllers, however, has been more challenging and the precise correlation between the systemic viral suppression level and rate of reservoir's reseeding in those individuals is not fully understood. In this sense, we examined the proviral DNA quasispecies by single genome amplification of the env gene in a cohort of 23 HIV controllers from Brazil, divided in three groups, according to the level of systemic viral suppression: (1) elite controllers with persistent undetectable viral load (PEC, n = 6); (2) elite controllers with occasional episodes of transient (51-400 copies/mL) viremia (EEC, n = 7); and (3) viremic controllers with persistent low-level (80-2000 copies/mL) viremia (VC, n = 10).
   Results: The HIV-1 diversity of the PBMC-associated proviral quasispecies in EC was significantly (P < 0.01) lower than in VC, but not significantly different between PEC and EEC groups. We detected a considerable variation in the average pairwise nucleotide distance and proportion of unique sequences in the HIV-1 proviral quasispecies of PEC and EEC. Some PEC and EEC displayed highly homogenous proviral populations with large clusters of identical sequences, while others exhibited relatively diverse proviral populations with a high proportion of unique sequences comparable to VC subjects. The long-term (10-15 years) follow-up of the HIV-1 proviral populations revealed a complete evolutionary stasis in one PEC and measurable divergence rates in one EEC [3.1 (1.2-5.6) x 10(-3) substitutions/site/year and one VC [2.9 (0.7-5.1) x 10(-3) substitutions/site/year].
   Conclusions: There is no simple relationship between systemic viral suppression and intra-host proviral diversity or rate of reservoir's reseeding in chronically infected HIV controllers. Our results demonstrate that very divergent patterns of intra-host viral diversity and divergence could be detected in the setting of natural suppression of HIV-1 replication and that ongoing evolution and reseeding of the PBMC proviral reservoir occurs in some elite controllers.
C1 [de Azevedo, Suwellen S. D.; Caetano, Diogo Gama; Cortes, Fernanda H.; Teixeira, Sylvia L. M.; Silva, Karina dos Santos; Morgado, Mariza G.; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM gbello@ioc.fiocruz.br
RI Cortes, Fernanda/AAF-9254-2020; Bello, Gonzalo/E-6842-2013; Bentancor,
   Gonzalo Jose Bello/N-7377-2019; de Azevedo, Suwellen/P-7199-2017
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; de Azevedo,
   Suwellen/0000-0001-6681-0987
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro-FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ) [E-26/110.123/2014]; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX SSDA is supported by funding from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq). This work was supported
   by Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro-FAPERJ
   (Grant Number E-26/110.123/2014).
CR Abrahams MR, 2009, J VIROL, V83, P3556, DOI 10.1128/JVI.02132-08
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Avila-Rios S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158560
   Bagnarelli P, 1999, J VIROL, V73, P3764, DOI 10.1128/JVI.73.5.3764-3777.1999
   Bailey JR, 2006, J EXP MED, V203, P1357, DOI 10.1084/jem.20052319
   Bailey JR, 2006, J VIROL, V80, P4758, DOI 10.1128/JVI.80.10.4758-4770.2006
   Bar KJ, 2010, J VIROL, V84, P6241, DOI 10.1128/JVI.00077-10
   Bello G, 2005, J GEN VIROL, V86, P355, DOI 10.1099/vir.0.80410-0
   Bello G, 2004, J GEN VIROL, V85, P399, DOI 10.1099/vir.0.19365-0
   Bello G, 2007, AIDS RES HUM RETROV, V23, P1242, DOI 10.1089/aid.2007.0074
   Bello G, 2007, VIROLOGY, V362, P294, DOI 10.1016/j.virol.2006.11.039
   Boritz EA, 2016, CELL, V166, P1004, DOI 10.1016/j.cell.2016.06.039
   Buchbinder S, 1999, MICROBES INFECT, V1, P1113, DOI 10.1016/S1286-4579(99)00204-X
   Cortes FH, 2015, JAIDS-J ACQ IMM DEF, V68, P377, DOI 10.1097/QAI.0000000000000500
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Gottlieb GS, 2008, J INFECT DIS, V197, P1011, DOI 10.1086/529206
   Gregori J, 2016, VIROLOGY, V493, P227, DOI 10.1016/j.virol.2016.03.017
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   Grinsztejn B, 2011, ANTIVIR THER, V16, P1057, DOI 10.3851/IMP1872
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Kearney M, 2009, J VIROL, V83, P2715, DOI 10.1128/JVI.01960-08
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lengauer T, 2007, NAT BIOTECHNOL, V25, P1407, DOI 10.1038/nbt1371
   Li HC, 2010, J NANOMATER, V2010, DOI 10.1155/2010/962718
   Mens H, 2010, J VIROL, V84, P12971, DOI 10.1128/JVI.00387-10
   Miura T, 2009, J VIROL, V83, P3407, DOI 10.1128/JVI.02459-08
   Miura T, 2009, J VIROL, V83, P2743, DOI 10.1128/JVI.02265-08
   Novitsky V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016714
   O'Connell KA, 2011, P NATL ACAD SCI USA, V108, pE689, DOI 10.1073/pnas.1108866108
   O'Connell KA, 2010, J VIROL, V84, P7018, DOI 10.1128/JVI.00548-10
   Oksanen J, 2017, VEGAN COMMUNITY ECOL
   Okulicz JF, 2009, J INFECT DIS, V200, P1714, DOI 10.1086/646609
   Pereyra F, 2009, J INFECT DIS, V200, P984, DOI 10.1086/605446
   Pernas M, 2013, JAIDS-J ACQ IMM DEF, V64, P225, DOI 10.1097/QAI.0b013e31829bdc85
   Pimentel VF, 2013, AIDS RES HUM RETROV, V29, P1553, DOI [10.1089/aid.2013.0050, 10.1089/AID.2013.0050]
   Pinheiro Rejane Sobrino, 2002, Ciênc. saúde coletiva, V7, P687
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Rodrigo AG, 1997, AIDS RES HUM RETROV, V13, P737, DOI 10.1089/aid.1997.13.737
   Rose PP, 2000, BIOINFORMATICS, V16, P400, DOI 10.1093/bioinformatics/16.4.400
   Ruel TD, 2011, CLIN INFECT DIS, V53, P592, DOI 10.1093/cid/cir484
   Sagar M, 2006, AIDS RES HUM RETROV, V22, P430, DOI 10.1089/aid.2006.22.430
   Sagar M, 2004, J VIROL, V78, P7279, DOI 10.1128/JVI.78.13.7279-7283.2004
   Salgado M, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-94
   Sandonis V, 2009, VIROLOGY, V391, P73, DOI 10.1016/j.virol.2009.05.022
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Sharkey M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001303
   Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967
   Wang B, 2003, VIROLOGY, V312, P135, DOI 10.1016/S0042-6822(03)00159-4
   Wang B, 2000, AIDS, V14, P213, DOI 10.1097/00002030-200002180-00002
NR 54
TC 15
Z9 15
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD MAY 2
PY 2017
VL 14
AR 29
DI 10.1186/s12977-017-0354-5
PG 13
WC Virology
SC Virology
GA EU0MA
UT WOS:000400704600001
PM 28464889
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Hoagland, B
   De Boni, RB
   Moreira, RI
   Madruga, JV
   Kallas, EG
   Goulart, SP
   Cerqueira, N
   Torres, TS
   Luz, PM
   Fernandes, NM
   Liu, AY
   Grinsztejn, B
   Veloso, VG
AF Hoagland, Brenda
   De Boni, Raquel B.
   Moreira, Ronaldo I.
   Madruga, Jose Valdez
   Kallas, Esper G.
   Goulart, Silvia Pereira
   Cerqueira, Natalia
   Torres, Thiago S.
   Luz, Paula M.
   Fernandes, Nilo Martinez
   Liu, Albert Y.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
CA PrEP Brasil Study Team
TI Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among
   Men Who Have Sex with Men and Transgender Women in Brazil
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Pre-exposure prophylaxis; HIV prevention; MSM; Transvestite; Transgender
   women; Awareness; Willingness
ID ANTIRETROVIRAL PROPHYLAXIS; HIV-INFECTION; HETEROSEXUAL MEN; BISEXUAL
   MEN; CONDOM USE; HIGH-RISK; PREVENTION; GAY; MSM; EPIDEMIOLOGY
AB Antiretroviral pre-exposure prophylaxis (PrEP) is recommended to prevent HIV infection among high-risk men who have sex with men (MSM) though not available in Brazil where the HIV epidemic persists unabated in this group. This cross-sectional study describes PrEP awareness and willingness and associated factors among MSM and transvestite/transgender women (trans women) pre-screened for the PrEP Brasil study. Awareness was reported by 61.3 % of the participants and was associated with age, education, site, study period and prior HIV testing. Most participants (82.1 %) were willing to use PrEP, which was associated with site, study period, number of male condomless anal sexual partners and anal sex with HIV positive/unknown partners. PrEP information is need among young and less educated individuals. Willingness to use PrEP was high and future studies should be conducted to confirm PrEP acceptability and the characteristics of the population who chose to adopt this intervention.
C1 [Hoagland, Brenda; De Boni, Raquel B.; Moreira, Ronaldo I.; Torres, Thiago S.; Luz, Paula M.; Fernandes, Nilo Martinez; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz INI FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
   [Madruga, Jose Valdez; Goulart, Silvia Pereira] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Kallas, Esper G.; Cerqueira, Natalia] Univ Sao Paulo, Sao Paulo, Brazil.
   [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
RP Hoagland, B (corresponding author), Fundacao Oswaldo Cruz INI FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM brenda.hoagland@ini.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; TORRES, THIAGO SILVA/D-6548-2014
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; TORRES, THIAGO
   SILVA/0000-0002-2557-601X; Luz, Paula/0000-0001-9746-719X; Kallas,
   Esper/0000-0003-2026-6925
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq) [PROEP 402004/2012-4, Universal 45931/2014-0]; FAPERJ
   (Fundacao Carlos Chagas de Amparo a Pesquisa do Estado do Rio de
   Janeiro)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/110.261/2017, 2012/51743]; SVS-MS
   (Secretaria de Vigilancia em Saude do Ministerio da Saude) [281/2013];
   Departamento de HIV/AIDS e Hepatites Virais-Ministerio da Saude
   [01/2013, BRA/K27]
FX This study was funded by CNPq (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico-Grant PROEP 402004/2012-4; Grant Universal
   45931/2014-0), FAPERJ (Fundacao Carlos Chagas de Amparo a Pesquisa do
   Estado do Rio de Janeiro-Grant E-26/110.261/2017; Grant 2012/51743),
   SVS-MS (Secretaria de Vigilancia em Saude do Ministerio da Saude-Grant
   281/2013) and Departamento de HIV/AIDS e Hepatites Virais-Ministerio da
   Saude (Grant 01/2013 projeto BRA/K27). The funders had no hole in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aghaizu A, 2013, SEX TRANSM INFECT, V89, P207, DOI 10.1136/sextrans-2012-050648
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Barash EA, 2010, AIDS PATIENT CARE ST, V24, P689, DOI 10.1089/apc.2010.0173
   Bassichetto KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001423
   Bavinton BR, 2015, VIRAL LOAD AWARENESS, P141
   Bil JP, 2015, AIDS, V29, P955, DOI 10.1097/QAD.0000000000000639
   Blumenthal J, 2015, AIDS BEHAV, V19, P802, DOI 10.1007/s10461-015-0996-z
   Brooks RA, 2012, AIDS PATIENT CARE ST, V26, P87, DOI 10.1089/apc.2011.0283
   Calabrese SK, 2015, AM J PUBLIC HEALTH, V105, P1960, DOI 10.2105/AJPH.2015.302816
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Cohen SE, 2015, JAIDS-J ACQ IMM DEF, V68, P439, DOI 10.1097/QAI.0000000000000479
   Costa AB, 2015, ARCH SEX BEHAV, V44, P521, DOI 10.1007/s10508-014-0386-z
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Departamento de DST Aids e Hepatites Virais, 2015, B EPI DEMIOLOGICO AI
   Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4
   Eisingerich AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028238
   Escudero DJ, 2015, AIDS CARE, V27, P637, DOI 10.1080/09540121.2014.986051
   Golub SA, 2014, AIDS BEHAV, V18, P1686, DOI 10.1007/s10461-014-0770-7
   Grant RM, 2016, CURR OPIN HIV AIDS, V11, P3, DOI 10.1097/COH.0000000000000216
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Hojilla JC, 2016, AIDS BEHAV, V20, P1461, DOI 10.1007/s10461-015-1055-5
   Holt M, 2012, SEX TRANSM INFECT, V88, P258, DOI 10.1136/sextrans-2011-050312
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Krakower DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033119
   Kurtz SP, 2016, LGBT HEALTH, DOI [10.1089/lgbt.2015.0069, DOI 10.1089/LGBT.2015.0069.]
   Lebouche B, 2016, HIV MED, V17, P152, DOI 10.1111/hiv.12286
   Liu A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001613
   Martins TA, 2013, AIDS CARE, V25, P606, DOI 10.1080/09540121.2012.726342
   Mascena MADS, 2015, AIDS BEHAV, V19, P1589
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P77, DOI 10.1097/QAI.0b013e31818d5a27
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Mugwanya KK, 2013, LANCET INFECT DIS, V13, P1021, DOI 10.1016/S1473-3099(13)70226-3
   Saude M., 2013, PROTOCOLO CLIN DIRET
   Silva DS, 2015, AIDS BEHAV, DOI [10.1007/s10461-015-1235-3, DOI 10.1007/S10461-015-1235-3.]
   Sineath R Craig, 2013, J Int Assoc Provid AIDS Care, V12, P227, DOI 10.1177/2325957413488184
   Smith DK, 2015, SEX TRANSM DIS, V42, P88, DOI 10.1097/OLQ.0000000000000238
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Ware NC, 2012, JAIDS-J ACQ IMM DEF, V59, P463, DOI 10.1097/QAI.0b013e31824a060b
   Wheelock A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054288
   Yang DZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054495, 10.1371/journal.pone.0059020]
   Young I, 2014, REV RES ACCEPTABILIT, P195
   Zhou F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032329
NR 46
TC 39
Z9 39
U1 1
U2 11
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD MAY
PY 2017
VL 21
IS 5
BP 1278
EP 1287
DI 10.1007/s10461-016-1516-5
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA ER9JL
UT WOS:000399142400006
PM 27531461
DA 2020-11-24
ER

PT J
AU Hoagland, B
   Moreira, RI
   De Boni, RB
   Kallas, EG
   Madruga, JV
   Vasconcelos, R
   Goulart, S
   Torres, TS
   Marins, LMS
   Anderson, PL
   Luz, PM
   Leite, ID
   Liu, AY
   Veloso, VG
   Grinsztejn, B
AF Hoagland, Brenda
   Moreira, Ronaldo I.
   De Boni, Raquel B.
   Kallas, Esper G.
   Madruga, Jose Valdez
   Vasconcelos, Ricardo
   Goulart, Silvia
   Torres, Thiago S.
   Marins, Luana M. S.
   Anderson, Peter L.
   Luz, Paula M.
   Leite, Iuri da Costa
   Liu, Albert Y.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
CA PrEP Brasil Study Team
TI High pre-exposure prophylaxis uptake and early adherence among men who
   have sex with men and transgender women at risk for HIV Infection: the
   PrEP Brasil demonstration project
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE Pre-exposure prophylaxis; HIV prevention; MSM; transgender women; PrEP
   uptake; PrEP adherence; DRUG Levels
ID TENOFOVIR DISOPROXIL FUMARATE; EMTRICITABINE; VALIDITY; BEHAVIOR; MSM
AB Introduction: The efficacy of pre-exposure prophylaxis (PrEP) in preventing sexual acquisition of human immunodeficiency virus (HIV) is well established. Little is known about the feasibility of PrEP implementation in middle-income settings with concentrated epidemics among men who have sex with men (MSM) and transgender women (TGW).
   Methods: PrEP Brasil is a prospective, multicentre, open-label demonstration project assessing PrEP delivery in the context of the Brazilian Public Health System. HIV-uninfected MSM and TGW in 3 referral centres in Rio de Janeiro and Sao Paulo were evaluated for eligibility and offered 48 weeks of daily emtricitabine/tenofovir for PrEP. Concentrations of tenofovir diphosphate in dried blood spot samples (DBS) at week 4 after enrolment (early adherence) were measured. Predictors of drug levels were assessed using ordinal logistic regression models considering the DBS drug level as a 3 level variable (<350 fmol/punch, >= 350-699 fmol/punch and >= 700 fmol/punch).
   Results: 1,270 individuals were assessed for participation; n = 738 were potentially eligible and n = 450 were offered PrEP (PrEP uptake was 60.9%). Eligible but not enrolled individuals were younger, had lower HIV risk perception and had lower PrEP awareness. At week 4, 424 participants (of the 450 enrolled) had DBS TFV-DP concentrations, 94.1% in the protective range (>= 350 fmol/punch, consistent with >= 2 pills per week), and 78% were in the highly protective range (>= 700 fmol/punch, >= 4 pills per week). Participants with >= 12 years of schooling had 1.9 times the odds (95% CI 1.10-3.29) of a higher versus lower drug level than participants with <12 years of schooling. Condomless receptive anal intercourse in the prior 3 months was also associated with higher drug levels (adjusted OR = 1.78; 95% CI 1.08-2.94).
   Conclusions: The high uptake and early adherence indicate that PrEP for high-risk MSM and TGW can be successfully delivered in the context of the Brazilian Public Health System. Interventions to address disparities on PrEP awareness and HIV risk perception among the younger and less educated are urgently needed in order to maximize the impact of this prevention strategy on the reduction of HIV infection among MSM and TGW in Brazil.
C1 [Hoagland, Brenda; Moreira, Ronaldo I.; De Boni, Raquel B.; Torres, Thiago S.; Marins, Luana M. S.; Luz, Paula M.; Leite, Iuri da Costa; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Kallas, Esper G.; Vasconcelos, Ricardo] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Madruga, Jose Valdez; Goulart, Silvia] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Anderson, Peter L.] Univ Colorado Denver, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA.
   [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
RP Grinsztejn, B (corresponding author), INI FIOCRUZ, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM gbeatriz@ini.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Vasconcelos,
   Ricardo/AAL-4634-2020; TORRES, THIAGO SILVA/D-6548-2014
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Vasconcelos,
   Ricardo/0000-0002-9753-0563; TORRES, THIAGO SILVA/0000-0002-2557-601X;
   Luz, Paula/0000-0001-9746-719X; Kallas, Esper/0000-0003-2026-6925
FU Brazilian Ministry of Health [01/2013 BRA/K57]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [402004/2012-4,
   454931/2014-0]; SVS [281/2013]; FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/110.261/2014]; FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2012/51743-0]; National Council of Technological and
   Scientific DevelopmentNational Council for Scientific and Technological
   Development (CNPq); FAPERJ (Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de JaneiroCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); FAPESP
   (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de Amparo
   a Pesquisa do Estado de Sao Paulo (FAPESP); NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX The study was sponsored by the Brazilian Ministry of Health (#01/2013
   BRA/K57), CNPq (#402004/2012-4, #454931/2014-0) SVS (#281/2013), FAPERJ
   (#E-26/110.261/2014) and FAPESP (#2012/51743-0). PML and BG acknowledge
   funding from the National Council of Technological and Scientific
   Development and the FAPERJ (Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro. EGK acknowledges funding from
   FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo).
CR Allison P. D., 1999, LOGISTIC REGRESSION
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   [Anonymous], 2015, TECHN UPD PREEXP PRO
   [Anonymous], 2015, PROT CLIN DIR TER MA
   Avila-Rios S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158560
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Blaschke TF, 2012, ANNU REV PHARMACOL, V52, P275, DOI 10.1146/annurev-pharmtox-011711-113247
   CARLINI EA, 2006, LEVANTAMENTO DOMICIL
   Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/AID.2012.0089, 10.1089/aid.2012.0089]
   CDC UPH, 2014, PREEXP PROPH PREV HI
   Cohen SE, 2015, JAIDS-J ACQ IMM DEF, V68, P439, DOI 10.1097/QAI.0000000000000479
   Costa AB, 2015, ARCH SEX BEHAV, V44, P521, DOI 10.1007/s10508-014-0386-z
   Cottrell ML, 2016, J INFECT DIS, V214, P55, DOI 10.1093/infdis/jiw077
   Departamento de DST Aids e Hepatites Virais, 2015, B EP AIDS DST
   Costa EMF, 2014, ARQ BRAS ENDOCRINOL, V58, P188, DOI 10.1590/0004-2730000003091
   Glidden DV, 2015, PREP ENGAGEMENT HIV
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hembree WC, 2009, J CLIN ENDOCR METAB, V94, P3132, DOI 10.1210/jc.2009-0345
   Hoagland B, 2015, AWARENESS WILLINGNES
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   IBGE-I [ISTITUTO BRAS I LEI RO DE GEOGRAFIA E ESTATiSTICA, 2010, CENS DEM 2010 ED DES
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Koblin BA, 2006, AIDS CARE, V18, P961, DOI 10.1080/09540120500467182
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C
   Laranjeira R, 2010, REV BRAS PSIQUIATR, V32, P231, DOI 10.1590/S1516-44462009005000012
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
   Luz PM, 2016, COST EFFECTIVENESS H
   Marcus JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081997
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Mugwanya KK, 2015, JAMA INTERN MED, V175, P246, DOI 10.1001/jamainternmed.2014.6786
   National Institute on Alcohol Abuse and Alcoholism (NIAAA), 2004, NIAAA COUNC APPR DEF
   Osorio FD, 2009, PERSPECT PSYCHIATR C, V45, P216, DOI 10.1111/j.1744-6163.2009.00224.x
   Ostrow DG, 2009, JAIDS-J ACQ IMM DEF, V51, P349, DOI 10.1097/QAI.0b013e3181a24b20
   Rothman KJ, 2014, J GEN INTERN MED, V29, P1060, DOI 10.1007/s11606-013-2755-z
   Sander PM, 2013, AIDS, V27, P815, DOI 10.1097/QAD.0b013e32835cff4b
   Schackman BR, 2012, CURR OPIN HIV AIDS, V7, P587, DOI 10.1097/COH.0b013e3283582c8b
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   U.S. Department of Health and Human Services, 2009, DIV AIDS TABL GRAD S
   Volk JE, 2015, CLIN INFECT DIS, V61, P1601, DOI 10.1093/cid/civ778
   Woolf SE, 2009, AIDS BEHAV, V13, P757, DOI 10.1007/s10461-007-9354-0
   Woolf-King SE, 2013, J URBAN HEALTH, V90, P948, DOI 10.1007/s11524-013-9820-0
   WPATH, 2012, STAND CAR HLTH TRANS
   Zheng JH, 2016, J PHARMACEUT BIOMED, V122, P16, DOI 10.1016/j.jpba.2016.01.038
NR 46
TC 42
Z9 42
U1 0
U2 6
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD APR 6
PY 2017
VL 20
AR 21472
DI 10.7448/IAS.20.1.21472
PG 14
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EU4XM
UT WOS:000401035000001
PM 28418232
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Jalil, EM
   Monteiro, L
   Velasque, L
   Moreira, RI
   Garcia, ACF
   Castro, CV
   Kruger, A
   Luz, PM
   Liu, AY
   McFarland, W
   Buchbinder, S
   Veloso, VG
   Wilson, EC
AF Grinsztejn, Beatriz
   Jalil, Emilia M.
   Monteiro, Laylla
   Velasque, Luciane
   Moreira, Ronaldo I.
   Garcia, Ana Cristina F.
   Castro, Cristiane V.
   Kruger, Alcia
   Luz, Paula M.
   Liu, Albert Y.
   McFarland, Willi
   Buchbinder, Susan
   Veloso, Valdilea G.
   Wilson, Erin C.
CA Transcender Study Team
TI Unveiling of HIV dynamics among transgender women: a respondent-driven
   sampling study in Rio de Janeiro, Brazil
SO LANCET HIV
LA English
DT Article
ID HIDDEN POPULATIONS; RISK BEHAVIORS; SAN-FRANCISCO; PREVALENCE;
   PREVENTION; INFECTION; FRAMEWORK; PEOPLE; HEALTH; COLOR
AB Background The burden of HIV in transgender women (transwomen) in Brazil remains unknown. We aimed to estimate HIV prevalence among transwomen in Rio de Janeiro and to identify predictors of newly diagnosed HIV infections.
   Methods We recruited transwomen from Rio de Janeiro, Brazil, by respondent-driven sampling. Eligibility criteria were self-identification as transwomen, being 18 years of age or older, living in Rio de Janeiro or its metropolitan area, and having a valid peer recruitment coupon. We recruited 12 seed participants from social movements and formative focus groups who then used peer recruitment coupons to refer subsequent peers to the study. We categorised participants as HIV negative, known HIV infected, or newly diagnosed as HIV infected. We assessed predictors of newly diagnosed HIV infections by comparing newly diagnosed with HIV-negative participants. We derived population estimates with the Respondent-Driven Sampling II estimator.
   Findings Between Aug 1, 2015, and Jan 29, 2016, we enrolled 345 eligible transwomen. 29.1% (95% CI 23.2-35.4) of participants had no previous HIV testing (adjusted from 60 participants), 31.2% (18.8-43.6) had HIV infections (adjusted from 141 participants), and 7.0% (0.0-15.9) were newly diagnosed as HIV infected (adjusted from 40 participants). We diagnosed syphilis in 28.9% (18.0-39.8) of participants, rectal chlamydia in 14.6% (5.4-23.8), and gonorrhoea in 13.5% (3.2-23.8). Newly diagnosed HIV infections were associated with black race (odds ratio 22.8 [95% CI 2.9-178.9]; p=0.003), travesti (34.1 [5.8-200.2]; p=0.0001) or transsexual woman (41.3 [6.3-271.2]; p=0.0001) gender identity, history of sex work (30.7 [3.5-267.3]; p=0.002), and history of sniffing cocaine (4.4 [1.4-14.1]; p=0.01).
   Interpretation Our results suggest that transwomen bear the largest burden of HIV among any population at risk in Brazil. The high proportion of HIV diagnosis among young participants points to the need for tailored long-term health-care and prevention services to curb the HIV epidemic and improve the quality of life of transwomen in Brazil.
C1 [Grinsztejn, Beatriz; Jalil, Emilia M.; Monteiro, Laylla; Moreira, Ronaldo I.; Garcia, Ana Cristina F.; Castro, Cristiane V.; Luz, Paula M.; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, BR-21040360 Rio De Janeiro, Brazil.
   [Velasque, Luciane] Fed Univ State Rio de Janeiro, Rio De Janeiro, Brazil.
   [Kruger, Alcia] Brazilian Minist Hlth, Dept Surveillance Prevent & Control Sexually Tran, Aids & Viral Hepatitis, Brasilia, DF, Brazil.
   [Liu, Albert Y.; Buchbinder, Susan; Wilson, Erin C.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [McFarland, Willi; Buchbinder, Susan] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [McFarland, Willi; Buchbinder, Susan] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
   [McFarland, Willi; Buchbinder, Susan] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, BR-21040360 Rio De Janeiro, Brazil.
EM gbeatriz@ini.fiocruz.br
RI Kruger, Alicia/AAU-6385-2020
OI Kruger, Alicia/0000-0002-9154-8412; Luz, Paula/0000-0001-9746-719X
FU Brazilian Research Council; National Institute of Allergy and Infectious
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); Brazilian Sexually Transmitted
   Disease/AIDS; Viral Hepatitis Department of the Brazilian Ministry of
   Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069496, UM1AI069496,
   UM1AI069496, UM1AI069476, UM1AI069476, UM1AI069496, UM1AI069496,
   UM1AI069496, UM1AI069496, UM1AI069476, UM1AI069496, UM1AI069496,
   UM1AI069476, UM1AI069476, UM1AI069496, UM1AI069476, UM1AI069476] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246] Funding Source: NIH
   RePORTER
FX Brazilian Research Council, National Institute of Allergy and Infectious
   Diseases, Brazilian Sexually Transmitted Disease/AIDS, and Viral
   Hepatitis Department of the Brazilian Ministry of Health.
CR Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Brito AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130445
   Centers for Disease Control and Prevention, 2015, MMWR RECOMM REP, V64, P15
   Chor D, 2013, CAD SAUDE PUBLICA, V29, P1272, DOI 10.1590/S0102-311X2013000700002
   Costa AB, 2015, ARCH SEX BEHAV, V44, P521, DOI 10.1007/s10508-014-0386-z
   Dehne KL, 2016, LANCET HIV, V3, pE323, DOI 10.1016/S2352-3018(16)30035-2
   GRANDI JL, 2000, AIDS BEHAV, V4, P129
   Grant RM, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv126
   Handcock MS, 2014, RDS ANAL SOFTWARE AN
   Heckathorn DD, 2002, SOC PROBL, V49, P11, DOI 10.1525/sp.2002.49.1.11
   Heckathorn DD, 1997, SOC PROBL, V44, P174, DOI 10.1525/sp.1997.44.2.03x0221m
   Heckathorn DD, 2007, SOCIOL METHODOL, V37, P151, DOI 10.1111/j.1467-9531.2007.00188.x
   Herbst JH, 2008, AIDS BEHAV, V12, P1, DOI 10.1007/s10461-007-9299-3
   Instituto Brasileiro de Geografia e Estatastica, 2014, DIR PESQ COORD TRAB
   Joint UN Programme on HIV/ AIDS, 2014, GLOB AIDS RESP PROGR
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Lansky Amy, 2012, Open AIDS J, V6, P77, DOI 10.2174/1874613601206010077
   Leon SR, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-008245
   Lombardi EL, 2001, J HOMOSEXUAL, V42, P89, DOI 10.1300/J082v42n01_05
   Martins TA, 2013, AIDS CARE, V25, P606, DOI 10.1080/09540121.2012.726342
   Mayer KH, 2016, JAIDS-J ACQ IMM DEF, V72, pS207, DOI 10.1097/QAI.0000000000001086
   McCreesh N, 2012, EPIDEMIOLOGY, V23, P138, DOI 10.1097/EDE.0b013e31823ac17c
   Ministerio da Saude, 2013, MAN TECN DIAGN INF P
   Ministerio da Saude, 2014, PESQ NAC US CRACK
   Ministerio da Saude (BR) Secretaria de Vigilancia em Saude, 2016, B EPIDEMIOLOGICO
   Nemoto T, 2004, AM J PUBLIC HEALTH, V94, P1193, DOI 10.2105/AJPH.94.7.1193
   Nuttbrock LA, 2016, AIDS BEHAV, DOI [10.1007/s10461-016-1509-4, DOI 10.1007/S10461-016-1509-4.]
   Poteat T, 2016, JAIDS-J ACQ IMM DEF, V72, pS210, DOI 10.1097/QAI.0000000000001087
   Rapues J, 2013, AM J PUBLIC HEALTH, V103, P1485, DOI 10.2105/AJPH.2012.301109
   Sevelius JM, 2013, SEX ROLES, V68, P675, DOI 10.1007/s11199-012-0216-5
   Brignol SMS, 2015, CAD SAUDE PUBLICA, V31, pS170, DOI 10.1590/0102-311X00085614
   Silva-Santisteban A, 2012, AIDS BEHAV, V16, P872, DOI 10.1007/s10461-011-0053-5
   Szwarcwald CL, 2011, JAIDS-J ACQ IMM DEF, V57, pS129, DOI 10.1097/QAI.0b013e31821e9a36
   Tebbe EA, 2016, J COUNS PSYCHOL, V63, P520, DOI 10.1037/cou0000152
   Weissman A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152906
   Wejnert C, 2008, SOCIOL METHOD RES, V37, P105, DOI 10.1177/0049124108318333
   Wilson EC, 2015, J URBAN HEALTH, V92, P182, DOI 10.1007/s11524-014-9921-4
NR 37
TC 30
Z9 31
U1 0
U2 24
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD APR
PY 2017
VL 4
IS 4
BP E169
EP E176
DI 10.1016/S2352-3018(17)30015-2
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EQ2VI
UT WOS:000397928700015
PM 28188030
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Couto, I
   Victoria, M
   Veloso, VG
   Rodrigues, L
   Grinsztejn, B
   Lacerda, M
   Victoria, F
   Perazzo, H
AF Couto, Ingrid
   Victoria, Marilu
   Veloso, Valdilea G.
   Rodrigues, Lorena
   Grinsztejn, Beatriz
   Lacerda, Marcus
   Victoria, Flamir
   Perazzo, Hugo
TI Prevalence and predictors for compensated Advanced Chronic Liver Disease
   (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection
SO PLOS ONE
LA English
DT Article
ID SPLEEN TRANSIENT ELASTOGRAPHY; PORTAL-HYPERTENSION; ESOPHAGEAL-VARICES;
   FIBROSIS; STIFFNESS; CIRRHOSIS; BIOPSY; COINFECTION; VARIABILITY;
   FIBROTEST
AB Objective
   The study aimed to evaluate the prevalence and predictor factors for compensated advanced chronic liver disease (c-ACLD) in patients with hepatitis Delta virus (HDV) infection.
   Methods
   This cross-sectional study included consecutive HDV-infected patients defined by positive anti-HDV. Patients with hepatitis C coinfection, liver transplantation or presence of conditions that limit liver (LSM) or spleen stiffness measurement (SSM) were excluded. Blood tests, abdominal ultrasound, SSM and LSM by transient elastography (FibroScan (R)) were performed at the same day. Alcohol consumption was quantified using the AUDIT score and c-ACLD was defined by LSM >= 15 kPa performed by an experimented operator blinded for clinical and laboratory data.
   Results
   101 patients were eligible and few patients were excluded due to negative anti-HDV (n = 7), hepatitis C coinfection (n = 2), liver transplantation (n = 10) and limitation for LSM or SSM (n = 5). Therefore, 77 patients [61% male, age = 43 (IQR,36-52) years] were included. The prevalence of c-ACLD was 57% (n = 44/77). Patients with c-ACLD had a higher rate of detectable HBV viral load (p = 0.039), higher levels of transaminases, GGT, alkaline phosphatases, total bilirubin and INR (p<0.001 for all), as well as lower platelet count and albumin levels (p>0.001 for both) compared to those without c-ACLD. Patients with c-ACLD had higher SSM [65.2 (IQR,33.8-75.0) vs 21.8 (16.5-32.0) kPa; p<0.001] and higher splenic volume [475 (IQR,311-746) vs 154 (112-283) cm(3); p<0.001] compared to those without. Detectable HBV viral load (>10 UI/ml), alkaline phosphatase (per IU/L) and GGT levels (per IU/L) were independently associated with c-ACLD in all multivariate models. Splenic volume [per cm(3),OR = 1.01 (95%Cl,1.01 -1.02);p = 0.002], SSM [per kPa, OR = 1.04 (1.01-1.07); p = 0.012] and splenomegaly [yes vs no,OR = 28.45 (4.42-182.95);p<0.001] were independently associated with c-ACLD.
   Conclusions
   The prevalence of c-ACLD was high in patients with chronic HDV infection in western Amazon basin. HBV viral load, liver enzymes and splenic features can be used to predict severe liver disease in HDV-infected patients.
C1 [Couto, Ingrid; Victoria, Marilu; Rodrigues, Lorena; Victoria, Flamir] Fundacao Med Trop Dr Heitor Vieira Dourado FMT HV, Manaus, Amazonas, Brazil.
   [Veloso, Valdilea G.; Grinsztejn, Beatriz; Perazzo, Hugo] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin DST AIDS LAPCLIN AIDS, Rio De Janeiro, Brazil.
   [Lacerda, Marcus] Fundacao Med Trop Dr Heitor Vieira Dourado FMT HV, Diretoria Ensino & Pesquisa, Manaus, Amazonas, Brazil.
   [Lacerda, Marcus] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Pesquisas Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
RP Perazzo, H (corresponding author), Fundacao Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin DST AIDS LAPCLIN AIDS, Rio De Janeiro, Brazil.
EM perazzohugo@gmail.com
OI Perazzo, Hugo/0000-0003-0931-6418
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ) [E-26/110.268/2014]; Fundacao para
   o Desenvolvimento Cientffico e Tecnologico em Saiide (FIOTEC); Rio de
   Janeiro, Brazil; Brazilian Ministry of Health through the
   Interfederative Cooperation for AIDS and Viral Hepatitis control;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX This work was supported by funding from Fundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) under grant
   E-26/110.268/2014 (VGV) and Fundacao para o Desenvolvimento Cientffico e
   Tecnologico em Saiide (FIOTEC), Rio de Janeiro, Brazil (VGV). ML and BG
   are productivity fellows from Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq). BG and VGV are research fellows from
   Fundagao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM). The study
   was also supported by the Brazilian Ministry of Health through the
   Interfederative Cooperation for AIDS and Viral Hepatitis control (ML).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR [Anonymous], 2015, J HEPATOL, V63, P237, DOI 10.1016/j.jhep.2015.04.006
   Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022
   Burra P, 2016, J HEPATOL, V64, P433, DOI 10.1016/j.jhep.2015.10.006
   Cassinotto C, 2015, DIGEST LIVER DIS, V47, P695, DOI 10.1016/j.dld.2015.04.008
   Castera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018
   Castera L, 2010, HEPATOLOGY, V51, P828, DOI 10.1002/hep.23425
   Colecchia A, 2012, GASTROENTEROLOGY, V143, P646, DOI 10.1053/j.gastro.2012.05.035
   de Franchis R, 2015, J HEPATOL, V63, P743, DOI 10.1016/j.jhep.2015.05.022
   de Ledinghen V, 2008, GASTROEN CLIN BIOL, V32, P58, DOI 10.1016/S0399-8320(08)73994-0
   De Odorico I, 1999, J ULTRAS MED, V18, P231, DOI 10.7863/jum.1999.18.3.231
   Fraquelli M, 2014, J VIRAL HEPATITIS, V21, P90, DOI 10.1111/jvh.12119
   Gheorghe L, 2015, J GASTROINTEST LIVER, V24, P413, DOI 10.15403/jgld.2014.1121.244.dtv
   Heidrich B, 2014, HEPATOLOGY, V60, P87, DOI 10.1002/hep.27102
   Kay A, 2014, J VIRAL HEPATITIS, V21, P921, DOI 10.1111/jvh.12267
   Le Gal F, 2016, HEPATOLOGY, V64, P1483, DOI 10.1002/hep.28772
   Li Y, 2016, ALIMENT PHARM THER, V43, P458, DOI 10.1111/apt.13488
   Lutterkort GL, 2017, LIVER INT, V37, P196, DOI 10.1111/liv.13205
   Braga WSM, 2014, J HEPATOL, V61, P1205, DOI 10.1016/j.jhep.2014.05.041
   Perazzo H, 2015, LIVER INT, V35, P1533, DOI 10.1111/liv.12551
   Poynard T, 2012, CLIN GASTROENTEROL H, V10, P657, DOI 10.1016/j.cgh.2012.01.023
   Poynard T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003857
   Rizzetto M, 2016, LIVER INT, V36, P135, DOI 10.1111/liv.13018
   Sagnelli E, 2000, HEPATOLOGY, V32, P1106, DOI 10.1053/jhep.2000.19288
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Serrano BC, 2014, J VIRAL HEPATITIS, V21, pE154, DOI 10.1111/jvh.12251
   Stroffolini T, 2016, INFECTION
   Vallet-Pichard A, 2007, HEPATOLOGY, V46, P32, DOI 10.1002/hep.21669
   Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346
   Wedemeyer H, 2010, NAT REV GASTRO HEPAT, V7, P31, DOI 10.1038/nrgastro.2009.205
   Wong GLH, 2016, J DIGEST DIS, V17, P538, DOI 10.1111/1751-2980.12359
   Wranke A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101002
   Zykus R, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0414-z
NR 32
TC 5
Z9 6
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 22
PY 2017
VL 12
IS 3
AR e0174453
DI 10.1371/journal.pone.0174453
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ER8SZ
UT WOS:000399094700094
PM 28329027
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Celum, C
   Hong, T
   Cent, A
   Donnell, D
   Morrow, R
   Baeten, JM
   Firnhaber, C
   Grinsztejn, B
   Hosseinipour, MC
   Lalloo, U
   Nyirenda, M
   Riviere, C
   Sanchez, J
   Santos, B
   Supparatpinyo, K
   Hakim, J
   Kumarasamy, N
   Campbell, TB
AF Celum, Connie
   Hong, Ting
   Cent, Anne
   Donnell, Deborah
   Morrow, Rhoda
   Baeten, Jared M.
   Firnhaber, Cynthia
   Grinsztejn, Beatriz
   Hosseinipour, Mina C.
   Lalloo, Umesh
   Nyirenda, Mulinda
   Riviere, Cynthia
   Sanchez, Jorge
   Santos, Breno
   Supparatpinyo, Khuanchai
   Hakim, James
   Kumarasamy, N.
   Campbell, Thomas B.
CA ACTG PEARLS A5175 Team
TI Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults
   Treated With Tenofovir Disoproxyl Fumarate as Part of Combination
   Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; HSV-2; prevention; tenofovir; antiretroviral therapy; Africa
ID HIV-1 TRANSMISSION; ORAL TENOFOVIR; PROPHYLAXIS; MEN
AB Objective. Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus type 2 (HSV-2) and reduced HSV-2 acquisition as preexposure prophylaxis. Whether TDF-containing antiretroviral therapy (ART) reduces HSV-2 acquisition is unknown.
   Design. Secondary analysis of AIDS Clinical Trials Group A5175, a randomized, open-label study of 3 ART regimens among 1571 participants.
   Methods. HSV-2 serostatus was assessed at baseline, at study exit, and before a change in ART regimen.
   Results. Of 365 HSV-2-seronegative persons, 68 acquired HSV-2, with 24 receiving TDF-containing ART and 44 receiving ART without TDF (HSV-2 seroconversion incidence, 6.42 and 6.63 cases/100 person-years, respectively; hazard ratio, 0.89; 95% confidence interval,.55-1.44).
   Conclusions. HSV-2 acquisition was not reduced in HIV-infected, HSV-2-uninfected persons during TDF-containing ART.
C1 [Celum, Connie; Hong, Ting; Donnell, Deborah; Baeten, Jared M.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Celum, Connie; Baeten, Jared M.] Univ Washington, Dept Med, Seattle, WA USA.
   [Celum, Connie; Baeten, Jared M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Cent, Anne; Morrow, Rhoda] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
   [Donnell, Deborah; Morrow, Rhoda] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Firnhaber, Cynthia] Univ Witwatersrand, Fac Hlth Sci, Dept Med, Clin HIV Res Unit, Johannesburg, South Africa.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   [Hosseinipour, Mina C.] Kamuzu Cent Hosp, Lilongwe, Malawi.
   [Lalloo, Umesh] Nelson R Mandela Sch Med, Durban, South Africa.
   [Nyirenda, Mulinda] Coll Med, Dept Med, Blantyre, Malawi.
   [Riviere, Cynthia] Inst Nacl Lab & Rech, Port Au Prince, Haiti.
   [Sanchez, Jorge] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Santos, Breno] Hosp Nossa Senhora Conceicao GHC, Serv Infectol, Porto Alegre, RS, Brazil.
   [Supparatpinyo, Khuanchai] Chiang Mai Univ, Dept Med, Chiang Mai, Thailand.
   [Supparatpinyo, Khuanchai] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Hakim, James] Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe.
   [Kumarasamy, N.] YRG Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
   [Campbell, Thomas B.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA.
RP Celum, C (corresponding author), Univ Washington, Int Clin Res Ctr, Dept Global Hlth, Box 359927,325 Ninth Ave, Seattle, WA 98104 USA.
EM ccelum@uw.edu
OI Nyirenda, Mulinda/0000-0003-2037-7449
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI068636]; National Institute of Mental HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH); National Institute
   of Dental and Craniofacial ResearchUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Dental & Craniofacial Research (NIDCR); NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P01AI030731,
   P01AI030731, P01AI030731, P01AI030731, UM1AI068636, P30AI050410,
   P01AI030731, P01AI030731, P30AI050410, UM1AI068634, UM1AI069424,
   P01AI030731, UM1AI069463, P01AI030731, P01AI030731, P01AI030731,
   P01AI030731, P01AI030731, P01AI030731, UM1AI068636, P01AI030731,
   P01AI030731, UM1AI068636, P30AI050410, P01AI030731, P30AI050410,
   P01AI030731, P01AI030731, P01AI030731, UM1AI069424, P01AI030731,
   U01AI068636, UM1AI069432, P30AI050410, UM1AI068634, P01AI030731,
   UM1AI069399, P01AI030731, P01AI030731, P30AI050410, P30AI050410,
   P01AI030731, UM1AI069432, P30AI050410, P01AI030731, P30AI050410,
   UM1AI069463, P01AI030731, P01AI030731, UM1AI069399, P01AI030731,
   UM1AI069399, P30AI050410, P01AI030731, P01AI030731, P01AI030731,
   P01AI030731, P01AI030731, P01AI030731, P30AI050410, P01AI030731,
   UM1AI069399, P01AI030731, P01AI030731, P01AI030731, P01AI030731,
   P01AI030731, P01AI030731, P01AI030731, P01AI030731, P01AI030731,
   P01AI030731, P01AI030731, P01AI030731, P30AI050410, P01AI030731,
   UM1AI069399, UM1AI069463, U01AI068636, P01AI030731, UM1AI069424,
   P01AI030731, P01AI030731, P01AI030731, P01AI030731, P01AI030731,
   P30AI050410, UM1AI069424, P01AI030731, P01AI030731, P30AI050410,
   UM1AI069432, P01AI030731, P01AI030731, P01AI030731, P01AI030731,
   P01AI030731, P01AI030731, P30AI050410, UM1AI069432, P01AI030731,
   P01AI030731, P01AI030731, P01AI030731, UM1AI068634, UM1AI069424,
   UM1AI069423, P01AI030731, UM1AI069423, P01AI030731, P30AI050410,
   UM1AI069424, UM1AI069399, P01AI030731, P01AI030731, P01AI030731,
   P30AI050410, P01AI030731, P01AI030731, P01AI030731, P01AI030731,
   U01AI068636, P01AI030731, P01AI030731, UM1AI068636, UM1AI069423,
   P01AI030731, P30AI050410, U01AI068636, UM1AI069518, P01AI030731,
   P01AI030731, UM1AI069432, P01AI030731, P01AI030731, UM1AI069463,
   P01AI030731, UM1AI068634, UM1AI069463, P01AI030731, P01AI030731,
   P01AI030731, P01AI030731, P01AI030731, UM1AI069424, P01AI030731,
   UM1AI069399, UM1AI069423, P01AI030731, P01AI030731, P01AI030731,
   UM1AI069518, P01AI030731, U01AI068636, P01AI030731, P01AI030731,
   UM1AI069424, P01AI030731, P01AI030731, P01AI030731, P01AI030731,
   UM1AI069399, P01AI030731, UM1AI069432, P30AI050410, P01AI030731,
   UM1AI069518, P01AI030731, P30AI050410, UM1AI068636, P01AI030731,
   P01AI030731, UM1AI069518, P01AI030731, UM1AI069423, P01AI030731,
   UM1AI068636, P01AI030731, P01AI030731, P01AI030731, P30AI050410,
   P01AI030731, P30AI050410, P01AI030731, P30AI050410, P01AI030731,
   P01AI030731, P01AI030731, UM1AI069432, P01AI030731, UM1AI069518,
   P30AI050410, P01AI030731, P01AI030731, P01AI030731, P01AI030731,
   UM1AI069463, P01AI030731, P30AI050410, P30AI050410, P01AI030731,
   P01AI030731, P01AI030731, P01AI030731, P01AI030731, P30AI050410,
   UM1AI069518, P01AI030731, UM1AI068636, P01AI030731, UM1AI069463,
   P30AI050410, P01AI030731, P01AI030731, UM1AI069518, P01AI030731,
   UM1AI069518, P01AI030731, UM1AI068636, P01AI030731, P30AI050410,
   P01AI030731, P01AI030731, P01AI030731, P01AI030731, UM1AI069423,
   P30AI050410, P30AI050410, UM1AI068634, P01AI030731, P01AI030731,
   P01AI030731, P01AI030731, P01AI030731, P30AI050410, P01AI030731,
   P30AI050410, P01AI030731, P01AI030731, P01AI030731, P01AI030731,
   UM1AI069463, P01AI030731, UM1AI069424, UM1AI069518, U01AI068636,
   P01AI030731, P30AI050410, UM1AI068636, P01AI030731, UM1AI068634,
   P30AI050410, U01AI068636, P01AI030731, P30AI050410, UM1AI069399,
   P01AI030731, P01AI030731, UM1AI069423, P01AI030731, UM1AI069423,
   P30AI050410, P01AI030731, P30AI050410, P30AI050410, UM1AI068636,
   P30AI050410, UM1AI069463, P01AI030731, UM1AI068636, UM1AI069424,
   P01AI030731, P01AI030731, P30AI050410, UM1AI069423, P01AI030731,
   P01AI030731, P01AI030731, P01AI030731, P30AI050410, P01AI030731,
   P01AI030731, P01AI030731, P01AI030731, P30AI050410, P01AI030731,
   P30AI050410, P01AI030731, P01AI030731, P01AI030731, UM1AI069423,
   P01AI030731, P01AI030731, P01AI030731, UM1AI069432, P01AI030731,
   P01AI030731, P01AI030731, P30AI050410, P01AI030731, P01AI030731,
   P01AI030731] Funding Source: NIH RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (award U01AI068636), the National Institute of
   Mental Health, and the National Institute of Dental and Craniofacial
   Research.
CR Andrei G, 2011, CELL HOST MICROBE, V10, P379, DOI 10.1016/j.chom.2011.08.015
   ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Barnabas RV, 2012, CURR HIV RES, V10, P228, DOI 10.2174/157016212800618156
   Bender Ignacio RA, 2015, J INFECT DIS, V212, P1949, DOI 10.1093/infdis/jiv317
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   Celum C, 2014, ANN INTERN MED, V161, P11, DOI 10.7326/M13-2471
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2
   Karim SSA, 2015, NEW ENGL J MED, V373, P530, DOI 10.1056/NEJMoa1410649
   Lingappa J, 2010, INT J STD AIDS, V21, P611, DOI 10.1258/ijsa.2009.008477
   Lingappa JR, 2010, LANCET, V375, P824, DOI 10.1016/S0140-6736(09)62038-9
   Marcus JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091513
   Safren SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104178
   Tan DHS, 2011, AIDS, V25, P207, DOI 10.1097/QAD.0b013e328341ddf7
NR 15
TC 2
Z9 2
U1 1
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 15
PY 2017
VL 215
IS 6
BP 907
EP 910
DI 10.1093/infdis/jix029
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA EV7UE
UT WOS:000401986300011
PM 28453835
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Coelho, LE
   Ribeiro, SR
   Veloso, VG
   Grinsztejn, B
   Luz, PM
AF Coelho, Lara E.
   Ribeiro, Sayonara R.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Luz, Paula M.
TI Hospitalization rates, length of stay and in-hospital mortality in a
   cohort of HIV infected patients from Rio de Janeiro, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Hospitalization; Length of stay; In-hospital mortalitya
ID UNITED-STATES; HAART; TRENDS; ERA
AB In this study, we evaluated trends in hospitalization rates, length of stay and in-hospital mortality in a cohort of HIV-infected patients in Rio de Janeiro, Brazil, from 2007 through 2013. Among the 3991 included patients, 1861 hospitalizations occurred (hospitalization rate of 10.44/100 person-years, 95% confidence interval 9.98-10.93/ 100 person-years). Hospitalization rates decreased annually (per year incidence rate ratio 0.92, 95% confidence interval 0.89-0.95) as well as length of stay (median of 15 days in 2007 vs. 11 days in 2013, p-value for trend <0.001), and in-hospital mortality (13.4% in 2007 to 8.1% in 2013, p-value for trend = 0.053). Our results show that, in a middle-income setting, hospitalization rates are decreasing over time and non-AIDS hospitalizations are currently more frequent than those related to AIDS. Notwithstanding, compared with high-income settings, our patients had longer length of stay and higher in-hospital mortality. Further studies addressing these outcomes are needed to provide information that may guide protocols and interventions to further reduce health-care costs and in-hospital mortality. (C) 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.
C1 [Coelho, Lara E.; Ribeiro, Sayonara R.; Veloso, Valdilea G.; Grinsztejn, Beatriz; Luz, Paula M.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
RP Coelho, LE (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
EM lara.coelho@ini.fiocruz.br
OI Luz, Paula/0000-0001-9746-719X
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [U01AI069923];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI069923, U01AI069923, UM1AI069476, UM1AI069476, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, UM1AI069476,
   U01AI069923, U01AI069923, UM1AI069476, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, UM1AI069476, UM1AI069476,
   U01AI069923, U01AI069923, UM1AI069476, U01AI069923, U01AI069923,
   U01AI069923, UM1AI069476, U01AI069923, U01AI069923, U01AI069923,
   UM1AI069476] Funding Source: NIH RePORTER
FX BG and PML acknowledge funding from the National Council of
   Technological and Scientific Development (CNPq) and the Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ). This work was supported
   in part by the NIH-funded Caribbean, Central and South America network
   for HIV epidemiology (CCASAnet), a member cohort of the International
   Epidemiologic Databases to Evaluate AIDS(leDEA) (U01AI069923).
CR Akinkuotu A, 2011, INT J STD AIDS, V22, P465, DOI 10.1258/ijsa.2011.011021
   Berry SA, 2012, JAIDS-J ACQ IMM DEF, V59, P368, DOI 10.1097/QAI.0b013e318246b862
   Buchacz K, 2008, AIDS, V22, P1345, DOI 10.1097/QAD.0b013e328304b38b
   Catumbela E, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0801-8
   Coelho L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098666
   Crum-Cianflone NF, 2010, JAIDS-J ACQ IMM DEF, V54, P248, DOI 10.1097/QAI.0b013e3181c8ef22
   Goncalves MJF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060487
   Ford N, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20714
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Hontelez JAC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158015
   Kim JH, 2013, INFECTION, V41, P545, DOI 10.1007/s15010-012-0386-7
   Krentz HB, 2006, HIV MED, V7, P457, DOI 10.1111/j.1468-1293.2006.00408.x
   Long LC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148546
   Mocroft A, 2004, HIV MED, V5, P437, DOI 10.1111/j.1468-1293.2004.00250.x
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249
   Ribeiro SR, 2014, ANTIVIR THER, V19, P387, DOI 10.3851/IMP2716
NR 18
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAR-APR
PY 2017
VL 21
IS 2
BP 190
EP 195
DI 10.1016/j.bjid.2016.10.007
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA EQ3HZ
UT WOS:000397963900012
PM 27918889
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Pacheco, AG
   De Boni, R
   Luz, PM
   Fittipaldi, J
   Cardoso, SW
   Grinsztejn, B
   Veloso, VG
AF Perazzo, Hugo
   Pacheco, Antonio G.
   De Boni, Raquel
   Luz, Paula M.
   Fittipaldi, Juliana
   Cardoso, Sandra W.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
TI Age-Standardized Mortality Rates Related to Cirrhosis in Brazil from
   2000 to 2012: A Nationwide Analysis
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE Liver disease; Fibrosis; Death certificate; Age-standardized mortality;
   Brazil
ID ILL-DEFINED CAUSES; LIVER-DISEASE; UNITED-STATES; DEATH; EUROPE; BURDEN;
   STATISTICS; SYSTEM
AB Background. Cirrhosis remains the moat frequent liver-related cause of death worldwide and we aimed to evaluate its burden in Brazil from 2000 to 2012. Material and methods. The Brazilian National Death Registry was analyzed from 2000 to 2012. Death by cirrhosis was defined by the presence of 185, K73 and/or K74 LCD-10 codes in contributing or underlying causes of death on the death certificate (DC). Crude mortality rates were calculated as the ratio of the absolute number of deaths and the estimated population. Mortality rates were age-adjusted by the direct standardization method using the WHO standard population. Results. A total of 265,180 deaths where cirrhosis was mentioned on the Dc [77% male, aged 56 years] occurred from 2000 to 2012. Cirrhosis codes were present in 46% of liver-related deaths and 2% of all deaths in this period. Despite an increase in the absolute number of deaths (n =18,245 to 22,340), the age-standardized mortality rates (95%Cl) decreased from 13.32 (13.16-13.48) to 11.71 (11.59-11.83) per 100,000 inhabitants from 2000 to 2012 (p < 0.001). This trend was not uniform across the country, with decreases in death rates in the South [14.48 (14.07-14.87) to 10.89 (10.59-11.19)] and Southeast [15.85 (15.6-16.09) to 12.52 (12.34-12.70)] and increases in the North [8.84 (8.24-9.43) to 11.53 (11.08-11.99)] and Northeast [9.41 (9.13-9.69) to 10.93 (10.68-11.17)] (p < 0.001 for all). Conduation. Cirrhosis remains a major public health issue, despite the reduction in mortality rates in the last decade.
C1 [Perazzo, Hugo; De Boni, Raquel; Luz, Paula M.; Fittipaldi, Juliana; Cardoso, Sandra W.; Grinsztejn, Beatriz; Veloso, Valdilea G.] Evandro Chagas Natl Inst Infect Dis INI, Fundacao Oswaldo Cruz FIOCRUZ, Lab clin Res STD AIDS, Av Brasil,4365, BR-21040360 Rio De Janeiro, Brazil.
   [Pacheco, Antonio G.] Programa Computagao Cientif PROCC, Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, Brazil.
RP Perazzo, H (corresponding author), Evandro Chagas Natl Inst Infect Dis INI, Fundacao Oswaldo Cruz FIOCRUZ, Lab clin Res STD AIDS, Av Brasil,4365, BR-21040360 Rio De Janeiro, Brazil.
EM perazzohugo@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Pacheco, Antonio
   Guilherme/E-6378-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Pacheco, Antonio
   Guilherme/0000-0003-3095-1774; Luz, Paula/0000-0001-9746-719X; Perazzo,
   Hugo/0000-0003-0931-6418
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)/Bolsa Jovem Talento (BJT) - Programa Ciencias Scm
   FronteirasNational Council for Scientific and Technological Development
   (CNPq) [301520/2014-3]; Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   Fundagao para Desenvolvimento Cientifico e Tecnologico em Saude (FioTec)
   [IPEC-010-PPE-13]
FX This work was supported by funding from:Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)/Bolsa Jovem Talento
   (BJT) - Programa Ciencias Scm Fronteiras under grant 301520/2014-3; from
   Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ) and Fundagao para Desenvolvimento Cientifico e
   Tecnologico em Saude (FioTec) under grant IPEC-010-PPE-13.
CR Ahmad OB, 2001, GPE DISCUSSION PAPER, V31
   Anderson P, 2009, LANCET, V373, P2234, DOI 10.1016/S0140-6736(09)60744-3
   Asrani SK, 2013, GASTROENTEROLOGY, V145, P375, DOI 10.1053/j.gastro.2013.04.005
   Blachier M, 2013, J HEPATOL, V58, P593, DOI 10.1016/j.jhep.2012.12.005
   Breslow N.E., 1987, STAT METHODS CANC RE, V2
   de Lima EEC, 2014, CAD SAUDE PUBLICA, V30, P1721, DOI 10.1590/0102-311X00131113
   Chapmann, 2012, CRCBIOSTATISTICS SER
   Dalmau-Bueno A, 2010, J EPIDEMIOL COMMUN H, V64, P720, DOI 10.1136/jech.2008.086538
   Franca EB, 2014, REV BRAS EPIDEMIOL, V17, P119, DOI [10.1590/1415-790X201400010010, DOI 10.1590/1415-790X201400010010ENG]
   Franca E, 2008, INT J EPIDEMIOL, V37, P891, DOI 10.1093/ije/dyn121
   Franca E, 2014, REV SAUDE PUBL, V48, P671, DOI 10.1590/S0034-8910.2014048005146
   Franca E, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-39
   Heffler S, 2001, HEALTH AFFAIR, V20, P193, DOI 10.1377/hlthaff.20.2.193
   Innes H, 2015, GUT, V64, P1800, DOI 10.1136/gutjnl-2014-308166
   Kulhanova I, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1295
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Marchand JL, 2003, REV EPIDEMIOL SANTE, V51, P469
   Marinho RT, 2015, LIVER INT, V35, P746, DOI 10.1111/liv.12569
   Sanchez NM, 2010, ANN HEPATOL, V9, P428, DOI 10.1016/S1665-2681(19)31619-9
   Mendez-Sanchez Nahum, 2005, Ann Hepatol, V4, P52
   Mokdad AA, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0145-y
   Nader LA, 2014, LIVER INT, V34, P844, DOI 10.1111/liv.12470
   Scaglione S, 2015, J CLIN GASTROENTEROL, V49, P690, DOI 10.1097/MCG.0000000000000208
   Sheron N, 2016, J HEPATOL, V64, P957, DOI 10.1016/j.jhep.2015.11.006
   Smith P, 1987, CANC INCIDENCE 5 CON, VV
   Spearman CW, 2015, LIVER INT, V35, P2063, DOI 10.1111/liv.12884
   Vong S, 2004, HEPATOLOGY, V39, P476, DOI 10.1002/hep.20049
   WHO, 2014, WHO WORLD STAND POP
   Zatonski WA, 2010, EUR ADDICT RES, V16, P193, DOI 10.1159/000317248
NR 29
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER ESPANA
PI MADRID
PA CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN
SN 1665-2681
J9 ANN HEPATOL
JI Ann. Hepatol.
PD MAR-APR
PY 2017
VL 16
IS 2
BP 269
EP 278
DI 10.5604/16652681.1231586
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EP0LF
UT WOS:000397078100015
PM 28233749
OA Other Gold
DA 2020-11-24
ER

PT J
AU O'Connor, J
   Vjecha, MJ
   Phillips, AN
   Angus, B
   Cooper, D
   Grinsztejn, B
   Lopardo, G
   Das, S
   Wood, R
   Wilkin, A
   Klinker, H
   Kantipong, P
   Klingman, KL
   Jilich, D
   Herieka, E
   Denning, E
   Abubakar, I
   Gordin, F
   Lundgren, JD
AF O'Connor, Jemma
   Vjecha, Michael J.
   Phillips, Andrew N.
   Angus, Brian
   Cooper, David
   Grinsztejn, Beatriz
   Lopardo, Gustavo
   Das, Satyajit
   Wood, Robin
   Wilkin, Aimee
   Klinker, Hartwig
   Kantipong, Pacharee
   Klingman, Karin L.
   Jilich, David
   Herieka, Elbushra
   Denning, Eileen
   Abubakar, Ibrahim
   Gordin, Fred
   Lundgren, Jens D.
CA INSIGHT START Study Grp
TI Effect of immediate initiation of antiretroviral therapy on risk of
   severe bacterial infections in HIV-positive people with CD4 cell counts
   of more than 500 cells per mu L: secondary outcome results from a
   randomised controlled trial
SO LANCET HIV
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; BODY-MASS INDEX; NEUTROPHILS;
   TUBERCULOSIS; ADULTS; PREVENTION; MORTALITY; IMMUNITY; DISEASES; COHORT
AB Background The effects of antiretroviral therapy on risk of severe bacterial infections in people with high CD4 cell counts have not been well described. In this study, we aimed to quantify the effects of immediate versus deferred ART on the risk of severe bacterial infection in people with high CD4 cell counts in a preplanned analysis of the START trial.
   Methods The START trial was a randomised controlled trial in ART-naive HIV-positive patients with CD4 cell count of more than 500 cells per mu L assigned to immediate ART or deferral until their CD4 cell counts were lower than 350 cells per mu L. We used Cox proportional hazards regression to model time to severe bacterial infection, which was defined as a composite endpoint of bacterial pneumonia (confirmed by the endpoint review committee), pulmonary or extrapulmonary tuberculosis, or any bacterial infectious disorder of grade 4 severity, that required unscheduled hospital admissions, or caused death. This study is registered with ClinicalTrials.gov, number NCT00867048.
   Findings Patients were recruited from April 15, 2009, to Dec 23, 2013. The data cutoff for follow-up was May 26, 2015. Of 4685 HIV-positive people enrolled, 120 had severe bacterial infections (immediate-initiation group n=34, deferredinitiation group n=86; median 2 . 8 years of follow-up). Immediate ART was associated with a reduced risk of severe bacterial infection compared with deferred ART (hazard ratio [HR] 0.39, 95% CI 0. 26-0 . 57, p < 0.0001). In the immediate-initiation group, average neutrophil count over follow-up was 321 cells per mu L\higher, and average CD4 cell count 194 cells per mu L higher than the deferred-initiation group (p < 0 . 0001). In univariable analysis, higher timeupdated CD4 cell count (0 . 78, 0 . 71-0-85, p=0.0001) was associated with reduced risk of severe bacterial infection. Time-updated neutrophil count was not associated with severe bacterial infection. After adjustment for time-updated factors in multivariable analysis, particularly the CD4 cell count, the HR for immediate-initiation group moved closer to 1 (HR 0. 84, 0. 50-1.41, p=0.52). These results were consistent when subgroups of the severe bacterial infection composite were analysed separately.
   Interpretation Immediate ART reduces the risk of several severe bacterial infections in HIV- positive people with high CD4 cell count. This is partly explained by ART-induced increases in CD4 cell count, but not by increases in neutrophil count.
   Funding National Institute of Allergy and Infectious Diseases National Institutes of Health, Agence Nationale de Recherches sur le SIDA et les Hepatites Virales, Bundesministerium f-r Bildung und Forschung, European AIDS Treatment Network, Australian National Health and Medical Research Council, UK National Institute for Health Research and Medical Research Council, Danish National Research Foundation. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
C1 [O'Connor, Jemma; Phillips, Andrew N.] UCL, Res Dept Infect & Populat Hlth, London, England.
   [Abubakar, Ibrahim] UCL, Inst Global Hlth, London, England.
   [Vjecha, Michael J.; Gordin, Fred] Vet Affairs Med Ctr, Washington, DC USA.
   [Gordin, Fred] George Washington Univ, Washington, DC USA.
   [Angus, Brian] Univ Oxford, Oxford Ctr Clin Trop Med, Nuffield Dept Med, Oxford, England.
   [Cooper, David] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Grinsztejn, Beatriz] Evandro Chagas Clin Res Inst IPEC, STD & AIDS Clin Res Lab, Rio De Janeiro, Brazil.
   [Lopardo, Gustavo] Fundacion Ctr Estudios Infectol, Buenos Aires, DF, Argentina.
   [Das, Satyajit] Univ Warwick, Coventry & Warwickshire Partnership Trust, HIV & GU Med, Coventry, W Midlands, England.
   [Wood, Robin] Univ Cape Town, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, Cape Town, South Africa.
   [Wilkin, Aimee] Wake Forest Univ, Sch Med, Infect Dis Sect, Winston Salem, NC USA.
   [Klinker, Hartwig] Univ Wurzburg, Med Ctr, Dept Internal Med II, Wurzburg, Germany.
   [Kantipong, Pacharee] Chaingrai Hosp, Chaingrai, Thailand.
   [Klingman, Karin L.] Natl Inst Hlth, Natl Inst Allergy & Infect Dis, Div Aids, Bethesda, MD USA.
   [Jilich, David] Charles Univ Prague, First Fac Med, Dept Infect & Trop Dis, CR-11636 Prague 1, Czech Republic.
   [Jilich, David] Na Baulovce Hosp, Prague, Czech Republic.
   [Herieka, Elbushra] Royal Bournemouth Hosp, Bournemouth, Dorset, England.
   [Denning, Eileen] Univ Minnesota, Div Biostatist, Minneapolis, MN USA.
   [Lundgren, Jens D.] Univ Copenhagen, Dept Infect Dis Rigshospitalet, Copenhagen, Denmark.
RP Phillips, AN (corresponding author), Dept Infect & Populat Hlth, Univ Coll London Royal Free Campus,Rowland Hill s, London NW3 2PF, England.
EM andrew.phillips@ucl.ac.uk
RI Lundgren, Jens/AAE-6876-2019; Angus, Brian/L-9246-2019; Phillips, Andrew
   N/B-4427-2008
OI Angus, Brian/0000-0003-3598-7784; Phillips, Andrew N/0000-0003-2384-4807
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Institutes of Health Clinical CenterUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA;
   National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); National Heart, Lung, and Blood InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI); Eunice Kennedy
   Shriver National Institute of Child Health and Human Development;
   National Institute of Mental Health; National Institute of Neurological
   Disorders and StrokeUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS); National Institute of
   Arthritis and Musculoskeletal and Skin DiseasesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Arthritis & Musculoskeletal & Skin Diseases
   (NIAMS); Agence Nationale de Recherches sur le SIDA et les Hepatites
   Virales (France)ANRS; National Health and Medical Research Council
   (Australia)National Health and Medical Research Council of Australia;
   National Research Foundation (Denmark); Bundesministerium fur Bildung
   und Forschung (Germany)Federal Ministry of Education & Research (BMBF);
   European AIDS Treatment Network; Medical Research Council (United
   Kingdom)Medical Research Council UK (MRC); National Institute for Health
   ResearchNational Institute for Health Research (NIHR); National Health
   Service (United Kingdom); University of MinnesotaUniversity of Minnesota
   System; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069476, UM1AI068641, UM1AI068641, UM1AI069476,
   UM1AI069476, UM1AI120197, UM1AI069476, UM1AI068641, UM1AI120197,
   UM1AI120197, UM1AI069476, UM1AI069476, UM1AI068641, UM1AI069476,
   UM1AI069476, UM1AI068641, UM1AI069476] Funding Source: NIH RePORTER;
   Medical Research CouncilMedical Research Council UK (MRC)
   [MC_UU_12023/23] Funding Source: researchfish
FX This study was supported by the National Institute of Allergy and
   Infectious Diseases; National Institutes of Health Clinical Center;
   National Cancer Institute; National Heart, Lung, and Blood Institute;
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development; National Institute of Mental Health; National Institute of
   Neurological Disorders and Stroke; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases; Agence Nationale de Recherches sur le
   SIDA et les Hepatites Virales (France); National Health and Medical
   Research Council (Australia); National Research Foundation (Denmark);
   Bundesministerium fur Bildung und Forschung (Germany); European AIDS
   Treatment Network; Medical Research Council (United Kingdom); National
   Institute for Health Research; National Health Service (United Kingdom);
   and University of Minnesota. Antiretroviral drugs were donated to the
   central drug repository by AbbVie, Bristol-Myers Squibb, Gilead
   Sciences, GlaxoSmithKline-ViiV Healthcare, Janssen Scientific Affairs,
   and Merck. We thank all the patients who participated in this study.
CR Almirall J, 1999, EUR RESPIR J, V13, P349, DOI 10.1183/09031936.99.13234999
   Anglaret X, 2003, AIDS, V17, P575, DOI 10.1097/00002030-200303070-00013
   Babiker AG, 2013, CLIN TRIALS, V10, pS5, DOI 10.1177/1740774512440342
   Baik I, 2000, ARCH INTERN MED, V160, P3082, DOI 10.1001/archinte.160.20.3082
   Bennouna S, 2003, J IMMUNOL, V171, P6052, DOI 10.4049/jimmunol.171.11.6052
   Bjerk SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056249
   Blumentals WA, 2012, INFLUENZA OTHER RESP, V6, P28, DOI 10.1111/j.1750-2659.2011.00262.x
   British HIV Association, BRIT HIV ASS GUID TR
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Corbett EL, 2002, CLIN INFECT DIS, V34, P1251, DOI 10.1086/339540
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0
   Elliott A, 2015, INFECT IMMUN, V83, P3104, DOI 10.1128/IAI.00042-15
   European AIDS Clinical Society, 2015, GUID VERS 8 0
   Ford N, 2015, LANCET HIV, V2, pE438, DOI 10.1016/S2352-3018(15)00137-X
   Grosskurth H, 2000, LANCET, V355, P1981, DOI 10.1016/S0140-6736(00)02336-9
   Inoue Y, 2007, J EPIDEMIOL, V17, P194, DOI 10.2188/jea.17.194
   INSIGHT, 2010, CRIT EV REP START 20
   Kenyon C, 2014, INT J INFECT DIS, V18, P73, DOI 10.1016/j.ijid.2013.09.014
   Kohli R, 2006, CLIN INFECT DIS, V43, P90, DOI 10.1086/504871
   Kornum JB, 2010, EUR RESPIR J, V36, P1330, DOI 10.1183/09031936.00184209
   Kufa T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111209
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x
   Normark S, 2001, NAT MED, V7, P1182, DOI 10.1038/nm1101-1182
   Phung DT, 2013, OBES REV, V14, P839, DOI 10.1111/obr.12055
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370
   Toossi Z, 2001, CLIN EXP IMMUNOL, V123, P233, DOI 10.1046/j.1365-2249.2001.01401.x
   World Health Organization, 2015, GUID START ANT THER
NR 32
TC 23
Z9 23
U1 0
U2 13
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD MAR
PY 2017
VL 4
IS 3
BP E105
EP E112
DI 10.1016/S2352-3018(16)30216-8
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EP3FB
UT WOS:000397267100011
PM 28063815
OA Other Gold, Green Published
DA 2020-11-24
ER

PT J
AU Manhica, I
   Bhatt, N
   Ismael, N
   Nhavene, E
   Grinsztejn, B
   Veloso, V
   Maueia, C
   Augusto, O
   Jani, I
   Gudo, ES
AF Manhica, Ivan
   Bhatt, Nilesh
   Ismael, Nalia
   Nhavene, Egidio
   Grinsztejn, Beatriz
   Veloso, Valdileia
   Maueia, Cremildo
   Augusto, Orvalho
   Jani, Ilesh
   Gudo, Eduardo S.
TI First Report of Prevalence of HTLV-1 Among HIV-1/2-Infected Children in
   Mozambique
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV VIRAL LOAD; FOLLOW-UP; COINFECTION;
   TYPE-1; GHANA; AIDS; TRANSMISSION; PROGRESSION; MORTALITY
C1 [Manhica, Ivan] Minist Hlth, Natl TB Control Program, Natl Directorate Publ Hlth, Maputo, Mozambique.
   [Bhatt, Nilesh; Ismael, Nalia; Nhavene, Egidio; Maueia, Cremildo; Jani, Ilesh; Gudo, Eduardo S.] Minist Hlth, Inst Nacl Saude, Maputo, Mozambique.
   [Grinsztejn, Beatriz; Veloso, Valdileia] Fundacao Oswaldo Cruz, Inst Nacl Infectol, Rio De Janeiro, Brazil.
   [Augusto, Orvalho] Eduardo Mondlane Univ, Fac Med, Maputo, Mozambique.
RP Manhica, I (corresponding author), Minist Hlth, Natl TB Control Program, Natl Directorate Publ Hlth, Maputo, Mozambique.
RI Augusto, Orvalho/J-8767-2019
OI Augusto, Orvalho/0000-0002-0005-3968; Nhavene, Egidio Paulo
   Francisco/0000-0002-3067-1484; Maueia, Cremildo
   Gomes/0000-0002-1511-6175; Jani, Ilesh/0000-0002-6880-6655
FU National Research Fund, Ministry of Science and Technology, Mozambique
FX Supported by funds from the National Research Fund, Ministry of Science
   and Technology, Mozambique.
CR Adeiza MA, 2010, ANN NIGER MED, V6, P59
   Adjei AA, 2003, JPN J INFECT DIS, V56, P57
   Austin NIR, 2014, ANN MED HEALTH SCI R, V4, P619, DOI 10.4103/2141-9248.139349
   Bhatt NB, 2009, INT J STD AIDS, V20, P863, DOI 10.1258/ijsa.2008.008401
   Brites C, 2005, CLIN INFECT DIS, V40, P329, DOI 10.1086/426690
   Casoli C, 2007, AIDS REV, V9, P140
   Cunha L, 2007, J MED VIROL, V79, P1832, DOI 10.1002/jmv.21010
   Essajee S, 2015, J INT AIDS SOC, V18, P14, DOI 10.7448/IAS.18.7.20299
   Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
   Gudo ES, 2012, INT J STD AIDS, V23, P717, DOI 10.1258/ijsa.2012.011446
   Gudo ES, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-211
   HISHIDA O, 1994, AIDS, V8, P1257, DOI 10.1097/00002030-199409000-00006
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2013, UNAIDS REP GLOB AIDS
   Lee TH, 2004, J CLIN VIROL, V31, P275, DOI 10.1016/j.jcv.2004.05.016
   Li HC, 2004, J INFECT DIS, V190, P1275, DOI 10.1086/423941
   Melo J, 2000, J ACQ IMMUN DEF SYND, V23, P203
   Ministerio da Saude (MISAU), 2013, PLAN AC RESP HIV SID
   Nadler JP, 1996, CLIN INFECT DIS, V23, P415, DOI 10.1093/clinids/23.2.415
   NORRGREN H, 1995, J ACQ IMMUN DEF SYND, V9, P422, DOI 10.1097/00042560-199508000-00014
   Nyambi PN, 1996, J ACQ IMMUN DEF SYND, V12, P187, DOI 10.1097/00042560-199606010-00013
   OLALEYE DO, 1995, INT J EPIDEMIOL, V24, P198, DOI 10.1093/ije/24.1.198
   Orish VN, 2016, AM J TROP MED HYG, V94, P691, DOI 10.4269/ajtmh.15-0310
   Pedroso C, 2011, JAIDS-J ACQ IMM DEF, V57, pS208, DOI 10.1097/QAI.0b013e31821e9baf
   SaUde INd Estatistica INd Macro I., 2010, INQ NAC PREV RISC CO
   Scapellato PG, 2004, MEDICINA-BUENOS AIRE, V64, P413
   Schechter M, 1997, J ACQ IMMUN DEF SYND, V15, P308, DOI 10.1097/00042560-199708010-00010
   UNAIDS, 2014, 2014 PROGR REP GLOB, pe55
   UNAIDS, 2014, 90 90 90 AMB TREATM
   United Nations GA, 2011, POL DECL HIV AIDS IN
   WHO Unicef, 2008, UNIVERSAL ACCESS SCA
   World Health Organization, 2006, ANT THER HIV INF AD
NR 31
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD FEB 1
PY 2017
VL 74
IS 2
BP E54
EP E56
DI 10.1097/QAI.0000000000001194
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EN4SS
UT WOS:000395997800004
PM 27753683
DA 2020-11-24
ER

PT J
AU da Silva, DST
   Luz, PM
   Lake, JE
   Cardoso, SW
   Ribeiro, S
   Moreira, RI
   Clark, JL
   Veloso, VG
   Grinsztejn, B
   De Boni, RB
AF da Silva, Daniel S. Teixeira
   Luz, Paula M.
   Lake, Jordan E.
   Cardoso, Sandra W.
   Ribeiro, Sayonara
   Moreira, Ronaldo I.
   Clark, Jesse L.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   De Boni, Raquel B.
TI Poor retention in early care increases risk of mortality in a Brazilian
   HIV-infected clinical cohort
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE Retention; HIV; survival analysis; cohort studies; urban population
ID POST-HAART ERAS; RIO-DE-JANEIRO; ANTIRETROVIRAL THERAPY; AIDS PATIENTS;
   SURVIVAL; PREDICTORS; ACCESS
AB Retention in early HIV care has been associated with decreased mortality and improved viral suppression, however the consequences of poor retention in early care in Brazil remain unknown. We assessed the effect of poor retention on mortality in a Brazilian HIV-infected clinical cohort. The analysis included ART-naive, HIV-infected adults linked to care at the Instituto Nacional de Infectologia Evandro Chagas, FundacAo Oswaldo Cruz between 2000 and 2010, who did not become pregnant nor participate in a clinical trial during the first two years in care (early care). Poor retention in early care was defined as less than 3 out of 4 six-month intervals with a CD4 or HIV-1 RNA laboratory result during early care. Cox proportional hazards models were used to identify factors associated with mortality, and Kaplan-Meier plots were used to describe the survival probability for participants with poor retention versus good retention. Among 1054 participants with a median (interquartile range) follow-up time of 4.2 years (2.6, 6.3), 20% had poor retention in early care and 8% died. Poor retention in early care [adjusted hazard ratio (aHR) 3.09; 95% CI 1.65-5.79], AIDS defining illness (aHR 1.95; 95% CI 1.20-3.18) and lower education (aHR 2.33; 95% CI 1.45-3.75) were associated with increased mortality risk. Our findings highlight the importance of adopting strategies to improve retention in early HIV care.
C1 [da Silva, Daniel S. Teixeira; Lake, Jordan E.; Clark, Jesse L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   [da Silva, Daniel S. Teixeira] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Luz, Paula M.; Cardoso, Sandra W.; Ribeiro, Sayonara; Moreira, Ronaldo I.; Veloso, Valdilea G.; Grinsztejn, Beatriz; De Boni, Raquel B.] Inst Nacl Infectol Evandro Chagas, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RP da Silva, DST (corresponding author), Boston Univ, Sch Med, Off Student Affairs, 72 East Concord, Boston, MA 02118 USA.
EM dsilva@bu.edu
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Clark,
   Jesse/0000-0001-5862-6530; Teixeira da Silva,
   Daniel/0000-0003-3525-605X; Luz, Paula/0000-0001-9746-719X
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R25 MH087222, K23
   AI110532, U01 AI069923]; Brazilian National Council of Technological and
   Scientific Development; Research Funding Agency of the State of Rio de
   Janeiro; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01AI069923, K23AI110532, U01AI069923, UM1AI069476,
   U01AI069923, U01AI069923, U01AI069923, UM1AI069476, U01AI069923,
   U01AI069923, K23AI110532, UM1AI069476, K23AI110532, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, UM1AI069476,
   UM1AI069476, K23AI110532, UM1AI069476, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, UM1AI069476, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, K23AI110532, U01AI069923,
   U01AI069923, K23AI110532, UM1AI069476] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, R25MH087222, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health [Grant
   numbers R25 MH087222, K23 AI110532, U01 AI069923]. PML and BG
   acknowledge support from the Brazilian National Council of Technological
   and Scientific Development and the Research Funding Agency of the State
   of Rio de Janeiro.
CR [Anonymous], 2013, PROT CLIN DIR TER MA
   Buchanan David, 2009, Am J Public Health, V99 Suppl 3, pS675, DOI 10.2105/AJPH.2008.137810
   Burkey MD, 2014, JAIDS-J ACQ IMM DEF, V66, P41, DOI 10.1097/QAI.0000000000000094
   Cardoso SW, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-29
   Fox MP, 2015, JAIDS-J ACQ IMM DEF, V69, P98, DOI 10.1097/QAI.0000000000000553
   Giordano TP, 2007, CLIN INFECT DIS, V44, P1493, DOI 10.1086/516778
   Giordano TR, 2009, HIV CLIN TRIALS, V10, P299, DOI 10.1310/hct1005-299
   Grangeiro A, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-99
   Grangeiro A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014585
   Greco DB, 2007, AIDS, V21, pS37, DOI 10.1097/01.aids.0000279705.24428.a3
   Greenland S, 2015, ANNU REV PUBL HEALTH, V36, P89, DOI 10.1146/annurev-publhealth-031914-122559
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Malta M, 2009, JAIDS-J ACQ IMM DEF, V52, P629, DOI 10.1097/QAI.0b013e3181b31b8a
   Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012
   Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249
   Silva DS, 2016, AIDS BEHAV, V20, P1039, DOI 10.1007/s10461-015-1235-3
   Szwarcwald CL, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-217
   Tancredi MV, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0599-8
   Tancredi MV, 2014, T ROY SOC TROP MED H, V108, P408, DOI 10.1093/trstmh/tru078
   Tobias CR, 2007, AIDS PATIENT CARE ST, V21, P426, DOI 10.1089/apc.2006.0138
NR 22
TC 5
Z9 5
U1 0
U2 15
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0954-0121
EI 1360-0451
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PD FEB
PY 2017
VL 29
IS 2
BP 263
EP 267
DI 10.1080/09540121.2016.1211610
PG 5
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychology, Multidisciplinary; Respiratory System; Social Sciences,
   Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychology; Respiratory System; Biomedical Social Sciences
GA EF5ZA
UT WOS:000390407400019
PM 27461407
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Eshleman, SH
   Wilson, EA
   Zhang, XYC
   Ou, SS
   Piwowar-Manning, E
   Eron, JJ
   McCauley, M
   Gamble, T
   Gallant, JE
   Hosseinipour, MC
   Kumarasamy, N
   Hakim, JG
   Kalonga, B
   Pilotto, JH
   Grinsztejn, B
   Godbole, SV
   Chotirosniramit, N
   Santos, BR
   Shava, E
   Mills, LA
   Panchia, R
   Mwelase, N
   Mayer, KH
   Chen, YQ
   Cohen, MS
   Fogel, JM
AF Eshleman, Susan H.
   Wilson, Ethan A.
   Zhang, Xinyi C.
   Ou, San-San
   Piwowar-Manning, Estelle
   Eron, Joseph J.
   McCauley, Marybeth
   Gamble, Theresa
   Gallant, Joel E.
   Hosseinipour, Mina C.
   Kumarasamy, Nagalingeswaran
   Hakim, James G.
   Kalonga, Ben
   Pilotto, Jose H.
   Grinsztejn, Beatriz
   Godbole, Sheela V.
   Chotirosniramit, Nuntisa
   Santos, Breno Riegel
   Shava, Emily
   Mills, Lisa A.
   Panchia, Ravindre
   Mwelase, Noluthando
   Mayer, Kenneth H.
   Chen, Ying Q.
   Cohen, Myron S.
   Fogel, Jessica M.
TI Virologic outcomes in early antiretroviral treatment: HPTN 052
SO HIV CLINICAL TRIALS
LA English
DT Article
DE HIV; HPTN 052; Early ART; Viral suppression; Virologic failure;
   Virologic outcomes; HIV prevention
ID INTEGRASE INHIBITOR RALTEGRAVIR; TRIALS NETWORK 052; HIV-1 SUBTYPE C;
   IMMUNOLOGICAL RESPONSE; VIRAL SUPPRESSION; DRUG-RESISTANCE;
   CLINICAL-TRIAL; UNITED-STATES; THERAPY; TRANSMISSION
AB Introduction: The HIV Prevention Trials Network (HPTN) 052 trial demonstrated that early antiretroviral therapy (ART) prevented 93% of HIV transmission events in serodiscordant couples. Some linked infections were observed shortly after ART initiation or after virologic failure.
   Objective: To evaluate factors associated with time to viral suppression and virologic failure in participants who initiated ART in HPTN 052.
   Methods: 1566 participants who had a viral load (VL) > 400 copies/mL at enrollment were included in the analyses. This included 832 in the early ART arm (CD4 350-550 cells/mm(3) at ART initiation) and 734 in the delayed ART arm (204 with a CD4 < 250 cells/mm(3) at ART initiation; 530 with any CD4 at ART initiation). Viral suppression was defined as two consecutive VLs <= 400 copies/mL after ART initiation; virologic failure was defined as two consecutive VLs > 1000 copies/mL > 24 weeks after ART initiation.
   Results: Overall, 93% of participants achieved viral suppression by 12 months. The annual incidence of virologic failure was 3.6%. Virologic outcomes were similar in the two study arms. Longer time to viral suppression was associated with younger age, higher VL at ART initiation, and region (Africa vs. Asia). Virologic failure was strongly associated with younger age, lower educational level, and lack of suppression by three months; lower VL and higher CD4 at ART initiation were also associated with virologic failure.
   Conclusions: Several clinical and demographic factors were identified that were associated with longer time to viral suppression and virologic failure. Recognition of these factors may help optimize ART for HIV treatment and prevention.
C1 [Eshleman, Susan H.; Piwowar-Manning, Estelle; Fogel, Jessica M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Wilson, Ethan A.; Zhang, Xinyi C.; Ou, San-San; Chen, Ying Q.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Eron, Joseph J.; Cohen, Myron S.] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA.
   [McCauley, Marybeth] FHI 360, Sci Facilitat Dept, Washington, DC USA.
   [Gamble, Theresa] FHI 360, Sci Facilitat Dept, Durham, NC USA.
   [Gallant, Joel E.] Southwest CARE Ctr, Santa Fe, NM USA.
   [Hosseinipour, Mina C.] Univ North Carolina Chapel Hill, Inst Global Hlth & Infect Dis, Chapel Hill, NC USA.
   [Hosseinipour, Mina C.] UNC Project Malawi, Inst Global Hlth & Infect Dis, Lilongwe, Malawi.
   [Kumarasamy, Nagalingeswaran] VHS, YRGCARE Med Ctr, Madras, Tamil Nadu, India.
   [Hakim, James G.] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
   [Kalonga, Ben] Johns Hopkins Project, Coll Med, Blantyre, Malawi.
   [Pilotto, Jose H.] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, Jose H.] Lab AIDS & Imunol Mol IOC Fiocruz, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Inst Nacl Infectol Evandro Chagas INI Fiocruz, Rio De Janeiro, Brazil.
   [Godbole, Sheela V.] Natl AIDS Res Inst ICMR, Pune, Maharashtra, India.
   [Chotirosniramit, Nuntisa] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Santos, Breno Riegel] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Shava, Emily] Botswana Harvard AIDS Inst, Gaborone, Botswana.
   [Mills, Lisa A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Kisumu, Kenya.
   [Mills, Lisa A.] Kenya Med Res Inst KEMRI, CDC Clin Res Site, Kisumu, Kenya.
   [Panchia, Ravindre] Univ Witwatersrand, Perinatal HIV Res Unit, Soweto HPTN CRS, Soweto, South Africa.
   [Mwelase, Noluthando] Univ Witwatersrand, Dept Med, Clin HIV Res Unit, Johannesburg, South Africa.
   [Mayer, Kenneth H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Fenway Hlth Infect Dis Div, Fenway Inst,Dept Med, Boston, MA USA.
RP Eshleman, SH (corresponding author), Johns Hopkins Med Inst, Dept Pathol, Ross Bldg,Room 646,720 Rutland Ave, Baltimore, MD 21205 USA.
EM seshlem@jhmi.edu
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Shava,
   Emily/0000-0001-9288-7881
FU Division of AIDS of the U.S. National Institute of Allergy and
   Infectious Diseases (NIAID); Office of AIDS Research of the U.S.
   National Institutes of Health (NIH) [UM1-AI068613, UM1-AI068617,
   UM1-AI068619];  [U01-AI018136]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI069456, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069518, P30AI050410,
   P30AI050410, UM1AI069518, P30AI050410, P30AI050410, P30AI050410,
   UM1AI068617, UM1AI068613, P30AI050410, UM1AI068613, P30AI050410,
   P30AI050410, UM1AI068613, UM1AI068617, UM1AI069432, P30AI050410,
   P30AI050410, P30AI050410, UM1AI069518, P30AI050410, P30AI050410,
   P30AI050410, UM1AI069432, P30AI050410, UM1AI069423, P30AI050410,
   UM1AI069432, UM1AI069423, UM1AI068617, UM1AI068617, UM1AI069432,
   UM1AI068617, UM1AI068613, P30AI050410, UM1AI069456, UM1AI068617,
   UM1AI068617, UM1AI069456, UM1AI069432, UM1AI068613, UM1AI069432,
   UM1AI069432, UM1AI069518, UM1AI068617, UM1AI069456, UM1AI069453,
   UM1AI069518, UM1AI068617, UM1AI069432, P30AI050410, UM1AI068619,
   UM1AI069453, UM1AI068613, UM1AI068617, P30AI050410, UM1AI068613,
   P30AI050410, UM1AI068619, UM1AI069456, UM1AI068619, P30AI050410,
   UM1AI069518, P30AI050410, UM1AI068619, UM1AI068619, P30AI050410,
   UM1AI069518, UM1AI068619, UM1AI069432, P30AI050410, P30AI050410,
   UM1AI068613, UM1AI069453, UM1AI069423, UM1AI068619, P30AI050410,
   UM1AI068613, UM1AI068619, UM1AI069456, P30AI050410, UM1AI069456,
   P30AI050410, UM1AI068619, UM1AI069456, UM1AI068619, P30AI050410,
   P30AI050410, UM1AI069432, P30AI050410, P30AI050410, UM1AI069518,
   UM1AI069453, P30AI050410, UM1AI069423, UM1AI069456, UM1AI069423,
   P30AI050410, P30AI050410, P30AI050410, UM1AI068619, P30AI050410,
   P30AI050410, UM1AI068613, P30AI050410, UM1AI069518, P30AI050410,
   P30AI050410, UM1AI068613] Funding Source: NIH RePORTER
FX This work was supported by the grants from the Division of AIDS of the
   U.S. National Institute of Allergy and Infectious Diseases (NIAID); and
   by the Office of AIDS Research of the U.S. National Institutes of Health
   (NIH) [UM1-AI068613 (Eshleman); UM1-AI068617 (Donnell); and UM1-AI068619
   (Vermund/El-Sadr)]. The HPTN 052 trial also received funding through
   U01-AI018136. Study drugs used in HPTN 052 were donated by Abbott
   Laboratories, Boehringer-Ingelheim Pharmaceuticals, Inc, Bristol-Myers
   Squibb, Gilead Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, and
   Merck & Co., Inc.
CR Anglemyer A, 2013, COCHRANE DB SYST REV, V4
   Beer L, 2014, AIDS EDUC PREV, V26, P521, DOI 10.1521/aeap.2014.26.6.521
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2
   Eshleman SH, 2016, J ACQ IMMUN DEF SYND, V74, P112
   Eshleman SH, 2011, J INFECT DIS, V204, P1918, DOI 10.1093/infdis/jir651
   Fogel JM, 2013, J INFECT DIS, V208, P1624, DOI 10.1093/infdis/jit390
   Geretti AM, 2009, CLIN INFECT DIS, V48, P1296, DOI 10.1086/598502
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Haggblom A, 2016, LANCET HIV, V3, pE166, DOI 10.1016/S2352-3018(16)00023-0
   Haubrich RH, 2011, AIDS, V25, P2269, DOI 10.1097/QAD.0b013e32834d0c20
   Kantor R, 2015, CLIN INFECT DIS, V60, P1541, DOI 10.1093/cid/civ102
   Kuritzkes DR, 2007, J INFECT DIS, V195, P1169, DOI 10.1086/512619
   Labhardt ND, 2014, J INT AIDS SOC, V17, P115, DOI 10.7448/IAS.17.4.19666
   Lingappa JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012598
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Markowitz M, 2007, JAIDS-J ACQ IMM DEF, V46, P125, DOI 10.1097/QAI.0b013e318157131c
   Mujugira A, 2016, JAIDS-J ACQ IMM DEF, V72, P579, DOI 10.1097/QAI.0000000000001019
   Mujugira A, 2016, AIDS RES HUM RETROV, V32, P148, DOI [10.1089/aid.2015.0296, 10.1089/AID.2015.0296]
   Murray JM, 2007, AIDS, V21, P2315, DOI 10.1097/QAD.0b013e3282f12377
   Nachega JB, 2009, JAIDS-J ACQ IMM DEF, V51, P65, DOI 10.1097/QAI.0b013e318199072e
   Paraskevis D, 2013, AIDS RES HUM RETROV, V29, P461, DOI [10.1089/AID.2012.0143, 10.1089/aid.2012.0143]
   Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560
   Ping LH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071557
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   Ruperez M, 2015, J ANTIMICROB CHEMOTH, V70, P2639, DOI 10.1093/jac/dkv143
   Sabin CA, 2008, AIDS, V22, P1463
   Safren SA, 2015, JAIDS-J ACQ IMM DEF, V69, P234, DOI 10.1097/QAI.0000000000000593
   Wang L, 2010, JAIDS-J ACQ IMM DEF, V55, P232, DOI 10.1097/QAI.0b013e3181e9b6b7
   WHO, 2016, CONS GUID US ANT DRU
   Zanoni BC, 2014, AIDS PATIENT CARE ST, V28, P128, DOI 10.1089/apc.2013.0345
NR 34
TC 10
Z9 10
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1528-4336
EI 1945-5771
J9 HIV CLIN TRIALS
JI HIV Clin. Trials
PY 2017
VL 18
IS 3
BP 100
EP 109
DI 10.1080/15284336.2017.1311056
PG 10
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA FD9BF
UT WOS:000407817100002
PM 28385131
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Nicol, AF
   Tugizov, SM
   Herrera, R
   Grinsztejn, B
   Friedman, RK
   Veloso, VG
   Cunha, CB
   Chein, A
   Wechsler, EI
   Da Costa, M
   Palefsky, JM
AF Nicol, Alcina F.
   Tugizov, Sharof M.
   Herrera, Rossana
   Grinsztejn, Beatriz
   Friedman, Ruth K.
   Veloso, Valdilea G.
   Cunha, Cynthia B.
   Chein, A.
   Wechsler, Erin Isaacson
   Da Costa, Maria
   Palefsky, Joel M.
TI Claudin-1 expression in HIV/HPV co-infected anal intra-epithelial
   neoplasia
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE HPV; HIV-1; claudin-1; anal dysplasia; men who have sex with men; women
ID SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS INFECTIONS; MEN;
   PREVALENCE; SEX
AB Background: Claudin-1 expression is poorly characterized in anal intraepithelial neoplasia (AIN) from HIV-positive individuals. Aim: To investigate claudin-1 in situ expression in HPV-positive AIN lesions from HIV-positive individuals compared with non-dysplastic anal tissues. Materials and Methods: By means of immunofluorescence microscopy, claudin-1 was analyzed in 46 anal tissues: 18 AIN1; 14 AIN2/3 and 14 non-dysplastic specimens. Results: A higher proportion of cells with overexpression of claudin-1 were found in HIV-positive AIN lesions compared with controls. Overexpression of claudin-1 was most evident in AIN 2/3 lesions. HPV16 was detected in 21.8% anal specimens and HPV18 in 3.1%. A great diversity of 18 low-risk HPV types were detected, 40% of AIN specimens had multiple HPV types. Conclusions: Our data show that there is an over-expression of claudin-1 in HIV-positive AIN lesions compared with non-dysplastic anal biopsies. A high prevalence of HPV16 and diversity of HPV types was detected. The overexpression of claudin-1 in HIV-positive AIN specimens may play a role on the development of anal cancer, however further studies should be performed to better understand the role of claudin-1 in AIN and anal cancer development in the HIV-positive individuals.
C1 [Nicol, Alcina F.] IOC Fiocruz, Lab Interdisciplinary Med Res LIPMED, Rio De Janeiro, Brazil.
   [Tugizov, Sharof M.; Herrera, Rossana; Chein, A.; Wechsler, Erin Isaacson; Da Costa, Maria; Palefsky, Joel M.] Univ Calif San Francisco, Dept Med, 513 Parnassus Ave, San Francisco, CA 94143 USA.
   [Grinsztejn, Beatriz; Friedman, Ruth K.; Veloso, Valdilea G.; Cunha, Cynthia B.] Fiocruz MS, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
RP Palefsky, JM (corresponding author), Univ Calif San Francisco, Dept Med, 513 Parnassus Ave, San Francisco, CA 94143 USA.
EM Joel.Palefsky@ucsf.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01-DE023315]; Programa Estrategico de
   Apoio a Pesquisa em Saude (PAPES VII) Fundacao Instituto Oswaldo Cruz
   (FIOCRUZ); Laboratory of Interdisciplinary Medical Research (LIPMED)
   Instituto Oswaldo Cruz; CNPq, BrazilNational Council for Scientific and
   Technological Development (CNPq); Proep, Brazil; FAPERJ-cientista do
   nosso Estado, Brazil
FX This work was partly supported by NIH R01-DE023315 grant; Programa
   Estrategico de Apoio a Pesquisa em Saude (PAPES VII) Fundacao Instituto
   Oswaldo Cruz (FIOCRUZ); Laboratory of Interdisciplinary Medical Research
   (LIPMED) Instituto Oswaldo Cruz. AFN was scholar in Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq-CSF). BGrinsztejn
   received support from CNPq, Proep and FAPERJ-cientista do nosso Estado,
   Brazil. We would like to thank Dr Gerard J Nuovo and Bill Provance Jr
   for their helpful comments and Ricardo Batista S. from the image
   Department-IOC-Fiocruz.
CR Benczik M, 2016, PATHOL ONCOL RES, V22, P179, DOI 10.1007/s12253-015-9990-z
   Brickman C, 2015, CURR HIV-AIDS REP, V12, P388, DOI 10.1007/s11904-015-0283-7
   Colon-Lopez V, 2015, P R HEALTH SCI J, V34, P128
   dos Reis PP, 2008, CANCER-AM CANCER SOC, V113, P3169, DOI 10.1002/cncr.23934
   Godfrey C, 2015, INT J STD AIDS
   Julio RS, 2015, ARCH SEX BEHAV, V44, P357, DOI 10.1007/s10508-014-0357-4
   Kondoh A, 2011, ACTA OTO-LARYNGOL, V131, P861, DOI 10.3109/00016489.2011.562537
   Krause G, 2009, ANN NY ACAD SCI, V1165, P34, DOI 10.1111/j.1749-6632.2009.04057.x
   Leech AO, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.08.01
   Li WJ, 2015, GENET MOL RES, V14, P11814, DOI 10.4238/2015.October.2.15
   Majer A, 2016, DNA CELL BIOL, V35, P328, DOI 10.1089/dna.2015.3188
   Mendez-Martinez R, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0671-4
   Nazli A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000852
   Nicol AF, 2005, DIAGN MOL PATHOL, V14, P39, DOI 10.1097/01.pas.0000143309.81183.6c
   Nowak RG, 2016, SEX TRANSM DIS, V43, P243, DOI 10.1097/OLQ.0000000000000431
   Palefsky JM, 1998, AIDS, V12, P495, DOI 10.1097/00002030-199805000-00011
   Tugizov SM, 2013, VIROLOGY, V446, P378, DOI 10.1016/j.virol.2013.08.018
NR 17
TC 1
Z9 1
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2017
VL 10
IS 6
BP 6946
EP 6955
PG 10
WC Oncology; Pathology
SC Oncology; Pathology
GA EZ2NL
UT WOS:000404545900087
DA 2020-11-24
ER

PT J
AU Fernandes, NM
   Hennington, EA
   Bernardes, JD
   Grinsztejn, BG
AF Fernandes, Nilo Martinez
   Hennington, Elida Azevedo
   Bernardes, Jefferson de Souza
   Grinsztejn, Beatriz G.
TI Vulnerability to HIV infection in serodiscordant couples in Rio de
   Janeiro, Brazil
SO CADERNOS DE SAUDE PUBLICA
LA Portuguese
DT Article
DE HIV; Health Vulnerability; Disease Prevention
ID PREVENTION; MEN; SEX
AB A new era in HIV/AIDS treatment began in 1996 with the advent of highly active antiretroviral therapy (HAART). The advent of these new medicines expanded the treatment resources and improved life expectancy and quality of life for persons living with HIV and AIDS, favoring the maintenance and initiation of relationships between partners with discordant HIV serological status. The main objective of this study with serodiscordant couples was to understand the three dimensions of vulnerability - programmatic, social, and individual - in these couples. The study, belonging to the field of social constructionism, used analysis of discursive practices and production of meanings. Forty in-depth interviews were conducted with couples followed in a clinical research institute. The main results include the lack of information on sexuality in the family and in schools, distorted knowledge on HIV prevention and transmission, inadequacies in HIV testing, and flaws in communicating test results.
C1 [Fernandes, Nilo Martinez; Grinsztejn, Beatriz G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Av Brasil 4-365, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Hennington, Elida Azevedo] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, Brazil.
   [Bernardes, Jefferson de Souza] Univ Fed Alagoas, Maceio, Brazil.
RP Fernandes, NM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Av Brasil 4-365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM nilomartinez.fernandes@gmail.com
RI Hennington, Elida Azevedo/AAK-3354-2020
OI Hennington, Elida Azevedo/0000-0001-5280-8827
CR AUSTIN J. L., 1990, QUANDO DIZER E FAZER
   Ayres J. R. C. M., 1999, SEXUALIDADE PELO AVE, p[50, 34]
   Ayres JRCM, 1996, VULNERABILIDADE AVAL
   BAKHTIN Mikhail, 2009, MARXISMO FILOSOFIA L
   Brasil. Ministerio da Saude, 2013, PROT CLIN DIR TER MA
   Brasil RG, 2001, REV CIENTIFICA UFPA, V1, P1
   Camargo RF, ENTREVISTA AGENCIA N
   Castro M. G., 2004, JUVENTUDES SEXUALIDA
   Chambers R, 2006, IDS BULL-I DEV STUD, V37, P33, DOI 10.1111/j.1759-5436.2006.tb00284.x
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   da Silva AM, 2011, CIENC SAUDE COLETIVA, V16, P4865, DOI 10.1590/S1413-81232011001300035
   Delaney M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-S1-S6
   Delor F, 2000, SOC SCI MED, V50, P1557, DOI 10.1016/S0277-9536(99)00465-7
   Departamento de DST e AIDS e Hepatites Virais Secretaria de Vigilancia em Saude Ministerio da Saude, REC TER ANT AD INF H
   Fernandes N, 2013, THESIS
   GERGEN KJ, 1985, AM PSYCHOL, V40, P266, DOI 10.1037/0003-066X.40.3.266
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, J INT AIDS SOC S3, V15, P60
   Heilborn M. L., 2004, DOIS GENERO IDENTIDA
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Knauth DR, 2002, CONJUGALITY AIDS SER, P37
   Knauth DR, AN 26 REUN BRAS ANTR
   Liu AY, 2013, JAIDS-J ACQ IMM DEF, V64, P87, DOI 10.1097/QAI.0b013e31828f097a
   Maksud I., 2007, THESIS
   Maksud I., 2002, CONJUGALIDADES AIDS, P11
   Maksud Ivia, 2009, Physis, V19, P349, DOI 10.1590/S0103-73312009000200006
   Maksud I, 2012, CAD SAUDE PUBLICA, V28, P1196, DOI 10.1590/S0102-311X2012000600018
   Oviedo RAM, 2015, INTERFACE-BOTUCATU, V19, P237, DOI 10.1590/1807-57622014.0436
   Mann J, 1994, A AIDS NO MUNDO
   Mayer K, 2012, J INT AIDS SOC, V15, P118
   Ministerio da Saude, B EP AIDS DST 2012
   Nascimento V.E.d., 2002, THESIS
   PARKER R. G., 2000, CORPOS PRAZERES PAIX
   Perussi A, 2009, 14 C BRAS SOC
   Polejack L., 2001, THESIS
   Queiroz TN, AN 160 ENC NAC ABRAP
   Remien R., 2002, CONJUGALIDADE AIDS Q, P21
   Schechter M, 2004, JAIDS-J ACQ IMM DEF, V35, P519, DOI 10.1097/00126334-200404150-00010
   Seffner Fernando, 2008, Cienc Soc Relig, V10, P159
   SILVA Lucilene Costa e, 2012, THESIS
   SONTAG Susan, 1989, AIDS SUAS METAFORAS
   Spink M J, 2001, Cad Saude Publica, V17, P1277, DOI 10.1590/S0102-311X2001000600002
   SPINK M. J. P., 1999, PRATICAS DISCURSIVAS, P41
   Spink MJ, 2004, PRATICAS DISCURSIVAS
   Watts M. J., 1993, Geojournal, V30, P117, DOI 10.1007/BF00808128
   White R, 1991, RYAN WHITE MY OWN ST
   WHO, CONGUID UANT DRU
   World Health Organization, MAL CIRC
   Zakabi D., 2012, THESIS
NR 49
TC 1
Z9 1
U1 0
U2 1
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
EI 1678-4464
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PY 2017
VL 33
IS 4
AR e00053415
DI 10.1590/0102-311X00053415
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EX5GB
UT WOS:000403265500001
PM 28591373
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Cardoso, SW
   Yanavich, C
   Munteanu, M
   Morata, M
   Simplicio, P
   Cardoso, C
   Almeida, C
   Poynard, T
   Veloso, VG
   Grinsztejn, B
AF Perazzo, H.
   Cardoso, S. W.
   Yanavich, C.
   Munteanu, M.
   Morata, M.
   Simplicio, P.
   Cardoso, C.
   Almeida, C.
   Poynard, T.
   Veloso, V. G.
   Grinsztejn, B.
TI Presence of metabolic syndrome and low CD4 count are independently
   associated with liver fibrosis in human immunodeficiency virus-infected
   patients with non-alcoholic fatty liver
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 52nd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 19-23, 2017
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver
C1 [Perazzo, H.; Cardoso, S. W.; Yanavich, C.; Morata, M.; Simplicio, P.; Cardoso, C.; Almeida, C.; Veloso, V. G.; Grinsztejn, B.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Munteanu, M.] BioPredicitve, Paris, France.
   [Poynard, T.] Univ Paris 06, INSERM, UMR S 938, Paris, France.
EM perazzohugo@gmail.com
RI Poynard, Thierry/C-1355-2010; DE ALMEIDA, CARLOS CAETANO/K-4265-2016
OI Poynard, Thierry/0000-0002-3726-7230; DE ALMEIDA, CARLOS
   CAETANO/0000-0002-3215-5731
NR 0
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2017
VL 66
IS 1
SU S
MA THU-360
BP S158
EP S159
DI 10.1016/S0168-8278(17)30591-3
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EU5FI
UT WOS:000401056600329
DA 2020-11-24
ER

PT J
AU Eshleman, SH
   Hudelson, SE
   Redd, AD
   Swanstrom, R
   Ou, SS
   Zhang, XC
   Ping, LH
   Piwowar-Manning, E
   Porcella, SF
   Sievers, MF
   Martens, CA
   Bruno, D
   Dukhovlinova, E
   McCauley, M
   Gamble, T
   Fogel, JM
   Sabin, D
   Quinn, TC
   Gunde, L
   Maliwichi, M
   Nhando, N
   Akelo, V
   Moyo, S
   Panchia, R
   Kumarasamy, N
   Chotirosniramit, N
   de Melo, MG
   Pilotto, J
   Grinsztejn, B
   Mayer, K
   Chen, YQ
   Hughes, JP
   Cohen, MS
AF Eshleman, Susan H.
   Hudelson, Sarah E.
   Redd, Andrew D.
   Swanstrom, Ronald
   Ou, San-San
   Zhang, Xinyi Cindy
   Ping, Li-Hua
   Piwowar-Manning, Estelle
   Porcella, Stephen F.
   Sievers, Matthew F.
   Martens, Craig A.
   Bruno, Daniel
   Dukhovlinova, Elena
   McCauley, Marybeth
   Gamble, Theresa
   Fogel, Jessica M.
   Sabin, Devin
   Quinn, Thomas C.
   Gunde, Laurence
   Maliwichi, Madalitso
   Nhando, Nehemiah
   Akelo, Victor
   Moyo, Sikhulile
   Panchia, Ravindre
   Kumarasamy, Nagalingeswaran
   Chotirosniramit, Nuntisa
   de Melo, Marineide Goncalves
   Pilotto, Jose
   Grinsztejn, Beatriz
   Mayer, Kenneth
   Chen, Ying Q.
   Hughes, James P.
   Cohen, Myron S.
TI Treatment as Prevention: Characterization of Partner Infections in the
   HIV Prevention Trials Network 052 Trial
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-1; serodiscordant couples; partner; transmission; linkage; HPTN 052
ID INTEGRASE INHIBITOR RALTEGRAVIR; ANTIRETROVIRAL THERAPY; TRANSMISSION;
   RISK
AB HIV Prevention Trials Network 052 demonstrated that antiretroviral therapy (ART) prevents HIV transmission in serodiscordant couples. HIV from index-partner pairs was analyzed to determine the genetic linkage status of partner infections. Forty-six infections were classified as linked, indicating that the index was the likely source of the partner's infection. Lack of viral suppression and higher index viral load were associated with linked infection. Eight linked infections were diagnosed after the index started ART: 4 near the time of ART initiation and 4 after ART failure. Linked infections were not observed when the index participant was stably suppressed on ART.
C1 [Eshleman, Susan H.; Piwowar-Manning, Estelle; Fogel, Jessica M.; Sabin, Devin] Johns Hopkins Univ, Sch Med, Dept Pathol, 720 Rutland Ave,Ross Bldg,Room 646, Baltimore, MD 21205 USA.
   [Swanstrom, Ronald] Univ North Carolina Chapel Hill, Dept Biochem & Biophys, Chapel Hill, NC USA.
   [Ou, San-San; Zhang, Xinyi Cindy] Fred Hutchinson Canc Res Inst, Vaccine & Infect Dis Sci Div, Seattle, WA USA.
   [Ping, Li-Hua; Dukhovlinova, Elena] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
   [Porcella, Stephen F.; Martens, Craig A.; Bruno, Daniel] NIAID, Genom Unit, Res Technol Sect, Rocky Mt Labs,DIR,NIH, Hamilton, MT USA.
   [Sievers, Matthew F.; Quinn, Thomas C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD USA.
   [McCauley, Marybeth] FHI360, Sci Facilitat Dept, Washington, DC USA.
   [Gamble, Theresa] FHI360, Sci Facilitat Dept, Durham, NC USA.
   [Gunde, Laurence] Johns Hopkins Project, Coll Med, Blantyre, Malawi.
   [Maliwichi, Madalitso] UNC Project, Lilongwe, Malawi.
   [Nhando, Nehemiah] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
   [Akelo, Victor] CDC, Kenya Med Res Inst KEMRI, Ctr Global Hlth, HIV Res Branch, Kisumu, Kenya.
   [Moyo, Sikhulile] Botswana Harvard AIDS Inst Partnership, BHHRL Clin Trials Unit, Gaborone, Botswana.
   [Panchia, Ravindre] Chris Hani Baragwanath Hosp, Soweto HPTN CRS, Soweto, South Africa.
   [Kumarasamy, Nagalingeswaran] YRGCARE Med Ctr, Chennai, Tamil Nadu, India.
   [Chotirosniramit, Nuntisa] Chiang Mai Univ, Ctr AIDS & STDs, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
   [de Melo, Marineide Goncalves] Hosp Nossa Senhora Conceicao, Serv Infectol, Porto Alegre, RS, Brazil.
   [Pilotto, Jose] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, Jose] Lab AIDS & Imunol Mol IOC Fiocruz, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Inst Nacl Infectol Evandro Chagas INI Fiocruz, Rio De Janeiro, Brazil.
   [Mayer, Kenneth] Fenway Inst, Fenway Hlth & Infect Dis Div, Boston, MA USA.
   [Mayer, Kenneth] Beth Israel Deaconess Med Ctr, Harvard Med Sch, Dept Med, Boston, MA USA.
   [Chen, Ying Q.] Fred Hutchinson Canc Res Inst, Vaccine & Infect Dis Div, Seattle, WA USA.
   [Chen, Ying Q.] Fred Hutchinson Canc Res Inst, Div Publ Hlth Sci, Seattle, WA USA.
   [Hughes, James P.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Cohen, Myron S.] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA.
RP Eshleman, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, 720 Rutland Ave,Ross Bldg,Room 646, Baltimore, MD 21205 USA.
EM seshlem@jhmi.edu
RI Pilotto, Jose Henrique/AAD-9773-2019; Moyo, Sikhulile/E-1464-2015
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Moyo,
   Sikhulile/0000-0003-3821-4592; Dukhovlinova, Elena/0000-0002-2094-2543
FU HIV Prevention Trials Network (HPTN) - National Institute of Allergy and
   Infectious Diseases (NIAID); National Institute on Drug Abuse
   (NIDA)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA); National Institute of Mental Health (NIMH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH); Office of AIDS
   Research, of the National Institutes of Health (NIH), Department of
   Health and Human Services (DHHS) [UM1AI068613, UM1AI068617,
   UM1AI068619]; Division of Intramural Research, NIAID, NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID); 
   [R37-AI44667]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069456, UM1AI069476, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, R37AI044667, P30AI050410,
   P30AI050410, UM1AI069424, P30AI050410, UM1AI068619, P30AI050410,
   P30AI050410, R37AI044667, R37AI044667, P30AI050410, P30AI050410,
   P30AI050410, UM1AI069456, P30AI050410, UM1AI068619, P30AI050410,
   UM1AI068617, P30AI050410, UM1AI069453, UM1AI069453, UM1AI069456,
   P30AI050410, R37AI044667, P30AI050410, P30AI050410, UM1AI068619,
   P30AI050410, P30AI050410, UM1AI068619, P30AI050410, UM1AI069423,
   P30AI050410, UM1AI069476, P30AI050410, UM1AI069424, ZICAI001052,
   P30AI050410, P30AI050410, UM1AI069476, UM1AI069453, P30AI050410,
   ZIAAI000361, P30AI050410, ZIAAI000361, UM1AI069453, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, UM1AI068613, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069424, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, UM1AI069424, P30AI050410, P30AI050410,
   R37AI044667, P30AI050410, P30AI050410, P30AI050410, UM1AI069453,
   UM1AI068617, ZICAI001052, UM1AI069423, UM1AI068619, R37AI044667,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, UM1AI068617,
   ZIAAI000361, UM1AI069476, R37AI044667, UM1AI069456, P30AI050410,
   UM1AI069424, R37AI044667, UM1AI068619, P30AI050410, UM1AI068613,
   UM1AI068613, UM1AI069423, UM1AI069423, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, UM1AI069456, P30AI050410, UM1AI069456,
   P30AI050410, R37AI044667, P30AI050410, P30AI050410, UM1AI068617,
   UM1AI069423, UM1AI068617, UM1AI068619, P30AI050410, P30AI050410,
   R37AI044667, ZICAI001052, P30AI050410, P30AI050410, UM1AI068617,
   ZIAAI000361, P30AI050410, ZIAAI000361, P30AI050410, UM1AI068613,
   P30AI050410, UM1AI069424, UM1AI068617, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069424, P30AI050410,
   P30AI050410, P30AI050410, ZIAAI000361, R37AI044667, UM1AI069476,
   P30AI050410, P30AI050410, R37AI044667, P30AI050410, P30AI050410,
   UM1AI069453, P30AI050410, ZIAAI000361, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069453, P30AI050410,
   ZIAAI000361, P30AI050410, P30AI050410, P30AI050410, UM1AI068619,
   P30AI050410, P30AI050410, UM1AI069453, P30AI050410, UM1AI069423,
   ZICAI001052, UM1AI069456, P30AI050410, P30AI050410, P30AI050410,
   UM1AI068613, P30AI050410, UM1AI069476, P30AI050410, UM1AI069453,
   UM1AI068619, ZIAAI000361, P30AI050410, P30AI050410, P30AI050410,
   UM1AI068617, P30AI050410, P30AI050410, UM1AI068619, P30AI050410,
   P30AI050410, P30AI050410, UM1AI068617, P30AI050410, UM1AI069424,
   P30AI050410, ZICAI001052, P30AI050410, P30AI050410, ZICAI001052,
   P30AI050410, UM1AI068613, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, ZICAI001052, P30AI050410,
   P30AI050410, UM1AI069423, P30AI050410, P30AI050410, P30AI050410,
   UM1AI069424, P30AI050410, UM1AI069423, UM1AI069476, UM1AI069476,
   P30AI050410, UM1AI069456, UM1AI068613, P30AI050410, P30AI050410,
   UM1AI069476, P30AI050410, UM1AI068617, UM1AI069456, UM1AI068613,
   P30AI050410, UM1AI068613, P30AI050410, P30AI050410, UM1AI068613,
   P30AI050410, ZICAI001052, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, UM1AI069423, P30AI050410, ZIAAI000361, UM1AI068617,
   ZICAI001052, UM1AI068619, ZIAAI000361, UM1AI069423, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, UM1AI068613, ZICAI001052,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410] Funding Source: NIH
   RePORTER
FX Supported by (1) The HIV Prevention Trials Network (HPTN) sponsored by
   the National Institute of Allergy and Infectious Diseases (NIAID), the
   National Institute on Drug Abuse (NIDA), the National Institute of
   Mental Health (NIMH), and the Office of AIDS Research, of the National
   Institutes of Health (NIH), Department of Health and Human Services
   (DHHS) [grant numbers UM1AI068613 (HPTN Network Laboratory-S.H.E., PI),
   UM1AI068617 (HPTN Statistical and Data Management Center-Deborah
   Donnell, PI), and UM1AI068619 (HPTN Core and Operations Center-Wafaa
   El-Sadr, PI)], (2) the Division of Intramural Research, NIAID, NIH, and
   (3) R37-AI44667 (R.S., PI).
CR Brenner B, 2013, AIDS, V27, P1045, DOI 10.1097/QAD.0b013e32835cffd9
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Eshleman SH, 2011, J INFECT DIS, V204, P1918, DOI 10.1093/infdis/jir651
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005
   Fogel JM, 2013, J INFECT DIS, V208, P1624, DOI 10.1093/infdis/jit390
   Fogel JM, 2015, 8 IAS C HIV PATH TRE
   Giorgi EE, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-532
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Markowitz M, 2007, JAIDS-J ACQ IMM DEF, V46, P125, DOI 10.1097/QAI.0b013e318157131c
   Mujugira A, 2016, JAIDS-J ACQ IMM DEF, V72, P579, DOI 10.1097/QAI.0000000000001019
   Murray JM, 2007, AIDS, V21, P2315, DOI 10.1097/QAD.0b013e3282f12377
   Ping LH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071557
   Poon AFY, 2016, LANCET HIV, V3, pE231, DOI 10.1016/S2352-3018(16)00046-1
   Poon AFY, 2015, J INFECT DIS, V211, P926, DOI 10.1093/infdis/jiu560
   Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148
   Supervie V, 2014, CLIN INFECT DIS, V59, P115, DOI 10.1093/cid/ciu223
NR 18
TC 32
Z9 32
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JAN 1
PY 2017
VL 74
IS 1
BP 112
EP 116
DI 10.1097/QAI.0000000000001158
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EN4RL
UT WOS:000395994500022
PM 27532476
OA Green Accepted
DA 2020-11-24
ER

PT J
AU de Almeida, DV
   Macieira, KV
   Grinsztejn, BGJ
   dos Santos, VGV
   Guimaraes, ML
AF de Almeida, Dalziza Victalina
   Macieira, Karine Venegas
   Jegerhorn Grinsztejn, Beatriz Gilda
   Veloso dos Santos, Valdilea Goncalves
   Guimaraes, Monick Lindenmeyer
TI Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes
   B, F1, C or the B/Bbr Variant in Relation to the Genetics and
   Biochemical Characteristics of the env Gene
SO PLOS ONE
LA English
DT Article
ID HUMAN MONOCLONAL-ANTIBODIES; RIO-DE-JANEIRO; DRUG-USERS; VACCINE;
   PREVALENCE; EPITOPES; BRAZIL; GP120; REGION; BROAD
AB Various HIV-1 env genetic and biochemical features impact the elicitation of cross-reactive neutralizing antibodies in natural infections. Thus, we aimed to investigate cross-neutralizing antibodies in individuals infected with HIV-1 env subtypes B, F1, C or the B/Bbr variant as well as env characteristics. Therefore, plasma samples from Brazilian chronically HIV-1 infected individuals were submitted to the TZM-bl neutralization assay. We also analyzed putative N-glycosylation sites (PNGLs) and the size of gp120 variable domains in the context of HIV-1 subtypes prevalent in Brazil. We observed a greater breadth and potency of the anti-Env neutralizing response in individuals infected with the F1 or B HIV-1 subtypes compared with the C subtype and the variant B/Bbr. We observed greater V1 B/Bbr and smaller V4 F1 than those of other subtypes (p<0.005), however neither was there a correlation verified between the variable region length and neutralization potency, nor between PNLG and HIV-1 subtypes. The enrichment of W at top of V3 loop in weak neutralizing response viruses and the P in viruses with higher neutralization susceptibility was statistically significant (p = 0.013). Some other signatures sites were associated to HIV-1 subtype-specific F1 and B/Bbr samples might influence in the distinct neutralizing response. These results indicate that a single amino acid substitution may lead to a distinct conformational exposure or load in the association domain of the trimer of gp120 and interfere with the induction power of the neutralizing response, which affects the sensitivity of the neutralizing antibody and has significant implications for vaccine design.
C1 [de Almeida, Dalziza Victalina; Macieira, Karine Venegas; Guimaraes, Monick Lindenmeyer] Oswaldo Cruz Inst FIOCRUZ, Lab AIDS & Mol Immunol, Rio De Janeiro, Brazil.
   [Jegerhorn Grinsztejn, Beatriz Gilda; Veloso dos Santos, Valdilea Goncalves] Natl Inst Infectol FIOCRUZ, Rio De Janeiro, Brazil.
RP de Almeida, DV (corresponding author), Oswaldo Cruz Inst FIOCRUZ, Lab AIDS & Mol Immunol, Rio De Janeiro, Brazil.
EM dalziza@ioc.fiocruz.br
FU Collaboration for AIDS Vaccine Discovery (CAVD) - Bill & Melinda Gates
   Foundation [38619]; Global HIV Vaccine Enterprise (GHVE) Central Service
   Facilities (CSFs), Dr D Montefiori's Vaccine Immune Monitoring Center
   (VIMC) [383-0920]; Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro-FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ) [E26/110.517/2012]; CNPqNational
   Council for Scientific and Technological Development (CNPq)
FX This work was supported by the Collaboration for AIDS Vaccine Discovery
   (CAVD) funded by the Bill & Melinda Gates Foundation (Grant # 38619)
   Global HIV Vaccine Enterprise (GHVE) Central Service Facilities (CSFs),
   especially Dr D Montefiori's Vaccine Immune Monitoring Center (VIMC)
   (Grant # 383-0920). This work was partially supported by Fundacao de
   Amparo a Pesquisa do Estado do Rio de Janeiro-FAPERJ (grant number
   E26/110.517/2012). Monick Lindenmeyer Guimaraes is recipient of a CNPq
   Fellowship. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Almeida DV, 2013, AIDS RES HUM RETROV, V29, P488, DOI [10.1089/aid.2012.0052, 10.1089/AID.2012.0052]
   Asokan M, 2015, J VIROL, V89, P12501, DOI 10.1128/JVI.02097-15
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   BONGERTZ V, 1994, BRAZ J MED BIOL RES, V27, P1225
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   BONGERTZ V, 1991, BRAZ J MED BIOL RES, V24, P815
   Bonsignori M, 2012, J VIROL, V86, P4688, DOI 10.1128/JVI.07163-11
   BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R
   Chuang GY, 2013, J VIROL, V87, P10047, DOI 10.1128/JVI.00984-13
   Cortes FH, 2013, VACCINE, V31, P1106, DOI 10.1016/j.vaccine.2012.12.023
   Corti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008805
   Covas DT, 1998, J ACQ IMMUN DEF SYND, V19, P74, DOI 10.1097/00042560-199809010-00012
   Delatorre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074072
   Delgado E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143325
   Doria-Rose NA, 2015, CURR OPIN VIROL, V11, P137, DOI 10.1016/j.coviro.2015.04.002
   Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036
   Edwards TG, 2002, J VIROL, V76, P2683, DOI 10.1128/JVI.76.6.2683-2691.2002
   Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996
   Georgiev IS, 2013, SCIENCE, V340, P751, DOI 10.1126/science.1233989
   Gnanakaran S, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000955
   Gorman J, 2016, NAT STRUCT MOL BIOL, V23, P81, DOI 10.1038/nsmb.3144
   Graf T, 2013, VIROLOGY, V435, P170, DOI 10.1016/j.virol.2012.08.048
   Guenaga J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002806
   Guimaraes ML, 2001, J CLIN VIROL, V21, P143, DOI 10.1016/S1386-6532(01)00158-5
   Guimaraes ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141372
   Hraber P, 2014, AIDS, V28, P163, DOI 10.1097/QAD.0000000000000106
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Alcantara LCJ, 2009, NUCLEIC ACIDS RES, V37, pW634, DOI 10.1093/nar/gkp455
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Klein F, 2012, J EXP MED, V209, P1469, DOI 10.1084/jem.20120423
   Kong R, 2015, J VIROL, V89, P2659, DOI 10.1128/JVI.03136-14
   Korbie DJ, 2008, NAT PROTOC, V3, P1452, DOI 10.1038/nprot.2008.133
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Li M, 2006, J VIROL, V80, P11776, DOI 10.1128/JVI.01730-06
   Li YX, 2009, J VIROL, V83, P1045, DOI 10.1128/JVI.01992-08
   MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001
   Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385
   Niculescu I, 2015, AIDS RES HUM RETROV, V31, P488, DOI 10.1089/aid.2014.0189
   Pimentel VF, 2013, AIDS RES HUM RETROV, V29, P1553, DOI [10.1089/aid.2013.0050, 10.1089/AID.2013.0050]
   Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998
   Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022
   Sather DN, 2009, J VIROL, V83, P757, DOI 10.1128/JVI.02036-08
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Tang HL, 2011, J VIROL, V85, P9286, DOI 10.1128/JVI.02286-10
   van Gils MJ, 2011, J VIROL, V85, P6986, DOI 10.1128/JVI.00268-11
   Walker LM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001028
   Ward AB, 2015, TRENDS BIOCHEM SCI, V40, P101, DOI 10.1016/j.tibs.2014.12.006
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
   Wibmer CK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003738
   Yoon H, 2015, NUCLEIC ACIDS RES, V43, pW213, DOI 10.1093/nar/gkv404
   Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106
   Zhu ZY, 2011, J VIROL, V85, P11401, DOI 10.1128/JVI.05312-11
   Zolla-Pazner S, 2004, NAT REV IMMUNOL, V4, P199, DOI 10.1038/nri1307
NR 61
TC 1
Z9 1
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 9
PY 2016
VL 11
IS 12
AR e0167690
DI 10.1371/journal.pone.0167690
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE4PU
UT WOS:000389587100153
PM 27936047
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Moreira, RC
   Pacheco, AG
   Paula, A
   Cardoso, SW
   Moreira, RI
   Ribeiro, SR
   Nunes, EP
   Guimaraes, MR
   Mello, FC
   Veloso, VG
   Grinsztejn, B
AF Moreira, Rodrigo C.
   Pacheco, Antonio G.
   Paula, Adelzon
   Cardoso, Sandra W.
   Moreira, Ronaldo I.
   Ribeiro, Sayonara R.
   Nunes, Estevao P.
   Guimaraes, Maria R.
   Mello, Fernanda C.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI Diabetes Mellitus is Associated with Increased Death Rates Among
   HIV-Infected Patients in Rio de Janeiro, Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
DE people living with HIV; diabetes mellitus; death rates
ID ACTIVE ANTIRETROVIRAL THERAPY; RISK-FACTORS; MORTALITY; AIDS; ERA;
   INDIVIDUALS; SURVIVAL; DISEASE; COHORT
AB Diabetes mellitus (DM) is a major cause of morbidity worldwide and a known factor leading to increased risk of death, especially in conjunction with other risk factors. In this study, we evaluated the prevalence of DM among HIV-infected patients and its association with overall mortality. All HIV-infected patients 18 years or older who were followed in the Instituto Nacional de Infectologia Evandro Chagas (INI) cohort from January 1991 to December 2011 were included. Time-updated covariables included DM status, calendar year, combination antiretroviral therapy (cART), and CD4 cell counts. Fixed demographic covariables included gender and age at entry. Poisson models were used to calculate mortality rate ratios (RR) with robust variances. Among the 4,871 patients included, 1,192 (24.4%) died (mortality rate=4.72/100 person-years [PY]; 95% confidence interval [CI]=4.46-5.00). Death rates were significantly higher among those presenting with DM compared with those who did not (6.16/100 vs. 4.61/100 PY, respectively. p=0.001). In the final model, DM was significantly associated with mortality (RR=1.74; 95% CI=1.57-1.94; p<0.001). When the analysis was restricted to those on cART or the period post-1996, the association between DM and mortality was even stronger (RR=2.17; 95% CI=1.91-2.46; p<0.001 and RR=1.95; 95% CI=1.75-2.18; p<0.001, respectively). Among the major groups of cause of deaths (CODs), the proportion of AIDS-related conditions in patients with DM was lower (74.27% vs. 58.93%, respectively; p<0.001); whereas in non-AIDS-related conditions, nonimmunodeficiency-related causes (22.44% vs. 34.82%, respectively; p=0.004) were more common in patients with DM. In conclusion, DM was associated with increased mortality rates even after controlling for HIV-related variables associated to this outcome. Differences in the underlying CODs were identified, reinforcing the necessity to assess and treat comorbidities such as DM in HIV-infected patients.
C1 [Moreira, Rodrigo C.; Pacheco, Antonio G.; Paula, Adelzon] Fiocruz MS, Programa Comp Cient, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
   [Moreira, Rodrigo C.; Cardoso, Sandra W.; Moreira, Ronaldo I.; Ribeiro, Sayonara R.; Nunes, Estevao P.; Guimaraes, Maria R.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Mello, Fernanda C.] Univ Fed Rio de Janeiro, Inst Doencas Torax, Rio De Janeiro, Brazil.
RP Pacheco, AG (corresponding author), Fiocruz MS, Programa Comp Cient, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM apacheco@fiocruz.br
RI Pacheco, Antonio Guilherme/E-6378-2013; Mello, Fernanda/AAU-3860-2020
OI Pacheco, Antonio Guilherme/0000-0003-3095-1774; 
CR Anderson LA, 2008, CANCER EPIDEM BIOMAR, V17, P3435, DOI 10.1158/1055-9965.EPI-08-0671
   [Anonymous], 1993, JAMA, V269, P729
   [Anonymous], 2014, R LANG ENV STAT COMP
   [Anonymous], 2016, CLIN PROTOCOL THERAP
   Brown TT, 2005, ARCH INTERN MED, V165, P1179, DOI 10.1001/archinte.165.10.1179
   Cheng S, 2014, CIRCULATION, V130, P820, DOI 10.1161/CIRCULATIONAHA.113.008506
   Chu C, 2011, J URBAN HEALTH, V88, P507, DOI 10.1007/s11524-010-9540-7
   Crabtree-Ramirez B, 2014, JAIDS-J ACQ IMM DEF, V67, pS96, DOI 10.1097/QAI.0000000000000261
   Durand M, 2011, JAIDS-J ACQ IMM DEF, V57, P245, DOI 10.1097/QAI.0b013e31821d33a5
   Dyal HK, 2016, DIGEST DIS SCI, V61, P636, DOI 10.1007/s10620-015-3983-3
   El-Zayadi AR, 2012, WORLD J GASTROENTERO, V18, P212, DOI 10.3748/wjg.v18.i3.212
   Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3
   Grinspoon S, 2005, NEW ENGL J MED, V352, P48, DOI 10.1056/NEJMra041811
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Justman JE, 2003, JAIDS-J ACQ IMM DEF, V32, P298, DOI 10.1097/00126334-200303010-00009
   Liu XS, 2015, INT J ANAL CHEM, V2015, DOI 10.1155/2015/313471
   Lo YC, 2009, HIV MED, V10, P302, DOI 10.1111/j.1468-1293.2008.00687.x
   Lucas GM, 2003, JAIDS-J ACQ IMM DEF, V33, P321, DOI 10.1097/00126334-200307010-00005
   Luz PM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093039
   Miguez-Burbano Maria Jose, 2013, J AIDS Clin Res, V4, P245
   Negro F, 2014, J HEPATOL, V61, pS69, DOI 10.1016/j.jhep.2014.08.003
   Neuhaus J, 2010, AIDS, V24, P697, DOI 10.1097/QAD.0b013e3283365356
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636
   Paula AA, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-32
   Phillips AN, 2010, AIDS, V24, P1561, DOI 10.1097/QAD.0b013e32833a6056
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Szablewski L, 2014, DIABETES-METAB RES, V30, P543, DOI 10.1002/dmrr.2573
   Vance DE, 2011, J ASSOC NURSE AIDS C, V22, P17, DOI 10.1016/j.jana.2010.04.002
   WHO, GLOB UPD HIV TREATM
NR 33
TC 2
Z9 2
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC
PY 2016
VL 32
IS 12
BP 1210
EP 1218
DI 10.1089/aid.2015.0265
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA EF8PZ
UT WOS:000390592600011
PM 27329066
DA 2020-11-24
ER

PT J
AU Perez, F
   Ravasi, G
   Figueroa, JP
   Grinsztejn, B
   Kamb, M
   Sued, O
   Ghidinelli, M
AF Perez, Freddy
   Ravasi, Giovanni
   Figueroa, J. Peter
   Grinsztejn, Beatriz
   Kamb, Mary
   Sued, Omar
   Ghidinelli, Massimo
TI HIV/AIDS prevention, care and treatment in the Region of the Americas:
   achievements, challenges and perspectives
SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC
   HEALTH
LA English
DT Editorial Material
C1 [Perez, Freddy; Ravasi, Giovanni; Ghidinelli, Massimo] Pan Amer Hlth Org, HIV Hepatitis TB & STI Unit, Washington, DC 20037 USA.
   [Figueroa, J. Peter] Univ West Indies, Kingston, Jamaica.
   [Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Kamb, Mary] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Ctr Dis Control & Prevent CDC, Div STD Prevent, Atlanta, GA USA.
   [Sued, Omar] Fdn Huesped, Buenos Aires, DF, Argentina.
RP Perez, F (corresponding author), Pan Amer Hlth Org, HIV Hepatitis TB & STI Unit, Washington, DC 20037 USA.
EM perezf@paho.org
RI Perez, Freddy/AAN-3893-2020
OI Perez, Freddy/0000-0003-2001-0057
CR Acosta LMW, 2016, REV PANAM SALUD PUBL, V40, P435
   Meirelles MQB, 2016, REV PANAM SALUD PUBL, V40, P427
   Caffe S, 2016, SEX TRANSM DIS, V43, P733, DOI 10.1097/OLQ.0000000000000528
   Cesar C, 2016, REV PANAM SALUD PUBL, V40, P448
   Evans Ceri, 2016, Lancet Infect Dis, V16, pe92, DOI 10.1016/S1473-3099(16)00055-4
   Ferreira S, 2016, REV PANAM SALUD PUBL, V40, P410
   Forbes N, 2016, REV PANAM SALUD PUBL, V40, P443
   Gebre Y, 2016, REV PANAM SALUD PUBL, V40, P468
   Gomez Suarez M, 2016, REV PANAM SALUD PUBL, V40, P479
   Gaitan-Duarte HG, 2016, REV PANAM SALUD PUBL, V40, P455
   Lopez LM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010243.pub3
   MacCarthy S, 2016, REV PANAM SALUD PUBL, V40, P418
   Ochoa-Manjarres MT, 2016, INTRO PRUEBAS RAPIDA, V40, P462
   Pierre RB, 2016, REV PANAM SALUD PUBL, V40, P401
   Ravasi G, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.7.21113
   Shrestha RK, 2016, REV PANAM SALUD PUBL, V40, P474
   Tucker JD, 2010, LANCET INFECT DIS, V10, P381, DOI 10.1016/S1473-3099(10)70092-X
   UNAIDS, 2016, PREV GAP REP
   UNAIDS, 2016, GLOB AIDS UPD 2016
   Vermund SH, 2013, CURR HIV-AIDS REP, V10, P169, DOI 10.1007/s11904-013-0155-y
NR 20
TC 1
Z9 1
U1 0
U2 1
PU PAN AMER HEALTH ORGANIZATION
PI WASHINGTON
PA 525 23RD ST NW, WASHINGTON, DC 20037 USA
SN 1020-4989
J9 REV PANAM SALUD PUBL
JI Rev. Panam. Salud Publica
PD DEC
PY 2016
VL 40
IS 6
BP 398
EP 400
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ4VI
UT WOS:000393214700002
PM 28718487
DA 2020-11-24
ER

PT J
AU Gandhi, M
   Glidden, DV
   Mayer, K
   Schechter, M
   Buchbinder, S
   Grinsztejn, B
   Hosek, S
   Casapia, M
   Guanira, J
   Bekker, LG
   Louie, A
   Horng, H
   Benet, LZ
   Liu, A
   Grant, RM
AF Gandhi, Monica
   Glidden, David V.
   Mayer, Kenneth
   Schechter, Mauro
   Buchbinder, Susan
   Grinsztejn, Beatriz
   Hosek, Sybil
   Casapia, Martin
   Guanira, Juan
   Bekker, Linda-Gail
   Louie, Alexander
   Horng, Howard
   Benet, Leslie Z.
   Liu, Albert
   Grant, Robert M.
TI Association of age, baseline kidney function, and medication exposure
   with declines in creatinine clearance on pre-exposure prophylaxis: an
   observational cohort study
SO LANCET HIV
LA English
DT Article
ID DRIED BLOOD SPOTS; RENAL-FUNCTION; HIV-INFECTION; ANTIRETROVIRAL
   PROPHYLAXIS; TUBULAR DYSFUNCTION; BANGKOK TENOFOVIR; SERUM CREATININE;
   AFRICAN WOMEN; DOUBLE-BLIND; MEN
AB Background As pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine for the prevention of HIV infection is rolled out internationally, strategies to maintain effectiveness and to minimise adverse effects merit consideration. In this study, we aimed to assess reductions in renal function and predictors of renal toxicity in a large open-label study of PrEP.
   Methods As part of the iPrEx open-label extension (OLE) study, men who have sex with men or transgender women aged 18-70 years who were HIV negative and had participated in three previous PrEP trials from Brazil, Ecuador, Peru, South Africa, Thailand, and the USA were enrolled into an open-label PrEP study. There were no restrictions on current renal function for enrolment into iPrEx OLE, in which participants were given combination tablets of tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) and advised to take one tablet per day. At follow-up sessions every 12 weeks, participants' creatinine clearance on PrEP was estimated and in a subset of participants, hair samples were collected to measure tenofovir and emtricitabine concentrations (a measure of adherence and exposure) via liquid-chromatography-tandem-mass-spectrometry. Reductions in creatinine clearance from baseline were calculated and predictors of decline were identified by use of multivariate models. iPrEx is registered with ClinicalTrials.com, number NCT00458393.
   Findings Baseline characteristics were similar between all participants in iPrEx-OLE (1224 participants with 7475 person-visits) and those participating in the hair substudy (220 participants with 1114 person-visits). During a median of 72 weeks, the mean decline in creatinine clearance was -2.9% (95% CI -2.4 to -3.4; p(trend)<0.0001),but declines were greater for those who started PrEP at older ages: participants aged 40-50 years at baseline had declines of -4.2% (95% CI -2.8 to -5.5) and participants older than 50 years at baseline had declines of -4.9% (-3.1 to -6.8). In multivariate models, age and baseline creatinine clearance less than 90 mL/min predicted declines in renal function. We identified a monotonic association between percentage decrease in creatinine clearance and the number of doses of tenofovir disoproxil fumarate and emtricitabine taken per week, as estimated by hair concentrations of tenofovir and emtricitabine (p(trend)=0.008).
   Interpretation Our data suggest that the frequency of safety monitoring for PrEP might need to be different between age groups and that pharmacological measures can monitor for toxic effects as well as adherence.
C1 [Gandhi, Monica] Univ Calif San Francisco, Div HIV Infect Dis & Global Med, San Francisco, CA 94143 USA.
   [Grant, Robert M.] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA.
   [Louie, Alexander] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Glidden, David V.] Univ Calif San Francisco, Dept Biostat & Epidemiol, San Francisco, CA 94143 USA.
   [Horng, Howard; Benet, Leslie Z.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, Hosp Escola Sao Francisco Assis, Projeto Praca Onze, Rio De Janeiro, Brazil.
   [Liu, Albert] San Francisco Dept Publ Hlth, HIV Prevent Intervent Studies Bridge HIV, San Francisco, CA USA.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas IPEC, CRS, Rio De Janeiro, Brazil.
   [Hosek, Sybil] John H Stroger Jr Hosp Cook Cty, Dept Psychiat, Chicago, IL USA.
   [Casapia, Martin] ACSA, CRS, Iquitos, Peru.
   [Guanira, Juan] Invest Med Salud, Lima, Peru.
   [Bekker, Linda-Gail] Desmond Tutu Hlth Fdn, Fac Hlth Sci, Cape Town, South Africa.
RP Gandhi, M (corresponding author), Univ Calif San Francisco, Dept Med, Div HIV Infect Dis & Global Med, San Francisco, CA 94110 USA.
EM monica.gandhi@ucsf.edu
RI Glidden, David/AAD-4730-2020; Schechter, Mauro/AAG-7445-2020; Bekker,
   Linda-Gail/AAZ-8929-2020
OI BEKKER, LINDA-GAIL/0000-0002-0755-4386; Grant,
   Robert/0000-0002-0851-7085; Glidden, David/0000-0001-5888-1419
FU Division of Acquired Immunodeficiency Syndrome (DAIDS), National
   Institute of Allergy and Infectious Diseases (NIAID), National
   Institutes of Health (NIH) [UO1 AI84735, UO1 AI64002, 2R01 AI062333, UM1
   AI068619]; NIAIDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01 AI098472, R03 AI120819,
   R03 AI122908]; Women's Interagency HIV Study [U01 AI034989]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI034989, U01AI034989, UM1AI068619, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   UM1AI069476, U01AI034989, R01AI098472, U01AI034989, R03AI122908,
   U01AI034989, U01AI034989, U01AI034989, R01AI062333, R01AI098472,
   UM1AI068619, U01AI034989, U01AI064002, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI084735, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   UM1AI069476, U01AI034989, UM1AI069476, U01AI034989, R01AI062333,
   U01AI034989, UM1AI069476, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, R01AI062333, U01AI034989, U01AI034989,
   U01AI064002, U01AI034989, U01AI034989, U01AI034989, R03AI122908,
   U01AI034989, U01AI034989, U01AI084735, UM1AI068619, R01AI118575,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   R01AI118575, UM1AI069476, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI064002, U01AI034989,
   U01AI034989, U01AI034989, U01AI064002, R01AI062333, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, R01AI062333, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, R01AI118575, U01AI034989, U01AI034989,
   U01AI034989, U01AI084735, R03AI120819, U01AI034989, U01AI034989,
   U01AI034989, UM1AI068619, U01AI064002, U01AI034989, R01AI098472,
   U01AI034989, R01AI062333, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, R01AI098472, U01AI034989, U01AI034989, U01AI034989,
   UM1AI068619, UM1AI068619, UM1AI068619, U01AI034989, U01AI034989,
   U01AI034989, R01AI098472, U01AI064002, R01AI118575, R03AI120819,
   U01AI034989, U01AI034989, UM1AI068619, U01AI034989, U01AI064002,
   U01AI034989, R01AI062333, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI064002, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI084735, U01AI034989, U01AI034989, U01AI034989,
   UM1AI069476, U01AI034989, R01AI118575, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, R01AI062333, R01AI098472, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, UM1AI068619,
   U01AI034989, U01AI034989, UM1AI069476, U01AI034989, U01AI034989,
   U01AI034989, R01AI098472, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, UM1AI068619, UM1AI068619, R01AI098472,
   U01AI034989, R01AI118575, UM1AI069476, U01AI064002, UM1AI069476,
   R01AI098472, U01AI034989] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246] Funding Source: NIH
   RePORTER
FX This work was supported by the Division of Acquired Immunodeficiency
   Syndrome (DAIDS), National Institute of Allergy and Infectious Diseases
   (NIAID), National Institutes of Health (NIH), as a cooperative agreement
   (UO1 AI84735, UO1 AI64002, 2R01 AI062333 to RG and UM1 AI068619). NIAID
   also supported the hair assays for this work (R01 AI098472, principal
   investigator MG) and data analysis (R03 AI120819, R03 AI122908,
   principal investigator DG). U01 AI034989 (Women's Interagency HIV Study)
   supported positive controls and reagents for the hair assays. We thank
   the participants in the iPrEx OLE study and the study staff. We also
   thank the Hair Analytical Laboratory at University of California, San
   Francisco (CA, USA) for work on the hair assays, as well as Stephen May
   for research coordination work. We acknowledge and are grateful to Hao
   Zhang (programme officer at NIAD for R01 AI098472) for his invaluable
   support and scientific input.
CR Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Berg KM, 2006, JAIDS-J ACQ IMM DEF, V43, pS79, DOI 10.1097/01.qai.0000248337.97814.66
   Casado JL, 2016, JAIDS-J ACQ IMM DEF, V72, P416, DOI 10.1097/QAI.0000000000000986
   Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/AID.2012.0089, 10.1089/aid.2012.0089]
   CDC, 2014, PREEXP PROPH PREV HI
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   DiFrancesco R, 2013, CLIN PHARMACOL THER, V93, P479, DOI 10.1038/clpt.2013.62
   Ezinga M, 2014, ANTIVIR THER, V19, P765, DOI 10.3851/IMP2761
   Gandhi M, 2015, J INFECT DIS, V212, P1402, DOI 10.1093/infdis/jiv239
   Grant RM, 2016, C RETR OPP INF CROI
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grohskopf LA, 2013, JAIDS-J ACQ IMM DEF, V64, P79, DOI 10.1097/QAI.0b013e31828ece33
   Hosek SG, 2013, JAIDS-J ACQ IMM DEF, V62, P447, DOI 10.1097/QAI.0b013e3182801081
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Liu A, 2016, C RETR OPP INF CROI
   Liu AY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083736
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Martin M, 2014, CLIN INFECT DIS, V59, P716, DOI 10.1093/cid/ciu355
   Mocroft A, 2016, LANCET HIV, V3, pE23, DOI 10.1016/S2352-3018(15)00211-8
   Mocroft A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001809
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Monteiro N, 2014, J INT AIDS SOC, V17, P52, DOI 10.7448/IAS.17.4.19565
   Mugwanya KK, 2016, JAIDS-J ACQ IMM DEF, V71, P374, DOI 10.1097/QAI.0000000000000868
   Mugwanya KK, 2016, EXPERT OPIN DRUG SAF, V15, P265, DOI 10.1517/14740338.2016.1128412
   Mugwanya KK, 2015, JAMA INTERN MED, V175, P246, DOI 10.1001/jamainternmed.2014.6786
   Mulligan K, 2015, CLIN INFECT DIS, V61, P572, DOI 10.1093/cid/civ324
   Rodriguez-Novoa S, 2010, AIDS, V24, P1064, DOI 10.1097/QAD.0b013e32833202e2
   Ryom L, 2013, J INFECT DIS, V207, P1359, DOI 10.1093/infdis/jit043
   Scherzer R, 2012, AIDS, V26, P867, DOI 10.1097/QAD.0b013e328351f68f
   Solomon MM, 2014, AIDS, V28, P851, DOI 10.1097/QAD.0000000000000156
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Zachor H, 2016, AIDS, V30, P1221, DOI 10.1097/QAD.0000000000001041
NR 36
TC 43
Z9 43
U1 1
U2 7
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD NOV
PY 2016
VL 3
IS 11
BP E521
EP E528
DI 10.1016/S2352-3018(16)30153-9
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA ED7TB
UT WOS:000389072300009
PM 27658870
OA Green Accepted
DA 2020-11-24
ER

PT J
AU De Boni, RB
   Shepherd, BE
   Grinsztejn, B
   Cesar, C
   Cortes, C
   Padgett, D
   Gotuzzo, E
   Belaunzaran-Zamudio, PF
   Rebeiro, PF
   Duda, SN
   McGowan, CC
AF De Boni, Raquel B.
   Shepherd, Bryan E.
   Grinsztejn, Beatriz
   Cesar, Carina
   Cortes, Claudia
   Padgett, Denis
   Gotuzzo, Eduardo
   Belaunzaran-Zamudio, Pablo F.
   Rebeiro, Peter F.
   Duda, Stephany N.
   McGowan, Catherine C.
TI Substance Use and Adherence Among People Living with HIV/AIDS Receiving
   cART in Latin America
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Substance use; Adherence; HIV/AIDS; Latin America
ID HIV TREATMENT OUTCOMES; ALCOHOL-USE DISORDERS; ILLICIT DRUG-USE;
   ANTIRETROVIRAL THERAPY; HEALTH-CARE; COCAINE USE; MEDICATION ADHERENCE;
   VIRAL SUPPRESSION; INFECTED PEOPLE; BRAZIL
AB This cross-sectional study describes substance use prevalence and its association with combination antiretroviral therapy (cART) adherence among 3343 individuals receiving care at HIV clinics in Argentina, Brazil, Chile, Honduras, Mexico, and Peru. A rapid screening tool evaluated self-reported 7-day recall of alcohol, marijuana, cocaine, heroin, and methamphetamine use, and missed cART doses. Overall, 29.3 % individuals reported having aeyen1 alcoholic drinks, 5.0 % reported any illicit drug use and 17.0 % reported missed cART doses. In the logistic regression model, compared to no substance use, alcohol use [adjusted odds ratio (AOR) = 2.46, 95 % confidence interval (CI): 1.99-3.05], illicit drug use (AOR = 3.57, 95 % CI: 2.02-6.30), and using both alcohol and illicit drugs (AOR = 4.98, 95 % CI: 3.19-7.79) were associated with missed cART doses. The associations between substance use and likelihood of missing cART doses point to the need of targeting alcohol and illicit drug use to improve adherence among people living with HIV in Latin America.
C1 [De Boni, Raquel B.; Grinsztejn, Beatriz] Inst Nacl Infectol Evandro Chagas FIOCRUZ, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
   [Shepherd, Bryan E.; Rebeiro, Peter F.; Duda, Stephany N.; McGowan, Catherine C.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Cesar, Carina] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Cortes, Claudia] Fdn Arriaran, Santiago, Chile.
   [Gotuzzo, Eduardo] Inst Hondureno Seguridad Social & Hosp Escuela, Tegucigalpa, Honduras.
   [Padgett, Denis] Univ Peruana Cayetano Heredia, Lima, Peru.
   [Belaunzaran-Zamudio, Pablo F.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Mexico City, DF, Mexico.
RP De Boni, RB (corresponding author), Inst Nacl Infectol Evandro Chagas FIOCRUZ, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM raqueldeboni@gmail.com
RI Belaunzaran-Zamudio, Pablo Francisco/T-4085-2019; Cesar,
   Carina/H-2831-2019; Belaunzaran-Zamudio, Pablo F./T-4218-2019; DE BONI,
   RAQUEL BRANDINI/D-4212-2013; Cortes, Claudia/AAF-7326-2020
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Cortes,
   Claudia/0000-0001-9101-9783; Belaunzaran, Pablo/0000-0003-4775-4734;
   Rebeiro, Peter/0000-0003-1951-9104
FU National Institute of Allergy and Infectious Diseases (NIAID) as part of
   the International Epidemiologic Databases to Evaluate AIDS (IeDEA)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01 AI069923]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI069476, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, UM1AI069476, U01AI069923,
   U01AI069923, UM1AI069476, U01AI069923, UM1AI069476, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, UM1AI069476, U01AI069923,
   U01AI069923, UM1AI069476, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, UM1AI069476, UM1AI069476,
   UM1AI069476, U01AI069923, U01AI069923, U01AI069923] Funding Source: NIH
   RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (NIAID) as part of the International Epidemiologic
   Databases to Evaluate AIDS (IeDEA): U01 AI069923.
CR Abdalla RR, 2014, ADDICT BEHAV, V39, P297, DOI 10.1016/j.addbeh.2013.10.019
   Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201
   Azar MM, 2010, DRUG ALCOHOL DEPEN, V112, P178, DOI 10.1016/j.drugalcdep.2010.06.014
   Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015
   Barclay TR, 2010, HEAL PSYCHOL, V26, P40
   Bastos FI, 2012, CAD SAUDE PUBLICA, V28, P1016, DOI 10.1590/S0102-311X2012000600001
   Bell C, 2010, JAIDS-J ACQ IMM DEF, V54, P376, DOI 10.1097/QAI.0b013e3181d01d31
   Binford MC, 2012, CURR HIV-AIDS REP, V9, P287, DOI 10.1007/s11904-012-0134-8
   Chibanda D, 2014, JAIDS-J ACQ IMM DEF, V67, pS54, DOI 10.1097/QAI.0000000000000258
   Cofrancesco J, 2008, AIDS, V22, P357, DOI 10.1097/QAD.0b013e3282f3cc21
   Cohn SE, 2011, AIDS CARE, V23, P775, DOI 10.1080/09540121.2010.525617
   Cruz MS, 2013, INT J DRUG POLICY, V24, P432, DOI 10.1016/j.drugpo.2013.03.012
   Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0
   EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106
   Elliott JC, 2014, ALCOHOL CLIN EXP RES, V38, P3052, DOI 10.1111/acer.12570
   Ferro EG, 2015, AIDS CARE, V27, P93, DOI 10.1080/09540121.2014.963013
   Ghidei L, 2013, DRUG AGING, V30, P809, DOI 10.1007/s40266-013-0107-7
   Gonzalez Adam, 2011, Curr HIV/AIDS Rep, V8, P223, DOI 10.1007/s11904-011-0093-5
   Hinkin CH, 2004, AIDS, V18, pS19, DOI 10.1097/00002030-200418001-00004
   Hugen PWH, 2002, J ACQ IMMUN DEF SYND, V30, P324, DOI [10.1097/00126334-200207010-00009, 10.1097/01.QAI.0000014768.35851.DB]
   Inciardi JA, 2006, J PSYCHOACTIVE DRUGS, V38, P305, DOI 10.1080/02791072.2006.10399856
   Kipp AM, 2011, J SUBST ABUSE TREAT, V40, P386, DOI 10.1016/j.jsat.2011.01.001
   Lima VD, 2009, JAIDS-J ACQ IMM DEF, V50, P529, DOI 10.1097/QAI.0b013e31819675e9
   Lucas GM, 2011, LIFE SCI, V88, P948, DOI 10.1016/j.lfs.2010.09.025
   Macdonald S, 2014, SUBST USE MISUSE, V49, P1899, DOI 10.3109/10826084.2014.935791
   Malta M, 2010, AIDS BEHAV, V14, P731, DOI 10.1007/s10461-008-9489-7
   Mathers BM, 2008, LANCET, V372, P1733, DOI 10.1016/S0140-6736(08)61311-2
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   McGowan CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018462
   Metsch LR, 2001, J SUBST ABUSE, V13, P155, DOI 10.1016/S0899-3289(01)00064-5
   Meyer JP, 2013, CLIN INFECT DIS, V57, P1309, DOI 10.1093/cid/cit427
   Mimiaga MJ, 2013, AM J PUBLIC HEALTH, V103, P1457, DOI 10.2105/AJPH.2012.301162
   Mitchell AJ, 2012, BRIT J PSYCHIAT, V201, P93, DOI 10.1192/bjp.bp.110.091199
   Ortego C, 2011, AIDS BEHAV, V15, P1381, DOI 10.1007/s10461-011-9942-x
   Rasbach DA, 2013, AIDS CARE, V25, P109, DOI 10.1080/09540121.2012.687814
   Rentsch C, 2016, AIDS BEHAV, V20, P555, DOI 10.1007/s10461-015-1025-y
   Teixeira C, 2013, AIDS RES HUM RETROV, V29, P799, DOI [10.1089/aid.2012.0296, 10.1089/AID.2012.0296]
   UNODC, 2013, WORLD DRUG REP
   Wakefield JC, 2015, ADDICTION, V110, P931, DOI 10.1111/add.12859
   Yehia BR, 2015, JAIDS-J ACQ IMM DEF, V68, P413, DOI 10.1097/QAI.0000000000000489
NR 40
TC 18
Z9 18
U1 0
U2 7
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD NOV
PY 2016
VL 20
IS 11
BP 2692
EP 2699
DI 10.1007/s10461-016-1398-6
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA EA3KA
UT WOS:000386499800022
PM 27091028
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Belaunzaran-Zamudio, P
   Shepherd, B
   Caro-Vega, Y
   Cortes, C
   Crabtree-Ramirez, B
   Grinsztejn, B
   Gotuzzo, E
   Mejia, F
   Padgett, D
   Pape, J
   Rebeiro, P
   Rouzier, V
   Veloso, V
   Wagner-Cardoso, S
   McGowan, C
   Sierra-Madero, J
AF Belaunzaran-Zamudio, Pablo
   Shepherd, Bryan
   Caro-Vega, Yanink
   Cortes, Claudia
   Crabtree-Ramirez, Brenda
   Grinsztejn, Beatriz
   Gotuzzo, Eduardo
   Mejia, Fernando
   Padgett, Denis
   Pape, Jean
   Rebeiro, Peter
   Rouzier, Vanessa
   Veloso, Valdilea
   Wagner-Cardoso, Sandra
   McGowan, Catherine
   Sierra-Madero, Juan
TI High mortality attributable to late presentation and delayed ART
   initiation in HIV-infected adults receiving care in Latin America
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Belaunzaran-Zamudio, Pablo; Caro-Vega, Yanink; Crabtree-Ramirez, Brenda; Sierra-Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Mexico City, DF, Mexico.
   [Shepherd, Bryan] Vanderbilt Univ, Dept Biostat, Nashville, TN USA.
   [Cortes, Claudia] Univ Chile, Fundac Arriaran, Santiago, Chile.
   [Grinsztejn, Beatriz; Veloso, Valdilea; Wagner-Cardoso, Sandra] Inst Pesquisa Clin Evandro Chagas, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Gotuzzo, Eduardo; Mejia, Fernando] Inst Med Trop Alexander Humboldt, Lima, Peru.
   [Padgett, Denis] Inst Hondureno Seguridad Social, Tegucigalpa, Honduras.
   [Padgett, Denis] Hosp Escuela Tegucigalpa, Tegucigalpa, Honduras.
   [Pape, Jean; Rouzier, Vanessa] Grp Haitien Etude Sarcome Kaposi & Infect Opportu, Port Au Prince, Haiti.
   [Rebeiro, Peter; McGowan, Catherine] Vanderbilt Univ, Dept Med, Nashville, TN USA.
RI Belaunzaran-Zamudio, Pablo F./T-4218-2019; Cortes,
   Claudia/AAF-7326-2020; Belaunzaran-Zamudio, Pablo Francisco/T-4085-2019
OI Cortes, Claudia/0000-0001-9101-9783; 
NR 0
TC 1
Z9 1
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2016
VL 19
SU 7
MA P340
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EM6AJ
UT WOS:000395394900374
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Ravasi, G
   Grinsztejn, B
   Baruch, R
   Guanira, JV
   Luque, R
   Caceres, CF
   Ghidinelli, M
AF Ravasi, Giovanni
   Grinsztejn, Beatriz
   Baruch, Ricardo
   Guanira, Juan Vicente
   Luque, Ricardo
   Caceres, Carlos F.
   Ghidinelli, Massimo
TI Towards a fair consideration of PrEP as part of combination HIV
   prevention in Latin America
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE pre-exposure prophylaxis; HIV; prevention; antiretrovirals; Latin
   America
ID PREEXPOSURE PROPHYLAXIS; HIGH-RISK; MEN; SEX; ACCEPTABILITY; PREVALENCE;
   INFECTION
AB Introduction: Despite progress in scaling up antiretroviral treatment, HIV prevention strategies have not been successful in significantly curbing HIV incidence in Latin America. HIV prevention interventions need to be expanded to target the most affected key populations with a combination approach, including new high impact technologies. Oral pre-exposure prophylaxis ( PrEP) is recommended as additional prevention choice for individuals at higher risk of infection and could become a costeffective prevention tool. We discuss the barriers and solutions for a fair consideration of PrEP as part of combination HIV prevention strategies in Latin America.
   Discussion: Although demonstration projects are ongoing or being planned in a number of countries, to date no Latin American country has implemented a public PrEP programme. The knowledge of policymakers about PrEP implementation needs to be strengthened, and programmatic guidance and cost estimate tools need to be developed to support adequate planning. Despite high levels of awareness among health providers, especially if engaged in HIV or key population care, willingness to prescribe PrEP is still low due to the lack of national policies and guidelines. Key populations, especially men who have sex with men, transgender women and sex workers, have been engaged in demonstration projects, and qualitative research shows high awareness and willingness to use PrEP, especially if accessible in the public sector for free or at affordable price. Concerns of safety, adherence, effectiveness and risk compensation need to be addressed through targeted social communication strategies to improve PrEP knowledge and stimulate demand. Alliance among policymakers, civil society and representatives from key populations, healthcare providers and researchers will be critical for the design and successful implementation of PrEP demonstration projects of locally adapted delivery models. The use of mechanisms of joint negotiation and procurement of antiretrovirals could reduce costs and significantly increase the cost-effectiveness of PrEP.
   Conclusions: PrEP is an additional prevention tool and should be implemented in combination and synergy with other prevention interventions. PrEP programmes should target high-risk individuals from key populations for higher cost-effectiveness. Demonstration projects may generate strategic information for and lead to the implementation of full-scale PrEP programmes.
C1 [Ravasi, Giovanni; Ghidinelli, Massimo] Pan Amer Hlth Org, 525 23rd St NW, Washington, DC 20037 USA.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Baruch, Ricardo] Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico.
   [Guanira, Juan Vicente] Invest Med Salud, Lima, Peru.
   [Luque, Ricardo] Minist Salud & Protecc Social, Bogota, Colombia.
   [Caceres, Carlos F.] Univ Peruana Cayetano Heredia, Ctr Invest Interdisciplinaria Sexualidad SIDA & S, Lima, Peru.
RP Ravasi, G (corresponding author), Pan Amer Hlth Org, 525 23rd St NW, Washington, DC 20037 USA.
EM ravasigi@paho.org
CR Anderson PL, 2012, 19 C RETR OPP INF 20
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P65
   Centers of Disease Control and Prevention, 2014, PREEXP PROPH PREV HI
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Veras MADM, 2015, AIDS BEHAV, V19, P1589, DOI 10.1007/s10461-014-0944-3
   Eisingerich AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028238
   Galea JT, 2011, INT J STD AIDS, V22, P256, DOI 10.1258/ijsa.2009.009255
   GILEAD, 2016, GIL STAT APPR PREP P
   Gilead Sience Inc, TRUV REG DEV WORLD
   Glidden DV, 2015, C RETR OPP INF CROI
   Gomez GB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001323
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hankins C, 2015, J INT AIDS SOC, V18, P71, DOI 10.7448/IAS.18.4.19973
   Hoagland B, 2015, 8 IAS C HIV PATH TRE
   Holt M, 2014, SEX HEALTH, V11, P166, DOI 10.1071/SH13060
   Joint United Nations Programme on HIV/ AIDS, GLOB AIDS RESP PROGR
   Joint United Nations Programme on HIV/AIDS, 2014, GAP REP
   Joint United Nations Programme on HIV/ AIDS, 2015, AIDS CHANG EV MDG6 1
   Joint United Nations Programme on HIV/ AIDS, 2014, PROGR REP NARR REP
   Joint United Nations Programme on HIV/AIDS UNAIDS (Joint United Nations Programme on HIV/AIDS), 2014, FAST TRACK END AIDS
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Koester KA, 2015, AIDS CARE, V22, P1
   Krakower D, 2012, CURR OPIN HIV AIDS, V7, P593, DOI 10.1097/COH.0b013e3283590446
   Krakower DS, 2015, DRUGS, V75, P243, DOI 10.1007/s40265-015-0355-4
   Lippman SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121044
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Pan American Health Organization, 2013, ADDR CAUS DISP HLTH
   Pan American Health Organization, 2013, ANT TREATM SPORT LIG
   Pan American Health Organization, 2017, STRAT FUND PROD PRIC
   Pan American Health Organization, 2005, REG HIV STI PLAN HLT
   Peinado Jesus, 2013, J Int Assoc Provid AIDS Care, V12, P278, DOI 10.1177/1545109712473650
   Second Latin American and Caribbean Forum on the Continuum of HIV Care, 2015, ENHANCING COMBINATIO
   Tang EC, 2014, AIDS RES HUM RETROV, V30, P416, DOI [10.1089/aid.2013.0212, 10.1089/AID.2013.0212]
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   United Nations Millennium Development Goals, GOAL 6 COMB HIV AIDS
   de Castro CAV, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-224
   Veloso VG, 2015, J INT AIDS SOC, V18, P48, DOI 10.7448/IAS.18.4.20010
   Wheelock A, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001234
   World Health Organization, 2015, GUID START ANT THER
   World Health Organization, 2014, CONS GUID HIV PREV D
NR 44
TC 15
Z9 15
U1 0
U2 6
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2016
VL 19
SU 6
AR 21113
DI 10.7448/IAS.19.7.21113
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EM6AH
UT WOS:000395394700006
PM 27760687
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Coelho, L
   Grinsztejn, B
   Castilho, JL
   De Boni, R
   Quintana, MSB
   Campos, DP
   Ribeiro, SR
   Pacheco, AG
   Veloso, VG
   Luz, PM
AF Coelho, Lara
   Grinsztejn, Beatriz
   Castilho, Jessica L.
   De Boni, Raquel
   Quintana, Marcel S. B.
   Campos, Dayse P.
   Ribeiro, Sayonara R.
   Pacheco, Antonio G.
   Veloso, Valdilea G.
   Luz, Paula M.
TI Mortality in HIV-infected women, heterosexual men, and men who have sex
   with men in Rio de Janeiro, Brazil: an observational cohort study
SO LANCET HIV
LA English
DT Article
ID RECEIVING ANTIRETROVIRAL THERAPY; STRUCTURAL STIGMA; LATIN-AMERICA;
   RISK-FACTORS; COLLABORATION; ORIENTATION; GENDER; HEALTH; IMPACT; CARE
AB Background Mortality in HIV-infected individuals might differ by sex and mode of HIV acquisition. We aimed to study mortality in HIV-infected women, heterosexual men, and men who have sex with men (MSM) in a cohort from Rio de Janeiro, Brazil.
   Methods In this observational cohort study, we included HIV-infected women, heterosexual men, and MSM (aged >= 18 years) from the Instituto Nacional de Infectologia Evandro Chagas database who were enrolled between Jan 1, 2000, and Oct 30, 2011, and who had at least 60 days of follow-up. Causes of deaths, defined with the Coding of Death in HIV protocol, were documented. Cox proportional hazards models accounting for competing risks were used to explore risk factors for AIDS-related and non-AIDS-related deaths.
   Findings We had 10 142 person-years of follow-up from 2224 individuals: 817 (37%) women, 554 (25%) heterosexual men, and 853 (38%) MSM. Of 103 deaths occurred, 64 were AIDS related, 31 were non-AIDS related, and eight were of unknown causes. In unadjusted analyses, compared with women, the hazard of AIDS-related deaths was higher for heterosexual men (hazard ratio [HR] 3 . 52, 95% CI 1 . 30-9 . 08; p=0 . 009) and for MSM (2 . 30, 0 . 89-5 . 94; p=0 . 084). After adjustment for age, CD4 cell counts, last HIV viral load, antiretroviral therapy use, and AIDS-defi ning infection, AIDS-defi ning malignant disease, and hospital admission during follow-up, the excess risk of AIDS-related death decreased for heterosexual men (adjusted HR 1 . 99, 0 . 75-5 . 25; p=0 . 163) but was unchanged for MSM (2 . 24, 0 . 82-6 . 11; p=0 . 114). Non-AIDS-related mortality did not differ by group.
   Interpretation Compared with women, increased risk of AIDS-related death in heterosexual men was partly mitigated by risk factors for AIDS mortality, whereas the excess risk in MSM was unchanged. Further study of reasons for disparity in AIDS-related mortality by mode of transmission is needed.
C1 [Coelho, Lara; Grinsztejn, Beatriz; De Boni, Raquel; Quintana, Marcel S. B.; Campos, Dayse P.; Ribeiro, Sayonara R.; Pacheco, Antonio G.; Veloso, Valdilea G.; Luz, Paula M.] Fundacao Oswaldo Cruz Fdn, Inst Nacl Infectol Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Castilho, Jessica L.] Vanderbilt Univ, Sch Med, Div Infect Dis, Nashville, TN 37212 USA.
   [Pacheco, Antonio G.] Fundacao Oswaldo Cruz Fdn, Programa Computacao Cient, Rio De Janeiro, Brazil.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz Fdn, Inst Nacl Infectol Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
EM paula.luz@ini.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Pacheco, Antonio
   Guilherme/E-6378-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Pacheco, Antonio
   Guilherme/0000-0003-3095-1774; Luz, Paula/0000-0001-9746-719X
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA; Brazilian
   National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF
   CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [K12HD043483, K12HD043483, K12HD043483, K12HD043483,
   K12HD043483, K12HD043483, K12HD043483, K12HD043483, K12HD043483,
   K12HD043483] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [K12HD043483, K12HD043483, K12HD043483,
   K12HD043483, K12HD043483, K12HD043483, K12HD043483, K12HD043483,
   K12HD043483, K12HD043483] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI069923, U01AI069923, UM1AI069476, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, UM1AI069476, UM1AI069476, U01AI069923, UM1AI069476,
   U01AI069923, U01AI069923, U01AI069923, UM1AI069476, UM1AI069476,
   U01AI069923, UM1AI069476, U01AI069923, U01AI069923, U01AI069923,
   UM1AI069476, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, UM1AI069476] Funding Source: NIH RePORTER
FX US National Institutes of Health, Brazilian National Council of
   Technological and Scientific Development (CNPq), and Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ).
CR [Anonymous], 2015, B EPIDEMIOLOGICO AID
   Biello KB, 2016, AIDS CARE, V28, P84, DOI 10.1080/09540121.2016.1146205
   Boulle A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001718
   Braitstein P, 2008, J WOMENS HEALTH, V17, P47, DOI 10.1089/jwh.2007.0353
   Castilho JL, 2014, AIDS RES HUM RETROV, V30, P446, DOI [10.1089/aid.2013.0208, 10.1089/AID.2013.0208]
   Chu R, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-19
   Cochran SD, 2011, AM J PUBLIC HEALTH, V101, P1133, DOI 10.2105/AJPH.2010.300013
   Coelho LE, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1462-x
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cornell M, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001304
   Costa AB, 2013, INT J PSYCHOL, V48, P900, DOI 10.1080/00207594.2012.729839
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Dunlay Shannon M, 2012, Curr Heart Fail Rep, V9, P267, DOI 10.1007/s11897-012-0107-7
   Giovino GA, 2012, LANCET, V380, P668, DOI 10.1016/S0140-6736(12)61085-X
   Grangeiro A, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-99
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Hanif H, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-574
   Hatzenbuehler ML, 2014, SOC SCI MED, V103, P33, DOI 10.1016/j.socscimed.2013.06.005
   Ingle SM, 2014, CLIN INFECT DIS, V59, P287, DOI 10.1093/cid/ciu261
   Jarrin I, 2015, ANTIVIR THER, V20, P21, DOI 10.3851/IMP2768
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Malta M, 2009, JAIDS-J ACQ IMM DEF, V52, P629, DOI 10.1097/QAI.0b013e3181b31b8a
   Maskew M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064392
   May MT, 2015, JAIDS-J ACQ IMM DEF, V69, P348, DOI 10.1097/QAI.0000000000000603
   Mayer KH, 2012, LANCET, V380, P378, DOI 10.1016/S0140-6736(12)60835-6
   Mills EJ, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-52
   Oksuzyan A, 2010, EUR J EPIDEMIOL, V25, P471, DOI 10.1007/s10654-010-9460-6
   Pachankis JE, 2015, AIDS, V29, P1239, DOI 10.1097/QAD.0000000000000724
   Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249
   Pinkhasov RM, 2010, INT J CLIN PRACT, V64, P465, DOI 10.1111/j.1742-1241.2009.02289.x
   Simmons RD, 2013, HIV MED, V14, P596, DOI 10.1111/hiv.12045
   Smith CJ, 2014, LANCET, V384, P241, DOI 10.1016/S0140-6736(14)60604-8
   Tancredi MV, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0599-8
   Thorsteinsson K, 2012, SCAND J INFECT DIS, V44, P766, DOI 10.3109/00365548.2012.684220
   Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6
   Yan HJ, 2014, AIDS BEHAV, V18, pS5, DOI 10.1007/s10461-013-0520-2
NR 36
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD OCT
PY 2016
VL 3
IS 10
BP E490
EP E498
DI 10.1016/S2352-3018(16)30052-2
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA ED7SY
UT WOS:000389072000015
PM 27658875
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Jalil, EM
   Wilson, E
   Velasque, L
   Moreira, RI
   Luz, PM
   Castro, C
   Monteiro, L
   Ferreira, ACG
   Wagner, S
   Coelho, LE
   Mc Farland, W
   Liu, A
   Buchbinder, S
   Veloso, VG
   Grinsztejn, B
AF Jalil, Emilia Moreira
   Wilson, Erin
   Velasque, Luciane
   Moreira, Ronaldo Ismerio
   Luz, Paula Mendes
   Castro, Cristiane
   Monteiro, Laylla
   Garcia Ferreira, Ana Cristina
   Wagner, Sandra
   Coelho, Lara Esteves
   Mc Farland, Willi
   Liu, Albert
   Buchbinder, Susan
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI HIV Treatment Cascade among Transgender Women: Population Estimates from
   Rio de Janeiro, Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on HIV Research for Prevention (HIV R4P)
CY OCT 17-20, 2016
CL Chicago, IL
C1 [Jalil, Emilia Moreira; Moreira, Ronaldo Ismerio; Luz, Paula Mendes; Castro, Cristiane; Monteiro, Laylla; Garcia Ferreira, Ana Cristina; Wagner, Sandra; Coelho, Lara Esteves; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fiocruz MS, Rio De Janeiro, Brazil.
   [Wilson, Erin; Mc Farland, Willi; Liu, Albert; Buchbinder, Susan] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Velasque, Luciane] Fed Univ State Rio de Janeiro, Rio De Janeiro, Brazil.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2016
VL 32
SU 1
MA OA05.06LB
BP 50
EP 50
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA EA6YH
UT WOS:000386774600079
DA 2020-11-24
ER

PT J
AU Jalil, EM
   Wilson, E
   Velasque, L
   Moreira, RI
   Hoagland, B
   Castro, C
   Monteiro, L
   Ferreira, ACG
   McFarland, W
   Liu, A
   Buchbinder, S
   Veloso, VG
   Grinsztejn, B
AF Jalil, Emilia Moreira
   Wilson, Erin
   Velasque, Luciane
   Moreira, Ronaldo Ismerio
   Hoagland, Brenda
   Castro, Cristiane
   Monteiro, Laylla
   Garcia Ferreira, Ana Cristina
   McFarland, Willi
   Liu, Albert
   Buchbinder, Susan
   Veloso, Valdilea Goncalves
   Grinsztejn, Beatriz
TI PrEP for Transwomen in Rio De Janeiro, Brazil: Low Awareness but High
   Willingness and Candidacy to Take PrEP
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on HIV Research for Prevention (HIV R4P)
CY OCT 17-20, 2016
CL Chicago, IL
C1 [Jalil, Emilia Moreira; Moreira, Ronaldo Ismerio; Hoagland, Brenda; Castro, Cristiane; Monteiro, Laylla; Garcia Ferreira, Ana Cristina; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz] Fiocruz MS, Rio De Janeiro, Brazil.
   [Wilson, Erin; McFarland, Willi; Liu, Albert; Buchbinder, Susan] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Velasque, Luciane] Univ Fed Rio de Janeiro, BR-21941 Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2016
VL 32
SU 1
MA P24.09
BP 379
EP 379
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA EA6YH
UT WOS:000386774600706
DA 2020-11-24
ER

PT J
AU Bozza, FA
   Grinsztejn, B
AF Bozza, Fernando A.
   Grinsztejn, Beatriz
TI Key points on Zika infection for the intensivist
SO INTENSIVE CARE MEDICINE
LA English
DT Editorial Material
ID VIRUS-INFECTION; BRAZIL; OUTBREAK; STATES
C1 [Bozza, Fernando A.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Intens Care Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, HIV Lab, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Intens Care Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM fernando.bozza@ini.fiocruz.br
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
CR Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cerbino-Neto J, 2016, EMERG INFECT DIS, V22, P1318, DOI 10.3201/eid2207.160375
   Cunha MS, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00032-16
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Heymann DL, 2016, LANCET, V387, P719, DOI 10.1016/S0140-6736(16)00320-2
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Roth A, 2014, EURO SURVEILL, V19
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
NR 15
TC 2
Z9 2
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2016
VL 42
IS 9
BP 1490
EP 1492
DI 10.1007/s00134-016-4378-4
PG 3
WC Critical Care Medicine
SC General & Internal Medicine
GA DU2IJ
UT WOS:000382034200027
PM 27172823
OA Bronze
DA 2020-11-24
ER

PT J
AU Bozza, FA
   Grinsztejn, B
AF Bozza, Fernando A.
   Grinsztejn, Beatriz
TI Key points on Zika infection for the intensivist (vol 42, pg 1490, 2016)
SO INTENSIVE CARE MEDICINE
LA English
DT Correction
C1 [Bozza, Fernando A.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Intens Care Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, HIV Lab, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Intens Care Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM fernando.bozza@ini.fiocruz.br
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
CR Bozza FA, 2016, INTENS CARE MED, V42, P1490, DOI 10.1007/s00134-016-4378-4
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2016
VL 42
IS 9
BP 1522
EP 1522
DI 10.1007/s00134-016-4408-2
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA DU2IJ
UT WOS:000382034200042
PM 27299353
OA Bronze
DA 2020-11-24
ER

PT J
AU Nicol, AF
   Brunette, LL
   Nuovo, GJ
   Grinsztejn, B
   Friedman, RK
   Veloso, VG
   Cunha, CB
   Coutinho, JR
   de Andrade, CV
   Oliveira, NS
   Woodham, AW
   Da Silva, DM
   Kast, WM
AF Nicol, Alcina F.
   Brunette, Laurie L.
   Nuovo, Gerard J.
   Grinsztejn, Beatriz
   Friedman, Ruth K.
   Veloso, Valdilea G.
   Cunha, Cynthia B.
   Coutinho, Jose R.
   de Andrade, Cecilia Vianna
   Oliveira, Nathalia S.
   Woodham, Andrew W.
   Da Silva, Diane M.
   Kast, W. Martin
TI Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV
   Infection in Anal Lesions of HIV-Positive Patients
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE secretory leukocyte protease inhibitor; anal intraepithelial neoplasia;
   human immunodeficiency virus; human papillomavirus
ID HUMAN-PAPILLOMAVIRUS INFECTION; ANNEXIN A2 HETEROTETRAMER; SQUAMOUS-CELL
   CARCINOMA; IN-SITU DETECTION; INTRAEPITHELIAL NEOPLASIA; UTERINE CERVIX;
   SLPI; CANCER; WOMEN; ANTILEUKOPROTEASE
AB Objective:The aim of this study was to evaluate secretory leukocyte protease inhibitor (SLPI) expression in anal biopsies from HIV-positive (HIV+) individuals, and compare that to anal intraepithelial neoplasia (AIN) diagnoses and human papillomavirus (HPV) status.Design:This is a cross-sectional study of a cohort of 54 HIV+ (31 males and 23 females) from an AIDS clinic in Rio de Janeiro, Brazil.Methods:The study material consisted of anorectal tissue biopsies obtained from HIV+ subjects, which were used to construct tissue microarray paraffin blocks for immunohistochemical analysis of SLPI expression. Biopsies were evaluated by an expert pathologist and classified as low-grade AIN1, high-grade AIN2/3, or normal squamous epithelium. In addition, DNA from the biopsies was extracted and analyzed for the presence of low- or high-risk HPV DNA.Results:Histologically, normal squamous epithelium from the anorectal region showed strong positive SLPI staining in 17/20 (85%) samples. In comparison, 9/17 (53%) dysplastic squamous epithelial samples from AIN1 patients showed strong SLPI staining, and only 5/17 (29%) samples from AIN2/3 patients exhibited strong SPLI staining, which both were significantly fewer than those from normal tissue (P = 0.005). Furthermore, there was a significantly higher proportion of samples in which oncogenic high-risk HPV genotypes were detected in low SLPI-expressing tissues than that in tissues with high SLPI expression (P = 0.040).Conclusions:Taken together these results suggest that low SLPI expression is associated with high-risk HPV infections in the development of AIN.
C1 [Nicol, Alcina F.; Oliveira, Nathalia S.] Fundacao Oswaldo Cruz, Lab Interdisciplinary Med Res, Rio De Janeiro, Brazil.
   [Brunette, Laurie L.; Woodham, Andrew W.; Da Silva, Diane M.; Kast, W. Martin] Univ Southern Calif, Dept Obstet & Gynecol, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
   [Brunette, Laurie L.; Woodham, Andrew W.; Da Silva, Diane M.; Kast, W. Martin] Univ Southern Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA USA.
   [Nuovo, Gerard J.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Grinsztejn, Beatriz; Friedman, Ruth K.; Veloso, Valdilea G.; Cunha, Cynthia B.; Coutinho, Jose R.] Fundacao Oswaldo Cruz, LabClin DST AIDS, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [de Andrade, Cecilia Vianna] Fernandes Figueira Oswaldo Cruz Fdn, Dept Pathol, Natl Inst Women Children & Teenagers Hlth, Rio De Janeiro, Brazil.
RP Kast, WM (corresponding author), Univ Southern Calif, 1450 Biggy St, Los Angeles, CA 90033 USA.
EM martin.kast@med.usc.edu
RI Oliveira, Nathalia/M-8830-2019; ANDRADE, CECILIA/B-5916-2017
OI Oliveira, Nathalia/0000-0003-3733-0022; ANDRADE,
   CECILIA/0000-0001-7980-4367; Kast, W Martin/0000-0003-2321-3159;
   Brunette, Laurie/0000-0003-1049-764X
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 CA074397]; PAPES
   VII/CNPq-FIOCRUZ, Brazil; LIPMED-IOC-FIOCRUZ, Brazil; Proep;
   FAPERJ-Cientista do Nosso Estado, Brazil; ARCS Foundation John and Edith
   Leonis Award; SC-CTSI (NIH/NCRR/NCATS)United States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [TL1TR000132];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, R01CA074397, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, R01CA074397, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, R01CA074397,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, R01CA074397, P30CA014089, P30CA014089, R01CA074397,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, R01CA074397, P30CA014089,
   R01CA074397, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, R01CA074397, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, R01CA074397,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, R01CA074397, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, R01CA074397, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, R01CA074397,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   R01CA074397, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, R01CA074397, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, R01CA074397, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, R01CA074397, P30CA014089,
   P30CA014089, R01CA074397, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   R01CA074397, P30CA014089, R01CA074397, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, R01CA074397, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, R01CA074397,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, P30CA014089, P30CA014089, P30CA014089, P30CA014089,
   P30CA014089, R01CA074397, P30CA014089] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [TL1TR000132, TL1TR000132, TL1TR000132] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH
   RePORTER
FX Supported by National Institutes of Health Grant R01 CA074397 to W.M.K.,
   who also holds the Walter A. Richter Cancer Research Chair. A.F.N. was a
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq-CSF)
   scholar and received support from PAPES VII/CNPq-FIOCRUZ, Brazil and
   LIPMED-IOC-FIOCRUZ, Brazil. B.G. received support from Proep and
   FAPERJ-Cientista do Nosso Estado, Brazil. A.W.W. received support from
   the ARCS Foundation John and Edith Leonis Award and a SC-CTSI
   (NIH/NCRR/NCATS) Grant #TL1TR000132.
CR ABE T, 1991, J CLIN INVEST, V87, P2207, DOI 10.1172/JCI115255
   Bingle CD, 2008, TRENDS IMMUNOL, V29, P444, DOI 10.1016/j.it.2008.07.001
   Campbell CMP, 2013, J IMMUNOL METHODS, V400, P117, DOI 10.1016/j.jim.2013.10.005
   Cordes C, 2011, INT J ONCOL, V39, P185, DOI 10.3892/ijo.2011.1006
   Pires ARC, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-14
   DALING JR, 1992, AM J EPIDEMIOL, V135, P180, DOI 10.1093/oxfordjournals.aje.a116270
   Drannik AG, 2011, BIOCHEM SOC T, V39, P1427, DOI 10.1042/BST0391427
   Dreier R, 1998, HISTOCHEM CELL BIOL, V110, P137, DOI 10.1007/s004180050275
   FRANKEN C, 1989, J HISTOCHEM CYTOCHEM, V37, P493, DOI 10.1177/37.4.2926127
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Hiemstra PS, 2002, BIOCHEM SOC T, V30, P116, DOI 10.1042/bst0300116
   Hiemstra PS, 1996, INFECT IMMUN, V64, P4520, DOI 10.1128/IAI.64.11.4520-4524.1996
   Hoffmann M, 2013, ONCOL REP, V29, P1962, DOI 10.3892/or.2013.2327
   Kido H, 2007, CURR PHARM DESIGN, V13, P405, DOI 10.2174/138161207780162971
   Konopka K, 1999, J DENT RES, V78, P1773, DOI 10.1177/00220345990780120201
   KRAMPS JA, 1984, AM REV RESPIR DIS, V129, P959
   Lin AL, 2004, J ORAL PATHOL MED, V33, P410, DOI 10.1111/j.1600-0714.2004.00218.x
   Ma G, 2004, J EXP MED, V200, P1337, DOI 10.1084/jem.20041115
   Martin F, 2001, SEX TRANSM INFECT, V77, P327, DOI 10.1136/sti.77.5.327
   Mcnairn AJ, 2011, EUR J DERMATOL, V21, P21, DOI 10.1684/ejd.2011.1267
   McNeely TB, 1997, BLOOD, V90, P1141, DOI 10.1182/blood.V90.3.1141.1141_1141_1149
   Mitchell CM, 2008, AIDS RES HUM RETROV, V24, P667, DOI [10.1089/aid.2007.0268, 10.1089/aid.2008.0268]
   Moriyama A, 1999, MOL HUM REPROD, V5, P656, DOI 10.1093/molehr/5.7.656
   Morrison C, 2014, JAIDS-J ACQ IMM DEF, V66, P109, DOI 10.1097/QAI.0000000000000103
   Moutsopoulos NM, 2007, AM J PATHOL, V171, P571, DOI 10.2353/ajpath.2007.061006
   Nicol AF, 2006, EXP MOL PATHOL, V81, P42, DOI 10.1016/j.yexmp.2006.01.002
   Nicol AF, 2005, DIAGN MOL PATHOL, V14, P39, DOI 10.1097/01.pas.0000143309.81183.6c
   Nittayananta W, 2013, J ORAL PATHOL MED, V42, P208, DOI 10.1111/jop.12023
   NUOVO GJ, 1993, AM J PATHOL, V143, P40
   Park LS, 2016, AIDS, V30, P273, DOI 10.1097/QAD.0000000000000922
   Pushpanshu K, 2014, INDIAN J PALLIAT CAR, V20, P26, DOI 10.4103/0973-1075.125551
   Quabius ES, 2015, CANCER LETT, V357, P339, DOI 10.1016/j.canlet.2014.11.043
   Quabius ES, 2014, INT J CANCER, V134, P1323, DOI 10.1002/ijc.28462
   Sachdeva N, 2008, AM J REPROD IMMUNOL, V60, P264, DOI 10.1111/j.1600-0897.2008.00627.x
   Schofield AM, 2016, AIDS, V30, P1375, DOI 10.1097/QAD.0000000000001045
   Scott A, 2011, BIOCHEM SOC T, V39, P1437, DOI 10.1042/BST0391437
   Skeate JG, 2016, J GEN VIROL, V97, P422, DOI 10.1099/jgv.0.000341
   Skott P, 2002, ORAL DIS, V8, P160, DOI 10.1034/j.1601-0825.2002.01807.x
   Stanley MA, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-398
   Stier EA, 2015, AM J OBSTET GYNECOL, V213, P278, DOI 10.1016/j.ajog.2015.03.034
   Tugizov SM, 2011, VIROLOGY, V409, P211, DOI 10.1016/j.virol.2010.10.004
   Wahl S M, 1997, Oral Dis, V3 Suppl 1, pS64
   WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592
   Woodham AW, 2015, J ANTIMICROB CHEMOTH, V70, P1686, DOI 10.1093/jac/dkv045
   Woodham AW, 2014, J IMMUNOL, V192, P4748, DOI 10.4049/jimmunol.1303190
   Woodham AW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043519
NR 46
TC 6
Z9 7
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD SEP 1
PY 2016
VL 73
IS 1
BP 27
EP 33
DI 10.1097/QAI.0000000000001049
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DW3SQ
UT WOS:000383563500006
PM 27149102
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Cohen, MS
   Chen, YQ
   McCauley, M
   Gamble, T
   Hosseinipour, MC
   Kumarasamy, N
   Hakim, JG
   Kumwenda, J
   Grinsztejn, B
   Pilotto, JHS
   Godbole, SV
   Chariyalertsak, S
   Santos, BR
   Mayer, KH
   Hoffman, IF
   Eshleman, SH
   Piwowar-Manning, E
   Cottle, L
   Zhang, XC
   Makhema, J
   Mills, LA
   Panchia, R
   Faesen, S
   Eron, J
   Gallant, J
   Havlir, D
   Swindells, S
   Elharrar, V
   Burns, D
   Taha, TE
   Nielsen-Saines, K
   Celentano, DD
   Essex, M
   Hudelson, SE
   Redd, AD
   Fleming, TR
AF Cohen, M. S.
   Chen, Y. Q.
   McCauley, M.
   Gamble, T.
   Hosseinipour, M. C.
   Kumarasamy, N.
   Hakim, J. G.
   Kumwenda, J.
   Grinsztejn, B.
   Pilotto, J. H. S.
   Godbole, S. V.
   Chariyalertsak, S.
   Santos, B. R.
   Mayer, K. H.
   Hoffman, I. F.
   Eshleman, S. H.
   Piwowar-Manning, E.
   Cottle, L.
   Zhang, X. C.
   Makhema, J.
   Mills, L. A.
   Panchia, R.
   Faesen, S.
   Eron, J.
   Gallant, J.
   Havlir, D.
   Swindells, S.
   Elharrar, V.
   Burns, D.
   Taha, T. E.
   Nielsen-Saines, K.
   Celentano, D. D.
   Essex, M.
   Hudelson, S. E.
   Redd, A. D.
   Fleming, T. R.
CA HPTN 052 Study Team
TI Antiretroviral Therapy for the Prevention of HIV-1 Transmission
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID SERODISCORDANT COUPLES; RANDOMIZED-TRIAL; VIRAL LOAD; HPTN 052;
   INFECTION; POPULATION; CHALLENGES; INITIATION
AB BACKGROUND
   An interim analysis of data from the HIV Prevention Trials Network (HPTN) 052 trial showed that antiretroviral therapy (ART) prevented more than 96% of genetically linked infections caused by human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. ART was then offered to all patients with HIV-1 infection (index participants). The study included more than 5 years of follow-up to assess the durability of such therapy for the prevention of HIV-1 transmission.
   METHODS
   We randomly assigned 1763 index participants to receive either early or delayed ART. In the early-ART group, 886 participants started therapy at enrollment (CD4+ count, 350 to 550 cells per cubic millimeter). In the delayed-ART group, 877 participants started therapy after two consecutive CD4+ counts fell below 250 cells per cubic millimeter or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defining illness) developed. The primary study end point was the diagnosis of genetically linked HIV-1 infection in the previously HIV-1-negative partner in an intention-to-treat analysis.
   RESULTS
   Index participants were followed for 10,031 person-years; partners were followed for 8509 person-years. Among partners, 78 HIV-1 infections were observed during the trial (annual incidence, 0.9%; 95% confidence interval [CI], 0.7 to 1.1). Viral-linkage status was determined for 72 (92%) of the partner infections. Of these infections, 46 were linked (3 in the early-ART group and 43 in the delayed-ART group; incidence, 0.5%; 95% CI, 0.4 to 0.7) and 26 were unlinked (14 in the early-ART group and 12 in the delayed-ART group; incidence, 0.3%; 95% CI, 0.2 to 0.4). Early ART was associated with a 93% lower risk of linked partner infection than was delayed ART (hazard ratio, 0.07; 95% CI, 0.02 to 0.22). No linked infections were observed when HIV-1 infection was stably suppressed by ART in the index participant.
   CONCLUSIONS
   The early initiation of ART led to a sustained decrease in genetically linked HIV-1 infections in sexual partners. (Funded by the National Institute of Allergy and Infectious Diseases; HPTN 052 ClinicalTrials.gov number, NCT00074581.)
C1 [Cohen, M. S.; Hosseinipour, M. C.; Hoffman, I. F.; Eron, J.] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA.
   [Chen, Y. Q.; Zhang, X. C.] Fred Hutchinson Canc Res Ctr, Div Vaccine & Infect Dis, 1124 Columbia St, Seattle, WA 98104 USA.
   [Chen, Y. Q.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA.
   [Cottle, L.] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, 1124 Columbia St, Seattle, WA 98104 USA.
   [Fleming, T. R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [McCauley, M.] FHI 360, Washington, DC USA.
   [Gamble, T.] FHI 360, Durham, NC USA.
   [Kumarasamy, N.] YR Gaitonde Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
   [Godbole, S. V.] Natl AIDS Res Inst, Pune, Maharashtra, India.
   [Hakim, J. G.] Univ Zimbabwe, Harare, Zimbabwe.
   [Kumwenda, J.] Johns Hopkins Project, Coll Med, Blantyre, Malawi.
   [Grinsztejn, B.] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Pilotto, J. H. S.] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, J. H. S.] Fiocruz MS, IOC, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Santos, B. R.] Hosp Nossa Senhora Conceicao GHC, Serv Infectol, Porto Alegre, RS, Brazil.
   [Chariyalertsak, S.] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Mayer, K. H.] Fenway Inst, Boston, MA USA.
   [Essex, M.] Harvard Sch Publ Hlth, Boston, MA USA.
   [Eshleman, S. H.; Piwowar-Manning, E.; Hudelson, S. E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Redd, A. D.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Taha, T. E.] Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Celentano, D. D.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Elharrar, V.; Burns, D.] NIAID, Div Aids, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Redd, A. D.] NIAID, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Makhema, J.] Botswana Harvard AIDS Inst, Gaborone, Botswana.
   [Mills, L. A.] Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, KEMRI CDC Res & Publ Hlth Collaborat HIV Res Bran, Kisumu, Kenya.
   [Panchia, R.] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa.
   [Faesen, S.] Univ Witwatersrand, Clin HIV Res Unit, Dept Med, Fac Hlth Sci, Johannesburg, South Africa.
   [Gallant, J.] Southwest CARE Ctr, Santa Fe, NM USA.
   [Havlir, D.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Swindells, S.] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Nielsen-Saines, K.] David Geffen UCLA Sch Med, Div Infect Dis, Los Angeles, CA USA.
RP Cohen, MS (corresponding author), Univ N Carolina, Inst Global Hlth & Infect Dis, Bioinformat Bldg,2nd Fl,130 Mason Farm Rd, Chapel Hill, NC 27599 USA.
EM mscohen@med.unc.edu
RI Godbole, Sheela/K-4177-2017; Khopkar, Priyanka S/K-4159-2017; Pilotto,
   Jose Henrique/AAD-9773-2019
OI Khopkar, Priyanka S/0000-0003-3276-3881; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Kabudula,
   Chodziwadziwa/0000-0002-5867-0336; Taha, Taha/0000-0001-9814-4894;
   Nyirenda, Mulinda/0000-0003-2037-7449
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HPTN 052]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01AI068617, P30AI050410, U01AI068613, P30AI050410,
   UM1AI069456, UM1AI068613, UM1AI069424, UM1AI069518, UM1AI068617,
   UM1AI068619, P30AI050410, UM1AI068619, ZIAAI000361, UM1AI069463,
   U01AI068617, P30AI050410, P30AI050410, P30AI050410, UM1AI068613,
   UM1AI068613, P30AI050410, UM1AI068619, UM1AI069399, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069399, UM1AI069423,
   P30AI050410, UM1AI069423, U01AI068619, P30AI050410, P30AI050410,
   UM1AI069423, UM1AI068634, UM1AI069453, P30AI050410, P30AI050410,
   UM1AI069453, P30AI050410, UM1AI069423, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   UM1AI068613, P30AI050410, UM1AI068617, P30AI050410, UM1AI068617,
   P30AI050410, UM1AI069424, U01AI068613, ZIAAI000361, P30AI050410,
   P30AI050410, UM1AI069518, UM1AI069456, UM1AI069453, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, UM1AI069518,
   P30AI050410, U01AI068636, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, UM1AI069432, UM1AI069518, UM1AI069518, U01AI068617,
   P30AI050410, UM1AI069424, U01AI068617, UM1AI069399, P30AI050410,
   U01AI068619, U01AI068636, UM1AI069518, UM1AI069496, UM1AI068613,
   ZIAAI000361, UM1AI069496, P30AI050410, ZIAAI000361, UM1AI069456,
   UM1AI068619, UM1AI069463, UM1AI069463, UM1AI069424, P30AI050410,
   P30AI050410, UM1AI068617, UM1AI068613, P30AI050410, P30AI050410,
   UM1AI068617, P30AI050410, P30AI050410, UM1AI069496, P30AI050410,
   U01AI068619, P30AI050410, UM1AI068613, U01AI068619, UM1AI069424,
   P30AI050410, UM1AI068619, P30AI050410, P30AI050410, P30AI050410,
   ZIAAI000361, ZIAAI000361, P30AI050410, P30AI050410, UM1AI068619,
   P30AI050410, UM1AI069423, P30AI050410, P30AI050410, UM1AI068617,
   UM1AI069463, P30AI050410, P30AI050410, P30AI050410, UM1AI069463,
   P30AI050410, UM1AI069432, UM1AI069456, P30AI050410, P30AI050410,
   P30AI050410, UM1AI068619, U01AI068613, P30AI050410, P30AI050410,
   P30AI050410, U01AI068636, UM1AI068613, UM1AI069456, P30AI050410,
   ZIAAI000361, UM1AI068617, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, U01AI068636, ZIAAI000361, P30AI050410,
   P30AI050410, UM1AI069453, P30AI050410, UM1AI069399, UM1AI069432,
   P30AI050410, ZIAAI000361, P30AI050410, P30AI050410, P30AI050410,
   UM1AI069423, UM1AI069496, P30AI050410, U01AI068613, UM1AI069432,
   P30AI050410, UM1AI069399, UM1AI069496, UM1AI068619, P30AI050410,
   P30AI050410, P30AI050410, UM1AI069496, UM1AI069463, U01AI068613,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069456, P30AI050410,
   UM1AI068613, UM1AI069463, P30AI050410, UM1AI068619, UM1AI069424,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069456, P30AI050410,
   UM1AI069496, UM1AI069496, P30AI050410, UM1AI068617, P30AI050410,
   P30AI050410, UM1AI069453, P30AI050410, P30AI050410, P30AI050410,
   UM1AI069456, P30AI050410, P30AI050410, P30AI050410, UM1AI069496,
   P30AI050410, U01AI068636, UM1AI069432, P30AI050410, P30AI050410,
   P30AI050410, U01AI068636, P30AI050410, P30AI050410, P30AI050410,
   UM1AI068634, P30AI050410, UM1AI069399, UM1AI069423, P30AI050410,
   U01AI068619, P30AI050410, P30AI050410, P30AI050410, UM1AI069399,
   UM1AI068617, UM1AI069424, P30AI050410, UM1AI068613, P30AI050410,
   UM1AI069424, UM1AI069424, P30AI050410, P30AI050410, UM1AI069423,
   P30AI050410, UM1AI068634, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, UM1AI069518, P30AI050410, UM1AI068617,
   P30AI050410, UM1AI069432, UM1AI069496, P30AI050410, UM1AI068634,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   UM1AI068613, P30AI050410, P30AI050410, P30AI050410, UM1AI068613,
   UM1AI069424, U01AI068617, P30AI050410, UM1AI069518, UM1AI069456,
   P30AI050410, UM1AI068617, UM1AI068619, P30AI050410, UM1AI069463,
   P30AI050410, ZIAAI000361, P30AI050410, UM1AI069518, P30AI050410,
   P30AI050410, P30AI050410, UM1AI069463, P30AI050410, P30AI050410,
   U01AI068636, UM1AI069399, ZIAAI000361, UM1AI069399, UM1AI069432,
   P30AI050410, UM1AI069423, UM1AI068619, UM1AI069432, P30AI050410] Funding
   Source: NIH RePORTER
FX Funded by the National Institute of Allergy and Infectious Diseases;
   HPTN 052 ClinicalTrials.gov number, NCT00074581.
CR Anglemyer A, 2013, COCHRANE DB SYST REV, V4
   Boily MC, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001250
   Celum C, 2010, NEW ENGL J MED, V362, P427, DOI 10.1056/NEJMoa0904849
   Chen YQ, 2012, CONTEMP CLIN TRIALS, V33, P1280, DOI 10.1016/j.cct.2012.07.007
   Cohen MS, 2013, LANCET, V382, P1515, DOI 10.1016/S0140-6736(13)61998-4
   Cohen MS, 2012, CLIN TRIALS, V9, P340, DOI 10.1177/1740774512443594
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cori A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084511
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   El-Sadr WM, 2013, JAIDS-J ACQ IMM DEF, V63, pS115, DOI 10.1097/QAI.0b013e318299c3d9
   Eshleman SH, 2011, J INFECT DIS, V204, P1918, DOI 10.1093/infdis/jir651
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Hallett TB, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001123
   Hayes R, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-57
   Le T, 2013, NEW ENGL J MED, V368, P218, DOI 10.1056/NEJMoa1110187
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Muessig KE, 2014, CURR HIV-AIDS REP, V11, P434, DOI 10.1007/s11904-014-0225-9
   Ping LH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071557
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Roberts T, 2016, CLIN INFECT DIS, V62, P1043, DOI 10.1093/cid/ciw001
   Rodger A, 2016, JAMA
   Rodger AJ, 2013, AIDS, V27, P973, DOI 10.1097/QAD.0b013e32835cae9c
   Sturmer M, 2008, ANTIVIR THER, V13, P729
   UNAIDS, 2014, PEOPL LIV HIV
   UNAIDS, 2014, 90 90 90 AMB TREATM
   Vernazza PL, 2008, ANTIVIR THER, V13, P641
   World Health Organization, 2013, CONS GUID US ANT DRU
   World Health Organization, 2015, GUID START ANT THER
   World Health Organization, 2012, GUID COUPL HIV TEST
NR 29
TC 587
Z9 604
U1 6
U2 102
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 1
PY 2016
VL 375
IS 9
BP 830
EP 839
DI 10.1056/NEJMoa1600693
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA DU9HA
UT WOS:000382526000006
PM 27424812
OA Bronze, Green Accepted
DA 2020-11-24
ER

PT J
AU Mayer, KH
   Grinsztejn, B
   El-Sadr, WM
AF Mayer, Kenneth H.
   Grinsztejn, Beatriz
   El-Sadr, Wafaa M.
TI Transgender People and HIV Prevention: What We Know and What We Need to
   Know, a Call to Action
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV prevention; transgender; HIV/AIDS
ID RISK BEHAVIORS; HORMONE USE; PREEXPOSURE PROPHYLAXIS; NONTRANSGENDER
   MEN; WOMEN; HEALTH; CARE; SEX; TRANSMISSION; PREVALENCE
AB Transgender people have been disproportionally affected by HIV, particularly transgender women. Their increased vulnerability to HIV is due to multiple issues, including biological (eg, increased efficiency of HIV transmission through receptive anal sex), epidemiological (eg, increased likelihood of having HIV-infected partners), structural (eg, social stigma limiting employment options), and individual factors (eg, internalized stigma leading to depression and substance use and risk-taking behaviors). There have been limited culturally appropriate HIV prevention interventions for transgender people, with many key prevention studies (eg, the iPrEx PrEP study) enrolling transgender women in a study focusing on men who have sex with men. This has resulted in limited understanding of the optimal ways to decrease transgender people's risk for HIV acquisition. The current supplement of JAIDS is designed to review what is known about HIV prevention for transgender people and to highlight new insights and best practices. The study reviews recent epidemiologic data, the pharmacology of HIV prophylactic agents in individuals who may be using exogenous hormones, and several recent multi-component interventions designed to address the lived experience of transgender people. Additionally, the study reviews the work going on at the NIH to address transgender health in general and HIV prevention in specific, as well as two important papers related to clinical trial design issues and the ethical conduct of research in this frequently disenfranchised population. It is the hope of the HIV Prevention Trials Network (HPTN) that this supplement will promote new knowledge around transgender health and the requisite issues that need to be addressed in order to conduct optimal clinical trials. The ultimate hope is that the information distilled in this supplement will inform investigators, clinicians, and public health officials in order to design further research to develop optimal prevention interventions for transgender people and to implement these interventions in ways that are culturally congruent and health promoting.
C1 [Mayer, Kenneth H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Fenway Hlth, Boston, MA USA.
   [Grinsztejn, Beatriz] Fiocruz MS, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [El-Sadr, Wafaa M.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA.
RP Mayer, KH (corresponding author), 1340 Boylston St, Boston, MA 02215 USA.
EM kmayer@fenwayhealth.org
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; NIAIDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [3UM1AI069480-06S1, UM1 AI068619, UM1AI069476-08]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI068619,
   UM1AI068619, UM1AI068619, UM1AI069476, UM1AI068619, UM1AI069480,
   UM1AI068619, UM1AI068619, UM1AI069476, UM1AI068619, UM1AI068619,
   UM1AI069480, UM1AI068619, UM1AI069476, UM1AI068619, UM1AI069476,
   UM1AI069476, UM1AI069480, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI068619, UM1AI069476] Funding Source: NIH RePORTER
FX Funding for the work on this article was provided by NIH and NIAID
   grants 3UM1AI069480-06S1 (Clinical Trial Unit for HIV Prevention and
   Microbicide Research), UM1 AI068619 (HPTN Leadership and Operations
   Center), and UM1AI069476-08 (The Fiocruz Therapeutic and Prevention
   HIV/AIDS Clinical Trials Unit).
CR Anderson PL, 2016, JAIDS-J ACQ IMM DEF, V72, pS230, DOI 10.1097/QAI.0000000000001105
   [Anonymous], 2012, PROR UPD ANT TREATM
   Bockting WO, 1998, AIDS CARE, V10, P505, DOI 10.1080/09540129850124028
   Brennan J, 2012, AM J PUBLIC HEALTH, V102, P1751, DOI 10.2105/AJPH.2011.300433
   Castillo R, 2015, JAIDS-J ACQ IMM DEF, V69, P567, DOI 10.1097/QAI.0000000000000667
   Clements-Nolle K, 2001, AM J PUBLIC HEALTH, V91, P915, DOI 10.2105/AJPH.91.6.915
   Cohen MS, 2012, NEW ENGL J MED, V367, P459, DOI 10.1056/NEJMe1207438
   Collin L, 2016, J SEX MED, V13, P613, DOI 10.1016/j.jsxm.2016.02.001
   de Haan G, 2015, LGBT HEALTH, V2, P313, DOI 10.1089/lgbt.2014.0128
   Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4
   Garofalo R, 2016, JAIDS-J ACQ IMM DEF, V72, pS220, DOI 10.1097/QAI.0000000000001084
   Gooren LJ, 2015, CULT HEALTH SEX, V17, P92, DOI 10.1080/13691058.2014.950982
   Grant RM, 2016, JAIDS-J ACQ IMM DEF, V72, pS226, DOI 10.1097/QAI.0000000000001090
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Herbst JH, 2008, AIDS BEHAV, V12, P1, DOI 10.1007/s10461-007-9299-3
   Hotton AL, 2013, AIDS EDUC PREV, V25, P62, DOI 10.1521/aeap.2013.25.1.62
   Hughes JP, 2016, JAIDS-J ACQ IMM DEF, V72, pS248, DOI 10.1097/QAI.0000000000001077
   Hughto JMW, 2015, SOC SCI MED, V147, P222, DOI 10.1016/j.socscimed.2015.11.010
   Lurie S, 2005, INT J TRANSGENDERISM, V8, P93, DOI 10.1300/J485v08n02_09
   Mayer KH, 2015, CURR OPIN HIV AIDS, V10, P226, DOI 10.1097/COH.0000000000000170
   Melendez RM, 2009, J ASSOC NURSE AIDS C, V20, P387, DOI 10.1016/j.jana.2009.06.002
   Nemoto T, 2012, AIDS CARE, V24, P210, DOI 10.1080/09540121.2011.597709
   Opeiario D, 2008, JAIDS-J ACQ IMM DEF, V48, P97, DOI 10.1097/QAI.0b013e31816e3971
   Polis CB, 2013, AIDS, V27, P493, DOI 10.1097/QAD.0b013e32835ad539
   Poteat T, 2016, JAIDS-J ACQ IMM DEF, V72, pS210, DOI 10.1097/QAI.0000000000001087
   Poteat T, 2014, CURR OPIN HIV AIDS, V9, P168, DOI 10.1097/COH.0000000000000030
   Reisner SL, 2016, JAIDS-J ACQ IMM DEF, V72, pS235, DOI 10.1097/QAI.0000000000001088
   Reisner SL, 2016, GLOB PUBLIC HEALTH, V11, P866, DOI 10.1080/17441692.2015.1134613
   Reisner SL, 2010, AIDS PATIENT CARE ST, V24, P501, DOI 10.1089/apc.2010.0059
   Reisner SL, LANCET IN PRESS
   Rotondi NK, 2013, AM J PUBLIC HEALTH, V103, P1830, DOI 10.2105/AJPH.2013.301348
   Sanchez NF, 2009, AM J PUBLIC HEALTH, V99, P713, DOI 10.2105/AJPH.2007.132035
   Sevelius J, 2009, J ASSOC NURSE AIDS C, V20, P398, DOI 10.1016/j.jana.2009.06.001
   Singh JA, 2016, JAIDS-J ACQ IMM DEF, V72, pS252, DOI 10.1097/QAI.0000000000001089
   Siskind RL, 2016, JAIDS-J ACQ IMM DEF, V72, pS243, DOI 10.1097/QAI.0000000000001085
   Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003
NR 36
TC 17
Z9 17
U1 1
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 15
PY 2016
VL 72
SU 3
BP S207
EP S209
DI 10.1097/QAI.0000000000001086
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY6YM
UT WOS:000385275700001
PM 27429184
OA Green Published
DA 2020-11-24
ER

PT J
AU Diaz, CM
   Segura, ER
   Luz, PM
   Clark, JL
   Ribeiro, SR
   De Boni, R
   Eksterman, L
   Moreira, R
   Currier, JS
   Veloso, VG
   Grinsztejn, B
   Lake, JE
AF Diaz, Chanelle M.
   Segura, Eddy R.
   Luz, Paula M.
   Clark, Jesse L.
   Ribeiro, Sayonara R.
   De Boni, Raquel
   Eksterman, Leonardo
   Moreira, Rodrigo
   Currier, Judith S.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Lake, Jordan E.
TI Traditional and HIV-specific risk factors for cardiovascular morbidity
   and mortality among HIV-infected adults in Brazil: a retrospective
   cohort study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV; AIDS; Cardiovascular disease; Antiretroviral therapy; Brazil
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE MYOCARDIAL-INFARCTION;
   CORONARY-HEART-DISEASE; COMBINATION ANTIRETROVIRAL THERAPY;
   RIO-DE-JANEIRO; IMMUNE ACTIVATION; VENOUS THROMBOEMBOLISM;
   CEREBROVASCULAR EVENTS; PROTEASE INHIBITORS; EXPOSURE
AB Background: Antiretroviral therapy (ART) agents potentially associated with adverse metabolic profiles are commonly used in low-and middle-income countries. We assessed risk factors for cardiovascular disease (CVD)-related morbidity and mortality in a cohort of HIV-infected, ART-treated adults in Rio de Janeiro, Brazil.
   Methods: Hospital records and mortality data between 2000-2010 were examined for incident CVD-related ICD-10 and Coding of Death in HIV diagnoses among adults >= 18 years old on ART, enrolled in an observational cohort. Poisson regression models assessed associations between demographic and clinical characteristics and ART agent or class on CVD event risk.
   Results: Of 2960 eligible persons, 109 had a CVD event (89 hospitalizations, 20 deaths). Participants were 65 % male, 54 % white, and had median age of 37 and 4.6 years on ART. The median nadir CD4(+) T lymphocyte count was 149 cells/mm(3). The virologic suppression rate at the end of study follow-up was 60 %. In multivariable models, detectable HIV-1 RNA prior to the event, prior CVD, less time on ART, age >= 40 at study baseline, nadir CD4(+) T lymphocyte count <= 50 cells/mm(3), non-white race, male gender, and a history of hypertension were significantly associated with CVD event incidence (p < 0.05), in order of decreasing strength. In multivariate models, cumulative use of tenofovir, zidovudine, efavirenz and ritonavir-boosted atazanavir, darunavir and/or lopinavir were associated with decreased CVD event risk. Recent tenofovir and boosted atazanavir use were associated with decreased risk, while recent stavudine, nevirapine and unboosted nelfinavir and/or indinavir use were associated with increased CVD event risk.
   Conclusions: Virologic suppression and preservation of CD4(+) T-lymphocyte counts were as important as traditional CVD risk factor burden in determining incident CVD event risk, emphasizing the overall benefit of ART on CVD risk and the need for metabolically-neutral first-and second-line ART in resource-limited settings.
C1 [Diaz, Chanelle M.; Segura, Eddy R.; Clark, Jesse L.; Currier, Judith S.; Lake, Jordan E.] Univ Calif Los Angeles, David Geffen Sch Med, 11075 Santa Monica Blvd St 100, Los Angeles, CA 90025 USA.
   [Diaz, Chanelle M.] Albert Einstein Coll Med, Montefiore Univ Hosp, Bronx, NY 10467 USA.
   [Luz, Paula M.; Ribeiro, Sayonara R.; De Boni, Raquel; Eksterman, Leonardo; Moreira, Rodrigo; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
RP Lake, JE (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, 11075 Santa Monica Blvd St 100, Los Angeles, CA 90025 USA.
EM JLake@mednet.ucla.edu
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Segura, Eddy
   R/0000-0003-3580-7712; Luz, Paula/0000-0001-9746-719X; Clark,
   Jesse/0000-0001-5862-6530
FU South American Program in HIV Prevention Research (SAPHIR) [NIH R25
   MH087222]; Infectious Diseases Society of America Medical Scholars
   Program; NIH-funded Caribbean, Central and South America network;  [K23
   AI110532]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069476, U01AI069923, K23AI110532, U01AI069923,
   U01AI069923, K23AI110532, U01AI069923, U01AI069923, U01AI069923,
   UM1AI069476, K23AI110532, U01AI069923, UM1AI069476, U01AI069923,
   K23AI110532, K23AI110532, U01AI069923, UM1AI069476, UM1AI069476,
   U01AI069923, U01AI069923, U01AI069923, K23AI110532, U01AI069923,
   U01AI069923, U01AI069923, UM1AI069476, U01AI069923, UM1AI069476,
   U01AI069923, UM1AI069476, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, UM1AI069476, U01AI069923, U01AI069923] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, R25MH087222, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, R25MH087222, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107] Funding Source: NIH
   RePORTER
FX Support for CD provided by the South American Program in HIV Prevention
   Research (SAPHIR: NIH R25 MH087222) and the Infectious Diseases Society
   of America Medical Scholars Program. JEL is supported by K23 AI110532.
   This work was also supported in part by the NIH-funded Caribbean,
   Central and South America network for HIV epidemiology (CCASAnet), a
   member cohort of the International Epidemiologic Databases to Evaluate
   AIDS (IeDEA) (U01AI069923).
CR Aberg JA, 2010, J INFECT DIS, V201, P315, DOI 10.1086/649898
   Alencastro PR, 2012, AIDS RES THER, V9, DOI 10.1186/1742-6405-9-29
   Araujo DV, 2013, THESCIENTIFICWORLDJO, V2013, DOI DOI 10.1155/2013/864962
   Bavinger C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059551
   Becattini C, 2005, EUR HEART J, V26, P77, DOI 10.1093/eurheartj/ehi018
   Bedimo RJ, 2011, CLIN INFECT DIS, V53, P84, DOI 10.1093/cid/cir269
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bilora F, 2016, INT ANGIOL
   Bloomfield GS, 2014, JAIDS-J ACQ IMM DEF, V67, pS40, DOI 10.1097/QAI.0000000000000257
   Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048
   Brouwer ES, 2014, EPIDEMIOLOGY, V25, P406, DOI 10.1097/EDE.0000000000000041
   Burdo TH, 2011, J INFECT DIS, V204, P1227, DOI 10.1093/infdis/jir520
   Cahn P, 2010, BRAZ J INFECT DIS, V14, P158, DOI 10.1590/S1413-86702010000200008
   Choi AI, 2011, AIDS, V25, P1289, DOI 10.1097/QAD.0b013e328347fa16
   Cole SR, 2010, AM J EPIDEMIOL, V171, P198, DOI 10.1093/aje/kwp347
   Crabtree-Ramirez B, 2014, JAIDS-J ACQ IMM DEF, V67, pS96, DOI 10.1097/QAI.0000000000000261
   Crum-Cianflone NF, 2008, AIDS PATIENT CARE ST, V22, P771, DOI 10.1089/apc.2008.0010
   Currier JS, 2003, JAIDS-J ACQ IMM DEF, V33, P506, DOI 10.1097/00126334-200308010-00012
   Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7
   Desai M, 2015, CLIN INFECT DIS, V61, P445, DOI 10.1093/cid/civ316
   Drozd D, 2015, TOP ANTIVIR MED, P23
   Fitch KV, 2013, J INFECT DIS, V208, P1737, DOI 10.1093/infdis/jit508
   Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993
   Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010
   Fultz SL, 2004, AM J MED, V116, P420, DOI 10.1016/j.amjmed.2003.10.011
   Funderburg NT, 2014, THROMB RES, V133, pS21, DOI 10.1016/j.thromres.2014.03.012
   Funderburg NT, 2012, BLOOD, V120, P4599, DOI 10.1182/blood-2012-05-433946
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Hattab S, 2015, HIV MED, V16, P553, DOI 10.1111/hiv.12257
   Iloeje UH, 2005, HIV MED, V6, P37, DOI 10.1111/j.1468-1293.2005.00265.x
   Independent Task Force, 2014, EM GLOB HLTH CRIS NO
   Kelesidis T, 2015, CLIN INFECT DIS, V61, P651, DOI 10.1093/cid/civ327
   Klein D, 2002, J ACQ IMMUN DEF SYND, V30, P471, DOI 10.1097/00126334-200208150-00002
   Klein SK, 2005, NETH J MED, V63, P129
   Kowalska JD, 2011, EPIDEMIOLOGY, V22, P516, DOI 10.1097/EDE.0b013e31821b5332
   Kwong GPS, 2006, AIDS, V20, P1941, DOI 10.1097/01.aids.0000247115.81832.a1
   Lake JE, 2013, LANCET INFECT DIS, V13, P964, DOI 10.1016/S1473-3099(13)70271-8
   Lang S, 2012, CLIN INFECT DIS, V55, P600, DOI 10.1093/cid/cis489
   Lang S, 2010, ARCH INTERN MED, V170, P1228, DOI 10.1001/archinternmed.2010.197
   Lang S, 2010, AIDS, V24, P1228, DOI 10.1097/QAD.0b013e328339192f
   Lichtenstein KA, 2010, CLIN INFECT DIS, V51, P435, DOI 10.1086/655144
   Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010
   Ministerio da Saude. Pesquisa Nacional de Saude, 2013, PERC EST SAUD EST VI
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Newson RB, 2010, STATA J, V10, P568, DOI 10.1177/1536867X1101000403
   O'Halloran JA, 2015, HIV MED, V16, P608, DOI 10.1111/hiv.12270
   Obel N, 2010, HIV MED, V11, P130, DOI 10.1111/j.1468-1293.2009.00751.x
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249
   Paisible AL, 2015, JAIDS-J ACQ IMM DEF, V68, P209, DOI 10.1097/QAI.0000000000000419
   Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636
   Phillips AN, 2008, ANTIVIR THER, V13, P177
   Prandoni P, 2009, EUR J INTERN MED, V20, P660, DOI 10.1016/j.ejim.2009.02.001
   Ribeiro SR, 2014, ANTIVIR THER, V19, P387, DOI 10.3851/IMP2716
   Rose KAM, 2016, JAIDS-J ACQ IMM DEF, V71, P514, DOI 10.1097/QAI.0000000000000900
   Sabin CA, 2008, LANCET, V371, P1417, DOI 10.1016/S0140-6736(08)60423-7
   Smith CJ, 2014, LANCET, V384, P241, DOI 10.1016/S0140-6736(14)60604-8
   Sorensen HT, 2007, LANCET, V370, P1773, DOI 10.1016/S0140-6736(07)61745-0
   Torres TS, 2014, BRAZ J INFECT DIS, V18, P34, DOI 10.1016/j.bjid.2013.04.005
   Torriani FJ, 2008, J AM COLL CARDIOL, V52, P569, DOI 10.1016/j.jacc.2008.04.049
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   Triant VA, 2014, REV CARDIOVASC MED, V15, pS1
   Triant VA, 2010, JAIDS-J ACQ IMM DEF, V55, P615, DOI 10.1097/QAI.0b013e3181f4b752
   Vaughn G, 2007, AIDS CARE, V19, P492, DOI 10.1080/09540120701203329
   Wada NI, 2015, AIDS, V29, P463, DOI 10.1097/QAD.0000000000000545
   Worm SW, 2010, J INFECT DIS, V201, P318, DOI 10.1086/649897
   Young J, 2015, JAIDS-J ACQ IMM DEF, V69, P413, DOI 10.1097/QAI.0000000000000662
   Zanni MV, 2012, CURR HIV-AIDS REP, V9, P200, DOI 10.1007/s11904-012-0123-y
NR 69
TC 13
Z9 14
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD AUG 8
PY 2016
VL 16
AR 376
DI 10.1186/s12879-016-1735-4
PG 13
WC Infectious Diseases
SC Infectious Diseases
GA DS7XU
UT WOS:000380997300001
PM 27503230
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Adachi, K
   Klausner, JD
   Xu, JH
   Ank, B
   Bristow, CC
   Morgado, MG
   Watts, DH
   Weir, F
   Persing, D
   Mofenson, LM
   Veloso, VG
   Pilotto, JH
   Joao, E
   Gray, G
   Theron, G
   Santos, B
   Fonseca, R
   Kreitchmann, R
   Pinto, J
   Mussi-Pinhata, MM
   Ceriotto, M
   Machado, DM
   Bryson, YJ
   Grinsztejn, B
   Bastos, FI
   Siberry, G
   Nielsen-Saines, K
AF Adachi, Kristina
   Klausner, Jeffrey D.
   Xu, Jiahong
   Ank, Bonnie
   Bristow, Claire C.
   Morgado, Mariza G.
   Watts, D. Heather
   Weir, Fred
   Persing, David
   Mofenson, Lynne M.
   Veloso, Valdilea G.
   Pilotto, Jose Henrique
   Joao, Esau
   Gray, Glenda
   Theron, Gerhard
   Santos, Breno
   Fonseca, Rosana
   Kreitchmann, Regis
   Pinto, Jorge
   Mussi-Pinhata, Marisa M.
   Ceriotto, Mariana
   Machado, Daisy Maria
   Bryson, Yvonne J.
   Grinsztejn, Beatriz
   Bastos, Francisco I.
   Siberry, George
   Nielsen-Saines, Karin
CA NICHD HPTN 040 Study Team
TI Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-infected Pregnant
   Women and Adverse Infant Outcomes
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE HIV; pregnancy; chlamydia; gonorrhea; sexually transmitted infections;
   adverse infant outcomes
ID ACTIVE ANTIRETROVIRAL THERAPY; PRETERM BIRTH; PERINATAL-MORTALITY;
   ASSOCIATION; CHILDREN; SYPHILIS; TRANSMISSION; METAANALYSIS; MORBIDITY;
   DISEASE
AB Background: Sexually transmitted infections (STIs) in pregnancy such as Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) may lead to adverse infant outcomes.
   Methods: Individual urine specimens from HIV-infected pregnant women diagnosed with HIV during labor were collected at the time of infant birth and tested by polymerase chain reaction for CT and NG. Infant HIV infection was determined at 3 months with morbidity/mortality assessed through 6 months.
   Results: Of 1373 maternal urine samples, 277 (20.2%) were positive for CT and/or NG; 249 (18.1%) for CT, 63 (4.6%) for NG and 35 (2.5%) for both CT and NG. HIV infection was diagnosed in 117 (8.5%) infants. Highest rates of adverse outcomes (sepsis, pneumonia, congenital syphilis, septic arthritis, conjunctivitis, low birth weight, preterm delivery and death) were noted in infants of women with CT and NG (23/35, 65.7%) compared with NG (16/28, 57.1%), CT (84/214, 39.3%) and no STI (405/1096, 37%, P = 0.001). Death (11.4% vs. 3%, P = 0.02), low birth weight (42.9% vs. 16.9%, P = 0.001) and preterm delivery (28.6% vs. 10.2%, P = 0.008) were higher among infants of CT and NG-coinfected women. Infants who had any adverse outcome and were born to women with CT and/or NG were 3.5 times more likely to be HIV infected after controlling for maternal syphilis (odds ratio: 3.5, 95% confidence interval: 1.4-8.3). By adjusted multivariate logistic regression, infants born to mothers with any CT and/or NG were 1.35 times more likely to have an adverse outcome (odds ratio, 1.35; 95% confidence interval, 1.03-1.76).
   Conclusions: STIs in HIV-infected pregnant women are associated with adverse outcomes in HIV-exposed infected and uninfected infants.
C1 [Adachi, Kristina; Klausner, Jeffrey D.; Ank, Bonnie; Bryson, Yvonne J.; Nielsen-Saines, Karin] David Geffen UCLA Sch Med, Los Angeles, CA USA.
   [Klausner, Jeffrey D.; Bristow, Claire C.] UCLA Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA.
   [Xu, Jiahong] WESTAT Corp, Rockville, MD 20850 USA.
   [Morgado, Mariza G.; Veloso, Valdilea G.; Grinsztejn, Beatriz; Bastos, Francisco I.] Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, Brazil.
   [Watts, D. Heather] US Dept State, Off Global AIDS Coordinator, Washington, DC 20520 USA.
   [Weir, Fred; Persing, David] Cepheid, Sunnyvale, CA USA.
   [Mofenson, Lynne M.; Siberry, George] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, DST AIDS, Rio De Janeiro, Brazil.
   [Joao, Esau] Hosp Fed Servidores Estado, Rio De Janeiro, Brazil.
   [Gray, Glenda] Univ Witwatersrand, SAMRC, Cape Town, South Africa.
   [Gray, Glenda] Univ Witwatersrand, Perinatal HIV Res Unit, Cape Town, South Africa.
   [Theron, Gerhard] Univ Stellenbosch, Tygerberg Hosp, Dept Obstet & Gynecol, Cape Town, South Africa.
   [Santos, Breno] Hosp Conceicao, Serv Infectol, Porto Alegre, RS, Brazil.
   [Fonseca, Rosana] Hosp Femina, Porto Alegre, RS, Brazil.
   [Kreitchmann, Regis] Irmandade Santa Casa de Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Dept Pediat, Belo Horizonte, MG, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Sao Paulo, Brazil.
   [Ceriotto, Mariana] Fdn Maternal & Infant Hlth FUNDASAMIN, Buenos Aires, DF, Argentina.
   [Machado, Daisy Maria] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
RP Adachi, K (corresponding author), David Geffen Sch Med UCLA, Dept Pediat, Div Infect Dis, 10833 Conte Ave,MDCC 22-442, Los Angeles, CA 90095 USA.
EM kadachi@mednet.ucla.edu
RI Mofenson, Lynne/P-9631-2019; Mussi-Pinhata, Marisa/G-6568-2012; Pilotto,
   Jose Henrique/AAD-9773-2019; Pinto, Jorge A/D-1743-2014
OI Mofenson, Lynne/0000-0002-2818-9808; Mussi-Pinhata,
   Marisa/0000-0001-8985-1570; Pilotto, Jose Henrique/0000-0003-0521-8597;
   Pinto, Jorge A/0000-0003-2987-3238; Machado, Daisy/0000-0003-1993-6442;
   Joao, Esau/0000-0002-2412-0627; Kreitchmann, Regis/0000-0002-1146-0497;
   Bastos, Francisco/0000-0001-5970-8896
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [HHSN267200800001C, N01-HD-8-0001, U01 AI047986]; National Institute of
   Allergy and Infectious Diseases (NIAID)/NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID); National
   Institutes of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [NIAIDU01 AI068632,
   UM1AI068632, UM1AI068616, UM1AI106716]; Eunice Kennedy Shriver National
   Institute of Child Health and Human Development (NICHD)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD); National Institute of Mental HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH)
   [AI068632]; Boehringer Ingelheim Pharmaceuticals Inc. (BIPI)Boehringer
   Ingelheim; GlaxoSmithKline on behalf of ViiV Healthcare; Cepheid,
   Sunnyvale, CA; UCLA Center for AIDS Research (CFAR) NIH/NIAIDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [AI028697]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI047986, UM1AI068616,
   P30AI028697, UM1AI106716, P30AI028697, UM1AI069453, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069476, UM1AI069476, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI069476,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068616, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI106716, UM1AI106716, P30AI028697, P30AI028697, P30AI028697,
   UM1AI106716, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069476, UM1AI069453, P30AI028697, U01AI047986, P30AI028697,
   P30AI028697, UM1AI069476, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068632, UM1AI106716, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, U01AI068632, UM1AI068632, U01AI047986, P30AI028697,
   U01AI047986, P30AI028697, UM1AI068616, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068632,
   UM1AI106716, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069453, UM1AI068616, P30AI028697, UM1AI069476, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI068616, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI068616, P30AI028697,
   UM1AI106716, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI069453, P30AI028697, P30AI028697, UM1AI069476, U01AI047986,
   UM1AI069476, P30AI028697, P30AI028697, P30AI028697, UM1AI106716,
   U01AI047986, UM1AI068632, U01AI047986, P30AI028697, P30AI028697,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   U01AI068632, P30AI028697, UM1AI106716, UM1AI069476, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, UM1AI068632, P30AI028697, UM1AI068632, P30AI028697,
   P30AI028697, P30AI028697, U01AI068632, UM1AI068632, P30AI028697,
   P30AI028697, UM1AI069453, U01AI068632, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   UM1AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI069453, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, UM1AI068616,
   U01AI068632, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   U01AI068632, P30AI028697, P30AI028697, UM1AI068632, P30AI028697,
   U01AI068632, P30AI028697, P30AI028697, UM1AI068616, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI069453, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, U01AI068632,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, UM1AI068632, P30AI028697,
   U01AI047986, UM1AI069453, P30AI028697, UM1AI069453, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697] Funding
   Source: NIH RePORTER
FX The NICHD HPTN 040 study was supported by NICHD Contract #
   HHSN267200800001C (NICHD Control # N01-HD-8-0001) and U01 AI047986
   (Brazilian AIDS Prevention Trials International Network), National
   Institute of Allergy and Infectious Diseases (NIAID)/NIH. Overall
   support for the International Maternal Pediatric Adolescent AIDS
   Clinical Trials Group (IMPAACT) was provided by the National Institute
   of Allergy and Infectious Diseases (NIAID) of the National Institutes of
   Health (NIH) under Award Numbers NIAIDU01 AI068632, UM1AI068632 (IMPAACT
   LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with
   co-funding from the Eunice Kennedy Shriver National Institute of Child
   Health and Human Development (NICHD) and the National Institute of
   Mental Health (NIMH (AI068632). In addition, the parent study was
   supported in part by Boehringer Ingelheim Pharmaceuticals Inc. (BIPI),
   and GlaxoSmithKline on behalf of ViiV Healthcare. The authors meet
   criteria for authorship as recommended by the International Committee of
   Medical Journal Editors (ICMJE) and were fully responsible for all
   aspects of manuscript development. This particular sub-study was
   supported by Cepheid, Sunnyvale, CA, where CT and NG testing of
   specimens was performed. Support was also provided by the UCLA Center
   for AIDS Research (CFAR) NIH/NIAID AI028697. Support for Kristina
   Adachi's work on this sub-study was also provided in part by the UCLA
   Children's Discovery and Innovation Institute (CDI). The content,
   conclusions and opinions expressed in this article are those of the
   authors and do not necessarily represent those of the National
   Institutes of Health, the U.S. Department of Health and Human Services,
   or the U.S. Department of State, affiliated universities, programs or
   companies of the authors.
CR Adachi K, 2015, SEX TRANSM DIS, V42, P554, DOI 10.1097/OLQ.0000000000000340
   Andrews WW, 2006, AM J OBSTET GYNECOL, V194, P493, DOI 10.1016/j.ajog.2005.08.054
   Andrews WW, 2000, AM J OBSTET GYNECOL, V183, P662, DOI 10.1067/mob.2000.106556
   Bias MM, 2007, SEX TRANSM INFECT, V83, DOI 10.1136/sti.2006.022665
   Bouwhuis SA, 2004, INT J DERMATOL, V43, P27, DOI 10.1111/j.1365-4632.2004.01841.x
   Brahmbhatt H, 2006, JAIDS-J ACQ IMM DEF, V41, P504, DOI 10.1097/01.qai.0000188122.15493.0a
   Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/j.1471-0528.1998.tb10227.x
   Chen JY, 2012, J INFECT DIS, V206, P1695, DOI 10.1093/infdis/jis553
   COHEN I, 1990, JAMA-J AM MED ASSOC, V263, P3160, DOI 10.1001/jama.263.23.3160
   DONDERS GGG, 1993, GENITOURIN MED, V69, P98
   GENCAY M, 1995, CLIN INFECT DIS, V21, P424, DOI 10.1093/clinids/21.2.424
   Goldenberg RL, 2006, AM J OBSTET GYNECOL, V194, P650, DOI 10.1016/j.ajog.2006.01.004
   Goldenberg RL, 2006, AM J OBSTET GYNECOL, V195, P1065, DOI 10.1016/j.ajog.2006.05.046
   Gomez GB, 2013, B WORLD HEALTH ORGAN, V91, P217, DOI 10.2471/BLT.12.107623
   Gray RH, 2001, AM J OBSTET GYNECOL, V185, P1209, DOI 10.1067/mob.2001.118158
   Hammerschlag MR, 2011, CLIN INFECT DIS, V53, pS99, DOI 10.1093/cid/cir699
   Howson C. P., 2012, BORN TOO SOON GLOBAL
   Kapogiannis BG, 2011, CLIN INFECT DIS, V53, P1024, DOI 10.1093/cid/cir641
   Kim HY, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-138
   Kourtis AP, 2013, AIDS, V27, P749, DOI 10.1097/QAD.0b013e32835ca29f
   Kovacs L, 1998, INT J GYNECOL OBSTET, V62, P47, DOI 10.1016/S0020-7292(98)00075-7
   Koyanagi A, 2011, PEDIATR INFECT DIS J, V30, P45, DOI 10.1097/INF.0b013e3181ecbf7e
   Kuznik A, 2015, SEX TRANSM DIS, V42, P369, DOI 10.1097/OLQ.0000000000000291
   Lawn JE, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-S1-S1
   Marazzi MC, 2011, AIDS, V25, P1611, DOI 10.1097/QAD.0b013e3283493ed0
   Martin D H, 1997, Infect Dis Obstet Gynecol, V5, P10, DOI 10.1002/(SICI)1098-0997(1997)5:1<10::AID-IDOG5>3.0.CO;2-I
   MARTIN DH, 1982, JAMA-J AM MED ASSOC, V247, P1585, DOI 10.1001/jama.247.11.1585
   MCGREGOR JA, 1990, AM J OBSTET GYNECOL, V163, P1580, DOI 10.1016/0002-9378(90)90632-H
   Mussi-Pinhata MM, 2007, PEDIATRICS, V119, pE694, DOI 10.1542/peds.2006-1856
   Newell ML, 2003, PEDIATRICS, V111
   Nielsen-Saines K, 2011, 3 PED HIV C ROM IT
   Nielsen-Saines K, 2012, NEW ENGL J MED, V366, P2368, DOI 10.1056/NEJMoa1108275
   Nielsen-Saines K, 2012, PEDIATRICS, V129, pE1525, DOI 10.1542/peds.2011-2340
   Owor M, 2013, JAIDS-J ACQ IMM DEF, V64, P464, DOI 10.1097/QAI.0000000000000015
   Panaretto KS, 2006, AUST NZ J OBSTET GYN, V46, P217, DOI 10.1111/j.1479-828X.2006.00577.x
   Silva MJPMD, 2011, BRAZ J INFECT DIS, V15, P533, DOI 10.1590/S1413-86702011000600006
   Rollins NC, 2007, JAIDS-J ACQ IMM DEF, V44, P321, DOI 10.1097/QAI.0b013e31802ea4b0
   RYAN GM, 1990, AM J OBSTET GYNECOL, V162, P34, DOI 10.1016/0002-9378(90)90815-O
   Silveira MF, 2009, INT J STD AIDS, V20, P465, DOI 10.1258/ijsa.2008.008388
   Turner AN, 2013, JAIDS-J ACQ IMM DEF, V64, P392, DOI 10.1097/QAI.0b013e3182a2d13c
   WHO, 2012, GLOB INC PREV SEL CU
   Woods Charles R, 2005, Semin Pediatr Infect Dis, V16, P258, DOI 10.1053/j.spid.2005.06.006
   World Health Organization, 2006, GLOB STRAT PREV CONT
   Yeganeh N, 2015, PEDIATR INFECT DIS J, V34, pE52, DOI 10.1097/INF.0000000000000578
NR 44
TC 15
Z9 16
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD AUG
PY 2016
VL 35
IS 8
BP 894
EP 900
DI 10.1097/INF.0000000000001199
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA DS4MK
UT WOS:000380755000018
PM 27164464
OA Green Accepted, Green Published
DA 2020-11-24
ER

PT J
AU Pacheco, AG
   Grinsztejn, B
   da Fonseca, MDM
   Griep, RH
   Lotufo, P
   Bensenor, I
   Mill, JG
   Moreira, RD
   Moreira, RI
   Friedman, RK
   Santini-Oliveira, M
   Cardoso, SW
   Veloso, VG
   Chor, D
AF Pacheco, Antonio G.
   Grinsztejn, Beatriz
   da Fonseca, Maria de Jesus M.
   Griep, Rosane Harter
   Lotufo, Paulo
   Bensenor, Isabela
   Mill, Jose G.
   Moreira, Rodrigo de C.
   Moreira, Ronaldo I.
   Friedman, Ruth K.
   Santini-Oliveira, Marilia
   Cardoso, Sandra W.
   Veloso, Valdilea G.
   Chor, Dora
TI HIV Infection Is Not Associated with Carotid Intima-Media Thickness in
   Brazil: A Cross-Sectional Analysis from the INI/ELSA-Brasil Study
SO PLOS ONE
LA English
DT Article
ID RIO-DE-JANEIRO; ANTIRETROVIRAL THERAPY; CARDIOVASCULAR-DISEASE;
   RISK-FACTORS; ELSA-BRAZIL; HAART ERA; ATHEROSCLEROSIS; DEATH;
   INDIVIDUALS; PROGRESSION
AB Background
   Carotid intima-media thickness (cIMT) has been used as an early marker of atherosclerotic disease in the general population. Recently its role among HIV-infected patients has been questioned. To date, no Brazilian study has compared cIMT in respect to HIV status.
   Methods
   We compared data from 535 patients actively followed in a prospective cohort in Rio de Janeiro (HIV group); 88 HIV-negative individuals who were nominated by patients (friend controls-FCs); and 10,943 participants of the ELSA-Brasil study. Linear regression models were used to study associations of the 3 groups and several covariables with cIMT. Propensity scores weighting (PSW) were also employed to balance data.
   Results
   Median thickness in mm (IQR) were 0.54 (0.49,0.62); 0.58 (0.52,0.68); and 0.57 (0.49,0.70), HIV, FCs and ELSA-Brasil groups, respectively (p-value<0.001). The best linear model chosen did not include the group variables, after adjusting for all the variables chosen, showing no difference of cIMT across groups. Similar results were obtained with PSW. Several traditional CVD risk factors were also significantly associated with cIMT: female gender, higher education and higher HDL were negatively associated while risk factors were older age, current/former smoker, AMI/stroke family history, CVD history, hypertension, DM, higher BMI and total cholesterol.
   Conclusions
   We show for the first time in a middle-income setting that cIMT, is not different in HIV-infected patients in Rio de Janeiro compared with 2 different groups of non-HIV-infected individuals. Traditional CVD risk factors are associated with this outcome. Our results point out that high standards of care and prevention for CVD risk factors should always be sought both in the HIV-infected and non-infected populations to prevent CVD-related events.
C1 [Pacheco, Antonio G.; Moreira, Rodrigo de C.] Fiocruz MS, Programa Comp Cient, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz; Moreira, Rodrigo de C.; Moreira, Ronaldo I.; Friedman, Ruth K.; Santini-Oliveira, Marilia; Cardoso, Sandra W.; Veloso, Valdilea G.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [da Fonseca, Maria de Jesus M.; Chor, Dora] Fiocruz MS, Dept Epidemiol & Metodos Quantitat Saude, Rio De Janeiro, Brazil.
   [Griep, Rosane Harter] Fiocruz MS, Lab Hlth & Environm Educ, Rio De Janeiro, Brazil.
   [Lotufo, Paulo; Bensenor, Isabela] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Mill, Jose G.] Univ Fed Espirito Santo, Dept Ciencias Fisiol, Vitoria, Brazil.
RP Pacheco, AG (corresponding author), Fiocruz MS, Programa Comp Cient, Rio De Janeiro, Brazil.
EM antgui@gmail.com
RI Lotufo, Paulo/A-9843-2008; Griep, Rosane Harter/ABB-4509-2020; Pacheco,
   Antonio Guilherme/E-6378-2013; Griep, Rosane Harter/E-3763-2013
OI Lotufo, Paulo/0000-0002-4856-8450; Pacheco, Antonio
   Guilherme/0000-0003-3095-1774; Griep, Rosane Harter/0000-0002-6250-2036
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   JaneiroCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/102398/2009, E-26/201.471/2014];
   Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq) [01 06
   0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01 06
   0115.00 SP, 01 06 0071.00 RJ, 407446/2012-5, 304614/2012-2]; Programa
   Estrategico de Apoio a Pesquisa em Saude-Fundacao Oswaldo Cruz
   [407446/2012-5]; Brazilian Ministry of Science and Technology; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX This work has been supported by the Fundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado do Rio de Janeiro [E-26/102398/2009 to DC
   and E-26/201.471/2014 to AGP]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico [grant numbers 01 06 0010.00 RS, 01 06 0212.00
   BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01 06 0115.00 SP, 01 06 0071.00
   RJ, 407446/2012-5 to AGP and 304614/2012-2 to AGP]; Programa Estrategico
   de Apoio a Pesquisa em Saude-Fundacao Oswaldo Cruz [407446/2012-5 to
   AGP] and the Brazilian Ministry of Science and Technology. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Althoff KN, 2013, HIV MED, V14, P191, DOI 10.1111/hiv.12007
   Bavinger C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059551
   Falcao MDBD, 2012, ARQ BRAS CARDIOL, V99, P971
   Calcagno V, 2010, J STAT SOFTW, V34, P1
   Calza L, 2008, J INFECTION, V57, P16, DOI 10.1016/j.jinf.2008.02.006
   Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16
   Duprez DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044454
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Albuquerque VMG, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-274
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grunfeld C, 2009, AIDS, V23, P1841, DOI 10.1097/QAD.0b013e32832d3b85
   Hanna DB, 2015, CLIN INFECT DIS, V61, P640, DOI 10.1093/cid/civ325
   Hsue PY, 2012, J INFECT DIS, V205, pS375, DOI 10.1093/infdis/jis200
   Hsue PY, 2004, CIRCULATION, V109, P1603, DOI 10.1161/01.CIR.0000124480.32233.8A
   Hulten E, 2009, HEART, V95, P1826, DOI 10.1136/hrt.2009.177774
   Islam FM, 2012, HIV MED, V13, P453, DOI 10.1111/j.1468-1293.2012.00996.x
   Kaplan RC, 2008, AIDS, V22, P1615, DOI 10.1097/QAD.0b013e328300581d
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   McCaffrey DF, 2004, PSYCHOL METHODS, V9, P403, DOI 10.1037/1082-989X.9.4.403
   Ministerio da Saude-Secretaria de Vigilancia em Saude-Programa Nacional de DST; Aids e Hepatites Virais, 2014, B EP HIV AIDS
   Mugavero MJ, 2011, CLIN INFECT DIS, V53, P927, DOI 10.1093/cid/cir526
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Pacheco AG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117461
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Pan W, 2015, PROPENSITY SCORE ANA, Vxiv
   Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636
   Paula AA, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-32
   Polak JF, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000087
   R Development Core Team, 2014, R LANG ENV STAT COMP
   Ridgeway G., 2015, TWANG TOOLKIT WEIGHT
   Santos IS, 2015, ARTERIOSCL THROM VAS, V35, P2054, DOI 10.1161/ATVBAHA.115.305765
   Santos IS, 2014, ATHEROSCLEROSIS, V237, P227, DOI 10.1016/j.atherosclerosis.2014.09.004
   Schmidt MI, 2015, INT J EPIDEMIOL, V44, P68, DOI 10.1093/ije/dyu027
   Schoffelen AF, 2015, CLIN INFECT DIS, V61, P1606, DOI 10.1093/cid/civ586
   Spence JD, 2015, ARTERIOSCL THROM VAS, V35, P1910, DOI 10.1161/ATVBAHA.115.306209
   Ssinabulya I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089537
   Stein JH, 2014, JACC-CARDIOVASC IMAG, V7, P515, DOI 10.1016/j.jcmg.2013.08.019
   Stein JH, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.001396
   Torres TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115900
   Torres TS, 2013, BRAZ J INFECT DIS, V17, P324, DOI 10.1016/j.bjid.2012.10.024
   Touboul PJ, 2012, CEREBROVASC DIS, V34, P290, DOI 10.1159/000343145
NR 42
TC 9
Z9 9
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 8
PY 2016
VL 11
IS 7
AR e0158999
DI 10.1371/journal.pone.0158999
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DR6IK
UT WOS:000380005400186
PM 27391355
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Bavinton, BR
   Phanuphak, N
   Jin, F
   Zablotska, I
   Grinsztejn, B
   Prestage, G
   Grulich, AE
AF Bavinton, B. R.
   Phanuphak, N.
   Jin, F.
   Zablotska, I.
   Grinsztejn, B.
   Prestage, G.
   Grulich, A. E.
CA Opposites Attract Study Grp
TI A small proportion of acts of anal intercourse within homosexual male
   serodiscordant couples in three countries are high-risk for HIV
   transmission
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Bavinton, B. R.; Jin, F.; Zablotska, I.; Prestage, G.; Grulich, A. E.; Opposites Attract Study Grp] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Phanuphak, N.] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand.
   [Grinsztejn, B.] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Prestage, G.] La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Vic, Australia.
EM bbavinton@kirby.unsw.edu.au
RI Phanuphak, Nittaya/AAA-8579-2019
NR 0
TC 1
Z9 1
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2016
VL 19
SU 5
MA THAC0101
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EM6AD
UT WOS:000395394300158
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Luz, PM
   Osher, B
   Grinsztejn, B
   MacLean, RL
   Losina, E
   Struchiner, CJ
   Parker, RA
   Freedberg, KA
   Mesquita, F
   Walensky, RP
   Veloso, VG
   Paltiel, AD
AF Luz, P. M.
   Osher, B.
   Grinsztejn, B.
   MacLean, R. L.
   Losina, E.
   Struchiner, C. J.
   Parker, R. A.
   Freedberg, K. A.
   Mesquita, F.
   Walensky, R. P.
   Veloso, V. G.
   Paltiel, A. D.
TI The cost-effectiveness of HIV pre-exposure prophylaxis (PrEP) in
   high-risk men who have sex with men (MSM) and transgendered women (TGW)
   in Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Luz, P. M.; Grinsztejn, B.; Struchiner, C. J.; Veloso, V. G.] Fundacao Oswaldo Cruz, Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Osher, B.; MacLean, R. L.; Losina, E.] Massachusetts Gen Hosp, Dept MedicineMed Practice Evaluat Ctr, Boston, MA USA.
   [Losina, E.; Parker, R. A.; Walensky, R. P.] Harvard Univ, Ctr AIDS Res, Boston, MA USA.
   [Losina, E.] Brigham & Womens Hosp, Dept Orthoped, Dept Med, Div Rheumatol, Boston, MA USA.
   [Parker, R. A.] Massachusetts Gen Hosp, Biostat Ctr, Med Practice Evaluat Ctr, Dept Med,Div Gen Med, Boston, MA USA.
   [Parker, R. A.] Harvard Med Sch, Boston, MA USA.
   [Freedberg, K. A.; Walensky, R. P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Dept Med, Div Gen Med,Div Infect Dis, Boston, MA USA.
   [Freedberg, K. A.] Harvard Univ, Ctr AIDS Res, Dept Epidemiol, Dept Hlth Policy & Management Boston, Boston, MA USA.
   [Freedberg, K. A.] Boston Univ Sch Publ Hlth, Dept Biostat, Dept Epidemiol, Boston, MA USA.
   [Mesquita, F.] World Hlth Org WHO, Brasilia, DF, Brazil.
   [Walensky, R. P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA USA.
   [Paltiel, A. D.] Yale Sch Publ Hlth, New Haven, CT USA.
EM fabio.mesquita@aids.gov.br
RI Mesquita, Fabio/AAZ-7021-2020; Struchiner, Claudio J/M-9360-2013
OI Struchiner, Claudio J/0000-0003-2114-847X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2016
VL 19
SU 5
MA THAE0305
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EM6AD
UT WOS:000395394300188
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Fogel, JM
   Hudelson, SE
   Ou, SS
   Hart, S
   Wallis, C
   Morgado, MG
   Saravanan, S
   Tripathy, S
   Hovind, L
   Piwowar-Manning, E
   Sabin, D
   McCauley, M
   Gamble, T
   Zhang, XYC
   Eron, JJ
   Gallant, JE
   Kumwenda, J
   Makhema, J
   Kumarasamy, N
   Chariyalertsak, S
   Hakim, J
   Badal-Faesen, S
   Akelo, V
   Hosseinipour, MC
   Santos, BR
   Godbole, SV
   Pilotto, JH
   Grinsztejn, B
   Panchia, R
   Mayer, KH
   Chen, YQ
   Cohen, MS
   Eshleman, SH
AF Fogel, Jessica M.
   Hudelson, Sarah E.
   Ou, San-San
   Hart, Stephen
   Wallis, Carole
   Morgado, Mariza G.
   Saravanan, Shanmugam
   Tripathy, Srikanth
   Hovind, Laura
   Piwowar-Manning, Estelle
   Sabin, Devin
   McCauley, Marybeth
   Gamble, Theresa
   Zhang, Xinyi C.
   Eron, Joseph J.
   Gallant, Joel E.
   Kumwenda, Johnstone
   Makhema, Joseph
   Kumarasamy, Nagalingeswaran
   Chariyalertsak, Suwat
   Hakim, James
   Badal-Faesen, Sharlaa
   Akelo, Victor
   Hosseinipour, Mina C.
   Santos, Breno R.
   Godbole, Sheela V.
   Pilotto, Jose H.
   Grinsztejn, Beatriz
   Panchia, Ravindre
   Mayer, Kenneth H.
   Chen, Ying Q.
   Cohen, Myron S.
   Eshleman, Susan H.
TI HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment:
   Results From the HIV Prevention Trials Network 052 Trial
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; HPTN 052; early ART; ART failure; resistance
ID RANDOMIZED CONTROLLED-TRIAL; VIROLOGICAL FAILURE; CLINICAL-TRIAL; CELL
   COUNTS; THERAPY; INFECTION; INITIATION; MUTATIONS; OUTCOMES; AFRICA
AB Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2% had baseline resistance and 35.3% had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5%) participants who started ART at lower CD4 cell counts.
C1 [Fogel, Jessica M.; Hudelson, Sarah E.; Piwowar-Manning, Estelle; Sabin, Devin; Eshleman, Susan H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Ou, San-San; Zhang, Xinyi C.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Hart, Stephen; Hovind, Laura] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA.
   [Wallis, Carole] Lancet Labs, Specialty Mol Div, Johannesburg, South Africa.
   [Wallis, Carole] BARC SA, Johannesburg, South Africa.
   [Morgado, Mariza G.] Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, BR-20001 Rio De Janeiro, Brazil.
   [Saravanan, Shanmugam] YR Gaitonde Ctr AIDS Res & Educ, Chennai, Tamil Nadu, India.
   [Tripathy, Srikanth] Natl JALMA Inst Leprosy & Other Mycobacterial Dis, Agra, Uttar Pradesh, India.
   [McCauley, Marybeth] FHI 360, Sci Facilitat Dept, Washington, DC USA.
   [Gamble, Theresa] FHI 360, Sci Facilitat Dept, Durham, NC USA.
   [Eron, Joseph J.; Cohen, Myron S.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
   [Gallant, Joel E.] Southwest CARE Ctr, Santa Fe, NM USA.
   [Kumwenda, Johnstone] Johns Hopkins Project, Coll Med, Blantyre, Malawi.
   [Makhema, Joseph] Botswana Harvard AIDS Inst, Gaborone, Botswana.
   [Kumarasamy, Nagalingeswaran] VHS, YRGCARE Med Ctr, Chennai, Tamil Nadu, India.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
   [Hakim, James] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
   [Badal-Faesen, Sharlaa] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa.
   [Akelo, Victor] Ctr Dis Control, Kenya Med Res Inst, Kisumu, Kenya.
   [Hosseinipour, Mina C.] Univ N Carolina, Div Infect Dis, Chapel Hill, NC USA.
   [Hosseinipour, Mina C.] UNC Project Malawi, Inst Global Hlth & Infect Dis, Lilongwe, Malawi.
   [Santos, Breno R.] Hosp Nossa Senhora da Conceicao, Serv Infectol, Porto Alegre, RS, Brazil.
   [Godbole, Sheela V.] Natl AIDS Res Inst ICMR, Dept Epidemiol & Biostat, Pune, Maharashtra, India.
   [Pilotto, Jose H.] Hosp Geral de Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, Jose H.] Fiocruz MS, Lab AIDS & Imunol Mol IOC, BR-21045900 Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, BR-21045900 Rio De Janeiro, Brazil.
   [Panchia, Ravindre] Univ Witwatersrand, Soweto HPTN CRS, Perinatal HIV Res Unit, Soweto, South Africa.
   [Mayer, Kenneth H.] Fenway Inst, Fenway Hlth & Infect Dis Div, Boston, MA USA.
   [Mayer, Kenneth H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA.
   [Chen, Ying Q.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Chen, Ying Q.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA.
RP Eshleman, SH (corresponding author), Johns Hopkins Med Inst, Dept Pathol, Ross Bldg,Room 646,720 Rutland Ave, Baltimore, MD 21205 USA.
EM seshlem@jhmi.edu
RI Godbole, Sheela/K-4177-2017; Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Wallis,
   Carole/0000-0001-8408-8772
FU Division of AIDS of the U.S. National Institute of Allergy and
   Infectious Diseases (NIAID); Office of AIDS Research of the U.S.
   National Institutes of Health (NIH) [U01-AI068613/UM1-AI068613,
   U01-AI068617/UM1-AI068617, U01-AI068619/UM1-AI068619]; ViiV Healthcare;
   JanssenJohnson & Johnson USAJanssen Biotech Inc; Bristol-Myers
   SquibbBristol-Myers Squibb; Gilead SciencesGilead Sciences; Janssen
   Therapeutics; Merck Co.Merck & Company; AbbVieAbbott Laboratories;
   Sangamo Biosciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI068617, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, UM1AI069424, P30AI050410, UM1AI069436,
   UM1AI068613, UM1AI069476, P30AI050410, P30AI050410, UM1AI068617,
   P30AI050410, UM1AI069412, P30AI050410, P30AI050410, P30AI050410,
   UM1AI069453, P30AI050410, UM1AI069453, P30AI050410, P30AI050410,
   P30AI050410, UM1AI068617, P30AI050410, UM1AI068613, U01AI068613,
   UM1AI069423, P30AI050410, UM1AI069463, UM1AI069399, UM1AI069456,
   UM1AI068617, UM1AI069476, UM1AI069412, UM1AI069518, P30AI050410,
   P30AI050410, UM1AI069424, P30AI050410, U01AI068613, UM1AI069423,
   UM1AI069453, P30AI050410, P30AI050410, P30AI050410, UM1AI068613,
   P30AI050410, P30AI050410, UM1AI069476, P30AI050410, UM1AI068613,
   UM1AI069412, UM1AI069423, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069423, UM1AI068619,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, UM1AI069518,
   U01AI068613, P30AI050410, P30AI050410, UM1AI069456, P30AI050410,
   P30AI050410, U01AI068619, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, UM1AI069476, UM1AI069424, UM1AI069463, UM1AI069463,
   UM1AI069399, P30AI050410, P30AI050410, P30AI050410, UM1AI069412,
   P30AI050410, U01AI068613, UM1AI069423, P30AI050410, P30AI050410,
   P30AI050410, UM1AI068619, UM1AI069518, UM1AI068619, P30AI050410,
   UM1AI069463, UM1AI068619, P30AI050410, U01AI068613, UM1AI068613,
   UM1AI069453, U01AI068617, UM1AI069436, UM1AI069456, P30AI050410,
   P30AI050410, P30AI050410, UM1AI068613, P30AI050410, P30AI050410,
   P30AI050410, UM1AI069423, UM1AI069412, UM1AI068613, P30AI050410,
   U01AI068619, P30AI050410, UM1AI069412, P30AI050410, UM1AI069456,
   P30AI050410, P30AI050410, UM1AI069412, UM1AI069456, UM1AI068617,
   UM1AI069476, UM1AI069453, P30AI050410, UM1AI069423, U01AI068617,
   UM1AI069399, P30AI050410, UM1AI069518, UM1AI069399, UM1AI069412,
   UM1AI069424, UM1AI069518, P30AI050410, P30AI050410, UM1AI068617,
   P30AI050410, UM1AI069424, UM1AI068613, P30AI050410, UM1AI068617,
   UM1AI069463, UM1AI069463, UM1AI069436, P30AI050410, P30AI050410,
   UM1AI069518, UM1AI068619, P30AI050410, P30AI050410, UM1AI069463,
   UM1AI069456, P30AI050410, P30AI050410, P30AI050410, UM1AI069453,
   P30AI050410, P30AI050410, UM1AI068619, P30AI050410, P30AI050410,
   U01AI068617, P30AI050410, UM1AI069436, UM1AI068617, U01AI068619,
   UM1AI069424, P30AI050410, UM1AI069436, UM1AI069476, P30AI050410,
   UM1AI069456, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, UM1AI069423,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069456, P30AI050410,
   P30AI050410, P30AI050410, UM1AI068613, P30AI050410, P30AI050410,
   UM1AI069399, UM1AI069456, U01AI068617, P30AI050410, UM1AI069424,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069436, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, UM1AI069399,
   P30AI050410, UM1AI069399, UM1AI068619, P30AI050410, UM1AI069423,
   P30AI050410, P30AI050410, UM1AI068617, UM1AI068619, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069424, P30AI050410,
   UM1AI069453, P30AI050410, UM1AI068613, P30AI050410, UM1AI069518,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069412, P30AI050410,
   P30AI050410, P30AI050410, UM1AI069518, P30AI050410, UM1AI068617,
   P30AI050410, U01AI068619, P30AI050410, UM1AI069453, P30AI050410,
   UM1AI069399, U01AI068617, P30AI050410, UM1AI068619, P30AI050410,
   UM1AI068613, UM1AI068619, P30AI050410, P30AI050410, UM1AI069453,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, UM1AI069424, UM1AI068613,
   P30AI050410, UM1AI069436, P30AI050410, UM1AI069463, P30AI050410,
   P30AI050410, UM1AI069476, P30AI050410, P30AI050410, P30AI050410,
   UM1AI069399, P30AI050410, UM1AI069436, P30AI050410, UM1AI069423,
   P30AI050410, UM1AI069463, UM1AI069476, U01AI068619, UM1AI069412,
   P30AI050410] Funding Source: NIH RePORTER
FX Supported by the grants from the Division of AIDS of the U.S. National
   Institute of Allergy and Infectious Diseases (NIAID); and by the Office
   of AIDS Research of the U.S. National Institutes of Health (NIH)
   [U01-AI068613/UM1-AI068613 (S.H.E.); U01-AI068617/UM1-AI068617
   (Donnell); and U01-AI068619/UM1-AI068619 (Vermund/El-Sadr)]. Study drugs
   used in HPTN 052 were donated by Abbott Laboratories,
   Boehringer-Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Gilead
   Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, and Merck & Co., Inc.r
   S.H.E. has collaborated with investigators from Abbott Diagnostics on
   research studies. J.J.E. is a consultant to Bristol Myers Squibb, Gilead
   Sciences, ViiV Healthcare and Merck; he receives research support from
   ViiV Healthcare and Janssen through contracts to the University of North
   Carolina. J.E.G. receives honoraria for advisory board and/or membership
   on Data Safety and Monitoring Boards from Bristol-Myers Squibb, Gilead
   Sciences, Janssen Therapeutics, Merck & Co., and ViiV Healthcare; his
   organization receives grant support from those companies as well as
   AbbVie and Sangamo Biosciences. C.W. served as a consultant for Celera
   for development of software updates related to the HIV drug resistance
   algorithm used with the ViroSeq HIV-1 Genotyping System. The remaining
   authors have no conflicts of interest to disclose.
CR Cohen M, 2015, 8 IAS C HIV PATH TRE
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Fogel JM, 2013, J INFECT DIS, V208, P1624, DOI 10.1093/infdis/jit390
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Gulick RM, 2006, JAMA-J AM MED ASSOC, V296, P769, DOI 10.1001/jama.296.7.769
   Hamers RL, 2012, CLIN INFECT DIS, V54, P1660, DOI 10.1093/cid/cis254
   Harrigan PR, 2005, J INFECT DIS, V191, P339, DOI 10.1086/427192
   Hoen B, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19034
   HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992
   Kantor R, 2015, CLIN INFECT DIS, V60, P1541, DOI 10.1093/cid/civ102
   Lima VD, 2015, AIDS, V29, P1871, DOI 10.1097/QAD.0000000000000790
   Liu TF, 2006, CLIN INFECT DIS, V42, P1608, DOI 10.1086/503914
   Lodi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075608
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Marconi VC, 2008, CLIN INFECT DIS, V46, P1589, DOI 10.1086/587109
   Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services, GUIDELINES USE ANTIR
   Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370
   Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961
   Uy J, 2009, JAIDS-J ACQ IMM DEF, V51, P450, DOI 10.1097/QAI.0b013e3181acb630
   World Health Organization, 2015, GUID START ANT THER
   World Health Organization, 2015, MAX TREATM PREV POT
NR 22
TC 6
Z9 6
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUL 1
PY 2016
VL 72
IS 3
BP 304
EP 309
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DO8UM
UT WOS:000378059800017
PM 26859828
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Castro, R
   Ribeiro-Alves, M
   Correa, RG
   Derrico, M
   Lemos, K
   Grangeiro, JR
   de Jesus, B
   Pires, D
   Veloso, VG
   Grinsztejn, B
AF Castro, Rodolfo
   Ribeiro-Alves, Marcelo
   Correa, Renato Girade
   Derrico, Monica
   Lemos, Katia
   Grangeiro, Jose Roberto
   de Jesus, Beto
   Pires, Denise
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI The Men Who Have Sex with Men HIV Care Cascade in Rio de Janeiro, Brazil
SO PLOS ONE
LA English
DT Article
ID MEDICAL-CARE; INFECTION; STIGMA; EPIDEMIOLOGY; RETENTION; HEALTH; MSM;
   TRANSMISSION; ENGAGEMENT; CONTINUUM
AB Brazil has a concentrated HIV epidemic and men who have sex with men (MSM) are disproportionately affected. Yet, no data is available on the HIV care cascade for this population. This study aimed to assess the HIV care cascade among MSM newly diagnosed through innovative testing strategies in Rio de Janeiro. Data from 793 MSM and travestites/transgender women (transwomen) tested for HIV at a non-governmental LGBT organization and a mobile testing unit located at a gay friendly venue were analyzed. A 12-month-after-HIV-diagnosis- censored cohort was established using CD4, viral load and combination antiretro-viral therapy (cART) longitudinal data from those diagnosed with HIV. A cross-sectional HIV care cascade was built using this data. The relative risks of achieving each cascade-stage were estimated using generalized linear models according to age, self-declared skin-color, education, history of sexually transmitted diseases (STD), drug use and prior HIV testing. From Jan-2013 to Jan-2014, 793 MSM and transwomen were tested, 131 (16.5%) were HIV-infected. As of January 2015, 95 (72.5%) were linked to HIV care, 90 (68.7%) were retained in HIV care, 80 (61.1%) were on cART, and 50 (38.2%) were virally suppressed one year after HIV diagnosis. Being non-white (Relative risk [lower bound; upper bound of 95% confidence interval] = 1.709 [1.145; 2.549]) and having a prior HIV-test (1.954 [1.278; 2.986]) were associated with an HIV-positive diagnosis. A higher linkage (2.603 [1.091; 6.211]) and retention in care (4.510 [1.880; 10.822]) were observed among those who were older than 30 years of age. Using community-based testing strategies, we were able to access a high-risk MSM population and a small sample of transwomen. Despite universal care coverage and the test-and-treat policy adopted in Brazil, the MSM cascade of care indicates that strategies to increase linkage to care and prompt cART initiation targeted to these populations are critically needed. Interventions targeting non-white and young MSM should be prioritized.
C1 [Castro, Rodolfo; Ribeiro-Alves, Marcelo; Derrico, Monica; Lemos, Katia; Grangeiro, Jose Roberto; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Castro, Rodolfo] Univ Fed Estado Rio de Janeiro, Inst Saude Colet, Rio De Janeiro, RJ, Brazil.
   [Correa, Renato Girade] Minist Saude, Dept DST Aids & Hepatites Virais, Brasilia, DF, Brazil.
   [Lemos, Katia; Pires, Denise] Secretaria Estado Saude Sao Paulo, Gerrncia DST Aids Sangue & Hemoderivados, Rio De Janeiro, RJ, Brazil.
   [Grangeiro, Jose Roberto] Grp Arco Iris, Rio De Janeiro, RJ, Brazil.
   [de Jesus, Beto] Assoc Int Lesbicas Gays Bissexuais Transexuais &, Buenos Aires, DF, Argentina.
RP Castro, R (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
EM rodolfo.castro@ini.fiocruz.br
RI Castro, Rodolfo/D-4231-2013
OI Castro, Rodolfo/0000-0002-0701-2528; Ribeiro-Alves,
   Marcelo/0000-0002-8663-3364
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH
   RePORTER; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1 AI069476] Funding Source:
   Medline
CR Agwu AL, 2015, J ADOLESCENT HEALTH, V56, P345, DOI 10.1016/j.jadohealth.2014.11.009
   Anonymous, 2005, Morbidity and Mortality Weekly Report, V54, P597
   Ayala G., 2014, Journal of AIDS and Clinical Research, V5, P331
   Baral SD, 2014, CURR OPIN HIV AIDS, V9, P156, DOI 10.1097/COH.0000000000000037
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude, 2014, B EP AIDS DST ANO 3
   Brito AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130445
   Coates TJ, 2008, LANCET, V372, P669, DOI 10.1016/S0140-6736(08)60886-7
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Veras MADM, 2015, AIDS BEHAV, V19, P1589, DOI 10.1007/s10461-014-0944-3
   Dickson NP, 2012, HIV MED, V13, P182, DOI 10.1111/j.1468-1293.2011.00959.x
   Dowshen N, 2009, AIDS PATIENT CARE ST, V23, P371, DOI 10.1089/apc.2008.0256
   Gardner EM, 2014, LANCET INFECT DIS, V14, P5, DOI 10.1016/S1473-3099(13)70272-X
   Giordano TR, 2009, HIV CLIN TRIALS, V10, P299, DOI 10.1310/hct1005-299
   Grangeiro A, 2009, REV SAUDE PUBL, V43, DOI 10.1590/S0034-89102009000300006
   Grangeiro A, 2009, CAD SAUDE PUBLICA, V25, P2053, DOI 10.1590/S0102-311X2009000900019
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Hallett TB, 2013, JAIDS-J ACQ IMM DEF, V63, pS228, DOI 10.1097/QAI.0b013e318298721b
   Hoenigl M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0458-5
   Instituto Nacional de Estudos e Pesquisas Educacionais Anisio Teixeira, 2014, SIN EST ED SUP GRAD
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Leaity S, 2000, AIDS, V14, P547, DOI 10.1097/00002030-200003310-00010
   Logie C, 2009, AIDS CARE, V21, P742, DOI 10.1080/09540120802511877
   Lorente N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061225
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   MacCarthy S, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1313
   Magidson JF, 2016, AIDS BEHAV, V20, P699, DOI 10.1007/s10461-015-1142-7
   Mayer KH, 2014, ANN BEHAV MED, V47, P165, DOI 10.1007/s12160-013-9527-1
   Mello A, 2008, ASSESSMENT RISK FACT
   Mimiaga MJ, 2009, AIDS PATIENT CARE ST, V23, P825, DOI 10.1089/apc.2009.0086
   Mugavero MJ, 2013, CLIN INFECT DIS, V57, P1164, DOI 10.1093/cid/cit420
   Mugavero MJ, 2011, CLIN INFECT DIS, V52, pS238, DOI 10.1093/cid/ciq048
   Nachega JB, 2014, CLIN INFECT DIS, V59, pS21, DOI 10.1093/cid/ciu299
   Nosyk B, 2014, LANCET INFECT DIS, V14, P40, DOI 10.1016/S1473-3099(13)70254-8
   Pachankis JE, 2015, AIDS, V29, P1239, DOI 10.1097/QAD.0000000000000724
   Peretti-Watel P, 2006, AIDS CARE, V18, P254, DOI 10.1080/09540120500456193
   Peretti-Watel P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000411
   Pines HA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010388
   Puljic VM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093734
   R Core Team, 2014, R LANG ENV STAT COMP
   Rodger ABT, 2014, HIV TRANSMISSION RIS
   Mota RMS, 2011, JAIDS-J ACQ IMM DEF, V57, pS153, DOI 10.1097/QAI.0b013e31821e9c10
   Shivaji T, 2014, J INT AIDS SOC, V17, P129, DOI 10.7448/IAS.17.4.19690
   Silva DS, 2016, AIDS BEHAV, V20, P1039, DOI 10.1007/s10461-015-1235-3
   Tripathi A, 2011, AIDS RES HUM RETROV, V27, P751, DOI [10.1089/AID.2010.0268, 10.1089/aid.2010.0268]
   Ulett KB, 2009, AIDS PATIENT CARE ST, V23, P41, DOI 10.1089/apc.2008.0132
   UNAIDS, 2014, GLOB AIDS RESP PROGR
   World Health Organization, 2015, CONS GUID HIV TEST S
NR 49
TC 9
Z9 9
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 14
PY 2016
VL 11
IS 6
AR e0157309
DI 10.1371/journal.pone.0157309
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DO5KO
UT WOS:000377822200035
PM 27299524
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Pecego, AC
   Amancio, RT
   Ribeiro, C
   Mesquita, EC
   Medeiros, DM
   Cerbino, J
   Grinsztejn, B
   Bozza, FA
   Japiassu, AM
AF Pecego, Ana Carla
   Amancio, Rodrigo T.
   Ribeiro, Camila
   Mesquita, Emersom C.
   Medeiros, Denise M.
   Cerbino, Jose
   Grinsztejn, Beatriz
   Bozza, Fernando A.
   Japiassu, Andre M.
TI Six-month survival of critically ill patients with HIV-related disease
   and tuberculosis: a retrospective study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV; AIDS; Tuberculosis; Critical care; Patient outcome
ID INTENSIVE-CARE-UNIT; ACTIVE ANTIRETROVIRAL THERAPY; RIO-DE-JANEIRO;
   IMMUNODEFICIENCY-VIRUS-INFECTION; ACUTE RESPIRATORY-FAILURE; LONG-TERM
   SURVIVAL; PULMONARY TUBERCULOSIS; ORGAN DYSFUNCTION/FAILURE;
   PROGNOSTIC-FACTORS; ICU
AB Background: Tuberculosis is one of the leading causes of death from infectious diseases worldwide, mainly after the human immunodeficiency virus (HIV) epidemics. Patient with HIV-related illness are more likely to present with severe TB due to immunosuppression. Very few studies have explored HIV/TB co-infection in critically ill patients. The goal of this study was to analyze factors associated with long-term mortality in critically ill patient with HIV-related disease coinfected with TB.
   Methods: We conducted a retrospective study in an infectious disease reference center in Brazil that included all patient with HIV-related illness admitted to the ICU with laboratory-confirmed tuberculosis from March 2007 until June 2012. Clinical and laboratory variables were analyzed based on six-month survival.
   Results: Forty-four patients with HIV-related illness with a confirmed diagnosis of tuberculosis were analyzed. The six-month mortality was 52 % (23 patients). The main causes of admission were respiratory failure (41 %), severe sepsis/septic shock (32 %) and coma/torpor (14 %). The median time between HIV diagnosis and ICU admission was 5 (1-60) months, and 41 % of patients received their HIV infection diagnosis = 30 days before admission. The median CD4 count was 72 (IQR: 23-136) cells/mm(3). The clinical presentation was pulmonary tuberculosis in 22 patients (50 %) and disseminated TB in 20 patients (45.5 %). No aspect of TB diagnosis or treatment was different between survivors and nonsurvivors. Neurological dysfunction was more prevalent among nonsurvivors (43 % vs. 14 %, p = 0.04). The nadir CD4 cell count lower than 50 cells/mm3 was independently associated with Six-month mortality (hazard ratio 4.58 [1.64-12.74], p < 0.01), while HIV diagnosis less than three months after positive serology was protective (hazard ratio 0.27, CI 95 % [0.10-0.72], p = 0.01).
   Conclusion: The Six-month mortality of HIV critically ill patients with TB coinfection is high and strongly associated with the nadir CD4 cell count less than 50 cels/mm(3).
C1 [Pecego, Ana Carla; Amancio, Rodrigo T.; Ribeiro, Camila; Mesquita, Emersom C.; Medeiros, Denise M.; Cerbino, Jose; Bozza, Fernando A.; Japiassu, Andre M.] Natl Inst Infect Dis, Intens Care Clin Res Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Grinsztejn, Beatriz] Natl Inst Infect Dis, STD AIDS Clin Res Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] Inst DOr Pesquisa & Ensino, Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, RJ, Brazil.
RP Japiassu, AM (corresponding author), Natl Inst Infect Dis, Intens Care Clin Res Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM andrejapi@gmail.com
RI Neto, Jose Cerbino/P-3713-2018; Bozza, Fernando A/A-2618-2013; MIZEKA,
   PANU/A-3952-2017
OI Neto, Jose Cerbino/0000-0001-9254-917X; Bozza, Fernando
   A/0000-0003-4878-0256; Mesquita, Emersom/0000-0002-5132-3315; Pecego da
   Silva, Ana Carla/0000-0002-4131-1425
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476] Funding Source: NIH RePORTER
FX National Council of Technological and Scientific Development (CNPq).;
   Research Funding Agency of the State of Rio de Janeiro (FAPERJ).
CR Afessa B, 2000, CHEST, V118, P138, DOI 10.1378/chest.118.1.138
   Alshimemeri A A, 2011, CRIT CARE SHOCK, V14, P1
   Amancio FF, 2012, INT J STD AIDS, V23, P692, DOI 10.1258/ijsa.2012.011389
   Amancio RT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068730
   Balkema CA, 2014, INT J TUBERC LUNG D, V18, P824, DOI 10.5588/ijtld.13.0044
   Barbier F, 2009, INTENS CARE MED, V35, P1678, DOI 10.1007/s00134-009-1559-4
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Epidemiologica, 2011, MAN REC CONTR TUB A
   Bray S, 2012, HIV AIDS-RES PALLIAT, V4, P135, DOI 10.2147/HIV.S35374
   Burman W, 2007, INT J TUBERC LUNG D, V11, P1282
   Cardoso SW, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0699-5
   Cardoso SW, 2010, AIDS RES HUM RETROV, V26, P865, DOI 10.1089/aid.2009.0274
   Casalino E, 1998, CHEST, V113, P421, DOI 10.1378/chest.113.2.421
   Chiang HH, 2011, CRIT CARE, V15, DOI 10.1186/cc10419
   Coelho L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098666
   Conde MB, 2009, J BRAS PNEUMOL, V35, P1018, DOI 10.1590/S1806-37132009001000011
   Corona A, 2009, CURR HIV RES, V7, P569, DOI 10.2174/157016209789973592
   Croda J, 2009, CRIT CARE MED, V37, P1605, DOI 10.1097/CCM.0b013e31819da8c7
   Crump JA, 2012, CLIN INFECT DIS, V55, P242, DOI 10.1093/cid/cis409
   Dickson SJ, 2007, THORAX, V62, P964, DOI 10.1136/thx.2006.072256
   Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703
   Erbes R, 2006, EUR RESPIR J, V27, P1223, DOI 10.1183/09031936.06.00088105
   Gary J, 2013, SEMIN RESP CRIT CARE, V34
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Hagan G, 2013, CRIT CARE, V17, DOI 10.1186/cc12760
   Holland DP, 2009, PHARMACOTHERAPY, V29, P503, DOI 10.1592/phco.29.5.503
   Huang L, 2006, NEW ENGL J MED, V355, P173, DOI 10.1056/NEJMra050836
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Kim YJ, 2008, EUR RESPIR J, V32, P1625, DOI 10.1183/09031936.00070907
   Kogmar S, 2013, PLOS ONE, V8
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Lockman S, 2003, INT J TUBERC LUNG D, V7, P714
   Meybeck A, 2012, AIDS RES THER, V9, DOI 10.1186/1742-6405-9-27
   Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005
   Moreno R, 1999, INTENS CARE MED, V25, P686, DOI 10.1007/s001340050931
   Morris A, 2006, CRIT CARE MED, V34, P42, DOI 10.1097/01.CCM.0000194539.50905.81
   Morris AM, 2000, AM J RESP CRIT CARE, V162, P612, DOI 10.1164/ajrccm.162.2.9912058
   Narasimhan M, 2004, CHEST, V125, P1800, DOI 10.1378/chest.125.5.1800
   Nickas G, 2000, ARCH INTERN MED, V160, P541, DOI 10.1001/archinte.160.4.541
   Nicolls DJ, 2005, LANCET INFECT DIS, V5, P795, DOI 10.1016/S1473-3099(05)70299-1
   Orsini J, 2013, INTERDISCIP PERSPECT, V2013
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003132
   Pawlowski A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002464
   Powell K, 2009, CHEST, V135, P11, DOI 10.1378/chest.08-0980
   Sarkar P, 2013, CRIT CARE, V17, DOI 10.1186/cc12552
   Segal Leopoldo N, 2011, Proc Am Thorac Soc, V8, P282, DOI 10.1513/pats.201006-044WR
   Silva DR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-54
   Silva DR, 2012, J BRAS PNEUMOL, V38, P386, DOI 10.1590/S1806-37132012000300015
   Sonneville R, 2011, J INFECTION, V62, P301, DOI 10.1016/j.jinf.2011.02.003
   Thwaites GE, 2013, LANCET NEUROL, V12, P999, DOI 10.1016/S1474-4422(13)70168-6
   Torok ME, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001772
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156
   Waddell RD, 2001, AIDS, V15, P55, DOI 10.1097/00002030-200101050-00009
   WHO, GLOB TUB REP 2014
   Wilkinson KA, 2012, SAMJ S AFR MED J, V102, P512, DOI 10.7196/SAMJ.5358
   World Health Organization. Communicable Diseases Cluster Stop TB Department, 2011, UN ACC DIAGN TREATM
   Wunderink RG, 2012, AM J RESP CRIT CARE, V185, P1261, DOI 10.1164/rccm.201203-0540UP
   Zahar JR, 2001, INTENS CARE MED, V27, P513, DOI 10.1007/s001340000849
   Zumla A, 2013, NEW ENGL J MED, V368, P745, DOI 10.1056/NEJMra1200894
NR 58
TC 5
Z9 5
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUN 10
PY 2016
VL 16
AR 270
DI 10.1186/s12879-016-1644-6
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA DO7FY
UT WOS:000377949000001
PM 27286652
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Crabtree-Ramirez, B
   Caro-Vega, Y
   Shepherd, BE
   Grinsztejn, B
   Wolff, M
   Cortes, CP
   Padgett, D
   Carriquiry, G
   Fink, V
   Jayathilake, K
   Person, AK
   McGowan, C
   Sierra-Madero, J
AF Crabtree-Ramirez, Brenda
   Caro-Vega, Yanink
   Shepherd, Bryan E.
   Grinsztejn, Beatriz
   Wolff, Marcelo
   Cortes, Claudia P.
   Padgett, Denis
   Carriquiry, Gabriela
   Fink, Valeria
   Jayathilake, Karu
   Person, Anna K.
   McGowan, Catherine
   Sierra-Madero, Juan
CA Int Epidemiol Databases Evaluate
TI Time to HAART Initiation after Diagnosis and Treatment of Opportunistic
   Infections in Patients with AIDS in Latin America
SO PLOS ONE
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; CRYPTOCOCCAL MENINGITIS; HIV;
   TUBERCULOSIS; INDIVIDUALS; COHORT; MORTALITY; ENGLAND; ADULTS; WALES
AB Background
   Since 2009, earlier initiation of highly active antiretroviral therapy (HAART) after an opportunistic infection (OI) has been recommended based on lower risks of death and AIDS-related progression found in clinical trials. Delay in HAART initiation after OIs may be an important barrier for successful outcomes in patients with advanced disease. Timing of HAART initiation after an OI in "real life" settings in Latin America has not been evaluated.
   Methods
   Patients in the Caribbean, Central and South America network for HIV Epidemiology (CCA-SAnet) >= 18 years of age at enrolment, from 2001-2012 who had an OI before HAART initiation were included. Patients were divided in an early HAART (EH) group (those initiating within 4 weeks of an OI) and a delayed HAART (DH) group (those initiating more than 4 weeks after an OI). All patients with an AIDS-defining OI were included. In patients with more than one OI the first event reported was considered. Calendar trends in the proportion of patients in the EH group (before and after 2009) were estimated by site and for the whole cohort. Factors associated with EH were estimated using multivariable logistic regression models.
   Results
   A total of 1457 patients had an OI before HAART initiation and were included in the analysis: 213 from Argentina, 686 from Brazil, 283 from Chile, 119 from Honduras and 156 from Mexico. Most prevalent OI were Tuberculosis (31%), followed by Pneumocystis pneumonia (24%), Invasive Candidiasis (16%) and Toxoplasmosis (9%). Median time from OI to HAART initiation decreased significantly from 5.7 (interquartile range [IQR] 2.8-12.1) weeks before 2009 to 4.3 (IQR 2.0-7.1) after 2009 (p<0.01). Factors associated with starting HAART within 4 weeks of OI diagnosis were lower CD4 count at enrolment (p-<0.001), having a non-tuberculosis OI (p<0.001), study site (p<0.001), and more recent years of OI diagnosis (p<0.001).
   Discussion
   The time from diagnosis of an OI to HAART initiation has decreased in Latin America coinciding with the publication of evidence of its benefit. We found important heterogeneity between sites which may reflect differences in clinical practices, local guidelines, and access to HAART. The impact of the timing of HAART initiation after OI on patient survival in this "real life" context needs further evaluation.
C1 [Crabtree-Ramirez, Brenda; Caro-Vega, Yanink; Sierra-Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City, DF, Mexico.
   [Shepherd, Bryan E.] Vanderbilt Univ, Dept Biostat, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Grinsztejn, Beatriz] Inst Nacl Infectol Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Wolff, Marcelo; Cortes, Claudia P.] Univ Chile, Fdn Arriaran, Santiago, Chile.
   [Padgett, Denis] Inst Hondureno Seguro Social, Tegucigalpa, Honduras.
   [Padgett, Denis] Hosp Escuela Univ, Tegucigalpa, Honduras.
   [Carriquiry, Gabriela] Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Fink, Valeria] Fdn Huesped, Invest Clin, Buenos Aires, DF, Argentina.
   [Jayathilake, Karu; Person, Anna K.; McGowan, Catherine] Vanderbilt Univ, Dept Med, Nashville, TN USA.
RP Crabtree-Ramirez, B (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City, DF, Mexico.
EM brendcrabtree@hotmail.com
RI Cortes, Claudia/AAF-7326-2020
OI Cortes, Claudia/0000-0001-9101-9783; Crabtree-Ramirez,
   Brenda/0000-0002-2587-1123; Wolff, Marcelo/0000-0002-9956-8872
FU National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); National Cancer Institute (NCI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI); Eunice Kennedy Shriver
   National Institute of Child Health and Human Development (NICHD) as part
   of the International epidemiologic Databases to Evaluate AIDS (IeDEA)
   [U01 AI069923]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   UM1AI069476, U01AI069923, U01AI069923, U01AI069923, UM1AI069476,
   U01AI069923, UM1AI069476, U01AI069923, U01AI069923, UM1AI069476,
   UM1AI069476, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, UM1AI069476,
   UM1AI069476, UM1AI069476, U01AI069923, UM1AI069476] Funding Source: NIH
   RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (NIAID), the National Cancer Institute (NCI) and the
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD) as part of the International epidemiologic Databases
   to Evaluate AIDS (IeDEA): U01 AI069923.
CR Bisson GP, 2013, CLIN INFECT DIS, V56, P1165, DOI 10.1093/cid/cit019
   Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911
   Boulware DR, 2014, NEW ENGL J MED, V370, P2487, DOI 10.1056/NEJMoa1312884
   Centers for Disease Control and Prevention, 1993, JAMA-J AM MED ASSOC, V269, P460
   Chadborn TR, 2006, AIDS, V20, P2371, DOI 10.1097/QAD.0b013e32801138f7
   Chadborn TR, 2005, AIDS, V19, P513, DOI 10.1097/01.aids.0000162340.43310.08
   Cingolani A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089861
   Crabtree-Ramirez B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020272
   Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   Hocking JS, 2000, INT J STD AIDS, V11, P503, DOI 10.1258/0956462001916407
   Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181
   Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Manzardo C, 2013, CLIN MICROBIOL INFEC, V19, P646, DOI 10.1111/j.1469-0691.2012.03991.x
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   Sax PE, 2010, HIV CLIN TRIALS, V11, P248, DOI 10.1310/hct1105-248
   Vijayan T, 2013, CLIN INFECT DIS, V57, P1766, DOI 10.1093/cid/cit654
   World Health Organization, 2010, ANT THER HIV INF AD
   World Health Organization, 2007, WHO CAS DEF HIV SURV
   Worodria W, 2011, JAIDS-J ACQ IMM DEF, V58, P32, DOI 10.1097/QAI.0b013e3182255dc2
   Zolopa AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005575
NR 22
TC 8
Z9 9
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 7
PY 2016
VL 11
IS 6
AR e0153921
DI 10.1371/journal.pone.0153921
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DO1TC
UT WOS:000377561000002
PM 27271083
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Volk, JE
   Lippman, SA
   Grinsztejn, B
   Lama, JR
   Fernandes, NM
   Gonzales, P
   Hessol, NA
   Buchbinder, S
AF Volk, Jonathan E.
   Lippman, Sheri A.
   Grinsztejn, Beatriz
   Lama, Javier R.
   Fernandes, Nilo M.
   Gonzales, Pedro
   Hessol, Nancy A.
   Buchbinder, Susan
TI Acceptability and feasibility of HIV self-testing among men who have sex
   with men in Peru and Brazil
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE HIV; AIDS; self-testing; men; MSM; viral disease; homosexual; diagnosis;
   South America; screening
ID INFECTIONS
AB HIV self-testing has the potential to increase testing frequency and uptake. This pilot study assessed the feasibility and acceptability of HIV self-testing in a sample of sexually active men who have sex with men (MSM) in Peru and Brazil. Participants were trained to use a whole blood rapid HIV self-test and instructed to use the self-test monthly during this three-month study. Test acceptability was measured with self-reported use of the test at the one-month and three-month study visits, and test feasibility was assessed by direct observation of self-test administration at the final three-month visit. A total of 103 participants (52 in Peru and 51 in Brazil) were enrolled, and 86% completed the three-month study. Nearly all participants reported use of the self-test (97% at one-month and 98% at three-month visit), and all participants correctly interpreted the self-administered test results when observed using the test at the final study visit. HIV self-testing with a blood-based assay was highly acceptable and feasible. HIV self-testing may have the potential to increase testing frequency and to reach high-risk MSM not currently accessing HIV-testing services.
C1 [Volk, Jonathan E.; Buchbinder, Susan] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [Lippman, Sheri A.] Univ Calif San Francisco, Dept Med, Ctr AIDS Prevent Studies, San Francisco, CA USA.
   [Grinsztejn, Beatriz; Fernandes, Nilo M.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Lama, Javier R.; Gonzales, Pedro] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Hessol, Nancy A.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA.
   [Hessol, Nancy A.; Buchbinder, Susan] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Buchbinder, Susan] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
   [Buchbinder, Susan] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
RP Volk, JE (corresponding author), 25 Van Ness Ave,Suite 100, San Francisco, CA 94102 USA.
EM jvolk@stanfordalumni.org
OI Lippman, Sheri/0000-0003-3152-9372
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01-AI083060]; National Institutes of
   Mental Health of the U.S. Public Health Service [MH-19105-23]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI083060, UM1AI069476, R01AI083060, UM1AI069476, UM1AI069476,
   UM1AI069476, R01AI083060, R01AI083060, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, T32MH019105, T32MH019105, P30MH062246,
   P30MH062246, P30MH062246, T32MH019105, T32MH019105, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, T32MH019105,
   P30MH062246, P30MH062246, P30MH062246, T32MH019105, P30MH062246,
   T32MH019105, P30MH062246, T32MH019105, T32MH019105, T32MH019105,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   T32MH019105, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, T32MH019105, P30MH062246, T32MH019105,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, T32MH019105, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, T32MH019105, P30MH062246, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, T32MH019105, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   T32MH019105, P30MH062246, P30MH062246, P30MH062246, T32MH019105,
   T32MH019105, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, T32MH019105, T32MH019105, P30MH062246, T32MH019105,
   P30MH062246, T32MH019105, P30MH062246, T32MH019105, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246] Funding Source: NIH
   RePORTER
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work is
   supported by NIH grant R01-AI083060. Dr. J.E.V. received support from
   the Traineeship in AIDS Prevention Studies T32 post-doctoral fellowship
   (MH-19105-23) from the National Institutes of Mental Health of the U.S.
   Public Health Service.
CR Alarcón Jorge O, 2012, Rev. perú. med. exp. salud publica, V29, P452, DOI 10.1590/s1726-46342012000400006
   [Anonymous], 2012, ORASURE REC FDA APPR
   Choko AT, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001102
   Holigrave DR, 2007, JAIDS-J ACQ IMM DEF, V44, P360, DOI 10.1097/QAI.0b013e31802ea4dd
   Katz DA, 2014, SEX TRANSM DIS, V41, P2, DOI 10.1097/OLQ.0000000000000046
   Lee VJ, 2007, JAIDS-J ACQ IMM DEF, V45, P449, DOI 10.1097/QAI.0b013e318095a3f3
   Lippman SA, 2007, SEX TRANSM DIS, V34, P421, DOI 10.1097/01.olq.0000245958.34961.27
   Lippman SA, 2014, CAD SAUDE PUBLICA, V30, P724, DOI 10.1590/0102-311X00008913
   Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d
   Ministerio de Salud, 2012, CON INF VIR INM HUM
   Ministry of Health, 2007, NAT PLAN COP AIDS ST
   Ministry of Health, 2013, TECHN GUID HIV INF D
   Mota Rosa Maria Salani, 2012, THESIS FEDERAL U CEA
   Pai NP, 2012, LANCET INFECT DIS, V12, P373, DOI 10.1016/S1473-3099(11)70368-1
   Pinkerton SD, 2008, JAIDS-J ACQ IMM DEF, V47, P354, DOI 10.1097/QAI.0b013e318160d57e
NR 15
TC 38
Z9 40
U1 0
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD JUN
PY 2016
VL 27
IS 7
BP 531
EP 536
DI 10.1177/0956462415586676
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DM9DG
UT WOS:000376664100003
PM 25971262
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Rohner, E
   Buetikofer, L
   Maskew, M
   Fink, V
   Grinsztejn, B
   Achenbach, C
   Goedert, JJ
   Bohlius, J
AF Rohner, Eliane
   Buetikofer, Lukas
   Maskew, Mhairi
   Fink, Valeria
   Grinsztejn, Beatriz
   Achenbach, Chad
   Goedert, James J.
   Bohlius, Julia
TI NHL risk in HIV plus adults on antiretroviral therapy in four continents
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 03-07, 2016
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.
   Univ Bern, Clin Trials Unit, Bern, Switzerland.
   Univ Witwatersrand, Hlth Econ & Epidemiol Res Off, Wits Health Consortium, Johannesburg, South Africa.
   Fdn Huesped, Buenos Aires, DF, Argentina.
   Inst Nacl Infectol Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   NCI, Rockville, MD USA.
RI Achenbach, Chad/AAQ-4035-2020
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2016
VL 34
IS 15
SU S
MA 1578
DI 10.1200/JCO.2016.34.15_suppl.1578
PG 2
WC Oncology
SC Oncology
GA EZ4EM
UT WOS:000404665402126
DA 2020-11-24
ER

PT J
AU Landovitz, RJ
   Grinsztejn, B
AF Landovitz, Raphael J.
   Grinsztejn, Beatriz
TI M Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in
   South Africa: Is There a Will and a Way?
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Editorial Material
DE HIV prevention; cost efficacy; antiretroviral agent; PrEP; extended
   release; long acting
ID ANTIRETROVIRAL PROPHYLAXIS; INFECTION; WOMEN; INITIATION; TENOFOVIR;
   THERAPY; TRIAL
C1 [Landovitz, Raphael J.] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, 11075 Santa Monica Blvd,Ste 100, Los Angeles, CA 90025 USA.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
RP Landovitz, RJ (corresponding author), Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, 11075 Santa Monica Blvd,Ste 100, Los Angeles, CA 90025 USA.
EM rlandovitz@mednet.ucla.edu
CR Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cottrell ML, 2014, HIV RES PREV 28 31 O
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Penrose KJ, 2014, HIV RES PREV 28 31 O
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Walensky RP, 2012, CLIN INFECT DIS, V54, P1504, DOI 10.1093/cid/cis225
NR 13
TC 2
Z9 2
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2016
VL 213
IS 10
BP 1519
EP 1520
DI 10.1093/infdis/jiv524
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DM8XX
UT WOS:000376648900001
PM 26681779
OA Bronze
DA 2020-11-24
ER

PT J
AU Wilson, EC
   Jalil, E
   Siqueira, BH
   Moreira, RI
   Veloso, VG
   Monteiro, L
   Grinsztejn, B
AF Wilson, Erin C.
   Jalil, Emilia
   Siqueira, Brenda H.
   Moreira, Ronaldo I.
   Veloso, Valdilea G.
   Monteiro, Laylla
   Grinsztejn, Beatriz
TI PrEP adherence among trans women in Brazil-access needed for this key
   population
SO LANCET HIV
LA English
DT Letter
ID PREEXPOSURE PROPHYLAXIS
C1 [Wilson, Erin C.] San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA.
   [Jalil, Emilia; Siqueira, Brenda H.; Moreira, Ronaldo I.; Veloso, Valdilea G.; Monteiro, Laylla; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas IPEC, Fiocruz, Brazil.
RP Wilson, EC (corresponding author), San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA.
EM erin.wilson@sfdph.org
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01 AI048022] Funding Source: Medline
CR Baral SD, 2013, LANCET INFECT DIS, V13, P13, DOI 10.1016/S1473-3099(12)70319-5
   Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
NR 3
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD MAY
PY 2016
VL 3
IS 5
BP E200
EP E200
DI 10.1016/S2352-3018(16)30022-4
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DQ1GR
UT WOS:000378950000007
PM 27126485
OA Bronze
DA 2020-11-24
ER

PT J
AU Luetkemeyer, AF
   Firnhaber, C
   Kendall, MA
   Wu, XY
   Mazurek, GH
   Benator, DA
   Arduino, R
   Fernandez, M
   Guy, E
   Johnson, P
   Metchock, B
   Sattler, F
   Telzak, E
   Wang, YF
   Weiner, M
   Swindells, S
   Sanne, IM
   Havlir, DV
   Grinsztejn, B
   Alland, D
AF Luetkemeyer, Anne F.
   Firnhaber, Cynthia
   Kendall, Michelle A.
   Wu, Xingye
   Mazurek, Gerald H.
   Benator, Debra A.
   Arduino, Roberto
   Fernandez, Michel
   Guy, Elizabeth
   Johnson, Pamela
   Metchock, Beverly
   Sattler, Fred
   Telzak, Edward
   Wang, Yun F.
   Weiner, Marc
   Swindells, Susan
   Sanne, Ian M.
   Havlir, Diane V.
   Grinsztejn, Beatriz
   Alland, David
CA AIDS Clinical Trials Grp A5295
   TB Trials Consortium Study 34 Team
TI Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify
   Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low
   and Higher Prevalence Settings
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Xpert MTB/RIF; tuberculosis diagnosis; respiratory isolation;
   nontuberculous mycobacteria; HIV/tuberculosis coinfection
AB Background. The Xpert MTB/RIF (Xpert) assay is a rapid nucleic acid amplification test widely used in settings of high tuberculosis prevalence to detect tuberculosis as well as rpoB mutations associated with rifampin resistance. Data are needed on the diagnostic performance of Xpert in lower-prevalence settings to inform appropriate use for both tuberculosis detection and the need for respiratory isolation.
   Methods. Xpert was compared to 2 sputum samples, each evaluated with acid-fast bacilli (AFB) smear and mycobacterial culture using liquid and solid culture media, from participants with suspected pulmonary tuberculosis from the United States, Brazil, and South Africa.
   Results. Of 992 participants enrolled with evaluable results, 22% had culture-confirmed tuberculosis. In 638 (64%) US participants, 1 Xpert result demonstrated sensitivity of 85.2% (96.7% in participants with AFB smear-positive [AFB(+)] sputum, 59.3% with AFB smear-negative [AFB(-)] sputum), specificity of 99.2%, negative predictive value (NPV) of 97.6%, and positive predictive value of 94.9%. Results did not differ between higher-and low-prevalence settings. A second Xpert assay increased overall sensitivity to 91.1% (100% if AFB(+), 71.4% if AFB(-)), with specificity of 98.9%. In US participants, a single negative Xpert result predicted the absence of AFB(+)/culture-positive tuberculosis with an NPV of 99.7%; NPV of 2 Xpert assays was 100%, suggesting a role in removing patients from airborne infection isolation. Xpert detected tuberculosis DNA and mutations associated with rifampin resistance in 5 of 7 participants with rifampin-resistant, culture-positive tuberculosis. Specificity for rifampin resistance was 99.5% and NPV was 98.9%.
   Conclusions. In the United States, Xpert testing performed comparably to 2 higher-tuberculosis-prevalence settings. These data support the use of Xpert in the initial evaluation of tuberculosis suspects and in algorithms assessing need for respiratory isolation.
C1 [Luetkemeyer, Anne F.; Havlir, Diane V.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV Infect Dis & Global Med, Box 0874,Bldg 80,995 Potrero Ave, San Francisco, CA 94110 USA.
   [Firnhaber, Cynthia] Univ Witwatersrand, Fac Hlth Sci, Clin HIV Res Unit, Dept Internal Med, ZA-2050 Johannesburg, South Africa.
   [Firnhaber, Cynthia; Sanne, Ian M.] Right Care, Johannesburg, South Africa.
   [Kendall, Michelle A.; Wu, Xingye] Harvard Univ, TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [Mazurek, Gerald H.; Metchock, Beverly] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA.
   [Benator, Debra A.] Vet Affairs Med Ctr, Infect Dis Sect, 50 Irving St NW, Washington, DC 20422 USA.
   [Benator, Debra A.] George Washington Univ, Washington, DC USA.
   [Arduino, Roberto] Univ Texas Hlth Sci Ctr Houston, Div Infect Dis, Dept Internal Med, Houston, TX 77030 USA.
   [Fernandez, Michel] Univ N Texas, Hlth Sci Ctr, Tarrant Cty Hlth Dept, Ft Worth, TX USA.
   [Guy, Elizabeth] Baylor Coll Med, Ben Taub Gen Hosp, Sect Pulm Crit Care & Sleep Med, Houston, TX 77030 USA.
   [Johnson, Pamela] Cepheid, Sunnyvale, CA USA.
   [Sattler, Fred] Univ So Calif, Keck Sch Med, Div Infect Dis, Los Angeles, CA 90033 USA.
   [Telzak, Edward] Albert Einstein Coll Med, St Barnabus Hosp Hlth Syst, Bronx, NY 10467 USA.
   [Wang, Yun F.] Emory Univ, Sch Med, Grady Mem Hosp, Atlanta, GA USA.
   [Weiner, Marc] Univ Texas Hlth Sci Ctr San Antonio, Vet Adm Med Ctr, Dept Med, San Antonio, TX 78229 USA.
   [Swindells, Susan] Univ Nebraska Med Ctr, Internal Med Infect Dis, Lincoln, NE USA.
   [Sanne, Ian M.] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Johannesburg, South Africa.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas Fiocruz, Dept Infect Dis, Rio De Janeiro, Brazil.
   [Alland, David] Rutgers New Jersey Med Sch, Div Infect Dis, Newark, NJ USA.
RP Luetkemeyer, AF (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV Infect Dis & Global Med, Box 0874,Bldg 80,995 Potrero Ave, San Francisco, CA 94110 USA.
EM annie.luetkemeyer@ucsf.edu
RI Kendall, Michelle A/B-7665-2016
OI Kendall, Michelle A/0000-0001-9160-4544
FU National Institute of Allergy and Infectious Diseases through the ACTG
   [AI068634, U01AI068636, UM1 AI106701]; CDC through the TBTCUnited States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA; Division of Tuberculosis Elimination; National Center
   for HIV; Viral Hepatitis; STD; TB Prevention; National Institute of
   Mental HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH); National Institute of Dental and Craniofacial ResearchUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Dental & Craniofacial
   Research (NIDCR); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI068636, UM1AI068634, U01AI068636,
   UM1AI068634, U01AI068636, U01AI068634, UM1AI069463, UM1AI069496,
   UM1AI069476, UM1AI069463, UM1AI068636, U01AI068634, UM1AI069463,
   UM1AI068634, UM1AI069496, UM1AI068634, UM1AI069496, UM1AI068636,
   UM1AI068634, U01AI068636, UM1AI069463, U01AI068636, UM1AI069496,
   UM1AI068636, UM1AI106701, UM1AI068636, UM1AI068634, UM1AI068634,
   UM1AI069463, U01AI068634, UM1AI069476, UM1AI068634, UM1AI068636,
   UM1AI069476, UM1AI106701, UM1AI069476, UM1AI069476, UM1AI068636,
   U01AI068634, UM1AI069496, UM1AI069496, U01AI068636, UM1AI069496,
   UM1AI106701, UM1AI069463, U01AI068634, UM1AI106701, U01AI068636,
   UM1AI068636, UM1AI068634, UM1AI068636, UM1AI068636, UM1AI106701,
   UM1AI069463, UM1AI068634, UM1AI069496, U01AI068636, UM1AI069476,
   UM1AI069496, UM1AI069463, UM1AI069463, UM1AI106701, UM1AI106701,
   UM1AI068636, UM1AI106701, UM1AI068634, UM1AI069476, UM1AI068636,
   UM1AI069496, UM1AI106701, UM1AI069476] Funding Source: NIH RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases through the ACTG (grant numbers AI068634,
   U01AI068636, and UM1 AI106701); the CDC through the TBTC and the
   Division of Tuberculosis Elimination, National Center for HIV, Viral
   Hepatitis, STD, and TB Prevention; the National Institute of Mental
   Health, and the National Institute of Dental and Craniofacial Research.
CR Bevilaqua AA, 2014, B TUBERCULOSE 2014
   Blakemore R, 2010, J CLIN MICROBIOL, V48, P2495, DOI 10.1128/JCM.00128-10
   Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847
   Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010
   Centers for Disease Control and Prevention, LAB US GUID US PUBL
   Cepheid, 2013, XPERT MTB RIF PACK I
   DUTT AK, 1989, AM REV RESPIR DIS, V139, P867, DOI 10.1164/ajrccm/139.4.867
   Gitterman S, 2015, MMWR-MORBID MORTAL W, V64, P193
   Iademarco MF, 2013, MMWR-MORBID MORTAL W, V62, P821
   Jensen Paul A., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Kent P.T., 1985, PUBLIC HLTH MYCOBACT
   Nanoo A, 2015, LANCET INFECT DIS, V15, P1066, DOI 10.1016/S1473-3099(15)00147-4
   Shah NS, 2012, INT J TUBERC LUNG D, V16, P1234, DOI 10.5588/ijtld.11.0794
   Steingart KR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009593.pub3
NR 14
TC 38
Z9 40
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 1
PY 2016
VL 62
IS 9
BP 1081
EP 1088
DI 10.1093/cid/ciw035
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DM5IO
UT WOS:000376381800004
PM 26839383
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Glidden, DV
   Amico, KR
   Liu, AY
   Hosek, SG
   Anderson, PL
   Buchbinder, SP
   McMahan, V
   Mayer, KH
   David, B
   Schechter, M
   Grinsztejn, B
   Guanira, J
   Grant, RM
AF Glidden, David V.
   Amico, K. Rivet
   Liu, Albert Y.
   Hosek, Sybil G.
   Anderson, Peter L.
   Buchbinder, Susan P.
   McMahan, Vanessa
   Mayer, Kenneth H.
   David, Burns
   Schechter, Mauro
   Grinsztejn, Beatriz
   Guanira, Juan
   Grant, Robert M.
TI Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV prevention; pre-exposure prophylaxis; tenofovir/emtricitabine; PrEP
ID PREEXPOSURE PROPHYLAXIS; HIV-INFECTION; ANTIRETROVIRAL PROPHYLAXIS;
   BANGKOK TENOFOVIR; RENAL-FUNCTION; AFRICAN WOMEN; DOUBLE-BLIND; TRIAL;
   MEN; EMTRICITABINE
AB Background. Blinded clinical trials have reported a modest and transient "start-up syndrome" with initiation of tenofovir-based pre-exposure prophylaxis (PrEP). We evaluate this phenomenon and its effect on adherence in an open-label PrEP study.
   Methods. In the iPrEx open-label extension (OLE) study, an 18-month open-label, multi-site PrEP cohort taking daily oral co-formulated tenofovir/emtricitabine, we examined the prevalence and duration of PrEP-associated symptoms and their effect on adherence, assessed by drug levels in dried blood spots tested monthly for the first 3 months.
   Results. Symptom reports peaked within the first month, with 39% reporting potentially PrEP-related symptoms compared to 22% at baseline. Symptoms largely resolved to pre-PrEP levels by 3 months. Symptoms varied substantially in frequency by study site (range in 1-month symptoms: 11% to 70%). Nongastrointestinal (GI) symptoms were not associated with adherence (odds ratio [OR] = 1.2, 95% confidence interval [CI], .4-3.7); however, GI-associated symptoms in the first 4 weeks were inversely associated with adherence at 4 weeks (OR = 0.47, 95% CI, .23-.96). Reports of GI symptoms were associated with 7% (95% CI, 4%-11%) of suboptimal adherence in this cohort.
   Conclusions. PrEP-associated symptoms in the open-label setting occur in a minority of users and largely resolve within 3 months. GI symptoms are associated with a modest reduction in PrEP adherence, but good adherence is possible even in the presence of frequent symptom reports.
C1 [Glidden, David V.] Univ Calif San Francisco, San Francisco, CA 94158 USA.
   [Amico, K. Rivet] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Liu, Albert Y.; Buchbinder, Susan P.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [Hosek, Sybil G.] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA.
   [Anderson, Peter L.] Univ Colorado, Denver, CO 80202 USA.
   [McMahan, Vanessa] Univ Washington, Seattle, WA 98195 USA.
   [Mayer, Kenneth H.] Fenway Hlth, Boston, MA USA.
   [Mayer, Kenneth H.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [David, Burns] NIAID, Rockville, MD USA.
   [Schechter, Mauro] Hosp Escola Sao Francisco Assis, Projeto Pra Onze, Rio De Janeiro, Brazil.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Natl Inst Infect Dis, BR-21045900 Rio De Janeiro, Brazil.
   [Guanira, Juan] Invest Med Salud, Lima, Peru.
   [Grant, Robert M.] Gladstone Inst Virol & San Francisco AIDS Fdn, San Francisco, CA USA.
RP Glidden, DV (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 550 16th St, San Francisco, CA 94158 USA.
EM david.glidden@ucsf.edu
RI /AAE-4700-2020; Glidden, David/AAD-4730-2020; Schechter,
   Mauro/AAG-7445-2020
OI Glidden, David/0000-0001-5888-1419; Guanira, Juan/0000-0002-2746-3086;
   Grant, Robert/0000-0002-0851-7085; Amico, K Rivet/0000-0002-4458-6934
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01 AI106499, UM1 AI068619, U01 AI064002, R03 AI120819, R03 AI122908];
   US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA; Bill and
   Melinda Gates FoundationBill & Melinda Gates Foundation; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069496, UM1AI068619, UM1AI068619, U01AI106499, U01AI106499,
   UM1AI069476, UM1AI068619, U01AI064002, U01AI064002, UM1AI068619,
   UM1AI069496, R03AI122908, U01AI064002, UM1AI069496, U01AI106499,
   UM1AI069476, U01AI064002, R03AI120819, UM1AI068619, UM1AI069476,
   R03AI122908, UM1AI068619, U01AI064002, UM1AI069476, UM1AI069496,
   U01AI064002, UM1AI069496, UM1AI069476, UM1AI069476, UM1AI068619,
   U01AI064002, UM1AI069476, UM1AI069496, UM1AI069496, UM1AI069476,
   U01AI106499, U01AI064002, UM1AI068619, UM1AI069496, U01AI064002,
   UM1AI069496, UM1AI068619, R03AI120819, UM1AI068619, UM1AI068619,
   UM1AI069476] Funding Source: NIH RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases. (U01 AI106499, UM1 AI068619, U01 AI064002, R03
   AI120819, R03 AI122908). Study medication was donated by Gilead
   Sciences. The iPrEx studies were sponsored by the US National Institutes
   of Health with cofunding from the Bill and Melinda Gates Foundation.
CR Agresti A., 2010, ANAL ORDINAL CATEGOR
   Ammassari A, 2001, J ACQ IMMUN DEF SYND, V28, P445, DOI 10.1097/00042560-200112150-00006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/AID.2012.0089, 10.1089/aid.2012.0089]
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   FLEISS JL, 1979, AM J EPIDEMIOL, V110, P103, DOI 10.1093/oxfordjournals.aje.a112794
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grohskopf LA, 2013, JAIDS-J ACQ IMM DEF, V64, P79, DOI 10.1097/QAI.0b013e31828ece33
   Hosek SG, 2013, JAIDS-J ACQ IMM DEF, V62, P447, DOI 10.1097/QAI.0b013e3182801081
   Liu AY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023688
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Martin M, 2014, CLIN INFECT DIS, V59, P716, DOI 10.1093/cid/ciu355
   Mayer KH, 2008, JAIDS-J ACQ IMM DEF, V47, P494, DOI 10.1097/QAI.0b013e318162afcb
   Michael K, 2014, PLOS ONE, V9
   Molina J-M, 2015, 22 C RETR OPP INF SE
   Mugwanya KK, 2015, JAMA INTERN MED, V175, P246, DOI 10.1001/jamainternmed.2014.6786
   Mulligan K, 2015, CLIN INFECT DIS, V61, P572, DOI 10.1093/cid/civ324
   PRENTICE RL, 1986, BIOMETRIKA, V73, P1
   Solomon MM, 2014, AIDS, V28, P851, DOI 10.1097/QAD.0000000000000156
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
NR 22
TC 27
Z9 27
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 1
PY 2016
VL 62
IS 9
BP 1172
EP 1177
DI 10.1093/cid/ciw022
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DM5IO
UT WOS:000376381800019
PM 26797207
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Silva, DS
   De Boni, RB
   Lake, JE
   Cardoso, SW
   Ribeiro, S
   Moreira, RI
   Clark, JL
   Veloso, VG
   Grinsztejn, B
   Luz, PM
AF Silva, Daniel S.
   De Boni, Raquel B.
   Lake, Jordan E.
   Cardoso, Sandra W.
   Ribeiro, Sayonara
   Moreira, Ronaldo I.
   Clark, Jesse L.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Luz, Paula M.
TI Retention in Early Care at an HIV Outpatient Clinic in Rio de Janeiro,
   Brazil, 2000-2013
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Retention; Acquired immunodeficiency syndrome; Highly active
   antiretroviral therapy; Cohort studies; Urban population
ID MEDICAL-CARE; ANTIRETROVIRAL THERAPY; ANCILLARY SERVICES; UNITED-STATES;
   IMPROVES RETENTION; RISK BEHAVIORS; HEALTH SURVEY; ENGAGEMENT;
   INFECTION; COHORT
AB Retention in early HIV care has been associated with virologic suppression and improved survival, but remains understudied in Brazil. We estimated retention in early HIV care for the period 2000-2013, and identified socio-demographic and clinical factors associated with good retention in an urban cohort from Rio de Janeiro, Brazil. Antiretroviral therapy-na < ve, HIV-infected persons a parts per thousand yen18 years old linked to care between 2000 and 2011 were included. Retention in the first 2 years post-linkage (i.e. early care) was defined by the proportion of 6-month intervals with a parts per thousand yen1 HIV laboratory result. "Good" retention was defined as a parts per thousand yen1 HIV laboratory result recorded in at least three intervals. Overall, 80 % of participants met criteria for good retention and retention significantly improved over the study period. Older age, higher education level and early antiretroviral therapy initiation were associated with good retention. Efforts to improve retention in early care in this population should target younger and less-educated HIV-infected persons.
C1 [Silva, Daniel S.; Lake, Jordan E.; Clark, Jesse L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   [Silva, Daniel S.] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [De Boni, Raquel B.; Cardoso, Sandra W.; Ribeiro, Sayonara; Moreira, Ronaldo I.; Veloso, Valdilea G.; Grinsztejn, Beatriz; Luz, Paula M.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
RP Silva, DS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.; Silva, DS (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.
EM dsilva@bu.edu
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Clark,
   Jesse/0000-0001-5862-6530; Teixeira da Silva,
   Daniel/0000-0003-3525-605X; Luz, Paula/0000-0001-9746-719X
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R25 MH087222, K23 AI110532];
   Infectious Disease Society of America; American Society of Tropical
   Medicine and Hygiene; National Council of Technological and Scientific
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); Research Funding Agency of the State of Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [K23AI110532, K23AI110532,
   UM1AI069476, UM1AI069476, K23AI110532, UM1AI069476, K23AI110532,
   UM1AI069476, UM1AI069476, K23AI110532, UM1AI069476, UM1AI069476,
   UM1AI069476, K23AI110532, UM1AI069476] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, R25MH087222,
   R25MH087222, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, R25MH087222, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, R25MH087222, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107] Funding Source: NIH RePORTER
FX We would like to thank all the participants enrolled in the INI HIV/AIDS
   program, as well as the hard working and dedicated staff at INI. We
   would also like to thank Eddy Segura for his assistance in translating
   our abstract into Spanish. Support for DS provided by the NIH R25
   MH087222 (South American Program in HIV Prevention Research), the
   Infectious Disease Society of America and the American Society of
   Tropical Medicine and Hygiene. Support for JEL provided by the NIH K23
   AI110532. PL and BG acknowledge funding from the National Council of
   Technological and Scientific Development (CNPq) and the Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ).
CR [Anonymous], 2014, B EP AIDS DST SECR H
   [Anonymous], 2008, REC TER ANT AD INF P
   [Anonymous], 2013, PROT CLIN DIR TER MA
   [Anonymous], 2013, BOLETIM EPIDEMIOLOGI
   [Anonymous], 1993 REV CLASS SYST, V41
   [Anonymous], 2014, UNAIDS GLOB AIDS RES
   Ashman JJ, 2002, AIDS CARE, V14, pS109, DOI [10.1080/09540120220149993a, 10.1080/09540120220149993]
   Barclay TR, 2007, HEALTH PSYCHOL, V26, P40, DOI 10.1037/0278-6133.26.1.40
   Nemes MIB, 2013, REV SAUDE PUBL, V47, P137, DOI [10.1590/S0034-89102013000100018, 10.1590/s0034-89102013000100018]
   Berkman A, 2005, AM J PUBLIC HEALTH, V95, P1162, DOI 10.2105/AJPH.2004.054593
   Bradley H, 2014, MMWR-MORBID MORTAL W, V63, P1113
   Brito Ana Maria de, 2005, Braz J Infect Dis, V9, P9, DOI 10.1590/S1413-86702005000100004
   Cardoso SW, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0699-5
   Cardoso SW, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-29
   Carthery-Goulart MT, 2009, REV SAUDE PUBL, V43, P631, DOI 10.1590/S0034-89102009005000031
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cohen SM, 2014, JAIDS-J ACQ IMM DEF, V67, P519, DOI 10.1097/QAI.0000000000000349
   Crawford TN, 2014, AIDS BEHAV, V18, P617, DOI 10.1007/s10461-013-0524-y
   Crawford TN, 2013, AIDS BEHAV, V17, P3145, DOI 10.1007/s10461-013-0559-0
   Davila JA, 2013, AIDS CARE, V25, P202, DOI 10.1080/09540121.2012.689811
   de Souza CTV, 2002, J ACQ IMMUN DEF SYND, V29, P95, DOI 10.1097/00126334-200201010-00013
   Dowshen N, 2009, AIDS PATIENT CARE ST, V23, P371, DOI 10.1089/apc.2008.0256
   Gardner LI, 2014, CLIN INFECT DIS, V59, P725, DOI 10.1093/cid/ciu357
   Geng Elvin H, 2010, Curr HIV/AIDS Rep, V7, P234, DOI 10.1007/s11904-010-0061-5
   Giordano TP, 2007, CLIN INFECT DIS, V44, P1493, DOI 10.1086/516778
   Giordano TR, 2009, HIV CLIN TRIALS, V10, P299, DOI 10.1310/hct1005-299
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   Lo W, 2002, AIDS CARE, V14, pS45, DOI 10.1080/0954012022014992049984
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Messeri PA, 2002, AIDS CARE, V14, pS15, DOI 10.1080/09540120220149948
   Metsch LR, 2008, CLIN INFECT DIS, V47, P577, DOI 10.1086/590153
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Mugavero MJ, 2012, JAIDS-J ACQ IMM DEF, V61, P574, DOI 10.1097/QAI.0b013e318273762f
   Mugavero MJ, 2012, JAIDS-J ACQ IMM DEF, V59, P86, DOI 10.1097/QAI.0b013e318236f7d2
   Mugavero MJ, 2011, CLIN INFECT DIS, V52, pS238, DOI 10.1093/cid/ciq048
   Mugavero MJ, 2010, AIDS PATIENT CARE ST, V24, P607, DOI 10.1089/apc.2010.0086
   Naar-King S, 2007, AIDS CARE, V19, P248, DOI 10.1080/09540120600726958
   Nemes MIB, 2004, AIDS, V18, pS15, DOI 10.1097/00002030-200406003-00004
   Olatosi BA, 2009, AIDS, V23, P725, DOI 10.1097/QAD.0b013e328326f546
   Rao D, 2007, AIDS CARE, V19, P28, DOI 10.1080/09540120600652303
   Reveles KR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120953
   Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298
   Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056
   Ryscavage PA, 2011, JAIDS-J ACQ IMM DEF, V58, P193, DOI [10.1097/QAI.0b013e31822d7564, 10.1097/QAI.0B013E31822D7564]
   Sevelius JM, 2014, ANN BEHAV MED, V47, P5, DOI 10.1007/s12160-013-9565-8
   Silveira CM, 2011, ALCOHOL ALCOHOLISM, V46, P324, DOI 10.1093/alcalc/agr007
   Silveira MF, 2002, SEX TRANSM DIS, V29, P536, DOI 10.1097/00007435-200209000-00008
   Szwarcwald CL, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-217
   Tobias CR, 2007, AIDS PATIENT CARE ST, V21, P426, DOI 10.1089/apc.2006.0138
   Tripathi A, 2011, AIDS RES HUM RETROV, V27, P751, DOI [10.1089/AID.2010.0268, 10.1089/aid.2010.0268]
   Ulett KB, 2009, AIDS PATIENT CARE ST, V23, P41, DOI 10.1089/apc.2008.0132
   Wohl AR, 2011, AIDS CARE, V23, P988, DOI 10.1080/09540121.2010.542125
   Yehia BR, 2012, AIDS, V26, P1131, DOI 10.1097/QAD.0b013e3283528afa
   Yehia BR, 2014, J ACQ IMMUN DEF SYND, V68, P413
NR 56
TC 3
Z9 4
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD MAY
PY 2016
VL 20
IS 5
BP 1039
EP 1048
DI 10.1007/s10461-015-1235-3
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DK3XM
UT WOS:000374850700010
PM 26525222
OA Green Accepted, Green Published
DA 2020-11-24
ER

PT J
AU Althoff, KN
   Rebeiro, PF
   Hanna, DB
   Padgett, D
   Horberg, MA
   Grinsztejn, B
   Abraham, AG
   Hogg, R
   Gill, MJ
   Wolff, MJ
   Mayor, A
   Rachlis, A
   Williams, C
   Sterling, TR
   Kitahata, MM
   Buchacz, K
   Thorne, JE
   Cesar, C
   Cordero, FM
   Rourke, SB
   Sierra-Madero, J
   Pape, JW
   Cahn, P
   McGowan, C
AF Althoff, Keri N.
   Rebeiro, Peter F.
   Hanna, David B.
   Padgett, Denis
   Horberg, Michael A.
   Grinsztejn, Beatriz
   Abraham, Alison G.
   Hogg, Robert
   Gill, M. John
   Wolff, Marcelo J.
   Mayor, Angel
   Rachlis, Anita
   Williams, Carolyn
   Sterling, Timothy R.
   Kitahata, Mari M.
   Buchacz, Kate
   Thorne, Jennifer E.
   Cesar, Carina
   Cordero, Fernando M.
   Rourke, Sean B.
   Sierra-Madero, Juan
   Pape, Jean W.
   Cahn, Pedro
   McGowan, Catherine
CA na-Accord
   Caribbean Cent South Amer Network
TI A picture is worth a thousand words: maps of HIV indicators to inform
   research, programs, and policy from NA-ACCORD and CCASAnet clinical
   cohorts
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE Map; HIV indicators; CD4 T-lymphocyte count; retention in care;
   antiretroviral therapy; HIV RNA suppression; North America; Central
   America; South America; implementation science
ID ANTIRETROVIRAL THERAPY; INFECTION; CARE; PREVENTION; STATES
AB Introduction: Maps are powerful tools for visualization of differences in health indicators by geographical region, but multicountry maps of HIV indicators do not exist, perhaps due to lack of consistent data across countries. Our objective was to create maps of four HIV indicators in North, Central, and South American countries.
   Methods: Using data from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) and the Caribbean, Central, and South America network for HIV epidemiology (CCASAnet), we mapped median CD4 at presentation for HIV clinical care, proportion retained in HIV primary care, proportion prescribed antiretroviral therapy (ART), and the proportion with suppressed plasma HIV viral load (VL) from 2010 to 2012 for North, Central, and South America. The 15 Canadian and US clinical cohorts and 7 clinical cohorts in Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru represented approximately 2 similar to 7% of persons known to be living with HIV in these countries.
   Results: Study populations were selected for each indicator: median CD4 at presentation for care was estimated among 14,811 adults; retention was estimated among 87,979 adults; ART use was estimated among 84,757 adults; and suppressed VL was estimated among 51,118 adults. Only three US states and the District of Columbia had a median CD4 at presentation similar to 350 cells/mm(3). Haiti, Mexico, and several states had >85% retention in care; lower (50 74%) retention in care was observed in the US West, South, and Mid-Atlantic, and in Argentina, Brazil, and Peru. ART use was highest (90%) in Mexico. The percentages of patients with suppressed VL in the US South and Northeast were lower than in most of Central and South America.
   Conclusions: These maps provide visualization of gaps in the quality of HIV care and allow for comparison between and within countries as well as monitoring policy and programme goals within geographical boundaries.
C1 [Althoff, Keri N.; Abraham, Alison G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Rebeiro, Peter F.; Sterling, Timothy R.; McGowan, Catherine] Vanderbilt Univ, Dept Med, Nashville, TN USA.
   [Hanna, David B.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Padgett, Denis] Inst Hondureno Seguridad Social, Infect Dis Serv, Dept Internal Med, Tegucigalpa, Honduras.
   [Horberg, Michael A.] Kaiser Permanente Mid Atlantic States, Mid Atlantic Permanente Res Inst, Rockville, MD USA.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Natl Inst Infect Dis, BR-21045900 Rio De Janeiro, Brazil.
   [Hogg, Robert] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
   [Gill, M. John] Univ Calgary, Dept Med, Calgary, AB, Canada.
   [Wolff, Marcelo J.] Univ Chile, Fac Med, Dept Med, Santiago 7, Chile.
   [Wolff, Marcelo J.] Fdn Arriaran, Santiago, Chile.
   [Mayor, Angel] Univ Cent Caribe, Dept Internal Med, Bayamon, PR USA.
   [Rachlis, Anita; Thorne, Jennifer E.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON, Canada.
   [Williams, Carolyn] NIAID, Epidemiol, Basic Sci Program, Div Aids, Rockville, MD USA.
   [Kitahata, Mari M.] Univ Washington, Dept Med, Seattle, WA USA.
   [Buchacz, Kate] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
   [Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Cesar, Carina; Cahn, Pedro] Fdn Huesped, Invest Clin, Buenos Aires, DF, Argentina.
   [Cordero, Fernando M.] Univ Peruana Cayetano Heredia, Inst Medicina Trop Alexander von Humboldt, HIV Res Grp, Lima, Peru.
   [Rourke, Sean B.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
   [Sierra-Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Mexico City, DF, Mexico.
   [Pape, Jean W.] Grp Haitien Etud Sarcome Kaposi & Infect Opportun, Port Au Prince, Haiti.
   [Pape, Jean W.] Weill Cornell Med Coll, Dept Med, New York, NY USA.
RP Althoff, KN (corresponding author), 615 N Wolfe St,Rm E7142, Baltimore, MD 21201 USA.
EM kalthoff@jhu.edu
RI Hogg, Robert S/B-2783-2012; Dodsley, Maria/G-7083-2016; Cesar,
   Carina/H-2831-2019; Gill, Michael John/G-7083-2016
OI Hogg, Robert S/0000-0003-3463-5488; Dodsley, Maria/0000-0001-7587-558X;
   Gill, Michael John/0000-0002-8546-8790; Mayor, Angel
   M./0000-0002-7705-837X; Wolff, Marcelo/0000-0002-9956-8872; Rebeiro,
   Peter/0000-0003-1951-9104; Justice, Amy/0000-0003-0139-5502
FU National Institutes of Health, USAUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [P30-AI094189,
   P30-AI27757, P30-AI27767, P30-AI036219, P30-AI50410, P30-AI54999,
   P30-MH62246, R01-AA16893, R01-CA165937, R01-DA04334, R01-DA11602,
   R01-DA12568, R24-AI067039, R56-AI102622, Z01-CP010214, Z01-CP010176];
   Center's for Disease Control and Prevention, USAUnited States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
   [CDC200-2006-18797]; Agency for Healthcare Research and Quality,
   USAUnited States Department of Health & Human ServicesAgency for
   Healthcare Research & Quality [90047713]; Health Resources and Services
   Administration, USA [90051652]; Canadian Institutes of Health Research,
   CanadaCanadian Institutes of Health Research (CIHR) [TGF-96118,
   HCP-97105, CBR-86906, CBR-94036]; Canadian Institutes of Health Research
   (CIHR) New Investigator awardCanadian Institutes of Health Research
   (CIHR); Ontario Ministry of Health and Long Term CareMinistry of Health
   and Long-Term Care, Ontario; Government of Alberta, Canada; Intramural
   Research Program of the National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI); National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA;  [U01-AI69434];  [U01-DA036935]; 
   [U01-HD32632];  [U10-EY08052];  [U10-EY08057];  [U10-EY08067]; 
   [U24-AA020794];  [U54-MD007587];  [UL1-RR024131];  [UL1-TR000083]; 
   [F31-DA037788];  [F31-DA030254];  [G12-MD007583];  [K01-AI071754]; 
   [K01-AI093197];  [K23-EY013707];  [K24-DA00432];  [K24-AI065298]; 
   [KL2-TR000421];  [MO1-RR-00052];  [N02-CP55504];  [P30-AI027763]; 
   [U01-AI069918];  [U01-AA013566];  [U01-AA020790];  [U01-AI31834]; 
   [U01-AI34989];  [U01-AI34993];  [U01-AI34994];  [U01-AI35004]; 
   [U01-AI35039];  [U01-AI35040];  [U01-AI35041];  [U01-AI35042]; 
   [UM1-AI35043];  [U01-AI37613];  [U01-AI37984];  [U01AI38855]; 
   [U01-AI38858];  [U01-AI42590];  [U01-AI68634];  [U01-AI68636]; 
   [U01-AI69432]; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI)NIH National Cancer Institute-
   Division of Cancer Epidemiology & Genetics [Z01CP010176, Z01CP010176,
   Z01CP010176, Z01CP010176, Z01CP010176, Z01CP010176] Funding Source: NIH
   RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &
   HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [U01HD032632] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [U01HD032632, U01HD032632, U01HD032632,
   U01HD032632, U01HD032632, U01HD032632, U01HD032632, U01HD032632,
   U01HD032632, U01HD032632, U01HD032632, U01HD032632, U01HD032632,
   U01HD032632, U01HD032632, U01HD032632, U01HD032632, U01HD032632,
   U01HD032632, U01HD032632, U01HD032632, U01HD032632, U01HD032632,
   U01HD032632, U01HD032632] Funding Source: NIH RePORTER; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [ZIACP010214, R01CA165937, ZIACP010214, ZIACP010214, ZIACP010214,
   ZIACP010214, ZIACP010214, R01CA165937, ZIACP010214, Z01CP010176,
   ZIACP010214, Z01CP010176, R01CA165937, ZIACP010214, R01CA165937] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR000421, KL2TR002317, KL2TR000421,
   UL1TR000083, KL2TR000421, KL2TR002317, KL2TR002317, KL2TR002317,
   KL2TR000421, KL2TR000421, UL1TR000083, KL2TR002317] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   UL1RR024131, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, UL1RR024131, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, UL1RR024131, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, UL1RR024131,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   UL1RR024131, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, UL1RR024131,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, UL1RR024131, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, UL1RR024131,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, UL1RR024131, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   UL1RR024131, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, UL1RR024131, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, UL1RR024131, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, UL1RR024131, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   UL1RR024131, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, UL1RR024131, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, UL1RR024131, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   UL1RR024131, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   UL1RR024131, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, UL1RR024131, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   UL1RR024131, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   UL1RR024131, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   UL1RR024131, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, UL1RR024131,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, UL1RR024131,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, UL1RR024131,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, UL1RR024131, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, UL1RR024131, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, UL1RR024131,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, UL1RR024131,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   UL1RR024131, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, UL1RR024131,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, UL1RR024131, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052, M01RR000052, M01RR000052,
   M01RR000052, M01RR000052, M01RR000052] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [U10EY008067, U10EY008057, U10EY008067, U10EY008052,
   U10EY008052, U10EY008057, U10EY008067, U10EY008057, U10EY008067,
   U10EY008057, K23EY013707, U10EY008057, U10EY008052, U10EY008067,
   U10EY008052, U10EY008067, U10EY008052, U10EY008052, U10EY008067,
   U10EY008052, U10EY008057, U10EY008057, U10EY008067, U10EY008052,
   K23EY013707, U10EY008057, U10EY008052, U10EY008057, U10EY008052,
   U10EY008052, U10EY008052, U10EY008057, U10EY008067, U10EY008052,
   U10EY008057, U10EY008067, U10EY008057, U10EY008057, U10EY008052,
   U10EY008067, U10EY008067, U10EY008057, U10EY008052, U10EY008067,
   U10EY008057, U10EY008067, U10EY008067, U10EY008067, U10EY008052,
   U10EY008057, K23EY013707, U10EY008057, U10EY008057, U10EY008057,
   U10EY008052, U10EY008052, K23EY013707, U10EY008067, U10EY008057,
   U10EY008057, U10EY008057, U10EY008057, U10EY008067, U10EY008057,
   U10EY008057, K23EY013707, U10EY008052, U10EY008067, U10EY008057,
   U10EY008067, U10EY008057, U10EY008052, U10EY008067, U10EY008052,
   U10EY008057, U10EY008067, U10EY008052, U10EY008052, U10EY008052,
   U10EY008052, U10EY008067, U10EY008067, U10EY008067, U10EY008052,
   U10EY008052, U10EY008057, U10EY008052] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI027757, P30AI036219, U01AI031834, U01AI034989,
   U01AI031834, P30AI027767, P30AI027767, U01AI035040, P30AI050410,
   U01AI034994, U01AI035004, U01AI035004, P30AI027757, P30AI027767,
   U01AI035041, U01AI034993, U01AI034994, P30AI050410, P30AI027763,
   P30AI027757, P30AI036219, P30AI094189, U01AI069923, P30AI036219,
   U01AI035041, P30AI027757, P30AI027767, U01AI035004, P30AI094189,
   U01AI069923, P30AI094189, P30AI050410, U01AI034989, P30AI050410,
   U01AI069923, P30AI027767, U01AI034994, P30AI027767, P30AI036219,
   U01AI042590, P30AI036219, P30AI036219, U01AI038855, P30AI027757,
   P30AI027767, P30AI094189, P30AI027767, U01AI031834, P30AI094189,
   P30AI036219, P30AI027757, P30AI036219, P30AI027763, P30AI027767,
   P30AI027757, U01AI035042, U01AI069923, U01AI035004, P30AI027757,
   U01AI034989, P30AI036219, P30AI027767, P30AI027757, U01AI035004,
   P30AI027757, U01AI035042, P30AI094189, U01AI042590, P30AI027767,
   P30AI027757, P30AI036219, P30AI036219, P30AI027763, P30AI027767,
   P30AI027767, P30AI050410, U01AI035041, P30AI027757, P30AI036219,
   U01AI042590, U01AI034993, UM1AI069476, P30AI027757, P30AI094189,
   U01AI034989, P30AI050410, P30AI050410, P30AI027757, P30AI050410,
   U01AI042590, U01AI035041, P30AI027757, P30AI050410, P30AI036219,
   P30AI027757, P30AI036219, K01AI071754, U01AI035004, U01AI038858,
   P30AI036219, U01AI038858, P30AI094189, U01AI035040, P30AI036219,
   U01AI035039, P30AI050410, P30AI027763, U01AI035039, P30AI027767,
   P30AI027767, P30AI050410, P30AI050410, U01AI031834, U01AI034993,
   P30AI027767, U01AI035041, U01AI038858, P30AI036219, U01AI035004,
   P30AI027767, U01AI038855, P30AI027757, U01AI069923, P30AI027767,
   U01AI034989, P30AI036219, P30AI050410, P30AI036219, P30AI027763,
   P30AI036219, P30AI027767, P30AI027757, U01AI035004, U01AI042590,
   P30AI094189, P30AI036219, P30AI027767, P30AI027767, P30AI027767,
   P30AI094189, P30AI050410, U01AI034989, P30AI036219, U01AI034989,
   U01AI034989, UM1AI068636, P30AI027763, P30AI027767, P30AI027757,
   P30AI027767, P30AI036219, U01AI035041, P30AI050410, U01AI034993,
   UM1AI068634, P30AI027763, U01AI034989, P30AI050410, P30AI027763,
   P30AI027763, U01AI035040, P30AI036219, P30AI027767, P30AI027767,
   P30AI036219, P30AI027757, U01AI034989, P30AI050410, P30AI027757,
   P30AI036219, U01AI035004, U01AI038858, P30AI027757, P30AI027767,
   U01AI068636, P30AI027763, P30AI027767, P30AI027757, UM1AI035043,
   U01AI035042, U01AI034989, U01AI035004, P30AI027757, P30AI027757,
   UM1AI068636, P30AI050410, P30AI094189, U01AI069923, U01AI068634,
   P30AI027757, K01AI071754, P30AI027767, P30AI036219, P30AI036219,
   P30AI027763, U01AI035041, U01AI038858, P30AI027767, P30AI050410,
   P30AI027767, P30AI036219, P30AI036219, U01AI035042, P30AI036219,
   P30AI050410, U01AI035042, UM1AI068634, P30AI027757, P30AI027767,
   U01AI037984, P30AI036219, P30AI027767, P30AI027763, P30AI027763,
   P30AI027763, P30AI027767, U01AI034989, P30AI036219, U01AI034989,
   P30AI027757, P30AI036219, P30AI027757, P30AI027767, P30AI027767,
   P30AI027767, P30AI050410, U01AI034989, U01AI034989, P30AI036219,
   P30AI027767, P30AI027757, U01AI031834, P30AI050410, P30AI027767,
   U01AI068636, P30AI027763, P30AI050410, P30AI027757, K24AI065298,
   P30AI027757, P30AI027757, P30AI050410, P30AI050410, P30AI094189,
   P30AI027767, P30AI036219, P30AI027767, P30AI050410, P30AI036219,
   P30AI036219, UM1AI069476, P30AI027757, U01AI038855, P30AI050410,
   U01AI034993, U01AI034989, U01AI038855, P30AI050410, P30AI094189,
   U01AI042590, U01AI035042, U01AI034993, P30AI027763, P30AI027767,
   U01AI034989, P30AI027763, U01AI038858, P30AI027757, P30AI050410,
   U01AI035040, P30AI027763, P30AI036219, P30AI036219, U01AI034989,
   P30AI027763, P30AI036219, P30AI050410, U01AI038858, P30AI027757,
   U01AI034989, U01AI034989, U01AI038855, P30AI036219, P30AI027767,
   P30AI050410, P30AI027757, U01AI035004, U01AI035004, P30AI027757,
   U01AI034989, P30AI050410, P30AI027757, P30AI094189, U01AI034989,
   P30AI027763, P30AI036219, U01AI035041, U01AI034989, U01AI068634,
   P30AI027767, P30AI027767, U01AI034989, P30AI027757, P30AI027757,
   P30AI036219, P30AI027757, U01AI035042, P30AI027757, P30AI036219,
   P30AI027767, U01AI034989, U01AI034994, P30AI050410, P30AI027763,
   P30AI036219, P30AI027757, P30AI027767, P30AI027767, U01AI034989,
   P30AI027763, P30AI050410, P30AI036219, U01AI035040, P30AI027763,
   U01AI034989, P30AI094189, P30AI027767, P30AI027767, U01AI034989,
   U01AI031834, U01AI035040, U01AI035004, P30AI036219, U01AI038858,
   P30AI027767, P30AI027757, P30AI027757, P30AI036219, P30AI094189,
   P30AI027757, P30AI050410, U01AI035039, P30AI027763, U01AI034994,
   U01AI035040, P30AI027767, P30AI036219, P30AI027763, U01AI034994,
   U01AI034994, P30AI094189, P30AI027767, K01AI093197, P30AI027767,
   P30AI050410, P30AI027763, UM1AI068636, P30AI027763, P30AI027767,
   P30AI027767, U01AI069923, U01AI035042, P30AI036219, P30AI027757,
   U01AI034993, P30AI036219, P30AI027767, U01AI034994, P30AI094189,
   P30AI036219, P30AI036219, P30AI027763, U01AI035004, P30AI036219,
   P30AI027763, P30AI036219, P30AI027757, P30AI027763, P30AI050410,
   P30AI027767, P30AI036219, P30AI027767, U01AI035004, P30AI036219,
   P30AI027767, U01AI035040, P30AI094189, P30AI050410, U01AI031834,
   P30AI050410, U01AI034993, U01AI034993, P30AI036219, UM1AI068634,
   P30AI027757, P30AI027757, P30AI027757, U01AI038858, P30AI027757,
   P30AI094189, U01AI034989, P30AI027757, P30AI027757, P30AI036219,
   P30AI027763, P30AI050410, P30AI027757, K01AI093197, U01AI035040,
   U01AI034989, P30AI036219, P30AI036219, P30AI027767, U01AI034989,
   U01AI034989, P30AI027757, U01AI034989, P30AI036219, P30AI036219,
   P30AI027757, P30AI036219, P30AI036219, P30AI027767, U01AI035042,
   P30AI027763, U01AI038858, U01AI034989, P30AI027757, U01AI034993,
   P30AI027757, U01AI034989, P30AI050410, P30AI027763, P30AI036219,
   P30AI027757, U01AI038858, P30AI027767, P30AI036219, U01AI042590,
   U01AI038855, P30AI036219, P30AI027767, P30AI036219, P30AI027763,
   P30AI036219, U01AI038855, P30AI050410, U01AI034989, P30AI050410,
   P30AI050410, P30AI027763, P30AI027767, P30AI050410, P30AI027767,
   P30AI050410, U01AI034993, U01AI038858, U01AI034994, P30AI027757,
   P30AI050410, U01AI034994, P30AI027767, P30AI027767, P30AI036219,
   P30AI027757, U01AI034989, UM1AI068634, P30AI036219, U01AI034989,
   P30AI027767, U01AI031834, P30AI027763, P30AI027767, P30AI027757,
   P30AI027757, P30AI036219, U01AI034989, P30AI027763, U01AI035041,
   U01AI069432, P30AI050410, U01AI034993, U01AI031834, P30AI027767,
   P30AI036219, P30AI027767, P30AI027757, P30AI036219, P30AI027757,
   U01AI035039, P30AI027763, U01AI069923, P30AI036219, U01AI034989,
   P30AI027757, U01AI035039, U01AI035004, P30AI027767, P30AI036219,
   P30AI027757, P30AI036219, P30AI094189, P30AI036219, P30AI027763,
   P30AI027763, U01AI068636, U01AI038858, P30AI027763, P30AI027767,
   P30AI027763, K24AI065298, P30AI050410, P30AI027757, P30AI050410,
   U01AI034989, P30AI050410, P30AI027757, P30AI036219, P30AI027767,
   U01AI037613, P30AI050410, U01AI069434, P30AI027767, U01AI038858,
   P30AI027763, P30AI094189, U01AI034989, P30AI050410, U01AI035042,
   K01AI071754, U01AI035040, U01AI069918, U01AI035041, U01AI069923,
   P30AI094189, P30AI050410, P30AI036219, U01AI034993, U01AI034989,
   U01AI035040, P30AI027763, U01AI034989, U01AI035039, P30AI027767,
   P30AI027767, U01AI035040, U01AI069918, P30AI050410, P30AI050410,
   P30AI027757, P30AI036219, P30AI027767, U01AI069918, P30AI094189,
   U01AI034989, P30AI094189, P30AI050410, P30AI027767, P30AI036219,
   U01AI037613, P30AI036219, P30AI036219, P30AI027763, P30AI027763,
   P30AI094189, P30AI027757, U01AI035042, P30AI027757, P30AI050410,
   P30AI094189, P30AI027767, P30AI036219, P30AI036219, P30AI027757,
   P30AI036219, P30AI027763, U01AI034989, U01AI034993, U01AI034994,
   U01AI035040, U01AI034989, U01AI034994, P30AI094189, P30AI027757,
   P30AI027763, U01AI035042, P30AI094189, P30AI027757, P30AI027763,
   P30AI036219, P30AI027767, U01AI035042, P30AI094189, U01AI034989,
   P30AI027763, P30AI027767, P30AI036219, P30AI027767, P30AI094189,
   P30AI027763, P30AI027767, P30AI027767, P30AI036219, U01AI035041,
   P30AI027767, U01AI034994, U01AI035004, U01AI069432, P30AI050410,
   U01AI034994, P30AI027763, P30AI094189, P30AI094189, U01AI035039,
   U01AI037984, U01AI035042, P30AI036219, P30AI050410, U01AI038858,
   P30AI036219, P30AI027757, P30AI027767, U01AI038858, P30AI027767,
   U01AI031834, P30AI027757, UM1AI068634, U01AI035039, U01AI035039,
   P30AI027757, P30AI094189, P30AI094189, P30AI027757, P30AI050410,
   U01AI038855, P30AI027757, P30AI027763, U01AI034989, P30AI027767,
   P30AI027757, P30AI036219, U01AI034994, P30AI036219, U01AI034989,
   P30AI036219, U01AI037984, P30AI036219, U01AI037984, P30AI050410,
   P30AI027763, P30AI027757, P30AI036219, P30AI050410, P30AI036219,
   P30AI094189, P30AI027757, P30AI050410, U01AI034989, P30AI027757,
   U01AI035039, P30AI027767, U01AI042590, P30AI036219, U01AI035041,
   U01AI034989, U01AI031834, U01AI034989, P30AI050410, P30AI027757,
   U01AI034994, U01AI069918, U01AI034994, U01AI034989, P30AI027767,
   U01AI034989, P30AI094189, U01AI031834, P30AI027757, P30AI027757,
   P30AI094189, U01AI034989, P30AI027767, P30AI027767, U01AI069918,
   K24AI065298, P30AI050410, U01AI034989, P30AI050410, P30AI036219,
   U01AI034993, P30AI027767, P30AI027767, U01AI034994, U01AI069434,
   U01AI035040, P30AI050410, P30AI094189, P30AI027767, P30AI036219,
   P30AI050410, U01AI035039, P30AI027757, U01AI069923, P30AI027757,
   P30AI027767, P30AI027757, P30AI094189, U01AI035039, P30AI027767,
   P30AI050410, P30AI036219, P30AI027757, P30AI027757, U01AI035004,
   U01AI035041, U01AI038858, P30AI036219, U01AI038858, U01AI035039,
   U01AI042590, P30AI027767, U01AI034989, P30AI094189, U01AI035041,
   P30AI027757, P30AI027757, U01AI031834, U01AI042590, P30AI027757,
   U01AI031834, P30AI036219, U01AI034989, P30AI027767, P30AI027763,
   U01AI037984, U01AI042590, U01AI034989, U01AI069918, P30AI027767,
   P30AI027757, P30AI027767, U01AI038855, P30AI027757, P30AI027763,
   UM1AI069476, K01AI093197, P30AI094189, P30AI027767, U01AI038858,
   U01AI034989, U01AI035040, P30AI027763, P30AI050410, P30AI036219,
   P30AI027767, U01AI034994, P30AI027757, P30AI027767, P30AI027767,
   P30AI036219, UM1AI069476, U01AI069923, P30AI027767, P30AI027763,
   U01AI038855, U01AI034989, P30AI027757, P30AI027767, P30AI027763,
   P30AI027757, P30AI036219, U01AI035042, P30AI094189, P30AI027763,
   P30AI027757, P30AI027767, P30AI036219, P30AI050410, U01AI034989,
   P30AI027767, U01AI034989, P30AI027767, P30AI036219, P30AI027763,
   U01AI069918, UM1AI068634, P30AI050410, P30AI027767, U01AI034989,
   U01AI034993, U01AI035039, P30AI027767, P30AI027757, U01AI035039,
   P30AI027763, P30AI027767, U01AI035039, P30AI027763, P30AI036219,
   U01AI035041, U01AI035042, P30AI027763, P30AI027757, P30AI027763,
   U01AI034989, P30AI027763, P30AI027757, U01AI035040, U01AI035040,
   U01AI035042, P30AI027767, P30AI027757, U01AI034989, P30AI050410,
   P30AI027767, U01AI034993, P30AI027767, P30AI027757, U01AI042590,
   U01AI069918, P30AI050410, P30AI027767, P30AI036219, U01AI035040,
   P30AI036219, P30AI027757, P30AI027757, P30AI036219, U01AI035041,
   U01AI035039, P30AI027757, U01AI035041, U01AI038858, U01AI031834,
   P30AI050410, U01AI069923, P30AI027767, P30AI027763, P30AI027767,
   U01AI069923, P30AI027757, U01AI034989, U01AI038858, P30AI027763,
   P30AI027763, P30AI027767, P30AI027763, U01AI035004, P30AI036219,
   P30AI094189, P30AI027757, P30AI027763, U01AI034989, U01AI034989,
   P30AI027757, U01AI034994, U01AI035041, U01AI069923, P30AI027763,
   P30AI036219, P30AI027767, P30AI027757, P30AI027767, P30AI036219,
   U01AI035041, P30AI027757, U01AI034994, P30AI036219, U01AI035040,
   U01AI034989, P30AI094189, P30AI027763, P30AI050410, U01AI034993,
   U01AI034989, U01AI034989, P30AI094189, U01AI038858, P30AI027763,
   P30AI027757, P30AI027757, P30AI036219, U01AI034993, P30AI027763,
   P30AI027757, P30AI027767, P30AI050410, P30AI036219, U01AI069918,
   P30AI050410, P30AI050410, U01AI038858, P30AI027767, P30AI036219,
   U01AI035041, U01AI034994, P30AI027763, U01AI035004, P30AI027767,
   P30AI036219, U01AI038855, U01AI034993, P30AI027763, P30AI027767,
   P30AI027767, UM1AI069476, P30AI027757, U01AI035042, P30AI027763,
   P30AI027757, P30AI027767, UM1AI035043, P30AI094189, P30AI027763,
   P30AI036219, U01AI034989, P30AI027767, U01AI034989, P30AI036219,
   U01AI037984, P30AI027763, P30AI027763, U01AI035041, P30AI094189,
   P30AI027757, P30AI027767, UM1AI069476, U01AI035040, P30AI027757,
   U01AI038858, U01AI034989, U01AI038858, P30AI027763, P30AI036219,
   P30AI027757, UM1AI068634, P30AI027763, P30AI027767, U01AI035042,
   P30AI027767, U01AI037984, U01AI069918, P30AI050410, P30AI036219,
   U01AI035004, P30AI027763, U01AI035040, U01AI034993, P30AI036219,
   P30AI036219, P30AI027763, U01AI035041, P30AI027767, U01AI035004,
   U01AI068636, R56AI102622, P30AI027767, P30AI027767, P30AI036219,
   U01AI031834, UM1AI035043, P30AI050410, U01AI034989, P30AI027757,
   P30AI027767, P30AI027767, U01AI034989, P30AI050410, U01AI034994,
   U01AI035039, P30AI027767, P30AI027767, P30AI027757, U01AI069923,
   P30AI027767, P30AI050410, U01AI042590, P30AI050410, P30AI036219,
   P30AI050410, U01AI035042, P30AI050410, P30AI027767, P30AI036219,
   P30AI094189, P30AI027763, U01AI034989, P30AI027763, P30AI027757,
   P30AI094189, U01AI034993, U01AI035042, P30AI027763, P30AI027757,
   P30AI050410, U01AI034989, P30AI027757, U01AI038858, U01AI034989,
   U01AI042590, P30AI027767, P30AI050410, P30AI027757, P30AI050410,
   P30AI050410, P30AI027757, P30AI027767, P30AI027767, P30AI036219,
   P30AI094189, P30AI036219, P30AI050410, U01AI034989, U01AI035041,
   P30AI050410, P30AI027757, P30AI027767, P30AI036219, P30AI027767,
   P30AI094189, P30AI027767, P30AI036219, U01AI042590, P30AI027763,
   P30AI027757, U01AI038858, U01AI037613, P30AI027767, U01AI035041,
   P30AI036219, P30AI094189, U01AI034989, P30AI027763, P30AI027757,
   U01AI034989, U01AI034989, P30AI050410, P30AI036219, U01AI035039,
   U01AI038858, P30AI036219, P30AI027757, U01AI035042, P30AI027767,
   P30AI027757, P30AI050410, P30AI027757, P30AI027767, P30AI027767,
   U01AI034994, U01AI034993, P30AI027757, U01AI035041, U01AI034994,
   P30AI050410, P30AI027757, P30AI036219, P30AI036219, U01AI035004,
   UM1AI035043, U01AI069918, P30AI027757, P30AI050410, P30AI027763,
   U01AI035042, P30AI036219, P30AI050410, P30AI036219, P30AI050410,
   P30AI094189, P30AI027767, P30AI036219, P30AI027767, P30AI036219,
   P30AI027767, P30AI050410, P30AI036219, U01AI034994, U01AI035039,
   P30AI027757, P30AI036219, U01AI069918, P30AI027763, U01AI034989,
   P30AI027763, K24AI065298, P30AI050410, P30AI027757, U01AI034993,
   K24AI065298, U01AI035042, P30AI050410, P30AI027757, U01AI035042,
   U01AI034993, P30AI027767, U01AI034993, P30AI027763, U01AI069923,
   U01AI038858, U01AI035042, P30AI027763, P30AI027757, P30AI027757,
   P30AI027767, U01AI035041, U01AI038858, U01AI035004, P30AI027763,
   P30AI027763, UM1AI035043, P30AI027767, P30AI027767, P30AI050410,
   U01AI034989, U01AI069923, P30AI027757, P30AI027763, P30AI027767,
   P30AI027763, P30AI036219, P30AI050410, P30AI027767, P30AI027767,
   P30AI050410, P30AI027763, P30AI027763, P30AI027757, P30AI027757,
   P30AI027757, P30AI050410, P30AI027757, P30AI027763, P30AI027757,
   U01AI035004, P30AI050410, P30AI027763, P30AI027763, U01AI034989,
   U01AI038858, U01AI069918, U01AI069918, U01AI069432, P30AI036219,
   P30AI027763, P30AI094189, UM1AI035043, P30AI027767, U01AI034989,
   P30AI027757, U01AI034989, P30AI027757, P30AI027763, P30AI027767,
   P30AI050410, U01AI038858, P30AI027763, P30AI050410, P30AI050410,
   P30AI050410, P30AI027757, P30AI027757, U01AI034989, P30AI027757,
   P30AI050410, P30AI027767, U01AI035039, P30AI027767, U01AI068634,
   P30AI027767, P30AI050410, P30AI027767, P30AI036219, U01AI034989,
   P30AI094189, P30AI094189, U01AI069434, P30AI027757, P30AI027767,
   P30AI027767, U01AI042590, P30AI036219, P30AI036219, P30AI027767,
   U01AI069923, U01AI042590, UM1AI035043, P30AI027757, P30AI036219,
   U01AI034989, P30AI027767, P30AI027757, U01AI035041, U01AI038855,
   P30AI036219, U01AI031834, P30AI094189, P30AI036219, P30AI027763,
   P30AI036219, P30AI094189, P30AI027757, P30AI027757, U01AI068636,
   U01AI035039, P30AI027767, P30AI036219, P30AI027763, P30AI050410,
   P30AI050410, P30AI050410, P30AI027767, P30AI027767, P30AI027757,
   U01AI034989, U01AI069923, P30AI027767, U01AI038858, P30AI036219,
   U01AI068634, P30AI027767, P30AI027757, P30AI036219, P30AI036219,
   U01AI035041, UM1AI069476, P30AI027763, P30AI027767, U01AI035004,
   U01AI035004, P30AI027767, UM1AI068634, U01AI068636, P30AI036219,
   P30AI027767, UM1AI068634, P30AI027767, U01AI035004, U01AI035040,
   U01AI035039, P30AI027757, P30AI027757, P30AI027763, P30AI027763,
   U01AI035039, U01AI038858, U01AI035041, U01AI035004, U01AI068634,
   U01AI042590, P30AI027767, U01AI038858, P30AI050410, P30AI036219,
   P30AI027767, U01AI038858, P30AI027763, P30AI027757, P30AI027767,
   U01AI034994, P30AI036219, P30AI027763, P30AI027767, P30AI094189,
   U01AI069918, P30AI027757, U01AI035042, P30AI094189, U01AI035040,
   U01AI034989, P30AI094189, P30AI050410, U01AI069923, P30AI027767,
   U01AI035039, U01AI035042, P30AI027763, P30AI027767, P30AI027757,
   P30AI027757, U01AI035004, P30AI027767, P30AI027757, P30AI027767,
   U01AI035004, P30AI036219, P30AI050410, U01AI042590, U01AI034994,
   P30AI027767, U01AI038858, P30AI050410, U01AI035004, P30AI036219,
   U01AI038858, P30AI027757, P30AI027757, P30AI036219, U01AI035004,
   U01AI035004, P30AI027763, P30AI050410, U01AI034994, P30AI036219,
   P30AI036219, P30AI027763, U01AI069918, U01AI035039, U01AI034989,
   P30AI027757, P30AI027757, U01AI034989, U01AI034989, P30AI027757,
   U01AI035004, P30AI027767, P30AI027757, U01AI035041, P30AI036219,
   P30AI027767, U01AI034989, P30AI036219, P30AI027767, P30AI027767,
   P30AI027763, P30AI027763, P30AI027763, U01AI038858, P30AI036219,
   P30AI036219, U01AI034989, P30AI027767, U01AI038858, P30AI036219,
   U01AI035040, P30AI036219, U01AI034993, P30AI050410, U01AI031834,
   P30AI027757, P30AI027757, P30AI027757, P30AI027757, P30AI027757,
   P30AI027767, P30AI027757, P30AI050410, U01AI035042, P30AI036219,
   U01AI034994, U01AI034994, U01AI037984, U01AI035042, U01AI035004,
   P30AI027767, U01AI034989, P30AI027767, P30AI027763, P30AI027757,
   P30AI027757, P30AI027767, U01AI035041, P30AI027767, P30AI036219,
   P30AI027757, K01AI093197, P30AI050410, UM1AI068634, U01AI035041,
   P30AI027757, P30AI027767, P30AI027757, U01AI034994, U01AI034989,
   U01AI037613, U01AI037613, U01AI035004, P30AI036219, P30AI027767,
   P30AI036219, P30AI027767, P30AI027767, P30AI050410, P30AI027757,
   P30AI050410, U01AI034989, P30AI036219, P30AI027757, P30AI027757,
   P30AI027767, P30AI027757, P30AI027767, P30AI027757, P30AI027767,
   U01AI069918, U01AI035039, U01AI034989, P30AI027763, P30AI094189,
   P30AI036219, P30AI036219, P30AI036219, P30AI094189, P30AI027757,
   P30AI094189, P30AI027763, P30AI094189, P30AI027767, P30AI027757,
   P30AI027767, P30AI027767, P30AI036219, U01AI035041, U01AI034989,
   P30AI027757, U01AI035004, P30AI094189, U01AI042590, P30AI027757,
   U01AI037613, U01AI038858, P30AI027757, P30AI027763, U01AI031834,
   P30AI036219, P30AI027763, P30AI050410, U01AI034989, P30AI036219,
   U01AI034993, P30AI027757, P30AI027757, P30AI050410, P30AI027757,
   P30AI094189, P30AI027767, P30AI027767, U01AI035039, P30AI036219,
   P30AI027767, P30AI027757, P30AI036219, P30AI027767, P30AI094189,
   P30AI094189, P30AI027767, P30AI027757, P30AI027757, P30AI094189,
   P30AI027767, U01AI031834, U01AI042590, U01AI034994, P30AI027757,
   U01AI038858, P30AI027757, P30AI027763, P30AI027757, U01AI034989,
   P30AI027767, P30AI036219, P30AI050410, U01AI031834, P30AI050410,
   P30AI027767, P30AI027767, U01AI037613, P30AI036219, U01AI034989,
   U01AI069434, P30AI027763, U01AI069432, P30AI027757, P30AI027757,
   P30AI027763, U01AI037984, U01AI035042, P30AI050410, U01AI034989,
   P30AI027767, P30AI027763, P30AI027763, P30AI050410, UM1AI068636,
   P30AI027763, P30AI050410, P30AI027757, P30AI027757, U01AI034993,
   P30AI050410, P30AI094189, P30AI036219, U01AI034994, P30AI027767,
   P30AI036219, P30AI027757, P30AI027763, U01AI034989, P30AI027757,
   P30AI027757, P30AI027767, P30AI036219, U01AI035040, P30AI027767,
   U01AI035040, U01AI031834, P30AI050410, U01AI034989, P30AI027763,
   U01AI035042, P30AI027757, P30AI094189, U01AI069923, P30AI027767,
   P30AI027767, P30AI050410, P30AI027757, P30AI027767, U01AI035040,
   U01AI035041, U01AI038858, P30AI036219, P30AI036219, U01AI038858,
   P30AI027763, P30AI027767, U01AI038858, P30AI027757, P30AI027763,
   U01AI034989, P30AI050410, U01AI034989, P30AI036219, U01AI038858,
   U01AI031834, P30AI027757, P30AI050410, U01AI031834, P30AI027757,
   P30AI027757, P30AI036219, P30AI027757, U01AI037984, P30AI050410,
   U01AI042590, P30AI050410, U01AI035040, P30AI027767, U01AI035039,
   P30AI036219, U01AI035039, P30AI027757, P30AI036219, U01AI034993,
   P30AI027763, P30AI027767, P30AI027767, U01AI069918, P30AI050410,
   U01AI035004, P30AI027767, P30AI027767, U01AI069923, P30AI094189,
   U01AI034989, P30AI027763, P30AI027767, P30AI027757, P30AI036219,
   U01AI035004, P30AI036219, P30AI027767, P30AI027767, P30AI027757,
   P30AI027763, P30AI027757, P30AI027757, P30AI027763, U01AI035039,
   P30AI036219, P30AI027763, P30AI027767, P30AI027767, P30AI027763,
   P30AI027757, U01AI034989, U01AI034994, U01AI038858, K24AI065298,
   P30AI036219, P30AI036219, K24AI065298, K24AI065298, U01AI034989,
   P30AI094189, P30AI036219, P30AI027767, U01AI035004, P30AI027763,
   P30AI036219, U01AI035039, P30AI027767, P30AI027767, P30AI027767,
   P30AI027763, P30AI094189, U01AI034994, U01AI034989, U01AI038858,
   P30AI027767, P30AI027757, K01AI071754, P30AI027757, U01AI034989,
   P30AI027763, P30AI027763, U01AI035004, P30AI027767, P30AI027763,
   P30AI027757, P30AI027757, U01AI034989, P30AI027767, P30AI027757,
   P30AI027757, P30AI027763, P30AI027757, P30AI027763, P30AI027763,
   U01AI034989, U01AI038858, P30AI027763, U01AI035042, P30AI094189,
   P30AI036219, P30AI050410, P30AI050410, U01AI034989, P30AI027757,
   P30AI050410, U01AI031834, P30AI027767, P30AI036219, P30AI027767,
   P30AI027757, P30AI027763, P30AI050410, P30AI027757, K01AI093197,
   P30AI027767, P30AI027767, K01AI071754, U01AI034994, P30AI027757,
   P30AI050410, P30AI027757, P30AI036219, K24AI065298, P30AI050410,
   UM1AI068636, P30AI036219, P30AI036219, U01AI035042, P30AI027767,
   P30AI027767, U01AI038858, P30AI027763, U01AI042590, UM1AI035043,
   P30AI036219, UM1AI069476, P30AI050410, U01AI034994, U01AI034989,
   P30AI027767, P30AI050410, P30AI027763, P30AI050410, P30AI027767,
   P30AI027757, P30AI027767, U01AI035004, P30AI050410, U01AI034989,
   U01AI034989, K24AI065298, U01AI034989, P30AI027767, P30AI036219,
   P30AI036219, UM1AI068634, U01AI037613, U01AI034989, P30AI027767,
   P30AI027767, P30AI027767, P30AI027767, P30AI027767, U01AI035004,
   P30AI027757, U01AI038858, P30AI027757, P30AI027763, U01AI034994,
   U01AI069432, U01AI035040, U01AI034989, U01AI034989, U01AI037613,
   U01AI034989, U01AI035040, U01AI034989, P30AI094189, P30AI050410,
   U01AI031834, P30AI036219, P30AI027757, P30AI027767, U01AI035040,
   U01AI035004, U01AI069434, P30AI027767, U01AI038858, P30AI027757,
   U01AI042590, P30AI027757, P30AI027757, P30AI027757, P30AI036219,
   P30AI027767, U01AI068636, P30AI027767, P30AI027763, P30AI027757,
   P30AI050410, P30AI050410, P30AI036219, P30AI050410, U01AI034993,
   P30AI036219, P30AI027757, U01AI034989, P30AI027757, UM1AI035043,
   U01AI034989, P30AI050410, P30AI036219] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)
   [U01AA013566, U24AA020794, U01AA020790, U24AA020794, U01AA020790,
   U01AA020790, U01AA013566, U24AA020794, U01AA020790, U01AA013566,
   U01AA013566, U01AA013566, U24AA020794, U24AA020794, U01AA020790,
   U01AA020790, U24AA020794, U24AA020794, U01AA020790, U24AA020794,
   U01AA020790, U24AA020794, U01AA020790, U01AA013566, U24AA020794,
   U24AA020794, U01AA020790, U24AA020794, U24AA020794] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [U01DA036935, K24DA000432,
   K24DA000432, K24DA000432, K24DA000432, F31DA030254, F31DA037788,
   U01DA036935, K24DA000432, U01DA036935, F31DA030254, K24DA000432,
   K24DA000432, U01DA036935, U01DA036935, F31DA030254, K24DA000432,
   U01DA036935, F31DA037788, K24DA000432, K24DA000432] Funding Source: NIH
   RePORTER; National Institute on Minority Health and Health
   DisparitiesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Minority
   Health & Health Disparities (NIMHD) [U54MD007587, G12MD007583,
   U54MD007587, G12MD007583, G12MD007583, G12MD007583, U54MD007587,
   U54MD007587, U54MD007587, G12MD007583, G12MD007583, G12MD007583,
   U54MD007587, G12MD007583, U54MD007587, G12MD007583, U54MD007587,
   U54MD007587, G12MD007583, U54MD007587, G12MD007583, G12MD007583,
   G12MD007583, G12MD007583, U54MD007587, U54MD007587, U54MD007587,
   U54MD007587, U54MD007587, G12MD007583, U54MD007587, G12MD007583,
   U54MD007587, U54MD007587, U54MD007587, G12MD007583, G12MD007583,
   G12MD007583, G12MD007583, G12MD007583, G12MD007583, U54MD007587,
   G12MD007583, U54MD007587, G12MD007583, G12MD007583, G12MD007583,
   G12MD007583, G12MD007583, U54MD007587, G12MD007583, U54MD007587,
   G12MD007583, G12MD007583, G12MD007583, G12MD007583, G12MD007583,
   G12MD007583, G12MD007583, U54MD007587, G12MD007583, G12MD007583,
   G12MD007583, G12MD007583, U54MD007587, G12MD007583, G12MD007583,
   G12MD007583, U54MD007587, U54MD007587, G12MD007583, G12MD007583,
   G12MD007583, G12MD007583, G12MD007583, U54MD007587, U54MD007587,
   G12MD007583, U54MD007587, G12MD007583, G12MD007583, G12MD007583,
   G12MD007583, G12MD007583, G12MD007583] Funding Source: NIH RePORTER
FX The NA-ACCORD and collaborating cohorts were supported by grants
   U01-AI069918, U01-AA013566, U01-AA020790, U01-AI31834, U01-AI34989,
   U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040,
   U01-AI35041, U01-AI35042, UM1-AI35043, U01-AI37613, U01-AI37984,
   U01AI38855, U01-AI38858, U01-AI42590, U01-AI68634, U01-AI68636,
   U01-AI69432, U01-AI69434, U01-DA036935, U01-HD32632, U10-EY08052,
   U10-EY08057, U10-EY08067, U24-AA020794, U54-MD007587, UL1-RR024131,
   UL1-TR000083, F31-DA037788, F31-DA030254, G12-MD007583, K01-AI071754,
   K01-AI093197, K23-EY013707, K24-DA00432, K24-AI065298, KL2-TR000421,
   MO1-RR-00052, N02-CP55504, P30-AI027763, P30-AI094189, P30-AI27757,
   P30-AI27767, P30-AI036219, P30-AI50410, P30-AI54999, P30-MH62246,
   R01-AA16893, R01-CA165937, R01-DA04334, R01-DA11602, R01-DA12568,
   R24-AI067039, R56-AI102622, Z01-CP010214, and Z01-CP010176 from the
   National Institutes of Health, USA; contract CDC200-2006-18797 from the
   Center's for Disease Control and Prevention, USA; contract 90047713 from
   the Agency for Healthcare Research and Quality, USA; contract 90051652
   from the Health Resources and Services Administration, USA; grants
   TGF-96118, HCP-97105, CBR-86906, CBR-94036 from the Canadian Institutes
   of Health Research, Canada; Canadian Institutes of Health Research
   (CIHR) New Investigator award (A. Burchell); Ontario Ministry of Health
   and Long Term Care; and the Government of Alberta, Canada. Additional
   support was provided by the Intramural Research Program of the National
   Cancer Institute, and National Institutes of Health.
CR Althoff KN, 2012, ANN INTERN MED, V157, P325, DOI 10.7326/0003-4819-157-5-201209040-00005
   Althoff KN, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-45
   Althoff KN, 2010, CLIN INFECT DIS, V50, P1512, DOI 10.1086/652650
   Centers for Disease Control and Prevention National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention Division of HIV/AIDS Prevention, NAT CTR HIV AIDS VIR
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   EuroCoord, HIV COH DAT EXCH PRO
   Gange SJ, 2007, INT J EPIDEMIOL, V36, P294, DOI 10.1093/ije/dyl286
   Gao S, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-8
   Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243
   Hanna DB, 2012, AIDS, V26, P95, DOI 10.1097/QAD.0b013e32834dcf87
   Institute of Medicine, 2012, MON HIV CAR US IND D
   Koch T, 2004, J GEOGR, V103, P76, DOI 10.1080/00221340408978578
   McGowan CC, INT J EPIDEMIOL, V36, P969
   Proctor EK, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-96
   Rebeiro PF, 2015, AM J EPIDEMIOL, V182, P952, DOI 10.1093/aje/kwv181
   Rebeiro PF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111772
   Richards TB, 1999, PUBLIC HEALTH REP, V114, P359, DOI 10.1093/phr/114.4.359
   The Henry J Kaiser Family Foundation, CURR STAT GLOB HIV A
   The World Bank, PREV HIV TOT POP AG
   UNAIDS, AIDSINFO
   Valdiserri Ronald O, 2013, Public Health Rep, V128, P354
   Walensky Rochelle P, 2009, Top HIV Med, V17, P130
   White House Office of AIDS Policy, 2015, NAT HIV AIDS STRAT U
   World Health Organization, GLOB HLTH OBS DAT HI
NR 24
TC 7
Z9 7
U1 0
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD APR 4
PY 2016
VL 19
AR 20707
DI 10.7448/IAS.19.1.20707
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DM2JY
UT WOS:000376174100001
PM 27049052
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Luz, PM
   Girouard, MP
   Grinsztejn, B
   Freedberg, KA
   Veloso, VG
   Losina, E
   Struchiner, CJ
   MacLean, RL
   Parker, RA
   Paltiel, AD
   Walensky, RP
AF Luz, Paula M.
   Girouard, Michael P.
   Grinsztejn, Beatriz
   Freedberg, Kenneth A.
   Veloso, Valdilea G.
   Losina, Elena
   Struchiner, Claudio J.
   MacLean, Rachel L.
   Parker, Robert A.
   Paltiel, A. David
   Walensky, Rochelle P.
TI Survival benefits of antiretroviral therapy in Brazil: a model-based
   analysis
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE HIV; Brazil; highly active antiretroviral therapy; survival; modelling;
   Latin America
ID RIO-DE-JANEIRO; HIV-INFECTED PATIENTS; TWICE-DAILY LOPINAVIR/RITONAVIR;
   ONCE-DAILY ATAZANAVIR/RITONAVIR; TENOFOVIR DISOPROXIL FUMARATE;
   COST-EFFECTIVENESS; AIDS PATIENTS; HIV-1-INFECTED PATIENTS; NAIVE
   PATIENTS; SAO-PAULO
AB Objective: In Brazil, universal provision of antiretroviral therapy (ART) has been guaranteed free of charge to eligible HIV-positive patients since December 1996. We sought to quantify the survival benefits of ART attributable to this programme.
   Methods: We used a previously published microsimulation model of HIV disease and treatment (CEPAC-International) and data from Brazil to estimate life expectancy increase for HIV-positive patients initiating ART in Brazil. We divided the period of 1997 to 2014 into six eras reflecting increased drug regimen efficacy, regimen availability and era-specific mean CD4 count at ART initiation. Patients were simulated first without ART and then with ART. The 2014-censored and lifetime survival benefits attributable to ART in each era were calculated as the product of the number of patients initiating ART in a given era and the increase in life expectancy attributable to ART in that era.
   Results: In total, we estimated that 598,741 individuals initiated ART. Projected life expectancy increased from 2.7, 3.3, 4.1, 4.9, 5.5 and 7.1 years without ART to 11.0, 17.5, 20.7, 23.0, 25.3, and 27.0 years with ART in Eras 1 through 6, respectively. Of the total projected lifetime survival benefit of 9.3 million life-years, 16% (or 1.5 million life-years) has been realized as of December 2014.
   Conclusions: Provision of ART through a national programme has led to dramatic survival benefits in Brazil, the majority of which are still to be realized. Improvements in initial and subsequent ART regimens and higher CD4 counts at ART initiation have contributed to these increasing benefits.
C1 [Luz, Paula M.; Grinsztejn, Beatriz; Veloso, Valdilea G.; Struchiner, Claudio J.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
   [Girouard, Michael P.; Freedberg, Kenneth A.; Losina, Elena; MacLean, Rachel L.; Parker, Robert A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
   [Girouard, Michael P.; Freedberg, Kenneth A.; MacLean, Rachel L.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
   [Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Freedberg, Kenneth A.; Losina, Elena; Parker, Robert A.; Walensky, Rochelle P.] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA.
   [Freedberg, Kenneth A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Freedberg, Kenneth A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
   [Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA.
   [Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Parker, Robert A.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
   [Paltiel, A. David] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA.
   [Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM paula.luz@ipec.fiocruz.br
RI Struchiner, Claudio J/M-9360-2013
OI Struchiner, Claudio J/0000-0003-2114-847X; Paltiel, A.
   David/0000-0002-4861-3290; Luz, Paula/0000-0001-9746-719X; Walensky,
   Rochelle P./0000-0002-8795-379X
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01 AI058736]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069476, R01AI058736, R01AI058736,
   R01AI058736, R01AI058736, R01AI058736, R01AI058736, R01AI058736,
   R01AI058736, UM1AI069476, UM1AI069476, UM1AI069476, R01AI058736,
   UM1AI069476, R01AI058736, R01AI058736, R01AI058736, UM1AI069476,
   UM1AI069476, R01AI058736, R01AI058736, R01AI058736, R01AI058736,
   UM1AI069476, UM1AI069476, R01AI058736, R01AI058736, R01AI058736] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (R01 AI058736).
CR Acurcio F de A, 1998, Cad Saude Publica, V14, P811
   Albrecht MA, 2001, NEW ENGL J MED, V345, P398, DOI 10.1056/NEJM200108093450602
   April MD, 2014, J INFECT DIS, V209, P491, DOI 10.1093/infdis/jit584
   Arribas JR, 2008, JAIDS-J ACQ IMM DEF, V47, P74, DOI 10.1097/QAI.0b013e31815acab8
   Avila D, 2014, JAIDS-J ACQ IMM DEF, V65, pE8, DOI 10.1097/QAI.0b013e3182a39979
   Baxter JD, 2000, AIDS, V14, pF83, DOI 10.1097/00002030-200006160-00001
   Braga P, 2007, AIDS PATIENT CARE ST, V21, P321, DOI 10.1089/apc.2006.0111
   Brazilian Ministry of Health, 2014, PROT CLIN DIR TER MA
   Brazilian Ministry of Health, 2013, 2013 HIV AIDS EP B B
   Caceres CF, 2009, JAIDS-J ACQ IMM DEF, V51, pS60, DOI 10.1097/QAI.0b013e3181a66208
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   Cardoso SW, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-29
   Caro-Vega Y, 2013, AIDS RES TREAT, V2013, DOI 10.1155/2013/170417
   Caseiro MM, 2008, BRAZ J INFECT DIS, V12, P162, DOI 10.1590/S1413-86702008000300001
   CHEQUER P, 1992, AIDS, V6, P483, DOI 10.1097/00002030-199205000-00007
   Clotet B, 2004, AIDS, V18, P1137, DOI 10.1097/00002030-200405210-00007
   Comision del SIDA, 2007, ESTR AT INT PERS QUE
   Cost-effectiveness of preventing AIDS complications (CEPAC), MOD US GUID
   Fonseca LAM, 1999, INT J EPIDEMIOL, V28, P1156, DOI 10.1093/ije/28.6.1156
   Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108
   Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871
   Goldie SJ, 2006, NEW ENGL J MED, V355, P1141, DOI 10.1056/NEJMsa060247
   Grangeiro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095673
   Greco DB, 2007, AIDS, V21, pS37, DOI 10.1097/01.aids.0000279705.24428.a3
   Gulick RM, 2008, NEW ENGL J MED, V359, P1429, DOI 10.1056/NEJMoa0803152
   Gutierrez EB, 2012, AIDS BEHAV, V16, P1482, DOI 10.1007/s10461-012-0168-3
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   Johnson M, 2006, AIDS, V20, P711, DOI 10.1097/01.aids.0000216371.76689.63
   Kilsztajn S, 2007, JAIDS-J ACQ IMM DEF, V45, P342
   Luz PM, 2015, JAIDS-J ACQ IMM DEF, V68, P152, DOI 10.1097/QAI.0000000000000426
   Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2
   Malta M, 2009, JAIDS-J ACQ IMM DEF, V52, P629, DOI 10.1097/QAI.0b013e3181b31b8a
   Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012
   Martin DA, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-322
   Molina JM, 2010, JAIDS-J ACQ IMM DEF, V53, P323, DOI 10.1097/QAI.0b013e3181c990bf
   Noubary F, 2010, STAT MED, V29, P1932, DOI 10.1002/sim.3955
   Pozniak AL, 2006, JAIDS-J ACQ IMM DEF, V43, P535
   Resch S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025310
   Ribeiro SR, 2014, ANTIVIR THER, V19, P387, DOI 10.3851/IMP2716
   Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498
   Ross EL, 2015, CLIN INFECT DIS, V60, P1102, DOI 10.1093/cid/ciu1159
   Santoro-Lopes G, 1998, J ACQ IMMUN DEF SYND, V19, P403, DOI 10.1097/00042560-199812010-00012
   SANTOS B, 1994, INT J STD AIDS, V5, P279, DOI 10.1177/095646249400500410
   Steigbigel RT, 2008, NEW ENGL J MED, V359, P339, DOI 10.1056/NEJMoa0708975
   United Nations Department of Economic and Social Affairs Population Division, 2014, WORLD POP PROSP 2012
   Walensky RP, 2008, J INFECT DIS, V197, P1324, DOI 10.1086/587184
   Walensky RP, 2006, J INFECT DIS, V194, P11, DOI 10.1086/505147
   Walensky RP, 2013, NEW ENGL J MED, V369, P1715, DOI 10.1056/NEJMsa1214720
NR 48
TC 8
Z9 8
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD MAR 29
PY 2016
VL 19
AR 20623
DI 10.7448/IAS.19.1.20623
PG 11
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DM2JV
UT WOS:000376173800001
PM 27029828
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Coelho, LE
   Cardoso, SW
   Amancio, RT
   Moreira, RI
   Ribeiro, SR
   Coelho, AB
   Campos, DP
   Veloso, VG
   Grinsztejn, B
   Luz, PM
AF Coelho, Lara E.
   Cardoso, Sandra W.
   Amancio, Rodrigo T.
   Moreira, Ronaldo I.
   Ribeiro, Sayonara R.
   Coelho, Alessandra B.
   Campos, Dayse P.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Luz, Paula M.
TI Predictors of opportunistic illnesses incidence in post combination
   antiretroviral therapy era in an urban cohort from Rio de Janeiro,
   Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE AIDS-related opportunistic infections; HIV; Acquired immunodeficiency
   syndrome; Incidence; Cohort study; Cox proportional hazards regression
   models
ID ISONIAZID PREVENTIVE THERAPY; HIV-INFECTED PATIENTS; HIV/AIDS SERVICES;
   EARLY MORTALITY; TUBERCULOSIS; AIDS; ADULTS; INITIATION; HAART; RISK
AB Background: Opportunistic illnesses still account for a huge proportion of hospitalizations and deaths among HIV-infected patients in the post combination antiretroviral therapy (cART) era, particularly in middle- and low-income countries. The aim of this study was to assess predictors of the top four most incident opportunistic illnesses (tuberculosis, esophageal candidiasis, cerebral toxoplasmosis and Pneumocystis jiroveci pneumonia) in an HIV clinical cohort from a middle-income country in the post cART era.
   Methods: A total of 2835 HIV infected participants aged >= 18 years at enrollment were followed from January 2000 to December 2012 until the occurrence of their first opportunistic illness, death or end of study, whichever occurred first. Extended Cox proportional hazards regression models, stratified by use of cART, were fitted to assess predictors of opportunistic illness incidence during follow-up.
   Results: The incidence rates of tuberculosis, esophageal candidiasis, cerebral toxoplasmosis and Pneumocystis jiroveci pneumonia were 15.3, 8.6, 6.0, 4.8 per 1000 persons-year, respectively. Disease specific adjusted Cox models showed that presence of an opportunistic illness at enrollment significantly increased disease incidence while higher nadir CD4+ T lymphocyte count had a significant protective effect in patients not in use of cART. Duration of cART use also significantly reduced disease incidence.
   Conclusions: Our findings show that, still in the post-cART era, prevention of opportunistic infections can be achieved by preventing immune deterioration by instituting early use of cART. Interventions focusing on early diagnosis and linkage to care in addition to the prompt initiation of cART are essential to reduce the incidence of opportunistic illnesses among HIV infected patients in post-cART era.
C1 [Coelho, Lara E.; Cardoso, Sandra W.; Amancio, Rodrigo T.; Moreira, Ronaldo I.; Ribeiro, Sayonara R.; Coelho, Alessandra B.; Campos, Dayse P.; Veloso, Valdilea G.; Grinsztejn, Beatriz; Luz, Paula M.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
RP Coelho, LE (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM lara.coelho@ini.fiocruz.br
OI Luz, Paula/0000-0001-9746-719X
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [U01AI069923];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI069923, U01AI069923, UM1AI069476, U01AI069923, U01AI069923,
   UM1AI069476, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, UM1AI069476, UM1AI069476, UM1AI069476,
   U01AI069923, UM1AI069476, U01AI069923, UM1AI069476, U01AI069923,
   U01AI069923, UM1AI069476, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923] Funding Source: NIH RePORTER
FX BG and PML acknowledge funding from the National Council of
   Technological and Scientific Development (CNPq) and the Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ). This work was supported
   in part by the NIH-funded Caribbean, Central and South America network
   for HIV epidemiology (CCASAnet), a member cohort of the International
   Epidemiologic Databases to Evaluate AIDS (leDEA) (U01AI069923).
CR Akolo C, 2010, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD000171.PUB3)
   [Anonymous], 2013, UNAIDS GLOB REP UNAI
   Brasil. Ministerio da Saude, 2013, PROT CLIN DIR TER MA
   Brinkhof MWG, 2007, CLIN INFECT DIS, V45, P1518, DOI 10.1086/522986
   Buchacz K, 2010, AIDS, V24, P1549, DOI 10.1097/QAD.0b013e32833a3967
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   Coelho L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098666
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Ximenes RAD, 2009, INT J EPIDEMIOL, V38, P1285, DOI 10.1093/ije/dyp224
   Detels R, 2001, AIDS, V15, P347, DOI 10.1097/00002030-200102160-00008
   Dourado I, 2014, AIDS CARE, V26, P1514, DOI 10.1080/09540121.2014.938016
   Durovni B, 2013, LANCET INFECT DIS, V13, P852, DOI 10.1016/S1473-3099(13)70187-7
   Ford N, 2015, LANCET HIV, V2, pE438, DOI 10.1016/S2352-3018(15)00137-X
   Golub JE, 2007, AIDS, V21, P1441, DOI 10.1097/QAD.0b013e328216f441
   Golub JE, 2015, CLIN INFECT DIS, V60, P639, DOI 10.1093/cid/ciu849
   Golub JE, 2009, AIDS, V23, P631, DOI 10.1097/QAD.0b013e328327964f
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Hanna DB, 2007, AIDS CARE, V19, P264, DOI 10.1080/09540120600834729
   Houben RMGJ, 2014, P NATL ACAD SCI USA, V111, P5325, DOI 10.1073/pnas.1317660111
   Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd
   Lesko CR, 2013, CLIN INFECT DIS, V57, P1027, DOI 10.1093/cid/cit421
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   MacCarthy S, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1313
   Ministerio da Saude, 2011, PROGR NAC CONTR TUB
   Mocroft A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001510
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6
   Perbost I, 2005, HIV MED, V6, P232, DOI 10.1111/j.1468-1293.2005.00282.x
   Rangaka MX, 2014, LANCET, V384, P682, DOI 10.1016/S0140-6736(14)60162-8
   Ribeiro SR, 2014, ANTIVIR THER, V19, P387, DOI 10.3851/IMP2716
   Sackoff JE, 2006, ANN INTERN MED, V145, P397, DOI 10.7326/0003-4819-145-6-200609190-00003
   Schwarcz L, 2013, AIDS, V27, P597, DOI 10.1097/QAD.0b013e32835b0fa2
   Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370
   Siedner MJ, 2015, CLIN INFECT DIS, V60, P1120, DOI 10.1093/cid/ciu1137
   Suthar AB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001270
   Van Rie A, 2011, JAIDS-J ACQ IMM DEF, V56, P349, DOI 10.1097/QAI.0b013e3181f9fb39
   von Wyl V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077691
   Waaler HT, 2002, INT J TUBERC LUNG D, V6, P745
   WHO, 2014, WHO GLOB TUB REP
   Wilson KD, 2014, AIDS CARE, V26, pS83, DOI 10.1080/09540121.2014.906554
   World Health Organization, 2011, GUID INT TUB CAS FIN
NR 43
TC 6
Z9 8
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAR 22
PY 2016
VL 16
AR 134
DI 10.1186/s12879-016-1462-x
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA DH3RM
UT WOS:000372704200001
PM 27001753
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Cesar, C
   Koethe, JR
   Giganti, MJ
   Rebeiro, P
   Althoff, KN
   Napravnik, S
   Mayor, A
   Grinsztejn, B
   Wolff, M
   Padgett, D
   Sierra-Madero, J
   Gotuzzo, E
   Sterling, TR
   Willig, J
   Levison, J
   Kitahata, M
   Rodriguez-Barradas, MC
   Moore, RD
   McGowan, C
   Shepherd, BE
   Cahn, P
AF Cesar, Carina
   Koethe, John R.
   Giganti, Mark J.
   Rebeiro, Peter
   Althoff, Keri N.
   Napravnik, Sonia
   Mayor, Angel
   Grinsztejn, Beatriz
   Wolff, Marcelo
   Padgett, Denis
   Sierra-Madero, Juan
   Gotuzzo, Eduardo
   Sterling, Timothy R.
   Willig, James
   Levison, Julie
   Kitahata, Mari
   Rodriguez-Barradas, Maria C.
   Moore, Richard D.
   McGowan, Catherine
   Shepherd, Bryan E.
   Cahn, Pedro
CA Caribbean Cent South Amer Network
   North Amer AIDS Cohort
TI Health outcomes among HIV-positive Latinos initiating antiretroviral
   therapy in North America versus Central and South America
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE HIV; antiretroviral therapy; highly active; mortality; Latin America;
   North America; cohort studies
ID LONG-TERM OUTCOMES; UNITED-STATES; HIV-1-INFECTED PATIENTS; INFECTED
   PATIENTS; COHORT PROFILE; 1ST YEAR; AIDS; MORTALITY; HISPANICS;
   DIAGNOSIS
AB Introduction: Latinos living with HIV in the Americas share a common ethnic and cultural heritage. In North America, Latinos have a relatively high rate of new HIV infections but lower rates of engagement at all stages of the care continuum, whereas in Latin America antiretroviral therapy (ART) services continue to expand to meet treatment needs. In this analysis, we compare HIV treatment outcomes between Latinos receiving ART in North America versus Latin America.
   Methods: HIV-positive adults initiating ART at Caribbean, Central and South America Network for HIV (CCASAnet) sites were compared to Latino patients (based on country of origin or ethnic identity) starting treatment at North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) sites in the United States and Canada between 2000 and 2011. Cox proportional hazards models compared mortality, treatment interruption, antiretroviral regimen change, virologic failure and loss to follow-up between cohorts.
   Results: The study included 8400 CCASAnet and 2786 NA-ACCORD patients initiating ART. CCASAnet patients were younger (median 35 vs. 37 years), more likely to be female (27% vs. 20%) and had lower nadir CD4 count (median 148 vs. 195 cells/mu L, p<0.001 for all). In multivariable analyses, CCASAnet patients had a higher risk of mortality after ART initiation (adjusted hazard ratio (AHR) 1.61; 95% confidence interval (CI): 1.32 to 1.96), particularly during the first year, but a lower hazard of treatment interruption (AHR: 0.46; 95% CI: 0.42 to 0.50), change to second-line ART (AHR: 0.56; 95% CI: 0.51 to 0.62) and virologic failure (AHR: 0.52; 95% CI: 0.48 to 0.57).
   Conclusions: HIV-positive Latinos initiating ART in Latin America have greater continuity of treatment but are at higher risk of death than Latinos in North America. Factors underlying these differences, such as HIV testing, linkage and access to care, warrant further investigation.
C1 [Cesar, Carina; Cahn, Pedro] Fdn Huesped, Invest Clin, Buenos Aires, DF, Argentina.
   [Koethe, John R.; Rebeiro, Peter; Sterling, Timothy R.; McGowan, Catherine] Vanderbilt Univ, Sch Med, Div Infect Dis, Nashville, TN 37212 USA.
   [Giganti, Mark J.; Shepherd, Bryan E.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.
   [Althoff, Keri N.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Napravnik, Sonia] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
   [Mayor, Angel] Univ Cent Caribe, Dept Internal Med, Bayamon, PR USA.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Wolff, Marcelo] Fdn Arriaran, Santiago, Chile.
   [Wolff, Marcelo] Univ Chile, Fac Med, Santiago 7, Chile.
   [Padgett, Denis] Inst Hondureno Seguridad Social, Tegucigalpa, Honduras.
   [Padgett, Denis] Hosp Escuela Univ, Tegucigalpa, Honduras.
   [Sierra-Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [Gotuzzo, Eduardo] Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Willig, James] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA.
   [Levison, Julie] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
   [Levison, Julie] Harvard Univ, Sch Med, Boston, MA USA.
   [Kitahata, Mari] Univ Washington, Div Infect Dis, Seattle, WA 98195 USA.
   [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Infect Dis Sect, Michael E De Bakey VAMC, Houston, TX 77030 USA.
   [Moore, Richard D.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
RP Cesar, C (corresponding author), Peluffo 3932,C1202ABB, Buenos Aires, DF, Argentina.
EM carina.cesar@huesped.org.ar
RI Cesar, Carina/H-2831-2019
OI Mayor, Angel M./0000-0002-7705-837X; Rebeiro, Peter/0000-0003-1951-9104;
   Wolff, Marcelo/0000-0002-9956-8872; Justice, Amy/0000-0003-0139-5502
FU National Institutes of Health, USAUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [U01-AI069918,
   U01-AA013566, U24-AA020794, U01-AA020790, U01-AI31834, U01-AI34989,
   U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039]; Disease Control and
   Prevention, USA [CDC200-2006-18797]; Agency for Healthcare Research and
   Quality, USAUnited States Department of Health & Human ServicesAgency
   for Healthcare Research & Quality [90047713]; Health Resources and
   Services Administration, USA [90051652]; National Institute of Mental
   Health of the National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [K23MH100978]; Canadian
   Institutes of Health Research, CanadaCanadian Institutes of Health
   Research (CIHR) [TGF-96118, HCP-97105, CBR-86906, CBR-94036]; Canadian
   Institutes of Health Research New Investigator AwardCanadian Institutes
   of Health Research (CIHR); Ontario Ministry of Health and Long Term
   CareMinistry of Health and Long-Term Care, Ontario; Government of
   Alberta, Canada; Intramural Research Program of the National Cancer
   Institute, National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI);  [P30-AI027763];  [P30-AI094189]; 
   [P30-AI27757];  [P30-AI27767];  [P30-AI036219];  [P30-AI50410]; 
   [P30-AI54999];  [P30-MH62246];  [P30 AI110527];  [R01-AA16893]; 
   [R01-CA165937];  [R01-DA04334];  [R01-DA11602];  [R01-DA12568]; 
   [R24-AI067039];  [R56-AI102622];  [F31-DA037788];  [Z01-CP010214]; 
   [Z01-CP010176];  [U01-AI35040];  [U01-AI35041];  [U01-AI35042]; 
   [U01-AI37613];  [U01-AI37984];  [U01-AI38855];  [U01-AI38858]; 
   [U01-AI42590];  [U01-AI68634];  [U01-AI68636];  [U01-AI69432]; 
   [U01-AI69434];  [U01-DA036935];  [U01-HD32632];  [U10-EY08052]; 
   [U10-EY08057];  [U10-EY08067];  [U54-MD007587];  [UL1-RR024131]; 
   [UL1-TR000083];  [UM1-AI35043];  [G12-MD007583];  [K01-AI071754]; 
   [K01-AI093197];  [K23-EY013707];  [K24-DA00432];  [K24-AI065298]; 
   [KL2-TR000421];  [MO1-RR-00052];  [N02-CP55504]; DIVISION OF CANCER
   EPIDEMIOLOGY AND GENETICSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI)NIH National Cancer Institute- Division of Cancer
   Epidemiology & Genetics [Z01CP010176, Z01CP010176, Z01CP010176,
   Z01CP010176, Z01CP010176, Z01CP010176] Funding Source: NIH RePORTER;
   EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [U01HD032632]
   Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE
   OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [U01HD032632, U01HD032632, U01HD032632, U01HD032632,
   U01HD032632, U01HD032632, U01HD032632, U01HD032632, U01HD032632,
   U01HD032632, U01HD032632, U01HD032632, U01HD032632, U01HD032632,
   U01HD032632, U01HD032632, U01HD032632, U01HD032632, U01HD032632,
   U01HD032632, U01HD032632, U01HD032632, U01HD032632, U01HD032632,
   U01HD032632] Funding Source: NIH RePORTER; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [ZIACP010214, R01CA165937, Z01CP010176, ZIACP010214, ZIACP010214,
   R01CA165937, ZIACP010214, ZIACP010214, R01CA165937, Z01CP010176,
   ZIACP010214, R01CA165937, ZIACP010214, ZIACP010214, ZIACP010214] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2TR000421, KL2TR000421, KL2TR002317,
   KL2TR000421, UL1TR000083, KL2TR002317, UL1TR000083, KL2TR000421,
   KL2TR002317, KL2TR000421, KL2TR002317, KL2TR002317] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Eye Institute (NEI)
   [U10EY008052, U10EY008067, U10EY008057, U10EY008057, U10EY008067,
   U10EY008067, U10EY008057, U10EY008052, U10EY008052, K23EY013707,
   U10EY008052, U10EY008057, U10EY008067, U10EY008052, U10EY008057,
   U10EY008067, K23EY013707, U10EY008067, U10EY008067, U10EY008057,
   U10EY008057, U10EY008052, U10EY008052, U10EY008057, U10EY008052,
   U10EY008057, U10EY008067, U10EY008052, U10EY008067, K23EY013707,
   U10EY008067, U10EY008052, U10EY008057, U10EY008052, U10EY008067,
   U10EY008052, U10EY008057, U10EY008057, U10EY008052, U10EY008052,
   U10EY008057, U10EY008057, K23EY013707, U10EY008052, U10EY008067,
   U10EY008057, U10EY008067, U10EY008067, U10EY008052, U10EY008067,
   U10EY008057, U10EY008052, U10EY008057, U10EY008052, U10EY008057,
   U10EY008052, U10EY008052, U10EY008052, U10EY008057, K23EY013707,
   U10EY008057, U10EY008052, U10EY008057, U10EY008052, U10EY008067,
   U10EY008067, U10EY008057, U10EY008067, U10EY008052, U10EY008067,
   U10EY008057, U10EY008067, U10EY008057, U10EY008057, U10EY008067,
   U10EY008052, U10EY008052, U10EY008057, U10EY008057, U10EY008057,
   U10EY008052, U10EY008067, U10EY008067, U10EY008067, U10EY008057,
   U10EY008067, U10EY008052] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI037984, P30AI036219, P30AI027763, P30AI027767, P30AI036219,
   P30AI036219, P30AI027767, P30AI027767, U01AI037613, P30AI027767,
   P30AI094189, P30AI050410, U01AI037984, U01AI031834, P30AI036219,
   U01AI031834, P30AI027767, U01AI034993, P30AI027767, P30AI027763,
   P30AI036219, P30AI036219, P30AI027767, P30AI036219, P30AI050410,
   P30AI027757, P30AI036219, P30AI036219, P30AI050410, P30AI027763,
   U01AI037613, U01AI035039, P30AI027757, P30AI036219, P30AI027757,
   P30AI027767, U01AI034989, U01AI034993, P30AI110527, P30AI027763,
   P30AI050410, P30AI027767, P30AI027763, P30AI027767, P30AI027757,
   P30AI027767, U01AI035004, U01AI035039, P30AI050410, P30AI036219,
   U01AI031834, U01AI034994, P30AI027767, P30AI027763, P30AI027757,
   P30AI027763, P30AI027757, P30AI027767, P30AI094189, P30AI050410,
   P30AI050410, P30AI027763, U01AI035039, P30AI094189, P30AI050410,
   R24AI067039, P30AI027767, P30AI054999, P30AI027757, UM1AI069476,
   U01AI035040, P30AI036219, U01AI035039, U01AI037984, P30AI054999,
   P30AI027763, P30AI050410, P30AI094189, P30AI027767, U01AI038858,
   P30AI027757, P30AI027763, P30AI054999, U01AI042590, U01AI037613,
   P30AI027757, P30AI094189, P30AI027767, U01AI035040, P30AI027757,
   P30AI027763, P30AI027767, U01AI035041, P30AI050410, P30AI094189,
   U01AI069434, P30AI027763, U01AI035040, P30AI027763, U01AI034989,
   P30AI027763, P30AI027763, P30AI027757, P30AI027767, P30AI050410,
   K24AI065298, P30AI027767, P30AI027767, P30AI054999, P30AI027763,
   P30AI054999, P30AI094189, P30AI027757, P30AI036219, P30AI027763,
   P30AI027757, U01AI038858, P30AI094189, P30AI027763, UM1AI069476,
   P30AI036219, U01AI068634, P30AI027757, U01AI034989, U01AI034989,
   P30AI027767, P30AI027767, P30AI027767, U01AI035004, P30AI036219,
   P30AI036219, U01AI034989, P30AI027767, U01AI035040, P30AI027757,
   R24AI067039, P30AI050410, U01AI034994, P30AI027757, P30AI094189,
   P30AI110527, U01AI031834, U01AI035004, P30AI027767, P30AI094189,
   U01AI035040, P30AI054999, U01AI034989, P30AI027763, P30AI036219,
   P30AI027767, P30AI036219, P30AI027767, P30AI027767, P30AI027757,
   P30AI027767, P30AI027767, P30AI027767, P30AI036219, U01AI034994,
   U01AI035040, P30AI027767, U01AI035041, P30AI027767, P30AI027767,
   U01AI034989, P30AI027767, P30AI110527, P30AI036219, P30AI027757,
   P30AI036219, P30AI036219, R24AI067039, P30AI027763, U01AI034993,
   P30AI027763, P30AI027767, K24AI065298, P30AI036219, P30AI036219,
   U01AI034993, P30AI027767, P30AI050410, P30AI027767, P30AI027763,
   U01AI038858, P30AI036219, U01AI031834, P30AI036219, U01AI034989,
   P30AI027767, P30AI036219, U01AI034989, P30AI050410, U01AI035004,
   P30AI050410, P30AI094189, P30AI027767, U01AI034989, P30AI027757,
   P30AI027767, U01AI038858, P30AI027757, U01AI038858, U01AI035039,
   P30AI027757, U01AI034989, P30AI027757, U01AI034993, U01AI034994,
   U01AI068636, U01AI035040, P30AI027757, U01AI035040, P30AI027757,
   U01AI035039, U01AI069923, U01AI034994, U01AI042590, U01AI068634,
   P30AI027763, U01AI031834, U01AI035041, P30AI050410, P30AI036219,
   P30AI027763, U01AI035004, P30AI050410, U01AI068634, U01AI038858,
   P30AI054999, P30AI027767, P30AI027767, P30AI027767, U01AI031834,
   P30AI036219, U01AI035041, U01AI038858, U01AI042590, P30AI050410,
   P30AI036219, U01AI035042, U01AI069923, P30AI027767, P30AI027767,
   P30AI027763, P30AI027763, P30AI094189, P30AI036219, P30AI050410,
   P30AI036219, P30AI036219, P30AI110527, U01AI034989, P30AI050410,
   U01AI035039, U01AI042590, P30AI027757, P30AI027757, P30AI027757,
   P30AI027763, P30AI036219, U01AI042590, U01AI069918, P30AI027757,
   U01AI034993, P30AI050410, P30AI027757, P30AI054999, P30AI036219,
   P30AI027767, U01AI034989, U01AI031834, P30AI027763, U01AI034989,
   P30AI036219, P30AI036219, P30AI027767, P30AI027767, U01AI034989,
   U01AI034989, U01AI034989, P30AI050410, P30AI027767, P30AI027767,
   U01AI034989, P30AI027767, U01AI034993, UM1AI068634, U01AI034989,
   R24AI067039, P30AI027757, P30AI027757, P30AI050410, P30AI027757,
   U01AI069918, P30AI027757, P30AI036219, P30AI036219, P30AI036219,
   P30AI050410, P30AI027757, U01AI034989, U01AI034989, U01AI042590,
   P30AI050410, P30AI036219, P30AI027757, K24AI065298, P30AI027767,
   P30AI027757, P30AI094189, P30AI094189, U01AI034989, U01AI035039,
   P30AI036219, P30AI027763, U01AI034993, K01AI071754, P30AI050410,
   P30AI050410, U01AI034989, U01AI034989, U01AI069918, U01AI035040,
   P30AI027763, P30AI027767, P30AI027757, U01AI035039, U01AI035039,
   P30AI027767, U01AI069432, P30AI027767, P30AI036219, U01AI038855,
   U01AI038858, P30AI027757, P30AI027767, R24AI067039, P30AI027767,
   U01AI034989, P30AI027757, P30AI027757, P30AI027767, P30AI027763,
   U01AI035042, P30AI027757, P30AI027757, P30AI027757, P30AI027757,
   P30AI027763, UM1AI068636, U01AI035041, U01AI034989, P30AI050410,
   U01AI034994, P30AI027767, P30AI027767, U01AI035040, U01AI035040,
   U01AI038858, U01AI034989, P30AI050410, P30AI027763, U01AI035041,
   P30AI027763, P30AI094189, P30AI036219, P30AI027757, P30AI027767,
   U01AI034989, P30AI027763, U01AI034989, U01AI069918, U01AI035004,
   UM1AI068634, P30AI050410, P30AI036219, P30AI036219, P30AI027757,
   P30AI027763, P30AI036219, P30AI050410, P30AI027757, P30AI094189,
   P30AI027767, U01AI034989, P30AI027757, UM1AI069476, P30AI027757,
   P30AI027767, P30AI027757, U01AI069918, U01AI069923, P30AI050410,
   P30AI027757, U01AI035004, P30AI027757, U01AI034989, P30AI027763,
   U01AI034989, P30AI027763, P30AI027767, R24AI067039, U01AI035041,
   U01AI035004, U01AI034989, P30AI094189, P30AI027757, U01AI038858,
   P30AI027757, P30AI110527, P30AI027767, P30AI050410, P30AI027767,
   P30AI027763, P30AI036219, P30AI027767, U01AI035040, P30AI027757,
   P30AI027757, P30AI027767, P30AI027767, P30AI094189, P30AI027767,
   P30AI027763, U01AI034989, P30AI050410, P30AI027757, U01AI035004,
   P30AI027767, P30AI027757, P30AI054999, P30AI027767, P30AI027757,
   P30AI050410, U01AI069923, P30AI036219, U01AI035040, P30AI027757,
   P30AI054999, U01AI038858, P30AI027763, U01AI035004, P30AI110527,
   P30AI050410, P30AI027767, P30AI027763, P30AI050410, P30AI027757,
   U01AI035041, P30AI094189, U01AI042590, P30AI027757, P30AI027767,
   P30AI050410, P30AI027763, P30AI027757, P30AI027767, U01AI038858,
   P30AI036219, U01AI034989, U01AI035039, P30AI036219, P30AI027757,
   P30AI050410, U01AI035040, P30AI027757, P30AI027757, U01AI034989,
   P30AI050410, P30AI054999, U01AI034989, U01AI034989, P30AI027763,
   U01AI035042, U01AI034993, P30AI050410, U01AI031834, U01AI035041,
   U01AI035039, U01AI035004, P30AI027767, U01AI034989, K01AI071754,
   P30AI027757, U01AI034993, U01AI034989, P30AI027757, P30AI050410,
   K01AI093197, P30AI027767, U01AI038858, U01AI038855, P30AI027757,
   U01AI035042, UM1AI068636, P30AI027767, P30AI027767, P30AI027767,
   U01AI038855, P30AI027767, P30AI050410, P30AI036219, P30AI050410,
   U01AI035042, P30AI027767, U01AI035039, P30AI110527, U01AI034989,
   P30AI036219, P30AI027757, U01AI038855, P30AI050410, P30AI027757,
   P30AI027763, UM1AI068634, P30AI027767, U01AI034994, P30AI110527,
   U01AI038858, U01AI034989, P30AI027763, P30AI036219, P30AI036219,
   P30AI050410, P30AI027767, U01AI034994, U01AI034989, U01AI034989,
   P30AI036219, U01AI038858, P30AI036219, P30AI027757, P30AI027763,
   P30AI036219, P30AI050410, P30AI094189, P30AI027767, P30AI027767,
   U01AI034989, P30AI027767, P30AI027757, P30AI027767, P30AI027757,
   P30AI027767, P30AI027767, P30AI050410, U01AI034989, P30AI027757,
   P30AI094189, P30AI036219, P30AI027763, P30AI027757, P30AI050410,
   U01AI034989, U01AI038858, P30AI094189, U01AI034989, U01AI035004,
   P30AI050410, P30AI027767, P30AI050410, U01AI038858, U01AI035039,
   UM1AI068636, P30AI027767, P30AI027767, P30AI094189, P30AI036219,
   P30AI027757, P30AI027757, P30AI036219, U01AI035004, U01AI035041,
   P30AI027757, P30AI027757, P30AI036219, P30AI027757, P30AI027757,
   U01AI069923, U01AI035042, P30AI110527, U01AI042590, U01AI034993,
   P30AI094189, P30AI110527, P30AI027757, U01AI038858, P30AI036219,
   U01AI038858, P30AI027763, P30AI027767, U01AI037613, P30AI050410,
   P30AI027767, U01AI035041, P30AI027767, U01AI034993, P30AI027767,
   P30AI027757, P30AI036219, P30AI027767, P30AI050410, P30AI027763,
   U01AI038858, P30AI027757, P30AI027757, P30AI027757, U01AI038858,
   R24AI067039, U01AI069923, P30AI094189, P30AI027763, U01AI035004,
   P30AI027757, P30AI027763, P30AI027757, P30AI027767, P30AI027757,
   P30AI027757, P30AI027757, U01AI035041, P30AI027757, UM1AI068634,
   P30AI027757, U01AI035042, U01AI042590, P30AI027767, P30AI050410,
   U01AI031834, P30AI036219, P30AI027763, P30AI110527, P30AI050410,
   P30AI027767, U01AI034989, P30AI054999, P30AI036219, P30AI036219,
   P30AI094189, P30AI027757, P30AI027763, U01AI034989, U01AI035042,
   P30AI027763, P30AI027767, P30AI094189, P30AI036219, P30AI027763,
   P30AI027767, P30AI027757, P30AI027763, U01AI031834, UM1AI035043,
   P30AI027757, P30AI036219, P30AI027763, P30AI036219, U01AI035004,
   U01AI034994, K24AI065298, P30AI027757, P30AI036219, P30AI036219,
   U01AI035040, P30AI027767, P30AI027757, P30AI027757, P30AI027763,
   P30AI027757, U01AI034989, U01AI035042, K01AI093197, U01AI069923,
   U01AI034994, P30AI027763, U01AI034989, U01AI037613, P30AI027763,
   P30AI027757, U01AI034989, P30AI027767, P30AI036219, U01AI035004,
   P30AI094189, P30AI110527, P30AI027767, P30AI094189, U01AI034994,
   P30AI036219, P30AI110527, P30AI027757, P30AI027763, U01AI034989,
   P30AI036219, P30AI027757, U01AI034989, UM1AI068634, P30AI110527,
   U01AI034989, P30AI050410, U01AI038858, U01AI034989, P30AI027763,
   UM1AI068636, P30AI036219, P30AI027763, P30AI050410, U01AI038858,
   R24AI067039, K24AI065298, P30AI027757, P30AI027757, P30AI036219,
   P30AI110527, UM1AI035043, P30AI027757, P30AI027763, U01AI034994,
   P30AI027763, U01AI031834, P30AI027757, U01AI034989, U01AI034989,
   P30AI027767, U01AI035041, P30AI050410, P30AI050410, U01AI038858,
   P30AI050410, P30AI050410, P30AI027763, P30AI050410, P30AI027767,
   P30AI036219, P30AI027767, P30AI036219, P30AI094189, U01AI035042,
   P30AI027757, P30AI027767, P30AI027763, P30AI036219, P30AI094189,
   P30AI027767, U01AI035040, P30AI050410, P30AI036219, P30AI036219,
   P30AI027767, P30AI050410, U01AI035041, U01AI034989, U01AI038858,
   P30AI036219, P30AI036219, P30AI027767, P30AI050410, P30AI027757,
   U01AI031834, P30AI027763, P30AI094189, P30AI027757, P30AI027767,
   P30AI027767, P30AI050410, P30AI027757, P30AI027763, P30AI050410,
   P30AI027757, U01AI038855, U01AI034994, P30AI036219, P30AI027757,
   P30AI027767, P30AI027757, P30AI036219, P30AI036219, U01AI035042,
   P30AI110527, P30AI027767, P30AI027767, P30AI027763, P30AI036219,
   U01AI068636, U01AI035040, P30AI027763, U01AI034989, P30AI050410,
   P30AI036219, P30AI027757, P30AI027767, P30AI027767, U01AI034989,
   P30AI054999, P30AI027757, P30AI050410, P30AI027763, P30AI036219,
   P30AI027757, P30AI050410, P30AI027757, U01AI038858, P30AI036219,
   U01AI031834, P30AI054999, U01AI034989, P30AI094189, P30AI027767,
   P30AI027757, U01AI035041, R24AI067039, U01AI034989, P30AI027757,
   P30AI054999, U01AI034994, P30AI027757, P30AI036219, P30AI036219,
   U01AI034994, U01AI042590, P30AI027767, U01AI037984, U01AI034989,
   P30AI036219, U01AI034989, P30AI027757, U01AI068636, P30AI027757,
   P30AI027763, UM1AI035043, U01AI038858, P30AI050410, P30AI027757,
   U01AI035042, P30AI036219, U01AI035004, U01AI069923, P30AI027763,
   U01AI034989, P30AI027767, P30AI027757, U01AI035040, P30AI050410,
   P30AI050410, P30AI050410, P30AI110527, K01AI071754, U01AI035039,
   P30AI027767, P30AI050410, P30AI036219, P30AI050410, P30AI027767,
   P30AI027767, U01AI038858, U01AI035042, UM1AI068634, P30AI027757,
   U01AI035039, P30AI050410, P30AI027757, P30AI027763, U01AI042590,
   U01AI035041, P30AI027767, P30AI110527, P30AI027763, U01AI034994,
   P30AI027763, UM1AI035043, U01AI042590, R24AI067039, P30AI027763,
   P30AI036219, P30AI036219, P30AI036219, P30AI027767, P30AI027763,
   P30AI027757, U01AI069923, U01AI035040, P30AI027763, P30AI050410,
   R24AI067039, P30AI027757, P30AI027757, U01AI034989, P30AI027763,
   P30AI050410, U01AI069918, U01AI035042, P30AI027757, P30AI036219,
   P30AI054999, P30AI036219, R24AI067039, U01AI034994, P30AI036219,
   U01AI035004, P30AI027763, P30AI036219, P30AI036219, U01AI034989,
   P30AI036219, U01AI035004, P30AI050410, U01AI038858, P30AI027757,
   U01AI042590, P30AI027767, P30AI027767, U01AI069434, U01AI035041,
   UM1AI068634, P30AI027763, UM1AI035043, U01AI034989, P30AI050410,
   P30AI027767, P30AI027763, P30AI036219, P30AI027757, U01AI034989,
   P30AI027757, P30AI027757, P30AI027767, P30AI050410, U01AI038858,
   P30AI027767, P30AI027767, P30AI050410, P30AI027757, U01AI034989,
   U01AI035041, P30AI050410, U01AI034989, U01AI035042, P30AI027757,
   P30AI050410, P30AI027757, P30AI094189, U01AI034994, U01AI035004,
   U01AI038855, P30AI036219, U01AI038858, P30AI036219, P30AI036219,
   U01AI034994, P30AI036219, P30AI050410, U01AI034993, U01AI034989,
   P30AI036219, P30AI027757, P30AI027757, P30AI027757, P30AI036219,
   U01AI034989, U01AI035042, U01AI069432, U01AI034989, U01AI042590,
   P30AI027767, P30AI027767, P30AI036219, P30AI050410, K24AI065298,
   P30AI027763, P30AI027757, P30AI036219, P30AI027757, P30AI027757,
   U01AI035041, P30AI027763, P30AI027757, P30AI036219, U01AI034989,
   U01AI042590, P30AI027757, U01AI037613, P30AI027767, P30AI050410,
   P30AI094189, P30AI054999, U01AI035042, P30AI027757, P30AI027767,
   U01AI035042, P30AI027767, P30AI027763, P30AI036219, U01AI035040,
   P30AI027763, P30AI094189, P30AI027757, P30AI027763, P30AI050410,
   P30AI094189, P30AI036219, P30AI027763, U01AI034989, U01AI034993,
   P30AI094189, U01AI069923, U01AI035042, P30AI094189, U01AI035041,
   U01AI035040, P30AI036219, P30AI027767, P30AI027767, U01AI035042,
   P30AI094189, P30AI050410, P30AI027763, P30AI027757, P30AI027767,
   U01AI035040, U01AI031834, U01AI069923, P30AI027757, P30AI094189,
   UM1AI035043, U01AI069923, U01AI034989, P30AI027757, P30AI027767,
   P30AI027767, P30AI027763, U01AI038858, K01AI093197, P30AI027757,
   P30AI027767, P30AI036219, U01AI069432, P30AI050410, U01AI038858,
   P30AI054999, P30AI036219, P30AI027767, P30AI027767, P30AI027767,
   P30AI027767, P30AI036219, P30AI050410, P30AI050410, P30AI027767,
   P30AI027757, P30AI027757, P30AI027763, P30AI050410, P30AI027767,
   U01AI035042, U01AI035039, P30AI094189, P30AI027767, U01AI034993,
   P30AI036219, P30AI027767, P30AI027767, P30AI027763, P30AI027767,
   U01AI069923, P30AI027767, U01AI069918, P30AI027763, P30AI094189,
   U01AI035039, U01AI069923, U01AI035040, P30AI050410, P30AI050410,
   P30AI027757, U01AI035041, P30AI110527, P30AI027767, P30AI050410,
   P30AI027767, P30AI027763, UM1AI069476, P30AI050410, U01AI034989,
   P30AI036219, P30AI027767, P30AI027767, P30AI027763, P30AI110527,
   U01AI035004, UM1AI069476, P30AI094189, P30AI054999, P30AI094189,
   U01AI034989, P30AI027767, P30AI050410, P30AI036219, K01AI093197,
   P30AI027757, UM1AI035043, P30AI110527, U01AI034989, U01AI037613,
   U01AI034994, P30AI036219, P30AI027763, U01AI069918, U01AI042590,
   P30AI027763, U01AI035004, P30AI050410, P30AI027763, U01AI035004,
   R24AI067039, P30AI050410, U01AI031834, P30AI036219, U01AI034989,
   U01AI038858, P30AI027763, U01AI035040, P30AI027763, U01AI035004,
   P30AI027763, P30AI036219, P30AI094189, P30AI036219, P30AI027757,
   P30AI094189, P30AI027767, P30AI027757, P30AI027757, U01AI035042,
   U01AI031834, U01AI034993, P30AI036219, P30AI054999, P30AI050410,
   P30AI054999, R24AI067039, P30AI027767, P30AI054999, U01AI034989,
   P30AI036219, P30AI050410, UM1AI068636, P30AI050410, U01AI034989,
   U01AI042590, U01AI035004, U01AI038858, P30AI050410, U01AI069918,
   P30AI036219, U01AI037984, P30AI027763, P30AI027767, P30AI054999,
   U01AI035039, U01AI035040, U01AI034989, U01AI034989, U01AI037613,
   U01AI069434, P30AI110527, UM1AI069476, P30AI027767, P30AI027757,
   P30AI027767, P30AI027757, P30AI027757, U01AI035041, P30AI027767,
   U01AI034989, U01AI035041, P30AI036219, P30AI036219, P30AI110527,
   UM1AI068636, P30AI027767, P30AI027767, U01AI034994, P30AI036219,
   P30AI050410, P30AI036219, P30AI050410, U01AI069432, U01AI034993,
   U01AI038858, U01AI037984, U01AI031834, P30AI027757, U01AI035039,
   U01AI034994, R56AI102622, P30AI027763, P30AI036219, P30AI027757,
   U01AI035039, P30AI027757, P30AI027767, P30AI027767, U01AI034989,
   P30AI027763, P30AI027757, P30AI027757, P30AI036219, U01AI038858,
   P30AI027767, U01AI034989, P30AI027757, P30AI036219, P30AI027757,
   P30AI027767, P30AI036219, U01AI042590, U01AI035039, P30AI027757,
   P30AI027767, P30AI027757, P30AI036219, P30AI027767, P30AI094189,
   P30AI054999, P30AI027763, U01AI034993, U01AI069918, U01AI042590,
   P30AI036219, P30AI050410, U01AI037984, P30AI027767, P30AI027767,
   U01AI035041, P30AI050410, P30AI027767, P30AI054999, P30AI050410,
   U01AI034993, P30AI027767, U01AI068636, U01AI034989, P30AI036219,
   P30AI027767, P30AI027757, P30AI027763, P30AI027763, P30AI027763,
   U01AI035039, P30AI027757, R24AI067039, U01AI035042, P30AI094189,
   U01AI031834, U01AI069918, P30AI027763, P30AI027767, U01AI034994,
   U01AI034989, U01AI035042, U01AI035039, U01AI035004, P30AI027767,
   U01AI042590, P30AI054999, P30AI036219, P30AI094189, U01AI035042,
   U01AI035041, P30AI050410, P30AI027767, P30AI027757, P30AI050410,
   P30AI027763, P30AI027763, U01AI035039, P30AI036219, P30AI027763,
   P30AI027763, U01AI038858, P30AI036219, P30AI054999, P30AI027763,
   P30AI027757, U01AI038858, P30AI036219, U01AI068634, U01AI034989,
   U01AI034989, P30AI027763, P30AI027757, P30AI027757, U01AI042590,
   U01AI038858, P30AI050410, U01AI035042, P30AI110527, P30AI027767,
   P30AI027767, U01AI034994, P30AI036219, U01AI034989, P30AI110527,
   P30AI027767, U01AI034989, P30AI027767, P30AI036219, K01AI071754,
   P30AI094189, P30AI094189, P30AI027757, U01AI068636, P30AI027767,
   U01AI069918, P30AI050410, P30AI036219, P30AI027767, P30AI036219,
   P30AI036219, P30AI027767, P30AI027757, P30AI110527, P30AI027757,
   U01AI034994, P30AI027763, P30AI050410, U01AI031834, P30AI027767,
   P30AI027767, P30AI050410, P30AI110527, P30AI110527, P30AI027757,
   P30AI110527, P30AI027757, P30AI027767, P30AI036219, P30AI036219,
   U01AI031834, P30AI094189, P30AI027757, U01AI069923, P30AI027757,
   P30AI036219, P30AI027763, U01AI037613, P30AI027757, P30AI050410,
   P30AI050410, P30AI027757, P30AI027767, U01AI035004, U01AI034989,
   P30AI027757, P30AI027763, P30AI027763, U01AI038855, P30AI110527,
   P30AI027757, U01AI034994, P30AI027763, U01AI038858, U01AI035042,
   U01AI069918, P30AI027767, P30AI027757, P30AI110527, P30AI036219,
   K01AI071754, U01AI035004, U01AI031834, P30AI036219, P30AI027767,
   P30AI036219, P30AI036219, P30AI027757, P30AI036219, U01AI034994,
   P30AI036219, U01AI034989, P30AI027767, U01AI034989, U01AI034989,
   P30AI094189, P30AI050410, P30AI036219, U01AI035040, U01AI068634,
   U01AI035039, U01AI038858, P30AI027767, P30AI027767, U01AI035004,
   U01AI035042, U01AI035042, P30AI027767, UM1AI068634, P30AI027757,
   U01AI034994, U01AI034994, P30AI027767, P30AI036219, P30AI027767,
   U01AI069923, P30AI036219, P30AI027767, P30AI050410, P30AI027757,
   P30AI050410, U01AI042590, P30AI027763, U01AI034989, P30AI027763,
   U01AI035041, P30AI054999, P30AI036219, P30AI027757, P30AI036219,
   P30AI036219, P30AI094189, P30AI027767, P30AI027767, P30AI027757,
   P30AI027757, P30AI036219, U01AI035039, P30AI027763, P30AI027767,
   P30AI036219, U01AI035040, P30AI050410, P30AI050410, P30AI027767,
   P30AI094189, U01AI038858, U01AI035004, P30AI050410, P30AI027767,
   P30AI050410, P30AI036219, P30AI027757, P30AI094189, P30AI027767,
   P30AI027757, P30AI027767, P30AI027763, P30AI027757, P30AI027763,
   P30AI094189, U01AI038858, P30AI027757, K01AI093197, U01AI035042,
   P30AI027767, U01AI038855, U01AI069918, U01AI038858, P30AI027763,
   U01AI034993, U01AI034989, P30AI027757, P30AI036219, P30AI036219,
   P30AI036219, U01AI069923, P30AI036219, P30AI027757, U01AI034993,
   U01AI035041, U01AI035042, P30AI027767, U01AI034994, P30AI027757,
   P30AI054999, P30AI036219, U01AI031834, P30AI110527, P30AI027767,
   P30AI036219, P30AI027767, P30AI027757, P30AI027767, P30AI054999,
   P30AI027757, P30AI050410, U01AI035041, U01AI034989, U01AI037984,
   P30AI094189, U01AI031834, P30AI094189, U01AI069923, P30AI054999,
   P30AI110527, P30AI027757, U01AI035042, P30AI027767, P30AI036219,
   P30AI036219, P30AI027767, P30AI036219, P30AI094189, P30AI050410,
   U01AI035041, P30AI027767, P30AI027757, P30AI110527, P30AI036219,
   U01AI034994, P30AI027757, U01AI035004, P30AI027767, K24AI065298,
   P30AI027767, P30AI094189, U01AI035004, UM1AI069476, UM1AI068634,
   P30AI027757, UM1AI035043, P30AI050410, P30AI094189, P30AI027763,
   P30AI027767, P30AI054999, P30AI027757, P30AI094189, R24AI067039,
   P30AI027767, P30AI027763, P30AI027767, P30AI050410, U01AI034994,
   P30AI050410, P30AI036219, P30AI050410, P30AI027767, U01AI034989,
   U01AI035004, P30AI050410, P30AI027767, P30AI050410, P30AI050410,
   P30AI027763, P30AI027757, P30AI036219, UM1AI069476, P30AI036219,
   P30AI027767, U01AI034993, U01AI034989, U01AI038855, P30AI050410,
   P30AI027767, P30AI036219, P30AI027767, P30AI036219, P30AI050410,
   P30AI027757, P30AI027757, P30AI036219, P30AI027767, U01AI035039,
   P30AI027757, P30AI027763, U01AI034989, U01AI034993, U01AI034993,
   U01AI034989, P30AI027757, P30AI027757, U01AI034989, P30AI027767,
   U01AI034989, P30AI027767, P30AI027757, P30AI027767, P30AI094189,
   P30AI027757, P30AI036219, U01AI069918, U01AI038858, U01AI034994,
   P30AI027757, P30AI027757, U01AI035004, P30AI050410, U01AI068636,
   P30AI027767, P30AI027767, P30AI027763, P30AI027757, P30AI036219,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, P30AI036219,
   P30AI036219, P30AI027757, P30AI027763, U01AI034994, P30AI036219,
   P30AI027757, P30AI050410, U01AI042590, P30AI027767, P30AI050410,
   U01AI034994, P30AI027757, K24AI065298, P30AI036219, U01AI038858,
   U01AI034989, U01AI035041, P30AI027757, P30AI027757, U01AI069923,
   U01AI034993, P30AI050410, P30AI094189, U01AI038855, P30AI027763,
   U01AI035004, P30AI050410, P30AI054999, UM1AI069476, U01AI038858,
   P30AI036219, U01AI034993, P30AI094189, U01AI034989, P30AI027767,
   P30AI050410, P30AI027767, P30AI027767, P30AI027767, P30AI027757,
   P30AI027757, U01AI034989, U01AI035039, P30AI027757, U01AI035004,
   P30AI050410, P30AI027767, U01AI034989, P30AI036219, P30AI036219,
   U01AI034989, P30AI036219, U01AI034989, P30AI027763, P30AI027767,
   U01AI034989, P30AI027767, P30AI027763, P30AI050410, P30AI027767,
   P30AI036219, U01AI035039, P30AI110527, P30AI027767, P30AI036219,
   P30AI036219, U01AI035039, U01AI069432, P30AI050410, P30AI094189,
   P30AI110527, U01AI069923, U01AI034989, P30AI027757, P30AI027767,
   P30AI027757, U01AI068636, P30AI027767, U01AI034994, P30AI027767,
   P30AI027767, P30AI027757, P30AI027757, U01AI037984, P30AI027763,
   P30AI050410, P30AI050410, P30AI050410, U01AI038858, U01AI035040,
   P30AI027763, P30AI050410, P30AI054999, U01AI031834, U01AI034989,
   U01AI037984, P30AI050410, P30AI110527, P30AI054999, U01AI034994,
   U01AI034993, P30AI027757, U01AI035040, P30AI110527, P30AI027757,
   P30AI094189, P30AI027763, U01AI035040, U01AI034993, P30AI027757,
   P30AI050410, U01AI034989, P30AI036219, P30AI036219, P30AI027767,
   U01AI035004, P30AI027757, P30AI027757, P30AI027763, P30AI036219,
   P30AI027767, P30AI027757, U01AI069923, P30AI027767, P30AI036219,
   U01AI034994, P30AI036219, U01AI034989, P30AI027763, U01AI035004,
   U01AI038855, P30AI094189, P30AI027763, P30AI054999, U01AI035040,
   P30AI036219, P30AI094189, P30AI036219, K24AI065298, P30AI054999,
   U01AI034989, P30AI027763, P30AI027767, P30AI027757, P30AI027767,
   P30AI036219, P30AI027767, UM1AI068634, P30AI027763, P30AI050410,
   P30AI027763, P30AI027763, U01AI034994, U01AI035004, U01AI035004,
   U01AI038858, U01AI034989, U01AI034989, P30AI027767, P30AI027763,
   P30AI027763, U01AI034989, U01AI035039, P30AI094189, P30AI110527,
   P30AI036219, P30AI027763, P30AI027757, U01AI069918, P30AI027757,
   U01AI069923, P30AI050410, P30AI027767, P30AI027763, P30AI027767,
   P30AI094189, P30AI027757, P30AI036219, P30AI050410, U01AI034989,
   U01AI069434, P30AI036219, U01AI038858, U01AI035041, P30AI036219,
   P30AI027757, U01AI069923, P30AI050410, P30AI027767, P30AI036219,
   P30AI050410, P30AI027767, P30AI027763, P30AI027757, P30AI027757,
   P30AI036219, P30AI027757, P30AI110527, P30AI027757, U01AI034993,
   P30AI027767, P30AI027757, P30AI027757, P30AI027767, K24AI065298,
   U01AI031834, P30AI036219, P30AI027757, P30AI094189, U01AI035042,
   P30AI027763, U01AI035004, U01AI042590, P30AI027763, P30AI054999,
   U01AI069434, U01AI035004, U01AI035041, U01AI035004, U01AI069918,
   P30AI110527, U01AI034993, R24AI067039, U01AI035004, P30AI094189,
   P30AI036219, U01AI034989, P30AI036219, U01AI035004, U01AI038858,
   U01AI034989, P30AI050410, UM1AI035043, P30AI027763, P30AI036219,
   P30AI027763, P30AI094189, U01AI038855, P30AI036219, U01AI034989,
   P30AI094189, P30AI027767, P30AI027767, P30AI027767, U01AI035042,
   U01AI035041, P30AI036219, P30AI094189, U01AI035041, P30AI027757,
   P30AI027767, U01AI034993] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, K23MH100978, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, K23MH100978,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, K23MH100978, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, K23MH100978, P30MH062246,
   K23MH100978, P30MH062246, P30MH062246, P30MH062246] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism
   (NIAAA) [U01AA020790, U01AA020790, U01AA020790, U24AA020794,
   U01AA020790, U01AA013566, U24AA020794, U01AA020790, U01AA013566,
   U01AA020790, U01AA020790, U24AA020794, U01AA013566, U01AA013566,
   U01AA013566, U24AA020794, U24AA020794, U01AA020790, U24AA020794,
   R01AA016893, U24AA020794, U24AA020794, R01AA016893, U24AA020794,
   U24AA020794, U24AA020794, R01AA016893, R01AA016893, U01AA020790,
   U24AA020794, U01AA013566, U24AA020794] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [R01DA012568, R01DA004334, R01DA004334,
   R01DA012568, R01DA011602, R01DA011602, R01DA011602, R01DA012568,
   R01DA012568, R01DA011602, R01DA004334, R01DA012568, R01DA012568,
   R01DA012568, R01DA012568, R01DA012568, R01DA004334, R01DA004334,
   R01DA012568, R01DA004334, R01DA004334, U01DA036297, R01DA012568,
   R01DA012568, R01DA011602, R01DA004334, U01DA036297, R01DA004334,
   R01DA011602, U01DA036935, U01DA036297, U01DA036935, R01DA004334,
   R01DA012568, R01DA004334, R01DA011602, U01DA036297, R01DA012568,
   R01DA004334, R01DA012568, R01DA004334, R01DA011602, R01DA004334,
   R01DA004334, R01DA012568, R01DA004334, U01DA036297, U01DA036935,
   U01DA036935, R01DA012568, U01DA036297, R01DA004334, R01DA012568,
   R01DA011602, U01DA036935, R01DA011602, R01DA011602, R01DA011602,
   F31DA037788, U01DA036935, R01DA011602, U01DA036297, R01DA012568,
   R01DA011602, R01DA004334, R01DA012568, R01DA011602, R01DA012568,
   R01DA011602, R01DA012568, R01DA012568, R01DA012568, R01DA012568,
   R01DA004334, F31DA037788, R01DA004334, R01DA012568, R01DA012568,
   R01DA004334, R01DA004334] Funding Source: NIH RePORTER; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD) [G12MD007583, G12MD007583, U54MD007587, G12MD007583,
   U54MD007587, G12MD007583, U54MD007587, G12MD007583, U54MD007587,
   G12MD007583, U54MD007587, G12MD007583, G12MD007583, G12MD007583,
   U54MD007587, G12MD007583, U54MD007587, G12MD007583, G12MD007583,
   G12MD007583, U54MD007587, G12MD007583, G12MD007583, U54MD007587,
   U54MD007587, G12MD007583, G12MD007583, U54MD007587, U54MD007587,
   G12MD007583, G12MD007583, U54MD007587, U54MD007587, G12MD007583,
   G12MD007583, G12MD007583, G12MD007583, G12MD007583, U54MD007587,
   G12MD007583, G12MD007583, G12MD007583, U54MD007587, U54MD007587,
   G12MD007583, G12MD007583, G12MD007583, G12MD007583, G12MD007583,
   U54MD007587, G12MD007583, U54MD007587, G12MD007583, U54MD007587,
   G12MD007583, G12MD007583, U54MD007587, G12MD007583, G12MD007583,
   G12MD007583, G12MD007583, G12MD007583, U54MD007587, U54MD007587,
   U54MD007587, G12MD007583, U54MD007587, U54MD007587, G12MD007583,
   G12MD007583, U54MD007587, G12MD007583, G12MD007583, G12MD007583,
   U54MD007587, G12MD007583, U54MD007587, G12MD007583, G12MD007583,
   U54MD007587, G12MD007583, G12MD007583, G12MD007583, G12MD007583,
   G12MD007583] Funding Source: NIH RePORTER
FX NA-ACCORD: This work was supported by the National Institutes of Health,
   USA (grants U01-AI069918, U01-AA013566, U24-AA020794, U01-AA020790,
   U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004,
   U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI37613,
   U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634,
   U01-AI68636, U01-AI69432, U01-AI69434, U01-DA036935, U01-HD32632,
   U10-EY08052, U10-EY08057, U10-EY08067, U54-MD007587, UL1-RR024131,
   UL1-TR000083, UM1-AI35043, G12-MD007583, K01-AI071754, K01-AI093197,
   K23-EY013707, K24-DA00432, K24-AI065298, KL2-TR000421, MO1-RR-00052,
   N02-CP55504, P30-AI027763, P30-AI094189, P30-AI27757, P30-AI27767,
   P30-AI036219, P30-AI50410, P30-AI54999, P30-MH62246, P30 AI110527,
   R01-AA16893, R01-CA165937, R01-DA04334, R01-DA11602, R01-DA12568,
   R24-AI067039, R56-AI102622, F31-DA037788, Z01-CP010214, and
   Z01-CP010176); Disease Control and Prevention, USA (contract
   CDC200-2006-18797); the Agency for Healthcare Research and Quality, USA
   (contract 90047713); the Health Resources and Services Administration,
   USA (contract 90051652); National Institute of Mental Health of the
   National Institutes of Health (grant K23MH100978); the Canadian
   Institutes of Health Research, Canada (grants TGF-96118, HCP-97105,
   CBR-86906, CBR-94036); Canadian Institutes of Health Research New
   Investigator Award (A. Burchell); Ontario Ministry of Health and Long
   Term Care; and the Government of Alberta, Canada. Additional support was
   provided by the Intramural Research Program of the National Cancer
   Institute, National Institutes of Health.; CCASAnet: This work was
   supported by the National Institutes of Health, USA (grant
   2-U01-AI069923).
CR Beach MC, 2010, J GEN INTERN MED, V25, P682, DOI 10.1007/s11606-010-1310-4
   Boulle A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001718
   Braitstein P, 2006, LANCET, V367, P817
   Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248
   Carriquiry G, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20016
   Castillo-Mancilla J, 2012, J IMMIGR MINOR HEALT, V14, P89, DOI 10.1007/s10903-011-9529-7
   Centers for Disease Control and Prevention, 2013, HIV SURV REP 2011
   Cesar C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106887
   Cesar C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010490
   Chen NE, 2012, J IMMIGR MINOR HEALT, V14, P65, DOI 10.1007/s10903-011-9497-y
   Ennis S. R., 2011, HISPANIC POPULATION
   Espinoza L, 2008, JAIDS-J ACQ IMM DEF, V49, P94, DOI 10.1097/QAI.0b013e3181820129
   Espinoza L, 2009, AIDS EDUC PREV, V21, P19, DOI 10.1521/aeap.2009.21.5_supp.19
   Gange SJ, 2007, INT J EPIDEMIOL, V36, P294, DOI 10.1093/ije/dyl286
   Gant Z, 2014, MMWR-MORBID MORTAL W, V63, P886
   Garland Joseph Metmowlee, 2010, Curr HIV/AIDS Rep, V7, P107, DOI 10.1007/s11904-010-0049-1
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Gupta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022730
   Hall HI, 2007, AM J PUBLIC HEALTH, V97, P1060, DOI 10.2105/AJPH.2006.087551
   Hall HI, 2006, ANN EPIDEMIOL, V16, P824, DOI 10.1016/j.annepidem.2006.01.009
   Hall HI, 2009, JAIDS-J ACQ IMM DEF, V51, pS13, DOI 10.1097/QAI.0b013e3181a2639e
   Harrell F, 2001, REGRESSION MODELING
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Perez E, 2005, MEDICINA-BUENOS AIRE, V65, P482
   Prosser AT, 2012, JAMA-J AM MED ASSOC, V308, P601, DOI 10.1001/jama.2012.9046
   RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410
   Sanne IM, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-38
   Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7
   Taylor BS, 2014, JAIDS-J ACQ IMM DEF, V65, pE33, DOI 10.1097/QAI.0000000000000010
   Torrone EA, 2007, SEX TRANSM DIS, V34, P846, DOI 10.1097/OLQ.0b013e31809505f7
   Tuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a
   UNAIDS, 2013, GLOB REP UNAIDS REP
   Wohl AR, 2009, AIDS CARE, V21, P1203, DOI 10.1080/09540120902729957
   Wolff MJ, 2010, JAIDS-J ACQ IMM DEF, V55, P368, DOI 10.1097/QAI.0b013e3181eb4fb9
   World Bank, WORLD BANK OP DAT 20
   YIANNOUTSOS CT, 2010, SEX TRANSM INFECT S2, V88, P33
NR 38
TC 7
Z9 7
U1 0
U2 6
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD MAR 18
PY 2016
VL 19
AR 20684
DI 10.7448/IAS.19.1.20684
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DM2JL
UT WOS:000376172800001
PM 26996992
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Gupta, A
   Mathad, JS
   Abdel-Rahman, SM
   Albano, JD
   Botgros, R
   Brown, V
   Browning, RS
   Dawson, L
   Dooley, KE
   Gnanashanmugam, D
   Grinsztejn, B
   Hernandez-Diaz, S
   Jean-Philippe, P
   Kim, P
   Lyerly, AD
   Mirochnick, M
   Mofenson, LM
   Montepiedra, G
   Piper, J
   Sahin, L
   Savic, R
   Smith, B
   Spiegel, H
   Swaminathan, S
   Watts, DH
   White, A
AF Gupta, Amita
   Mathad, Jyoti S.
   Abdel-Rahman, Susan M.
   Albano, Jessica D.
   Botgros, Radu
   Brown, Vikki
   Browning, Renee S.
   Dawson, Liza
   Dooley, Kelly E.
   Gnanashanmugam, Devasena
   Grinsztejn, Beatriz
   Hernandez-Diaz, Sonia
   Jean-Philippe, Patrick
   Kim, Peter
   Lyerly, Anne D.
   Mirochnick, Mark
   Mofenson, Lynne M.
   Montepiedra, Grace
   Piper, Jeanna
   Sahin, Leyla
   Savic, Radojka
   Smith, Betsy
   Spiegel, Hans
   Swaminathan, Soumya
   Watts, D. Heather
   White, Amina
TI Toward Earlier Inclusion of Pregnant and Postpartum Women in
   Tuberculosis Drug Trials: Consensus Statements From an International
   Expert Panel
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE tuberculosis; MDR tuberculosis; latent tuberculosis infection;
   pregnancy; clinical trials
ID MATERNAL MORTALITY; GLOBAL BURDEN; HIV-1; PHARMACOKINETICS; FRAMEWORK;
   REGIMENS; ISSUES; RISK
AB Tuberculosis is a major cause of morbidity and mortality in women of childbearing age (15-44 years). Despite increased tuberculosis risk during pregnancy, optimal clinical treatment remains unclear: safety, tolerability, and pharmacokinetic data for many tuberculosis drugs are lacking, and trials of promising new tuberculosis drugs exclude pregnant women. To advance inclusion of pregnant and postpartum women in tuberculosis drug trials, the US National Institutes of Health convened an international expert panel. Discussions generated consensus statements (>75% agreement among panelists) identifying high-priority research areas during pregnancy, including: (1) preventing progression of latent tuberculosis infection, especially in women coinfected with human immunodeficiency virus; (2) evaluating new agents/regimens for treatment of multidrug-resistant tuberculosis; and (3) evaluating safety, tolerability and pharmacokinetics of tuberculosis drugs already in use during pregnancy and postpartum. Incorporating pregnant women into clinical trials would extend evidence-based tuberculosis prevention and treatment standards to this special population.
C1 [Gupta, Amita] Johns Hopkins Univ, Div Infect Dis, Baltimore, MD USA.
   [Gupta, Amita] Johns Hopkins Univ, Dept Int Hlth, 600 N Wolfe St,Phipps 540B, Baltimore, MD 21287 USA.
   [Dooley, Kelly E.] Johns Hopkins Univ, Sch Med, Div Clin Pharmacol, Baltimore, MD USA.
   [Dooley, Kelly E.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA.
   [Browning, Renee S.; Dawson, Liza; Gnanashanmugam, Devasena; Kim, Peter; Piper, Jeanna; Smith, Betsy] NIAID, Div Aids, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Jean-Philippe, Patrick; Spiegel, Hans] HJF DAIDS, Dept Hlth & Human Serv, Bethesda, MD USA.
   [Mofenson, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
   [White, Amina] NIH, Ctr Clin, Dept Bioeth, Bethesda, MD 20892 USA.
   [Sahin, Leyla] FDA Off New Drugs, Div Pediat & Maternal Hlth, Silver Spring, MD USA.
   [Mathad, Jyoti S.] Weill Cornell Med Coll, Ctr Global Hlth, Div Infect Dis, New York, NY USA.
   [Abdel-Rahman, Susan M.] Childrens Mercy Hosp, Div Clin Pharmacol, Kansas City, MO 64108 USA.
   [Albano, Jessica D.] Post Approval & Strateg Serv, Raleigh, NC USA.
   [Brown, Vikki] INC Res, Womens Hlth & Med Affairs, Raleigh, NC USA.
   [Lyerly, Anne D.] Univ N Carolina, Ctr Bioeth, Chapel Hill, NC USA.
   [Lyerly, Anne D.] Univ N Carolina, Dept Social Med, Chapel Hill, NC USA.
   [Hernandez-Diaz, Sonia] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA.
   [Montepiedra, Grace] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Ctr Biostat AIDS Res, Cambridge, MA 02138 USA.
   [Mirochnick, Mark] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02215 USA.
   [Savic, Radojka] Univ Calif San Francisco, Sch Pharm, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
   [Savic, Radojka] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.
   [Watts, D. Heather] US Dept State, Off Global AIDS Coordinator, Washington, DC 20520 USA.
   [Botgros, Radu] European Med Agcy, London, England.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Swaminathan, Soumya] Natl Inst Res TB, Chennai, Tamil Nadu, India.
RP Gupta, A (corresponding author), Johns Hopkins Univ, Dept Int Hlth, 600 N Wolfe St,Phipps 540B, Baltimore, MD 21287 USA.; Gupta, A (corresponding author), Johns Hopkins Univ, Div Infect Dis, Ctr Clin Global Hlth Educ, 600 N Wolfe St,Phipps 540B, Baltimore, MD 21287 USA.
EM agupta25@jhmi.edu
RI Spiegel, Hans/AAC-4220-2020; Mofenson, Lynne/P-9631-2019
OI Mofenson, Lynne/0000-0002-2818-9808; Lyerly, Anne/0000-0003-2211-6920
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [HHSN272200800014C, T32 AI007613, UM1
   AI069476, UM1 AI068616, UM1 AI068632] Funding Source: Medline; NIGMS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [T32 GM066691] Funding Source: Medline; PHS
   HHSUnited States Public Health Service [HHSN272200800014C] Funding
   Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI068632, UM1AI068632, UM1AI068616,
   T32AI007613, UM1AI069476, UM1AI068616, UM1AI068616, UM1AI069476,
   T32AI007613, T32AI007613, T32AI007613, T32AI007613, T32AI007613,
   T32AI007613, UM1AI068632, UM1AI068632, T32AI007613, T32AI007613,
   UM1AI068616, UM1AI068616, UM1AI069476, T32AI007613, UM1AI068616,
   T32AI007613, UM1AI068616, T32AI007613, UM1AI068632, T32AI007613,
   UM1AI068632, T32AI007613, UM1AI068632, UM1AI068616, UM1AI069476,
   T32AI007613, T32AI007613, UM1AI068616, UM1AI069476, UM1AI069476,
   UM1AI068616, UM1AI068632, T32AI007613, UM1AI069476, UM1AI069476,
   UM1AI068632, UM1AI068632, T32AI007613, T32AI007613, UM1AI069476,
   T32AI007613, UM1AI068632, T32AI007613] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [T32GM066691,
   T32GM066691, T32GM066691, T32GM066691, T32GM066691, T32GM066691,
   T32GM066691, T32GM066691, T32GM066691, T32GM066691, T32GM066691,
   T32GM066691, T32GM066691, T32GM066691, T32GM066691, T32GM066691,
   T32GM066691] Funding Source: NIH RePORTER
CR Ahmed Y, 1999, INT J TUBERC LUNG D, V3, P675
   American Thoracic Society, 2003, MMWR Recomm Rep, V52, P1
   Anderson GD, 2005, CLIN PHARMACOKINET, V44, P989, DOI 10.2165/00003088-200544100-00001
   [Anonymous], 2011, ICH HARM TRIP GUID G
   [Anonymous], 1993, FED REGISTER, V58, P39407
   [Anonymous], 2005, DET TOX REPR MED PRO
   [Anonymous], 2015, REC 36 MONTHS IS PRE
   Blehar MC, 2013, WOMEN HEALTH ISS, V23, pE39, DOI 10.1016/j.whi.2012.10.003
   Brown V, 2012, RISK MANAGEMENT PRIN, P95
   Calvert C, 2014, NEW ENGL J MED, V371, P1075, DOI 10.1056/NEJMc1408436
   Chasela CS, 2010, NEW ENGL J MED, V362, P2271, DOI 10.1056/NEJMoa0911486
   Chervenak FA, 2011, AM J BIOETHICS, V11, P39, DOI 10.1080/15265161.2011.562595
   Desai M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068733
   Dooley KE, 2015, J INFECT DIS, V211, P197, DOI 10.1093/infdis/jiu429
   European Medicines Agency, 2008, GUID RISK ASS MED PR
   European Medicines Agency, 2005, GUID EXP MED PROD PR
   European Medicines Agency, 2013, EUR MED AG REC 2 NEW
   Food and Drug Administration, 2004, GUID IND PHARM PREGN
   Food and Drug Administration, 2014, GUID IND PHARM PREGN
   Food and Drug Administration, 2015, PREGN LACT LAB FIN R
   Food and Drug Administration, 2002, GUID IND EST PREGN E
   Food and Drug Administration, 2005, REV GUID EV RISKS DR
   Food and Drug Administration, 2003, GUID IND EXP RESP RE
   Food and Drug Administration, GUID IND PULM TUB DE
   Frederiksen MC, 2001, SEMIN PERINATOL, V25, P120, DOI 10.1053/sper.2001.24565
   Grange J, 2010, INT J GYNECOL OBSTET, V108, P181, DOI 10.1016/j.ijgo.2009.12.005
   International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2009, ICH HARM TRIP GUID
   Jana N, 2012, J OBSTET GYNAECOL RE, V38, P1125, DOI 10.1111/j.1447-0756.2012.01856.x
   Karabay O, 2013, INDIAN J MED RES, V138, P147
   Kass NE, 1996, J LAW MED ETHICS, V24, P36, DOI 10.1111/j.1748-720X.1996.tb01831.x
   Ke AB, 2014, ANNU REV PHARMACOL, V54, P53, DOI 10.1146/annurev-pharmtox-011613-140009
   Khan M, 2001, AIDS, V15, P1857, DOI 10.1097/00002030-200109280-00016
   KRASULA RW, 1991, AM J MED, V91, pS38, DOI 10.1016/0002-9343(91)90309-L
   Loto OM, 2012, J PREGNANCY, V2012, DOI 10.1155/2012/379271
   Lyerly AD, 2008, HASTINGS CENT REP, P38
   Lyerly AD, 2011, AM J BIOETHICS, V11, P50, DOI 10.1080/15265161.2011.560353
   Lyerly AD, 2009, HASTINGS CENT REP, V39, P34
   Martinson NA, 2011, NEW ENGL J MED, V365, P11, DOI 10.1056/NEJMoa1005136
   Mathad JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092308
   Mathad JS, 2012, CLIN INFECT DIS, V55, P1532, DOI 10.1093/cid/cis732
   Matsui D., 2012, OBSTET GYNECOL INT, V2012, DOI DOI 10.1155/2012/796590]
   McIlleron H, 2015, J INFECT DIS, V211, pS115, DOI 10.1093/infdis/jiu600
   Nachega JB, 2012, AIDS, V26, P2039, DOI 10.1097/QAD.0b013e328359590f
   Nachman S, 2015, LANCET INFECT DIS, V15, P711, DOI 10.1016/S1473-3099(15)00007-9
   Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, 2014, REC US ANT DRUGS PRE
   Pillay T, 2004, LANCET INFECT DIS, V4, P155, DOI 10.1016/S1473-3099(04)00939-9
   Searle C, 2013, INT J TUBERC LUNG D, V17, P1247, DOI 10.5588/ijtld.13.0624
   Shapiro RL, 2010, NEW ENGL J MED, V362, P2282, DOI 10.1056/NEJMoa0907736
   Sheffield JS, 2014, CLIN INFECT DIS, V59, pS437, DOI 10.1093/cid/ciu709
   Sterling TR, 2011, NEW ENGL J MED, V365, P2155, DOI 10.1056/NEJMoa1104875
   Sugarman J, 2014, LANCET GLOB HEALTH, V2, pE710, DOI 10.1016/S2214-109X(14)70330-4
   Taylor Allan W, 2013, Infect Dis Obstet Gynecol, V2013, P195637, DOI 10.1155/2013/195637
   Tiam A, 2014, JAIDS-J ACQ IMM DEF, V67, pE5, DOI 10.1097/QAI.0000000000000209
   Tittle V, 2015, CLIN PHARMACOKINET, V54, P23, DOI 10.1007/s40262-014-0204-8
   Uwimana J, 2013, INT J TUBERC LUNG D, V17, P1285, DOI 10.5588/ijtld.12.0068
   WHO, 2010, TREATMENT OF TUBERCULOSIS: GUIDELINES, FOURTH EDITION, P1
   World Health Organization, 2015, GLOB TUB REP 2015
   World Health Organization Stop TB Partnership, 2015, GLOB PLAN STOP TB 20
   Wyska E, 2001, SEMIN PERINATOL, V25, P124, DOI 10.1053/sper.2001.24905
   Zenner D, 2012, AM J RESP CRIT CARE, V185, P779, DOI 10.1164/rccm.201106-1083OC
   Zumla A, 2014, LANCET GLOB HEALTH, V2, pE675, DOI 10.1016/S2214-109X(14)70338-9
NR 61
TC 23
Z9 24
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAR 15
PY 2016
VL 62
IS 6
BP 761
EP 769
DI 10.1093/cid/civ991
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DF9XU
UT WOS:000371716700013
PM 26658057
OA Bronze, Green Published
DA 2020-11-24
ER

PT J
AU Souza, TML
   Santini-Oliveira, M
   Martorelli, A
   Luz, PM
   Vasconcellos, MTL
   Giacoia-Gripp, CBW
   Morgado, M
   Nunes, EP
   Lemos, AS
   Ferreira, ACG
   Moreira, RI
   Veloso, VG
   Siqueira, M
   Grinsztejn, B
   Camacho, LAB
AF Souza, Thiago Moreno L.
   Santini-Oliveira, Marilia
   Martorelli, Andressa
   Luz, Paula M.
   Vasconcellos, Mauricio T. L.
   Giacoia-Gripp, Carmem B. W.
   Morgado, Mariza
   Nunes, Estevao P.
   Lemos, Alberto S.
   Ferreira, Ana C. G.
   Moreira, Ronaldo I.
   Veloso, Valdilea G.
   Siqueira, Marilda
   Grinsztejn, Beatriz
   Camacho, Luiz A. B.
TI Immunogenicity and Sustainability of the Immune Response in Brazilian
   HIV-1-Infected Individuals Vaccinated With Inactivated Triple Influenza
   Vaccine
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE influenza; vaccine; HIV; immunogenicity; vaccine mismatch
ID SEASONAL INFLUENZA
AB HIV-infected individuals have a higher risk of serious illnesses following infection by infection with influenza. Although anti-influenza vaccination is recommended, immunosuppression may limit their response to active immunization. We followed-up a cohort of HIV-infected individuals vaccinated against influenza to assess the immunogenicity and sustainability of the immune response to vaccination. Individuals were vaccinated 2011 with inactivated triple influenza vaccine (TIV), and they had received in 2010 the monovalent anti-A(H1N1)pdm09 vaccine. The sustainability of the immune response to A (H1N1) pdm09 at 12 months after monovalent vaccination fell, both in individuals given two single or two double doses. For these individuals, A(H1N1) pdm09 component from TIV acted as a booster, raising around 40% the number of seroprotected individuals. Almost 70% of the HIV-infected individuals were already seroprotected to A/H3N2 at baseline. Again, TIV boosted over 90% the seroprotection to A/H3N2. Anti-A/H3N2 titers dropped by 20% at 6 months after vaccination. Pre-vaccination seroprotection rate to influenza B (victoria lineage) was the lowest among those tested, seroconversion rates were higher after vaccination. Seroconversion/protection after TIV vaccination did not differ significantly across categories of clinical and demographic variables. Anti-influenza responses in Brazilian HIV-infected individuals reflected both the previous history of virus circulation in Brazil and vaccination. (C) 2015 Wiley Periodicals, Inc.
C1 [Souza, Thiago Moreno L.; Martorelli, Andressa; Siqueira, Marilda] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, NIC WHO, Lab Virus Resp & Sarampo, Rio De Janeiro, Brazil.
   [Souza, Thiago Moreno L.; Martorelli, Andressa] Fundacao Oswaldo Cruz, Ctr Desenvolvimento Tecnol Saude, Rio De Janeiro, Brazil.
   [Souza, Thiago Moreno L.; Martorelli, Andressa] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Santini-Oliveira, Marilia; Luz, Paula M.; Vasconcellos, Mauricio T. L.; Nunes, Estevao P.; Lemos, Alberto S.; Ferreira, Ana C. G.; Moreira, Ronaldo I.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Giacoia-Gripp, Carmem B. W.; Morgado, Mariza] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Rio De Janeiro, Brazil.
   [Camacho, Luiz A. B.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil.
RP Souza, TML (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, NIC WHO, Lab Virus Resp & Sarampo, Rio De Janeiro, Brazil.; Souza, TML (corresponding author), Fundacao Oswaldo Cruz, Ctr Desenvolvimento Tecnol Saude, Rio De Janeiro, Brazil.; Souza, TML (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.; Souza, TML (corresponding author), Pavilhao Osorio Almeida,Sala 16,Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM tmoreno@ioc.fiocruz.br
RI de Lemos, Alberto dos Santos/M-4246-2013; Souza, Thiago Moreno
   L./G-2900-2012
OI de Lemos, Alberto dos Santos/0000-0003-0138-6577; Souza, Thiago Moreno
   L./0000-0003-2212-3899; Luz, Paula/0000-0001-9746-719X
CR Alicino C, 2014, MINERVA MED, V105, P89
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   Anonymous, 2009, Morbidity and Mortality Weekly Report, V58, P1100
   [Anonymous], 2011, C UPDATED INTERIM RE
   Barte H, 2014, COCHRANE DB SYST REV, V1
   Brydak LB, 2000, DRUGS, V60, P35, DOI 10.2165/00003495-200060010-00004
   CDC, 2009, EM INF DIS, P1547
   Ceravolo A, 2013, J Prev Med Hyg, V54, P1
   Oliveira MJC, 2014, MEM I OSWALDO CRUZ, V109, P912, DOI 10.1590/0074-0276140210
   Crum-Cianflone NF, 2011, VACCINE, V29, P3183, DOI 10.1016/j.vaccine.2011.02.040
   Fabbiani M, 2013, VACCINE, V31, P2914, DOI 10.1016/j.vaccine.2013.04.033
   Fevrier M, 2011, VIRUSES-BASEL, V3, P586, DOI 10.3390/v3050586
   Fiore Anthony E., 2009, Morbidity and Mortality Weekly Report, V58, P1
   Frasca D, 2014, CURR OPIN IMMUNOL, V29, P112, DOI 10.1016/j.coi.2014.05.008
   GARTNER S, 1986, JAMA-J AM MED ASSOC, V256, P2365, DOI 10.1001/jama.256.17.2365
   Kroon FP, 2000, VACCINE, V18, P3040, DOI 10.1016/S0264-410X(00)00079-7
   Lee YT, 2014, CLIN EXP VACCINE RES, V3, P12, DOI 10.7774/cevr.2014.3.1.12
   Lisco A, 2009, CELL HOST MICROBE, V6, P403, DOI 10.1016/j.chom.2009.10.010
   McKittrick N, 2013, ANN INTERN MED, V158, P19, DOI 10.7326/0003-4819-158-1-201301010-00005
   Miller E, 2010, LANCET, V375, P1100, DOI 10.1016/S0140-6736(09)62126-7
   Ministerio da Saude M, INFL PAND H1N1 2009
   Moura FEA, 2009, AM J TROP MED HYG, V81, P180, DOI 10.4269/ajtmh.2009.81.180
   Noronha AS, 2014, VACCINE, V32, P2670, DOI 10.1016/j.vaccine.2013.12.037
   Ormsby CE, 2011, AIDS, V25, P435, DOI 10.1097/QAD.0b013e3283434844
   Paraskevis D, 2005, VIRUS RES, V112, P115, DOI 10.1016/j.virusres.2005.03.004
   Rodriguez-Arenas MA, 2006, AIDS RES HUM RETROV, V22, P715, DOI 10.1089/aid.2006.22.715
   Rosen MJ, 2008, RESPIROLOGY, V13, P181, DOI 10.1111/j.1440-1843.2007.01167.x
   Ryan J, 2006, VACCINE, V24, P6812, DOI 10.1016/j.vaccine.2006.07.042
   Santini-Oliveira M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039310
   Sheth AN, 2011, CLIN INFECT DIS, V52, P219, DOI 10.1093/cid/ciq110
   Silva RD, 2014, MEM I OSWALDO CRUZ, V109, P229, DOI 10.1590/0074-0276140273
   Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853
   Szretter Kristy J, 2006, Curr Protoc Microbiol, VChapter 15, DOI 10.1002/0471729256.mc15g01s3
   Tang JW, 2010, INFECT DIS CLIN N AM, V24, P603, DOI 10.1016/j.idc.2010.04.001
   Tebas P, 2010, AIDS, V24, P2187, DOI 10.1097/QAD.0b013e32833c6d5c
   WHO, 2011, CIRC INFL
   World Health Organization, 2014, WHO REC COMP INFL VI
NR 37
TC 1
Z9 1
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD MAR
PY 2016
VL 88
IS 3
BP 426
EP 436
DI 10.1002/jmv.24351
PG 11
WC Virology
SC Virology
GA DC4II
UT WOS:000369184000010
PM 26267817
DA 2020-11-24
ER

PT J
AU De Boni, RB
   Zheng, L
   Rosenkranz, SL
   Sun, X
   Lavenberg, J
   Cardoso, SW
   Grinsztejn, B
   La Rosa, A
   Pierre, S
   Severe, P
   Cohn, SE
   Collier, AC
   Gross, R
AF De Boni, Raquel B.
   Zheng, Lu
   Rosenkranz, Susan L.
   Sun, Xin
   Lavenberg, Jeffrey
   Cardoso, Sandra W.
   Grinsztejn, Beatriz
   La Rosa, Alberto
   Pierre, Samuel
   Severe, Patrice
   Cohn, Susan E.
   Collier, Ann C.
   Gross, Robert
TI Binge drinking is associated with differences in weekday and weekend
   adherence in HIV-infected individuals
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article; Proceedings Paper
CT IAPAC 10th International Conference on HIV Treatment and Prevention
   Adherence
CY JUN 28-30, 2015
CL Miami, FL
SP IAPAC
DE Alcohol; Binge drinking; HIV/AIDS; Adherence; Microelectronic monitors;
   Low and middle income countries
ID ANTIRETROVIRAL THERAPY ADHERENCE; ALCOHOL-USE DISORDERS; PATTERNS; CARE;
   NONADHERENCE; CONSUMPTION; POPULATION; MORTALITY; FAILURE; PATIENT
AB Background: Understanding patterns of antiretroviral adherence and its predictors is important for designing tailored interventions. Alcohol use is associated with non-adherence. This study aimed to evaluate: (1) if there was a difference in weekday compared with weekend adherence in HIV-infected individuals from low and middle income countries (LMIC), and (2) whether binge drinking was associated with this difference.
   Methods: Data from a randomized trial conducted at 9 sites in 8 LMIC were analyzed. Microelectronic monitors were used to measure adherence. Differences between weekday and weekend adherence in each quarter (successive 12-week periods) were compared using Wilcoxon signed rank tests and predictors of adherence, including baseline binge drinking, were evaluated using Generalized Estimating Equations.
   Results: Data from 255 participants were analyzed: 49.8% were male, median age was 37 years and 28.6% enrolled in Haiti. At study entry, only 2.7% reported illicit substance use, but 22.3% reported binge drinking at least once in the 30 days prior to enrollment. Adherence was higher on weekdays than weekends (median percent doses taken: 96.0% vs 94.4%; 93.7% vs 91.7%; 92.6% vs 89.7% and 93.7% vs 89.7% in quarters 1-4 respectively, all p <0.001). Binge drinking at baseline and time on study were both associated with greater differences between weekday and weekend adherence.
   Conclusions: Adherence was worse on weekends compared to weekdays: difference was small at treatment initiation, increased over time and was associated with binge drinking. Screening and new interventions to address binge drinking, a potentially modifiable behavior, may improve adherence in HIV-infected individuals in LMIC. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [De Boni, Raquel B.; Zheng, Lu; Rosenkranz, Susan L.; Sun, Xin; Lavenberg, Jeffrey] Harvard Univ, Sch Publ Hlth, CBAR, 665 Huntington Ave, Boston, MA 02115 USA.
   [De Boni, Raquel B.; Cardoso, Sandra W.; Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [La Rosa, Alberto] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Pierre, Samuel; Severe, Patrice] Ctr Gheskio, Inst Natl Lab & Rech, Port Au Prince, Haiti.
   [Cohn, Susan E.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Collier, Ann C.] Univ Washington, Harborview Med Ctr, 325 9Th Ave, Seattle, WA 98104 USA.
   [Gross, Robert] Univ Penn, Perelman Sch Med, Dept Med Infect Dis, Philadelphia, PA 19104 USA.
   [Gross, Robert] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
RP De Boni, RB (corresponding author), Fiocruz MS, Inst Nacl Infectol Evandro Chagas, LAPCLIN DST AIDS, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM raqueldeboni@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Cohn, Susan E/ABB-3629-2020
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; 
FU ACTG CTU; ACTG CTU [U01-A1069501, UM 1AI069436, AI069463,
   2UM1AI069438-08, AI069438, 7UMIA1069455, 2UMIAI069456-08, AI069476];
   CFDA [93.865]; Northwestern ACTG [1U01AI069471]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI045008,
   P30AI045008, UM1AI069463, UM1AI069481, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, UM1AI069481, UM1AI069463, UM1AI069436,
   P30AI045008, U01AI069463, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, UM1AI069438, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, U01AI069471, P30AI045008, U01AI068636,
   U01AI068636, P30AI045008, P30AI045008, U01AI069463, U01AI069471,
   P30AI045008, UM1AI069481, UM1AI069436, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, UM1AI068634, P30AI045008,
   P30AI045008, P30AI045008, UM1AI068634, UM1AI069438, U01AI069471,
   UM1AI069481, UM1AI068636, P30AI045008, P30AI045008, P30AI045008,
   UM1AI069463, P30AI045008, P30AI045008, P30AI045008, UM1AI069471,
   UM1AI068636, P30AI045008, P30AI045008, P30AI045008, P30AI045008,
   U01AI069476, UM1AI068634, P30AI045008, P30AI045008, UM1AI068634,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, U01AI068636,
   P30AI045008, UM1AI068636, U01AI068636, UM1AI069471, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, UM1AI069436, U01AI069471,
   UM1AI069463, P30AI045008, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, UM1AI069438, P30AI045008, P30AI045008, P30AI045008,
   UM1AI069476, P30AI045008, P30AI045008, U01AI069476, P30AI045008,
   P30AI045008, P30AI045008, UM1AI069438, P30AI045008, UM1AI068634,
   UM1AI068636, UM1AI069438, UM1AI069481, UM1AI069463, UM1AI069481,
   UM1AI068636, P30AI045008, P30AI045008, P30AI045008, UM1AI068636,
   UM1AI069436, P30AI045008, P30AI045008, P30AI045008, U01AI069463,
   UM1AI068636, P30AI045008, P30AI045008, UM1AI069471, P30AI045008,
   P30AI045008, UM1AI069476, P30AI045008, UM1AI068634, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, UM1AI069463,
   P30AI045008, P30AI045008, P30AI045008, U01AI069463, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, UM1AI069534,
   U01AI069438, UM1AI069471, P30AI045008, UM1AI069436, P30AI045008,
   P30AI045008, U01AI069463, U01AI069476, P30AI045008, UM1AI069476,
   P30AI045008, P30AI045008, P30AI045008, UM1AI069463, P30AI045008,
   P30AI045008, UM1AI069436, UM1AI069434, P30AI045008, P30AI045008,
   UM1AI069476, P30AI045008, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, UM1AI069534, P30AI045008, P30AI045008, P30AI045008,
   UM1AI069476, P30AI045008, P30AI045008, UM1AI069481, UM1AI069436,
   P30AI045008, P30AI045008, P30AI045008, UM1AI068636, UM1AI069438,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, UM1AI068636, P30AI045008,
   UM1AI069476, P30AI045008, P30AI045008, U01AI069438, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, UM1AI069534, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, U01AI069438, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, U01AI069463, UM1AI069481,
   UM1AI069471, UM1AI069471, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, UM1AI069534, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, UM1AI069463, P30AI045008, P30AI045008,
   P30AI045008, UM1AI069438, UM1AI068636, P30AI045008, UM1AI069481,
   P30AI045008, UM1AI069534, UM1AI069471, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, U01AI069471,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, UM1AI069534, P30AI045008, P30AI045008,
   UM1AI069471, P30AI045008, UM1AI069434, P30AI045008, UM1AI068634,
   P30AI045008, P30AI045008, UM1AI069534, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, U01AI069463, UM1AI069534, P30AI045008,
   P30AI045008, UM1AI068634, P30AI045008, U01AI068636, UM1AI069438,
   P30AI045008, P30AI045008, P30AI045008, U01AI068636, UM1AI069471,
   P30AI045008, P30AI045008, P30AI045008, UM1AI068634, P30AI045008,
   U01AI068636, P30AI045008, P30AI045008, P30AI045008, U01AI069438,
   P30AI045008, U01AI069471, UM1AI069476, U01AI069438, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, UM1AI069436, P30AI045008,
   UM1AI069534, P30AI045008, UM1AI068636, U01AI069438, UM1AI068634,
   P30AI045008, UM1AI069476, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, UM1AI069463,
   UM1AI068636, U01AI069476, P30AI045008, P30AI045008, P30AI045008,
   UM1AI069534, UM1AI069471, UM1AI069481, P30AI045008, UM1AI068634,
   UM1AI069476, P30AI045008, P30AI045008, P30AI045008] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488, P30MH097488, P30MH097488,
   P30MH097488, P30MH097488, P30MH097488] Funding Source: NIH RePORTER
FX The authors wish to thank to the AIDS Clinical Trials Group (ACTG) and
   SDMC. We would like to acknowledge the following individual sites' grant
   support, study team members, and site personnel: Les Centres GHESKIO CRS
   (Site 30022) ACTG CTU Grant; Joint Clinical Research Centre CRS (Site
   12401) ACTG CTU Grant U01-A1069501; Parirenyatwa CRS (Site 30313) ACTG
   CTU Grant UM 1AI069436; Wits HIV CRS (Site 11101) ACTG CTU Grant
   AI069463; Barranco CRS (Site 11301) ACTG CTU Grant 2UM1AI069438-08; San
   Miguel CRS (Site 11302) ACTG CTU Grant AI069438; Kalingalinga Clinic CRS
   (Site 12801) ACTG CTU Grant 7UMIA1069455; Gaborone Prevention/Treatment
   Trials CRS (Site 12701) ACTG CTU Grant 2UMIAI069456-08; CFDA Grant
   93.865; Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site
   12101) ACTG CTU Grant AI069476 and Northwestern ACTG Grant 1U01AI069471.
   We also would like to thank to AbbVie Inc. and Gilead Pharmaceuticals,
   which provided the medications for the trial.
CR Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201
   Azar MM, 2010, DRUG ALCOHOL DEPEN, V112, P178, DOI 10.1016/j.drugalcdep.2010.06.014
   Babor T, 2001, AUDIT ALCOHOL USE DI
   Bachhuber M., 2011, J ACQ IMMUN DEF SYND, V54, P109
   Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015
   Bisson GP, 2008, JAIDS-J ACQ IMM DEF, V49, P107, DOI 10.1097/QAI.0b013e3181820141
   Bova CA, 2005, AIDS BEHAV, V9, P103, DOI 10.1007/s10461-005-1685-0
   Bradley KA, 2014, JAMA-J AM MED ASSOC, V311, P1861, DOI 10.1001/jama.2014.3629
   CDC, 2010, MMWR-MORBID MORTAL W, V61, P14
   Chibanda D, 2014, JAIDS-J ACQ IMM DEF, V67, pS54, DOI 10.1097/QAI.0000000000000258
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cohn SE, 2011, AIDS CARE, V23, P775, DOI 10.1080/09540121.2010.525617
   Deschamps AE, 2004, AIDS PATIENT CARE ST, V18, P644, DOI 10.1089/apc.2004.18.644
   Gardner EM, 2009, AIDS, V23, P1035, DOI 10.1097/QAD.0b013e32832ba8ec
   Genberg BL, 2012, AIDS, V26, P1415, DOI 10.1097/QAD.0b013e328354bed6
   Graff-Iversen S, 2013, J EPIDEMIOL COMMUN H, V67, P350, DOI 10.1136/jech-2012-201564
   Gras G, 2012, JAIDS-J ACQ IMM DEF, V61, P265, DOI 10.1097/QAI.0b013e31826cc592
   Gross R, 2001, AIDS, V15, P2109, DOI 10.1097/00002030-200111090-00006
   Gross R, 2015, LANCET HIV, V2, pE12, DOI 10.1016/S2352-3018(14)00007-1
   Heeb JL, 2008, INT J METH PSYCH RES, V17, P1, DOI 10.1002/mpr.238
   Hendershot C.S., 2009, J ACQ IMMUN DEF SYND, V52, P1
   Horne R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080633
   Hugen PWH, 2002, J ACQ IMMUN DEF SYND, V30, P324, DOI [10.1097/00126334-200207010-00009, 10.1097/01.QAI.0000014768.35851.DB]
   Jonas DE, 2014, JAMA-J AM MED ASSOC, V311, P1889, DOI 10.1001/jama.2014.3628
   Jonas DE, 2012, ANN INTERN MED, V157, P645, DOI 10.7326/0003-4819-157-9-201211060-00544
   Kalichman SC, 2013, J GEN INTERN MED, V28, P399, DOI 10.1007/s11606-012-2231-1
   Kenya S, 2013, AIDS BEHAV, V17, P61, DOI 10.1007/s10461-012-0307-x
   Knafl GJ, 2010, AIDS BEHAV, V14, P755, DOI 10.1007/s10461-008-9512-z
   Laranjeira R, 2010, REV BRAS PSIQUIATR, V32, P231, DOI 10.1590/S1516-44462009005000012
   Lazo M, 2007, CLIN INFECT DIS, V45, P1377, DOI 10.1086/522762
   Lima VD, 2007, AIDS, V21, P685, DOI 10.1097/QAD.0b013e32802ef30c
   Lyimo RA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-92
   Mitchell AJ, 2012, BRIT J PSYCHIAT, V201, P93, DOI 10.1192/bjp.bp.110.091199
   Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1
   NIAAA, 2004, NIAAA NEWS
   Ortego C, 2011, AIDS BEHAV, V15, P1381, DOI 10.1007/s10461-011-9942-x
   Padrao P, 2011, DRUG ALCOHOL DEPEN, V115, P87, DOI 10.1016/j.drugalcdep.2010.10.010
   Parienti JJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002783
   Plunk AD, 2014, ALCOHOL CLIN EXP RES, V38, P471, DOI 10.1111/acer.12250
   Samji H, 2014, AIDS BEHAV, V18, P2240, DOI 10.1007/s10461-014-0776-1
   Sieri S, 2002, PUBLIC HEALTH NUTR, V5, P1287, DOI 10.1079/PHN2002405
   Thirumurthy H, 2012, AIDS, V26, P2399, DOI 10.1097/QAD.0b013e328359aa68
   US reventive Services Task Force, 2014, AM FAM PHYSICIAN, V89, p970A
   Vriesendorp R, 2007, EUR J CLIN PHARMACOL, V63, P1115, DOI 10.1007/s00228-007-0369-2
   WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1
   Wilson IB, 2013, JAIDS-J ACQ IMM DEF, V64, P448, DOI 10.1097/QAI.0000000000000025
NR 46
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD FEB 1
PY 2016
VL 159
BP 174
EP 180
DI 10.1016/j.drugalcdep.2015.12.013
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA DC8LX
UT WOS:000369472200023
PM 26774947
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Fernandes, FF
   Soares, JC
   Fittipaldi, J
   Cardoso, SW
   Grinsztejn, B
   Veloso, VG
AF Perazzo, Hugo
   Fernandes, Flavia F.
   Soares, Joao Carlos
   Fittipaldi, Juliana
   Cardoso, Sandra W.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
TI Learning curve and intra/interobserver agreement of transient
   elastography in chronic hepatitis C patients with or without HIV
   co-infection
SO CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
LA English
DT Article
ID LIVER STIFFNESS MEASUREMENT; 7 CATEGORIES; FIBROSIS; REPRODUCIBILITY;
   APPLICABILITY; VIRUS; FIBROTEST(R); VARIABILITY; DIAGNOSIS; CIRRHOSIS
AB Background and objectives: Liver stiffness measurement (LSM) by transient elastography has been validated as a noninvasive method to stage liver fibrosis. Few studies have evaluated the learning curve of this method and its reproducibility has led to controversy results. We aimed to evaluate the intra- and interobserver agreement of transient elastography as well as its learning curve for definition of an experimented operator.
   Methods: We retrospectively analyzed 922 examinations performed in 544 patients during a training program of transient elastography. Patients with chronic hepatitis C with or without HIV co-infection that had two examinations by the training operator (intraobserver analysis; n=125) or examination by both training and experimented operators (interobserver analysis; n=151) in the same day were included. LSM was converted to METAVIR score: < 7.1 as FOF1, 7.1-9.4 as F2, 9.5-12.4, as F3 and > 12.4 kPa as F4.
   Results: The overall intra- and interobserver intraclass correlation coefficient [ICC 95% CI] were 0.926 (0.901-0.951) and 0.912 (0.885-0.939), respectively. Measurements were correlated [Spearman's] in intra- [0.906, P<0.0001] and interobserver [0.907, P<0.0001] analysis. Reliability values [kappa (SE)] were k=0.74 (0.09) and k=0.85 (0.08) for fibrosis stages F > 2 and k=0.77 (0.09) and k = 0.75 (0.08) for cirrhosis in intra- and interobserver analysis, respectively. Agreement was improved when operator's experience was higher than 100 exams. However, it was observed discordance for fibrosis staging between examinations in a quarter of patients.
   Conclusion: Although there was a considerable discrepancy on fibrosis staging between examinations and a small power, transient elastography had an acceptable reproducibility in our population. Performance of at least 100 examinations should be used to define an experimented operator. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Perazzo, Hugo; Soares, Joao Carlos; Fittipaldi, Juliana; Cardoso, Sandra W.; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Natl Inst Infect Dis, Lab Clin Res STDAIDS, Rio De Janeiro, Brazil.
   [Fernandes, Flavia F.] Bonsucesso Fed Hosp, Dept Gastroenterol, Rio De Janeiro, Brazil.
RP Perazzo, H (corresponding author), Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM hugo.perazzo@ini.fiocruz.br
RI Fernandes, Flavia Ferreira/I-8010-2019
OI Fernandes, Flavia Ferreira/0000-0002-3149-3667; Perazzo,
   Hugo/0000-0003-0931-6418
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)/Bolsa Jovem Talento (BJT) - Programa Ciencias Sem Fronteiras,
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [301520/2014-3]; Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ), Rio de Janeiro,
   BrazilCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/110.268/2014]
FX This work was supported by funding from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)/Bolsa Jovem Talento
   (BJT) - Programa Ciencias Sem Fronteiras, Brazil under grant
   301520/2014-3 and from Fundacao Carlos Chagas Filho de Amparo a Pesquisa
   do Estado do Rio de Janeiro (FAPERJ) under grant E-26/110.268/2014, Rio
   de Janeiro, Brazil.
CR Arena U, 2013, HEPATOLOGY, V58, P65, DOI 10.1002/hep.26343
   BEDOSSA P, 1994, HEPATOLOGY, V20, P15
   Bota S, 2013, LIVER INT, V33, P1138, DOI 10.1111/liv.12240
   Boursier J, 2008, CLIN GASTROENTEROL H, V6, P1263, DOI 10.1016/j.cgh.2008.07.006
   Boursler J, 2008, EUR J GASTROEN HEPAT, V20, P693, DOI 10.1097/MEG.0b013e3282f51992
   Castera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018
   Castera L, 2010, HEPATOLOGY, V51, P828, DOI 10.1002/hep.23425
   Chou R, 2013, ANN INTERN MED, V158, P807, DOI 10.7326/0003-4819-158-11-201306040-00005
   Colli A, 2010, RADIOLOGY, V257, P872, DOI 10.1148/radiol.10100013
   de Ledinghen V, 2008, GASTROEN CLIN BIOL, V32, P58, DOI 10.1016/S0399-8320(08)73994-0
   de Ledinghen V, 2012, J HEPATOL, V56, P833, DOI 10.1016/j.jhep.2011.10.017
   Fraquelli M, 2007, GUT, V56, P968, DOI 10.1136/gut.2006.111302
   Frulio N, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-405
   Fung J, 2011, AM J GASTROENTEROL, V106, P492, DOI 10.1038/ajg.2010.463
   Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141
   Ingiliz P, 2009, WORLD J GASTROENTERO, V15, P3398, DOI 10.3748/wjg.15.3398
   Lacombe K, 2012, GUT, V61, P47, DOI 10.1136/gutjnl-2012-302062
   Millonig G, 2008, HEPATOLOGY, V48, P1718, DOI 10.1002/hep.22577
   Mutimer D, 2014, J HEPATOL, V60, P392, DOI 10.1016/j.jhep.2013.11.003
   Nascimbeni F, 2015, CLIN GASTROENTEROL H, V13, P763, DOI 10.1016/j.cgh.2014.07.037
   Neukam K, 2010, EUR J GASTROEN HEPAT, V22, P801, DOI 10.1097/MEG.0b013e328331a5d0
   Perazzo H, 2015, LIVER INT, V35, P1533, DOI 10.1111/liv.12551
   Poynard T, 2014, J HEPATOL, V61, P994, DOI 10.1016/j.jhep.2014.06.027
   Poynard T, 2014, J HEPATOL, V60, P706, DOI 10.1016/j.jhep.2013.11.016
   Poynard T, 2012, CLIN GASTROENTEROL H, V10, P657, DOI 10.1016/j.cgh.2012.01.023
   Poynard T, 2011, CLIN RES HEPATOL GAS, V35, P720, DOI 10.1016/j.clinre.2011.07.003
   Poynard T, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-39
   Poynard T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003857
   Roca B, 2012, J VIRAL HEPATITIS, V19, P711, DOI 10.1111/j.1365-2893.2012.01608.x
   Vergara S, 2007, CLIN INFECT DIS, V45, P969, DOI 10.1086/521857
   Ziol M, 2005, HEPATOLOGY, V41, P48, DOI 10.1002/hep.20506
NR 31
TC 7
Z9 7
U1 0
U2 4
PU ELSEVIER MASSON, CORPORATION OFFICE
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
SN 2210-7401
EI 2210-741X
J9 CLIN RES HEPATOL GAS
JI Clin. Res. Hepatol. Gastroenterol.
PD FEB
PY 2016
VL 40
IS 1
BP 73
EP 82
DI 10.1016/j.clinre.2015.04.004
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DC0OM
UT WOS:000368917200014
PM 26056050
DA 2020-11-24
ER

PT J
AU Luz, PM
   Grinsztejn, B
   Veloso, VG
   Paltiel, AD
AF Luz, Paula M.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Paltiel, A. David
TI Authors' Reply: Is Genotype Testing Really Cost-Effective for Primary
   Resistance in Brazil?
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
C1 [Luz, Paula M.; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Paltiel, A. David] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
OI Luz, Paula/0000-0001-9746-719X
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI058736, R01AI058736, R01AI058736, R01AI058736, R01AI058736,
   UM1AI068636, R01AI058736, R01AI058736, UM1AI068636, UM1AI069476,
   UM1AI069476, UM1AI068636, R01AI058736, UM1AI068636, R01AI058736,
   UM1AI069476, UM1AI068636, R01AI058736, UM1AI068636, UM1AI069476,
   UM1AI068636, UM1AI068636, UM1AI068636, R01AI058736, R01AI058736,
   R01AI058736, UM1AI069476, UM1AI069476, R01AI058736, UM1AI069476,
   UM1AI069476, R01AI058736, R01AI058736, UM1AI068636, R01AI058736,
   UM1AI069476, R01AI058736, UM1AI068636, R01AI058736] Funding Source: NIH
   RePORTER; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1 AI069476, R01 AI058736,
   UM1 AI068636] Funding Source: Medline
CR Lorenzana SB, 2012, AIDS, V26, P1083, DOI 10.1097/QAD.0b013e32835221eb
   Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606
NR 2
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD FEB 1
PY 2016
VL 71
IS 2
BP E56
EP E56
DI 10.1097/QAI.0000000000000877
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DB8YW
UT WOS:000368804100006
PM 26579987
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Ford, N
   Matteelli, A
   Shubber, Z
   Hermans, S
   Meintjes, G
   Grinsztejn, B
   Waldrop, G
   Kranzer, K
   Doherty, M
   Getahun, H
AF Ford, Nathan
   Matteelli, Alberto
   Shubber, Zara
   Hermans, Sabine
   Meintjes, Graeme
   Grinsztejn, Beatriz
   Waldrop, Greer
   Kranzer, Katharina
   Doherty, Meg
   Getahun, Haileyesus
TI TB as a cause of hospitalization and in-hospital mortality among people
   living with HIV worldwide: a systematic review and meta-analysis
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Review
DE HIV/AIDS; hospitalization; morbidity; mortality; tuberculosis
ID ISONIAZID PREVENTIVE THERAPY; SUB-SAHARAN AFRICA; RIO-DE-JANEIRO;
   ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; XPERT(R) MTB/RIF;
   CONTROLLED-TRIAL; TUBERCULOSIS; IMPACT; INITIATION
AB Introduction: Despite significant progress in improving access to antiretroviral therapy over the past decade, substantial numbers of people living with HIV (PLHIV) in all regions continue to experience severe illness and require hospitalization. We undertook a global review assessing the proportion of hospitalizations and in-hospital deaths because of tuberculosis (TB) in PLHIV.
   Methods: Seven databases were searched to identify studies reporting causes of hospitalizations among PLHIV from 1 January 2007 to 31 January 2015 irrespective of age, geographical region or language. The proportion of hospitalizations and in-hospital mortality attributable to TB was estimated using random effects meta-analysis.
   Results: From an initial screen of 9049 records, 66 studies were identified, providing data on 35,845 adults and 2792 children across 42 countries. Overall, 17.7% (95% CI 16.0 to 20.2%) of all adult hospitalizations were because of TB, making it the leading cause of hospitalization overall; the proportion of adult hospitalizations because of TB exceeded 10% in all regions except the European region. Of all paediatric hospitalizations, 10.8% (95% CI 7.6 to 13.9%) were because of TB. There was insufficient data among children for analysis by region. In-hospital mortality attributable to TB was 24.9% (95% CI 19.0 to 30.8%) among adults and 30.1% (95% CI 11.2 to 48.9%) among children.
   Discussion: TB remains a leading cause of hospitalization and in-hospital death among adults and children living with HIV worldwide.
C1 [Ford, Nathan; Doherty, Meg] WHO, Dept HIV, Ave Appia 20, CH-1211 Geneva, Switzerland.
   [Matteelli, Alberto; Getahun, Haileyesus] WHO, Global TB Programme, CH-1211 Geneva, Switzerland.
   [Matteelli, Alberto] Univ Brescia, Clin Infect & Trop Dis, WHO Collaborating Ctr TB HIV & TB Eliminat, Brescia, Italy.
   [Shubber, Zara] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England.
   [Hermans, Sabine] Univ Cape Town, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa.
   [Hermans, Sabine] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands.
   [Meintjes, Graeme] Univ Cape Town, Clin Infect Dis Res Initiat, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
   [Grinsztejn, Beatriz] Minist Hlth, Inst Nacl Infectol Evandro Chagas, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Waldrop, Greer] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Kranzer, Katharina] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England.
   [Kranzer, Katharina] Res Ctr Borstel, Natl & Supranat TB Reference Lab, Borstel, Germany.
RP Ford, N (corresponding author), WHO, Dept HIV, Ave Appia 20, CH-1211 Geneva, Switzerland.
EM fordn@who.int
RI Getahun, Haileyesus/ABC-5181-2020
OI Meintjes, Graeme/0000-0003-1196-4414; Waldrop,
   Greer/0000-0001-6408-2330; Hermans, Sabine/0000-0001-5146-2932
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1 AI069476] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH
   RePORTER
CR Avila D, 2014, JAIDS-J ACQ IMM DEF, V65, pE8, DOI 10.1097/QAI.0b013e3182a39979
   Cingolani A, 2012, CLIN INFECT DIS, V54, P853, DOI 10.1093/cid/cir900
   Cox JA, 2010, AIDS REV, V12, P183
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Durovni B, 2013, LANCET INFECT DIS, V13, P852, DOI 10.1016/S1473-3099(13)70187-7
   Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202
   Ford N, 2015, LANCET HIV, V2, pE438, DOI 10.1016/S2352-3018(15)00137-X
   FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756
   Getahun H, 2007, LANCET, V369, P2042, DOI 10.1016/S0140-6736(07)60284-0
   Golub JE, 2007, AIDS, V21, P1441, DOI 10.1097/QAD.0b013e328216f441
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Gupta A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055824
   Gupta A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034156
   Gupta RK, 2015, AIDS, V29, P1987, DOI 10.1097/QAD.0000000000000802
   Gupta S, 2014, INT J TUBERC LUNG D, V18, P1149, DOI 10.5588/ijtld.13.0889
   Gupta-Wright A, 2013, JAIDS-J ACQ IMM DEF, V64, P261, DOI 10.1097/QAI.0b013e3182a23e9a
   Hanrahan CF, 2015, INT J TUBERC LUNG D, V19, P811, DOI 10.5588/ijtld.15.0013
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Meintjes G, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-72
   Melo-Uribe MA, 2014, 103 ANN M US CAN AC
   MILLER JJ, 1978, AM STAT, V32, P138, DOI 10.2307/2682942
   Namutebi AMN, 2013, AFR HEALTH SCI, V13, P977, DOI 10.4314/ahs.v13i4.17
   Rangaka MX, 2014, LANCET, V384, P682, DOI 10.1016/S0140-6736(14)60162-8
   Siedner MJ, 2015, CLIN INFECT DIS, V60, P1120, DOI 10.1093/cid/ciu1137
   UNAIDS, 2015, 15 15 GLOB TARG ACH
   Van den Handel T, 2015, INT J TUBERC LUNG D, V19, P392, DOI 10.5588/ijtld.14.0653
   Wen Y, 2014, INTERNAL MED, V53, P2455, DOI 10.2169/internalmedicine.53.2502
   Whitehorn J, 2011, INT J STD AIDS, V22, P225, DOI 10.1258/ijsa.2009.009456
   WHO, 2015, GLOB UPD HIV TREATM
   WHO, 2014, GLOB TUB REP
   Wong EB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047542
   World Health Organization, 2010, ANT THER HIV INF AD
   World Health Organization, 2012, WHO POL COLL TB HIV
   World Health Organization, 2013, XPERT MTB RIF ASS DI
NR 34
TC 35
Z9 35
U1 1
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JAN 12
PY 2016
VL 19
DI 10.7448/IAS.19.1.20714
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DA8ZG
UT WOS:000368094900001
PM 26765347
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Pacheco, A
   De Boni, R
   Luz, P
   Fittipaldi, J
   Cardoso, S
   Grinsztejn, B
   Veloso, V
AF Perazzo, H.
   Pacheco, A.
   De Boni, R.
   Luz, P.
   Fittipaldi, J.
   Cardoso, S.
   Grinsztejn, B.
   Veloso, V.
TI A NATIONWIDE ANALYSIS OF AGE-STANDARDIZED CIRRHOSIS MORTALITY RATES IN
   BRAZIL FROM 2000 TO 2012
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT EASL International Liver Congress
CY APR 13-17, 2016
CL Barcelona, SPAIN
SP EASL
C1 [Perazzo, H.; De Boni, R.; Luz, P.; Fittipaldi, J.; Cardoso, S.; Grinsztejn, B.; Veloso, V.] Fiocruz MS, LaPClin, Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Pacheco, A.] Fiocruz MS, PROCC, Rio De Janeior, Brazil.
EM perazzohugo@gmail.com
RI Pacheco, Antonio Guilherme/E-6378-2013
OI Pacheco, Antonio Guilherme/0000-0003-3095-1774
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2016
VL 64
SU 2
MA FRI-409
BP S459
EP S459
DI 10.1016/S0168-8278(16)00768-6
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ER3QE
UT WOS:000398711700762
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Pacheco, A
   Fittipaldi, J
   Rigolon, C
   Cardoso, S
   Veloso, V
   Grinsztejn, B
AF Perazzo, H.
   Pacheco, A.
   Fittipaldi, J.
   Rigolon, C.
   Cardoso, S.
   Veloso, V.
   Grinsztejn, B.
TI AGE-STANDARDIZED LIVER-RELATED MORTALITY IN BRAZIL FROM 2008 TO 2012: A
   NATIONWIDE ANALYSIS OF MORE THAN 270,000 LIVER DEATHS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT EASL International Liver Congress
CY APR 13-17, 2016
CL Barcelona, SPAIN
SP EASL
C1 [Perazzo, H.; Fittipaldi, J.; Rigolon, C.; Cardoso, S.; Veloso, V.; Grinsztejn, B.] Fiocruz MS, LaPClin, Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Pacheco, A.] Fiocruz MS, PROCC, Rio De Janeiro, Brazil.
EM perazzohugo@gmail.com
RI Pacheco, Antonio Guilherme/E-6378-2013
OI Pacheco, Antonio Guilherme/0000-0003-3095-1774
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2016
VL 64
SU 2
MA FRI-408
BP S458
EP S459
DI 10.1016/S0168-8278(16)00767-4
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ER3QE
UT WOS:000398711700761
DA 2020-11-24
ER

PT J
AU Oliveira, NS
   Andrade, CV
   Grinsztejn, B
   Friedman, RK
   Cunha, CB
   Veloso, VG
   Coutinho, JR
   Chicarino-Oliveira, JM
   Ferreira, DD
   Pereira, LOR
   Amaro, SM
   Moreira, MA
   Nuovo, GJ
   Nicol, AF
AF Oliveira, Nathalia S.
   Andrade, Cecilia V.
   Grinsztejn, Beatriz
   Friedman, Ruth K.
   Cunha, Cynthia B.
   Veloso, Valdileia G.
   Coutinho, Jose R.
   Chicarino-Oliveira, Janice M.
   Ferreira, Dennis De C.
   Pereira, Luiza O. R.
   Amaro-Filho, Sergio M.
   Moreira, Miguel A.
   Nuovo, Gerard J.
   Nicol, Alcina F.
TI In situ FoxP3+and IL-10 over-expression is associated with high grade
   anal lesions in HIV infected patients
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE HPV/HIV-1; anal intra epithelial neoplasia; immune response; genotype
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL
   NEOPLASIA; TISSUE; MECHANISMS; CARCINOMA; MUCOSAL; CELLS; WOMEN
AB Human papillomavirus (HPV) is the main etiologic agent of lower genital tract cancers. The natural history of HPV infection and the immune response to HIV/HPV co-infection, particularly in the anal mucosa, is poorly understood. The aim was evaluate the in situ immune response in anorectal biopsies from HIV-infected patients. A total of 114 biopsies were analyzed by Tissue Micro-Array: 15 were from HIV-negative individuals with normal squamous epithelium and 99 from HIV-positive individuals (21 normal squamous epithelium, 39 with anal intra-epithelial lesion grade 1 and 39 with anal intra-epithelial lesion grade 2/3). PCR and sequencing were used to identify HPV DNA. Staining for CD4, CD8, Foxp3+, T-bet and IL-10 were analyzed via immunohistochemistry. HIV-positive patients with AIN 2/3 showed a lower number of CD4+ cells (< 50 cells/mm(3)) compared to HIV negative subjects (P = 0.01). HIV infected individuals showed a higher expression of FoxP3+ and IL-10 that correlated with the severity of the lesion (P = 0.002). A positive coefficient correlation was found between FoxP3+ and IL-10 (r = 0.34; P = 0.027). HPV DNA was detected in 93.4% (101/107) of the samples and the most common types were HPV 16 (26.9%), followed by HPV 6 (15.7%), HPV 59 (13%) and HPV 18 (10.2%). Our results showed a strong association between the increased T-reg cells and IL-10 expression in HIV-positive patients with AIN 2/3. HPV 16 was the most prevalent type. Our study suggests that the immune regulatory in situ profile may favor HPV persistence in HIV-positive individuals. Further in situ studies should be done in order to elucidate the development of anal cancer in HPV/HIV co-infected individuals.
C1 [Oliveira, Nathalia S.; Pereira, Luiza O. R.; Nicol, Alcina F.] Fiocruz MS, Lab Interdisciplinary Med Res LIPMED, IOC, BR-21045900 Rio De Janeiro, Brazil.
   [Andrade, Cecilia V.] Fiocruz MS, Dept Pathol, Fernandes Figueira Inst, BR-21045900 Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz; Friedman, Ruth K.; Cunha, Cynthia B.; Veloso, Valdileia G.; Coutinho, Jose R.; Chicarino-Oliveira, Janice M.] Fiocruz MS, LapClin DST AIDS, Natl Inst Infectol, INI, BR-21045900 Rio De Janeiro, Brazil.
   [Ferreira, Dennis De C.] Univ Estacio Sa, Posgrad Program Dent, Dept Endodont, Rio De Janeiro, RJ, Brazil.
   [Amaro-Filho, Sergio M.; Moreira, Miguel A.] Natl Canc Inst, Div Genet, Rio De Janeiro, Brazil.
   [Nuovo, Gerard J.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
RP Nicol, AF (corresponding author), Fiocruz MS, Interdisciplinary Lab Med Res, IOC, RJ Av Brasil 4365 Manguinhos, BR-21045900 Rio De Janeiro, Brazil.
EM nicol@ioc.fiocruz.br
RI Ferreira, Dennis/AAC-7407-2020; Moreira, Miguel/AAN-7405-2020; Pereira,
   Luiza O R/P-7606-2018; Oliveira, Nathalia/M-8830-2019
OI Pereira, Luiza O R/0000-0002-8132-1724; Oliveira,
   Nathalia/0000-0003-3733-0022; Ferreira, Dennis/0000-0003-4166-3284
FU Fogarty International Center, National Institute of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Fogarty International Center (FIC) [2 D 43 TW000010-23]; Proep;
   FAPERJ-cientista do nosso Estado, Brazil; Fundacao de Amparo a Pesquisa
   do Estado do Rio de Janeiro (FAPERJ- APQ1); Laboratory of
   Interdisciplinary Medical Research (LIPMED) InstitutoOswaldo Cruz
FX Nathalia Silva Oliveira was scholar from Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES), Brazil; AFN and SMAF were scholars
   in the International AIDS Research and Training Program, supported by
   the Fogarty International Center, National Institute of Health Research
   Grant 2 D 43 TW000010-23. BGrinsztejn received support from Proep and
   FAPERJ-cientista do nosso Estado, Brazil. This work was supported in
   part by grants from Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ- APQ1); Laboratory of Interdisciplinary Medical Research
   (LIPMED) InstitutoOswaldo Cruz. Programa Estrategico de Apoio a Pesquisa
   em Saude (PAPES VII) Fundacao Instituto Oswaldo Cruz (FIOCRUZ)/Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). We would
   like to thank Rodrigo Mexas for the images, Maria Dulce Portugal and
   Marcos F L de Almeida for the excellent technical support.
CR Alves DB, 2010, REV SOC BRAS MED TRO, V43, P425, DOI 10.1590/S0037-86822010000400018
   Amaro-Filho SM, 2013, PLOS ONE, V8, P1, DOI DOI 10.1371/J0URNAL.P0NE.0057810
   Cambou MC, 2015, AIDS PATIENT CARE ST, V29, P4, DOI 10.1089/apc.2014.0166
   Pires ARC, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-14
   Denny LA, 2012, VACCINE, V30, pF168, DOI 10.1016/j.vaccine.2012.06.045
   Feng QH, 2012, GYNECOL ONCOL, V127, P412, DOI 10.1016/j.ygyno.2012.07.098
   Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500
   Gohy L, 2008, JAIDS-J ACQ IMM DEF, V49, P32, DOI 10.1097/qai.0b013e318183a905
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Guimaraes AGDP, 2015, JAIDS-J ACQ IMM DEF, V68, P112, DOI 10.1097/QAI.0000000000000412
   Hoory T, 2008, J FORMOS MED ASSOC, V107, P198, DOI 10.1016/S0929-6646(08)60138-2
   Julio RS, 2015, ARCH SEX BEHAV, V44, P357, DOI 10.1007/s10508-014-0357-4
   Kanodia S, 2007, CURR CANCER DRUG TAR, V7, P79, DOI 10.2174/156800907780006869
   Kobayashi A, 2004, CANCER RES, V64, P6766, DOI 10.1158/0008-5472.CAN-04-1091
   Mendez-Martinez R, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0671-4
   Nicol AF, 2008, J CLIN PATHOL, V61, P84, DOI 10.1136/jcp.2007.047290
   Nicol AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032936
   Palefsky J, 2009, CURR OPIN HIV AIDS, V4, P52, DOI 10.1097/COH.0b013e32831a7246
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Tong WWY, 2014, HIV MED, V15, P65, DOI 10.1111/hiv.12080
   Torres-Poveda K, 2014, WORLD J CLIN ONCOL, V5, P753, DOI 10.5306/wjco.v5.i4.753
   Woo YL, 2008, J CLIN PATHOL, V61, P969, DOI 10.1136/jcp.2008.056200
   Yaghoobi M, 2011, COLORECTAL DIS, V13, P768, DOI 10.1111/j.1463-1318.2010.02283.x
NR 23
TC 3
Z9 3
U1 0
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 2
BP 1520
EP 1532
PG 13
WC Oncology; Pathology
SC Oncology; Pathology
GA DG1EU
UT WOS:000371809200115
DA 2020-11-24
ER

PT J
AU Montes, ML
   Nelson, M
   Girard, PM
   Sasadeusz, J
   Horban, A
   Grinsztejn, B
   Zakharova, N
   Rivero, A
   Durant, J
   Ortega-Gonzalez, E
   Lathouwers, E
   Janssen, K
   Ouwerkerk-Mahadevan, S
   Witek, J
   Gonzalez-Garcia, J
AF Luisa Montes, Maria
   Nelson, Mark
   Girard, Pierre-Marie
   Sasadeusz, Joe
   Horban, Andrzej
   Grinsztejn, Beatriz
   Zakharova, Natalia
   Rivero, Antonio
   Durant, Jacques
   Ortega-Gonzalez, Enrique
   Lathouwers, Erkki
   Janssen, Katrien
   Ouwerkerk-Mahadevan, Sivi
   Witek, James
   Gonzalez-Garcia, Juan
TI Telaprevir-based therapy in patients coinfected with chronic hepatitis C
   virus infection and HIV: INSIGHT study
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID ALPHA-2A PLUS RIBAVIRIN; GENOTYPE 1 INFECTION; DRUG-INTERACTIONS;
   RANDOMIZED-TRIAL; INTERFERON-ALPHA-2B; PHARMACOKINETICS; MANAGEMENT
AB Objectives: INSIGHT (ClinicalTrials.gov NCT01513941) evaluated the efficacy, safety and pharmacokinetics of telaprevir-based therapy and specific antiretroviral agents in hepatitis C virus genotype 1 (HCV-1)/HIV-1-coinfected patients.
   Patients and methods: Open-label, Phase IIIb, multicentre study of telaprevir with pegylated-IFN (Peg-IFN) alpha 2a and ribavirin in treatment-naive or -experienced HCV-1/HIV-1-coinfected patients on stable HIV HAART comprising efavirenz, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, etravirine or rilpivirine with two nucleos(t)ide analogues. Patients received 750 mg telaprevir (1125 mg, if on efavirenz) every 8 h plus 180 mu g/week Peg-IFN alpha 2a and 800 mg/day ribavirin for 12 weeks, followed by Peg-IFN alpha 2a and ribavirin alone for 12 weeks (HCV treatment naive and relapsers without cirrhosis, with extended rapid virological response) or 36 weeks (all others).
   Results: Overall, 162 patients (median age of 46 years, 78% male, 92% Caucasian and mean CD4 count of 687 cells/mm(3)) were treated; 13% had cirrhosis. One-hundred-and-thirty-two patients (81%) completed telaprevir; 14 (9%) discontinued due to an adverse event (AE). Sustained virological response (SVR) 12 rates (< 25 IU/mL HCV RNA 12 weeks after the last planned treatment dose) in treatment-naive patients, relapsers and non-responders were 64% (41 of 64), 62% (18 of 29) and 49% (34 of 69), respectively. SVR12 rates ranged from 51% (33 of 65) (patients receiving efavirenz) to 77% (13 of 17) (patients receiving raltegravir). Most frequently reported AEs during telaprevir treatment were pruritus (43%) and rash (34%) special search categories. Anaemia special search category occurred in 15% of patients; 6% of patients reported a serious AE.
   Conclusions: In treatment-naive/-experienced HCV-1/HIV-1 patients there were significantly higher SVR rates with telaprevir-based therapy compared with pre-specified historical controls, and safety comparable to that in HCV-monoinfected patients.
C1 [Luisa Montes, Maria; Gonzalez-Garcia, Juan] Hosp Univ La Paz, Med Interna Serv, IdiPAZ, Unidad VIH, Madrid, Spain.
   [Nelson, Mark] Chelsea & Westminster Hosp, London, England.
   [Girard, Pierre-Marie] Hop St Antoine, F-75571 Paris, France.
   [Girard, Pierre-Marie] Inst Pierre Louis Epidemiol & Sante Publ, INSERM, UMR S1136, F-75571 Paris, France.
   [Sasadeusz, Joe] Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia.
   [Horban, Andrzej] Med Univ Warsaw, Warsaw, Poland.
   [Horban, Andrzej] Hosp Infect Dis, Warsaw, Poland.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas, STD AIDS Clin Res Lab, Rio De Janeiro, Brazil.
   [Zakharova, Natalia] St Petersburg AIDS Ctr, St Petersburg, Russia.
   [Rivero, Antonio] Hosp Univ Reina Sofia IMIBIC, Unidad Enfermedades Infecciosas, Cordoba, Spain.
   [Durant, Jacques] Univ Nice, LArchet Hosp, Dept Infect Dis, Nice, France.
   [Ortega-Gonzalez, Enrique] Hosp Gen Univ, Unidad Enfermedades Infecciosas, Valencia, Spain.
   [Lathouwers, Erkki; Janssen, Katrien; Ouwerkerk-Mahadevan, Sivi] Janssen Infect Dis BVBA, Beerse, Belgium.
   [Witek, James] Janssen Res & Dev LLC, Titusville, NJ USA.
RP Witek, J (corresponding author), Janssen Res & Dev LLC, Titusville, NJ USA.
EM jwitek@its.jnj.com
RI Ramirez, Maria Luisa Montes/H-8065-2017; Rivero, Antonio/ABE-5294-2020
OI Ramirez, Maria Luisa Montes/0000-0003-1748-813X; Rivero,
   Antonio/0000-0001-5005-8268
FU Janssen PharmaceuticalsJohnson & Johnson USAJanssen Biotech Inc
FX This work was supported by Janssen Pharmaceuticals. In addition, the
   editorial support (see below) was funded by Janssen Pharmaceuticals.
CR Arends JE, 2005, NETH J MED, V63, P156
   Back D, 2008, ANTIVIR THER, V13, P1
   Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501
   Colombo M, 2013, J HEPATOL, V58, pS329, DOI 10.1016/S0168-8278(13)60808-9
   EMA. INCIVO&REG;, 2013, INCIVO TEL TABL SUMM
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   INCIVEK&REG;, 2013, INCIVEK TELAPREVIR T
   Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912
   Kiang TKL, 2013, CLIN PHARMACOKINET, V52, P487, DOI 10.1007/s40262-013-0053-x
   Kieffer TL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034372
   Laprise C, 2013, AIDS PATIENT CARE ST, V27, P378, DOI 10.1089/apc.2013.0009
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   Mutimer D, 2014, J HEPATOL, V60, P392, DOI 10.1016/j.jhep.2013.11.003
   Perry CM, 2012, DRUGS, V72, P619, DOI 10.2165/11208370-000000000-00000
   Rockstroh JK, 2014, CLIN INFECT DIS, V59, P1777, DOI 10.1093/cid/ciu662
   Rodriguez-Torres M, 2012, HIV CLIN TRIALS, V13, P142, DOI 10.1310/hct1303-142
   Sulkowski M, 2013, LANCET INFECT DIS, V13, P597, DOI 10.1016/S1473-3099(13)70149-X
   Sulkowski MS, 2013, ANN INTERN MED, V159, P86, DOI 10.7326/0003-4819-159-2-201307160-00654
   Torriani FJ, 2004, NEW ENGL J MED, V351, P438, DOI 10.1056/NEJMoa040842
   Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086
NR 20
TC 2
Z9 2
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JAN
PY 2016
VL 71
IS 1
BP 244
EP 250
DI 10.1093/jac/dkv323
PG 7
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA DF3IS
UT WOS:000371238100035
PM 26483516
OA Bronze
DA 2020-11-24
ER

PT J
AU Cambou, MC
   Levi, JE
   Lake, JE
   de Andrade, A
   Jalil, EM
   Russomano, F
   Derrico, M
   Veloso, VG
   Friedman, RK
   Luz, PM
   Grinsztejn, B
AF Cambou, Mary C.
   Levi, Jose Eduardo
   Lake, Jordan E.
   de Andrade, Angela
   Jalil, Emilia M.
   Russomano, Fabio
   Derrico, Monica
   Veloso, Valdilea G.
   Friedman, Ruth K.
   Luz, Paula M.
   Grinsztejn, Beatriz
TI Time trend analysis of cervical high-risk human papillomavirus (HPV) in
   HIV-infected women in an urban cohort from Rio de Janeiro, Brazil: the
   rise of non-16/18 HPV
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Women; Cervical HPV; High-risk HPV; HPV vaccine; Epidemiology
ID SQUAMOUS INTRAEPITHELIAL LESIONS; PREVALENCE
AB Objectives: HIV-infected women are at increased risk of human papillomavirus (HPV) infection. Time trends in annual prevalences of cervical high-risk human papillomavirus (HR-HPV) genotypes among a non-vaccinated, HIV-infected female cohort in urban Brazil were assessed for the period 2006-2012.
   Methods: Cervical specimens were collected for HPV genotyping yearly between January 2006 and December 2012 in a cross-sectional analysis of participants aged >= 18 years enrolled in the Women's HIV Cohort at Fiocruz in Rio de Janeiro, Brazil. Age-adjusted generalized estimating equation models with an exchangeable matrix were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for annual HPV positivity (reference year: 2006).
   Results: Among the 590 participants, the median age across all study years ranged from 35.5 to 40.0 years. The prevalence of any HR-HPV was >= 53% every year; prevalences of HR-HPV 16, 58, 59, and 68 were >= 24% in at least 1 year. The odds of HPV 16 and 68 decreased in 2012. HPV 58 prevalence followed a U-shape, beginning and ending at >20%. HPV 59 prevalence followed a linear trend, with increased odds in 2012 (OR 16.0, 95% CI 3.8-67.3; Bonferroni-adjusted p-value <0.01).
   Conclusions: The prevalences of HR-HPV 58, 59, and 68 were high in this cohort. Given current HR-HPV vaccine coverage and availability, further investigations are needed to optimize vaccine recommendations for this population. (C) 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Cambou, Mary C.; Lake, Jordan E.] Univ Calif Los Angeles, David Geffen Sch Med, Program Global Hlth, Dept Med,Div Infect Dis, Los Angeles, CA 90095 USA.
   [Cambou, Mary C.] Montefiore Univ Hosp, Albert Einstein Coll Med, Dept Internal Med, Bronx, NY USA.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop, Virol Lab, Sao Paulo, SP, Brazil.
   [de Andrade, Angela; Jalil, Emilia M.; Derrico, Monica; Veloso, Valdilea G.; Friedman, Ruth K.; Luz, Paula M.; Grinsztejn, Beatriz] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas IPEC, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Russomano, Fabio] Fiocruz MS, Inst Fernandes Figueira, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Cambou, MC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Program Global Hlth, Dept Med,Div Infect Dis, 10833 Le Conte Ave,CHS 37-121, Los Angeles, CA 90095 USA.
EM mcambou@montefiore.org
OI Luz, Paula/0000-0001-9746-719X
FU South American Program in HIV Prevention Research (SAPHIR) [NIH R25
   MH087222]; Brazilian National Counsel of Technological and Scientific
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); Research Funding Agency of the State of Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Instituto de Pesquisa Clinica
   Evandro Chagas; Fundacao Oswaldo Cruz; Brazilian National STD/AIDS
   Program of the Brazilian Ministry of Health; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [K23AI110532]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   K23AI110532, UM1AI069476, UM1AI069476, K23AI110532, K23AI110532,
   UM1AI069476, K23AI110532, K23AI110532, UM1AI069476, UM1AI069476,
   K23AI110532, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [R25MH087222, R25MH087222,
   R25MH087222, R25MH087222, R25MH087222, R25MH087222, R25MH087222,
   R25MH087222] Funding Source: NIH RePORTER
FX MCC, JEL, PML, and BG are supported by the South American Program in HIV
   Prevention Research (SAPHIR; NIH R25 MH087222). BG and PML acknowledge
   funding from the Brazilian National Counsel of Technological and
   Scientific Development (CNPq) and the Research Funding Agency of the
   State of Rio de Janeiro (FAPERJ). This study was funded by the Instituto
   de Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz and the
   Brazilian National STD/AIDS Program of the Brazilian Ministry of Health.
   JEL has served as a consultant to Gilead Sciences and GSK. JEL is
   supported by the National Institutes of Health (K23AI110532). The
   authors would like to acknowledge the participants and Fiocruz staff who
   made the IPEC Women's HIV Cervical HPV Genotyping Study possible.
CR Cambou MC, 2015, AIDS PATIENT CARE ST, V29, P4, DOI 10.1089/apc.2014.0166
   Choi YH, 2012, VACCINE, V30, P3383, DOI 10.1016/j.vaccine.2012.03.065
   Drolet M, 2015, LANCET INFECT DIS, V15, P565, DOI 10.1016/S1473-3099(14)71073-4
   Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031
   Fernandes Jose V, 2010, BMC Res Notes, V3, P96, DOI 10.1186/1756-0500-3-96
   Grinsztejn B, 2009, INT J INFECT DIS, V13, P72, DOI 10.1016/j.ijid.2008.03.031
   Luz PM, 2012, INT J STD AIDS, V23, P12, DOI 10.1258/ijsa.2009.009409
   Malagon T, 2012, LANCET INFECT DIS, V12, P781, DOI 10.1016/S1473-3099(12)70187-1
   McKenzie ND, 2010, GYNECOL ONCOL, V116, P572, DOI 10.1016/j.ygyno.2009.10.058
   Paesi S, 2009, J MED VIROL, V81, P1270, DOI 10.1002/jmv.21410
NR 10
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD DEC
PY 2015
VL 41
BP 17
EP 20
DI 10.1016/j.ijid.2015.10.017
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA DA8FI
UT WOS:000368040100006
PM 26518062
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-11-24
ER

PT J
AU Gandhi, M
   Glidden, DV
   Liu, A
   Anderson, PL
   Horng, H
   Defechereux, P
   Guanira, JV
   Grinsztejn, B
   Chariyalertsak, S
   Bekker, LG
   Grant, RM
AF Gandhi, Monica
   Glidden, David V.
   Liu, Albert
   Anderson, Peter L.
   Horng, Howard
   Defechereux, Patricia
   Guanira, Juan V.
   Grinsztejn, Beatriz
   Chariyalertsak, Suwat
   Bekker, Linda-Gail
   Grant, Robert M.
CA iPrEx Study Team
TI Strong Correlation Between Concentrations of Tenofovir (TFV)
   Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in
   Dried Blood Spots in the iPrEx Open Label Extension: Implications for
   Pre-exposure Prophylaxis Adherence Monitoring
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV prevention; pre-exposure prophylaxis; PrEP; pharmacologic
   monitoring; adherence; tenofovir/emtricitabine; hair concentrations;
   dried blood spot (DBS) concentrations; iPrEx Open Label Extension (OLE)
ID HIV-INFECTION; ANTIRETROVIRAL PROPHYLAXIS; AFRICAN WOMEN; MEN
AB Self-reported adherence to pre-exposure prophylaxis (PrEP) has limitations, raising interest in pharmacologic monitoring. Drug concentrations in hair and dried blood spots (DBS) are used to assess long-term-exposure; hair shipment/storage occurs at room temperature. The iPrEx Open Label Extension collected DBS routinely, with opt-in hair collection; concentrations were measured with liquid chromatography/tandem mass spectrometry. In 806 hair-DBS pairs, tenofovir (TFV) hair levels and TFV diphosphate (DP) in DBS were strongly correlated (Spearman coefficient r = 0.734; P < .001), as were hair TFV/DBS emtricitabine (FTC) triphosphate (TP) (r = 0.781; P < .001); hair FTC/DBS TFV-DP (r = 0.74; P < .001); hair FTC/DBS FTC-TP (r = 0.587; P < .001). Drug detectability was generally concordant by matrix. Hair TFV/FTC concentrations correlate strongly with DBS levels, which are predictive of PrEP outcomes.
C1 [Gandhi, Monica; Liu, Albert; Grant, Robert M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA.
   [Glidden, David V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA.
   [Horng, Howard] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94110 USA.
   [Liu, Albert] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [Defechereux, Patricia; Grant, Robert M.] Gladstone Inst, San Francisco, CA USA.
   [Anderson, Peter L.] Univ Colorado, Dept Pharmaceut Sci, Denver, CO 80202 USA.
   [Guanira, Juan V.] Invest Med Salud, Lima, Peru.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Natl Inst Infect Dis, STD AIDS Clin Res Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Bekker, Linda-Gail] Univ Cape Town, Desmond Tutu HIV Ctr, ZA-7700 Rondebosch, South Africa.
RP Gandhi, M (corresponding author), Univ Calif San Francisco, Div HIV AIDS, 995 Potrero Ave,Fourth Flr, San Francisco, CA 94110 USA.
EM monica.gandhi@ucsf.edu
RI Glidden, David/AAD-4730-2020; Bekker, Linda-Gail/AAZ-8929-2020
OI Kallas, Esper/0000-0003-2026-6925; Glidden, David/0000-0001-5888-1419;
   Guanira, Juan/0000-0002-2746-3086; Grant, Robert/0000-0002-0851-7085;
   BEKKER, LINDA-GAIL/0000-0002-0755-4386
FU Division of Acquired Immunodeficiency Syndrome, National Institute of
   Allergy and Infectious Diseases (NIAID), National Institutes of Health
   [UO1 AI84735, UO1 AI64002, 2R01 AI062333, UM1 AI068619]; NIAIDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01 AI098472, U01 AI034989]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01AI064002,
   R01AI062333, U01AI034989, UM1AI068619, U01AI034989, U01AI034989,
   U01AI084735, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, UM1AI068619, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, UM1AI068619, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI064002, U01AI034989, U01AI034989,
   U01AI034989, R01AI098472, U01AI034989, U01AI034989, U01AI064002,
   U01AI034989, R01AI098472, U01AI034989, U01AI034989, R01AI062333,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, R01AI098472,
   R01AI062333, U01AI034989, U01AI064002, U01AI064002, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI084735, U01AI034989, R01AI098472, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, UM1AI068619,
   U01AI034989, UM1AI068619, U01AI034989, UM1AI068619, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, R03AI120819, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI064002, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, R01AI062333, U01AI034989,
   U01AI064002, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, R01AI098472, U01AI034989, R01AI062333,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   R01AI098472, U01AI034989, UM1AI068619, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, UM1AI068619, U01AI034989, U01AI034989,
   U01AI034989, U01AI064002, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, R01AI062333, U01AI034989,
   U01AI034989, R01AI062333, U01AI034989, U01AI034989, R01AI098472,
   U01AI084735, U01AI034989, U01AI034989, U01AI034989, UM1AI068619,
   U01AI034989, U01AI084735, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, R01AI098472, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   U01AI064002, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   R03AI120819, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, R01AI062333, U01AI034989, U01AI034989,
   U01AI034989, U01AI034989, U01AI034989, U01AI034989, U01AI034989,
   U01AI034989] Funding Source: NIH RePORTER
FX This work was supported by the Division of Acquired Immunodeficiency
   Syndrome, National Institute of Allergy and Infectious Diseases (NIAID),
   National Institutes of Health, as a cooperative agreement (UO1 AI84735
   to P. L. A., UO1 AI64002, 2R01 AI062333 to R. M. G., and UM1 AI068619).
   The NIAID also supported the hair assays for this work (R01 AI098472
   [principal investigator M. G. with support to H. H.] and U01 AI034989
   [San Francisco WIHS, principal investigator Ruth Greenblatt] for hair
   assay development work).
CR Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Baxi SM, 2015, JAIDS-J ACQ IMM DEF, V68, P13, DOI 10.1097/QAI.0000000000000386
   Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/AID.2012.0089, 10.1089/aid.2012.0089]
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Coetzee B, 2012, FUTURE VIROL, V7, P1135, DOI 10.2217/FVL.12.100
   Donnell D, 2014, JAIDS-J ACQ IMM DEF, V66, P340, DOI 10.1097/QAI.0000000000000172
   Gandhi M, 2014, AIDS RES HUM RETROV, V30, P25, DOI [10.1089/aid.2013.0239, 10.1089/AID.2013.0239]
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hickey MD, 2014, JAIDS-J ACQ IMM DEF, V66, P311, DOI 10.1097/QAI.0000000000000154
   Liu AY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083736
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Podsadecki TJ, 2008, HIV CLIN TRIALS, V9, P238, DOI 10.1310/hct0904-238
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
NR 15
TC 39
Z9 39
U1 1
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2015
VL 212
IS 9
BP 1402
EP 1406
DI 10.1093/infdis/jiv239
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CW1QX
UT WOS:000364767500009
PM 25895984
OA Green Published
DA 2020-11-24
ER

PT J
AU Taburet, AM
   Sauvageon, H
   Grinsztejn, B
   Assuied, A
   Veloso, V
   Pilotto, JH
   De Castro, N
   Grondin, C
   Fagard, C
   Molina, JM
AF Taburet, Anne-Marie
   Sauvageon, Helene
   Grinsztejn, Beatriz
   Assuied, Alex
   Veloso, Valdilea
   Pilotto, Jose Henrique
   De Castro, Nathalie
   Grondin, Carine
   Fagard, Catherine
   Molina, Jean-Michel
TI Pharmacokinetics of Raltegravir in HIV-Infected Patients on
   Rifampicin-Based Antitubercular Therapy
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE raltegravir; rifampicin; tuberculosis; HIV; pharmacokinetics
ID ANTIRETROVIRAL THERAPY; EFAVIRENZ; DRUG; TUBERCULOSIS; EXPOSURE;
   PHARMACOLOGY; INDIVIDUALS; MULTICENTER; SAFETY
AB Background. Rifampicin (RIF) induces UGT1A1, an enzyme involved in raltegravir (RAL) elimination, thereby potentially lowering RAL exposure. We examined the pharmacokinetics of RAL in human immunodeficiency virus (HIV)-infected patients on RIF-based antitubercular therapy in the French National Agency for HIV/AIDS and Viral Hepatitis Research 12 180 Reflate Tuberculosis trial.
   Methods. Patients started RAL in combination with tenofovir disoproxil fumarate and lamivudine after initiation of RIF (10 mg/kg/day). In arm 1 (n = 21), they received 400 mg RAL twice daily; in arm 2 (n = 16), they received RAL 800 mg twice daily initially then 400 mg twice daily 4 weeks after RIF discontinuation. Pharmacokinetic sampling was performed over 12-hour periods, 4 weeks after initiation of RAL together with RIF (period 1), 4 weeks after RIF discontinuation (period 2), and after the RAL dose reduction in arm 2 (period 3).
   Results. In arm 1, the geometric mean ratio (GMR) between period 1 and period 2 was 0.94 (90% confidence interval [CI],.64-1.37) for the 12-hour area under the time-concentration curve (AUC(0-12)), and 0.69 (90% CI,.42-1.13) for the concentration at 12 hours (C-12). In arm 2, the corresponding GMRs were 0.75 (90% CI,.48-1.17) and 1.10 (90% CI,.61-2.00) for period 1 vs period 2, and 1.10 (90% CI,.78-1.55) and 1.68 (90% CI,.88-3.23) for period 1 vs period 3.
   Conclusions. The double dose of RAL overcompensated for RIF induction, but the standard dose was associated with only small decreases in AUC(0-12) and C12 during RIF coadministration, warranting further evaluation in patients with HIV/tuberculosis coinfection.
C1 [Taburet, Anne-Marie] Univ Paris 11, AP HP, Hosp Bicetre,INSERM U1184, Ctr Immunol Viral Infect & Autoimmune Dis,DHU Hep, Le Kremlin Bicetre, France.
   [Sauvageon, Helene; De Castro, Nathalie; Molina, Jean-Michel] Hosp St Louis, AP HP, Paris, France.
   [Grinsztejn, Beatriz; Veloso, Valdilea] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Assuied, Alex; Grondin, Carine; Fagard, Catherine] Univ Bordeaux, Ctr INSERM Epidemiol Biostat U987, Bordeaux, France.
   [Pilotto, Jose Henrique] Hosp Gen Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Lab AIDS Imunol Mol, Rio De Janeiro, Brazil.
   [Molina, Jean-Michel] Univ Paris Diderot, Paris, France.
   [Molina, Jean-Michel] INSERM U941, Paris, France.
RP Taburet, AM (corresponding author), Bicetre Hosp, Dept Clin Pharm, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.
EM anne-marie.taburet@bct.aphp.fr
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
FU French National Agency for HIV/AIDS; Viral Hepatitis Research (ANRS)
   (Paris, France); ANRSANRSFrench National Research Agency (ANR);
   Brazilian government
FX This study was sponsored by French National Agency for HIV/AIDS and
   Viral Hepatitis Research (ANRS) (Paris, France) and was funded by ANRS
   and the Brazilian government.
CR Barbarino JM, 2014, PHARMACOGENET GENOM, V24, P177, DOI 10.1097/FPC.0000000000000024
   Barrail-Tran A, 2010, AIDS, V24, P2572, DOI 10.1097/QAD.0b013e32833d89fa
   Bertrand J, 2014, J INFECT DIS, V209, P399, DOI 10.1093/infdis/jit466
   Bhatt NB, 2015, J ANTIMICROB CHEMOTH, V70, P225, DOI 10.1093/jac/dku348
   Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911
   Brainard DM, 2011, J CLIN PHARMACOL, V51, P1376, DOI 10.1177/0091270010387428
   Brainard DM, 2011, J CLIN PHARMACOL, V51, P422, DOI 10.1177/0091270010367652
   Burger DM, 2010, EXPERT OPIN DRUG MET, V6, P1151, DOI 10.1517/17425255.2010.513383
   Cattaneo D, 2012, ANTIMICROB AGENTS CH, V56, P6132, DOI 10.1128/AAC.00942-12
   Cattaneo D, 2012, J ANTIMICROB CHEMOTH, V67, P460, DOI 10.1093/jac/dkr498
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P459, DOI 10.1016/S1473-3099(14)70711-X
   Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181
   Luetkemeyer AF, 2013, CLIN INFECT DIS, V57, P586, DOI 10.1093/cid/cit246
   Merschman SA, 2007, J CHROMATOGR B, V857, P15, DOI 10.1016/j.jchromb.2007.06.032
   Moss DM, 2012, ANTIMICROB AGENTS CH, V56, P3020, DOI 10.1128/AAC.06407-11
   Reynolds HE, 2015, J ANTIMICROB CHEMOTH, V70, P550, DOI 10.1093/jac/dku376
   Rizk ML, 2012, ANTIMICROB AGENTS CH, V56, P3101, DOI 10.1128/AAC.06417-11
   Rockstroh JK, 2013, JAIDS-J ACQ IMM DEF, V63, P77, DOI 10.1097/QAI.0b013e31828ace69
   Scourfield A, 2012, AIDS, V26, P1399, DOI 10.1097/QAD.0b013e328353b047
   Shelton MJ, 2000, J ACQ IMMUN DEF SYND, V24, P79
   Wenning LA, 2009, CLIN PHARMACOL THER, V85, P623, DOI 10.1038/clpt.2009.12
   Wenning LA, 2009, ANTIMICROB AGENTS CH, V53, P2852, DOI 10.1128/AAC.01468-08
   World Health Organization, HIV AIDS PROGR CONS
NR 25
TC 16
Z9 17
U1 1
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2015
VL 61
IS 8
BP 1328
EP 1335
DI 10.1093/cid/civ477
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CT6WN
UT WOS:000362953800018
PM 26105170
OA Bronze
DA 2020-11-24
ER

PT J
AU Ford, N
   Shubber, Z
   Meintjes, G
   Grinsztejn, B
   Eholie, S
   Mills, EJ
   Davies, MA
   Vitoria, M
   Penazzato, M
   Nsanzimana, S
   Frigati, L
   O'Brien, D
   Ellman, T
   Ajose, O
   Calmy, A
   Doherty, M
AF Ford, Nathan
   Shubber, Zara
   Meintjes, Graeme
   Grinsztejn, Beatriz
   Eholie, Serge
   Mills, Edward J.
   Davies, Mary-Ann
   Vitoria, Marco
   Penazzato, Martina
   Nsanzimana, Sabin
   Frigati, Lisa
   O'Brien, Daniel
   Ellman, Tom
   Ajose, Olawale
   Calmy, Alexandra
   Doherty, Meg
TI Causes of hospital admission among people living with HIV worldwide: a
   systematic review and meta-analysis
SO LANCET HIV
LA English
DT Review
ID STARTING ANTIRETROVIRAL THERAPY; INTENSIVE-CARE-UNIT; SUB-SAHARAN
   AFRICA; INFECTED PATIENTS; STAPHYLOCOCCUS-AUREUS; SEVERE MORBIDITY;
   HEPATITIS-C; MORTALITY; CHILDREN; TRENDS
AB Background Morbidity associated with HIV infection is poorly characterised, so we aimed to investigate the contribution of different comorbidities to hospital admission and in-hospital mortality in adults and children living with HIV worldwide.
   Methods Using a broad search strategy combining terms for hospital admission and HIV infection, we searched MEDLINE via PubMed, Embase, Web of Science, LILACS, AIM, IMEMR and WPIMR from inception to Jan 31, 2015, to identify studies reporting cause of hospital admission in people living with HIV. We focused on data reported after 2007, the period in which access to antiretroviral therapy started to become widespread. We estimated pooled proportions of hospital admissions and deaths per disease category by use of random-effects models. We stratified data by geographical region and age.
   Findings We obtained data from 106 cohorts, with reported causes of hospital admission for 313 006 adults and 6182 children living with HIV. For adults, AIDS-related illnesses (25 119 patients, 46%, 95% CI 40-53) and bacterial infections (14 034 patients, 31%, 20-42) were the leading causes of hospital admission. These two categories were the most common causes of hospital admission for adults in all geographical regions and the most common causes of mortality. Common region-specific causes of hospital admission included malnutrition and wasting, parasitic infections, and haematological disorders in the Africa region; respiratory disease, psychiatric disorders, renal disorders, cardiovascular disorders, and liver disease in Europe; haematological disorders in North America; and respiratory, neurological, digestive and liver-related conditions, viral infections, and drug toxicity in South and Central America. For children, AIDS-related illnesses (783 patients, 27%, 95% CI 19-34) and bacterial infections (1190 patients, 41%, 26-56) were the leading causes of hospital admission, followed by malnutrition and wasting, haematological disorders, and, in the African region, malaria. Mortality in individuals admitted to hospital was 20% (95% CI 18-23, 12 902 deaths) for adults and 14% (10-19, 643 deaths) for children.
   Interpretation This review shows the importance of prompt HIV diagnosis and treatment, and the need to reinforce existing recommendations to provide chemoprophylaxis and vaccination against major preventable infectious diseases to people living with HIV to reduce serious AIDS and non-AIDS morbidity. Copyright (C) 2015. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved.
C1 [Ford, Nathan; Vitoria, Marco; Penazzato, Martina; Doherty, Meg] WHO, Dept HIV AIDS, CH-1211 Geneva, Switzerland.
   [Shubber, Zara] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England.
   [Meintjes, Graeme] Univ Cape Town, Inst Infect Dis & Mol Med, Clin Infect Dis Res Initiat, ZA-7925 Cape Town, South Africa.
   [Grinsztejn, Beatriz] Minist Hlth, Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Eholie, Serge] Treichville Univ, Teaching Hosp, Unit Infect & Trop Dis, Abidjan, Cote Ivoire.
   [Mills, Edward J.] Global Evaluat Sci, Vancouver, BC, Canada.
   [Ford, Nathan; Davies, Mary-Ann] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7700 Rondebosch, South Africa.
   [Nsanzimana, Sabin] Rwanda Biomed Ctr, Inst HIV Dis Prevent & Control, Kigali, Rwanda.
   [Nsanzimana, Sabin] Univ Basel, Swiss Trop & Publ Hlth Res Inst, CH-4003 Basel, Switzerland.
   [Nsanzimana, Sabin] Univ Basel, Basel Inst Clin Epidemiol & Biostat, CH-4003 Basel, Switzerland.
   [Frigati, Lisa] Univ Stellenbosch, Fac Med & Hlth Sci, Dept Paediat & Child Hlth, Div Paediat Infect Dis, Cape Town, South Africa.
   [O'Brien, Daniel] Medecins Sans Frontieres, Manson Unit, London, England.
   [O'Brien, Daniel] Univ Melbourne, Royal Melbourne Hosp, Dept Med & Infect Dis, Melbourne, Vic 3050, Australia.
   [Ellman, Tom] Medecins Sans Frontieres, South Africa Med Unit, Cape Town, South Africa.
   [Ajose, Olawale] Clinton Hlth Access Initiat, Boston, MA USA.
   [Calmy, Alexandra] Univ Hosp Geneva, Infect Dis Serv, HIV AIDS Unit, Geneva, Switzerland.
RP Ford, N (corresponding author), WHO, Dept HIV AIDS, CH-1211 Geneva, Switzerland.
EM fordn@who.int
RI Eholie, Serge/T-6008-2019
OI Meintjes, Graeme/0000-0003-1196-4414; O'Brien,
   Daniel/0000-0001-5418-3330
FU World Health OrganizationWorld Health Organization [001] Funding Source:
   Medline
CR Adlakha A, 2011, INT J STD AIDS, V22, P498, DOI 10.1258/ijsa.2011.010496
   Akgun KM, 2013, CRIT CARE MED, V41, P1458, DOI 10.1097/CCM.0b013e31827caa46
   Akinkuotu A, 2011, INT J STD AIDS, V22, P465, DOI 10.1258/ijsa.2011.011021
   Anglaret X, 2012, CLIN INFECT DIS, V54, P714, DOI 10.1093/cid/cir898
   Avila D, 2014, JAIDS-J ACQ IMM DEF, V65, pE8, DOI 10.1097/QAI.0b013e3182a39979
   Barbier F, 2014, INTENS CARE MED, V40, P1906, DOI 10.1007/s00134-014-3481-7
   Berry SA, 2014, PEDIATR INFECT DIS J, V33, P488, DOI 10.1097/INF.0000000000000126
   Berry SA, 2012, JAIDS-J ACQ IMM DEF, V59, P368, DOI 10.1097/QAI.0b013e318246b862
   Cotton MF, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-40
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Dicko F, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18818
   Dramowski A, 2011, S AFR J HIV MED, P16
   Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202
   Ford N, 2015, CLIN INFECT DIS, V60, P1128, DOI 10.1093/cid/ciu1138
   FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756
   Frigati LJ, 2011, THORAX, V66, P496, DOI 10.1136/thx.2010.156752
   Groome MJ, 2012, PAEDIATR INT CHILD H, V32, P140, DOI 10.1179/1465328111Y.0000000044
   Kim JH, 2013, INFECTION, V41, P545, DOI 10.1007/s15010-012-0386-7
   Koller M, 2015, JAIDS-J ACQ IMM DEF, V68, P62, DOI 10.1097/QAI.0000000000000380
   Luz PM, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-278
   Medrano J, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0475-3
   Meyer-Rath G, 2013, JAIDS-J ACQ IMM DEF, V62, P322, DOI 10.1097/QAI.0b013e31827e8785
   Meyers T, 2012, JAIDS-J ACQ IMM DEF, V60, P503, DOI 10.1097/QAI.0b013e318256b4f8
   MILLER JJ, 1978, AM STAT, V32, P138, DOI 10.2307/2682942
   Mills EJ, 2015, JAMA-J AM MED ASSOC, V313, P419, DOI 10.1001/jama.2014.16482
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
   Nijhawan AE, 2012, JAIDS-J ACQ IMM DEF, V61, P349, DOI 10.1097/QAI.0b013e31826ebc83
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Rao VB, 2015, LANCET INFECT DIS, V15, P819, DOI 10.1016/S1473-3099(15)00006-7
   Ribeiro SR, 2014, ANTIVIR THER, V19, P387, DOI 10.3851/IMP2716
   Siedner MJ, 2015, CLIN INFECT DIS, V60, P1120, DOI 10.1093/cid/ciu1137
   Suthar AB, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001496
   Weber R, 2013, HIV MED, V14, P195, DOI 10.1111/j.1468-1293.2012.01051.x
   Wester CW, 2011, AIDS, V25, P1471, DOI 10.1097/QAD.0b013e328347f9d4
   WHO, 2011, INT TUB CAS FIND IS
   WHO, 2014, GUID US COTR PROPH H
   WHO, 2013, GLOB REP HIV TREATM
   WHO, 2013, HDB DISTR HLTH FAC S
   Wong EB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047542
   World Health Organization, 2013, CONS GUID US ANT DRU
   World Health Organization (WHO), 2010, INT STAT CLASS DIS R
NR 42
TC 101
Z9 101
U1 0
U2 15
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD OCT
PY 2015
VL 2
IS 10
BP E438
EP E444
DI 10.1016/S2352-3018(15)00137-X
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CU8LL
UT WOS:000363794100013
PM 26423651
DA 2020-11-24
ER

PT J
AU Balagopal, A
   Asmuth, DM
   Yang, WT
   Campbell, TB
   Gupte, N
   Smeaton, L
   Kanyama, C
   Grinsztejn, B
   Santos, B
   Supparatpinyo, K
   Badal-Faesen, S
   Lama, JR
   Lalloo, UG
   Zulu, F
   Pawar, JS
   Riviere, C
   Kumarasamy, N
   Hakim, J
   Li, XD
   Pollard, RB
   Semba, RD
   Thomas, DL
   Bollinger, RC
   Gupta, A
AF Balagopal, Ashwin
   Asmuth, David M.
   Yang, Wei-Teng
   Campbell, Thomas B.
   Gupte, Nikhil
   Smeaton, Laura
   Kanyama, Cecilia
   Grinsztejn, Beatriz
   Santos, Breno
   Supparatpinyo, Khuanchai
   Badal-Faesen, Sharlaa
   Lama, Javier R.
   Lalloo, Umesh G.
   Zulu, Fatima
   Pawar, Jyoti S.
   Riviere, Cynthia
   Kumarasamy, Nagalingeswaran
   Hakim, James
   Li, Xiao-Dong
   Pollard, Richard B.
   Semba, Richard D.
   Thomas, David L.
   Bollinger, Robert C.
   Gupta, Amita
TI Pre-cART Elevation of CRP and CD4(+) T-Cell Immune Activation Associated
   With HIV Clinical Progression in a Multinational Case-Cohort Study
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE immune activation; global HIV; cART clinical outcomes; C-reactive
   protein; T-cell activation
ID ACTIVE ANTIRETROVIRAL THERAPY; MICROBIAL TRANSLOCATION; HIV-1-INFECTED
   PATIENTS; DISEASE PROGRESSION; COLLABORATIVE ANALYSIS; TREATMENT
   RESPONSE; VIRAL SUPPRESSION; INFECTED PATIENTS; HEPATITIS-C; 1ST YEAR
AB Background:Despite the success of combination antiretroviral therapy (cART), a subset of HIV-infected patients who initiate cART develop early clinical progression to AIDS; therefore, some cART initiators are not fully benefitted by cART. Immune activation pre-cART may predict clinical progression in cART initiators.Methods:A case-cohort study (n = 470) within the multinational Prospective Evaluation of Antiretrovirals in Resource-Limited Settings clinical trial (1571 HIV treatment-naive adults who initiated cART; CD4(+) T-cell count <300 cells/mm(3); 9 countries) was conducted. A subcohort of 30 participants per country was randomly selected; additional cases were added from the main cohort. Cases [n = 236 (random subcohort 36; main cohort 200)] had clinical progression (incident WHO stage 3/4 event or death) within 96 weeks after cART initiation. Immune activation biomarkers were quantified pre-cART. Associations between biomarkers and clinical progression were examined using weighted multivariable Cox-proportional hazards models.Results:Median age was 35 years, 45% were women, 49% black, 31% Asian, and 9% white. Median CD4(+) T-cell count was 167 cells per cubic millimeter. In multivariate analysis, highest quartile C-reactive protein concentration [adjusted hazard ratio (aHR), 2.53; 95% confidence interval (CI): 1.02 to 6.28] and CD4(+) T-cell activation (aHR, 5.18; 95% CI: 1.09 to 24.47) were associated with primary outcomes, compared with lowest quartiles. sCD14 had a trend toward association with clinical failure (aHR, 2.24; 95% CI: 0.96 to 5.21).Conclusions:Measuring C-reactive protein and CD4(+) T-cell activation may identify patients with CD4(+) T-cell counts <300 cells per cubic millimeter at risk for early clinical progression when initiating cART. Additional vigilance and symptom-based screening may be required in this subset of patients even after beginning cART.
C1 [Balagopal, Ashwin; Yang, Wei-Teng; Gupte, Nikhil; Thomas, David L.; Bollinger, Robert C.; Gupta, Amita] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Asmuth, David M.; Pollard, Richard B.] Univ Calif Davis, Dept Med, Sacramento, CA 95817 USA.
   [Campbell, Thomas B.] Univ Colorado Denver, Dept Med, Aurora, CO USA.
   [Smeaton, Laura] Harvard Univ, Sch Publ Hlth, Ctr AIDS Res, Boston, MA 02115 USA.
   [Kanyama, Cecilia] Univ North Carolina Project, Lilongwe, Malawi.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas, Manguinho, Brazil.
   [Santos, Breno] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Supparatpinyo, Khuanchai] Chiang Mai Univ, Dept Med, Chiang Mai 50000, Thailand.
   [Badal-Faesen, Sharlaa] Univ Witwatersrand, Dept Med, Johannesburg, South Africa.
   [Lama, Javier R.] Asociac Civil Impacta Salud & Educ, IMPACTA PERU Clin Trials Unit, Lima, Peru.
   [Lalloo, Umesh G.] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Pulmonol, Durban, South Africa.
   [Zulu, Fatima] Malawi Coll Med Johns Hopkins Res Project, Kachere Rehabil Ctr, Blantyre, Malawi.
   [Pawar, Jyoti S.] Natl AIDS Res Inst, Pune, Maharashtra, India.
   [Riviere, Cynthia] Ctr GHESKIO, Port Au Prince, Haiti.
   [Kumarasamy, Nagalingeswaran] YR Gaitonde Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
   [Hakim, James] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
   [Semba, Richard D.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA.
RP Balagopal, A (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 855 N Wolfe St,Rangos Room 535, Baltimore, MD 21205 USA.
EM abalago1@jhmi.edu
RI pawar, jyoti/AAG-3163-2019
FU US National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI68636, AI069450, 1 U01 AI068634]; US National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 AI080417, R01 DA016078];
   Boehringer-IngelheimBoehringer Ingelheim; Bristol-Myers
   SquibbBristol-Myers Squibb; Gilead SciencesGilead Sciences;
   GlaxoSmithKlineGlaxoSmithKline; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI068634, UM1AI069476,
   UM1AI069518, UM1AI068634, UM1AI069399, U01AI068634, UM1AI069465,
   U01AI069450, UM1AI069423, UM1AI069463, UM1AI069424, UM1AI069465,
   UM1AI068636, UM1AI069476, UM1AI069476, UM1AI069399, U01AI068636,
   UM1AI069424, U01AI068634, UM1AI069432, UM1AI069465, UM1AI069518,
   R01AI080417, UM1AI069465, UM1AI068634, U01AI068634, UM1AI069518,
   UM1AI069432, UM1AI068634, UM1AI068636, UM1AI069424, UM1AI068636,
   UM1AI069518, UM1AI068636, UM1AI069432, UM1AI069424, U01AI069450,
   UM1AI069432, UM1AI069423, U01AI068634, UM1AI069518, U01AI069450,
   UM1AI068634, UM1AI068636, UM1AI068634, U01AI068636, UM1AI069518,
   UM1AI069463, U01AI068636, UM1AI068634, UM1AI069423, UM1AI069518,
   UM1AI069424, UM1AI069450, UM1AI069463, UM1AI069518, UM1AI069399,
   U01AI068636, UM1AI069399, R01AI080417, UM1AI069423, UM1AI069432,
   UM1AI069432, UM1AI069450, UM1AI069463, UM1AI069476, UM1AI069423,
   UM1AI068636, UM1AI069476, U01AI068634, UM1AI068634, UM1AI069423,
   UM1AI068636, UM1AI069463, UM1AI069424, UM1AI069424, UM1AI069476,
   UM1AI069399, U01AI068636, UM1AI069432, U01AI069450, R01AI080417,
   UM1AI069463, UM1AI069423, UM1AI069463, UM1AI069463, UM1AI069465,
   UM1AI069476, U01AI068636, UM1AI069399, UM1AI068636, UM1AI068636,
   UM1AI069465, U01AI069450, UM1AI069423, UM1AI069399, UM1AI069424,
   UM1AI069432, U01AI068636, UM1AI069465, R01AI080417, UM1AI069399,
   UM1AI068634, UM1AI069476, UM1AI069465] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [R01DA016078, R01DA016078, R01DA016078,
   R01DA016078, R01DA016078, R01DA016078, R01DA016078, R01DA016078,
   R01DA016078, R01DA016078, R01DA016078, R01DA016078, R01DA016078,
   R01DA016078, R01DA016078, R01DA016078] Funding Source: NIH RePORTER
FX Supported by the US National Institute of Allergy and Infectious
   Diseases (AI68636, AI069450, and 1 U01 AI068634 to the Statistical and
   Data Management Center of the AIDS Clinical Trials Group); the US
   National Institutes of Health (R01 AI080417 to A.G. and R01 DA016078 to
   A.B.); and additional grants from Boehringer-Ingelheim, Bristol-Myers
   Squibb, Gilead Sciences, and GlaxoSmithKline.
CR Ancuta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002516
   Bagchi S, 2007, CLIN INFECT DIS, V44, P135, DOI 10.1086/510072
   Balagopal A, 2008, GASTROENTEROLOGY, V135, P226, DOI 10.1053/j.gastro.2008.03.022
   Balagopal A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041258
   Barlow WE, 1999, J CLIN EPIDEMIOL, V52, P1165, DOI 10.1016/S0895-4356(99)00102-X
   Boulle A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001718
   Boulware DR, 2011, J INFECT DIS, V203, P1637, DOI 10.1093/infdis/jir134
   Braitstein P, 2006, LANCET, V367, P817
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   Carsenti-Dellamonica H, 2011, HIV MED, V12, P65, DOI 10.1111/j.1468-1293.2010.00848.x
   Chene G, 2003, LANCET, V362, P679
   Drain PK, 2007, AIDS, V21, P2067, DOI 10.1097/QAD.0b013e32826fb6c7
   Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4
   Fregonese F, 2012, JAIDS-J ACQ IMM DEF, V60, P91, DOI 10.1097/QAI.0b013e31824bd33f
   Grinsztejn B, 2011, ANTIVIR THER, V16, P1057, DOI 10.3851/IMP1872
   Gupta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022730
   Helleberg M, 2013, AIDS, V27, P1021, DOI 10.1097/QAD.0b013e32835cba4c
   Hunt PW, 2011, AIDS, V25, P2123, DOI 10.1097/QAD.0b013e32834c4ac1
   Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786
   Jiao YM, 2012, VIRAL IMMUNOL, V25, P333, DOI 10.1089/vim.2012.0011
   Kalayjian RC, 2010, J INFECT DIS, V201, P1796, DOI 10.1086/652750
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lapadula G, 2013, AIDS, V27, P769, DOI 10.1097/QAD.0b013e32835cb747
   Larson HJ, 2011, B WORLD HEALTH ORGAN, V89, P846, DOI 10.2471/BLT.11.087114
   Marchetti G, 2011, AIDS, V25, P1385, DOI 10.1097/QAD.0b013e3283471d10
   May M, 2007, AIDS, V21, P1185
   Mildvan D, 2004, J INFECT DIS, V189, P1811, DOI 10.1086/383277
   Mocroft A, 2013, CLIN INFECT DIS, V57, P1038, DOI 10.1093/cid/cit423
   Mora S, 2006, AM J CARDIOL, V97, p33A, DOI 10.1016/j.amjcard.2005.11.014
   Ondoa P, 2005, CLIN EXP IMMUNOL, V140, P138, DOI 10.1111/j.1365-2249.2005.02734.x
   Onland-Moret NC, 2007, J CLIN EPIDEMIOL, V60, P350, DOI 10.1016/j.jclinepi.2006.06.022
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   Pedersen KK, 2013, JAIDS-J ACQ IMM DEF, V63, P272, DOI 10.1097/QAI.0b013e318289bced
   Poka-Mayap V, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003210
   Redd AD, 2010, JAIDS-J ACQ IMM DEF, V54, P556, DOI 10.1097/QAI.0b013e3181e0cdea
   Redd AD, 2009, P NATL ACAD SCI USA, V106, P6718, DOI 10.1073/pnas.0901983106
   Rodger AJ, 2013, AIDS, V27, P973, DOI 10.1097/QAD.0b013e32835cae9c
   Rodger AJ, 2009, J INFECT DIS, V200, P973, DOI 10.1086/605447
   Roine I, 1997, CLIN INFECT DIS, V24, P849, DOI 10.1093/clinids/24.5.849
   Rudy BJ, 2006, AIDS RES HUM RETROV, V22, P213, DOI 10.1089/aid.2006.22.213
   Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118
   Shepherd BE, 2013, AIDS, V27, P1321, DOI 10.1097/QAD.0b013e32835faa95
   Smith CJ, 2014, LANCET, V384, P241, DOI 10.1016/S0140-6736(14)60604-8
   Sodora DL, 2008, AIDS, V22, P439, DOI 10.1097/QAD.0b013e3282f2dbe7
   Taiwo B, 2013, J ANTIMICROB CHEMOTH, V68, P1857, DOI 10.1093/jac/dkt120
   Duong T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043375
   Young J, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001194
   Zeremski M, 2007, JAIDS-J ACQ IMM DEF, V45, P262
   Zhang JC, 2013, SCAND J INFECT DIS, V45, P368, DOI 10.3109/00365548.2012.744465
NR 50
TC 15
Z9 15
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2015
VL 70
IS 2
BP 163
EP 171
DI 10.1097/QAI.0000000000000696
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CR8OC
UT WOS:000361612600008
PM 26017661
OA Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU Fernandes, ATG
   Rocha, NP
   Vendrame, E
   Russomano, F
   Grinsztejn, BJ
   Friedman, RK
   Pinto, AC
   Klumb, EM
   Avvad, E
   Macedo, J
   Martinez-Maza, O
   Bonecini-Almeida, MD
AF Fernandes, Ana Teresa G.
   Rocha, Natalia P.
   Vendrame, Elena
   Russomano, Fabio
   Grinsztejn, Beatriz J.
   Friedman, Ruth K.
   Pinto, Amanda C.
   Klumb, Evandro M.
   Avvad, Elyzabeth
   Macedo, Jacyara
   Martinez-Maza, Otoniel
   Bonecini-Almeida, Maria da Gloria
TI Polymorphism in apoptotic BAX (-248G > A) gene but not in anti-apoptotic
   BCL2 (-938C > A) gene and its protein and mRNA expression are associated
   with cervical intraepithelial neoplasia
SO APOPTOSIS
LA English
DT Article
DE Cervical lesions; Apoptosis markers; Polymorphism; mRNA and protein
   expression
ID CHRONIC-LYMPHOCYTIC-LEUKEMIA; SQUAMOUS-CELL CARCINOMA;
   HUMAN-PAPILLOMAVIRUS; PROMOTER POLYMORPHISM; DISEASE PROGRESSION;
   CANCER; SURVIVAL; E6; IDENTIFICATION; CHEMOTHERAPY
AB HPV is associated with cervical cancer and plays a crucial role in tumor formation. Apoptosis is regulated by different pathways involving genes that either promote (BCL2 gene) or inhibit (BAX gene) cell death. Our goal was to determine whether the BCL2-938C > A (rs2279115) and BAX-248G > A (rs4645878) single nucleotide polymorphisms (SNPs) are associated with squamous intraepithelial neoplasia (SIL) risk, and whether their phenotypic expression was impaired in these lesions. Two hundred and thirty-one cases showing SIL were classified as low SIL (LSIL, n = 101) or high SIL (HSIL, n = 130), and control subjects (n = 266) with no gynecologically proven SIL were recruited. No statistical difference in the genotype and allelic frequency of the BCL-2-938C > A polymorphism was observed among the groups. BCL2-938C/A and A/A homozygotes carriers had higher distribution of BCL-2-expressing cells in stroma in the SIL group. BCL2 mRNA-expression was not correlated with BCL2-938C > A SNPs in both groups. We did find a strong association of the BAX GG genotype and risk for SIL. No difference was observed between LSIL and HSIL groups. In BAX-248G/A and A/A homozygote carriers, the number of BAX-expressing cells was lower the epithelium area in SIL. However, mRNA expression was higher in SIL patients than in the control group. In conclusion, our data provide evidence that allele G carriers in the BAX-248G > A promoter SNP may influence the development of SIL. However, this genotype does not influence the SIL outcome. Additionally, we suggest a possible role of HPV infection in the inhibition of the expression of BAX protein, decreasing cell death, and favoring cervical carcinogenesis.
C1 [Fernandes, Ana Teresa G.; Rocha, Natalia P.; Bonecini-Almeida, Maria da Gloria] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Lab Immunol & Immunogenet Infect Dis, BR-21040900 Rio De Janeiro, Brazil.
   [Vendrame, Elena; Martinez-Maza, Otoniel] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.
   [Vendrame, Elena; Martinez-Maza, Otoniel] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol, Los Angeles, CA 90095 USA.
   [Russomano, Fabio] Fundacao Oswaldo Cruz, Child & Adolescent Natl Inst, Dept Gynecol, Fernandes Figueira Woman, BR-21040900 Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz J.; Friedman, Ruth K.] Fundacao Oswaldo Cruz, STD AIDS Clin Res Lab, INI, BR-21040900 Rio De Janeiro, Brazil.
   [Pinto, Amanda C.; Macedo, Jacyara] State Univ Rio de Janeiro UERJ, Dept Biochem, Rio De Janeiro, Brazil.
   [Klumb, Evandro M.] State Univ, Dept Rheumatol, Lupus Clin, Rio De Janeiro, Brazil.
   [Avvad, Elyzabeth] Fundacao Oswaldo Cruz, Child & Adolescent Natl Inst, Dept Pathol Anat, Fernandes Figueira Woman, BR-21040900 Rio De Janeiro, Brazil.
   [Martinez-Maza, Otoniel] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA.
RP Bonecini-Almeida, MD (corresponding author), Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Lab Immunol & Immunogenet Infect Dis, Ave Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
EM gloria.bonecini@ini.fiocruz.br
RI Bonecini-Almeida, Gloria Maria/C-7237-2012; Martinez-Maza,
   Otoniel/B-2667-2009
OI Martinez-Maza, Otoniel/0000-0003-1364-0675; Vendrame,
   Elena/0000-0002-5595-1773; Bonecini-Almeida, Maria da
   Gloria/0000-0001-6030-5576
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ) [170485/2006]; Evandro Chagas National Institute of
   Infectious Diseases-Fiocruz, Rio de Janeiro, RJ, Brazil; CAPES,
   BrazilCAPES
FX Funding from the Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ, 170485/2006) and Evandro Chagas National Institute of
   Infectious Diseases-Fiocruz, Rio de Janeiro, RJ, Brazil. ATGF received
   fellowship from CAPES, Brazil.
CR Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004
   Bachmann HS, 2011, INT J CANCER, V129, P2390, DOI 10.1002/ijc.25904
   Bozovic-Spasojevic I, 2014, BREAST, V23, P473, DOI 10.1016/j.breast.2014.03.012
   CASTELLSAGUE X, 2007, VACCINE, V25, pC110, DOI DOI 10.1016/S0264-410X(07)01183-8
   Chen KX, 2007, CARCINOGENESIS, V28, P2008, DOI 10.1093/carcin/bgm172
   Chung TKH, 2002, CANCER LETT, V180, P63, DOI 10.1016/S0304-3835(01)00842-4
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Fegan C, 2006, LEUKEMIA, V20, P1460, DOI 10.1038/sj.leu.2404280
   Fernandes ATG, 2013, EXP MOL PATHOL, V95, P166, DOI 10.1016/j.yexmp.2013.06.006
   Filippova M, 2004, J BIOL CHEM, V279, P25729, DOI 10.1074/jbc.M401172200
   Fonseca Gilvan Neiva, 2004, Sao Paulo Med. J., V122, P124, DOI 10.1590/S1516-31802004000300009
   HELLBERG D, 1988, AM J OBSTET GYNECOL, V158, P910, DOI 10.1016/0002-9378(88)90093-2
   Heubner M, 2009, INT J BIOL MARKER, V24, P223
   Hirata H, 2009, J UROLOGY, V181, P1907, DOI 10.1016/j.juro.2008.11.093
   Kim HJ, 2004, AM J CHINESE MED, V32, P377, DOI 10.1142/S0192415X0400203X
   Knudsen BS, 2008, J MOL DIAGN, V10, P169, DOI 10.2353/jmoldx.2008.070127
   Ko YH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/329839
   Kontos CK, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-293
   Kuhlmann T, 2002, J NEUROIMMUNOL, V129, P154, DOI 10.1016/S0165-5728(02)00167-4
   Lehnerdt GF, 2009, ANN ONCOL, V20, P1094, DOI 10.1093/annonc/mdn763
   Li JH, 2011, GYNECOL ONCOL, V120, P145, DOI 10.1016/j.ygyno.2010.09.009
   Lorincz Attila T, 2011, Expert Opin Med Diagn, V5, P375
   Martin CM, 2006, EXPERT REV MOL DIAGN, V6, P217, DOI 10.1586/14737159.6.2.217
   Masago K, 2013, ONCOLOGY-BASEL, V84, P214, DOI 10.1159/000342854
   Mehta SV, 2013, NEOPLASMA, V60, P666, DOI 10.4149/neo_2013_085
   Melikian AA, 1999, CANCER LETT, V146, P127, DOI 10.1016/S0304-3835(99)00203-7
   Minkoff H, 2004, J INFECT DIS, V189, P1821, DOI 10.1086/383479
   Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016/S0140-6736(02)08151-5
   Noble P, 2013, BRIT J CANCER, V108, P2097, DOI 10.1038/bjc.2013.166
   Nueckel H, 2006, LEUKEMIA, V20, P724, DOI 10.1038/sj.leu.2404126
   Nuckel H, 2007, BLOOD, V109, P290, DOI 10.1182/blood-2006-03-007567
   Ocana MG, 2007, GENET MED, V9, P249, DOI 10.1097/GIM.0b013e318039b23d
   Oh JM, 2010, CARCINOGENESIS, V31, P402, DOI 10.1093/carcin/bgp318
   Qiu DM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-327
   Rosty C, 2005, ONCOGENE, V24, P7094, DOI 10.1038/sj.onc.1208854
   Saxena A, 2002, CANCER LETT, V187, P199, DOI 10.1016/S0304-3835(02)00378-6
   Skogsberg A, 2006, LEUKEMIA, V20, P77, DOI 10.1038/sj.leu.2404030
   Tjalma WA, 2001, EUR J OBSTET GYN R B, V97, P223, DOI 10.1016/S0301-2115(00)00541-8
   de Andrade ACV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018297
   Vogt M, 2006, ONCOGENE, V25, P4009, DOI 10.1038/sj.onc.1209429
   Wentzensen N, 2009, GYNECOL ONCOL, V112, P293, DOI 10.1016/j.ygyno.2008.10.012
   WHO, 2014, HUM PAP HPV CERV CAN
   YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686
   Yu Dian-ke, 2010, Zhonghua Zhong Liu Za Zhi, V32, P324
   Yuan HD, 2005, ONCOGENE, V24, P5069, DOI 10.1038/sj.onc.1208691
   Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987
NR 46
TC 6
Z9 6
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD OCT
PY 2015
VL 20
IS 10
BP 1347
EP 1357
DI 10.1007/s10495-015-1156-7
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CQ8EO
UT WOS:000360839500007
PM 26272263
DA 2020-11-24
ER

PT J
AU da Silva, AP
   Lopes, AD
   Vieira, YR
   de Almeida, AJ
   Sion, FS
   Grinsztejn, B
   Wagner, S
   de Paula, VS
AF da Silva, Amanda Perse
   Lopes, Amanda de Oliveira
   Vieira, Yasmine Rangel
   de Almeida, Adilson Jose
   Sion, Fernando Samuel
   Grinsztejn, Beatriz
   Wagner, Sandra
   de Paula, Vanessa Salete
TI Genotypic Characterization of Herpes Simplex Virus Type 1 Isolates in
   Immunocompromised Patients in Rio de Janeiro, Brazil
SO PLOS ONE
LA English
DT Article
ID ACYCLOVIR-RESISTANT; THYMIDINE KINASE; DNA-REPLICATION; POLYMERASE;
   EVOLUTION; VIREMIA; SEROPREVALENCE; RECOMBINATION; EPIDEMIOLOGY;
   POLYMORPHISM
AB Herpes simplex virus type 1 (HSV-1) is a prevalent human pathogen that causes a variety of diseases, including an increased risk of developing more severe disease in HIV-infected individuals. In Brazil, there is no information about the molecular epidemiology of HSV-1 infection, especially in HIV-infected individuals. The aim of this study was to perform the genotypic characterization of HSV-1 among HIV-infected patients. A total of 214 serum samples from HIV-positive patients without HSV infection symptoms were enrolled in one of two reference hospitals for HIV infection managing in Rio de Janeiro. The gG and gI genes were analyzed by restriction fragment length polymorphism (RFLP) and full nucleotide sequencing of the US8 (1601 bp), UL44 (1996 bp), and UL23 (1244 bp) regions was performed. A total of 38.3%(82/214) and 32.7%(70/214) of the serum samples tested positive for gG and gI genes, respectively. RFLP analysis classified the HSV-1 as belonging to genotype A. Phylogenetic analysis of the Brazilian samples for the US8, UL44, and UL23 regions demonstrated that the nucleotide identity between Brazilian samples was higher than 97% for all genes. No acyclovir mutation was detected in the patients. The shedding of HSV in the serum samples from HIV-positive patients who were asymptomatic for HSV infection was detected in this work. This is the first report of molecular characterization of HSV-1 in Brazilian samples since there is no previous data available in the literature concerning the genotypic classification and stable distribution of Brazilian strains of HSV-1 in Rio de Janeiro, Brazil.
C1 [da Silva, Amanda Perse; Lopes, Amanda de Oliveira; Vieira, Yasmine Rangel; de Paula, Vanessa Salete] Fiocruz MS, Oswaldo Cruz Fdn, BR-21045900 Rio De Janeiro, Brazil.
   [de Almeida, Adilson Jose; Sion, Fernando Samuel] Fed Univ State Rio De Janeiro UNIRIO, Gaffree & Guinle Univ Hosp, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz; Wagner, Sandra] Evandro Chagas Natl Inst Infectol INI, Rio De Janeiro, Brazil.
RP da Silva, AP (corresponding author), Fiocruz MS, Oswaldo Cruz Fdn, BR-21045900 Rio De Janeiro, Brazil.
EM amandaps@ioc.fiocruz.br; vdepaula@ioc.fiocruz.br
RI da Silva, Amanda Perse/S-7036-2019; de Paula, Vanessa S/I-8037-2016;
   Lopes, Amanda/AAJ-6598-2020
OI de Paula, Vanessa S/0000-0002-6314-754X; Sion, Fernando
   Samuel/0000-0001-6315-139X
FU research and support foundation of the Rio de Janeiro-FAPERJ/PPSUS
   [E_35/2013]
FX This work was supported by the research and support foundation of the
   Rio de Janeiro-FAPERJ/PPSUS E_35/2013.
CR Bacon TH, 2003, CLIN MICROBIOL REV, V16, P114, DOI 10.1128/CMR.16.1.114-128.2003
   Berrington WR, 2009, CLIN INFECT DIS, V49, P1295, DOI 10.1086/606053
   Bestman-Smith J, 2001, J VIROL, V75, P3105, DOI 10.1128/JVI.75.7.3105-3110.2001
   Burrel S, 2010, ANTIMICROB AGENTS CH, V54, P4833, DOI 10.1128/AAC.00669-10
   Celum C, 2010, NEW ENGL J MED, V362, P427, DOI 10.1056/NEJMoa0904849
   Celum C, 2008, LANCET, V371, P2109, DOI 10.1016/S0140-6736(08)60920-4
   Chakraborty N, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-147
   Chayavichitsilp P, 2009, PEDIATR REV, V30, P119, DOI 10.1542/pir.30-4-119
   Clemens SAC, 2010, REV SAUDE PUBL, V44, P726, DOI 10.1590/s0034-89102010000400017
   DUTCH RE, 1995, J VIROL, V69, P3084, DOI 10.1128/JVI.69.5.3084-3089.1995
   Gaudreau A, 1998, J INFECT DIS, V178, P297, DOI 10.1086/515626
   Harel L, 2004, CLIN INFECT DIS, V39, P636, DOI 10.1086/422643
   Harishankar A, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-65
   JOHNSON JR, 1992, CLIN INFECT DIS, V14, P38, DOI 10.1093/clinids/14.1.38
   Johnston C, 2008, J INFECT DIS, V198, P31, DOI 10.1086/588676
   Juhl D, 2010, TRANSFUSION MED, V20, P38, DOI 10.1111/j.1365-3148.2009.00951.x
   Kolb AW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076267
   Kolb AW, 2011, INVEST OPHTH VIS SCI, V52, P9061, DOI 10.1167/iovs.11-7812
   Kolb AW, 2011, INVEST OPHTH VIS SCI, V52, P4630, DOI 10.1167/iovs.10-7032
   KUSNE S, 1991, J INFECT DIS, V163, P1001, DOI 10.1093/infdis/163.5.1001
   Magaret AS, 2007, J CLIN MICROBIOL, V45, P1618, DOI 10.1128/JCM.01405-06
   Mertz GJ, 2003, SEX TRANSM DIS, V30, P801, DOI 10.1097/01.OLQ.0000093080.55201.D1
   Morfin F, 2000, J INFECT DIS, V182, P290, DOI 10.1086/315696
   Morfin F, 2003, J CLIN VIROL, V26, P29, DOI 10.1016/S1386-6532(02)00263-9
   MULLER SA, 1972, AM J MED, V52, P102, DOI 10.1016/0002-9343(72)90012-5
   Norberg P, 2004, J VIROL, V78, P10755, DOI 10.1128/JVI.78.19.10755-10764.2004
   Norberg P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022527
   Norberg P, 2006, J CLIN MICROBIOL, V44, P4511, DOI 10.1128/JCM.00421-06
   Piret J, 2011, ANTIMICROB AGENTS CH, V55, P459, DOI 10.1128/AAC.00615-10
   Roizman B, 2013, FIELDS VIROLOGY, P2456
   Roizman B TB, 2007, STRATEGY HERPES SIMP
   SAKAOKA H, 1994, J GEN VIROL, V75, P513, DOI 10.1099/0022-1317-75-3-513
   Sauerbrei A, 2010, ANTIVIR RES, V86, P246, DOI 10.1016/j.antiviral.2010.03.002
   Sauerbrei A, 2012, J MED VIROL, V84, P651, DOI 10.1002/jmv.23223
   Schiffer Joshua T, 2009, Curr Infect Dis Rep, V11, P457, DOI 10.1007/s11908-009-0066-7
   Schmidt-Chanasit J, 2009, J CLIN VIROL, V44, P235, DOI 10.1016/j.jcv.2008.12.016
   Schomogyi M, 1998, INFECT DIS CLIN N AM, V12, P47, DOI 10.1016/S0891-5520(05)70408-6
   Schubert A, 2014, ANTIVIR RES, V107, P16, DOI 10.1016/j.antiviral.2014.03.015
   SHELDRICK P, 1974, COLD SPRING HARB SYM, V39, P667, DOI 10.1101/SQB.1974.039.01.080
   Stanberry L, 1999, ANTIVIR RES, V42, P1, DOI 10.1016/S0166-3542(99)00004-2
   STANBERRY LR, 1994, CLIN INFECT DIS, V18, P401, DOI 10.1093/clinids/18.3.401
   Szpara ML, 2014, J VIROL, V88, P1209, DOI 10.1128/JVI.01987-13
   Taylor TJ, 2004, J VIROL, V78, P5856, DOI 10.1128/JVI.78.11.5856-5866.2004
   Umene K, 1999, ARCH VIROL, V144, P637, DOI 10.1007/s007050050533
   van Velzen M, 2013, J MED VIROL, V85, P1669, DOI 10.1002/jmv.23634
   WADSWORTH S, 1975, J VIROL, V15, P1487, DOI 10.1128/JVI.15.6.1487-1497.1975
   Wald A, 2003, J INFECT DIS, V188, P1345, DOI 10.1086/379043
   Xu FJ, 2006, JAMA-J AM MED ASSOC, V296, P964, DOI 10.1001/jama.296.8.964
NR 48
TC 2
Z9 3
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 25
PY 2015
VL 10
IS 9
AR e0136825
DI 10.1371/journal.pone.0136825
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS1CR
UT WOS:000361800700016
PM 26407292
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
AF Grinsztejn, Beatriz
TI Syphilis in HIV-infected Mothers and Infants: Results from the
   NICHD/HPTN 040 Study: ERRATUM
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Correction
CR Yeganeh N, 2015, PEDIATR INFECT DIS J, V34, pE52, DOI 10.1097/INF.0000000000000578
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD SEP
PY 2015
VL 34
IS 9
BP 1038
EP 1038
DI 10.1097/INF.0000000000000869
PG 1
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA CQ1ZH
UT WOS:000360398600030
DA 2020-11-24
ER

PT J
AU Bavinton, BR
   Jin, F
   Prestage, G
   Zablotska, IB
   Grinsztejn, B
   Phanuphak, N
   Moore, R
   Koelsch, KK
   Grulich, AE
AF Bavinton, B. R.
   Jin, F.
   Prestage, G.
   Zablotska, I. B.
   Grinsztejn, B.
   Phanuphak, N.
   Moore, R.
   Koelsch, K. K.
   Grulich, A. E.
CA Opposites Attract Study Grp
TI HIV TRANSMISSION IN MALE SERODISCORDANT COUPLES IN AUSTRALIA, THAILAND
   AND BRAZIL
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Meeting Abstract
C1 [Bavinton, B. R.; Jin, F.; Prestage, G.; Zablotska, I. B.; Koelsch, K. K.; Grulich, A. E.] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Grinsztejn, B.] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Rio De Janiero, Brazil.
   [Phanuphak, N.] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand.
   [Phanuphak, N.; Moore, R.] Northside Clin, Melbourne, Vic, Australia.
RI Phanuphak, Nittaya/AAA-8579-2019
NR 0
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
EI 1472-3263
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD SEP
PY 2015
VL 91
SU 2
MA O20.3
BP A70
EP A71
DI 10.1136/sextrans-2015-052270.189
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA VB5YH
UT WOS:000416106400191
OA Bronze
DA 2020-11-24
ER

PT J
AU Coelho, L
   Cardoso, SW
   Luz, PM
   Hoffman, RM
   Mendona, L
   Veloso, VG
   Currier, JS
   Grinsztejn, B
   Lake, JE
AF Coelho, Lara
   Cardoso, Sandra W.
   Luz, Paula M.
   Hoffman, Risa M.
   Mendona, Laura
   Veloso, Valdilea G.
   Currier, Judith S.
   Grinsztejn, Beatriz
   Lake, Jordan E.
TI Vitamin D-3 supplementation in HIV infection: effectiveness and
   associations with antiretroviral therapy
SO NUTRITION JOURNAL
LA English
DT Article
ID BONE-MINERAL DENSITY; IMMUNODEFICIENCY-VIRUS-INFECTION; D DEFICIENCY; D
   INSUFFICIENCY; CONTROLLED-TRIAL; 25-HYDROXYVITAMIN-D; PREVALENCE;
   EFAVIRENZ; ADULTS; HEALTH
AB Background: HIV infection and antiretroviral therapy (ART) may create unique risk factors for vitamin D insufficiency, including alterations of vitamin D metabolism by ART. We prospectively compared demographic and clinical parameters between vitamin D sufficient and insufficient HIV-infected (HIV+) adults, and assessed changes in these parameters among insufficient participants following standardized vitamin D supplementation.
   Methods: HIV+ adults (>= 18 years old) with HIV-1 RNA <50 copies/mL on ART were enrolled. Vitamin D sufficiency and insufficiency were defined as 25-hydroxyvitamin D (25(OH)D) >= 30 or <30 ng/mL, respectively. Insufficient participants received open-label vitamin D3 50,000 IU twice weekly for 5 weeks, then 8000 IU twice weekly to complete 24 weeks. The primary endpoint was success or failure to achieve 25(OH)D >= 30 ng/mL at week 24.
   Results: Ninety-seven participants enrolled (34 vitamin D sufficient, 63 insufficient); 32 % female, 47 % non-White, median age 46 years, ART duration 5 years, CD4+ T lymphocyte count (CD4) 673 cells/mm(3). 25(OH)D repletion was 83 % (95 % CI 71 %-90 %) successful. 25(OH)D levels correlated with both CD4 (r = 0.44, p = 0.01) and time on protease inhibitor (r = -0.35, p = 0.01). After adjusting for age, sex, race, nadir CD4 and baseline 25(OH)D: 1) current use of efavirenz exposure was associated with a 21.1 ng/mL higher week 24 25(OH)D level (p = 0.007), 2) per year use of zidovudine was associated with 7.1 ng/mL reduction in week 24 serum 25(OH)D (p = 0.05) and 3) every 1 ng/mL 25(OH)D increase was associated with a 3.3 cell/mm(3) CD4 increase (p = 0.06).
   Conclusion: Vitamin D-3 supplementation was effective in repleting 25(OH)D levels after 24 weeks. Current efavirenz use was positively associated with post-repletion 25(OH)D levels, while greater time on zidovudine was associated with lower post-repletion 25(OH)D levels. The association between improved CD4 recovery and vitamin D repletion suggests a potential benefit of vitamin D supplementation on immunologic recovery during HIV treatment.
C1 [Coelho, Lara; Cardoso, Sandra W.; Luz, Paula M.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Hoffman, Risa M.; Currier, Judith S.; Lake, Jordan E.] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Mendona, Laura] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
RP Coelho, L (corresponding author), Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM lara.coelho@ini.fiocruz.br
OI Luz, Paula/0000-0001-9746-719X
FU Instituto Nacional de Infectologia Evandro Chagas; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01AI069476,
   K23AI110532, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   K23AI110532, UM1AI069476, UM1AI069476, K23AI110532, U01AI069476,
   UM1AI069476, U01AI069476, K23AI110532, UM1AI069476, K23AI110532,
   U01AI069476, K23AI110532] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [T32MH080634, T32MH080634, T32MH080634,
   T32MH080634, T32MH080634, T32MH080634, T32MH080634, T32MH080634,
   T32MH080634, T32MH080634, T32MH080634, T32MH080634, T32MH080634] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Aging (NIA) [P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748,
   P30AG028748, P30AG028748, P30AG028748, P30AG028748, P30AG028748] Funding
   Source: NIH RePORTER
FX The present study is funded by Instituto Nacional de Infectologia
   Evandro Chagas.
CR Ackert-Bicknell CL, 2012, BONE, V50, P525, DOI 10.1016/j.bone.2011.07.002
   Adams JS, 2010, J CLIN ENDOCR METAB, V95, P471, DOI 10.1210/jc.2009-1773
   Adams JS, 1999, J CLIN ENDOCR METAB, V84, P2729, DOI 10.1210/jc.84.8.2729
   Allavena C, 2012, J ANTIMICROB CHEMOTH, V67, P2222, DOI 10.1093/jac/dks176
   Arantes HP, 2013, OSTEOPOROSIS INT, V24, P2707, DOI 10.1007/s00198-013-2366-x
   Aziz M, 2013, AIDS, V27, P573, DOI 10.1097/QAD.0b013e32835b9ba1
   Bajaj Sarita, 2012, Indian J Endocrinol Metab, V16, pS411, DOI 10.4103/2230-8210.104111
   Bang U, 2012, HIV CLIN TRIALS, V13, P162, DOI 10.1310/hct1303-162
   Bearden A, 2013, J CLIN ENDOCR METAB, V98, P1726, DOI 10.1210/jc.2012-4031
   Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18
   Boonstra A, 2001, J IMMUNOL, V167, P4974, DOI 10.4049/jimmunol.167.9.4974
   Brito A, 2013, FOOD NUTR BULL, V34, P52, DOI 10.1177/156482651303400107
   Cabral MA, 2013, CLIN INTERV AGING, V8, P1347, DOI 10.2147/CIA.S47058
   Cervero M, 2013, HIV MED, V14, P556, DOI 10.1111/hiv.12049
   Conesa-Botella A, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-40
   Cozzolino M, 2003, AIDS, V17, P513, DOI 10.1097/00002030-200303070-00006
   de Luis D A, 2002, Nutr Hosp, V17, P285
   Eckard AR, 2012, ANTIVIR THER, V17, P1069, DOI 10.3851/IMP2318
   Fabre-Mersseman V, 2014, AIDS, V28, P2677, DOI 10.1097/QAD.0000000000000472
   Forouhi NG, 2008, DIABETES, V57, P2619, DOI 10.2337/db08-0593
   Giacomet V, 2013, HIV CLIN TRIALS, V14, P51, DOI 10.1310/hct1402-51
   Ginde AA, 2009, J AM GERIATR SOC, V57, P1595, DOI 10.1111/j.1532-5415.2009.02359.x
   Gonzalez G, 2013, DERM-ENDOCRINOL, V5, DOI 10.4161/derm.24807
   Gyllensten K, 2006, AIDS, V20, P1906, DOI 10.1097/01.aids.0000244216.08327.39
   Hariparsad N, 2004, J CLIN PHARMACOL, V44, P1273, DOI 10.1177/0091270004269142
   HAUG C, 1994, J INFECT DIS, V169, P889, DOI 10.1093/infdis/169.4.889
   Haug CJ, 1998, J CLIN ENDOCR METAB, V83, P3832, DOI 10.1210/jc.83.11.3832
   Havens PL, 2012, J CLIN ENDOCR METAB, V97, P4004, DOI 10.1210/jc.2012-2600
   Havers FP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095164
   Hiremath GS, 2009, MULT SCLER J, V15, P735, DOI 10.1177/1352458509102844
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
   Kantorovich V, 2000, J CLIN ENDOCR METAB, V85, P3541, DOI 10.1210/jc.85.10.3541
   Lai H, 2013, VASC HEALTH RISK MAN, V9, P729, DOI 10.2147/VHRM.S50537
   Lake Jordan E, 2011, Curr HIV/AIDS Rep, V8, P133, DOI 10.1007/s11904-011-0082-8
   Longenecker CT, 2012, ANTIVIR THER, V17, P613, DOI 10.3851/IMP1983
   Martini LA, 2013, NUTRITION, V29, P845, DOI 10.1016/j.nut.2012.12.009
   Melamed ML, 2008, ARCH INTERN MED, V168, P1629, DOI 10.1001/archinte.168.15.1629
   Mueller NJ, 2010, AIDS, V24, P1127, DOI 10.1097/QAD.0b013e328337b161
   Ross AC, 2011, ANTIVIR THER, V16, P555, DOI 10.3851/IMP1784
   Scragg R, 2004, DIABETES CARE, V27, P2813, DOI 10.2337/diacare.27.12.2813
   da Rocha AKS, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657-013-0134-3
   Stein EM, 2011, OSTEOPOROSIS INT, V22, P477, DOI 10.1007/s00198-010-1299-x
   Theodorou M, 2014, CLIN NUTR, V33, P274, DOI 10.1016/j.clnu.2013.04.018
   Van Den Bout-Van Den Beukel CJP, 2008, AIDS RES HUM RETROV, V24, P1375, DOI 10.1089/aid.2008.0058
   Villamor E, 2006, NUTR REV, V64, P226, DOI 10.1111/j.1753-4887.2006.tb00205.x
   Wang ZC, 2013, J STEROID BIOCHEM, V136, P54, DOI 10.1016/j.jsbmb.2012.09.012
   Welz T, 2010, AIDS, V24, P1923, DOI 10.1097/QAD.0b013e32833c3281
NR 47
TC 24
Z9 25
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2891
J9 NUTR J
JI Nutr. J.
PD AUG 18
PY 2015
VL 14
AR 81
DI 10.1186/s12937-015-0072-6
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CO9TP
UT WOS:000359519200001
PM 26283663
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Belaunzaran-Zamudio, PF
   Caro-Vega, YN
   Shepherd, BE
   Crabtree-Ramirez, BE
   Luz, PM
   Grinsztejn, B
   Cesar, C
   Cahn, P
   Cortes, C
   Wolff, M
   Pape, JW
   Padgett, D
   Gotuzzo, E
   McGowan, C
   Sierra-Madero, JG
AF Belaunzaran-Zamudio, Pablo F.
   Caro-Vega, Yanink N.
   Shepherd, Bryan E.
   Crabtree-Ramirez, Brenda E.
   Luz, Paula M.
   Grinsztejn, Beatriz
   Cesar, Carina
   Cahn, Pedro
   Cortes, Claudia
   Wolff, Marcelo
   Pape, Jean W.
   Padgett, Denis
   Gotuzzo, Eduardo
   McGowan, Catherine
   Sierra-Madero, Juan G.
CA CCASAnet
TI Monitoring of HIV treatment in seven countries in the WHO Region of the
   Americas
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; SUPPRESSION; MORTALITY; CARE
AB Objective To determine the prevalence of adequate monitoring and the costs of measuring CD4+T-Iymphocytes (CD4+ cell) and human immunodeficiency virus (HIV) viral load in people receiving antiretroviral therapy (ART) in seven countries in the WHO Region of the Americas.
   Methods We obtained retrospective, longitudinal data for 14 476 adults who started a first ART regimen at seven HIV clinics in Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru between 2000 and 2011. We estimated the proportion of 180-day periods with adequate monitoring, which we defined as at least one CD4+ cell count and one viral load measurement. Factors associated with adequate monitoring were analysed using regression methods. The costs of the tests were estimated.
   Findings The median follow-up time was 50.4 months; the proportion of 180-day periods with adequate CD4+ cell counts was 69% while the proportion with adequate monitoring was 62%. Adequate monitoring was more likely in participants who were older, who started ART more recently, whose first regimen included a non-nucleoside reverse transcriptase inhibitor or who had a CD4+ cell count less than 200 cells/mu l at ART initiation. The cost of one CD4+ cell count ranged from 7.37 United States dollars (US$) in Argentina to US$ 64.09 in Chile; the cost of one viral load measurement ranged from US$ 20.34 in Brazil to US$ 186.28 in Haiti.
   Conclusion In HIV-infected participants receiving ART in the WHO Region of the Americas, CD4+ cell count and viral load monitoring was often carried out less frequently than regional guidelines recommend. The laboratory costs of monitoring varied greatly.
C1 [Belaunzaran-Zamudio, Pablo F.; Caro-Vega, Yanink N.; Crabtree-Ramirez, Brenda E.; Sierra-Madero, Juan G.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Clin Inmunoinfectol, Mexico City 14080, DF, Mexico.
   [Shepherd, Bryan E.] Vanderbilt Univ, Dept Biostat, Nashville, TN 37235 USA.
   [Luz, Paula M.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Cesar, Carina; Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Cortes, Claudia; Wolff, Marcelo] Univ Chile, Fdn Arriaran, Santiago, Chile.
   [Pape, Jean W.] Grp Haitien Etud Sarcome Kaposi & Infect Opportun, Port Au Prince, Haiti.
   [Padgett, Denis] Inst Hondureno Seguridad Social & Hosp Escuela, Tegucigalpa, Honduras.
   [Gotuzzo, Eduardo] Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [McGowan, Catherine] Vanderbilt Univ, Dept Med, Nashville, TN USA.
RP Caro-Vega, YN (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Clin Inmunoinfectol, Calle Vasco de Quiroga 15, Mexico City 14080, DF, Mexico.
EM yaninkc@yahoo.com.mx
RI Belaunzaran-Zamudio, Pablo F./T-4218-2019; Cortes,
   Claudia/AAF-7326-2020; Cesar, Carina/H-2831-2019; Belaunzaran-Zamudio,
   Pablo Francisco/T-4085-2019
OI Cortes, Claudia/0000-0001-9101-9783; Wolff, Marcelo/0000-0002-9956-8872;
   Crabtree-Ramirez, Brenda/0000-0002-2587-1123; Belaunzaran,
   Pablo/0000-0003-4775-4734; Luz, Paula/0000-0001-9746-719X
FU United States National Institute of Allergy and Infectious Diseases
   (NIAID) as part of the International Epidemiologic Databases to Evaluate
   AIDS (IeDEA) network [U01 AI069923]; Mexican National Council for
   Science and Technology (CONACYT)Consejo Nacional de Ciencia y Tecnologia
   (CONACyT); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   U01AI069923, U01AI069923] Funding Source: NIH RePORTER
FX This work was supported by the United States National Institute of
   Allergy and Infectious Diseases (NIAID) as part of the International
   Epidemiologic Databases to Evaluate AIDS (IeDEA) network: U01 AI069923.
   Pablo Belaunzaran-Zamudio received funding for postgraduate studies from
   the Mexican National Council for Science and Technology (CONACYT).
CR Ahonkhai AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032993
   [Anonymous], 2014, COT DOL
   [Anonymous], 2015, CAR CENTR S AM NETW
   [Anonymous], 2002, PAUT TRAT ANT AD PAI
   [Anonymous], 2014, TAUX REF
   [Anonymous], 2013, GUIA MAN PAC AD CON
   [Anonymous], 2015, DAT LAT AM CAR DEV O
   [Anonymous], 2014, WALL STREET J
   [Anonymous], 2012, GUIA MAN ANT PERS CO, V5th
   [Anonymous], 2012, REC SEG TRAT INF HIV
   [Anonymous], 2015, COUNTR
   [Anonymous], 2008, REC TER ANT AD INF P
   [Anonymous], 2015, GUID US ANT AG HIV 1
   Buscher A, 2013, AIDS PATIENT CARE ST, V27, P459, DOI 10.1089/apc.2013.0105
   Estill J, 2012, AIDS, V26, P1403, DOI 10.1097/QAD.0b013e3283536988
   Gale HB, 2013, CLIN INFECT DIS, V56, P1340, DOI 10.1093/cid/cit004
   Horberg MA, 2013, AIDS PATIENT CARE ST, V27, P442, DOI 10.1089/apc.2013.0073
   Joint United Nations Programme on HIV/AIDS, 2013, GLOB REP UNAIDS REP
   Lanoy E, 2009, AIDS, V23, P2199, DOI 10.1097/QAD.0b013e3283305a00
   Mermin J, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6792
   Ministerio de Salud, 2005, NORM TECN TRAT ANT G
   Ministerio de Salud, 2010, GUIA CLIN SINDR INM
   Muya Aisa N, 2015, J Int Assoc Provid AIDS Care, V14, P163, DOI 10.1177/2325957414539193
   Nelson LJ, 2014, AIDS, V28, pS217, DOI 10.1097/QAD.0000000000000239
   Organizacion Panamericana de la Salud, 2012, TRAT ANT BAJ LUP AN
   Pan American Health Organization, 2013, ANT TREATM SPOTL PUB
   Rouzier V, 2013, AM J TROP MED HYG, V89, P671, DOI 10.4269/ajtmh.13-0171
   Sax PE, 2013, CLIN INFECT DIS, V56, P1344, DOI 10.1093/cid/cit008
   Tuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a
   Waning B, 2009, B WORLD HEALTH ORGAN, V87, P520, DOI 10.2471/BLT.08.058925
   Whitlock GG, 2013, CLIN INFECT DIS, V57, P327, DOI 10.1093/cid/cit203
   WHO, 2015, COUNTR
   World Health Organization, 2013, CONS GUID US ANT DRU
   Young B, 2014, 20 INT AIDS C JUL 20
NR 34
TC 10
Z9 10
U1 0
U2 2
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
EI 1564-0604
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD AUG
PY 2015
VL 93
IS 8
BP 529
EP 539
DI 10.2471/BLT.14.147447
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CP6AJ
UT WOS:000359966400010
PM 26478610
OA Green Published
DA 2020-11-24
ER

PT J
AU Cunha, CB
   Friedman, RK
   de Boni, RB
   Gaydos, C
   Guimaraes, MRC
   Siqueira, BH
   Cardoso, SW
   Chicayban, L
   Coutinho, JR
   Yanavich, C
   Veloso, VG
   Grinsztejn, B
AF Cunha, Cynthia B.
   Friedman, Ruth K.
   de Boni, Raquel B.
   Gaydos, Charlotte
   Guimaraes, Maria R. C.
   Siqueira, Brenda H.
   Cardoso, Sandra W.
   Chicayban, Leonardo
   Coutinho, Jose R.
   Yanavich, Carolyn
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI Chlamydia trachomatis, Neisseria gonorrhoeae and syphilis among men who
   have sex with men in Brazil
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Sexually transmitted diseases; Resource limited settings; HIV
   prevention; Rectal chlamydia; Rectal gonorrhea; Nucleic acid
   amplification tests (NAAT); Brazil
ID SEXUALLY-TRANSMITTED INFECTIONS; RECTAL CHLAMYDIA; HIGH PREVALENCE;
   SAN-FRANCISCO; HIV-INFECTION; PHARYNGEAL; BEHAVIOR
AB Background: Sexually transmitted diseases (STD) are frequently asymptomatic and increase the likelihood of transmitting and acquiring HIV. In Brazil, the guidelines for STDs diagnosis and treatment are based on the syndromic approach. Nucleic acid amplification tests (NAAT) has been recommended as routine STDs screening in some countries, especially for men who have sex with men (MSM). Limited data are available about how to best define target groups for routine screening by NAATs within this population. We aimed to assess the prevalence of rectal and urethral Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections and syphilis, and the factors associated with having at least one STD among HIV-infected and uninfected MSM in Rio de Janeiro, Brazil.
   Methods: From August 2010 to June 2012, 391 MSM were enrolled into the Evandro Chagas National Institute of Infectious Diseases-INI-Fiocruz cohort, and 292 MSM (HIV-infected: 211 and HIV-uninfected: 81) were included in this study. NAATs were performed on the rectal swabs and urine for CT and NG. The rapid plasma reagin test and microhemagglutination assay for Treponema pallidum were performed for syphilis diagnosis.
   Results: The overall prevalence of STD was 20.0 % (95% CI: 15.7-25.1): 10 % anorectal chlamydia; syphilis 9.9 %; anorectal gonorrheae 2.5 %; and urethral chlamydia 2.2 %; no case of urethral gonorrheae was detected. The proportion of HIV-positive MSM who had at least one STD was nearly two times that of HIV-negative MSM (22.6 % vs 13.2 %; P = 0.09). The frequency of each STD, except for anorectal NG (1.5 % vs. 5.2 %), was higher among HIV-positive than HIV-negative individuals. Among the 211 asymptomatic participants, 17.5 % (n = 37) were identified as having at least one STD; 10.4 % (n = 22/211) tested positive for anorectal chlamydia. Sixty five percent of HIV-positive MSM were asymptomatic at the time of the STD diagnosis, while 100.0 % of the HIV-negative MSM. Age (APR = 0.78; 95% CI: 0.60-1.00 for each additional ten years) and a positive-HIV serostatus (APR = 2.05; 95% CI: 1.03-4.08) were significantly associated with STD diagnosis.
   Conclusion: An overall high STD-prevalence rate was observed, especially among HIV-infected and in younger individuals, and the majority of STDs were asymptomatic. STD screening using NAATs among asymptomatic MSM is a potentially cost-effective intervention for the prevention of HIV infection among MSM.
C1 [Cunha, Cynthia B.; Friedman, Ruth K.; de Boni, Raquel B.; Guimaraes, Maria R. C.; Siqueira, Brenda H.; Cardoso, Sandra W.; Chicayban, Leonardo; Coutinho, Jose R.; Yanavich, Carolyn; Veloso, Valdilea G.; Grinsztejn, Beatriz] Evandro Chagas Natl Inst Infect Dis INI Fiocruz, Lab Clin Res STD AIDS, Rio De Janeiro, Brazil.
   [Gaydos, Charlotte] Johns Hopkins Univ, Div Infect Dis, Baltimore, MD USA.
RP Grinsztejn, B (corresponding author), Evandro Chagas Natl Inst Infect Dis INI Fiocruz, Lab Clin Res STD AIDS, Rio De Janeiro, Brazil.
EM gbeatriz@ini.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Gaydos, Charlotte A./E-9937-2010
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Chicaybam Peixoto,
   Leonardo/0000-0002-1541-9029
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476,
   U01AI069476, U01AI069476, UM1AI068613, UM1AI068613, UM1AI069476,
   UM1AI069476, UM1AI069476, U01AI068613, UM1AI069476, U01AI068613,
   UM1AI068613, UM1AI068613, UM1AI068613, UM1AI068613, UM1AI068613,
   UM1AI068613, U01AI068613, U01AI068613, UM1AI069476, U01AI069476,
   U01AI069476, UM1AI068613, U01AI068613, UM1AI068613] Funding Source: NIH
   RePORTER
FX This study was supported by funding from the National Council of
   Technological and Scientific Development (CNPq) and the Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ). We thank Sandro Nazer
   and Vanessa Cummings for their technical support during the study and
   Dr. Hugo Perazzo for his help in the configuration of the manuscript for
   submission.
CR Ananworanich J, 2013, MMWR-MORBID MORTAL W, V62, P518
   [Anonymous], 2006, DON
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Belda W, 2009, AN BRAS DERMATOL, V84, P151, DOI 10.1590/S0365-05962009000200008
   Benn PD, 2007, SEX TRANSM INFECT, V83, P106, DOI 10.1136/sti.2006.021329
   Berry SA, 2014, SEX TRANSM INFECT, V90, P574, DOI 10.1136/sextrans-2014-051700
   Beyrer C, 2012, LANCET, V380, P424, DOI 10.1016/S0140-6736(12)61022-8
   Brown LD, 2001, STAT SCI, V16, P101, DOI 10.1214/ss/1009213286
   Chesson HW, 2013, SEX TRANSM DIS, V40, P366, DOI 10.1097/OLQ.0b013e318284e544
   Cohen MS, 2006, SEX TRANSM DIS, V33, P149, DOI 10.1097/01.olq.0000204530.19762.e4
   Cohen Myron S, 2004, Top HIV Med, V12, P104
   Cunha CB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-379
   Dang T, 2009, CLIN INFECT DIS, V49, P1532, DOI 10.1086/644740
   Departamento de DST Aids e Hepatites Virais Secretaria de Vigilancia em Saude Ministerio da Saude, 2013, PROT CLIN DIR TER MA
   Dudareva-Vizule S, 2014, SEX TRANSM INFECT, V90, P46, DOI 10.1136/sextrans-2012-050929
   GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340
   Heiligenberg M, 2012, SEX TRANSM DIS, V39, P8, DOI 10.1097/OLQ.0b013e3182354e81
   Jin FY, 2007, SEX TRANSM INFECT, V83, P397, DOI 10.1136/sti.2007.025684
   Keaveney S, 2014, INT J STD AIDS, V25, P758, DOI 10.1177/0956462414521165
   Kent CK, 2005, CLIN INFECT DIS, V41, P67, DOI 10.1086/430704
   Koblin BA, 2006, AIDS, V20, P731, DOI 10.1097/01.aids.0000216374.61442.55
   Lim MSC, 2012, SEX HEALTH, V9, P247, DOI 10.1071/SH11019
   Mayaud P, 2004, SEX TRANSM INFECT, V80, P174, DOI 10.1136/sti.2002.004101
   Mayer KH, 2012, SEX TRANSM DIS, V39, P1, DOI 10.1097/OLQ.0b013e31823b1922
   Mccoy SI, 2009, SEX TRANSM DIS, V36, P372, DOI 10.1097/OLQ.0b013e3181997252
   Mimiaga MJ, 2009, SEX TRANSM DIS, V36, P507, DOI 10.1097/OLQ.0b013e3181a2ad98
   Ministerio da Safide-Secretaria de Vigilancia em Saude - Departamento de DST Aids e Hepatites Virais, 2014, B EP AIDS DST
   Papp JR, 2014, MMWR RECOMM REP, V63, P1
   Repiso B, 2010, ACTAS DERMO-SIFILOGR, V101, P847, DOI 10.1016/j.ad.2010.06.014
   Templeton DJ, 2014, SEX HEALTH, V11, P217, DOI 10.1071/SH14003
   Truong HHM, 2006, SEX TRANSM INFECT, V82, P461, DOI 10.1136/sti.2006.019950
   Turner AN, 2013, SEX TRANSM DIS, V40, P433, DOI 10.1097/OLQ.0b013e31828fd163
NR 32
TC 18
Z9 24
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD JUL 21
PY 2015
VL 15
AR 686
DI 10.1186/s12889-015-2002-0
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CN0PI
UT WOS:000358115400009
PM 26195002
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Carriquiry, G
   Fink, V
   Koethe, JR
   Giganti, MJ
   Jayathilake, K
   Blevins, M
   Cahn, P
   Grinsztejn, B
   Wolff, M
   Pape, JW
   Padgett, D
   Madero, JS
   Gotuzzo, E
   McGowan, CC
   Shepherd, BE
AF Carriquiry, Gabriela
   Fink, Valeria
   Koethe, John Robert
   Giganti, Mark Joseph
   Jayathilake, Karu
   Blevins, Meridith
   Cahn, Pedro
   Grinsztejn, Beatriz
   Wolff, Marcelo
   Pape, Jean William
   Padgett, Denis
   Sierra Madero, Juan
   Gotuzzo, Eduardo
   McGowan, Catherine Carey
   Shepherd, Bryan Earl
TI Mortality and loss to follow-up among HIV-infected persons on long-term
   antiretroviral therapy in Latin America and the Caribbean
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE HIV; AIDS; ART; Latin America; the Caribbean; long-term mortality
ID HIV-1-INFECTED PATIENTS; TREATMENT OUTCOMES; POSITIVE PATIENTS;
   SCALE-UP; AIDS; PROGRAMS; HETEROGENEITY; DATABASES; EUROPE; ADULTS
AB Introduction: Long-term survival of HIV patients after initiating highly active antiretroviral therapy (ART) has not been sufficiently described in Latin America and the Caribbean, as compared to other regions. The aim of this study was to describe the incidence of mortality, loss to follow-up (LTFU) and associated risk factors for patients enrolled in the Caribbean, Central and South America Network (CCASAnet).
   Methods: We assessed time from ART initiation (baseline) to death or LTFU between 2000 and 2014 among ART-naive adults (>= 18 years) from sites in seven countries included in CCASAnet: Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru. Kaplan-Meier techniques were used to estimate the probability of mortality over time. Risk factors for death were assessed using Cox regression models stratified by site and adjusted for sex, baseline age, nadir pre-ART CD4 count, calendar year of ART initiation, clinical AIDS at baseline and type of ART regimen.
   Results: A total of 16,996 ART initiators were followed for a median of 3.5 years (interquartile range (IQR): 1.6-6.2). The median age at ART initiation was 36 years (IQR: 30-44), subjects were predominantly male (63%), median CD4 count was 156 cells/mL (IQR: 60-251) and 26% of subjects had clinical AIDS prior to starting ART. Initial ART regimens were predominantly nonnucleoside reverse transcriptase inhibitor based (86%). The cumulative incidence of LTFU five years after ART initiation was 18.2% (95% confidence interval (CI) 17.5-18.8%). A total of 1582 (9.3%) subjects died; the estimated probability of death one, three and five years after ART initiation was 5.4, 8.3 and 10.3%, respectively. The estimated five-year mortality probability varied substantially across sites, from 3.5 to 14.0%. Risk factors for death were clinical AIDS at baseline (adjusted hazard ratio (HR)-1.65 (95% CI 1.47-1.87); p<0.001), lower baseline CD4 (HR-1.95 (95% CI 1.63-2.32) for 50 vs. 350 cells/mL; pB0.001) and older age (HR-1.47 (95% CI 1.29-1.69) for 50 vs. 30 years at ART initiation; p<0.001).
   Conclusions: In this large, long-term study of mortality among HIV-positive adults initiating ART in Latin America and the Caribbean, overall estimates of mortality were heterogeneous, generally falling between those reported in high-income countries and sub-Saharan Africa.
C1 [Carriquiry, Gabriela; Gotuzzo, Eduardo] Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Fink, Valeria; Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Koethe, John Robert; Jayathilake, Karu; McGowan, Catherine Carey] Vanderbilt Univ, Dept Med, Nashville, TN 37235 USA.
   [Giganti, Mark Joseph; Blevins, Meridith; Shepherd, Bryan Earl] Vanderbilt Univ, Dept Biostat, Nashville, TN 37235 USA.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fundacao Oswald, Rio De Janeiro, Brazil.
   [Wolff, Marcelo] Fdn Arriaran, Santiago, Chile.
   [Pape, Jean William] Le Grp Haitien Etud Sarcome Kaposi & Infect Oppor, Port Au Prince, Haiti.
   [Pape, Jean William] Weill Cornell Med Coll, New York, NY USA.
   [Padgett, Denis] Inst Hondureno Seguridad Social, Tegucigalpa, Honduras.
   [Padgett, Denis] Hosp Escuela Tegucigalpa, Tegucigalpa, Honduras.
   [Sierra Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
RP Carriquiry, G (corresponding author), Av Angamos Oeste, Lima 11, Peru.
EM gabriela.carriquiry.c@upch.pe
OI Wolff, Marcelo/0000-0002-9956-8872
FU National Institute of Allergy and Infectious Diseases (NIAID) as part of
   the International Epidemiologic Databases to Evaluate AIDS (IeDEA)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01 AI069923]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI069476, UM1AI069421,
   U01AI069923, UM1AI069421, U01AI069923, UM1AI069476, U01AI069923,
   U01AI069923, U01AI069923, UM1AI069421, U01AI069923, U01AI069923,
   U01AI069923, UM1AI069476, UM1AI069476, U01AI069923, UM1AI069476,
   U01AI069923, UM1AI069421, UM1AI069476, U01AI069923, UM1AI069476,
   U01AI069923, UM1AI069421, U01AI069923, U01AI069923, U01AI069923,
   UM1AI069476, U01AI069923, U01AI069923, U01AI069923, U01AI069923,
   UM1AI069421, U01AI069923, UM1AI069421, U01AI069923, UM1AI069421] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (NIAID) as part of the International Epidemiologic
   Databases to Evaluate AIDS (IeDEA): U01 AI069923.
CR Boulle A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001718
   Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248
   Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790
   Duda SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033908
   Egger M, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000390
   Farahani M, 2014, LANCET GLOB HEALTH, V2, pE44, DOI 10.1016/S2214-109X(13)70149-9
   Geng EH, 2008, JAMA-J AM MED ASSOC, V300, P506, DOI 10.1001/jama.300.5.506
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Gupta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022730
   Gutierrez F, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000089
   Hawkins C, 2011, AIDS, V25, P1189, DOI 10.1097/QAD.0b013e3283471deb
   Keiser O, 2008, PLOS MED, V5, P1409, DOI 10.1371/journal.pmed.0050195
   Koenig Serena, 2010, HIV Therapy, V4, P145, DOI 10.2217/HIV.10.6
   Koenig SP, 2012, JAIDS-J ACQ IMM DEF, V59, pE60, DOI 10.1097/QAI.0b013e318245d3c1
   Koethe JR, 2010, JAIDS-J ACQ IMM DEF, V53, P507, DOI 10.1097/QAI.0b013e3181b32baf
   Leger P, 2009, NEW ENGL J MED, V361, P828, DOI 10.1056/NEJMc0809485
   May MT, 2012, INT J EPIDEMIOL, V41, P1807, DOI 10.1093/ije/dys164
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249
   Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123
   Sanne IM, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-38
   Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908
   Shepherd BE, 2009, J CLIN EPIDEMIOL, V62, P729, DOI 10.1016/j.jclinepi.2008.09.002
   Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7
   Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782
   Tuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a
   UNAIDS, 2013, GLOB REP UNAIDS REP
   Wolff MJ, 2010, JAIDS-J ACQ IMM DEF, V55, P368, DOI 10.1097/QAI.0b013e3181eb4fb9
   World Bank, WORLD BANK OP DAT 20
   YIANNOUTSOS CT, 2010, SEX TRANSM INFECT S2, V88, P33
NR 30
TC 26
Z9 31
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL 10
PY 2015
VL 18
AR 20016
DI 10.7448/IAS.18.1.20016
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CN2EG
UT WOS:000358232800001
PM 26165322
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Bavinton, BR
   Jin, FY
   Prestage, G
   Zablotska, I
   Grinsztejn, B
   Phanuphak, N
   Friedman, RK
   Grulich, AE
AF Bavinton, Benjamin Robert
   Jin, Fengyi
   Prestage, Garrett
   Zablotska, Iryna
   Grinsztejn, Beatriz
   Phanuphak, Nittaya
   Friedman, Ruth Khalili
   Grulich, Andrew Edwin
CA Opposites Attract Study Grp
TI Viral load awareness and risk behaviour in male serodiscordant couples
   in Australia, Brazil and Thailand
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Bavinton, Benjamin Robert; Jin, Fengyi; Prestage, Garrett; Zablotska, Iryna; Grulich, Andrew Edwin] Univ New S Wales, Kirby Inst, Kensington, NSW 2033, Australia.
   [Prestage, Garrett] La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Vic, Australia.
   [Grinsztejn, Beatriz; Friedman, Ruth Khalili] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Phanuphak, Nittaya] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand.
EM bbavinton@kirby.unsw.edu.au
RI Phanuphak, Nittaya/AAA-8579-2019
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2015
VL 18
SU 4
MA TUAC0306
DI 10.7448/IAS.18.5.20378
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CN8FS
UT WOS:000358675700087
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Cohen, M
   Chen, Y
   McCauley, M
   Gamble, T
   Hosseinipour, M
   Kumarasamy, N
   Hakim, J
   Kumwenda, N
   Brum, T
   Grinsztejn, B
   Godbole, S
   Chariyalertsak, S
   Santos, BR
   Mayer, K
   Hoffman, I
   Eshleman, S
   Piwowar-Manning, E
   Ou, SS
   Cottle, L
   Makhema, J
   Mills, L
   Panchia, R
   Badal-Faesen, S
   Eron, J
   Gallant, J
   Havlir, D
   Swindells, S
   Elharrar, V
   Burns, D
   Taha, T
   Nielsen, K
   Celentano, D
   Essex, M
   Fleming, T
AF Cohen, Myron
   Chen, Ying
   McCauley, Marybeth
   Gamble, Theresa
   Hosseinipour, Mina
   Kumarasamy, Nagalingeshwaran
   Hakim, James
   Kumwenda, Newton
   Brum, Tania
   Grinsztejn, Beatriz
   Godbole, Sheela
   Chariyalertsak, Suwat
   Santos, Breno Riegel
   Mayer, Kenneth
   Hoffman, Irving
   Eshleman, Susan
   Piwowar-Manning, Estelle
   Ou, San-San
   Cottle, Leslie
   Makhema, Joseph
   Mills, Lisa
   Panchia, Ravindre
   Badal-Faesen, Sharlaa
   Eron, Joseph
   Gallant, Joel
   Havlir, Diane
   Swindells, Susan
   Elharrar, Vanessa
   Burns, David
   Taha, Taha
   Nielsen, Karin
   Celentano, David
   Essex, Max
   Fleming, Thomas
CA HPTN 052 Study Grp
TI Final results of the HPTN 052 randomized controlled trial:
   antiretroviral therapy prevents HIV transmission
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Cohen, Myron] Univ N Carolina, Dept Med, Div Infect Dis, Chapel Hill, NC USA.
   [Chen, Ying; Cottle, Leslie] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, Seattle, WA 98104 USA.
   [McCauley, Marybeth; Gamble, Theresa] HIV Prevent Trials Network, HPTN, Washington, DC USA.
   [Hosseinipour, Mina; Eron, Joseph] Univ N Carolina, Inst Global Hlth & Infect Dis, Chapel Hill, NC USA.
   [Hosseinipour, Mina] Inst Global Hlth & Infect Dis, UNC Project Malawi, Lilongwe, Malawi.
   [Kumarasamy, Nagalingeshwaran] YR Gaitonade Ctr AIDS Res & Educ, Chennai, Tamil Nadu, India.
   [Hakim, James] Univ Zimbabwe, Harare, Zimbabwe.
   [Kumwenda, Newton] Coll Med, Johns Hopkins Project, Blantyre, Malawi.
   [Brum, Tania] Hosp Geral Nova Iguacu, Lab AIDS & Imunol Mol IOC Fiocruz, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Inst Nacl Infectol Evandro Chagas INI Fiocruz, Rio De Janeiro, Brazil.
   [Godbole, Sheela] Natl AIDS Res Inst ICMR, Pune, Maharashtra, India.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
   [Santos, Breno Riegel] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Mayer, Kenneth] Fenway Inst, Boston, MA USA.
   [Mayer, Kenneth] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
   [Hoffman, Irving] Univ N Carolina, Inst Global Hlth & Infect Dis, Chapel Hill, NC USA.
   [Eshleman, Susan; Piwowar-Manning, Estelle] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Ou, San-San] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   [Makhema, Joseph] Botswana Harvard Aids Inst, Gaborone, Botswana.
   [Mills, Lisa] KEMRI Ctr Dis Control & Prevent, Kisumu, Kenya.
   [Panchia, Ravindre] Soweto HPTN CRS, Chris Hani Baragwanath Hosp, Soweto, South Africa.
   [Badal-Faesen, Sharlaa] Univ Witwatersrand, Clin HIV Res Unit, Johannesburg, South Africa.
   [Gallant, Joel] Southwest CARE Ctr, Albuquerque, NM USA.
   [Havlir, Diane] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Swindells, Susan] Univ Nebraska, Med Ctr, Omaha, NE USA.
   [Elharrar, Vanessa] NIAID, Clin Prevent Res Branch, Prevent Sci Program, Div Aids,NIH, Bethesda, MD 20892 USA.
   [Taha, Taha] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Nielsen, Karin] David Geffen UCLA Sch Med, Los Angeles, CA USA.
   [Celentano, David] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Essex, Max] Harvard TH Chan Sch Publ Hlth AIDS Initiat, Boston, MA USA.
   [Essex, Max] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana.
   [Fleming, Thomas] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
NR 0
TC 18
Z9 19
U1 0
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2015
VL 18
SU 4
MA MOAC0101LB
DI 10.7448/IAS.18.5.20482
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CN8FS
UT WOS:000358675700025
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Eshleman, SH
   Hudelson, SE
   Ou, SS
   Redd, AD
   Swanstrom, R
   Porcella, SF
   Chen, YQ
   Piwowar-Manning, E
   McCauley, M
   Gamble, T
   Sievers, M
   Martens, CA
   Bruno, D
   Ping, LH
   Dukhovlinova, E
   Quinn, TC
   Kumwenda, J
   Maliwichi, M
   Nhando, N
   Akelo, V
   Moyo, S
   Panchia, R
   Kumarasamy, N
   Chotirosniramit, N
   Rocha, MM
   Bustorff, F
   Grinsztejn, B
   Mayer, KH
   Hughes, JP
   Cohen, MS
AF Eshleman, Susan H.
   Hudelson, Sarah E.
   Ou, San San
   Redd, Andrew D.
   Swanstrom, Ronald
   Porcella, Stephen F.
   Chen, Ying Q.
   Piwowar-Manning, Estelle
   McCauley, Marybeth
   Gamble, Theresa
   Sievers, Matthew
   Martens, Craig A.
   Bruno, Daniel
   Ping, Li-Hua
   Dukhovlinova, Elena
   Quinn, Thomas C.
   Kumwenda, Johnstone
   Maliwichi, Madalitso
   Nhando, Nehemiah
   Akelo, Victor
   Moyo, Sikhulile
   Panchia, Ravindre
   Kumarasamy, Nagalingeshwaran
   Chotirosniramit, Nuntisa
   Rocha, Marineide M.
   Bustorff, Flavio
   Grinsztejn, Beatriz
   Mayer, Kenneth H.
   Hughes, James P.
   Cohen, Myron S.
CA HPTN 052 Study Team
TI Treatment as prevention: characterization of partner infections in the
   HIV Prevention Trials Network 052 trial
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Eshleman, Susan H.; Hudelson, Sarah E.; Piwowar-Manning, Estelle] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Ou, San San; Chen, Ying Q.; Hughes, James P.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA.
   [Redd, Andrew D.; Sievers, Matthew; Quinn, Thomas C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Redd, Andrew D.; Quinn, Thomas C.] NIAID, Immunoregulat Lab, NIH, Baltimore, MD USA.
   [Swanstrom, Ronald] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC USA.
   [Porcella, Stephen F.; Martens, Craig A.; Bruno, Daniel] NIAID, Genom Unit, Res Technol Sect, Rocky Mt Labs,Div Intramural Res,NIH, Hamilton, MT USA.
   [McCauley, Marybeth] FHI 360, Washington, DC USA.
   [Gamble, Theresa] FHI 360, Durham, NC USA.
   [Ping, Li-Hua; Dukhovlinova, Elena] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Kumwenda, Johnstone] Coll Med, Johns Hopkins Project, Blantyre, Malawi.
   [Maliwichi, Madalitso] UNC Project, Lilongwe, Malawi.
   [Nhando, Nehemiah] Univ Zimbabwe, Harare, Zimbabwe.
   [Akelo, Victor] KEMRI CDC, Kisumu, Kenya.
   [Moyo, Sikhulile] Botswana Harvard AIDS Inst, Gaborone, Botswana.
   [Panchia, Ravindre] Chris Hani Baragwanath Hosp, Soweto HPTN CRS, Soweto, South Africa.
   [Kumarasamy, Nagalingeshwaran] YR Gaitonade Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
   [Chotirosniramit, Nuntisa] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
   [Rocha, Marineide M.] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Bustorff, Flavio] Hosp Geral de Nova Iguacu, Lab AIDS & Imunol Mol IOC Fiocruz, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI Fiocruz, BR-21045900 Rio De Janeiro, Brazil.
   [Mayer, Kenneth H.] Fenway Inst, Boston, MA USA.
   [Mayer, Kenneth H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
   [Cohen, Myron S.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
RI Moyo, Sikhulile/E-1464-2015
OI Moyo, Sikhulile/0000-0003-3821-4592
NR 0
TC 1
Z9 1
U1 0
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2015
VL 18
SU 4
MA MOAC0106LB
DI 10.7448/IAS.18.5.20484
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CN8FS
UT WOS:000358675700030
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Hoagland, B
   Veloso, VG
   De Boni, RB
   Madruga, JV
   Kallas, EG
   Fernandes, NM
   Moreira, RI
   Liu, AY
   Grinsztejn, B
AF Hoagland, Brenda
   Veloso, Valdilea G.
   De Boni, Raquel B.
   Madruga, Jose Valdez
   Kallas, Esper G.
   Fernandes, Nilo Martinez
   Moreira, Ronaldo I.
   Liu, Albert Y.
   Grinsztejn, Beatriz
CA PrEP Brasil Study Team
TI Pre-exposure prophylaxis uptake and associated factors among MSM and TGW
   in the PrEP Brasil demonstration project
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Hoagland, Brenda] Fundacao Oswaldo Cruz, IPEC, Rio De Janeiro, Brazil.
   [Veloso, Valdilea G.; De Boni, Raquel B.; Fernandes, Nilo Martinez; Moreira, Ronaldo I.; Grinsztejn, Beatriz] Fiocruz MS, BR-21045900 Rio De Janeiro, Brazil.
   [Madruga, Jose Valdez] CRT, Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, BR-09500900 Sao Paulo, Brazil.
   [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
EM beatriz.grinsztejn@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2015
VL 18
SU 4
MA TUAC0205LB
DI 10.7448/IAS.18.5.20550
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CN8FS
UT WOS:000358675700080
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Veloso, VG
   Mesquita, F
   Grinsztejn, B
AF Veloso, Valdilea G.
   Mesquita, Fabio
   Grinsztejn, Beatriz
TI Pre-exposure prophylaxis for men and transgender women who have sex with
   men in Brazil: opportunities and challenges
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Editorial Material
DE pre-exposure prophylaxis; MSM; TGW; prevention; Brazil; resource-limited
   setting; health system
ID ANTIRETROVIRAL PROPHYLAXIS; HIV TRANSMISSION; PREVENTION; INFECTION;
   HIV/AIDS; IMPACTS; RISK; MSM
AB Introduction: The World Health Organization recently released guidelines on the use of pre-exposure prophylaxis (PrEP) for prevention of HIV infection among men and transgender women (TGW) who have sex with men based on results of randomized clinical trials. The aim of this commentary is to discuss the opportunities and challenges of incorporating PrEP into the Brazilian continuum of HIV care and prevention for men who have sex with men (MSM) and TGW.
   Discussion: Key aspects of the AIDS epidemic among MSM and TGW in Brazil and the comprehensive Brazilian response to the epidemic are presented. The universal access to health care provided through the Brazilian Unified Health System (SUS) and the range of prevention and care services already available countrywide to HIV-positive individuals and at-risk MSM and TGW are identified as the main facilitators for the implementation of PrEP. Limited PrEP awareness among MSM, TGW and health care providers, low HIV testing frequency and low HIV risk perception among MSM and TGW represent the core challenges to be addressed. Data generated by demonstration projects in Brazil will provide an important contribution to PrEP rollout in Brazil.
   Conclusions: The implementation of PrEP in Brazil is feasible. A synergistic rollout of treatment as prevention and PrEP will maximize public health and individual benefits of the country's comprehensive response to the AIDS epidemic.
C1 [Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, BR-21040360 Rio De Janeiro, Brazil.
   [Mesquita, Fabio] Minist Saude, Dept Doencas Sexualmente Transmissiveis AIDS & He, Brasilia, DF, Brazil.
RP Veloso, VG (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM valdilea.veloso@ipec.fiocruz.br
RI Mesquita, Fabio/AAZ-7021-2020
OI Mesquita, Fabio/0000-0002-8297-0224
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1 AI069476] Funding Source: Medline
CR Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Barash EA, 2010, AIDS PATIENT CARE ST, V24, P689, DOI 10.1089/apc.2010.0173
   Castro R, 2015, 10 INT C HIV TREATM
   CDC, 2011, PREEXP PROPH PREP
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   de Sousa Mascena Veras MA, 2014, AIDS BEHAV
   Departamento de DST/AIDS e Hepatites Virais, 2010, B EP DST AIDS MIN SA
   Departamento de DST/AIDS e Hepatites Virais, 2010, REC TER ANT AD IN S3
   Departamento de DST/AIDS e Hepatites Virais, 2013, PROT CLIN DIR TER MA
   Departamento de DST/AIDS e Hepatites Virais, 2014, B EP AIDS DST
   Eisingerich AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028238
   Galvao J, 2005, AM J PUBLIC HEALTH, V95, P1110, DOI 10.2105/AJPH.2004.044313
   Glidden DV, 2015, C RETR OPP INF 2015
   Gomez GB, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001401
   Gouws E, 2012, SEX TRANSM INFECT, V88, pI76, DOI 10.1136/sextrans-2012-050719
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hoagland B, 2015, 8 IAS C HIV PATH TRE
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Lippman SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121044
   Lippman SA, 2014, CAD SAUDE PUBLICA, V30, P724, DOI 10.1590/0102-311X00008913
   Liu A, 2014, JAIDS-J ACQ IMM DEF, V67, P528, DOI 10.1097/QAI.0000000000000351
   Marrazzo JM, 2014, JAMA-J AM MED ASSOC, V312, P390, DOI 10.1001/jama.2014.7999
   Martins TA, 2013, AIDS CARE, V25, P606, DOI 10.1080/09540121.2012.726342
   McCormack S, 2015, C RETR OPP INF 2015
   Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P77, DOI 10.1097/QAI.0b013e31818d5a27
   Ministerio da Saude, 1999, TER ANT SAUD PUBL
   Molina J, 2015, C RETR OPP INF 2015
   Nunn A, 2012, GLOB PUBLIC HEALTH, V7, P1031, DOI 10.1080/17441692.2012.736681
   Nunn AS, 2009, HEALTH AFFAIR, V28, P1103, DOI 10.1377/hlthaff.28.4.1103
   Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8
   Perisse ARS, 2013, 7 IAS C HIV PATH TRE
   Rocha GM, 2013, AIDS BEHAV, V17, P1288, DOI 10.1007/s10461-012-0398-4
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   UNAIDS, 2014, GLOB AIDS RESP PROGR
   UNAIDS, 2014, GAP REP
   UNAIDS, 2014, 90 90 90 AMB TREATM
   de Castro CAV, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-224
   Wheelock A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054288
   World Health Organization, 2014, CONS GUID HIV PREV D
   Yang DZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054495, 10.1371/journal.pone.0059020]
NR 45
TC 10
Z9 11
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2015
VL 18
SU 3
BP 48
EP 53
DI 10.7448/IAS.18.4.20010
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CN8FQ
UT WOS:000358675400008
PM 26198347
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Castilho, JL
   Levi, JE
   Luz, PM
   Cambou, MC
   Vanni, T
   de Andrade, A
   Derrico, M
   Veloso, VG
   Grinsztejn, B
   Friedman, RK
AF Castilho, Jessica L.
   Levi, Jose Eduardo
   Luz, Paula M.
   Cambou, Mary Catherine
   Vanni, Tazio
   de Andrade, Angela
   Derrico, Monica
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Friedman, Ruth K.
TI A cross-sectional study of high-risk human papillomavirus clustering and
   cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil
SO BMC CANCER
LA English
DT Article
DE HPV; Women; HIV; Cervical cancer; Epidemiology
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SQUAMOUS INTRAEPITHELIAL LESIONS;
   CYTOLOGICAL ABNORMALITIES; POSITIVE WOMEN; CELL COUNT; HPV TYPES;
   PREVALENCE; GENOTYPES; CANCER; VACCINE
AB Background: In Brazil, the rate of cervical cancer remains high despite the availability of screening programs. With ongoing vaccine development and implementation, information on the prevalence of specific HPV types is needed, particularly among high-risk populations, such as HIV-infected women.
   Methods: We performed a study of HIV-infected women in Rio de Janeiro, Brazil, who underwent cervical HPV genotype testing between 2005-2013. We examined the prevalence of high-risk HPV types and the patterns of high-risk HPV type clustering. Using logarithmic binomial regression, we estimated the risk of abnormal cytology by HPV genotype result.
   Results: Of the 562 women included, 498 (89 %) had at least one HPV type detected. 364 women (65 %) had at least one high-risk HPV type detected and 181 (32 %) had more than one high-risk type detected. HPV 58 was the most frequent HPV type detected overall (prevalence 19.8 % [95 % confidence interval 16.4-23.1]), followed by HPV 53 (prevalence 15.5 % [12.5-18.5]) and HPV 16 (prevalence 13 % [10.2-15.8]). Women infected with more than one high-risk HPV type were younger, had lower CD4+ lymphocyte counts, and were more likely to be infected with HPV 16 or 18. In adjusted analyses, presence of more than one high-risk HPV type was associated with a two-fold increased risk of abnormal cytology after adjusting for presence of individual high-risk type, age, and CD4+ lymphocyte count (adjusted prevalence ratios 1.88-2.07, all p < 0.001). No single high-risk HPV type was statistically associated with abnormal cytology after adjusting for the presence of more than one high-risk HPV type.
   Conclusions: In the largest study of cervical HPV genotypes among HIV-infected women in Latin America, infection by high-risk HPV types other than 16 or 18 and infection by more than one high-risk HPV types were common. Infection by more than one high-risk type was more strongly associated with abnormal cervical cytology than any individual high-risk HPV type, highlighting the need for multi-valent HPV vaccines.
C1 [Castilho, Jessica L.] Vanderbilt Univ, Div Infect Dis, Sch Med, Nashville, TN 37235 USA.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Luz, Paula M.; de Andrade, Angela; Derrico, Monica; Veloso, Valdilea G.; Grinsztejn, Beatriz; Friedman, Ruth K.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Cambou, Mary Catherine] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
   [Cambou, Mary Catherine] Univ Calif Los Angeles, David Geffen Sch Med, Program Global Hlth, Los Angeles, CA 90095 USA.
   [Vanni, Tazio] Minist Saude, Dept Ciencia & Tecnol, Brasilia, DF, Brazil.
RP Castilho, JL (corresponding author), Vanderbilt Univ, Div Infect Dis, Sch Med, 221 Kirkland Hall, Nashville, TN 37235 USA.
EM jessica.castilho@vanderbilt.edu
RI Vanni, Tazio P./B-7925-2018
OI Luz, Paula/0000-0001-9746-719X
FU National Institutes of Health (United States)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [T32
   AI007474, K24 AI65298, UO1 AI069923, R25 MH087222]; National Council of
   Technological and Scientific Development (Brazil)National Council for
   Scientific and Technological Development (CNPq); Research Agency of the
   State of Rio de Janeiro (Brazil); Brazilian National STD/AIDS Program
   (Brazil); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [T32AI007474, U01AI069923, U01AI069923, K24AI065298,
   T32AI007474, T32AI007474, UM1AI069476, U01AI069923, U01AI069923,
   U01AI069923, T32AI007474, U01AI069923, T32AI007474, U01AI069923,
   U01AI069923, K24AI065298, T32AI007474, U01AI069923, T32AI007474,
   K24AI065298, U01AI069923, U01AI069923, U01AI069923, UM1AI069476,
   T32AI007474, T32AI007474, K24AI065298, U01AI069923, T32AI007474,
   K24AI065298, UM1AI069476, T32AI007474, U01AI069923, T32AI007474,
   T32AI007474, U01AI069923, U01AI069923, T32AI007474, T32AI007474,
   T32AI007474, T32AI007474, K24AI065298, T32AI007474, U01AI069923,
   UM1AI069476, T32AI007474, U01AI069923, UM1AI069476, UM1AI069476,
   T32AI007474, T32AI007474, T32AI007474, T32AI007474, UM1AI069476,
   K24AI065298, UM1AI069476, U01AI069923, T32AI007474, U01AI069923,
   K24AI065298, K24AI065298, U01AI069923, K24AI065298, T32AI007474] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [R25MH087222,
   R25MH087222, R25MH087222, R25MH087222, R25MH087222, R25MH087222,
   R25MH087222, R25MH087222] Funding Source: NIH RePORTER
FX We would like to thank the patients of the Women's HIV Cohort at INI for
   their time and participation in our study. This work was supported by
   the National Institutes of Health (T32 AI007474 [JLC], K24 AI65298
   [JLC], UO1 AI069923 [JLC, BG, VGV, PML], and R25 MH087222 [MCC]) (United
   States). PML and BG were also supported by the National Council of
   Technological and Scientific Development (Brazil), Research Agency of
   the State of Rio de Janeiro (Brazil), and the Brazilian National
   STD/AIDS Program (Brazil).
CR Abraham AG, 2013, JAIDS-J ACQ IMM DEF, V62, P405, DOI 10.1097/QAI.0b013e31828177d7
   Brandao VDRAB, 2009, MEM I OSWALDO CRUZ, V104, P755, DOI 10.1590/S0074-02762009000500016
   Arbyn M, 2014, J PATHOL, V234, P431, DOI 10.1002/path.4424
   Ayres Andréia Rodrigues Gonçalves, 2010, Rev. Saúde Pública, V44, P963
   da Silva MFPTB, 2012, GENET MOL RES, V11, P462, DOI 10.4238/2012.March.1.3
   Boldrini NT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102169
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Camargo M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-451
   Carozzi F, 2012, EUR J CANCER, V48, P1633, DOI 10.1016/j.ejca.2011.10.010
   Chaturvedi AK, 2005, CANCER EPIDEM BIOMAR, V14, P2439, DOI 10.1158/1055-9965.EPI-05-0465
   Ciapponi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025493
   Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14
   Correa CM, 2011, REV ASSOC MED BRAS, V57, P425, DOI 10.1590/S0104-42302011000400017
   Dartell M, 2013, SEX TRANSM DIS, V40, P737, DOI 10.1097/OLQ.0000000000000005
   Resende LSDA, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-214
   de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033
   Fernandes Jose V, 2010, BMC Res Notes, V3, P96, DOI 10.1186/1756-0500-3-96
   Fife KH, 2009, JAIDS-J ACQ IMM DEF, V51, P274, DOI 10.1097/QAI.0b013e3181a97be5
   Franceschi S, 2007, CLIN INFECT DIS, V45, P510, DOI 10.1086/520022
   Goncalves MAG, 1999, INT J STD AIDS, V10, P803, DOI 10.1258/0956462991913583
   Grinsztejn B, 2009, INT J INFECT DIS, V13, P72, DOI 10.1016/j.ijid.2008.03.031
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Hanisch RA, 2013, J CLIN VIROL, V58, P696, DOI 10.1016/j.jcv.2013.10.012
   Kahn JA, 2013, CLIN INFECT DIS, V57, P735, DOI 10.1093/cid/cit319
   Kang M, 2012, HIV MED, V13, P372, DOI 10.1111/j.1468-1293.2011.00979.x
   Kiatpongsan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048426
   Konopnicki D, 2013, J INFECT DIS, V207, P1723, DOI 10.1093/infdis/jit090
   Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396
   Luque AE, 2006, J INFECT DIS, V194, P428, DOI 10.1086/505876
   Luz PM, 2012, INT J STD AIDS, V23, P12, DOI 10.1258/ijsa.2009.009409
   MacLeod IJ, 2011, J MED VIROL, V83, P1689, DOI 10.1002/jmv.22178
   Mbulawa ZZA, 2013, J INFECTION, V67, P51, DOI 10.1016/j.jinf.2013.03.009
   MCDONALD AC, 2014, S AFRICA FRONT ONCOL, V4, P48
   McKenzie ND, 2010, GYNECOL ONCOL, V116, P572, DOI 10.1016/j.ygyno.2009.10.058
   Meyrelles ARI, 2013, GYNECOL ONCOL, V128, P107, DOI 10.1016/j.ygyno.2012.10.003
   Minkoff H, 2001, AIDS, V15, P2157, DOI 10.1097/00002030-200111090-00011
   Nicol AF, 2013, J CLIN VIROL, V57, P147, DOI 10.1016/j.jcv.2013.02.007
   Paesi S, 2009, J MED VIROL, V81, P1270, DOI 10.1002/jmv.21410
   Palefsky JM, 2003, CURR OPIN ONCOL, V15, P382, DOI 10.1097/00001622-200309000-00007
   Pista A, 2011, CLIN MICROBIOL INFEC, V17, P941, DOI 10.1111/j.1469-0691.2010.03387.x
   Powell SE, 2012, VACCINE, V31, P109, DOI 10.1016/j.vaccine.2012.10.092
   Rocha-Brischiliari SC, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-6
   Rositch AF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055383
   Sahasrabuddhe VV, 2007, BRIT J CANCER, V96, P1480, DOI 10.1038/sj.bjc.6603737
   Schiffman Mark, 2009, Infect Agent Cancer, V4, P8, DOI 10.1186/1750-9378-4-8
   Smelov V, 2015, INT J CANCER, V136, P1171, DOI 10.1002/ijc.29085
   Vaccarella S, 2013, INFECT AGENTS CANCER, V8, DOI 10.1186/1750-9378-8-50
   Vaccarella S, 2010, CANCER EPIDEM BIOMAR, V19, P503, DOI 10.1158/1055-9965.EPI-09-0983
   Vanni T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093376
   Vanni T, 2012, VACCINE, V30, P4866, DOI 10.1016/j.vaccine.2012.04.087
   de Andrade ACV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018297
   Villa LL, 2012, CANCER EPIDEM BIOMAR, V21, P1409, DOI 10.1158/1055-9965.EPI-12-0147
   Wentzensen N, 2014, J INFECT DIS, V209, P855, DOI 10.1093/infdis/jit577
NR 53
TC 9
Z9 9
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 23
PY 2015
VL 15
AR 478
DI 10.1186/s12885-015-1486-4
PG 10
WC Oncology
SC Oncology
GA CK9SQ
UT WOS:000356580200001
PM 26100400
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Luetkemeyer, AF
   Rosenkranz, SL
   Lu, D
   Grinsztejn, B
   Sanchez, J
   Ssemmanda, M
   Sanne, I
   McIlleron, H
   Havlir, DV
   Haas, DW
AF Luetkemeyer, Anne F.
   Rosenkranz, Susan L.
   Lu, Darlene
   Grinsztejn, Beatriz
   Sanchez, Jorge
   Ssemmanda, Michael
   Sanne, Ian
   McIlleron, Helen
   Havlir, Diane V.
   Haas, David W.
CA Adult AIDS Clinical Trials Grp A52
   Adult AIDS Clinical Trials Grp A52
TI Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure
   During Rifampin-based Antituberculosis Therapy in the STRIDE Study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
DE HIV/AIDS; tuberculosis; efavirenz; rifampin; pharmacogenetic
ID HIV-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; TUBERCULOSIS TREATMENT;
   PHARMACOKINETICS; POLYMORPHISMS; ADULTS; WOMEN
AB In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.
C1 [Luetkemeyer, Anne F.; Havlir, Diane V.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94110 USA.
   [Rosenkranz, Susan L.; Lu, Darlene] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Sanchez, Jorge] IMPACTA, Lima, Peru.
   [Ssemmanda, Michael] Joint Clin Res Ctr, Kampala, Uganda.
   [Sanne, Ian] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
   [McIlleron, Helen] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7700 Rondebosch, South Africa.
   [Haas, David W.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.
RP Luetkemeyer, AF (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, 995 Potrero Ave,Box 0874, San Francisco, CA 94110 USA.
EM aluetkemeyer@php.ucsf.edu
OI McIlleron, Helen/0000-0002-0982-6226
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR000445, TR000445] Funding Source:
   Medline; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1 AI069476, AI077505, UM1
   AI106701, UM1 AI069463, UM1 AI069496, R01 AI077505, UM1 AI069456, UM1
   AI069439, UM1 AI068636, UM1 AI068634] Funding Source: Medline; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000445, UL1TR000445, UL1TR000445, UL1TR000445, UL1TR000445,
   UL1TR000445, UL1TR000445] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069463, UM1AI068634, U01AI069456, U01AI069463, U01AI068634,
   R01AI077505, UM1AI068636, UM1AI069496, UM1AI068634, UM1AI068634,
   U01AI068634, UM1AI068636, UM1AI068636, UM1AI069463, UM1AI068634,
   UM1AI069476, UM1AI069476, U01AI069463, UM1AI106701, UM1AI068636,
   U01AI069496, U01AI068636, U01AI069463, UM1AI069439, U01AI069439,
   UM1AI069456, UM1AI068636, UM1AI069476, U01AI069456, UM1AI069463,
   UM1AI069496, U01AI069496, UM1AI069496, R01AI077505, UM1AI069463,
   UM1AI069496, U01AI068636, UM1AI069476, U01AI069439, U01AI069439,
   UM1AI068636, UM1AI069476, UM1AI069439, R01AI077505, UM1AI068634,
   UM1AI106701, U01AI069496, U01AI068636, UM1AI069439, U01AI069476,
   UM1AI069476, UM1AI069463, U01AI069496, UM1AI069439, U01AI069456,
   U01AI068634, UM1AI068634, U01AI068636, UM1AI069456, R01AI077505,
   R01AI077505, U01AI068636, UM1AI069456, U01AI069476, UM1AI069456,
   U01AI069463, UM1AI069439, R01AI077505, R01AI077505, U01AI069476,
   UM1AI106701, U01AI068636, UM1AI069439, UM1AI069476, UM1AI106701,
   UM1AI069439, UM1AI069456, UM1AI106701, U01AI069463, U01AI069463,
   UM1AI106701, U01AI068634, UM1AI068636, R01AI077505, UM1AI069456,
   U01AI069496, UM1AI069463, U01AI069476, U01AI069496, U01AI069456,
   R01AI077505, UM1AI069496, R01AI077505, U01AI069463, UM1AI069439,
   UM1AI068634, UM1AI069476, UM1AI069463, UM1AI068634, U01AI068634,
   UM1AI069463, U01AI069456, UM1AI068634, UM1AI069439, U01AI069496,
   U01AI068636, UM1AI069456, UM1AI069456, UM1AI068636, UM1AI069496,
   UM1AI068636, UM1AI069496, U01AI069439, U01AI069439, R01AI077505,
   UM1AI069496] Funding Source: NIH RePORTER
CR Bertrand J, 2014, J INFECT DIS, V209, P399, DOI 10.1093/infdis/jit466
   Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911
   Cohen K, 2009, ANTIVIR THER, V14, P687
   Court MH, 2013, 20 C RETR OPP INF AT
   DHHS, 2014, GUID US ANT AG HIV 1
   Dooley KE, 2015, J INFECT DIS, V211, P197, DOI 10.1093/infdis/jiu429
   Gandhi M, 2009, JAIDS-J ACQ IMM DEF, V50, P482, DOI 10.1097/QAI.0b013e31819c3376
   Gengiah TN, 2012, EUR J CLIN PHARMACOL, V68, P689, DOI 10.1007/s00228-011-1166-5
   Haas DW, 2014, J ANTIMICROB CHEMOTH, V69, P2175, DOI 10.1093/jac/dku110
   Haas DW, 2004, AIDS, V18, P2391
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   Holzinger ER, 2012, PHARMACOGENET GENOM, V22, P858, DOI 10.1097/FPC.0b013e32835a450b
   Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181
   King J, 2008, AIDS, V22, P1709, DOI 10.1097/QAD.0b013e32830163ad
   Kwara A, 2011, AIDS, V25, P388, DOI 10.1097/QAD.0b013e3283427e05
   Kwara A, 2009, BRIT J CLIN PHARMACO, V67, P427, DOI 10.1111/j.1365-2125.2009.03368.x
   Lee L, 2013, 20 C RETR OPP INF AT
   Luetkemeyer AF, 2013, CLIN INFECT DIS, V57, P586, DOI 10.1093/cid/cit246
   Marzolini C, 2001, AIDS, V15, P71, DOI 10.1097/00002030-200101050-00011
   McIlleron HM, 2013, AIDS, V27, P1933, DOI 10.1097/QAD.0b013e328360dbb4
   Ramachandran G, 2009, ANTIMICROB AGENTS CH, V53, P863, DOI 10.1128/AAC.00899-08
   World Health Organization, 2013, CONS GUID US ANT DRU
   Yenny, 2011, INT J CLIN PHARM TH, V49, P162, DOI 10.5414/CP201473
NR 23
TC 16
Z9 16
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 15
PY 2015
VL 60
IS 12
BP 1860
EP 1863
DI 10.1093/cid/civ155
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CN0BC
UT WOS:000358075800022
PM 25722197
OA Bronze, Green Published
DA 2020-11-24
ER

PT J
AU Safren, SA
   Mayer, KH
   Ou, SS
   McCauley, M
   Grinsztejn, B
   Hosseinipour, MC
   Kumarasamy, N
   Gamble, T
   Hoffman, I
   Celentano, D
   Chen, YQ
   Cohen, MS
AF Safren, Steven A.
   Mayer, Kenneth H.
   Ou, San-San
   McCauley, Marybeth
   Grinsztejn, Beatriz
   Hosseinipour, Mina C.
   Kumarasamy, Nagalingeswaran
   Gamble, Theresa
   Hoffman, Irving
   Celentano, David
   Chen, Ying Qing
   Cohen, Myron S.
CA HPTN 052 Study Team
TI Adherence to Early Antiretroviral Therapy: Results From HPTN 052, a
   Phase III, Multinational Randomized Trial of ART to Prevent HIV-1 Sexual
   Transmission in Serodiscordant Couples
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE ART for prevention; treatment as prevention; adherence
ID SELF-REPORTED ADHERENCE; SUBSTANCE USE; VIRAL LOAD; MEDICATION;
   QUESTIONNAIRE; NONADHERENCE; INITIATION; INFECTION; OUTCOMES; LIFE
AB Background: Combination antiretroviral therapy (ART) for HIV-1-infected individuals prevents sexual transmission if viral load is suppressed.
   Methods: Participants were HIV-1-infected partners randomized to early ART (CD4 350-550) in HPTN052 (n = 886, median follow-up = 2.1 years), a clinical trial of early ART to prevent sexual transmission of HIV-1 in serodiscordant couples at 13 sites in 9 countries. Adherence was assessed through pill count (dichotomized at <95%) and through self-report items. Predictors of adherence were mental health and general health perceptions, substance use, binge drinking, social support, sexual behaviors, and demographics. Viral suppression was defined as HIV plasma viral load <400 copies per milliliter. Adherence counseling and couples' counseling about safer sex were provided. Logistic and linear regression models using generalized estimating equation for repeated measurements were used.
   Findings: Through pill count, 82% of participants were adherent at 1 month and 83.3% at 1 year. Mental health was the only psychosocial variable associated with adherence [pill count, odds ratios (OR) = 1.05, 95% confidence intervals (CIs): 1.00 to 1.11; self-report parameter estimate, OR = 0.02, 95% CI: 0.01 to 0.04], although regional differences emerged. Pill count (OR = 1.19, 95% CI: 1.10 to 1.30) and self-report (OR = 1.42, 95% CI: 1.14 to 1.77) adherence were associated with viral suppression.
   Interpretation: Although adherence was high among individuals in stable relationships taking ART for prevention, mental health and adherence covaried. Assessing and intervening on mental health inthe context of promoting adherence to ART as prevention should be explored. Adherence and couples' counseling, feedback about viral suppression, and/or altruism may also help explain the magnitude of adherence observed.
C1 [Safren, Steven A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
   [Safren, Steven A.; Mayer, Kenneth H.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
   [Safren, Steven A.; Mayer, Kenneth H.] Fenway Hlth, Dept Med, Boston, MA USA.
   [Mayer, Kenneth H.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
   [Ou, San-San; Chen, Ying Qing] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, Vaccine & Infect Dis Div, Seattle, WA 98104 USA.
   [McCauley, Marybeth] FHI 360, Sci Facilitat Dept, Washington, DC USA.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas, HIV AIDS Clin Trials Unit, Rio De Janeiro, Brazil.
   [Hosseinipour, Mina C.] Univ North Carolina Chapel Hill, Div Infect Dis, Inst Global Hlth & Infect Dis, Lilongwe, Malawi.
   [Kumarasamy, Nagalingeswaran] VHS Chennai CRS, YRGCARE Med Ctr, CART CRS, Madras, Tamil Nadu, India.
   [Gamble, Theresa] FHI 360, Sci Facilitat Dept, Durham, NC USA.
   [Hoffman, Irving; Cohen, Myron S.] Univ N Carolina, Sch Med, Dept Med, Div Infect Dis, Chapel Hill, NC USA.
   [Celentano, David] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Safren, SA (corresponding author), MGH Behav Med Serv, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA.
EM ssafren@mgh.harvard.edu
FU National Institute of Allergy and Infectious Diseases (NIAID) of the
   National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI068619,
   UM1AI068617, UM1AI068613]; NIH/NIAIDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01 AI089341];
   NIH/NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA172415]; Gilead ScienceGilead Sciences;  [5K24MH094214]; 
   [1P30AI094189]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA172415, R01CA172415, R01CA172415,
   R01CA172415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI069412, U01AI068619,
   P30AI094189, UM1AI069412, P30AI094189, UM1AI068617, U01AI068619,
   UM1AI068617, P30AI094189, P30AI094189, P30AI094189, R01AI089341,
   UM1AI068613, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, UM1AI069412, UM1AI069412, P30AI094189,
   UM1AI068613, UM1AI068619, U01AI069412, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, R01AI089341, UM1AI068617,
   P30AI094189, UM1AI068617, UM1AI068613, U01AI068613, UM1AI068619,
   UM1AI068613, UM1AI069476, U01AI069412, UM1AI068617, P30AI094189,
   U01AI068619, P30AI094189, UM1AI068613, UM1AI069476, UM1AI069476,
   U01AI068613, P30AI094189, U01AI068619, P30AI094189, UM1AI068619,
   UM1AI068619, R01AI121259, P30AI094189, P30AI094189, U01AI069412,
   UM1AI069412, P30AI094189, P30AI094189, UM1AI068619, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   UM1AI069456, P30AI094189, UM1AI068619, P30AI094189, R01AI121259,
   P30AI094189, UM1AI069412, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, UM1AI068617, P30AI094189, P30AI094189, U01AI068613,
   UM1AI068619, P30AI094189, P30AI094189, UM1AI069476, U01AI068617,
   P30AI094189, UM1AI068619, U01AI069412, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, UM1AI069456, P30AI094189, UM1AI068617,
   P30AI094189, UM1AI068613, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, R01AI121259, UM1AI069476, P30AI094189, UM1AI068613,
   UM1AI069476, UM1AI069456, UM1AI069456, P30AI094189, UM1AI068617,
   UM1AI069412, P30AI094189, U01AI068613, UM1AI069456, P30AI094189,
   P30AI094189, P30AI094189, UM1AI069456, U01AI068619, U01AI068617,
   U01AI068617, P30AI094189, UM1AI068613, UM1AI068617, R01AI089341,
   UM1AI069476, P30AI094189, UM1AI068613, U01AI068613, P30AI094189,
   UM1AI069476, UM1AI068613, UM1AI069456, P30AI094189, U01AI068617,
   U01AI069412, R01AI121259, UM1AI069456, P30AI094189, P30AI094189,
   UM1AI068619, UM1AI069412, P30AI094189, U01AI068617] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [K24MH094214, K24MH094214,
   K24MH094214, K24MH094214, K24MH094214, K24MH094214] Funding Source: NIH
   RePORTER
FX Overall support for the HIV Prevention Trials Network (HPTN) was
   provided by the National Institute of Allergy and Infectious Diseases
   (NIAID) of the National Institutes of Health (NIH) under Award Numbers
   UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN
   Statistical and Data Management Center), and UM1AI068613 (HPTN
   Laboratory Center). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institute of Allergy and Infectious Diseases or the National
   Institutes of Health. Additionally, S.A.S. was partially supported by
   5K24MH094214, Y.Q.C. was partially supported by NIH/NIAID R01 AI089341
   and NIH/NCI R01 CA172415, and D.C. was partially supported by
   1P30AI094189. NIAID assumes all sponsor responsibilities through an
   investigational new drug application with the US Food and Drug
   Administration. The antiretroviral drugs used in this study were donated
   by Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals,
   Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare,
   and Merck. MMC, BG, MH, NK, TG, IH, DC, MC and YC have no relevant
   disclosures to report. SAS receives book royalties from Oxford
   University Press and Guilford Publications. KM receives a grant for
   clinical research from Gilead Science.
CR ACTG, 1999, ACTG QOL 601 602 QOL
   Adakun SA, 2013, JAIDS-J ACQ IMM DEF, V62, P317, DOI 10.1097/QAI.0b013e3182800daf
   Amico K, 2012, ED COUNSELING SUPPOR
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10
   Center for Disease Control, MED ADH EFF INT HIV
   Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2
   Dunkle KL, 2008, LANCET, V371, P2183, DOI 10.1016/S0140-6736(08)60953-8
   Friedman MS, 2009, AIDS CARE, V21, P692, DOI 10.1080/09540120802513709
   Gonzalez JS, 2011, JAIDS-J ACQ IMM DEF, V58, P181, DOI [10.1097/QAI.0B013E31822D490A, 10.1097/QAI.0b013e31822d490a]
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Kabore Lassane, 2015, J Int Assoc Provid AIDS Care, V14, P156, DOI 10.1177/2325957414557263
   KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116
   King RM, 2012, AIDS PATIENT CARE ST, V26, P479, DOI 10.1089/apc.2012.0070
   Lehavot K, 2011, AIDS PATIENT CARE ST, V25, P181, DOI 10.1089/apc.2010.0314
   Malow R, 2013, AIDS BEHAV, V17, P1221, DOI 10.1007/s10461-012-0400-1
   Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679
   Muessig KE, 2014, CURR HIV-AIDS REP, V11, P434, DOI 10.1007/s11904-014-0225-9
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Reda AA, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/574656
   Reynolds NR, 2007, JAIDS-J ACQ IMM DEF, V46, P402, DOI 10.1097/QAI.0b013e318158a44f
   Rodger A, 2014, C RETR OPP INF MARCH
   Sabin LL, 2008, AIDS CARE, V20, P1242, DOI 10.1080/09540120801918651
   Safren SA, 2001, BEHAV RES THER, V39, P1151, DOI 10.1016/S0005-7967(00)00091-7
   Safren SA, 1999, COGN BEHAV PRACT, V6, P332, DOI DOI 10.1016/S1077-7229(99)80052-2
   Safren SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104178
   Safren SA, 2012, AIDS BEHAV, V16, P266, DOI 10.1007/s10461-011-9947-5
   Simoni JM, 2006, JAIDS-J ACQ IMM DEF, V43, pS23, DOI 10.1097/01.qai.0000248342.05438.52
   Simoni JM, 2011, AIDS BEHAV, V15, P919, DOI 10.1007/s10461-010-9828-3
   Wall K, 2014, 20 INT AIDS C JUL ME
   Wasti SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035547
   WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011
NR 34
TC 39
Z9 39
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN 1
PY 2015
VL 69
IS 2
BP 234
EP 240
DI 10.1097/QAI.0000000000000593
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DC5GW
UT WOS:000369250500021
PM 26009832
OA Green Accepted, Green Published
DA 2020-11-24
ER

PT J
AU Calvet, GA
   Grinsztejn, BGJ
   Quintana, MDB
   Derrico, M
   Jalil, EM
   Cytryn, A
   de Andrade, ACV
   Moreira, RI
   Alves, MR
   dos Santos, VGV
   Friedman, RK
AF Calvet, Guilherme Amaral
   Jegerhorn Grinsztejn, Beatriz Gilda
   Borges Quintana, Marcel de Souza
   Derrico, Monica
   Jalil, Emilia Moreira
   Cytryn, Andrea
   Vasconcelos de Andrade, Angela Cristina
   Moreira, Ronaldo Ismerio
   Alves, Marcelo Ribeiro
   Veloso dos Santos, Valdilea Goncalves
   Friedman, Ruth Khalili
TI Predictors of early menopause in HIV-infected women: a prospective
   cohort study
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE chronic hepatitis C; cohort studies; early menopause; human
   immunodeficiency virus; menopause
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RIO-DE-JANEIRO; BODY-MASS INDEX; NATURAL
   MENOPAUSE; HEPATITIS-C; PREMATURE MENOPAUSE; LIVER FIBROSIS;
   RISK-FACTORS; AGE; SYMPTOMS
AB OBJECTIVE: This study sought to investigate the age at natural menopause and its predictors in a cohort of human immunodeficiency virus (HIV)-infected women in Rio de Janeiro, Brazil.
   STUDY DESIGN: HIV-infected women >= 30 years of age were included. Menopause was defined as having >= 1 year since the last menstrual period. Early age at natural menopause was defined as the onset of menopause at <= 45 years of age. Multivariate Cox proportional hazards analysis was applied.
   RESULTS: A total of 667 women were included, and the median age at baseline was 34.9 years (interquartile range, 30.9-40.5 years). In all, 507 (76%) women were premenopausal, and 160 (24%) reached menopause during the observational period; of these, 36 of 160 (27%) had early menopause. The median age at natural menopause was 48 years (interquartile range, 45-50 years). Menarche at <11 years of age (hazard ratio [HR], 2.03; 95% confidence interval [CI], 1.23-3.37), cigarette smoking during the observational period (HR, 1.59; 95% CI, 1.08-2.33), chronic hepatitis C virus (HCV) infection (HR, 2.53; 95% CI, 1.27-5.07), and CD4 count <50 cells/mm(3) (HR, 3.07; 95% CI, 1.07-8.80) were significantly associated with an earlier age at natural menopause. The magnitudes of the effects of menarche at <11 years of age (HR, 2.7; 95% CI, 1.23-5.94), cigarette smoking during the observational period (HR, 3.00; 95% CI, 1.39-6.45), chronic HCV infection (HR, 6.26; 95% CI, 2.12-18.52), and CD4 count <50 cells/mm(3) (HR, 6.64; 95% CI, 1.91-23.20) were much higher and significantly associated with early natural menopause.
   CONCLUSION: Early natural menopause was frequent among the HIV-infected women. In addition to menarche and cigarette smoking, which are menopausal factors among women in general, HIV-related immunodeficiency and chronic HCV were additional predictors for an earlier age at natural menopause. Adequate management of HIV in women is critical, as early onset of menopause has been associated with increased morbidity and mortality.
C1 [Calvet, Guilherme Amaral; Jegerhorn Grinsztejn, Beatriz Gilda; Borges Quintana, Marcel de Souza; Derrico, Monica; Jalil, Emilia Moreira; Cytryn, Andrea; Vasconcelos de Andrade, Angela Cristina; Moreira, Ronaldo Ismerio; Alves, Marcelo Ribeiro; Veloso dos Santos, Valdilea Goncalves; Friedman, Ruth Khalili] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
RP Calvet, GA (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM guilherme.calvet@ipec.fiocruz.br
RI Calvet, GA/G-6959-2013
OI Calvet, GA/0000-0002-3545-5238; Ribeiro-Alves,
   Marcelo/0000-0002-8663-3364
CR Aldrighi José Mendes, 2005, Rev. Assoc. Med. Bras., V51, P51, DOI 10.1590/S0104-42302005000100020
   Allison P.D., 1995, SURVIVAL ANAL USING
   [Anonymous], 1992, MMWR Recomm Rep, V41, P1
   [Anonymous], 1996, WHO TECH REP SER, V866, P1
   Blumel JE, 2006, MENOPAUSE, V13, P706, DOI 10.1097/01.gme.0000227338.73738.2d
   Boonyanurak P, 2012, MENOPAUSE, V19, P820, DOI 10.1097/gme.0b013e31824cfc0f
   Bromberger JT, 1997, AM J EPIDEMIOL, V145, P124
   Burra P, 2013, BEST PRACT RES CL GA, V27, P553, DOI 10.1016/j.bpg.2013.06.014
   Calvet GA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089299
   Cejtin HE, 2012, AM J OBSTET GYNECOL, V207, P87, DOI 10.1016/j.ajog.2011.12.031
   Cicconi P, 2012, JAIDS-J ACQ IMM DEF, V61, pE19, DOI 10.1097/QAI.0b013e3182683cb5
   Cieloszyk K, 2009, MENOPAUSE, V16, P401, DOI 10.1097/gme.0b013e318186d7cf
   Clark RA, 2000, J ACQ IMMUN DEF SYND, V23, P99
   Codes L, 2007, GUT, V56, P390, DOI 10.1136/gut.2006.101931
   Coelho L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098666
   de Pommerol M, 2011, INT J STD AIDS, V22, P67, DOI 10.1258/ijsa.2010.010187
   Di Martino V, 2004, HEPATOLOGY, V40, P1426, DOI 10.1002/hep.20463
   Dratva J, 2009, MENOPAUSE, V16, P385, DOI 10.1097/gme.0b013e31818aefef
   Fantry LE, 2005, AIDS PATIENT CARE ST, V19, P703, DOI 10.1089/apc.2005.19.703
   Ferreira CE, 2007, GYNECOL ENDOCRINOL, V23, P198, DOI 10.1080/09513590701253743
   FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1
   Friedman RK, 2011, REV SAUDE PUBL, V45, P373, DOI 10.1590/S0034-89102011000200016
   Gold EB, 2001, AM J EPIDEMIOL, V153, P865, DOI 10.1093/aje/153.9.865
   Gold EB, 2013, AM J EPIDEMIOL, V178, P70, DOI 10.1093/aje/kws421
   Gold EB, 2011, OBSTET GYN CLIN N AM, V38, P425, DOI 10.1016/j.ogc.2011.05.002
   GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Hardy R, 2008, MATURITAS, V59, P304, DOI 10.1016/j.maturitas.2008.02.009
   Henderson KD, 2008, AM J EPIDEMIOL, V167, P1287, DOI 10.1093/aje/kwn046
   Jabiry-Zieniewicz Z, 2009, TRANSPL P, V41, P1735, DOI 10.1016/j.transproceed.2009.03.073
   Kaczmarek M, 2007, MATURITAS, V57, P139, DOI 10.1016/j.maturitas.2006.12.001
   Kanapathipillai R, 2013, MENOPAUSE, V20, P983, DOI [10.1097/GME.0b013e318282aa57, 10.1097/gme.0b013e318282aa57]
   Kim TJ, 1997, OBSTET GYNECOL, V89, P777, DOI 10.1016/S0029-7844(97)00077-X
   Kinney A, 2006, MATURITAS, V54, P27, DOI 10.1016/j.maturitas.2005.10.001
   Mishra GD, 2009, WOMENS HEALTH, V5, P175, DOI 10.2217/17455057.5.2.175
   Monterrosa-Castro A, 2013, CLIMACTERIC, V16, P663, DOI 10.3109/13697137.2013.798272
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Morris DH, 2012, AM J EPIDEMIOL, V175, P998, DOI 10.1093/aje/kwr447
   North American Menopause Society, 2007, MEN PRACT CLIN GUID
   Palacios S, 2010, CLIMACTERIC, V13, P419, DOI 10.3109/13697137.2010.507886
   Parazzini F, 2007, MATURITAS, V56, P280, DOI 10.1016/j.maturitas.2006.09.003
   Parente RC, 2008, MATURITAS, V61, P287, DOI 10.1016/j.maturitas.2008.09.021
   Pedro Adriana Orcesi, 2003, Cad Saude Publica, V19, P17, DOI 10.1590/S0102-311X2003000100003
   Pencina MJ, 2007, STAT MED, V26, P1343, DOI 10.1002/sim.2699
   Programa Nacional de DST/AIDS, 2012, B EPIDEMIOLOGICO HIV
   Rocca WA, 2012, MENOPAUSE, V19, P272, DOI 10.1097/gme.0b013e31822a9937
   Schoenbaum EE, 2005, CLIN INFECT DIS, V41, P1517, DOI 10.1086/497270
   Shimizu I, 2007, HEPATOL RES, V37, P239, DOI 10.1111/j.1872-034X.2007.00032.x
   Shuster LT, 2010, MATURITAS, V65, P161, DOI 10.1016/j.maturitas.2009.08.003
   Sidibe EH, 2005, ANN ENDOCRINOL-PARIS, V66, P105, DOI 10.1016/S0003-4266(05)81706-8
   Sun L, 2012, MENOPAUSE, V19, P126, DOI 10.1097/gme.0b013e318224f9ac
   Svejme O, 2012, BJOG-INT J OBSTET GY, V119, P810, DOI 10.1111/j.1471-0528.2012.03324.x
   Tehrani FR, 2014, CLIMACTERIC, V17, P164, DOI 10.3109/13697137.2013.828197
   Thomas F, 2001, HUM BIOL, V73, P271, DOI 10.1353/hub.2001.0029
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   Tziomalos K, 2004, CLIN ENDOCRINOL, V61, P664, DOI 10.1111/j.1365-2265.2004.02161.x
   United Nations Program on HIV/AIDS (UNAIDS), 2012, GLOB REP UNAIDS REP
   VALIMAKI M, 1984, J CLIN ENDOCR METAB, V59, P133, DOI 10.1210/jcem-59-1-133
   van Asselt KM, 2004, EPIDEMIOLOGY, V15, P634, DOI 10.1097/01.ede.0000134868.53468.b7
   Villa E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044624
   Villa E, 2011, GASTROENTEROLOGY, V140, P818, DOI 10.1053/j.gastro.2010.12.027
   Wellons M, 2012, MENOPAUSE, V19, P1081, DOI 10.1097/gme.0b013e3182517bd0
   World Health Organization, GLOB DAT BOD MASS IN
   Yang JD, 2014, HEPATOLOGY, V59, P1406, DOI 10.1002/hep.26761
   Yasui T, 2012, MATURITAS, V72, P249, DOI 10.1016/j.maturitas.2012.04.002
   Yin MT, 2012, J CLIN ENDOCR METAB, V97, P554, DOI 10.1210/jc.2011-2197
NR 67
TC 22
Z9 22
U1 1
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD JUN
PY 2015
VL 212
IS 6
AR 765.e1
DI 10.1016/j.ajog.2014.12.040
PG 13
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CJ1RN
UT WOS:000355262000016
PM 25557206
DA 2020-11-24
ER

PT J
AU Kantor, R
   Smeaton, L
   Vardhanabhuti, S
   Hudelson, SE
   Wallis, CL
   Tripathy, S
   Morgado, MG
   Saravanan, S
   Balakrishnan, P
   Reitsma, M
   Hart, S
   Mellors, JW
   Halvas, E
   Grinsztejn, B
   Hosseinipour, MC
   Kumwenda, J
   La Rosa, A
   Lalloo, UG
   Lama, JR
   Rassool, M
   Santos, BR
   Supparatpinyo, K
   Hakim, J
   Flanigan, T
   Kumarasamy, N
   Campbell, TB
   Eshleman, SH
AF Kantor, Rami
   Smeaton, Laura
   Vardhanabhuti, Saran
   Hudelson, Sarah E.
   Wallis, Carol L.
   Tripathy, Srikanth
   Morgado, Mariza G.
   Saravanan, Shanmugham
   Balakrishnan, Pachamuthu
   Reitsma, Marissa
   Hart, Stephen
   Mellors, John W.
   Halvas, Elias
   Grinsztejn, Beatriz
   Hosseinipour, Mina C.
   Kumwenda, Johnstone
   La Rosa, Alberto
   Lalloo, Umesh G.
   Lama, Javier R.
   Rassool, Mohammed
   Santos, Breno R.
   Supparatpinyo, Khuanchai
   Hakim, James
   Flanigan, Timothy
   Kumarasamy, Nagalingeswaran
   Campbell, Thomas B.
   Eshleman, Susan H.
CA AIDS Clinical Trials Grp ACTG A517
TI Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently
   Associated With Virologic Failure: Results From the Multinational PEARLS
   (ACTG A5175) Clinical Trial
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV; drug resistance; subtype; clinical trial
ID RESOURCE-LIMITED SETTINGS; REVERSE-TRANSCRIPTASE INHIBITORS;
   ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; INDIVIDUALS; MUTATION;
   IMPACT; PARTICIPANTS; SURVEILLANCE; PROTEASE
AB Background. Evaluation of pretreatment HIV genotyping is needed globally to guide treatment programs. We examined the association of pretreatment (baseline) drug resistance and subtype with virologic failure in a multinational, randomized clinical trial that evaluated 3 antiretroviral treatment (ART) regimens and included resource-limited setting sites.
   Methods. Pol genotyping was performed in a nested case-cohort study including 270 randomly sampled participants (subcohort), and 218 additional participants failing ART (case group). Failure was defined as confirmed viral load (VL) >1000 copies/mL. Cox proportional hazards models estimated resistance-failure association.
   Results. In the representative subcohort (261/270 participants with genotypes; 44% women; median age, 35 years; median CD4 cell count, 151 cells/mu L; median VL, 5.0 log(10) copies/mL; 58% non-B subtypes), baseline resistance occurred in 4.2%, evenly distributed among treatment arms and subtypes. In the subcohort and case groups combined (466/488 participants with genotypes), used to examine the association between resistance and treatment failure, baseline resistance occurred in 7.1% (9.4% with failure, 4.3% without). Baseline resistance was significantly associated with shorter time to virologic failure (hazard ratio [HR], 2.03; P = .035), and after adjusting for sex, treatment arm, sex-treatment arm interaction, pretreatment CD4 cell count, baseline VL, and subtype, was still independently associated (HR, 2.1; P = .05). Compared with subtype B, subtype C infection was associated with higher failure risk (HR, 1.57; 95% confidence interval [CI], 1.04-2.35), whereas non-B/C subtype infection was associated with longer time to failure (HR, 0.47; 95% CI, .22-.98).
   Conclusions. In this global clinical trial, pretreatment resistance and HIV-1 subtype were independently associated with virologic failure. Pretreatment genotyping should be considered whenever feasible.
C1 [Kantor, Rami; Reitsma, Marissa; Flanigan, Timothy] Brown Univ, Dept Med, Div Infect Dis, Providence, RI 02912 USA.
   [Smeaton, Laura; Vardhanabhuti, Saran] Harvard Univ, Harvard Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [Hudelson, Sarah E.; Eshleman, Susan H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Wallis, Carol L.] Lancet Labs, Johannesburg, South Africa.
   [Tripathy, Srikanth] Natl AIDS Res Inst, Pune, Maharashtra, India.
   [Morgado, Mariza G.; Kumarasamy, Nagalingeswaran] Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, BR-20001 Rio De Janeiro, Brazil.
   [Saravanan, Shanmugham; Balakrishnan, Pachamuthu] YRG CARE, Madras, Tamil Nadu, India.
   [Hart, Stephen] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA.
   [Mellors, John W.; Halvas, Elias] Univ Penn, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Hosseinipour, Mina C.] Univ North Carolina Project Malawi, Lilongwe, Malawi.
   [Kumwenda, Johnstone] Univ Malawi, Coll Med, Dept Internal Med, Blantyre, Malawi.
   [La Rosa, Alberto; Lama, Javier R.] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Lalloo, Umesh G.] Enhancing Care Fdn, Durban, South Africa.
   [Rassool, Mohammed] Univ Witwatersrand, Dept Med, ZA-2001 Johannesburg, South Africa.
   [Rassool, Mohammed] Helen Joseph Hosp, Themba Lethu Clin, Johannesburg, South Africa.
   [Santos, Breno R.] Hosp Nossa Senhora Conceicao, Serv Infect, Porto Alegre, RS, Brazil.
   [Supparatpinyo, Khuanchai] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Supparatpinyo, Khuanchai] Chiang Mai Univ, Fac Med, Chiang Mai, Thailand.
   [Hakim, James] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
   [Campbell, Thomas B.] Univ Colorado Denver, Dept Med, Div Infect Dis, Aurora, CO USA.
RP Kantor, R (corresponding author), Miriam Hosp, RISE 154,164 Summit Ave, Providence, RI 02906 USA.
EM rkantor@brown.edu
RI Reitsma, Marissa/AAE-7719-2020
OI Wallis, Carole/0000-0001-8408-8772
FU Statistical and Data Management Center of the ACTG, under the NIAID [UM1
   AI068634, UM1AI068636]; NIAIDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [RO1AI066922, P30AI042853,
   UM1AI068613]; Boehringer IngelheimBoehringer Ingelheim; Bristol-Myers
   SquibbBristol-Myers Squibb; Gilead SciencesGilead Sciences;
   GlaxoSmithKlineGlaxoSmithKline; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI106701, P30AI050410,
   P30AI042853, UM1AI069436, P30AI050410, UM1AI069399, P30AI042853,
   P30AI050410, UM1AI069399, UM1AI068636, UM1AI069494, P30AI042853,
   P30AI042853, P30AI050410, P30AI042853, P30AI042853, P30AI050410,
   R01AI066922, P30AI042853, P30AI050410, P30AI042853, P30AI050410,
   UM1AI069518, P30AI050410, P30AI042853, UM1AI068613, P30AI042853,
   P30AI042853, UM1AI068636, P30AI042853, P30AI050410, UM1AI069463,
   UM1AI069436, R01AI066922, UM1AI069518, P30AI042853, P30AI042853,
   UM1AI068636, P30AI042853, P30AI042853, P30AI042853, UM1AI069518,
   P30AI050410, P30AI050410, UM1AI068636, P30AI042853, P30AI042853,
   P30AI050410, P30AI050410, P30AI050410, P30AI042853, P30AI050410,
   P30AI050410, UM1AI069436, P30AI042853, P30AI042853, P30AI050410,
   P30AI042853, P30AI042853, P30AI050410, P30AI050410, P30AI050410,
   P30AI042853, P30AI042853, UM1AI069494, UM1AI068636, P30AI050410,
   P30AI042853, P30AI050410, P30AI050410, R01AI066922, P30AI050410,
   UM1AI069494, P30AI042853, UM1AI069424, P30AI042853, P30AI050410,
   P30AI042853, P30AI050410, P30AI050410, P30AI050410, P30AI042853,
   UM1AI069463, P30AI050410, UM1AI069399, UM1AI069424, P30AI050410,
   P30AI042853, UM1AI068634, UM1AI068613, UM1AI069518, P30AI042853,
   P30AI050410, P30AI050410, P30AI042853, P30AI042853, P30AI050410,
   P30AI050410, UM1AI069424, P30AI050410, P30AI042853, P30AI042853,
   P30AI042853, P30AI042853, P30AI042853, UM1AI068613, P30AI050410,
   P30AI042853, P30AI050410, P30AI050410, P30AI050410, UM1AI068613,
   P30AI042853, P30AI042853, P30AI042853, P30AI042853, P30AI050410,
   P30AI042853, UM1AI069494, P30AI042853, P30AI042853, P30AI050410,
   P30AI050410, P30AI042853, P30AI042853, P30AI042853, UM1AI068634,
   UM1AI069518, UM1AI069436, P30AI042853, P30AI050410, UM1AI068634,
   UM1AI069436, UM1AI069476, P30AI050410, P30AI050410, UM1AI069436,
   UM1AI068613, P30AI050410, P30AI042853, P30AI050410, P30AI042853,
   P30AI050410, P30AI042853, P30AI050410, UM1AI069463, P30AI042853,
   P30AI050410, P30AI042853, P30AI042853, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI042853, P30AI050410, UM1AI068613, UM1AI068634, UM1AI069423,
   P30AI042853, P30AI042853, P30AI042853, P30AI050410, P30AI042853,
   P30AI050410, P30AI042853, P30AI042853, UM1AI069476, P30AI042853,
   UM1AI068634, P30AI050410, UM1AI069494, UM1AI069424, P30AI042853,
   P30AI042853, UM1AI068636, UM1AI106701, P30AI042853, P30AI042853,
   P30AI042853, P30AI050410, P30AI042853, P30AI042853, UM1AI068634,
   P30AI042853, UM1AI069423, UM1AI068634, P30AI050410, UM1AI069399,
   UM1AI069476, P30AI042853, UM1AI068636, P30AI042853, P30AI050410,
   P30AI042853, P30AI050410, UM1AI069423, P30AI050410, P30AI042853,
   P30AI042853, UM1AI069399, P30AI042853, UM1AI069494, P30AI042853,
   P30AI042853, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI042853, P30AI042853, P30AI042853, P30AI042853, P30AI042853,
   P30AI042853, UM1AI069463, P30AI050410, P30AI042853, UM1AI069423,
   P30AI042853, UM1AI069494, P30AI050410, UM1AI068636, UM1AI069424,
   P30AI050410, UM1AI106701, P30AI042853, P30AI042853, P30AI042853,
   P30AI050410, R01AI066922, P30AI050410, P30AI050410, P30AI050410,
   UM1AI069436, UM1AI069399, P30AI050410, P30AI042853, P30AI050410,
   P30AI050410, P30AI050410, P30AI042853, P30AI050410, P30AI042853,
   P30AI042853, P30AI042853, P30AI050410, UM1AI069518, P30AI050410,
   P30AI042853, P30AI050410, P30AI042853, UM1AI069476, P30AI050410,
   UM1AI069476, P30AI042853, P30AI042853, P30AI050410, UM1AI106701,
   P30AI050410, P30AI050410, UM1AI069436, P30AI042853, P30AI042853,
   P30AI050410, P30AI042853, UM1AI069476, P30AI042853, P30AI050410,
   UM1AI068613, P30AI042853, P30AI050410, UM1AI069423, P30AI042853,
   P30AI042853, P30AI042853, UM1AI069423, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, UM1AI068634, P30AI050410, P30AI050410,
   P30AI050410, UM1AI068636, P30AI042853, P30AI042853, P30AI050410,
   UM1AI068634, UM1AI069423, P30AI042853, UM1AI069518, P30AI050410,
   P30AI042853, R01AI066922, P30AI050410, UM1AI069424, P30AI050410,
   P30AI042853, P30AI042853, P30AI050410, P30AI042853, P30AI042853,
   P30AI042853, P30AI042853, P30AI042853, UM1AI069463, P30AI050410,
   P30AI042853, P30AI050410, P30AI050410, P30AI050410, UM1AI069399,
   UM1AI069518, P30AI042853, P30AI042853, P30AI050410, P30AI050410,
   P30AI050410, UM1AI069463, P30AI042853, P30AI042853, P30AI050410,
   R01AI066922, P30AI042853, P30AI050410, UM1AI069476, P30AI042853,
   UM1AI069423, P30AI042853, P30AI050410, P30AI050410, P30AI042853,
   P30AI050410, UM1AI106701, P30AI050410, P30AI042853, P30AI050410,
   UM1AI069424, P30AI050410, P30AI050410, UM1AI068613, P30AI042853,
   UM1AI106701, P30AI042853, P30AI050410, P30AI050410, P30AI050410,
   P30AI042853, P30AI050410, P30AI050410, UM1AI069463, P30AI042853,
   P30AI042853, P30AI042853, UM1AI068613, UM1AI069399, UM1AI069476,
   P30AI042853, P30AI042853, P30AI042853, P30AI050410, P30AI042853,
   P30AI050410, P30AI050410, P30AI050410, P30AI042853, P30AI042853,
   P30AI050410, P30AI050410, P30AI042853, P30AI050410, P30AI042853,
   P30AI042853, P30AI042853, P30AI042853, P30AI042853, P30AI050410,
   UM1AI069424, P30AI042853, P30AI042853, P30AI050410, P30AI050410,
   P30AI050410, P30AI042853, P30AI050410, P30AI042853, P30AI042853,
   UM1AI069494, P30AI042853, P30AI042853, UM1AI068613, UM1AI069463,
   P30AI042853, P30AI042853, P30AI050410] Funding Source: NIH RePORTER
FX This work was supported by the Statistical and Data Management Center of
   the ACTG, under the NIAID (grant number UM1 AI068634) and the Leadership
   grant (grant number UM1AI068636); and the NIAID (grant numbers
   RO1AI066922 and P30AI042853 to R. K. and UM1AI068613 to S. H. E.). The
   pharmaceutical sponsors for this study included Boehringer Ingelheim,
   Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline.
CR Amornkul PN, 2013, AIDS, V27, P2775, DOI 10.1097/QAD.0000000000000012
   Bansi L, 2010, JAIDS-J ACQ IMM DEF, V53, P633, DOI 10.1097/QAI.0b013e3181c070d2
   Barth RE, 2012, ANTIVIR THER, V17, P377, DOI 10.3851/IMP2010
   Bennett DE, 2008, ANTIVIR THER, V13, P25
   Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724
   Boltz VF, 2011, P NATL ACAD SCI USA, V108, P9202, DOI 10.1073/pnas.1105688108
   Brenner B, 2003, AIDS, V17, pF1, DOI 10.1097/00002030-200301030-00001
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891
   Church JD, 2006, J MOL DIAGN, V8, P430, DOI 10.2353/jmoldx.2006.050148
   DeLong AK, 2012, AIDS RES HUM RETROV, V28, P894, DOI [10.1089/aid.2011.0120, 10.1089/AID.2011.0120]
   Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001
   Easterbrook PJ, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-4
   Fogel JM, 2013, J INFECT DIS, V208, P1624, DOI 10.1093/infdis/jit390
   Gray CM, 2005, AIDS RES HUM RETROV, V21, P285, DOI 10.1089/aid.2005.21.285
   Gupta RK, 2012, LANCET, V380, P1250, DOI 10.1016/S0140-6736(12)61038-1
   Hamers RL, 2012, LANCET INFECT DIS, V12, P307, DOI 10.1016/S1473-3099(11)70255-9
   Hingankar NK, 2012, CLIN INFECT DIS, V54, pS348, DOI 10.1093/cid/cis005
   HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992
   Huang A, 2013, INT WORKSH HIV HEP V
   Johnson Victoria A, 2011, Top Antivir Med, V19, P156
   Kahle EM, 2014, JAIDS-J ACQ IMM DEF, V65, pE90, DOI 10.1097/QAI.0b013e3182a2db02
   Kantor R, 2005, PLOS MED, V2, P325, DOI 10.1371/journal.pmed.0020112
   Kantor R, 2009, CLIN INFECT DIS, V49, P454, DOI 10.1086/600396
   Kolomeets AN, 2014, AIDS, V28, pF1, DOI 10.1097/QAD.0000000000000485
   Kuritzkes DR, 2008, J INFECT DIS, V197, P867, DOI 10.1086/528802
   Kyeyune F, 2013, AIDS, V27, P1899, DOI 10.1097/QAD.0b013e3283610ec7
   Marzinke MA, 2014, CLIN INFECT DIS, V58, P117, DOI 10.1093/cid/cit672
   Piot P, 2013, NEW ENGL J MED, V368, P2210, DOI 10.1056/NEJMra1201533
   Roberts T, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17324
   Sax PE, 2005, CLIN INFECT DIS, V41, P1316, DOI 10.1086/496984
   Scherrer AU, 2011, CLIN INFECT DIS, V53, P1143, DOI 10.1093/cid/cir669
   Shafer R., STANFORD HIV SEQUENC
   Soares EAJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000730
   Sunpath H, 2012, AIDS, V26, P1679, DOI 10.1097/QAD.0b013e328356886d
   Tang MW, 2012, DRUGS, V72, pE1, DOI 10.2165/11633630-000000000-00000
   Touloumi G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071174
   Turner D, 2004, ANTIMICROB AGENTS CH, V48, P2993, DOI 10.1128/AAC.48.8.2993-2998.2004
   Wainberg MA, 2010, VIRUSES-BASEL, V2, P2493, DOI 10.3390/v2112493
   Wittkop L, 2011, LANCET INFECT DIS, V11, P363, DOI 10.1016/S1473-3099(11)70032-9
NR 40
TC 45
Z9 47
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2015
VL 60
IS 10
BP 1541
EP 1549
DI 10.1093/cid/civ102
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CH0ON
UT WOS:000353721300016
PM 25681380
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Firnhaber, C
   Smeaton, LM
   Grinsztejn, B
   Lalloo, U
   Faesen, S
   Samaneka, W
   Infante, R
   Rana, A
   Kumarasamy, N
   Hakim, J
   Campbell, TB
AF Firnhaber, Cynthia
   Smeaton, Laura M.
   Grinsztejn, Beatriz
   Lalloo, Umesh
   Faesen, Sharla
   Samaneka, Wadzanai
   Infante, Rosa
   Rana, Aadia
   Kumarasamy, Nagalingeswaran
   Hakim, James
   Campbell, Thomas B.
CA PEARLS Study Team
TI Differences in antiretroviral safety and efficacy by sex in a
   multinational randomized clinical trial
SO HIV CLINICAL TRIALS
LA English
DT Article
DE Women; Resource-limited settings; Clinical studies; HIV; ARVs
ID GENDER-DIFFERENCES; ADVERSE EVENTS; HIV-INFECTION; THERAPY; WOMEN; MEN;
   RITONAVIR; OUTCOMES; ADULTS; ATAZANAVIR/RITONAVIR
AB Background and objective: Worldwide, 50% of human immunodeficiency virus (HIV)-infected people are women. This study was to evaluate whether the safety and efficacy outcomes of three initial antiretroviral regimens (ARVs) differed by sex.
   Methods: Antiretroviral regimen naive participants from nine countries in four continents were assigned to ARVs with efavirenz (EFV) plus lamivudine-zidovudine, atazanavir (ATV) plus didanosine (ddI)-EC/emtricitabine (FTC) or EFV plus FTC-tenofovir-DF. The primary objective was to estimate the sex difference on efficacy outcome of treatment failure defined as one of the following: 1. Time to 1st of confirmed virologic failure, 2. WHO Stage 4 progression or 3. death with hazard ratio (HR) and 95% confidence interval (CI) from adjusted Cox regression models.
   Results: In all, 739 (47%) women and 832 (53%) men with HIV were evaluated. Women had higher pretreatment CD4+(182 vs 165 cells/mm(3); P < 0.001) and lower HIV-1 RNA (4.9 log10 vs 5.2 log10 copies/ml; P<0.001) compared to men. Association of sex with time to regimen failure differed by treatment arm (P=0.018). For atazanavir plus didanosine-EC plus emtricitabine, women had a longer time to treatment failure compared to men [adjusted HR (aHR) = 0.59; 95% CI 0.40-0.87]. Women were less likely to prematurely discontinue treatment prematurely (aHR=0.74; 95% CI 0.56-0.98). Women assigned to efavirenz plus lamivudine-zidovudine were more likely to have a primary safety event compared to men (aHR=1.49; 95% CI 1.18-1.88).
   Conclusion: Antiretroviral efficacy and safety differed by sex in this study. Consideration of potential effects of sex on antiretroviral outcomes is important for the design of future clinical trials and for HIV treatment guidelines.
C1 [Firnhaber, Cynthia; Faesen, Sharla] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, ZA-2050 Johannesburg, South Africa.
   [Firnhaber, Cynthia] Right To Care, Johannesburg, South Africa.
   [Smeaton, Laura M.] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA USA.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Clin Res Inst, BR-21045900 Rio De Janeiro, Brazil.
   [Lalloo, Umesh] Durban Univ Technol, Durban, South Africa.
   [Samaneka, Wadzanai; Hakim, James] Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe.
   [Infante, Rosa] IMPACTA Peru, San Miguel, Peru.
   [Rana, Aadia] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
   [Kumarasamy, Nagalingeswaran] VHS, YRGCARE Med Ctr, Madras, Tamil Nadu, India.
   [Campbell, Thomas B.] Univ Colorado, Sch Med, Dept Med, Div Infect Dis, Aurora, CO USA.
RP Firnhaber, C (corresponding author), Helen Joseph Hosp, Perth Rd, ZA-2092 Johannesburg, South Africa.
EM cindy.firnhaber@righttocare.org
OI Rana, Aadia/0000-0002-1963-528X
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI068636]; National Institute of Mental
   Health (NIMH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH); National Institute of Dental and Craniofacial Research
   (NIDCR)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Dental &
   Craniofacial Research (NIDCR); Statistical and Data Management Center of
   the AIDS Clinical Trials Group, under the National Institute of Allergy
   and Infectious Diseases [1 U01 AI068634]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR001111, UL1TR001111,
   UL1TR000457, UL1TR000124, UL1TR001111, UL1TR000457, UL1TR000457,
   UL1TR000457, UL1TR000457, UL1TR000124, UL1TR000124, UL1TR001111,
   UL1TR001111, UL1TR000457, UL1TR001111, UL1TR000457, UL1TR001111,
   UL1TR000124, UL1TR000124, UL1TR001111] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [UL1RR024156, UL1RR024156,
   UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156,
   UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156,
   UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156,
   UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156,
   UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156,
   UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156,
   UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156,
   UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156, UL1RR024156,
   UL1RR024156, UL1RR024156] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069419, U01AI069439, P30AI050410, P30AI045008, P30AI045008,
   UM1AI069463, P30AI050410, P30AI045008, P30AI050410, P30AI045008,
   P30AI045008, P30AI045008, UM1AI069417, U01AI069518, P30AI045008,
   P30AI050410, P30AI045008, U01AI032782, P30AI045008, P30AI050410,
   P30AI045008, UM1AI069399, U01AI032782, U01AI032782, P30AI045008,
   P30AI050410, U01AI032782, U01AI046370, P30AI050410, P30AI050410,
   P30AI050410, U01AI046376, P30AI045008, U01AI069439, P30AI045008,
   P30AI045008, UM1AI069463, P30AI045008, U01AI032782, P30AI050410,
   U01AI046370, UM1AI069419, P30AI045008, P30AI045008, U01AI069432,
   P30AI045008, P30AI045008, U01AI032782, P30AI045008, P30AI045008,
   U01AI032782, P30AI050410, P30AI045008, U01AI032782, P30AI045008,
   U01AI032782, UM1AI069424, P30AI045008, P30AI050410, U01AI032782,
   P30AI050410, P30AI045008, P30AI045008, U01AI069426, U01AI032782,
   U01AI069439, UM1AI069424, U01AI069421, U01AI032782, P30AI050410,
   UM1AI068634, P30AI045008, P30AI045008, P30AI045008, U01AI032782,
   U01AI032782, P30AI045008, U01AI069401, UM1AI068634, P30AI050410,
   U01AI032782, P30AI045008, UM1AI069438, U01AI068634, UM1AI068634,
   U01AI069428, P30AI045008, P30AI050410, P30AI045008, U01AI069423,
   P30AI050410, U01AI069438, P30AI045008, P30AI045008, UM1AI069534,
   P30AI050410, UM1AI069399, P30AI050410, P30AI045008, P30AI045008,
   P30AI050410, UM1AI069471, P30AI050410, UM1AI068634, P30AI045008,
   P30AI045008, P30AI050410, U01AI069513, P30AI045008, U01AI069423,
   P30AI050410, U01AI032782, P30AI045008, U01AI068634, U01AI032782,
   P30AI050410, P30AI045008, P30AI045008, U01AI069423, P30AI045008,
   U01AI032782, P30AI050410, U01AI032782, P30AI045008, U01AI069421,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, U01AI069428,
   U01AI032782, P30AI050410, UM1AI069534, UM1AI069438, P30AI045008,
   P30AI045008, P30AI050410, P30AI050410, P30AI050410, P30AI045008,
   P30AI045008, UM1AI069399, P30AI045008, UM1AI069438, P30AI050410,
   P30AI045008, UM1AI069423, P30AI045008, P30AI045008, P30AI050410,
   P30AI050410, P30AI050410, P30AI045008, U01AI032782, P30AI050410,
   P30AI045008, U01AI032782, U01AI069518, UM1AI069423, UM1AI069534,
   UM1AI069399, P30AI045008, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, U01AI046376, U01AI046370, U01AI069401, P30AI045008,
   UM1AI069423, P30AI045008, P30AI050410, P30AI045008, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, UM1AI069534, P30AI050410,
   P30AI045008, U01AI069476, P30AI050410, UM1AI068636, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, U01AI046370, P30AI050410,
   UM1AI069470, UM1AI069471, U01AI069438, U01AI069432, P30AI045008,
   P30AI050410, P30AI045008, P30AI045008, P30AI050410, UM1AI068636,
   UM1AI069463, U01AI069438, P30AI050410, P30AI045008, UM1AI069423,
   U01AI046376, P30AI050410, U01AI069474, UM1AI068634, P30AI050410,
   P30AI050410, UM1AI069471, UM1AI068636, P30AI045008, UM1AI069439,
   U01AI032782, P30AI050410, P30AI050410, UM1AI069438, P30AI045008,
   P30AI050410, U01AI069423, P30AI050410, U01AI032782, U01AI069513,
   UM1AI069423, UM1AI069439, P30AI045008, UM1AI069439, P30AI050410,
   P30AI045008, P30AI050410, UM1AI069417, P30AI045008, P30AI045008,
   P30AI050410, UM1AI069428, P30AI045008, P30AI045008, UM1AI068636,
   P30AI050410, P30AI050410, U01AI032782, P30AI045008, U01AI032782,
   UM1AI069423, U01AI032782, UM1AI069439, UM1AI069439, P30AI050410,
   UM1AI069471, P30AI045008, U01AI069432, U01AI069428, U01AI069439,
   UM1AI068634, UM1AI069424, P30AI045008, U01AI069401, UM1AI069438,
   UM1AI069424, P30AI045008, P30AI045008, P30AI050410, U01AI069401,
   P30AI045008, P30AI045008, P30AI050410, U01AI068634, P30AI050410,
   P30AI050410, P30AI045008, UM1AI069417, U01AI032782, P30AI050410,
   P30AI045008, P30AI045008, P30AI045008, P30AI050410, P30AI050410,
   U01AI069513, UM1AI068636, UM1AI069428, U01AI069426, P30AI045008,
   UM1AI069424, UM1AI069470, U01AI032782, P30AI050410, U01AI032782,
   P30AI045008, P30AI045008, U01AI069423, P30AI050410, P30AI045008,
   U01AI032782, P30AI045008, U01AI032782, P30AI050410, UM1AI069419,
   P30AI050410, U01AI046370, U01AI032782, UM1AI069471, P30AI045008,
   UM1AI069472, P30AI050410, P30AI045008, P30AI045008, P30AI050410,
   UM1AI069399, U01AI069426, U01AI069518, UM1AI069399, U01AI032782,
   U01AI032782, P30AI050410, UM1AI069463, U01AI069438, P30AI050410,
   U01AI069428, U01AI046370, P30AI045008, U01AI032782, U01AI069513,
   P30AI045008, P30AI050410, P30AI045008, P30AI045008, UM1AI069417,
   U01AI032782, P30AI050410, P30AI045008, P30AI050410, UM1AI069419,
   P30AI045008, UM1AI069419, UM1AI069439, UM1AI069439, P30AI045008,
   P30AI045008, U01AI069474, P30AI050410, P30AI045008, P30AI050410,
   P30AI045008, P30AI045008, P30AI045008, U01AI032782, P30AI050410,
   P30AI045008, UM1AI069424, UM1AI068634, P30AI045008, UM1AI069470,
   U01AI069426, P30AI045008, P30AI050410, P30AI050410, P30AI045008,
   P30AI045008, P30AI045008, P30AI050410, P30AI045008, P30AI045008,
   P30AI045008, P30AI050410, P30AI045008, UM1AI069439, U01AI032782,
   UM1AI069470, P30AI045008, P30AI050410, P30AI050410, P30AI050410,
   P30AI045008, P30AI050410, P30AI045008, P30AI045008, U01AI069421,
   P30AI050410, P30AI050410, U01AI032782, P30AI045008, P30AI050410,
   P30AI050410, P30AI045008, U01AI046376, P30AI050410, P30AI045008,
   P30AI050410, U01AI069432, P30AI050410, P30AI045008, U01AI069439,
   U01AI032782, P30AI045008, UM1AI069472, U01AI032782, P30AI045008,
   P30AI045008, P30AI050410, P30AI050410, UM1AI069399, U01AI069401,
   U01AI069423, P30AI045008, UM1AI069470, P30AI050410, P30AI045008,
   P30AI045008, UM1AI069401, UM1AI069424, P30AI045008, U01AI069474,
   U01AI069428, U01AI032782, P30AI045008, UM1AI069423, P30AI045008,
   P30AI050410, U01AI069432, P30AI045008, P30AI050410, U01AI032782,
   P30AI045008, U01AI069438, UM1AI069419, UM1AI069471, P30AI050410,
   U01AI032782, P30AI045008, P30AI050410, P30AI045008, U01AI069423,
   P30AI045008, P30AI050410, U01AI069513, U01AI069421, UM1AI068634,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, UM1AI068636,
   P30AI045008, UM1AI069463, U01AI069474, UM1AI069419, UM1AI068636,
   P30AI045008, U01AI032782, UM1AI069463, U01AI046370, UM1AI069534,
   P30AI045008, U01AI032782, P30AI045008, P30AI050410, P30AI045008,
   U01AI032782, U01AI069401, P30AI045008, P30AI045008, U01AI032782,
   P30AI050410, U01AI069476, U01AI032782, P30AI045008, U01AI032782,
   U01AI046376, P30AI045008, P30AI050410, U01AI032782, U01AI046370,
   P30AI045008, P30AI045008, U01AI032782, P30AI045008, P30AI045008,
   U01AI069423, UM1AI069472, P30AI050410, U01AI069474, P30AI050410,
   P30AI045008, P30AI045008, UM1AI069471, P30AI045008, P30AI045008,
   UM1AI069438, P30AI050410, P30AI045008, P30AI045008, UM1AI069419,
   U01AI032782, P30AI050410, P30AI050410, P30AI045008, P30AI045008,
   UM1AI069439, P30AI045008, P30AI045008, UM1AI069534, UM1AI069470,
   UM1AI069401, P30AI045008, UM1AI069463, P30AI050410, P30AI050410,
   U01AI069426, P30AI050410, P30AI050410, U01AI032782, U01AI068634,
   P30AI045008, P30AI050410, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, P30AI050410, P30AI045008, P30AI050410, UM1AI069424,
   P30AI045008, P30AI050410, U01AI032782, P30AI045008, UM1AI068636,
   P30AI045008, U01AI046376, P30AI050410, U01AI068634, P30AI045008,
   U01AI032782, U01AI032782, U01AI069476, P30AI050410, UM1AI069470,
   P30AI050410, UM1AI069438, P30AI050410, P30AI050410, P30AI050410,
   P30AI045008, P30AI045008, UM1AI069471, P30AI050410, U01AI069518,
   UM1AI069534, UM1AI069438, P30AI050410, P30AI045008, P30AI045008,
   UM1AI069534, P30AI045008, P30AI045008, U01AI032782, P30AI045008,
   U01AI032782, U01AI032782, U01AI069438, P30AI050410, U01AI032782,
   P30AI045008, P30AI045008, UM1AI069463, P30AI050410, UM1AI069401,
   P30AI050410, UM1AI069470, U01AI069476, U01AI032782, U01AI069518,
   P30AI045008, P30AI050410, P30AI050410, P30AI050410, U01AI032782,
   P30AI045008, U01AI046376, P30AI045008, P30AI050410, U01AI046370,
   P30AI050410, P30AI045008, UM1AI068634, U01AI069421, U01AI046376,
   UM1AI069423, U01AI032782, P30AI045008, P30AI045008, P30AI045008,
   U01AI032782, U01AI046376, P30AI050410, P30AI045008, UM1AI068636,
   U01AI032782, P30AI050410, P30AI050410, UM1AI069399, P30AI045008,
   U01AI032782, P30AI050410, P30AI045008] Funding Source: NIH RePORTER
FX The project was supported by Award Number UM1AI068636 NIAID and by
   National Institute of Mental Health (NIMH) and National Institute of
   Dental and Craniofacial Research (NIDCR). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NIAIDS or the National Institutes of Health.
   Employees of the NIAID participated as study team members provided
   recommendations on the study and approved the final study design. They
   had no role in data collection and analysis, decision to publish, or
   preparation of the manuscript. Boehringer Ingelheim, Bristol-Myers
   Squibb, Gilead Sciences, and GlaxoSmithKline provided study drug and
   Gilead Sciences purchased study drug that was not available. This work
   was supported by the Statistical and Data Management Center of the AIDS
   Clinical Trials Group, under the National Institute of Allergy and
   Infectious Diseases grant No. 1 U01 AI068634.
CR American College of Obstetricians and Gynecologists, 2010, OBSTET GYNECOL, V116, P1492
   Burger DM, 2002, J ACQ IMMUN DEF SYND, V29, P101
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   Castelnuovo B, 2011, JAIDS-J ACQ IMM DEF, V56, P59, DOI 10.1097/QAI.0b013e3181f5bd03
   Clark R, 2005, DRUG SAFETY, V28, P1075, DOI 10.2165/00002018-200528120-00003
   Currier JS, 2000, J ACQ IMMUN DEF SYND, V24, P316
   Currier J, 2010, ANN INTERN MED, V153, P349, DOI 10.7326/0003-4819-153-6-201009210-00002
   Da Silva B, 2008, 17 INT AIDS C AUG 3
   Division of AIDS (DAIDS), 2004, TABL GRAD SEV AD PED
   Dong BJ, 2012, AIDS, V26, P833, DOI 10.1097/QAD.0b013e328351a521
   Eluwa GI, 2012, BMC CLIN PHARM, V12, P1472
   Farley John, 2010, J Int Assoc Physicians AIDS Care (Chic), V9, P218, DOI 10.1177/1545109710371133
   Fletcher CV, 2004, J INFECT DIS, V189, P1176, DOI 10.1086/382754
   Grinsztejn B, 2011, ANTIVIR THER, V16, P1057, DOI 10.3851/IMP1872
   Harris RZ, 1996, CLIN PHARMACOL THER, V59, P429, DOI 10.1016/S0009-9236(96)90112-5
   Hawkins C, 2011, AIDS, V25, P1189, DOI 10.1097/QAD.0b013e3283471deb
   Hoffman RM, 2007, HIV CLIN TRIALS, V8, P371, DOI 10.1310/hct0806-371
   Isoherranen N, 2013, DRUG METAB DISPOS, V41, P256, DOI 10.1124/dmd.112.050245
   Johannessen A, 2011, AIDS, V25, P1225, DOI 10.1097/QAD.0b013e32834403b8
   Kumarasamy N, 2008, J WOMENS HEALTH, V17, P1471, DOI 10.1089/jwh.2007.0670
   Molina JM, 2010, JAIDS-J ACQ IMM DEF, V53, P323, DOI 10.1097/QAI.0b013e3181c990bf
   Monforte AD, 2010, AIDS, V24, P1091, DOI 10.1097/QAD.0b013e3283390db3
   Moore AL, 2003, JAIDS-J ACQ IMM DEF, V32, P452, DOI 10.1097/00126334-200304010-00017
   Nachega JB, 2006, JAIDS-J ACQ IMM DEF, V43, P78, DOI 10.1097/01.qai.0000225015.43266.46
   Nicastri E, 2005, AIDS, V19, P577, DOI 10.1097/01.aids.0000163934.22273.06
   Nicastri E, 2007, J ANTIMICROB CHEMOTH, V60, P724, DOI 10.1093/jac/dkm302
   Nielsen-Saines K, 2012, PEDIATRICS, V129, pE1525, DOI 10.1542/peds.2011-2340
   Ochieng-Ooko V, 2010, B WORLD HEALTH ORGAN, V88, P681, DOI 10.2471/BLT.09.064329
   Prins M, 2005, AIDS, V19, P357, DOI 10.1097/01.aids.0000161765.75663.27
   Safren SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104178
   Sanne I, 2005, J INFECT DIS, V191, P825, DOI 10.1086/428093
   Sekar V, 2008, 9 INT WORKSH CLIN PH
   Smith KY, 2014, CLIN INFECT DIS, V58, P555, DOI 10.1093/cid/cit747
   Squires KE, 2007, GENDER MED, V4, P294, DOI 10.1016/S1550-8579(07)80060-X
   Squires KE, 2013, AIDS RES HUM RETROV, V29, P859, DOI [10.1089/aid.2012.0292, 10.1089/AID.2012.0292]
   Squires KE, 2011, J ANTIMICROB CHEMOTH, V66, P363, DOI 10.1093/jac/dkq457
   Wester CW, 2012, AIDS RES HUM RETROV, V28, P759, DOI [10.1089/aid.2011.0303, 10.1089/AID.2011.0303]
NR 37
TC 5
Z9 5
U1 1
U2 2
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1528-4336
EI 1945-5771
J9 HIV CLIN TRIALS
JI HIV Clin. Trials
PD MAY
PY 2015
VL 16
IS 3
BP 89
EP 99
DI 10.1179/1528433614Z.0000000013
PG 11
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA CK1WV
UT WOS:000356000500001
PM 25979186
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Luz, PM
   De Boni, R
   Fittipaldi, J
   Cardoso, SW
   Grinsztejn, B
   Veloso, V
AF Perazzo, H.
   Luz, P. M.
   De Boni, R.
   Fittipaldi, J.
   Cardoso, S. W.
   Grinsztejn, B.
   Veloso, V.
TI ALCOHOLIC LIVER DISEASE AND LIVER CANCER AS PUBLIC HEALTH ISSUES IN THE
   BURDEN OF LIVER-RELATED MORTALITY IN THE LAST 15 YEARS IN BRAZIL
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 50th International Liver Congress of the
   European-Association-for-the-Study-of-the-Liver
CY APR 22-26, 2015
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Perazzo, H.; Luz, P. M.; De Boni, R.; Fittipaldi, J.; Cardoso, S. W.; Grinsztejn, B.; Veloso, V.] Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, Brazil.
EM perazzohugo@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2015
VL 62
SU 2
MA P1249
BP S826
EP S826
DI 10.1016/S0168-8278(15)31444-6
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CT5EL
UT WOS:000362830900439
DA 2020-11-24
ER

PT J
AU Cortes, FH
   Passaes, CPB
   Bello, G
   Teixeira, SLM
   Vorsatz, C
   Babic, D
   Sharkey, M
   Grinsztejn, B
   Veloso, V
   Stevenson, M
   Morgado, MG
AF Cortes, Fernanda H.
   Passaes, Caroline P. B.
   Bello, Gonzalo
   Teixeira, Sylvia L. M.
   Vorsatz, Carla
   Babic, Dunja
   Sharkey, Mark
   Grinsztejn, Beatriz
   Veloso, Valdilea
   Stevenson, Mario
   Morgado, Mariza G.
TI HIV Controllers With Different Viral Load Cutoff Levels Have Distinct
   Virologic and Immunologic Profiles
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-1; elite controllers; viral load blips; ongoing replication; immune
   activation and microbial translocation; immune response
ID T-CELL RESPONSES; HUMAN-IMMUNODEFICIENCY-VIRUS; ELITE CONTROLLERS;
   IMMUNE ACTIVATION; RNA LEVELS; INFECTION; INDIVIDUALS; VIREMIA;
   REPLICATION; ASSOCIATION
AB Background: The mechanisms behind natural control of HIV replication are still unclear, and several studies pointed that elite controllers (ECs) are a heterogeneous group.
   Methods: We performed analyses of virologic, genetic, and immunologic parameters of HIV-1 controllers groups: (1) ECs (viral load, <80 copies/mL); (2) ebbing elite controllers (EECs; transient viremia/blips); and viremic controllers (VCs; detectable viremia, <5000 copies/mL). Untreated noncontrollers (NCs), patients under suppressive highly active antiretroviral therapy (HAART), and HIV-1-negative individuals were analyzed as controls.
   Results: Total and integrated HIV-1 DNA for EC were significantly lower than for NC and HAART groups. 2-LTR circles were detected in EEC (3/5) and VC (6/7) but not in EC. Although EC and EEC maintain normal T-cell counts over time, some VC displayed negative CD4(+) T-cell slopes. VC and EEC showed a higher percentage of activated CD8(+) T cells and microbial translocation than HIV-1-negative controls. EC displayed a weaker Gag/Nef IFN-gamma T-cell response and a significantly lower proportion of anti-HIV IgG antibodies than EEC, VC, and NC groups.
   Conclusion: Transient/persistent low-level viremia in HIV controllers may have an impact on immunologic and virologic profiles. Classified HIV controller patients taking into account their virologic profile may decrease the heterogeneity of HIV controllers cohorts, which may help to clarify the mechanisms associated to the elite control of HIV.
C1 [Cortes, Fernanda H.; Passaes, Caroline P. B.; Bello, Gonzalo; Teixeira, Sylvia L. M.; Morgado, Mariza G.] Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, BR-21040900 Rio De Janeiro, Brazil.
   [Vorsatz, Carla; Grinsztejn, Beatriz; Veloso, Valdilea] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin DST AIDS, BR-21045900 Rio De Janeiro, Brazil.
   [Babic, Dunja; Sharkey, Mark; Stevenson, Mario] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
RP Morgado, MG (corresponding author), Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, Av Brasil 4365,Leonidas Deane Bldg,Room 413, BR-21040900 Rio De Janeiro, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Cortes, Fernanda/AAF-9254-2020; Passaes,
   Caroline/AAH-3392-2020; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Passaes, Caroline/0000-0002-0813-2521; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793
FU Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPqNational Council for Scientific and Technological
   Development (CNPq) [480875/2010-33]; Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro-FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/103.095/2011, E-26/100.299/2011]; National Institutes of Allergy
   and Infectious Diseases of the National Institutes of Health [U19
   AI096109]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P30AI073961, P30AI073961, U19AI096109, U19AI096109,
   P30AI073961, U19AI096109, P30AI073961, P30AI073961, P30AI073961,
   U19AI096109, P30AI073961, P30AI073961, P30AI073961, P30AI073961,
   UM1AI069476, P30AI073961, P30AI073961, U19AI096109, P30AI073961,
   P30AI073961, U19AI096109, U19AI096109, P30AI073961, U19AI096109,
   P30AI073961, P30AI073961, P30AI073961, U19AI096109, UM1AI069476,
   P30AI073961, P30AI073961, P30AI073961, P30AI073961, U19AI096109,
   P30AI073961, UM1AI069476, P30AI073961, P30AI073961, P30AI073961,
   U19AI096109, P30AI073961, U19AI096109, P30AI073961, P30AI073961,
   P30AI073961, P30AI073961, P30AI073961, P30AI073961, P30AI073961,
   U19AI096109, U19AI096109, U19AI096109, U19AI096109, U19AI096109,
   U19AI096109, U19AI096109, P30AI073961, P30AI073961, U19AI096109,
   P30AI073961, U19AI096109, P30AI073961, U19AI096109, U19AI096109,
   U19AI096109, U19AI096109, P30AI073961, P30AI073961, U19AI096109,
   P30AI073961, P30AI073961, P30AI073961, U19AI096109, U19AI096109,
   U19AI096109, U19AI096109, P30AI073961, U19AI096109, UM1AI069476,
   U19AI096109, P30AI073961, UM1AI069476, U19AI096109, P30AI073961,
   P30AI073961, UM1AI069476, P30AI073961, P30AI073961, U19AI096109,
   P30AI073961, P30AI073961, P30AI073961, P30AI073961, UM1AI069476,
   P30AI073961, U19AI096109, U19AI096109, U19AI096109, P30AI073961,
   P30AI073961, P30AI073961, P30AI073961, U19AI096109, U19AI096109,
   P30AI073961, P30AI073961, U19AI096109, P30AI073961, P30AI073961,
   P30AI073961, U19AI096109, P30AI073961, U19AI096109, P30AI073961,
   U19AI096109, P30AI073961, P30AI073961, P30AI073961, P30AI073961,
   P30AI073961, P30AI073961, U19AI096109, P30AI073961, P30AI073961,
   P30AI073961, U19AI096109, U19AI096109, U19AI096109, P30AI073961,
   U19AI096109, UM1AI069476, U19AI096109, P30AI073961, U19AI096109,
   U19AI096109, U19AI096109, P30AI073961, P30AI073961, U19AI096109,
   P30AI073961, P30AI073961] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [R01MH093306, R01MH093306, R01MH093306,
   R01MH093306, R01MH093306] Funding Source: NIH RePORTER
FX Supported by Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPq (grant number 480875/2010-33); by Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro-FAPERJ (grant numbers
   E-26/103.095/2011 and E-26/100.299/2011 to C.P.B.P.); and by National
   Institutes of Allergy and Infectious Diseases of the National Institutes
   of Health (grant number U19 AI096109 to M. Stevenson).
CR Andrade A, 2008, CLIN INFECT DIS, V46, pE78, DOI 10.1086/529387
   [Anonymous], 1995, EP INF COMP PROGR VE
   Bello G, 2009, J MED VIROL, V81, P1681, DOI 10.1002/jmv.21565
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   Boufassa F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018726
   Calarota SA, 2008, J IMMUNOL, V180, P5907, DOI 10.4049/jimmunol.180.9.5907
   Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0
   Cortes FH, 2013, VACCINE, V31, P1106, DOI 10.1016/j.vaccine.2012.12.023
   Emu B, 2008, J VIROL, V82, P5398, DOI 10.1128/JVI.02176-07
   Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767
   Graf EH, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001300
   Hatano H, 2009, J VIROL, V83, P329, DOI 10.1128/JVI.01763-08
   Hayashida T, 2008, AIDS RES HUM RETROV, V24, P495, DOI 10.1089/aid.2007.0150
   Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Karlsson AC, 2004, AIDS, V18, P981, DOI 10.1097/00002030-200404300-00005
   Klatt NR, 2013, IMMUNOL REV, V254, P326, DOI 10.1111/imr.12065
   Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188
   Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d
   Lecuroux C, 2014, J VIROL, V88, P176, DOI 10.1128/JVI.02098-13
   Madec Y, 2005, AIDS, V19, P2001, DOI 10.1097/01.aids.0000194134.28135.cd
   Teixeira SLM, 2009, INFECT GENET EVOL, V9, P638, DOI 10.1016/j.meegid.2009.03.007
   Mens H, 2010, J VIROL, V84, P12971, DOI 10.1128/JVI.00387-10
   Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397
   Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010
   O'Connell KA, 2010, J VIROL, V84, P7018, DOI 10.1128/JVI.00548-10
   Okulicz JF, 2009, J INFECT DIS, V200, P1714, DOI 10.1086/646609
   Owen RE, 2010, AIDS, V24, P1095, DOI 10.1097/QAD.0b013e3283377a1e
   Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874
   Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786
   Pereyra F, 2012, AIDS, V26, P2409, DOI 10.1097/QAD.0b013e32835a9950
   Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271
   Pereyra F, 2009, J INFECT DIS, V200, P984, DOI 10.1086/605446
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Saez-Cirion A, 2009, J IMMUNOL, V182, P7828, DOI 10.4049/jimmunol.0803928
   Sedaghat AR, 2009, CLIN INFECT DIS, V49, P1763, DOI 10.1086/648081
   Sharkey M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001303
   Teixeira SLM, 2014, GENES IMMUN, V15, P256, DOI 10.1038/gene.2014.14
   Tomescu C, 2012, AIDS, V26, P1869, DOI 10.1097/QAD.0b013e32835861b0
   Velasco-de-Castro CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087622
   Wendel SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055525
   Williams LD, 2011, J VIROL, V85, P2316, DOI 10.1128/JVI.01476-10
NR 43
TC 24
Z9 24
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 1
PY 2015
VL 68
IS 4
BP 377
EP 385
DI 10.1097/QAI.0000000000000500
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CE1RC
UT WOS:000351588600008
PM 25564106
OA Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU Lippman, SA
   Koester, KA
   Amico, KR
   Lama, JR
   Fernandes, NM
   Gonzales, P
   Grinsztejn, B
   Liu, A
   Buchbinder, S
   Koblin, BA
AF Lippman, Sheri A.
   Koester, Kimberly A.
   Amico, K. Rivet
   Lama, Javier R.
   Fernandes, Nilo Martinez
   Gonzales, Pedro
   Grinsztejn, Beatriz
   Liu, Al
   Buchbinder, Susan
   Koblin, Beryl A.
TI Client and Provider Perspectives on New HIV Prevention Tools for MSM in
   the Americas
SO PLOS ONE
LA English
DT Article
ID MALE CIRCUMCISION; MEN; SEX; BRAZIL; RISK; INFECTION; AIDS; PROPHYLAXIS;
   HIV/AIDS; ACCESS
AB Men who have sex with men (MSM) in the Americas require targeted, combination HIV prevention approaches. We solicited client and provider perspectives on emerging prevention interventions including HIV pre-exposure prophylaxis (PrEP) and HIV self-tests through focus groups and in-depth interviews with 130 MSM and 41 providers across four sites: New York, San Francisco, Lima, and Rio de Janeiro. Among the MSM participants, we identified three prevention typologies: non-condom users, inconsistent condom users, and consistent condom users. Northern and Southern MSM differed in the variety of harm reduction strategies utilized: where U.S. MSM relied on condom use as well as disclosure and seroadaptive behaviors for prevention, condom use without disclosure or serostatus discussions was the norm in South America. Interest in new prevention technologies was shaped by the social context. U.S. MSM preferences differed by typology, such that non-condom users were interested in taking PrEP and using home HIV tests. MSM in Brazil, regardless of typology, were interested in exploring new prevention options. MSM in Peru demonstrated moderate interest but were less comfortable with adopting new strategies. MSM and providers' opinions differed substantially with respect to new prevention options. Across sites, most providers were reticent to engage with new prevention options, though some NGO-based providers were more supportive of exploring new prevention tools. Both clients and providers will need to be engaged in developing integrated prevention strategies for MSM.
C1 [Lippman, Sheri A.; Koester, Kimberly A.] Univ Calif San Francisco, Dept Med, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.
   [Amico, K. Rivet] Univ Connecticut, Ctr Hlth Intervent & Prevent, Storrs, CT USA.
   [Lama, Javier R.; Gonzales, Pedro] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Fernandes, Nilo Martinez; Grinsztejn, Beatriz] Fiocruz MS, HIV AIDS Clin Res Ctr, BR-21045900 Rio De Janeiro, Brazil.
   [Liu, Al; Buchbinder, Susan] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [Koblin, Beryl A.] New York Blood Ctr, Lab Infect Dis Prevent, New York, NY 10021 USA.
RP Lippman, SA (corresponding author), Univ Calif San Francisco, Dept Med, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.
EM sheri.lippman@ucsf.edu
RI /AAE-4700-2020
OI Amico, K Rivet/0000-0002-4458-6934; Lippman, Sheri/0000-0003-3152-9372
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI083060]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, U01AI069476, R01AI083060, UM1AI069476, U01AI069476,
   UM1AI069476, U01AI069476, R01AI083060, UM1AI069476, UM1AI069476,
   R01AI083060, UM1AI069476, R01AI083060] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246] Funding Source: NIH RePORTER
FX The data collection for this study was funded by the National Institute
   of Allergy and Infectious Diseases R01AI083060. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ackers ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034972
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Balaji AB, 2013, AIDS, V27, P269, DOI 10.1097/QAD.0b013e32835ad489
   Berkman A, 2005, AM J PUBLIC HEALTH, V95, P1162, DOI 10.2105/AJPH.2004.054593
   Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6
   Caceres C, 2014, POLICY DIALOGUE ENHA, pA256
   California HIV/AIDS Policy Research Centers, 2014, US HIV OV THE COUNT
   Carballo-Dieguez A, 2011, J SEX RES
   Carballo-Dieguez A, 2012, AIDS BEHAV, V16, P1753, DOI 10.1007/s10461-012-0274-2
   Celum C, 2013, JAIDS-J ACQ IMM DEF, V63, pS213, DOI 10.1097/QAI.0b013e3182986f3a
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cohen SE, 2014, C RETR OPP INF CROI
   Galvao J, 2005, AM J PUBLIC HEALTH, V95, P1110, DOI 10.2105/AJPH.2004.044313
   Grangeiro A, 2009, REV PANAM SALUD PUBL, V26, P87, DOI 10.1590/S1020-49892009000700013
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hirshfield S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046252
   Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687
   Koblin BA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070413
   Kong XR, 2012, AM J EPIDEMIOL, V176, P875, DOI 10.1093/aje/kws179
   Kurth Ann E, 2011, Curr HIV/AIDS Rep, V8, P62, DOI 10.1007/s11904-010-0063-3
   Lippman SA, 2014, CAD SAUDE PUBLICA, V30, P724, DOI 10.1590/0102-311X00008913
   Liu AY, 2013, JAIDS-J ACQ IMM DEF, V64, P87, DOI 10.1097/QAI.0b013e31828f097a
   MacKellar DA, 2011, SEX TRANSM DIS, V38, P419, DOI 10.1097/OLQ.0b013e31820369dd
   Marcus JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081997
   McFarland W, 2012, AIDS BEHAV, V16, P121, DOI 10.1007/s10461-011-9936-8
   Miles M. B., 1994, QUALITATIVE DATA ANA
   Nagaraj S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-181
   Nunn AS, 2009, HEALTH AFFAIR, V28, P1103, DOI 10.1377/hlthaff.28.4.1103
   Pai NP, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001414
   Pines HA, 2013, J ACQUIR IMMUNE DEFI
   Sanchez J, 2011, AIDS, V25, P519, DOI 10.1097/QAD.0b013e328340fd81
   Sanchez J, 2009, JAIDS-J ACQ IMM DEF, V51, pS47, DOI 10.1097/QAI.0b013e3181a2671d
   Sandoval C, 2013, GLOBALIZATION HEALTH, V9, DOI 10.1186/1744-8603-9-23
   Smith JH, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-47
   Snowden JM, 2009, SEX TRANSM INFECT, V85, P469, DOI 10.1136/sti.2009.036269
   Sturges JE, 2004, QUAL RES, V4, P107, DOI DOI 10.1177/1468794104041110
   Sullivan PS, 2012, LANCET, V380, P388, DOI 10.1016/S0140-6736(12)60955-6
   Tang EC, 2014, AIDS RES HUM RETROVI
   UNAIDS, 2010, GLOB REP UNAIDS REP, DOI [10.1189/jlb.0811394, DOI 10.1189/JLB.0811394]
   US Food and Drug Administration (USFDA), 2012, ORAQUICK IN HOM HIV
   Vallabhaneni S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055397
   Vallabhaneni S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045718
   de Castro CAV, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-224
NR 43
TC 9
Z9 9
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 31
PY 2015
VL 10
IS 3
AR e0121044
DI 10.1371/journal.pone.0121044
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CE8IF
UT WOS:000352084800033
PM 25826246
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Cerda, R
   Perez, F
   Domingues, RMSM
   Luz, PM
   Grinsztejn, B
   Veloso, VG
   Caffe, S
   Francke, JA
   Freedberg, KA
   Ciaranello, AL
AF Cerda, Rodrigo
   Perez, Freddy
   Domingues, Rosa Maria S. M.
   Luz, Paula M.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Caffe, Sonja
   Francke, Jordan A.
   Freedberg, Kenneth A.
   Ciaranello, Andrea L.
TI Prenatal Transmission of Syphilis and Human Immunodeficiency Virus in
   Brazil: Achieving Regional Targets for Elimination
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE congenital syphilis; disease elimination; human immunodeficiency virus;
   infectious disease transmission; mathematical models; vertical
   transmission
ID MOTHER-TO-CHILD; HIV TRANSMISSION; CONGENITAL-SYPHILIS; ANTIRETROVIRAL
   THERAPY; COST-EFFECTIVENESS; RANDOMIZED-TRIAL; PREGNANT-WOMEN;
   SOUTH-AFRICA; SAO-PAULO; PREVENTION
AB Background. The Pan-American Health Organization has called for reducing (1) human immunodeficiency virus (HIV) mother-to-child transmission (MTCT) to <= 0.30 infections/1000 live births (LB), (2) HIV MTCT risk to <= 2.0%, and (3) congenital syphilis (CS) incidence to <= 0.50/1000 LB in the Americas by 2015.
   Methods. Using published Brazilian data in amathematical model, we simulated a cohort of pregnant women from antenatal care (ANC) through birth. We investigated 2 scenarios: "current access" (89.1% receive one ANC syphilis test and 41.1% receive 2; 81.7% receive one ANC HIV test and 18.9% receive birth testing; if diagnosed, 81.0% are treated for syphilis and 87.5% are treated for HIV) and "ideal access" (95% of women undergo 2 HIV and syphilis screenings; 95% receive appropriate treatment). We conducted univariate and multivariate sensitivity analyses on key inputs.
   Results. With current access, we projected 2.95 CS cases/1000 LB, 0.29 HIV infections/1000 LB, 7.1% HIV MTCT risk, and 11.11 intrauterine fetal demises (IUFD)/1000 pregnancies, with significant regional variation. With ideal access, we projected improved outcomes: 1.00 CS cases/1000 LB, 0.10 HIV infections/1000 LB, HIV MTCT risk of 2.4%, and 10.65 IUFD/1000 pregnancies. Increased testing drove the greatest improvements. Even with ideal access, only HIV infections/1000 LB met elimination goals. Achieving all targets required testing and treatment >95% and reductions in prevalence and incidence of HIV and syphilis.
   Conclusions. Increasing access to care and HIV and syphilis antenatal testing will substantially reduce HIV and syphilis MTCT in Brazil. In addition, regionally tailored interventions reducing syphilis incidence and prevalence and supporting HIV treatment adherence are necessary to completely meet elimination goals.
C1 [Cerda, Rodrigo; Francke, Jordan A.; Freedberg, Kenneth A.] Pan Amer Hlth Org, Div Gen Med, Washington, DC USA.
   [Perez, Freddy; Caffe, Sonja] Pan Amer Hlth Org, Communicable Dis & Hlth Anal Dept, HIV Hepatitis TB & Sexually Transmitted Infect Un, Washington, DC USA.
   [Domingues, Rosa Maria S. M.; Luz, Paula M.; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Francke, Jordan A.; Freedberg, Kenneth A.; Ciaranello, Andrea L.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Dept Med, Boston, MA 02114 USA.
   [Freedberg, Kenneth A.; Ciaranello, Andrea L.] Harvard Univ, Sch Publ Hlth, Div Infect Dis, Boston, MA 02115 USA.
   [Freedberg, Kenneth A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
RP Ciaranello, AL (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, 50 Staniford St,Room 936, Boston, MA 02114 USA.
EM aciaranello@partners.org
RI Domingues, Rosa/AAS-3606-2020; Perez, Freddy/AAN-3893-2020
OI Domingues, Rosa/0000-0001-5722-8127; 
FU National Institutes of Health (NIH), including the National Institute of
   Allergy and Infectious Diseases (Harvard Center for AIDS Research) [K01
   AI078754, R01 HD079214, R01 AI058736, U01 AI069911]; IMPAACT network;
   Massachusetts General Hospital Executive Committee on Research; French
   Ministry of Foreign Affairs; National Council of Technological and
   Scientific DevelopmentNational Council for Scientific and Technological
   Development (CNPq); Research Funding Agency of the State of Rio de
   Janeiro; National Institute of Allergy and Infectious Diseases
   (NIAID)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01 AI068632]; Eunice Kennedy Shriver
   National Institute of Child Health and Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); National Institute of Mental Health
   (NIMH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [AI068632]; Statistical and Data Analysis Center at Harvard
   School of Public Health, under the National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [5 U01 AI41110]; Pediatric AIDS
   Clinical Trials Group [1 U01 AI068616]; IMPAACT Group; NIAIDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); NICHD International and Domestic Pediatric and
   Maternal HIV Clinical Trials Network - NICHDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [N01-DK-9-001/HHSN267200800001C]
FX This work was supported by the National Institutes of Health (NIH),
   including the National Institute of Allergy and Infectious Diseases
   (Harvard Center for AIDS Research and grant numbers K01 AI078754, R01
   HD079214, R01 AI058736, U01 AI069911); the IMPAACT network*; and the
   Massachusetts General Hospital Executive Committee on Research. F. P. is
   funded through a secondment award to PAHO from the French Ministry of
   Foreign Affairs. B. G. and P. M. L. acknowledge funding from the
   National Council of Technological and Scientific Development and the
   Research Funding Agency of the State of Rio de Janeiro.; Overall support
   for the International Maternal Pediatric Adolescent AIDS Clinical Trials
   Group (IMPAACT) was provided by the National Institute of Allergy and
   Infectious Diseases (NIAID) (grant number U01 AI068632); the Eunice
   Kennedy Shriver National Institute of Child Health and Human Development
   (NICHD); and the National Institute of Mental Health (NIMH) (grant
   number AI068632). This work was also supported by the Statistical and
   Data Analysis Center at Harvard School of Public Health, under the
   National Institute of Allergy and Infectious Diseases cooperative
   agreement #5 U01 AI41110 with the Pediatric AIDS Clinical Trials Group
   and #1 U01 AI068616 with the IMPAACT Group. Support of the sites was
   provided by the NIAID and the NICHD International and Domestic Pediatric
   and Maternal HIV Clinical Trials Network funded by NICHD (contract
   number N01-DK-9-001/HHSN267200800001C).
CR 50th Directing Council, 2010, STRAT PLAN ACT EL MO
   Alarcon JO, 2003, AIDS, V17, P613, DOI 10.1097/00002030-200303070-00017
   Alcantara KC, 2012, J CLIN VIROL, V54, P15, DOI 10.1016/j.jcv.2012.01.011
   Alexander JM, 1999, OBSTET GYNECOL, V93, P5, DOI 10.1016/S0029-7844(98)00338-X
   Barker PM, 2011, JAIDS-J ACQ IMM DEF, V56, pE45, DOI 10.1097/QAI.0b013e3181fdbf20
   Blandford JM, 2007, SEX TRANSM DIS, V34, pS61, DOI 10.1097/01.olq.0000258314.20752.5f
   Blencowe H, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S9
   Branson B.M., 2005, RAPID HIV TESTING 20
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude, 2007, PROGR NAC DST AIDS P
   Cavalcante MS, 2008, REV BRAS SAUDE MATER, V8, P7
   Chigwedere P, 2008, AIDS RES HUM RETROV, V24, P827, DOI 10.1089/aid.2007.0291
   Ciaranello AL, 2013, CLIN INFECT DIS, V56, P430, DOI 10.1093/cid/cis858
   Ciaranello AL, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001156
   Ciaranello AL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020224
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Cowan FA, 2008, AIDS, V22, P193, DOI 10.1097/QAD.0b013e3282f2a939
   Gouveia PAD, 2013, TROP MED INT HEALTH, V18, P276, DOI 10.1111/tmi.12042
   Dabis F, 2005, AIDS, V19, P309
   Soeiro CMD, 2011, REV SOC BRAS MED TRO, V44, P537, DOI 10.1590/S0037-86822011000500001
   de Vincenzi I, 2010, JAIDS-J ACQ IMM DEF, V54, P533, DOI 10.1097/QAI.0b013e3181e36634
   Delicio AM, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-35
   Departamento de DST; AIDS e Hepatites Virais, 2012, B EPIDEMIOLOGICO
   Elizabeth Glaser Pediatric AIDS Foundation, 2011, MAL INV PMTCT REACH
   Fawzi WW, 2002, AIDS, V16, P1935, DOI 10.1097/00002030-200209270-00011
   Geusau A, 2005, INT J STD AIDS, V16, P722, DOI 10.1258/095646205774763207
   Gomez G, 2013, UNTREATED MATERNAL S
   Hacker MA, 2007, CAD SAUDE PUBLICA, V23, pS345, DOI 10.1590/S0102-311X2007001500003
   Kesho Bora Study Group, 2011, LANCET INFECT DIS, V1, P159
   Kilewo C, 2009, JAIDS-J ACQ IMM DEF, V52, P406, DOI 10.1097/QAI.0b013e3181b323ff
   Konopka CK, 2010, REV BRAS GINECOL OBS, V32, P184, DOI 10.1590/S0100-72032010000400006
   Kreitchmann R, 2012, AIDS PATIENT CARE ST, V26, P486, DOI 10.1089/apc.2012.0013
   Leroy V, 2002, AIDS, V16, P631, DOI 10.1097/00002030-200203080-00016
   Lumbiganon P, 2002, INT J STD AIDS, V13, P486, DOI 10.1258/09564620260079653
   Lynn WA, 2004, LANCET INFECT DIS, V4, P456, DOI 10.1016/S1473-3099(04)01061-8
   Mabey DC, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001233
   Matida LH, 2005, AIDS, V19, pS37, DOI 10.1097/01.aids.0000191489.59112.13
   Matida LH, 2011, JAIDS-J ACQ IMM DEF, V57, pS164, DOI 10.1097/QAI.0b013e31821e9d13
   Ministerio da Saude. Datasus. Brasilia-DF: Departamento de Informatica do SUS, 2012, DAT
   Ministerio da Saude Departamento de DST AIDS e Hepatites Virais, 2012, B EP SIF
   Mwapasa V, 2006, AIDS, V20, P1869, DOI 10.1097/01.aids.0000244206.41500.27
   Nachega JB, 2012, AIDS, V26, P2039, DOI 10.1097/QAD.0b013e328359590f
   Okie S, 2006, NEW ENGL J MED, V354, P1977, DOI 10.1056/NEJMp068069
   Pan American Health Organization, 2014, EL MOTH TO CHILD TRA
   Pan American Health Organization, 2011, 2010 SIT AN EL MOTH
   Pan American Health Organization, 2013, 2012 PROGR REP EL MO
   Pan-American Health Organization, 2009, EP PROF NEGL DIS OTH
   Peeling RW, 2004, B WORLD HEALTH ORGAN, V82, P439
   Potter D, 2008, JAIDS-J ACQ IMM DEF, V47, P79, DOI 10.1097/QAI.0b013e31815d2f71
   Saba J, 2002, LANCET, V359, P1178
   Schmid G, 2004, B WORLD HEALTH ORGAN, V82, P402
   Shapiro RL, 2010, NEW ENGL J MED, V362, P2282, DOI 10.1056/NEJMoa0907736
   Domingues RMSM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0837-8
   Domingues RMSM, 2014, REV SAUDE PUBL, V48, P766, DOI 10.1590/S0034-8910.2014048005114
   Szwarcwald CL, 2008, BRAZ J INFECT DIS, V12, P167, DOI 10.1590/S1413-86702008000300002
   Szwarcwald CL, 2007, J BRAS DOENCAS SEX T, V19, P6
   Thior I, 2006, JAMA-J AM MED ASSOC, V296, P794, DOI 10.1001/jama.296.7.794
   Victora CG, 2011, LANCET, V377, P2042, DOI 10.1016/S0140-6736(11)60055-X
   WHO, 2015, MOTH TO CHILD TRANSM
   World Health Organization, 2011, PROGR REP 2011 GLOB
   World Health Organization, 2010, CHOOSING INT COST EF
   World Health Organization (WHO), 2007, GLOB EL CONG SYPH RA
NR 61
TC 8
Z9 8
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD SPR
PY 2015
VL 2
IS 2
DI 10.1093/ofid/ofv073
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CX6BM
UT WOS:000365786200005
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Luz, PM
   Belaunzaran-Zamudio, PF
   Crabtree-Ramirez, B
   Caro-Vega, Y
   Hoces, D
   Rebeiro, PF
   Blevins, M
   Pape, JW
   Cortes, CP
   Padgett, D
   Cahn, P
   Veloso, VG
   McGowan, CC
   Grinsztejn, B
   Shepherd, BE
AF Luz, Paula M.
   Belaunzaran-Zamudio, Pablo F.
   Crabtree-Ramirez, Brenda
   Caro-Vega, Yanink
   Hoces, Daniel
   Rebeiro, Peter F.
   Blevins, Meridith
   Pape, Jean W.
   Cortes, Claudia P.
   Padgett, Denis
   Cahn, Pedro
   Veloso, Valdilea G.
   McGowan, Catherine C.
   Grinsztejn, Beatriz
   Shepherd, Bryan E.
CA Carribbean Cent South Amer Network
TI CD4 Response Up to 5 Years After Combination Antiretroviral Therapy in
   Human Immunodeficiency Virus-Infected Patients in Latin America and the
   Caribbean
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE cART; cohort; combination antiretroviral therapy; HIV/AIDS; immune
   recovery; inverse probability of censoring weights; Latin America and
   the Caribbean
ID T-CELL COUNT; INCOME COUNTRIES; EXPERIENCE; RECOVERY; OUTCOMES; PROGRAM;
   COHORT
AB We describe CD4 counts at 6-month intervals for 5 years after combination antiretroviral therapy initiation among 12 879 antiretroviral-naive human immunodeficiency virus-infected adults from Latin America and the Caribbean. Median CD4 counts increased from 154 cells/mm(3) at baseline (interquartile range [IQR], 60-251) to 413 cells/mm(3) (IQR, 234-598) by year 5.
C1 [Luz, Paula M.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
   [Belaunzaran-Zamudio, Pablo F.; Crabtree-Ramirez, Brenda; Caro-Vega, Yanink] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City, DF, Mexico.
   [Hoces, Daniel] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Rebeiro, Peter F.; Blevins, Meridith; McGowan, Catherine C.; Shepherd, Bryan E.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Pape, Jean W.] Weill Cornell Med Coll, Div Infect Dis, Dept Med, New York, NY USA.
   [Cortes, Claudia P.] Univ Chile, Sch Med, Santiago, Chile.
   [Padgett, Denis] Univ Nacl Autonoma Honduras, Tegucigalpa, Honduras.
   [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM paula.luz@ini.fiocruz.br
RI Belaunzaran-Zamudio, Pablo F./T-4218-2019; Cortes,
   Claudia/AAF-7326-2020; Belaunzaran-Zamudio, Pablo Francisco/T-4085-2019
OI Cortes, Claudia/0000-0001-9101-9783; Luz, Paula/0000-0001-9746-719X;
   Crabtree-Ramirez, Brenda/0000-0002-2587-1123; Hoces,
   Daniel/0000-0002-1451-5166; Rebeiro, Peter/0000-0003-1951-9104;
   Belaunzaran, Pablo/0000-0003-4775-4734
FU National Institute of Allergy and Infectious Diseases as part of the
   International Epidemiologic Databases to Evaluate AIDS [U01 AI069923];
   National Council of Technological and Scie.jpegic Development; Research
   Funding Agency of the State of Rio de Janeiro; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   UM1AI069476, U01AI069421, U01AI069476, UM1AI069476, UM1AI069476,
   U01AI069421, UM1AI069476, U01AI069476, U01AI069421, UM1AI069476,
   UM1AI069421, UM1AI069421, UM1AI069421, UM1AI069476, U01AI069421,
   UM1AI069421, UM1AI069421, UM1AI069421, UM1AI069421, U01AI069421,
   UM1AI069421, UM1AI069476, U01AI069476, U01AI069476] Funding Source: NIH
   RePORTER
FX This work was funded by the National Institute of Allergy and Infectious
   Diseases as part of the International Epidemiologic Databases to
   Evaluate AIDS (grant U01 AI069923). P. M. L. and B. G. acknowledge
   funding from the National Council of Technological and Scie.jpegic
   Development and the Research Funding Agency of the State of Rio de
   Janeiro.
CR Achhra AC, 2011, CURR OPIN HIV AIDS, V6, P258, DOI 10.1097/COH.0b013e3283476c72
   Bastard M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-27
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164
   Garcia F, 2004, JAIDS-J ACQ IMM DEF, V36, P702, DOI 10.1097/00126334-200406010-00007
   Hunt PW, 2003, AIDS, V17, P1907, DOI 10.1097/00002030-200309050-00009
   Khanna N, 2008, CLIN INFECT DIS, V47, P1093, DOI 10.1086/592113
   Le Moing V, 2007, HIV MED, V8, P156, DOI 10.1111/j.1468-1293.2007.00446.x
   Lok JJ, 2010, AIDS, V24, P1867, DOI 10.1097/QAD.0b013e32833adbcf
   Luz PM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093039
   McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073
   Nash D, 2008, AIDS, V22, P2291, DOI 10.1097/QAD.0b013e3283121ca9
   Wolff MJ, 2010, JAIDS-J ACQ IMM DEF, V55, P368, DOI 10.1097/QAI.0b013e3181eb4fb9
   Wright ST, 2013, HIV MED, V14, P208, DOI 10.1111/j.1468-1293.2012.01053.x
NR 14
TC 6
Z9 6
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD SPR
PY 2015
VL 2
IS 2
DI 10.1093/ofid/ofv079
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CX6BM
UT WOS:000365786200030
PM 26180829
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Pacheco, AG
   Grinsztejn, B
   da Fonseca, MDM
   Moreira, RI
   Veloso, VG
   Friedman, RK
   Santini-Oliveira, M
   Cardoso, SW
   Falcao, M
   Mill, JG
   Bensenor, I
   Lotufo, P
   Chor, D
AF Pacheco, Antonio G.
   Grinsztejn, Beatriz
   da Fonseca, Maria de Jesus M.
   Moreira, Ronaldo I.
   Veloso, Valdilea G.
   Friedman, Ruth K.
   Santini-Oliveira, Marilia
   Cardoso, Sandra W.
   Falcao, Melissa
   Mill, Jose G.
   Bensenor, Isabela
   Lotufo, Paulo
   Chor, Dora
TI Traditional Risk Factors Are More Relevant than HIV-Specific Ones for
   Carotid Intima-Media Thickness (cIMT) in a Brazilian Cohort of
   HIV-Infected Patients
SO PLOS ONE
LA English
DT Article
ID CARDIOVASCULAR RISK; HAART ERA; ATHEROSCLEROSIS; PROGRESSION; MORTALITY;
   DISEASE; EVENTS; DEATH; EQUATION
AB Background
   Combination antiretroviral therapy (cART) had a dramatic impact on the mortality profile in human immunodeficiency virus (HIV) infected individuals and increased their life-expectancy. Conditions associated with the aging process have been diagnosed more frequently among HIV-infected patients, particularly, cardiovascular diseases.
   Methods
   Patients followed in the Instituto de Pesquisa Clinica Evandro Chagas (IPEC) prospective cohort in Rio de Janeiro were submitted to the general procedures from the Brazilian Longitudinal Study of Adult Health, comprising several anthropometric, laboratory and imaging data. Carotid intima-media thickness (cIMT) was measured by ultrasonography, following the Mannheim protocol. Linear regression and proportional odds models were used to compare groups and covariables in respect to cIMT. The best model was chosen with the adaptive lasso procedure.
   Results
   A valid cIMT exam was available for 591 patients. Median cIMT was significantly larger for men than women (0.56mm vs. 0.53mm; p = 0.002; overall = 0.54mm). In univariable linear regression analysis, both traditional risk factors for cardiovascular diseases (CVD) and HIV-specific characteristics were significantly associated with cIMT values, but the best multivariable model chosen included only traditional characteristics. Hypertension presented the strongest association with higher cIMT terciles (OR = 2.51; 95% CI = 1.69-3.73), followed by current smoking (OR = 1,82; 95% CI = 1.19-2.79), family history of acute myocardial infarction or stroke (OR = 1.60; 95% CI = 1.10-2.32) and age (OR per year = 1.12; 95% CI = 1.10-1.14).
   Conclusions
   Our results show that traditional cardiovascular disease (CVD) risk factors are the major players in determining increased cIMT among HIV infected patients in Brazil. This finding reinforces the need for thorough assessment of those risk factors in these patients to guarantee the incidence of CVD events remain under control.
C1 [Pacheco, Antonio G.; Falcao, Melissa] Fiocruz MS, Programa Comp Cientif, BR-21045900 Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz; Moreira, Ronaldo I.; Veloso, Valdilea G.; Friedman, Ruth K.; Santini-Oliveira, Marilia; Cardoso, Sandra W.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [da Fonseca, Maria de Jesus M.] Fiocruz MS, Dept Epidemiol & Metodos Quantitati Saude, BR-21045900 Rio De Janeiro, Brazil.
   [Mill, Jose G.] Univ Fed Espirito Santo, Dept Ciencias Fisiol, Vitoria, Brazil.
   [Bensenor, Isabela; Lotufo, Paulo] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RP Pacheco, AG (corresponding author), Fiocruz MS, Programa Comp Cientif, BR-21045900 Rio De Janeiro, Brazil.
EM antgui@gmail.com
RI Cardoso, Sandra W/D-7965-2015; Pacheco, Antonio Guilherme/E-6378-2013;
   Lotufo, Paulo/A-9843-2008
OI Cardoso, Sandra W/0000-0001-5230-0003; Pacheco, Antonio
   Guilherme/0000-0003-3095-1774; Lotufo, Paulo/0000-0002-4856-8450
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Programa Estrategico de
   Apoio a Pesquisa em Saude (PAPES)-Fundacao Oswaldo Cruz; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI069476, U01AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   U01AI069476, U01AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX This study has been supported by the Fundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Programa
   Estrategico de Apoio a Pesquisa em Saude (PAPES)-Fundacao Oswaldo Cruz.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
   Baker JV, 2011, CLIN INFECT DIS, V53, P826, DOI 10.1093/cid/cir497
   Bavinger C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059551
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048
   Falcao MDBD, 2012, ARQ BRAS CARDIOL, V99, P971
   Calza L, 2008, J INFECTION, V57, P16, DOI 10.1016/j.jinf.2008.02.006
   Ceccarelli G, 2013, INT J CLIN PRACT, V67, P1, DOI 10.1111/ijcp.12066
   Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16
   D'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579
   Duprez DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044454
   Fitch KV, 2013, AIDS, V27, P49, DOI 10.1097/QAD.0b013e328358b29c
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   Fuchs SC, 2013, SCI WORLD J, DOI 10.1155/2013/163418
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Albuquerque VMG, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-274
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grunfeld C, 2009, AIDS, V23, P1841, DOI 10.1097/QAD.0b013e32832d3b85
   Hsue PY, 2012, J INFECT DIS, V205, pS375, DOI 10.1093/infdis/jis200
   Hsue PY, 2004, CIRCULATION, V109, P1603, DOI 10.1161/01.CIR.0000124480.32233.8A
   Justice Amy C, 2012, AIDS, V26 Suppl 1, pS11
   Kelesidis T, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-23
   Law MG, 2006, HIV MED, V7, P218, DOI 10.1111/j.1468-1293.2006.00362.x
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Lorenz MW, 2007, CIRCULATION, V115, P459, DOI 10.1161/CIRCULATIONAHA.106.628875
   Mangili A, 2011, JAIDS-J ACQ IMM DEF, V58, P148, DOI [10.1097/QAI.0B013E31822D4993, 10.1097/QAI.0b013e31822d4993]
   Masia M, 2012, ENFERM INFEC MICR CL, V30, P517, DOI 10.1016/j.eimc.2012.02.014
   Mill JG, 2013, REV SAUDE PUBL, V47, P54, DOI 10.1590/S0034-8910.2013047003851
   Mugavero MJ, 2011, CLIN INFECT DIS, V53, P927, DOI 10.1093/cid/cir526
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636
   Paula AA, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-32
   Polak JF, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000087
   R Development Core Team, 2014, R LANG ENV STAT COMP
   Ssinabulya I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089537
   Stein JH, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.001396
   Stein James H, 2012, Top Antivir Med, V20, P129
   Stein JH, 2012, TOP ANTIVIR MED, V20, P123
   Touboul PJ, 2012, CEREBROVASC DIS, V34, P290, DOI 10.1159/000343145
   Volpe GE, 2013, JAIDS-J ACQ IMM DEF, V64, P51, DOI 10.1097/QAI.0b013e31829ed726
   Zou H, 2006, J AM STAT ASSOC, V101, P1418, DOI 10.1198/016214506000000735
NR 43
TC 11
Z9 11
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 18
PY 2015
VL 10
IS 2
AR e0117461
DI 10.1371/journal.pone.0117461
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC0WZ
UT WOS:000350061500058
PM 25692764
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Castilho, JL
   Luz, PM
   Shepherd, BE
   Turner, M
   Ribeiro, SR
   Bebawy, SS
   Netto, JS
   McGowan, CC
   Veloso, VG
   Engels, EA
   Sterling, TR
   Grinsztejn, B
AF Castilho, Jessica L.
   Luz, Paula M.
   Shepherd, Bryan E.
   Turner, Megan
   Ribeiro, Sayonara R.
   Bebawy, Sally S.
   Netto, Juliana S.
   McGowan, Catherine C.
   Veloso, Valdilea G.
   Engels, Eric A.
   Sterling, Timothy R.
   Grinsztejn, Beatriz
TI HIV and cancer: a comparative retrospective study of Brazilian and US
   clinical cohorts
SO INFECTIOUS AGENTS AND CANCER
LA English
DT Review
DE HIV; Malignancy; Cancer; Brazil; Anal cancer; Kaposi sarcoma;
   Non-Hodgkin lymphoma; Lung cancer; Age; Sex
ID HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-DEFINING MALIGNANCIES; ACTIVE
   ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; KAPOSIS-SARCOMA;
   CERVICAL-CANCER; UNITED-STATES; HAART ERA; DEATH; RISK
AB Background: With successful antiretroviral therapy, non-communicable diseases, including malignancies, are increasingly contributing to morbidity and mortality among HIV-infected persons. The epidemiology of AIDS-defining cancers (ADCs) and non-AIDS-defining cancers (NADCs) in HIV-infected populations in Brazil has not been well described. It is not known if cancer trends in HIV-infected populations in Brazil are similar to those of other countries where antiretroviral therapy is also widely available.
   Methods: We performed a retrospective analysis of clinical cohorts at Instituto Nacional de Infectologia Evandro Chagas (INI) in Rio de Janeiro and Vanderbilt Comprehensive Care Clinic (VCCC) in Nashville from 1998 to 2010. We used Poisson regression and standardized incidence ratios (SIRs) to examine incidence trends. Clinical and demographic predictors of ADCs and NADCs were examined using Cox proportional hazards models.
   Results: This study included 2,925 patients at INI and 3,927 patients at VCCC. There were 57 ADCs at INI (65% Kaposi sarcoma), 47 at VCCC (40% Kaposi sarcoma), 45 NADCs at INI, and 82 at VCCC. From 1998 to 2004, incidence of ADCs remained statistically unchanged at both sites. From 2005 to 2010, ADC incidence decreased in both cohorts (INI incidence rate ratio per year = 0.74, p < 0.01; VCCC = 0.75, p < 0.01). Overall Kaposi sarcoma incidence was greater at INI than VCCC (3.0 vs. 1.2 cases per 1,000 person-years, p < 0.01). Incidence of NADCs remained constant throughout the study period (overall INI incidence 3.6 per 1,000 person-years and VCCC incidence 5.3 per 1,000 person-years). Compared to general populations, overall risk of NADCs was increased at both sites (INI SIR = 1.4 [95% CI 1.1-1.9] and VCCC SIR = 1.3 [ 1.0-1.7]). After non-melanoma skin cancers, the most frequent NADCs were anal cancer at INI (n = 7) and lung cancer at VCCC (n = 11). In multivariate models, risk of ADC was associated with male sex and immunosuppression. Risk of NADC was associated with increased age.
   Conclusions: In both cohorts, ADCs have decreased over time, though incidence of KS was higher at INI than VCCC. Rates of NADCs remained constant over time at both sites.
C1 [Castilho, Jessica L.; Turner, Megan; Bebawy, Sally S.; McGowan, Catherine C.; Sterling, Timothy R.] Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Med, Nashville, TN 37232 USA.
   [Luz, Paula M.; Ribeiro, Sayonara R.; Netto, Juliana S.; Veloso, Valdilea G.; Grinsztejn, Beatriz] HIV AIDS Clin Res Ctr, Inst Nacl Infectol Evandro Chagas, Fundacao Oswaldo Cruz, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Shepherd, Bryan E.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37203 USA.
   [Engels, Eric A.] Natl Canc Inst, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
RP Castilho, JL (corresponding author), Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Med, MCN A2200,1611 21st Ave South, Nashville, TN 37232 USA.
EM jessica.castilho@vanderbilt.edu
RI Harding, Richard/G-9729-2012
OI Luz, Paula/0000-0001-9746-719X
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [T32 AI007474, K24
   AI65298, UO1 AI069923]; National Council of Technological and Scientific
   DevelopmentNational Council for Scientific and Technological Development
   (CNPq); Research Agency of the State of Rio de Janeiro; Intramural
   Research Program of the National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI); NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [ZIACP010150, ZIACP010150, ZIACP010150, ZIACP010150, ZIACP010150,
   ZIACP010150, ZIACP010150, ZIACP010150, ZIACP010150, ZIACP010150] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01AI069923, U01AI069923, UM1AI069476,
   T32AI007474, T32AI007474, T32AI007474, T32AI007474, U01AI069923,
   U01AI069476, U01AI069923, UM1AI069476, U01AI069923, T32AI007474,
   T32AI007474, UM1AI069476, U01AI069923, T32AI007474, UM1AI069476,
   T32AI007474, UM1AI069476, T32AI007474, U01AI069923, U01AI069923,
   U01AI069923, T32AI007474, T32AI007474, U01AI069923, T32AI007474,
   U01AI069923, T32AI007474, U01AI069476, T32AI007474, T32AI007474,
   U01AI069923, U01AI069923, UM1AI069476, U01AI069923, U01AI069923,
   T32AI007474, U01AI069923, T32AI007474, T32AI007474, U01AI069923,
   U01AI069923, U01AI069923, T32AI007474, UM1AI069476, T32AI007474,
   T32AI007474, T32AI007474, U01AI069476, U01AI069923, U01AI069923,
   T32AI007474, T32AI007474, U01AI069476, T32AI007474, UM1AI069476] Funding
   Source: NIH RePORTER
FX We are grateful to individuals at INI and VCCC who made this study
   possible. We thank Dan Rasbach, and Sam Stinnette at Vanderbilt for
   their work abstracting and validating the cancer diagnoses at VCCC. This
   study was the result of an INI-Vanderbilt partnership developed through
   the Caribbean, Central and South American network for HIV epidemiology
   (CCASAnet) study, a multisite HIV cohort study in which INI participates
   and Vanderbilt coordinates. We thank CCASAnet data manager Karu
   Jayathilake for his statistical assistance in this project. This project
   was funded by grants from the National Institutes of Health (T32
   AI007474 [JLC], K24 AI65298 [TRS, SSB, MT], UO1 AI069923 [JLC, PML, BES,
   CCM, VGV, BG]), the National Council of Technological and Scientific
   Development (PML, BG), and the Research Agency of the State of Rio de
   Janeiro (PML, BG). Eric Engels was supported by the Intramural Research
   Program of the National Cancer Institute.
CR Abayomi EA, 2011, TRANSFUS APHER SCI, V44, P161, DOI 10.1016/j.transci.2011.01.007
   Amuyunzu-Nyamongo Mary, 2010, Glob Health Promot, V17, P31, DOI 10.1177/1757975910363928
   Beaglehole R, 2008, LANCET, V372, P940, DOI 10.1016/S0140-6736(08)61404-X
   Bedimo RJ, 2009, JAIDS-J ACQ IMM DEF, V52, P203, DOI 10.1097/QAI.0b013e3181b033ab
   Bonnet F, 2004, CANCER-AM CANCER SOC, V101, P317, DOI 10.1002/cncr.20354
   Casper C, 2011, ANNU REV MED, V62, P157, DOI 10.1146/annurev-med-050409-103711
   Chaturvedi AK, 2008, ANN EPIDEMIOL, V18, P230, DOI 10.1016/j.annepidem.2007.10.005
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   D'Souza G, 2014, JAIDS-J ACQ IMM DEF, V65, P603, DOI 10.1097/QAI.0000000000000083
   Dorrucci M, 2003, INT J CANCER, V104, P251, DOI 10.1002/ijc.10938
   Engels EA, 2006, J CLIN ONCOL, V24, P1383, DOI 10.1200/JCO.2005.03.4413
   Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487
   Fazito E, 2013, CAD SAUDE PUBLICA, V29, P1644, DOI [10.1590/0102-311X00128912, 10.1590/S0102-311X2013001200016]
   Fink VI, 2011, JAIDS-J ACQ IMM DEF, V56, P467, DOI 10.1097/QAI.0b013e31820bb1c3
   Gopal S, 2014, J CLIN ONCOL, V32, P876, DOI 10.1200/JCO.2013.53.1376
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Guiguet M, 2009, LANCET ONCOL, V10, P1152, DOI 10.1016/S1470-2045(09)70282-7
   Kesselring A, 2011, CLIN INFECT DIS, V52, P1458, DOI 10.1093/cid/cir207
   Krishnan S, 2011, ONCOLOGY-BASEL, V80, P42, DOI 10.1159/000328032
   Rezende ELLF, 2010, BRAZ J INFECT DIS, V14, P558, DOI [10.1590/S1413-86702010000600003, 10.1016/S1413-8670(10)70112-4]
   Massad LS, 2009, CANCER-AM CANCER SOC, V115, P524, DOI 10.1002/cncr.24067
   Massad LS, 2004, AIDS, V18, P109, DOI 10.1097/00002030-200401020-00013
   Mbulaiteye SM, 2006, J CLIN VIROL, V35, P442, DOI 10.1016/j.jcv.2005.10.010
   Mbulaiteye SM, 2003, JAIDS-J ACQ IMM DEF, V32, P527, DOI 10.1097/00126334-200304150-00010
   Monforte AD, 2008, AIDS, V22, P2143, DOI 10.1097/QAD.0b013e3283112b77
   Nguyen Minh Ly, 2010, Curr Infect Dis Rep, V12, P46, DOI 10.1007/s11908-009-0075-6
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636
   Perez C, 2004, J MED VIROL, V72, P661, DOI 10.1002/jmv.20029
   Ribeiro SR, 2014, ANTIVIR THER, V19, P387, DOI 10.3851/IMP2716
   Saraceni V, 2013, INT J DERMATOL, V52, P1525, DOI 10.1111/ijd.12116
   Sasco AJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008621
   Selik RM, 2002, J ACQ IMMUN DEF SYND, V29, P378, DOI 10.1097/00126334-200204010-00009
   Shiels MS, 2011, J NATL CANCER I, V103, P753, DOI 10.1093/jnci/djr076
   Silverberg MJ, 2013, JNCI-J NATL CANCER I, V105, P350, DOI 10.1093/jnci/djs529
   ULM K, 1990, AM J EPIDEMIOL, V131, P373, DOI 10.1093/oxfordjournals.aje.a115507
NR 36
TC 15
Z9 15
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1750-9378
J9 INFECT AGENTS CANCER
JI Infect. Agents Cancer
PD FEB 2
PY 2015
VL 10
AR 4
DI 10.1186/1750-9378-10-4
PG 10
WC Oncology; Immunology
SC Oncology; Immunology
GA CA8RN
UT WOS:000349188700001
PM 25685180
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Julio, RS
   Friedman, RK
   Cunha, CB
   De Boni, RB
   Cardoso, SW
   Torres, T
   Alves, CA
   Castro, C
   Fernandes, NM
   Veloso, VG
   Grinsztejn, B
AF Julio, Renata Siqueira
   Friedman, Ruth Khalili
   Cunha, Cynthia B.
   De Boni, Raquel Brandini
   Cardoso, Sandra Wagner
   Torres, Thiago
   Alves, Carla Almeida
   Castro, Cristiane
   Fernandes, Nilo Martinez
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI Unprotected Sexual Practices Among Men Who Have Sex with Women and Men
   Who Have Sex with Men Living with HIV/AIDS in Rio de Janeiro
SO ARCHIVES OF SEXUAL BEHAVIOR
LA English
DT Article
DE HIV/AIDS; Unprotected sexual behavior; MSM; MSW
ID HIV-POSITIVE MEN; RISK BEHAVIOR; ANAL INTERCOURSE; UNITED-STATES;
   BISEXUAL MEN; ANTIRETROVIRAL THERAPY; TRANSMISSION RISK; LIMITED
   KNOWLEDGE; HOMOSEXUAL-MEN; PREVENTION
AB Combined antiretroviral therapy is now acknowledged for preventing new HIV infections, besides decreasing mortality and morbidity. However, in many Latin America countries the epidemic is still driven by unprotected sexual intercourse. This study aims to describe sexual practices related to HIV/STD and to evaluate factors associated to unprotected sex among men who have sex with women (MSW) and men who have sex with men (MSM) under care at a reference center for HIV in Rio de Janeiro, Brazil. A cross-sectional study, nested in a Brazilian clinical cohort, evaluated the sexual practices of 404 sexually active HIV-positive MSW and men who have MSM. Approximately 30 % of them reported unprotected sexual practices during the 6 months prior to the interview. Most frequent risky practices reported were unprotected vaginal sex among MSW and unprotected receptive anal sex among MSM. Factors increasing the chance of unprotected sexual practices among MSW were the partner's desire of becoming pregnant (OR 2.81; CI 95 %: 1.36-5.95). To have received comments about excessive consumption of alcohol (OR 2.43; CI 95 %: 1.01-5.83), illicit drug use (OR 4.41; CI 95 %: 1.75-11.60) and lived in marital situation (OR 2.10; CI 95 %: 1.09-4.08) were significantly associated with unsafe sexual practices among MSM. The results highlight that health care of men living with HIV, as well as the prevention strategies, must consider the particularities of sexual behavior practiced by people who differ in sexual orientation.
C1 [Julio, Renata Siqueira] Superintendencia Reg Saude Varginha Ctr Univ Sul, Varginha, MG, Brazil.
   [Friedman, Ruth Khalili; Cunha, Cynthia B.; De Boni, Raquel Brandini; Cardoso, Sandra Wagner; Torres, Thiago; Alves, Carla Almeida; Castro, Cristiane; Fernandes, Nilo Martinez; Veloso, Valdilea G.; Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas FIOCRUZ, BR-21040360 Rio De Janeiro, Brazil.
RP De Boni, RB (corresponding author), Inst Pesquisa Clin Evandro Chagas FIOCRUZ, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM raqueldeboni@gmail.com
RI Cardoso, Sandra W/D-7965-2015; DE BONI, RAQUEL BRANDINI/D-4212-2013;
   TORRES, THIAGO SILVA/D-6548-2014
OI Cardoso, Sandra W/0000-0001-5230-0003; DE BONI, RAQUEL
   BRANDINI/0000-0002-2455-5997; TORRES, THIAGO SILVA/0000-0002-2557-601X
CR Aidala AA, 2006, J URBAN HEALTH, V83, P637, DOI 10.1007/s11524-006-9074-1
   Baggaley RF, 2010, INT J EPIDEMIOL, V39, P1048, DOI 10.1093/ije/dyq057
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Barbosa A, 2009, CAD SAUDE PUBLICA, V25, P727, DOI 10.1590/S0102-311X2009000400003
   Benn P, 2011, INT J STD AIDS, V22, P695, DOI 10.1258/ijsa.2011.171011
   Benotsch EG, 2001, SEXUAL ADDICTION COM, V8, P83, DOI [10.1080/10720160127561, DOI 10.1080/10720160127561]
   Beyrer C, 2012, LANCET, V380, P424, DOI 10.1016/S0140-6736(12)61022-8
   Beyrer C, 2010, SEX TRANSM INFECT, V86, P323, DOI 10.1136/sti.2009.040162
   Bruce D, 2013, AIDS CARE, V25, P559, DOI 10.1080/09540121.2012.720363
   Chin-Hong PV, 2005, JAIDS-J ACQ IMM DEF, V40, P463, DOI 10.1097/01.qai.0000162238.93988.0c
   Clark J, 2013, AIDS BEHAV, V17, P1313, DOI 10.1007/s10461-012-0210-5
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Courtenay-Quirk C, 2008, AIDS BEHAV, V12, P685, DOI 10.1007/s10461-007-9259-y
   Crepaz N, 2009, AIDS, V23, P1617, DOI 10.1097/QAD.0b013e32832effae
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   de Brito A. M., 2013, AIDS BEHAV, V27, P427, DOI [10.1097/QAD.0b013e32835ad504, DOI 10.1097/QAD.0B013E32835AD504]
   de Ven PV, 1999, AIDS, V13, P2289, DOI 10.1097/00002030-199911120-00011
   Delvaux T, 2007, REPROD HEALTH MATTER, V15, P46, DOI 10.1016/S0968-8080(07)29031-7
   Desquilbet L, 2002, AIDS, V16, P2329, DOI 10.1097/00002030-200211220-00014
   Dodge B, 2013, ARCH SEX BEHAV, V42, P247, DOI 10.1007/s10508-011-9878-2
   Durham MD, 2013, JAIDS-J ACQ IMM DEF, V63, P372, DOI 10.1097/QAI.0b013e31828c20d8
   Eisele TP, 2008, AIDS BEHAV, V12, P570, DOI 10.1007/s10461-007-9279-7
   Fisher JD, 2010, JAIDS-J ACQ IMM DEF, V55, pS106, DOI 10.1097/QAI.0b013e3181fbca2f
   Glick SN, 2012, JAIDS-J ACQ IMM DEF, V60, P83, DOI 10.1097/QAI.0b013e318247925e
   Golin C, 2009, AIDS BEHAV, V13, P1129, DOI 10.1007/s10461-009-9613-3
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grov C, 2010, ARCH SEX BEHAV, V39, P788, DOI [10.1007/s10508-008-9439-5, 10.1007/s10508-009-9483-9]
   Guimaraes MDC, 2008, AIDS BEHAV, V12, P741, DOI 10.1007/s10461-008-9407-z
   Halkitis PN, 2013, AM J PUBLIC HEALTH, V103, P889, DOI 10.2105/AJPH.2012.300963
   Hart GJ, 2005, SEX TRANSM INFECT, V81, P367, DOI 10.1136/sti.2004.013995
   Kelly BC, 2009, J SEX RES, V46, P301, DOI 10.1080/00224490802666225
   Kerani RP, 2007, SEX TRANSM DIS, V34, P154, DOI 10.1097/01.olq.0000233709.93891.e5
   Lim SH, 2012, AIDS BEHAV, V16, P151, DOI 10.1007/s10461-010-9866-x
   Liu AY, 2008, JAIDS-J ACQ IMM DEF, V47, P241, DOI 10.1097/QAI.0b013e31815e4041
   Malta M, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-317
   Mansergh G, 2008, SEX TRANSM INFECT, V84, P509, DOI 10.1136/sti.2008.031807
   MARKS G, 1994, J ACQ IMMUN DEF SYND, V7, P866
   Mayer K., 2013, 7 IAS C HIV PATH TRE
   Mayer KH, 2011, CLIN INFECT DIS, V53, pS79, DOI 10.1093/cid/cir696
   Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P77, DOI 10.1097/QAI.0b013e31818d5a27
   Ministerio da Saude Brasil, 2012, B EP AIDS DST
   Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0
   Morin SF, 2007, AIDS BEHAV, V11, pS6, DOI 10.1007/s10461-007-9253-4
   New York State Department of Health AIDS Institute, 2013, HIV PROPH FOLL NON E
   Page-Shafer K, 2002, AIDS, V16, P2350, DOI 10.1097/00002030-200211220-00022
   Parsons JT, 2005, J PSYCHOACTIVE DRUGS, V37, P27, DOI 10.1080/02791072.2005.10399746
   Purcell DW, 2006, J URBAN HEALTH, V83, P656, DOI 10.1007/s11524-006-9066-1
   Sander PM, 2013, AIDS, V27, P815, DOI 10.1097/QAD.0b013e32835cff4b
   Scanavino MD, 2013, PSYCHIAT RES, V209, P518, DOI 10.1016/j.psychres.2013.01.021
   Schmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9
   Semple SJ, 2011, J STUD ALCOHOL DRUGS, V72, P954, DOI 10.15288/jsad.2011.72.954
   Seng R, 2011, AIDS, V25, P977, DOI 10.1097/QAD.0b013e328345ef12
   Smith Dawn K., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Stolte IG, 2004, AIDS, V18, P1943, DOI 10.1097/00002030-200409240-00010
   UNAIDS, 2013, GLOB REP UNAIDS REP
   Varghese B, 2002, SEX TRANSM DIS, V29, P38, DOI 10.1097/00007435-200201000-00007
   de Castro CAV, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-224
   Wolitski RJ, 2003, AIDS BEHAV, V7, P363, DOI 10.1023/B:AIBE.0000004728.73443.32
NR 58
TC 11
Z9 12
U1 0
U2 16
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0004-0002
EI 1573-2800
J9 ARCH SEX BEHAV
JI Arch. Sex. Behav.
PD FEB
PY 2015
VL 44
IS 2
BP 357
EP 365
DI 10.1007/s10508-014-0357-4
PG 9
WC Psychology, Clinical; Social Sciences, Interdisciplinary
SC Psychology; Social Sciences - Other Topics
GA CB3SB
UT WOS:000349547500009
PM 25318623
DA 2020-11-24
ER

PT J
AU Luz, PM
   Morris, BL
   Grinsztejn, B
   Freedberg, KA
   Veloso, VG
   Walensky, RP
   Losina, E
   Nakamura, YM
   Girouard, MP
   Sax, PE
   Struchiner, CJ
   Paltiel, AD
AF Luz, Paula M.
   Morris, Bethany L.
   Grinsztejn, Beatriz
   Freedberg, Kenneth A.
   Veloso, Valdilea G.
   Walensky, Rochelle P.
   Losina, Elena
   Nakamura, Yoriko M.
   Girouard, Michael P.
   Sax, Paul E.
   Struchiner, Claudio J.
   Paltiel, A. David
TI Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE genotype; cost-effectiveness; Brazil; HIV; drug resistance
ID HIV-INFECTED PATIENTS; HIV-1-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY;
   CONTROLLED-TRIAL; EFFICACY; SAFETY; ETRAVIRINE; BENEFITS; IMPACT
AB Objective:HIV genotype-resistance testing can help identify more effective antiretroviral treatment (ART) regimens for patients, substantially increasing the likelihood of viral suppression and immune recovery. We sought to evaluate the cost-effectiveness of genotype-resistance testing before first-line ART initiation in Brazil.Design:We used a previously published microsimulation model of HIV disease (CEPAC-International) and data from Brazil to compare the clinical impact, costs, and cost-effectiveness of initial genotype testing (Genotype) with no initial genotype testing (No genotype).Methods:Model parameters were derived from the HIV Clinical Cohort at the Evandro Chagas Clinical Research Institute and from published data, using Brazilian sources whenever possible. Baseline patient characteristics included 69% male, mean age of 36 years (SD, 10 years), mean CD4 count of 347 per microliter (SD, 300/mu L) at ART initiation, annual ART costs from 2012 US $1400 to US $13,400, genotype test cost of US $230, and primary resistance prevalence of 4.4%. Life expectancy and costs were discounted 3% per year. Genotype was defined as cost-effective compared with No Genotype if its incremental cost-effectiveness ratio was less than 3 times the 2012 Brazilian per capita GDP of US $12,300.Results:Compared with No genotype, Genotype increased life expectancy from 18.45 to 18.47 years and reduced lifetime cost from US $45,000 to $44,770; thus, in the base case, Genotype was cost saving. Genotype was cost-effective at primary resistance prevalence as low as 1.4% and remained cost-effective when subsequent-line ART costs decreased to 30% of baseline value. Cost-inefficient results were observed only when simultaneously holding multiple parameters to extremes of their plausible ranges.Conclusions:Genotype-resistance testing in ART-naive individuals in Brazil will improve survival and decrease costs and should be incorporated into HIV treatment guidelines in Brazil.
C1 [Luz, Paula M.; Grinsztejn, Beatriz; Veloso, Valdilea G.; Struchiner, Claudio J.] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, BR-21040360 Rio De Janeiro, Brazil.
   [Morris, Bethany L.; Freedberg, Kenneth A.; Walensky, Rochelle P.; Nakamura, Yoriko M.; Girouard, Michael P.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
   [Morris, Bethany L.; Freedberg, Kenneth A.; Walensky, Rochelle P.; Losina, Elena; Nakamura, Yoriko M.; Girouard, Michael P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
   [Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Freedberg, Kenneth A.; Walensky, Rochelle P.; Sax, Paul E.] Harvard Univ, Ctr AIDS Res, Sch Med, Boston, MA 02115 USA.
   [Freedberg, Kenneth A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
   [Freedberg, Kenneth A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
   [Walensky, Rochelle P.; Sax, Paul E.] Brigham & Womens Hosp, Div Infect Dis, Dept Med, Boston, MA 02115 USA.
   [Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
   [Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA.
   [Paltiel, A. David] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM paula.luz@ipec.fiocruz.br
RI Struchiner, Claudio J/M-9360-2013
OI Struchiner, Claudio J/0000-0003-2114-847X; Paltiel, A.
   David/0000-0002-4861-3290; Losina, ELENA/0000-0002-3424-0892; Luz,
   Paula/0000-0001-9746-719X; Walensky, Rochelle P./0000-0002-8795-379X
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1 AI068636, R01 AI058736]; National Council of Technological and
   Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Research Funding Agency of the State
   of Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); BMSBristol-Myers
   Squibb; GileadGilead Sciences; GSKGlaxoSmithKline; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01AI068636,
   U01AI069476, UM1AI069476, R01AI058736, R01AI058736, UM1AI068636,
   R01AI058736, UM1AI069476, UM1AI069476, U01AI069476, UM1AI068636,
   UM1AI068636, R01AI058736, R01AI058736, R01AI058736, U01AI068636,
   R01AI058736, UM1AI068636, UM1AI068636, U01AI068636, UM1AI068636,
   R01AI058736, UM1AI069476, U01AI068636, R01AI058736, U01AI069476,
   U01AI069476, UM1AI068636, UM1AI069476, UM1AI069476, UM1AI069476,
   R01AI058736, R01AI058736, R01AI058736, UM1AI068636, R01AI058736,
   U01AI068636, U01AI068636, R01AI058736, R01AI058736, U01AI068636,
   UM1AI069476, UM1AI068636, R01AI058736, R01AI058736, R01AI058736,
   R01AI058736] Funding Source: NIH RePORTER
FX Supported by the National Institute of Allergy and Infectious Diseases
   (UM1 AI068636 and R01 AI058736).; P.M.L., B.G., and C.J.S. acknowledge
   funding from the National Council of Technological and Scientific
   Development (CNPq) and the Research Funding Agency of the State of Rio
   de Janeiro (FAPERJ). P.E.S. is a consultant to Abbott, BMS, Gilead, GSK,
   Merck, and Janssen and receives grant support from BMS, Gilead, and GSK.
   The remaining authors have no conflicts of interest to disclose.
CR [Anonymous], 2012, WORLD EC OUTLOOK DAT
   Berkman A, 2005, AM J PUBLIC HEALTH, V95, P1162, DOI 10.2105/AJPH.2004.054593
   Brazilian Ministry of Health, FORM RESP DAT REQ RE
   Brazilian Ministry of Health, 2013, REC TER ANT AD VIV C
   Brazilian Ministry of Health, 2012, POL BRAS ENFR AIDS R
   Brazilian Ministry of Health Health Surveillance Secretariat Department of STD AIDS and Viral Hepatitis, 2012, PROGR REP BRAZ RESP
   Cahn P, 2011, AIDS, V25, P929, DOI 10.1097/QAD.0b013e328345ee95
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   Departamento de Informatica do Sistema Unico de Saude (DATASUS), 2009, INT HOSP SUS LOC INT
   Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2
   Freedberg KA, 1998, JAMA-J AM MED ASSOC, V279, P130, DOI 10.1001/jama.279.2.130
   Goldie SJ, 2006, NEW ENGL J MED, V355, P1141, DOI 10.1056/NEJMsa060247
   Goodman DD, 2011, AIDS, V25, P325, DOI 10.1097/QAD.0b013e3283427dcb
   Gulick RM, 2008, NEW ENGL J MED, V359, P1429, DOI 10.1056/NEJMoa0803152
   Katlama C, 2009, AIDS, V23, P2289, DOI 10.1097/QAD.0b013e3283316a5e
   Lalezari J, 2007, C RETR OPP INF
   Levison JH, 2013, CLIN INFECT DIS, V56, P587, DOI 10.1093/cid/cis887
   Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2
   Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003
   Molina JM, 2008, LANCET, V372, P646, DOI 10.1016/S0140-6736(08)61081-8
   Noubary F, 2010, STAT MED, V29, P1932, DOI 10.1002/sim.3955
   Nunn AS, 2009, HEALTH AFFAIR, V28, P1103, DOI 10.1377/hlthaff.28.4.1103
   Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498
   Sax PE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031591
   Sax PE, 2005, CLIN INFECT DIS, V41, P1316, DOI 10.1086/496984
   Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339
   Sistema de Gerenciamento da Tabela de Procedimentos Medicamentos e OPM ( SIGTAP), 2010, PROC PUBL CONS MED A
   Sprinz E, 2009, AIDS RES HUM RETROV, V25, P861, DOI 10.1089/aid.2009.0012
   Steigbigel RT, 2008, NEW ENGL J MED, V359, P339, DOI 10.1056/NEJMoa0708975
   Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09
   Veloso Valdiléa G, 2008, Rev. Saúde Pública, V42, P859, DOI 10.1590/S0034-89102008000500011
   Walensky RP, 2012, CLIN INFECT DIS, V54, P1504, DOI 10.1093/cid/cis225
   Walensky RP, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000382
   Weinstein MC, 2001, ANN INTERN MED, V134, P440, DOI 10.7326/0003-4819-134-6-200103200-00008
   World Health Organization, 2001, MACR HLTH INV HLTH E
   Yazdanpanah Y, 2007, HIV MED, V8, P439, DOI 10.1111/j.1468-1293.2007.00491.x
NR 36
TC 10
Z9 10
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD FEB 1
PY 2015
VL 68
IS 2
BP 152
EP 161
DI 10.1097/QAI.0000000000000426
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AZ8IF
UT WOS:000348458200011
PM 25415289
OA Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU Ford, N
   Meintjes, G
   Pozniak, A
   Bygrave, H
   Hill, A
   Peter, T
   Davies, MA
   Grinsztejn, B
   Calmy, A
   Kumarasamy, N
   Phanuphak, P
   deBeaudrap, P
   Vitoria, M
   Doherty, M
   Stevens, W
   Siberry, GK
AF Ford, Nathan
   Meintjes, Graeme
   Pozniak, Anton
   Bygrave, Helen
   Hill, Andrew
   Peter, Trevor
   Davies, Mary-Ann
   Grinsztejn, Beatriz
   Calmy, Alexandra
   Kumarasamy, N.
   Phanuphak, Praphan
   deBeaudrap, Pierre
   Vitoria, Marco
   Doherty, Meg
   Stevens, Wendy
   Siberry, George K.
TI The future role of CD4 cell count for monitoring antiretroviral therapy
SO LANCET INFECTIOUS DISEASES
LA English
DT Editorial Material
ID RESOURCE-LIMITED SETTINGS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME;
   HIGH-INCOME COUNTRIES; HIV-INFECTED PATIENTS; LIFE EXPECTANCY;
   SOUTH-AFRICA; VIRAL LOAD; COHORT ANALYSIS; HOMOSEXUAL-MEN; INDIVIDUALS
AB For more than two decades, CD4 cell count measurements have been central to understanding HIV disease progression, making important clinical decisions, and monitoring the response to antiretroviral therapy (ART). In well resourced settings, the monitoring of patients on ART has been supported by routine virological monitoring. Viral load monitoring was recommended by WHO in 2013 guidelines as the preferred way to monitor people on ART, and efforts are underway to scale up access in resource-limited settings. Recent studies suggest that in situations where viral load is available and patients are virologically suppressed, long-term CD4 monitoring adds little value and stopping CD4 monitoring will have major cost savings. CD4 cell counts will continue to play an important part in initial decisions around ART initiation and clinical management, particularly for patients presenting late to care, and for treatment monitoring where viral load monitoring is restricted. However, in settings where both CD4 cell counts and viral load testing are routinely available, countries should consider reducing the frequency of CD4 cell counts or not doing routine CD4 monitoring for patients who are stable on ART.
C1 [Ford, Nathan; Vitoria, Marco; Doherty, Meg] WHO, Dept HIV AIDS, CH-1211 Geneva, Switzerland.
   [Meintjes, Graeme] Univ Cape Town, Inst Infect Dis & Mol Med, Clin Infect Dis Res Initiat, ZA-7925 Cape Town, South Africa.
   [Pozniak, Anton] Chelsea & Westminster Hosp, London, England.
   [Bygrave, Helen] Med Sans Frontieres, Southern Africa Med Unit, Cape Town, South Africa.
   [Hill, Andrew] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England.
   [Peter, Trevor] Clinton Hlth Access Initiat, Boston, MA USA.
   [Ford, Nathan; Davies, Mary-Ann] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Minist Hlth, Salvador, BA, Brazil.
   [Calmy, Alexandra] Univ Hosp Geneva, Infect Dis Serv, HIV AIDS Unit, Geneva, Switzerland.
   [Kumarasamy, N.] YRG Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
   [Phanuphak, Praphan] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand.
   [deBeaudrap, Pierre] IRD, Montpellier, France.
   [Stevens, Wendy] Univ Witwatersrand, Dept Mol Med & Haematol, Johannesburg, South Africa.
   [Stevens, Wendy] Natl Hlth Lab Serv, Johannesburg, South Africa.
   [Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, Rockville, MD USA.
RP Ford, N (corresponding author), WHO, Dept HIV AIDS, CH-1211 Geneva, Switzerland.
EM fordn@who.int
RI De Beaudrap, Pierre/K-3113-2017
OI De Beaudrap, Pierre/0000-0002-9037-6057; Meintjes,
   Graeme/0000-0003-1196-4414
FU World Health OrganizationWorld Health Organization [001] Funding Source:
   Medline
CR Bonner K, 2013, JAIDS-J ACQ IMM DEF, V64, P74, DOI 10.1097/QAI.0b013e31829f05ac
   Bor J, 2013, SCIENCE, V339, P961, DOI 10.1126/science.1230413
   Braitstein P, 2006, LANCET, V367, P817
   Carter M, 2013, 6 MONTHLY CD4 CELL M
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Davies M-A, 2014, 18 INT WORKSH HIV OB
   *DEP HLTH HUM SERV, 1998, MMWR-MORBID MORTAL W, V47, P43
   FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305
   FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92
   Ford N, 2014, AIDS, V28, P2003, DOI 10.1097/QAD.0000000000000406
   Gaardbo JC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/670957
   Gale HB, 2013, CLIN INFECT DIS, V56, P1340, DOI 10.1093/cid/cit004
   Gaur AH, 2013, AIDS RES HUM RETROV, V29, P418, DOI [10.1089/aid.2012.0175, 10.1089/AID.2012.0175]
   Girard PM, 2013, AIDS, V27, P2759, DOI 10.1097/01.aids.0000432458.98851.c1
   GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331
   Gras L, 2007, JAIDS-J ACQ IMM DEF, V45, P183, DOI 10.1097/QAI.0b013e31804d685b
   Guihot A, 2010, AIDS, V24, P614, DOI 10.1097/QAD.0b013e32833556f3
   Hamers RL, 2012, AIDS, V26, P1663, DOI 10.1097/QAD.0b013e3283560678
   Harrigan R, 1995, J ACQ IMMUN DEF SYND, V10, pS34
   HHS Panel on Antiretroviral Guidelines for Adults and Adolescents-a working group of the Office of AIDS Research Advisory Council (OARAC), GUIDELINES USE ANTIR
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568
   Hyle EP, 2013, JAMA INTERN MED, V173, P1746, DOI 10.1001/jamainternmed.2013.9329
   Jarvis JN, 2009, CLIN INFECT DIS, V48, P856, DOI 10.1086/597262
   Johnson LF, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001418
   Kanters S, 2014, ANTIVIR THER, V19, P31, DOI 10.3851/IMP2670
   Kaufmann GR, 2005, CLIN INFECT DIS, V41, P361, DOI 10.1086/431484
   Loutfy MR, 2010, JAIDS-J ACQ IMM DEF, V55, P451, DOI 10.1097/QAI.0b013e3181ec28ff
   Meintjes G, 2012, S AFR J HIV MED, DOI 10.7196/SAJHIVMED.862
   Mills EJ, 2011, AIDS, V25, P851, DOI 10.1097/QAD.0b013e32834564e9
   Mills EJ, 2011, ANN INTERN MED, V155, P209, DOI 10.7326/0003-4819-155-4-201108160-00358
   Mocroft A, 2007, LANCET, V370, P407, DOI 10.1016/S0140-6736(07)60948-9
   Nelson LJ, 2014, AIDS, V28, pS217, DOI 10.1097/QAD.0000000000000239
   Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), 2010, Clin Infect Dis, V51, P611, DOI 10.1086/655761
   Park BJ, 2009, AIDS, V23, P525, DOI 10.1097/QAD.0b013e328322ffac
   PEDERSEN C, 1990, AIDS, V4, P1111, DOI 10.1097/00002030-199011000-00009
   PHILLIPS AN, 1991, LANCET, V337, P389
   Phillips AN, 2002, AIDS, V16, P1073, DOI 10.1097/00002030-200205030-00016
   POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201
   Puls RL, 2010, CLIN INFECT DIS, V51, P855, DOI 10.1086/656363
   Reynolds S, 2014, 2014 C RETR OPP INF
   Roberts T, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17324
   Rowley CF, 2014, CLIN INFECT DIS, V58, P407, DOI 10.1093/cid/cit733
   Rutherford GW, 2014, AIDS, V28, pS161, DOI 10.1097/QAD.0000000000000236
   SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287
   Sax PE, 2013, CLIN INFECT DIS, V56, P1344, DOI 10.1093/cid/cit008
   Shubber Z, 2013, AIDS, V27, P1403, DOI 10.1097/QAD.0b013e32835f1db0
   Suthar AB, 2012, B WORLD HEALTH ORGAN, V90, P128, DOI 10.2471/BLT.11.093260
   Tuboi SH, 2010, JAIDS-J ACQ IMM DEF, V53, P70, DOI 10.1097/QAI.0b013e3181c22d19
   UNITAID Diagnostics Technology and Market Landscape, 2014, UNITAID DIAGN TECHN
   Vitoria M, 2013, CURR OPIN HIV AIDS, V8, P12, DOI 10.1097/COH.0b013e32835b8123
   Whitlock GG, 2013, CLIN INFECT DIS, V57, P327, DOI 10.1093/cid/cit203
   WHO, 2006, GUID COTR PROPH HIV
   Wilson D, 2009, T ROY SOC TROP MED H, V103, P601, DOI 10.1016/j.trstmh.2008.11.007
   World Health Organization, 2013, CONS GUID US ANT DRU
   World Health Organization, 2010, SCAL ANT THER RES LT
   World Health Organization, 2002, SCAL ANT THER RES LT
   Zoufaly A, 2011, J INFECT DIS, V203, P364, DOI 10.1093/jinfdis/jiq055
NR 58
TC 79
Z9 83
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD FEB
PY 2015
VL 15
IS 2
BP 241
EP 247
DI 10.1016/S1473-3099(14)70896-5
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA AZ7PJ
UT WOS:000348410200034
PM 25467647
DA 2020-11-24
ER

PT J
AU Crump, JA
   Wu, XY
   Kendall, MA
   Ive, PD
   Kumwenda, JJ
   Grinsztejn, B
   Jentsch, U
   Swindells, S
AF Crump, John A.
   Wu, Xingye
   Kendall, Michelle A.
   Ive, Prudence D.
   Kumwenda, Johnstone J.
   Grinsztejn, Beatriz
   Jentsch, Ute
   Swindells, Susan
TI Predictors and outcomes of Mycobacterium tuberculosis bacteremia among
   patients with HIV and tuberculosis co-infection enrolled in the ACTG
   A5221 STRIDE study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Africa; Asia; Bacteremia; HIV; Treatment outcome; Tuberculosis
ID RECONSTITUTION INFLAMMATORY SYNDROME; ANTIRETROVIRAL THERAPY; TANZANIA;
   INFECTIONS; SEVERITY; ADULTS
AB Background: We evaluated predictors and outcomes of Mycobacterium tuberculosis bacteremia among participants undergoing baseline mycobacterial blood culture in the ACTG A5221 STRIDE study, a randomized clinical trial comparing earlier with later ART among HIV-infected patients suspected of having tuberculosis with CD4-positive T-lymphocyte counts (CD4 counts) <250 cells/mm(3). We conducted a secondary analysis comparing participants with respect to presence or absence of M. tuberculosis bacteremia.
   Methods: Participants with a baseline mycobacterial blood culture were compared with respect to the presence or absence of M. tuberculosis bacteremia. Baseline predictors of M. tuberculosis bacteremia were identified and participant outcomes were compared by mycobacteremia status.
   Results: Of 90 participants with baseline mycobacterial blood cultures, 29 (32.2%) were female, the median (IQR) age was 37 (31-45) years, CD4 count was 81 (33-131) cells/mm(3), HIV-1 RNA level was 5.39 (4.96-5.83) log(10) copies/mL, and 18 (20.0%) had blood cultures positive for M. tuberculosis. In multivariable analysis, lower CD4 count (OR 0.85 per 10-cell increase, p = 0.012), hemoglobin <= 8.5 g/dL (OR 5.8, p = 0.049), and confirmed tuberculosis (OR 17.4, p = 0.001) were associated with M. tuberculosis bacteremia. There were no significant differences in survival and AIDS-free survival, occurrence of tuberculosis immune reconstitution inflammatory syndrome (IRIS), or treatment interruption or discontinuation by M. tuberculosis bacteremia status. IRIS did not differ significantly between groups despite trends toward more virologic suppression and greater CD4 count increases at week 48 in the bacteremic group.
   Conclusions: Among HIV-infected tuberculosis suspects, lower CD4 count, hemoglobin <= 8.5 g/dL, and the presence of microbiologically confirmed pulmonary tuberculosis were associated with increased adjusted odds of mycobacteremia. No evidence of an association between M. tuberculosis bacteremia and the increased risk of IRIS was detected.
C1 [Crump, John A.] Duke Univ, Dept Med, Div Infect Dis & Int Hlth, Durham, NC 27710 USA.
   [Crump, John A.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
   [Crump, John A.] Duke Univ, Duke Global Hlth Inst, Durham, NC 27708 USA.
   [Crump, John A.] Kilimanjaro Christian Med Ctr, Moshi, Tanzania.
   [Crump, John A.] Tumaini Univ, Kilimanjaro Christian Med Univ Coll, Moshi, Tanzania.
   [Wu, Xingye; Kendall, Michelle A.] Harvard Univ, Ctr Biostat AIDS Res, Sch Publ Hlth, Boston, MA 02115 USA.
   [Ive, Prudence D.] Univ Witwatersrand, Dept Med, ZA-2050 Johannesburg, South Africa.
   [Jentsch, Ute] Univ Witwatersrand, Sch Pathol, ZA-2050 Johannesburg, South Africa.
   [Kumwenda, Johnstone J.] Univ Malawi, Dept Internal Med, Coll Med, Blantyre 3, Malawi.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, BR-21040360 Rio De Janeiro, Brazil.
   [Swindells, Susan] Univ Nebraska Med Ctr, Dept Internal Med, Div Infect Dis, Omaha, NE 68198 USA.
RP Crump, JA (corresponding author), Duke Univ, Dept Med, Div Infect Dis & Int Hlth, Durham, NC 27710 USA.
EM john.crump@duke.edu
RI Crump, John A./AAZ-6412-2020; Kendall, Michelle A/B-7665-2016; Crump,
   John A./AAZ-6289-2020
OI Crump, John A./0000-0002-4529-102X; Kendall, Michelle
   A/0000-0001-9160-4544; Crump, John A./0000-0002-4529-102X
FU Division of AIDS, National Institute of Allergy and Infectious Diseases,
   US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01 AI068636]; Duke
   Clinical Trials Unit and Clinical Research Sites [U01 AI069484, U01
   AI069450]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069463, UM1AI069463, UM1AI069424, UM1AI069424,
   UM1AI069518, U01AI069484, UM1AI068634, UM1AI068634, U01AI069450,
   UM1AI069518, UM1AI069476, U01AI069450, UM1AI069432, U01AI068636,
   UM1AI068634, UM1AI069456, UM1AI069476, UM1AI069432, UM1AI069476,
   U01AI069484, UM1AI069463, UM1AI068634, UM1AI068636, UM1AI106701,
   UM1AI106701, UM1AI069518, UM1AI068636, UM1AI069463, UM1AI069456,
   UM1AI069424, UM1AI069463, UM1AI106701, UM1AI069456, UM1AI069518,
   UM1AI068634, U01AI069484, U01AI068636, UM1AI068634, UM1AI069463,
   UM1AI069463, U01AI069484, UM1AI106701, UM1AI069463, UM1AI069432,
   UM1AI068636, UM1AI069476, UM1AI068634, UM1AI069424, UM1AI106701,
   UM1AI069424, UM1AI069424, UM1AI069518, U01AI068636, UM1AI069476,
   UM1AI068634, U01AI068636, UM1AI069424, UM1AI069456, U01AI069484,
   UM1AI069432, UM1AI069476, UM1AI069518, UM1AI069518, UM1AI068636,
   U01AI069484, UM1AI069432, UM1AI068636, U01AI068636, UM1AI069432,
   UM1AI069456, UM1AI069432, UM1AI069456, U01AI068636, UM1AI068636,
   UM1AI069476, U01AI068636, UM1AI069476, UM1AI069456, U01AI069484,
   UM1AI069518, UM1AI068634, UM1AI069432, U01AI069450, UM1AI069424,
   U01AI069484, UM1AI068636, UM1AI068636, U01AI069450, UM1AI069456,
   UM1AI068636, UM1AI106701, U01AI069450] Funding Source: NIH RePORTER
FX A5221 was supported by the Division of AIDS, National Institute of
   Allergy and Infectious Diseases, US National Institutes of Health (U01
   AI068636). JAC received support from the Duke Clinical Trials Unit and
   Clinical Research Sites U01 AI069484 and SS from U01 AI069450.
CR Archibald LK, 1998, CLIN INFECT DIS, V26, P290, DOI 10.1086/516297
   Burman W, 2007, INT J TUBERC LUNG D, V11, P1282
   Crump JA, 1998, CLIN INFECT DIS, V26, P1008, DOI 10.1086/517636
   Crump JA, 2012, CLIN INFECT DIS, V55, P242, DOI 10.1093/cid/cis409
   Crump JA, 2011, CLIN INFECT DIS, V52, P341, DOI 10.1093/cid/ciq103
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   ISEMAN MD, 2000, CLIN GUIDE TUBERCULO, P145
   Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181
   Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848
   Luetkemeyer AF, 2014, JAIDS-J ACQ IMM DEF, V65, P423, DOI 10.1097/QAI.0000000000000030
   McDonald LC, 1999, LANCET, V354, P1159, DOI 10.1016/S0140-6736(98)12325-5
   Meintjes G, 2008, LANCET INFECT DIS, V8, P516, DOI 10.1016/S1473-3099(08)70184-1
   Shao HJ, 2009, AIDS RES HUM RETROV, V25, P1277, DOI 10.1089/aid.2009.0100
NR 13
TC 9
Z9 9
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JAN 13
PY 2015
VL 15
AR 12
DI 10.1186/s12879-014-0735-5
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA CA4LL
UT WOS:000348875500001
PM 25582793
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Escuder, MML
   Grangeiro, AM
   Cassenote, AJF
   Kalichman, AO
   Souza, RA
   Tupinamba, U
   Veloso, V
   Barcellos, N
   Grinsztejn, B
   Castilho, EA
AF Escuder, M. M. L.
   Grangeiro, A. M.
   Cassenote, A. J. F.
   Kalichman, A. O.
   Souza, R. A.
   Tupinamba, U.
   Veloso, V.
   Barcellos, N.
   Grinsztejn, B.
   Castilho, E. A.
TI Antiretroviral Therapy at Public Health Care Facilities in Brazil:
   HIV/AIDS Cohort-Brazil.
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
CT 20th IEA World Congress of Epidemiology (WCE)
CY AUG 17-21, 2014
CL Anchorage, AK
SP Int Epidemiol Assoc
C1 [Escuder, M. M. L.] Inst Hlth Sao Paulo, Sao Paulo, Brazil.
   [Grangeiro, A. M.; Cassenote, A. J. F.; Castilho, E. A.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Kalichman, A. O.; Souza, R. A.] Ctr Referencia & Treinamento DST & Aids, Sao Paulo, Brazil.
   [Tupinamba, U.] Med Sch UFMG, Belo Horizonte, MG, Brazil.
   [Veloso, V.; Grinsztejn, B.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, Rio De Janeiro, Brazil.
   [Barcellos, N.] Hosp Sanatorio Partenon, Porto Alegre, RS, Brazil.
RI DE CASTILHO, EUCLIDES AYRES/K-7906-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PY 2015
VL 44
SU 1
MA 2519
BP 186
EP 186
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DM9BV
UT WOS:000376659900474
DA 2020-11-24
ER

PT J
AU Diaz, CM
   Segura, E
   Luz, PM
   Clark, JL
   Ribeiro, SR
   Eksterman, L
   Moreira, R
   Currier, JS
   Veloso, VG
   Grinsztejn, B
   Lake, JE
AF Diaz, C. M.
   Segura, E.
   Luz, P. M.
   Clark, J. L.
   Ribeiro, S. R.
   Eksterman, L.
   Moreira, R.
   Currier, J. S.
   Veloso, V. G.
   Grinsztejn, B.
   Lake, J. E.
TI Traditional and HIV-specific risk factors for cardiovascular morbidity
   and mortality among HIV-infected adults in Brazil
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT 17th International Workshop on Co-Morbidities and Adverse Drug Reaction
   in HIV
CY OCT 20-22, 2015
CL Barcelona, SPAIN
C1 [Diaz, C. M.; Segura, E.; Clark, J. L.; Currier, J. S.; Lake, J. E.] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Diaz, C. M.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Luz, P. M.; Ribeiro, S. R.; Eksterman, L.; Moreira, R.; Veloso, V. G.; Grinsztejn, B.] Inst Nacl Infectol Evandro Chagas, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2015
VL 20
SU 1
MA P31
BP A59
EP A59
PG 1
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA DE8VV
UT WOS:000370915700061
DA 2020-11-24
ER

PT J
AU Bhatt, NB
   Baudin, E
   Meggi, B
   da Silva, C
   Barrail-Tran, A
   Furlan, V
   Grinsztejn, B
   Bonnet, M
   Taburet, AM
AF Bhatt, Nilesh B.
   Baudin, Elisabeth
   Meggi, Bindiya
   da Silva, Carlota
   Barrail-Tran, Aurelie
   Furlan, Valerie
   Grinsztejn, Beatriz
   Bonnet, Maryline
   Taburet, Anne-Marie
CA ANRS 12146-12214 CARINEMO Study
TI Nevirapine or efavirenz for tuberculosis and HIV coinfected patients:
   exposure and virological failure relationship
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
DE TB/HIV coinfection; nevirapine; efavirenz; drug-drug interactions
ID ANTIRETROVIRAL THERAPY; PLASMA-CONCENTRATIONS; INFECTED PATIENTS;
   ANTITUBERCULAR THERAPY; GENETIC POLYMORPHISMS; CYTOCHROME-P450 2B6;
   RIFAMPICIN; CYP2B6; PHARMACOKINETICS; ADULTS
AB Objectives: We describe nevirapine and efavirenz exposure on and off tuberculosis treatment and consequences for virological efficacy and tolerance in patients included in the ANRS 12146/12214-CARINEMO trial.
   Methods: Participants were randomly selected to receive either nevirapine at 200 mg twice daily (n = 256) or efavirenz at 600mg daily (n = 270), both combined with two nucleoside analogues. Blood samples were drawn 12 h after nevirapine or efavirenz administration, while on tuberculosis treatment and after tuberculosis treatment discontinuation. In 62 participants, samples taken 12 h after drug administration were drawn weekly for the first month of ART. Sixteen participants participated in an extensive pharmacokinetic study of nevirapine. Concentrations were compared with the therapeutic ranges of 3000-8000 ng/mL for nevirapine and 1000-4000 ng/mL for efavirenz.
   Results: Nevirapine concentrations at the end of the first week of treatment (on antituberculosis drugs) did not differ from concentrations off tuberculosis treatment, but declined thereafter. Concentrations at steady-state were 4111 ng/mL at week 12 versus 6095 ng/mL at week 48 (P<0.0001). Nevirapine concentrations <3000 ng/mL were found to be a risk factor for virological failure. Efavirenz concentrations were higher on than off tuberculosis treatment (2700 versus 2450 ng/mL, P < 0.0001).
   Conclusions: The omission of the 2 week lead-in dose of nevirapine prevented low concentrations at treatment initiation but did not prevent the risk of virological failure. Results support the WHO recommendation to use efavirenz at 600 mg daily in patients on rifampicin-based antituberculosis therapy.
C1 [Bhatt, Nilesh B.; Meggi, Bindiya] Minist Hlth, Inst Nacl Saude, Maputo, Mozambique.
   [Bhatt, Nilesh B.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Baudin, Elisabeth; da Silva, Carlota; Bonnet, Maryline] Epictr, Paris, France.
   [Barrail-Tran, Aurelie; Furlan, Valerie; Taburet, Anne-Marie] Hop Univ Paris Sud, Bicetre Hosp, AP HP, Clin Pharm, Paris, France.
   [Barrail-Tran, Aurelie] Univ Paris 11, Fac Pharm, EA4123, Paris, France.
RP Bhatt, NB (corresponding author), Minist Hlth, Inst Nacl Saude, Maputo, Mozambique.
EM nbhatt.mz@gmail.com
RI Barrail-Tran, Aurelie/ABC-5935-2020
OI Barrail-Tran, Aurelie/0000-0002-6053-6275; Baudin,
   Elisabeth/0000-0002-6575-6971
FU French Research Agency for HIV/AIDS and Hepatitis (ANRS-Inserm), France
   [12214]; Medecins Sans Frontieres, Operational Center Geneva,
   Switzerland; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476, U01AI069476,
   UM1AI069476, U01AI069476, UM1AI069476, U01AI069476, UM1AI069476,
   UM1AI069476, U01AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX This study was funded by a research grant from the French Research
   Agency for HIV/AIDS and Hepatitis (ANRS-Inserm), France (grant no.
   12214) and co-funded by Medecins Sans Frontieres, Operational Center
   Geneva, Switzerland.
CR Arnaldo P, 2013, MALAYS J MED SCI, V20, P13
   Avihingsanon A, 2008, ANTIVIR THER, V13, P529
   Bertrand J, 2014, J INFECT DIS, V209, P399, DOI 10.1093/infdis/jit466
   Bertranda J, 2012, PHARMACOGENET GENOM, V22, P868, DOI 10.1097/FPC.0b013e32835a5af2
   Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911
   Bonnet M, 2013, LANCET INFECT DIS, V13, P303, DOI 10.1016/S1473-3099(13)70007-0
   Cohen K, 2008, J ANTIMICROB CHEMOTH, V61, P389, DOI 10.1093/jac/dkm484
   Cohen K, 2009, ANTIVIR THER, V14, P687
   Fan-Havard P, 2013, ANTIMICROB AGENTS CH, V57, P2154, DOI 10.1128/AAC.02294-12
   Gengiah TN, 2012, EUR J CLIN PHARMACOL, V68, P689, DOI 10.1007/s00228-011-1166-5
   Haas DW, 2004, AIDS, V18, P2391
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   JAIN A, 1993, TUBERCLE LUNG DIS, V74, P87, DOI 10.1016/0962-8479(93)90032-S
   Karim QA, 2010, SAMJ S AFR MED J, V100, P808, DOI 10.7196/SAMJ.4621
   Koegelenberg CFN, 2013, SAMJ S AFR MED J, V103, P394, DOI [10.7196/samj.6344, 10.7196/SAMJ.6344]
   Kwara A, 2009, AIDS, V23, P2101, DOI 10.1097/QAD.0b013e3283319908
   Lamorde M, 2011, J ANTIMICROB CHEMOTH, V66, P180, DOI 10.1093/jac/dkq411
   Luetkemeyer AF, 2013, CLIN INFECT DIS, V57, P586, DOI 10.1093/cid/cit246
   Manosuthi W, 2006, CLIN INFECT DIS, V43, P253, DOI 10.1086/505210
   Manosuthi W, 2009, CLIN INFECT DIS, V48, P1752, DOI 10.1086/599114
   Marzolini C, 2001, AIDS, V15, P71, DOI 10.1097/00002030-200101050-00011
   Matteelli A, 2009, JAIDS-J ACQ IMM DEF, V52, P64, DOI 10.1097/QAI.0b013e3181b0328f
   Mugusi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040180
   Ngaimisi E, 2010, CLIN PHARMACOL THER, V88, P676, DOI 10.1038/clpt.2010.172
   Ogburn ET, 2010, DRUG METAB DISPOS, V38, P1218, DOI 10.1124/dmd.109.031393
   Proust V, 2000, J CHROMATOGR B, V742, P453, DOI 10.1016/S0378-4347(00)00208-5
   Riska P, 1999, DRUG METAB DISPOS, V27, P895
   Rotger M, 2007, CLIN PHARMACOL THER, V81, P557, DOI 10.1038/sj.clpt.6100072
   Scourfield A, 2012, AIDS, V26, P1399, DOI 10.1097/QAD.0b013e328353b047
   Titier K, 2002, THER DRUG MONIT, V24, P417, DOI 10.1097/00007691-200206000-00015
   Tostmann A, 2013, ANTIMICROB AGENTS CH, V57, P3208, DOI 10.1128/AAC.02599-12
   Uttayamakul S, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-8
   van Oosterhout JJ, 2007, ANTIVIR THER, V12, P515
   Veldkamp AI, 2001, AIDS, V15, P1089, DOI 10.1097/00002030-200106150-00003
   Wang J, 2006, PHARMACOGENET GENOM, V16, P191
   World Health Organization, 2013, CONS GUID US ANT DRU
   Yimer G, 2012, PHARMACOGENOMICS J, V12, P499, DOI 10.1038/tpj.2011.34
NR 37
TC 14
Z9 14
U1 1
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JAN
PY 2015
VL 70
IS 1
BP 225
EP 232
DI 10.1093/jac/dku348
PG 8
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA CC2YJ
UT WOS:000350210800031
PM 25239466
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Cambou, MC
   Luz, PM
   Lake, JE
   Levi, JE
   Coutinho, JR
   de Andrade, A
   Heinke, T
   Derrico, M
   Veloso, VG
   Friedman, RK
   Grinsztejn, B
AF Cambou, Mary C.
   Luz, Paula M.
   Lake, Jordan E.
   Levi, Jose Eduardo
   Coutinho, Jose Ricardo
   de Andrade, Angela
   Heinke, Thais
   Derrico, Monica
   Veloso, Valdilea G.
   Friedman, Ruth K.
   Grinsztejn, Beatriz
TI Anal Human Papillomavirus (HPV) Prevalences and Factors Associated with
   Abnormal Anal Cytology in HIV-Infected Women in an Urban Cohort from Rio
   de Janeiro, Brazil
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID SQUAMOUS INTRAEPITHELIAL LESIONS; NEOPLASIA; CANCER; GUIDELINES;
   CARCINOMA; RISK
AB Identifying factors, including human papillomavirus (HPV) genotypes, associated with abnormal anal cytology in HIV-infected women have implications for anal squamous cell cancer (SCC) prevention in HIV-infected women. Anal and cervical samples were collected for cytology, and tested for high-(HR-HPV) and low-risk HPV (LR-HPV) genotypes in a cross-sectional analysis of the IPEC Women's HIV Cohort (Rio de Janeiro, Brazil). Multivariate log-binomial regression models estimated prevalence ratios for factors associated with abnormal anal cytology [>= atypical squamous cells of undetermined significance, (ASC-US)]. Characteristics of the 863 participants included: median age 42 years, 57% non-white, 79% current CD4+ T-cell count >350 cells/mm(3), 53% HIV-1 viral load <50 copies/mL, median ART duration 5.8 years. Fifty-one percent of anal specimens contained >= 1 HR-HPV genotype; 31% had abnormal anal cytology [14% ASC-US, 11% low-grade squamous intra-epithelial lesion, (LSIL); 2% atypical squamous cells-cannot exclude high-grade SIL (ASC-H); 4% high-grade SIL/cancer (HSIL+)]. In multivariate analysis, cervical LSIL+, nadir CD4+ T-cell count <= 50 cells/mm(3), HIV-1 viral load >= 50 copies/mL, and anal HPV 6, 11, 16, 18, 33, 45, 52, 56, and 58 were associated with >= anal ASC-US (p<0.05). Abnormal anal cytology and HR-HPV prevalences were high. HIV-infected women with cervical LSIL+, low nadir CD4+ counts, or detectable HIV-1 viral loads should be a particular focus for enhanced anal SCC screening efforts.
C1 [Cambou, Mary C.; Lake, Jordan E.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
   [Cambou, Mary C.; Lake, Jordan E.] Univ Calif Los Angeles, David Geffen Sch Med, Program Global Hlth, Los Angeles, CA 90095 USA.
   [Luz, Paula M.; Coutinho, Jose Ricardo; de Andrade, Angela; Derrico, Monica; Veloso, Valdilea G.; Friedman, Ruth K.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop, Sao Paulo, Brazil.
   [Heinke, Thais] SalomaoZoppi Diagnost, Sao Paulo, Brazil.
RP Cambou, MC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM mcambou@mednet.ucla.edu
OI Luz, Paula/0000-0001-9746-719X; Heinke, Thais/0000-0002-2842-496X
FU South American Program in HIV Prevention Research (SAPHIR) [NIH R25
   MH087222]; Brazilian National Counsel of Technological and Scientific
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); Research Funding Agency of the State of Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Instituto de Pesquisa Clinica
   Evandro Chagas; Fundacao Oswaldo Cruz; Brazilian National STD/AIDS
   Program of the Brazilian Ministry of Health; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [K23MH084611, K23MH084611, K23MH084611,
   R25MH087222, R25MH087222, R25MH087222, R25MH087222, R25MH087222,
   R25MH087222, R25MH087222, K23MH084611, K23MH084611, R25MH087222] Funding
   Source: NIH RePORTER
FX MCC, JEL, PML, and BG are supported by the South American Program in HIV
   Prevention Research (SAPHIR; NIH R25 MH087222). BG and PML acknowledge
   funding from the Brazilian National Counsel of Technological and
   Scientific Development (CNPq) and the Research Funding Agency of the
   State of Rio de Janeiro (FAPERJ). This study was funded by the Instituto
   de Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz and the
   Brazilian National STD/AIDS Program of the Brazilian Ministry of Health.
CR Abraham AG, 2013, JAIDS-J ACQ IMM DEF, V62, P405, DOI 10.1097/QAI.0b013e31828177d7
   Ahdieh L, 2001, J INFECT DIS, V184, P682, DOI 10.1086/323081
   [Anonymous], 2014, Cancer Discov, V4, pOF2, DOI 10.1158/2159-8290.CD-NB2013-168
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Boldrini NT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102169
   Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321
   Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14
   Daling JR, 2004, CANCER-AM CANCER SOC, V101, P270, DOI 10.1002/cncr.20365
   Darragh TM, 2011, CANCER CYTOPATHOL, V119, P5, DOI 10.1002/cncy.20126
   De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002/ijc.24116
   Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031
   Fernandes Jose V, 2010, BMC Res Notes, V3, P96, DOI 10.1186/1756-0500-3-96
   Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
   Goncalves Maria Alice G, 2008, Infect Agent Cancer, V3, P5, DOI 10.1186/1750-9378-3-5
   Gravitt PE, 2011, J CLIN INVEST, V121, P4593, DOI 10.1172/JCI57149
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Hessol NA, 2013, AIDS, V27, P1743, DOI 10.1097/QAD.0b013e3283601b09
   Huh WK, 2009, OBSTET GYNECOL, V114, P139, DOI 10.1097/AOG.0b013e3181ab6878
   Institute NC, SEER STAT FACT SHEET
   Kojic EM, 2011, SEX TRANSM DIS, V38, P253, DOI 10.1097/OLQ.0b013e3181f70253
   Luz PM, 2012, INT J STD AIDS, V23, P12, DOI 10.1258/ijsa.2009.009409
   Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3
   Mani D, 2013, CURR OPIN ONCOL, V25, P518, DOI 10.1097/CCO.0b013e328363e04a
   Chaves EBM, 2012, J MED VIROL, V84, P1335, DOI 10.1002/jmv.23346
   McKenzie ND, 2010, GYNECOL ONCOL, V116, P572, DOI 10.1016/j.ygyno.2009.10.058
   Nagle Deborah, 2009, Clin Colon Rectal Surg, V22, P102, DOI 10.1055/s-0029-1223841
   Paesi S, 2009, J MED VIROL, V81, P1270, DOI 10.1002/jmv.21410
   Petersen MR, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-9
   Robbins HA, 2014, AIDS, V28, P881, DOI 10.1097/QAD.0000000000000163
   Saude Md, 2013, PROTOCOL CLINICO E D
   Sehnal B, 2014, J CLIN VIROL, V59, P18, DOI 10.1016/j.jcv.2013.11.004
   Silverberg MJ, 2012, CLIN INFECT DIS, V54, P1026, DOI 10.1093/cid/cir1012
   Stanley MA, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-398
   Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903
   Tandon R, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.01.010
   Tong WWY, 2014, HIV MED, V15, P65, DOI 10.1111/hiv.12080
   UCSF, AN CANC INF
   Wells JS, 2014, AIDS PATIENT CARE ST, V28, P350, DOI 10.1089/apc.2013.0358
   Bosch FX, 2013, VACCINE, V31, P1, DOI 10.1016/j.vaccine.2013.07.026
   Zbar AP, 2002, INT J COLORECTAL DIS, V17, P203, DOI 10.1007/s00384-001-0369-0
NR 40
TC 20
Z9 21
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD JAN 1
PY 2015
VL 29
IS 1
BP 4
EP 12
DI 10.1089/apc.2014.0166
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AY0MI
UT WOS:000347290100002
PM 25361401
OA Green Published
DA 2020-11-24
ER

PT J
AU Castro, R
   Perazzo, H
   Grinsztejn, B
   Veloso, VG
   Hyde, C
AF Castro, Rodolfo
   Perazzo, Hugo
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Hyde, Chris
TI Chronic Hepatitis C: An Overview of Evidence on Epidemiology and
   Management from a Brazilian Perspective
SO INTERNATIONAL JOURNAL OF HEPATOLOGY
LA English
DT Review
ID QUALITY-OF-LIFE; TREATMENT-NAIVE PATIENTS; VIRUS GENOTYPE 1; LIVER
   FIBROSIS; PEGYLATED INTERFERON; TRANSIENT ELASTOGRAPHY; NATURAL-HISTORY;
   RESISTANCE MUTATIONS; COST-EFFECTIVENESS; PLUS SOFOSBUVIR
AB Chronic hepatitis C remains one of the main causes of chronic liver disease worldwide and presents a variable natural history ranging from minimal changes to advanced fibrosis and cirrhosis and its complications, such as development of hepatocellular carcinoma. Approximately, 1.45 million people are estimated to be infected by HCV in Brazil representing a major public health issue. The aim of this paper was to review the epidemiology and management of chronic hepatitis C from a Brazilian perspective. The management of chronic hepatitis Chas been challenged by the use of noninvasive methods to stage liver fibrosis as an alternative to liver biopsy and the high cost of new interferon-free antiviral treatments. Moreover, the need of cost-effectiveness analysis in hepatitis C and the recent changes in treatment protocols were discussed.
C1 [Castro, Rodolfo; Perazzo, Hugo; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Lab Clin Res STD AIDS, Evandro Chagas Natl Inst Infect Dis, Ave Brasil 4365, BR-21040900 Manguinho, RJ, Brazil.
   [Hyde, Chris] Univ Exeter, Med Sch, Evidence Synth & Modelling Hlth Improvement ESMI, Inst Hlth Res,Peninsula Technol Assessment Grp Pe, Exeter EX1 2LU, Devon, England.
RP Castro, R (corresponding author), Fundacao Oswaldo Cruz, Lab Clin Res STD AIDS, Evandro Chagas Natl Inst Infect Dis, Ave Brasil 4365, BR-21040900 Manguinho, RJ, Brazil.
EM rodolfoalcastro@gmail.com
RI Castro, Rodolfo/D-4231-2013
OI Castro, Rodolfo/0000-0002-0701-2528; Perazzo, Hugo/0000-0003-0931-6418
FU Newton Fund RCUK-CONFAP Research Partnerships call; Fundacao Carlos
   Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ),
   (Brazil)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/170.021/2015]; Medical Research Council
   (MRC), (UK)Medical Research Council UK (MRC) [MR/M026515/1]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Bolsa Jovem
   Talento (BJT), Programa Ciencias Sem Fronteiras, Brazil,National Council
   for Scientific and Technological Development (CNPq) [301520/2014-3];
   Brazil-UK collaboration in Health Technology Assessment of diagnostic
   strategies for infectious diseases; Medical Research CouncilMedical
   Research Council UK (MRC) [MR/M026515/1] Funding Source: researchfish
FX The authors would like to acknowledge the following research grants:
   Newton Fund RCUK-CONFAP Research Partnerships call, Project "Brazil-UK
   collaboration in Health Technology Assessment of diagnostic strategies
   for infectious diseases," Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ) under Grant
   E-26/170.021/2015 (Brazil) and Medical Research Council (MRC) Grant
   Reference MR/M026515/1 (UK), and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Bolsa Jovem Talento (BJT), Programa
   Ciencias Sem Fronteiras, Brazil, under Grant 301520/2014-3.
CR Abrantes J, 2013, POSTGRAD MED J, V89, P433, DOI 10.1136/postgradmedj-2012-131185
   Afdhal N, 2014, NEW ENGL J MED, V370, P1483, DOI 10.1056/NEJMoa1316366
   Akamatsu N, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/686135
   Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505
   ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702
   Alves GA, 2012, REV SOC BRAS MED TRO, V45, P553, DOI 10.1590/S0037-86822012000500003
   [Anonymous], 2002, HEPATOLOGY, V36, pS3, DOI 10.1053/jhep.2002.37117
   Ansaldi F, 2014, WORLD J GASTROENTERO, V20, P9633, DOI 10.3748/wjg.v20.i29.9633
   Artico S, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-377
   Bansal S, 2015, WORLD J HEPATOL, V7, P806, DOI 10.4254/wjh.v7.i5.806
   BARRERA JM, 1995, HEPATOLOGY, V21, P639, DOI 10.1016/0270-9139(95)90511-1
   Barros Fabio Mr, 2013, Cost Eff Resour Alloc, V11, P25, DOI 10.1186/1478-7547-11-25
   Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022
   BEDOSSA P, 1994, HEPATOLOGY, V20, P15
   Bichoupan K, 2014, HEPATOLOGY, V60, P1187, DOI 10.1002/hep.27340
   Booth JCL, 2001, GUT, V49, pI1, DOI 10.1136/gut.49.suppl_1.I1
   Bota S, 2013, LIVER INT, V33, P1138, DOI 10.1111/liv.12240
   Botero Rafael Claudino, 2015, Clin Liver Dis (Hoboken), V5, P8, DOI 10.1002/cld.438
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de DST Aids e Hepatites Virais, 2015, PROT CLIN DIR TER HE
   Brasil. Ministerio da Saude Secretaria de Vigilancia em Saude Departamento de DST and Aids e Hepatites Virais, 2015, B EP HEP VIR
   Brasil. Ministerio da Saude Secretaria de Vigilancia em Saude Departamento de DST and Aids e Hepatites Virais, 2012, B EP OG HEP VIR
   Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706
   Castera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018
   Chen Stephen L, 2006, Int J Med Sci, V3, P47
   Chevaliez S, 2011, CLIN RES HEPATOL GAS, V35, pS31, DOI 10.1016/S2210-7401(11)70005-5
   Chou R, 2013, ANN INTERN MED, V158, P807, DOI 10.7326/0003-4819-158-11-201306040-00005
   Chung RT, 2015, HEPATOLOGY, V62, P932, DOI 10.1002/hep.27950
   Cohen P, 2000, PRESSE MED, V29, P209
   D'Incao RB, 2013, ANN HEPATOL, V12, P876, DOI 10.1016/S1665-2681(19)31292-X
   da Silva RG, 2008, BRAZ J INFECT DIS, V12, P15, DOI 10.1590/S1413-86702008000100005
   Rodrigues MPD, 2013, CAD SAUDE PUBLICA, V29, pS146, DOI 10.1590/0102-311X00014613
   Das B R, 2002, Indian J Pathol Microbiol, V45, P323
   de Ledinghen V, 2008, GASTROEN CLIN BIOL, V32, P58, DOI 10.1016/S0399-8320(08)73994-0
   El Khoury AC, 2014, REV PANAM SALUD PUBL, V35, P200
   EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER, 2014, EASL REC TREATM HEP
   Fabregas BC, 2014, REV SOC BRAS MED TRO, V47, P564, DOI 10.1590/0037-8682-0147-2014
   Fabregas BC, 2013, BRAZ J INFECT DIS, V17, P633, DOI 10.1016/j.bjid.2013.03.008
   Amorim TGF, 2012, ANN HEPATOL, V11, P855
   Fernandes FF, 2015, J CLIN GASTROENTEROL, V49, P235, DOI 10.1097/MCG.0000000000000128
   Gane EJ, 2014, J HEPATOL, V60, pS3, DOI 10.1016/S0168-8278(14)60008-8
   Hezode C, 2014, J HEPATOL, V60, pS24, DOI 10.1016/S0168-8278(14)60060-X
   Hezode C, 2014, GASTROENTEROLOGY, V147, P132, DOI 10.1053/j.gastro.2014.03.051
   Hoffmann L, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-57
   Imran M, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-299
   ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6
   Jacobson IM, 2013, NEW ENGL J MED, V368, P1867, DOI 10.1056/NEJMoa1214854
   Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912
   Kiser JJ, 2013, NAT REV GASTRO HEPAT, V10, P596, DOI 10.1038/nrgastro.2013.106
   Klaus F, 2014, TRANSPL P, V46, P1819, DOI 10.1016/j.transproceed.2014.05.053
   Kowdley KV, 2014, NEW ENGL J MED, V370, P1879, DOI 10.1056/NEJMoa1402355
   Kowdley KV, 2013, LANCET, V381, P2100, DOI 10.1016/S0140-6736(13)60247-0
   Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x
   Lawitz E, 2014, LANCET, V384, P1756, DOI 10.1016/S0140-6736(14)61036-9
   Liang TJ, 2013, NEW ENGL J MED, V368, P1907, DOI 10.1056/NEJMra1213651
   Fonseca MCM, 2009, BRAZ J INFECT DIS, V13, P191, DOI 10.1590/S1413-86702009000300007
   Maity S, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-290
   Manns M, 2014, LANCET, V384, P414, DOI 10.1016/S0140-6736(14)60538-9
   Massad E, 2009, EPIDEMIOL INFECT, V137, P241, DOI 10.1017/S0950268808000873
   MCGILL DB, 1990, GASTROENTEROLOGY, V99, P1396, DOI 10.1016/0016-5085(90)91167-5
   Ministerio da Saude Secretaria de Vigilancia em Saude Sistema de Informacao de Agravos de Notificacao and Sinan Net, 2015, HEP VIR CAS CONF NOT
   Morais-de-Jesus M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110529
   Moyer VA, 2013, ANN INTERN MED, V159, P349, DOI 10.7326/0003-4819-159-5-201309030-00672
   Murphy DG, 2007, J CLIN MICROBIOL, V45, P1102, DOI 10.1128/JCM.02366-06
   Myers RP, 2015, CAN J GASTROENTEROL, V29, P19, DOI 10.1155/2015/692408
   Nelson DR, 2015, HEPATOLOGY, V61, P1127, DOI 10.1002/hep.27726
   Nunes D, 2010, AM J GASTROENTEROL, V105, P1346, DOI 10.1038/ajg.2009.746
   Paranagua-Vezozzo DC, 2014, ANN HEPATOL, V13, P386, DOI 10.1016/S1665-2681(19)30845-2
   Parise ER, 2006, LIVER INT, V26, P1095, DOI 10.1111/j.1478-3231.2006.01356.x
   Pawlotsky JM, 2011, HEPATOLOGY, V53, P1742, DOI 10.1002/hep.24262
   Pawlotsky JM, 2006, J HEPATOL, V44, pS10, DOI 10.1016/j.jhep.2005.11.005
   Perazzo H., 2015, CLIN RES HEPATOLOGY
   Perazzo H, 2015, LIVER INT, V35, P1533, DOI 10.1111/liv.12551
   Perazzo H, 2014, CLIN RES HEPATOL GAS, V38, P432, DOI 10.1016/j.clinre.2014.04.006
   Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
   Planas R, 2004, J HEPATOL, V40, P823, DOI 10.1016/j.jhep.2004.01.005
   Poordad F, 2014, NEW ENGL J MED, V370, P1973, DOI 10.1056/NEJMoa1402869
   Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494
   Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8
   Poynard T, 2000, SEMIN LIVER DIS, V20, P47, DOI 10.1055/s-2000-9258
   Poynard T, 2014, J HEPATOL, V60, P706, DOI 10.1016/j.jhep.2013.11.016
   Poynard Thierry, 2011, Gastroenterol Hepatol (N Y), V7, P445
   Poynard Thierry, 2008, Saudi J Gastroenterol, V14, P163, DOI 10.4103/1319-3767.43273
   Prati D, 1999, BRIT J HAEMATOL, V105, P841, DOI 10.1046/j.1365-2141.1999.01486.x
   Rousselet MC, 2005, HEPATOLOGY, V41, P257, DOI 10.1002/hep.20535
   Ruane P. J., 2013, P 64 ANN M AM ASS ST
   Salvalaggio PR, 2014, TRANSPLANTATION, V98, P241, DOI 10.1097/TP.0000000000000198
   Sarrazin C., 2015, J HEPATOLOGY
   Sharma S, 2014, WORLD J GASTROENTERO, V20, P16820, DOI 10.3748/wjg.v20.i45.16820
   Silva RG, 2014, SCAND J GASTROENTERO, V49, P986, DOI 10.3109/00365521.2014.909528
   Smith BD, 2011, J INFECT DIS, V204, P825, DOI 10.1093/infdis/jir422
   Soriano V, 2011, J ANTIMICROB CHEMOTH, V66, P1673, DOI 10.1093/jac/dkr215
   Strauss E, 2014, CLIN RES HEPATOL GAS, V38, P40, DOI 10.1016/j.clinre.2013.08.008
   Sy Theodore, 2006, Int J Med Sci, V3, P41
   Teixeira MCD, 2006, TRANSFUSION, V46, P278, DOI 10.1111/j.1537-2995.2006.00712.x
   Terrault NA, 2013, HEPATOLOGY, V57, P881, DOI 10.1002/hep.26164
   van der Meer AJ, 2012, JAMA-J AM MED ASSOC, V308, P2584, DOI 10.1001/jama.2012.144878
   Vergniol J, 2011, GASTROENTEROLOGY, V140, P1970, DOI 10.1053/j.gastro.2011.02.058
   Vigani AG, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-164
   Vigani AG, 2012, BRAZ J INFECT DIS, V16, P232, DOI 10.1590/S1413-86702012000300003
   Villano SA, 1999, HEPATOLOGY, V29, P908, DOI 10.1002/hep.510290311
   Reggiardo MV, 2012, ANN HEPATOL, V11, P658
   Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346
   Webster DP, 2015, LANCET, V385, P1124, DOI 10.1016/S0140-6736(14)62401-6
   Zeminian LB, 2013, MEM I OSWALDO CRUZ, V108, P13, DOI 10.1590/S0074-02762013000100002
   Zeuzem S, 2014, NEW ENGL J MED, V370, P1993, DOI 10.1056/NEJMoa1316145
   Zeuzem S, 2014, NEW ENGL J MED, V370, P1604, DOI 10.1056/NEJMoa1401561
   Ziol M, 2005, HEPATOLOGY, V41, P48, DOI 10.1002/hep.20506
NR 107
TC 3
Z9 3
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-3448
EI 2090-3456
J9 INT J HEPATOL
JI Int. J. Hepatol.
PY 2015
VL 2015
AR 852968
DI 10.1155/2015/852968
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V25SP
UT WOS:000215244600008
PM 26693356
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Veloso, VG
   Grinsztejn, B
   Hyde, C
   Castro, R
AF Perazzo, Hugo
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Hyde, Chris
   Castro, Rodolfo
TI Factors That Could Impact on Liver Fibrosis Staging by Transient
   Elastography
SO INTERNATIONAL JOURNAL OF HEPATOLOGY
LA English
DT Review
ID CHRONIC HEPATITIS-C; STIFFNESS MEASUREMENT; DIAGNOSTIC-ACCURACY;
   HEART-FAILURE; GOLD STANDARD; VALUES; CURVE; REPRODUCIBILITY;
   APPLICABILITY; FIBROTEST(R)
AB Transient elastography (TE) based on liver stiffness measurement (LSM) is one of the most validated noninvasive methods for liver fibrosis staging in patients with chronic liver diseases. This method is painless, has no potential complications, is rapid (<10 min), and can be performed at the patient's bedside. However, several points should be considered when interpreting TE results. This review aims to discuss the critical points that might influence liver stiffness and TE results. Spectrum bias and the impact of the prevalence of fibrosis stages should be taken into account when interpreting the studies that validated this method using liver biopsy as a gold-standard. LSM might be influenced by nonfasting status, flare of transaminases, heart failure, extrahepatic cholestasis, presence of steatosis, aetiology of liver disease, type and position of probe, and operator's experience. In addition, interobserver variability can impact on the management of patients with chronic liver diseases. TE should be performed by an experienced operator (>100 exams), in a 3-hour fasting status, and its results should be handled by specialist clinicians that are aware of the limitations of this method.
C1 [Perazzo, Hugo; Veloso, Valdilea G.; Grinsztejn, Beatriz; Castro, Rodolfo] Oswaldo Cruz Fdn FIOCRUZ, Lab Clin Res STD AIDS, Evandro Chagas Natl Inst Infect Dis INI, Ave Brasil 4365, BR-21040900 Manguinho, RJ, Brazil.
   [Hyde, Chris] Univ Exeter, Med Sch, Evidence Synth & Modelling Hlth Improvement ESMI, Inst Hlth Res,Peninsula Technol Assessment Grp Pe, Exeter EX1 2LU, Devon, England.
RP Perazzo, H (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Lab Clin Res STD AIDS, Evandro Chagas Natl Inst Infect Dis INI, Ave Brasil 4365, BR-21040900 Manguinho, RJ, Brazil.
EM hugo.perazzo@ini.fiocruz.br
RI Castro, Rodolfo/D-4231-2013
OI Castro, Rodolfo/0000-0002-0701-2528; Perazzo, Hugo/0000-0003-0931-6418
FU Newton Fund RCUK-CONFAP Research Partnerships Call; Fundacao Carlos
   Chagas Filho de Amparoa Pesquisa do Estado do Rio de Janeiro (FAPERJ),
   (Brazil)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/170.021/2015]; Medical Research Council
   (MRC), (UK)Medical Research Council UK (MRC) [MR/M026515/1]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)/Bolsa Jovem
   Talento (BJT)National Council for Scientific and Technological
   Development (CNPq) [301520/2014-3]; FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/110.268/2014]; Fundacao para Desenvolvimento Cientifico e
   Tecnologico em Saude (FioTec), Rio de Janeiro, Brazil; Medical Research
   CouncilMedical Research Council UK (MRC) [MR/M026515/1] Funding Source:
   researchfish
FX This work was supported by funding from Newton Fund RCUK-CONFAP Research
   Partnerships Call, Fundacao Carlos Chagas Filho de Amparoa Pesquisa do
   Estado do Rio de Janeiro (FAPERJ) under Grant E-26/170.021/2015
   (Brazil), and Medical Research Council (MRC) Grant reference
   MR/M026515/1 (UK); from Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq)/Bolsa Jovem Talento (BJT) under Grant
   301520/2014-3; from FAPERJ under Grant E-26/110.268/2014; and from
   Fundacao para Desenvolvimento Cientifico e Tecnologico em Saude
   (FioTec), Rio de Janeiro, Brazil.
CR Arena U, 2008, HEPATOLOGY, V47, P380, DOI 10.1002/hep.22007
   Arena U, 2013, HEPATOLOGY, V58, P65, DOI 10.1002/hep.26343
   Bota S, 2013, LIVER INT, V33, P1138, DOI 10.1111/liv.12240
   Boursler J, 2008, EUR J GASTROEN HEPAT, V20, P693, DOI 10.1097/MEG.0b013e3282f51992
   Castera L, 2008, J HEPATOL, V48, P835, DOI 10.1016/j.jhep.2008.02.008
   Castera L, 2010, HEPATOLOGY, V51, P828, DOI 10.1002/hep.23425
   Colli A, 2010, RADIOLOGY, V257, P872, DOI 10.1148/radiol.10100013
   Corpechot C, 2014, GASTROENTEROLOGY, V146, P970, DOI 10.1053/j.gastro.2013.12.030
   Das K, 2012, HEPATOLOGY, V55, P584, DOI 10.1002/hep.24694
   de Ledinghen V, 2008, GASTROEN CLIN BIOL, V32, P58, DOI 10.1016/S0399-8320(08)73994-0
   de Ledinghen V, 2012, J HEPATOL, V56, P833, DOI 10.1016/j.jhep.2011.10.017
   Fernandes FF, 2015, J CLIN GASTROENTEROL, V49, P235, DOI 10.1097/MCG.0000000000000128
   Fernandez M, 2015, EUR J GASTROEN HEPAT, V27, P1074, DOI 10.1097/MEG.0000000000000392
   Fraquelli M, 2007, GUT, V56, P968, DOI 10.1136/gut.2006.111302
   Fung J, 2011, AM J GASTROENTEROL, V106, P492, DOI 10.1038/ajg.2010.463
   Fung J, 2010, AM J GASTROENTEROL, V105, P1116, DOI 10.1038/ajg.2009.665
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Hopper I, 2012, EUR J HEART FAIL, V14, P621, DOI 10.1093/eurjhf/hfs044
   Ingiliz P, 2009, WORLD J GASTROENTERO, V15, P3398, DOI 10.3748/wjg.15.3398
   Lambert J, 2008, CLIN CHEM, V54, P1372, DOI 10.1373/clinchem.2007.097923
   Macaluso FS, 2014, J HEPATOL, V61, P523, DOI 10.1016/j.jhep.2014.04.045
   Mederacke I, 2009, LIVER INT, V29, P1500, DOI 10.1111/j.1478-3231.2009.02100.x
   Melita SH, 2009, J HEPATOL, V50, P36, DOI 10.1016/j.jhep.2008.07.039
   Millonig G, 2008, HEPATOLOGY, V48, P1718, DOI 10.1002/hep.22577
   Nascimbeni F, 2015, CLIN GASTROENTEROL H, V13, P763, DOI 10.1016/j.cgh.2014.07.037
   Obuchowski NA, 2006, STAT MED, V25, P481, DOI 10.1002/sim.2228
   Pawlotsky JM, 2015, J HEPATOL, V63, P199, DOI 10.1016/j.jhep.2015.03.025
   Perazzo H., 2015, CLIN RES HEPATOLOGY
   Perazzo H, 2015, J HEPATOL, V63, P1048, DOI 10.1016/j.jhep.2015.06.036
   Perazzo H, 2015, LIVER INT, V35, P1533, DOI 10.1111/liv.12551
   Petta S, 2015, HEPATOLOGY, V62, P1101, DOI 10.1002/hep.27844
   Poynard T., 2012, CLIN GASTROENTEROLOG, V10
   Poynard T, 2007, CLIN CHEM, V53, P1615, DOI 10.1373/clinchem.2007.085795
   Poynard T, 2014, J HEPATOL, V61, P994, DOI 10.1016/j.jhep.2014.06.027
   Poynard T, 2011, CLIN RES HEPATOL GAS, V35, P720, DOI 10.1016/j.clinre.2011.07.003
   Poynard Thierry, 2011, Curr Hepat Rep, V10, P87, DOI 10.1007/s11901-011-0096-0
   Poynard T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003857
   Roca B, 2012, J VIRAL HEPATITIS, V19, P711, DOI 10.1111/j.1365-2893.2012.01608.x
   Roulot D, 2008, J HEPATOL, V48, P606, DOI 10.1016/j.jhep.2007.11.020
   Singh S, 2013, CLIN GASTROENTEROL H, V11, P1573, DOI 10.1016/j.cgh.2013.07.034
   Snowdon VK, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/691089
   Trifan A, 2011, HEPAT MON, V11, P372
   Vispo E, 2009, ANTIVIR THER, V14, P187
NR 43
TC 6
Z9 8
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-3448
EI 2090-3456
J9 INT J HEPATOL
JI Int. J. Hepatol.
PY 2015
VL 2015
AR 624596
DI 10.1155/2015/624596
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V25SP
UT WOS:000215244600006
PM 26770833
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Torres, TS
   Luz, PM
   Derrico, M
   Velasque, L
   Grinsztejn, E
   Veloso, VG
   Cardoso, SW
   Santini-Oliveira, M
   Grinsztejn, B
   De Boni, RB
AF Torres, Thiago S.
   Luz, Paula M.
   Derrico, Monica
   Velasque, Luciane
   Grinsztejn, Eduarda
   Veloso, Valdilea G.
   Cardoso, Sandra W.
   Santini-Oliveira, Marilia
   Grinsztejn, Beatriz
   De Boni, Raquel Brandini
TI Factors Associated with Tobacco Smoking and Cessation among HIV-Infected
   Individuals under Care in Rio de Janeiro, Brazil
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; CIGARETTE-SMOKING;
   RISK-FACTORS; POSITIVE PATIENTS; CLINICAL CARE; HEALTH-RISKS; USE
   PATTERNS; MORTALITY; SMOKERS
AB Worldwide the prevalence of smoking among people living with HIV/AIDS is elevated compared to the general population. This probably reflects the cluster of individual characteristics that have shared risk factors for HIV infection and smoking. A cross-sectional study, enrolling a convenience sample from a Brazilian HIV clinical cohort was conducted to evaluate the prevalence of tobacco smoking and the factors associated with current smoking and abstinence. A total of 2,775 HIV-infected individuals were interviewed: 46.2% have never smoked, 29.9% were current smokers and 23.9% were former smokers. Current smokers had a higher prevalence of alcohol and illicit drug use when compared to the other two groups. A higher proportion of heterosexual individuals were former smokers or never smokers while among men who have sex with men (MSM) a higher proportion were current smokers. Former smokers had been more frequently diagnosed with high blood pressure, diabetes mellitus, cardiovascular diseases and depression, while for current smokers lung diseases were more frequent. Former smokers and current smokers were more likely to have had any hospital admission (42.0% and 41.2%, respectively) than participants who never smoked (33.5%) (p<0.001). Multivariate model results showed that current smokers (versus never smokers) were more likely to be less educated, to report the use of alcohol, crack and cocaine and to present clinical comorbidities. Former smokers (versus current smokers) were more likely to be older, to have smoked for a shorter amount of time and to have smoked >31 cigarettes/day. MSM (compared to heterosexuals) and cocaine users (versus non-users) had lower odds of being former smokers. Considering our results, smoking cessation interventions should be tailored to younger individuals, MSM and substance users.
C1 [Torres, Thiago S.; Luz, Paula M.; Derrico, Monica; Velasque, Luciane; Grinsztejn, Eduarda; Veloso, Valdilea G.; Cardoso, Sandra W.; Santini-Oliveira, Marilia; Grinsztejn, Beatriz; De Boni, Raquel Brandini] Fundacao Oswaldo Cruz, HIV AIDS Clin Res Ctr, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Velasque, Luciane] Univ Fed Estado Rio de Janeiro UniRio, Dept Matemat, Rio De Janeiro, Brazil.
RP Torres, TS (corresponding author), Fundacao Oswaldo Cruz, HIV AIDS Clin Res Ctr, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM thiago.torres@ipec.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Cardoso, Sandra W/D-7965-2015;
   TORRES, THIAGO SILVA/D-6548-2014
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Cardoso, Sandra
   W/0000-0001-5230-0003; TORRES, THIAGO SILVA/0000-0002-2557-601X; Luz,
   Paula/0000-0001-9746-719X
CR Alavi-Naini R, 2013, J RES MED SCI, V18, P52
   Amiya RM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-677
   Arcavi L, 2004, ARCH INTERN MED, V164, P2206, DOI 10.1001/archinte.164.20.2206
   Batista Joanna d’Arc Lyra, 2013, Rev. bras. epidemiol., V16, P432, DOI 10.1590/S1415-790X2013000200018
   Benard A, 2007, AIDS PATIENT CARE ST, V21, P458, DOI 10.1089/apc.2006.0142
   Benard A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008896
   Berhe Gebretsadik, 2013, Ethiop Med J, V51, P227
   Collins RL, 2001, HEALTH PSYCHOL, V20, P351, DOI 10.1037//0278-6133.20.5.351
   Crabtree-Ramirez B, 2014, JAIDS-J ACQ IMM DEF, V67, pS96, DOI 10.1097/QAI.0000000000000261
   Cropsey KL, 2013, ADDICT BEHAV, V38, P2541, DOI 10.1016/j.addbeh.2013.05.003
   Dale L C, 1997, Tob Control, V6, P181
   Dube S. R., 2010, Morbidity and Mortality Weekly Report, V59, P1135
   Duval X, 2008, ANTIVIR THER, V13, P389
   Ehrlich RI, 2004, INT J TUBERC LUNG D, V8, P369
   Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6
   Feldman DN, 2009, AIDS EDUC PREV, V21, P81, DOI 10.1521/aeap.2009.21.3_supp.81
   Fuster M, 2009, HIV MED, V10, P614, DOI 10.1111/j.1468-1293.2009.00735.x
   Goren A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093014
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Gritz ER, 2013, CLIN INFECT DIS, V57, P608, DOI 10.1093/cid/cit349
   Gritz ER, 2004, NICOTINE TOB RES, V6, P71, DOI 10.1080/14622200310001656885
   HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
   Helleberg M, 2013, CLIN INFECT DIS, V56, P727, DOI 10.1093/cid/cis933
   Humfleet GL, 2013, NICOTINE TOB RES, V15, P1436, DOI 10.1093/ntr/ntt005
   Humfleet GL, 2009, AIDS EDUC PREV, V21, P54, DOI 10.1521/aeap.2009.21.3_supp.54
   Jaquet A, 2009, INT J TUBERC LUNG D, V13, P1433
   Kumar SR, 2009, INDIAN J MED RES, V130, P15
   Lewden C, 2005, INT J EPIDEMIOL, V34, P121, DOI 10.1093/ije/dyh307
   Lifson AR, 2012, CURR HIV-AIDS REP, V9, P223, DOI 10.1007/s11904-012-0121-0
   Lifson AR, 2010, AM J PUBLIC HEALTH, V100, P1896, DOI 10.2105/AJPH.2009.188664
   Louwagie GMC, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1031
   Malta DC, 2013, CAD SAUDE PUBLICA, V29, P812, DOI [10.1590/S0102-311X2013000800018, 10.1590/S0102-311X2013000400018]
   Mamary EM, 2002, AIDS PATIENT CARE ST, V16, P39, DOI 10.1089/108729102753429389
   Matthews AK, 2013, AIDS PATIENT CARE ST, V27, P22, DOI 10.1089/apc.2012.0253
   Mayer KH, 2012, LANCET, V380, P378, DOI 10.1016/S0140-6736(12)60835-6
   Ministerio da Saude do Brasil, 2012, B EP ESP TUB
   Munyati SS, 2006, INT J TUBERC LUNG D, V10, P1279
   Nahvi S, 2009, AIDS EDUC PREV, V21, P14, DOI 10.1521/aeap.2009.21.3_supp.14
   Naidoo P, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-396
   Nakhaee F, 2009, SEX HEALTH, V6, P129, DOI 10.1071/SH08007
   Narasimhan P, 2013, PULM MED, V2013, DOI 10.1155/2013/828939
   Niaura R, 2000, CLIN INFECT DIS, V31, P808, DOI 10.1086/314048
   O'Cleirigh C, 2014, AIDS BEHAV
   Oka F, 2013, J INFECT CHEMOTHER, V19, P542, DOI 10.1007/s10156-012-0489-1
   Pacek LR, 2013, AIDS BEHAV
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Peretti-Watel P, 2006, DRUG ALCOHOL DEPEN, V82, pS71, DOI 10.1016/S0376-8716(06)80012-8
   Pines H, 2011, AIDS BEHAV, V15, P243, DOI 10.1007/s10461-010-9682-3
   Reynolds NR, 2009, AIDS EDUC PREV, V21, P106, DOI 10.1521/aeap.2009.21.3_supp.106
   Ribeiro SR, 2014, ANTIVIR THER
   Robinson WT, 2014, AIDS BEHAV, V18, pS324, DOI 10.1007/s10461-013-0585-y
   Saves M, 2003, CLIN INFECT DIS, V37, P292, DOI 10.1086/375844
   Shirley DK, 2013, AIDS PATIENT CARE ST, V27, P604, DOI 10.1089/apc.2013.0128
   Shirley DK, 2013, CLIN INFECT DIS, V57, P275, DOI 10.1093/cid/cit207
   Smith CJ, 2014, LANCET, V384, P241, DOI 10.1016/S0140-6736(14)60604-8
   Souza PRB, 2007, CLINICS, V62, P579, DOI 10.1590/S1807-59322007000500008
   Tesoriero JM, 2010, AIDS BEHAV, V14, P824, DOI 10.1007/s10461-008-9449-2
   Torres TS, 2013, BRAZ J INFECT DIS, V17, P324, DOI 10.1016/j.bjid.2012.10.024
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   van Wijk JPH, 2012, INT J VASC MED, V2012, DOI 10.1155/2012/201027
   Vidrine DJ, 2006, AIDS, V20, P253, DOI 10.1097/01.aids.0000198094.23691.58
   Villanti A, 2012, AIDS EDUC PREV, V24, P132, DOI 10.1521/aeap.2012.24.2.132
   Waweru P, 2013, SAMJ S AFR MED J, V103, P858, DOI [10.7196/samj.7388, 10.7196/SAMJ.7388]
   Webb MS, 2007, J BEHAV MED, V30, P371, DOI 10.1007/s10865-007-9112-9
   Webb MS, 2009, AIDS EDUC PREV, V21, P94, DOI 10.1521/aeap.2009.21.3_supp.94
   World Health Organization, 2007, UN TUB LUNG DIS WHO
NR 67
TC 12
Z9 12
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 23
PY 2014
VL 9
IS 12
AR e115900
DI 10.1371/journal.pone.0115900
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AZ9UY
UT WOS:000348563300081
PM 25536064
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Cardoso, SW
   Luz, PM
   Velasque, L
   Torres, TS
   Tavares, IC
   Ribeiro, SR
   Moreira, RI
   Veloso, VG
   Moore, RD
   Grinsztejn, B
AF Cardoso, Sandra W.
   Luz, Paula M.
   Velasque, Luciane
   Torres, Thiago S.
   Tavares, Isabel C.
   Ribeiro, Sayonara R.
   Moreira, Ronaldo I.
   Veloso, Valdilea G.
   Moore, Richard D.
   Grinsztejn, Beatriz
TI Outcomes of second-line combination antiretroviral therapy for
   HIV-infected patients: a cohort study from Rio de Janeiro, Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE cART; Second-line; Cox proportional hazards regression; HIV/AIDS; Cohort
   study; Brazil
ID RESOURCE-LIMITED COUNTRIES; HIV-1-INFECTED PATIENTS; VIROLOGICAL
   FAILURE; 1-INFECTED PATIENTS; DRUG-RESISTANCE; REGIMENS; AGE;
   NEVIRAPINE; MORTALITY; EFFICACY
AB Background: World-wide, the notable expansion of HIV/AIDS treatment programs in resource-limited settings has lead to an increasing number of patients in need of second-line cART. To adequately address and prepare for this scenario, critical assessments of the outcomes of second-line cART are particularly relevant in settings where monitoring strategies may be inadequate. We evaluated virologic outcomes of second-line combination antiretroviral therapy (cART) among HIV-infected individuals from Brazil.
   Methods: This study was conducted at the Instituto Nacional de Infectologia Evandro Chagas, Fundacao Oswaldo Cruz, at Rio de Janeiro, Brazio. For this study we included all patients who started first-line and second-line cART between 2000 and 2013. Second-line cART required a switch in the anchor drug of first-line cART. We evaluated time from second-line start to virologic failure and factors associated with increased risk of failure using multivariable Cox proportional hazards regression models.
   Results: Among the 1,311 patients who started first-line cART a total of 386 patients (29.5%) initiated second-line cART, out of which 35.0% and 60.6% switched from their first-line to their second-line cART when their HIV RNA was undetectable and after documented virologic failure, respectively. At second line cART initiation, median age was 38 years [ interquartile range (IQR): 31-45years]. Median CD4 count was significantly different for patients starting second-line cART undetectable [412 cells/mm(3) (IQR: 240-617)] compared to those starting second-line cART after documented virologic failure [230 cells/mm(3) (IQR: 118-322.5)] (p < 0.01). Median time from second-line cART initiation to failure was also significantly different for patients starting second-line cART undetectable compared to those who with documented virologic failure (log-rank test p < 0.01). Multivariable Cox models showed that younger age, lower education, and HIV RNA level were independently associated with an increased hazard of second-line failure among those with documented virologic failure at start of second-line cART.
   Conclusions: We have shown that in a middle-income country with universal access to cART, having a detectable HIV RNA at the start of second-line cART as well as younger age and lower education negatively impact second-line outcomes. Our findings could guide HIV treatment efforts as to which strategies would help maximize the durability of these regimens.
C1 [Cardoso, Sandra W.; Luz, Paula M.; Velasque, Luciane; Torres, Thiago S.; Tavares, Isabel C.; Ribeiro, Sayonara R.; Moreira, Ronaldo I.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Inst Nacl Infectol Evandro Chagas, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil.
   [Moore, Richard D.] Johns Hopkins Univ, Baltimore, MD USA.
RP Luz, PM (corresponding author), Inst Nacl Infectol Evandro Chagas, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
EM paula.luz@ini.fiocruz.br
RI Cardoso, Sandra W/D-7965-2015; TORRES, THIAGO SILVA/D-6548-2014
OI Cardoso, Sandra W/0000-0001-5230-0003; TORRES, THIAGO
   SILVA/0000-0002-2557-601X; Luz, Paula/0000-0001-9746-719X
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding
   Source: NIH RePORTER
FX BG and PML acknowledge funding from the National Council of
   Technological and Scientific Development (CNPq) and the Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ). The funding bodies had
   no role in the design, collection, analysis, or interpretation of data;
   in the writing of the manuscript; or in the decision to submit the
   manuscript for publication.
CR Boyd MA, 2007, AIDS, V21, pS55, DOI 10.1097/01.aids.0000279707.01557.b2
   [BRASIL Ministerio da Saude CNdDeA], 2013, PROTOCOLO CLINICO E
   Brinson C, 2012, NNRTI BASED ANTIRETR, V1, P542, DOI [10.4172/scientificreports.542, DOI 10.4172/SCIENTIFICREPORTS.542]
   Cardoso SW, 2010, AIDS RES HUM RETROV, V26, P865, DOI 10.1089/aid.2009.0274
   Fox MP, 2010, JAIDS-J ACQ IMM DEF, V53, P500, DOI 10.1097/QAI.0b013e3181bcdac1
   Galarraga O, 2007, AIDS, V21, pS97, DOI 10.1097/01.aids.0000279712.32051.29
   Gallant JE, 2007, CLIN INFECT DIS, V44, P453, DOI 10.1086/510752
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Gupta RK, 2014, CLIN INFECT DIS, V58, P1023, DOI 10.1093/cid/cit933
   Hosseinipour MC, 2009, AIDS, V23, P1127, DOI 10.1097/QAD.0b013e32832ac34e
   Kumarasamy N, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P71, DOI 10.1177/1545109710382780
   Le Moing V, 2014, CONFERENCE ON RETROV
   Lima VD, 2009, JAIDS-J ACQ IMM DEF, V50, P529, DOI 10.1097/QAI.0b013e31819675e9
   Napravnik S, 2007, AIDS, V21, P825, DOI 10.1097/QAD.0b013e32805e8764
   Napravnik S, 2013, AIDS RES HUM RETROV, V29, P574, DOI [10.1089/aid.2012.0210, 10.1089/AID.2012.0210]
   Organization WH, 2013, CONSOLIDATED GUIDELI
   Orrell C, 2009, ANTIVIR THER, V14, P523
   PAHO, 2013, ANTIRETROVIRAL TREAT
   Pujades-Rodriguez M, 2010, JAMA-J AM MED ASSOC, V304, P303, DOI 10.1001/jama.2010.980
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   Sigaloff KCE, 2012, J INFECT DIS, V205, P1739, DOI 10.1093/infdis/jis261
   Silverberg MJ, 2007, ARCH INTERN MED, V167, P684, DOI 10.1001/archinte.167.7.684
   Siripassorn K, 2010, AIDS RES HUM RETROV, V26, P139, DOI 10.1089/aid.2009.0125
   Sungkanuparph S, 2007, CLIN INFECT DIS, V44, P447, DOI 10.1086/510745
   Taiwo B, 2011, AIDS, V25, P2113, DOI 10.1097/QAD.0b013e32834bbaa9
   Torres TS, 2014, BRAZ J INFECT DIS, V18, P34, DOI 10.1016/j.bjid.2013.04.005
   Torres TS, 2013, BRAZ J INFECT DIS, V17, P324, DOI 10.1016/j.bjid.2012.10.024
   UNICEF WU, 2013, GLOBAL HIV AIDS RESP
   van Leth F, 2005, AIDS, V19, P463, DOI 10.1097/01.aids.0000162334.12815.5b
   von Wyl V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077691
   Wallis CL, 2010, JAIDS-J ACQ IMM DEF, V53, P480, DOI 10.1097/QAI.0b013e3181bc478b
   Walmsley S, 2009, JAIDS-J ACQ IMM DEF, V50, P367, DOI 10.1097/QAI.0b013e318198a815
   Waters L, 2012, INT J STD AIDS, V23, P546, DOI 10.1258/ijsa.2012.011412
   Waters L, 2013, ANTIVIR THER, V18, P213, DOI 10.3851/IMP2329
   Win May Myat, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P57, DOI 10.1177/1545109710387301
NR 35
TC 6
Z9 6
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 19
PY 2014
VL 14
AR 699
DI 10.1186/s12879-014-0699-5
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA AZ5RI
UT WOS:000348277100001
PM 25523385
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Santini-Oliveira, M
   Grinsztejn, B
AF Santini-Oliveira, Marilia
   Grinsztejn, Beatriz
TI Adverse drug reactions associated with antiretroviral therapy during
   pregnancy
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review
DE adverse drug reactions; antiretroviral; HIV; pregnancy
ID TO-CHILD-TRANSMISSION; IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-INFECTED
   WOMEN; IN-UTERO EXPOSURE; TENOFOVIR DISOPROXIL FUMARATE; RANDOMIZED
   CONTROLLED-TRIAL; LOW-BIRTH-WEIGHT; RIO-DE-JANEIRO; ZIDOVUDINE
   PROPHYLAXIS; PERINATAL TRANSMISSION
AB Introduction: Antiretroviral (ARV) drug use during pregnancy significantly reduces mother-to-child HIV transmission, delays disease progression in the women and reduces the risk of HIV transmission to HIV-serodiscordant partners. Pregnant women are susceptible to the same adverse reactions to ARVs as nonpregnant adults as well as to specific pregnancy-related reactions. In addition, we should consider adverse pregnancy outcomes and adverse reactions in children exposed to ARVs during intrauterine life. However, studies designed to assess the safety of ARV in pregnant women are rare, usually with few participants and short follow-up periods.
   Areas covered: In this review, we discuss studies reporting adverse reactions to ARV drugs, including maternal toxicity, adverse pregnancy outcomes and the consequences of exposure to ARV in infants. We included results of observational studies, both prospective and retrospective, as well as randomized clinical trials, systematic reviews and meta-analyses.
   Expert opinion: The benefits of ARV use during pregnancy outweigh the risks of adverse reactions identified to date. More studies are needed to assess the adverse effects in the medium- and long term in children exposed to ARVs during pregnancy, as well as pregnant women using lifelong antiretroviral therapy and more recently available drugs.
C1 [Santini-Oliveira, Marilia; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Clin Res STD & AIDS Lab, Rio De Janeiro, Brazil.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Clin Res STD & AIDS Lab, Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
CR Aaron E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012617
   Alimenti A, 2006, PEDIATRICS, V118, pE1139, DOI 10.1542/peds.2006-0525
   Anderson PL, 2003, AIDS, V17, P2159, DOI 10.1097/00002030-200310170-00003
   Andiman W, 1999, NEW ENGL J MED, V340, P977
   [Anonymous], 2012, REC US ANT DRUGS PRE
   [Anonymous], GUID US ANT AG HIV 1
   Antiretroviral Pregnancy Registry Steering Committee, 2013, ANT PREGN REG INT IN
   Azria E, 2009, ANTIVIR THER, V14, P423
   Bailey A, 1999, AIDS, V13, P1377
   Bera E, 2012, SAMJ S AFR MED J, V102, P855, DOI [10.7196/SAMJ.5700, 10.7196/samj.5700]
   Best BM, 2010, JAIDS-J ACQ IMM DEF, V54, P381, DOI 10.1097/QAI.0b013e3181d6c9ed
   Bishop JB, 2004, TOXICOL SCI, V81, P512, DOI 10.1093/toxsci/kfh208
   Bonafe SM, 2013, AIDS PATIENT CARE ST, V27, P589, DOI 10.1089/apc.2013.0159
   Boucher CA, 1997, J ACQ IMMUN DEF SYND, V14, P26
   Boyajian T, 2012, J OBSTET GYNAECOL CA, V34, P136, DOI 10.1016/S1701-2163(16)35156-8
   Briand N, 2009, AIDS, V23, P1235, DOI 10.1097/QAD.0b013e32832be0df
   Bryson YJ, 1996, AIDS, V10, pS33
   Bulterys M, 2000, ANN NY ACAD SCI, V918, P212
   Bunders MJ, 2005, ACTA PAEDIATR, V94, P1571, DOI 10.1080/08035250510042951
   Calamandrei G, 2002, NEUROSCI LETT, V333, P111, DOI 10.1016/S0304-3940(02)01023-6
   CDC (Centers for Disease Control and Prevention), 2004, REC US ANT DRUGS PRE
   Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P151
   Cespedes MS, 2013, JAIDS-J ACQ IMM DEF, V62, P550, DOI 10.1097/QAI.0b013e318285d918
   Chaix ML, 2007, ANTIMICROB AGENTS CH, V51, P896, DOI 10.1128/AAC.00910-06
   Chen JY, 2012, J INFECT DIS, V206, P1695, DOI 10.1093/infdis/jis553
   Chersich Matthew F, 2006, AIDS Res Ther, V3, P11, DOI 10.1186/1742-6405-3-11
   Chougrani I, 2013, HIV AIDS-RES PALLIAT, V5, P253, DOI 10.2147/HIV.S33058
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Colbers A, 2013, CURR OPIN INFECT DIS, V26, P575, DOI 10.1097/QCO.0000000000000017
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Conradie F, 2011, HIV MED, V12, P570, DOI 10.1111/j.1468-1293.2011.00927.x
   Cotter AM, 2006, J INFECT DIS, V193, P1195, DOI 10.1086/503045
   Cressey TR, 2010, AIDS, V24, P2193, DOI 10.1097/QAD.0b013e32833ce57d
   Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151
   Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2
   DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134
   De Santis M, 2002, ARCH INTERN MED, V162, P355, DOI 10.1001/archinte.162.3.355
   Dola CP, 2012, J PERINAT MED, V40, P51, DOI 10.1515/JPM.2011.111
   Dominguez K, 2000, ANN NY ACAD SCI, V918, P236
   DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V
   Ekouevi DK, 2008, AIDS, V22, P1815, DOI 10.1097/QAD.0b013e32830b8ab9
   Ekouevi DK, 2006, PEDIATRICS, V118, pE1071, DOI 10.1542/peds.2006-0371
   El Beitune P, 2006, DIABETES-METAB RES, V22, P59, DOI 10.1002/dmrr.576
   El Beitune P, 2006, EUR J OBSTET GYN R B, V128, P59, DOI 10.1016/j.ejogrb.2006.01.013
   Ellis GM, 2011, JAIDS-J ACQ IMM DEF, V58, P241, DOI 10.1097/QAI.0b013e31822b4edc
   Else LJ, 2012, ANTIMICROB AGENTS CH, V56, P816, DOI 10.1128/AAC.05186-11
   Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006
   Fao P, 2012, CLIN INFECT DIS, V55, P449, DOI 10.1093/cid/cis461
   Fawzi W, 2001, AIDS, V15, P1157, DOI 10.1097/00002030-200106150-00011
   Feiterna-Sperling C, 2007, JAIDS-J ACQ IMM DEF, V45, P43, DOI 10.1097/QAI.0b013e318042d5e3
   Ford N, 2014, AIDS, V28, pS123, DOI 10.1097/QAD.0000000000000231
   Ford N, 2013, AIDS, V27, P1135, DOI 10.1097/QAD.0b013e32835e0752
   Foster C, 2009, HIV MED, V10, P397, DOI 10.1111/j.1468-1293.2009.00709.x
   Fowler MG, 2007, AM J OBSTET GYNECOL, V197, pS3, DOI 10.1016/j.ajog.2007.06.048
   Frank KA, 2004, OBSTET GYNECOL, V104, P238, DOI 10.1097/01.AOG.0000130066.75671.b2
   Fujinaga M, 2000, TERATOLOGY, V62, P108, DOI 10.1002/1096-9926(200008)62:2<108::AID-TERA7>3.3.CO;2-U
   Furco A, 2009, AIDS, V23, P434, DOI 10.1097/QAD.0b013e32832027d6
   Gandhi M, 2013, JAIDS-J ACQ IMM DEF, V63, P578, DOI 10.1097/QAI.0b013e31829c48ad
   Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602
   Giaquinto C, 2006, CLIN DRUG INVEST, V26, P611, DOI 10.2165/00044011-200626110-00001
   Gonzalez-Tome MI, 2008, HIV MED, V9, P868, DOI 10.1111/j.1468-1293.2008.00639.x
   Gray GE, 2005, AIDS, V19, P1289, DOI 10.1097/01.aids.0000180100.42770.a7
   Grosch-Woerner I, 2008, HIV MED, V9, P6, DOI 10.1111/j.1468-1293.2008.00520.x
   Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7
   Haeri S, 2009, AM J OBSTET GYNECOL, V201, pe311
   Heidari S, 2011, JAIDS-J ACQ IMM DEF, V57, P290, DOI 10.1097/QAI.0b013e318221c56a
   Hitti J, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.11.037
   Ioannidis JPA, 2001, J INFECT DIS, V183, P539, DOI 10.1086/318530
   Ivanovic J, 2009, CURR HIV RES, V7, P620, DOI 10.2174/157016209789973628
   Izurieta P, 2011, HIV MED, V12, P257, DOI 10.1111/j.1468-1293.2010.00874.x
   Jamisse L, 2007, JAIDS-J ACQ IMM DEF, V44, P371, DOI 10.1097/QAI.0b013e318032bbee
   Jaworsky D, 2010, ANTIVIR THER, V15, P677, DOI 10.3851/IMP1558
   Joao EC, 2003, AIDS, V17, P1853, DOI [10.1097/01.aids.0000076326.42412.7a, 10.1097/00002030-200308150-00016]
   Katz IT, 2010, JAIDS-J ACQ IMM DEF, V54, P27, DOI 10.1097/QAI.0b013e3181caea89
   Knoppert D, 2011, J POPUL THER CLIN PH, V18, pE509
   Kondo W, 2007, BRAZ J INFECT DIS, V11, P544, DOI 10.1590/S1413-86702007000600004
   Kourtis AP, 2007, AIDS, V21, P607, DOI 10.1097/QAD.0b013e32802ef2f6
   Kreitchmann R, 2004, BJOG-INT J OBSTET GY, V111, P579, DOI 10.1111/j.1471-0528.2004.00147.x
   Lallemant M, 2000, NEW ENGL J MED, V343, P982, DOI 10.1056/NEJM200010053431401
   Lambert JS, 2011, HIV MED, V12, P166, DOI 10.1111/j.1468-1293.2010.00865.x
   Le Chenadec J, 2003, AIDS, V17, P2053, DOI 10.1097/00002030-200309260-00006
   Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6
   Lindegren ML, 2000, ANN NY ACAD SCI, V918, P222
   Lockman S, 2007, NEW ENGL J MED, V356, P135, DOI 10.1056/NEJMoa062876
   Lyons F, 2006, HIV MED, V7, P255, DOI 10.1111/j.1468-1293.2006.00369.x
   Machado ES, 2014, J INFECTION, V68, P572, DOI 10.1016/j.jinf.2013.12.018
   Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55
   Mandelbrot L, 2011, EUR J OBSTET GYN R B, V157, P18, DOI 10.1016/j.ejogrb.2011.02.005
   Martorell C, 2010, PEDIATR INFECT DIS J, V29, P985, DOI 10.1097/INF.0b013e3181ef0336
   Mattar R, 2004, EUR J OBSTET GYN R B, V117, P240, DOI 10.1016/j.ejogrb.2004.04.014
   Mawson AR, 2003, LANCET, V361, P347, DOI 10.1016/S0140-6736(03)12359-8
   Mayaux MJ, 1997, J INFECT DIS, V175, P172, DOI 10.1093/infdis/175.1.172
   Mirochnick M, 2002, PEDIATR INFECT DIS J, V21, P835, DOI 10.1097/00006454-200209000-00010
   Mirochnick M, 2000, ANN NY ACAD SCI, V918, P287
   Mofenson LM, 1997, OBSTET GYN CLIN N AM, V24, P759, DOI 10.1016/S0889-8545(05)70343-0
   Mofenson LM, 1997, OBSTET GYN CLIN N AM, V24, P75
   Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898
   Mussi-Pinhata MM, 2003, INT J STD AIDS, V14, P818, DOI 10.1258/095646203322556156
   Naver L, 2011, SCAND J INFECT DIS, V43, P411, DOI 10.3109/00365548.2011.567392
   Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167
   Newell ML, 2003, JAIDS-J ACQ IMM DEF, V32, P380
   Newell ML, 2000, T ROY SOC TROP MED H, V94, P1, DOI 10.1016/S0035-9203(00)90413-9
   Nielsen K, 1998, 12 WORLD AIDS C GEN
   Nielsen-Saines K, 2012, NEW ENGL J MED, V366, P2368, DOI 10.1056/NEJMoa1108275
   Nightingale SL, 1998, JAMA-J AM MED ASSOC, V280, P1472, DOI 10.1001/jama.280.17.1472-b
   Noguera A, 2004, PEDIATRICS, V114, pE598, DOI 10.1542/peds.2004-0955
   Olivero OA, 2002, J ACQ IMMUN DEF SYND, V29, P323
   Olivero OA, 2008, MUTAT RES-REV MUTAT, V658, P184, DOI 10.1016/j.mrrev.2007.12.001
   Organization WH, 2012, TECHN UPD TREATM OPT
   Pacheco SE, 2006, J INFECT DIS, V194, P1089, DOI 10.1086/507645
   Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2
   Parekh N, 2011, INT J GYNECOL OBSTET, V115, P20, DOI 10.1016/j.ijgo.2011.04.008
   Patel K, 2010, J INFECT DIS, V201, P1035, DOI 10.1086/651232
   Patterson KB, 2011, 18 CROI BOST MA EUA
   Peixoto MF, 2011, BRAZ J INFECT DIS, V15, P253, DOI [10.1590/S1413-86702011000300013, 10.1016/S1413-8670(11)70185-4]
   Phadke MA, 2008, LANCET, V372, P287, DOI 10.1016/S0140-6736(08)61100-9
   Phanuphak N, 2007, HIV MED, V8, P357, DOI 10.1111/j.1468-1293.2007.00477.x
   Poirier MC, 2003, JAIDS-J ACQ IMM DEF, V33, P175, DOI 10.1097/00126334-200306010-00010
   Ravizza M, 2007, J INFECT DIS, V195, P913, DOI 10.1086/507045
   Read JS, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005479
   Ripamonti D, 2007, AIDS, V21, P2409, DOI 10.1097/QAD.0b013e32825a69d1
   Rondinini C, 1999, PSYCHOPHARMACOLOGY, V145, P317, DOI 10.1007/s002130051064
   Roustit M, 2008, BRIT J CLIN PHARMACO, V66, P179, DOI 10.1111/j.1365-2125.2008.03220.x
   Rubini N, 1998, 12 WORLD AIDS C GEN
   Saba J, 2002, LANCET, V359, P1178
   Santini-Oliveira M, 2014, BRAZ J INFECT DIS, V18, P372, DOI 10.1016/j.bjid.2013.11.008
   Santini-Oliveira M, 2014, ANTIMICROB AGENTS CH, V58, P2884, DOI 10.1128/AAC.02599-13
   Sarner L, 2002, SEX TRANSM INFECT, V78, P58, DOI 10.1136/sti.78.1.58
   Senise JF, 2011, AIDS REV, V13, P198
   Shaffer N, 1999, J INFECT DIS, V179, P590, DOI 10.1086/314641
   Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7
   Shapiro D, 2004, 1 CROI SAN FRANC CA
   Shapiro RL, 2010, NEW ENGL J MED, V362, P2282, DOI 10.1056/NEJMoa0907736
   Siberry GK, 2012, AIDS, V26, P1151, DOI 10.1097/QAD.0b013e328352d135
   Sibiude J, 2011, 18 C RETR OPP INF FE
   Simon A, 2011, JAMA-J AM MED ASSOC, V306, P70, DOI 10.1001/jama.2011.915
   Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201
   Stek AM, 2006, AIDS, V20, P1931, DOI 10.1097/01.aids.0000247114.43714.90
   Sturt AS, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008440
   Szyld EG, 2006, AIDS, V20, P2345, DOI 10.1097/01.aids.0000253362.01696.9d
   Taha TE, 2000, ANN NY ACAD SCI, V918, P84
   Tang JH, 2006, OBSTET GYNECOL, V107, P1115, DOI 10.1097/01.AOG.0000207657.94360.78
   Taylor GP, 2012, HIV MED, V13, P87, DOI [10.1111/j.1468-1293.2012.01030_2.x, 10.1111/j.1468-1293.2012.01030.x]
   Taylor N, 2011, INT J STD AIDS, V22, P358, DOI 10.1258/ijsa.2011.010469
   Thior I, 2006, JAMA-J AM MED ASSOC, V296, P794, DOI 10.1001/jama.296.7.794
   Thorne C, 2004, AIDS, V18, P2337, DOI 10.1097/00002030-200411190-00019
   Thorne Claire, 2003, Med Wieku Rozwoj, V7, P425
   TOLTZIS P, 1994, J INFECT DIS, V169, P1100, DOI 10.1093/infdis/169.5.1100
   Townsend CL, 2007, AIDS, V21, P1019, DOI 10.1097/QAD.0b013e328133884b
   Tubiana R, 2011, 18 C RETR OPP INF BO
   UNAIDS, 2013, GLOB REP UNAIDS REP
   Van Dyke RB, 1999, J INFECT DIS, V179, P319, DOI 10.1086/314580
   Venerosi A, 2001, TERATOLOGY, V63, P26, DOI 10.1002/1096-9926(200101)63:1<26::AID-TERA1005>3.0.CO;2-G
   Vigano A, 2011, ANTIVIR THER, V16, P1259, DOI 10.3851/IMP1909
   Wabwire-Mangen F, 1999, J ACQ IMMUN DEF SYND, V22, P379
   Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001
   Watts DH, 2013, J INFECT DIS, V207, P612, DOI 10.1093/infdis/jis728
   Watts DH, 2012, J INFECT DIS, V206, P1639, DOI 10.1093/infdis/jis581
   Watts DH, 2004, AM J OBSTET GYNECOL, V190, P506, DOI 10.1016/j.ajog.2003.07.018
   Weizsaecker K, 2011, INT J STD AIDS, V22, P294, DOI 10.1258/ijsa.2009.009166
   Wimalasundera RC, 2002, LANCET, V360, P1152, DOI 10.1016/S0140-6736(02)11195-0
   World Health Organization, 2013, CONS GUID US ANT DRU
   Zorrilla CD, 2014, HIV MED, V15, P50, DOI 10.1111/hiv.12047
NR 163
TC 5
Z9 5
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD DEC
PY 2014
VL 13
IS 12
BP 1623
EP 1652
DI 10.1517/14740338.2014.975204
PG 30
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AU0XR
UT WOS:000345346100007
PM 25390463
DA 2020-11-24
ER

PT J
AU Pacheco, AG
   Veloso, VG
   Nunes, EP
   Ribeiro, S
   Guimaraes, MRC
   Lourenco, MC
   Mello, FCQ
   Grinsztejn, B
AF Pacheco, A. G.
   Veloso, V. G.
   Nunes, E. P.
   Ribeiro, S.
   Guimaraes, M. R. C.
   Lourenco, M. C.
   Mello, F. C. Q.
   Grinsztejn, B.
TI Tuberculosis is associated with non-tuberculosis-related deaths among
   HIV/AIDS patients in Rio de Janeiro
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE cohort; antiretroviral therapy; mortality
ID RECONSTITUTION INFLAMMATORY SYNDROME; ISONIAZID PREVENTIVE THERAPY;
   HIV-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; EARLY MORTALITY; HAART
   ERA; BRAZIL; INDIVIDUALS; GUIDELINES; COHORT
AB SETTING: Human immunodeficiency virus (HIV) infected patients followed in a large cohort in Rio de Janeiro, Brazil.
   OBJECTIVE: To evaluate the association of tuberculosis (TB) and other covariables with non-TB-related (NTR) causes of death (CODs).
   DESIGN: Patients aged >18 years were followed from 1997 to 2009, until death or 31 December 2009, whichever was earlier. CODs were ascertained using a standardised algorithm. TB diagnosis and prophylaxis followed Brazilian guidelines. Poisson models were used to calculate adjusted rate ratios (aRRs).
   RESULTS: Of 2887 patients included in the study, 761 had TB (26.4%). NTR death rates were twice as high among patients with TB (4/100 vs. 2.09/100 patient-years). TB was associated with NTR deaths (aRR 1.4, 95%CI 1.05-1.86, P = 0.01). Highly active antiretroviral treatment (HAART) was protective against NTR (aRR 0.46, 95%CI 0.34-0.61, P < 0.001). Among patients who had never had active TB, prophylaxis was also protective against NTR (aRR 0.45, P = 0.04). The CD4 cell count increase was very modest for both TB and NTR CODs compared to those who did not die (0 vs. 249 cells, P < 0.001).
   CONCLUSIONS: TB was significantly associated with increased NTR CODs, indicating rapid progression of disease and increased long-term risk of mortality, probably related to persistent immunodeficiency or incomplete immune recovery. Our results confirm the benefits of HAART and TB prophylaxis.
C1 [Pacheco, A. G.] Fundacao Oswaldo Cruz, Programa Comp Cient, Rio De Janeiro, Brazil.
   [Veloso, V. G.; Nunes, E. P.; Ribeiro, S.; Guimaraes, M. R. C.; Lourenco, M. C.; Grinsztejn, B.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Mello, F. C. Q.] Univ Fed Rio de Janeiro, Inst Doencas Torax, Rio De Janeiro, Brazil.
RP Pacheco, AG (corresponding author), Fiocruz MS, PROCC, Av Brasil 4365, BR-21045360 Rio De Janeiro, RJ, Brazil.
EM apacheco@fiocruz.br
RI Pacheco, Antonio Guilherme/E-6378-2013; de Q Mello, Fernanda
   C/I-2957-2013
OI Pacheco, Antonio Guilherme/0000-0003-3095-1774; 
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Programa Estrategico de Apoio a Pesquisa em Saude
   (PAPES)National Council for Scientific and Technological Development
   (CNPq); Fundacao Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
FX The study was supported by the Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro (FAPERJ), the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Programa Estrategico de Apoio a
   Pesquisa em Saude (PAPES) and Fundacao Oswaldo Cruz, Rio de Janeiro, RJ,
   Brazil.
CR [Anonymous], 2013, R LANG ENV STAT COMP
   Brasil. Ministerio da Saude, 2013, PROT CLIN DIR TER MA
   Cain KP, 2009, EMERG INFECT DIS, V15, P258, DOI 10.3201/eid1502.080942
   Castelnuovo B, 2009, CLIN INFECT DIS, V49, P965, DOI 10.1086/605500
   Cavalcante SC, 2007, INT J TUBERC LUNG D, V11, P544
   Charalambous S, 2010, AIDS, V24, pS5, DOI 10.1097/01.aids.0000391010.02774.6f
   Durovni B, 2013, LANCET INFECT DIS, V13, P852, DOI 10.1016/S1473-3099(13)70187-7
   Greig Jane, 2012, AIDS, V26 Suppl 1, pS31
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Gupta A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055824
   Gupta-Wright A, 2013, JAIDS-J ACQ IMM DEF, V64, P261, DOI 10.1097/QAI.0b013e3182a23e9a
   Harries AD, 2001, INT J TUBERC LUNG D, V5, P1000
   Kanters S, 2013, HIV AIDS-RES PALLIAT, V5, P111, DOI 10.2147/HIV.S42521
   Kantipong P, 2012, HIV AIDS-RES PALLIAT, V4, P159, DOI 10.2147/HIV.S33535
   Kowalska JD, 2011, EPIDEMIOLOGY, V22, P516, DOI 10.1097/EDE.0b013e31821b5332
   Leung CC, 2013, INT J TUBERC LUNG D, V17, P687, DOI 10.5588/ijtld.12.0816
   Loo VS, 2004, AIDS CARE, V16, P834, DOI 10.1080/09540120412331290121
   Ministerio da Saude, 2013, SINAN SIST INF AGR N
   Ministerio da Saude, 2013, B EP AIDS DST AN 2
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003132
   Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249
   Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636
   Podlekareva DN, 2014, EUR RESPIR J, V43, P166, DOI 10.1183/09031936.00138712
   Samji H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081355
   Saraceni V, 2011, BRAZ J INFECT DIS, V15, P249, DOI [10.1590/S1413-86702011000300012, 10.1016/S1413-8670(11)70184-2]
   Siika AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053022
   Simard EP, 2012, ARCH INTERN MED, V172, P1591, DOI 10.1001/archinternmed.2012.4508
   WHO, 2013, WHOHTMTB201311
   Worodria W, 2011, JAIDS-J ACQ IMM DEF, V58, P32, DOI 10.1097/QAI.0b013e3182255dc2
NR 32
TC 4
Z9 4
U1 0
U2 6
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
EI 1815-7920
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD DEC
PY 2014
VL 18
IS 12
BP 1473
EP 1478
DI 10.5588/ijtld.14.0181
PG 6
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA AT9OQ
UT WOS:000345256800016
PM 25517814
DA 2020-11-24
ER

PT J
AU Montes, M
   Nelson, M
   Girard, PM
   Sasadeusz, J
   Horban, A
   Grinsztejn, B
   Zakharova, N
   Rivero, A
   Lathouwers, E
   Janssen, K
   Ouwerkerk-Mahadevan, S
   Witek, J
AF Montes, Marisa
   Nelson, Mark
   Girard, Pierre Marie
   Sasadeusz, Joe
   Horban, Andrzej
   Grinsztejn, Beatriz
   Zakharova, Natalia
   Rivero, Antonio
   Lathouwers, Erkki
   Janssen, Katrien
   Ouwerkerk-Mahadevan, Sivi
   Witek, James
TI Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT
   study): sustained virologic response at 12 weeks final analysis
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Montes, Marisa] Univ Autonoma Madrid, IdiPAZ, Hosp La Paz, HIV Unit, Madrid, Spain.
   [Nelson, Mark] Chelsea & Westminster Hosp, London, England.
   [Girard, Pierre Marie] Hop St Antoine, F-75571 Paris, France.
   [Sasadeusz, Joe] Royal Melbourne Hosp, Melbourne, Vic, Australia.
   [Sasadeusz, Joe] Alfred Hosp, Melbourne, Vic, Australia.
   [Horban, Andrzej] Med Univ Warsaw, Hosp Infect Dis, Warsaw, Poland.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas, STD AIDS Clin Res Lab, Rio De Janeiro, Brazil.
   [Zakharova, Natalia] St Petersburg AIDS Ctr, St Petersburg, Russia.
   [Rivero, Antonio] Hosp Univ Reina Sofia IMIBIC, Cordoba, Spain.
   [Lathouwers, Erkki] Janssen Infect Dis BVBA, Beerse, Belgium.
   [Janssen, Katrien; Ouwerkerk-Mahadevan, Sivi; Witek, James] Janssen Res & Dev LLC, Titusville, NJ USA.
RI Ramirez, Maria Luisa Montes/H-8065-2017; Rivero, Antonio/ABE-5294-2020
OI Ramirez, Maria Luisa Montes/0000-0003-1748-813X; Rivero,
   Antonio/0000-0001-5005-8268
NR 0
TC 5
Z9 5
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD NOV
PY 2014
VL 17
SU 3
MA P094
BP 90
EP 91
DI 10.7448/IAS.17.4.19626
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AT5CR
UT WOS:000344961700145
PM 25394130
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Bavinton, BR
   Jin, FY
   Prestage, G
   Zablotska, I
   Koelsch, KK
   Phanuphak, N
   Grinsztejn, B
   Cooper, DA
   Fairley, C
   Kelleher, A
   Triffitt, K
   Grulich, AE
AF Bavinton, Benjamin R.
   Jin, Fengyi
   Prestage, Garrett
   Zablotska, Iryna
   Koelsch, Kersten K.
   Phanuphak, Nittaya
   Grinsztejn, Beatriz
   Cooper, David A.
   Fairley, Christopher
   Kelleher, Anthony
   Triffitt, Kathy
   Grulich, Andrew E.
CA Opposites Attract Study Grp
TI The Opposites Attract Study of viral load, HIV treatment and HIV
   transmission in serodiscordant homosexual male couples: design and
   methods
SO BMC PUBLIC HEALTH
LA English
DT Article
DE HIV treatment as prevention; Serodiscordant; Homosexual; HIV
   transmission; Antiretroviral therapy
ID IMMUNODEFICIENCY-VIRUS TRANSMISSION; ANTIRETROVIRAL TREATMENT; GAY MEN;
   PREVENTION; SYDNEY
AB Background: Studies in heterosexual HIV serodiscordant couples have provided critical evidence on the role of HIV treatments and undetectable viral load in reducing the risk of HIV transmission. There is very limited data on the risk of transmission from anal sex in homosexual male serodiscordant couples.
   Methods/Design: The Opposites Attract Study is an observational prospective longitudinal cohort study of male homosexual serodiscordant partnerships running from 2012 to 2015 and conducted in clinics throughout Australia, Brazil and Thailand. Couples attend two or more clinic visits per year. The HIV-positive partner's viral load is tested and the HIV-negative partner is tested for HIV antibodies at every clinic visit. Results from any tests for sexually transmitted infections are also collected. Detailed behavioural questionnaires are completed by both partners at the time of each visit. The primary research question is whether HIV incidence is lower in those couples where the HIV-positive partner is receiving HIV treatment compared to couples where he is not receiving treatment. A voluntary semen sub-study will examine semen plasma viral load in a subsample of HIV-positive partners in Sydney, Rio de Janeiro and Bangkok. In cases of seroconversion of the initially HIV-negative partner, phylogenetic analysis will be conducted at the end of the study on virus from stored blood samples from both partners to determine if the infection came from the HIV-positive study partner. Men in new serodiscordant relationships will specifically be targeted for recruitment.
   Discussion: This study will provide critical data on the reduction in HIV transmission risk associated with being on HIV treatment in homosexual male serodiscordant couples in different regions of the world. Data from men in new relationships will be particularly valuable given that the highest transmission risk is in the first year of serodiscordant relationships. Furthermore, the detailed behavioural and attitudinal data from the participant questionnaires will allow exploration of many contextual factors associated with HIV risk, condom use and the negotiation of sexual practice within couples.
C1 [Bavinton, Benjamin R.; Jin, Fengyi; Prestage, Garrett; Zablotska, Iryna; Koelsch, Kersten K.; Cooper, David A.; Kelleher, Anthony; Triffitt, Kathy; Grulich, Andrew E.] Univ New S Wales, Kirby Inst, Sydney, NSW 2052, Australia.
   [Prestage, Garrett] La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Vic 3000, Australia.
   [Koelsch, Kersten K.; Cooper, David A.; Kelleher, Anthony] St Vincents Hosp, Darlinghurst, NSW 2010, Australia.
   [Phanuphak, Nittaya] Red Cross AIDS Res Ctr, Bangkok 10330, Thailand.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, Brazil.
   [Fairley, Christopher] Melbourne Sexual Hlth Ctr, Carlton, Vic 3053, Australia.
   [Fairley, Christopher] Monash Univ, Clayton, Vic 3800, Australia.
   [Kelleher, Anthony] St Vincents Hosp, St Vincents Ctr Appl Med Res, Darlinghurst, NSW 2010, Australia.
RP Bavinton, BR (corresponding author), Univ New S Wales, Kirby Inst, Sydney, NSW 2052, Australia.
EM bbavinton@kirby.unsw.edu.au
RI Emery, Sean/J-3825-2017; Emery, Sean/O-9122-2019; Phanuphak,
   Nittaya/AAA-8579-2019
OI Emery, Sean/0000-0001-6072-8309; Emery, Sean/0000-0001-6072-8309; Jin,
   Fengyi/0000-0002-8573-637X; Bavinton, Benjamin
   Robert/0000-0001-5834-8278; Templeton, David/0000-0003-2157-9587;
   Prestage, Garrett/0000-0003-3917-8992; Christopher,
   Fairley/0000-0001-9081-1664
FU National Health and Medical Research CouncilNational Health and Medical
   Research Council of Australia [APP1008367]
FX The Opposites Attract Study is funded by National Health and Medical
   Research Council Project Grant #APP1008367: 'Viral load, HIV treatment
   and HIV transmission in serodiscordant male homosexual couples'.
CR Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca
   Australia National Health and Medical Research Council, 2007, NAT STAT ETH COND HU
   Bavinton BR, 2014, 20 INT AIDS C AIDS 2
   Bavinton BR, 2012, M2012 INT MICR C SYD
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   de Visser RO, 2003, AUST NZ J PUBL HEAL, V27, P146, DOI 10.1111/j.1467-842X.2003.tb00802.x
   DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601
   Falster K, 2008, SEX HEALTH, V5, P141, DOI 10.1071/SH07082
   Fernandez-Davila P, 2011, INT J SEX HEALTH, V23, P139, DOI 10.1080/19317611.2011.574785
   Guthrie BL, 2007, CURR HIV RES, V5, P416, DOI 10.2174/157016207781023992
   Hammer SM, 2011, NEW ENGL J MED, V365, P561, DOI 10.1056/NEJMe1107487
   Jin F, 2009, 21 ANN C AUSTR SOC H
   Jin FJ, 2008, SEX HEALTH, V5, P109, DOI 10.1071/SH07073
   Jin FY, 2010, AIDS, V24, P907, DOI 10.1097/QAD.0b013e3283372d90
   Lam TTY, 2010, CRIT REV CL LAB SCI, V47, P5, DOI 10.3109/10408361003633318
   Montaner JSG, 2011, LANCET, V378, P208, DOI 10.1016/S0140-6736(11)60821-0
   Muessig KE, 2012, AIDS, V26, P2267, DOI 10.1097/QAD.0b013e328355713d
   Padian NS, 1997, AM J EPIDEMIOL, V146, P350, DOI 10.1093/oxfordjournals.aje.a009276
   Rodger A, 2014, 21 C RETR OPP INF BO
   Rodger A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-296
   Smith K, 2011, CURR OPIN HIV AIDS, V6, P315, DOI 10.1097/COH.0b013e32834788e7
   STIs In Gay Men Action Group, 2010, STI TEST GUID MEN WH
   Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Zablotska IB, 2011, AIDS BEHAV, V15, P607, DOI 10.1007/s10461-010-9675-2
NR 25
TC 24
Z9 24
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD SEP 4
PY 2014
VL 14
AR 917
DI 10.1186/1471-2458-14-917
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO9BY
UT WOS:000341651800001
PM 25190360
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Cardoso, SW
   Luz, PM
   Velasque, L
   Torres, T
   Coelho, L
   Freedberg, KA
   Veloso, VG
   Walensky, RP
   Grinsztejn, B
AF Cardoso, Sandra W.
   Luz, Paula M.
   Velasque, Luciane
   Torres, Thiago
   Coelho, Lara
   Freedberg, Kenneth A.
   Veloso, Valdilea G.
   Walensky, Rochelle P.
   Grinsztejn, Beatriz
TI Effectiveness of first-line antiretroviral therapy in the IPEC cohort,
   Rio de Janeiro, Brazil
SO AIDS RESEARCH AND THERAPY
LA English
DT Article
DE HIV/AIDS; Antiretroviral treatment; Effectiveness; Cohort study; Rio de
   Janeiro; Brazil
ID HIV-INFECTED PATIENTS; HIV-1-INFECTED PATIENTS; CLINICAL-RESPONSE;
   INITIAL TREATMENT; HAART REGIMEN; AIDS PATIENTS; EFFICACY; OUTCOMES;
   PREDICTORS; RITONAVIR
AB Background: While Brazil has had a long-standing policy of free access to antiretroviral therapy (ART) for all in need, the epidemiological impact of ART on human immunodeficiency virus (HIV) RNA suppression in this middle-income country has not been well evaluated. We estimate first-line ART effectiveness in a large Brazilian cohort and examine the socio-demographic, behavioral, clinical and structural factors associated with virologic suppression.
   Methods: Virologic suppression on first-line ART at 6, 12, and 24 months from start of ART was defined as having a viral load measurement <= 400 copies/mL without drug class modification and/or discontinuation. Drug class modification and/or discontinuation were defined based on the class of a particular drug. Quasi-Poisson regression was used to quantify the association of factors with virologic suppression.
   Results: From January 2000 through June 2010, 1311 patients started first-line ART; 987 (75%) patients used NNRTI-based regimens. Virologic suppression was achieved by 77%, 76% and 68% of patients at 6, 12 and 24 months, respectively. Factors associated with virologic suppression at 12 months were: >8 years of formal education (compared to <4 years, risk ratio (RR) 1.13, 95% confidence interval (95% CI) 1.03-1.24), starting ART in 2005-2010 (compared to 2000-2004, RR 1.25 95% CI 1.15-1.35), and clinical trial participation (compared to no participation, RR 1.08 95% CI 1.01-1.16). Also at 12 months, women showed less virologic suppression compared to heterosexual men (RR 0.90 95% CI 0.82-0.99). For the 24-month endpoint, in addition to higher education, starting ART in the later period, and clinical trial participation, older age and an NNRTI-based regimen were also independently associated with virologic suppression.
   Conclusions: Our results show that in Brazil, a middle-income country with free access to treatment, over three-quarters of patients receiving routine care reached virologic suppression on first-line ART by the end of the first year. Higher education, more recent ART initiation and clinical trial participation were associated with improved outcomes both for the 12-month and the 24-month endpoints, suggesting that further studies are needed to understand what aspects relating to these factors lead to higher virologic suppression.
C1 [Cardoso, Sandra W.; Luz, Paula M.; Velasque, Luciane; Torres, Thiago; Coelho, Lara; Veloso, Valdilea G.; Grinsztejn, Beatriz] FundaCao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil.
   [Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
   [Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Dept Med, Boston, MA 02114 USA.
   [Freedberg, Kenneth A.; Walensky, Rochelle P.] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA.
RP Luz, PM (corresponding author), FundaCao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM paula.luz@ipec.fiocruz.br
RI TORRES, THIAGO SILVA/D-6548-2014; Cardoso, Sandra W/D-7965-2015
OI TORRES, THIAGO SILVA/0000-0002-2557-601X; Cardoso, Sandra
   W/0000-0001-5230-0003; Luz, Paula/0000-0001-9746-719X; Walensky,
   Rochelle P./0000-0002-8795-379X
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); National Institute of Allergy and Infectious
   Diseases (NIAID)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01 AI058736, R01 AI093269];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI093269, R01AI093269, R01AI093269, R01AI093269, R01AI093269]
   Funding Source: NIH RePORTER
FX BG acknowledges funding from the National Council of Technological and
   Scientific Development (CNPq) and the Research Funding Agency of the
   State of Rio de Janeiro (FAPERJ). PML acknowledges funding from the
   National Council of Technological and Scientific Development (CNPq) and
   the Research Funding Agency of the State of Rio de Janeiro (FAPERJ). KAF
   and RPW acknowledge funding from National Institute of Allergy and
   Infectious Diseases (NIAID, R01 AI058736, R01 AI093269).
CR Alves SDAS, 2012, BOOK PROGR REPORT BR
   Barth RE, 2008, EUR J CLIN MICROBIOL, V27, P977, DOI 10.1007/s10096-008-0534-2
   Bartlett JA, 2006, AIDS, V20, P2051, DOI 10.1097/01.aids.0000247578.08449.ff
   Bosch RJ, 2007, JAIDS-J ACQ IMM DEF, V44, P268, DOI 10.1097/QAI.0b013e31802c7e20
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   Cardoso SW, 2010, AIDS RES HUM RETROV, V26, P865, DOI 10.1089/aid.2009.0274
   Carr A, 2009, AIDS, V23, P343, DOI 10.1097/QAD.0b013e32831db232
   Collazos J, 2007, AIDS, V21, P835, DOI 10.1097/QAD.0b013e3280b0774a
   Currier J, 2010, ANN INTERN MED, V153, P349, DOI 10.7326/0003-4819-153-6-201009210-00002
   Daar ES, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00316
   Elliott JH, 2008, AIDS, V22, P2053, DOI 10.1097/QAD.0b013e328309520d
   Elzi L, 2012, ARCH INTERN MED, V172, P1313, DOI 10.1001/archinternmed.2012.3216
   Fielding KL, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-93
   Fletcher CV, 2007, DRUGS, V67, P1969, DOI 10.2165/00003495-200767140-00001
   Fox MP, 2012, JAIDS-J ACQ IMM DEF, V60, P428, DOI 10.1097/QAI.0b013e3182557785
   Greenbaum AH, 2008, AIDS, V22, P2331, DOI 10.1097/QAD.0b013e32831883f9
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Guerreiro MF, 2002, REV SAUDE PUBL, V36, P278, DOI [10.1590/S0034-89102002000300004, 10.1590/s0034-89102002000300004]
   Hansen ABE, 2008, J CLIN EPIDEMIOL, V61, P87, DOI 10.1016/j.jclinepi.2007.04.001
   Hinkin CH, 2004, AIDS, V18, pS19, DOI 10.1097/00002030-200418001-00004
   Ivers LC, 2005, CLIN INFECT DIS, V41, P217, DOI 10.1086/431199
   Lichterfeld M, 2003, EUR J MED RES, V8, P56
   Lopez-Martinez A, 2012, JAIDS-J ACQ IMM DEF, V59, P155, DOI 10.1097/QAI.0b013e31823ff035
   Marconi VC, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-14
   Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012
   May M, 2007, AIDS, V21, P1185
   May MT, 2012, INT J EPIDEMIOL, V41, P1807, DOI 10.1093/ije/dys164
   Mocroft A, 2000, AIDS, V14, P1545, DOI 10.1097/00002030-200007280-00010
   Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005
   Mugavero MJ, 2011, JAIDS-J ACQ IMM DEF, V58, P253, DOI 10.1097/QAI.0b013e318230372e
   Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249
   Perez-Elias Maria Jesus, 2009, J Int Assoc Physicians AIDS Care (Chic), V8, P308, DOI 10.1177/1545109709343965
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   Samaranayake A, 2010, HIV MED, V11, P427, DOI 10.1111/j.1468-1293.2009.00808.x
   Silverberg MJ, 2007, ARCH INTERN MED, V167, P684, DOI 10.1001/archinte.167.7.684
   Squires KE, 2011, J ANTIMICROB CHEMOTH, V66, P363, DOI 10.1093/jac/dkq457
   Taniguchi Toshibumi, 2013, J Int Assoc Provid AIDS Care, V12, P138, DOI 10.1177/1545109712467057
   Tuboi SH, 2005, JAIDS-J ACQ IMM DEF, V40, P324, DOI 10.1097/01.qai.0000182627.28595.01
   Zaragoza-Macias E, 2010, AIDS RES HUM RETROV, V26, P133, DOI 10.1089/aid.2009.0001
NR 40
TC 10
Z9 10
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-6405
J9 AIDS RES THER
JI Aids Res. Ther.
PD SEP 1
PY 2014
VL 11
AR 29
DI 10.1186/1742-6405-11-29
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA AQ9LC
UT WOS:000343174000001
PM 25206924
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Crabtree-Ramirez, B
   Del Rio, C
   Grinsztejn, B
   Sierra-Madero, J
AF Crabtree-Ramirez, Brenda
   Del Rio, Carlos
   Grinsztejn, Beatriz
   Sierra-Madero, Juan
TI HIV and Noncommunicable Diseases (NCDs) in Latin America: A Call for an
   Integrated and Comprehensive Response
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE noncommunicable diseases; HIV/AIDS; Latin America and the Caribbean;
   aging with HIV; cardiovascular disease; cancer
ID INFECTED PATIENTS; CARDIOVASCULAR RISK; AIDS; BRAZIL; ATHEROSCLEROSIS;
   MALIGNANCIES; ASSOCIATION; PROGRESSION; LYMPHOMA; ADULTS
AB The life expectancy of people living with HIV has dramatically improved with the much increased access to antiretroviral therapy. Consequently, a larger number of people living with HIV are living longer and facing the increased burden of noncommunicable diseases (NCDs). NCDs and HIV infection share common epidemiologic and sociodemographic characteristics that influence their outcomes, which may be difficult to address in the relatively weak health systems of the region. Data on the prevalence and interactions of NCDs and HIV in Latin American countries remain very limited, which hinders their governments' ability to make informed decisions about health care policies. Therefore, there is an urgent need to develop a research agenda that will be the basis for an integrated and comprehensive health care approach to HIV and NCD comorbidities in Latin America.
C1 [Crabtree-Ramirez, Brenda; Sierra-Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City 14000, DF, Mexico.
   [Del Rio, Carlos] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
   [Del Rio, Carlos] Emory Univ, Ctr AIDS Res, Atlanta, GA 30322 USA.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
RP Sierra-Madero, J (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Vasco Quiroga 15,Col Secc XVI, Mexico City 14000, DF, Mexico.
EM jsmadero@yahoo.com
RI del Rio, Carlos/B-3763-2012
OI del Rio, Carlos/0000-0002-0153-3517; Crabtree-Ramirez,
   Brenda/0000-0002-2587-1123
CR Aguilar S, 2004, REV ENDOCRINOL NUTR, V12, P1
   Bacchi CE, 1996, AM J CLIN PATHOL, V105, P230
   Bellorin-Font Ezequiel, 2013, Nefrología (Madr.), V33, P1, DOI 10.3265/Nefrologia.pre2013.Feb.11945
   Belloso WH, 2010, HIV MED, V11, P554, DOI 10.1111/j.1468-1293.2010.00824.x
   BonillaChacin ME, 2014, DIR DEV, P1, DOI 10.1596/978-1-4648-0016-0
   Cahn P, 2010, BRAZ J INFECT DIS, V14, P158, DOI 10.1590/S1413-86702010000200008
   Collins JA, 2005, JAIDS-J ACQ IMM DEF, V40, P558, DOI 10.1097/01.qai.0000185135.54920.79
   Crabtree-Ramirez B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020272
   Cusumano AM, 2008, CLIN J AM SOC NEPHRO, V3, P594, DOI 10.2215/CJN.03420807
   De Socio GVL, 2007, SCAND J INFECT DIS, V39, P805, DOI 10.1080/00365540701230884
   Dutta A, 2013, DIR DEV, P1, DOI 10.1596/978-0-8213-9776-3
   Ferrera A, 1997, AM J TROP MED HYG, V57, P138, DOI 10.4269/ajtmh.1997.57.138
   Fink VI, 2011, JAIDS-J ACQ IMM DEF, V56, P467, DOI 10.1097/QAI.0b013e31820bb1c3
   Fonseca Pacheco AG, 2013, 7 IAS C HIV PATH TRE
   Friedman R, 2013, PREVALENCE ANAL HUMA
   Albuquerque VMG, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-274
   Greig Jane, 2012, AIDS, V26 Suppl 1, pS31
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Osorio SG, 2007, REV CHIL INFECTOL, V24, P117, DOI 10.4067/S0716-10182007000200005
   Justice Amy C, 2012, AIDS, V26 Suppl 1, pS11
   Kort Rodney, 2009, J Int AIDS Soc, V12 Suppl 1, pS7, DOI 10.1186/1758-2652-12-S1-S7
   Laurido M, 2007, MEDICINA-BUENOS AIRE, V67, P243
   Lee JGL, 2009, TOB CONTROL, V18, P275, DOI 10.1136/tc.2008.028241
   Mangili A, 2011, JAIDS-J ACQ IMM DEF, V58, P148, DOI [10.1097/QAI.0B013E31822D4993, 10.1097/QAI.0b013e31822d4993]
   Melo VH, 2014, J LOW GENIT TRACT DI, V18, P128, DOI 10.1097/LGT.0b013e31829ee855
   Ministerio de Salud y Proteccion Social, 2011, PIAN NAZ EL MORB ROS, P1
   Moyer VA, 2013, ANN INTERN MED, V159, P51, DOI 10.7326/0003-4819-159-1-201307020-00645
   Murray CJLLA, 1996, GLOBAL BURDEN DIS CO
   Negin Joel, 2012, AIDS, V26 Suppl 1, pS55
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   PAHO, PAHO PLAN ACT CANC P
   Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088
   Paula AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094636
   Sampaio J, 2007, CURR OPIN ONCOL, V19, P476, DOI 10.1097/CCO.0b013e3282c8c8eb
   Santiago P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093748
   Schargrodsky H, 2008, AM J MED, V121, P58, DOI 10.1016/j.amjmed.2007.08.038
   Ssinabulya I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089537
   Trujillo AJ, 2013, J AGING HEALTH, V25, P1398, DOI 10.1177/0898264313508190
   Vagenas P, 2013, REV PANAM SALUD PUBL, V34, P267
   Volpe GE, 2013, JAIDS-J ACQ IMM DEF, V64, P51, DOI 10.1097/QAI.0b013e31829ed726
NR 40
TC 12
Z9 12
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD SEP 1
PY 2014
VL 67
SU 1
BP S96
EP S98
DI 10.1097/QAI.0000000000000261
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AO1PT
UT WOS:000341086200011
PM 25117966
DA 2020-11-24
ER

PT J
AU Marrazzo, JM
   del Rio, C
   Holtgrave, DR
   Cohen, MS
   Kalichman, SC
   Mayer, KH
   Montaner, JSG
   Wheeler, DP
   Grant, RM
   Grinsztejn, B
   Kumarasamy, N
   Shoptaw, S
   Walensky, RP
   Dabis, F
   Sugarman, J
   Benson, CA
AF Marrazzo, Jeanne M.
   del Rio, Carlos
   Holtgrave, David R.
   Cohen, Myron S.
   Kalichman, Seth C.
   Mayer, Kenneth H.
   Montaner, Julio S. G.
   Wheeler, Darrell P.
   Grant, Robert M.
   Grinsztejn, Beatriz
   Kumarasamy, N.
   Shoptaw, Steven
   Walensky, Rochelle P.
   Dabis, Francois
   Sugarman, Jeremy
   Benson, Constance A.
TI HIV Prevention in Clinical Care Settings 2014 Recommendations of the
   International Antiviral Society-USA Panel
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; SEXUAL RISK BEHAVIOR; NONOCCUPATIONAL
   POSTEXPOSURE PROPHYLAXIS; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL
   MEDICATION ADHERENCE; TRANSMITTED-DISEASE PREVENTION; NATIONAL HIV/AIDS
   STRATEGY; UNITED-STATES; COST-EFFECTIVENESS; MALE CIRCUMCISION
AB IMPORTANCE Emerging data warrant the integration of biomedical and behavioral recommendations for human immunodeficiency virus (HIV) prevention in clinical care settings.
   OBJECTIVE To provide current recommendations for the prevention of HIV infection in adults and adolescents for integration in clinical care settings.
   DATA SOURCES, STUDY SELECTION, AND DATA SYNTHESIS Data published or presented as abstracts at scientific conferences (past 17 years) were systematically searched and reviewed by the International Antiviral (formerly AIDS) Society USA HIV Prevention Recommendations Panel. Panel members supplied additional relevant publications, reviewed available data, and formed recommendations by full-panel consensus.
   RESULTS Testing for HIV is recommended at least once for all adults and adolescents, with repeated testing for those at increased risk of acquiring HIV. Clinicians should be alert to the possibility of acute HIV infection and promptly pursue diagnostic testing if suspected. At diagnosis of HIV, all individuals should be linked to care for timely initiation of antiretroviral therapy (ART). Support for adherence and retention in care, individualized risk assessment and counseling, assistance with partner notification, and periodic screening for common sexually transmitted infections (STIs) is recommended for HIV-infected individuals as part of care. In HIV-uninfected patients, those persons at high risk of HIV infection should be prioritized for delivery of interventions such as preexposure prophylaxis and individualized counseling on risk reduction. Daily emtricitabine/tenofovir disoproxil fumarate is recommended as preexposure prophylaxis for persons at high risk for HIV based on background incidence or recent diagnosis of incident STIs, use of injection drugs or shared needles, or recent use of nonoccupational postexposure prophylaxis; ongoing use of preexposure prophylaxis should be guided by regular risk assessment. For persons who inject drugs, harm reduction services should be provided (needle and syringe exchange programs, supervised injection, and available medically assisted therapies, including opioid agonists and antagonists); low-threshold detoxification and drug cessation programs should be made available. Postexposure prophylaxis is recommended for all persons who have sustained a mucosal or parenteral exposure to HIV from a known infected source and should be initiated as soon as possible.
   CONCLUSIONS AND RELEVANCE Data support the integration of biomedical and behavioral approaches for prevention of HIV infection in clinical care settings. A concerted effort to implement combination strategies for HIV prevention is needed to realize the goal of an AIDS-free generation.
C1 [Marrazzo, Jeanne M.] Univ Washington, Seattle, WA 98104 USA.
   [del Rio, Carlos] Emory Univ, Atlanta, GA 30322 USA.
   [Holtgrave, David R.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Cohen, Myron S.] Univ N Carolina, Chapel Hill, NC USA.
   [Kalichman, Seth C.] Univ Connecticut, Storrs, CT USA.
   [Mayer, Kenneth H.] Harvard Univ, Sch Med, Boston, MA USA.
   [Montaner, Julio S. G.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
   [Wheeler, Darrell P.] Loyola Univ, Chicago, IL 60611 USA.
   [Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Clin Res Inst IPEC, BR-21045900 Rio De Janeiro, Brazil.
   [Kumarasamy, N.] YR Gaitonde Ctr AIDS Res & Educ, Chennai, Tamil Nadu, India.
   [Shoptaw, Steven] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
   [Walensky, Rochelle P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Dabis, Francois] Univ Bordeaux, Bordeaux, France.
   [Sugarman, Jeremy] Johns Hopkins Univ, Baltimore, MD USA.
   [Benson, Constance A.] Univ Calif San Diego, La Jolla, CA 92093 USA.
RP Marrazzo, JM (corresponding author), Univ Washington, Harborview Med Ctr, Box 359932,325 9th Ave, Seattle, WA 98104 USA.
EM jmm2@uw.edu
RI DABIS, FRANCOIS/S-9298-2019; del Rio, Carlos/B-3763-2012
OI DABIS, FRANCOIS/0000-0002-1614-8857; del Rio,
   Carlos/0000-0002-0153-3517; Holtgrave, David/0000-0002-4321-7395;
   Walensky, Rochelle P./0000-0002-8795-379X; Grant,
   Robert/0000-0002-0851-7085; Sugarman, Jeremy/0000-0001-7022-8332;
   Marrazzo, Jeanne/0000-0002-9277-7364
FU International Antiviral Society-USA (IAS-USA), a mission-based,
   nonmembership, not-for-profit organization [501(c)(3)]; IAS-USA;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069432, UM1AI069432, UM1AI069432, UM1AI069432, UM1AI069432,
   UM1AI069432, UM1AI069432, UM1AI069432] Funding Source: NIH RePORTER
FX This work is supported and funded by the International Antiviral
   (formerly AIDS) Society-USA (IAS-USA), a mission-based, nonmembership,
   501(c)(3) not-for-profit organization. The IAS-USA appointed members to
   the IAS-USA HIV Prevention Recommendations Panel to develop the
   recommendations and provided staff support. In the last 5 years, IAS-USA
   has received commercial support (grants) for selected continuing medical
   education (CME) activities that are pooled (ie, no single company
   supports any single effort) from Abbott Laboratories, AbbVie, Boehringer
   Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences,
   GlaxoSmithKline, Janssen Therapeutics, Merck & Co, Mylan, Pfizer, Salix
   Pharmaceuticals, Tibotec Therapeutics, Vertex Pharmaceuticals, and ViiV
   Healthcare. The designation of selected CME activities refers to the
   IAS-USA structure of accepting commercial support only if there are
   enough companies with competing products to meet the criteria for
   independence and only on programs appropriate for support by commercial
   sources (eg, recommendations are not supported by industry grants). No
   private sector funding was used to support the effort. Panel members are
   not compensated for participation in the effort.
CR Aberg JA, 2014, CLIN INFECT DIS, V58, P1, DOI 10.1093/cid/cit757
   Amorosa V, 2005, JAIDS-J ACQ IMM DEF, V39, P557
   Andersen M, 2003, AM J DRUG ALCOHOL AB, V29, P847, DOI 10.1081/ADA-120026264
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Archin NM, 2012, P NATL ACAD SCI USA, V109, P9523, DOI 10.1073/pnas.1120248109
   Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca
   Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298
   Auvert B, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001509
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bailey RC, 2002, AIDS CARE, V14, P27, DOI 10.1080/09540120220097919
   Bassett IV, 2004, CLIN INFECT DIS, V39, P395, DOI 10.1086/422459
   Berg KM, 2011, DRUG ALCOHOL DEPEN, V113, P192, DOI 10.1016/j.drugalcdep.2010.07.025
   Binford MC, 2012, CURR HIV-AIDS REP, V9, P287, DOI 10.1007/s11904-012-0134-8
   Birungi J, 2012, 19 INT AIDS C IAS JU
   Blank S, 2012, PEDIATRICS, V130, P585, DOI 10.1542/peds.2012-1989
   Blankenship KM, 2000, AIDS, V14, pS11, DOI 10.1097/00002030-200006001-00003
   Blish CA, 2012, JAIDS-J ACQ IMM DEF, V61, P436, DOI 10.1097/QAI.0b013e31826c2edd
   Bocour A, 2013, AIDS, V27, P2961, DOI 10.1097/QAD.0000000000000031
   Bolu OO, 2004, SEX TRANSM DIS, V31, P469, DOI 10.1097/01.olq.0000135987.12346.f2
   Bonolo PD, 2005, AIDS, V19, pS5
   Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Branson BM, 2012, J INFECT DIS, V205, P521, DOI 10.1093/infdis/jir793
   Branson BM, 2006, MMWR RECOMM REP, V55, pCE1, DOI DOI 10.1016/J.ANNEMERGMED.2007.03.001
   Brenner BG, 2011, J INFECT DIS, V204, P1115, DOI 10.1093/infdis/jir468
   Butler AR, 2013, AIDS, V27, P105, DOI 10.1097/QAD.0b013e32835a5a52
   Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101
   Center for Disease control and Prevention (CDC), PREEXP PROPH PREV HI
   Centers for Disease Control and Prevention, HIGH IMP HIV PREV CD
   Centers for Disease Control and Prevention, 2011, SEX TRANSM DIS SURV
   Centers for disease control and prevention, MON SEL NAT HIV PREV
   Centers for Disease Control and Prevention (CDC), LIST ALL RISK RED IN
   Centers for Disease Control and Prevention (CDC), QUADR HUM PAP VACC R
   Centers for Disease Control and Prevention (CDC), STAT HIV LAWS
   Centers for Disease Control and Prevention (CDC), HIV SPEC CRIM LAWS
   Chibo D, 2012, AIDS RES HUM RETROV, V28, P460, DOI [10.1089/AID.2011.0137, 10.1089/aid.2011.0137]
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Coffin PO, 2014, AIDS BEHAV, V18, P1390, DOI 10.1007/s10461-014-0712-4
   Cohen MS, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001232
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Colfax GN, 2011, ARCH GEN PSYCHIAT, V68, P1168, DOI 10.1001/archgenpsychiatry.2011.124
   Cornett JK, 2013, CLIN INFECT DIS, V57, P712, DOI 10.1093/cid/cit281
   Craw JA, 2008, JAIDS-J ACQ IMM DEF, V47, P597, DOI 10.1097/QAI.0b013e3181684c51
   Crepaz N, 2014, AIDS, V28, P633, DOI 10.1097/QAD.0000000000000108
   Crosby R, 2009, AM J PUBLIC HEALTH, V99, pS96, DOI 10.2105/AJPH.2007.123893
   Diaz-Brito V, 2012, ANTIVIR THER, V17, P337, DOI 10.3851/IMP1955
   Dilley JW, 2007, JAIDS-J ACQ IMM DEF, V44, P569, DOI 10.1097/QAI.0b013e318033ffbd
   Dilley JW, 2002, J ACQ IMMUN DEF SYND, V30, P177, DOI [10.1097/00042560-200206010-00006, 10.1097/01.QAI.0000016823.19906.41]
   Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2
   Eaton Lisa A, 2012, Am J Public Health, V102, pe34, DOI 10.2105/AJPH.2012.300968
   Eaton LA, 2013, AIDS CARE, V25, P805, DOI 10.1080/09540121.2012.748870
   El-Bassel N, 2010, ARCH INTERN MED, V170, P1594, DOI 10.1001/archinternmed.2010.261
   Farber S, 2013, AIDS BEHAV, V17, P2293, DOI 10.1007/s10461-013-0416-1
   Fauci AS, 2013, NAT IMMUNOL, V14, P1104, DOI 10.1038/ni.2735
   FDA, COMPL LIST DON SCREE
   Fisher JD, 2006, JAIDS-J ACQ IMM DEF, V41, P44, DOI 10.1097/01.qai.0000192000.15777.5c
   Ford N, 2012, AIDS, V26, P559, DOI 10.1097/QAD.0b013e32834f3264
   Fu TC, 2012, AIDS, V26, P2383, DOI 10.1097/QAD.0b013e32835ad438
   Fuchs J, 2007, JAIDS-J ACQ IMM DEF, V46, P362, DOI 10.1097/QAI.0b013e3181565dcb
   Garcia-Lerma JG, 2012, CURR OPIN HIV AIDS, V7, P505, DOI 10.1097/COH.0b013e328358e484
   Garcia-Lerma JG, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000391
   Gardner LI, 2005, AIDS, V19, P423, DOI 10.1097/01.aids.0000161772.51900.eb
   Gardner LI, 2014, CLIN INFECT DIS, V59, P725, DOI 10.1093/cid/ciu357
   Gardner LI, 2012, CLIN INFECT DIS, V55, P1124, DOI 10.1093/cid/cis623
   Garg S, 2013, CLIN INFECT DIS, V56, P1480, DOI 10.1093/cid/cit054
   Gebremedhin Samson, 2010, East Afr J Public Health, V7, P295
   Geren K, 2013, MMWR-MORBID MORTAL W, V62, P489
   Gilbert P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001988
   Golden MR, 2009, AIDS, V23, P133, DOI 10.1097/QAD.0b013e32831fb52f
   Golden MR, 2004, JAIDS-J ACQ IMM DEF, V36, P734, DOI 10.1097/00126334-200406010-00011
   Golin CE, 2012, AIDS BEHAV, V16, P1182, DOI 10.1007/s10461-011-0025-9
   Golin CE, 2010, AIDS PATIENT CARE ST, V24, P237, DOI 10.1089/apc.2009.0252
   Golin CE, 2006, JAIDS-J ACQ IMM DEF, V42, P42, DOI 10.1097/01.qai.0000219771.97303.0a
   Gopalappa C, 2012, JAIDS-J ACQ IMM DEF, V61, P99, DOI 10.1097/QAI.0b013e31825bd862
   Gowing L, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004145.pub3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gray RH, 2000, AIDS, V14, P2371, DOI 10.1097/00002030-200010200-00019
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Gross R, 2013, JAMA INTERN MED, V173, P300, DOI 10.1001/jamainternmed.2013.2152
   Hall HI, 2013, AIDS BEHAV, V17, P1632, DOI 10.1007/s10461-013-0426-z
   Hall HI, 2012, AIDS, V26, P893, DOI 10.1097/QAD.0b013e328351f73f
   Hallett TB, 2011, SEX TRANSM INFECT, V87, P88, DOI 10.1136/sti.2010.043372
   Herbst JH, 2005, JAIDS-J ACQ IMM DEF, V39, P228
   Hightow-Weidman LB, 2011, AIDS PATIENT CARE ST, V25, pS31, DOI 10.1089/apc.2011.9878
   Hightow-Weidman LB, 2011, AIDS PATIENT CARE ST, V25, P37, DOI 10.1089/apc.2010.0192
   Hill S, 2012, AIDS CARE, V24, P583, DOI 10.1080/09540121.2011.630354
   Himelhoch S, 2013, AIDS BEHAV, V17, P2756, DOI 10.1007/s10461-013-0465-5
   Holtgrave D, 2007, CLIN INFECT DIS, V45, pS240, DOI 10.1086/522544
   Holtgrave DR, 2014, JAIDS-J ACQ IMM DEF, V65, pE125, DOI 10.1097/QAI.0b013e3182a8ef0e
   Holtgrave DR, 2012, AIDS BEHAV, V16, P1365, DOI 10.1007/s10461-012-0207-0
   Holtgrave DR, 2012, AIDS BEHAV, V16, P1085, DOI 10.1007/s10461-012-0186-1
   Holtgrave DR, 2010, JAIDS-J ACQ IMM DEF, V55, P139, DOI 10.1097/QAI.0b013e3181f4107a
   Hoover KW, 2010, SEX TRANSM DIS, V37, P771, DOI 10.1097/OLQ.0b013e3181e50058
   Horvath KJ, 2013, AIDS BEHAV, V17, P2031, DOI 10.1007/s10461-013-0469-1
   Hughes JP, 2012, J INFECT DIS, V205, P358, DOI 10.1093/infdis/jir747
   James NJ, 1998, AIDS, V12, P1235, DOI 10.1097/00002030-199810000-00016
   Jemmott LS, 2007, AM J PUBLIC HEALTH, V97, P1034, DOI 10.2105/AJPH.2003.020271
   Jin FY, 2010, JAIDS-J ACQ IMM DEF, V53, P144, DOI 10.1097/QAI.0b013e3181b48f33
   Johnson BT, 2009, JAIDS-J ACQ IMM DEF, V51, P492, DOI 10.1097/QAI.0b013e3181a28121
   Johnson MO, 2011, ANN BEHAV MED, V41, P83, DOI 10.1007/s12160-010-9230-4
   Justman J, 2013, JAIDS-J ACQ IMM DEF, V63, pS140, DOI 10.1097/QAI.0b013e31829875cc
   Juusola JL, 2012, ANN INTERN MED, V156, P541, DOI [10.7326/0003-4819-156-8-201204170-00001, 10.7326/0003-4819-156-8-201204170-00004]
   Kahn JA, 2013, CLIN INFECT DIS, V57, P735, DOI 10.1093/cid/cit319
   Kalichman SC, 2005, J ASSOC NURSE AIDS C, V16, P3, DOI 10.1016/j.jana.2005.07.001
   Kalichman SC, 2005, HEALTH PSYCHOL, V24, P198, DOI 10.1037/0278-6133.24.2.198
   Kalichman SC, 2001, AM J PREV MED, V21, P84, DOI 10.1016/S0749-3797(01)00324-5
   Kalichman SC, 2013, JAIDS-J ACQ IMM DEF, V63, P42, DOI 10.1097/QAI.0b013e318286ce49
   Kalichman SC, 2011, AIDS PATIENT CARE ST, V25, P303, DOI 10.1089/apc.2010.0367
   Kalichman SC, 2011, AM J PUBLIC HEALTH, V101, P531, DOI 10.2105/AJPH.2010.197608
   Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161
   Karim SSA, 2011, AIDS, V25, P957, DOI 10.1097/QAD.0b013e32834541d9
   Koblin B, 2004, LANCET, V364, P41, DOI 10.1016/S0140-6736(04)16588-4
   Kuhar DT, 2013, INFECT CONT HOSP EP, V34, P1238, DOI 10.1086/673726
   Kuhar DT, 2013, INFECT CONT HOSP EP, V34, P875, DOI 10.1086/672271
   Landovitz RJ, 2009, NEW ENGL J MED, V361, P1768, DOI 10.1056/NEJMcp0904189
   Le T, 2013, NEW ENGL J MED, V368, P218, DOI 10.1056/NEJMoa1110187
   Lee MB, 2005, AIDS EDUC PREV, V17, P105, DOI 10.1521/aeap.17.3.105.62906
   Letourneau EJ, 2013, AIDS CARE, V25, P507, DOI 10.1080/09540121.2012.715134
   Li JH, 2012, AIDS, V26, P2069, DOI 10.1097/QAD.0b013e3283574e54
   Lightfoot M, 2007, BEHAV MODIF, V31, P345, DOI 10.1177/0145445506293787
   Lissouba P, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000309
   Long EF, 2013, J GEN INTERN MED, V28, P1294, DOI 10.1007/s11606-013-2417-1
   Long EF, 2010, ANN INTERN MED, V153, P778, DOI 10.7326/0003-4819-153-12-201012210-00004
   Lucas GM, 2010, ANN INTERN MED, V152, P704, DOI 10.7326/0003-4819-152-11-201006010-00003
   Marrazzo JM, 2013, 20 C RETR OPP INF CR
   Marshall BDL, 2009, SEX TRANSM INFECT, V85, P121, DOI 10.1136/sti.2008.032524
   Marshall BDL, 2010, AIDS, V24, P2271, DOI 10.1097/QAD.0b013e32833dd101
   Mathes T, 2013, HIV MED, V14, P583, DOI 10.1111/hiv.12051
   Mausbach BT, 2007, DRUG ALCOHOL DEPEN, V87, P249, DOI 10.1016/j.drugalcdep.2006.08.026
   Mavhu W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032475
   Mayer KH, 2008, JAIDS-J ACQ IMM DEF, V47, P494, DOI 10.1097/QAI.0b013e318162afcb
   Mayer KH, 2012, JAIDS-J ACQ IMM DEF, V59, P354, DOI 10.1097/QAI.0b013e31824a03b8
   Mayer KH, 2012, SEX TRANSM DIS, V39, P1, DOI 10.1097/OLQ.0b013e31823b1922
   McCoy SI, 2013, J ACQ IMMUN DEF SYND, V63, P56
   McKirnan DJ, 2010, J CONSULT CLIN PSYCH, V78, P952, DOI 10.1037/a0020759
   Mehta SD, 2013, AIDS, V27, P2899, DOI 10.1097/01.aids.0000432444.30308.2d
   Metcalf CA, 2005, SEX TRANSM DIS, V32, P130, DOI 10.1097/01.olq.0000151421.97004.c0
   Metcalf CA, 2005, SEX TRANSM DIS, V32, P123, DOI 10.1097/01.olq.0000151420.92624.c0
   Metsch LR, 2008, CLIN INFECT DIS, V47, P577, DOI 10.1086/590153
   Metsch LR, 2013, JAMA-J AM MED ASSOC, V310, P1701, DOI 10.1001/jama.2013.280034
   Metsch LR, 2012, AM J PUBLIC HEALTH, V102, P1160, DOI 10.2105/AJPH.2011.300460
   Miller WC, 2009, AIDS, V23, P835, DOI 10.1097/QAD.0b013e328326f55e
   Milloy MJS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003351
   Milloy MJ, 2012, CURR OPIN HIV AIDS, V7, P332, DOI 10.1097/COH.0b013e328354bcc8
   Mizuno Y, 2014, AIDS, V28, P407, DOI 10.1097/QAD.0000000000000057
   Montaner J, 2011, JAIDS-J ACQ IMM DEF, V56, pE101, DOI 10.1097/QAI.0b013e318202e41d
   Montaner JSG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087872
   Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1
   Morin SF, 2007, JAIDS-J ACQ IMM DEF, V44, P213
   Moyer VA, 2013, ANN INTERN MED, V159, P51, DOI 10.7326/0003-4819-159-1-201307020-00645
   Mugavero MJ, 2012, JAIDS-J ACQ IMM DEF, V59, P86, DOI 10.1097/QAI.0b013e318236f7d2
   Murphy Debra A, 2007, J Int Assoc Physicians AIDS Care (Chic), V6, P113, DOI 10.1177/1545109707301243
   Naar-King S, 2012, CURR HIV-AIDS REP, V9, P335, DOI 10.1007/s11904-012-0132-x
   Naar-King S, 2009, AIDS CARE, V21, P868, DOI 10.1080/09540120802612824
   Nagelkerke NJD, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-16
   Napper LE, 2010, AIDS BEHAV, V14, P152, DOI 10.1007/s10461-009-9575-5
   National Network of STDHIV Prevention Training Centers, ASK SCREEN INT INC H
   Neaigus A, 2008, J URBAN HEALTH, V85, P309, DOI 10.1007/s11524-008-9271-1
   Noar SM, 2008, AIDS BEHAV, V12, P335, DOI 10.1007/s10461-007-9313-9
   Noguchi LM, 2014, TOP ANTIVIR MED, V22, P441
   Nosyk B, 2012, CAN MED ASSOC J, V184, pE317, DOI 10.1503/cmaj.110669
   Oviedo-Joekes E, 2009, NEW ENGL J MED, V361, P777, DOI 10.1056/NEJMoa0810635
   Palepu A, 2011, J URBAN HEALTH, V88, P545, DOI 10.1007/s11524-011-9562-9
   Paltiel AD, 2006, ANN INTERN MED, V145, P797, DOI 10.7326/0003-4819-145-11-200612050-00004
   Paltiel AD, 2012, ANN INTERN MED, V157, P744, DOI 10.7326/0003-4819-157-10-201211200-00545
   Paltiel AD, 2009, CLIN INFECT DIS, V48, P806, DOI 10.1086/597095
   Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088
   Panel on Antiretroviral Guidelines for Adults and Adolescents, 2012, GUIDELINES USE ANTIR
   Parsons JT, 2005, AIDS PATIENT CARE ST, V19, P31, DOI 10.1089/apc.2005.19.31
   Pathela P, 2013, CLIN INFECT DIS, V57, P1203, DOI 10.1093/cid/cit437
   Pati R, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18490
   Patterson TL, 2008, AM J PUBLIC HEALTH, V98, P2051, DOI 10.2105/AJPH.2007.130096
   Patton ME, 2014, CLIN INFECT DIS, V58, P1564, DOI 10.1093/cid/ciu184
   Patton ME, 2014, MMWR-MORBID MORTAL W, V63, P402
   Pettifor A, 2011, AIDS BEHAV, V15, P1243, DOI 10.1007/s10461-010-9839-0
   Phillips AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055312
   Phillips SJ, 2013, AIDS, V27, P787, DOI 10.1097/QAD.0b013e32835bb672
   Polis CB, 2013, LANCET INFECT DIS, V13, P797, DOI 10.1016/S1473-3099(13)70155-5
   Polis CB, 2013, AIDS, V27, P493, DOI 10.1097/QAD.0b013e32835ad539
   Powers KA, 2011, LANCET, V378, P256, DOI 10.1016/S0140-6736(11)60842-8
   Poynten IM, 2009, AIDS, V23, P1119, DOI 10.1097/QAD.0b013e32832c1776
   Prejean J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017502
   Reynolds NR, 2008, JAIDS-J ACQ IMM DEF, V47, P62, DOI 10.1097/QAI.0b013e3181582d54
   Reznick OG, 2013, J CORRECT HEALTH CAR, V19, P178, DOI 10.1177/1078345813486442
   Richardson JL, 2004, AIDS, V18, P1179, DOI 10.1097/00002030-200405210-00011
   Rodger A, 2014, 2014 C RETR OPP INF
   Roland ME, 2005, CLIN INFECT DIS, V41, P1507, DOI 10.1086/497268
   Rotheram-Borus MJ, 2009, AIDS BEHAV, V13, P387, DOI 10.1007/s10461-009-9531-4
   Rotheram-Borus MJ, 2004, JAIDS-J ACQ IMM DEF, V37, pS68, DOI 10.1097/01.qai.0000140604.57478.67
   Rotheram-Borus MJ, 2002, AP PRA H PS, P15
   Rotheram-Borus MJ, 2001, AM J PUBLIC HEALTH, V91, P400, DOI 10.2105/AJPH.91.3.400
   Safren SA, 2009, HEALTH PSYCHOL, V28, P1, DOI 10.1037/a0012715
   Sanchez J, 2011, AIDS, V25, P519, DOI 10.1097/QAD.0b013e328340fd81
   Sanders GD, 2005, NEW ENGL J MED, V352, P570, DOI 10.1056/NEJMsa042657
   Schechter M, 2004, JAIDS-J ACQ IMM DEF, V35, P519, DOI 10.1097/00126334-200404150-00010
   Schroder KEE, 2003, ANN BEHAV MED, V26, P76, DOI 10.1207/S15324796ABM2602_02
   Scott-Sheldon LAJ, 2011, JAIDS-J ACQ IMM DEF, V58, P489, DOI 10.1097/QAI.0b013e31823554d7
   Scott-Sheldon LAJ, 2010, ANN BEHAV MED, V40, P191, DOI 10.1007/s12160-010-9202-8
   Semaan S, 2010, DRUG ALCOHOL DEPEN, V106, P7, DOI 10.1016/j.drugalcdep.2009.07.015
   Shrier LA, 2001, ARCH PEDIAT ADOL MED, V155, P73, DOI 10.1001/archpedi.155.1.73
   Sikkema KJ, 2008, JAIDS-J ACQ IMM DEF, V47, P506, DOI 10.1097/QAI.0b013e318160d727
   Simoni JM, 2007, HEALTH PSYCHOL, V26, P488, DOI 10.1037/0278-6133.26.4.488
   Simoni JM, 2013, AIDS BEHAV, V17, P2816, DOI 10.1007/s10461-013-0538-5
   Simoni JM, 2011, AIDS BEHAV, V15, P919, DOI 10.1007/s10461-010-9828-3
   Smith Dawn K., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Soorapanth S, 2013, P 2010 WINT SIM C BA
   Spreen W, 2013, 7 IAS C HIV PATH TRE
   Steward WT, 2009, AIDS BEHAV, V13, P1054, DOI 10.1007/s10461-009-9582-6
   Stoltz JA, 2007, J PUBLIC HEALTH, V29, P35, DOI 10.1093/pubmed/fdl090
   Strathdee SA, 2010, LANCET, V376, P268, DOI 10.1016/S0140-6736(10)60743-X
   Sullivan Patrick S, 2014, J Int Assoc Provid AIDS Care, V13, P135, DOI 10.1177/2325957413500534
   Tanser F, 2013, SCIENCE, V339, P966, DOI 10.1126/science.1228160
   Taylor MM, 2010, SEX TRANSM DIS, V37, P767, DOI 10.1097/OLQ.0b013e3181e65e8b
   Tepper Naomi K., 2012, Morbidity and Mortality Weekly Report, V61, P449
   The Well Project, DISCL HIV
   The White House Office of National AIDS Policy (ONAP). National HIV/AIDS Strategy for the United States. ONAP, NAT HIV AIDS STRAT U
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961
   Thompson MA, 2012, ANN INTERN MED, V156, P817, DOI 10.7326/0003-4819-156-11-201206050-00419
   Tobian AAR, 2011, LANCET INFECT DIS, V11, P604, DOI 10.1016/S1473-3099(11)70038-X
   Tobian AAR, 2009, AIDS, V23, P1589, DOI 10.1097/QAD.0b013e32832d4042
   Townsend L, 2013, PREV SCI, V14, P88, DOI 10.1007/s11121-012-0300-7
   Tsai CC, 1998, J VIROL, V72, P4265, DOI 10.1128/JVI.72.5.4265-4273.1998
   Uhlmann S, 2010, ADDICTION, V105, P907, DOI 10.1111/j.1360-0443.2010.02905.x
   United Nations Office on Drugs and Crime (UNODC), COERC COH TREAT DRUG
   US Department of State, PEPFAR BLUEPR CREAT
   US Preventive Services Task Force (USPSTF), BEH COUNS PREV SEX T
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Wagner GA, 2014, J INFECT DIS, V209, P1032, DOI 10.1093/infdis/jit633
   Walensky RP, 2013, NEW ENGL J MED, V369, P1715, DOI 10.1056/NEJMsa1214720
   Walensky RP, 2005, MED DECIS MAKING, V25, P321, DOI 10.1177/0272989X05276955
   Wandeler G, 2012, CLIN INFECT DIS, V55, P1408, DOI 10.1093/cid/cis694
   Wang L, 2010, JAIDS-J ACQ IMM DEF, V55, P232, DOI 10.1097/QAI.0b013e3181e9b6b7
   Warner L, 2008, PLOS MED, V5, P919, DOI 10.1371/journal.pmed.0050135
   Wawer MJ, 2009, LANCET, V374, P229, DOI 10.1016/S0140-6736(09)60998-3
   Weinhardt LS, 1999, AM J PUBLIC HEALTH, V89, P1397, DOI 10.2105/AJPH.89.9.1397
   Weintrob AC, 2003, ARCH INTERN MED, V163, P2097, DOI 10.1001/archinte.163.17.2097
   *WHO, GUID COUPL HIV TEST
   WHO, 2016, CONS GUID US ANT DRU
   Wilkin T, 2010, J INFECT DIS, V202, P1246, DOI 10.1086/656320
   Wingood GM, 2004, JAIDS-J ACQ IMM DEF, V37, pS58, DOI 10.1097/01.qai.0000140603.57478.a9
   Wohl AR, 2011, AIDS CARE, V23, P988, DOI 10.1080/09540121.2010.542125
   Wolitski RJ, 2005, AIDS, V19, pS99, DOI 10.1097/01.aids.0000167356.94664.59
   Wood E, 2006, NEW ENGL J MED, V354, P2512, DOI 10.1056/NEJMc052939
   Wood E, 2006, SUBST ABUSE TREAT PR, V1, DOI 10.1186/1747-597X-1-13
   Wood E, 2006, CAN MED ASSOC J, V175, P1399, DOI 10.1503/cmaj.060863
   Workowski Kimberly A., 2011, Morbidity and Mortality Weekly Report, V60, P18
   Workowski Kimberly A., 2010, Morbidity and Mortality Weekly Report, V59, P1
   World Health Organization, 2012, UNODC UNAIDS TECHN G
   World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS. (UNAIDS), GUID HIV TEST COUNS
   World Health Organization (WHO) Department of Reproductive Health and Research, 2012, HORM CONTR HIV TECHN
   Young MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047395
   1979, CAN MED ASSOC J, V121, P1193
NR 252
TC 79
Z9 83
U1 0
U2 39
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUL 23
PY 2014
VL 312
IS 4
BP 390
EP 409
DI 10.1001/jama.2014.7999
PG 20
WC Medicine, General & Internal
SC General & Internal Medicine
GA AL6QN
UT WOS:000339257800026
PM 25038358
OA Bronze, Green Accepted
DA 2020-11-24
ER

PT J
AU Kojic, EM
   Kang, M
   Cespedes, MS
   Umbleja, T
   Godfrey, C
   Allen, RT
   Firnhaber, C
   Grinsztejn, B
   Palefsky, JM
   Webster-Cyriaque, JY
   Saah, A
   Aberg, JA
   Cu-Uvin, S
AF Kojic, Erna Milunka
   Kang, Minhee
   Cespedes, Michelle S.
   Umbleja, Triin
   Godfrey, Catherine
   Allen, Reena T.
   Firnhaber, Cynthia
   Grinsztejn, Beatriz
   Palefsky, Joel M.
   Webster-Cyriaque, Jennifer Y.
   Saah, Alfred
   Aberg, Judith A.
   Cu-Uvin, Susan
TI Immunogenicity and Safety of the Quadrivalent Human Papillomavirus
   Vaccine in HIV-1-Infected Women
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HPV vaccine; HIV-infected women; immunogenicity; vaccine safety;
   anogenital disease
ID ANAL INTRAEPITHELIAL NEOPLASIA; HIV-INFECTED PERSONS; CERVICAL-CANCER;
   HPV VACCINE; EFFICACY; RISK; MEN
AB Background. Women infected with human immunodeficiency virus (HIV) are disproportionately affected by human papillomavirus (HPV)-related anogenital disease, particularly with increased immunosuppression. AIDS Clinical Trials Group protocol A5240 was a trial of 319 HIV-infected women in the United States, Brazil, and South Africa to determine immunogenicity and safety of the quadrivalent HPV vaccine in 3 strata based on screening CD4 count: >350 (stratum A), 201-350 (stratum B), and <= 200 cells/L (stratum C).
   Methods. Safety and serostatus of HPV types 6, 11, 16, and 18 were examined. HPV serological testing was performed using competitive Luminex immunoassay (HPV-4 cLIA). HPV type-specific seroconversion analysis was done for participants who were seronegative for the given type at baseline.
   Results. Median age of patients was 36 years; 11% were white, 56% black, and 31% Hispanic. Median CD4 count was 310 cells/L, and 40% had undetectable HIV-1 load. No safety issues were identified. Seroconversion proportions among women at week 28 for HPV types 6, 11,16, and 18 were 96%, 98%, 99%, and 91%, respectively, for stratum A; 100%, 98%, 98%, and 85%, respectively, for stratum B, and 84%, 92%, 93%, and 75%, respectively, for stratum C.
   Conclusions. The quadrivalent HPV vaccine targeted at types 6, 11, 16, and 18 was safe and immunogenic in HIV-infected women aged 13-45 years. Women with HIV RNA load > 10 000 copies/mL and/or CD4 count <200 cells/L had lower rates of seroconversion rates.
C1 [Kojic, Erna Milunka; Cu-Uvin, Susan] Brown Univ, Dept Infect Dis, Providence, RI 02906 USA.
   [Kang, Minhee; Umbleja, Triin] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [Cespedes, Michelle S.; Aberg, Judith A.] Icahn Sch Med Mt Sinai, Div Infect Dis, New York, NY 10029 USA.
   [Godfrey, Catherine] NIAID, HIV Res Branch, Therapeut Res Program, Div Aids,NIH, Bethesda, MD 20892 USA.
   [Allen, Reena T.] AIDS Clin Trials Grp Network Coordinating Ctr, Silver Spring, MD USA.
   [Firnhaber, Cynthia] Univ Witwatersrand, Dept Internal Med, Fac Hlth Sci, Clin HIV Res Unit, Johannesburg, South Africa.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Infect Dis Dept, Rio De Janeiro, Brazil.
   [Palefsky, Joel M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Webster-Cyriaque, Jennifer Y.] Univ N Carolina, Oral HIV AIDS Res Alliance OHARA, Chapel Hill, NC USA.
   [Saah, Alfred] Merck Res Labs, N Wales, PA USA.
RP Kojic, EM (corresponding author), Brown Univ, 1125 N Main St, Providence, RI 02906 USA.
EM ekojic@lifespan.org
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI068636]; National Institute of Dental and Craniofacial
   ResearchUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Dental &
   Craniofacial Research (NIDCR); Statistical and Data Management Center of
   the ACTG [UM1AI68634]; Harvard Center for AIDS Research [P30 AI060354];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR001079, UL1TR000042, UL1TR001079, UL1TR000042, UL1TR000457,
   UL1TR001079, UL1TR000457, UL1TR000457, UL1TR000058, UL1TR000457,
   UL1TR000058, UL1TR000457, UL1TR000042, UL1TR001079, UL1TR001079,
   UL1TR001079, UL1TR000457, UL1TR001079, UL1TR000058, UL1TR000058,
   UL1TR000058, UL1TR000457, UL1TR001079, UL1TR000042, UL1TR000042] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Research Resources (NCRR)
   [UL1RR025747, UL1RR025747, UL1RR025747, UL1RR025747, UL1RR025747,
   UL1RR025747, UL1RR033176, UL1RR025747, UL1RR025747, UL1RR025747,
   UL1RR025747, UL1RR025747, UL1RR033176, UL1RR025747, UL1RR025747,
   UL1RR025747, UL1RR025747, UL1RR033176, UL1RR025747, UL1RR033176,
   UL1RR025747, UL1RR033176, UL1RR025747, UL1RR025747, UL1RR025747,
   UL1RR025747, UL1RR025747, UL1RR025747, UL1RR025747, UL1RR025747,
   UL1RR025747, UL1RR033176, UL1RR025747, UL1RR025747, UL1RR025747,
   UL1RR025747, UL1RR025747, UL1RR025747, UL1RR025747] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI069412, P30AI060354, UM1AI069465, P30AI060354,
   U01AI069502, P30AI045008, P30AI060354, UM1AI069496, P30AI073961,
   U01AI069467, P30AI073961, P30AI045008, P30AI073961, UM1AI069463,
   P30AI045008, U01AI069476, P30AI050410, P30AI073961, UM1AI069481,
   P30AI045008, UM1AI069423, U01AI069495, UM1AI069415, P30AI045008,
   P30AI045008, P30AI060354, P30AI060354, P30AI060354, P30AI050410,
   P30AI045008, P30AI045008, U01AI068636, UM1AI069481, UM1AI069495,
   P30AI073961, P30AI045008, P30AI045008, U01AI069471, P30AI050410,
   P30AI045008, UM1AI069423, P30AI050410, U01AI069471, P30AI060354,
   P30AI045008, P30AI060354, UM1AI068636, UM1AI069494, P30AI045008,
   P30AI050410, U01AI069439, U01AI069503, P30AI045008, P30AI050410,
   P30AI045008, P30AI045008, P30AI073961, UM1AI069423, U01AI069465,
   P30AI050410, U01AI069452, U01AI069494, P30AI073961, P30AI050410,
   P30AI045008, P30AI045008, P30AI060354, P30AI045008, U01AI069477,
   UM1AI068634, P30AI060354, P30AI045008, P30AI060354, P30AI073961,
   UM1AI069511, UM1AI069471, U01AI069428, UM1AI106701, P30AI045008,
   P30AI045008, U01AI069423, P30AI073961, UM1AI069423, P30AI050410,
   P30AI073961, U01AI069503, UM1AI069511, U01AI069470, P30AI045008,
   P30AI045008, P30AI050410, U01AI068636, UM1AI069471, U01AI069556,
   U01AI069477, UM1AI069415, P30AI045008, U01AI069495, P30AI050410,
   P30AI060354, P30AI045008, UM1AI069463, P30AI060354, P30AI045008,
   UM1AI069501, P30AI050410, P30AI045008, UM1AI068636, P30AI045008,
   P30AI060354, P30AI073961, UM1AI069474, U01AI069502, UM1AI069432,
   U01AI069503, P30AI050410, U01AI069424, P30AI050410, U01AI069494,
   P30AI045008, P30AI060354, P30AI045008, UM1AI069428, P30AI045008,
   P30AI073961, P30AI050410, P30AI045008, U01AI069423, P30AI073961,
   P30AI045008, P30AI045008, UM1AI069424, U01AI069412, P30AI060354,
   UM1AI068634, P30AI073961, U01AI069412, P30AI073961, U01AI069423,
   P30AI045008, UM1AI106701, P30AI073961, P30AI050410, UM1AI069503,
   P30AI045008, P30AI060354, P30AI045008, P30AI045008, UM1AI069496,
   UM1AI069471, UM1AI069424, P30AI060354, UM1AI069465, P30AI045008,
   UM1AI069432, U01AI069432, P30AI045008, P30AI050410, U01AI069423,
   UM1AI069415, P30AI073961, P30AI060354, P30AI045008, P30AI050410,
   P30AI045008, U01AI069471, P30AI050410, P30AI050410, U01AI069465,
   UM1AI069428, UM1AI069511, P30AI050410, UM1AI068636, P30AI045008,
   P30AI045008, P30AI045008, P30AI073961, P30AI045008, P30AI045008,
   P30AI045008, U01AI069467, P30AI045008, UM1AI069412, UM1AI069481,
   P30AI073961, P30AI045008, P30AI060354, P30AI060354, P30AI045008,
   U01AI069474, P30AI073961, P30AI073961, P30AI073961, U01AI069502,
   P30AI060354, UM1AI068636, P30AI045008, P30AI045008, UM1AI069415,
   P30AI060354, UM1AI069503, UM1AI069501, P30AI050410, P30AI060354,
   P30AI050410, U01AI069439, UM1AI069501, U01AI069556, P30AI073961,
   U01AI069424, P30AI073961, P30AI073961, P30AI045008, P30AI045008,
   P30AI050410, P30AI060354, P30AI050410, P30AI045008, U01AI068636,
   P30AI045008, P30AI050410, U01AI069494, P30AI073961, UM1AI069501,
   P30AI060354, U01AI069465, P30AI073961, U01AI069556, P30AI073961,
   U01AI069494, U01AI069495, U01AI069447, P30AI045008, P30AI045008,
   P30AI073961, P30AI050410, P30AI045008, P30AI073961, P30AI050410,
   P30AI073961, P30AI045008, U01AI069471, P30AI060354, P30AI073961,
   U01AI069556, P30AI045008, UM1AI069463, P30AI050410, P30AI045008,
   P30AI050410, P30AI045008, P30AI045008, P30AI050410, P30AI060354,
   UM1AI069556, P30AI045008, P30AI045008, P30AI060354, UM1AI069476,
   P30AI045008, P30AI050410, P30AI045008, UM1AI069415, U01AI069428,
   P30AI045008, P30AI045008, P30AI050410, P30AI050410, U01AI069477,
   P30AI045008, P30AI050410, UM1AI068636, P30AI045008, U01AI069428,
   P30AI050410, UM1AI069432, P30AI045008, P30AI060354, P30AI045008,
   P30AI045008, P30AI050410, UM1AI069556, P30AI050410, P30AI045008,
   P30AI045008, UM1AI069511, UM1AI069481, P30AI045008, P30AI073961,
   U01AI069470, P30AI050410, UM1AI068634, P30AI073961, P30AI045008,
   P30AI045008, UM1AI069481, P30AI060354, P30AI045008, UM1AI069423,
   U01AI069424, P30AI050410, P30AI045008, P30AI045008, UM1AI069476,
   P30AI050410, UM1AI069501, P30AI073961, UM1AI069494, U01AI069423,
   P30AI060354, P30AI045008, P30AI060354, UM1AI069494, P30AI050410,
   P30AI045008, P30AI045008, U01AI069474, U01AI069447, U01AI068636,
   P30AI050410, P30AI045008, UM1AI069496, P30AI045008, U01AI069439,
   P30AI060354, UM1AI069503, P30AI060354, UM1AI069476, P30AI045008,
   P30AI050410, UM1AI069511, U01AI069476, P30AI050410, P30AI045008,
   UM1AI069503, P30AI045008, UM1AI069463, U01AI069495, P30AI045008,
   U01AI069494, P30AI073961, P30AI045008, P30AI060354, P30AI045008,
   P30AI045008, P30AI050410, UM1AI069432, P30AI050410, P30AI050410,
   P30AI050410, P30AI045008, P30AI060354, P30AI050410, UM1AI069423,
   P30AI050410, P30AI050410, P30AI060354, U01AI069432, P30AI050410,
   P30AI050410, P30AI073961, U01AI069477, P30AI073961, UM1AI069412,
   P30AI050410, P30AI045008, U01AI068636, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, U01AI069424, P30AI045008, P30AI060354,
   U01AI069447, UM1AI069476, P30AI060354, P30AI073961, U01AI069470,
   P30AI050410, P30AI060354, P30AI045008, P30AI060354, UM1AI069501,
   P30AI060354, UM1AI069412, UM1AI069501, P30AI073961, P30AI050410,
   UM1AI069503, P30AI050410, P30AI050410, UM1AI069412, P30AI045008,
   P30AI045008, P30AI050410, UM1AI069415, P30AI050410, U01AI069503,
   P30AI073961, U01AI069452, P30AI045008, U01AI069432, P30AI045008,
   P30AI045008, P30AI060354, P30AI060354, U01AI069494, P30AI045008,
   P30AI045008, P30AI060354, P30AI060354, UM1AI069463, UM1AI069474,
   P30AI073961, P30AI073961, P30AI045008, P30AI050410, U01AI069465,
   P30AI050410, P30AI045008, P30AI073961, P30AI045008, P30AI045008,
   P30AI050410, P30AI050410, UM1AI069465, P30AI050410, UM1AI069463,
   P30AI060354, P30AI060354, P30AI050410, P30AI050410, P30AI045008,
   UM1AI069511, P30AI050410, P30AI045008, P30AI045008, P30AI060354,
   U01AI069476, P30AI073961, P30AI045008, P30AI050410, P30AI060354,
   UM1AI068636, P30AI045008, P30AI060354, P30AI045008, P30AI060354,
   P30AI050410, UM1AI069415, P30AI045008, UM1AI069511, P30AI073961,
   P30AI050410, P30AI060354, P30AI073961, UM1AI069501, P30AI060354,
   U01AI069452, P30AI050410, P30AI045008, P30AI073961, P30AI050410,
   P30AI060354, U01AI069474, P30AI045008, P30AI045008, U01AI069467,
   U01AI069470, P30AI060354, UM1AI069424, UM1AI069496, P30AI073961,
   UM1AI069467, P30AI045008, P30AI060354, P30AI045008, U01AI069477,
   UM1AI069476, P30AI045008, UM1AI068636, UM1AI069432, UM1AI069465,
   P30AI050410, P30AI050410, UM1AI106701, P30AI073961, P30AI045008,
   UM1AI106701, U01AI069424, P30AI060354, P30AI050410, P30AI045008,
   P30AI060354, U01AI069470, P30AI045008, P30AI045008, UM1AI069471,
   UM1AI069496, P30AI045008, UM1AI069496, UM1AI069556, P30AI060354,
   UM1AI069412, UM1AI069503, P30AI060354, P30AI050410, P30AI045008,
   P30AI045008, UM1AI069432, UM1AI069511, P30AI060354, U01AI068636,
   P30AI045008, P30AI050410, P30AI045008, P30AI073961, U01AI069470,
   U01AI069452, P30AI050410, P30AI060354, P30AI045008, P30AI073961,
   P30AI050410, UM1AI069481, P30AI045008, P30AI060354, P30AI045008,
   P30AI060354, P30AI050410, P30AI045008, U01AI069447, P30AI060354,
   P30AI060354, P30AI060354, UM1AI069495, UM1AI068634, P30AI045008,
   UM1AI069465, P30AI050410, P30AI050410, U01AI069494, P30AI060354,
   P30AI050410, P30AI050410, P30AI050410, P30AI045008, P30AI045008,
   U01AI069467, UM1AI069463, P30AI060354, P30AI045008, P30AI050410,
   P30AI050410, P30AI045008, U01AI069432, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, U01AI069452, U01AI069501,
   U01AI069502, P30AI050410, P30AI050410, UM1AI069467, U01AI069556,
   UM1AI069494, P30AI045008, U01AI069503, UM1AI069503, P30AI050410,
   P30AI045008, UM1AI069424, P30AI045008, P30AI045008, P30AI045008,
   P30AI073961, P30AI045008, U01AI069424, P30AI045008, P30AI045008,
   P30AI050410, UM1AI069424, U01AI069428, P30AI045008, U01AI069412,
   U01AI069465, P30AI060354, UM1AI068634, P30AI045008, UM1AI068634,
   P30AI045008, UM1AI069424, U01AI069503, U01AI069412, P30AI050410,
   P30AI060354, UM1AI106701, P30AI050410, UM1AI069465, U01AI069477,
   P30AI050410, P30AI050410, P30AI045008, P30AI073961, P30AI060354,
   UM1AI069476, UM1AI069496, P30AI045008, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI045008, UM1AI068636, P30AI060354,
   P30AI073961, P30AI050410, U01AI069471, P30AI050410, UM1AI069465,
   P30AI073961, U01AI069476, P30AI060354, P30AI045008, P30AI045008,
   P30AI060354, P30AI073961, UM1AI069432, P30AI045008, P30AI045008,
   UM1AI069423, UM1AI068634, UM1AI069463, U01AI069501, U01AI069494,
   P30AI050410, UM1AI069471, U01AI069503, P30AI045008, P30AI050410,
   P30AI050410, P30AI050410, P30AI073961, P30AI050410, P30AI073961,
   P30AI050410, P30AI050410, P30AI060354, P30AI073961, P30AI045008,
   P30AI045008, P30AI045008, UM1AI068634, P30AI045008, P30AI045008,
   P30AI045008, P30AI050410, P30AI060354, P30AI060354, P30AI050410,
   P30AI045008, U01AI069495, P30AI050410, U01AI069501, P30AI045008,
   P30AI045008, P30AI073961, P30AI045008, U01AI069467, P30AI050410,
   UM1AI069496, P30AI045008, P30AI050410, U01AI069501, P30AI073961,
   P30AI045008, U01AI068636, P30AI060354, P30AI050410, P30AI050410,
   P30AI073961, P30AI073961, UM1AI069494, P30AI050410, UM1AI069412,
   P30AI050410, UM1AI068636, P30AI060354, U01AI069423, UM1AI069511,
   U01AI069502, P30AI060354, UM1AI068634, P30AI060354, UM1AI069481,
   P30AI045008, P30AI050410, P30AI073961, P30AI050410, U01AI069503,
   P30AI073961, P30AI073961, P30AI050410, UM1AI069424, P30AI073961,
   P30AI073961, P30AI045008, P30AI045008, P30AI045008, UM1AI069465,
   P30AI045008, UM1AI069476, P30AI073961, P30AI045008, U01AI069439,
   P30AI045008, P30AI045008, P30AI045008, UM1AI069503, P30AI073961,
   P30AI060354, UM1AI069494, P30AI045008, U01AI069494, P30AI050410,
   P30AI073961, P30AI045008, UM1AI069423, UM1AI069481, P30AI045008,
   P30AI073961, UM1AI069412, P30AI073961, UM1AI069471, U01AI069471,
   P30AI073961, U01AI069447, UM1AI069432, P30AI060354, P30AI045008,
   P30AI050410, P30AI050410, P30AI045008, U01AI069428, P30AI045008,
   UM1AI069471, P30AI060354, P30AI073961, P30AI050410, P30AI073961,
   P30AI045008, P30AI050410, P30AI045008, UM1AI106701, UM1AI069415,
   P30AI045008, P30AI045008, U01AI069465, P30AI045008, P30AI045008,
   U01AI069439, P30AI060354, U01AI069412, P30AI060354, U01AI069424,
   P30AI073961, P30AI060354, UM1AI069471, P30AI045008, UM1AI069424,
   P30AI045008, P30AI060354, P30AI060354, U01AI069432, UM1AI069494,
   U01AI069423, P30AI045008, P30AI073961, P30AI050410, UM1AI069494,
   U01AI069452, P30AI050410, P30AI073961, P30AI060354, P30AI045008,
   U01AI069474, UM1AI069467, UM1AI069476, U01AI069474, U01AI069465,
   U01AI069501, P30AI045008, U01AI069423, P30AI060354, P30AI045008,
   U01AI069452, P30AI045008, P30AI045008, P30AI045008] Funding Source: NIH
   RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (award number UM1AI068636); the National Institute
   of Dental and Craniofacial Research; and the Statistical and Data
   Management Center of the ACTG (grant number UM1AI68634). Massachusetts
   General Hospital receives support from the Harvard Center for AIDS
   Research (number P30 AI060354).
CR Abraham AG, 2013, JAIDS-J ACQ IMM DEF, V62, P405, DOI 10.1097/QAI.0b013e31828177d7
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Brown DR, 2011, HUM VACCINES, V7, P230, DOI 10.4161/hv.7.2.13948
   Cervical Cancer Global Crisis Card, 2013, CERV CANC GLOB CRIS
   Clark LR, 2013, J ADOLESCENT HEALTH, V52, P322, DOI 10.1016/j.jadohealth.2012.07.003
   D'Souza G, 2008, JAIDS-J ACQ IMM DEF, V48, P491, DOI 10.1097/QAI.0b013e31817aebfe
   FUTURE II Study Group, 2007, N ENGL J MED, V359, P1915
   Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760
   Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537
   Hessol NA, 2009, AIDS, V23, P59, DOI 10.1097/QAD.0b013e32831cc101
   Joura EA, 2008, VACCINE, V26, P6844, DOI 10.1016/j.vaccine.2008.09.073
   Kahn JA, 2013, CLIN INFECT DIS, V57, P735, DOI 10.1093/cid/cit319
   Kojic EM, 2011, SEX TRANSM DIS, V38, P253, DOI 10.1097/OLQ.0b013e3181f70253
   Longet S, 2011, J VIROL, V85, P13253, DOI 10.1128/JVI.06093-11
   MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K
   Munoz N, 2009, LANCET, V373, P1949, DOI 10.1016/S0140-6736(09)60691-7
   Overton ET, 2005, CLIN INFECT DIS, V41, P1045, DOI 10.1086/433180
   Palefsky JM, 1998, J INFECT DIS, V177, P361, DOI 10.1086/514194
   Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971
   Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005
   Roberts CC, 2012, HUM VACC IMMUNOTHER, V8, P431, DOI 10.4161/hv.19179
   Shire NJ, 2006, VACCINE, V24, P272, DOI 10.1016/j.vaccine.2005.07.102
   TAYAL SC, 1994, AIDS, V8, P558, DOI 10.1097/00002030-199404000-00024
   Weinberg A, 2006, J INFECT DIS, V193, P302, DOI 10.1086/498979
   Wilkin T, 2010, J INFECT DIS, V202, P1246, DOI 10.1086/656320
NR 25
TC 77
Z9 81
U1 1
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL 1
PY 2014
VL 59
IS 1
BP 127
EP 135
DI 10.1093/cid/ciu238
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AM2FL
UT WOS:000339665000023
PM 24723284
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Santini-Oliveira, M
   Friedman, RK
   Veloso, VG
   Cunha, CB
   Pilotto, JH
   Marins, LMS
   Joao, EC
   Torres, TS
   Grinsztejn, B
AF Santini-Oliveira, Marilia
   Friedman, Ruth Khalili
   Veloso, Valdilea Goncalves
   Cunha, Cynthia Braga
   Pilotto, Jose Henrique
   Spindola Marins, Luana Monteiro
   Joao, Esau Custodio
   Torres, Thiago Silva
   Grinsztejn, Beatriz
TI Incidence of antiretroviral adverse drug reactions in pregnant women in
   two referral centers for HIV prevention of mother-to-child-transmission
   care and research in Rio de Janeiro, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Antiretroviral; Prevention of mother-to-child transmission; Adverse
   drug reaction; Toxicity
ID INFECTED PATIENTS; NEVIRAPINE; THERAPY; REGIMENS; SAFETY; TOXICITY;
   REASONS; ANEMIA; COHORT; HAART
AB Mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) infection remains an important cause of new HIV infections worldwide, especially in low and middle-resource limited countries. Safety data from studies involving pregnant women and prenatal antiretroviral (ARV) exposure are still needed once these studies are often small and with a limited duration to assess adverse drug reactions (ADR). The aim of this study was to estimate the incidence of ADR related to the use of antiretroviral therapy (ART) in pregnant women in two referral centers in Rio de Janeiro State. A prospective study was carried out from February 2005 to May 2006. Women were classified according to their ART status during pregnancy diagnosis: ARV-experienced (ARTexp) or ARV-naive (ARTn). Two hundred fourteen HIV-infected pregnant women were included: 36 ARTexp and 178 ARTn. ARTexp women have not experienced ADR. Among ARTn, 20.2% presented ADR. Incidence rate of ADR was 70.8 per 1000 person-months and the most common ADRs observed were: gastrointestinal (belly or abdominal cramps, diarrhea, nausea and vomit) in 16.3%, cutaneous (pruritus and rash) in 6.2%, anemia (2.2%) and hepatitis (1.7%). The frequency of obstetrical complications, preterm delivery, low birth weight and birth abnormalities was low in this population. ADRs ranged from mild to moderate intensity, none of them being potentially fatal. Only in a few cases it was necessary to discontinue ART. In conclusion, the high effectiveness of ARV for HIV prevention of MTCT (PMTCT) overcomes the risk of ADR. (C) 2014 Elsevier Editora Ltda. All rights reserved.
C1 [Santini-Oliveira, Marilia; Friedman, Ruth Khalili; Veloso, Valdilea Goncalves; Cunha, Cynthia Braga; Spindola Marins, Luana Monteiro; Torres, Thiago Silva; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Lab Pesquisa Clin DST AIDS, Rio De Janeiro, RJ, Brazil.
   [Pilotto, Jose Henrique] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Dept DST AIDS, Rio De Janeiro, RJ, Brazil.
   [Joao, Esau Custodio] Hosp Fed Servidores Estado, Serv Doencas Infecciosas & Parasitarias, Rio De Janeiro, RJ, Brazil.
RP Santini-Oliveira, M (corresponding author), Av Brasil,4365,Manguinhos, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM marilia.santini@ipec.fiocruz.br
RI Pilotto, Jose Henrique/AAD-9773-2019; TORRES, THIAGO SILVA/D-6548-2014
OI Pilotto, Jose Henrique/0000-0003-0521-8597; TORRES, THIAGO
   SILVA/0000-0002-2557-601X; Joao, Esau/0000-0002-2412-0627
CR [Anonymous], 2012, VIR NEV PACK INS
   Becquet R, 2011, LANCET INFECT DIS, V11, P154, DOI 10.1016/S1473-3099(10)70299-1
   Becquet R, 2009, CLIN INFECT DIS, V49, P1936, DOI 10.1086/648446
   Bera E, 2012, SAMJ S AFR MED J, V102, P855, DOI [10.7196/SAMJ.5700, 10.7196/samj.5700]
   Bersoff-Matcha SJ, 2001, CLIN INFECT DIS, V32, P124, DOI 10.1086/317536
   Cardoso SW, 2010, AIDS RES HUM RETROV, V26, P865, DOI 10.1089/aid.2009.0274
   Cecchini D, 2011, MEDICINA-BUENOS AIRE, V71, P432
   Cressey TR, 2012, JAIDS-J ACQ IMM DEF, V59, P245, DOI 10.1097/QAI.0b013e31823ff052
   Curkendall SM, 2007, HIV MED, V8, P483, DOI 10.1111/j.1468-1293.2007.00500.x
   DAIDS (Division of AIDS USA), 2013, TABL GRAD SEV AD PED
   Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9
   Edwards S G, 2001, HIV Med, V2, P89, DOI 10.1046/j.1468-1293.2001.00059.x
   Floridia M, 2013, BJOG
   Ford N, 2013, AIDS
   Johnson M, 1998, 38 ICAAC
   Johnson N, 2008, W INDIAN MED J, V57, P216
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2013, UNAIDS REP GLOB AIDS
   Kourtis AP, 2010, CLIN PERINATOL, V37, P721, DOI 10.1016/j.clp.2010.08.004
   Kumarasamy N, 2006, JAIDS-J ACQ IMM DEF, V41, P53, DOI 10.1097/01.qai.0000188123.15493.43
   Lorenzi P, 1998, AIDS, V12, pF241, DOI 10.1097/00002030-199818000-00002
   Lyons F, 2006, HIV MED, V7, P255, DOI 10.1111/j.1468-1293.2006.00369.x
   Marazzi MC, 2006, HIV MED, V7, P338, DOI 10.1111/j.1468-1293.2006.00386.x
   Mildvan D, 2007, CURR MED RES OPIN, V23, P343, DOI 10.1185/030079906X162683
   Mocroft A, 2001, AIDS, V15, P185, DOI 10.1097/00002030-200101260-00007
   Newell ML, 2013, CURR OPIN HIV AIDS
   Patel D, 2005, JAIDS-J ACQ IMM DEF, V40, P116, DOI 10.1097/01.qai.0000156854.99769.a5
   Saag MS, 2001, AIDS, V15, P1971, DOI 10.1097/00002030-200110190-00009
   Thorne C, 2007, SEMIN FETAL NEONAT M, V12, P174, DOI 10.1016/j.siny.2007.01.009
   Tuomala RK, 2005, JAIDS-J ACQ IMM DEF, V38, P449, DOI 10.1097/01.qai.0000139398.38236.4d
   van Schalkwyk JE, 2008, BJOG-INT J OBSTET GY, V115, P1297, DOI 10.1111/j.1471-0528.2008.01820.x
   VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437
   Watts DH, 2006, DRUG SAFETY, V29, P467, DOI 10.2165/00002018-200629060-00002
   Watts DH, 2004, AM J OBSTET GYNECOL, V190, P506, DOI 10.1016/j.ajog.2003.07.018
   Weinberg Adriana, 2011, Infect Dis Obstet Gynecol, V2011, P867674, DOI 10.1155/2011/867674
   Wills Todd S, 2004, AIDS Read, V14, P305
   WILLS TS, 2004, AIDS READ, V14, P313
NR 36
TC 7
Z9 7
U1 0
U2 6
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUL-AUG
PY 2014
VL 18
IS 4
BP 372
EP 378
DI 10.1016/j.bjid.2013.11.008
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA AO2QV
UT WOS:000341171200004
PM 24662139
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Martin, DA
   Luz, PM
   Lake, JE
   Clark, JL
   Veloso, VG
   Moreira, RI
   Cardoso, SW
   Klausner, JD
   Grinsztejn, B
AF Martin, David A.
   Luz, Paula M.
   Lake, Jordan E.
   Clark, Jesse L.
   Veloso, Valdilea G.
   Moreira, Ronaldo I.
   Cardoso, Sandra W.
   Klausner, Jeffrey D.
   Grinsztejn, Beatriz
TI Improved virologic outcomes over time for HIV-infected patients on
   antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Antiretroviral therapy; Cohort studies; Brazil; Viral load; Adherence
ID HIV-1-INFECTED PATIENTS; VIRAL SUPPRESSION; ADHERENCE; MORTALITY;
   SURVIVAL; REGIMENS; BRAZIL; ASSOCIATION; FAILURE; TRENDS
AB Background: Previous cohort studies have demonstrated the beneficial effects of antiretroviral therapy (ART) on viral load suppression. We aimed to examine the factors associated with virologic suppression for HIV-infected patients on ART receiving care at the Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation in Rio de Janeiro, Brazil.
   Methods: HIV-1 RNA levels and CD4+ T-cell counts at the date closest to midyear (1 July) were evaluated for 1,678 ART-naive patients >= 18 years of age initiating ART between 1997 and 2010. The odds ratios (OR) and 95% confidence intervals (CI) for having an undetectable viral load (<= 400 copies/mL) were estimated using generalized estimating equations regression models adjusted for clinical and demographic factors. Time-updated covariates included age, years since HIV diagnosis, hepatitis C diagnosis and ART interruptions.
   Results: Between 1997 and 2011, the proportion of patients with an undetectable viral load increased from 6% to 78% and the median [interquartile range] CD4+ T-cell count increased from 207 [162, 343] to 554 [382, 743] cells/mu L. Pre-treatment median CD4+ T-cell count significantly increased over the observation period from 114 [37, 161] to 237 [76, 333] cells/mu L (p < .001). The per-year adjusted OR (aOR) for having undetectable viral load was 1.18 (95% CI = 1.16-1.21). ART interruptions >1 month per calendar significantly decreased the odds [aOR = 0.32 (95% CI = 0.27-0.38)] of having an undetectable viral load. Patients initiating on a protease inhibitor (PI)-based first-line regimen were less likely to have undetectable viral load [aOR = 0.72 (95% CI = 0.63-0.83)] compared to those initiating on a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen.
   Conclusions: Our results demonstrate significant improvements in virologic outcomes from 1997 to 2011, which persisted after adjusting for other factors. This may in part be due to improvements in care and new treatment options. NNRTI-versus PI-based first-line regimens were found to be associated with increased odds of having an undetectable viral load, consistent with previous studies. Treatment interruptions were found to be the most important determinant of not having an undetectable viral load. Studies are needed to characterize the reasons for treatment interruptions and to develop subsequent strategies for improving adherence to ART.
C1 [Martin, David A.; Lake, Jordan E.; Clark, Jesse L.; Klausner, Jeffrey D.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
   [Luz, Paula M.; Veloso, Valdilea G.; Moreira, Ronaldo I.; Cardoso, Sandra W.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, HIV AIDS Clin Res Ctr, Rio De Janeiro, Brazil.
RP Martin, DA (corresponding author), Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
EM dmartin@post.harvard.edu
RI Cardoso, Sandra W/D-7965-2015
OI Cardoso, Sandra W/0000-0001-5230-0003; Luz, Paula/0000-0001-9746-719X;
   Clark, Jesse/0000-0001-5862-6530
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R25 MH087222]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000124,
   UL1TR000124, UL1TR000124, UL1TR000124, UL1TR000124] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, R25MH087222,
   P30MH058107, P30MH058107, P30MH058107, K23MH084611, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, K23MH084611,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, K23MH084611, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, R25MH087222, R25MH087222,
   P30MH058107, P30MH058107, K23MH084611, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, K23MH084611, P30MH058107, R25MH087222, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, R25MH087222, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, R25MH087222, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107, P30MH058107,
   P30MH058107, P30MH058107, P30MH058107, P30MH058107] Funding Source: NIH
   RePORTER
FX We would like to acknowledge and thank all of the patients enrolled in
   the IPEC clinical cohort for their time and contributions to our past,
   current and future research projects. This work would also not be
   possible without the hard work and dedication of the staff at IPEC.
   Support provided by the NIH R25 MH087222 (South American Program in HIV
   Prevention Research).
CR Althoff KN, 2012, ANN INTERN MED, V157, P325, DOI 10.7326/0003-4819-157-5-201209040-00005
   Amoroso A, 2012, JAIDS-J ACQ IMM DEF, V60, P314, DOI 10.1097/QAI.0b013e31824e5256
   Beer Linda, 2012, Open AIDS J, V6, P213, DOI 10.2174/1874613601206010213
   Cardoso SW, 2010, AIDS RES HUM RETROV, V26, P865, DOI 10.1089/aid.2009.0274
   Chaisson RE, 2000, JAMA-J AM MED ASSOC, V284, P3128, DOI 10.1001/jama.284.24.3128
   Felix G, 2012, REV ESC ENFERM USP, V46, P882
   Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252
   Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106
   Lampe FC, 2006, ARCH INTERN MED, V166, P521, DOI 10.1001/archinte.166.5.521
   Ledergerber B, 2011, HIV MED, V12, P279, DOI 10.1111/j.1468-1293.2010.00880.x
   Lima VD, 2009, JAIDS-J ACQ IMM DEF, V50, P529, DOI 10.1097/QAI.0b013e31819675e9
   Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1
   Moore RD, 2005, JAIDS-J ACQ IMM DEF, V39, P195
   Moore RD, 2011, CLIN INFECT DIS, V53, P600, DOI 10.1093/cid/cir467
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249
   Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Phillips AN, 2001, AIDS, V15, P2379, DOI 10.1097/00002030-200112070-00005
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301
   Sherr L, 2010, AIDS CARE, V22, P939, DOI 10.1080/09540121.2010.482126
   Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7
   Tuboi SH, 2005, JAIDS-J ACQ IMM DEF, V40, P324, DOI 10.1097/01.qai.0000182627.28595.01
   Yehia BR, 2012, JAMA-J AM MED ASSOC, V308, P339, DOI 10.1001/jama.2012.5927
NR 26
TC 13
Z9 14
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUN 11
PY 2014
VL 14
AR 322
DI 10.1186/1471-2334-14-322
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA AK7DT
UT WOS:000338587200001
PM 24919778
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Coelho, L
   Cardoso, SW
   Amancio, RT
   Moreira, RI
   Campos, DP
   Veloso, VG
   Grinsztejn, B
   Luz, PM
AF Coelho, Lara
   Cardoso, Sandra Wagner
   Amancio, Rodrigo Teixeira
   Moreira, Ronaldo Ismerio
   Campos, Dayse Pereira
   Veloso, Valdilea Goncalves
   Grinsztejn, Beatriz
   Luz, Paula Mendes
TI Trends in AIDS-Defining Opportunistic Illnesses Incidence over 25 Years
   in Rio de Janeiro, Brazil
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; ISONIAZID
   PREVENTIVE THERAPY; HIV-INFECTED ADULTS; UNITED-STATES; EARLY MORTALITY;
   CLINICAL CARE; SOUTH-AFRICA; COHORT; TUBERCULOSIS
AB Objectives: To assess the temporal trends in incidence of AIDS-defining opportunistic illnesses in an urban cohort of a middle-income country.
   Methods: HIV infected patients aged >= 18 years at cohort entry were included in this analysis. We calculated incidence rates per 1000 persons-years of observation for the first opportunistic illness presented after cohort enrollment, from 1987 to 2012. Trends for overall and specific opportunistic illnesses were tested and incidence rate ratios for the most recent calendar period were calculated as the ratio between the incidence rate observed in the most recent period of the study (2009-2012) and the incidence rate observed in first period of the study (1987-1990).
   Results: Overall, 3378 patients were included in this analysis; of which 1119 (33%) patients presented an opportunistic illness during follow up. Incidence rates of all opportunistic illnesses decreased over time, and the overall opportunistic illness incidence rates fell from 295.4/1000 persons-years in 1987-1990 to 34.6/1000 persons-years in 2009-2012. Tuberculosis, esophageal candidiasis, cerebral toxoplasmosis and Pneumocystis jirovecii pneumonia were the most incident opportunistic illnesses in the cohort. Tuberculosis had the highest incidence rate in the study period. The peak in tuberculosis incidence occurred in 1991-1993 (80.8/1000 persons-years). Cerebral toxoplasmosis was the third most incident opportunistic illness in the study, with a peak of incidence of 43.6/1000 persons-year in 1987-1990.
   Conclusions: All opportunistic illnesses incidence rates decreased over the years but they still occur in an unacceptable frequency. Tuberculosis co-infection among HIV-infected persists as an important challenge for health care professionals and policy makers in our setting. Impressively high rates of cerebral toxoplasmosis were found suggesting that its incidence among HIV-infected is linked to the high prevalence of Toxoplasma gondii infection in the general population.
C1 [Coelho, Lara; Cardoso, Sandra Wagner; Amancio, Rodrigo Teixeira; Moreira, Ronaldo Ismerio; Campos, Dayse Pereira; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz; Luz, Paula Mendes] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
RP Coelho, L (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM lara.coelho@ipec.fiocruz.br
RI Cardoso, Sandra W/D-7965-2015
OI Cardoso, Sandra W/0000-0001-5230-0003; Luz, Paula/0000-0001-9746-719X
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)
FX BG and PML acknowledge funding from the National Council of
   Technological and Scientific Development (CNPq) and the Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akolo C, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000171.pub3
   Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3
   Badri M, 2005, S AFRIC J HIV MED, V6, P11
   Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010
   Buchacz K, 2008, AIDS, V22, P1345, DOI 10.1097/QAD.0b013e328304b38b
   Buchacz K, 2010, AIDS, V24, P1549, DOI 10.1097/QAD.0b013e32833a3967
   CDC, 1992, MMWR RECOMM REP, V41
   *CDC, 1991, MMWR-MORBID MORTAL W, V40, P27
   CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285
   Charurat M, 2004, J WOMENS HEALTH, V13, P719, DOI 10.1089/jwh.2004.13.719
   Coelho L, 2013, BRAZILIAN J INFECT D
   Conde MB, 2009, J BRAS PNEUMOL, V35, P1018, DOI 10.1590/S1806-37132009001000011
   Dubey JP, 2012, PARASITOLOGY, V139, P1375, DOI 10.1017/S0031182012000765
   Durovni B, 2013, LANCET INFECT DIS, V13, P852, DOI 10.1016/S1473-3099(13)70187-7
   Golub JE, 2009, AIDS, V23, P631, DOI 10.1097/QAD.0b013e328327964f
   Grinsztejn B, 2014, LANCET INFE IN PRESS
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   ISRAELSKI DM, 1993, J ACQ IMMUN DEF SYND, V6, P414
   Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843
   Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd
   Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220
   MATHEWS WC, 1994, ARCH PATHOL LAB MED, V118, P807
   Mocroft A, 1999, J ACQ IMMUN DEF SYND, V21, P401
   Mocroft A, 1998, ARCH INTERN MED, V158, P491, DOI 10.1001/archinte.158.5.491
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6
   Podlasin RB, 2006, INFECTION, V34, P196, DOI 10.1007/s15010-006-5030-y
   Ribeiro S, 2013, ANTIVIRAL THERAPY
   Rojanawiwat A, 2011, INT HEALTH, V3, P101, DOI 10.1016/j.inhe.2010.12.004
   Sackoff JE, 2006, ANN INTERN MED, V145, P397, DOI 10.7326/0003-4819-145-6-200609190-00003
   Sacktor N, 2001, NEUROLOGY, V56, P257, DOI 10.1212/WNL.56.2.257
   San-Andres FJ, 2003, CLIN INFECT DIS, V36, P1177, DOI 10.1086/374358
   Santoro-Lopes G, 2002, CLIN INFECT DIS, V34, P543, DOI 10.1086/338641
   Schwarcz L, 2013, AIDS, V27, P597, DOI 10.1097/QAD.0b013e32835b0fa2
   Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370
   Suthar AB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001270
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   World Health Organization, 2007, WHO CAS DEF HIV SURV
   World Health Organization, 2011, GUID INT TUB CAS FIN
   Xavier GA, 2013, REV INST MED TROP SP, V55, P25, DOI 10.1590/S0036-46652013000100005
   Yazdanpanah Y, 2001, INT J EPIDEMIOL, V30, P864, DOI 10.1093/ije/30.4.864
NR 45
TC 20
Z9 22
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 5
PY 2014
VL 9
IS 6
AR e98666
DI 10.1371/journal.pone.0098666
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4NF
UT WOS:000336841400043
PM 24901419
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Bhatt, NB
   Barau, C
   Amin, A
   Baudin, E
   Meggi, B
   Silva, C
   Furlan, V
   Grinsztejn, B
   Barrail-Tran, A
   Bonnet, M
   Taburet, AM
AF Bhatt, N. B.
   Barau, C.
   Amin, A.
   Baudin, E.
   Meggi, B.
   Silva, C.
   Furlan, V.
   Grinsztejn, B.
   Barrail-Tran, A.
   Bonnet, M.
   Taburet, A. M.
CA ANRS 12146-CARINEMO Study Grp
TI Pharmacokinetics of Rifampin and Isoniazid in
   Tuberculosis-HIV-Coinfected Patients Receiving Nevirapine- or
   Efavirenz-Based Antiretroviral Treatment
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ANTITUBERCULOSIS DRUGS; PULMONARY TUBERCULOSIS; POPULATION
   PHARMACOKINETICS; MYCOBACTERIUM-TUBERCULOSIS; ANTIMYCOBACTERIAL DRUGS;
   BACTERICIDAL ACTIVITY; PLASMA-CONCENTRATIONS; SERUM CONCENTRATIONS;
   FASTING CONDITIONS; INFECTED PATIENTS
AB This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique. Thirty-eight patients on antituberculosis therapy based on rifampin and isoniazid participated in the substudy (57.9% males; median age, 33 years; median weight, 51.9 kg; median CD4(+) T cell count, 104 cells/mu l; median HIV-1 RNA load, 5.5 log copies/ml). The daily doses of rifampin and isoniazid were 10 and 5 mg/kg of body weight, respectively. Twenty-one patients received 200 mg of nevirapine twice a day (b.i.d.), and 17 patients received 600 mg of efavirenz once a day (q.d.) in combination with lamivudine and stavudine from day 1 until the end of the study. Blood samples were collected at regular time-dosing intervals after morning administration of a fixed-dose combination of rifampin and isoniazid. When rifampin was administered alone, the median maximum concentration of drug in serum (C-max) and the area under the concentration-time curve (AUC) at steady state were 6.59 mg/liter (range, 2.70 to 14.07 mg/liter) and 27.69 mg.h/liter (range, 11.41 to 109.75 mg.h/liter), respectively. Concentrations remained unchanged when rifampin was coadministered with nevirapine or efavirenz. When isoniazid was administered alone, the median isoniazid Cmax and AUC at steady state were 5.08 mg/liter (range, 1.26 to 11.51 mg/liter) and 20.92 mg.h/liter (range, 7.73 to 56.95 mg.h/liter), respectively. Concentrations remained unchanged when isoniazid was coadministered with nevirapine; however, a 29% decrease in the isoniazid AUC was observed when isoniazid was combined with efavirenz. The pharmacokinetic parameters of rifampin and isoniazid when coadministered with nevirapine or efavirenz were not altered to a clinically significant extent in these severely immunosuppressed HIV-infected patients. Patients experienced favorable clinical outcomes.
C1 [Bhatt, N. B.; Meggi, B.] Minist Saude, Inst Nacl Saude, Maputo, Mozambique.
   [Bhatt, N. B.; Grinsztejn, B.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Barau, C.; Amin, A.; Furlan, V.; Barrail-Tran, A.; Taburet, A. M.] Hop Univ Paris Sud, Bicetre Hosp, AP HP, Paris, France.
   [Baudin, E.; Silva, C.; Bonnet, M.] Epicentre, Paris, France.
   [Barrail-Tran, A.] Univ Paris 11, Fac Pharm, EA4123, Paris, France.
RP Taburet, AM (corresponding author), Hop Univ Paris Sud, Bicetre Hosp, AP HP, Paris, France.
EM anne-marie.taburet@bct.aphp.fr
RI Barrail-Tran, Aurelie/ABC-5935-2020
OI Barrail-Tran, Aurelie/0000-0002-6053-6275; Barau,
   Caroline/0000-0003-4289-3276; Baudin, Elisabeth/0000-0002-6575-6971
FU Agence Nationale de Recherches sur le Sida et les Hepatites
   ViralesANRSFrench National Research Agency (ANR) [ANRS 12214]
FX This work was supported by the Agence Nationale de Recherches sur le
   Sida et les Hepatites Virales (project no. ANRS 12214).
CR Aparicio I, 2006, BIOMED CHROMATOGR, V20, P748, DOI 10.1002/bmc.591
   Back D, 2003, JAIDS-J ACQ IMM DEF, V34, pS8, DOI 10.1097/00126334-200309011-00003
   Barroso EC, 2009, AM J TROP MED HYG, V81, P322, DOI 10.4269/ajtmh.2009.81.322
   Barry C, 2012, COMMUN DIS INTELL, V36, P82
   BERNING SE, 1992, NEW ENGL J MED, V327, P1817, DOI 10.1056/NEJM199212173272514
   BHATT NB, 2012, 43 C INT UN AG TUB L, pS82
   Bonnet M, 2013, LANCET INFECT DIS, V13, P303, DOI 10.1016/S1473-3099(13)70007-0
   Chideya S, 2009, CLIN INFECT DIS, V48, P1685, DOI 10.1086/599040
   DICKINSON JM, 1977, AM REV RESPIR DIS, V116, P627, DOI 10.1164/arrd.1977.116.4.627
   Gumbo T, 2007, ANTIMICROB AGENTS CH, V51, P3781, DOI 10.1128/AAC.01533-06
   Gumbo T, 2007, ANTIMICROB AGENTS CH, V51, P2329, DOI 10.1128/AAC.00185-07
   Gurumurthy P, 2004, ANTIMICROB AGENTS CH, V48, P4473, DOI 10.1128/AAC.48.11.4473-4475.2004
   Gurumurthy P, 2004, CLIN INFECT DIS, V38, P280, DOI 10.1086/380795
   Hoa NB, 2013, INT J TUBERC LUNG D, V17, P61, DOI 10.5588/ijtld.12.0369
   Holland DP, 2009, PHARMACOTHERAPY, V29, P503, DOI 10.1592/phco.29.5.503
   Huang YS, 2003, HEPATOLOGY, V37, P924, DOI 10.1053/jhep.2003.50144
   Iseman MD, 2002, EUR RESPIR J, V20, p87S, DOI 10.1183/09031936.02.00309102
   Ismail I, 2013, PREV MED, V57, pS27, DOI 10.1016/j.ypmed.2012.12.023
   JAIN A, 1993, TUBERCLE LUNG DIS, V74, P87, DOI 10.1016/0962-8479(93)90032-S
   Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848
   Koegelenberg CFN, 2013, SAMJ S AFR MED J, V103, P394, DOI [10.7196/samj.6344, 10.7196/SAMJ.6344]
   Lienhardt C, 2011, JAMA-J AM MED ASSOC, V305, P1415, DOI 10.1001/jama.2011.436
   LOOS U, 1985, KLIN WOCHENSCHR, V63, P1205, DOI 10.1007/BF01733779
   McIlleron H, 2006, ANTIMICROB AGENTS CH, V50, P1170, DOI 10.1128/AAC.50.4.1170-1177.2006
   McIlleron H, 2012, ANTIMICROB AGENTS CH, V56, P3232, DOI 10.1128/AAC.05526-11
   MISCORIA G, 1988, ANN BIOL CLIN-PARIS, V46, P734
   ONeil WM, 1997, CLIN PHARMACOL THER, V62, P261, DOI 10.1016/S0009-9236(97)90028-X
   Peloquin CA, 2002, DRUGS, V62, P2169, DOI 10.2165/00003495-200262150-00001
   Peloquin CA, 1999, INT J TUBERC LUNG D, V3, P703
   Peloquin CA, 1999, CHEST, V115, P12, DOI 10.1378/chest.115.1.12
   Peloquin CA, 1998, CHEST, V113, P1154, DOI 10.1378/chest.113.5.1154
   Perlman DC, 2005, CLIN INFECT DIS, V41, P1638, DOI 10.1086/498024
   Rakhmanina NY, 2010, EXPERT OPIN DRUG MET, V6, P95, DOI 10.1517/17425250903483207
   Sahai J, 1997, ANN INTERN MED, V127, P289, DOI 10.7326/0003-4819-127-4-199708150-00006
   Saleri N, 2012, J ANTIMICROB CHEMOTH, V67, P469, DOI 10.1093/jac/dkr445
   Sanchez M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033129
   Shaheen A, 2012, SCAND J INFECT DIS, V44, P459, DOI 10.3109/00365548.2011.647832
   Shenfield Gillian M, 2004, Clin Biochem Rev, V25, P203
   Singla R, 2009, INT J TUBERC LUNG D, V13, P521
   Tabarsi P, 2012, Int J STD AIDS, V23, pe1, DOI 10.1258/ijsa.2009.009093
   Tirona RG, 2003, J PHARMACOL EXP THER, V304, P223, DOI 10.1124/jpet.102.043026
   Titier K, 2002, THER DRUG MONIT, V24, P417, DOI 10.1097/00007691-200206000-00015
   Tostmann A, 2013, ANTIMICROB AGENTS CH, V57, P3208, DOI 10.1128/AAC.02599-12
   van Crevel R, 2002, INT J TUBERC LUNG D, V6, P497
   Weiner M, 2010, ANTIMICROB AGENTS CH, V54, P4192, DOI 10.1128/AAC.00353-10
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   WHO, 2010, GUID TREATM TUB
   *WHO, 2013, WHO CONS ID GUID USE
   Wilkins JJ, 2008, ANTIMICROB AGENTS CH, V52, P2138, DOI 10.1128/AAC.00461-07
   Wilkins JJ, 2011, BRIT J CLIN PHARMACO, V72, P51, DOI 10.1111/j.1365-2125.2011.03940.x
   World Health Organization, 2010, ANT THER HIV INF AD
NR 51
TC 20
Z9 20
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2014
VL 58
IS 6
BP 3182
EP 3190
DI 10.1128/AAC.02379-13
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AK9VP
UT WOS:000338776900025
PM 24663014
OA Bronze, Green Published
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   De Castro, N
   Arnold, V
AF Grinsztejn, B.
   De Castro, N.
   Arnold, V
TI Raltegravir for the treatment of patients co-infected with HIV and
   tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2,
   non-comparative, open-label, randomised trial (vol 14, pg 459, 2014)
SO LANCET INFECTIOUS DISEASES
LA English
DT Correction
CR Grinsztejn B, 2014, LANCET INFECT DIS, V14, P459, DOI 10.1016/S1473-3099(14)70711-X
NR 1
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUN
PY 2014
VL 14
IS 6
BP 448
EP 448
DI 10.1016/S1473-3099(14)70069-6
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA AH8UW
UT WOS:000336414700006
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   De Castro, N
   Arnold, V
   Veloso, VG
   Morgado, M
   Pilotto, JH
   Brites, C
   Madruga, JV
   Barcellos, NT
   Santos, BR
   Vorsatz, C
   Fagard, C
   Santini-Oliveira, M
   Patey, O
   Delaugerre, C
   Chene, G
   Molina, JM
AF Grinsztejn, Beatriz
   De Castro, Nathalie
   Arnold, Vincent
   Veloso, Valdilea G.
   Morgado, Mariza
   Pilotto, Jose Henrique
   Brites, Carlos
   Madruga, Jose Valdez
   Barcellos, Nemora Tregnago
   Santos, Breno Riegel
   Vorsatz, Carla
   Fagard, Catherine
   Santini-Oliveira, Marina
   Patey, Olivier
   Delaugerre, Constance
   Chene, Genevieve
   Molina, Jean-Michel
CA ANRS 12 180 Reflate TB Study Grp
TI Raltegravir for the treatment of patients co-infected with HIV and
   tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2,
   non-comparative, open-label, randomised trial
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; ACTIVE TUBERCULOSIS; EFAVIRENZ; SAFETY;
   PHARMACOKINETICS; METAANALYSIS; INDIVIDUALS; PREVENTION; SETTINGS;
   EFFICACY
AB Background Concurrent treatment of HIV and tuberculosis is complicated by drug interactions. We explored the safety and efficacy of raltegravir as an alternative to efavirenz for patients co-infected with HIV and tuberculosis.
   Methods We did a multicentre, phase 2, non-comparative, open-label, randomised trial at eight sites in Brazil and France. Using a computer-generated randomisation sequence, we randomly allocated antiretroviral-naive adult patients with HIV-1 and tuberculosis (aged >= 18 years with a plasma HIV RNA concentration of >1000 copies per mL) to receive raltegravir 400 mg twice a day, raltegravir 800 mg twice daily, or efavirenz 600 mg once daily plus tenofovir and lamivudine (1:1:1; stratified by country). Patients began study treatment after the start of tuberculosis treatment. The primary endpoint was virological suppression at 24 weeks (HIV RNA <50 copies per mL) in all patients who received at least one dose of study drug (modified intention-to-treat analysis). We recorded death, study drug discontinuation, and loss to follow-up as failures to achieve the primary endpoint. We assessed safety in all patients who received study drugs. This study is registered in ClinicalTrials.gov, number NCT00822315.
   Findings Between July 3, 2009, and June 6, 2011, we enrolled and randomly assigned treatment to 155 individuals; 153 (51 in each group) received at least one dose of the study drug and were included in the primary analysis. 133 patients (87%) completed follow-up at week 48. At week 24, virological suppression was achieved in 39 patients (76%, 95% CI 65-88) in the raltegravir 400 mg group, 40 patients (78%, 67-90) in the raltegravir 800 mg group, and 32 patients (63%, 49-76) in the efavirenz group. The adverse-event profile was much the same across the three groups. Three (6%) patients allocated to efavirenz and three (6%) patients allocated to raltegravir 800 mg twice daily discontinued the study drugs due to adverse events. Seven patients died during the study (one in the raltegravir 400 mg group, four in the raltegravir 800 mg group, and two in the efavirenz group): none of the deaths was deemed related to study treatment.
   Interpretation Raltegravir 400 mg twice daily might be an alternative to efavirenz for the treatment of patients co-infected with HIV and tuberculosis.
C1 [Grinsztejn, Beatriz; Veloso, Valdilea G.; Vorsatz, Carla; Santini-Oliveira, Marina] Fiocruz MS, Evandro Chagas Clin Res Inst, STD AIDS Clin Res Lab, Paris, France.
   [De Castro, Nathalie; Molina, Jean-Michel] Univ Paris 07, Sorbonne Paris Cite, INSERM, Dept Infect Dis,U941, F-75221 Paris 05, France.
   [Delaugerre, Constance] Hop St Louis, AP HP, Dept Virol, Paris, France.
   [Arnold, Vincent; Fagard, Catherine; Chene, Genevieve] Univ Bordeaux, ISPED, INSERM U897, Bordeaux, France.
   [Morgado, Mariza] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Dept DST AIDS, Rio De Janeiro, Brazil.
   [Brites, Carlos] Hosp Univ Prof Edgar Santos, Lab Pesquisa Doencas Infecciosas, Salvador, BA, Brazil.
   [Madruga, Jose Valdez] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Barcellos, Nemora Tregnago] Hosp Sanatorio Partenon, Hlth State Secretariat RS, Porto Alegre, RS, Brazil.
   [Santos, Breno Riegel] Hosp Nossa Senhora Conceicao, Serv Infectiol, Porto Alegre, RS, Brazil.
   [Patey, Olivier] Dept Internal & Trop Med, Villeneuve St Georges, France.
   [Chene, Genevieve] CHU Bordeaux, Pole Sante Publ, Serv Informat Med, Bordeaux, France.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin DST AIDS, Av Brasil,4365 Manguinhos, BR-21040900 Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI chene, genevieve/H-8665-2014; Pilotto, Jose Henrique/AAD-9773-2019;
   Anglaret, Xavier/F-7333-2013; Brites, Carlos/D-1353-2013
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Brites,
   Carlos/0000-0002-4673-6991; Anglaret, Xavier/0000-0003-3319-8423
FU ANRSANRSFrench National Research Agency (ANR); Brazilian HIV/AIDS
   Program-Ministry of Health
FX Findings from this study were presented at the XIX International AIDS
   Conference, (Washington USA; July 22-27, 2012) and at the 20th
   Conference on Retroviruses and Opportunistic Infections (Atlanta, GA,
   USA; March 3-6, 2013). This trial was funded by ANRS and the Brazilian
   HIV/AIDS Program-Ministry of Health. We thank the members of the
   independent data and safety monitoring committee (F Raffi [chair], J P
   Aboulker, D Descamps, B Durovni) and members of the events validation
   committee (G Breton, B Denis, S Wagner). We thank Merck Sharp
   Dohme-Chibret who donated raltegravir (F Durand, A De Jacquelot), and
   Gilead Sciences who donated tenofovir (A Jacob, P Petour, V Tilliet).
CR A'Hern RP, 2001, STAT MED, V20, P859, DOI 10.1002/sim.721
   Agence Francaise de Recherche sur le SIDA et les Hepatites Virales, 2008, 2008 ANRS SCAL GRAD
   Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911
   Bonnet M, 2013, LANCET INFECT DIS, V13, P303, DOI 10.1016/S1473-3099(13)70007-0
   Burger DM, 2010, AIDS, V24, P328, DOI 10.1097/QAD.0b013e3283350f08
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Ford N, 2010, AIDS, V24, P1461, DOI 10.1097/QAD.0b013e32833a2a14
   Gervasoni C, 2013, CLIN INFECT DIS, V57, P480, DOI 10.1093/cid/cit258
   Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181
   Khan FA, 2012, CLIN INFECT DIS, V55, P1154, DOI 10.1093/cid/cis630
   Lawn SD, 2010, LANCET INFECT DIS, V10, P489, DOI 10.1016/S1473-3099(10)70078-5
   Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1
   Meintjes G, 2008, LANCET INFECT DIS, V8, P516, DOI 10.1016/S1473-3099(08)70184-1
   Mena A, 2011, J ANTIMICROB CHEMOTH, V66, P951, DOI 10.1093/jac/dkq540
   Rockstroh JK, 2013, JAIDS-J ACQ IMM DEF, V63, P77, DOI 10.1097/QAI.0b013e31828ace69
   Sauvageon H, 2013, 20 C RETR OPP INF AT
   Scourfield A, 2012, AIDS, V26, P1399, DOI 10.1097/QAD.0b013e328353b047
   Sibiude J, 2013, C RETR OPP INF ATL G
   Wenning LA, 2009, ANTIMICROB AGENTS CH, V53, P2852, DOI 10.1128/AAC.01468-08
   WHO, TUB CAR TB HIV COM I
   World Health Organization, HIV AIDS PROGR CONS
NR 23
TC 53
Z9 53
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUN
PY 2014
VL 14
IS 6
BP 459
EP 467
DI 10.1016/S1473-3099(14)70711-X
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA AH8UW
UT WOS:000336414700017
PM 24726095
DA 2020-11-24
ER

PT J
AU Luz, PM
   Bruyand, M
   Ribeiro, S
   Bonnet, F
   Moreira, RI
   Hessamfar, M
   Campos, DP
   Greib, C
   Cazanave, C
   Veloso, VG
   Dabis, F
   Grinsztejn, B
   Chene, G
AF Luz, Paula Mendes
   Bruyand, Mathias
   Ribeiro, Sayonara
   Bonnet, Fabrice
   Moreira, Ronaldo Ismerio
   Hessamfar, Mojgan
   Campos, Dayse Perreira
   Greib, Carine
   Cazanave, Charles
   Veloso, Valdilea Goncalves
   Dabis, Francois
   Grinsztejn, Beatriz
   Chene, Genevieve
CA IPEC FIOCRUZ Cohort Aquitaine ANRS
TI AIDS and non-AIDS severe morbidity associated with hospitalizations
   among HIV-infected patients in two regions with universal access to care
   and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based
   cohort studies
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV; AIDS; Antiretroviral therapy; Severe morbidity; Hospitalization;
   Cohort study; Brazil; France
ID RIO-DE-JANEIRO; UNITED-STATES; CLINICAL CARE; IMMUNE STATUS;
   LUNG-CANCER; HAART ERA; EFFICACY; TRENDS; RISK; IMMUNODEFICIENCY
AB Background: In high-income settings, the spectrum of morbidity and mortality experienced by Human Immunodeficiency Virus (HIV)-infected individuals receiving combination antiretroviral therapy (cART) has switched from predominantly AIDS-related to non-AIDS-related conditions. In the context of universal access to care, we evaluated whether that shift would apply in Brazil, a middle-income country with universal access to treatment, as compared to France.
   Methods: Two hospital-based cohorts of HIV-infected individuals were used for this analysis: the ANRS CO3 Aquitaine Cohort in South Western France and the Evandro Chagas Research Institute (IPEC) Cohort of the Oswaldo Cruz Foundation in Rio de Janeiro, Brazil. Severe morbid events (AIDS-and non-AIDS-related) were defined as all clinical diagnoses associated with a hospitalization of >= 48 hours. Trends in the incidence rate of events and their determinants were estimated while adjusting for within-subject correlation using generalized estimating equations models with an auto-regressive correlation structure and robust standard errors.
   Result: Between January 2000 and December 2008, 7812 adult patients were followed for a total of 41,668 personyears (PY) of follow-up. Throughout the study period, 90% of the patients were treated with cART. The annual incidence rate of AIDS and non-AIDS events, and of deaths significantly decreased over the years, from 6.2, 21.1, and 1.9 AIDS, non-AIDS events, and deaths per 100 PY in 2000 to 4.3, 14.9, and 1.5/100 PY in 2008. The annual incidence rates of non-AIDS events surpassed that of AIDS-events during the entire study period. High CD4 cell counts were associated with a lower incidence rate of AIDS and non-AIDS events as well as with lower rates of specific non-AIDS events, such as bacterial, hepatic, viral, neurological, and cardiovascular conditions. Adjusted analysis showed that severe morbidity was associated with lower CD4 counts and higher plasma HIV RNAs but not with setting (IPEC versus Aquitaine).
   Conclusions: As information on severe morbidities for HIV-infected patients remain scarce, data on hospitalizations are valuable to identify priorities for case management and to improve the quality of life of patients with a chronic disease requiring life-long treatment. Immune restoration is highly effective in reducing AIDS and non-AIDS severe morbid events irrespective of the setting.
C1 [Luz, Paula Mendes; Ribeiro, Sayonara; Moreira, Ronaldo Ismerio; Campos, Dayse Perreira; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21040 Rio De Janeiro, Brazil.
   [Bruyand, Mathias; Bonnet, Fabrice; Hessamfar, Mojgan; Dabis, Francois; Chene, Genevieve] Ctr Hosp Univ Bordeaux, Pole Sante Publ, COREVIH Aquitaine, F-33000 Bordeaux, France.
   [Bruyand, Mathias; Bonnet, Fabrice; Hessamfar, Mojgan; Dabis, Francois; Chene, Genevieve] Ctr Inserm U897 Epidemiol Biostat, ISPED, INSERM, F-33000 Bordeaux, France.
   [Bruyand, Mathias; Bonnet, Fabrice; Hessamfar, Mojgan; Dabis, Francois; Chene, Genevieve] CIC EC7, F-33000 Bordeaux, France.
   [Greib, Carine] Ctr Hosp Univ Bordeaux, Hop Haut Leveque, F-33600 Pessac, France.
   [Cazanave, Charles] Ctr Hosp Univ Bordeaux, Hop Pellegrin, F-33000 Bordeaux, France.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21040 Rio De Janeiro, Brazil.
EM luzpaulamendes@gmail.com
RI Bruyand, Mathias/AAP-6177-2020; chene, genevieve/H-8665-2014; molimard,
   mathieu/T-2762-2019; Bonnet, Fabrice/T-3254-2019; DABIS,
   FRANCOIS/S-9298-2019
OI molimard, mathieu/0000-0002-4346-8346; DABIS,
   FRANCOIS/0000-0002-1614-8857; Luz, Paula/0000-0001-9746-719X
FU "Cooperation Franco-Bresilienne en Recherche Medicale Accord Inserm
   (Institut National de la Sante et de la Recherche Medicale)/FIOCRUZ
   2010"; French Agency for AIDS and hepatitis research (ANRS) through the
   HIV Cohort Program (AC7); Bordeaux School of Public Health (ISPED -
   Bordeaux University), Inserm CIC-EC7; COREVIH Aquitaine (Bordeaux
   University Hospital); National Council of Technological and Scientific
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); Agency of the State of Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ)
FX This study was partially funded by the grant "Cooperation
   Franco-Bresilienne en Recherche Medicale Accord Inserm (Institut
   National de la Sante et de la Recherche Medicale)/FIOCRUZ 2010". The
   ANRS C03 Aquitaine Cohort is supported by grants from the French Agency
   for AIDS and hepatitis research (ANRS) through the HIV Cohort Program
   (AC7) together with the Bordeaux School of Public Health (ISPED -
   Bordeaux University), Inserm CIC-EC7 and U897 (Bordeaux) and the COREVIH
   Aquitaine (Bordeaux University Hospital). BG and PML acknowledge funding
   from the National Council of Technological and Scientific Development
   (CNPq) and the Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ). The funding bodies had no role in the design, collection,
   analysis, or interpretation of data; in the writing of the manuscript;
   or in the decision to submit the manuscript for publication.
CR Anglaret X, 2012, CLIN INFECT DIS, V54, P714, DOI 10.1093/cid/cir898
   Ballinger GA, 2004, ORGAN RES METHODS, V7, P127, DOI 10.1177/1094428104263672
   Benard A, 2007, AIDS PATIENT CARE ST, V21, P458, DOI 10.1089/apc.2006.0142
   Berry SA, 2012, JAIDS-J ACQ IMM DEF, V59, P368, DOI 10.1097/QAI.0b013e318246b862
   Bonnet F, 2009, CLIN INFECT DIS, V48, P633, DOI 10.1086/596766
   Bonnet F, 2007, HIV MED, V8, P547, DOI 10.1111/j.1468-1293.2007.00508.x
   Buchacz K, 2008, AIDS, V22, P1345, DOI 10.1097/QAD.0b013e328304b38b
   Clifford GM, 2012, BRIT J CANCER, V106, P447, DOI 10.1038/bjc.2011.558
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Crum-Cianflone N, 2009, AIDS, V23, P41, DOI 10.1097/QAD.0b013e328317cc2d
   Crum-Cianflone NF, 2010, JAIDS-J ACQ IMM DEF, V54, P248, DOI 10.1097/QAI.0b013e3181c8ef22
   DeJesus E, 2012, HIV CLIN TRIALS, V13, P228, DOI 10.1310/hct1304-228
   Elzi L, 2006, ANTIVIR THER, V11, P787
   Gebo KA, 2003, JAIDS-J ACQ IMM DEF, V34, P165, DOI 10.1097/00126334-200310010-00006
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   Guaraldi G, 2011, CLIN INFECT DIS, V53, P1120, DOI 10.1093/cid/cir627
   Guiguet M, 2009, LANCET ONCOL, V10, P1152, DOI 10.1016/S1470-2045(09)70282-7
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Katlama C, 2007, AIDS, V21, P395, DOI 10.1097/QAD.0b013e328013d9d7
   Kaulich-Bartz J, 2013, AIDS, V27, P1641, DOI 10.1097/QAD.0b013e3283601199
   Lang S, 2012, CLIN INFECT DIS, V55, P600, DOI 10.1093/cid/cis489
   Lanoy E, 2007, ANTIVIR THER, V12, P89
   Leutscher PDC, 2013, SCAND J INFECT DIS, V45, P645, DOI 10.3109/00365548.2013.773067
   Lewden C, 2008, JAIDS-J ACQ IMM DEF, V48, P590, DOI 10.1097/QAI.0b013e31817efb54
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267
   Mocroft A, 2004, HIV MED, V5, P437, DOI 10.1111/j.1468-1293.2004.00250.x
   MOCROFT A, 2010, HIV MED, V11, P554
   Mocroft A, 2010, JAIDS-J ACQ IMM DEF, V55, P262, DOI 10.1097/QAI.0b013e3181e9be6b
   Molina JM, 2010, JAIDS-J ACQ IMM DEF, V53, P323, DOI 10.1097/QAI.0b013e3181c990bf
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Nunez-Fernandez C, 2009, AIDS RES HUM RETROV, V25, P383, DOI 10.1089/aid.2008.0242
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Shebl FM, 2010, JAIDS-J ACQ IMM DEF, V55, P375, DOI 10.1097/QAI.0b013e3181eef4f7
   Sigel K, 2012, AIDS, V26, P1017, DOI 10.1097/QAD.0b013e328352d1ad
   Thiebaut R, 2000, AIDS, V14, P971, DOI 10.1097/00002030-200005260-00008
   Torres TS, 2013, BRAZ J INFECT DIS, V17, P324, DOI 10.1016/j.bjid.2012.10.024
   Yehia BR, 2011, HIV MED, V12, P535, DOI 10.1111/j.1468-1293.2011.00919.x
NR 42
TC 17
Z9 18
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAY 21
PY 2014
VL 14
AR 278
DI 10.1186/1471-2334-14-278
PG 13
WC Infectious Diseases
SC Infectious Diseases
GA AI3JB
UT WOS:000336756100001
PM 24885790
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Araujo, ESP
   Friedman, RK
   Camacho, LAB
   Derrico, M
   Moreira, RI
   Calvet, GA
   de Oliveira, MS
   Veloso, VG
   Pilotto, JH
   Grinsztejn, B
AF Pires Araujo, Elaine S.
   Friedman, Ruth Khalili
   Bastos Camacho, Luis Antonio
   Derrico, Monica
   Moreira, Ronaldo Ismerio
   Calvet, Guilherme Amaral
   de Oliveira, Marilia Santini
   Veloso, Valdilea Goncalves
   Pilotto, Jose Henrique
   Grinsztejn, Beatriz
TI Cascade of access to interventions to prevent HIV mother to child
   transmission in the metropolitan area of Rio de Janeiro, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; HIV vertical transmission; Antiretroviral chemoprophylaxis; Cohort
   studies; Brazil
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VERTICAL TRANSMISSION; PREGNANT-WOMEN;
   SAO-PAULO; INFECTION; STATE; INEQUALITY; HEALTH; RISK
AB Objectives: To describe the access to the interventions for the prevention of Human Immunodeficiency Virus (HIV) mother to child transmission and mother to child transmission rates in the outskirts of Rio de Janeiro, from 1999 to 2009.
   Methods: This is a retrospective cohort study. Prevention of HIV mother to child transmission interventions were accessed and mother to child transmission rates were calculated.
   Results: The study population is young (median: 26 years; interquartile range: 22.0-31.0), with low monthly family income (40.4% up to one Brazilian minimum wage) and schooling (62.1% less than 8 years). Only 47.1% (n = 469) knew the HIV status of their partner; of these women, 39.9% had an HIV-seronegative partner. Among the 1259 newborns evaluated, access to the antenatal, intrapartum and postpartum prevention of HIV mother to child transmission components occurred in 59.2%, 74.2%, and 97.5% respectively; 91.0% of the newborns were not breastfed. Overall 52.7% of the newborns have benefited from all the recommended interventions. In subsequent pregnancies (n = 289), 67.8% of the newborns received the full package of interventions. The overall rate of HIV vertical transmission was 4.7% and the highest annual rate occurred in 2005 (7.4%), with no definite trend in the period.
   Conclusions: Access to the full package of interventions for the prevention of HIV vertical transmission was low, with no significant trend of improvement over the years. The vertical transmission rates observed were higher than those found in reference services in the municipality of Rio de Janeiro and in the richest regions of the country. (C) 2014 Published by Elsevier Editora Ltda.
C1 [Pires Araujo, Elaine S.; Friedman, Ruth Khalili; Derrico, Monica; Moreira, Ronaldo Ismerio; Calvet, Guilherme Amaral; de Oliveira, Marilia Santini; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Lab Pesquisa DST AIDS, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Bastos Camacho, Luis Antonio] Fiocruz MS, Escola Nacl Saude Publ, Dept Epidemiol & Metodos Quantitativos Saude, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Pires Araujo, Elaine S.; Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Serv DST HIV AIDS, Rio De Janeiro, RI, Brazil.
   [Pilotto, Jose Henrique] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Araujo, ESP (corresponding author), Inst Pesquisa Clin Evandro Chagas IPEC, Lab Pesquisa Clin DST AIDS, Rio De Janeiro, RJ, Brazil.
EM elainespiresba@yahoo.com.br
RI Pilotto, Jose Henrique/AAD-9773-2019; Calvet, GA/G-6959-2013
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Calvet,
   GA/0000-0002-3545-5238
FU Brazilian Ministry of Health, PN-DST/AIDS - SVS/Ministerio da
   Saude/BIRD/UNODC; Acordo de Emprestimo [BIRD 4713-BR, TC 292/07]; 
   [AD/BRA/03/H34]
FX This study was supported by Brazilian Ministry of Health, PN-DST/AIDS -
   SVS/Ministerio da Saude/BIRD/UNODC. Projeto AD/BRA/03/H34. Acordo de
   Emprestimo BIRD 4713-BR. TC 292/07.
CR Andrade MV, 2012, HEALTH PLACE, V18, P942, DOI 10.1016/j.healthplace.2012.06.014
   Vieira ACBC, 2011, REV SAUDE PUBL, V45, P644, DOI 10.1590/s0034-89102011005000041
   Barcellos C, 2009, REV SAUDE PUBL, V43
   Brasil Ministerio da Safide Secretaria de Vigilancia em Sadde Programa Nacional de DST e Aids, 2009, REC TER ANT CRIANG A
   Brasil. Ministerio da Saude, 2013, B EP AIDS DST
   Brasil. Ministerio da Saude, 2011, B EP AIDS DST
   Brasil Ministerio da Saude, 2013, DATASUS INF SAUD TAB
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834
   Gouveia PAD, 2013, TROP MED INT HEALTH, V18, P276, DOI 10.1111/tmi.12042
   Dal Fabbro Márcia Maria Ferrairo Janini, 2005, Braz J Infect Dis, V9, P20, DOI 10.1590/S1413-86702005000100005
   Dao H, 2007, AM J OBSTET GYNECOL, V197, pS42, DOI 10.1016/j.ajog.2007.03.001
   de Lemos LMD, 2013, INT J INFECT DIS, V17, pE913, DOI 10.1016/j.ijid.2013.04.015
   Succi RCD, 2007, CAD SAUDE PUBLICA, V23, pS379, DOI 10.1590/S0102-311X2007001500006
   Soeiro CMD, 2011, REV SOC BRAS MED TRO, V44, P537, DOI 10.1590/S0037-86822011000500001
   de Souza PRB, 2004, REV SAUDE PUBL, V38, P764, DOI 10.1590/S0034-89102004000600003
   ESRI, 2011, ARCGIS DESKT REL 10
   Fernandes Regina Célia de Souza Campos, 2005, Cad. Saúde Pública, V21, P1153, DOI 10.1590/S0102-311X2005000400017
   Filippi V, 2006, LANCET, V368, P1535, DOI 10.1016/S0140-6736(06)69384-7
   Joao EC, 2003, AIDS, V17, P1853, DOI [10.1097/01.aids.0000076326.42412.7a, 10.1097/00002030-200308150-00016]
   Kakehasi FM, 2008, MEM I OSWALDO CRUZ, V103, P351, DOI 10.1590/S0074-02762008000400007
   Konopka CK, 2010, REV BRAS GINECOL OBS, V32, P184, DOI 10.1590/S0100-72032010000400006
   Matida LH, 2011, JAIDS-J ACQ IMM DEF, V57, pS164, DOI 10.1097/QAI.0b013e31821e9d13
   Menezes Daniela Contage Siccardi, 2006, Cad. Saúde Pública, V22, P553, DOI 10.1590/S0102-311X2006000300010
   Messias E, 2003, AM J PUBLIC HEALTH, V93, P1294, DOI 10.2105/AJPH.93.8.1294
   Ministerio do Planejamento, 2010, ORG GEST I BRAS GEOG
   Ministerio do Planejamento,Orgamento e Gestao,Instituto Brasileiro de Geografia e Estatistica-IBGE,Diretoria de Pesquisas,Coordenagdo de Populag5o e Indicadores Sociais, 2009, EST PESQ INF DEM SOC
   Miranda AE, 2005, AIDS CARE, V17, P721, DOI 10.1080/09540120500038033
   Mugo NR, 2011, AIDS, V25, P1887, DOI 10.1097/QAD.0b013e32834a9338
   Mussi-Pinhata MM, 2003, INT J STD AIDS, V14, P818, DOI 10.1258/095646203322556156
   Read JS, 2007, PEDIATRICS, V120, pE1547, DOI 10.1542/peds.2007-2951
   SZWARCWALD C, 2004, ESTIMATIVA PREVALENC
   Tess BH, 1998, J ACQ IMMUN DEF SYND, V19, P189, DOI 10.1097/00042560-199810010-00014
   Tornatore M, 2010, INT J STD AIDS, V21, P351, DOI 10.1258/ijsa.2009.009033
   Townsend CL, 2008, AIDS, V22, P973, DOI 10.1097/QAD.0b013e3282f9b67a
   Turchi MD, 2007, CAD SAUDE PUBLICA, V23, pS390, DOI 10.1590/S0102-311X2007001500007
   UNAIDS, 2010, GLOB REP UNAIDS REP
   UNAIDS Geneva Switzerland Countdown to zero, 2011, GEN SWITZ COUNTD ZER
   Veloso VG, 2010, REV SAUDE PUBL, V44, P803, DOI 10.1590/S0034-89102010005000034
   Veloso Valdiléa G, 2008, Rev. Saúde Pública, V42, P859, DOI 10.1590/S0034-89102008000500011
   World Health Organization, 2013, US ANT DRUGS TREAT P
NR 41
TC 5
Z9 7
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2014
VL 18
IS 3
BP 252
EP 260
DI 10.1016/j.bjid.2013.11.002
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA AL4XA
UT WOS:000339136900003
PM 24389286
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Grangeiro, A
   Escuder, MM
   Cassanote, AJF
   Souza, RA
   Kalichman, AO
   Veloso, V
   Ikeda, MLR
   Barcellos, NT
   Brites, C
   Tupinanbas, U
   Lucena, NO
   da Silva, CL
   Lacerda, HR
   Grinsztejn, B
   Castilho, EA
AF Grangeiro, Alexandre
   Escuder, Maria Mercedes
   Flores Cassanote, Alex Jones
   Souza, Rosa Alencar
   Kalichman, Artur O.
   Veloso, Valdilea
   Rodrigues Ikeda, Maria Leticia
   Barcellos, Nemora Tregnago
   Brites, Carlos
   Tupinanbas, Unai
   Lucena, Noaldo O.
   da Silva, Carlos Lima
   Lacerda, Heloisa Ramos
   Grinsztejn, Beatriz
   Castilho, Euclides Ayres
TI The HIV-Brazil Cohort Study: Design, Methods and Participant
   Characteristics
SO PLOS ONE
LA English
DT Article
ID RIO-DE-JANEIRO; ANTIRETROVIRAL TREATMENT; UNIVERSAL ACCESS;
   DRUG-RESISTANCE; AIDS TREATMENT; SURVIVAL; HIV/AIDS; INDIVIDUALS;
   CHALLENGES; DEATH
AB Background: The HIV-Brazil Cohort Study was established to analyze the effectiveness of combination antiretroviral therapy (cART) and the impact of this treatment on morbidity, quality of life (QOL) and mortality. The study design, patients' profiles and characteristics of cART initiation between 2003 and 2010 were described.
   Methodology/Principal Findings: Since 2003, the HIV-Brazil Cohort has been following HIV-infected adults receiving cART at 26 public health care facilities, using routine clinical care data and self-reported QOL questionnaires. When not otherwise available, data are obtained from national information systems. The main outcomes of interest are diseases related or unrelated to HIV; suppression of viral replication; adverse events; virological, clinical and immunological failures; changes in the cART; and mortality. For the 5,061 patients who started cART between 2003 and 2010, the median follow-up time was 4.1 years (IQR 2.2-5.9 years) with an 83.4% retention rate. Patient profiles were characterized by a predominance of men (male/female ratio 1.7:1), with a mean age of 36.9 years (SD 9.9 years); 55.2% had been infected with HIV via heterosexual contact. The majority of patients (53.4%) initiated cART with a CD4(+) T-cell count <= 200 cells/mm(3). The medications most often used in the various treatment regimens were efavirenz (59.7%) and lopinavir/ritonavir (18.2%). The proportion of individuals achieving viral suppression within the first 12 months of cART use was 77.4% (95% CI 76.1-78.6). Nearly half (45.4%) of the patients presented HIV-related clinical manifestations after starting cART, and the AIDS mortality rate was 13.9 per 1,000 person-years.
   Conclusions/Significance: Results from cART use in the daily practice of health services remain relatively unknown in low- and middle-income countries, and studies with the characteristics of the HIV-Brazil Cohort contribute to minimizing these shortcomings, given its scope and patient profile, which is similar to that of the AIDS epidemic in the country.
C1 [Grangeiro, Alexandre; Castilho, Euclides Ayres] Univ Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil.
   [Escuder, Maria Mercedes] Sao Paulo State Dept Hlth, Hlth Inst, Sao Paulo, Brazil.
   [Flores Cassanote, Alex Jones] Univ Sao Paulo, Sch Med, Postgrad Program Infect & Parasit Dis, Sao Paulo, Brazil.
   [Souza, Rosa Alencar; Kalichman, Artur O.] Sao Paulo State Dept Hlth, STD AIDS Referral & Training Ctr, Sao Paulo, Brazil.
   [Veloso, Valdilea; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   [Rodrigues Ikeda, Maria Leticia; Barcellos, Nemora Tregnago] Rio Grande do Sul State Dept Hlth, Care & Treatment Clin Partenon Sanat, Porto Alegre, RS, Brazil.
   [Brites, Carlos] Univ Fed Bahia, Edgar Santos Univ Hosp Complex, Salvador, BA, Brazil.
   [Tupinanbas, Unai] Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, Brazil.
   [Lucena, Noaldo O.] Amazonas State Dept Hlth, Trop Med Fdn, Manaus, Amazonas, Brazil.
   [da Silva, Carlos Lima] Bahia State Dept Hlth, State Ctr Diag Treatment & Res, Salvador, BA, Brazil.
   [Lacerda, Heloisa Ramos] Univ Fed Pernambuco, Recife, PE, Brazil.
RP Grangeiro, A (corresponding author), Univ Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil.
EM ale.grangeiro@gmail.com
RI Brites, Carlos/D-1353-2013; DE CASTILHO, EUCLIDES AYRES/K-7906-2016
OI Brites, Carlos/0000-0002-4673-6991; ikeda, maria
   leticia/0000-0002-2727-2298; Castilho, Euclides/0000-0002-7352-8784
FU Brazilian National Council for Scientific and Technological
   DevelopmentNational Council for Scientific and Technological Development
   (CNPq); Brazilian National Ministry of Health; Pan American Health
   Organization; STD/AIDS Referral and Training Centre of the Sao Paulo
   State Department of Health; Evandro Chagas Clinical Research Institute
   of the Oswaldo Cruz Foundation
FX The study is funded by the Brazilian National Council for Scientific and
   Technological Development, the Brazilian National Ministry of Health,
   the Pan American Health Organization, the STD/AIDS Referral and Training
   Centre of the Sao Paulo State Department of Health and the Evandro
   Chagas Clinical Research Institute of the Oswaldo Cruz Foundation. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alencastro PR, 2011, AIDS PATIENT CARE ST, V25, P627, DOI 10.1089/apc.2010.0360
   Silva ACAL, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/186850
   Belloso WH, 2010, HIV MED, V11, P554, DOI 10.1111/j.1468-1293.2010.00824.x
   Veras MADM, 2011, CAD SAUDE PUBLICA, V27, pS104, DOI 10.1590/S0102-311X2011001300011
   Grangeiro A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014585
   Greco DB, 2007, AIDS, V21, pS37, DOI 10.1097/01.aids.0000279705.24428.a3
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Guibu IA, 2011, CAD SAUDE PUBLICA, V27, pS79, DOI 10.1590/S0102-311X2011001300009
   Hacker MA, 2007, CAD SAUDE PUBLICA, V23, pS345, DOI 10.1590/S0102-311X2007001500003
   Hofer CB, 2004, JAIDS-J ACQ IMM DEF, V36, P967, DOI 10.1097/00126334-200408010-00011
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Rezende ELLF, 2010, BRAZ J INFECT DIS, V14, P558, DOI [10.1590/S1413-86702010000600003, 10.1016/S1413-8670(10)70112-4]
   Malta M, 2009, JAIDS-J ACQ IMM DEF, V52, P629, DOI 10.1097/QAI.0b013e3181b31b8a
   Maruza M, 2012, INT J TUBERC LUNG D, V16, P618, DOI 10.5588/ijtld.11.0110
   Medeiros Roseane, 2002, Braz J Infect Dis, V6, P298, DOI 10.1590/S1413-86702002000600005
   Miranda A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000826
   Nunn AS, 2009, HEALTH AFFAIR, V28, P1103, DOI 10.1377/hlthaff.28.4.1103
   Okie S, 2006, NEW ENGL J MED, V354, P1977, DOI 10.1056/NEJMp068069
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Portela MC, 2006, REV SAUDE PUBL, V40, P70, DOI 10.1590/S0034-89102006000800010
   Ribeiro FA, 2012, BRAZ J INFECT DIS, V16, P27, DOI 10.1590/S1413-86702012000100005
   Soares MA, 2004, AIDS, V18, pS9, DOI 10.1097/00002030-200406003-00003
   Teixeira PR, 2004, AIDS, V18, pS5, DOI 10.1097/00002030-200406003-00002
   Torres TS, 2013, BRAZ J INFECT DIS, V17, P324, DOI 10.1016/j.bjid.2012.10.024
NR 24
TC 21
Z9 21
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2014
VL 9
IS 5
AR e95673
DI 10.1371/journal.pone.0095673
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG6EE
UT WOS:000335510600046
PM 24789106
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Santini-Oliveira, M
   Estrela, RDE
   Veloso, VG
   Cattani, VB
   Yanavich, C
   Velasque, L
   Torres, TS
   Marins, LMS
   Pilotto, JH
   Joao, EC
   Goncalves, JCS
   Grinsztejn, B
AF Santini-Oliveira, Marilia
   Elias Estrela, Rita de Cassia
   Veloso, Valdilea Goncalves
   Cattani, Vitoria Berg
   Yanavich, Carolyn
   Velasque, Luciane
   Torres, Thiago Silva
   Spindola Marins, Luana Monteiro
   Pilotto, Jose Henrique
   Joao, Esau Custodio
   Saraiva Goncalves, Jose Carlos
   Grinsztejn, Beatriz
TI Randomized Clinical Trial Comparing the Pharmacokinetics of Standard-
   and Increased- Dosage Lopinavir- Ritonavir Coformulation Tablets in HIV-
   Positive Pregnant Women
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID 3RD TRIMESTER; VIROLOGICAL RESPONSE; INFECTION; ADHERENCE; PLASMA;
   ADULTS; LOPINAVIR/RITONAVIR; PHARMACOGENETICS; VARIABILITY; EFAVIRENZ
AB A lopinavir- ritonavir (LPV/ r)- based regimen is recommended during pregnancy to reduce the risk of HIV mother- to- child transmission, but the appropriate dose is controversial. We compared the pharmacokinetics of standard and increased LPV/ r doses during pregnancy. This randomized, open- label prospective study enrolled 60 pregnant women between gestational weeks 14 and 30. The participants received either the standard dose (400/ 100 mg twice a day [BID]) or increased dose (600/ 150 mg BID) of LPV/ r tablets during pregnancy and the standard dose for 6 weeks after childbirth. Pharmacokinetics analysis was performed using a high- performance liquid chromatography- tandem mass spectrometry method. Adherent participants who received the standard dose presented minimum LPV concentrations of 4.4, 4.3, and 6.1 mu g/ ml in the second and third trimesters and postpartum, respectively. The increased- dose group exhibited values of 7.9, 6.9, and 9.2 mu g/ ml at the same three time points. Although LPV exposure was significantly higher in the increased- dose group, the standard dose produced therapeutic levels of LPV against wild- type virus in all adherent participants, except one patient in the third trimester; 50%, 37.5%, and 25%, and 0%, 15%, and 0% of the participants in the standard- and increased- dose groups failed to achieve therapeutic levels against resistant viruses during the second and third trimesters and after childbirth, respectively. After 12 weeks of treatment and after childbirth, all adherent participants achieved undetectable HIV viral loads, and their babies (49/ 54) were uninfected. No serious drug- related adverse events were observed. We conclude that the standard dose is appropriate for use during pregnancy and that an increased dose may be necessary for women harboring resistant HIV. (This study has been registered at ClinicalTrials. gov under registration no. NCT00605098.)
C1 [Santini-Oliveira, Marilia; Veloso, Valdilea Goncalves; Cattani, Vitoria Berg; Torres, Thiago Silva; Spindola Marins, Luana Monteiro; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz Fiocruz, Inst Pesquisa Clin Evandro Chagas IPEC, Lab Pesquisa Clin DST AIDS, Manguinho, RJ, Brazil.
   [Elias Estrela, Rita de Cassia; Saraiva Goncalves, Jose Carlos] Univ Fed Rio do Janeiro UFRJ, Ctr Ciencias Saude, Fac Farm, Lab Farmacometria LabFarma, Rio De Janeiro, Brazil.
   [Yanavich, Carolyn] Childrens Hosp Los Angeles, Div Infect Dis, Los Angeles, CA 90027 USA.
   [Velasque, Luciane] Univ Fed Estado Rio de Janeiro UniRio, Dept Matemat, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Fiocruz MS, Hosp Geral Nova Iguacu, Manguinho, RJ, Brazil.
   [Pilotto, Jose Henrique] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS Imunol Mol, Manguinho, RJ, Brazil.
   [Joao, Esau Custodio] Hosp Fed Servidores Estado, Serv Doencas Infecciosas & Parasitarias, Rio De Janeiro, Brazil.
RP Santini-Oliveira, M (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Inst Pesquisa Clin Evandro Chagas IPEC, Lab Pesquisa Clin DST AIDS, Manguinho, RJ, Brazil.
EM marilia.santini@ipec.fiocruz.br
RI TORRES, THIAGO SILVA/D-6548-2014; Pilotto, Jose Henrique/AAD-9773-2019
OI TORRES, THIAGO SILVA/0000-0002-2557-601X; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Joao, Esau/0000-0002-2412-0627
FU Brazilian National AIDS Program-Ministry of Health
FX This trial was supported by a grant from the Brazilian National AIDS
   Program-Ministry of Health.
CR Abbott Laboratories, 2012, KAL PACK INS
   Arab-Alameddine M, 2009, CLIN PHARMACOL THER, V85, P485, DOI 10.1038/clpt.2008.271
   Atkinson MJ, 2009, AIDS PATIENT CARE ST, V23, P903, DOI 10.1089/apc.2009.0024
   Baroncelli S, 2009, AIDS PATIENT CARE ST, V23, P513, DOI 10.1089/apc.2008.0263
   Best BM, 2010, JAIDS-J ACQ IMM DEF, V54, P381, DOI 10.1097/QAI.0b013e3181d6c9ed
   Bolaffi G, 2003, DICT RACE ETHNICITY
   Burger DM, 2002, J ACQ IMMUN DEF SYND, V29, P101
   Buxton ILO, 2007, BASES FARMACOLOGICAS, P1
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Cressey TR, 2010, AIDS, V24, P2193, DOI 10.1097/QAD.0b013e32833ce57d
   de Ruiter A, 2008, HIV MED, V9, P452, DOI 10.1111/j.1468-1293.2008.00619.x
   Else LJ, 2012, ANTIMICROB AGENTS CH, V56, P816, DOI 10.1128/AAC.05186-11
   Estrela RCE, 2008, RAPID COMMUN MASS SP, V22, P657, DOI 10.1002/rcm.3411
   Fletcher CV, 2004, J INFECT DIS, V189, P1176, DOI 10.1086/382754
   Floridia M, 2008, PHARMACOL RES, V58, P173, DOI 10.1016/j.phrs.2008.07.007
   Gorowara M, 2010, CURR OPIN HIV AIDS, V5, P90, DOI 10.1097/COH.0b013e3283339caf
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2011, GLOB REP UNAIDS REP
   Khuong-Josses MA, 2007, HIV CLIN TRIALS, V8, P254, DOI 10.1310/hct0804-254
   Koren G, 2011, J POPUL THER CLIN PH, V18, pE523
   Kreitchmann R, 2012, AIDS PATIENT CARE ST, V26, P486, DOI 10.1089/apc.2012.0013
   Lambert JS, 2011, HIV MED, V12, P166, DOI 10.1111/j.1468-1293.2010.00865.x
   LAPORTE CJL, 2006, REV ANTIVIR THER, V3, P4
   Lubomirov R, 2010, PHARMACOGENET GENOM, V20, P217, DOI 10.1097/FPC.0b013e328336eee4
   Ministerio da Saude Departamento de DST AIDS e Hepatites Virais, 2010, SER MAN, V46
   Mirochnick M, 2004, CLIN PHARMACOKINET, V43, P1071, DOI 10.2165/00003088-200443150-00002
   Murphy RL, 2001, AIDS, V15, pF1, DOI 10.1097/00002030-200101050-00002
   Nachega Jean B., 2011, Infectious Disorders - Drug Targets, V11, P167
   National Institutes of Health, 2004, DIV AIDS TABL GRAD S
   Nicastri E, 2007, J ANTIMICROB CHEMOTH, V60, P724, DOI 10.1093/jac/dkm302
   Ofotokun I, 2007, GENDER MED, V4, P106, DOI 10.1016/S1550-8579(07)80025-8
   Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, 2012, REC US ANT VIR DRUGS
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Patterson K, 2011, 18 C RETR OPP INF BO
   Pena SDJ, 2009, BRAZ J MED BIOL RES, V42, P870, DOI 10.1590/S0100-879X2009005000026
   Rakhmanina NY, 2011, THER DRUG MONIT, V33, P417, DOI 10.1097/FTD.0b013e318225384f
   Ramautarsing RA, 2011, AIDS, V25, P1299, DOI 10.1097/QAD.0b013e328347f7e9
   Roca Bernardino, 2008, Recent Pat Antiinfect Drug Discov, V3, P132, DOI 10.2174/157489108784746650
   SHAPIRO D, 2004, 11 C RETR OPP INF SA
   Stek AM, 2006, AIDS, V20, P1931, DOI 10.1097/01.aids.0000247114.43714.90
   Stohr W, 2010, J ANTIMICROB CHEMOTH, V65, P129, DOI 10.1093/jac/dkp408
   Sturt AS, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008440
   Urban TJ, 2010, MT SINAI J MED, V77, P133, DOI 10.1002/msj.20168
   van der Leur MR, 2006, THER DRUG MONIT, V28, P650, DOI 10.1097/01.ftd.0000245681.12092.d6
   van der Lugt J, 2008, J ANTIMICROB CHEMOTH, V61, P1145, DOI 10.1093/jac/dkn050
NR 44
TC 14
Z9 14
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAY
PY 2014
VL 58
IS 5
BP 2884
EP 2893
DI 10.1128/AAC.02599-13
PG 10
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AE9XF
UT WOS:000334364300048
PM 24614377
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Lippman, SA
   Veloso, VG
   Buchbinder, S
   Fernandes, NM
   Terto, V
   Sullivan, PS
   Grinsztejn, B
AF Lippman, Sheri A.
   Veloso, Valdilea G.
   Buchbinder, Susan
   Fernandes, Nilo Martinez
   Terto, Veriano
   Sullivan, Patrick S.
   Grinsztejn, Beatriz
TI Over-the-counter human immunodeficiency virus self-test kits: time to
   explore their use for men who have sex with men in Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Brazil; HIV testing; MSM; Self-testing; Home-based testing
ID RISK BEHAVIORS; HIV-INFECTION; UNITED-STATES; RANDOMIZED-TRIAL; PERSONS
   AWARE; PREVENTION; HOME; TRANSMISSION; METAANALYSIS; PREVALENCE
AB Increasing access and frequency of human immunodeficiency virus testing are critical to stemming the epidemic. In Brazil's concentrated epidemic, human immunodeficiency virus prevalence in the men who have sex with men/transgender population far exceeds that in the general population, but testing rates fall below what is needed to ensure early detection and treatment. Over-the-counter human immunodeficiency virus self-testing kits, now available in stores in the U.S., have enormous potential to increase testing access and frequency and to facilitate early detection and treatment. With the advent of human immunodeficiency virus self-testing upon us, it is timely to engage the scientific community, government, and civil society in a dialog around how to best utilize this technology in Brazil. We summarize recent research on over-the-counter testing among men who have sex with men, raise potential questions and challenges to using self-tests, suggest implementation strategies, and outline a research agenda moving forward. (C) 2014 Elsevier Editora Ltda. All rights reserved.
C1 [Lippman, Sheri A.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.
   [Veloso, Valdilea G.; Fernandes, Nilo Martinez; Grinsztejn, Beatriz] Fundacao Oswald Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Buchbinder, Susan] Bridge HIV, San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Terto, Veriano] Univ Fed Rio de Janeiro, Inst Estudos Saude Colet, Rio De Janeiro, RJ, Brazil.
   [Sullivan, Patrick S.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswald Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, RJ, Brazil.
EM gbeatriz@ipec.fiocruz.br
OI Lippman, Sheri/0000-0003-3152-9372
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30 AI050409] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409] Funding Source: NIH RePORTER
CR Altman D., 1995, PODER E COMUNIDADE R
   Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339
   BAYER R, 1995, NEW ENGL J MED, V332, P1296, DOI 10.1056/NEJM199505113321911
   Carballo-Dieguez A, 2011, J SEX RES
   Carballo-Dieguez A, 2012, AIDS BEHAV, V16, P1753, DOI 10.1007/s10461-012-0274-2
   Coates TJ, 2000, LANCET, V356, P103, DOI 10.1016/S0140-6736(00)02446-6
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Colfax GN, 2002, AIDS, V16, P1529, DOI 10.1097/00002030-200207260-00010
   de Souza V, 2008, CAD SAUDE PUBLICA, V24, P1536, DOI 10.1590/S0102-311X2008000700008
   Fonner VA, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001224.pub4
   França Junior Ivan, 2008, Rev. Saúde Pública, V42, P84, DOI [10.1590/S0034-89102008000800011, 10.1590/s0034-89102008000800011]
   French National AIDS Council, 2013, AUT DEP INF VIH FEU
   Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243
   Grangeiro A, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-99
   Holigrave DR, 2007, JAIDS-J ACQ IMM DEF, V44, P360, DOI 10.1097/QAI.0b013e31802ea4dd
   Ibitoye M, 2013, AIDS BEHAV
   Katz DA, 2014, SEX TRANSM DIS, V41, P2, DOI 10.1097/OLQ.0000000000000046
   Kerr LR, 2012, HIV MSM BRAZIL
   Kong XR, 2012, AM J EPIDEMIOL, V176, P875, DOI 10.1093/aje/kws179
   Koo DJ, 2006, AM J PUBLIC HEALTH, V96, P962, DOI 10.2105/AJPH.2006.089235
   Lippman SA, 2014, CAD SAUDE P IN PRESS
   Liu AY, 2013, JAIDS-J ACQ IMM DEF, V64, P87, DOI 10.1097/QAI.0b013e31828f097a
   MacKellar DA, 2011, SEX TRANSM DIS, V38, P419, DOI 10.1097/OLQ.0b013e31820369dd
   Malta M, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-317
   Marcus JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081997
   Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79
   Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d
   Metsch LR, 2013, JAMA-J AM MED ASSOC, V310, P1701, DOI 10.1001/jama.2013.280034
   Myers JE, 2013, AIDS, V27, P1687, DOI 10.1097/QAD.0b013e32835fd7a0
   Obermeyer CM, 2007, AM J PUBLIC HEALTH, V97, P1762, DOI 10.2105/AJPH.2006.096263
   Padian NS, 2011, LANCET, V378, P269, DOI 10.1016/S0140-6736(11)60877-5
   Pai NP, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001414
   Pinkerton SD, 2008, JAIDS-J ACQ IMM DEF, V47, P354, DOI 10.1097/QAI.0b013e318160d57e
   Mota RMS, 2011, JAIDS-J ACQ IMM DEF, V57, pS153, DOI 10.1097/QAI.0b013e31821e9c10
   Sharma A, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-109
   Sweat M, 2011, LANCET INFECT DIS, V11, P525, DOI 10.1016/S1473-3099(11)70060-3
   Terto Jr V., 1997, THESIS DOUTORADO
   Tun W, 2008, SEX TRANSM INFECT, V84, P455, DOI 10.1136/sti.2008.031336
   United Kingdom Department of Health, 2013, RED TAP CHALL REM UN
   US Food and Drug Administration (USFDA), 2012, ORAQUICK HOME HIV TE
   Walensky RP, 2006, ANN INTERN MED, V145, P459, DOI 10.7326/0003-4819-145-6-200609190-00010
   Weinhardt LS, 1999, AM J PUBLIC HEALTH, V89, P1397, DOI 10.2105/AJPH.89.9.1397
NR 42
TC 5
Z9 6
U1 0
U2 6
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2014
VL 18
IS 3
BP 239
EP 244
DI 10.1016/j.bjid.2014.02.002
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA AL4XA
UT WOS:000339136900001
PM 24704388
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Cunha, CB
   De Boni, RB
   Guimaraes, MRC
   Yanavich, C
   Veloso, VG
   Moreira, RI
   Hoagland, B
   Grinsztejn, B
   Friedman, RK
AF Cunha, Cynthia Braga
   De Boni, Raquel Brandini
   Cotrim Guimaraes, Maria Regina
   Yanavich, Carolyn
   Veloso, Valdilea Goncalves
   Moreira, Ronaldo Ismerio
   Hoagland, Brenda
   Grinsztejn, Beatriz
   Friedman, Ruth Khalili
TI Unprotected sex among men who have sex with men living with HIV in
   Brazil: a cross-sectional study in Rio de Janeiro
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Men who have sex with men; HIV/AIDS; Unprotected anal intercourse; Low
   and middle income countries
ID ACTIVE ANTIRETROVIRAL THERAPY; ANAL INTERCOURSE; RISK BEHAVIOR; BISEXUAL
   MEN; GAY MEN; INTERNALIZED HOMOPHOBIA; UNITED-STATES; ALCOHOL-USE;
   INFECTION; PARTNERS
AB Background: Many countries are facing concentrated HIV epidemics among vulnerable populations, including men who have sex with men (MSM). Unprotected anal intercourse (UAI) is the main HIV transmission route among them and its understanding in the different cultures and how it relates to HIV transmission, re-infection and development of HIV antiretroviral resistance has important public health implications. Data on UAI among Brazilian MSM are scarce. This study aims to evaluate the prevalence and associated factors of UAI among HIV-infected MSM who had sex with seronegative or male partners with an unknown serostatus.
   Method: A cross-sectional study nested in a cohort was conducted in Rio de Janeiro, Brazil. The one hundred and fifty five MSM included in the study answered an ACASI interview and provided biological samples. Generalized linear models were used to identify variables associated with UAI.
   Results: Overall, UAI with an HIV-negative or unknown serostatus male partner was reported by 40.6% (63/155) of MSM. Lifetime sexual abuse or domestic violence was reported by 35.9%, being more frequent among MSM who reported UAI compared to those who did not (P = 0.001). Use of stimulants before sex was reported by 20% of the MSM, being slightly higher among those who reported UAI (27.0% vs. 15.2%; P = 0.072). Commercial sex was frequent among all MSM (48.4%). After multivariate modeling, the report of sexual abuse or domestic violence (OR = 2.70; 95% CI: 1.08-7.01), commercial sex (OR = 2.28; 95% CI: 1.04-5.10), the number of male sexual partners (p = 0.039) and exclusively receptive anal intercourse (OR = 0.21; 95% CI: 0.06-0.75) remained associated with UAI. CD4 levels, HIV viral load and antiretroviral therapy were not associated with UAI.
   Conclusion: The UAI prevalence found with negative or unknown HIV status partners points out that other interventions are needed as additional prevention tools to vulnerable MSM. The main factors associated with UAI were a lifetime history of violence, commercial sex and the number of male sexual partners. This clustering of different behavioral, health and social problems in this population reinforce the need of a comprehensive approach on treating and preventing HIV among MSM.
C1 [Cunha, Cynthia Braga; De Boni, Raquel Brandini; Cotrim Guimaraes, Maria Regina; Yanavich, Carolyn; Veloso, Valdilea Goncalves; Moreira, Ronaldo Ismerio; Hoagland, Brenda; Grinsztejn, Beatriz; Friedman, Ruth Khalili] Fundacao Oswaldo Cruz Inst Pesquisa Clin Evandro, Lab Pesquisa Clin DST AIDS, BR-21040900 Rio De Janeiro, Brazil.
RP De Boni, RB (corresponding author), Fundacao Oswaldo Cruz Inst Pesquisa Clin Evandro, Lab Pesquisa Clin DST AIDS, Ave Brasil 4365 Manguinhos, BR-21040900 Rio De Janeiro, Brazil.
EM raqueldeboni@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997
CR Ackers ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034972
   Bajunirwe F, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-430
   Bauermeister JA, 2009, AIDS EDUC PREV, V21, P156, DOI 10.1521/aeap.2009.21.2.156
   Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6
   Brahmam GNV, 2008, AIDS, V22, pS45, DOI 10.1097/01.aids.0000343763.54831.15
   Bruce D, 2013, AIDS CARE, V25, P559, DOI 10.1080/09540121.2012.720363
   Carey JW, 2009, AIDS BEHAV, V13, P1084, DOI 10.1007/s10461-008-9403-3
   Chow EPF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048025
   Clark J, 2013, AIDS BEHAV, V17, P1313, DOI 10.1007/s10461-012-0210-5
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Crepaz N, 2004, JAMA-J AM MED ASSOC, V292, P224, DOI 10.1001/jama.292.2.224
   Crepaz N, 2009, AIDS, V23, P1617, DOI 10.1097/QAD.0b013e32832effae
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Deiss RG, 2013, PROBLEM DRINKING IS
   Di Pietro N, 2006, ACRIA UPDATE, V15, P12
   Durham MD, 2013, JAIDS-J ACQ IMM DEF, V63, P372, DOI 10.1097/QAI.0b013e31828c20d8
   Elford J, 2006, CURR OPIN INFECT DIS, V19, P26, DOI 10.1097/01.qco.0000199018.50451.e1
   Finneran C, 2013, TRAUMA VIOLENCE ABUS, V14, P168, DOI 10.1177/1524838012470034
   Finneran C, 2012, WEST J EMERG MED, V13, P260, DOI 10.5811/westjem.2012.3.11779
   Fritz K, 2010, LANCET, V376, P398, DOI 10.1016/S0140-6736(10)60884-7
   Frost DM, 2008, CULT HEALTH SEX, V10, P513, DOI 10.1080/13691050801905631
   George C, 2006, JAIDS-J ACQ IMM DEF, V42, P207, DOI 10.1097/01.qai.0000200664.24968.4c
   Golin C, 2009, AIDS BEHAV, V13, P1129, DOI 10.1007/s10461-009-9613-3
   Gomez GB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001323
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Greenland S, 1989, AM J PUBLIC HEALTH, V79, P240
   HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198
   Hosmer DW, 1997, STAT MED, V16, P965
   Houston E, 2007, J URBAN HEALTH, V84, P681, DOI 10.1007/s11524-007-9188-0
   Jansen IAV, 2011, AIDS, V25, P493, DOI 10.1097/QAD.0b013e328342fbe9
   Jin FY, 2009, AIDS, V23, P243, DOI 10.1097/QAD.0b013e32831fb51a
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Kippax S, 1997, AIDS, V11, P191, DOI 10.1097/00002030-199702000-00009
   Koblin BA, 2006, AIDS, V20, P731, DOI 10.1097/01.aids.0000216374.61442.55
   Mayer K, 2012, 19 INT AIDSCONFERENC
   McCullagh P, 1989, GEN LINEAR MODELS
   McDaid LM, 2012, SEX TRANSM DIS
   McFarland W, 2004, AIDS EDUC PREV, V16, P13, DOI 10.1521/aeap.16.1.13.27723
   Mimiaga M, 2012, J ACQ IMMUN DEF SYND, V51, P340
   Ministerio da Saude Brasil, 2012, B EP AIDS DST
   Moatti J, 2003, AIDS, V33, P69
   Nagaraj S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-181
   Newcomb ME, 2011, ARCH SEX BEHAV, V40, P189, DOI 10.1007/s10508-009-9573-8
   Pantalone David W, 2014, J Assoc Nurses AIDS Care, V25, pS15, DOI 10.1016/j.jana.2013.04.003
   Parsons JT, 2005, AIDS, V19, pS13, DOI 10.1097/01.aids.0000167348.15750.9a
   Phillips AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055312
   Rocha GM, 2013, AIDS BEHAV, V17, P1288, DOI 10.1007/s10461-012-0398-4
   Rosenberg ES, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-189
   Ross MW, 2013, INT J STD AIDS, V24, P409, DOI 10.1177/0956462412472793
   Sander PM, 2013, AIDS, V27, P815, DOI 10.1097/QAD.0b013e32835cff4b
   Schackman BR, 2012, CURR OPIN HIV AIDS, V7, P587, DOI 10.1097/COH.0b013e3283582c8b
   Seng R, 2011, AIDS, V25, P977, DOI 10.1097/QAD.0b013e328345ef12
   Siddiqui AUR, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000154
   Singer M, 2003, MED ANTHROPOL Q, V17, P423, DOI 10.1525/maq.2003.17.4.423
   Stoner SA, 2007, AIDS BEHAV, V11, P227, DOI 10.1007/s10461-006-9137-z
   Van de Ven P, 2005, AIDS, V19, P179
   Vosburgh HW, 2012, AIDS BEHAV, V16, P1394, DOI 10.1007/s10461-011-0131-8
   Wagner G, 1996, J HOMOSEXUAL, V32, P91
   Williamson IR, 2000, HEALTH EDUC RES, V15, P97, DOI 10.1093/her/15.1.97
   Xia Q, 2006, AIDS, V20, P2081, DOI 10.1097/01.aids.0000247566.57762.b2
   Zekan S, 2008, AIDS BEHAV, V12, pS86, DOI 10.1007/s10461-008-9420-2
   Zhang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058440
NR 62
TC 11
Z9 12
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD APR 17
PY 2014
VL 14
AR 379
DI 10.1186/1471-2458-14-379
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG6AW
UT WOS:000335501800001
PM 24742202
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Paula, AA
   Schechter, M
   Tuboi, SH
   Faulhaber, JC
   Luz, PM
   Veloso, VG
   Moreira, RI
   Grinsztejn, B
   Harrison, LH
   Pacheco, AG
AF Paula, Adelzon A.
   Schechter, Mauro
   Tuboi, Suely H.
   Faulhaber, Jose Claudio
   Luz, Paula M.
   Veloso, Valdilea G.
   Moreira, Ronaldo I.
   Grinsztejn, Beatriz
   Harrison, Lee H.
   Pacheco, Antonio G.
TI Continuous Increase of Cardiovascular Diseases, Diabetes, and Non-HIV
   Related Cancers as Causes of Death in HIV-Infected Individuals in
   Brazil: An Analysis of Nationwide Data
SO PLOS ONE
LA English
DT Article
ID RIO-DE-JANEIRO; HIGH-INCOME COUNTRIES; ANTIRETROVIRAL THERAPY;
   HIV-1-INFECTED PATIENTS; HAART ERA; MORTALITY; AIDS; TUBERCULOSIS;
   TRENDS
AB Introduction: After antiretroviral therapy (ART) became available, there was a decline in the number of deaths in persons infected with HIV. Thereafter, there was a decrease in the proportion of deaths attributed to opportunistic infections and an increase in the proportion of deaths attributed to chronic comorbidities. Herein we extend previous observations from a nationwide survey on temporal trends in causes of death in HIV-infected patients in Brazil.
   Methods: We describe temporal trends in causes of death among adults who had HIV/AIDS listed in the death certificate to those who did not. All death certificates issued in Brazil from 1999 to 2011 and listed in the national mortality database were included. Generalized linear mixed-effects logistic models were used to study temporal trends in proportions.
   Results: In the HIV-infected population, there was an annual adjusted average increase of 6.0%, 12.0%, 4.0% and 4.1% for cancer, external causes, cardiovascular diseases (CVD) and diabetes mellitus (DM), respectively, compared to 3.0%, 4.0%, 1.0% and 3.9%, in the non-HIV group. For tuberculosis (TB), there was an adjusted average increase of 0.3%/year and a decrease of 3.0%/year in the HIV and the non-HIV groups, respectively. Compared to 1999, the odds ratio (OR) for cancer, external causes, CVD, DM, or TB in the HIV group were, respectively, 2.31, 4.17, 1.76, 2.27 and 1.02, while for the non-HIV group, the corresponding OR were 1.31, 1.63, 1.14, 1.62 and 0.67. Interactions between year as a continuous or categorical variable and HIV were significant (p<0.001) for all conditions, except for DM when year was considered as a continuous variable (p = 0.76).
   Conclusions: Non HIV-related co-morbidities continue to increase more rapidly as causes of death among HIV-infected individuals than in those without HIV infection, highlighting the need for targeting prevention measures and surveillance for chronic diseases among those patients.
C1 [Paula, Adelzon A.; Pacheco, Antonio G.] Fundacao Oswaldo Cruz, Programa Comp, Rio De Janeiro, Brazil.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, Projeto Praca Onze, Hosp Escola Sao Francisco de Assis, Rio De Janeiro, Brazil.
   [Tuboi, Suely H.] GlaxoSmithKline, Rio De Janeiro, Brazil.
   [Faulhaber, Jose Claudio] Univ Estado Rio de Janeiro, Inst Matemat & Estat, BR-20550011 Rio De Janeiro, Brazil.
   [Luz, Paula M.; Veloso, Valdilea G.; Moreira, Ronaldo I.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Harrison, Lee H.] Univ Pittsburgh, Grad Sch Publ Hlth, Infect Dis Epidemiol Res Unit, Pittsburgh, PA USA.
   [Harrison, Lee H.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
RP Pacheco, AG (corresponding author), Fundacao Oswaldo Cruz, Programa Comp, Rio De Janeiro, Brazil.
EM apacheco@fiocruz.br
RI Pacheco, Antonio Guilherme/E-6378-2013; Schechter, Mauro/AAG-7445-2020
OI Pacheco, Antonio Guilherme/0000-0003-3095-1774; Luz,
   Paula/0000-0001-9746-719X
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro/FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico/CNPqNational Council for Scientific and Technological
   Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior/CapesCAPES; GlaxoSmithKline Group
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado do
   Rio de Janeiro/FAPERJ (www.faperj.br); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico/CNPq (www.cnpq.br) and
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/Capes
   (www.capes.gov.br). GlaxoSmithKline Group provided support in the form
   of a salary for author SHT (for part of the duration of this study), but
   did not have any additional role in the study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Braitstein P, 2006, LANCET, V367, P817
   Brinkhof MWG, 2007, CLIN INFECT DIS, V45, P1518, DOI 10.1086/522986
   Cortes CP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074057
   Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16
   Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7
   Duprez DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044454
   Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Justice Amy C, 2010, Curr HIV/AIDS Rep, V7, P69, DOI 10.1007/s11904-010-0041-9
   Rezende ELLF, 2010, BRAZ J INFECT DIS, V14, P558, DOI [10.1590/S1413-86702010000600003, 10.1016/S1413-8670(10)70112-4]
   Lee SH, 2013, J KOREAN MED SCI, V28, P67, DOI 10.3346/jkms.2013.28.1.67
   Lewden C, 2005, INT J EPIDEMIOL, V34, P121, DOI 10.1093/ije/dyh307
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Pacheco AG, 2011, AIDS RES HUM RETROV, V27, P25, DOI 10.1089/aid.2010.0089
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003132
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Paula AA, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-32
   Petoumenos K, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17426
   Shiels MS, 2011, J NATL CANCER I, V103, P753, DOI 10.1093/jnci/djr076
   Stewart A, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/390406
   Wolff FH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010494
   Yang CH, 2008, HIV MED, V9, P535, DOI 10.1111/j.1468-1293.2008.00600.x
NR 24
TC 25
Z9 25
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2014
VL 9
IS 4
AR e94636
DI 10.1371/journal.pone.0094636
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI3CI
UT WOS:000336736200113
PM 24728320
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU Santiago, P
   Grinsztejn, B
   Friedman, RK
   Cunha, CB
   Coelho, LE
   Luz, PM
   de Oliveira, AV
   Moreira, RI
   Cardoso, SW
   Veloso, VG
   Suassuna, JHR
AF Santiago, Patricia
   Grinsztejn, Beatriz
   Friedman, Ruth Khalili
   Cunha, Cynthia B.
   Coelho, Lara Esteves
   Luz, Paula Mendes
   de Oliveira, Albanita Viana
   Moreira, Ronaldo Ismerio
   Cardoso, Sandra W.
   Veloso, Valdilea G.
   Rocco Suassuna, Jose H.
TI Screening for Decreased Glomerular Filtration Rate and Associated Risk
   Factors in a Cohort of HIV-Infected Patients in a Middle-Income Country
SO PLOS ONE
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; CHRONIC-RENAL-FAILURE; ANTIRETROVIRAL THERAPY;
   CARDIOVASCULAR MORTALITY; ESTIMATING EQUATIONS; ALL-CAUSE; PREVALENCE;
   PROGRESSION; POPULATION; ADULTS
AB With the introduction of combined active antiretroviral therapy and the improved survival of HIV-infected patients, degenerative diseases and drug toxicity have emerged as long-term concerns. We studied the prevalence of decreased glomerular filtration rate (GFR) and associated risk factors in a cohort of HIV-infected patients from a middle-income country. Our cross-sectional study included all adult patients who attended an urban outpatient clinic in 2008. GFR was estimated using the CKD-EPI equation. The prevalence ratio (PR) of decreased GFR (defined as < 60 mL/min/1.73 m(2)) was estimated using generalizing linear models assuming a Poisson distribution. We analyzed data from 1,970 patients, of which 82.9% had been exposed to ART. A total of 249 patients (12.6%) had a GFR between 60 and 89 mL/min/1.73 m(2), 3.1% had a GFR between 30 and 59, 0.3% had a GFR between 15 and 29, and 0.4% had a GFR < 15. Decreased GFR was found in only 74 patients (3.8%). In the multivariate regression model, the factors that were independently associated with a GFR below 60 mL/min/1.73 m(2) were as follows: age >= 50 years (PR=3.4; 95% CI: 1.7-6.8), diabetes (PR=2.0; 95% CI: 1.2-3.4), hypertension (PR=2.0; 95% CI: 1.3-3.2), current CD4+ cell count < 350 cells/mm3 (PR=2.1; 95% CI: 1.3-3.3), past exposure to tenofovir (PR=4.7; 95% CI: 2.3-9.4) and past exposure to indinavir (PR=1.7; 95% CI: 1.0-2.8). As in high-income countries, CKD was the predominant form of kidney involvement among HIV-infected individuals in our setting. The risk factors associated with decreased glomerular filtration were broad and included virus-related factors as well as degenerative and nephrotoxic factors. Despite the potential for nephrotoxicity associated with some antiretroviral drugs, in the short-term, advanced chronic renal disease remains very rare.
C1 [Santiago, Patricia; Grinsztejn, Beatriz; Friedman, Ruth Khalili; Cunha, Cynthia B.; Coelho, Lara Esteves; Luz, Paula Mendes; Moreira, Ronaldo Ismerio; Cardoso, Sandra W.; Veloso, Valdilea G.] Fundaco Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, STD AIDS Clin Res Lab, Rio De Janeiro, Brazil.
   [Santiago, Patricia; Rocco Suassuna, Jose H.] Univ Estado Rio de Janeiro, Fac Ciencias Med, Hosp Univ Pedro Ernesto, Clin & Acad Unit Nephrol, BR-20550011 Rio De Janeiro, Brazil.
   [de Oliveira, Albanita Viana] Univ Estado Rio de Janeiro, Fac Ciencias Med, Dept Pathol, BR-20550011 Rio De Janeiro, Brazil.
RP Suassuna, JHR (corresponding author), Univ Estado Rio de Janeiro, Fac Ciencias Med, Hosp Univ Pedro Ernesto, Clin & Acad Unit Nephrol, BR-20550011 Rio De Janeiro, Brazil.
EM jsuassuna@alternex.com.br
RI Suassuna, Jose H R/N-5074-2014; Cardoso, Sandra W/D-7965-2015
OI Suassuna, Jose H R/0000-0002-4720-5391; Cardoso, Sandra
   W/0000-0001-5230-0003; Luz, Paula/0000-0001-9746-719X
CR Alves TP, 2010, CLIN J AM SOC NEPHRO, V5, P2269, DOI 10.2215/CJN.00520110
   Astor BC, 2008, AM J EPIDEMIOL, V167, P1226, DOI 10.1093/aje/kwn033
   Atta MG, 2006, NEPHROL DIAL TRANSPL, V21, P2809, DOI 10.1093/ndt/gfl337
   Atta MG, 2008, SEMIN NEPHROL, V28, P563, DOI 10.1016/j.semnephrol.2008.08.009
   Campbell LJ, 2009, HIV MED, V10, P329, DOI 10.1111/j.1468-1293.2008.00691.x
   Choi AI, 2007, J AM SOC NEPHROL, V18, P2968, DOI 10.1681/ASN.2007040402
   Colson AW, 2010, ACTA CLIN BELG, V65, P392, DOI 10.1179/acb.2010.65.6.004
   Cooper RD, 2010, CLIN INFECT DIS, V51, P496, DOI 10.1086/655681
   Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038
   Crum-Cianflone N, 2010, AIDS PATIENT CARE ST, V24, P353, DOI 10.1089/apc.2009.0326
   DAVIES DF, 1950, J CLIN INVEST, V29, P496, DOI 10.1172/JCI102286
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Deti EK, 2010, HIV MED, V11, P308, DOI 10.1111/j.1468-1293.2009.00780.x
   Di Angelantonio E, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4986
   Earley A, 2012, ANN INTERN MED, V156, P785, DOI [10.7326/0003-4819-156-11-201203200-00391, 10.7326/0003-4819-156-6-201203200-00391]
   Effros RB, 2008, CLIN INFECT DIS, V47, P542, DOI 10.1086/590150
   Fernando SK, 2008, AM J MED SCI, V335, P89, DOI 10.1097/MAJ.0b013e31812e6b34
   Flandre P, 2011, CLIN J AM SOC NEPHRO
   Gardner LI, 2003, JAIDS-J ACQ IMM DEF, V32, P203, DOI 10.1097/00126334-200302010-00013
   Giles PD, 2007, BMJ-BRIT MED J, V334, P1198, DOI 10.1136/bmj.39226.400694.80
   Glassock RJ, 2008, CLIN J AM SOC NEPHRO, V3, P1563, DOI 10.2215/CJN.00960208
   Guaraldi G, 2011, CLIN INFECT DIS, V53, P1120, DOI 10.1093/cid/cir627
   Gupta SK, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-31
   Gupta SK, 2005, CLIN INFECT DIS, V40, P1559, DOI 10.1086/430257
   Hallan SI, 2006, BMJ-BRIT MED J, V333, P1047, DOI 10.1136/bmj.39001.657755.BE
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Holmberg SD, 2008, SCI ERRORS CONTROVER, P1
   Ibrahim F, 2012, AM J KIDNEY DIS, V60, P539, DOI 10.1053/j.ajkd.2012.03.006
   Inker LA, 2012, JAIDS-J ACQ IMM DEF, V61, P302, DOI 10.1097/QAI.0b013e31826a6c4f
   Jaar BG, 2008, CLIN J AM SOC NEPHRO, V3, P601, DOI 10.2215/CJN.02540607
   Kalyesubula R, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/562790
   Lucas GM, 2008, J INFECT DIS, V197, P1548, DOI 10.1086/587994
   Lucas GM, 2010, JAIDS-J ACQ IMM DEF, V55, P491, DOI 10.1097/QAI.0b013e3181e8d5a8
   Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5
   Matsushita K, 2010, AM J KIDNEY DIS, V55, P648, DOI 10.1053/j.ajkd.2009.12.016
   Medapalli RK, 2012, JAIDS-J ACQ IMM DEF, V60, P393, DOI 10.1097/QAI.0b013e31825b70d9
   Mocroft A, 2007, AIDS, V21, P1119, DOI 10.1097/QAD.0b013e3280f774ee
   Mocroft A, 2010, AIDS, V24, P1667, DOI 10.1097/QAD.0b013e328339fe53
   Mulenga LB, 2008, AIDS, V22, P1821, DOI 10.1097/QAD.0b013e328307a051
   Myers Jeffrey D, 2009, JAAPA, V22, P20
   O'Hare AM, 2007, J AM SOC NEPHROL, V18, P2758, DOI 10.1681/ASN.2007040422
   Overton ET, 2009, HIV MED, V10, P343, DOI 10.1111/j.1468-1293.2009.00693.x
   Phair J, 2011, CURR OPIN HIV AIDS, V6, P285, DOI 10.1097/COH.0b013e3283476bc3
   Ramos AN, 2011, AIDS PATIENT CARE ST, V25, P713, DOI 10.1089/apc.2011.0044
   Reid A, 2008, CLIN INFECT DIS, V46, P1271, DOI 10.1086/533468
   Roe J, 2008, CLIN INFECT DIS, V47, P242, DOI 10.1086/589296
   Ryom L, 2013, J INFECT DIS, V207, P1359, DOI 10.1093/infdis/jit043
   Scherzer R, 2012, AIDS, V26, P867, DOI 10.1097/QAD.0b013e328351f68f
   Scialla JJ, 2007, AIDS, V21, P263, DOI 10.1097/QAD.0b013e3280119592
   Sorli ML, 2008, J INT AIDS SOC, V11, pP130
   Szczech LA, 2004, CLIN INFECT DIS, V39, P1199, DOI 10.1086/424013
   US Renal Data System, 2011, USRDS 2011 ANN DAT R
   Van Biesen W, 2007, EUR HEART J, V28, P478, DOI 10.1093/eurheartj/ehl455
   Wever K, 2010, J ACQ IMMUN DEF SYND, V00, P1
   White SL, 2010, AM J KIDNEY DIS, V55, P660, DOI 10.1053/j.ajkd.2009.12.011
   WHO' UNAIDS and UNICEF Global HIV/AIDS response, WHO UNAIDS UNIEF GLO
   Wyatt CM, 2007, AIDS, V21, P2101, DOI 10.1097/QAD.0b013e3282ef1bb4
   Wyatt CM, 2006, AIDS, V20, P561, DOI 10.1097/01.aids.0000210610.52836.07
   Yahalom G, 2013, EUROPEAN J PREVENTIV
NR 59
TC 16
Z9 16
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 3
PY 2014
VL 9
IS 4
AR e93748
DI 10.1371/journal.pone.0093748
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE6LR
UT WOS:000334105000099
PM 24699873
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Luz, PM
   Grinsztejn, B
   Velasque, L
   Pacheco, AG
   Veloso, VG
   Moore, RD
   Struchiner, CJ
AF Luz, Paula M.
   Grinsztejn, Beatriz
   Velasque, Luciane
   Pacheco, Antonio G.
   Veloso, Valdilea G.
   Moore, Richard D.
   Struchiner, Claudio J.
TI Long-Term CD4+Cell Count in Response to Combination Antiretroviral
   Therapy
SO PLOS ONE
LA English
DT Article
ID T-CELL COUNTS; CLINICAL-RESPONSES; INFECTED PATIENTS; CD4 COUNT;
   RECOVERY; AGE; IMPACT; AIDS; INDIVIDUALS; MORTALITY
AB Objective: There is a continuous debate on how to adequately evaluate long-term CD4+ cell count in response to combination antiretroviral therapy (ART) among human immunodeficiency virus (HIV)-infected individuals. Our study evaluated the long-term CD4+ cell count response (up to ten years) after initiation of ART and described the differences in the CD4+ cell count response stratified by pretreatment CD4+ cell count, and other socio-demographic, behavioral, and clinical factors.
   Methods: The study population included patients starting ART in the clinical cohorts of Rio de Janeiro, Brazil, and Baltimore, United States. Inverse probability of censoring weighting was used to estimate mean annual CD4+ cell counts while adjusting for choice of initial ART regimen, ART discontinuation and losses-to-follow-up.
   Results: From 1997 to 2011, 3116 individuals started ART; preferred initial regimen was NNRTI-based (63%). The median follow-up time was 5 years, 10% of the individuals had nine or more years of follow-up. Observed CD4+ cell counts increased throughout the ten years of follow-up. Weighted results, in contrast, increased up to year four and plateaued thereafter with 50% of the population reaching CD4+ cell counts of 449/mu L or more. Out of all stratification variables considered, only individuals with pre-treatment CD4+ cell counts >= 350/mu L showed increasing CD4+ cell counts over time with 76% surpassing the CD4+ cell count >500/mu L threshold at year ten.
   Conclusion: The present study corroborates the growing body of knowledge advocating early start of ART by showing that only patients who start ART early fully recover to normal CD4+ cell counts.
C1 [Luz, Paula M.; Grinsztejn, Beatriz; Velasque, Luciane; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil.
   [Moore, Richard D.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
   [Pacheco, Antonio G.; Struchiner, Claudio J.] Fundacao Oswaldo Cruz, Programa Computacao Cient, Rio De Janeiro, Brazil.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM paula.luz@ipec.fiocruz.br
RI Pacheco, Antonio Guilherme/E-6378-2013; Struchiner, Claudio
   J/M-9360-2013
OI Pacheco, Antonio Guilherme/0000-0003-3095-1774; Struchiner, Claudio
   J/0000-0003-2114-847X; Luz, Paula/0000-0001-9746-719X
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01 DA116092,
   P30 AI094189]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Drug Abuse (NIDA) [R01DA011602,
   R01DA011602, R01DA011602, R01DA011602, R01DA011602, R01DA011602,
   R01DA011602, U01DA036935, U01DA036935, R01DA011602, R01DA011602,
   R01DA011602, U01DA036935, R01DA011602, R01DA011602, R01DA011602,
   R01DA011602, U01DA036935, R01DA011602, R01DA011602, U01DA036935] Funding
   Source: NIH RePORTER
FX PML, BG, AGP, and CJS acknowledge funding from the National Council of
   Technological and Scientific Development (CNPq) and the Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ). RDM acknowledges funding
   from NIH R01 DA116092, P30 AI094189. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Achhra AC, 2011, CURR OPIN HIV AIDS, V6, P258, DOI 10.1097/COH.0b013e3283476c72
   Baker JV, 2008, JAIDS-J ACQ IMM DEF, V48, P541, DOI 10.1097/QAI.0b013e31817bebb3
   Bastard M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-27
   Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164
   Cuzin L, 2007, CLIN INFECT DIS, V45, P654, DOI 10.1086/520652
   Gandhi RT, 2007, CLIN INFECT DIS, V44, P438, DOI 10.1086/510682
   Grabar S, 2004, AIDS, V18, P2029, DOI 10.1097/00002030-200410210-00007
   Gras L, 2007, JAIDS-J ACQ IMM DEF, V45, P183, DOI 10.1097/QAI.0b013e31804d685b
   Haynes L, 2009, CURR OPIN IMMUNOL, V21, P414, DOI 10.1016/j.coi.2009.05.009
   Hsieh MM, 2007, ANN INTERN MED, V146, P486, DOI 10.7326/0003-4819-146-7-200704030-00004
   Kaufmann GR, 2005, CLIN INFECT DIS, V41, P361, DOI 10.1086/431484
   Kolber MA, 2007, HIV MED, V8, P401, DOI 10.1111/j.1468-1293.2007.00479.x
   Le Moing V, 2007, HIV MED, V8, P156, DOI 10.1111/j.1468-1293.2007.00446.x
   Lok JJ, 2010, AIDS, V24, P1867, DOI 10.1097/QAD.0b013e32833adbcf
   Malta M, 2008, ADDICTION, V103, P1242, DOI 10.1111/j.1360-0443.2008.02269.x
   Maman D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031078
   Maskew M, 2013, J WOMENS HEALTH, V22, P113, DOI 10.1089/jwh.2012.3585
   McGovern BH, 2007, CLIN INFECT DIS, V44, P431, DOI 10.1086/509580
   Ministerio da Saude, 2014, GUID ANT TREATM
   Mocroft A, 2007, LANCET, V370, P407, DOI 10.1016/S0140-6736(07)60948-9
   Monforte AD, 2005, ARCH INTERN MED, V165, P416
   Moore RD, 1998, J ACQ IMMUN DEF SYND, V17, pS38, DOI 10.1097/00042560-199801001-00011
   Moore RD, 2007, CLIN INFECT DIS, V44, P441, DOI 10.1086/510746
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Nash D, 2008, AIDS, V22, P2291, DOI 10.1097/QAD.0b013e3283121ca9
   NIH, 2014, CLIN GUID PORT
   O'Connor JL, 2013, J INFECT DIS, V208, P40, DOI 10.1093/infdis/jis731
   Potter M, 2010, AIDS, V24, P1857, DOI 10.1097/QAD.0b013e32833adbb5
   Ray M, 2010, AIDS, V24, P123, DOI 10.1097/QAD.0b013e3283324283
   Tumbarello M, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-46
   Tumbarello M, 2003, AIDS, V17, P128, DOI 10.1097/00002030-200301030-00020
   Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678
   Zucchetto A, 2010, CLIN INFECT DIS, V51, P1099, DOI 10.1086/656629
NR 33
TC 11
Z9 11
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2014
VL 9
IS 4
AR e93039
DI 10.1371/journal.pone.0093039
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE6LC
UT WOS:000334103000036
PM 24695533
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Lippman, SA
   Perisse, ARS
   Veloso, VG
   Sullivan, PS
   Buchbinder, S
   Sineath, RC
   Grinsztejn, B
AF Lippman, Sheri A.
   Perisse, Andre R. S.
   Veloso, Valdilea G.
   Sullivan, Patrick S.
   Buchbinder, Susan
   Sineath, R. Craig
   Grinsztejn, Beatriz
TI Acceptability of self-conducted home-based HIV testing among men who
   have sex with men in Brazil: data from an on-line survey
SO CADERNOS DE SAUDE PUBLICA
LA English
DT Article
ID UNITED-STATES; ANTIRETROVIRAL THERAPY; INTERNET SAMPLE; RISK; INFECTION;
   CARE; MSM; TRANSMISSION; METAANALYSIS; BARRIERS
AB The Brazilian HIV/AIDS epidemic is concentrated among men who have sex with men (MSM), however HIV testing rates among MSM are not commensurate with their risk. Strategies to expand early diagnosis may include use of self-conducted home-based testing kits, which are now available for purchase in the US. In April 2011 we conducted a survey with Brazilian MSM using Facebook to assess HIV testing preferences and acceptability of home-based testing. Among 356 previously tested, HIV-negative MSM, 47% reported a preference for home-based testing, 27% preferred clinic-based testing, and 26% had no preference. Less frequent testers and those who had considered testing but failed to test were more likely to prefer home-based testing. Close to 90% reported that they would use self-test kits; 62% and 54% said they would use home-based testing to make choices about unprotected sex with regular and new partners, respectively. Concerns included difficulty to understand the tests (32%) and receiving results alone (23%). Overall, home-based testing may appeal to MSM and result in increased testing frequency. Research on feasibility and utilization of self-tests in practice is needed.
   Male Homosexuality; HIV; Serologic Tests
C1 [Lippman, Sheri A.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94105 USA.
   [Perisse, Andre R. S.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, Brazil.
   [Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Sullivan, Patrick S.; Sineath, R. Craig] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Buchbinder, Susan] San Francisco Dept Publ Hlth, San Francisco, CA USA.
RP Lippman, SA (corresponding author), Univ Calif San Francisco, Ctr AIDS Prevent Studies, 50 Beale St,Suite 1300, San Francisco, CA 94105 USA.
EM sheri.lippman@ucsf.edu
OI Lippman, Sheri/0000-0003-3152-9372
FU IPEC institutional development grant program (Projeto de Apoio ao
   Desenvolvimento Institucional do IPEC-Fiocruz) [IPEC-001-LIV-02];
   FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E26/102.244/2009]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [309524/2012-1];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409, P30AI050409, P30AI050409, P30AI050409, P30AI050409,
   P30AI050409] Funding Source: NIH RePORTER
FX This work was facilitated by the Center for AIDS Research at Emory
   University (P30 AI050409). The IPEC institutional development grant
   program (IPEC-001-LIV-02 Projeto de Apoio ao Desenvolvimento
   Institucional do IPEC-Fiocruz) also provided funding. B. Grinsztejn
   received support from FAPERJ (process n. E26/102.244/2009) and CNPq
   (process no 309524/2012-1).
CR Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Bowen A, 2004, AIDS BEHAV, V8, P311, DOI 10.1023/B:AIBE.0000044078.43476.1f
   Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Carballo-Dieguez A, 2012, AIDS BEHAV, V16, P1753, DOI 10.1007/s10461-012-0274-2
   Carballo-Dieguez A, 2012, J SEX RES, V49, P379, DOI 10.1080/00224499.2011.647117
   Coates TJ, 2000, LANCET, V356, P103, DOI 10.1016/S0140-6736(00)02446-6
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Colfax GN, 2002, AIDS, V16, P1529, DOI 10.1097/00002030-200207260-00010
   Colfax GN, 2002, AIDS CARE, V14, P675, DOI 10.1080/0954012021000005533a
   Departamento de DST AIDS e Hepatites virais. Ministerio da Saude, 2007, PLANO NACIONAL DE EN
   Departamento de DST AIDS e Hepatites Virais Secretaria de Vigilancia em Saude Ministerio da Saude, 2012, BOLETIM EPIDEMIOLOGI
   Department of STD AIDS and Viral Hepatitis Health Surveillance Secretariat Brazilian Ministry of Health, 2012, PROGRESS REPORT ON T
   Elford J, 2004, JAIDS-J ACQ IMM DEF, V35, P421, DOI 10.1097/00126334-200404010-00012
   Evans AR, 2007, SEX TRANSM INFECT, V83, P200, DOI 10.1136/sti.2006.023283
   França Junior Ivan, 2008, Rev. Saúde Pública, V42, P84, DOI [10.1590/S0034-89102008000800011, 10.1590/s0034-89102008000800011]
   Grangeiro A, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-99
   Grangeiro A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014585
   Holigrave DR, 2007, JAIDS-J ACQ IMM DEF, V44, P360, DOI 10.1097/QAI.0b013e31802ea4dd
   Instituto Brasileiro de Geografia e Estatistica, 2013, ACESSO A INTERNET E
   Joint United Nations Program on HIV/AIDS, 2010, UNAIDS REPORT ON THE
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   MacKellar DA, 2011, SEX TRANSM DIS, V38, P419, DOI 10.1097/OLQ.0b013e31820369dd
   Malta M, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-317
   Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d
   Martins TA, 2013, AIDS CARE, V25, P606, DOI 10.1080/09540121.2012.726342
   McCoy SI, 2009, AIDS CARE, V21, P1313, DOI 10.1080/09540120902803174
   Mello MB, 2008, ASSESSMENT OF RISK F
   Oster Alexandra M., 2011, Morbidity and Mortality Weekly Report, V60, P694
   Pai NP, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001414
   Pinkerton SD, 2008, JAIDS-J ACQ IMM DEF, V47, P354, DOI 10.1097/QAI.0b013e318160d57e
   Raymond HF, 2010, AIDS BEHAV, V14, P218, DOI 10.1007/s10461-009-9521-6
   Rhodes SD, 2002, AIDS EDUC PREV, V14, P41, DOI 10.1521/aeap.14.1.41.24334
   Sharma Akshay, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P357, DOI 10.1177/1545109711404946
   Souza PRB, 2007, CLINICS, V62, P579, DOI 10.1590/S1807-59322007000500008
   Sweat M, 2011, LANCET INFECT DIS, V11, P525, DOI 10.1016/S1473-3099(11)70060-3
   Tobias C, 2007, AIDS PATIENT CARE ST, V21, pS3, DOI 10.1089/apc.2007.9992
   Weinhardt LS, 1999, AM J PUBLIC HEALTH, V89, P1397, DOI 10.2105/AJPH.89.9.1397
NR 38
TC 21
Z9 26
U1 0
U2 12
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
EI 1678-4464
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PD APR
PY 2014
VL 30
IS 4
BP 724
EP 734
DI 10.1590/0102-311X00008913
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI8FK
UT WOS:000337144300006
PM 24896048
OA DOAJ Gold, Green Accepted
DA 2020-11-24
ER

PT J
AU Melo, VH
   Guimaraes, MDC
   Rocha, GM
   Araujo, ACL
   Carmo, RA
   Grinsztejn, B
   Pilotto, JH
   Palefsky, JM
AF Melo, Victor Hugo
   Crosland Guimaraes, Mark Drew
   Rocha, Gustavo Machado
   Labanca Araujo, Angela Cristina
   Carmo, Ricardo Andrade
   Grinsztejn, Beatriz
   Pilotto, Jose Henrique
   Palefsky, Joel Michael
TI Prevalence and Risk Factors Associated With Anal Intraepithelial
   Neoplasia Among HIV-Positive Men in Brazil
SO JOURNAL OF LOWER GENITAL TRACT DISEASE
LA English
DT Article
DE anus neoplasms; anal intraepithelial neoplasia; sexual behavior; HIV
   infections
ID HUMAN-PAPILLOMAVIRUS INFECTION; ANTIRETROVIRAL THERAPY; HOMOSEXUAL-MEN;
   UNITED-STATES; CANCER; LESIONS; CYTOLOGY; SMOKING; SEX; EPIDEMIOLOGY
AB Objective This study aimed to assess the prevalence of, and associated factors with, anal intraepithelial neoplasia (AIN) among HIV-positive men evaluated at public health services in Brazil.
   Materials and Methods This is a multicenter cross-sectional study of HIV-positive male patients attending 6 public AIDS referral clinics in urban Brazil. Participants were interviewed for sociodemographic and behavioral characteristics. Anal swab specimens were collected for anal cytology and HPV DNA testing using L1 polymerase chain reaction. Univariate and multivariate analyses were performed to evaluate risk factors associated with the presence of low-grade squamous intraepithelial lesion (LSIL) and/or high-grade squamous intraepithelial lesion (HSIL).
   Results Anal swabs were collected from 343 participants. Prevalence of LSIL/HSIL was 24.8%. The majority (60.1%) reported sexual intercourse with both men and women in their lifetime. At least 36.7% had 1 or more oncogenic HPV types. Four variables were independently associated with the presence of LSIL/HSIL in multivariate analysis: history of sex with both men and women (odds ratio [OR] = 4.8) or men only (OR = 6.2) compared with those having sex with women only; current cigarette smoking (OR = 2.2); current CD4(+) level between 200 and 500 cells/mm(3) (OR = 2.9) or below 200 cells/mm(3) (OR = 3.8) compared with CD4(+) level above 500 cells/mm(3); and presence of oncogenic anal HPV infection (OR = 9.6).
   Conclusions We found a high prevalence of AIN among HIV-positive men in Brazil. This population may serve as an important bridge population to women with implications for anogenital HPV infection in both men and women. Our findings confirm the need to assess screening programs for AIN among high-risk groups, similar to those used to prevent cervical cancer.
C1 [Melo, Victor Hugo] Univ Fed Minas Gerais, Dept Obstet & Gynecol, Fac Med, BR-30130100 Belo Horizonte, MG, Brazil.
   [Crosland Guimaraes, Mark Drew] Univ Fed Minas Gerais, Dept Prevent & Social Med, Fac Med, BR-30130100 Belo Horizonte, MG, Brazil.
   [Rocha, Gustavo Machado] Univ Fed Sao Joao del Rei, Divinopolis, MG, Brazil.
   [Labanca Araujo, Angela Cristina; Carmo, Ricardo Andrade] Dept Hlth Serv, Belo Horizonte, MG, Brazil.
   [Grinsztejn, Beatriz] Fiocruz MS, Lab Pesquisa Clin DST AIDS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguac, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Fiocruz MS, AIDS & Mol Immunol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Palefsky, Joel Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Melo, VH (corresponding author), Univ Fed Minas Gerais, Fac Med, Alfredo Balena 190,2th Floor, BR-30130100 Belo Horizonte, MG, Brazil.
EM victormelo@terra.com.br
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
FU Ministry of Health/Secretariat of Health Surveillance/Department of STD,
   AIDS, and Viral Hepatitis [914/BRA/1101]; Merck Investigator Studies
   Program; Merck and CoMerck & Company
FX This work was carried out by the Federal University of Minas Gerais with
   technical and financial support of the Ministry of Health/Secretariat of
   Health Surveillance/Department of STD, AIDS, and Viral Hepatitis through
   the Project of International Technical Cooperation 914/BRA/1101 between
   the Brazilian Government and the United Nations Educational, Scientific,
   and Cultural Organization. Additional financial support was also
   provided by the Merck Investigator Studies Program.; Dr Palefsky has
   received research grant and travel funding from Merck and Co and sits on
   Merck scientific advisory boards. He also participates in scientific
   advisory boards for Pharmajet and Aura Biosciences. For the remaining
   authors, no conflicts of interest are declared.
CR Apgar BS, 2003, AM FAM PHYSICIAN, V68, P1992
   Campaner AB, 2009, INT J GYNECOL PATHOL, V28, P549, DOI 10.1097/PGP.0b013e3181aa232d
   *CDCP, 1992, MMWR-MORBID MORTAL W, V41
   Chaturvedi AK, 2009, JNCI-J NATL CANCER I, V101, P1120, DOI 10.1093/jnci/djp205
   Chiao EY, 2006, CLIN INFECT DIS, V43, P223, DOI 10.1086/505219
   Chiao EY, 2005, JAIDS-J ACQ IMM DEF, V40, P451, DOI 10.1097/01.qai.0000159669.80207.12
   Conley L, 2010, J INFECT DIS, V202, P1567, DOI 10.1086/656775
   Guimaraes MDC, 2011, JAIDS-J ACQ IMM DEF, V57, pS217, DOI 10.1097/QAI.0b013e31821e9994
   D'Souza G, 2008, JAIDS-J ACQ IMM DEF, V48, P491, DOI 10.1097/QAI.0b013e31817aebfe
   Daling JR, 2004, CANCER-AM CANCER SOC, V101, P270, DOI 10.1002/cncr.20365
   de Pokomandy A, 2011, CLIN INFECT DIS, V52, P1174, DOI 10.1093/cid/cir064
   Gao L, 2010, PLOS ONE, P5
   Guimaraes MDC, 2008, AIDS BEHAV, V12, P741, DOI 10.1007/s10461-008-9407-z
   Hoots BE, 2009, INT J CANCER, V124, P2375, DOI 10.1002/ijc.24215
   KIVIAT NB, 1993, AIDS, V7, P43, DOI 10.1097/00002030-199301000-00007
   Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3
   Nordenvall C, 2011, INT J CANCER, V128, P157, DOI 10.1002/ijc.25305
   Palefsky JM, 2005, AIDS, V19, P1407, DOI 10.1097/01.aids.0000181012.62385.4a
   Palefsky JM, 1997, J ACQ IMMUN DEF SYND, V14, P415, DOI 10.1097/00042560-199704150-00004
   Palefsky JM, 1998, J INFECT DIS, V177, P361, DOI 10.1086/514194
   Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P320, DOI 10.1097/00042560-199804010-00005
   Palefsky JM, 2009, OBSTET GYN CLIN N AM, V36, P187, DOI 10.1016/j.ogc.2009.02.003
   Palefsky JM, 2009, CURR OPIN ONCOL, V21, P433, DOI 10.1097/CCO.0b013e32832f511a
   Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005
   Piketty C, 2008, AIDS, V22, P1203, DOI 10.1097/QAD.0b013e3283023f78
   Scott H, 2008, SEX TRANSM DIS, V35, P197, DOI 10.1097/OLQ.0b013e31815aba8c
   Wilkin TJ, 2004, J INFECT DIS, V190, P1685, DOI 10.1086/424599
NR 27
TC 14
Z9 15
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1089-2591
EI 1526-0976
J9 J LOW GENIT TRACT DI
JI J. Low. Genit. Tract. Dis.
PD APR
PY 2014
VL 18
IS 2
BP 128
EP 135
DI 10.1097/LGT.0b013e31829ee855
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AD7PK
UT WOS:000333455900016
PM 24556612
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Hosseinipour, MC
   Ribaudo, HJ
AF Grinsztejn, B.
   Hosseinipour, M. C.
   Ribaudo, H. J.
TI Effects of early versus delayed initiation of antiretroviral treatment
   on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN
   052 randomised controlled trial (vol 14, pg 281, 2014)
SO LANCET INFECTIOUS DISEASES
LA English
DT Correction
CR Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
NR 1
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD APR
PY 2014
VL 14
IS 4
BP 269
EP 269
DI 10.1016/S1473-3099(14)70720-0
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA AD8FJ
UT WOS:000333501600009
DA 2020-11-24
ER

PT J
AU Luetkemeyer, AF
   Kendall, MA
   Wu, XY
   Lourenco, MC
   Jentsch, U
   Swindells, S
   Qasba, SS
   Sanchez, J
   Havlir, DV
   Grinsztejn, B
   Sanne, IM
   Firnhaber, C
AF Luetkemeyer, Anne F.
   Kendall, Michelle A.
   Wu, Xingye
   Lourenco, Maria Cristina
   Jentsch, Ute
   Swindells, Susan
   Qasba, Sarojini S.
   Sanchez, Jorge
   Havlir, Diane V.
   Grinsztejn, Beatriz
   Sanne, Ian M.
   Firnhaber, Cynthia
CA Adult AIDS Clinical Trials Grp A52
TI Evaluation of Two Line Probe Assays for Rapid Detection of Mycobacterium
   tuberculosis, Tuberculosis (TB) Drug Resistance, and Non-TB Mycobacteria
   in HIV-Infected Individuals with Suspected TB
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID SOUTH-AFRICA; PULMONARY TUBERCULOSIS; MOLECULAR-DETECTION; GENOTYPE
   MTBDRPLUS; TREATMENT OUTCOMES; DIAGNOSIS; PERFORMANCE; RIFAMPIN;
   COMPLEX; CULTURE
AB Limited performance data from line probe assays (LPAs), nucleic acid tests used for the rapid diagnosis of tuberculosis (TB), nontuberculosis mycobacteria (NTM), and Mycobacterium tuberculosis drug resistance are available for HIV-infected individuals, in whom paucibacillary TB is common. In this study, the strategy of testing sputum with GenoType MTBDRplus (MTBDR-Plus) and GenoType Direct LPA (Direct LPA) was compared to a gold standard of one mycobacterial growth indicator tube (MGIT) liquid culture. HIV-positive (HIV+) individuals with suspected TB from southern Africa and South America with <7 days of TB treatment had 1 sputum specimen tested with Direct LPA, MTBDR-Plus LPA, smear microscopy, MGIT, biochemical identification of mycobacterial species, and culture-based drug-susceptibility testing (DST). Of 639 participants, 59.3% were MGIT M. tuberculosis culture positive, of which 276 (72.8%) were acid-fast bacillus (AFB) smear positive. MTBDR-Plus had a sensitivity of 81.0% and a specificity of 100%, with sensitivities of 44.1% in AFB smear-negative versus 94.6% in AFB smear-positive specimens. For specimens that were positive for M. tuberculosis by MTBDR-Plus, the sensitivity and specificity for rifampin resistance were 91.7% and 96.6%, respectively, and for isoniazid (INH) they were 70.6% and 99.1%. The Direct LPA had a sensitivity of 88.4% and a specificity of 94.6% for M. tuberculosis detection, with a sensitivity of 72.5% in smear-negative specimens. Ten of 639 MGIT cultures grew Mycobacterium avium complex or Mycobacterium kansasii, half of which were detected by Direct LPA. Both LPA assays performed well in specimens from HIV-infected individuals, including in AFB smear-negative specimens, with 72.5% sensitivity for M. tuberculosis identification with the Direct LPA and 44.1% sensitivity with MTBDR-Plus. LPAs have a continued role for use in settings where rapid identification of INH resistance and clinically relevant NTM are priorities.
C1 [Luetkemeyer, Anne F.; Havlir, Diane V.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94143 USA.
   [Kendall, Michelle A.; Wu, Xingye] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [Lourenco, Maria Cristina; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Jentsch, Ute] Univ Witwatersrand, Clin Lab Serv, Johannesburg, South Africa.
   [Jentsch, Ute] Univ Witwatersrand, Sch Pathol, Johannesburg, South Africa.
   [Swindells, Susan] Univ Nebraska Med Ctr, Div Infect Dis, Omaha, NE USA.
   [Qasba, Sarojini S.] Montgomery Cty Hlth Dept, Silver Spring, MD USA.
   [Sanchez, Jorge] Asociac Civil Impacta Salud Educacioo, Lima, Peru.
   [Sanne, Ian M.; Firnhaber, Cynthia] Univ Witwatersrand, Fac Hlth Sci, Clin HIV Res Unit, Johannesburg, South Africa.
   [Sanne, Ian M.; Firnhaber, Cynthia] Right Care, Johannesburg, South Africa.
RP Luetkemeyer, AF (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94143 USA.
EM aluetkemeyer@php.ucsf.edu
RI Kendall, Michelle A/B-7665-2016
OI Kendall, Michelle A/0000-0001-9160-4544
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI068636]; Statistical and Data Management Center (SDMC) [UM1
   AI068634]; National Institute of Allergy and Infectious DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); Cepheid; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U01AI068636, P30AI027763, P30AI027763, P30AI027763,
   UM1AI106701, P30AI027763, UM1AI069456, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U01AI068636, UM1AI069456,
   UM1AI069432, UM1AI068636, P30AI027763, UM1AI068634, P30AI027763,
   UM1AI068634, P30AI027763, UM1AI069463, P30AI027763, UM1AI069432,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, UM1AI068636,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, UM1AI069456, P30AI027763, UM1AI069496,
   P30AI027763, P30AI027763, UM1AI069432, UM1AI069496, P30AI027763,
   P30AI027763, UM1AI068636, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, UM1AI069496, UM1AI069496, P30AI027763, P30AI027763,
   P30AI027763, U01AI068636, UM1AI069432, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, UM1AI106701, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, UM1AI069463, UM1AI068636, P30AI027763,
   U01AI068636, P30AI027763, P30AI027763, P30AI027763, UM1AI069456,
   P30AI027763, UM1AI069496, P30AI027763, P30AI027763, UM1AI069432,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, UM1AI068634,
   P30AI027763, UM1AI069463, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, UM1AI069463, P30AI027763, P30AI027763,
   P30AI027763, UM1AI069456, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   UM1AI069463, UM1AI069496, UM1AI068634, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, UM1AI106701, P30AI027763,
   UM1AI069432, P30AI027763, P30AI027763, UM1AI069432, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, UM1AI068634, P30AI027763,
   UM1AI069432, UM1AI069456, P30AI027763, UM1AI069496, UM1AI068636,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, UM1AI069463,
   P30AI027763, P30AI027763, UM1AI069496, U01AI068636, UM1AI069456,
   UM1AI068634, P30AI027763, P30AI027763, U01AI068636, UM1AI069463,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   U01AI068636, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, UM1AI106701, UM1AI069456, UM1AI068636,
   P30AI027763, P30AI027763, P30AI027763, UM1AI068634, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, UM1AI068636, P30AI027763,
   P30AI027763, UM1AI068634, P30AI027763, UM1AI106701, P30AI027763,
   P30AI027763, P30AI027763, UM1AI106701, UM1AI069463, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, UM1AI068636,
   P30AI027763, UM1AI068636, UM1AI068634, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763] Funding Source: NIH RePORTER
FX This work was supported by award number U01AI068636 from the National
   Institute of Allergy and Infectious Diseases and the Statistical and
   Data Management Center (SDMC) (UM1 AI068634) funded by the National
   Institute of Allergy and Infectious Diseases. A. F. L. reports research
   grant support to the University of California, San Francisco, from
   Cepheid.
CR [Anonymous], 2002, MGIT PACK INS
   [Anonymous], 2010, MGIT SIRE PACK INS
   [Anonymous], 2008, MOL LIN PROB ASS RAP
   Bang D, 2010, J INFECTION, V60, P452, DOI 10.1016/j.jinf.2010.03.017
   Barnard M, 2012, J CLIN MICROBIOL, V50, P3712, DOI 10.1128/JCM.01958-12
   Barnard M, 2008, AM J RESP CRIT CARE, V177, P787, DOI 10.1164/rccm.200709-1436OC
   Bicmen C, 2011, J CLIN MICROBIOL, V49, P2874, DOI 10.1128/JCM.00612-11
   Boehme CC, 2011, LANCET, V377, P1495, DOI 10.1016/S0140-6736(11)60438-8
   Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847
   Cattamanchi A, 2009, CLIN INFECT DIS, V48, P179, DOI 10.1086/595689
   Chamie G, 2010, INT J TUBERC LUNG D, V14, P1295
   Chihota VN, 2010, INT J TUBERC LUNG D, V14, P1024
   Crudu V, 2012, J CLIN MICROBIOL, V50, P1264, DOI 10.1128/JCM.05903-11
   Diacon AH, 2009, NEW ENGL J MED, V360, P2397, DOI 10.1056/NEJMoa0808427
   Dorman SE, 2012, J CLIN MICROBIOL, V50, P1189, DOI 10.1128/JCM.05723-11
   Dowdy DW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004057
   Gandhi NR, 2010, LANCET, V375, P1830, DOI 10.1016/S0140-6736(10)60410-2
   Getahun H, 2007, LANCET, V369, P2042, DOI 10.1016/S0140-6736(07)60284-0
   Jacobson KR, 2011, CLIN INFECT DIS, V53, P369, DOI 10.1093/cid/cir406
   Jun HJ, 2009, RESP MED, V103, P1936, DOI 10.1016/j.rmed.2009.05.025
   Kang'ombe CT, 2004, INT J TUBERC LUNG D, V8, P829
   Karakousis PC, 2004, LANCET INFECT DIS, V4, P557, DOI 10.1016/S1473-3099(04)01130-2
   Kent P.T., 1985, PUBLIC HLTH MYCOBACT
   Kurbatova EV, 2012, INT J TUBERC LUNG D, V16, P355, DOI 10.5588/ijtld.11.0542
   Lan R, 2011, INT J TUBERC LUNG D, V15, P1669, DOI 10.5588/ijtld.11.0036
   Ling DI, 2008, EUR RESPIR J, V32, P1165, DOI 10.1183/09031936.00061808
   Marras TK, 2004, JAIDS-J ACQ IMM DEF, V36, P883, DOI 10.1097/00126334-200408010-00001
   McCarthy KD, 2008, INT J TUBERC LUNG D, V12, P1015
   McCarthy KD, 2012, AM J RESP CRIT CARE, V185, P981, DOI 10.1164/rccm.201107-1327OC
   Menzies D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000150
   Monkongdee P, 2009, AM J RESP CRIT CARE, V180, P903, DOI 10.1164/rccm.200905-0692OC
   Neonakis IK, 2007, EUR J CLIN MICROBIOL, V26, P151, DOI 10.1007/s10096-007-0255-y
   Pokam Benjamin Thumamo, 2012, Tuberc Res Treat, V2012, P301056, DOI 10.1155/2012/301056
   RIEDER HL, 2007, PRIORITIES TUBERCULO
   Smith SE, 2012, INT J TUBERC LUNG D, V16, P203, DOI 10.5588/ijtld.11.0445
   Steingart KR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009593.pub2
NR 36
TC 25
Z9 28
U1 0
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD APR
PY 2014
VL 52
IS 4
BP 1052
EP 1059
DI 10.1128/JCM.02639-13
PG 8
WC Microbiology
SC Microbiology
GA AC9CS
UT WOS:000332832300006
PM 24430455
OA Bronze, Green Published
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Hosseinipour, MC
   Ribaudo, HJ
   Swindells, S
   Eron, J
   Chen, YQ
   Wang, L
   Ou, SS
   Anderson, M
   McCauley, M
   Gamble, T
   Kumarasamy, N
   Hakim, JG
   Kumwenda, J
   Pilotto, JHS
   Godbole, SV
   Chariyalertsak, S
   de Melo, MG
   Mayer, KH
   Eshleman, SH
   Piwowar-Manning, E
   Makhema, J
   Mills, LA
   Panchia, R
   Sanne, I
   Gallant, J
   Hoffman, I
   Taha, TE
   Nielsen-Saines, K
   Celentano, D
   Essex, M
   Havlir, D
   Cohen, MS
AF Grinsztejn, Beatriz
   Hosseinipour, Mina C.
   Ribaudo, Heather J.
   Swindells, Susan
   Eron, Joseph
   Chen, Ying Q.
   Wang, Lei
   Ou, San-San
   Anderson, Maija
   McCauley, Marybeth
   Gamble, Theresa
   Kumarasamy, Nagalingeshwaran
   Hakim, James G.
   Kumwenda, Johnstone
   Pilotto, Jose H. S.
   Godbole, Sheela V.
   Chariyalertsak, Suwat
   de Melo, Marineide Goncalves
   Mayer, Kenneth H.
   Eshleman, Susan H.
   Piwowar-Manning, Estelle
   Makhema, Joseph
   Mills, Lisa A.
   Panchia, Ravindre
   Sanne, Ian
   Gallant, Joel
   Hoffman, Irving
   Taha, Taha E.
   Nielsen-Saines, Karin
   Celentano, David
   Essex, Max
   Havlir, Diane
   Cohen, Myron S.
CA HPTN 052-ACTG Study Team
TI Effects of early versus delayed initiation of antiretroviral treatment
   on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN
   052 randomised controlled trial
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID HIV-1-INFECTED PATIENTS; THERAPY; AIDS; ADULTS; MORTALITY; EVENTS
AB Background Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related morbidity and mortality and prevents sexual transmission of HIV-1. However, the best time to initiate antiretroviral treatment to reduce progression of HIV-1 infection or non-AIDS clinical events is unknown. We reported previously that early antiretroviral treatment reduced HIV-1 transmission by 96%. We aimed to compare the effects of early and delayed initiation of antiretroviral treatment on clinical outcomes.
   Methods The HPTN 052 trial is a randomised controlled trial done at 13 sites in nine countries. We enrolled HIV-1-serodiscordant couples to the study and randomly allocated them to either early or delayed antiretroviral treatment by use of permuted block randomisation, stratified by site. Random assignment was unblinded. The HIV-1-infected member of every couple initiated antiretroviral treatment either on entry into the study (early treatment group) or after a decline in CD4 count or with onset of an AIDS-related illness (delayed treatment group). Primary events were AIDS clinical events (WHO stage 4 HIV-1 disease, tuberculosis, and severe bacterial infections) and the following serious medical conditions unrelated to AIDS: serious cardiovascular or vascular disease, serious liver disease, end-stage renal disease, new-onset diabetes mellitus, and non-AIDS malignant disease. Analysis was by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT00074581.
   Findings 1763 people with HIV-1 infection and a serodiscordant partner were enrolled in the study; 886 were assigned early antiretroviral treatment and 877 to the delayed treatment group (two individuals were excluded from this group after randomisation). Median CD4 counts at randomisation were 442 (IQR 373-522) cells per mu L in patients assigned to the early treatment group and 428 (357-522) cells per mu L in those allocated delayed antiretroviral treatment. In the delayed group, antiretroviral treatment was initiated at a median CD4 count of 230 (IQR 197-249) cells per mu L. Primary clinical events were reported in 57 individuals assigned to early treatment initiation versus 77 people allocated to delayed antiretroviral treatment (hazard ratio 0.73, 95% CI 0.52-1.03; p=0.074). New-onset AIDS events were recorded in 40 participants assigned to early antiretroviral treatment versus 61 allocated delayed initiation (0.64, 0.43-0.96; p=0.031), tuberculosis developed in 17 versus 34 patients, respectively (0.49,0.28-0.89, p=0.018), and primary non-AIDS events were rare (12 in the early group vs nine with delayed treatment). In total, 498 primary and secondary outcomes occurred in the early treatment group (incidence 24.9 per 100 person-years, 95% CI 22.5-27.5) versus 585 in the delayed treatment group (29.2 per 100 person-years, 26.5-32.1; p=0.025). 26 people died, 11 who were allocated to early antiretroviral treatment and 15 who were assigned to the delayed treatment group.
   Interpretation Early initiation of antiretroviral treatment delayed the time to AIDS events and decreased the incidence of primary and secondary outcomes. The clinical benefits recorded, combined with the striking reduction in HIV-1 transmission risk previously reported, provides strong support for earlier initiation of antiretroviral treatment.
C1 [Chen, Ying Q.; Wang, Lei; Ou, San-San; Anderson, Maija] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   [Taha, Taha E.; Celentano, David] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chaing Mai, Thailand.
   [Hosseinipour, Mina C.; Eron, Joseph; Hoffman, Irving; Cohen, Myron S.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
   [Eshleman, Susan H.; Piwowar-Manning, Estelle; Gallant, Joel] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Ribaudo, Heather J.; Essex, Max] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Gamble, Theresa] FHI 360, Durham, NC USA.
   [Godbole, Sheela V.] Natl AIDS Res Inst, ICMR, Pune, Maharashtra, India.
   [de Melo, Marineide Goncalves] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas, Inst Pesquisa Clin, BR-21045900 Rio De Janeiro, Brazil.
   [Hakim, James G.] Univ Zimbabwe, Harare, Zimbabwe.
   [Havlir, Diane] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Hosseinipour, Mina C.] UNC Project Malawi, Lilongwe, Malawi.
   [Kumarasamy, Nagalingeshwaran] YR Gaitonade Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
   [Kumwenda, Johnstone] Johns Hopkins Project, Coll Med, Lilongwe, Malawi.
   [Makhema, Joseph] Botswana Harvard AIDS Inst, Gaborone, Botswana.
   [Mayer, Kenneth H.] Fenway Inst, Boston, MA USA.
   [McCauley, Marybeth] FHI 360, Washington, DC USA.
   [Mills, Lisa A.] KEMRI CDC, Kisumu, Kenya.
   [Nielsen-Saines, Karin] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Panchia, Ravindre; Sanne, Ian] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
   Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   Fiocruz MS, Lab AIDS Imunol Mol IOC, BR-21045900 Rio De Janeiro, Brazil.
RP Grinsztejn, B (corresponding author), Fiocruz MS, Evandro Chagas, Inst Pesquisa Clin, BR-21045900 Rio De Janeiro, Brazil.
RI Pilotto, Jose Henrique/AAD-9773-2019; Godbole, Sheela/K-4177-2017
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Taha,
   Taha/0000-0001-9814-4894
FU US National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI053217, U19AI053217, UM1AI069432, UM1AI068613, U19AI053217,
   UM1AI068636, P30AI050410, P30AI050410, U01AI068619, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, UM1AI068613, U19AI053217,
   P30AI050410, UM1AI068613, U19AI053217, UM1AI068617, P30AI050410,
   UM1AI069453, UM1AI068617, UM1AI069432, UM1AI068636, UM1AI068636,
   P30AI050410, P30AI050410, UM1AI068634, U01AI068613, P30AI050410,
   P30AI050410, P30AI050410, U19AI053217, UM1AI068636, P30AI050410,
   P30AI050410, P30AI050410, UM1AI069463, U19AI053217, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, U19AI053217, P30AI050410,
   P30AI050410, UM1AI069436, U19AI053217, U19AI053217, UM1AI069456,
   UM1AI068617, P30AI050410, UM1AI068617, U01AI068636, P30AI050410,
   P30AI050410, P30AI050410, U19AI053217, UM1AI069518, UM1AI069423,
   P30AI050410, P30AI050410, U19AI053217, P30AI050410, U01AI068617,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   UM1AI069423, UM1AI069436, P30AI050410, U01AI068617, U19AI053217,
   UM1AI069456, UM1AI069518, UM1AI068613, U19AI053217, P30AI050410,
   P30AI050410, UM1AI068636, U01AI068613, UM1AI069463, P30AI050410,
   UM1AI069453, U19AI053217, P30AI050410, P30AI050410, U19AI053217,
   P30AI050410, P30AI050410, UM1AI068634, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, U19AI053217, P30AI050410, U01AI068636,
   P30AI050410, P30AI050410, U01AI068617, UM1AI069424, P30AI050410,
   U19AI053217, UM1AI069496, UM1AI069518, UM1AI069424, P30AI050410,
   P30AI050410, UM1AI068613, P30AI050410, U19AI053217, P30AI050410,
   UM1AI068613, UM1AI106701, P30AI050410, UM1AI068613, UM1AI069456,
   UM1AI106701, UM1AI069432, UM1AI069423, U19AI053217, UM1AI069518,
   U19AI053217, UM1AI069496, UM1AI068619, P30AI050410, UM1AI069453,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   U01AI069463, UM1AI069496, U01AI068619, UM1AI069463, U19AI053217,
   U01AI068617, P30AI050410, UM1AI069453, P30AI050410, U19AI053217,
   UM1AI069432, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   U19AI053217, P30AI050410, P30AI050410, P30AI050410, UM1AI069456,
   P30AI050410, U01AI069463, UM1AI069456, U01AI068619, UM1AI068636,
   UM1AI069436, UM1AI069518, P30AI050410, P30AI050410, P30AI050410,
   U01AI068619, UM1AI106701, U19AI053217, UM1AI068619, UM1AI069432,
   UM1AI068634, U19AI053217, UM1AI069453, P30AI050410, P30AI050410,
   U19AI053217, UM1AI069436, U01AI068619, UM1AI069432, UM1AI068619,
   UM1AI068634, P30AI050410, P30AI050410, P30AI050410, UM1AI069424,
   UM1AI069463, UM1AI069496, U01AI069463, UM1AI069463, P30AI050410,
   UM1AI069496, UM1AI068634, P30AI050410, UM1AI069518, UM1AI069423,
   P30AI050410, UM1AI068636, P30AI050410, UM1AI069456, UM1AI069518,
   UM1AI069463, UM1AI069496, U01AI068636, P30AI050410, UM1AI069463,
   P30AI050410, P30AI050410, U19AI053217, UM1AI068634, UM1AI068613,
   P30AI050410, UM1AI069453, P30AI050410, UM1AI069456, U01AI069463,
   U01AI068617, P30AI050410, P30AI050410, U19AI053217, P30AI050410,
   U19AI053217, U01AI069463, UM1AI069432, UM1AI069423, P30AI050410,
   P30AI050410, UM1AI068617, U01AI069463, U19AI053217, P30AI050410,
   UM1AI069436, UM1AI068634, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, UM1AI068617, P30AI050410, P30AI050410, P30AI050410,
   UM1AI068619, P30AI050410, UM1AI069424, UM1AI068619, UM1AI106701,
   U19AI053217, P30AI050410, U01AI068636, P30AI050410, UM1AI069423,
   P30AI050410, P30AI050410, U01AI068613, U01AI068636, UM1AI068634,
   P30AI050410, U19AI053217, U19AI053217, P30AI050410, UM1AI068636,
   U19AI053217, UM1AI068619, P30AI050410, P30AI050410, UM1AI106701,
   P30AI050410, P30AI050410, U01AI068636, UM1AI069436, UM1AI068617,
   UM1AI068613, UM1AI068634, U19AI053217, P30AI050410, P30AI050410,
   P30AI050410, UM1AI068613, UM1AI068619, P30AI050410, UM1AI069436,
   P30AI050410, U19AI053217, P30AI050410, P30AI050410, U19AI053217,
   U01AI068636, P30AI050410, P30AI050410, UM1AI068619, UM1AI106701,
   P30AI050410, UM1AI069424, U01AI068613, P30AI050410, P30AI050410,
   UM1AI069424, U19AI053217, P30AI050410, UM1AI069453, U01AI069463,
   P30AI050410, UM1AI069424, P30AI050410, UM1AI069463, P30AI050410,
   U19AI053217, P30AI050410, UM1AI069496, P30AI050410, U19AI053217,
   UM1AI069456, UM1AI068636, P30AI050410, UM1AI068617, UM1AI069496,
   UM1AI069436, UM1AI069424, P30AI050410, UM1AI068617, P30AI050410,
   P30AI050410, U19AI053217, U19AI053217, UM1AI069453, P30AI050410,
   P30AI050410, UM1AI069423, UM1AI069432, P30AI050410, U19AI053217,
   UM1AI068619, UM1AI069423, U01AI068613, UM1AI069518, U19AI053217,
   P30AI050410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [R37DK049381, R37DK049381, R37DK049381, R37DK049381, R37DK049381,
   R37DK049381, R37DK049381, R37DK049381, R37DK049381, R37DK049381,
   R37DK049381] Funding Source: NIH RePORTER
FX Funding US National Institute of Allergy and Infectious Diseases.
CR Akolo C, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000171.pub3
   Anglaret X, 2012, CLIN INFECT DIS, V54, P714, DOI 10.1093/cid/cir898
   [Anonymous], GUID US ANT AG HIV 1
   Batani J, 2013, 20 C RETR OPP INF AT, P550
   Belloso WH, 2010, HIV MED, V11, P554, DOI 10.1111/j.1468-1293.2010.00824.x
   Braitstein P, 2006, LANCET, V367, P817
   Cain LE, 2011, ANN INTERN MED, V154, P509, DOI 10.7326/0003-4819-154-8-201104190-00001
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   Chakravorty S, 2005, J CLIN MICROBIOL, V43, P4357, DOI 10.1128/JCM.43.9.4357-4362.2005
   Clifford DB, 2005, ANN INTERN MED, V143, P714, DOI 10.7326/0003-4819-143-10-200511150-00008
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Emery S, 2008, J INFECT DIS, V197, P1133, DOI 10.1086/586713
   Funk MJ, 2011, ARCH INTERN MED, V171, P1560, DOI 10.1001/archinternmed.2011.401
   Hughes MD, 2008, J INFECT DIS, V197, P1084, DOI 10.1086/586712
   Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252
   Lawn SD, 2011, LANCET, V378, P57, DOI 10.1016/S0140-6736(10)62173-3
   Le T, 2013, NEW ENGL J MED, V368, P218, DOI 10.1056/NEJMoa1110187
   Naing C, 2013, LUNG, V191, P27, DOI 10.1007/s00408-012-9440-6
   Phillips AN, 2007, AIDS, V21, P1717
   Ray M, 2010, AIDS, V24, P123, DOI 10.1097/QAD.0b013e3283324283
   Schisterman EF, 2009, EPIDEMIOLOGY, V20, P488, DOI 10.1097/EDE.0b013e3181a819a1
   Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370
   Siegfried N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008272.pub2
   Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7
   Suthar AB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001270
   Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961
   Wester CW, 2011, AIDS, V25, P1471, DOI 10.1097/QAD.0b013e328347f9d4
   Williams I, 2012, HIV MED, V13, P1, DOI [10.1111/j.1468-1293.2012.01029.x, 10.1111/j.1468-1293.2012.01029_1.x]
   World Health Organization, 2013, CONS GUID US ANT DRU
   World Health Organization, 2011, GLOB TUB CONTR 2011
   World Health Organization, 2006, WHO CAS DEF HIV SURV
   Yang ZH, 2004, CLIN INFECT DIS, V38, P199, DOI 10.1086/380644
NR 32
TC 280
Z9 300
U1 0
U2 41
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD APR
PY 2014
VL 14
IS 4
BP 281
EP 290
DI 10.1016/S1473-3099(13)70692-3
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA AD8FJ
UT WOS:000333501600017
PM 24602844
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Coelho, L
   Veloso, VG
   Grinsztejn, B
   Luz, PM
AF Coelho, Lara
   Veloso, Valdilea Goncalves
   Grinsztejn, Beatriz
   Luz, Paula Mendes
TI Trends in overall opportunistic illnesses, Pneumocystis carinii
   pneumonia, cerebral toxoplasmosis and Mycobacterium avium complex
   incidence rates over the 30 years of the HIV epidemic: a systematic
   review
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Review
DE AIDS-related opportunistic infections; Opportunistic infection; Acquired
   immunodeficiency syndrome; Incidence
ID ACTIVE ANTIRETROVIRAL THERAPY; AIDS-DEFINING ILLNESSES;
   HUMAN-IMMUNODEFICIENCY-VIRUS; HOSPITAL-BASED COHORT; RIO-DE-JANEIRO;
   INFECTED PATIENTS; DECLINING INCIDENCE; DISEASE INCIDENCE;
   NATURAL-HISTORY; UNITED-STATES
AB Background: The natural history of HIV infection has changed dramatically after the introduction of highly active antiretroviral therapy. Currently, opportunistic illnesses still represent major cause of death and hospitalization in this population. In this study, we review the trends in opportunistic illnesses incidence rates and compare the results observed in high-income settings with that for low/middle-income settings, with special attention given to studies from Brazil.
   Methods: We systematically searched Pubmed, Web of Science, Lilacs and Google scholar for publications on HIV associated opportunistic illness. Studies reporting rates based on person-time for all opportunistic illnesses and/or the three opportunistic infections of interest, namely, Pneumocystis carinii pneumonia, cerebral toxoplasmosis, and Mycobacterium avium complex were included.
   Results: Significant reductions in the incidence rates were demonstrated for opportunistic illnesses overall and also for the specific opportunistic infections included in the present study, both in high and low/middle-income settings. Out of the 37 studies included in the present review, almost 70% were from high-income settings. All the studies conducted in low/middle-income settings were single center studies and four were from Brazil. We found no study from Brazil reporting annual incidence rates of opportunistic illnesses.
   Conclusions: Opportunistic illnesses remain an important public health problem. To better guide health policies in low/middle-income settings, multicenter cohort studies should be encouraged. Studies from Brazil are urgently needed to assess the current burden of opportunistic illnesses in our population and to support the planning of HIV/AIDS health care services organization. (C) 2013 Elsevier Editora Ltda. All rights reserved.
C1 [Coelho, Lara; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz; Luz, Paula Mendes] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
RP Coelho, L (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM lara.coelho@ipec.fiocruz.br
OI Luz, Paula/0000-0001-9746-719X
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)
FX BG acknowledges funding from the National Council of Technological and
   Scientific Development (CNPq) and the Research Funding Agency of the
   State of Rio de Janeiro (FAPERJ). PML acknowledges funding from the
   National Council of Technological and Scientific Development (CNPq).
CR BACELLAR H, 1994, J INFECT DIS, V170, P1284, DOI 10.1093/infdis/170.5.1284
   Badri M, 2005, S AFRIC J HIV MED, V6, P11
   Baril L, 2000, AIDS, V14, P2593, DOI 10.1097/00002030-200011100-00023
   Bonard D, 2004, AIDS, V18, P1961, DOI 10.1097/00002030-200409240-00015
   Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010
   Buchacz K, 2010, AIDS, V24, P1549, DOI 10.1097/QAD.0b013e32833a3967
   Cain LE, 2009, AM J EPIDEMIOL, V169, P1124, DOI 10.1093/aje/kwp002
   Cardoso SW, 2010, AIDS RES HUM RETROV, V26, P865, DOI 10.1089/aid.2009.0274
   Casseb J, 2003, AIDS PATIENT CARE ST, V17, P447, DOI 10.1089/108729103322395474
   CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285
   Charurat M, 2004, J WOMENS HEALTH, V13, P719, DOI 10.1089/jwh.2004.13.719
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   De Beaudrap P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-179
   Fonseca LAM, 1999, INT J EPIDEMIOL, V28, P1156, DOI 10.1093/ije/28.6.1156
   Forrest DM, 1998, CLIN INFECT DIS, V27, P1379, DOI 10.1086/515030
   Gadelha Ângela, 2002, Braz J Infect Dis, V6, P252, DOI 10.1590/S1413-86702002000500006
   GADELHA Ângela J., 2002, Rev. Inst. Med. trop. S. Paulo, V44, P179, DOI 10.1590/S0036-46652002000400001
   Garvey L, 2011, EUR J NEUROL, V18, P527, DOI 10.1111/j.1468-1331.2010.03291.x
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Hacker MA, 2007, CAD SAUDE PUBLICA, V23, pS345, DOI 10.1590/S0102-311X2007001500003
   Holmes CB, 2006, JAIDS-J ACQ IMM DEF, V42, P464, DOI 10.1097/01.qai.0000225729.79610.b7
   Hung CC, 2000, J ACQ IMMUN DEF SYND, V24, P378, DOI 10.1097/00126334-200008010-00013
   Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843
   Kirk O, 2000, AM J RESP CRIT CARE, V162, P865, DOI 10.1164/ajrccm.162.3.9908018
   Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220
   Losina E, 2007, ANTIVIR THER, V12, P543
   Mocroft A, 1999, J ACQ IMMUN DEF SYND, V21, P401
   Mocroft A, 1998, ARCH INTERN MED, V158, P491, DOI 10.1001/archinte.158.5.491
   Mocroft A, 2000, LANCET, V356, P291, DOI 10.1016/S0140-6736(00)02504-6
   Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003
   Moorman AC, 1998, J ACQ IMMUN DEF SYND, V19, P182, DOI 10.1097/00042560-199810010-00013
   Nemes MIB, 2004, AIDS, V18, pS15, DOI 10.1097/00002030-200406003-00004
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Perbost I, 2005, HIV MED, V6, P232, DOI 10.1111/j.1468-1293.2005.00282.x
   Plettenberg A, 2011, INFECTION, V39, P3, DOI 10.1007/s15010-010-0070-8
   Podlasin RB, 2006, INFECTION, V34, P196, DOI 10.1007/s15010-006-5030-y
   Riveiro-Barciela M, 2013, HIV MED, V14, P21, DOI 10.1111/j.1468-1293.2012.01033.x
   Rojanawiwat A, 2011, INT HEALTH, V3, P101, DOI 10.1016/j.inhe.2010.12.004
   Rossi M, 2001, SWISS MED WKLY, V131, P471
   Sacktor N, 2001, NEUROLOGY, V56, P257, DOI 10.1212/WNL.56.2.257
   San-Andres FJ, 2003, CLIN INFECT DIS, V36, P1177, DOI 10.1086/374358
   Schwarcz L, 2013, AIDS, V27, P597, DOI 10.1097/QAD.0b013e32835b0fa2
   UN Joint Programme on HIV/AIDS (UNAIDS), 2012, GLOB REP UNAIDS REP
   Wohl AR, 2003, AIDS PATIENT CARE ST, V17, P267, DOI 10.1089/108729103322108148
   Yazdanpanah Y, 2001, INT J EPIDEMIOL, V30, P864, DOI 10.1093/ije/30.4.864
NR 45
TC 13
Z9 18
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAR-APR
PY 2014
VL 18
IS 2
BP 196
EP 210
DI 10.1016/j.bjid.2013.10.003
PG 15
WC Infectious Diseases
SC Infectious Diseases
GA AH4FK
UT WOS:000336082500013
PM 24275372
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU De Boni, R
   Veloso, VG
   Grinsztejn, B
AF De Boni, Raquel
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI Epidemiology of HIV in Latin America and the Caribbean
SO CURRENT OPINION IN HIV AND AIDS
LA English
DT Review
DE HIV/AIDS; Latin America and the Caribbean; review
ID FEMALE SEX WORKERS; SEXUALLY-TRANSMITTED INFECTIONS; DRUG-RESISTANCE;
   BEHAVIORAL SURVEILLANCE; TRANSGENDER WOMEN; MEN; PREVALENCE; COUNTRIES;
   POPULATIONS; INCOME
AB Purpose of review
   The aim of the present review is to update HIV/AIDS Epidemiology in Latin America and the Caribbean highlighting the concentrated aspect of epidemic in the region.
   Recent findings
   Among general population, HIV prevalence in Latin America is at stable levels (0.2-0.7%). The Caribbean still has one of the highest HIV prevalence rates in the world (<0.1-3%), but incidences have declined around 49%. This is not the current situation for high-risk key populations; most incident cases occur among MSM. Available data on transgender women suggest that they are the most-at-risk group. Female sex workers still have a 12-fold the chance of being HIV positive compared with other women. IDU prevalence was revised to 0.45%, but non-IDU has been suggested as a mediator between sexual risk and HIV.
   Summary
   The increase in treatment coverage (mean is at 63%) resulted in modifications of HIV/AIDS epidemiology. New strategies to seek, test and link key populations to care are urgently needed and targeted interventions to prevent HIV expansion among them must be adopted. These strategies should consider the particular situation regarding social inequalities, discrimination and violence that pervade the HIV epidemic among key populations.
C1 [De Boni, Raquel; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, Brazil.
RP Grinsztejn, B (corresponding author), Fiocruz MS, IPEC, Av Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX B.G. would like to thank FAPERJ and CNPq for long-term funding.
CR Caetano KAA, 2013, AIDS PATIENT CARE ST, V27, P1, DOI 10.1089/apc.2012.0268
   Angulo-Arreola IA, 2011, J INT ASS PHYS AIDS, DOI 10.1177/1545109711417408
   Aran-Matero D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022373
   Baral S, 2012, LANCET INFECT DIS, V12, P538, DOI 10.1016/S1473-3099(12)70066-X
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Barrington C, 2012, AIDS BEHAV, V16, P214, DOI 10.1007/s10461-011-9959-1
   Bastos FI, 2008, INT J EPIDEMIOL, V37, P729, DOI 10.1093/ije/dyn127
   Bennett DE, 2008, ANTIVIR THER, V13, P25
   Beyrer C, 2013, CURR OPIN HIV AIDS, V8, P306, DOI 10.1097/COH.0b013e328361f53a
   Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6
   Blas MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027334
   Carcamo CP, 2012, LANCET INFECT DIS, V12, P765, DOI 10.1016/S1473-3099(12)70144-5
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Creswell J, 2012, SEX TRANSM INFECT, V88, P633, DOI 10.1136/sextrans-2012-050521
   Damacena GN, 2011, JAIDS-J ACQ IMM DEF, V57, pS144, DOI 10.1097/QAI.0b013e31821e9bf6
   de Lima KO, 2012, J CLIN MICROBIOL, V50, P2145, DOI 10.1128/JCM.05107-11
   Deiss RG, 2013, DRUG ALCOHOL DEPEN, V132, P134, DOI 10.1016/j.drugalcdep.2013.01.011
   Deiss RG, 2012, GLOB PUBLIC HEALTH, V7, P175, DOI 10.1080/17441692.2010.549141
   Dennis AM, 2013, JAIDS-J ACQ IMM DEF, V63, P135, DOI 10.1097/QAI.0b013e318288b246
   Diaz T, 2009, CURR OPIN HIV AIDS, V4, P253, DOI 10.1097/COH.0b013e32832c1898
   Duncan J, 2010, SEX TRANSM DIS, V37, P306, DOI 10.1097/OLQ.0b013e3181c6e851
   Geibel S, 2010, PUBLIC HEALTH REP, V125, P316, DOI 10.1177/003335491012500222
   Goldenberg SM, 2012, AIDS BEHAV, V16, P969, DOI 10.1007/s10461-011-0063-3
   Gomez GB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001323
   Goodreau SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050522
   Gouws E, 2012, SEX TRANSM INFECT, V88, pI76, DOI 10.1136/sextrans-2012-050719
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hakre S, 2013, SEX TRANSM INFECT, V89, P156, DOI 10.1136/sextrans-2012-050557
   Hallett TB, 2011, CURR OPIN HIV AIDS, V6, P102, DOI 10.1097/COH.0b013e328343bfdb
   Huedo-Medina TB, 2010, AIDS BEHAV, V14, P1237, DOI 10.1007/s10461-010-9763-3
   Junqueira DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027489
   Kendall C, 2008, AIDS BEHAV, V12, pS97, DOI 10.1007/s10461-008-9390-4
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Kim AA, 2013, AIDS RES HUM RETROV, V29, P516, DOI [10.1089/aid.2012.0032, 10.1089/AID.2012.0032]
   Kim EJ, 2013, AIDS BEHAV, V17, P1279, DOI 10.1007/s10461-012-0152-y
   Koenig SP, 2012, JAIDS-J ACQ IMM DEF, V59, pE60, DOI 10.1097/QAI.0b013e318245d3c1
   Malta M, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-317
   Miller WM, 2013, SALUD PUBLICA MEXICO, V55, pS65
   Montealegre JR, 2013, AIDS BEHAV, V17, P2313, DOI 10.1007/s10461-013-0466-4
   Murillo W, 2013, J VIROL, V87, P7463, DOI 10.1128/JVI.01602-12
   Ormaeche M, 2012, INT J INFECT DIS, V16, pE724, DOI 10.1016/j.ijid.2012.05.1032
   Gutierrez JP, 2012, TROP MED INT HEALTH, V17, P353, DOI 10.1111/j.1365-3156.2011.02934.x
   PAHO, 2012, ANT TREATM SPOTL PUB
   Pando MA, 2011, AIDS RES HUM RETROV, V27, P17, DOI 10.1089/aid.2010.0013
   Pando MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054147
   Pando MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039834
   Pineda-Pena AC, 2012, AIDS REV, V14, P256
   Rocha GM, 2013, AIDS BEHAV, V17, P1288, DOI 10.1007/s10461-012-0398-4
   Silva-Santisteban A, 2012, AIDS BEHAV, V16, P872, DOI 10.1007/s10461-011-0053-5
   Strathdee SA, 2012, ANN EPIDEMIOL, V22, P426, DOI 10.1016/j.annepidem.2012.04.002
   Ulibarri MD, 2011, AIDS BEHAV, V15, P179, DOI 10.1007/s10461-009-9595-1
   UNAIDS, 2013, GLOB REP UNAIDS REP
   UNAIDS Report on the Global AIDS Epidemic, 2012, UNAIDS REP GLOB AIDS
   UNODC, 2013, WORLD DRUG REP
   WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E
   Wilson EC, 2010, AM J PUBLIC HEALTH, V100, P1500, DOI 10.2105/AJPH.2009.160051
NR 56
TC 68
Z9 70
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1746-630X
EI 1746-6318
J9 CURR OPIN HIV AIDS
JI Curr. Opin. HIV AIDS
PD MAR
PY 2014
VL 9
IS 2
BP 192
EP 198
DI 10.1097/COH.0000000000000031
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AC3EQ
UT WOS:000332398200012
PM 24356327
DA 2020-11-24
ER

PT J
AU Calvet, GA
   Velasque, L
   Luz, PM
   Cardoso, SW
   Derrico, M
   Moreira, RI
   de Andrade, ACV
   Cytryn, A
   Pires, E
   Veloso, VG
   Grinsztejn, B
   Friedman, RK
AF Calvet, Guilherme Amaral
   Velasque, Luciane
   Luz, Paula Mendes
   Cardoso, Sandra Wagner
   Derrico, Monica
   Moreira, Ronaldo Ismerio
   Vasconcelos de Andrade, Angela Cristina
   Cytryn, Andrea
   Pires, Elaine
   Veloso, Valdilea Goncalves
   Grinsztejn, Beatriz
   Friedman, Ruth Khalili
TI Absence of Effect of Menopause Status at Initiation of First-Line
   Antiretroviral Therapy on Immunologic or Virologic Responses: A Cohort
   Study from Rio de Janeiro, Brazil
SO PLOS ONE
LA English
DT Article
ID HIV-INFECTED INDIVIDUALS; 1ST YEAR; HIV-1-INFECTED WOMEN; HAART REGIMEN;
   OLDER AGE; SEX; GENDER; CD4; TOLERABILITY; METAANALYSIS
AB Objective: To compare the effectiveness of first-line combination antiretroviral therapy (cART) between premenopausal and postmenopausal women.
   Methods: ART-naive women initiating cART between January 2000/June 2010 at the Instituto de Pesquisa Clinica Evandro Chagas Cohort were studied. Women were defined as postmenopausal after 12 consecutive months of amenorrhea. CD4 cell counts and HIV-1 RNA viral load (VL) measurements were compared between pre- and postmenopausal at 6, 12 and 24 months after cART initiation. Women who modified/discontinued a drug class or died due to an AIDS defining illness were classified as ART-failures. Variables were compared using Wilcoxon test, chi(2) or Fisher's exact test. The odds of cART effectiveness (VL, 400 copies/mL and/or no need to change cART) were compared using logistic regression. Linear model was used to access relationship between CD4 change and menopause.
   Results: Among 383 women, 328 (85%) were premenopausal and 55 (15%) postmenopausal. Median pre cART CD4 counts were 231 and 208 cells/mm 3 (p = 0.14) in pre- and postmenopausal women, respectively. No difference in the median pre cART VL was found (both 4.8 copies/mL). Median CD4 changes were similar at 6 and 12 months. At 24 months after cART initiation, CD4 changes among postmenopausal women were significantly lower among premenopausal women (p = 0.01). When the analysis was restricted to women with VL, 400 copies/mL, no statistical difference was observed. Overall, 63.7% achieved cART effectiveness at 24 months without differences between groups at 6, 12 and 24 months.
   Conclusion: Menopause status at the time of first-line cART initiation does not impact CD4 cell changes at 24 months among women with a virologic response. No relationship between menopause status and virologic response was observed.
C1 [Calvet, Guilherme Amaral; Velasque, Luciane; Luz, Paula Mendes; Cardoso, Sandra Wagner; Derrico, Monica; Moreira, Ronaldo Ismerio; Vasconcelos de Andrade, Angela Cristina; Cytryn, Andrea; Pires, Elaine; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz; Friedman, Ruth Khalili] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, Rio De Janeiro, Brazil.
   [Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil.
RP Calvet, GA (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, Rio De Janeiro, Brazil.
EM guilherme.calvet@ipec.fiocruz.br
RI Calvet, GA/G-6959-2013; Cardoso, Sandra W/D-7965-2015
OI Calvet, GA/0000-0002-3545-5238; Cardoso, Sandra W/0000-0001-5230-0003;
   Luz, Paula/0000-0001-9746-719X
CR Abrogoua DP, 2012, PATIENT PREFER ADHER, V6, P227, DOI 10.2147/PPA.S26507
   Althoff KN, 2010, AIDS, V24, P2467, DOI 10.1097/QAD.0b013e32833e6d14
   [Anonymous], 1996, World Health Organ Tech Rep Ser, V866, P1
   [Anonymous], 1992, MMWR Recomm Rep, V41, P1
   [Anonymous], 2011, UNAIDS WORLD AIDS DA
   Balestre E, 2012, AIDS, V26, P951, DOI 10.1097/QAD.0b013e3283528ad4
   Barber TJ, 2011, ANTIVIR THER, V16, P805, DOI 10.3851/IMP1818
   Blanco JR, 2012, AIDS RES HUM RETROV, V28, P800, DOI [10.1089/aid.2011.0377, 10.1089/AID.2011.0377]
   Cardoso SW, 2010, AIDS RES HUM RETROV, V26, P865, DOI 10.1089/aid.2009.0274
   Cejtin HE, 2012, AM J OBSTET GYNECOL, V207, P87, DOI 10.1016/j.ajog.2011.12.031
   Friedman RK, 2011, REV SAUDE PUBL, V45, P373, DOI 10.1590/S0034-89102011000200016
   Gameiro CM, 2010, MATURITAS, V67, P316, DOI 10.1016/j.maturitas.2010.08.003
   Gandhi M, 2002, CLIN INFECT DIS, V35, P313, DOI 10.1086/341249
   Grabar S, 2004, AIDS, V18, P2029, DOI 10.1097/00002030-200410210-00007
   Greenbaum AH, 2008, AIDS, V22, P2331, DOI 10.1097/QAD.0b013e32831883f9
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Grinsztejn B, 2011, ANTIVIR THER, V16, P1057, DOI 10.3851/IMP1872
   Haynes L, 2009, CURR OPIN IMMUNOL, V21, P414, DOI 10.1016/j.coi.2009.05.009
   Hermes A, 2012, HIV CLIN TRIALS, V13, P308, DOI 10.1310/hct1306-308
   *IBGE, 2002, PERF ID RESP PEL DOM
   Lazarus JV, 2010, HIV MED, V11, P479, DOI 10.1111/j.1468-1293.2009.00810.x
   Maman D, 2012, AIDS, V26, P1393, DOI 10.1097/QAD.0b013e328352d054
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Napravnik S, 2002, JAIDS-J ACQ IMM DEF, V31, P11, DOI 10.1097/00126334-200209010-00002
   Newman J, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/725713
   Oertelt-Prigione S, 2012, AUTOIMMUN REV, V11, pA479, DOI 10.1016/j.autrev.2011.11.022
   Patterson K, 2007, HIV MED, V8, P406, DOI 10.1111/j.1468-1293.2007.00485.x
   Patterson KB, 2009, CLIN INFECT DIS, V49, P473, DOI 10.1086/600398
   Raboud J, 2010, HIV CLIN TRIALS, V11, P340, DOI 10.1310/hct1106-340
   Silverberg MJ, 2007, ARCH INTERN MED, V167, P684, DOI 10.1001/archinte.167.7.684
   Torres TS, 2014, BRAZ J INFECT DIS, V18, P34, DOI 10.1016/j.bjid.2013.04.005
   Tumbarello M, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-46
   van Benthem BHB, 2002, AIDS, V16, P919, DOI 10.1097/00002030-200204120-00012
   Wellons MF, 2002, J AM GERIATR SOC, V50, P603, DOI 10.1046/j.1532-5415.2002.50152.x
   Yan J, 2013, REV ANTIVIRAL THERAP, V1, pO
   Yao Genhong, 2004, Wei Sheng Yan Jiu, V33, P759
   Young J, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001194
NR 37
TC 7
Z9 7
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2014
VL 9
IS 2
AR e89299
DI 10.1371/journal.pone.0089299
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AB3UC
UT WOS:000331714700095
PM 24586673
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Velasco-de-Castro, CA
   Grinsztejn, B
   Veloso, VG
   Bastos, FI
   Pilotto, JH
   Fernandes, N
   Morgado, MG
AF Velasco-de-Castro, Carlos A.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Bastos, Francisco I.
   Pilotto, Jose H.
   Fernandes, Nilo
   Morgado, Mariza G.
TI HIV-1 Diversity and Drug Resistance Mutations among People Seeking HIV
   Diagnosis in Voluntary Counseling and Testing Sites in Rio de Janeiro,
   Brazil
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; MODERATE
   PREVALENCE; GENETIC DIVERSITY; SURVEILLANCE; INDIVIDUALS; SUBTYPES;
   NAIVE; NETWORK; DRIVEN
AB The remarkable viral diversity remains a big challenge to the development of HIV vaccines and optimal therapy worldwide. In the latest years, as a consequence of the large expansion of highly active antiretroviral therapy (HAART) availability worldwide, an increase in transmitted drug resistance mutations (TDRM) has been observed, varying according the region. This study assessed HIV-1 diversity and TDRM profile over time among newly HIV-1 diagnosed individuals from Rio de Janeiro, Brazil. Blood samples were collected from individuals seeking HIV diagnosis in four voluntary counseling and testing (VCTs) sites located in the Rio de Janeiro Metropolitan Area, in 2005-2007. Recent (RS) and long-term (LTS) HIV-1 seroconverters were distinguished using BED-CEIA. Pol viral sequences were obtained for 102 LTS identified in 2005 and 144 RS from 2005-2007. HIV-1 subtype and pol recombinant genomes were determined using Rega HIV-1 Subtyping Tool and by phylogenetic inferences and bootscanning analyses. Surveillance of HIV-1 TDRM to protease and reverse transcriptase inhibitors were performed according to the Calibrated Population Resistance (CPR) Tool 6.0. Overall, subtype B remains the most prevalent in Rio de Janeiro in both LTS and RS HIV-1 infected individuals. An increased proportion of recombinant samples was detected over time, especially in RS heterosexual men, due to the emergence of CRF02_AG and URF samples bearing a subtype K fragment. The prevalence of HIV-1 samples carrying TDRM was high and similar between LTS and RS (15.7% vs 14.6%) or age (<25yo 17.9% vs >25yo 16.6%) along the study period. The high resistance levels detected in both populations are of concern, especially considering the dynamics of HIV-1 diversity over time. Our results suggest that the incorporation of resistance testing prior to HAART initiation should be highly considered, as well as permanent surveillance, aiming to carefully monitoring HIV-1 diversity, with focus on CRF/URF emergence and putative transmission.
C1 [Velasco-de-Castro, Carlos A.; Pilotto, Jose H.; Morgado, Mariza G.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
   [Velasco-de-Castro, Carlos A.; Grinsztejn, Beatriz; Veloso, Valdilea G.; Fernandes, Nilo] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Velasco-de-Castro, Carlos A.] Fundacao Oswaldo Cruz, Inst Fernandes Figueira, Dept Patol Clin, Virol Lab, Rio De Janeiro, RJ, Brazil.
   [Bastos, Francisco I.] Fundacao Oswaldo Cruz, Inst Comunicacao & Informacao Cient & Tecnol Saud, Rio De Janeiro, RJ, Brazil.
   [Bastos, Francisco I.] Fundacao Oswaldo Cruz, Lab Informacao Saude, Rio De Janeiro, RJ, Brazil.
   [Pilotto, Jose H.] Hosp Geral Nova Iguacu, Nova Iguacu, RJ, Brazil.
RP Velasco-de-Castro, CA (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
EM cavcastro@fiocruz.br; mmorgado@ioc.fiocruz.brand
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Bastos,
   Francisco/0000-0001-5970-8896
FU Brazilian Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq); FaperjCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ); NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI106701, UM1AI106701, UM1AI106701, UM1AI106701, UM1AI106701,
   UM1AI106701] Funding Source: NIH RePORTER
FX This study was supported by Brazilian Research Council (CNPq) and
   Faperj. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Almeida SEM, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-306
   Arruda E, 2011, AIDS RES HUM RETROV, V27, P153, DOI 10.1089/aid.2010.0028
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bennett DE, 2008, ANTIVIR THER, V13, P25
   Bermudez-Aza EH, 2011, JAIDS-J ACQ IMM DEF, V57, pS186, DOI 10.1097/QAI.0b013e31821e9c36
   Brindeiro R, 1999, ANTIMICROB AGENTS CH, V43, P1674, DOI 10.1128/AAC.43.7.1674
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Burland T G, 2000, Methods Mol Biol, V132, P71
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Delatorre EO, 2012, AIDS RES HUM RETROV, V28, P1369, DOI 10.1089/aid.2011.0381
   Dobbs T, 2004, J CLIN MICROBIOL, V42, P2623, DOI 10.1128/JCM.42.6.2623-2628.2004
   Dobbs T, 2003, MLO MED LAB OBS, V35, P19
   Dobbs T, 2003, MLO MED LAB OBS, V35, P24
   Dobbs T, 2003, MLO MED LAB OBS, V35, P16
   Dobbs Trudy, 2003, MLO Med Lab Obs, V35, P12
   Dumans AT, 2002, ANTIMICROB AGENTS CH, V46, P3075, DOI 10.1128/AAC.46.9.3075-3079.2002
   Ever-Silva WA, 2006, JAIDS-J ACQ IMM DEF, V41, P664, DOI 10.1097/01.qai.0000194736.66322.02
   Ferreira AS, 2011, J MED VIROL, V83, P1301, DOI 10.1002/jmv.22128
   Ferreira FGF, 2010, AIDS RES HUM RETROV, V26, P229, DOI 10.1089/aid.2009.0146
   Gifford RJ, 2009, BIOINFORMATICS, V25, P1197, DOI 10.1093/bioinformatics/btp134
   Graf T, 2011, J CLIN VIROL, V51, P186, DOI 10.1016/j.jcv.2011.04.011
   Guimaraes ML, 2010, INFECT GENET EVOL, V10, P1094, DOI 10.1016/j.meegid.2010.07.001
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Johnston KM, 2010, AIDS, V24, P1929, DOI 10.1097/QAD.0b013e32833af85d
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pilotto JH, 2013, AIDS RES HUM RETROV, V29, P681, DOI [10.1089/aid.2011.0333, 10.1089/AID.2011.0333]
   Pires IL, 2004, J CLIN MICROBIOL, V42, P426, DOI 10.1128/JCM.42.1.426-430.2004
   Richman DD, 2004, AIDS, V18, P1393, DOI 10.1097/01.aids.0000131310.52526.c7
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   Scott P, 2004, J ANTIMICROB CHEMOTH, V53, P469, DOI 10.1093/jac/dkh102
   Shafer RW, 2008, ANTIVIR THER, V13, P59
   Sprinz E, 2009, AIDS RES HUM RETROV, V25, P861, DOI 10.1089/aid.2009.0012
   Szwarcwald CL, 2008, BRAZ J INFECT DIS, V12, P167, DOI 10.1590/S1413-86702008000300002
   Tamalet C, 2003, AIDS, V17, P2383, DOI 10.1097/00002030-200311070-00014
   Taniguchi T, 2012, AIDS RES HUM RETROV, V28, P259, DOI 10.1089/aid.2011.0022
   Triques K, 2000, AIDS RES HUM RETROV, V16, P139, DOI 10.1089/088922200309485
   UN Joint Programme on HIV/AIDS (UNAIDS), 2012, GLOB REP UNAIDS REP
   UNAIDS, 2010, GLOB REP UNAIDS REP
   de Castro CAV, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-224
   Vicente ACP, 2000, J ACQ IMMUN DEF SYND, V23, P327
   Worobey M, 2008, NATURE, V455, P661, DOI 10.1038/nature07390
NR 46
TC 19
Z9 19
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 30
PY 2014
VL 9
IS 1
AR e87622
DI 10.1371/journal.pone.0087622
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 302PJ
UT WOS:000330617100102
PM 24498155
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Ribeiro, SR
   Luz, PM
   Campos, DP
   Moreira, RI
   Coelho, L
   Japiassu, A
   Bozza, F
   Veloso, VG
   Chene, G
   Grinsztejn, B
AF Ribeiro, Sayonara R.
   Luz, Paula M.
   Campos, Dayse P.
   Moreira, Ronaldo I.
   Coelho, Lara
   Japiassu, Andre
   Bozza, Fernando
   Veloso, Valdilea G.
   Chene, Genevieve
   Grinsztejn, Beatriz
TI Incidence and determinants of severe morbidity among HIV-infected
   patients from Rio de Janeiro, Brazil, 2000-2010
SO ANTIVIRAL THERAPY
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; LONGITUDINAL DATA-ANALYSIS;
   UNITED-STATES; CLINICAL CARE; HAART ERA; COHORT; MORTALITY; EFFICACY;
   TRENDS; AIDS
AB Background: Reliable information on severe morbidity is essential for identifying priorities for case management and to guide resource allocation within the health sector.
   Methods: This study describes overall, AIDS-and non-AIDS-related severe morbidity as well as mortality and its determinants in an urban cohort of HIV-infected individuals from a public healthcare institution, the Evandro Chagas Research Institute (IPEC) of the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Severe morbid events were defined as all clinical diagnoses listed in hospitalization discharge records; all diagnoses were checked and validated. Generalized estimating equation models were used to estimate incidence rates while adjusting for within-subject correlation.
   Results: Between 2000 and 2010, 3,537 patients were followed for a total of 16,960 person-years (PY) of follow-up. Over the years, annual incidence rate of severe morbid events, AIDS-related events, non-AIDS-related events, and deaths significantly decreased from, respectively, 36.6, 12.9, 23.7 and 3.2 per 100 PY in 2000 to 25.3, 7.9, 17.4 and 1.9 per 100 PY in 2010. Patients' immunological profiles significantly improved with time; 84% of the patients used combination antiretroviral therapy (cART) per year. Immunodeficiency was associated with a higher incidence rate of AIDS-and non-AIDS-related events as well as with the incidence rate of specific non-AIDS events (bacterial infections, toxicities, cardiovascular, renal and respiratory diseases).
   Conclusions: Our results show that in a middle income country with access to cART, non-AIDS-related events represent an important cause of severe morbidity alongside a still high incidence rate of AIDS-related events.
C1 [Ribeiro, Sayonara R.; Luz, Paula M.; Campos, Dayse P.; Moreira, Ronaldo I.; Coelho, Lara; Japiassu, Andre; Bozza, Fernando; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Chene, Genevieve] INSERM, U593, Bordeaux, France.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM luzpaulamendes@gmail.com
RI chene, genevieve/H-8665-2014; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Luz, Paula/0000-0001-9746-719X
CR Anglaret X, 2012, CLIN INFECT DIS, V54, P714, DOI 10.1093/cid/cir898
   Ballinger GA, 2004, ORGAN RES METHODS, V7, P127, DOI 10.1177/1094428104263672
   Belloso WH, 2010, HIV MED, V11, P554, DOI 10.1111/j.1468-1293.2010.00824.x
   Berry SA, 2012, JAIDS-J ACQ IMM DEF, V59, P368, DOI 10.1097/QAI.0b013e318246b862
   Bonnet F, 2009, CLIN INFECT DIS, V48, P633, DOI 10.1086/596766
   Bonnet F, 2007, HIV MED, V8, P547, DOI 10.1111/j.1468-1293.2007.00508.x
   Buchacz K, 2008, AIDS, V22, P1345, DOI 10.1097/QAD.0b013e328304b38b
   Cardoso SW, 2010, AIDS RES HUM RETROV, V26, P865, DOI 10.1089/aid.2009.0274
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Crum-Cianflone N, 2009, AIDS, V23, P41, DOI 10.1097/QAD.0b013e328317cc2d
   Crum-Cianflone NF, 2010, JAIDS-J ACQ IMM DEF, V54, P248, DOI 10.1097/QAI.0b013e3181c8ef22
   DeJesus E, 2012, HIV CLIN TRIALS, V13, P228, DOI 10.1310/hct1304-228
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Katlama C, 2007, AIDS, V21, P395, DOI 10.1097/QAD.0b013e328013d9d7
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267
   Ministerio da Saude Brazil, REC TER ANT AD INF P
   Mocroft A, 2004, HIV MED, V5, P437, DOI 10.1111/j.1468-1293.2004.00250.x
   Mocroft A, 2010, JAIDS-J ACQ IMM DEF, V55, P262, DOI 10.1097/QAI.0b013e3181e9be6b
   Molina JM, 2010, JAIDS-J ACQ IMM DEF, V53, P323, DOI 10.1097/QAI.0b013e3181c990bf
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Sogaard OS, 2008, CLIN INFECT DIS, V47, P1345, DOI 10.1086/592692
   Yehia BR, 2011, HIV MED, V12, P535, DOI 10.1111/j.1468-1293.2011.00919.x
   Zwahlen M, 2009, INT J EPIDEMIOL, V38, P1624, DOI 10.1093/ije/dyp306
NR 30
TC 12
Z9 12
U1 0
U2 5
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2014
VL 19
IS 4
BP 387
EP 397
DI 10.3851/IMP2716
PG 11
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA CA0IQ
UT WOS:000348601800008
PM 24445387
DA 2020-11-24
ER

PT J
AU Montes, ML
   Nelson, M
   Girard, PM
   Sasadeusz, J
   Horban, A
   Grinsztejn, B
   Zakharova, N
   Rivero, A
   Lathouwers, E
   Janssen, K
   Ouwerkerk-Mahadevan, S
   Witek, J
AF Montes, Marisa L.
   Nelson, Mark
   Girard, Pierre-Marie
   Sasadeusz, Joe
   Horban, Andrzej
   Grinsztejn, Beatriz
   Zakharova, Natalia
   Rivero, Antonio
   Lathouwers, Erkki
   Janssen, Katrien
   Ouwerkerk-Mahadevan, Sivi
   Witek, James
TI Telaprevir combination therapy in treatment-naive and -experienced
   patients co-infected with HCV/HIV (INSIGHT STUDY): sustained virologic
   response at 12 weeks final analysis
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 07-11, 2014
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Montes, Marisa L.] Univ Autonoma Madrid, Hosp La Paz, HIV Unit, IdiPAZ, Madrid, Spain.
   [Nelson, Mark] Chelsea & Westminster Hosp, St Stephens Ctr, London, England.
   [Girard, Pierre-Marie] Hop St Antoine, F-75571 Paris, France.
   [Sasadeusz, Joe] Royal Melbourne Hosp, Melbourne, Vic, Australia.
   [Sasadeusz, Joe] Alfred Hosp, Melbourne, Vic, Australia.
   [Horban, Andrzej] Med Univ Warsaw, Hosp Infect Dis, Warsaw, Poland.
   [Grinsztejn, Beatriz] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, STD AIDS Clin Res Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Zakharova, Natalia] St Petersburg AIDS Ctr, St Petersburg, Russia.
   [Rivero, Antonio] Hosp Univ Reina Sofia IMIBIC, Cordoba, Spain.
   [Lathouwers, Erkki] Janssen Infect Dis BVBA, Beerse, Belgium.
   [Janssen, Katrien; Ouwerkerk-Mahadevan, Sivi; Witek, James] Janssen Res & Dev LLC, Titusville, NJ USA.
RI Ramirez, Maria Luisa Montes/H-8065-2017; Rivero, Antonio/ABE-5294-2020
OI Ramirez, Maria Luisa Montes/0000-0003-1748-813X; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PY 2014
VL 60
SU 1
SI SI
MA 985
BP 678A
EP 678A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AS8EW
UT WOS:000344483803034
DA 2020-11-24
ER

PT J
AU Perazzo, H
   Soares, JC
   Fernandes, FF
   Fittipaldi, J
   Cardoso, SW
   Grinsztejn, B
   Veloso, V
AF Perazzo, Hugo
   Soares, Joao Carlos
   Fernandes, Flavia F.
   Fittipaldi, Juliana
   Cardoso, Sandra W.
   Grinsztejn, Beatriz
   Veloso, Valdilea
TI Learning curve and intraobserver agreement of liver stiffness
   measurement in chronic hepatitis C with or without HIV co-infection
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 07-11, 2014
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Perazzo, Hugo; Soares, Joao Carlos; Fittipaldi, Juliana; Cardoso, Sandra W.; Grinsztejn, Beatriz; Veloso, Valdilea] Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   [Fernandes, Flavia F.] Bonsucesso Fed Hosp, Rio De Janeiro, Brazil.
RI Cardoso, Sandra W/D-7965-2015; Fernandes, Flavia Ferreira/I-8010-2019
OI Cardoso, Sandra W/0000-0001-5230-0003; Fernandes, Flavia
   Ferreira/0000-0002-3149-3667
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PY 2014
VL 60
SU 1
SI SI
MA 1532
BP 935A
EP 936A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AS8EW
UT WOS:000344483804095
DA 2020-11-24
ER

PT J
AU Russomano, F
   Paz, BR
   Camargo, MJ
   Grinsztejn, B
   Friedman, RK
   Tristao, MAP
   Oliveira, CA
AF Russomano, F.
   Paz, B. R.
   Camargo, M. J.
   Grinsztejn, B.
   Friedman, R. K.
   Tristao, M. A. P.
   Oliveira, C. A.
TI Recurrence of cervical intraepithelial neoplasia in human
   immunodeficiency virus-infected women treated by means of
   electrosurgical excision of the transformation zone (LLETZ) in Rio de
   Janeiro, Brazil (vol 131, pg 405, 2013)
SO SAO PAULO MEDICAL JOURNAL
LA English
DT Correction
CR Russomano F, 2013, SAO PAULO MED J, V131, P405, DOI 10.1590/1516-3180.2013.1316578
NR 1
TC 0
Z9 0
U1 0
U2 3
PU ASSOCIACAO PAULISTA MEDICINA
PI SAO PAULO
PA AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL
SN 1516-3180
J9 SAO PAULO MED J
JI Sao Paulo Med. J.
PY 2014
VL 132
IS 2
BP 130
EP 130
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA AF3GK
UT WOS:000334599500014
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Torres, TS
   Cardoso, SW
   Velasque, LS
   Veloso, VG
   Grinsztejn, B
AF Torres, Thiago Silva
   Cardoso, Sandra Wagner
   Velasque, Luciane S.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
TI Incidence rate of modifying or discontinuing first combined
   antiretroviral therapy regimen due to toxicity during the first year of
   treatment stratified by age
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Toxicity; Aging; Antiretroviral
ID HIV-INFECTED PATIENTS; RIO-DE-JANEIRO; PROTEASE INHIBITOR; CLINICAL
   CARE; HAART REGIMEN; OLDER AGE; REASONS; ADHERENCE; COHORT; DETERMINANTS
AB Toxicity is the most frequently reported reason for modifying or discontinuing the first combined antiretroviral therapy regimens, and it can cause significant morbidity, poor quality of life and also can be an important barrier to adherence, ultimately resulting in treatment failure and viral resistance. Elderly patients with HIV/AIDS (>= 50 years) may have a different profile in terms of treatment modification due to higher incidence of comorbidities and polypharmacy. The aim of this study was to describe the incidence of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity (Tax-MOD) during the first year of treatment at the IPEC - FIOCRUZ HIV/AIDS cohort, Rio de Janeiro, Brazil, stratified by age. Demographic, clinical and treatment characteristics from antiretroviral-naive patients who first received combined antiretroviral therapy between Jan/1996 and Dec/2010 were collected. Incidence rate and confidence interval of each event were estimated using quasipoisson model. To estimate hazard ratio (HR) of TOX-MOD during the first year of combined antiretroviral therapy Cox's proportional hazards regression was applied. Overall, 1558 patients were included; 957 (61.4%), 420 (27.0%) and 181 (11.6%) were aged <40, 40-49, and >= 50 years, respectively. 239 (15.3%) events that led to any modifying or discontinuing within the first year of treatment were observed; 228 (95.4%) of these were TOX-MOD, corresponding to an incidence rate of 16.6/100 PY (95% CI: 14.6-18.9). The most frequent TOX-MOD during first combined antiretroviral therapy regimen were hematologic (59; 26.3%), central nervous system (47; 20.9%), rash (42; 19.1%) and gastrointestinal (GI) (38; 16.7%). In multivariate analysis, incidence ratio of TOX-MOD during the first year of combined antiretroviral therapy progressively increases with age, albeit not reaching statistical significance. This profile was maintained after adjusting the model for sex, combined antiretroviral therapy regimen and year of combined antiretroviral therapy initiation. These results are important because not only patients are living longer and aging with HIV but also new diagnoses are being made among the elderly. Prospective studies are needed to evaluate the safety profile of first line combined antiretroviral therapy on elderly individuals, especially in resource-limited countries, where initial regimens are mostly NNRTI-based. (C) 2013 Elsevier Editora Ltda. All rights reserved.
C1 [Torres, Thiago Silva; Cardoso, Sandra Wagner; Velasque, Luciane S.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Inst Pesquisa Clin Evandro Chagas, HIV AIDS Clin Res Ctr, Rio De Janeiro, RJ, Brazil.
   [Velasque, Luciane S.] Univ Fed Rio de Janeiro UFRJ, Dept Matemat, Rio De Janeiro, RJ, Brazil.
RP Grinsztejn, B (corresponding author), Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI TORRES, THIAGO SILVA/D-6548-2014; Cardoso, Sandra W/D-7965-2015
OI TORRES, THIAGO SILVA/0000-0002-2557-601X; Cardoso, Sandra
   W/0000-0001-5230-0003
CR Althoff KN, 2010, AIDS, V24, P2467, DOI 10.1097/QAD.0b013e32833e6d14
   Antoniou T, 2002, ANN PHARMACOTHER, V36, P1598
   Braithwaite RS, 2007, AIDS, V21, P1579, DOI 10.1097/QAD.0b013e3281532b31
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   Cardoso SW, 2010, AIDS RES HUM RETROV, V26, P865, DOI 10.1089/aid.2009.0274
   Carr A, 2009, AIDS, V23, P343, DOI 10.1097/QAD.0b013e32831db232
   Centers for Disease Control - CDC (USA), PERS AG 50 OLD
   Cesar C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010490
   Cicconi P, 2010, HIV MED, V11, P104, DOI 10.1111/j.1468-1293.2009.00750.x
   CICCONI P, 2005, 3 INT AIDS SOC C HIV
   Cordery DV, 2011, SEX HEALTH, V8, P534, DOI 10.1071/SH11026
   Cuzin L, 2007, CLIN INFECT DIS, V45, P654, DOI 10.1086/520652
   Dorrucci M, 2001, AIDS, V15, P1733, DOI 10.1097/00002030-200109070-00020
   Fonseca MGP, 2007, CAD SAUDE PUBLICA, V23, pS333, DOI 10.1590/S0102-311X2007001500002
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   Hansel A, 2001, J ACQ IMMUN DEF SYND, V26, P191, DOI 10.1097/00126334-200102010-00016
   Hart E, 2007, HIV MED, V8, P186, DOI 10.1111/j.1468-1293.2007.00451.x
   Knobel H, 2001, AIDS, V15, P1591, DOI 10.1097/00002030-200108170-00025
   Kumarasamy N, 2006, JAIDS-J ACQ IMM DEF, V41, P53, DOI 10.1097/01.qai.0000188123.15493.43
   Lazarus JV, 2010, HIV MED, V11, P479, DOI 10.1111/j.1468-1293.2009.00810.x
   Le Moing V, 2002, CLIN INFECT DIS, V34, P239, DOI 10.1086/324354
   Lodwick RK, 2008, AIDS, V22, P1039, DOI 10.1097/QAD.0b013e3282fec415
   MERCOSUL, B EP INT HIV AIDS RE
   Ministerio da Saude (Brazil), REC TER ANT AD VIV C
   Ministerio da Saude (Brazil) Secretaria de Vigilancia em Saude Departamento de DST AIDS e Hepatites Virais, 2011, B EP AIDS DST, VVIII
   Mocroft A, 2005, AIDS RES HUM RETROV, V21, P743, DOI 10.1089/aid.2005.21.743
   Mocroft A, 2001, AIDS, V15, P185, DOI 10.1097/00002030-200101260-00007
   Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Nakimuli-Mpungu E., 2011, NEUROBEHAV HIV MED, V3, P1
   O'Brien ME, 2003, JAIDS-J ACQ IMM DEF, V34, P407, DOI 10.1097/00126334-200312010-00008
   Rhee MS, 2008, J CLIN PHARMACOL, V48, P1212, DOI 10.1177/0091270008322177
   Sabin CA, 2009, HIV MED, V10, P35, DOI 10.1111/j.1468-1293.2008.00654.x
   Silverberg MJ, 2007, ARCH INTERN MED, V167, P684, DOI 10.1001/archinte.167.7.684
   Simone MJ, 2008, GERIATRICS, V63, P6
   Spire B, 2002, SOC SCI MED, V54, P1481, DOI 10.1016/S0277-9536(01)00125-3
   Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501
   Stone VE, 2004, JAIDS-J ACQ IMM DEF, V36, P808, DOI 10.1097/00126334-200407010-00007
   Teixeira PR, 2004, AIDS, V18, pS5, DOI 10.1097/00002030-200406003-00002
   Tumbarello M, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-46
   van Roon EN, 1999, J ACQ IMMUN DEF SYND, V20, P290, DOI 10.1097/00042560-199903010-00012
   Vo TTN, 2008, J INFECT DIS, V197, P1685, DOI 10.1086/588141
   Woldemedhin B, 2012, N AM J MED SCI, V4, P19, DOI 10.4103/1947-2714.92898
   Yuan Y, 2006, HIV MED, V7, P156, DOI 10.1111/j.1468-1293.2006.00355.x
NR 45
TC 13
Z9 13
U1 0
U2 7
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JAN-FEB
PY 2014
VL 18
IS 1
BP 34
EP 41
DI 10.1016/j.bjid.2013.04.005
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA AD0FY
UT WOS:000332911100006
PM 24029435
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Perisse, ARS
   Smeaton, L
   Chen, Y
   La Rosa, A
   Walawander, A
   Nair, A
   Grinsztejn, B
   Santos, B
   Kanyama, C
   Hakim, J
   Nyirenda, M
   Kumarasamy, N
   Lalloo, UG
   Flanigan, T
   Campbell, TB
   Hughes, MD
AF Perisse, Andre R. S.
   Smeaton, Laura
   Chen, Yun
   La Rosa, Alberto
   Walawander, Ann
   Nair, Apsara
   Grinsztejn, Beatriz
   Santos, Breno
   Kanyama, Cecilia
   Hakim, James
   Nyirenda, Mulinda
   Kumarasamy, Nagalingeswaran
   Lalloo, Umesh G.
   Flanigan, Timothy
   Campbell, Thomas B.
   Hughes, Michael D.
CA ACTG
TI Outcomes among HIV-1 Infected Individuals First Starting Antiretroviral
   Therapy with Concurrent Active TB or Other AIDS-Defining Disease
SO PLOS ONE
LA English
DT Article
ID IMMUNE RESTORATION DISEASE; HIV-INFECTED PATIENTS; OPPORTUNISTIC
   INFECTIONS; TREATMENT RESPONSE; TUBERCULOSIS; HAART; MORTALITY;
   SURVIVAL; INITIATION; DIAGNOSIS
AB Background: Tuberculosis (TB) is common among HIV-infected individuals in many resource-limited countries and has been associated with poor survival. We evaluated morbidity and mortality among individuals first starting antiretroviral therapy (ART) with concurrent active TB or other AIDS-defining disease using data from the "Prospective Evaluation of Antiretrovirals in Resource-Limited Settings" (PEARLS) study.
   Methods: Participants were categorized retrospectively into three groups according to presence of active confirmed or presumptive disease at ART initiation: those with pulmonary and/or extrapulmonary TB ("TB" group), those with other non-TB AIDS-defining disease ("other disease"), or those without concurrent TB or other AIDS-defining disease ("no disease"). Primary outcome was time to the first of virologic failure, HIV disease progression or death. Since the groups differed in characteristics, proportional hazard models were used to compare the hazard of the primary outcome among study groups, adjusting for age, sex, country, screening CD4 count, baseline viral load and ART regimen.
   Results: 31 of 102 participants (30%) in the "TB" group, 11 of 56 (20%) in the "other disease'' group, and 287 of 1413 (20%) in the "no disease'' group experienced a primary outcome event (p = 0.042). This difference reflected higher mortality in the TB group: 15 (15%), 0 (0%) and 41 (3%) participants died, respectively (p<0.001). The adjusted hazard ratio comparing the "TB" and "no disease'' groups was 1.39 (95% confidence interval: 0.93-2.10; p = 0.11) for the primary outcome and 3.41 (1.72-6.75; p<0.001) for death.
   Conclusions: Active TB at ART initiation was associated with increased risk of mortality in HIV-1 infected patients.
C1 [Perisse, Andre R. S.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Dept Ciencias Biol, Rio De Janeiro, Brazil.
   [Smeaton, Laura; Chen, Yun] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [La Rosa, Alberto] Asociac Civil Impacta Salud & Educ Barranco, Lima, Peru.
   [Walawander, Ann; Nair, Apsara] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Clin Res Inst, BR-21045900 Rio De Janeiro, Brazil.
   [Santos, Breno] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Kanyama, Cecilia] Kamuzu Cent Hosp, Lilongwe, Malawi.
   [Hakim, James] Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe.
   [Nyirenda, Mulinda] Univ Malawi, Coll Med, Blantyre, Malawi.
   [Kumarasamy, Nagalingeswaran] YRG Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
   [Lalloo, Umesh G.] Nelson R Mandela Sch Med, Durban, South Africa.
   [Flanigan, Timothy] Brown Med Sch, Providence, RI USA.
   [Campbell, Thomas B.] Univ Colorado, Sch Med, Dept Med, Div Infect Dis, Aurora, CO USA.
   [Hughes, Michael D.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Perisse, ARS (corresponding author), Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Dept Ciencias Biol, Rio De Janeiro, Brazil.
EM aperisse@ensp.fiocruz.br
OI Nyirenda, Mulinda/0000-0003-2037-7449
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UMAI068634, UMAI068636]; National Institute of Mental Health (NIMH),
   National Institute of Dental and Craniofacial Research (NIDCR)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH)NIH
   National Institute of Dental & Craniofacial Research (NIDCR); Gilead
   Sciences, Inc.Gilead Sciences; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000457, UL1TR000457,
   UL1TR000457, UL1TR000457, UL1TR000457, UL1TR000457, UL1TR000457] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069412, UM1AI069518, UM1AI069518,
   UM1AI069412, UM1AI069412, UM1AI069518, UM1AI069518, UM1AI069412,
   UM1AI069518, UM1AI069412, UM1AI069412, UM1AI069518, UM1AI069412,
   UM1AI069518, UM1AI069412, UM1AI069518] Funding Source: NIH RePORTER
FX The project described was supported by Award Numbers UMAI068634 and
   UMAI068636 from the National Institute of Allergy and Infectious
   Diseases and supported by National Institute of Mental Health (NIMH),
   National Institute of Dental and Craniofacial Research (NIDCR). The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institute of
   Allergy and Infectious Diseases or the National Institutes of Health.
   Bristol Myers Squibb provided atazanavir, didanosine-EC and efavirenz
   (with consent of Merck); Gilead Sciences, Inc. provided emtricitabine,
   tenofovir-DF, emtricitabine/tenofovir-DF and financial support for
   purchase of other study drugs; GlaxoSmithKline provided lamivudine,
   zidovudine and lamivudine/zidovudine; and Boehringer Ingelheim
   Pharmaceuticals, Inc. provided nevirapine. This does not alter the
   authors' adherence to all the PLOS ONE policies on sharing data and
   materials. Employees of the NIAID participated as study team members and
   authors of this manuscript. The NIAID provided recommendations on the
   study design and approved the final study design, but had no role in
   data collection and analysis, decision to publish, or preparation of the
   manuscript. Bristol Myers Squibb, Gilead Sciences Inc., GlaxoSmithKline
   and Boehringer Ingelheim Pharmaceuticals, Inc. had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. Representatives of the pharmaceutical
   company sponsors participated as study team members and authors of this
   manuscript, but did not participate in data collection, data analyses or
   interpretation.
CR Aiuti F, 2006, AIDS REV, V8, P88
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Degu WA, 2012, 19 C RETR OPP INF 5
   Dronda F, 2011, CURR HIV RES, V9, P229, DOI 10.2174/157016211796320324
   Esposito A, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-341
   French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06
   Granich R, 2011, CURR HIV RES, V9, P446, DOI 10.2174/157016211798038597
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   Jevtovic D, 2005, HIV MED, V6, P140, DOI 10.1111/j.1468-1293.2005.00277.x
   Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848
   Lawn SD, 2011, CURR OPIN INFECT DIS, V24, P34, DOI 10.1097/QCO.0b013e3283420f76
   Manosuthi W, 2006, JAIDS-J ACQ IMM DEF, V43, P42, DOI 10.1097/01.qai.0000230521.86964.86
   Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0
   Mocroft A, 2009, CLIN INFECT DIS, V48, P1138, DOI 10.1086/597468
   Panel on Antiretroviral Guidelines for Adults and Adolescents, GUIDELINES USE ANTIR
   Perez-Molina JA, 2012, J ANTIMICROB CHEMOTH, V67, P312, DOI 10.1093/jac/dkr478
   Sabin CA, 2002, AIDS, V16, pS61, DOI 10.1097/00002030-200216004-00009
   Straetemans M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015241
   Velasco M, 2009, JAIDS-J ACQ IMM DEF, V50, P148, DOI 10.1097/QAI.0b013e31819367e7
   Walensky RP, 2006, J INFECT DIS, V194, P11, DOI 10.1086/505147
   Westreich D, 2012, AIDS, V26, P770, DOI 10.1097/QAD.0b013e328351f6b8
   World Health Organization, 2010, ANT THER HIV INF AD
   Zolopa AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005575
NR 24
TC 2
Z9 2
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2013
VL 8
IS 12
AR e83643
DI 10.1371/journal.pone.0083643
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 284NF
UT WOS:000329325200099
PM 24391801
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Fogel, JM
   Wang, L
   Parsons, TL
   Ou, SS
   Piwowar-Manning, E
   Chen, Y
   Mudhune, VO
   Hosseinipour, MC
   Kumwenda, J
   Hakim, JG
   Chariyalertsak, S
   Panchia, R
   Sanne, I
   Kumarasamy, N
   Grinsztejn, B
   Makhema, J
   Pilotto, J
   Santos, BR
   Mayer, KH
   McCauley, M
   Gamble, T
   Bumpus, NN
   Hendrix, CW
   Cohen, MS
   Eshleman, SH
AF Fogel, Jessica M.
   Wang, Lei
   Parsons, Teresa L.
   Ou, San-San
   Piwowar-Manning, Estelle
   Chen, Ying
   Mudhune, Victor O.
   Hosseinipour, Mina C.
   Kumwenda, Johnstone
   Hakim, James G.
   Chariyalertsak, Suwat
   Panchia, Ravindre
   Sanne, Ian
   Kumarasamy, Nagalingeswaran
   Grinsztejn, Beatriz
   Makhema, Joseph
   Pilotto, Jose
   Santos, Breno R.
   Mayer, Kenneth H.
   McCauley, Marybeth
   Gamble, Theresa
   Bumpus, Namandje N.
   Hendrix, Craig W.
   Cohen, Myron S.
   Eshleman, Susan H.
TI Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial
   (HIV Prevention Trials Network 052)
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; antiretroviral drug; self-report; HPTN 052; Africa; clinical trial
ID PREEXPOSURE PROPHYLAXIS; TRANSMISSION; INFECTION; MEN
AB The HIV Prevention Trials Network 052 study enrolled serodiscordant couples. Index participants infected with human immunodeficiency virus reported no prior antiretroviral (ARV) treatment at enrollment. ARV drug testing was performed retrospectively using enrollment samples from a subset of index participants. ARV drugs were detected in 45 of 96 participants (46.9%) with an undetectable viral load, 2 of 48 (4.2%) with a low viral load, and 1 of 65 (1.5%) with a high viral load (P<.0001); they were also detected in follow-up samples from participants who were not receiving study-administered treatment. ARV drug testing may be useful in addition to self-report of ARV drug use in some clinical trial settings.
C1 [Fogel, Jessica M.; Piwowar-Manning, Estelle; Eshleman, Susan H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Parsons, Teresa L.; Bumpus, Namandje N.; Hendrix, Craig W.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Wang, Lei; Ou, San-San; Chen, Ying] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA.
   [Mayer, Kenneth H.] Fenway Hlth, Boston, MA USA.
   [McCauley, Marybeth] FHI360, Washington, DC USA.
   [Gamble, Theresa] FHI360, Durham, NC USA.
   [Cohen, Myron S.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
   [Mudhune, Victor O.] KEMRI CDC HIV Res Branch, Kisumu, Kenya.
   [Hosseinipour, Mina C.] Kamuzu Cent Hosp, UNC Project, Lilongwe, Malawi.
   [Kumwenda, Johnstone] Coll Med, Blantyre, Malawi.
   [Hakim, James G.] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Panchia, Ravindre] Univ Witwatersrand, Dept Med, Fac Hlth Sci, Perinatal HIV Res Unit, ZA-2001 Johannesburg, South Africa.
   [Sanne, Ian] Univ Witwatersrand, Dept Med, Fac Hlth Sci, Clin HIV Res Unit, ZA-2001 Johannesburg, South Africa.
   [Kumarasamy, Nagalingeswaran] YR Gaitonade Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
   [Grinsztejn, Beatriz] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Lab Pesquisa Clin DST AIDS, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, Jose] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, Jose] IOC Fiocruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Santos, Breno R.] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Makhema, Joseph] Botswana Harvard Sch Publ Hlth, AIDS Initiat Partnership, Gaborone, Botswana.
RP Eshleman, SH (corresponding author), Johns Hopkins Med Inst, Dept Pathol, Ross Bldg,Room 646,720 Rutland Ave, Baltimore, MD 21205 USA.
EM seshlem@jhmi.edu
RI Hendrix, Craig/G-4182-2014; Pilotto, Jose Henrique/AAD-9773-2019
OI Hendrix, Craig/0000-0002-5696-8665; Pilotto, Jose
   Henrique/0000-0003-0521-8597
FU Division of AIDS of the US National Institute of Allergy and Infectious
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); Office of AIDS Research of the US National
   Institutes of Health [U01-AI018136, U01-AI068613/UM1-AI068613,
   U01-AI068617/UM1-AI068617, U01-AI068619/UM1-AI068619]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069399, UM1AI069463, UM1AI068617, UM1AI068613, UM1AI069399,
   UM1AI068619, U01AI068613, UM1AI068613, UM1AI068613, UM1AI069456,
   UM1AI068619, U01AI068617, UM1AI068619, UM1AI068619, UM1AI069399,
   UM1AI069456, UM1AI068617, UM1AI069463, UM1AI069463, UM1AI068619,
   UM1AI069399, UM1AI068617, UM1AI068613, UM1AI069456, UM1AI069518,
   UM1AI069436, UM1AI068613, UM1AI068619, UM1AI069436, UM1AI068617,
   U01AI068613, UM1AI069436, UM1AI068613, UM1AI069518, UM1AI069518,
   U01AI068617, UM1AI068619, U01AI068619, UM1AI068617, UM1AI069436,
   UM1AI069518, UM1AI069518, UM1AI068613, UM1AI069463, UM1AI069456,
   UM1AI068617, UM1AI069518, UM1AI069399, UM1AI068619, U01AI068617,
   UM1AI069399, U01AI068613, U01AI068613, UM1AI069463, UM1AI069456,
   UM1AI069436, UM1AI069463, U01AI068619, UM1AI069518, UM1AI068619,
   U01AI068619, UM1AI069399, UM1AI069436, UM1AI068613, UM1AI069456,
   UM1AI069436, UM1AI069518, U01AI068617, U01AI068619, UM1AI069436,
   UM1AI068613, UM1AI068617, UM1AI069456, U01AI068619, U01AI068613,
   UM1AI069456, UM1AI069463, UM1AI069463, UM1AI069399, UM1AI068617,
   UM1AI068617, UM1AI068613, U01AI068617] Funding Source: NIH RePORTER
FX This work was supported by the Division of AIDS of the US National
   Institute of Allergy and Infectious Diseases and the Office of AIDS
   Research of the US National Institutes of Health (grants U01-AI018136,
   U01-AI068613/UM1-AI068613, U01-AI068617/UM1-AI068617, and
   U01-AI068619/UM1-AI068619). Study drugs used in HPTN 052 were donated by
   Abbott Laboratories, Boehringer-Ingelheim Pharmaceuticals, Bristol-Myers
   Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, and Merck.
CR Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Celum C, 2010, NEW ENGL J MED, V362, P427, DOI 10.1056/NEJMoa0904849
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grelotti DJ, 2013, LANCET INFECT DIS, V13, P10, DOI 10.1016/S1473-3099(12)70294-3
   Inciardi JA, 2007, PAIN MED, V8, P171, DOI 10.1111/j.1526-4637.2006.00255.x
   Kahle E, 2012, P INT MICR C 15 18 A
   Larkan F, 2010, AFR SOCIOL REV, V14, P62
   Marzinke MA, 2012, P 47 M AC CLIN LAB P
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Zablotska IB, 2013, JAIDS-J ACQ IMM DEF, V62, P334, DOI 10.1097/QAI.0b013e31827e854a
NR 11
TC 44
Z9 44
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 15
PY 2013
VL 208
IS 10
BP 1624
EP 1628
DI 10.1093/infdis/jit390
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 244HI
UT WOS:000326378000012
PM 23908493
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Montes, M
   Nelson, M
   Girard, M
   Sasadeusz, J
   Horban, A
   Grinsztejn, B
   Zakharova, N
   Falconer, K
   Dierynck, I
   Luo, DH
   Ma, YW
   Witek, J
AF Montes, Marisa
   Nelson, Mark
   Girard, Marie
   Sasadeusz, Joe
   Horban, Andrzej
   Grinsztejn, Beatriz
   Zakharova, Natalia
   Falconer, Karolin
   Dierynck, Inge
   Luo, Donghan
   Ma, Yi-Wen
   Witek, James
TI Telaprevir combination therapy in treatment-naive and experienced
   patients co-infected with HCV and HIV
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Montes, Marisa] Hosp La Paz, Madrid, Spain.
   [Nelson, Mark] Chelsea & Westminster Hosp, London, England.
   [Girard, Marie] Hop St Antoine, Paris, France.
   [Sasadeusz, Joe] Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia.
   [Horban, Andrzej] Hosp Infect Dis, Warsaw, Poland.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas, STD AIDS Clin Res Lab, Rio De Janeiro, Brazil.
   [Zakharova, Natalia] St Petersburg AIDS Ctr, St Petersburg, Russia.
   [Falconer, Karolin] Karolinska Univ Hosp, Stockholm, Sweden.
   [Dierynck, Inge] Janssen Infect Dis BVBA, Beerse, Belgium.
   [Luo, Donghan; Ma, Yi-Wen; Witek, James] Janssen Res & Dev LLC, Titusville, NJ USA.
RI Ramirez, Maria Luisa Montes/H-8065-2017
OI Ramirez, Maria Luisa Montes/0000-0003-1748-813X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 38
BP 225A
EP 226A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201038
DA 2020-11-24
ER

PT J
AU Fernandes, ATG
   da Rocha, NP
   Avvad, E
   Grinsztejn, BJ
   Russomano, F
   Tristao, A
   Quintana, MDB
   Perez, MA
   Conceicao-Silva, F
   Bonecini-Almeida, MD
AF Fernandes, Ana Teresa G.
   da Rocha, Natalia Pereira
   Avvad, Elyzabeth
   Grinsztejn, Beatriz J.
   Russomano, Fabio
   Tristao, Aparecida
   Borges Quintana, Marcel de Souza
   Perez, Mauricio A.
   Conceicao-Silva, Fatima
   Bonecini-Almeida, Maria da Gloria
TI Balance of apoptotic and anti-apoptotic marker and perforin granule
   release in squamous intraepithelial lesions. HIV infection leads to a
   decrease in perforin degranulation
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article
DE CTL; Cytotoxic dysfunction; Apoptosis; Uterine cervix; SIL;
   HIV-infection
ID HUMAN-PAPILLOMAVIRUS INFECTION; ESTROGEN-RECEPTOR; CERVICAL-CANCER; HPV
   GENOTYPES; NITRIC-OXIDE; INFLAMMATION; EXPRESSION; CELLS; PROGRESSION;
   NEOPLASIA
AB Cell-mediated cytotoxicity plays an important role in the regulation to HPV-associated cervical intraepithelial neoplasia. HIV co-infection is related to poorer prognosis and more rapid clinical progression to cancer. We evaluated the presence of cervical inflammatory cells, apoptotic (Bax, Bcl-2, FasL, NOS2, perforin) markers and the degranulating expressing cell marker (CD107a) in low and high squamous intraepithelial lesions (LSIL and HSIL, respectively) from HIV-negative and -positive women. Higher percentage of cervical CD4(+), CD8(+) T cells and macrophage were observed in LSIL and HSIL groups when compared with control, especially in epithelium and basal layer of epithelium. However, progression from LSIL to HSIL did not change the frequency of inflammatory cells. HIV-infection lead to a reduction on cervical CD4(+) T cell infiltration and an increased CD8(+) T cell distribution in LSIL groups. A balance between pro- and anti-apoptotic protein expressions was verified. Bax-expressing cells were present in all groups and were rarely expressed in keratinocytes in the epithelium in LSIL and control groups, but notably decreased in HSIL group. However, its frequency was enhanced in the basal layer of the epithelium meanly in LSIL group. Bcl2-expressing cells in the epithelium and the stroma were enhanced in HSIL group when compared with LSIL group. HIV-infection did not interfere in both expressions NOS2 expression was located on keratinocytes in both LSIL and HSIL groups when compared with control group. There were few FasL cervical expressing cells in all groups. Indeed, perforin was identified in few cervical cells. However, CD107a, a surface marker for cellular degranulation was significantly higher in epithelium, basal layer of epithelium and stroma in LSIL and HSIL, respectively, when compared with control group. These results support that HIV infection may induce reduction on inflammatory cervical cell degranulation corroborating to carcinogenesis process. This is the first description on the role of HIV in downregulation of perforin degranulation in the cervical lesions and it might be related to carcinogenesis. Published by Elsevier Inc.
C1 [Fernandes, Ana Teresa G.; da Rocha, Natalia Pereira; Bonecini-Almeida, Maria da Gloria] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Lab Immunol & Immunogenet Infect Dis, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Avvad, Elyzabeth; Tristao, Aparecida] Fundacao Oswaldo Cruz, Fernandes Figueira Woman Child & Adolescent Natl, Dept Pathol Anat, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Grinsztejn, Beatriz J.] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, STD AIDS Clin Res Lab, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Russomano, Fabio] Fundacao Oswaldo Cruz, Dept Gynaecol, Fernandes Figueira Woman Child & Adolescent Natl, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Borges Quintana, Marcel de Souza] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Tech Assistance Clin Res Serv, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Borges Quintana, Marcel de Souza] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Tech Assistance Reference Serv, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Perez, Mauricio A.] Univ Fed Rio de Janeiro, Nucleo Estudos Saude Colet, BR-21941 Rio De Janeiro, Brazil.
   [Conceicao-Silva, Fatima] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Immunoparasitol, BR-21040900 Rio De Janeiro, RJ, Brazil.
RP Bonecini-Almeida, MD (corresponding author), Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Lab Immunol & Immunogenet Infect Dis, Ave Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM gloria.bonecini@ipec.fiocruz.br
RI Bonecini-Almeida, Gloria Maria/C-7237-2012
OI Bonecini-Almeida, Maria da Gloria/0000-0001-6030-5576
FU IPEC/Fiocruz; FAPERJ, Rio de Janeiro, BrazilCarlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/170.485/2006]
FX We would like to thanks Mrs. Mary Jo Avaliotis for the English review
   and Rodrigo Mexas for technical assistance with the pictures. We also
   thank Dr. Otoniel Martinez-Maza for reviewing this manuscript. This work
   was funded by IPEC/Fiocruz and FAPERJ (E-26/170.485/2006), Rio de
   Janeiro, Brazil.
CR Ariumi Y, 2001, BIOCHEM BIOPH RES CO, V287, P556, DOI 10.1006/bbrc.2001.5626
   Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819
   Cheah Phaik-Leng, 2006, Malays J Pathol, V28, P1
   Chung CH, 2009, CLIN CANCER RES, V15, P6758, DOI 10.1158/1078-0432.CCR-09-0784
   da Silva CS, 2010, CLINICS, V65, P575, DOI 10.1590/S1807-59322010000600003
   De Andrea M, 2007, VIRUS RES, V124, P220, DOI 10.1016/j.virusres.2006.09.010
   Denny L, 2008, OBSTET GYNECOL, V111, P1380, DOI 10.1097/AOG.0b013e3181743327
   Eggen T, 2011, ANTICANCER RES, V31, P2319
   El-Ghobashy AA, 2007, EUR J CANCER, V43, P2011, DOI 10.1016/j.ejca.2007.06.019
   Ferlay J., 2010, GLOBOCAN 2008 V1 2 C, V2
   Fonseca-Moutinho JA, 2004, INT J GYNECOL CANCER, V14, P911, DOI 10.1111/j.1048-891X.2004.14529.x
   Galani E, 2009, CLIN MICROBIOL INFEC, V15, P977, DOI 10.1111/j.1469-0691.2009.03032.x
   Glynn SA, 2010, J CLIN INVEST, V120, P3843, DOI 10.1172/JCI42059
   Hammam O, 2012, HEPAT MON, V12, DOI 10.5812/hepatmon.6132
   Hammes LS, 2007, GYNECOL ONCOL, V105, P157, DOI 10.1016/j.ygyno.2006.11.023
   Hermann E, 1997, INT J IMMUNOPHARMACO, V19, P387, DOI 10.1016/S0192-0561(97)00060-X
   Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917
   Hong HS, 2010, AIDS, V24, P1823, DOI 10.1097/QAD.0b013e32833b556f
   Huh K, 2007, J VIROL, V81, P9737, DOI 10.1128/JVI.00881-07
   Hussain SP, 2008, CANCER RES, V68, P7130, DOI 10.1158/0008-5472.CAN-08-0410
   Instituto Nacional de Cancer (Brazil), 2006, REV BRAS CANCEROL, V52, P213
   Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115
   Kabsch K, 2002, J VIROL, V76, P12162, DOI 10.1128/JVI.76.23.12162-12172.2002
   KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614
   Kundu JK, 2012, FREE RADICAL BIO MED, V52, P2013, DOI 10.1016/j.freeradbiomed.2012.02.035
   Larrosa PNF, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-19
   Lehtovirta P, 2008, INT J STD AIDS, V19, P37, DOI 10.1258/ijsa.2007.005672
   Levi JE, 2002, J CLIN MICROBIOL, V40, P3341, DOI 10.1128/JCM.40.9.3341-3345.2002
   Liu K, 2010, WORLD J GASTRO ONCOL, V2, P399, DOI 10.4251/wjgo.v2.i11.399
   Manuri PR, 2007, VACCINE, V25, P3302, DOI 10.1016/j.vaccine.2007.01.010
   MEYAARD L, 1994, J CLIN INVEST, V93, P982, DOI 10.1172/JCI117105
   Mikaelsdottir EK, 2003, GYNECOL ONCOL, V89, P22, DOI 10.1016/S0090-8258(03)00053-2
   Munk A.C., 2012, GYNECOL ONCOL, VS0090-8258, P743
   Nappi L, 2005, EUR J OBSTET GYN R B, V121, P226, DOI 10.1016/j.ejogrb.2004.12.003
   Nicol AF, 2005, DIAGN MOL PATHOL, V14, P39, DOI 10.1097/01.pas.0000143309.81183.6c
   Oka K, 2003, INT J RADIAT ONCOL, V57, P217, DOI 10.1016/S0360-3016(03)00436-X
   Okayama H, 2013, INT J CANCER, V132, P9, DOI 10.1002/ijc.27644
   PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099
   Rahkola-Soisalo P, 2013, ANN MED, V45, P79, DOI 10.3109/07853890.2012.665472
   Schifitto G, 2011, J NEUROVIROL, V17, P17, DOI 10.1007/s13365-010-0010-5
   Scholten KBJ, 2005, CLIN IMMUNOL, V114, P119, DOI 10.1016/j.clim.2004.11.005
   Sigurdsson K, 2007, INT J CANCER, V121, P2682, DOI 10.1002/ijc.23034
   Spinillo A, 2004, GYNECOL ONCOL, V95, P500, DOI 10.1016/j.ygyno.2004.09.006
   Tao J, 2007, CLIN EXP DERMATOL, V32, P550, DOI 10.1111/j.1365-2230.2007.02455.x
   TAY SK, 1987, BRIT J OBSTET GYNAEC, V94, P1094, DOI 10.1111/j.1471-0528.1987.tb02296.x
   Waterhouse NJ, 2004, BIOCHEM PHARMACOL, V68, P1033, DOI 10.1016/j.bcp.2004.05.043
   Zheng L, 2007, INTERVIROLOGY, V50, P224, DOI 10.1159/000100565
NR 47
TC 3
Z9 3
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
EI 1096-0945
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD OCT
PY 2013
VL 95
IS 2
BP 166
EP 173
DI 10.1016/j.yexmp.2013.06.006
PG 8
WC Pathology
SC Pathology
GA 234WG
UT WOS:000325674400008
PM 23791892
DA 2020-11-24
ER

PT J
AU Cahn, P
   Pozniak, AL
   Mingrone, H
   Shuldyakov, A
   Brites, C
   Andrade-Villanueva, JF
   Richmond, G
   Buendia, CB
   Fourie, J
   Ramgopal, M
   Hagins, D
   Felizarta, F
   Madruga, J
   Reuter, T
   Newman, T
   Small, CB
   Lombaard, J
   Grinsztejn, B
   Dorey, D
   Underwood, M
   Griffith, S
   Min, S
AF Cahn, Pedro
   Pozniak, Anton L.
   Mingrone, Horacio
   Shuldyakov, Andrey
   Brites, Carlos
   Andrade-Villanueva, Jaime F.
   Richmond, Gary
   Beltran Buendia, Carlos
   Fourie, Jan
   Ramgopal, Moti
   Hagins, Debbie
   Felizarta, Franco
   Madruga, Jose
   Reuter, Tania
   Newman, Tamara
   Small, Catherine B.
   Lombaard, John
   Grinsztejn, Beatriz
   Dorey, David
   Underwood, Mark
   Griffith, Sandy
   Min, Sherene
CA Extended SAILING Study Team
TI Dolutegravir versus raltegravir in antiretroviral-experienced,
   integrase-inhibitor-naive adults with HIV: week 48 results from the
   randomised, double-blind, non-inferiority SAILING study
SO LANCET
LA English
DT Article
ID CO-FORMULATED ELVITEGRAVIR; INITIAL TREATMENT; CROSS-RESISTANCE;
   PHASE-II; INFECTION; TRIAL; PHARMACOKINETICS; EMTRICITABINE; COBICISTAT;
   EFAVIRENZ
AB Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance.
   Methods ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1: 1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov, NCT01231516.
   Findings Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7.4%, 95% CI 0.7 to 14.2); superiority of dolutegravir versus raltegravir was then concluded (p=0.03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference -3.7%, 95% CI -6.1 to -1.2; p=0.003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir).
   Interpretation Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group.
C1 [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Pozniak, Anton L.] Chelsea & Westminster Hosp NHS Fdn Trust, London, England.
   [Mingrone, Horacio] Fdn IDEAA, Buenos Aires, DF, Argentina.
   [Shuldyakov, Andrey] Saratov Reg Ctr Prophylact AIDS, Saratov, Russia.
   [Brites, Carlos] Univ Fed Bahia, Complexo Hosp Prof Edgard Santos, Salvador, BA, Brazil.
   [Andrade-Villanueva, Jaime F.] Univ Guadalajara, Fray Antonio Alcalde CUCS, Hosp Civil Guadalajara, Guadalajara 44430, Jalisco, Mexico.
   [Richmond, Gary] Broward Hlth Med Ctr, Ft Lauderdale, FL USA.
   [Beltran Buendia, Carlos] Hosp Barros Luco, Santiago, Chile.
   [Fourie, Jan] Fourie Med Ctr, Dundee, South Africa.
   [Ramgopal, Moti] Midway Immunol & Res Ctr, Ft Pierce, FL USA.
   [Hagins, Debbie] Chatham CARE Ctr, Savannah, GA USA.
   [Madruga, Jose] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Reuter, Tania] Univ Fed Espirito Santo, Vitoria, Brazil.
   [Newman, Tamara] Inst Infectol Emilio Ribas, Sao Paulo, Brazil.
   [Small, Catherine B.] New York Med Coll, Valhalla, NY 10595 USA.
   [Lombaard, John] JOSHA Res, Bloemfontein, South Africa.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Dorey, David] GlaxoSmithKline, Mississauga, ON, Canada.
   [Underwood, Mark; Griffith, Sandy; Min, Sherene] GlaxoSmithKline, Res Triangle Pk, NC USA.
RP Cahn, P (corresponding author), Fdn Huesped, C1202ABB, Buenos Aires, DF, Argentina.
EM pcahn@huesped.org.ar
RI Shuldyakov, Andrey/U-5598-2017; Streinu-Cercel, Adrian/M-5835-2017;
   Rugina, Sorin/U-5168-2019; Brites, Carlos/D-1353-2013
OI Shuldyakov, Andrey/0000-0002-3009-9262; Streinu-Cercel,
   Adrian/0000-0001-6382-5067; Brites, Carlos/0000-0002-4673-6991;
   Moutschen, Michel/0000-0002-6405-1785; Kozal,
   Michael/0000-0002-3100-8254; Ribera, Esteban/0000-0002-3752-8808;
   Griffith, Sandy/0000-0002-3430-5131
FU ViiV Healthcare
FX ViiV Healthcare.
CR Centres for disease control and prevention. National centre for infectious diseases division of HIV/ AIDS, 1993 REV CLASS SYST
   Committee for Medicinal Products for Human Use (CHMP), 2007, GUID CLIN D IN PRESS
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   DeJesus E, 2012, LANCET, V379, P2429, DOI 10.1016/S0140-6736(12)60918-0
   Eron JJ, 2011, LANCET INFECT DIS, V11, P907, DOI 10.1016/S1473-3099(11)70196-7
   Garrido C, 2012, ANTIMICROB AGENTS CH, V56, P2873, DOI 10.1128/AAC.06170-11
   German P, 2010, JAIDS-J ACQ IMM DEF, V55, P323, DOI 10.1097/QAI.0b013e3181eb376b
   Hazuda DJ, 2007, ANTIVIR THER, V12, pS10
   Hightower KE, 2011, ANTIMICROB AGENTS CH, V55, P4552, DOI 10.1128/AAC.00157-11
   KASTRUP J, 1985, BRIT J UROL, V57, P265, DOI 10.1111/j.1464-410X.1985.tb06340.x
   Koteff J, 2013, BRIT J CLIN PHARMACO, V75, P990, DOI 10.1111/j.1365-2125.2012.04440.x
   Lennox JL, 2010, JAIDS-J ACQ IMM DEF, V55, P39, DOI 10.1097/QAI.0b013e3181da1287
   Lepist E-I, 2011, 51 INT C ANT AG CHEM
   Liu TF, 2006, CLIN INFECT DIS, V42, P1608, DOI 10.1086/503914
   Margot NA, 2012, ANTIVIR RES, V93, P288, DOI 10.1016/j.antiviral.2011.12.008
   McColl DJ, 2007, ANTIVIR THER, V12, pS11
   Mesplede T, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-22
   Min S, 2010, ANTIMICROB AGENTS CH, V54, P254, DOI 10.1128/AAC.00842-09
   Molina JM, 2012, LANCET INFECT DIS, V12, P27, DOI 10.1016/S1473-3099(11)70249-3
   Nichols G, 2012, 11 INT C DRUG THER H
   Raffi F, 2013, LANCET, V381, P735, DOI 10.1016/S0140-6736(12)61853-4
   Sax PE, 2012, LANCET, V379, P2439, DOI 10.1016/S0140-6736(12)60917-9
   Smith F, 2011, DRUG INF J, V45, P291, DOI 10.1177/009286151104500309
   Song I, 2012, REV ANTIVIR THER INF, V3, P9
   Song I, 2011, ANTIMICROB AGENTS CH, V55, P3517, DOI 10.1128/AAC.00073-11
   Steigbigel RT, 2008, NEW ENGL J MED, V359, P339, DOI 10.1056/NEJMoa0708975
   [US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)], 2001, ICH GUID IND E 10 CH
   Walmsley S, 2012, 52 INT C ANT AG CHEM
NR 28
TC 321
Z9 327
U1 1
U2 59
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD AUG 24
PY 2013
VL 382
IS 9893
BP 700
EP 708
DI 10.1016/S0140-6736(13)61221-0
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 206SI
UT WOS:000323542400028
PM 23830355
DA 2020-11-24
ER

PT J
AU Luetkemeyer, AF
   Rosenkranz, SL
   Lu, D
   Marzan, F
   Ive, P
   Hogg, E
   Swindells, S
   Benson, CA
   Grinsztejn, B
   Sanne, IM
   Havlir, DV
   Aweeka, F
AF Luetkemeyer, Anne F.
   Rosenkranz, Susan L.
   Lu, Darlene
   Marzan, Florence
   Ive, Prudence
   Hogg, Evelyn
   Swindells, Susan
   Benson, Constance A.
   Grinsztejn, Beatriz
   Sanne, Ian M.
   Havlir, Diane V.
   Aweeka, Francesca
CA Adult AIDS Clinical Trials Grp
TI Relationship Between Weight, Efavirenz Exposure, and Virologic
   Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis
   Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV/AIDS; tuberculosis; efavirenz; rifampin; pharmacokinetics
ID ANTIRETROVIRAL THERAPY; PLASMA-CONCENTRATIONS; PHARMACOKINETIC
   INTERACTIONS; 600 MG/DAY; NEVIRAPINE; CYP2B6; ADULTS; OUTCOMES; DRUGS
AB Background. Rifampin (RIF) upregulates CYP 450 isoenzymes, potentially lowering efavirenz (EFV) exposure. The US EFV package insert recommends an EFV dose increase for patients on RIF weighing >= 50 kg. We conducted a pharmacokinetic study to evaluate EFV trough concentrations (C-min) and human immunodeficiency virus (HIV) virologic suppression in patients on EFV (600 mg) and RIF-based tuberculosis treatment in the multicenter randomized trial (ACTG A5221).
   Methods. EFV C-min was measured 20-28 hours post-EFV dose at weeks 4, 8, 16, 24 on-RIF and weeks 4, 8 off-RIF.
   Results were evaluated with 2-sided Wilcoxon rank-sum, chi(2), Fisher exact tests and logistic regression (5% type I error rate). Results. Seven hundred eighty patients received EFV; 543 provided >= 1 EFV C-min. Median weight was 52.8 kg (interquartile range [IQR], 48.0-59.5), body mass index 19.4 kg/m(2) (IQR, 17.5-21.6), and age 34 years (IQR, 2941); 63% were male, 74% black. Median C-min was 1.96 mu g/mL on-RIF versus 1.80 off-RIF (P = .067). C-min were significantly higher on-RIF versus off-RIF in blacks (2.08 vs 1.75, P = .005). Weight >= 60 kg on-RIF, compared to <60 kg, was associated with lower EFV C-min (1.68 vs 2.02, P = .021). However, weight >= 60 kg was associated with more frequent HIV RNA < 400 copies/mL at week 48, compared to weight <60 kg (81.9% vs 73.8%, P = .023).
   Conclusions. EFV and RIF-based tuberculosis therapy coadministration was associated with a trend toward higher, not lower, EFV C-min compared to EFV alone. Patients weighing >= 60 kg had lower median EFV C-min versus those <60 kg, but there was no association of higher weight with reduced virologic suppression. These data do not support weight-based dosing of EFV with RIF.
C1 [Luetkemeyer, Anne F.; Havlir, Diane V.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94110 USA.
   [Rosenkranz, Susan L.; Lu, Darlene] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [Marzan, Florence; Aweeka, Francesca] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94110 USA.
   [Ive, Prudence; Sanne, Ian M.] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa.
   [Hogg, Evelyn] Social & Sci Syst Inc, Silver Spring, MD USA.
   [Swindells, Susan] Univ Nebraska, Div Infect Dis, Omaha, NE 68182 USA.
   [Benson, Constance A.] Univ Calif San Diego, Antiviral Res Ctr, San Diego, CA 92103 USA.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
RP Luetkemeyer, AF (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, 995 Potrero Ave,Box 0874, San Francisco, CA 94110 USA.
EM aluetkemeyer@php.ucsf.edu
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI068636]; Statistical and Data Management Center [UM1 AI068634];
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI027763, P30AI027763, UM1AI068634, P30AI027763,
   P30AI027763, UM1AI068636, UM1AI068634, UM1AI068634, P30AI027763,
   P30AI027763, P30AI027763, UM1AI068634, UM1AI069463, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, UM1AI069463,
   P30AI027763, P30AI027763, UM1AI068636, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, UM1AI068634, P30AI027763, UM1AI069399,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, UM1AI069496, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   U01AI068636, UM1AI069463, P30AI027763, UM1AI069399, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, UM1AI068634,
   UM1AI069463, UM1AI068636, UM1AI069496, UM1AI069399, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, UM1AI068636, U01AI068636,
   P30AI027763, P30AI027763, UM1AI068634, UM1AI068636, U01AI068636,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   UM1AI068636, P30AI027763, UM1AI069463, UM1AI069496, P30AI027763,
   P30AI027763, P30AI027763, UM1AI069496, P30AI027763, P30AI027763,
   U01AI068636, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   UM1AI068636, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U01AI068636, UM1AI069463, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   UM1AI068636, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, UM1AI069496, UM1AI069496, UM1AI069496, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, UM1AI069463, P30AI027763, P30AI027763, UM1AI069463,
   P30AI027763, U01AI068636, UM1AI069399, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, UM1AI069399, UM1AI069399, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI068636,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, UM1AI069496,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   UM1AI069399, P30AI027763, P30AI027763, P30AI027763, UM1AI068634,
   P30AI027763, UM1AI069399, P30AI027763, P30AI027763, P30AI027763,
   UM1AI068634, P30AI027763, P30AI027763, P30AI027763, UM1AI068636,
   P30AI027763, P30AI027763] Funding Source: NIH RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (award number U01AI068636) and the Statistical and
   Data Management Center (UM1 AI068634) funded by the National Institute
   of Allergy and Infectious Diseases. Antiretroviral medications were
   donated by Gilead Sciences and Merck Pharmaceuticals.
CR Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911
   Bonnet M, 2013, LANCET INFECT DIS, V13, P303, DOI 10.1016/S1473-3099(13)70007-0
   Boulle A, 2008, JAMA-J AM MED ASSOC, V300, P530, DOI 10.1001/jama.300.5.530
   Brennan-Benson P, 2005, AIDS, V19, P1541, DOI 10.1097/01.aids.0000183519.45137.a6
   Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P333
   Chan-Tack K, SAN DIEG CA AM COLL
   Cohen K, 2009, ANTIVIR THER, V14, P687
   Court MH, 2013, 20 C RETR OPP INF AT
   Food and Drug Administration, SUST LAB UPD DOS ADJ
   Friedland G, 2006, J ANTIMICROB CHEMOTH, V58, P1299, DOI 10.1093/jac/dkl399
   Gengiah TN, 2012, EUR J CLIN PHARMACOL, V68, P689, DOI 10.1007/s00228-011-1166-5
   Grady BJ, 2012, 19 C RETR OPP INF SE
   Grijalva C. G., 2009, Morbidity and Mortality Weekly Report, V58, P1
   Gutierrez F, 2005, CLIN INFECT DIS, V41, P1648, DOI 10.1086/497835
   Haas DW, 2004, AIDS, V18, P2391
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   Huang LS, 2012, JAIDS-J ACQ IMM DEF, V61, P310, DOI 10.1097/QAI.0b013e31826ebb5c
   Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848
   King J, 2008, AIDS, V22, P1709, DOI 10.1097/QAD.0b013e32830163ad
   Kwara A, 2011, AIDS, V25, P388, DOI 10.1097/QAD.0b013e3283427e05
   Kwara A, 2009, BRIT J CLIN PHARMACO, V67, P427, DOI 10.1111/j.1365-2125.2009.03368.x
   Lee L, 2013, 20 C RETR OPP INF AT
   Liu EJ, 2011, J INFECT DIS, V204, P282, DOI 10.1093/infdis/jir246
   Lopez-Cortes LF, 2002, CLIN PHARMACOKINET, V41, P681, DOI 10.2165/00003088-200241090-00004
   Manosuthi W, 2006, AIDS, V20, P131, DOI 10.1097/01.aids.0000196181.18916.9b
   Marzolini C, 2001, AIDS, V15, P71, DOI 10.1097/00002030-200101050-00011
   Nishimura Y, 2004, J PHARMACOL SCI, V96, P293, DOI 10.1254/jphs.FP0040296
   Orrell C, 2011, ANTIVIR THER, V16, P527, DOI 10.3851/IMP1780
   Pedral-Sampaio Diana B., 2004, Braz J Infect Dis, V8, P211, DOI 10.1590/S1413-86702004000300004
   Pozniak AL, 2011, HIV MED, V12, P517, DOI 10.1111/j.1468-1293.2011.00954.x
   Ramachandran G, 2009, ANTIMICROB AGENTS CH, V53, P863, DOI 10.1128/AAC.00899-08
   Ren Y, 2009, JAIDS-J ACQ IMM DEF, V50, P439, DOI 10.1097/QAI.0b013e31819c33a3
   Rodolphe T, 2000, EUR J EPIDEMIOL, V16, P633, DOI 10.1023/A:1007696530440
   Rotger M, 2007, CLIN PHARMACOL THER, V81, P557, DOI 10.1038/sj.clpt.6100072
   Stahle L, 2004, THER DRUG MONIT, V26, P267, DOI 10.1097/00007691-200406000-00008
   Swaminathan S, 2011, CLIN INFECT DIS, V53, P716, DOI 10.1093/cid/cir447
   Van Lettow M, 2004, INT J TUBERC LUNG D, V8, P211
   Wang J, 2006, PHARMACOGENET GENOM, V16, P191
   World Health Organization, 2010, ANT THER HIV INF AD
   World Health Organization, 2012, WHO POL COLL TB HIV
   World Health Organization, WHO REP 2011 GLOB TU
   Yenny, 2011, INT J CLIN PHARM TH, V49, P162, DOI 10.5414/CP201473
NR 42
TC 43
Z9 45
U1 0
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2013
VL 57
IS 4
BP 586
EP 593
DI 10.1093/cid/cit246
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 190LV
UT WOS:000322342500024
PM 23592830
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Fiscus, SA
   Cu-Uvin, S
   Eshete, AT
   Hughes, MD
   Bao, YJ
   Hosseinipour, M
   Grinsztejn, B
   Badal-Faesen, S
   Dragavon, J
   Coombs, RW
   Braun, K
   Moran, L
   Hakim, J
   Flanigan, T
   Kumarasamy, N
   Campbell, TB
AF Fiscus, Susan A.
   Cu-Uvin, Susan
   Eshete, Abel Tilahun
   Hughes, Michael D.
   Bao, Yajing
   Hosseinipour, Mina
   Grinsztejn, Beatriz
   Badal-Faesen, Sharlaa
   Dragavon, Joan
   Coombs, Robert W.
   Braun, Ken
   Moran, Laura
   Hakim, James
   Flanigan, Timothy
   Kumarasamy, N.
   Campbell, Thomas B.
CA A5185s Team
TI Changes in HIV-1 Subtypes B and C Genital Tract RNA in Women and Men
   After Initiation of Antiretroviral Therapy
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1 genital tract RNA; HIV-1 subtypes B and C; antiretroviral drugs
ID IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL LOAD; PERINATAL TRANSMISSION;
   GENDER-DIFFERENCE; SEX-DIFFERENCES; PLASMA; INFECTION; SUPPRESSION;
   PREVENTION; TRIAL
AB Background. Combination antiretroviral therapy (cART) reduces genital tract human immunodeficiency virus type 1 (HIV-1) load and reduces the risk of sexual transmission, but little is known about the efficacy of cART for decreasing genital tract viral load (GTVL) and differences in sex or HIV-1 subtype.
   Methods. HIV-1 RNA from blood plasma, seminal plasma, or cervical wicks was quantified at baseline and at weeks 48 and 96 after entry in a randomized clinical trial of 3 cART regimens.
   Results. One hundred fifty-eight men and 170 women from 7 countries were studied (men: 55% subtype B and 45% subtype C; women: 24% subtype B and 76% subtype C). Despite similar baseline CD4(+) cell counts and blood plasma viral loads, women with subtype C had the highest GTVL (median, 5.1 log(10) copies/mL) compared to women with subtype B and men with subtype C or B (4.0, 4.0, and 3.8 log(10) copies/mL, respectively; P < .001). The proportion of participants with a GTVL below the lower limit of quantification (LLQ) at week 48 (90%) and week 96 (90%) was increased compared to baseline (16%; P < .001 at both times). Women were significantly less likely to have GTVL below the LLQ compared to men (84% vs 94% at week 48, P = .006; 84% vs 97% at week 96, P = .002), despite a more sensitive assay for seminal plasma than for cervical wicks. No difference in GTVL response across the 3 cART regimens was detected.
   Conclusions. The female genital tract may serve as a reservoir of persistent HIV-1 replication during cART and affect the use of cART to prevent sexual and perinatal transmission of HIV-1.
C1 [Fiscus, Susan A.] Univ N Carolina, Chapel Hill, NC 27599 USA.
   [Cu-Uvin, Susan; Flanigan, Timothy] Brown Univ, Providence, RI 02912 USA.
   [Eshete, Abel Tilahun; Hughes, Michael D.; Bao, Yajing] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Hosseinipour, Mina] UNC Project, Lilongwe, Malawi.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Badal-Faesen, Sharlaa] Univ Witwatersrand, Johannesburg, South Africa.
   [Dragavon, Joan; Coombs, Robert W.] Univ Washington, Seattle, WA 98195 USA.
   [Braun, Ken] Frontier Sci & Res Technol Fdn, Amherst, NY USA.
   [Moran, Laura] Social & Sci Syst, Silver Spring, MD USA.
   [Hakim, James] Univ Zimbabwe, Harare, Zimbabwe.
   [Kumarasamy, N.] YRG Ctr AIDS Res, Madras, Tamil Nadu, India.
   [Campbell, Thomas B.] Univ Colorado, Denver, CO 80202 USA.
RP Fiscus, SA (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, 709 Mary Ellen Jones Bldg,CB 7209, Chapel Hill, NC 27599 USA.
EM fiscussa@med.unc.edu
RI Cardoso, Sandra W/D-7965-2015
OI Cardoso, Sandra W/0000-0001-5230-0003
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01AI068636, AI68634, AI38858, AI069424,
   AI069428, AI027661, AI069495, AI069471, AI046370, AI069423, AI069439,
   AI69467, AI069463, AI069438, AI069432, AI069436, AI069518, AI069476-01];
   National Institute of Mental Health and the National Institute of Dental
   and Craniofacial Research; Boehringer IngelheimBoehringer Ingelheim;
   Bristol-Myers SquibbBristol-Myers Squibb; Gilead SciencesGilead
   Sciences; GlaxoSmithKlineGlaxoSmithKline; University of Washington
   Center for AIDS Research, a National Institutes of Health [P30
   AI027757]; NIAID, National Cancer Institute, National Institute of
   Mental Health; National Institute on Drug Abuse, National Institute of
   Child Health and Human Development, National Heart, Lung, and Blood
   Institute, and National Center for Complementary and Alternative
   Medicine; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Advancing Translational
   Sciences (NCATS) [UL1TR000457, UL1TR000457, UL1TR000457, UL1TR000457,
   UL1TR000457, UL1TR000457, UL1TR000457] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI050410, U01AI068636, P30AI050410, P30AI050410, U01AI038858,
   U01AI027661, P30AI027757, P30AI050410, U01AI027661, U01AI038858,
   U01AI069438, UM1AI069436, U01AI027661, U01AI069424, U01AI069424,
   P30AI050410, U01AI069423, UM1AI069467, P30AI027757, U01AI046370,
   U01AI027661, UM1AI069471, P30AI027757, P30AI027757, P30AI027757,
   U01AI038858, U01AI027661, P30AI050410, U01AI069428, P30AI027757,
   P30AI050410, UM1AI069424, P30AI027757, P30AI050410, UM1AI069423,
   P30AI027757, U01AI069423, P30AI027757, U01AI069463, U01AI038858,
   U01AI069423, U01AI027661, P30AI027757, P30AI027757, P30AI027757,
   P30AI027757, P30AI027757, U01AI069471, P30AI050410, U01AI038858,
   P30AI027757, P30AI027757, P30AI050410, U01AI038858, P30AI050410,
   P30AI027757, P30AI050410, P30AI027757, P30AI050410, U01AI038858,
   U01AI027661, P30AI027757, P30AI027757, P30AI027757, P30AI027757,
   UM1AI069412, P30AI050410, P30AI027757, P30AI027757, P30AI050410,
   U01AI069436, P30AI050410, UM1AI069476, U01AI069476, P30AI027757,
   U01AI027661, P30AI027757, P30AI027757, U01AI038858, UM1AI069439,
   U01AI038858, UM1AI069438, U01AI038858, P30AI050410, P30AI050410,
   U01AI068634, U01AI069495, U01AI027661, U01AI038858, U01AI027661,
   P30AI027757, P30AI027757, P30AI027757, P30AI027757, P30AI050410,
   UM1AI069463, P30AI050410, P30AI027757, U01AI027661, P30AI027757,
   P30AI027757, UM1AI069518, P30AI050410, P30AI027757, U01AI069518,
   P30AI027757, U01AI069495, P30AI050410, P30AI027757, U01AI069439,
   UM1AI068634, P30AI027757, U01AI069463, P30AI027757, U01AI027661,
   P30AI027757, UM1AI069428, P30AI027757, P30AI050410, U01AI068636,
   P30AI050410, U01AI038858, P30AI050410, P30AI027757, UM1AI068634,
   P30AI027757, U01AI068636, U01AI027661, P30AI027757, P30AI027757,
   P30AI027757, P30AI027757, U01AI069476, U01AI069438, U01AI046370,
   P30AI050410, UM1AI069423, U01AI069424, P30AI027757, U01AI038858,
   UM1AI069476, P30AI027757, U01AI038858, U01AI046370, P30AI050410,
   P30AI027757, P30AI027757, P30AI050410, UM1AI069518, P30AI027757,
   P30AI050410, P30AI027757, P30AI027757, P30AI027757, U01AI027661,
   UM1AI068634, UM1AI069439, U01AI038858, P30AI027757, UM1AI069471,
   P30AI027757, U01AI069467, UM1AI069476, U01AI069436, U01AI038858,
   U01AI069467, U01AI069423, P30AI027757, U01AI027661, P30AI027757,
   P30AI027757, U01AI027661, UM1AI069412, UM1AI069424, U01AI027661,
   U01AI069432, P30AI027757, U01AI068636, P30AI050410, P30AI027757,
   U01AI038858, P30AI050410, U01AI069423, P30AI027757, P30AI027757,
   U01AI069432, U01AI046370, P30AI027757, U01AI068634, P30AI050410,
   U01AI069439, U01AI038858, P30AI027757, P30AI027757, UM1AI068634,
   P30AI027757, P30AI050410, P30AI027757, U01AI038858, UM1AI069424,
   UM1AI069518, U01AI027661, UM1AI069423, P30AI027757, P30AI050410,
   U01AI069439, P30AI050410, P30AI027757, U01AI038858, UM1AI069463,
   P30AI027757, P30AI027757, U01AI038858, P30AI050410, U01AI038858,
   P30AI050410, P30AI027757, U01AI069518, U01AI027661, P30AI027757,
   P30AI027757, P30AI027757, U01AI027661, UM1AI069439, P30AI050410,
   P30AI027757, U01AI069428, U01AI069495, P30AI050410, U01AI038858,
   P30AI050410, P30AI050410, U01AI027661, P30AI027757, U01AI027661,
   P30AI050410, P30AI027757, P30AI027757, U01AI069428, P30AI050410,
   UM1AI069423, UM1AI069424, P30AI050410, P30AI050410, U01AI027661,
   P30AI027757, P30AI050410, P30AI027757, P30AI027757, P30AI050410,
   P30AI027757, UM1AI069439, P30AI050410, U01AI046370, UM1AI069471,
   P30AI027757, UM1AI069432, P30AI027757, U01AI027661, U01AI027661,
   UM1AI069518, P30AI027757, P30AI027757, U01AI038858, P30AI027757,
   P30AI050410, UM1AI069471, U01AI027661, U01AI069424, P30AI027757,
   P30AI027757, P30AI027757, UM1AI069423, UM1AI069412, U01AI068636,
   U01AI027661, UM1AI069463, P30AI027757, U01AI069471, P30AI027757,
   P30AI050410, P30AI027757, P30AI027757, P30AI027757, U01AI069438,
   U01AI038858, U01AI027661, UM1AI069439, P30AI027757, P30AI050410,
   U01AI038858, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   U01AI027661, U01AI069424, P30AI027757, P30AI027757, P30AI050410,
   P30AI027757, U01AI046370, P30AI050410, U01AI038858, P30AI027757,
   P30AI027757, P30AI027757, U01AI069428, P30AI027757, U01AI068634,
   UM1AI069438, P30AI027757, UM1AI068634, P30AI050410, U01AI069436,
   P30AI027757, P30AI027757, U01AI069495, P30AI027757, U01AI027661,
   P30AI050410, P30AI050410, U01AI069463, U01AI069436, P30AI050410,
   U01AI069467, UM1AI069476, P30AI027757, P30AI027757, P30AI050410,
   UM1AI069518, U01AI027661, UM1AI069463, P30AI050410, U01AI038858,
   P30AI027757, U01AI068636, P30AI050410, P30AI027757, U01AI069436,
   P30AI050410, P30AI027757, U01AI038858, UM1AI068634, P30AI027757,
   UM1AI069423, U01AI069423, U01AI027661, U01AI027661, P30AI050410,
   P30AI050410, UM1AI069432, UM1AI069476, UM1AI069432, U01AI069438,
   UM1AI069471, P30AI027757, U01AI038858, UM1AI069432, U01AI027661,
   P30AI027757, U01AI038858, P30AI027757, U01AI027661, UM1AI069495,
   UM1AI068634, P30AI027757, P30AI027757, P30AI050410, P30AI027757,
   P30AI027757, U01AI027661, U01AI069423, P30AI027757, P30AI050410,
   P30AI050410, U01AI069495, P30AI027757, P30AI050410, P30AI050410,
   P30AI027757, P30AI027757, P30AI027757, P30AI027757, P30AI027757,
   U01AI027661, U01AI027661, P30AI027757, P30AI027757, U01AI069438,
   U01AI069432, P30AI027757, P30AI027757, U01AI069518, P30AI027757,
   UM1AI069439, P30AI050410, P30AI027757, P30AI027757, P30AI050410,
   U01AI027661, P30AI050410, U01AI038858, U01AI068634, P30AI027757,
   P30AI027757, P30AI027757, P30AI027757, UM1AI069439, P30AI027757,
   P30AI050410, UM1AI069424, P30AI027757, U01AI027661, P30AI027757,
   UM1AI069438, P30AI027757, U01AI027661, UM1AI069432, P30AI027757,
   UM1AI069436, P30AI027757, P30AI027757, U01AI038858, P30AI050410,
   P30AI050410, U01AI027661, UM1AI069476, U01AI038858, P30AI027757,
   U01AI038858, P30AI027757, U01AI068636, P30AI050410, P30AI050410,
   U01AI027661, U01AI038858, UM1AI069428, U01AI027661, P30AI050410,
   UM1AI069432, P30AI050410, P30AI050410, U01AI027661, P30AI050410,
   UM1AI069463, P30AI027757, U01AI027661, P30AI050410, P30AI027757,
   UM1AI069471, UM1AI069495, P30AI027757, U01AI027661, P30AI050410,
   U01AI069424, U01AI069467, P30AI050410, U01AI038858, U01AI038858,
   P30AI027757, UM1AI069424, P30AI027757, P30AI027757, U01AI027661,
   P30AI027757, UM1AI069439, P30AI050410, U01AI069518, UM1AI069438,
   P30AI027757, U01AI038858, UM1AI069471, UM1AI069432, UM1AI068634,
   P30AI050410, U01AI038858, U01AI038858, P30AI027757, P30AI050410,
   P30AI027757, UM1AI069436, P30AI027757, P30AI050410, UM1AI069463,
   U01AI046370, P30AI050410, U01AI027661, U01AI068634, U01AI069436,
   P30AI027757, P30AI027757, UM1AI069424, P30AI027757, U01AI038858,
   P30AI027757, P30AI050410, U01AI027661, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI027757, UM1AI069412,
   U01AI069476, U01AI069518, P30AI027757, P30AI027757, UM1AI069463,
   U01AI069476, UM1AI069467, P30AI027757, P30AI050410, P30AI027757,
   P30AI050410, P30AI027757, P30AI027757, U01AI038858, P30AI027757,
   UM1AI069467, P30AI027757, U01AI069463, UM1AI069412, U01AI069424,
   UM1AI069423, P30AI027757, P30AI050410, P30AI027757, UM1AI069518,
   U01AI027661, P30AI027757, P30AI027757, U01AI027661, P30AI027757,
   P30AI027757, P30AI027757, P30AI050410, U01AI069428, U01AI038858,
   P30AI027757, P30AI027757, P30AI050410, UM1AI069412, P30AI027757,
   P30AI027757, UM1AI069518, P30AI027757, P30AI027757, P30AI050410,
   UM1AI069412, P30AI050410, U01AI069463, U01AI027661, P30AI027757,
   P30AI050410, U01AI038858, U01AI027661, U01AI038858, P30AI050410,
   P30AI027757, U01AI069439, P30AI027757, UM1AI069432, UM1AI069423,
   U01AI069463, UM1AI069436, U01AI038858, P30AI027757, P30AI027757,
   P30AI027757, U01AI046370, P30AI027757, P30AI050410, P30AI027757,
   P30AI027757, P30AI050410, UM1AI069436, P30AI050410, UM1AI069476,
   P30AI050410, P30AI027757, P30AI027757, P30AI050410, U01AI069423,
   P30AI027757, P30AI050410, P30AI050410, P30AI050410, P30AI027757,
   P30AI050410, P30AI027757, U01AI069438, UM1AI069436, P30AI027757,
   P30AI050410, U01AI038858, P30AI050410, U01AI069432, U01AI069471,
   U01AI046370, P30AI050410, P30AI027757, UM1AI069439, UM1AI069476,
   P30AI027757, UM1AI069518, P30AI050410, UM1AI069438, U01AI038858,
   P30AI027757, U01AI038858, UM1AI069438, P30AI027757, P30AI027757,
   P30AI027757, U01AI027661, P30AI027757, U01AI027661, U01AI027661,
   UM1AI069436, P30AI027757, P30AI027757, U01AI027661, UM1AI069438,
   P30AI027757, P30AI027757, P30AI027757, P30AI027757, P30AI050410,
   U01AI069439, P30AI027757, P30AI050410, U01AI069463, U01AI069467,
   U01AI069471, P30AI027757, U01AI027661, UM1AI069471, U01AI069471,
   UM1AI069412, P30AI050410, P30AI050410, P30AI027757, P30AI050410,
   P30AI050410, P30AI027757, P30AI027757, P30AI027757, P30AI027757,
   U01AI038858, P30AI027757, P30AI050410, UM1AI069438, U01AI027661,
   P30AI050410, P30AI050410, P30AI027757, UM1AI069436, P30AI050410,
   P30AI027757, U01AI027661, U01AI069432, UM1AI068634, P30AI027757,
   P30AI027757, P30AI027757, P30AI027757, P30AI027757, P30AI050410,
   UM1AI069463, UM1AI069424, P30AI027757, U01AI038858, P30AI027757,
   U01AI069471, P30AI027757, P30AI050410, P30AI027757, P30AI027757,
   P30AI027757, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI027757, P30AI027757, P30AI027757, P30AI050410, P30AI050410,
   P30AI027757] Funding Source: NIH RePORTER
FX The project described was supported by the NIAID (award number
   U01AI068636, AI68634, and AI38858), and by the National Institute of
   Mental Health and the National Institute of Dental and Craniofacial
   Research. The pharmaceutical sponsors (Boehringer Ingelheim,
   Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline) provided
   study drug, and Gilead Sciences provided funding to purchase study drug
   that was not otherwise available. Sites were supported by the following
   grants from the NIAID: AI069424, AI069428, AI027661, AI069495, AI069471,
   AI046370, AI069423, AI069439, AI69467, AI069463, AI069438, AI069432,
   AI069436, AI069518, and AI069476-01. Additional funding was provided by
   the University of Washington Center for AIDS Research, a National
   Institutes of Health-funded program (P30 AI027757), which is supported
   by the NIAID, National Cancer Institute, National Institute of Mental
   Health, National Institute on Drug Abuse, National Institute of Child
   Health and Human Development, National Heart, Lung, and Blood Institute,
   and National Center for Complementary and Alternative Medicine.
CR Baeten JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001888
   Baeten JM, 2008, J INFECT DIS, V198, P1804, DOI 10.1086/593214
   Campbell TB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001290
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Coombs RW, 2003, AIDS, V17, P455, DOI 10.1097/00002030-200303070-00001
   Cu-Uvin S, 2010, AIDS, V24, P2486, DOI 10.1097/QAD.0b013e32833e5043
   Donnelly CA, 2005, HIV MED, V6, P170, DOI 10.1111/j.1468-1293.2005.00285.x
   Dyer JR, 1998, J INFECT DIS, V177, P1742, DOI 10.1086/517436
   Else LJ, 2011, ANTIVIR THER, V16, P1149, DOI 10.3851/IMP1919
   Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1
   Fideli OS, 2001, AIDS RES HUM RETROV, V17, P901, DOI 10.1089/088922201750290023
   Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602
   Grinsztejn B, 2011, ANTIVIR THER, V16, P1057, DOI 10.3851/IMP1872
   Gunthard HF, 2001, J INFECT DIS, V183, P1318, DOI 10.1086/319864
   John GC, 2001, J INFECT DIS, V183, P206, DOI 10.1086/317918
   Lingappa JR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005272
   Los Alamos National Laboratory, HIV SEQ DAT
   Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601
   Morrison CS, 2010, AIDS, V24, P573, DOI 10.1097/QAD.0b013e32833433df
   Napravnik S, 2002, JAIDS-J ACQ IMM DEF, V31, P11, DOI 10.1097/00126334-200209010-00002
   Neilson JR, 1999, J VIROL, V73, P4393, DOI 10.1128/JVI.73.5.4393-4403.1999
   Nicol MR, 2010, CLIN PHARMACOL THER, V88, P598, DOI 10.1038/clpt.2010.189
   Novitsky V, 2011, AIDS, V25, P1515, DOI 10.1097/QAD.0b013e3283471eb2
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967
   Zuckerman RA, 2009, AIDS, V23, P479, DOI 10.1097/QAD.0b013e328326ca62
NR 26
TC 12
Z9 13
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL 15
PY 2013
VL 57
IS 2
BP 290
EP 297
DI 10.1093/cid/cit195
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 173AY
UT WOS:000321051600020
PM 23532477
OA Bronze, Green Published
DA 2020-11-24
ER

PT J
AU Amancio, RT
   Japiassu, AM
   Gomes, RN
   Mesquita, EC
   Assis, EF
   Medeiros, DM
   Grinsztejn, B
   Bozza, PT
   Neto, HCCF
   Bozza, FA
AF Amancio, Rodrigo T.
   Japiassu, Andre M.
   Gomes, Rachel N.
   Mesquita, Emersom C.
   Assis, Edson F.
   Medeiros, Denise M.
   Grinsztejn, Beatriz
   Bozza, Patricia T.
   Castro-Faria Neto, Hugo C.
   Bozza, Fernando A.
TI The Innate Immune Response in HIV/AIDS Septic Shock Patients: A
   Comparative Study
SO PLOS ONE
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED PATIENTS; C-REACTIVE
   PROTEIN; CRITICALLY-ILL PATIENTS; SEVERE SEPSIS; ORGAN DYSFUNCTION;
   INTENSIVE-CARE; UNITED-STATES; EPIDEMIOLOGY; OUTCOMES
AB Introduction: In recent years, the incidence of sepsis has increased in critically ill HIV/AIDS patients, and the presence of severe sepsis emerged as a major determinant of outcomes in this population. The inflammatory response and deregulated cytokine production play key roles in the pathophysiology of sepsis; however, these mechanisms have not been fully characterized in HIV/AIDS septic patients.
   Methods: We conducted a prospective cohort study that included HIV/AIDS and non-HIV patients with septic shock. We measured clinical parameters and biomarkers (C-reactive protein and cytokine levels) on the first day of septic shock and compared these parameters between HIV/AIDS and non-HIV patients.
   Results: We included 30 HIV/AIDS septic shock patients and 30 non-HIV septic shock patients. The HIV/AIDS patients presented low CD4 cell counts (72 [7-268] cells/mm(3)), and 17 (57%) patients were on HAART before hospital admission. Both groups were similar according to the acute severity scores and hospital mortality. The IL-6, IL-10 and G-CSF levels were associated with hospital mortality in the HIV/AIDS septic group; however, the CRP levels and the surrogates of innate immune activation (cytokines) were similar among HIV/AIDS and non-HIV septic patients. Age (odds ratio 1.05, CI 95% 1.02-1.09, p=0.002) and the IL-6 levels (odds ratio 1.00, CI 95% 1.00-1.01, p=0.05) were independent risk factors for hospital mortality.
   Conclusions: IL-6, IL-10 and G-CSF are biomarkers that can be used to predict prognosis and outcomes in HIV/AIDS septic patients. Although HIV/AIDS patients are immunocompromised, an innate immune response can be activated in these patients, which is similar to that in the non-HIV septic population. In addition, age and the IL-6 levels are independent risk factors for hospital mortality irrespective of HIV/AIDS disease.
C1 [Amancio, Rodrigo T.; Japiassu, Andre M.; Gomes, Rachel N.; Mesquita, Emersom C.; Medeiros, Denise M.; Bozza, Fernando A.] Inst Pesquisa Clin Evandro Chagas IPEC, Lab Med Intens, Rio De Janeiro, RJ, Brazil.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas IPEC, Lab HIV, Rio De Janeiro, RJ, Brazil.
   [Assis, Edson F.; Bozza, Patricia T.; Castro-Faria Neto, Hugo C.] Fundacao Oswaldo Cruz FIOCRUZ, IOC, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
   [Japiassu, Andre M.; Bozza, Fernando A.] Inst Or Pesquisa Ensino IDOR, Rio De Janeiro, RJ, Brazil.
RP Bozza, FA (corresponding author), Inst Pesquisa Clin Evandro Chagas IPEC, Lab Med Intens, Rio De Janeiro, RJ, Brazil.
EM fernando.bozza@ipec.fiocruz.br
RI Bozza, Fernando A/A-2618-2013; Gomes, Rachel N/I-7643-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Mesquita,
   Emersom/0000-0002-5132-3315; Bozza, Patricia/0000-0001-8349-9529
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); PAPES/FIOCRUZ
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ) and PAPES/FIOCRUZ. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andaluz-Ojeda D, 2012, CYTOKINE, V57, P332, DOI 10.1016/j.cyto.2011.12.002
   Ballester JCA, 2008, INFECT CONT HOSP EP, V29, P630, DOI 10.1086/589583
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087
   BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6
   Beale R, 2009, INFECTION, V37, P222, DOI 10.1007/s15010-008-8203-z
   Benito N, 2004, CLIN DIAGN LAB IMMUN, V11, P608, DOI 10.1128/CDLI.11.3.608-614.2004
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   Blanco J, 2008, CRIT CARE, V12, DOI 10.1186/cc7157
   Boumendil A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034387
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   CIPOLLE MD, 1993, CRIT CARE CLIN, V9, P261
   Coquet I, 2010, CRIT CARE, V14, DOI 10.1186/cc9056
   Deeks SG, 2012, CURR OPIN IMMUNOL, V24, P501, DOI 10.1016/j.coi.2012.05.004
   Dore GJ, 2002, J ACQ IMMUN DEF SYND, V29, P388, DOI 10.1097/00126334-200204010-00010
   Faix JD, 2013, CRIT REV CL LAB SCI, V50, P23, DOI 10.3109/10408363.2013.764490
   Gilstrap LG, 2012, CLIN CHEM, V58, P72, DOI 10.1373/clinchem.2011.165712
   GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401
   Greenberg JA, 2012, J CRIT CARE, V27, P51, DOI 10.1016/j.jcrc.2011.08.015
   Haddy RI, 2012, J AM BOARD FAM MED, V25, P318, DOI 10.3122/jabfm.2012.03.110106
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
   Huang L, 2006, NEW ENGL J MED, V355, P173, DOI 10.1056/NEJMra050836
   Jacob ST, 2009, PLOS ONE, V4, pA115, DOI 10.1371/journal.pone.0007782
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Rezende ELLF, 2010, BRAZ J INFECT DIS, V14, P558, DOI [10.1590/S1413-86702010000600003, 10.1016/S1413-8670(10)70112-4]
   Ledwaba L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0024243
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Lucas S, 2012, CURR OPIN INFECT DIS, V25, P36, DOI 10.1097/QCO.0b013e32834ef5c4
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Mera S, 2011, APMIS, V119, P155, DOI 10.1111/j.1600-0463.2010.02705.x
   Mrus JM, 2005, CRIT CARE, V9, pR623, DOI 10.1186/cc3811
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Povoa P, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-32
   Povoa P, 2011, CRIT CARE, V15, DOI 10.1186/cc10242
   Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523
   Rosenberg AL, 2001, CRIT CARE MED, V29, P548, DOI 10.1097/00003246-200103000-00013
   Ross AC, 2009, CLIN INFECT DIS, V49, P1119, DOI 10.1086/605578
   Salluh JIF, 2011, CRIT CARE, V15, DOI 10.1186/cc10301
   Schleicher GK, 2005, EUR RESPIR J, V25, P688, DOI 10.1183/09031936.05.00067604
   Suratt BT, 2009, CRIT CARE MED, V37, P1322, DOI 10.1097/CCM.0b013e31819c14fa
   Thyrault M, 1997, INTENS CARE MED, V23, P1018, DOI 10.1007/s001340050451
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156
NR 45
TC 15
Z9 16
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 11
PY 2013
VL 8
IS 7
AR e68730
DI 10.1371/journal.pone.0068730
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 188UA
UT WOS:000322218800042
PM 23874739
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Mayer, KH
   Wheeler, DP
   Bekker, LG
   Grinsztejn, B
   Remien, RH
   Sandfort, TGM
   Beyrer, C
AF Mayer, Kenneth H.
   Wheeler, Darrell P.
   Bekker, Linda-Gail
   Grinsztejn, Beatriz
   Remien, Robert H.
   Sandfort, Theodorus G. M.
   Beyrer, Chris
TI Overcoming Biological, Behavioral, and Structural Vulnerabilities: New
   Directions in Research to Decrease HIV Transmission in Men Who Have Sex
   With Men
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE men who have sex with men; transgender women; HIV prevention; HIV
   transmission
ID SEXUALLY-TRANSMITTED INFECTIONS; RISK BEHAVIOR; INTERNALIZED HOMOPHOBIA;
   BLACK-MEN; ANTIRETROVIRAL THERAPY; ENVIRONMENTAL-FACTORS; HIV/STI RISK;
   INTERNET USE; VIRAL LOADS; AFRICAN MEN
AB Men who have sex with men (MSM), including transgender women, comprise a heterogeneous group of individuals whose sexual behaviors and gender identities may vary widely between cultures and among individuals. Their sources of increased vulnerability to HIV are diverse, including the increased efficiency of HIV transmission via unprotected anal intercourse, sexual role versatility, asymptomatic sexually transmitted infections, and behavioral factors that may be associated with condomless sex with multiple partners. Societal stigmatization of homosexual behavior and gender nonconformity may result in internalized negative feelings that lead to depression, other affective disorders, and substance use, which in turn are associated with increased risk-taking behaviors. Social stigma and punitive civil environments may lead to delays in seeking HIV and sexually transmitted disease screening, and later initiation of antiretroviral therapy. The iPrEX study demonstrated that chemoprophylaxis can decrease HIV acquisition in MSM, and the HIV prevention trials network 052 study established the biological plausibility that earlier initiation of highly active antiretroviral therapy can decrease HIV transmission to uninfected partners. Despite these advances, MSM remain among the most significantly HIV-affected population in resource-rich and limited settings. New studies will integrate enhanced understanding of the biology of enhanced rectal transmission of HIV and the focused use of antiretrovirals for prevention with culturally tailored approaches that address the potentiating social and behavioral factors associated with enhanced HIV spread among MSM.
C1 [Mayer, Kenneth H.] Harvard Univ, Sch Med, Fac Med, Boston, MA 02215 USA.
   [Mayer, Kenneth H.] Fenway Hlth, Beth Israel Deaconess Med Ctr, HIV Prevent Res, Boston, MA 02215 USA.
   [Wheeler, Darrell P.] Loyola Univ, Sch Social Work, Chicago, IL 60611 USA.
   [Bekker, Linda-Gail] Univ Cape Town, Dept Med, Desmond Tutu HIV Ctr, IIDMM, ZA-7925 Cape Town, South Africa.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Remien, Robert H.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, Div Clin Psychol, New York, NY USA.
   [Remien, Robert H.] New York State Psychiat Inst & Hosp, HIV Ctr Clin & Behav Studies, New York, NY 10032 USA.
   [Remien, Robert H.] Columbia Univ, Med Ctr, Dept Psychiat, New York, NY USA.
   [Sandfort, Theodorus G. M.] New York State Psychiat Inst & Hosp, Div Gender Sexual & Hlth, New York, NY 10032 USA.
   [Sandfort, Theodorus G. M.] Columbia Univ, Dept Psychiat, New York, NY USA.
   [Beyrer, Chris] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Baltimore, MD 21205 USA.
RP Mayer, KH (corresponding author), Harvard Univ, Sch Med, 1340 Boylston St, Boston, MA 02215 USA.
EM kmayer@fenwayhealth.org
RI Bekker, Linda-Gail/AAZ-8929-2020; Sandfort, Theo/D-1796-2011
OI Sandfort, Theo/0000-0002-4986-1739; BEKKER,
   LINDA-GAIL/0000-0002-0755-4386
FU HIV Prevention Trials Network [UM1 AI068619]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069412,
   UM1AI069412, UM1AI068619, UM1AI068619, UM1AI068619, UM1AI068619,
   UM1AI068619, UM1AI068619, UM1AI069412, UM1AI069412, UM1AI068619,
   UM1AI069412, UM1AI069480, UM1AI069412, UM1AI069480, UM1AI069412,
   UM1AI069412, UM1AI068619, UM1AI069480, UM1AI068619] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520, P30MH043520, P30MH043520,
   P30MH043520, P30MH043520, P30MH043520] Funding Source: NIH RePORTER
FX Funding support provided by the HIV Prevention Trials Network through
   the following award (UM1 AI068619).
CR Allison S, 2012, J ADOLESCENT HEALTH, V51, P207, DOI 10.1016/j.jadohealth.2012.06.012
   Almeida J, 2009, J YOUTH ADOLESCENCE, V38, P1001, DOI 10.1007/s10964-009-9397-9
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Anton PA, 2012, AIDS RES HUM RETROV, V28, P1412, DOI [10.1089/aid.2012.0262, 10.1089/AID.2012.0262]
   Ayala G, 2012, AM J PUBLIC HEALTH, V102, pS242, DOI 10.2105/AJPH.2011.300641
   Baggaley RF, 2010, INT J EPIDEMIOL, V39, P1048, DOI 10.1093/ije/dyq057
   Baral SD, 2012, LANCET INFECT DIS, V3099, P70315
   Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339
   Baral S, 2013, AIDS BEHAV, V17, pS60, DOI 10.1007/s10461-012-0202-5
   Baral S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-766
   Baral S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004997
   Bastos FI, 2008, INT J EPIDEMIOL, V37, P729, DOI 10.1093/ije/dyn127
   Bekker LG, 2013, 20 C RETR OPP INF MA
   Berg RC, 2013, SOC SCI MED, V78, P61, DOI 10.1016/j.socscimed.2012.11.033
   Beyrer C, 2005, AIDS, V19, P1535, DOI 10.1097/01.aids.0000183122.01583.c7
   Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6
   Beyrer C, 2010, SEX TRANSM INFECT, V86, P323, DOI 10.1136/sti.2009.040162
   Beyrer C, 2010, EPIDEMIOL REV, V32, P137, DOI 10.1093/epirev/mxq011
   Bingham TA, 2013, AM J PUBLIC HEALTH, V103, P127, DOI 10.2105/AJPH.2012.300855
   Binson D, 2001, AM J PUBLIC HEALTH, V91, P1482, DOI 10.2105/AJPH.91.9.1482
   Birrell PJ, 2013, LANCET INFECT DIS, V13, P313, DOI 10.1016/S1473-3099(12)70341-9
   Bolding G, 2005, AIDS, V19, P961, DOI 10.1097/01.aids.0000171411.84231.f6
   Burrell E, 2010, SEX HEALTH, V7, P149, DOI 10.1071/SH09090
   Burrell ER, 2012, AIDS BEHAV, V16, P1816, DOI 10.1007/s10461-012-0277-z
   Cakeres CF, 2008, AIDS, V22, pS45, DOI 10.1097/01.aids.0000327436.36161.80
   Carballo-Dieguez A, 2006, AIDS EDUC PREV, V18, P475, DOI 10.1521/aeap.2006.18.6.475
   Carballo-Dieguez A, 2012, AIDS BEHAV, V16, P1753, DOI 10.1007/s10461-012-0274-2
   Centers for Disease Control (CDC), 1982, MMWR Morb Mortal Wkly Rep, V31, P507
   Centers for Disease Control (CDC), 1982, MMWR-MORBID MORTAL W, V31, P507
   Chiasson MA, 2010, JAIDS-J ACQ IMM DEF, V55, pS94, DOI 10.1097/QAI.0b013e3181fcb878
   Coates T, 2013, 20 C RETR OPP INF MA
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Dahoma M, 2011, AIDS BEHAV, V15, P186, DOI 10.1007/s10461-009-9646-7
   Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068
   Davis M, 2006, CULT HEALTH SEX, V8, P161, DOI 10.1080/13691050500526126
   DeHaan S, 2013, J SEX RES, V50, P421, DOI 10.1080/00224499.2012.661489
   DeLonga K, 2011, SEX ADDICT COMPULS, V18, P61, DOI 10.1080/10720162.2011.581897
   deWit JBF, 1997, INT J STD AIDS, V8, P130, DOI 10.1258/0956462971919552
   Diaz Rafael M, 2004, Cultur Divers Ethnic Minor Psychol, V10, P255, DOI 10.1037/1099-9809.10.3.255
   Dube EM, 1999, DEV PSYCHOL, V35, P1389, DOI 10.1037/0012-1649.35.6.1389
   Dudley MG, 2004, AIDS EDUC PREV, V16, P328, DOI 10.1521/aeap.16.4.328.40397
   Fenton KA, 2005, INFECT DIS CLIN N AM, V19, P311, DOI 10.1016/j.idc.2005.04.004
   Garofalo R, 2007, AM J PUBLIC HEALTH, V97, P1113, DOI 10.2105/AJPH.2005.075630
   George Sheba, 2012, AMIA Annu Symp Proc, V2012, P247
   Goodreau SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050522
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2011, IAS JUL 17 20 ROM IT
   Grov C, 2008, CULT HEALTH SEX, V10, P107, DOI 10.1080/13691050701564678
   Grov C, 2013, ARCH SEX BEHAV, V42, P291, DOI 10.1007/s10508-011-9854-x
   Grov C, 2012, AIDS EDUC PREV, V24, P102, DOI 10.1521/aeap.2012.24.2.102
   Guse K, 2012, J ADOLESCENT HEALTH, V51, P535, DOI 10.1016/j.jadohealth.2012.03.014
   Han XX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028792
   Hatzenbuehler ML, 2008, HEALTH PSYCHOL, V27, P455, DOI 10.1037/0278-6133.27.4.455
   Herrick AL, 2013, AIDS BEHAV, V17, P1423, DOI 10.1007/s10461-012-0392-x
   Horvath KJ, 2008, AM J PUBLIC HEALTH, V98, P1059, DOI 10.2105/AJPH.2007.111070
   Huebner DM, 2010, AIDS BEHAV, V14, P688, DOI 10.1007/s10461-008-9442-9
   JAFFE HW, 1983, J INFECT DIS, V148, P339, DOI 10.1093/infdis/148.2.339
   Jaganath D, 2012, AIDS CARE, V24, P593, DOI 10.1080/09540121.2011.630355
   Jeffries WL, 2013, AIDS BEHAV, V17, P1442, DOI 10.1007/s10461-012-0189-y
   Jenness SM, 2010, AIDS BEHAV, V14, P1353, DOI 10.1007/s10461-010-9769-x
   Kakietek J, 2011, AIDS EDUC PREV, V23, P118, DOI 10.1521/aeap.2011.23.2.118
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kelley CF, 2011, J INFECT DIS, V204, P761, DOI 10.1093/infdis/jir400
   Knox J, 2011, INT J STD AIDS, V22, P709, DOI 10.1258/ijsa.2011.010350
   Koblin B, 2012, AIDS 2012 19 INT AID
   Lane T, 2011, AIDS BEHAV, V15, P626, DOI 10.1007/s10461-009-9598-y
   Liau A, 2006, SEX TRANSM DIS, V33, P576, DOI 10.1097/01.olq.0000204710.35332.c5
   Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d
   Mayer K, 2012, 19 INT AIDS C AIDS 2
   McClintock MK, 1996, CURR DIR PSYCHOL SCI, V5, P178, DOI 10.1111/1467-8721.ep11512422
   McGowan I, 2012, CROI 2012 19 C RETR
   Merrigan M, 2011, SEX TRANSM INFECT, V87, P65, DOI 10.1136/sti.2008.034991
   Millett GA, 2006, AM J PUBLIC HEALTH, V96, P1007, DOI 10.2105/AJPH.2005.066720
   Mustanski BS, 2007, AIDS CARE, V19, P822, DOI 10.1080/09540120701237244
   Mustanski B, 2011, ARCH SEX BEHAV, V40, P289, DOI 10.1007/s10508-009-9596-1
   Mutua G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033103
   Newcomb ME, 2011, ARCH SEX BEHAV, V40, P189, DOI 10.1007/s10508-009-9573-8
   Noar SM, 2012, AIDS CARE, V24, P945, DOI 10.1080/09540121.2012.668167
   Ogilvie GS, 2008, CAN J PUBLIC HEALTH, V99, P185, DOI 10.1007/BF03405470
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Ostergren JE, 2011, CULT HEALTH SEX, V13, P123, DOI 10.1080/13691058.2010.520168
   Phillips AE, 2013, SEX TRANSM INFECT, V89, P245, DOI 10.1136/sextrans-2011-050373
   Politch JA, 2012, AIDS, V26, P1535, DOI 10.1097/QAD.0b013e328353b11b
   Pollock JA, 2009, AIDS EDUC PREV, V21, P340, DOI 10.1521/aeap.2009.21.4.340
   Preston DB, 2007, AIDS EDUC PREV, V19, P218, DOI 10.1521/aeap.2007.19.3.218
   Price MA, 2012, JAIDS-J ACQ IMM DEF, V59, P185, DOI 10.1097/QAI.0b013e31823d8693
   Reisner SL, 2009, AIDS BEHAV, V13, P822, DOI 10.1007/s10461-008-9430-0
   REMAFEDI G, 1987, PEDIATRICS, V79, P326
   Rispel LC, 2011, JAIDS-J ACQ IMM DEF, V57, P69, DOI 10.1097/QAI.0b013e318211b40a
   Ross MW, 2003, SUBST USE MISUSE, V38, P1173, DOI 10.1081/JA-120017657
   Rosser BRS, 2008, AIDS CARE, V20, P588, DOI 10.1080/09540120701867156
   Sanders EJ, 2007, AIDS, V21, P2513, DOI 10.1097/QAD.0b013e3282f2704a
   Sanders EJ, 2013, AIDS, V27, P437, DOI 10.1097/QAD.0b013e32835b0f81
   Shoptaw S, 2009, J URBAN HEALTH, V86, pS77, DOI 10.1007/s11524-009-9372-5
   STALL R, 1994, ADDICTION, V89, P131, DOI 10.1111/j.1360-0443.1994.tb00863.x
   Steinberg L, 2004, ANN NY ACAD SCI, V1021, P51, DOI 10.1196/annals.1308.005
   Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7
   Thomas B, 2012, AIDS CARE, V24, P1401, DOI 10.1080/09540121.2012.672717
   van Griensven F, 2009, CURR OPIN HIV AIDS, V4, P300, DOI 10.1097/COH.0b013e32832c3bb3
   van Rooyen H, 2012, AIDS BEHAV
   Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006
   Vu L, 2012, AIDS BEHAV, V16, P717, DOI 10.1007/s10461-011-9948-4
   Vuylsteke B, 2012, SEX TRANSM INFECT, V88, P288, DOI 10.1136/sextrans-2011-050276
   Wade AS, 2010, AIDS CARE, V22, P409, DOI 10.1080/09540120903253973
   Wade AS, 2005, AIDS, V19, P2133, DOI 10.1097/01.aids.0000194128.97640.07
   Wagenaar BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042953
   Wheeler T, 2012, J EPIDEMIOL COMMUN H, V66, pII16, DOI 10.1136/jech-2012-201081
   White JM, 2013, J URBAN HEALTH, V90, P464, DOI 10.1007/s11524-012-9701-y
   Wilson PA, 2008, SEX TRANSM INFECT, V84, P506, DOI 10.1136/sti.2008.031583
   Wirtz AL, 2013, INT J STD AIDS
   Woods WJ, 2010, JAIDS-J ACQ IMM DEF, V55, pS88, DOI 10.1097/QAI.0b013e3181fbca1b
   Woods WJ, 2003, J HOMOSEXUAL, V44, P1, DOI 10.1300/J082v44n03_01
   Zhang M, 2011, AIDS RES HUM RETROV, V27, P1139, DOI 10.1089/aid.2010.0356
NR 113
TC 50
Z9 50
U1 0
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUL 1
PY 2013
VL 63
SU 2
BP S161
EP S167
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 300JD
UT WOS:000330459300010
PM 23764630
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Cardoso, SW
   Torres, TS
   Santini-Oliveira, M
   Monteiro, L
   Marins, S
   Veloso, VG
   Grinsztejn, B
AF Cardoso, Sandra Wagner
   Torres, Thiago Silva
   Santini-Oliveira, Marilia
   Monteiro, Luana
   Marins, Spindola
   Veloso, Valdilea Goncalves
   Grinsztejn, Beatriz
TI Aging with HIV: a practical review
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Review
DE HIV; AIDS; Aging; Elderly; Brazil; Comorbidity; HAART
ID ACTIVE ANTIRETROVIRAL THERAPY; INFECTED PERSONS; HIV-1-INFECTED
   PATIENTS; CARDIOVASCULAR RISK; OLDER-ADULTS; CONDOM USE; AGE; DISEASE;
   HAART; IMMUNODEFICIENCY
AB The worldwide elderly population is expected to grow by an additional 694 million people by 2025. By that time, there will be approximately two billion elderly people in the world, most of whom (80%) will be living in developing countries. Based on recent estimates, this population will number over 40 million in 2030 in Brazil and a consequent increase in governmental spending for this population can be expected. Since highly active antiretroviral therapy became available in the mid-1990s, the life expectancy of people living with HIV has increased significantly. Approximately 12 million life years were added to the world between 1996 and 2008 as a consequence of wider access to highly active antiretroviral therapy. In Brazil, the incidence of AIDS among the population aged >= 50 years doubled between 1996 and 2006. The development of antiretroviral therapy has allowed individuals diagnosed at a younger age to live longer, which partially explains the aging tendency associated with the HIV/AIDS epidemic. It is estimated that by 2015, subjects aged >= 50 years will represent 50% of the people living with HIV undergoing clinical treatment. This scenario presents some challenges, including the fact that the diagnosis of HIV tends to be delayed in older patients compared to younger patients because the symptoms of HIV can be confused with those of other common diseases among the elderly and also because healthcare professionals do not consider this population to be at high risk for HIV infection. In regard to the individuals diagnosed with HIV, a further challenge is presented by the morbidity normally associated with aging. Finally, the elderly also exhibit higher susceptibility to the toxic effects and pharmacological interactions of medications. The present article reviews the literature regarding the profile of HIV infection among individuals aged >= 50 years focusing on practical features related to the clinical approach and long-term follow-up of this population. (c) 2013 Elsevier Editora Ltda. All rights reserved.
C1 [Cardoso, Sandra Wagner; Torres, Thiago Silva; Santini-Oliveira, Marilia; Monteiro, Luana; Marins, Spindola; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, HIV AIDS Clin Res Ctr, Rio De Janeiro, RJ, Brazil.
RP Grinsztejn, B (corresponding author), Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI TORRES, THIAGO SILVA/D-6548-2014; Cardoso, Sandra W/D-7965-2015
OI TORRES, THIAGO SILVA/0000-0002-2557-601X; Cardoso, Sandra
   W/0000-0001-5230-0003
CR Abel T, 2003, EUR J PUBLIC HEALTH, V13, P350, DOI 10.1093/eurpub/13.4.350
   Al-Harthi L, 2004, HIV MED, V5, P55, DOI 10.1111/j.1468-1293.2004.00186.x
   Althoff KN, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-45
   [Anonymous], 2002, WORLD POP AG 1950 20
   Appay V, 2011, AIDS, V25, P1813, DOI 10.1097/QAD.0b013e32834640e6
   Atta MG, 2008, SEMIN NEPHROL, V28, P563, DOI 10.1016/j.semnephrol.2008.08.009
   Baker JV, 2008, AIDS, V22, P841, DOI 10.1097/QAD.0b013e3282f7cb76
   Benard A, 2007, AIDS PATIENT CARE ST, V21, P458, DOI 10.1089/apc.2006.0142
   Bendavid Eran, 2012, AIDS, V26 Suppl 1, pS85
   Bolland MJ, 2011, J CLIN ENDOCR METAB, V96, P2721, DOI 10.1210/jc.2011-0591
   Boufassa F, 2001, HIV Clin Trials, V2, P339
   Cardoso S, 2010, 18 INT AIDS C 2010 V
   Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P21
   Centers for Disease Control-CDC (USA), HIV SURV REP
   Centers for Disease Control-CDC (USA), PERS AG 50 OLD
   Colafigli M, 2012, CLIN MICROBIOL INFEC, V18, pE299, DOI 10.1111/j.1469-0691.2012.03847.x
   Coleman CL, 2007, J ADV NURS, V60, P368, DOI 10.1111/j.1365-2648.2007.04390.x
   Cordery DV, 2011, SEX HEALTH, V8, P534, DOI 10.1071/SH11026
   Crum-Cianflone NF, 2010, AIDS, V24, P535, DOI 10.1097/QAD.0b013e328331f6e2
   de Luis D A, 2002, Nutr Hosp, V17, P285
   de Pommerol M, 2011, INT J STD AIDS, V22, P67, DOI 10.1258/ijsa.2010.010187
   Desquilbet L, 2009, JAIDS-J ACQ IMM DEF, V50, P299, DOI 10.1097/QAI.0b013e3181945eb0
   Elford J, 2008, SEX TRANSM INFECT, V84, P468, DOI 10.1136/sti.2008.031187
   Fisher M, 2012, CURR OPIN INFECT DIS, V25, P1, DOI 10.1097/QCO.0b013e32834f14fa
   Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010
   Gebo KA, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1460
   Greenbaum AH, 2008, AIDS, V22, P2331, DOI 10.1097/QAD.0b013e32831883f9
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grulich AE, 2011, SEX HEALTH, V8, P521, DOI 10.1071/SH11048
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Haynes L, 2005, CURR OPIN IMMUNOL, V17, P476, DOI 10.1016/j.coi.2005.07.003
   Hinkin CH, 2004, AIDS, V18, pS19, DOI 10.1097/00002030-200418001-00004
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   *IBGE, 2002, PERF ID RESP PEL DOM
   Instituto Brasileiro de Geografia e Estatistica-IBGE (Brazil), 2007, SINT IND SOC
   Jiang W, 2009, J INFECT DIS, V199, P1177, DOI 10.1086/597476
   Justice Amy C, 2010, Curr HIV/AIDS Rep, V7, P69, DOI 10.1007/s11904-010-0041-9
   Kaplan RC, 2008, AIDS, V22, P1615, DOI 10.1097/QAD.0b013e328300581d
   Kearney F, 2010, AGE AGEING, V39, P536, DOI 10.1093/ageing/afq083
   Keller MJ, 1999, AGING CLIN EXP RES, V11, P35
   Kotler DP, 2008, JAIDS-J ACQ IMM DEF, V49, pS79, DOI 10.1097/QAI.0b013e318186519c
   Lazarus JV, 2010, HIV MED, V11, P479, DOI 10.1111/j.1468-1293.2009.00810.x
   Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013
   Lindau ST, 2007, NEW ENGL J MED, V357, P762, DOI 10.1056/NEJMoa067423
   LINDEMAN RD, 1990, AM J KIDNEY DIS, V16, P275, DOI 10.1016/S0272-6386(12)80002-3
   de Souza PML, 2011, CLINICS, V66, P261, DOI 10.1590/S1807-59322011000200014
   Lotufo PA, 2008, REV MED SAO PAULO, V87, P232
   Marzolini C, 2011, J ANTIMICROB CHEMOTH, V66, P2107, DOI 10.1093/jac/dkr248
   Marzolini C, 2010, ANTIVIR THER, V15, P413, DOI 10.3851/IMP1540
   Mascolini M., 2010, 1 INT WORKSH HIV AG
   May MT, 2011, SEX HEALTH, V8, P526, DOI 10.1071/SH11046
   Ministerio da Saude (Brasil), 2006, MAN CTR REF IM ESP
   Ministerio da Saude (Brazil), 2010, B EP AIDS DST, VVIII
   Ministerio da Saude (Brazil), 2011, B EPIDEMIOLOGICO AID, VVIII
   Ministerio da Saude (Brazil), 2008, REC TER ANT AD INF P
   Ministerio de la Salud (Peru), INF NAC PROGR REAL A
   Monforte AD, 2008, AIDS, V22, P2143, DOI 10.1097/QAD.0b013e3283112b77
   Onen NF, 2009, J INFECTION, V59, P346, DOI 10.1016/j.jinf.2009.08.008
   Onen Nur F, 2011, Curr Aging Sci, V4, P33
   Orchi N, 2008, AIDS CARE, V20, P419, DOI 10.1080/09540120701867073
   Oursler KK, 2011, AIDS PATIENT CARE ST, V25, P13, DOI 10.1089/apc.2010.0242
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Patel D, 2003, SEX TRANSM DIS, V30, P216, DOI 10.1097/00007435-200303000-00008
   Petoumenos K, 2011, SEX HEALTH, V8, P465, DOI 10.1071/SH11020
   Phair J, 2011, CURR OPIN HIV AIDS, V6, P285, DOI 10.1097/COH.0b013e3283476bc3
   Piggott D, 2011, 2 INT WORKSH HIV AG
   POLLOCK ML, 1987, J APPL PHYSIOL, V62, P725
   Post Wendy S, 2011, Top Antivir Med, V19, P169
   Reekie J, 2010, CANCER-AM CANCER SOC, V116, P5306, DOI 10.1002/cncr.25311
   Roling J, 2006, CLIN INFECT DIS, V42, P1488, DOI 10.1086/503566
   Sanders GD, 2008, ANN INTERN MED, V148, P889, DOI 10.7326/0003-4819-148-12-200806170-00002
   Schick V, 2010, J SEX MED, V7, P315, DOI 10.1111/j.1743-6109.2010.02013.x
   Schmid GP, 2009, B WORLD HEALTH ORGAN, V87, P162, DOI 10.2471/BLT.09.064030
   Silverberg MJ, 2007, ARCH INTERN MED, V167, P684, DOI 10.1001/archinte.167.7.684
   Sociedade Brasileira de Diabetes (Brasil), DIR SOC BRAS DIAB
   STRAHL C, 1994, NUCLEIC ACIDS RES, V22, P893, DOI 10.1093/nar/22.6.893
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   Tumbarello M, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-46
   Turra CM, 2001, 26 USSP GEN POP C
   Tyerman Z, 2012, AIDS REV, V14, P3
   Valcour V, 2006, CLIN INFECT DIS, V42, P1449, DOI 10.1086/503565
   Van Den Bout-Van Den Beukel CJP, 2008, AIDS RES HUM RETROV, V24, P1375, DOI 10.1089/aid.2008.0058
   Vance DE, 2011, CLIN INTERV AGING, V6, P181, DOI 10.2147/CIA.S14726
   Vance DE, 2011, J ASSOC NURSE AIDS C, V22, P17, DOI 10.1016/j.jana.2010.04.002
   Vance DE, 2010, AM J NURS, V110, P42, DOI 10.1097/01.NAJ.0000368952.80634.42
   Vasto Sonya, 2006, Immun Ageing, V3, P2, DOI 10.1186/1742-4933-3-2
   Wellons MF, 2002, J AM GERIATR SOC, V50, P603, DOI 10.1046/j.1532-5415.2002.50152.x
   WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E
   (WHO) World Health Organization, 2005, ACT AG POL FRAM
   Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543
   Yin MT, 2012, J CLIN ENDOCR METAB, V97, P554, DOI 10.1210/jc.2011-2197
   Zelenetz PD, 1998, AIDS PATIENT CARE ST, V12, P255, DOI 10.1089/apc.1998.12.255
NR 92
TC 33
Z9 36
U1 0
U2 17
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUL-AUG
PY 2013
VL 17
IS 4
BP 464
EP 479
DI 10.1016/j.bjid.2012.11.007
PG 16
WC Infectious Diseases
SC Infectious Diseases
GA 204AN
UT WOS:000323336800013
PM 23711587
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Santos-Oliveira, JR
   Regis, EG
   Giacoia-Gripp, CBW
   Valverde, JG
   Alexandrino-de-Oliveira, P
   Lindoso, JAL
   Goto, H
   Oliveira-Neto, MP
   Guerra, JO
   Grinsztejn, B
   Jeronimo, SB
   Morgado, MG
   Da-Cruz, AM
AF Santos-Oliveira, Joanna R.
   Regis, Eduardo G.
   Giacoia-Gripp, Carmem B. W.
   Valverde, Joanna G.
   Alexandrino-de-Oliveira, Priscilla
   Lindoso, Jose Angelo L.
   Goto, Hiro
   Oliveira-Neto, Manoel P.
   Guerra, Jorge O.
   Grinsztejn, Beatriz
   Jeronimo, Selma B.
   Morgado, Mariza G.
   Da-Cruz, Alda M.
TI Microbial Translocation Induces an Intense Proinflammatory Response in
   PatientsWith Visceral Leishmaniasis and HIV Type 1 Coinfection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE visceral leishmaniasis-HIV/AIDS coinfection; microbial translocation;
   inflammatory cytokines
ID T-CELLS; IMMUNE ACTIVATION; INFECTED PATIENTS; DISEASE; VIRUS;
   CYTOKINES; REPLICATION; MACROPHAGES; EXPRESSION; DEPLETION
AB Background. Leishmania infection is a cofactor in the heightened cellular activation observed in patients with American visceral leishmaniasis and human immunodeficiency virus type 1 (HIV) infection, with or without progression to AIDS (AVL/HIV). Thus, the persistence of a high parasite load despite antileishmanial therapy could be responsible for the continued immune stimulation.
   Methods. CD8(+) T cells expressing CD38, parasite load, lipopolysaccharide (LPS), soluble CD14, macrophage migration inhibitory factor (MIF), intestinal fatty acid-binding protein (IFABP), and proinflammatory cytokines (interleukin 1 beta, interleukin 6, interleukin 8, interleukin 17, interferon gamma, and tumor necrosis factor) were measured in 17 patients with AVL/HIV, 16 with HIV, and 14 healthy subjects (HS).
   Results. Lower Leishmania parasitemia was observed after antileishmanial and antiretroviral therapies. However, higher levels of CD38(+) on CD8(+) T cells were observed in both clinical phases of leishmaniasis, compared with HIV cases. AVL/HIV and HIV patients showed higher levels of LPS and IFABP than HS. Proinflammatory cytokine levels were significantly augmented in patients with active coinfection, as well as those with remission of Leishmania infection. LPS levels and Leishmania infection were positively correlated with CD38 expression on CD8(+) T cells and with IL-6 and IL-8 levels.
   Conclusions. LPS levels along with the immune consequences of Leishmania infection were associated with elevated cellular activation in coinfected patients. As a consequence, secondary chemoprophylaxis for leishmaniasis or even the use of antiinflammatory drugs or antibiotics may be considered for improving the prognosis of AVL/HIV.
C1 [Santos-Oliveira, Joanna R.; Da-Cruz, Alda M.] Fiocruz MS, Inst Oswaldo Cruz, Lab Interdisciplinar Pesquisas Med, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Regis, Eduardo G.] Fiocruz MS, Inst Oswaldo Cruz, Lab Pesquisa Timo, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Giacoia-Gripp, Carmem B. W.; Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Oliveira-Neto, Manoel P.; Grinsztejn, Beatriz] Fiocruz MS, IPEC, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Da-Cruz, Alda M.] Univ Estado Rio de Janeiro, Fac Ciencias Med, Disciplina Parasitol, Rio De Janeiro, Brazil.
   [Valverde, Joanna G.; Jeronimo, Selma B.] Univ Fed Rio Grande do Norte, Dept Bioquim, BR-59072970 Natal, RN, Brazil.
   [Alexandrino-de-Oliveira, Priscilla] Univ Fed Mato Grosso do Sul, Univ Hosp, Hosp Dia Profa Esterina Corsini, Campo Grande, Brazil.
   [Lindoso, Jose Angelo L.; Goto, Hiro] Univ Sao Paulo, Inst Med Trop Sao Paulo, BR-05508 Sao Paulo, Brazil.
   [Guerra, Jorge O.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
RP Da-Cruz, AM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Interdisciplinar Pesquisas Med, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM alda@ioc.fiocruz.br
RI Valverde, Joanna G/C-1284-2014; Jeronimo, Selma/AAY-4033-2020; Goto,
   Hiro/B-5745-2009; Lindoso, Jose Angelo Lauletta/E-9339-2012; Da-Cruz,
   Alda Maria/J-2152-2012
OI Valverde, Joanna G/0000-0001-8064-6255; Jeronimo,
   Selma/0000-0002-4784-9904; Goto, Hiro/0000-0001-7048-562X; Lindoso, Jose
   Angelo Lauletta/0000-0002-4405-4401; 
FU Programa Nacional de DST/AIDS, Ministerio da Saude [ED00095/2007];
   Instituto Oswaldo Cruz; FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ) [FAPERJ nota
   10]; CNPqNational Council for Scientific and Technological Development
   (CNPq)
FX This work was supported by the Programa Nacional de DST/AIDS, Ministerio
   da Saude (grant ED00095/2007) and Instituto Oswaldo Cruz (internal
   funds). J. R. S. O. received a fellowship from FAPERJ (FAPERJ nota 10).
   A. M. C. is a researcher fellowship from CNPq and FAPERJ.
CR Alexandrino-de-Oliveira P, 2010, MEM I OSWALDO CRUZ, V105, P692, DOI 10.1590/S0074-02762010000500016
   Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07
   [Anonymous], 2006, MAN VIG CONTR LEISHM
   Antinori S, 2007, CLIN INFECT DIS, V44, P1602, DOI 10.1086/518167
   Appay V, 2008, J PATHOL, V214, P231, DOI 10.1002/path.2276
   Baba Chalamalasetty Sreenivasa, 2006, Indian J Gastroenterol, V25, P309
   Balkhair A, 2008, INT J INFECT DIS, V12, P111, DOI 10.1016/j.ijid.2007.04.009
   Barreto-De-Souza V, 2006, J INFECT DIS, V194, P846, DOI 10.1086/506618
   Bernier R, 1998, J IMMUNOL, V160, P2881
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brenchley JM, 2012, ANNU REV IMMUNOL, V30, P149, DOI 10.1146/annurev-immunol-020711-075001
   Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   Caradonna L, 2000, J ENDOTOXIN RES, V6, P205, DOI 10.1177/09680519000060030101
   Casado JL, 2001, EUR J CLIN MICROBIOL, V20, P202, DOI 10.1007/s10096-001-8082-z
   Connolly NC, 2005, AIDS REV, V7, P168
   Cooke KR, 2002, J ENDOTOXIN RES, V8, P441, DOI 10.1179/096805102125001046
   Cota GF, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001153
   de Sousa-Gomes ML, 2011, EPIDEMIOL SERV SAUDE, V20, P519, DOI 10.5123/S1679-49742011000400011
   Doisne JM, 2004, J IMMUNOL, V173, P2410, DOI 10.4049/jimmunol.173.4.2410
   Douek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549
   Estes JD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001052
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Senent SG, 2009, GASTROENTEROL HEPATO, V32, P176, DOI 10.1016/j.gastrohep.2008.09.021
   Gonzalez VD, 2009, J VIROL, V83, P11407, DOI 10.1128/JVI.01211-09
   Goto H, 2009, REV I MED TROP, V51, P241, DOI 10.1590/S0036-46652009000500002
   Hicks L, 2009, EUR J GASTROEN HEPAT, V21, P117, DOI 10.1097/MEG.0b013e32830e6fdb
   Lee PI, 2009, J INFECT DIS, V199, P1664, DOI 10.1086/598953
   Lieberman JM, 1997, SURGERY, V121, P335, DOI 10.1016/S0039-6060(97)90363-9
   Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003
   McCoy JJ, 1998, MOL BIOCHEM PARASIT, V95, P251, DOI 10.1016/S0166-6851(98)00112-1
   Medrano FJ, 1998, CLIN EXP IMMUNOL, V114, P403
   Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196
   Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068
   Ministerio da Saude [Ministry of Health], PROT CLIN DIR TER AD
   Mock DJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002635
   Nazli A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000852
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   Peruhype-Magalhaes V, 2006, CLIN EXP IMMUNOL, V146, P124, DOI 10.1111/j.1365-2249.2006.03171.x
   Rabello A, 2003, ANN TROP MED PARASIT, V97, P17, DOI 10.1179/000349803225002507
   Rodrigues Denise do Socorro S., 2003, Braz J Infect Dis, V7, P161, DOI 10.1590/S1413-86702003000200010
   Saha S, 2006, INDIAN J MED RES, V123, P245
   Sandler NG, 2011, GASTROENTEROLOGY, V141, P1220, DOI 10.1053/j.gastro.2011.06.063
   Santos-Oliveira JR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001198
   Santos-Oliveira JR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-358
   Sinha PK, 2006, INDIAN J MED RES, V123, P197
   Weirather JL, 2011, J CLIN MICROBIOL, V49, P3892, DOI 10.1128/JCM.r00764-11
   Wolday D, 1998, SCAND J INFECT DIS, V30, P29, DOI 10.1080/003655498750002268
   Zhao CQ, 2004, CLIN IMMUNOL, V113, P81, DOI 10.1016/j.clim.2004.06.003
NR 49
TC 22
Z9 22
U1 0
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 1
PY 2013
VL 208
IS 1
BP 57
EP 66
DI 10.1093/infdis/jit135
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 156NX
UT WOS:000319830300010
PM 23539743
OA Bronze
DA 2020-11-24
ER

PT J
AU Rodrigues, RA
   Oliveira, RL
   Grinsztejn, B
   Silva, MTT
AF Rodrigues, Roiza Almeida
   Oliveira, Raquel Lisboa
   Grinsztejn, Beatriz
   Silva, Marcus Tulius T.
TI Validity of the International HIV Dementia Scale in Brazil
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE Acquired Immunodeficiency Syndrome; HIV; dementia
ID NEUROCOGNITIVE DISORDERS
AB HIV-associated neurocognitive disorders (HAND) remain prevalent in highly active antiretroviral therapy (HAART) era. Tests to detect HAND are needed for early diagnosis and treatment. Validity of International HIV Dementia Scale (IHDS) has been determined in different countries. The aims of this study were validate IHDS in a Brazilian cohort of HIV-patients and verify if IHDS can be reliably administered by a non-clinician health professional. One hundred and eighty-seven (187) patients were submitted to a full neuropsychological assessment. IHDS was administered twice to each patient (by a non-clinician and by a neurologist). HAND was diagnosed in 98 individuals (68 on HAART). IHDS had sensitivity of 55% and specificity of 80%. IHDS had fair agreement with neuropsychological tests (k0.355) and moderate-to-strong agreement between different evaluators (interclass correlation coefficient (ICC) 0.684). HAND is prevalent nowadays. IHDS is quick and easy to administer, but has marginal sensitivity for the detection of HIV cognitive impairment other than dementia.
C1 [Rodrigues, Roiza Almeida] Fundacao Oswaldo Cruz FIOCRUZ, Evandro Chagas Clin Res Inst IPEC, Clin Res Lab Neuroinfect Dis, Rio De Janeiro, RJ, Brazil.
   [Oliveira, Raquel Lisboa] IPEC FIOCRUZ, Rio De Janeiro, RJ, Brazil.
   [Grinsztejn, Beatriz] IPEC FIOCRUZ, Clin Res Lab STD AIDS, Rio De Janeiro, RJ, Brazil.
   [Silva, Marcus Tulius T.] IPEC FIOCRUZ, Clin Res Lab Neuroinfect Dis, Rio De Janeiro, Brazil.
RP Silva, MTT (corresponding author), Ave Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM marcustulius@ipec.fiocruz.br
RI Silva, Marcus Tulius/AAM-1077-2020
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq)
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq).
CR [Anonymous], 1991, NEUROLOGY, V41, P778
   Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b
   Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135
   Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727
   Herlihy D, 2012, INT J STD AIDS, V23, P285, DOI 10.1258/ijsa.2009.009379
   LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786
   Njamnshi AK, 2008, JAIDS-J ACQ IMM DEF, V49, P393, DOI 10.1097/QAI.0b013e318183a9df
   Sacktor NC, 2005, AIDS, V19, P1367
   Wojna V, 2007, AIDS PATIENT CARE ST, V21, P930, DOI 10.1089/apc.2006.0180
NR 9
TC 15
Z9 16
U1 0
U2 1
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 2013
VL 71
IS 6
BP 376
EP 379
DI 10.1590/0004-282X20130042
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 173IF
UT WOS:000321071900009
PM 23828527
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Nicol, AF
   Grinsztejn, B
   Friedman, RK
   Veloso, VG
   Cunha, CB
   Georg, I
   Pilotto, JH
   Moreira, RI
   Castro, CAV
   Silver, B
   Viscidi, RP
AF Nicol, A. F.
   Grinsztejn, B.
   Friedman, R. K.
   Veloso, V. G.
   Cunha, C. B.
   Georg, I.
   Pilotto, J. H.
   Moreira, R. I.
   Castro, C. A. V.
   Silver, B.
   Viscidi, R. P.
TI Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and
   uninfected women from Brazil
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE HPV seroprevalence; HIV/AIDS; Pregnancy; VLP; Brazil; Q vaccine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY;
   HUMAN-PAPILLOMAVIRUS TYPE-6; ANTIBODY-RESPONSE; PREVALENCE; FREQUENCY;
   EFFICACY; CANCER; RISK
AB Background: Information on vaccine-type HPV seroprevalence is essential for vaccine strategies; however, limited data are available on past exposure to HPV-quadrivalent vaccine types in HIV-infected woman in Brazil.
   Objectives: To assess the seroprevalence for HPV types 6, 11, 16 and 18 in HIV-infected and uninfected women, from Rio de Janeiro, Brazil and to investigate potential associations with age and pregnancy status.
   Study-design: 1100-sera were tested by virus-like particle (VLPs)-based ELISA for antibodies to HPV types 16, 18, 6 and 11. Statistical analysis was carried out by STATA/SE 10.1 and comparisons among HIV-infected and HIV-uninfected women were assessed by Poisson regression models with robust variance. Results: HPV-6, 11, 16 and 18 seroprevalence was significantly higher among HIV-positive women (29.9%, 8.5%, 56.2% and 38.0%, respectively) compared to HIV-negative women (10.9%, 3.5%, 30.8% and 21.7%, respectively), when adjusted by age and pregnancy status. Overall, 69.4% of HIV-infected and 41.5% of HIV-uninfected women tested positive for any HPV quadrivalent vaccine type. However 4.7% and 1.1%, respectively, tested positive for all HPV vaccine type. In HIV-uninfected women who were pregnant, we found a higher HPV-11 seroprevalence (8.5% vs. 1.5%; P < 0.001) and a lower HPV 16 seroprevalence (22.6% vs. 34.2%; P = 0.010) compared to not pregnant women. HIV-uninfected women, aged 40 or more years old had a higher HPV 16 seroprevalence compared to women aged less than 40 years old.
   Conclusions: We did not observe a strong association between age and positive HPV antibodies nor an association between pregnancy and HPV seroprevalence. HPV seroprevalence was significantly higher among HIV-infected women compared to HIV negative women. In both populations the seroprevalence to all four HPV vaccine types was low suggesting that women may potentially benefit from the HPV vaccines. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Nicol, A. F.] Fiocruz MS, Inst Oswaldo Cruz, Lab Interdisciplinary Med, BR-21045900 Rio De Janeiro, Brazil.
   [Grinsztejn, B.; Friedman, R. K.; Veloso, V. G.; Cunha, C. B.; Georg, I.; Moreira, R. I.; Castro, C. A. V.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Pilotto, J. H.] Fundacao Oswaldo Cruz, Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, J. H.] Fundacao Oswaldo Cruz, Lab AIDS & Imunol Mol IOC, Rio De Janeiro, Brazil.
   [Silver, B.; Viscidi, R. P.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA.
RP Nicol, AF (corresponding author), IOC Fiocruz, Lab Interdisciplinary Med Res, Av Brasil 4365 Manguinhos, Rio De Janeiro, RJ, Brazil.
EM nicol@ioc.fiocruz.br; beatriz.grinsztejn@gmail.com; ruthkf@gmail.com;
   valdilea.veloso@gmail.com; ccunhav@gmail.com;
   ingebourg.georg@ipec.fiocruz.br; jhpilotto@gmail.com;
   Ronaldo@fiocruz.br; cavcastro@fiocruz.br; bclayman@jhmi.edu;
   rviscid1@jhmi.edu
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Viscidi,
   Raphael/0000-0002-7906-8002
FU Department of Pediatrics, Johns Hopkins University School of Medicine,
   Baltimore, USA; IPEC-Fiocruz Rio de Janeiro, Brazil
FX Funding was provided by Department of Pediatrics, Johns Hopkins
   University School of Medicine, Baltimore, USA, and by IPEC-Fiocruz Rio
   de Janeiro, Brazil.
CR Brandao VDRAB, 2009, MEM I OSWALDO CRUZ, V104, P755, DOI 10.1590/S0074-02762009000500016
   Arrossi S, 2003, SALUD PUBLICA MEXICO, V45, pS306
   Firnhaber C, 2011, J CLIN VIROL, V52, P265, DOI 10.1016/j.jcv.2011.08.011
   Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537
   Hagensee ME, 1999, OBSTET GYNECOL, V94, P653, DOI 10.1016/S0029-7844(99)00454-8
   Heard I, 2002, AIDS, V16, P1799, DOI 10.1097/00002030-200209060-00013
   Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703
   INCA, 2009, ESTIMATIVA 2010 INCI
   Jit M, 2007, BRIT J CANCER, V97, P989, DOI 10.1038/sj.bjc.6603955
   Kemp TJ, 2011, VACCINE, V29, P2011, DOI 10.1016/j.vaccine.2011.01.001
   Lacey CJ, 2006, VACCINE, V24, P533
   Laukkanen P, 2003, J GEN VIROL, V84, P2105, DOI 10.1099/vir.0.18995-0
   Lu BB, 2012, CANCER EPIDEM BIOMAR, V21, P1542, DOI 10.1158/1055-9965.EPI-12-0483
   Lu BB, 2011, CANCER EPIDEM BIOMAR, V20, P990, DOI 10.1158/1055-9965.EPI-10-1160
   Mariani L, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-105
   Meys R, 2010, BRIT J DERMATOL, V162, P6, DOI 10.1111/j.1365-2133.2009.09365.x
   Nonnenmacher B, 2003, INT J STD AIDS, V14, P258, DOI 10.1258/095646203321264872
   Olsson SE, 2007, VACCINE, V25, P4931, DOI 10.1016/j.vaccine.2007.03.049
   Perez G, 2008, INT J CANCER, V122, P1311, DOI 10.1002/ijc.23260
   Rama Cristina Helena, 2006, Rev. Assoc. Med. Bras., V52, P43, DOI 10.1590/S0104-42302006000100021
   Rama CH, 2010, INT J GYNECOL CANCER, V20, P1405, DOI 10.1111/IGC.0b013e3181f3c85e
   RANDO RF, 1989, AM J OBSTET GYNECOL, V161, P50, DOI 10.1016/0002-9378(89)90231-7
   SCHNEIDER A, 1987, INT J CANCER, V40, P198, DOI 10.1002/ijc.2910400212
   Shah KV, 1997, CANCER EPIDEM BIOMAR, V6, P233
   SUN XW, 1995, OBSTET GYNECOL, V85, P680, DOI 10.1016/0029-7844(95)00025-M
   Sun YP, 1999, CANCER EPIDEM BIOMAR, V8, P935
   Viscidi RP, 2005, CANCER EPIDEM BIOMAR, V14, P283
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Wang SS, 2003, BRIT J CANCER, V89, P1248, DOI 10.1038/sj.bjc.6601272
NR 29
TC 6
Z9 6
U1 0
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUN
PY 2013
VL 57
IS 2
BP 147
EP 151
DI 10.1016/j.jcv.2013.02.007
PG 5
WC Virology
SC Virology
GA 139EH
UT WOS:000318563900011
PM 23490398
DA 2020-11-24
ER

PT J
AU Torres, TS
   Cardoso, SW
   Velasque, LD
   Marins, LMS
   de Oliveira, MS
   Veloso, VG
   Grinsztejn, B
AF Torres, Thiago Silva
   Cardoso, Sandra Wagner
   Velasque, Luciane de Souza
   Spindola Marins, Luana Monteiro
   de Oliveira, Marlia Santini
   Veloso, Valdilea Goncalves
   Grinsztejn, Beatriz
TI Aging with HIV: an overview of an urban cohort in Rio de Janeiro
   (Brazil) across decades of life
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; AIDS; Aging; Elderly; Brazil; Comorbidity; HAART
ID QUALITY-OF-LIFE; ANTIRETROVIRAL THERAPY; INFECTED PERSONS; OLDER-ADULTS;
   AGE; CANCER; AIDS; PEOPLE; RISK; DETERMINANTS
AB The introduction of highly active antiretroviral therapy during the 1990s was crucial to the decline in the rates of morbidity and death related to the acquired immunodeficiency syndrome (AIDS) and turned human immunodeficiency virus (HIV) infection into a chronic condition. Consequently, the HIV/AIDS population is becoming older. The aim of this study was to describe the immunological, clinical and comorbidity profile of an urban cohort of patients with HIV/AIDS followed up at Instituto de Pesquisa Clinica Evandro Chagas, Oswaldo Cruz Foundation in Rio de Janeiro, Brazil. Retrospective data from 2307 patients during January 1st, 2008 and December 31st, 2008 were collected. For continuous variables, Cuzick's non-parametric test was used. For categorical variables, the Cochran-Armitage non-parametric test for tendency was used. For all tests, the threshold for statistical significance was set at 5%. In 2008, 1023 (44.3%), 823 (35.7%), 352 (15.3%) and 109 (4.7%) were aged 18-39, 40-49, 50-59 and >= 60 years-old, respectively. Older and elderly patients (>= 40 years) were more likely to have viral suppression than younger patients (18-39 years) (p < 0.001). No significant difference in the latest CD4(+) T lymphocyte count in the different age strata was observed, although elderly patients (>= 50 years) had lower CD4(+) T lymphocyte nadir (p < 0.02). The number of comorbidities increased with age and the same pattern was observed for the majority of the comorbidities, including diabetes mellitus, dyslipidemia, hypertension, cardiovascular diseases, erectile dysfunction, HCV, renal dysfunction and also for non-AIDS-related cancers (p < 0.001). With the survival increase associated to successful antiretroviral therapy and with the increasing new infections among elderly group, the burden associated to the diagnosis and treatment of the non-AIDS related HIV comorbidities will grow. Longitudinal studies on the impact of aging on the HIV/AIDS population are still necessary, especially in resource-limited countries. (c) 2013 Elsevier Editora Ltda. All rights reserved.
C1 [Torres, Thiago Silva; Cardoso, Sandra Wagner; Velasque, Luciane de Souza; Spindola Marins, Luana Monteiro; de Oliveira, Marlia Santini; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa, Clin Evandro Chagas, HIV AIDS Clin Res Ctr, Rio De Janeiro, RJ, Brazil.
   [Velasque, Luciane de Souza] Univ Fed Estado Rio de Janeiro, Dept Math, Rio De Janeiro, RJ, Brazil.
RP Grinsztejn, B (corresponding author), Av Brasil,4365 Manguinhos, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI Cardoso, Sandra W/D-7965-2015; TORRES, THIAGO SILVA/D-6548-2014
OI Cardoso, Sandra W/0000-0001-5230-0003; TORRES, THIAGO
   SILVA/0000-0002-2557-601X
CR Balbinotto Neto Giácomo, 2008, Arq. Bras. Cardiol., V91, P217, DOI 10.1590/S0066-782X2008001600002
   Belloso WH, 2010, HIV MED, V11, P554, DOI 10.1111/j.1468-1293.2010.00824.x
   Bini EJ, 2006, ARCH INTERN MED, V166, P1626, DOI 10.1001/archinte.166.15.1626
   Boonyanurak P, 2012, MENOPAUSE, V19, P820, DOI 10.1097/gme.0b013e31824cfc0f
   Brown TT, 2005, ARCH INTERN MED, V165, P1179, DOI 10.1001/archinte.165.10.1179
   CAMPOS DP, 2006, 10 C INF HLTH
   Centers for Disease Control-CDC (USA), PERS AG 50 OLD
   Crane HM, 2009, HIV MED, V10, P496, DOI 10.1111/j.1468-1293.2009.00720.x
   *DASAUDE M, 2011, B EP AIDS DST, V8
   de Arruda ER, 2010, BRAZ J INFECT DIS, V14, P281, DOI 10.1016/S1413-8670(10)70057-X
   de Pommerol M, 2011, INT J STD AIDS, V22, P67, DOI 10.1258/ijsa.2010.010187
   Elford J, 2008, SEX TRANSM INFECT, V84, P468, DOI 10.1136/sti.2008.031187
   Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010
   Goulet JL, 2007, CLIN INFECT DIS, V45, P1593, DOI 10.1086/523577
   Grabar S, 2006, J ANTIMICROB CHEMOTH, V57, P4, DOI 10.1093/jac/dki411
   Guaraldi G, 2011, CLIN INFECT DIS, V53, P1120, DOI 10.1093/cid/cir627
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Hinkin CH, 2004, AIDS, V18, pS19, DOI 10.1097/00002030-200418001-00004
   Hoang K, 2003, KIDNEY INT, V64, P1417, DOI 10.1046/j.1523-1755.2003.00207.x
   Ibrahim F, 2012, NEPHROL DIAL TRANSPL, V27, P2291, DOI 10.1093/ndt/gfr657
   Instituto Brasileiro de Geografia e Estatistica (IBGE), 2008, PESQ NAC AM DOM
   Instituto Brasileiro de Geografia e Estatistica-IBGE (Brazil), 2007, SINT IND SOC
   Justice AC, 2004, AIDS, V18, pS49, DOI 10.1097/00002030-200401001-00008
   Kirk GD, 2007, CLIN INFECT DIS, V45, P103, DOI 10.1086/518606
   Lazarus JV, 2010, HIV MED, V11, P479, DOI 10.1111/j.1468-1293.2009.00810.x
   Longo B, 2008, AIDS PATIENT CARE ST, V22, P365, DOI 10.1089/apc.2007.0168
   Manrique L, 2010, JAIDS-J ACQ IMM DEF, V54, P332, DOI 10.1097/QAI.0b013e3181d2eef1
   Massad LS, 2006, J WOMENS HEALTH, V15, P591, DOI 10.1089/jwh.2006.15.591
   *MIN SAUD, 2005, 2 LEV DOM US DROG PS
   Ministerio da Saude, 2008, REC TER ANT AD INF P
   MOREIRA E, PREVALENCE RISK FACT
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Nogueras M, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-159
   Orchi N, 2008, AIDS CARE, V20, P419, DOI 10.1080/09540120701867073
   Pedro Adriana Orcesi, 2003, Cad Saude Publica, V19, P17, DOI 10.1590/S0102-311X2003000100003
   Reis RK, 2011, REV LAT-AM ENFERM, V19, P874, DOI 10.1590/S0104-11692011000400004
   Roux P, 2011, AIDS CARE, V23, P1163, DOI 10.1080/09540121.2011.555738
   Schmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9
   Selvaraj V, 2013, AIDS CARE, V25, P169, DOI 10.1080/09540121.2012.689809
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Shiels MS, 2011, J NATL CANCER I, V103, P753, DOI 10.1093/jnci/djr076
   Shindel AW, 2011, AIDS PATIENT CARE ST, V25, P341, DOI 10.1089/apc.2011.0059
   Silverberg MJ, 2007, ARCH INTERN MED, V167, P684, DOI 10.1001/archinte.167.7.684
   Silverberg MJ, 2012, CLIN INFECT DIS, V54, P1026, DOI 10.1093/cid/cir1012
   Smith RD, 2010, AIDS, V24, P2109, DOI 10.1097/QAD.0b013e32833c7b9c
   Tumbarello M, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-46
   Vance DE, 2011, J ASSOC NURSE AIDS C, V22, P17, DOI 10.1016/j.jana.2010.04.002
   Vance DE, 2010, AM J NURS, V110, P42, DOI 10.1097/01.NAJ.0000368952.80634.42
   (WHO) World Health Organization, 2005, ACT AG POL FRAM
   Wolff C, 2010, REV CHIL INFECTOL, V27, P65, DOI [/S0716-10182010000100011, 10.4067/S0716-10182010000100011]
NR 50
TC 21
Z9 22
U1 0
U2 14
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2013
VL 17
IS 3
BP 324
EP 331
DI 10.1016/j.bjid.2012.10.024
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 165CA
UT WOS:000320459200004
PM 23602466
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Luz, PM
   Pacheco, AG
   Santos, DVG
   Velasque, L
   Moreira, RI
   Guimaraes, MRC
   Nunes, EOP
   Lemos, AS
   Ribeiro, SR
   Campos, DP
   Vitoria, MAA
   Veloso, VG
AF Grinsztejn, Beatriz
   Luz, Paula M.
   Pacheco, Antonio G.
   Santos, Desiree V. G.
   Velasque, Luciane
   Moreira, Ronaldo I.
   Guimaraes, Maria Regina C.
   Nunes, Esteva O. P.
   Lemos, Alberto S.
   Ribeiro, Sayonara R.
   Campos, Dayse P.
   Vitoria, Marco A. A.
   Veloso, Valdilea G.
TI Changing Mortality Profile among HIV-Infected Patients in Rio de
   Janeiro, Brazil: Shifting from AIDS to Non-AIDS Related Conditions in
   the HAART Era
SO PLOS ONE
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS;
   HIV-1-INFECTED PATIENTS; COLLABORATIVE ANALYSIS; CLINICAL CARE; IMMUNE
   STATUS; DEATH; RISK; PEOPLE; CANCER
AB Introduction: We describe temporal trends in the mortality rates and factors associated with AIDS and non-AIDS related mortality at the Evandro Chagas Clinical Research Institute (IPEC), Oswaldo Cruz Foundation (FIOCRUZ).
   Methods: Adult patients enrolling from 1986 through 2009 with a minimum follow up of 60 days were included. Vital status was exhaustively checked using patients' medical charts, through active contact with individuals and family members and by linkage with the Rio de Janeiro Mortality database using a previously validated algorithm. The CoDe protocol was used to establish the cause of death. Extended Cox proportional hazards models were used for multivariate modeling.
   Results: A total of 3530 individuals met the inclusion criteria, out of which 868 (24.6%) deceased; median follow up per patient was 3.9 years (interquartile range 1.7-9.2 years). The dramatic decrease in the overall mortality rates was driven by AIDS-related causes that decreased from 9.19 deaths/100PYs n 1986-1991 to 1.35/100PYs in 2007-2009. Non-AIDS related mortality rates remained stable overtime, at around 1 death/100PYs. Immunodeficiency significantly increased the hazard of both AIDS-related and non-AIDS-related causes of death, while HAART use was strongly associated with a lower hazard of death from either cause.
   Conclusions: Our results confirm the remarkable decrease in AIDS-related mortality as the HIV epidemic evolved and alerts to the conditions not traditionally related to HIV/AIDS which are now becoming more frequent, needing careful monitoring.
C1 [Grinsztejn, Beatriz; Luz, Paula M.; Santos, Desiree V. G.; Velasque, Luciane; Moreira, Ronaldo I.; Guimaraes, Maria Regina C.; Nunes, Esteva O. P.; Lemos, Alberto S.; Ribeiro, Sayonara R.; Campos, Dayse P.; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Pacheco, Antonio G.] Fundacao Oswaldo Cruz, Programa Comp Cient, Rio De Janeiro, Brazil.
   [Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil.
   [Vitoria, Marco A. A.] WHO, HIV Dept, CH-1211 Geneva, Switzerland.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI de Lemos, Alberto dos Santos/M-4246-2013; Pacheco, Antonio
   Guilherme/E-6378-2013
OI de Lemos, Alberto dos Santos/0000-0003-0138-6577; Pacheco, Antonio
   Guilherme/0000-0003-3095-1774; Luz, Paula/0000-0001-9746-719X
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)
FX B.G. acknowledges funding from the National Council of Technological and
   Scientific Development (CNPq) and the Research Funding Agency of the
   State of Rio de Janeiro (FAPERJ). A.G.P. acknowledges funding from the
   National Council of Technological and Scientific Development (CNPq) and
   the Research Funding Agency of the State of Rio de Janeiro (FAPERJ).
   P.M.L. acknowledges funding from the National Council of Technological
   and Scientific Development (CNPq). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Beral V, 2004, AIDS, V18, P51, DOI 10.1097/01.aids.0000096908.73209.5d
   Braitstein P, 2006, LANCET, V367, P817
   Cain LE, 2011, ANN INTERN MED, V154, P509, DOI 10.7326/0003-4819-154-8-201104190-00001
   Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16
   Diamond C, 2006, LEUKEMIA LYMPHOMA, V47, P1822, DOI 10.1080/10428190600658688
   Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4
   Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487
   Funk MJ, 2011, ARCH INTERN MED, V171, P1560, DOI 10.1001/archinternmed.2011.401
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252
   Kowalska JD, 2012, AIDS, V26, P315, DOI 10.1097/QAD.0b013e32834e8805
   Kowalska JD, 2011, EPIDEMIOLOGY, V22, P516, DOI 10.1097/EDE.0b013e31821b5332
   Lang S, 2012, CLIN INFECT DIS, V55, P600, DOI 10.1093/cid/cis489
   Lewden C, 2012, INT J EPIDEMIOL, V41, P433, DOI 10.1093/ije/dyr164
   Lichtenstein KA, 2010, CLIN INFECT DIS, V51, P435, DOI 10.1086/655144
   Martinson NA, 2007, AIDS, V21, P2043, DOI 10.1097/QAD.0b013e3282eea47f
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249
   Sackoff JE, 2006, ANN INTERN MED, V145, P397, DOI 10.7326/0003-4819-145-6-200609190-00003
   Schramm Joyce Mendes de Andrade, 2004, Ciênc. saúde coletiva, V9, P897, DOI 10.1590/S1413-81232004000400011
   Simard EP, 2010, CLIN INFECT DIS, V51, P957, DOI 10.1086/656416
   Smit C, 2006, AIDS, V20, P741
   Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7
   Triant VA, 2010, J ACQUIRED IMMUNODEF
   Weller I, 2009, AIDS, V23, P2029, DOI 10.1097/QAD.0b013e32832e531c
   WHO, 2012, WHO POL COLL TB HIV
   Worm SW, 2010, AIDS, V24, P1537, DOI 10.1097/QAD.0b013e32833a0918
NR 32
TC 79
Z9 80
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2013
VL 8
IS 4
AR e59768
DI 10.1371/journal.pone.0059768
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RZ
UT WOS:000319109800018
PM 23577074
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Pilotto, JH
   Grinsztejn, B
   Veloso, VG
   Velasque, LS
   Friedman, RK
   Moreira, RI
   Rodrigues-Pedro, A
   Oliveira, SM
   Currier, JS
   Morgado, MG
AF Pilotto, Jose H.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Velasque, Luciane S.
   Friedman, Ruth K.
   Moreira, Ronaldo I.
   Rodrigues-Pedro, Adriana
   Oliveira, Sandra M.
   Currier, Judith S.
   Morgado, Mariza G.
TI Moderate Prevalence of Transmitted Drug Resistance Mutations Among
   Antiretroviral-Naive HIV-Infected Pregnant Women in Rio de Janeiro,
   Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ASSOCIATION GUIDELINES;
   REVERSE-TRANSCRIPTASE; GENETIC DIVERSITY; THERAPY; SURVEILLANCE;
   INDIVIDUALS; TIME; EPIDEMIOLOGY; TRANSMISSION
AB Transmission of drug-resistant HIV-1 strains has been gaining attention and is becoming a growing problem throughout the world. The aim of this study was to determine the prevalence of transmitted drug resistance mutations (TDRM) among antiretroviral (ARV)-naive HIV-infected pregnant women in Rio de Janeiro, Brazil. ARV-naive pregnant women were recruited at Hospital Geral de Nova Iguacu (HGNI), Rio de Janeiro, from 2005 to 2008. HIV genotyping was carried out using ViroSeq (Abbott v. 2.0). TDRM were detected using the Calibrated Population Resistance Tool-CPR v. 6.0. The prevalence of mutations associated with resistance in the protease and reverse transcriptase regions of the HIV genome were assessed in samples collected prior to initiation of ARV prophylaxis or treatment. Among 238 eligible specimens that were collected, 197 samples were successfully amplified using reverse transcription polymerase chain reaction. Eighty-one percent of women were infected with HIV subtype B, 10% with subtype F1 viruses, 1.0% with subtype C virus, and 8.0% with recombinant forms of the virus. The prevalence of HIV TDRM was 5.6% for nucleoside reverse transcriptase inhibitors, 2.0% for nonnucleoside reverse transcriptase inhibitors, and 3.0% for protease inhibitors. The overall prevalence of any drug resistance was 10.7%. There were no multiclass resistant strains identified in the analyzed samples. The prevalence of HIV TDRM among the pregnant women in our cohort was moderate. Resistance testing should be encouraged in Rio de Janeiro, among other locations, for all HIV-infected pregnant women prior to prevention of mother-to-child transmission of HIV.
C1 [Pilotto, Jose H.; Rodrigues-Pedro, Adriana; Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, AIDS & Mol Immunol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, Jose H.; Oliveira, Sandra M.] HGNI, HIV Family Care Clin HHFCC, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz; Veloso, Valdilea G.; Velasque, Luciane S.; Friedman, Ruth K.; Moreira, Ronaldo I.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, Rio De Janeiro, Brazil.
   [Velasque, Luciane S.] Univ Fed Estado Rio de Janeiro UNIRIO, Dept Math & Stat, Rio De Janeiro, Brazil.
   [Currier, Judith S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
   [Currier, Judith S.] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA USA.
RP Morgado, MG (corresponding author), Lab AIDS & Imunol Mol, Av Brasil,4365 Pavilhao Leonidas Deanne Salas 413, Rio De Janeiro, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
FU Brazilian Ministry of Health (BMOH); Merck and CompanyMerck & Company;
   Tibotec Therapeutics
FX Financial support was provided by the Brazilian Ministry of Health
   (BMOH).; J.C. has received research grant support for UCLA for clinical
   trials from Merck and Company and Tibotec Therapeutics in the past 48
   months.
CR Ajoge HO, 2012, AIDS RES HUM RETROV, V28, P115, DOI [10.1089/AID.2011.0115, 10.1089/aid.2011.0115]
   Alcantara KC, 2012, J CLIN VIROL, V54, P15, DOI 10.1016/j.jcv.2012.01.011
   Castelbranco EPAF, 2010, AIDS RES HUM RETROV, V26, P1313, DOI 10.1089/aid.2010.0111
   Sucupira MCA, 2007, AIDS PATIENT CARE ST, V21, P116, DOI 10.1089/apc.2006.0079
   Booth CL, 2007, J ANTIMICROB CHEMOTH, V59, P1047, DOI 10.1093/jac/dkm082
   Brenner BG, 2007, J INFECT DIS, V195, P951, DOI 10.1086/512088
   Brigido L, 2004, AIDS PATIENT CARE ST, V18, P189, DOI 10.1089/108729104323038865
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   Coovadia H, 2004, NEW ENGL J MED, V351, P289, DOI 10.1056/NEJMe048128
   de Ruiter A, 2008, HIV MED, V9, P452, DOI 10.1111/j.1468-1293.2008.00619.x
   DHHS, 2010, PAN TREATM HIV INF P, P1
   Dumans AT, 2002, ANTIMICROB AGENTS CH, V46, P3075, DOI 10.1128/AAC.46.9.3075-3079.2002
   Duran AS, 2007, AIDS, V21, P199, DOI 10.1097/QAD.0b013e328011770b
   Ferreira AS, 2011, J MED VIROL, V83, P1301, DOI 10.1002/jmv.22128
   Garcia-Lerma JG, 2001, J CLIN VIROL, V21, P197, DOI 10.1016/S1386-6532(00)00163-3
   Gazzard BG, 2008, HIV MED, V9, P563, DOI 10.1111/j.1468-1293.2008.00636.x
   Geretti Anna Maria, 2007, J HIV Ther, V12, P81
   Ghosn J, 2006, AIDS, V20, P159, DOI 10.1097/01.aids.0000199820.47703.a0
   Gifford RJ, 2009, BIOINFORMATICS, V25, P1197, DOI 10.1093/bioinformatics/btp134
   Gonsalez CR, 2007, VIRUS RES, V129, P87, DOI 10.1016/j.virusres.2007.06.021
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   Hecht FM, 2005, CLIN INFECT DIS, V41, P1324, DOI 10.1086/496988
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Lama JR, 2006, JAIDS-J ACQ IMM DEF, V42, P501, DOI 10.1097/01.qai.0000221677.29693.dd
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012
   MS, 2008, REC TER ANT AD INFN
   Nyombi Balthazar M, 2008, AIDS Res Ther, V5, P13, DOI 10.1186/1742-6405-5-13
   Palma AC, 2007, INFECT GENET EVOL, V7, P391, DOI 10.1016/j.meegid.2007.01.009
   Paraskevis D, 2005, VIRUS RES, V112, P115, DOI 10.1016/j.virusres.2005.03.004
   Sax PE, 2005, CLIN INFECT DIS, V41, P1316, DOI 10.1086/496984
   Schackman BR, 2007, JAIDS-J ACQ IMM DEF, V46, P547, DOI 10.1097/QAI.0b013e31815ac499
   Shet A, 2006, JAIDS-J ACQ IMM DEF, V41, P439, DOI 10.1097/01.qai.0000219290.49152.6a
   Sprinz E, 2009, AIDS RES HUM RETROV, V25, P861, DOI 10.1089/aid.2009.0012
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   United States Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, 2011, GUID US ANT AG HIV 1, P1
   Van Laethem K, 2006, AIDS REV, V8, P37
   Vandamme AM, 2004, ANTIVIR THER, V9, P829
   Cardoso LPV, 2010, J MED VIROL, V82, P351, DOI 10.1002/jmv.21722
   Vercauteren J, 2008, AIDS RES HUM RETROV, V24, P355, DOI 10.1089/aid.2007.0212
   Viani RM, 2007, INT J STD AIDS, V18, P235, DOI 10.1258/095646207780658962
   Welles SL, 2007, JAIDS-J ACQ IMM DEF, V44, P329, DOI 10.1097/QAI.0b013e31802f1296
   Wensing AMJ, 2005, J INFECT DIS, V192, P958, DOI 10.1086/432916
   Wensing AMJ, 2008, AIDS, V22, P625, DOI 10.1097/QAD.0b013e3282f5e062
NR 45
TC 15
Z9 16
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD APR
PY 2013
VL 29
IS 4
BP 681
EP 686
DI 10.1089/aid.2011.0333
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 119RO
UT WOS:000317115300007
PM 23259924
DA 2020-11-24
ER

PT J
AU de Oliveira, RDC
   Shimakura, SE
   Campos, DP
   Victoriano, FP
   Ribeiro, SR
   Veloso, VG
   Grinsztejn, B
   Carvalho, MS
AF Carvalhaes de Oliveira, Raquel de Vasconcellos
   Shimakura, Silvia Emiko
   Campos, Dayse Pereira
   Victoriano, Flaviana Pavan
   Ribeiro, Sayonara Rocha
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Carvalho, Marilia Sa
TI Multi-state models for defining degrees of chronicity related to
   HIV-infected patient therapy adherence
SO CADERNOS DE SAUDE PUBLICA
LA English
DT Article
DE HIV; Disease Progression; Patient Compliance; Survival Analysis
ID ACTIVE ANTIRETROVIRAL THERAPY; MARKOV MODEL; HIV-1-INFECTED PATIENTS;
   CELL COUNT; SURVIVAL; DISEASE; MORTALITY; ADULTS; PROGRESSION;
   MEDICATION
AB Few studies on AIDS that evaluate factors associated with treatment failure have considered the slow evolution of the disease and multiple health state transitions following the use of antiretrovirals. In this article we study factors associated with the progression between different stages of the disease, focusing on therapy adherence using a sample of 722 HIV+ patients followed up for 3 years. States were defined using the following classifications of the CD4 cell count: s(1) (CD4 >= 500); s(2) (350 <= CD4 < 500); and s(3) (CD4 < 350). The transitions between states were modeled using multi-state models. Antiretroviral therapy adherence and disease duration were associated with transitions between immune states during follow-up. Low adherence increased the hazard ratio of a transition between s(1) to s(2) and intermediate adherence increased the hazard ratio of a transition between s(2) to s(3). On the other hand, older age and disease duration between two and four years are protective factors for AIDS progression. Multi-state modeling is a powerful approach for studying chronic diseases and estimating factors associated with transitions between each stage of progression, thus enabling the use of more individualized and effective interventions.
C1 [Carvalhaes de Oliveira, Raquel de Vasconcellos; Campos, Dayse Pereira; Victoriano, Flaviana Pavan; Ribeiro, Sayonara Rocha; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Shimakura, Silvia Emiko] Univ Fed Parana, Setor Ciencias Exatas, BR-80060000 Curitiba, Parana, Brazil.
   [Carvalho, Marilia Sa] Fundacao Oswaldo Cruz, Programa Comp Cient, BR-21040360 Rio De Janeiro, RJ, Brazil.
RP de Oliveira, RDC (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Lab Epidemiol Clin, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM raquel.vasconcellos@ipec.fiocruz.br
RI CARVALHO, MARILIA/AAD-8283-2020; Oliveira, Raquel de V C de/S-7443-2016
OI CARVALHO, MARILIA/0000-0002-9566-0284; Oliveira, Raquel de V C
   de/0000-0001-9387-8645
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); FIOTEC
FX The authors would like to thank the professionals involved in caring for
   the HIV+ patients and the staff of the Statistics and Documentation
   Service for maintaining the database. The authors would also like to
   thank FAPERJ and FIOTEC for their financial support.
CR Andersen PK, 2002, STAT METHODS MED RES, V11, P203, DOI 10.1191/0962280202sm281ra
   Beerenwinkel N, 2007, BIOSTATISTICS, V8, P53, DOI 10.1093/biostatistics/kxj033
   Bonneterre J, 2005, ANN ONCOL, V16, P915, DOI 10.1093/annonc/mdi195
   Brasil. Ministerio da Saude, 2008, REC TER ANT AD INF P
   Campos DP, 2009, THESIS FUNDACAO O CR
   Campos DP, BANCO DADOS INDIVIDU
   Chu KM, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-23
   Foucher Y, 2005, BIOMETRICAL J, V47, P825, DOI 10.1002/bimj.200410170
   Gil J, 2007, AMYOTROPH LATERAL SC, V8, P224, DOI 10.1080/17482960701278562
   Gross R, 2006, J INFECT DIS, V194, P1108, DOI 10.1086/507680
   Hogg RS, 2002, AIDS, V16, P1175
   Hougaard P, 1999, LIFETIME DATA ANAL, V5, P239, DOI 10.1023/A:1009672031531
   Huzurbazar AV, 2005, FLOWGRAPH MODELS MUL
   Jackson CH, 2011, J STAT SOFTW, V38, P1
   Keiser O, 2010, TROP MED INT HEALTH, V15, P251, DOI 10.1111/j.1365-3156.2009.02445.x
   Klein JP, 2002, STAT METHODS MED RES, V11, P117, DOI 10.1191/0962280202sm277ra
   Koethe JR, 2010, AIDS, V24, P2117, DOI 10.1097/QAD.0b013e32833b784a
   Kousignian I, 2003, JAIDS-J ACQ IMM DEF, V34, P50, DOI 10.1097/00126334-200309010-00007
   Lavole A, 2009, LUNG CANCER, V65, P345, DOI 10.1016/j.lungcan.2008.11.018
   Machado LM, 2007, COMPUT METH PROG BIO, V86, P131, DOI 10.1016/j.cmpb.2007.01.010
   Mathieu E, 2007, METHODOL COMPUT APPL, V9, P389, DOI 10.1007/s11009-007-9033-7
   Mathieu E, 2005, BIOMETRICAL J, V47, P834, DOI 10.1002/bimj.200410164
   Ministerio da Saude, 2007, REF RAP DISP MED ARV
   Ministerio da Saude, 2010, REC TER ANT AD IN S2
   Neuhaus J, 2010, AIDS, V24, P697, DOI 10.1097/QAD.0b013e3283365356
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Pan SL, 2007, STAT MED, V26, P5335, DOI 10.1002/sim.2999
   Ragni MV, 2009, HAEMOPHILIA, V15, P552, DOI 10.1111/j.1365-2516.2008.01935.x
   Shih HC, 2007, BMC MED INFORM DECIS, V7, DOI 10.1186/1472-6947-7-34
   Stone VE, 2004, CLIN INFECT DIS, V38, P400, DOI 10.1086/380969
   Titman AC, 2010, STAT METHODS MED RES, V19, P621, DOI 10.1177/0962280209105541
   United Nations Educational Scientific and Cultural Organization, 2005, ED ALL LIT LIF
   WHO, 2010, TECHN BRIEF CD4 TECH
   Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008
   Wood E, 2003, AIDS, V17, P711, DOI 10.1097/00002030-200303280-00009
   World Health Organization, 2008, GLOB BURD DIS 2004 U
   Zaccarelli M, 2009, INFECTION, V37, P203, DOI 10.1007/s15010-008-8142-8
NR 37
TC 10
Z9 10
U1 0
U2 9
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
EI 1678-4464
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PD APR
PY 2013
VL 29
IS 4
BP 801
EP 811
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 158WA
UT WOS:000320003300017
PM 23568309
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Almeida, DV
   Morgado, MG
   Cortes, FH
   Guimaraes, ML
   Mendonca-Lima, L
   Pilotto, JH
   Grinsztejn, B
   Veloso, VG
   Bongertz, V
AF Almeida, Dalziza Victalina
   Morgado, Mariza Goncalvez
   Cortes, Fernanda Heloise
   Guimaraes, Monick Lindermeyer
   Mendonca-Lima, Leila
   Pilotto, Jose Henrique
   Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
   Bongertz, Vera
TI Short Communication Neutralizing Antibodies in HIV-1-Infected Brazilian
   Individuals
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV NEUTRALIZATION; TYPE-1; AIDS;
   PREVALENCE; INFECTION; RESPONSES; STRAINS; ASSAYS; PANEL
AB Tests for the detection of the humoral immune response to HIV-1 have to be standardized and established, demanding regional efforts. For this purpose the neutralizing antibody (NAb) assay for HIV-1 in TZM-bl cells was introduced in Brazil. Twenty plasma samples from HIV-1-infected individuals were assayed: 10 progressors and 10 long-term nonprogressors. These were tested against eight env-pseudotyped viruses (psVs) in the TZM-bl NAb assay and against HIV-1 strain HTLV/IIIB (HIV-1 IIIB) in primary lymphocytes. Forty-four percent of the samples showed neutralizing titers for psVs and 55% for HIV-1 IIIB. Plasma from progressors showed a broader neutralization and a higher potency. The introduction of these reference reagents encourages the participation of Brazil in future comparative assessments of anti-HIV-1 antibodies.
C1 [Almeida, Dalziza Victalina; Morgado, Mariza Goncalvez; Cortes, Fernanda Heloise; Guimaraes, Monick Lindermeyer; Pilotto, Jose Henrique; Bongertz, Vera] Fiocruz MS, Inst Oswaldo Cruz, AIDS & Mol Immunol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Mendonca-Lima, Leila] Fiocruz MS, Inst Oswaldo Cruz, Funct Genom & Bioinformat Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz; Veloso, Valdilea Goncalves] Fiocruz MS, Evandro Chagas Clin Res Inst, BR-21045900 Rio De Janeiro, Brazil.
RP Almeida, DV (corresponding author), Minist Hlth, Fundacao Oswaldo Cruz, Av Brasil 4365,Pav 26,Sala 413, BR-21040900 Rio De Janeiro, Brazil.
EM dalziza@gmail.com
RI Mendonca-Lima, Leila/J-3390-2014; Cortes, Fernanda/AAF-9254-2020;
   Veloso, Valdilea Goncalves/J-6189-2012; Pilotto, Jose
   Henrique/AAD-9773-2019
OI Mendonca-Lima, Leila/0000-0003-4388-5083; Pilotto, Jose
   Henrique/0000-0003-0521-8597
FU Brazilian Ministry of Health [147/08 DST/AIDS-UNESCO/IOC-/LABAIDS]; Bill
   and Melinda Gates Foundation Collaboration for AIDS vaccine discovery
   (CAVD) project Global HIV Vaccine Enterprise [38619]; Bill and Melinda
   Gates Foundation Global HIV Vaccine Enterprise (GHVE) Central Service
   Facilities (CSFs), Vaccine Immune Monitoring Center (VIMC) [38619]; NIH
   AIDS Research and Reagent Program [8129]; Project Neut Net-EC
   FP6-2003-LifeSciHealth [LSSP-CT-2004-012190]
FX We are grateful to the Collaboration for AIDS Vaccine Discovery (CAVD)
   funded by the Bill and Melinda Gates Foundation (grant 38619) Global HIV
   Vaccine Enterprise (GHVE) Central Service Facilities (CSFs),
   specifically Dr. D. Montefiori's Vaccine Immune Monitoring Center (VIMC)
   (grant 383-0920). We thank the NIH AIDS Research and Reagent Program for
   the donation of HIV-1 psVs and TZM-bl cells (#8129). Monoclonal antibody
   2F5 and soluble CD4 (sCD4) were kindly donated by the National Institute
   for Biological Standards and Control with funding from the Project Neut
   Net-EC FP6-2003-LifeSciHealth contract no. LSSP-CT-2004-012190. We also
   thankful for the donation of normal human buffy coats by the University
   Hospital Clementino Fraga Filho/UFRJ and Dr. Luciene C. Scherer of the
   Central Laboratory of Public Health of the Porto Alegre, RS. We are
   grateful to all individuals for donating blood to enable us to carry out
   this study.; This study was supported by the Brazilian Ministry of
   Health (# 147/08 DST/AIDS-UNESCO/IOC-/LABAIDS). The Bill and Melinda
   Gates Foundation Collaboration for AIDS vaccine discovery (CAVD) project
   Global HIV Vaccine Enterprise (grant 38619) financed the training and
   materials for use in the TZM-bl NAb assay.
CR Baum Linda L, 2010, Curr HIV/AIDS Rep, V7, P11, DOI 10.1007/s11904-009-0036-6
   Bello G, 2009, J MED VIROL, V81, P1681, DOI 10.1002/jmv.21565
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Bongertz V, 2005, MEM I OSWALDO CRUZ, V100, P85, DOI 10.1590/S0074-02762005000100016
   Bongertz V, 2001, SCAND J IMMUNOL, V53, P302, DOI 10.1046/j.1365-3083.2001.00866.x
   Bongertz V, 2008, AIDS RES HUM RETRO S, V24, pP04
   Brown BK, 2008, VIROLOGY, V375, P529, DOI 10.1016/j.virol.2008.02.022
   Carotenuto P, 1998, AIDS, V12, P1591, DOI 10.1097/00002030-199813000-00005
   Casado C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011079
   Casseb J, 2004, MEM I OSWALDO CRUZ, V99, P69, DOI 10.1590/S0074-02762004000100012
   Choudhry V, 2006, BIOCHEM BIOPH RES CO, V348, P1107, DOI 10.1016/j.bbrc.2006.07.163
   Diaz RS, 2008, VIROLOGY, V381, P184, DOI 10.1016/j.virol.2008.08.014
   Fenyo EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004505
   Gray ES, 2011, J VIROL, V85, P4828, DOI 10.1128/JVI.00198-11
   HO DD, 1985, NEW ENGL J MED, V312, P649, DOI 10.1056/NEJM198503073121015
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Mascola JR, 2010, ANNU REV IMMUNOL, V28, P413, DOI 10.1146/annurev-immunol-030409-101256
   Montefiori D.C., 2005, CURR PROTOC IMMUNOL, V12, P11, DOI DOI 10.1002/0471142735.IM1211S64
   Montefiori DC, 2012, J INFECT DIS, V206, P431, DOI 10.1093/infdis/jis367
   Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   Ochsenbauer C, 2009, CURR OPIN HIV AIDS, V4, P418, DOI 10.1097/COH.0b013e32832f011e
   Polonis VR, 2008, VIROLOGY, V375, P315, DOI 10.1016/j.virol.2008.02.007
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   ROBERTGUROFF M, 1985, NATURE, V316, P72, DOI 10.1038/316072a0
   Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09
   van Gils MJ, 2009, AIDS, V23, P2405, DOI 10.1097/QAD.0b013e32833243e7
   Verity EE, 2007, J VIROL, V81, P9268, DOI 10.1128/JVI.00650-07
   WEISS RA, 1985, NATURE, V316, P69, DOI 10.1038/316069a0
NR 29
TC 2
Z9 2
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAR
PY 2013
VL 29
IS 3
BP 488
EP 492
DI 10.1089/aid.2012.0052
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 096VY
UT WOS:000315434000012
PM 23145941
OA Green Published
DA 2020-11-24
ER

PT J
AU Cortes, FH
   Bello, G
   Vorsatz, C
   Pilotto, JH
   Guimaraes, ML
   Grinsztejn, B
   Veloso, VG
   Pinto, AR
   Morgado, MG
AF Cortes, Fernanda Heloise
   Bello, Gonzalo
   Vorsatz, Carla
   Pilotto, Jose Henrique
   Guimaraes, Monick Lindenmeyer
   Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
   Pinto, Aguinaldo Roberto
   Morgado, Mariza Goncalves
TI Higher cross-subtype IFN-gamma ELISpot responses to Gag and Nef peptides
   in Brazilian HIV-1 subtype B- and F1-than in C-infected subjects
SO VACCINE
LA English
DT Article
DE T-cell response; Gag; Net; Consensus versus isolate sequences;
   Cross-reactivity; HIV-1 subtypes
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; GENETIC DIVERSITY;
   IMMUNE-RESPONSES; DRUG-RESISTANCE; CLADE; INDIVIDUALS; REACTIVITY;
   CONSENSUS; VACCINE
AB HIV-1 diversity has been considered a huge challenge for the HIV-1 vaccine development. To overcome it, immunogens based on centralized sequences, as consensus, have been tested. In Brazil, the co-circulation of three subtypes offers a suitable scenario to test T cell cross-subtype responses to consensus sequences. Furthermore, we included peptides based on closest viral isolates (CVI) from each subtype analyzed to compare with T cell responses detected against the consensus sequences. The study included 32 subjects infected with HIV-1 subtype B (n = 13),C (n = 11), and F1 (n = 8). Gag and Nef-specific T cell responses were evaluated by IFN-gamma-ELISpot assay. Peptides based on CVI sequences were similar to consensus in both reducing genetic distance and detecting T cell responses. A high cross-subtype response between B and F1 in both regions was observed in HIV-1 subtype B and F1-infected subjects. We also found no significant difference in responses to subtype B and C consensus peptides among subtype B-infected subjects. In contrast, the magnitude of T cell responses to consensus C peptides in the Gag region was higher than to consensus B peptides among HIV-1 subtype C-infected subjects. Regarding Nef, subtype C-infected subjects showed higher values to consensus C than to consensus F1 peptides. Moreover, subtype F1-infected subjects presented lower responses to subtype C peptides than to subtype F1 and B. A similar level of responses was detected with group M based peptides in subtype B and F1 infected subjects. However, among subtype C infected subjects, this set of peptides detected lower levels of response than consensus C. Overall, the level of cross-subtype response between subtypes B and F1 was higher than between subtype C and B or C and F1. Our data suggests that the barrier of genetic diversity in HIV-1 group M for vaccine design may be dependent on the subtypes involved. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Cortes, Fernanda Heloise; Bello, Gonzalo; Pilotto, Jose Henrique; Guimaraes, Monick Lindenmeyer; Morgado, Mariza Goncalves] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Vorsatz, Carla; Grinsztejn, Beatriz; Veloso, Valdilea Goncalves] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, BR-26030380 Nova Iguacu, RJ, Brazil.
   [Pinto, Aguinaldo Roberto] Univ Fed Santa Catarina, Dept Microbiol Imunol & Parasitol, Ctr Ciencias Biol, BR-88040900 Florianopolis, SC, Brazil.
RP Morgado, MG (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Ave Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Cortes, Fernanda/AAF-9254-2020; Bentancor,
   Gonzalo Jose Bello/N-7377-2019; Pilotto, Jose Henrique/AAD-9773-2019;
   Pinto, Aguinaldo Roberto/R-6625-2016
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Pinto, Aguinaldo
   Roberto/0000-0002-0991-8876
FU Department of STD; AIDS; Viral Hepatitis/Brazilian Ministry of Health;
   CNPq FellowshipNational Council for Scientific and Technological
   Development (CNPq)
FX This work was supported by Department of STD, AIDS and Viral
   Hepatitis/Brazilian Ministry of Health. Fernanda Heloise Cortes is
   recipient of a CNPq Fellowship. We thank all the patients that
   participated in this study, the Program for Technological Development in
   Tools for Health-PDTIS/FIOCRUZ for use of its facilities and Vera
   Bongertz for critical reviewing of the manuscript.
CR Aguayo N, 2008, REV SOC BRAS MED TRO, V41, P225, DOI 10.1590/S0037-86822008000300001
   Artenstein AW, 1996, AIDS RES HUM RETROV, V12, P557, DOI 10.1089/aid.1996.12.557
   Bansal A, 2006, AIDS, V20, P353, DOI 10.1097/01.aids.0000206501.16783.67
   Betts MR, 1997, J VIROL, V71, P8908, DOI 10.1128/JVI.71.11.8908-8911.1997
   Bongertz V, 2005, MEM I OSWALDO CRUZ, V100, P85, DOI 10.1590/S0074-02762005000100016
   Boutwell CL, 2010, J INFECT DIS, V202, pS309, DOI 10.1086/655653
   Brown SA, 2006, AIDS RES HUM RETROV, V22, P188, DOI 10.1089/aid.2006.22.188
   Calarota SA, 2008, J IMMUNOL, V180, P5907, DOI 10.4049/jimmunol.180.9.5907
   Caride E, 2000, VIROLOGY, V275, P107, DOI 10.1006/viro.2000.0487
   Coplan PM, 2005, J INFECT DIS, V191, P1427, DOI 10.1086/428450
   Cunha-Neto E, 2008, AIDS RES HUM RETROV, V24, P124
   Ferreira AS, 2011, J MED VIROL, V83, P1301, DOI 10.1002/jmv.22128
   Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461
   Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004
   Frahm N, 2008, AIDS, V22, P447, DOI 10.1097/QAD.0b013e3282f42412
   Gao F, 2005, J VIROL, V79, P1154, DOI 10.1128/JVI.79.2.1154-1163.2005
   Gao Feng, 2004, Expert Rev Vaccines, V3, pS161, DOI 10.1586/14760584.3.4.S161
   Garber DA, 2004, LANCET INFECT DIS, V4, P397, DOI 10.1016/S1473-3099(04)01056-4
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Geels MJ, 2005, J VIROL, V79, P11247, DOI 10.1128/JVI.79.17.11247-11258.2005
   Girard MP, 2011, VACCINE, V29, P6191, DOI [10.1016/j.vaccine.2011.08.031, 10.1016/j.vaccine.2011.06.085]
   Gomez-Carrillo M, 2006, AIDS RES HUM RETROV, V22, P1186, DOI 10.1089/aid.2006.22.1186
   Graf T, 2011, J CLIN VIROL, V51, P186, DOI 10.1016/j.jcv.2011.04.011
   Gupta SB, 2006, JAIDS-J ACQ IMM DEF, V42, P135, DOI 10.1097/01.qai.0000223017.01568.e7
   Heyndrickx L, 2000, J VIROL, V74, P363, DOI 10.1128/JVI.74.1.363-370.2000
   Kesturu GS, 2006, VIROLOGY, V348, P437, DOI 10.1016/j.virol.2005.11.055
   Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19
   Kothe DL, 2006, VIROLOGY, V352, P438, DOI 10.1016/j.virol.2006.05.011
   Lee CN, 1998, AIDS RES HUM RETROV, V14, P807, DOI 10.1089/aid.1998.14.807
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   McKinnon LR, 2005, JAIDS-J ACQ IMM DEF, V40, P245, DOI 10.1097/01.qai.0000184858.16447.04
   Montano SM, 2005, JAIDS-J ACQ IMM DEF, V40, P57, DOI 10.1097/01.qai.0000159667.72584.8b
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Nickle DC, 2003, SCIENCE, V299, P1515
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998
   Santra S, 2008, P NATL ACAD SCI USA, V105, P10489, DOI 10.1073/pnas.0803352105
   Serwanga J, 2012, AIDS RES HUM RETROV, V28, P384, DOI [10.1089/aid.2011.0175, 10.1089/AID.2011.0175]
   Sierra Maria, 2005, Infection Genetics and Evolution, V5, P209, DOI 10.1016/j.meegid.2004.07.010
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Thakar MR, 2005, J INFECT DIS, V192, P749, DOI 10.1086/432547
   Turk G, 2008, J VIROL, V82, P2853, DOI 10.1128/JVI.02260-07
   Williams F, 2001, HUM IMMUNOL, V62, P645, DOI 10.1016/S0198-8859(01)00247-6
   Yan J, 2011, VACCINE, V29, P7173, DOI 10.1016/j.vaccine.2011.05.076
   Yu XG, 2005, AIDS, V19, P1449, DOI 10.1097/01.aids.0000183126.32077.c8
   Zembe L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026096
NR 46
TC 6
Z9 6
U1 1
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD FEB
PY 2013
VL 31
IS 7
BP 1106
EP 1112
DI 10.1016/j.vaccine.2012.12.023
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 083TA
UT WOS:000314486900016
PM 23261042
DA 2020-11-24
ER

PT J
AU Couto-Fernandez, JC
   Ravasi, G
   Ferreira, O
   Grinsztejn, B
   Chequer-Fernandez, S
   Rachid-de-Lacerda, MC
   Tanuri, A
AF Couto-Fernandez, J. C.
   Ravasi, G.
   Ferreira, O., Jr.
   Grinsztejn, B.
   Chequer-Fernandez, S.
   Rachid-de-Lacerda, M. C.
   Tanuri, A.
TI Surveillance of transmitted HIV-1 drug resistance in newly diagnosed
   individuals from Rio de Janeiro, Brazil
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT International Workshop on HIV and Hepatitis Virus Drug Resistance and
   Curative Strategies
CY JUN 04-08, 2013
CL Toronto, CANADA
C1 [Couto-Fernandez, J. C.] Fiocruz MS, IOC, Lab AIDS & Mol Immunol, WHO Natl Reference HIV Genotyping & TDR Surveilla, BR-21045900 Rio De Janeiro, Brazil.
   [Ravasi, G.] WHO, PAHO, Brasilia, DF, Brazil.
   [Ravasi, G.] Brazilian Minist Hlth MS, Dept STD AIDS & Viral Hepatitis DDAHV, Brasilia, DF, Brazil.
   [Ferreira, O., Jr.; Tanuri, A.] Univ Fed Rio de Janeiro, Dept Genet, Lab Mol Virol, Rio De Janeiro, Brazil.
   [Grinsztejn, B.] Fiocruz MS, IPEC, Evandro Chagas Clin Res Inst, BR-21045900 Rio De Janeiro, Brazil.
   [Rachid-de-Lacerda, M. C.] Rio de Janeiro State Hlth Secretariat SES, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2013
VL 18
SU 1
BP A74
EP A74
PG 1
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA AG2ES
UT WOS:000335229500063
DA 2020-11-24
ER

PT J
AU Pacheco, AG
   Luz, PM
   Moreira, RI
   Campos, D
   Lemos, A
   Veloso, VG
   Grinsztejn, B
AF Pacheco, A. G.
   Luz, P. M.
   Moreira, R. I.
   Campos, D.
   Lemos, A.
   Veloso, V. G.
   Grinsztejn, B.
TI Pneumonia And Tuberculosis As Causes Of Death In Hiv-Infected Patients
   In Brazil: Comparison Between Pre-, Early And Highly Active
   Antiretroviral Therapy (haart) Eras
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Pacheco, A. G.; Luz, P. M.; Moreira, R. I.; Campos, D.; Lemos, A.; Veloso, V. G.; Grinsztejn, B.] Fiocruz MS, Rio De Janeiro, Brazil.
EM apacheco@fiocruz.br
RI Pacheco, Antonio Guilherme/E-6378-2013
OI Pacheco, Antonio Guilherme/0000-0003-3095-1774
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2013
VL 187
MA A2486
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TO
UT WOS:000209839101657
DA 2020-11-24
ER

PT J
AU Bertisch, B
   Grinsztejn, B
   Calmy, A
AF Bertisch, Barbara
   Grinsztejn, Beatriz
   Calmy, Alexandra
TI HIV-infected women in Europe: gender-specific needs and challenges
SO ANTIVIRAL THERAPY
LA English
DT Editorial Material
ID ANTIRETROVIRAL THERAPY; EFAVIRENZ; METAANALYSIS; RILPIVIRINE; PHASE-3;
   AFRICA; SAFETY; COHORT; TRIAL; MEN
AB In collaboration with the Strong, HIV positive, Empowered Women (SHE) programme, an industry-funded initiative aimed at improving the quality of life of HIV-positive women, Antiviral Therapy has taken the excellent step to dedicate a Supplement Issue addressing the needs and challenges related to the care of women living in Europe. Included articles present the multiple facets of gender-specific issues and research gaps, ranging from HIV testing strategies to antiretroviral combination therapy, including long-term challenges associated with chronic HIV infection.
C1 [Bertisch, Barbara] St Gall Cantonal Hosp, Div Infect Dis & Hosp Epidemiol, St Gallen, Switzerland.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Calmy, Alexandra] Univ Hosp Geneva, HIV Unit, Geneva, Switzerland.
RP Calmy, A (corresponding author), Univ Hosp Geneva, HIV Unit, Geneva, Switzerland.
EM alexandra.calmy@hcuge.ch
OI Bertisch, Barbara/0000-0003-1725-4245
CR Cohen CJ, 2011, LANCET, V378, P229, DOI 10.1016/S0140-6736(11)60983-5
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Cornell M, 2011, TROP MED INT HEALTH, V16, P828, DOI 10.1111/j.1365-3156.2011.02767.x
   Dominguez S, 2013, ANTIVIR THER, V18, P45, DOI 10.3851/IMP2639
   Druyts E, 2013, AIDS, V27, P417, DOI 10.1097/QAD.0b013e328359b89b
   Ford N, 2011, AIDS, V25, P2301, DOI 10.1097/QAD.0b013e32834cdb71
   Haberl A, 2013, ANTIVIR THER, V18, P35, DOI 10.3851/IMP2638
   Johannessen A, 2011, AIDS, V25, P1225, DOI 10.1097/QAD.0b013e32834403b8
   Johnson M, 2013, ANTIVIR THER, V18, P19, DOI 10.3851/IMP2637
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Marrazzo J, 2013, 20 C RETR OPP INF 3
   May M, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6016
   Miralles C, 2013, ANTIVIR THER, V18, P11, DOI 10.3851/IMP2646
   Molina JM, 2011, LANCET, V378, P238, DOI 10.1016/S0140-6736(11)60936-7
   Monforte AD, 2013, ANTIVIR THER, V18, P27, DOI 10.3851/IMP2647
   Monforte AD, 2010, AIDS, V24, P1091, DOI 10.1097/QAD.0b013e3283390db3
   Rahangdale L, 2013, 20 C RETR OPP INF 3
   Rosin C, 2011, 13 EUR AIDS C 12 15
   Saag MS, 2013, SANFORD GUIDE HIV AI
   Sibiude J, 2013, 20 C RETR OPP INF 3
   Squires KE, 2011, J ANTIMICROB CHEMOTH, V66, P363, DOI 10.1093/jac/dkq457
   Staehelin C, 2012, JAIDS-J ACQ IMM DEF, V59, P79, DOI 10.1097/QAI.0b013e318236be70
   UNAIDS, GLOB FACT SHEET
   UNAIDS Report on the Global AIDS Epidemic, 2012, UNAIDS REP GLOB AIDS
   Vernazza P, 2008, B MED SUISSES, V89, P165, DOI DOI 10.4414/BMS.2008.13252
   Wandeler G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027903
   WHO, 2016, CONS GUID US ANT DRU
   Yan J, 2000, 20 C RETR OPP INF 3
NR 28
TC 1
Z9 1
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2013
VL 18
IS 4
BP 549
EP 551
DI 10.3851/IMP2669
PG 3
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 290MF
UT WOS:000329761400001
PM 24218649
DA 2020-11-24
ER

PT J
AU Passaes, CPB
   Guimaraes, ML
   Cardoso, SW
   Pilotto, JH
   Veloso, V
   Grinsztejn, B
   Morgado, MG
AF Bittencourt Passaes, Caroline Pereira
   Guimaraes, Monick Lindenmeyer
   Cardoso, Sandra Wagner
   Pilotto, Jose Henrique
   Veloso, Valdilea
   Grinsztejn, Beatriz
   Morgado, Mariza Goncalves
TI Monitoring the emergence of resistance mutations in patients infected
   with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro,
   Brazil: A follow-up study
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HIV-1; integrase inhibitors; raltegravir; resistance mutations;
   enfuvirtide switches; Brazil
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TREATMENT-EXPERIENCED PATIENTS; OPTIMIZED
   BACKGROUND THERAPY; RANDOMIZED CONTROLLED-TRIAL; TREATMENT-NAIVE
   PATIENTS; DRUG-RESISTANCE; HIV-1-INFECTED PATIENTS; REVERSE
   TRANSCRIPTION; ANTIRETROVIRAL THERAPY; COMBINATION THERAPY
AB The present study describes a follow-up of a prospective and observational cohort of patients infected with HIV-1 and treated with raltegravir for salvage therapy in Brazil. Two groups of patients were analyzed: switching from T20 to RAL (Group 1, n?=?9) and salvage therapy containing RAL (Group 2, n?=?10). Blood samples were drawn for CD4+ T-cell counts and HIV-1 viral load determinations. Protease, reverse transcriptase, and integrase genotyping were performed at baseline and at the time of virologic failure. CD4+ T-cells increased at 6 and 12 months in both groups; HIV-1 viral load was continuously suppressed for Group 1, and for Group 2 it significantly decreased after starting a RAL-containing regimen. Three out of 10 patients from Group 2 could not suppress HIV-1 viral load. The mutations Q148H?+?G140S were observed for two patients and for the third patient only mutations to PR/RT inhibitors were detected. The genotypic sensitivity score (GSS) was analyzed for all patients of Group 2 and both patients who developed resistance to raltegravir presented a GSS?<?2.0 for the RAL-containing scheme, which could be associated to the lack of effectiveness of the proposed scheme. The present study describes, for the first time in Brazil, the close follow-up of a series of patients using a raltegravir-containing HAART, showing the safety of the enfuvirtide switch to RAL and the effectiveness of a therapeutic regimen with RAL in promoting immune reconstitution and suppressing HIV replication, as well as documenting the occurrence of resistance to integrase inhibitors in the country. J. Med. Virol. 84:18691875, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Bittencourt Passaes, Caroline Pereira; Guimaraes, Monick Lindenmeyer; Pilotto, Jose Henrique; Morgado, Mariza Goncalves] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, BR-21040900 Rio De Janeiro, Brazil.
   [Cardoso, Sandra Wagner; Veloso, Valdilea; Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Clin Res Inst IPEC, BR-21040900 Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] HGNI, Rio De Janeiro, Brazil.
RP Passaes, CPB (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, Av Brasil 4365,Room 413,Leonidas Deane Bldg, BR-21040900 Rio De Janeiro, Brazil.
EM cpassaes@ioc.fiocruz.br
RI Passaes, Caroline/AAH-3392-2020; Pilotto, Jose Henrique/AAD-9773-2019;
   Cardoso, Sandra W/D-7965-2015
OI Passaes, Caroline/0000-0002-0813-2521; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Cardoso, Sandra W/0000-0001-5230-0003
FU PAPES V-FIOCRUZ/CNPqNational Council for Scientific and Technological
   Development (CNPq); POM IOC/FIOCRUZ
FX Grant sponsor: PAPES V-FIOCRUZ/CNPq; Grant sponsor: POM IOC/FIOCRUZ.
CR [Anonymous], 2009, AIDS Alert, V24, P106
   [Anonymous], 2007, AIDS Patient Care STDS, V21, P889, DOI 10.1089/apc.2007.9967
   [Anonymous], 2007, AIDS Patient Care STDS, V21, P702
   Baldanti F, 2010, J MED VIROL, V82, P116, DOI 10.1002/jmv.21651
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   Bittencourt-Passaes C, 2009, JAIDS-J ACQ IMM DEF, V51, P7, DOI 10.1097/QAI.0b013e31819df3b3
   Buzon MJ, 2010, NAT MED, V16, P460, DOI 10.1038/nm.2111
   Caby F, 2010, SCAND J INFECT DIS, V42, P527, DOI 10.3109/00365541003621502
   Cahn P, 2007, LANCET, V369, P1235, DOI 10.1016/S0140-6736(07)60571-6
   Castor D, 2009, J MED VIROL, V81, P1323, DOI 10.1002/jmv.21500
   Charpentier C, 2008, HIV MED, V9, P765, DOI 10.1111/j.1468-1293.2008.00628.x
   Chiu TK, 2004, CURR TOP MED CHEM, V4, P965, DOI 10.2174/1568026043388547
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   De Castro N, 2009, CLIN INFECT DIS, V49, P1259, DOI 10.1086/605674
   De Luca A, 2003, J INFECT DIS, V187, P1934, DOI 10.1086/375355
   Delelis O, 2010, ANTIMICROB AGENTS CH, V54, P491, DOI 10.1128/AAC.01075-09
   Delelis O, 2009, NUCLEIC ACIDS RES, V37, P1193, DOI 10.1093/nar/gkn1050
   Dobard CW, 2007, J VIROL, V81, P10037, DOI 10.1128/JVI.00519-07
   Ferns RB, 2009, AIDS, V23, P2159, DOI 10.1097/QAD.0b013e32832ec4ae
   Fransen S, 2009, J VIROL, V83, P11440, DOI 10.1128/JVI.01168-09
   Fun A, 2010, J ANTIMICROB CHEMOTH, V65, P2300, DOI 10.1093/jac/dkq319
   Gallien S, 2011, J ANTIMICROB CHEMOTH, V66, P2099, DOI 10.1093/jac/dkr269
   Grant PM, 2009, J CLIN VIROL, V46, P305, DOI 10.1016/j.jcv.2009.09.025
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Hatano H, 2010, JAIDS-J ACQ IMM DEF, V54, P389, DOI 10.1097/QAI.0b013e3181c42ea4
   Lai CC, 2012, J ANTIMICROB CHEMOTH, V67, P1254, DOI 10.1093/jac/dkr601
   Lennox JL, 2010, JAIDS-J ACQ IMM DEF, V55, P39, DOI 10.1097/QAI.0b013e3181da1287
   Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1
   Maggiolo Franco, 2007, J Int Assoc Physicians AIDS Care (Chic), V6, P87, DOI 10.1177/1545109707299632
   Malet I, 2008, ANTIMICROB AGENTS CH, V52, P1351, DOI 10.1128/AAC.01228-07
   Malet I, 2009, J ANTIMICROB CHEMOTH, V63, P795, DOI 10.1093/jac/dkp014
   Markowitz M, 2006, JAIDS-J ACQ IMM DEF, V43, P509, DOI 10.1097/QAI.0b013e31802b4956
   Markowitz M, 2009, JAIDS-J ACQ IMM DEF, V52, P350, DOI 10.1097/QAI.0b013e3181b064b0
   Quercia R, 2009, J VIROL, V83, P10245, DOI 10.1128/JVI.00894-09
   Reigadas S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010311
   Santos JR, 2009, HIV CLIN TRIALS, V10, P432, DOI 10.1310/hct1006-432
   Skiest DJ, 2011, HIV CLIN TRIALS, V12, P131, DOI 10.1310/hct1203-131
   Steigbigel RT, 2008, NEW ENGL J MED, V359, P339, DOI 10.1056/NEJMoa0708975
   Steigbigel RT, 2010, CLIN INFECT DIS, V50, P605, DOI 10.1086/650002
   Talbot A, 2009, JAIDS-J ACQ IMM DEF, V51, P362, DOI 10.1097/QAI.0b013e3181aa1398
   Tommasi C, 2010, SCAND J INFECT DIS, V42, P237, DOI 10.3109/00365540903447018
   Wilkinson TA, 2009, J BIOL CHEM, V284, P7931, DOI 10.1074/jbc.M806241200
   Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999
   Zazzi M, 2009, J ANTIMICROB CHEMOTH, V64, P616, DOI 10.1093/jac/dkp252
   Zhu K, 2004, J VIROL, V78, P5045, DOI 10.1128/JVI.78.10.5045-5055.2004
NR 45
TC 1
Z9 1
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD DEC
PY 2012
VL 84
IS 12
BP 1869
EP 1875
DI 10.1002/jmv.23409
PG 7
WC Virology
SC Virology
GA 027GE
UT WOS:000310339300005
PM 23080489
DA 2020-11-24
ER

PT J
AU Goodreau, SM
   Carnegie, NB
   Vittinghoff, E
   Lama, JR
   Sanchez, J
   Grinsztejn, B
   Koblin, BA
   Mayer, KH
   Buchbinder, SP
AF Goodreau, Steven M.
   Carnegie, Nicole B.
   Vittinghoff, Eric
   Lama, Javier R.
   Sanchez, Jorge
   Grinsztejn, Beatriz
   Koblin, Beryl A.
   Mayer, Kenneth H.
   Buchbinder, Susan P.
TI What Drives the US and Peruvian HIV Epidemics in Men Who Have Sex with
   Men (MSM)?
SO PLOS ONE
LA English
DT Article
ID SEXUALLY-TRANSMITTED INFECTIONS; BASE-LINE DATA; UNITED-STATES;
   HOMOSEXUAL-MEN; TRANSMISSION EVENTS; CASUAL PARTNERSHIPS; MALE
   CIRCUMCISION; CONTROLLED-TRIAL; DRUG-RESISTANCE; PREVENTION
AB In this work, we estimate the proportions of transmissions occurring in main vs. casual partnerships, and by the sexual role, infection stage, and testing and treatment history of the infected partner, for men who have sex with men (MSM) in the US and Peru. We use dynamic, stochastic models based in exponential random graph models (ERGMs), obtaining inputs from multiple large-scale MSM surveys. Parallel main partnership and casual sexual networks are simulated. Each man is characterized by age, race, circumcision status, sexual role behavior, and propensity for unprotected anal intercourse (UAI); his history is modeled from entry into the adult population, with potential transitions including HIV infection, detection, treatment, AIDS diagnosis, and death. We implemented two model variants differing in assumptions about acute infectiousness, and assessed sensitivity to other key inputs. Our two models suggested that only 4-5% (Model 1) or 22-29% (Model 2) of HIV transmission results from contacts with acute-stage partners; the plurality (80-81% and 49%, respectively) stem from chronic-stage partners and the remainder (14-16% and 27-35%, respectively) from AIDS-stage partners. Similar proportions of infections stem from partners whose infection is undiagnosed (24-31%), diagnosed but untreated (36-46%), and currently being treated (30-36%). Roughly one-third of infections (32-39%) occur within main partnerships. Results by country were qualitatively similar, despite key behavioral differences; one exception was that transmission from the receptive to insertive partner appears more important in Peru (34%) than the US (21%). The broad balance in transmission contexts suggests that education about risk, careful assessment, pre-exposure prophylaxis, more frequent testing, earlier treatment, and risk-reduction, disclosure, and adherence counseling may all contribute substantially to reducing the HIV incidence among MSM in the US and Peru. Citation: Goodreau SM, Carnegie NB, Vittinghoff E, Lama JR, Sanchez J, et al. (2012) What Drives the US and Peruvian HIV Epidemics in Men Who Have Sex with Men (MSM)? PLoS ONE 7(11): e50522. doi:10.1371/journal.pone.0050522
C1 [Goodreau, Steven M.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA.
   [Carnegie, Nicole B.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Lama, Javier R.; Sanchez, Jorge] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Koblin, Beryl A.] New York Blood Ctr, Lab Infect Dis Prevent, New York, NY 10021 USA.
   [Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA USA.
   [Buchbinder, Susan P.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
RP Goodreau, SM (corresponding author), Univ Washington, Dept Anthropol, Seattle, WA 98195 USA.
EM goodreau@uw.edu
RI Goodreau, Steven/P-2366-2017
OI Goodreau, Steven/0000-0003-1009-5763; Carnegie,
   Nicole/0000-0001-7664-6682
FU National Institute of Allergy and Infectious Disease (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01-AI083060]; National Institute of Mental Health
   (NIMH), United States National Institutes of Health; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [R24HD042828, R24HD042828,
   R24HD042828, R01HD068395, R24HD042828, R24HD042828, R24HD042828,
   R24HD042828, R24HD042828, R01HD068395, R24HD042828, R24HD042828,
   R24HD042828, R24HD042828, R24HD042828, R24HD042828, R24HD042828,
   R24HD042828, R24HD042828, R24HD042828, R24HD042828, R24HD042828,
   R24HD042828, R24HD042828, R24HD042828, R24HD042828, R24HD042828,
   R01HD068395, R01HD068395, R24HD042828, R24HD042828, R24HD042828,
   R24HD042828, R24HD042828] Funding Source: NIH RePORTER; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [R24HD042828, R24HD042828,
   R24HD042828, R24HD042828, R24HD042828, R24HD042828, R24HD042828,
   R01HD068395, R24HD042828, R24HD042828, R24HD042828, R24HD042828] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI083060, R01AI083060, R01AI083060,
   R01AI083060] Funding Source: NIH RePORTER
FX The study was supported by a grant (R01-AI083060) from the National
   Institute of Allergy and Infectious Disease (NIAID) and the National
   Institute of Mental Health (NIMH), United States National Institutes of
   Health. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], 2010, MMWR-MORBID MORTAL W, V59, P1201
   [Anonymous], 2011, MMWR MORB MORTAL WKL, V60, P1618
   Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298
   Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2
   Beyrer C, 2011, DIR DEV, P1, DOI 10.1596/978-0-8213-8726-9
   Beyrer C, 2010, EPIDEMIOL REV, V32, P137, DOI 10.1093/epirev/mxq011
   Brenner BG, 2007, J INFECT DIS, V195, P951, DOI 10.1086/512088
   Brenner BG, 2011, J INFECT DIS, V204, P1115, DOI 10.1093/infdis/jir468
   Brown AE, 2009, J INFECT DIS, V199, P427, DOI 10.1086/596049
   BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014
   Celum C, 2008, LANCET, V371, P2109, DOI 10.1016/S0140-6736(08)60920-4
   Chesney MA, 2003, AM J PUBLIC HEALTH, V93, P933, DOI 10.2105/AJPH.93.6.933
   Chu HT, 2010, EPIDEMIOLOGY, V21, pS25, DOI 10.1097/EDE.0b013e3181ce9950
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Davidovich U, 2001, AIDS, V15, P1303, DOI 10.1097/00002030-200107060-00013
   Eshleman SH, 2009, JAIDS-J ACQ IMM DEF, V52, P121, DOI 10.1097/QAI.0b013e3181ab61e1
   Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243
   Goicochea P, 2004, 15 INT AIDS C BANGK
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4
   Hall HI, 2008, JAMA-J AM MED ASSOC, V300, P520, DOI 10.1001/jama.300.5.520
   HANDCOCK MS, 2008, STATNET SOFTWARE TOO
   Jansen IAV, 2011, AIDS, V25, P493, DOI 10.1097/QAD.0b013e328342fbe9
   Koblin BA, 2003, AM J PUBLIC HEALTH, V93, P926, DOI 10.2105/AJPH.93.6.926
   Lama JR, 2006, JAIDS-J ACQ IMM DEF, V42, P501, DOI 10.1097/01.qai.0000221677.29693.dd
   Lewis F, 2008, PLOS MED, V5, P392, DOI 10.1371/journal.pmed.0050050
   Little SJ, 1999, J EXP MED, V190, P841, DOI 10.1084/jem.190.6.841
   Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339
   Ma ZM, 2009, J VIROL, V83, P3288, DOI 10.1128/JVI.02423-08
   MacKellar DA, 2007, PUBLIC HEALTH REP, V122, P39, DOI 10.1177/00333549071220S107
   Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d
   Millett GA, 2006, AM J PUBLIC HEALTH, V96, P1007, DOI 10.2105/AJPH.2005.066720
   Ministry of Health of Peru, 2006, STEP FORW FIGHT AIDS
   Pao D, 2005, AIDS, V19, P85, DOI 10.1097/00002030-200501030-00010
   Pinkerton SD, 2007, AIDS, V21, P1625, DOI 10.1097/QAD.0b013e32826fb6a6
   Prabhu VS, 2009, AIDS, V23, P1792, DOI 10.1097/QAD.0b013e32832e7d04
   Prejean J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017502
   Rapatski BL, 2005, JAIDS-J ACQ IMM DEF, V38, P241
   Sanchez J, 2007, JAIDS-J ACQ IMM DEF, V44, P578, DOI 10.1097/QAI.0b013e318033ff82
   Sanchez J, 2011, AIDS, V25, P519, DOI 10.1097/QAD.0b013e328340fd81
   Sullivan PS, 2009, AIDS, V23, P1153, DOI 10.1097/QAD.0b013e32832baa34
   Tabet S, 2002, AIDS, V16, P1271, DOI 10.1097/00002030-200206140-00010
   Vaidya NK, 2010, J VIROL, V84, P4302, DOI 10.1128/JVI.02284-09
   Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003
   Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411
   Wilson DP, 2008, LANCET, V372, P314, DOI 10.1016/S0140-6736(08)61115-0
   Wilson DP, 2009, SEX HEALTH, V6, P19, DOI 10.1071/SH08081
   Xiridou M, 2004, AIDS, V18, P1311, DOI 10.1097/00002030-200406180-00010
   Xiridou M, 2003, AIDS, V17, P1029, DOI 10.1097/00002030-200305020-00012
   Yerly S, 2001, AIDS, V15, P2287, DOI 10.1097/00002030-200111230-00010
   2005, MMWR MORB MORTAL WKL, V54, P597
NR 51
TC 202
Z9 203
U1 0
U2 47
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 29
PY 2012
VL 7
IS 11
AR e50522
DI 10.1371/journal.pone.0050522
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 051DI
UT WOS:000312104900062
PM 23209768
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Luetkemeyer, AF
   Rosenkranz, SL
   Lu, D
   Lizak, PS
   Ive, P
   Swindells, S
   Benson, CA
   Grinsztejn, B
   Sanne, IM
   Havlir, DV
   Aweeka, F
AF Luetkemeyer, A. F.
   Rosenkranz, S. L.
   Lu, D.
   Lizak, P. S.
   Ive, P.
   Swindells, S.
   Benson, C. A.
   Grinsztejn, B.
   Sanne, I. M.
   Havlir, D. V.
   Aweeka, F.
CA Adult Aids Clinical Trials Grp A52
TI Relationship between weight, efavirenz (EFV) concentrations and
   virologic suppression in HIV plus patients on rifampin (RIF)-based TB
   treatment in the ACTG 5221 STRIDE study
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Luetkemeyer, A. F.; Havlir, D. V.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA USA.
   [Rosenkranz, S. L.; Lu, D.] Harvard Univ, Sch Publ Hlth, Stat Data Anal Ctr, Boston, MA 02115 USA.
   [Lizak, P. S.; Aweeka, F.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Clin Pharm, San Francisco, CA USA.
   [Sanne, I. M.] Univ Witwatersrand, Clin HIV Res Unit, Johannesburg, South Africa.
   [Swindells, S.] Univ Nebraska, Omaha, NE 68182 USA.
   [Benson, C. A.] Univ Calif San Diego, Div Infect Dis, San Diego, CA 92103 USA.
   [Grinsztejn, B.] Fundacao Oswaldo Cruz, STD AIDS Clin Res Lab, Rio De Janeiro, Brazil.
EM aluetkemeyer@php.ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 41
EP 42
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200092
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Sterling, T
   Benson, C
   Shang, N
   Miro, J
   Grinsztejn, B
   Chaisson, R
   Lucchetti, A
   Sanchez, J
   Scott, N
   Villarino, E
AF Sterling, T.
   Benson, C.
   Shang, N.
   Miro, J.
   Grinsztejn, B.
   Chaisson, R.
   Lucchetti, A.
   Sanchez, J.
   Scott, N.
   Villarino, E.
CA AIDS Clinical Trials Grp
   TB Trials Consortium
TI Tolerability among HIV-positive persons of three months of once-weekly
   rifapentine plus INH (3HP) versus 9 months of daily INH (9H) for
   treatment of latent tuberculosis infection: the PREVENT TB Study (TBTC
   Study 26/ACTG 5259)
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Sterling, T.] Vanderbilt Univ, Nashville, TN USA.
   [Benson, C.] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Shang, N.; Scott, N.; Villarino, E.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Miro, J.] Agencia Salut Publ, Barcelona, Spain.
   [Grinsztejn, B.] Fundaao Oswaldo Cruz, IPEC Evandro Chagas, Rio De Janeiro, Brazil.
   [Chaisson, R.] Johns Hopkins Univ, Baltimore, MD USA.
   [Lucchetti, A.] Inmensa, Lima, Peru.
   [Sanchez, J.] Impacta, Lima, Peru.
EM timothy.sterling@vanderbilt.edu
NR 0
TC 0
Z9 0
U1 0
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 42
EP 42
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200093
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   De Castro, N
   Arnold, V
   Veloso, V
   Morgado, M
   Pilotto, JH
   Brites, C
   Madruga, JV
   Barcellos, N
   Santos, BR
   Vorsatz, C
   Grondin, C
   Santini-Oliveira, M
   Patey, O
   Delaugerre, C
   Chene, G
   Molina, JM
AF Grinsztejn, B.
   De Castro, N.
   Arnold, V.
   Veloso, V.
   Morgado, M.
   Pilotto, J. H.
   Brites, C.
   Madruga, J. V.
   Barcellos, N.
   Riegel Santos, B.
   Vorsatz, C.
   Grondin, C.
   Santini-Oliveira, M.
   Patey, O.
   Delaugerre, C.
   Chene, G.
   Molina, J-M.
CA ANRS 12 180 Reflate TB Study Grp
TI A randomized multicentre open-label trial to estimate the efficacy and
   safety of two doses of raltegravir (RAL) to efavirenz (EFV) for the
   treatment of HIV-TB co-infected patients: results of the ANRS 12 180
   Reflate TB trial
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Grinsztejn, B.; Veloso, V.; Vorsatz, C.; Santini-Oliveira, M.] Inst Pesquisa Clin Evandro Chagas, FIOCRUZ, Lab Pesquisa Clin DST AIDS, Rio De Janeiro, Brazil.
   [De Castro, N.; Delaugerre, C.; Molina, J-M.] Univ Paris Diderot, INSERM, U941, Paris, France.
   [De Castro, N.; Delaugerre, C.; Molina, J-M.] Hosp St Louis, AP HP, Paris, France.
   [Arnold, V.; Grondin, C.; Chene, G.] Univ Bordeaux, INSERM, U897, Bordeaux, France.
   [Morgado, M.] Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, FIOCRUZ, BR-20001 Rio De Janeiro, Brazil.
   [Pilotto, J. H.] Hosp Geral Nova Iguac, Dept DST AIDS, Nova Iguac, Brazil.
   [Brites, C.] Hosp Univ Prof Edgar Santos, Lab Pesquisa Doencas Infecciosas, Salvador, BA, Brazil.
   [Madruga, J. V.] Ctr Referencia & Treinamento DST AIDS, Unidade Pesquisa, Sao Paulo, Brazil.
   [Barcellos, N.] Hlth State Secretariat Hosp Sanatorio Partenon, Porto Alegre, RS, Brazil.
   [Riegel Santos, B.] Hosp Nossa Senhora da Conceicao, Serv Infectol, Porto Alegre, RS, Brazil.
   [Patey, O.] CHG Villeneuve St George, Dept Internal & Trop Med, Villeneuve St Georges, France.
RI Pilotto, Jose Henrique/AAD-9773-2019; Brites, Carlos/D-1353-2013
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Brites,
   Carlos/0000-0002-4673-6991
NR 0
TC 0
Z9 0
U1 0
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 57
EP 57
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200122
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Hosseinipour, M
   Swindells, S
   Ribaudo, H
   Eron, J
   Chen, YQ
   Wang, L
   Ou, SS
   Anderson, M
   McCauley, M
   Gamble, T
   Kumarasamy, N
   Hakim, J
   Kumwenda, J
   Pilotto, J
   Godbole, S
   Chariyalertsak, S
   Santos, B
   Mayer, K
   Eshleman, S
   Piwowar-Manning, E
   Cottle, L
   Makhema, J
   Mills, L
   Panchia, R
   Sanne, I
   Elharrar, V
   Havlir, D
   Cohen, MS
AF Grinsztejn, B.
   Hosseinipour, M.
   Swindells, S.
   Ribaudo, H.
   Eron, J.
   Chen, Y. Q.
   Wang, L.
   Ou, S. -S.
   Anderson, M.
   McCauley, M.
   Gamble, T.
   Kumarasamy, N.
   Hakim, J.
   Kumwenda, J.
   Pilotto, J.
   Godbole, S.
   Chariyalertsak, S.
   Santos, B.
   Mayer, K.
   Eshleman, S.
   Piwowar-Manning, E.
   Cottle, L.
   Makhema, J.
   Mills, L.
   Panchia, R.
   Sanne, I.
   Elharrar, V.
   Havlir, D.
   Cohen, M. S.
CA HPTN 052 ACTG Study Team
TI Effect of early versus delayed initiation of antiretroviral therapy
   (ART) on clinical outcomes in the HPTN 052 randomized clinical trial
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Grinsztejn, B.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Hosseinipour, M.] UNC Project Malawi, Lilongwe, Malawi.
   [Hosseinipour, M.] Univ N Carolina Chapel Hill, Lilongwe, Malawi.
   [Swindells, S.] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Ribaudo, H.] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [Eron, J.; Cohen, M. S.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
   [Chen, Y. Q.; Wang, L.; Ou, S. -S.; Anderson, M.; Cottle, L.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA.
   [McCauley, M.] FHI 360, Washington, DC USA.
   [Gamble, T.] FHI 360, Durham, NC USA.
   [Kumarasamy, N.] YRG CARE Med Ctr, Madras, Tamil Nadu, India.
   [Hakim, J.] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
   [Kumwenda, J.] Johns Hopkins Project, Coll Med, Blantyre, Malawi.
   [Pilotto, J.] Hosp Geral Nova Iguau, Rio De Janeiro, Brazil.
   [Pilotto, J.] Lab AIDS & Imunol Mol IOC, Rio De Janeiro, Brazil.
   [Godbole, S.] Natl AIDS Res Inst ICMR, Pune, Maharashtra, India.
   [Chariyalertsak, S.] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
   [Santos, B.] Hosp Nossa Senhora Conceiao, Porto Alegre, RS, Brazil.
   [Mayer, K.] Harvard Univ, Sch Med, Fenway Hlth, Boston, MA USA.
   [Eshleman, S.] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA.
   [Piwowar-Manning, E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Makhema, J.] Botswana Harvard AIDS Inst, Gaborone, Botswana.
   [Mills, L.] CDC, KEMRI CDC Res & Publ Hlth Collaborat, Div HIV AIDS Prevent, Kisumu, Kenya.
   [Panchia, R.] Univ Witwatersrand, Perinatal HIV Res Unit PHRU, Johannesburg, South Africa.
   [Sanne, I.] Univ Witwatersrand, Dept Med, Johannesburg, South Africa.
   [Elharrar, V.] NIAID, NIH, Bethesda, MD 20892 USA.
   [Havlir, D.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
EM beatriz.grinsztejn@gmail.com
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
NR 0
TC 0
Z9 0
U1 0
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 60
EP 61
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200127
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Walensky, RP
   Ross, EL
   Kumarasamy, N
   Wood, R
   Noubary, F
   Paltiel, AD
   Nakamura, YM
   Godbole, S
   Hosseinipour, M
   Hakim, JG
   Kumwenda, J
   Makhema, J
   Akelo, V
   Panchia, R
   Sanne, I
   Weinstein, MC
   Losina, E
   Mayer, KH
   Grinsztejn, B
   Pilotto, J
   Chariyalertsak, S
   Santos, B
   Chen, YQ
   Wang, L
   Li, X
   McCauley, M
   Gamble, T
   Piwowar-Manning, E
   Cottle, L
   Hoffman, I
   Eron, J
   Gallant, J
   Swindells, S
   Taha, T
   Nielsen-Saines, K
   Celentano, D
   Essex, M
   Elharrar, V
   Burns, D
   Seage, GR
   Cohen, MS
   Freedberg, KA
AF Walensky, R. P.
   Ross, E. L.
   Kumarasamy, N.
   Wood, R.
   Noubary, F.
   Paltiel, A. D.
   Nakamura, Y. M.
   Godbole, S.
   Hosseinipour, M.
   Hakim, J. G.
   Kumwenda, J.
   Makhema, J.
   Akelo, V.
   Panchia, R.
   Sanne, I.
   Weinstein, M. C.
   Losina, E.
   Mayer, K. H.
   Grinsztejn, B.
   Pilotto, J.
   Chariyalertsak, S.
   Santos, B.
   Chen, Y. Q.
   Wang, L.
   Li, X.
   McCauley, M.
   Gamble, T.
   Piwowar-Manning, E.
   Cottle, L.
   Hoffman, I.
   Eron, J.
   Gallant, J.
   Swindells, S.
   Taha, T.
   Nielsen-Saines, K.
   Celentano, D.
   Essex, M.
   Elharrar, V.
   Burns, D.
   Seage, G. R.
   Cohen, M. S.
   Freedberg, K. A.
TI The cost-effectiveness of treatment as prevention: analysis of the HPTN
   052 trial
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Walensky, R. P.; Ross, E. L.; Noubary, F.; Nakamura, Y. M.; Freedberg, K. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Walensky, R. P.; Freedberg, K. A.] Harvard Univ, Sch Med, Boston, MA USA.
   [Losina, E.] Harvard Ctr AIDS Res, Boston, MA USA.
   [Weinstein, M. C.; Essex, M.; Seage, G. R.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Makhema, J.] Botswana Harvard AIDS Inst, Gaborone, Botswana.
   [Walensky, R. P.; Losina, E.] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Kumarasamy, N.] YR Gaitonade Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
   [Wood, R.] Univ Cape Town, ZA-7925 Cape Town, South Africa.
   [Wood, R.] Desmond Tutu HIV Ctr, Cape Town, South Africa.
   [Paltiel, A. D.] Yale Univ, Sch Med, New Haven, CT USA.
   [Godbole, S.] NARI, Pune, Maharashtra, India.
   [Hosseinipour, M.] Univ N Carolina Chapel Hill, Lilongwe, Malawi.
   [Hosseinipour, M.] UNC Project Malawi, Lilongwe, Malawi.
   [Hakim, J. G.] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
   [Kumwenda, J.] Coll Med Johns Hopkins Project, Blantyre, Malawi.
   [Akelo, V.] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya.
   [Panchia, R.] Univ Witwatersrand, PHRU, Johannesburg, South Africa.
   [Sanne, I.] Univ Witwatersrand, Dept Med, Johannesburg, South Africa.
   [Losina, E.; Freedberg, K. A.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
   [Mayer, K. H.] Fenway Inst, Boston, MA USA.
   [Grinsztejn, B.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, J.] Fiocruz MS, Hosp Geral Nova Iguacu, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, J.] Fiocruz MS, Lab AIDS & Imunol Mol IOC, BR-21045900 Rio De Janeiro, Brazil.
   [Chariyalertsak, S.] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
   [Santos, B.] Hosp Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil.
   [Chen, Y. Q.; Wang, L.; Li, X.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA.
   [McCauley, M.] FHI 360, Washington, DC USA.
   [Gamble, T.] FHI 360, Durham, NC USA.
   [Piwowar-Manning, E.; Gallant, J.] Johns Hopkins Sch Med, Baltimore, MD USA.
   [Cottle, L.] SCHARP, Seattle, WA USA.
   [Hoffman, I.; Eron, J.; Cohen, M. S.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
   [Swindells, S.] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Taha, T.; Celentano, D.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Nielsen-Saines, K.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
   [Elharrar, V.; Burns, D.] NIAID, NIH, Bethesda, MD 20892 USA.
EM kfreedberg@partners.org
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
NR 0
TC 0
Z9 0
U1 0
U2 12
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 116
EP 117
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200220
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Cortes, FH
   Bello, G
   Vorsatz, C
   Pilotto, JH
   Grinsztejn, B
   Veloso, VG
   Pinto, AR
   Morgado, MG
AF Cortes, F. H.
   Bello, G.
   Vorsatz, C.
   Pilotto, J. H.
   Grinsztejn, B.
   Veloso, V. G.
   Pinto, A. R.
   Morgado, M. G.
TI HIV-1 subtype B- and F1-infected subjects display higher cross-clade
   T-Cell response than subtype C-infected subjects
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Cortes, F. H.; Bello, G.; Morgado, M. G.] Fiocruz MS, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Vorsatz, C.; Grinsztejn, B.; Veloso, V. G.] Fiocruz MS, Evandro Chagas Clin Res Inst, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, J. H.] Nova Iguacu Gen Hosp, Nova Iguacu, Brazil.
   [Pinto, A. R.] Univ Fed Santa Catarina, Dept Microbiol Immunol & Parasitol, Florianopolis, SC, Brazil.
RI Veloso, Valdilea Goncalves/J-6189-2012; Cortes, Fernanda/AAF-9254-2020;
   Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD SEP 13
PY 2012
VL 9
SU 2
AR P150
DI 10.1186/1742-4690-9-S2-P150
PG 1
WC Virology
SC Virology
GA 015UO
UT WOS:000309472100223
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Kinsler, JJ
   Cunningham, WE
   Nurena, CR
   Nadjat-Haiem, C
   Grinsztejn, B
   Casapia, M
   Montoya-Herrera, O
   Sanchez, J
   Galea, JT
AF Kinsler, Janni J.
   Cunningham, William E.
   Nurena, Cesar R.
   Nadjat-Haiem, Carsten
   Grinsztejn, Beatriz
   Casapia, Martin
   Montoya-Herrera, Orlando
   Sanchez, Jorge
   Galea, Jerome T.
TI Using Conjoint Analysis to Measure the Acceptability of Rectal
   Microbicides Among Men Who Have Sex with Men in Four South American
   Cities
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV; MSM; Rectal microbicides; Acceptability; Conjoint analysis
ID DISCRETE-CHOICE EXPERIMENTS; WILLINGNESS-TO-PAY; PATIENT PREFERENCES;
   RISK COMPENSATION; HIV; TRANSMISSION; CARE; APPLICATORS; INTERCOURSE;
   THERAPY
AB Conjoint Analysis (CJA), a statistical market-based technique that assesses the value consumers place on product characteristics, may be used to predict acceptability of hypothetical products. Rectal Microbicides (RM)-substances that would prevent HIV infection during receptive anal intercourse-will require acceptability data from potential users in multiple settings to inform the development process by providing valuable information on desirable product characteristics and issues surrounding potential barriers to product use. This study applied CJA to explore the acceptability of eight different hypothetical RM among 128 MSM in Lima and Iquitos, Peru; Guayaquil, Ecuador; and Rio de Janeiro, Brazil. Overall RM acceptability was highest in Guayaquil and lowest in Rio. Product effectiveness had the greatest impact on acceptability in all four cities, but the impact of other product characteristics varied by city. This study demonstrates that MSM from the same region but from different cities place different values on RM characteristics that could impact uptake of an actual RM. Understanding specific consumer preferences is crucial during RM product development, clinical trials and eventual product dissemination.
C1 [Kinsler, Janni J.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90024 USA.
   [Cunningham, William E.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
   [Nurena, Cesar R.] Univ Nacl Mayor San Marcos, Escuela Antropol, Lima 14, Peru.
   [Nadjat-Haiem, Carsten] Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90024 USA.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   [Casapia, Martin] Asociac Civil Selva Amazon, Iquitos, Peru.
   [Montoya-Herrera, Orlando] Fdn Ecuatoriana Equidad, Guayaquil, Ecuador.
   [Sanchez, Jorge] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Galea, Jerome T.] Univ Calif Los Angeles, David Geffen Sch Med, Program Global Hlth, Los Angeles, CA 90095 USA.
RP Kinsler, JJ (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Community Hlth Sci, 650 Young Dr S, Los Angeles, CA 90024 USA.
EM jkinsler@yahoo.com
RI Galea, Jerome T./AAF-2172-2019
OI Galea, Jerome T./0000-0001-8732-6959; Nurena, Cesar
   R./0000-0002-3290-7948
CR Akkazieva B, 2006, APPL HEALTH ECON HEA, V5, P189, DOI 10.2165/00148365-200605030-00005
   Anton PA, 2011, 18 C RETR OPP INF BO
   Anton PA, 2008, PHASE 1 SAFETY ACCEP
   Aristides M, 2002, PHARMACOECONOMICS, V20, P775, DOI 10.2165/00019053-200220110-00006
   Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339
   Beusterien KM, 2005, VALUE HEALTH, V8, P453, DOI 10.1111/j.1524-4733.2005.00036.x
   Bhargava JS, 2008, BRIT J OPHTHALMOL, V92, P1601, DOI 10.1136/bjo.2008.140483
   Bishai D, 2007, PHARMACOECONOMICS, V25, P143, DOI 10.2165/00019053-200725020-00006
   Bishop AJ, 2004, BJOG-INT J OBSTET GY, V111, P775, DOI 10.1111/j.1471-0528.2004.00197.x
   Carballo-Dieguez A, 2008, SEX TRANSM INFECT, V84, P483, DOI 10.1136/sti.2008.030478
   Carballo-Dieguez A, 2008, AIDS BEHAV, V12, P860, DOI 10.1007/s10461-007-9301-0
   Carballo-Dieguez A, 2007, SEX TRANSM DIS, V34, P224, DOI 10.1097/01.olq.0000233715.59239.83
   Carballo-Dieguez A, 2010, SEX TRANSM DIS, V37, P228, DOI 10.1097/OLQ.0b013e3181bf9b2d
   CARROLL JD, 1995, J MARKETING RES, V32, P385, DOI 10.2307/3152174
   Cassell MM, 2006, BMJ-BRIT MED J, V332, P605, DOI 10.1136/bmj.332.7541.605
   Centers for Disease Control and Prevention, 2011, CDC TRIAL AN MAJ STU
   Cohen JA, 2007, SEX TRANSM DIS, V34, P15, DOI 10.1097/01.olq.0000218877.92778.fe
   Costa MLV, 2006, ANN SURG ONCOL, V13, P843, DOI 10.1245/ASO.2006.05.040
   Cunningham CE, 2009, J ABNORM CHILD PSYCH, V37, P929, DOI [10.1007/s10802-009-9324-2, 10.1007/s10802-009-9338-9]
   Fisher K, 2010, APPL NURS RES, V23, P30, DOI 10.1016/j.apnr.2008.03.004
   Foss A, 2010, MODELLING POTENTIAL
   Galea J, 2010, INT J STD AIDS, V22, P256
   Galea J, 2010, USE RECTAL DOUCHES P
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2
   GREEN PE, 1990, J MARKETING, V54, P3, DOI 10.2307/1251756
   GREEN PE, 1971, J MARKETING RES, V8, P355, DOI 10.2307/3149575
   Holmes WR, 2008, SEX HEALTH, V5, P273, DOI 10.1071/SH07093
   Hunink M., 2001, DECISION MAKING HLTH
   IRMA, 2010, PROM PROD ADV RECT M
   Joglekar NS, 2010, T ROY SOC TROP MED H, V104, P412, DOI 10.1016/j.trstmh.2009.12.007
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kinsler JJ, 2010, INT J STD AIDS, V21, P567, DOI 10.1258/ijsa.2010.010134
   Lancsar E, 2004, HEALTH ECON, V13, P901, DOI 10.1002/hec.870
   Lancsar EJ, 2007, RESPIROLOGY, V12, P127, DOI 10.1111/j.1440-1843.2006.01005.x
   Marshall P, 2002, J AM STAT ASSOC, V97, P674, DOI 10.1198/016214502388618410
   McGowan I, 2011, AIDS BEHAV, V15, pS66, DOI 10.1007/s10461-011-9899-9
   Newman PA, 2006, VACCINE, V24, P2094, DOI 10.1016/j.vaccine.2005.11.013
   Newman PA, 2004, JAIDS-J ACQ IMM DEF, V37, P1393, DOI 10.1097/01.qai.0000127064.84325.ad
   Orme B., 2010, GETTING STARTED CONJ
   Pickett J, 2008, 17 INT AIDS C MEX CI
   Pinkerton SD, 2001, RISK ANAL, V21, P727, DOI 10.1111/0272-4332.214146
   Ryan M, 2000, BMJ-BRIT MED J, V320, P1530, DOI 10.1136/bmj.320.7248.1530
   Saethre Eirik J, 2010, Anthropol Med, V17, P99, DOI 10.1080/13648470903569396
   SANCHEZ J, 2007, CTR HIV ID PREV TREA
   Stone VE, 2004, JAIDS-J ACQ IMM DEF, V36, P808, DOI 10.1097/00126334-200407010-00007
   UNAIDS, 2010, GLOB REP UNAIDS REP
   University of Washington International Clinical Research Center, 2011, PIV STUD FINDS HIV M
   Vail JG, 2004, AM J PUBLIC HEALTH, V94, P1089, DOI 10.2105/AJPH.94.7.1089
   Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003
NR 50
TC 24
Z9 24
U1 0
U2 6
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD AUG
PY 2012
VL 16
IS 6
BP 1436
EP 1447
DI 10.1007/s10461-011-0045-5
PG 12
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 977WI
UT WOS:000306695100008
PM 21959986
DA 2020-11-24
ER

PT J
AU Nicol, AF
   Golub, JE
   Silva, JRLE
   Cunha, CB
   Amaro, SM
   Oliveira, NS
   Menezes, W
   Andrade, CV
   Russomano, F
   Tristao, A
   Grinsztejn, B
   Friedman, RK
   Oliveira, MP
   Pires, A
   Nuovo, GJ
AF Nicol, Alcina F.
   Golub, Jonathan E.
   Lapa e Silva, Jose R.
   Cunha, Cynthia B.
   Amaro-Filho, Sergio M.
   Oliveira, Nathalia S.
   Menezes, Willker
   Andrade, Cecilia Viana
   Russomano, Fabio
   Tristao, Aparecida
   Grinsztejn, Beatriz
   Friedman, Ruth Khalili
   Oliveira, Marcia P.
   Pires, Andrea
   Nuovo, Gerard J.
TI An evaluation of p16(INK4a) expression in cervical intraepithelial
   neoplasia specimens, including women with HIV-1
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE CIN; p16(INK4a); HPV; HIV; TMA; ROC
ID HUMAN-PAPILLOMAVIRUS; HIV/HPV COINFECTION; UTERINE CERVIX; BIOMARKERS;
   BIOPSIES; CYTOLOGY; PREDICT; MARKER; GRADE; CELLS
AB Although several studies have evaluated the role of p16(INK4a) as a diagnostic marker of cervical intraepithelial neoplasia (CIN) and its association with disease progression, studies regarding the role of p16(INK4a) in human immunodeficiency virus (HIV)-infected patients remain scarce. The present study was designed to determine the potential utility of p16(INK4a) as a diagnostic marker for CIN and invasive cervical cancer in HIV-positive and negative cervical specimens. An immunohistochemical analysis of p16(INK4a) was performed in 326 cervical tissue microarray specimens. Performance indicators were calculated and compared using receiving operating characteristics curve (ROC)/area under the curve. In HIV-1-negative women, the percentage of cells that was positive for p16(INK4a) expression was significantly correlated with the severity of CIN (p < 0.0001). A ROC curve with a cut-off value of 55.28% resulted in a sensitivity of 89%, a specificity of 81%, a positive predictive value of 91% and a negative predictive value of 78%. HIV-seropositive women exhibited decreased expression of p16(INK4a) in CIN2-3 specimens compared with HIV-negative specimens (p = 0.031). The ROC data underscore the potential utility of p16(INK4a) under defined conditions as a diagnostic marker for CIN 2-3 staging and invasive cervical cancer. HIV-1 infection, however, is associated with relatively reduced p16(INK4a) expression in CIN 2-3.
C1 [Nicol, Alcina F.; Amaro-Filho, Sergio M.; Oliveira, Nathalia S.; Menezes, Willker; Oliveira, Marcia P.] Inst Oswaldo Cruz, Lab Interdisciplinar Pesquisas Med, BR-20001 Rio De Janeiro, Brazil.
   [Cunha, Cynthia B.; Grinsztejn, Beatriz; Friedman, Ruth Khalili] Inst Pesquisa Clin Evandro Chagas, Dept Doencas Infecciosas, Rio De Janeiro, Brazil.
   [Andrade, Cecilia Viana; Russomano, Fabio; Tristao, Aparecida] Inst Fernandes Figueira Fiocruz, Rio De Janeiro, Brazil.
   [Golub, Jonathan E.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Golub, Jonathan E.] Johns Hopkins Sch Med, Baltimore, MD USA.
   [Lapa e Silva, Jose R.] Univ Fed Rio de Janeiro, Lab Multidisciplinar, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.
   [Pires, Andrea] Fonte Med Diagnost, Niteroi, RJ, Brazil.
   [Pires, Andrea] Univ Fed Fluminense, Niteroi, RJ, Brazil.
   [Nuovo, Gerard J.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
RP Nicol, AF (corresponding author), Inst Oswaldo Cruz, Lab Interdisciplinar Pesquisas Med, BR-20001 Rio De Janeiro, Brazil.
EM nicol@ioc.fiocruz.br
RI Lapa e Silva, Jose R./AAS-4793-2020; Oliveira, Nathalia/M-8830-2019;
   ANDRADE, CECILIA/B-5916-2017
OI Lapa e Silva, Jose R./0000-0003-3116-0253; Oliveira,
   Nathalia/0000-0003-3733-0022; Amaro-Filho, Sergio/0000-0002-7374-4081;
   ANDRADE, CECILIA/0000-0001-7980-4367
FU FIC, NIH Research [2 D 43 TW000010-23-AITRP]; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010] Funding Source: NIH RePORTER
FX LIPMED-IOC-FIOCRUZ, Lewis Foundation AFN and SMAF are scholars in IARTP
   and are supported by the FIC, NIH Research (2 D 43 TW000010-23-AITRP),
   NO and WM are scholars of FAPERJ and SMAF from CAPES.
CR Branca M, 2004, INT J GYNECOL PATHOL, V23, P354, DOI 10.1097/01.pgp.0000139639.79105.40
   Pires ARC, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-14
   Eng J, 2005, ACAD RADIOL, V12, P909, DOI 10.1016/j.acra.2005.04.005
   Fan Jerome, 2006, CJEM, V8, P19
   Galgano MT, 2010, AM J SURG PATHOL, V34, P1077, DOI 10.1097/PAS.0b013e3181e8b2c4
   Guedes AC, 2007, INT J GYNECOL CANCER, V17, P1099, DOI 10.1111/j.1525-1438.2007.00899.x
   Gupta N, 2010, DIAGN CYTOPATHOL, V38, P618, DOI 10.1002/dc.21270
   Kreuter A, 2010, J AM ACAD DERMATOL, V63, P490, DOI 10.1016/j.jaad.2009.08.043
   McLaughlin-Drubin ME, 2011, P NATL ACAD SCI USA, V108, P2130, DOI 10.1073/pnas.1009933108
   Nicol AF, 2008, J CLIN PATHOL, V61, P84, DOI 10.1136/jcp.2007.047290
   Nicol AF, 2005, DIAGN MOL PATHOL, V14, P39, DOI 10.1097/01.pas.0000143309.81183.6c
   Nicol AF, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-289
   Nuovo GJ, 2010, METHODS, V52, P307, DOI 10.1016/j.ymeth.2010.08.009
   NUOVO GJ, 1990, JAMA-J AM MED ASSOC, V263, P1223, DOI 10.1001/jama.263.9.1223
   Pinto AP, 2008, MODERN PATHOL, V21, P1067, DOI 10.1038/modpathol.2008.101
   Queiroz C, 2006, PATHOL RES PRACT, V202, P77, DOI 10.1016/j.prp.2005.08.012
   Tringler B, 2004, HUM PATHOL, V35, P689, DOI 10.1016/j.humpath.2004.02.012
   Valasoulis G, 2011, EUR J GYNAECOL ONCOL, V32, P150
   Wang SS, 2004, CANCER EPIDEM BIOMAR, V13, P1355
   Wentzensen N, 2005, CANCER CYTOPATHOL, V105, P461, DOI 10.1002/cncr.21378
NR 20
TC 10
Z9 12
U1 0
U2 0
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD AUG
PY 2012
VL 107
IS 5
BP 571
EP 577
DI 10.1590/S0074-02762012000500001
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 981MW
UT WOS:000306973400001
PM 22850945
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU Campbell, TB
   Smeaton, LM
   Kumarasamy, N
   Flanigan, T
   Klingman, KL
   Firnhaber, C
   Grinsztejn, B
   Hosseinipour, MC
   Kumwenda, J
   Lalloo, U
   Riviere, C
   Sanchez, J
   Melo, M
   Supparatpinyo, K
   Tripathy, S
   Martinez, AI
   Nair, A
   Walawander, A
   Moran, L
   Chen, Y
   Snowden, W
   Rooney, JF
   Uy, J
   Schooley, RT
   De Gruttola, V
   Hakim, JG
AF Campbell, Thomas B.
   Smeaton, Laura M.
   Kumarasamy, N.
   Flanigan, Timothy
   Klingman, Karin L.
   Firnhaber, Cynthia
   Grinsztejn, Beatriz
   Hosseinipour, Mina C.
   Kumwenda, Johnstone
   Lalloo, Umesh
   Riviere, Cynthia
   Sanchez, Jorge
   Melo, Marineide
   Supparatpinyo, Khuanchai
   Tripathy, Srikanth
   Martinez, Ana I.
   Nair, Apsara
   Walawander, Ann
   Moran, Laura
   Chen, Yun
   Snowden, Wendy
   Rooney, James F.
   Uy, Jonathan
   Schooley, Robert T.
   De Gruttola, Victor
   Hakim, James Gita
CA PEARLS Study Team ACTG
TI Efficacy and Safety of Three Antiretroviral Regimens for Initial
   Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational
   Settings
SO PLOS MEDICINE
LA English
DT Article
ID RETROVIRAL-NAIVE PATIENTS; LOW-DOSE RITONAVIR; ADVERSE EVENTS;
   EFAVIRENZ; THERAPY; EMTRICITABINE; DIDANOSINE; LAMIVUDINE; INFECTION;
   ATAZANAVIR
AB Background: Antiretroviral regimens with simplified dosing and better safety are needed to maximize the efficiency of antiretroviral delivery in resource-limited settings. We investigated the efficacy and safety of antiretroviral regimens with once-daily compared to twice-daily dosing in diverse areas of the world.
   Methods and Findings: 1,571 HIV-1-infected persons (47% women) from nine countries in four continents were assigned with equal probability to open-label antiretroviral therapy with efavirenz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-disoproxil fumarate (DF) (EFV+FTC-TDF). ATV+DDI+FTC and EFV+FTC-TDF were hypothesized to be non-inferior to EFV+3TC-ZDV if the upper one-sided 95% confidence bound for the hazard ratio (HR) was <= 1.35 when 30% of participants had treatment failure. An independent monitoring board recommended stopping study follow-up prior to accumulation of 472 treatment failures. Comparing EFV+FTC-TDF to EFV+3TC-ZDV, during a median 184 wk of follow-up there were 95 treatment failures (18%) among 526 participants versus 98 failures among 519 participants (19%; HR 0.95, 95% CI 0.72-1.27; p = 0.74). Safety endpoints occurred in 243 (46%) participants assigned to EFV+FTC-TDF versus 313 (60%) assigned to EFV+3TC-ZDV (HR 0.64, CI 0.54-0.76; p<0.001) and there was a significant interaction between sex and regimen safety (HR 0.50, CI 0.39-0.64 for women; HR 0.79, CI 0.62-1.00 for men; p = 0.01). Comparing ATV+DDI+FTC to EFV+3TC-ZDV, during a median follow-up of 81 wk there were 108 failures (21%) among 526 participants assigned to ATV+DDI+FTC and 76 (15%) among 519 participants assigned to EFV+3TC-ZDV (HR 1.51, CI 1.12-2.04; p = 0.007).
   Conclusion: EFV+FTC-TDF had similar high efficacy compared to EFV+3TC-ZDV in this trial population, recruited in diverse multinational settings. Superior safety, especially in HIV-1-infected women, and once-daily dosing of EFV+FTC-TDF are advantageous for use of this regimen for initial treatment of HIV-1 infection in resource-limited countries. ATV+DDI+FTC had inferior efficacy and is not recommended as an initial antiretroviral regimen.
C1 [Campbell, Thomas B.] Univ Colorado, Sch Med, Dept Med, Div Infect Dis, Aurora, CO 80045 USA.
   [Smeaton, Laura M.; Chen, Yun; De Gruttola, Victor] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [Kumarasamy, N.] YRG Ctr AIDS Res & Educ, Chennai, Tamil Nadu, India.
   [Flanigan, Timothy] Brown Med Sch, Providence, RI USA.
   [Klingman, Karin L.; Martinez, Ana I.] NIH, Bethesda, MD 20892 USA.
   [Firnhaber, Cynthia] Univ Witwatersrand, Dept Med, Fac Hlth Sci, Clin HIV Res Unit, ZA-2001 Johannesburg, South Africa.
   [Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Clin Res Inst, BR-21045900 Rio De Janeiro, Brazil.
   [Hosseinipour, Mina C.] Kamuzu Cent Hosp, Lilongwe, Malawi.
   [Kumwenda, Johnstone] Coll Med, Dept Med, Blantyre, Malawi.
   [Lalloo, Umesh] Nelson R Mandela Sch Med, Durban, South Africa.
   [Riviere, Cynthia] Inst Nacl Lab & Rech, Port Au Prince, Haiti.
   [Sanchez, Jorge] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Melo, Marineide] Hosp Nossa Senhora da Conceicao GHC, Serv Infectol, Porto Alegre, RS, Brazil.
   [Supparatpinyo, Khuanchai] Chiang Mai Univ, Dept Med, Chiang Mai 50000, Thailand.
   [Supparatpinyo, Khuanchai] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
   [Tripathy, Srikanth] Natl AIDS Res Inst, Pune, Maharashtra, India.
   [Nair, Apsara; Walawander, Ann] Frontier Sci & Technol Res Fdn Inc, Amherst, MA USA.
   [Moran, Laura] Social & Sci Syst Inc, Silver Spring, MD USA.
   [Snowden, Wendy] GlaxoSmithKline, Res Triangle Pk, NC USA.
   [Rooney, James F.] Gilead Sci Inc, Foster City, CA 94404 USA.
   [Uy, Jonathan] Bristol Myers Squibb Co, Plainsboro, NJ USA.
   [Schooley, Robert T.] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Hakim, James Gita] Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe.
RP Campbell, TB (corresponding author), Univ Colorado, Sch Med, Dept Med, Div Infect Dis, Aurora, CO 80045 USA.
EM thomas.campbell@ucdenver.edu
RI Cardoso, Sandra W/D-7965-2015; Berendes, Sima/AAH-9616-2019
OI Cardoso, Sandra W/0000-0001-5230-0003; Berendes,
   Sima/0000-0001-7000-868X; Kumwenda, Newton/0000-0003-2622-4339; Taha,
   Taha/0000-0001-9814-4894; Tebas, Pablo/0000-0001-5345-7942
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI68636, AI68634,
   A1069432, AI069476, AI069518, AI069426, AI069436, AIO69463, AI069399,
   AI069401, AI069421, AI069417, AI069438, AI046376, AI069513, AI38858,
   AI69450, AI069474, AI069471, AI27661, AI069495, AI069484, AI47370,
   A1069472, AI069428, A1069424, AI069423, AI050410, AI-069439, AI54999,
   RR024975, A1069467, AI045008, AI069470, AI069532, AI032782, AI069511,
   AI069424, AI69419, RR024996, RR00865, RR024160, RR024156, RR025747,
   RR00424, RR025780]; Boehringer IngelheimBoehringer Ingelheim;
   Bristol-Myers SquibbBristol-Myers Squibb; Gilead SciencesGilead
   Sciences; GlaxoSmithKlineGlaxoSmithKline; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024156, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR025780, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024156, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024156, M01RR000865,
   M01RR000865, M01RR000865, UL1RR025780, M01RR000865, M01RR000865,
   UL1RR024156, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024975, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024156, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR025747,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR025747,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024160, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024160, M01RR000865, TL1RR024978, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024156, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024996, M01RR000865, UL1RR025780, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024160,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR025747, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024160,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR025780, UL1RR024156,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024160, M01RR000865,
   UL1RR024160, M01RR000865, M01RR000865, M01RR000865, UL1RR025780,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024975, M01RR000865,
   UL1RR024160, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024160, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024996, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024156, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024160, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024996, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024156, M01RR000865, M01RR000865, UL1RR024996, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, TL1RR024978,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024156, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR025780, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024996, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR025747, UL1RR024996,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024156,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024996,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024975,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR025780, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024996, M01RR000865, M01RR000865,
   UL1RR024996, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024975, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024975, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR025780, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024160, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024996, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024156, KL2RR024977, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024156, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024975, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024156,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024160, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024996,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024996, M01RR000865, M01RR000865, UL1RR025747,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024160, M01RR000865, M01RR000865, UL1RR024996, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024975, M01RR000865, M01RR000865,
   M01RR000865, UL1RR025780, UL1RR024160, M01RR000865, UL1RR025780,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR025780,
   M01RR000865, UL1RR024156, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024160,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024160, M01RR000865, M01RR000865, UL1RR024160, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024160, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024160, UL1RR024996, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024975, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024156, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024996, M01RR000865, M01RR000865, M01RR000865, UL1RR024975,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024160, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024156, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024160, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024156, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024160, M01RR000865,
   UL1RR025747, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024975, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024975, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024160, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024160, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR025747, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR025780, M01RR000865, TL1RR024978, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR025780, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024156, M01RR000865,
   UL1RR024160, M01RR000865, UL1RR024996, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, KL2RR024977, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024160, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024160, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR025780, M01RR000865, M01RR000865, UL1RR025747,
   M01RR000865, M01RR000865, UL1RR024996, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024156, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024160, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, KL2RR024977,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024996,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024160, M01RR000865, M01RR000865, UL1RR024156,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024975, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024156, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024975, UL1RR024996, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR025747, M01RR000865, UL1RR024160, M01RR000865,
   M01RR000865, M01RR000865, UL1RR025780, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024975, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024156, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024975, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024156,
   M01RR000865, M01RR000865, UL1RR025780, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024160,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR025747,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024156, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   KL2RR024977, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024975, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR025747, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR025747, M01RR000865, M01RR000865,
   UL1RR025747, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR025747, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024975, M01RR000865, UL1RR025747,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR025780, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024160,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024156, UL1RR024996, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024156,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024160,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024975, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024996, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024975, M01RR000865,
   M01RR000865, UL1RR025780, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024975, UL1RR025747, UL1RR025747, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024160, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024975, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024160, M01RR000865,
   M01RR000865, UL1RR025780, M01RR000865, UL1RR024996, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR025780, M01RR000865,
   M01RR000865, UL1RR024996, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024160, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024975, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR025780,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024156, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024975, M01RR000865,
   UL1RR025747, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024975, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024156, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024156,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024975, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024160,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR025747, M01RR000865, M01RR000865,
   UL1RR024160, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024156, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024160, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024996, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR025780, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR025747, M01RR000865,
   UL1RR024160, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024160,
   M01RR000865, M01RR000865, UL1RR024975, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024975, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024156, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024156, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024160, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR025747, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024975, UL1RR024996,
   M01RR000865, UL1RR024996, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024156, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR025780, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR025747, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR025747,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR025780, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024156, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024160, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024975,
   UL1RR025780, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024975, M01RR000865, UL1RR024160,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024160, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR025747, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR025747, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024160, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024156, M01RR000865, M01RR000865, M01RR000865, UL1RR024975,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024996,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024160, M01RR000865, M01RR000865, UL1RR025780, M01RR000865,
   M01RR000865, UL1RR024975, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024975, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR024996, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR025780, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024156, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR025747,
   M01RR000865, M01RR000865, UL1RR025747, UL1RR024996, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024975, UL1RR024975, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, TL1RR024978,
   M01RR000865, UL1RR025747, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, UL1RR025747, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024156,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024156, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR025747,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024156, M01RR000865, UL1RR024160,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR024975, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024156, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024156,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, UL1RR024156, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024975,
   TL1RR024978, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR025780, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR025780, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   UL1RR024975, M01RR000865, M01RR000865, UL1RR024996, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024996,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR024996,
   M01RR000865, UL1RR024975, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, UL1RR025780, KL2RR024977, UL1RR024156, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, M01RR000865,
   M01RR000865, M01RR000865, M01RR000865, M01RR000865, UL1RR025747,
   M01RR000865, M01RR000865, UL1RR025747, UL1RR025747] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P30AI045008, P30AI050410, U01AI069419, U01AI027661,
   UM1AI069423, U01AI027661, P30AI045008, U01AI038858, U01AI069401,
   P30AI045008, UM1AI069470, U01AI027661, P30AI050410, P30AI045008,
   U01AI038858, P30AI045008, U01AI032782, P30AI054999, UM1AI068634,
   P30AI050410, U01AI069438, UM1AI069511, U01AI069421, U01AI069476,
   P30AI050410, U01AI038858, P30AI045008, P30AI050410, P30AI054999,
   UM1AI069438, P30AI050410, P30AI050410, P30AI045008, P30AI045008,
   UM1AI069518, P30AI050410, P30AI054999, P30AI045008, P30AI054999,
   P30AI045008, P30AI045008, UM1AI069476, P30AI050410, P30AI050410,
   U01AI032782, P30AI045008, P30AI045008, U01AI032782, P30AI054999,
   P30AI050410, P30AI050410, U01AI069428, P30AI050410, P30AI045008,
   U01AI069424, U01AI069421, U01AI069401, P30AI050410, U01AI046376,
   U01AI027661, U01AI032782, P30AI050410, P30AI050410, UM1AI069450,
   P30AI054999, UM1AI069476, U01AI068636, U01AI069471, U01AI069484,
   U01AI069438, U01AI027661, U01AI032782, UM1AI069476, U01AI068636,
   UM1AI069471, UM1AI069419, U01AI069484, U01AI069399, P30AI054999,
   P30AI045008, U01AI068636, U01AI069495, UM1AI069426, U01AI069511,
   U01AI032782, P30AI050410, U01AI027661, UM1AI069439, P30AI045008,
   P30AI054999, U01AI038858, UM1AI069532, UM1AI069518, P30AI054999,
   P30AI045008, UM1AI069436, U01AI069439, P30AI050410, U01AI069399,
   P30AI045008, P30AI050410, U01AI069511, UM1AI069471, P30AI050410,
   P30AI045008, P30AI045008, U01AI038858, U01AI038858, U01AI027661,
   P30AI045008, P30AI045008, U01AI069424, U01AI038858, U01AI032782,
   R01AI047370, U01AI069470, P30AI045008, P30AI050410, UM1AI069424,
   P30AI054999, P30AI050410, P30AI045008, U01AI069471, UM1AI068636,
   UM1AI068636, UM1AI069426, U01AI069399, P30AI050410, U01AI069424,
   U01AI068634, P30AI045008, UM1AI069421, UM1AI069421, P30AI045008,
   U01AI027661, U01AI069513, P30AI050410, P30AI050410, P30AI045008,
   UM1AI069423, U01AI069513, P30AI045008, P30AI045008, UM1AI069439,
   P30AI045008, U01AI069511, U01AI069518, U01AI032782, P30AI045008,
   P30AI050410, P30AI050410, U01AI069518, P30AI045008, P30AI045008,
   P30AI045008, U01AI027661, P30AI045008, U01AI069470, UM1AI069428,
   P30AI050410, UM1AI069426, P30AI054999, P30AI045008, U01AI069471,
   P30AI050410, U01AI068636, P30AI050410, P30AI045008, P30AI045008,
   P30AI045008, U01AI027661, P30AI045008, U01AI032782, U01AI032782,
   P30AI050410, UM1AI069513, P30AI054999, R01AI047370, P30AI045008,
   P30AI045008, UM1AI068636, UM1AI068634, U01AI032782, U01AI038858,
   P30AI045008, P30AI045008, UM1AI069438, U01AI032782, P30AI045008,
   UM1AI069399, U01AI069450, UM1AI069424, P30AI050410, U01AI027661,
   P30AI050410, U01AI027661, UM1AI069419, UM1AI069438, U01AI069426,
   UM1AI068634, P30AI045008, UM1AI069436, U01AI027661, UM1AI068636,
   P30AI050410, P30AI045008, P30AI045008, U01AI032782, U01AI027661,
   UM1AI069439, U01AI068636, U01AI027661, UM1AI069419, U01AI027661,
   UM1AI069399, P30AI050410, U01AI032782, P30AI045008, U01AI032782,
   P30AI050410, U01AI032782, U01AI046376, P30AI050410, U01AI069495,
   P30AI045008, P30AI045008, P30AI045008, U01AI069399, UM1AI069518,
   UM1AI068636, P30AI050410, P30AI045008, U01AI038858, UM1AI069423,
   U01AI038858, P30AI045008, UM1AI069399, P30AI050410, P30AI045008,
   U01AI069436, P30AI054999, U01AI027661, U01AI069401, UM1AI069401,
   P30AI050410, P30AI045008, P30AI045008, P30AI045008, U01AI027661,
   UM1AI069419, UM1AI069511, P30AI045008, U01AI032782, P30AI050410,
   P30AI050410, P30AI050410, P30AI045008, U01AI038858, P30AI050410,
   P30AI045008, U01AI032782, P30AI045008, P30AI054999, UM1AI069428,
   P30AI050410, UM1AI069476, P30AI045008, P30AI050410, U01AI069484,
   P30AI045008, U01AI027661, UM1AI068634, P30AI045008, U01AI038858,
   U01AI027661, P30AI050410, P30AI050410, UM1AI069399, P30AI050410,
   U01AI069424, P30AI045008, P30AI045008, P30AI050410, U01AI069495,
   P30AI050410, U01AI027661, P30AI045008, P30AI045008, UM1AI069419,
   P30AI054999, P30AI050410, P30AI045008, P30AI045008, P30AI045008,
   U01AI038858, U01AI069419, UM1AI069439, P30AI045008, U01AI032782,
   U01AI038858, P30AI045008, P30AI054999, P30AI045008, P30AI050410,
   U01AI032782, P30AI045008, U01AI069438, P30AI045008, U01AI069438,
   U01AI069439, UM1AI069470, P30AI045008, P30AI050410, U01AI069426,
   U01AI032782, P30AI054999, P30AI045008, U01AI027661, P30AI045008,
   U01AI032782, U01AI069511, U01AI038858, U01AI069471, P30AI045008,
   P30AI054999, U01AI027661, P30AI054999, P30AI054999, U01AI069436,
   P30AI045008, P30AI050410, U01AI069471, P30AI050410, U01AI046376,
   U01AI032782, P30AI045008, U01AI038858, P30AI054999, P30AI045008,
   P30AI050410, U01AI069495, P30AI045008, P30AI045008, U01AI069417,
   P30AI050410, U01AI069532, P30AI045008, U01AI032782, P30AI045008,
   R01AI047370, U01AI069471, P30AI045008, U01AI032782, U01AI069417,
   U01AI027661, UM1AI069424, UM1AI069436, P30AI050410, U01AI032782,
   UM1AI069421, U01AI038858, P30AI045008, U01AI027661, U01AI027661,
   P30AI045008, P30AI045008, P30AI050410, P30AI045008, U01AI032782,
   UM1AI068634, U01AI046376, U01AI027661, U01AI069436, P30AI050410,
   UM1AI069495, P30AI045008, U01AI032782, UM1AI069439, P30AI045008,
   P30AI045008, U01AI027661, P30AI050410, U01AI069419, P30AI045008,
   P30AI045008, P30AI050410, P30AI045008, P30AI054999, U01AI069436,
   P30AI045008, P30AI045008, U01AI032782, U01AI027661, U01AI069401,
   U01AI038858, P30AI050410, UM1AI069421, U01AI032782, P30AI050410,
   U01AI069401, U01AI027661, P30AI050410, P30AI050410, UM1AI069470,
   U01AI069436, UM1AI069436, P30AI050410, UM1AI069424, U01AI038858,
   U01AI027661, P30AI045008, P30AI045008, U01AI038858, U01AI032782,
   P30AI045008, P30AI045008, U01AI069419, U01AI069474, P30AI045008,
   UM1AI069474, U01AI069419, UM1AI069399, U01AI032782, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, UM1AI069421,
   P30AI045008, P30AI050410, UM1AI069424, P30AI050410, P30AI045008,
   U01AI069511, UM1AI069518, UM1AI069450, U01AI038858, P30AI045008,
   UM1AI069423, U01AI027661, P30AI050410, P30AI050410, UM1AI069421,
   P30AI045008, P30AI054999, P30AI050410, U01AI027661, P30AI050410,
   U01AI027661, U01AI069513, R01AI047370, U01AI032782, P30AI050410,
   U01AI027661, P30AI050410, P30AI045008, P30AI045008, P30AI045008,
   P30AI045008, P30AI050410, UM1AI068634, UM1AI069518, U01AI069450,
   P30AI050410, UM1AI069423, U01AI069417, U01AI032782, UM1AI069471,
   UM1AI069399, P30AI045008, P30AI054999, P30AI054999, U01AI027661,
   UM1AI069518, U01AI038858, UM1AI069421, U01AI069428, P30AI054999,
   P30AI045008, P30AI045008, U01AI046376, UM1AI069495, UM1AI069518,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, P30AI050410,
   P30AI045008, U01AI032782, U01AI027661, U01AI069470, P30AI045008,
   U01AI038858, P30AI054999, U01AI069428, P30AI054999, P30AI050410,
   P30AI045008, P30AI045008, UM1AI069438, U01AI027661, P30AI045008,
   U01AI038858, P30AI050410, U01AI038858, P30AI050410, UM1AI069423,
   U01AI038858, P30AI045008, P30AI045008, P30AI050410, U01AI027661,
   U01AI069417, UM1AI069476, P30AI045008, UM1AI069511, P30AI045008,
   P30AI050410, U01AI038858, UM1AI069476, U01AI068634, P30AI050410,
   U01AI069532, UM1AI069511, UM1AI069474, P30AI050410, P30AI045008,
   U01AI027661, P30AI045008, U01AI069419, P30AI045008, P30AI050410,
   UM1AI069484, UM1AI069439, P30AI050410, U01AI069518, P30AI050410,
   P30AI050410, U01AI027661, P30AI050410, UM1AI069436, U01AI038858,
   P30AI045008, UM1AI069417, UM1AI069518, P30AI045008, UM1AI069470,
   UM1AI069439, UM1AI069417, UM1AI068634, U01AI032782, P30AI045008,
   U01AI027661, P30AI045008, P30AI050410, P30AI050410, UM1AI069471,
   U01AI069424, U01AI032782, U01AI027661, U01AI027661, UM1AI069471,
   U01AI032782, UM1AI069417, U01AI027661, P30AI050410, P30AI050410,
   U01AI069421, UM1AI069419, U01AI069476, U01AI069474, P30AI045008,
   U01AI032782, U01AI069438, U01AI032782, P30AI050410, P30AI050410,
   P30AI045008, P30AI045008, P30AI050410, U01AI032782, U01AI038858,
   P30AI054999, U01AI069424, P30AI045008, U01AI069484, P30AI045008,
   UM1AI069399, U01AI038858, P30AI045008, U01AI032782, U01AI038858,
   UM1AI069476, UM1AI069471, P30AI045008, U01AI069436, UM1AI069470,
   P30AI050410, UM1AI069419, U01AI069474, P30AI050410, P30AI054999,
   U01AI027661, UM1AI069417, U01AI027661, U01AI027661, U01AI038858,
   UM1AI069423, P30AI045008, UM1AI069436, P30AI054999, U01AI038858,
   UM1AI069401, P30AI050410, U01AI069428, P30AI054999, U01AI032782,
   P30AI045008, P30AI045008, UM1AI069439, U01AI027661, UM1AI069513,
   P30AI050410, U01AI032782, U01AI038858, P30AI050410, UM1AI068636,
   UM1AI068636, P30AI045008, U01AI038858, U01AI046376, P30AI050410,
   P30AI045008, UM1AI069424, UM1AI069476, P30AI045008, U01AI068634,
   P30AI045008, P30AI054999, P30AI050410, U01AI032782, U01AI032782,
   U01AI032782, U01AI038858, UM1AI069511, P30AI050410, U01AI069484,
   UM1AI069484, U01AI069470, UM1AI069484, UM1AI069511, P30AI045008,
   UM1AI069438, U01AI032782, U01AI038858, P30AI054999, U01AI032782,
   P30AI050410, U01AI069470, P30AI045008, U01AI027661, U01AI069450,
   U01AI027661, P30AI045008, U01AI032782, P30AI045008, P30AI050410,
   P30AI050410, P30AI045008, U01AI069532, UM1AI068634, U01AI069421,
   U01AI038858, U01AI032782, P30AI045008, U01AI069518, U01AI032782,
   U01AI069421, P30AI045008, U01AI068636, UM1AI069471, U01AI038858,
   U01AI069450, P30AI045008, U01AI069532, P30AI050410, UM1AI069421,
   P30AI045008, UM1AI069399, U01AI032782, U01AI069474, UM1AI069439,
   U01AI069484, P30AI045008, U01AI069428, P30AI050410, P30AI050410,
   U01AI032782, UM1AI069532, UM1AI069423, U01AI069439, U01AI038858,
   U01AI046376, U01AI069426, UM1AI069436, U01AI038858, P30AI054999,
   P30AI050410, P30AI045008, P30AI045008, U01AI027661, U01AI032782,
   U01AI027661, P30AI045008, P30AI050410, UM1AI069424, U01AI038858,
   P30AI050410, P30AI050410, P30AI050410, P30AI045008, P30AI050410,
   P30AI045008, U01AI069513, U01AI032782, P30AI050410, U01AI069399,
   U01AI038858, U01AI069495, P30AI045008, U01AI032782, U01AI069439,
   UM1AI068634, U01AI032782, U01AI069474, U01AI069450, P30AI050410,
   P30AI045008, U01AI027661, U01AI038858, U01AI027661, UM1AI069511,
   P30AI045008, UM1AI069438, P30AI045008, P30AI050410, P30AI050410,
   UM1AI069419, P30AI045008, U01AI069518, UM1AI069470, P30AI045008,
   U01AI068636, UM1AI068636, U01AI068634, U01AI027661, U01AI032782,
   P30AI045008, P30AI054999, P30AI050410, P30AI054999, P30AI045008,
   P30AI045008, P30AI045008, P30AI045008, P30AI045008, UM1AI069424,
   P30AI050410, P30AI045008, P30AI045008, UM1AI069532, U01AI069470,
   U01AI069511, P30AI050410, P30AI045008, P30AI050410, P30AI050410,
   P30AI045008, P30AI045008, UM1AI069470, U01AI069438, P30AI054999,
   P30AI045008, P30AI050410, P30AI045008, U01AI032782, UM1AI068636,
   P30AI045008, UM1AI069471, U01AI069484, U01AI032782, U01AI069439,
   UM1AI069438, U01AI069476, U01AI069417, U01AI027661, U01AI069476,
   U01AI038858, P30AI050410, P30AI045008, P30AI050410, U01AI068634,
   P30AI050410, P30AI045008, U01AI069401, P30AI050410, UM1AI069511,
   U01AI032782, U01AI027661, U01AI069532, U01AI069513, P30AI045008,
   P30AI045008, U01AI046376, U01AI027661, UM1AI069511, P30AI050410,
   P30AI045008, U01AI069426, U01AI027661, P30AI050410, U01AI038858,
   U01AI069484, P30AI045008, U01AI038858, U01AI038858, U01AI032782,
   U01AI046376, P30AI045008, P30AI045008, P30AI050410, UM1AI069436,
   P30AI045008, P30AI045008, U01AI032782, U01AI069426, UM1AI069438,
   UM1AI069401, U01AI038858, U01AI032782, P30AI050410, P30AI045008,
   U01AI069424, P30AI050410, U01AI038858, U01AI032782, P30AI045008,
   P30AI045008, UM1AI069470, U01AI032782, U01AI032782, U01AI038858,
   P30AI050410, U01AI027661, U01AI038858] Funding Source: NIH RePORTER
FX The study was funded by the National Institute of Allergy and Infectious
   Diseases and the following National Institutes of Health: grants
   AI68636, AI68634, A1069432, AI069476, AI069518, AI069426, AI069518,
   AI069436, AIO69463, AI069399, AI069401, AI069421, AI069417, AI069438,
   AI069438, AI046376, AI069417, AI069513, AI38858, AI069417, AI69450,
   AI069474, AI069471, AI27661, AI069495, AI069484, AI47370, A1069472,
   AI069428, A1069424, AI069423, AI050410, AI-069439; AI54999, RR024975,
   A1069467, AI045008, AI069470, AI069471, AI069532, AI032782, AI069511,
   AI069424, AI069471, AI69419, RR024996, RR00865, RR024160, RR024156,
   RR025747, RR00424 and RR025780. Employees of the NIAID participated as
   study team members and authors of this manuscript. The NIAID provided
   recommendations on the study design and approved the final study design,
   but had no role in data collection and analysis, decision to publish, or
   preparation of the manuscript. The pharmaceutical sponsors (Boehringer
   Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline)
   provided study drug and Gilead Sciences provided funding to purchase
   study drug that was not otherwise available. Bristol Myers Squibb
   provided atazanavir, didanosine-EC and efavirenz (with consent of
   Merck); Gilead Sciences, Inc. provided emtricitabine, tenofovir-DF,
   emtricitabine/tenofovir-DF; GlaxoSmithKline provided lamivudine,
   zidovudine and lamivudine/zidovudine; and Boehringer Ingelheim
   Pharmaceuticals, Inc. provided nevirapine. Representatives of the
   pharmaceutical company sponsors participated as study team members and
   authors of this manuscript, but did not participate in data collection,
   data analyses or interpretation. Bristol Myers Squibb, Gilead Sciences
   Inc., GlaxoSmithKline and Boehringer Ingelheim Pharmaceuticals, Inc. had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Berenguer J, 2008, CLIN INFECT DIS, V47, P1083, DOI 10.1086/592114
   Clark R, 2005, DRUG SAFETY, V28, P1075, DOI 10.2165/00002018-200528120-00003
   Currier JS, 2000, J ACQ IMMUN DEF SYND, V24, P316
   Division of AIDS, 2004, TABL GRAD SEV AD PED
   Fletcher CV, 2004, J INFECT DIS, V189, P1176, DOI 10.1086/382754
   Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871
   Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772
   Hermans P, 1999, J Hematother Stem Cell Res, V8 Suppl 1, pS23
   Hirnschall G, 2011, LANCET, V378, P209, DOI 10.1016/S0140-6736(11)60247-X
   Jacobson MA, 1997, ARCH INTERN MED, V157, P1825, DOI 10.1001/archinte.157.16.1825
   King JR, 2007, J CLIN PHARMACOL, V47, P201, DOI 10.1177/0091270006296763
   Kuritzkes DR, 1998, AIDS, V12, P65, DOI 10.1097/00002030-199801000-00008
   Molina JM, 2007, ANTIVIR THER, V12, P417
   Molina JM, 2005, J INFECT DIS, V191, P830, DOI 10.1086/428091
   Monforte AD, 2010, AIDS, V24, P1091, DOI 10.1097/QAD.0b013e3283390db3
   MOORE RD, 1995, ARCH INTERN MED, V155, P1965, DOI 10.1001/archinte.155.18.1965
   Moore RD, 1996, AM J MED, V101, P34, DOI 10.1016/S0002-9343(96)00077-0
   Malan DR, 2008, JAIDS-J ACQ IMM DEF, V47, P161, DOI 10.1097/QAI.0b013e31815ace6a
   Nielsen-Saines K, 2012, PEDIATRICS, V129, pE1525, DOI 10.1542/peds.2011-2340
   Pai MP, 2004, PHARMACOTHERAPY, V24, P592, DOI 10.1592/phco.24.6.592.34744
   Pozniak AL, 2006, JAIDS-J ACQ IMM DEF, V43, P535
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   Saag MS, 2004, JAMA-J AM MED ASSOC, V292, P180, DOI 10.1001/jama.292.2.180
   Sanchez-Conde M, 2007, AIDS RES HUM RETROV, V23, P1237, DOI 10.1089/aid.2006.0029
   Sanne I, 2003, JAIDS-J ACQ IMM DEF, V32, P18, DOI 10.1097/00126334-200301010-00004
   Squires K, 2004, JAIDS-J ACQ IMM DEF, V36, P1011, DOI 10.1097/00126334-200408150-00003
   Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501
   UNAIDS, 2010, GLOB REP UNAIDS REP
   US Food and Drug Administration, 2002, GUID IND ANT DRUGS U
   World Health Organization, 2010, ANT THER HIV INF AD
   World Health Organization, 2010, TREATM 2 0 IS THIS F
   Xu X, 2003, BIOSTATISTICS, V4, P223, DOI 10.1093/biostatistics/4.2.223
NR 32
TC 91
Z9 91
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1277
EI 1549-1676
J9 PLOS MED
JI PLos Med.
PD AUG
PY 2012
VL 9
IS 8
AR e1001290
DI 10.1371/journal.pmed.1001290
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA 001XU
UT WOS:000308494600011
PM 22936892
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Girard, PM
   Campbell, TB
   Grinsztejn, B
   Hartikainen, J
   Rachline, A
   Nijs, S
   Witek, J
AF Girard, P-M
   Campbell, T. B.
   Grinsztejn, B.
   Hartikainen, J.
   Rachline, A.
   Nijs, S.
   Witek, J.
TI Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of
   etravirine: further analysis of adverse events and laboratory
   abnormalities of special interest
SO HIV MEDICINE
LA English
DT Article
DE adverse events; DUET; etravirine; safety; treatment-experienced
ID EXPERIENCED HIV-1-INFECTED PATIENTS; TMC125 ETRAVIRINE; DOUBLE-BLIND;
   SAFETY; EFFICACY; EFAVIRENZ; THERAPY
AB Objectives The aim of the study was to investigate the frequency and severity of adverse events (AEs) and laboratory abnormalities of interest over 96 weeks of treatment with etravirine or placebo in the pooled TMC125 DUET (Demonstrate Undetectable viral load in patients Experienced with ARV Therapy) trials. Methods Treatment-experienced, HIV-1-infected patients randomly received etravirine 200?mg twice a day (bid) or placebo, plus a background regimen. The frequency and severity of neuropsychiatric, rash, hepatic and lipid AEs were analysed; frequencies were also adjusted for total patient-years of exposure (PYE). Results A total of 599 and 604 patients received etravirine and placebo, respectively (median treatment duration 96.0 and 69.6 weeks, respectively). There was no significant difference between the treatment groups in the frequency of neuropsychiatric AEs. However, a significant difference in the frequency of rash was observed (20.5% vs. 11.8%, respectively; P?<?0.0001); rash was generally mild to moderate in severity; the rate of discontinuation because of rash was low (2.2% vs. 0% in the etravirine and placebo groups, respectively). The frequency of hepatic AEs was low and similar between the treatment groups (8.7% vs. 7.1%, respectively; P?=?0.3370); hepatic enzyme levels did not increase over time. Lipid-related laboratory abnormalities and changes over time in lipid levels were generally comparable between treatment groups. Adjusting for treatment exposure, the frequency of AEs remained similar between treatment groups, with the exception of rash [13.7 vs. 9.3 per 100 PYE; relative risk (95% confidence interval) 1.48 (1.021.95)]. Conclusions The frequency of AEs of interest was generally similar between the treatment groups, both overall and when adjusted for treatment exposure, with the exception of rash which was more frequent in the etravirine group.
C1 [Girard, P-M] Hop St Antoine, Serv Malad Infect & Trop, F-75571 Paris 12, France.
   [Girard, P-M] Univ Paris 06, INSERM, U707, Paris, France.
   [Campbell, T. B.] Univ Colorado Denver, Aurora, CO USA.
   [Grinsztejn, B.] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Hartikainen, J.] Epimed Auguste Viktoria Klinikum, Berlin, Germany.
   [Rachline, A.] Hop St Louis, Paris, France.
   [Nijs, S.] Tibotec BVBA, Beerse, Belgium.
   [Witek, J.] Tibotec Inc, Titusville, NJ USA.
RP Girard, PM (corresponding author), Hop St Antoine, Serv Malad Infect & Trop, 184 Rue Faubourg, F-75571 Paris 12, France.
EM pierre-marie.girard@sat.aphp.fr
FU Tibotec Pharmaceuticals Ltd.; Janssen Pharmaceutic Inc.; Merck and Co
   Inc.Merck & Company; Schering Plough CorporationMerck & CompanySchering
   Plough Corporation
FX The authors thank the patients and their families, the investigators who
   recruited patients to the DUET trials, study centre staff, the Data
   Safety and Monitoring Board and Tibotec study personnel. They also
   acknowledge David Anderson, Eric Lefebvre and Frank Tomaka for their
   important contributions to the manuscript. Medical writing assistance
   was provided by Karen Pilgram (Medical Writer, Gardiner-Caldwell
   Communications, Macclesfield, UK); funding for this service was provided
   by Tibotec Pharmaceuticals Ltd. The DUET trials were sponsored by
   Tibotec Pharmaceuticals Ltd.; Conflicts of interest: The authors
   disclose the following conflicts. PMG has received support for travel to
   meetings for the study or other purposes from Abbot, Bristol Myers
   Squibb and Gilead Sciences, and renumeration for Board Membership from
   Abbott, Gilead Sciences and Tibotec/Janssen. TBC has received support
   for travel to a scientific meeting for presentation of this study. BG
   has received research support from Janssen Pharmaceutic Inc., Merck and
   Co Inc. and Schering Plough Corporation and has served as a consultant
   for ARDEA Biosciences. JH and AR have received support for travel to
   meetings from Tibotec/Janssen. SN and JW are full-time employees of
   Tibotec. JW is a J&J stockholder.
CR Andries K, 2004, ANTIMICROB AGENTS CH, V48, P4680, DOI 10.1128/AAC.48.12.4680-4686.2004
   Clotet B, 2010, J ANTIMICROB CHEMOTH, V65, P2450, DOI 10.1093/jac/dkq332
   Cohen CJ, 2009, AIDS, V23, P423, DOI 10.1097/QAD.0b013e32831c5040
   Katlama C, 2010, ANTIVIR THER, V15, P1045, DOI 10.3851/IMP1662
   Katlama C, 2009, AIDS, V23, P2289, DOI 10.1097/QAD.0b013e3283316a5e
   Lazzarin A, 2007, LANCET, V370, P39, DOI 10.1016/S0140-6736(07)61048-4
   Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2
   Manfredi R, 2005, HIV CLIN TRIALS, V6, P302, DOI 10.1310/EWWC-YLJ6-8LHE-054A
   Montaner J, 2008, CLIN INFECT DIS, V47, P969, DOI 10.1086/591705
   Nelson M, 2011, AIDS, V25, P335, DOI 10.1097/QAD.0b013e3283416873
   Tibotec Inc, 2010, INTELENCE ETR PRESCR
   van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
NR 13
TC 17
Z9 17
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD AUG
PY 2012
VL 13
IS 7
BP 427
EP 435
DI 10.1111/j.1468-1293.2012.00994.x
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 966GE
UT WOS:000305825100005
PM 22413938
OA Bronze
DA 2020-11-24
ER

PT J
AU Vanni, T
   Luz, PM
   Grinsztejn, B
   Veloso, VG
   Foss, A
   Mesa-Frias, M
   Legood, R
AF Vanni, Tazio
   Luz, Paula Mendes
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Foss, Anna
   Mesa-Frias, Marco
   Legood, Rosa
TI Cervical cancer screening among HIV-infected women: An economic
   evaluation in a middle-income country
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE cost-effectiveness; economic evaluation; cervical cancer; human
   papillomavirus; screening
ID HUMAN-PAPILLOMAVIRUS INFECTION; SQUAMOUS INTRAEPITHELIAL LESIONS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; RIO-DE-JANEIRO; COST-EFFECTIVENESS;
   NATURAL-HISTORY; COHORT; AIDS; DIAGNOSIS; RISK
AB Due to the recent widespread availability of highly active antiretroviral therapy (HAART) in middle-income countries, there has been an increase in life expectancy for women on HAART, but no corresponding decrease in cervical cancer incidence. This study evaluates the optimal cervical cancer screening strategy for HIV-infected women in a middle-income country. We developed a mathematical model, which simulates the natural history of the HPV infection, as well as the HIV-mediated immunosupression among women in Brazil. Our model was calibrated using data from the IPEC/FIOCRUZ Women's HIV-infected cohort. The model compares the lifetime effects, costs and cost-effectiveness of strategies combining cytology, HPV DNA test and colposcopy at different screening intervals for different CD4 count strata (27 strategies in total). We found that the strategy with the best cost-effectiveness profile (cost-effectiveness ratioU$4,911/year of life saved [YLS] and probability of being cost-effective86%) was HPV testing followed by cytology triage every year for all HIV infected women, considering a very cost-effective threshold given by Brazil's GDP per capita (US$8,625/YLS). The results were robust to changes in the input parameters as demonstrated in one-way, scenario, threshold and probabilistic sensitivity analysis. Our study indicates that annual HPV testing followed by cytology triage for all HIV-infected women is likely to be very cost-effective in a middle-income country like Brazil. The results reflect the synergic effect of using a highly sensitive screening test (HPV DNA test) in sequence with a highly specific test (cytology).
C1 [Vanni, Tazio; Foss, Anna; Mesa-Frias, Marco; Legood, Rosa] Univ London London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, Fac Publ Hlth & Policy, London WC1H 9SH, England.
   [Luz, Paula Mendes; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
RP Vanni, T (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, Fac Publ Hlth & Policy, 15-17 Tavistock Pl, London WC1H 9SH, England.
EM tazio.vanni@lshtm.ac.uk
RI Vanni, Tazio P./B-7925-2018; Mesa-Frias, Marco/E-4756-2014; Veloso,
   Valdilea Goncalves/J-6189-2012
OI Luz, Paula/0000-0001-9746-719X
FU Evandro Chagas Clinical Research Institute (IPEC/FIOCRUZ)
FX Grant sponsor: Evandro Chagas Clinical Research Institute (IPEC/FIOCRUZ)
   Incentive Program for the Research and Development of Technology
CR [Anonymous], 2008, METHODOLOGICAL GUIDE
   [Anonymous], 2008, CLASSIFICACAO BRASIL
   Arbyn M, 2004, JNCI-J NATL CANCER I, V96, P280, DOI 10.1093/jnci/djh037
   Berkhof J, 2010, INT J CANCER, V127, P2147, DOI 10.1002/ijc.25211
   Briggs A, 2006, DECISION MODELLING H
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   Central Intelligence Agency, 2009, WORLD FACTB
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Cuzick J, 2008, VACCINE, V26, pK29, DOI 10.1016/j.vaccine.2008.06.019
   Debicki D, 2008, VACCINE, V26, pF16, DOI 10.1016/j.vaccine.2008.02.040
   Diaz M, 2010, EUR J CANCER, V46, P2973, DOI 10.1016/j.ejca.2010.06.016
   Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59
   Franceschi S, 2003, JAIDS-J ACQ IMM DEF, V34, P84, DOI 10.1097/00126334-200309010-00013
   Franceschi S, 2007, CLIN INFECT DIS, V45, P510, DOI 10.1086/520022
   Franco EL, 1999, J INFECT DIS, V180, P1415, DOI 10.1086/315086
   Goldhaber-Fiebert Jeremy D, 2007, Popul Health Metr, V5, P11, DOI 10.1186/1478-7954-5-11
   Goldhaber-Fiebert JD, 2008, JNCI-J NATL CANCER I, V100, P308, DOI 10.1093/jnci/djn019
   Goldie SJ, 2005, NEW ENGL J MED, V353, P2158, DOI 10.1056/NEJMsa044278
   Goldie SJ, 1999, ANN INTERN MED, V130, P97, DOI 10.7326/0003-4819-130-2-199901190-00003
   Goldie SJ, 2001, AM J MED, V111, P140, DOI 10.1016/S0002-9343(01)00780-X
   Goldie SJ, 2008, VACCINE, V26, pM17, DOI 10.1016/j.vaccine.2008.06.018
   Goldie SJ, 2007, VACCINE, V25, P6257, DOI 10.1016/j.vaccine.2007.05.058
   Grinsztejn B, 2009, INT J INFECT DIS, V13, P72, DOI 10.1016/j.ijid.2008.03.031
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   INCA, 2009, EST 2010 INC CANC BR, P94
   INCA, 2006, NOM BRAS LAUD CERV C
   International Monetary Fund, 2010, WORLD EC OUTL DAT
   Jit M, 2010, MED DECIS MAKING, V30, P84, DOI 10.1177/0272989X09336140
   Kim JJ, 2007, AM J EPIDEMIOL, V166, P137, DOI 10.1093/aje/kwm086
   Legood R, 2006, BMJ-BRIT MED J, V332, P79, DOI 10.1136/bmj.38698.458866.7C
   Miners A H, 2001, HIV Med, V2, P52, DOI 10.1046/j.1468-1293.2001.00048.x
   Mitchell MF, 1998, OBSTET GYNECOL, V91, P626, DOI 10.1016/S0029-7844(98)00006-4
   Molano M, 2002, BRIT J CANCER, V87, P324, DOI 10.1038/sj.bjc.6600442
   Molano M, 2002, BRIT J CANCER, V87, P1417, DOI 10.1038/sj.bjc.6600650
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Myers ER, 2000, AM J EPIDEMIOL, V151, P1158, DOI 10.1093/oxfordjournals.aje.a010166
   Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009
   Orem J, 2004, CURR OPIN ONCOL, V16, P468, DOI 10.1097/00001622-200409000-00010
   Palefsky JM, 2003, CURR OPIN ONCOL, V15, P382, DOI 10.1097/00001622-200309000-00007
   Pecorelli SNH, STAGING CLASSIFICATI
   Pretorius RG, 2004, AM J OBSTET GYNECOL, V191, P430, DOI 10.1016/j.ajog.2004.02.065
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Schlecht NF, 2003, J NATL CANCER I, V95, P1336, DOI 10.1093/jnci/djg037
   Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073
   UNAIDS, AIDS EP UPD 2009 JOI
   Vanni T, 2011, INT J CANCER, V129, P671, DOI 10.1002/ijc.25708
   Vanni T, 2011, PHARMACOECONOMICS, V29, P35, DOI 10.2165/11584600-000000000-00000
   World Health Organization, 2001, MACR HLTH INV HLTH E
   Yang BH, 2004, INT J CANCER, V109, P418, DOI 10.1002/ijc.11719
NR 49
TC 16
Z9 17
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUL 15
PY 2012
VL 131
IS 2
BP E96
EP E104
DI 10.1002/ijc.26472
PG 9
WC Oncology
SC Oncology
GA 946KN
UT WOS:000304350600010
PM 21964797
OA Bronze
DA 2020-11-24
ER

PT J
AU Santini-Oliveira, M
   Camacho, LAB
   Souza, TML
   Luz, PM
   Vasconcellos, MTL
   Giacoia-Gripp, CBW
   Morgado, MG
   Nunes, EP
   Lemos, AS
   Ferreira, ACG
   Moreira, RI
   Veloso, VG
   Siqueira, MM
   Grinsztejn, B
AF Santini-Oliveira, Marilia
   Camacho, Luiz A. B.
   Souza, Thiago M. L.
   Luz, Paula M.
   Vasconcellos, Mauricio T. L.
   Giacoia-Gripp, Carmem B. W.
   Morgado, Mariza G.
   Nunes, Estevao P.
   Lemos, Alberto S.
   Ferreira, Ana C. G.
   Moreira, Ronaldo I.
   Veloso, Valdilea G.
   Siqueira, Marilda M.
   Grinsztejn, Beatriz
TI H1N1pdm09 Adjuvanted Vaccination in HIV-Infected Adults: A Randomized
   Trial of Two Single versus Two Double Doses
SO PLOS ONE
LA English
DT Article
ID CLINICAL-TRIALS; SPLIT VIRION; INFLUENZA; IMMUNOGENICITY; WOMEN;
   REPRESENTATION; IMMUNIZATION; IMMUNITY; VIRUS
AB Background: Since human immunodeficiency virus (HIV)-infected individuals are at increased risk of severe disease from pandemic influenza A (H1N1pdm09), vaccination was recommended as a prevention strategy. The aim of the present study was to evaluate the safety, immunogenicity and persistence of the immune response after vaccination against pandemic influenza A (H1N1pdm09) with an adjuvanted vaccine in human immunodeficiency virus (HIV)-infected adults using two single and two double doses.
   Methodology/Principal Findings: Open label, randomized trial to evaluate the immune response following H1N1pdm09 vaccination in HIV-infected participants compared to HIV-negative controls (NCT01155037). HIV-infected participants were randomized to receive 2 single (3.75 mu g hemagglutinin) or 2 double (7.5 mu g hemagglutinin) doses of the vaccine, 21 days apart. Controls received one dose of the vaccine. The primary endpoint was seroconversion as measured by hemagglutination inhibition assay. Two hundred fifty six HIV-infected participants (129 and 127 randomized to single and double doses, respectively) and 71 HIV-negative controls were enrolled. Among HIV-infected participants, seroconversion increased from 46.7% and 51.7% after the first dose to 77.2% and 83.8% after the second dose of the vaccine using single and double doses, respectively. Participants aged.40 years showed higher seroconversion compared to younger participants. Seroconversion among HIV-infected women and those with nadir CD4,200 cells/mm(3) was significantly higher with double doses. Persistence of protective antibodies six months after vaccination was achieved by 80% and 89.9% of the HIV-infected participants who received single and double doses, respectively.
   Conclusions/Significance: Our results support the recommendation of two double doses of adjuvanted H1N1pdm09 vaccine for HIV-infected individuals, particularly women, and those aged.40 years or with nadir CD4,200 cells/mm(3), to achieve antibody levels that are both higher and more sustained.
C1 [Santini-Oliveira, Marilia; Luz, Paula M.; Vasconcellos, Mauricio T. L.; Nunes, Estevao P.; Lemos, Alberto S.; Ferreira, Ana C. G.; Moreira, Ronaldo I.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Camacho, Luiz A. B.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil.
   [Souza, Thiago M. L.; Siqueira, Marilda M.] Fundacao Oswaldo Cruz, Lab Viroses Resp, NIC WHO, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Giacoia-Gripp, Carmem B. W.; Morgado, Mariza G.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
RP Santini-Oliveira, M (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI LEMOS, ALBERTO/G-6198-2012; Veloso, Valdilea Goncalves/J-6189-2012; de
   Lemos, Alberto dos Santos/M-4246-2013; Souza, Thiago Moreno
   L./G-2900-2012
OI de Lemos, Alberto dos Santos/0000-0003-0138-6577; Souza, Thiago Moreno
   L./0000-0003-2212-3899; Luz, Paula/0000-0001-9746-719X
FU Departamento Nacional de DST e AIDS
FX This study was supported by Departamento Nacional de DST e AIDS
   (funding) and Programa Nacional de Imunizacoes (vaccines donation),
   Ministry of Health, Brazil (www.saude.gov.br). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449
   Beck James M., 2001, American Journal of Respiratory and Critical Care Medicine, V164, P2120
   Bickel M, 2011, CLIN INFECT DIS, V52, P122, DOI 10.1093/cid/ciq003
   Bickel M, 2010, AIDS, V24, pF31, DOI 10.1097/QAD.0b013e3283398da1
   CDC, 2011, UPD CDC EST 2009 H1N
   CDC, 2011, IN INFL VACC WHAT YO
   CDC, 2011, UPD INT REC HIV INF
   Clark TW, 2009, NEW ENGL J MED, V361, P2424, DOI 10.1056/NEJMoa0907650
   COUCH RB, 1983, ANNU REV MICROBIOL, V37, P529, DOI 10.1146/annurev.mi.37.100183.002525
   Crum-Cianflone NF, 2011, VACCINE, V29, P3183, DOI 10.1016/j.vaccine.2011.02.040
   Crum-Cianflone NF, 2011, CLIN INFECT DIS, V52, P138, DOI 10.1093/cid/ciq019
   Dolin R, 2011, CLIN INFECT DIS, V52, P147, DOI 10.1093/cid/ciq017
   Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Fleiss J. L., 1981, STAT METHODS RATES P
   Harris DJ, 2000, NEW ENGL J MED, V343, P475, DOI 10.1056/NEJM200008173430706
   Jagsi R, 2009, CANCER, V115, P3293, DOI 10.1002/cncr.24366
   Klein MB, 2007, CLIN INFECT DIS, V45, P234, DOI 10.1086/518986
   Launay O, 2011, J INFECT DIS, V204, P124, DOI 10.1093/infdis/jir211
   Melloni C, 2010, CIRC-CARDIOVASC QUAL, V3, P135, DOI 10.1161/CIRCOUTCOMES.110.868307
   Miller E, 2010, LANCET, V375, P1100, DOI 10.1016/S0140-6736(09)62126-7
   MS, 2010, 672010 MS DEP DST AI
   OLIVEIRA WK, 2009, EURO SURVEILL, V14
   Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999
   Settembre EC, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000948
   Soonawala D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016496
   SVS, 2009, INF EP INFL H1N1 SIT
   Szretter Kristy J, 2006, Curr Protoc Microbiol, VChapter 15, DOI 10.1002/0471729256.mc15g01s3
   Tebas P, 2010, AIDS, V24, P2187, DOI 10.1097/QAD.0b013e32833c6d5c
   Wei CJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000799
   WHO, 2011, FLUNET
   World Health Organization, 2009, CDC PROT REALT RTPCR
   Xu R, 2010, SCIENCE, V328, P357, DOI 10.1126/science.1186430
NR 32
TC 8
Z9 8
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 25
PY 2012
VL 7
IS 6
AR e39310
DI 10.1371/journal.pone.0039310
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 965QG
UT WOS:000305781700028
PM 22761759
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Nielsen-Saines, K
   Watts, H
   Veloso, VG
   Bryson, YJ
   Joao, EC
   Pilotto, JH
   Gray, G
   Theron, G
   Santos, B
   Fonseca, R
   Kreitchmann, R
   Pinto, J
   Mussi-Pinhata, MM
   Ceriotto, M
   Machado, D
   Bethel, J
   Morgado, MG
   Dickover, R
   Camarca, M
   Mirochnick, M
   Siberry, G
   Grinsztejn, B
   Moreira, RI
   Bastos, FI
   Xu, JH
   Moye, J
   Mofenson, LM
AF Nielsen-Saines, Karin
   Watts, Heather
   Veloso, Valdilea G.
   Bryson, Yvonne J.
   Joao, Esau C.
   Pilotto, Jose Henrique
   Gray, Glenda
   Theron, Gerhard
   Santos, Breno
   Fonseca, Rosana
   Kreitchmann, Regis
   Pinto, Jorge
   Mussi-Pinhata, Marisa M.
   Ceriotto, Mariana
   Machado, Daisy
   Bethel, James
   Morgado, Marisa G.
   Dickover, Ruth
   Camarca, Margaret
   Mirochnick, Mark
   Siberry, George
   Grinsztejn, Beatriz
   Moreira, Ronaldo I.
   Bastos, Francisco I.
   Xu, Jiahong
   Moye, Jack
   Mofenson, Lynne M.
CA NICHD HPTN 040 PACTG Protocol Team
TI Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV
   Infection
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; MATERNAL-INFANT
   TRANSMISSION; PERINATAL TRANSMISSION; POSTEXPOSURE PROPHYLAXIS;
   ZIDOVUDINE TREATMENT; RANDOMIZED-TRIAL; VIRAL LOAD; NEVIRAPINE;
   RESISTANCE
AB BACKGROUND
   The safety and efficacy of adding antiretroviral drugs to standard zidovudine prophylaxis in infants of mothers with human immunodeficiency virus (HIV) infection who did not receive antenatal antiretroviral therapy (ART) because of late identification are unclear. We evaluated three ART regimens in such infants.
   METHODS
   Within 48 hours after their birth, we randomly assigned formula-fed infants born to women with a peripartum diagnosis of HIV type 1 (HIV-1) infection to one of three regimens: zidovudine for 6 weeks (zidovudine-alone group), zidovudine for 6 weeks plus three doses of nevirapine during the first 8 days of life (two-drug group), or zidovudine for 6 weeks plus nelfinavir and lamivudine for 2 weeks (three-drug group). The primary outcome was HIV-1 infection at 3 months in infants uninfected at birth.
   RESULTS A total of 1684 infants were enrolled in the Americas and South Africa (566 in the zidovudine-alone group, 562 in the two-drug group, and 556 in the three-drug group). The overall rate of in utero transmission of HIV-1 on the basis of Kaplan-Meier estimates was 5.7% (93 infants), with no significant differences among the groups. Intrapartum transmission occurred in 24 infants in the zidovudine-alone group (4.8%; 95% confidence interval [CI], 3.2 to 7.1), as compared with 11 infants in the two-drug group (2.2%; 95% CI, 1.2 to 3.9; P=0.046) and 12 in the three-drug group (2.4%; 95% CI, 1.4 to 4.3; P=0.046). The overall transmission rate was 8.5% (140 infants), with an increased rate in the zidovudine-alone group (P=0.03 for the comparisons with the two-and three-drug groups). On multivariate analysis, zidovudine monotherapy, a higher maternal viral load, and maternal use of illegal substances were significantly associated with transmission. The rate of neutropenia was significantly increased in the three-drug group (P < 0.001 for both comparisons with the other groups).
   CONCLUSIONS In neonates whose mothers did not receive ART during pregnancy, prophylaxis with a two-or three-drug ART regimen is superior to zidovudine alone for the prevention of intrapartum HIV transmission; the two-drug regimen has less toxicity than the three-drug regimen. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development [NICHD] and others; ClinicalTrials.gov number, NCT00099359.)
C1 [Nielsen-Saines, Karin] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
   [Gray, Glenda; Moye, Jack; Mofenson, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
   [Bethel, James; Camarca, Margaret; Xu, Jiahong] Westat Corp, Rockville, MD USA.
   [Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz Fiocruz, Lab Pesquisa Clin DST & AIDS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique; Morgado, Marisa G.] Fundacao Oswaldo Cruz Fiocruz, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Moreira, Ronaldo I.; Bastos, Francisco I.] Fundacao Oswaldo Cruz Fiocruz, Lab Informacoes Saude, Inst Informacao Cient & Tecnol Saude, Rio De Janeiro, Brazil.
   [Joao, Esau C.] Hosp Fed Servidores Estado, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Gray, Glenda] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa.
   [Gray, Glenda] Chris Hani Baragwanath Hosp, Johannesburg, South Africa.
   [Theron, Gerhard] Univ Stellenbosch, Cape Town, South Africa.
   [Theron, Gerhard] Tygerberg Hosp, Cape Town, South Africa.
   [Santos, Breno] Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Fonseca, Rosana] Hosp Femina, Porto Alegre, RS, Brazil.
   [Kreitchmann, Regis] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Pinto, Jorge] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, BR-14049 Ribeirao Preto, SP, Brazil.
   [Machado, Daisy] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Dickover, Ruth] Univ Calif Davis, Davis, CA 95616 USA.
   [Ceriotto, Mariana] Fdn Maternal & Infant Hlth, Buenos Aires, DF, Argentina.
   [Mirochnick, Mark] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Nielsen-Saines, K (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, MDCC 22-442 10833 LeConte Ave, Los Angeles, CA 90095 USA.
EM knielsen@mednet.ucla.edu
RI Veloso, Valdilea Goncalves/J-6189-2012; Mofenson, Lynne/P-9631-2019;
   Pilotto, Jose Henrique/AAD-9773-2019; Mussi-Pinhata, Marisa/G-6568-2012;
   Pinto, Jorge A/D-1743-2014
OI Mofenson, Lynne/0000-0002-2818-9808; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Mussi-Pinhata, Marisa/0000-0001-8985-1570;
   Pinto, Jorge A/0000-0003-2987-3238; moye, john/0000-0001-9976-8586;
   Bastos, Francisco/0000-0001-5970-8896; Machado,
   Daisy/0000-0003-1993-6442; Kreitchmann, Regis/0000-0002-1146-0497; Joao,
   Esau/0000-0002-2412-0627
FU NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD)
   [HHSN267200800001C, N01-HD-8-0001]; HIV Prevention Trials Network;
   National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01 AI047986, U01 AI068632]; National Institute of
   Mental HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [AI068632]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000454, UL1TR000454, UL1TR000454,
   UL1TR000454, UL1TR000454, UL1TR000454, UL1TR000454] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01AI047986, U01AI068632, UM1AI068632, U01AI068632,
   UM1AI068632, U01AI047986, UM1AI068632, U01AI068632, UM1AI068632,
   U01AI068632, U01AI068632, UM1AI068632, U01AI068632, U01AI068632,
   U01AI068632, U01AI068632, U01AI047986, UM1AI068632, U01AI047986,
   UM1AI068632, UM1AI068632, U01AI047986, U01AI047986, U01AI068632,
   U01AI047986, U01AI068632, U01AI047986, UM1AI068632] Funding Source: NIH
   RePORTER
FX Supported by the NICHD (HHSN267200800001C, N01-HD-8-0001) and by a grant
   from the HIV Prevention Trials Network, which is funded by the National
   Institute of Allergy and Infectious Diseases (NIAID), to the Brazilian
   AIDS Prevention Trials International Network at the University of
   California, Los Angeles (U01 AI047986). Overall support for IMPAACT,
   which endorsed the study, was provided by grants from the NIAID (U01
   AI068632), the NICHD, and the National Institute of Mental Health
   (AI068632).
CR [Anonymous], 2010, GUID US ANT AG PED H
   [Anonymous], 2011, REC US ANT DRUGS PRE
   BrazilianMinistry of Health, 2010, REC PREV VERT TRANSM
   Bulterys M, 2004, JAMA-J AM MED ASSOC, V292, P219, DOI 10.1001/jama.292.2.219
   Chasela CS, 2010, NEW ENGL J MED, V362, P2271, DOI 10.1056/NEJMoa0911486
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599
   Division of AIDS (DAIDS) Regulatory Support Center, 1994, TABL GRAD SEV PED AD
   El Beitune P, 2006, EUR J OBSTET GYN R B, V128, P59, DOI 10.1016/j.ejogrb.2006.01.013
   Ellis RJ, 2003, J INFECT DIS, V188, P1820, DOI 10.1086/379894
   Eshleman SH, 2006, J INFECT DIS, V193, P479, DOI 10.1086/499967
   Fiscus SA, 1999, J INFECT DIS, V180, P99, DOI 10.1086/314840
   Gray GE, 2005, AIDS, V19, P1289, DOI 10.1097/01.aids.0000180100.42770.a7
   Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7
   Haile-Selassie HT, 2011, HIV MED, V12, P422, DOI 10.1111/j.1468-1293.2010.00902.x
   HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Krogstad P, 1999, CLIN INFECT DIS, V28, P1109, DOI 10.1086/514759
   Krogstad P, 2002, CLIN INFECT DIS, V34, P991, DOI 10.1086/338814
   Lambert JS, 2003, SEX TRANSM INFECT, V79, P448, DOI 10.1136/sti.79.6.448
   Mandelbrot L, 2001, JAMA-J AM MED ASSOC, V285, P2083, DOI 10.1001/jama.285.16.2083
   Marazzi MC, 2010, AIDS, V24, P2819, DOI 10.1097/QAD.0b013e32833ff58c
   McKeegan K, 2011, AIDS PATIENT CARE ST, V25, P1, DOI 10.1089/apc.2010.0255
   Mirochnick M, 2008, JAIDS-J ACQ IMM DEF, V47, P334, DOI 10.1097/QAI.0b013e31815f3c23
   Mirochnick M, 2011, PEDIATR INFECT DIS J, V30, P769, DOI 10.1097/INF.0b013e3182242950
   Nogueira S A, 2001, Braz J Infect Dis, V5, P78
   Pedroso C, 2007, JAIDS-J ACQ IMM DEF, V45, P251, DOI 10.1097/QAI.0b013e318050d8b0
   Purohit V, 2010, J NEUROIMMUNE PHARM, V5, P507, DOI 10.1007/s11481-010-9242-7
   Simon A, 2011, JAMA-J AM MED ASSOC, V306, P70, DOI 10.1001/jama.2011.915
   Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201
   Sprinz E, 2009, AIDS RES HUM RETROV, V25, P861, DOI 10.1089/aid.2009.0012
   Taha TE, 2004, JAMA-J AM MED ASSOC, V292, P202, DOI 10.1001/jama.292.2.202
   Taha TE, 2003, LANCET, V362, P1171, DOI 10.1016/S0140-6736(03)14538-2
   Theron GB, 2011, INT J GYNECOL OBSTET, V113, P44, DOI 10.1016/j.ijgo.2010.10.011
   Veloso VG, 2010, REV SAUDE PUBL, V44, P803, DOI 10.1590/S0034-89102010005000034
   Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001
   World Health Organization, 2010, ANT THER HIV INF INF
NR 37
TC 117
Z9 122
U1 0
U2 8
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 21
PY 2012
VL 366
IS 25
BP 2368
EP 2379
DI 10.1056/NEJMoa1108275
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 961GH
UT WOS:000305451700006
PM 22716975
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Lorenzana, SB
   Hughes, MD
   Grinsztejn, B
   Collier, AC
   Luz, PM
   Freedberg, KA
   Wood, R
   Levison, JH
   Mugyenyi, PN
   Salata, R
   Wallis, CL
   Weinstein, MC
   Schooley, RT
   Walensky, RP
AF Lorenzana, Sarah B.
   Hughes, Michael D.
   Grinsztejn, Beatriz
   Collier, Ann C.
   Luz, Paula Mendes
   Freedberg, Kenneth A.
   Wood, Robin
   Levison, Julie H.
   Mugyenyi, Peter N.
   Salata, Robert
   Wallis, Carole L.
   Weinstein, Milton C.
   Schooley, Robert T.
   Walensky, Rochelle P.
TI Genotype assays and third-line ART in resource-limited settings: a
   simulation and cost-effectiveness analysis of a planned clinical trial
SO AIDS
LA English
DT Article
DE A5288; ACTG; antiretroviral therapy; ART; cost-effectiveness; genotype;
   HIV; resource-limited setting; third-line ART
ID ACTIVE ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; VIROLOGICAL FAILURE;
   DRUG-RESISTANCE; COTE-DIVOIRE; HIV-1-INFECTED PATIENTS; HIV-1 INFECTION;
   RISK-FACTORS; ADULTS; PREDICTORS
AB Objectives: To project the clinical and economic outcomes of a genotype assay for selection of third-line antiretroviral therapy (ART) in resource-limited settings, as per the planned international A5288 trial (MULTI-OCTAVE).
   Methods: We used the Cost-effectiveness of Preventing AIDS Complications (CEPAC)-International Model to compare three strategies for patients who have failed second-line ART in South Africa: sustained second-line: no genotype assay, all patients remain on second-line ART; A5288: genotype to determine the resistance profile and assign an appropriate regimen; or population-based third-line: no genotype, all patients switch to a potent third-line regimen. Model inputs are from published data in South Africa. Resistance profiles, ART regimens, and efficacy data were those used for trial planning.
   Results: Projected life expectancy for sustained second-line, A5288, and population-based third-line are 61.1, 103.8, and 104.2 months. Compared to sustained second-line ($ 12 460), per person lifetime costs increase for the A5288 ($ 39 250) and population-based ($ 44 120) strategies. The incremental cost-effectiveness ratio of A5288, compared to sustained second-line, is $ 7500/year of life saved (YLS), and for population-based third-line, compared to A5288, is $ 154 500/YLS. In the A5288 strategy, very late presentation to care, coupled with lengthy delays to obtain the genotype, dramatically reduces 5-year survival, making the population-based third-line strategy more attractive.
   Conclusions: We project that, whereas the public health approach to third-line therapy is unaffordable, genotype assays and third-line ART in resource-limited settings will increase survival and be cost-effective compared to the population-based approach, supporting the value of an efficacy study. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Freedberg, Kenneth A.; Levison, Julie H.; Walensky, Rochelle P.] Harvard Univ, Massachusetts Gen Hosp, Div Infect Dis, Sch Med, Boston, MA 02114 USA.
   [Lorenzana, Sarah B.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Harvard Univ, Massachusetts Gen Hosp, Div Gen Med, Sch Med, Boston, MA 02114 USA.
   [Freedberg, Kenneth A.; Walensky, Rochelle P.] Harvard Univ, Massachusetts Gen Hosp, Dept Med, Sch Med, Boston, MA 02114 USA.
   [Levison, Julie H.; Walensky, Rochelle P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   [Lorenzana, Sarah B.; Freedberg, Kenneth A.; Weinstein, Milton C.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Grinsztejn, Beatriz; Luz, Paula Mendes] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Collier, Ann C.] Univ Washington, Harborview Med Ctr, Sch Med, Seattle, WA 98104 USA.
   [Wood, Robin] Univ Cape Town, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa.
   [Mugyenyi, Peter N.] Joint Clin Res Ctr, Kampala, Uganda.
   [Salata, Robert] Case Western Reserve Univ, Sch Med, Div Infect Dis, Cleveland, OH 44106 USA.
   [Schooley, Robert T.] Univ Calif San Diego, Div Infect Dis, San Diego, CA 92103 USA.
RP Walensky, RP (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Div Infect Dis, Sch Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM rwalensky@partners.org
OI Luz, Paula/0000-0001-9746-719X; Walensky, Rochelle
   P./0000-0002-8795-379X
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01 AI058736, K24 AI062476, P30 AI060354, AI069434]; AIDS Clinical
   Trials Group [U01 AI068636, U01 AI068634]; Merck CompanyMerck & Company;
   Schering-PloughMerck & CompanySchering Plough Corporation; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI060354, P30AI060354, P30AI060354, P30AI060354, R01AI058736,
   R01AI058736, P30AI060354, P30AI060354, R01AI058736, P30AI060354,
   P30AI060354, P30AI060354, P30AI060354, P30AI060354, P30AI060354,
   R01AI093269, P30AI060354, U01AI068634, P30AI060354, U01AI068636,
   U01AI068636, P30AI060354, P30AI060354, P30AI060354, P30AI060354,
   P30AI060354, U01AI069434, P30AI060354, P30AI060354, P30AI060354,
   U01AI068636, P30AI060354, P30AI060354, U01AI069434, P30AI060354,
   P30AI060354, P30AI060354, P30AI060354, P30AI060354, U01AI068636,
   R01AI058736, R01AI058736, P30AI060354, P30AI060354, R01AI058736,
   R01AI058736, K24AI062476, R01AI058736, P30AI060354, P30AI060354,
   P30AI060354, P30AI060354, U01AI068634, P30AI060354, P30AI060354,
   P30AI060354, P30AI060354, P30AI060354, P30AI060354, P30AI060354,
   P30AI060354, U01AI068634, U01AI069434, U01AI068634, P30AI060354,
   U01AI068636, R01AI058736, P30AI060354, P30AI060354, P30AI060354,
   P30AI060354, P30AI060354, P30AI060354, P30AI060354, P30AI060354,
   P30AI060354, P30AI060354, P30AI060354, P30AI060354, P30AI060354,
   R01AI058736, R01AI093269, U01AI068634, R01AI058736, P30AI060354,
   P30AI060354, P30AI060354, K24AI062476, U01AI068636, P30AI060354,
   P30AI060354, P30AI060354, P30AI060354, P30AI060354, K24AI062476,
   P30AI060354, R01AI093269, P30AI060354, P30AI060354, UM1AI069434,
   K24AI062476, P30AI060354, P30AI060354, P30AI060354, P30AI060354,
   P30AI060354, R01AI058736, P30AI060354, P30AI060354, P30AI060354,
   P30AI060354, P30AI060354, P30AI060354, U01AI069434, P30AI060354,
   R01AI058736, R01AI093269, U01AI068636, P30AI060354, P30AI060354,
   P30AI060354, P30AI060354, P30AI060354, P30AI060354, P30AI060354,
   R01AI058736, R01AI093269, R01AI058736, R01AI058736, K24AI062476,
   R01AI058736, UM1AI069434, R01AI058736, P30AI060354, P30AI060354,
   U01AI069434, P30AI060354, P30AI060354, P30AI060354, R01AI058736,
   P30AI060354, P30AI060354] Funding Source: NIH RePORTER
FX The work was supported by the National Institute of Allergy and
   Infectious Diseases (R01 AI058736, K24 AI062476, P30 AI060354,
   AI069434), and the AIDS Clinical Trials Group (U01 AI068636, U01
   AI068634). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.; A.C.C.
   has current or recent past research support from Merck & Company and
   Schering-Plough. She was a member of a Data, Safety, and Monitoring
   Board for a Merck-sponsored study. She and an immediate family member
   own stock in Abbott Laboratories, Bristol Myers Squibb, Johnson and
   Johnson and Pfizer, Inc.; R.T.S. has served as a consultant to Merck &
   Company. He serves as a consultant to Johnson and Johnson and to Gilead
   Sciences. He serves as Chair of a Data, Safety, and Monitoring Board for
   a Gilead-sponsored study.
CR AIDS Clinical Trials Group, A5288 MAN US LAT TEC
   Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1
   [Anonymous], 2007, INFECT DIS NEWS 1101
   Badri M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-89
   Bendavid E, 2011, AIDS, V25, P211, DOI 10.1097/QAD.0b013e328340fdf8
   Bendavid E, 2009, JAIDS-J ACQ IMM DEF, V52, P106, DOI 10.1097/QAI.0b013e3181a4f9c4
   Cantor SB, 1999, J CLIN EPIDEMIOL, V52, P517, DOI 10.1016/S0895-4356(99)00021-9
   Charles M, 2008, B WORLD HEALTH ORGAN, V86, P970, DOI 10.2471/BLT.07.050120
   Ciaranello AL, 2011, AIDS, V25, P479, DOI 10.1097/QAD.0b013e3283428cbe
   Cleary S, 2004, COST EFFECTIVENESS A
   Clinton Foundation, 2010, HIV AIDS IN ANT ARV
   Cole SR, 2003, AM J EPIDEMIOL, V158, P687, DOI 10.1093/aje/kwg206
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   D'Aquila Richard T., OVERVIEW HIV 1 RESIS
   de Meyer S, 2008, AIDS RES HUM RETROV, V24, P379, DOI 10.1089/aid.2007.0173
   Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334
   Deeks SG, 2009, CLIN INFECT DIS, V49, P1582, DOI 10.1086/644768
   Egger M, 2007, 14 CROI C RETR OPP I
   El-Khatib Z, 2010, AIDS, V24, P1679, DOI 10.1097/QAD.0b013e32833a097b
   Eron J, 2010, 17 CROI C RETR OPP I
   Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871
   Gauteng Department of Health, 2004, GAIT HOSP NUM
   Gold M. R., 1996, COST EFFECTIVENESS H
   Goldie SJ, 2006, NEW ENGL J MED, V355, P1141, DOI 10.1056/NEJMsa060247
   Hammond R, 2008, INT J STD AIDS, V19, P291, DOI 10.1258/ijsa.2007.007248
   Holmes CB, 2006, JAIDS-J ACQ IMM DEF, V42, P464, DOI 10.1097/01.qai.0000225729.79610.b7
   Hosseinipour MC, 2009, AIDS, V23, P1127, DOI 10.1097/QAD.0b013e32832ac34e
   *INT MON FUND, 2009, WORLD EC OUTL DAT OC
   Johnson M, 2005, AIDS, V19, P685, DOI 10.1097/01.aids.0000166091.39317.99
   Kamya MR, 2007, JAIDS-J ACQ IMM DEF, V46, P187, DOI 10.1097/QAI.0b013e31814278c0
   Katlama C, 2010, ANTIVIR THER, V15, P1045, DOI 10.3851/IMP1662
   Keiser O, 2008, PLOS MED, V5, P1102, DOI 10.1371/journal.pmed.0050148
   Lawn SD, 2005, AIDS, V19, P2109, DOI 10.1097/01.aids.0000194808.20035.c1
   Lawn SD, 2007, AIDS, V21, P335, DOI 10.1097/QAD.0b013e328011efac
   Levison JH, 2011, ANTIVIR THER, V16, P853, DOI 10.3851/IMP1819
   Losina E, 2007, ANTIVIR THER, V12, P543
   Marconi VC, 2008, CLIN INFECT DIS, V46, P1589, DOI 10.1086/587109
   Mee P, 2008, AIDS, V22, P1971, DOI 10.1097/QAD.0b013e32830e4cd8
   Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003
   Murphy RA, 2010, AIDS, V24, P1007, DOI 10.1097/QAD.0b013e3283333639
   Napravnik S, 2007, AIDS, V21, P825, DOI 10.1097/QAD.0b013e32805e8764
   *OAND CORP, 2009, FXHISTORY HIST CURR
   Orrell C, 2009, ANTIVIR THER, V14, P523
   Petersen ML, 2008, AIDS, V22, P2097, DOI 10.1097/QAD.0b013e32830f97e2
   Tuboi SH, 2005, JAIDS-J ACQ IMM DEF, V40, P324, DOI 10.1097/01.qai.0000182627.28595.01
   Tuboi SH, 2007, JAIDS-J ACQ IMM DEF, V45, P52, DOI 10.1097/QAI.0b013e318042e1c3
   Walensky RP, 2008, J INFECT DIS, V197, P1324, DOI 10.1086/587184
   Walensky RP, 2009, ANN INTERN MED, V151, P157, DOI 10.7326/0003-4819-151-3-200908040-00138
   Wallis CL, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/769627
   Wallis CL, 2010, JAIDS-J ACQ IMM DEF, V53, P480, DOI 10.1097/QAI.0b013e3181bc478b
   Wegner SA, 2004, CLIN INFECT DIS, V38, P723, DOI 10.1086/381266
   *WHO, 2009, CHOOSING INT AR COST
   World Health Organization, UN ACC SCAL PRIOR HI
   World Health Organization, 2010, ANT THER HIV INF AD
   Yazdanpanah Y, 2005, AIDS, V19, P1299, DOI 10.1097/01.aids.0000180101.80888.c6
   Yazdanpanah Y, 2009, CLIN INFECT DIS, V49, P1441, DOI 10.1086/630210
NR 56
TC 21
Z9 21
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JUN 1
PY 2012
VL 26
IS 9
BP 1083
EP 1093
DI 10.1097/QAD.0b013e32835221eb
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 946PK
UT WOS:000304364900004
PM 22343964
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Wilkin, A
   Pozniak, AL
   Morales-Ramirez, J
   Lupo, SH
   Santoscoy, M
   Grinsztejn, B
   Ruxrungtham, K
   Rimsky, LT
   Vanveggel, S
   Boven, K
AF Wilkin, Aimee
   Pozniak, Anton L.
   Morales-Ramirez, Javier
   Lupo, Sergio H.
   Santoscoy, Mario
   Grinsztejn, Beatriz
   Ruxrungtham, Kiat
   Rimsky, Laurence T.
   Vanveggel, Simon
   Boven, Katia
CA TMC278-C204 Study Grp
TI Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV,
   TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192
   Results from a Phase IIb Randomized Trial
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID TENOFOVIR; EFAVIRENZ; EMTRICITABINE; THRIVE; ECHO
AB TMC278-C204 (NCT00110305), a 96-week trial of the nonnucleoside reverse transcription inhibitor (NNRTI) rilpivirine (RPV, TMC278) in 368 HIV-1-infected, treatment-naive patients, was extended to investigate long-term safety and efficacy. Week 192 analysis results are presented. This was a long-term follow-up of a Phase IIb, randomized trial. No significant RPV dose-response relationships with respect to the primary endpoint (composite ITT-TLOVR algorithm) were observed at week 48 or 96. All RPV-treated patients were switched to open-label 75 mg qd at week 96 and then to 25 mg qd, the Phase III dose, at approximately week 144 as it gave the best benefit-risk balance. All control patients continued receiving open-label efavirenz (EFV) 600 mg qd. At week 192, 59% of RPV and 61% of EFV-treated patients maintained confirmed viral load < 50 copies/ml (ITT-TLOVR algorithm). The mean changes from baseline in CD4 cell count were similar in both groups (RPV: 210 cells/mm(3) vs. EFV: 225 cells/mm 3). No new safety concerns were noted between week 48 and 192. In the week 192 analysis, RPV compared with EFV was associated with a lower overall incidence of grade 2-4 adverse events (AEs) at least possibly related to treatment, including rash (p < 0.001) and neurologic AEs (p < 0.05 Fisher's exact test, post hoc analyses) Incidences of serious AEs, grade 3 or 4 AEs, and discontinuations due to AEs were similar across groups. Increases in total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides were significantly lower with RPV than with EFV. RPV continued to show sustained efficacy similar to EFV at week 192 with a generally more favorable safety profile.
C1 [Wilkin, Aimee] Wake Forest Univ Hlth Sci, Winston Salem, NC 27157 USA.
   [Pozniak, Anton L.] Chelsea & Westminster NHS Fdn Trust, London, England.
   [Pozniak, Anton L.] PKR SSR, London, England.
   [Morales-Ramirez, Javier] Clin Res Puerto Rico Inc, San Juan, PR USA.
   [Lupo, Sergio H.] Univ Nacl Rosario, Santa Fe, Argentina.
   [Santoscoy, Mario] Hosp Carlos Mac Gregor IMSS, Mexico City, DF, Mexico.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Ruxrungtham, Kiat] Chulalongkorn Univ, Fac Med, HIV NAT, Thai Red Cross AIDS Res Ctr, Bangkok 10330, Thailand.
   [Ruxrungtham, Kiat] Chulalongkorn Univ, Fac Med, Dept Med, Bangkok 10330, Thailand.
   [Rimsky, Laurence T.; Vanveggel, Simon] Tibotec BVBA, Beerse, Belgium.
   [Boven, Katia] Tibotec Inc, Titusville, NJ USA.
RP Wilkin, A (corresponding author), Wake Forest Univ Hlth Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM awilkin@wakehealth.edu
CR [Anonymous], 2011, FDA LAB COMPLERAT EM
   Arribas JR, 2008, JAIDS-J ACQ IMM DEF, V47, P74, DOI 10.1097/QAI.0b013e31815acab8
   Azijn H, 2010, ANTIMICROB AGENTS CH, V54, P718, DOI 10.1128/AAC.00986-09
   *BRIST MYERS SQUIB, 2010, FDA LAB SUST EF CAPS
   Buelens A, 2009, 12 EUR AIDS C COL GE
   Cohen CJ, 2011, LANCET, V378, P229, DOI 10.1016/S0140-6736(11)60983-5
   Division of Acquired Immune Deficiency Syndrome (DAIDS), 2004, DIV ACQ IMM DEF SYND
   European AIDS Clinical Society, 2011, GUID CLIN MAN TREATM
   FDA Guidance for Industry, 2002, FDA GUID IND ANT DRU
   FDA label for EDURANT TM (rilpivirine), 2011, FDA LAB EDURANT RILP
   Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Hill A, 2005, ANTIVIR THER, V10, P367
   Katlama C, 2009, AIDS, V23, P2289, DOI 10.1097/QAD.0b013e3283316a5e
   Killingley B, 2007, DRUG TODAY, V43, P427, DOI 10.1358/dot.2007.43.7.1086178
   Molina JM, 2011, LANCET, V378, P238, DOI 10.1016/S0140-6736(11)60936-7
   Pozniak AL, 2010, AIDS, V24, P55, DOI 10.1097/QAD.0b013e32833032ed
   Rimsky LT, 2011, ANTIVIR THER, V16, pA17
   US DHHS, 2011, GUID US ANT AG HIV 1
NR 18
TC 41
Z9 41
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2012
VL 28
IS 5
BP 437
EP 446
DI 10.1089/aid.2011.0050
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 933XY
UT WOS:000303401500003
PM 21902621
DA 2020-11-24
ER

PT J
AU Cohen, CJ
   Molina, JM
   Cahn, P
   Clotet, B
   Fourie, J
   Grinsztejn, B
   Wu, H
   Johnson, MA
   Saag, M
   Supparatpinyo, K
   Crauwels, H
   Lefebvre, E
   Rimsky, LT
   Vanveggel, S
   Williams, P
   Boven, K
AF Cohen, Calvin J.
   Molina, Jean-Michel
   Cahn, Pedro
   Clotet, Bonaventura
   Fourie, Jan
   Grinsztejn, Beatriz
   Wu, Hao
   Johnson, Margaret A.
   Saag, Michael
   Supparatpinyo, Khuanchai
   Crauwels, Herta
   Lefebvre, Eric
   Rimsky, Laurence T.
   Vanveggel, Simon
   Williams, Peter
   Boven, Katia
CA ECHO Study Grp
   THRIVE Study Grp
TI Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks
   in Treatment-Naive HIV-1-Infected Patients: Pooled Results From the
   Phase 3 Double-Blind Randomized ECHO and THRIVE Trials
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT 20th International Workshop on HIV and Hepatitis Virus Drug Resistance
   and Curative Strategies
CY JUN 07-11, 2011
CL Los Cabos, MEXICO
DE HIV-1; treatment-naive; rilpivirine or RPV; efavirenz or EFV
ID ONCE-DAILY DARUNAVIR/RITONAVIR; ACTIVE ANTIRETROVIRAL THERAPY;
   HIV-INFECTED ADULTS; REVERSE-TRANSCRIPTASE; VIROLOGICAL FAILURE; DAILY
   LAMIVUDINE; EMTRICITABINE; COMBINATION; TENOFOVIR; LOPINAVIR/RITONAVIR
AB Background: Pooled analysis of phase 3, double-blind, double-dummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz.
   Methods: Treatment-naive HIV-1-infected adults were randomized 1:1 to rilpivirine 25 mg once daily or efavirenz 600 mg once daily, with background tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (ECHO) or TDF/FTC, zidovudine/lamivudine, or abacavir/lamivudine (THRIVE). The primary endpoint was confirmed response [viral load <50 copies per milliliter; intent-to-treat time-to-loss-of-virologic-response (ITT-TLOVR) algorithm] at week 48. The pooled data set enabled analyses of subgroups and predictors of response/virologic failure.
   Results: Confirmed responses were 84% (rilpivirine) and 82% (efavirenz). The difference in response rates (95% confidence interval) was 2.0% (-2.0% to 6.0%). The incidence of virologic failure was 9% (rilpivirine) versus 5% (efavirenz). Responses in ITT-TLOVR and ITT-snapshot analyses were consistent. Responses were similar for rilpivirine and efavirenz by background regimen, gender, race and clade. Suboptimal adherence and higher baseline viral load resulted in lower responses, higher virologic failure, and development of resistance in both groups; the effects on virologic failure were more apparent with rilpivirine. CD4(+) cell count increased over time in both groups. Rilpivirine compared with efavirenz gave smaller incidences of adverse events leading to discontinuation (3% vs. 8%, respectively), treatment-related grade 2-4 adverse events (16% vs. 31%), rash (3% vs. 14%), dizziness (8% vs. 26%), abnormal dreams/nightmares (8% vs. 13%), and grade 2-4 lipid abnormalities.
   Conclusions: At week 48, rilpivirine 25 mg once daily and efavirenz 600 mg once daily had comparable response rates. Rilpivirine had more virologic failures and improved tolerability versus efavirenz.
C1 [Cohen, Calvin J.] Community Res Initiat New England, Boston, MA 02109 USA.
   [Molina, Jean-Michel] St Louis Hosp, Dept Infect Dis, Paris, France.
   [Molina, Jean-Michel] Univ Paris, F-75252 Paris, France.
   [Cahn, Pedro] Hosp Juan A Fernandez, Buenos Aires, DF, Argentina.
   [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Clotet, Bonaventura] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain.
   [Clotet, Bonaventura] UAB, IrsiCaixa Fdn, Barcelona, Spain.
   [Fourie, Jan] Dr J Fourie Med Ctr, Dundee, Kwazulu Natal, South Africa.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Wu, Hao] Beijing Youan Hosp, Beijing, Peoples R China.
   [Johnson, Margaret A.] Royal Free Hosp, London NW3 2QG, England.
   [Saag, Michael] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA.
   [Supparatpinyo, Khuanchai] Chiang Mai Univ, Infect Dis Sect, Chiang Mai 50000, Thailand.
   [Crauwels, Herta; Rimsky, Laurence T.; Vanveggel, Simon; Williams, Peter] Janssen Infect Dis BVBA, Beerse, Belgium.
   [Boven, Katia] Janssen Res & Dev LLC, Titusville, NJ USA.
   [Lefebvre, Eric] Janssen, Tilburg, Netherlands.
RP Cohen, CJ (corresponding author), Community Res Initiat New England, Boston, MA 02109 USA.
EM ccohen@crine.org
CR Adams J, 2010, ANN PHARMACOTHER, V44, P157, DOI 10.1345/aph.1M359
   Azijn H, 2010, ANTIMICROB AGENTS CH, V54, P718, DOI 10.1128/AAC.00986-09
   Back DJ, 2000, THER DRUG MONIT, V22, P122, DOI 10.1097/00007691-200002000-00026
   Cohen CJ, 2011, LANCET, V378, P229, DOI 10.1016/S0140-6736(11)60983-5
   DeJesus E, 2004, CLIN INFECT DIS, V39, P1038, DOI 10.1086/424009
   DeJesus E, 2004, CLIN INFECT DIS, V39, P411, DOI 10.1086/422143
   Division of Acquired Immune Deficiency Syndrome (DAIDS), 2004, DIV ACQ IMM DEF SYND
   Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4
   *FDA GUID IND, 2002, ANT DRUGS US PLASM H
   Fourie J, 2011, HIV CLIN TRIALS, V12, P313, DOI 10.1310/hct1206-313
   Gilead Sciences, 2011, PRESCR INF COMPL EMT
   Gilead Sciences, 2011, EV EMTR RILP TEN DIS
   Goldman JD, 2008, AIDS RES HUM RETROV, V24, P1031, DOI 10.1089/aid.2008.0035
   Hu ZX, 2011, ANTIVIR THER, V16, pA20
   Jans-sen-Cilag, 2011, ED RILP TABL SUMM PR
   Janssen-Cilag, 2011, PRESCR INF ED RILP T
   Johnson Victoria A, 2009, Top HIV Med, V17, P138
   Knobel H, 2001, AIDS PATIENT CARE ST, V15, P193, DOI 10.1089/10872910151133729
   Kulkarni R, 2012, J ACQ IMMUN DEF SYND, V59, P48
   Kumar P, 2009, 47 ANN M INF DIS SOC
   Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1
   Mocroft A, 2002, ANTIVIR THER, V7, P21
   Molina JM, 2011, LANCET, V378, P238, DOI 10.1016/S0140-6736(11)60936-7
   Molina JM, 2010, JAIDS-J ACQ IMM DEF, V53, P323, DOI 10.1097/QAI.0b013e3181c990bf
   Moyle GJ, 2005, JAIDS-J ACQ IMM DEF, V38, P417, DOI 10.1097/01.qai.0000147521.34369.c9
   Nachega JB, 2007, ANN INTERN MED, V146, P564, DOI 10.7326/0003-4819-146-8-200704170-00007
   Ortiz R, 2008, AIDS, V22, P1389, DOI 10.1097/QAD.0b013e32830285fb
   Picchio G, 2010, 18 INT AIDS C JUL 18
   Pozniak AL, 2006, JAIDS-J ACQ IMM DEF, V43, P535
   Pozniak AL, 2010, AIDS, V24, P55, DOI 10.1097/QAD.0b013e32833032ed
   Rimsky L, 2012, JAIDS-J ACQ IMM DEF, V59, P39, DOI 10.1097/QAI.0b013e31823df4da
   Smith KY, 2009, 5 INT AIDS SOC C HIV
   van Velsen F, 2011, 50 ANN M SOC TOX MAR
   Vingerhoets J, 2011, ANTIVIR THER, V16, pA51
   Wilkin A, 2011, AIDS RES HUM RETROVI
   Xu HT, 2011, J VIROL, V85, P11300, DOI 10.1128/JVI.05584-11
NR 36
TC 125
Z9 129
U1 0
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAY 1
PY 2012
VL 60
IS 1
BP 33
EP 42
DI 10.1097/QAI.0b013e31824d006e
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 930BZ
UT WOS:000303112200013
PM 22343174
DA 2020-11-24
ER

PT J
AU Nicol, AF
   Silva, JRLE
   Cunha, CB
   Amaro, SM
   Oliveira, N
   Grinsztejn, B
   Khalil, R
   Russomano, F
   Pires, A
   Golub, JE
   Nuovo, GJ
AF Nicol, Alcina F.
   Lapa e Silva, Jose R.
   Cunha, Cynthia B.
   Amaro-Filho, Sergio M.
   Oliveira, Nathalia
   Grinsztejn, Beatriz
   Khalil, Ruth
   Russomano, Fabio
   Pires, Andrea
   Golub, Jonathan E.
   Nuovo, Gerard J.
TI Evaluation of MCM-2 Expression in TMA Cervical Specimens
SO PLOS ONE
LA English
DT Article
ID MINICHROMOSOME MAINTENANCE PROTEINS; HIV-POSITIVE MEN; INTRAEPITHELIAL
   NEOPLASIA; UTERINE CERVIX; HIV/HPV COINFECTION; CELL-CYCLE; BIOMARKERS;
   DYSPLASIA; MARKERS
AB Background: Minichromosome maintenance proteins (MCM) are highly expressed in actively replicating cells. The need for biological markers for cervical carcinoma and its precursor lesions is emerging. Our main aim was to determine the immunohistochemical expression of MCM-2 in HIV-positive and -negative dysplastic cervical specimens.
   Methods: Immunohistochemical analysis of MCM-2 was performed in a total of 352 cervical TMA specimens of normal control, low-grade CIN, high-grade CIN and invasive tumor. 38 specimens were from HIV-positive women. A receiver operating characteristic (ROC) curve was constructed to determine the best cutoff to diagnose high-grade CIN and invasive cervical cancer.
   Results: In the progression from normal epithelium to high-grade CIN and invasive tumor we found significant differences in the MCM-2 expression (p<0.05). Based on the ROC curve of 80% with an area under the curve (AUC) of 0.78, expression of MCM-2 to diagnose high-grade CIN and invasive tumor resulted in sensitivity of 81%, specificity of 66%, a positive predictive value (PPV) of 86% and a negative predictive value (NPV) of 57%. HIV-positive cervices revealed a decreasing expression of MCM-2 in both LGCIN and HGCIN compared with HIV-negative specimens (p<0.0001).
   Conclusions: The present study suggests that immunohistochemical MCM-2 may not be a promising biomarker for diagnosing high-grade CIN and invasive cancer.
C1 [Nicol, Alcina F.; Amaro-Filho, Sergio M.; Oliveira, Nathalia] Inst Oswaldo Cruz, Lab Interdisciplinary Med Res, BR-20001 Rio De Janeiro, Brazil.
   [Lapa e Silva, Jose R.] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Lab Multidisciplinar, Rio De Janeiro, Brazil.
   [Cunha, Cynthia B.; Grinsztejn, Beatriz; Khalil, Ruth] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Dept Infect Dis, Rio De Janeiro, Brazil.
   [Russomano, Fabio] Fundacao Oswaldo Cruz, Fernandes Figueira Inst, Dept Cerv Pathol, Rio De Janeiro, Brazil.
   [Pires, Andrea] Fonte Med Diagnost Lab, Niteroi, RJ, Brazil.
   [Pires, Andrea] Univ Fed Fluminense, Niteroi, RJ, Brazil.
   [Golub, Jonathan E.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Golub, Jonathan E.] Johns Hopkins Sch Med, Baltimore, MD USA.
   [Nuovo, Gerard J.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
RP Nicol, AF (corresponding author), Inst Oswaldo Cruz, Lab Interdisciplinary Med Res, BR-20001 Rio De Janeiro, Brazil.
EM nicol@ioc.fiocruz.br
RI Oliveira, Nathalia/M-8830-2019; Lapa e Silva, Jose R./AAS-4793-2020
OI Oliveira, Nathalia/0000-0003-3733-0022; Lapa e Silva, Jose
   R./0000-0003-3116-0253; Amaro-Filho, Sergio/0000-0002-7374-4081
FU Fogarty International Center, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Fogarty International Center (FIC) [2 D 43 TW000010-23-AITRP];
   Laboratory of Interdisciplinary Medical Research, Instituto Oswaldo
   Cruz, Brazil; Lewis Foundation (Dr. Gerard J Nuovo Laboratory); FOGARTY
   INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010] Funding Source: NIH RePORTER
FX AFN and SAF were scholars in the International AIDS Research and
   Training Program, supported by the Fogarty International Center,
   National Institutes of Health Research Grant 2 D 43 TW000010-23-AITRP.
   NO was a scholar in the Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro. This work was supported in part by
   grants from the Laboratory of Interdisciplinary Medical Research,
   Instituto Oswaldo Cruz, Brazil, and the Lewis Foundation (from the Dr.
   Gerard J Nuovo Laboratory). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Benevolo M, 2010, HISTOPATHOLOGY, V57, P580, DOI 10.1111/j.1365-2559.2010.03674.x
   Pires ARC, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-14
   Eng J, 2005, ACAD RADIOL, V12, P909, DOI 10.1016/j.acra.2005.04.005
   Fan Jerome, 2006, CJEM, V8, P19
   Freeman A, 1999, CLIN CANCER RES, V5, P2121
   Galgano MT, 2010, AM J SURG PATHOL, V34, P1077, DOI 10.1097/PAS.0b013e3181e8b2c4
   Giaginis C, 2010, HISTOL HISTOPATHOL, V25, P351, DOI 10.14670/HH-25.351
   Gupta N, 2010, DIAGN CYTOPATHOL, V38, P618, DOI 10.1002/dc.21270
   Kreuter A, 2008, J INVEST DERMATOL, V128, P2316, DOI 10.1038/jid.2008.72
   Kreuter A, 2010, J AM ACAD DERMATOL, V63, P490, DOI 10.1016/j.jaad.2009.08.043
   Mukherjee G, 2007, BRIT J CANCER, V96, P1107, DOI 10.1038/sj.bjc.6603679
   Nicol AF, 2008, J CLIN PATHOL, V61, P84, DOI 10.1136/jcp.2007.047290
   Nicol AF, DIAGN MOL PATHOL, V14, P39
   Nicol AF, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-289
   Nuovo GJ, 2010, METHODS, V52, P307, DOI 10.1016/j.ymeth.2010.08.009
   Scarpini C, 2008, CANCER EPIDEM BIOMAR, V17, P2855, DOI 10.1158/1055-9965.EPI-08-0288
   Tachibana KEK, 2005, J PATHOL, V205, P123, DOI 10.1002/path.1708
NR 17
TC 7
Z9 8
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 6
PY 2012
VL 7
IS 4
AR e32936
DI 10.1371/journal.pone.0032936
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 955JA
UT WOS:000305012700004
PM 22493662
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Silva, MTT
   Neves, ES
   Grinsztejn, B
   Espindola, OD
   Schor, D
   Araujo, A
AF Silva, Marcus T. T.
   Neves, Elizabeth S.
   Grinsztejn, Beatriz
   Espindola, Otavio de Melo
   Schor, Doris
   Araujo, Abelardo
TI Neurological manifestations of coinfection with HIV and human
   T-lymphotropic virus type 1
SO AIDS
LA English
DT Article
ID SPASTIC PARAPARESIS; DISEASE PROGRESSION; PROVIRAL LOAD; HTLV-I;
   MYELOPATHY; INFECTION
AB HIV-individuals are at risk for human T-lymphotropic virus (HTLV) coinfection and neurological diseases. Little is known about the impact of HAART among coinfected patients. In this study, 47 out of 428 HIV individuals were coinfected with HTLV (10.9%). Coinfection was an independent variable associated with neurological outcome (odds ratio 8.73). Coinfection was associated with myelopathy [chi square (X-2) = 93, P < 0.001], peripheral neuropathy (X-2 = 6.5, P = 0.01), and hepatitis C virus infection (X-2 = 36.5, P < 0.001). HAART did not appear to protect against neurological diseases and had no impact on HTLV proviral load.
C1 [Silva, Marcus T. T.; Neves, Elizabeth S.; Araujo, Abelardo] Fundacao Oswaldo Cruz FIOCRUZ, Inst Pesquisa Clin Evandro Chagas IPEC, Lab Pesquisa Clin Neuroinfeccao, Rio De Janeiro, Brazil.
   [Espindola, Otavio de Melo; Schor, Doris] Fundacao Oswaldo Cruz FIOCRUZ, Inst Pesquisa Clin Evandro Chagas IPEC, Lab Pesquisa Patogenia Viral, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Inst Pesquisa Clin Evandro Chagas IPEC, Lab Pesquisa Clin DST AIDS, Rio De Janeiro, Brazil.
RP Silva, MTT (corresponding author), IPEC FIOCRUZ, Lab Pesquisa Clin Neuroinfeccao, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM marcustulius@ipec.fiocruz.br
RI de Queiroz-Campos Araujo, Abelardo/N-3637-2013; Silva, Marcus
   Tulius/AAM-1077-2020
OI de Queiroz-Campos Araujo, Abelardo/0000-0001-7694-7223; Espindola,
   Otavio/0000-0002-4062-3785
FU Programa Nacional DST/AIDS do Ministerio da Saude; Fundacao Oswaldo Cruz
   (FIOCRUZ); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   - Programa Bolsa de Produtividade em Pesquisa (CNPq)
FX This study was sponsored by the Programa Nacional DST/AIDS do Ministerio
   da Saude, Fundacao Oswaldo Cruz (FIOCRUZ), and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - Programa Bolsa de
   Produtividade em Pesquisa (CNPq).
CR [Anonymous], 1991, NEUROLOGY, V41, P778
   Araujo AQC, 2006, LANCET NEUROL, V5, P1068, DOI 10.1016/S1474-4422(06)70628-7
   Beilke MA, 2005, CLIN INFECT DIS, V41, pE57, DOI 10.1086/432890
   Beilke MA, 1998, J ACQ IMMUN DEF SYND, V17, P391, DOI 10.1097/00042560-199804150-00002
   BERGER JR, 1991, NEUROLOGY, V41, P197, DOI 10.1212/WNL.41.2_Part_1.197
   Cohen J., 1988, STAT POWER ANAL BEHA
   De Castro-Costa CM, 2006, AIDS RES HUM RETROV, V22, P931, DOI 10.1089/aid.2006.22.931
   Harrison LH, 1997, NEUROLOGY, V48, P13, DOI 10.1212/WNL.48.1.13
   Harrison LH, 1997, J INFECT DIS, V176, P308, DOI 10.1086/514035
   Murphy EL, 2003, JAIDS-J ACQ IMM DEF, V33, P655, DOI 10.1097/00126334-200308150-00019
   SCHECHTER M, 1994, JAMA-J AM MED ASSOC, V271, P353, DOI 10.1001/jama.271.5.353
   Schechter M, 1997, J ACQ IMMUN DEF SYND, V15, P308, DOI 10.1097/00042560-199708010-00010
   Silva MT, 2009, AIDS REV, V11, P71
   Silva MTT, 2007, CLIN INFECT DIS, V44, P689, DOI 10.1086/510679
   Turci M, 2006, JAIDS-J ACQ IMM DEF, V41, P100, DOI 10.1097/01.qai.0000179426.04166.12
   ZEHENDER G, 1995, J INFECT DIS, V172, P1595, DOI 10.1093/infdis/172.6.1595
NR 16
TC 13
Z9 13
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD FEB 20
PY 2012
VL 26
IS 4
BP 521
EP 523
DI 10.1097/QAD.0b013e32834c4a3e
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 894FC
UT WOS:000300411500016
PM 21881482
DA 2020-11-24
ER

PT J
AU Luz, PM
   Velasque, L
   Friedman, RK
   Russomano, F
   Andrade, AC
   Moreira, RI
   Chicarino-Coelho, J
   Pires, E
   Veloso, VG
   Grinsztejn, B
AF Luz, P. M.
   Velasque, L.
   Friedman, R. K.
   Russomano, F.
   Andrade, A. C.
   Moreira, R. I.
   Chicarino-Coelho, J.
   Pires, E.
   Veloso, V. G.
   Grinsztejn, B.
TI Cervical cytological abnormalities and factors associated with
   high-grade squamous intraepithelial lesions among HIV-infected women
   from Rio de Janeiro, Brazil
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE HIV; women; HPV; HSIL; high-grade squamous intraepithelial lesions;
   prevalence; Brazil
ID HUMAN-PAPILLOMAVIRUS INFECTION; ACTIVE ANTIRETROVIRAL THERAPY;
   HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; CELL ABNORMALITIES; POSITIVE
   WOMEN; CANCER; PREVALENCE; NEOPLASIA; COUNT
AB Although cervical cancer remains a major public health problem in Brazil, knowledge of cervical cytological abnormalities among HIV-infected women remains scarce. At baseline evaluation of a cohort followed in Rio de Janeiro, Brazil, 703 HIV-infected women underwent cytology-based cervical cancer screening and human papillomavirus (HPV) DNA testing. Poisson regression analysis was used to evaluate the association of factors with the presence of high-grade squamous intraepithelial lesions (HSIL). Cervical cytology was abnormal in 24.3% of the women; 4.1% had HSIL. Beyond HPV infection, factors independently associated with the presence of HSIL was age (>= 25 and <= 40 years, prevalence ratio [PR] 2.60, 95% confidence interval [Cl] 1.11-6.10), and more than three pregnancies was protective (PR 0.33, 95% CI 0.11-0.94). High coverage of cervical cancer screening is warranted to prevent morbidity and mortality from cervical cancer in this population.
C1 [Luz, P. M.; Velasque, L.; Friedman, R. K.; Andrade, A. C.; Moreira, R. I.; Chicarino-Coelho, J.; Pires, E.; Veloso, V. G.; Grinsztejn, B.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Velasque, L.] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil.
   [Russomano, F.] Fundacao Oswaldo Cruz, Inst Fernandes Figueira, BR-21040360 Rio De Janeiro, RJ, Brazil.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI Veloso, Valdilea Goncalves/J-6189-2012
OI Luz, Paula/0000-0001-9746-719X
FU National Counsel of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Instituto de Pesquisa Clinica Evandro
   Chagas, Fundacao Oswaldo Cruz; Ministry of HealthMinistry of Health -
   Turkey
FX BG acknowledges funding from the National Counsel of Technological and
   Scientific Development (CNPq) and the Research Funding Agency of the
   State of Rio de Janeiro (FAPERJ). This study was funded by Instituto de
   Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz and the Brazilian
   National STD/AIDS Program of the Ministry of Health.
CR Ahdieh-Grant L, 2004, JNCI-J NATL CANCER I, V96, P1070, DOI 10.1093/jnci/djh192
   Almonte M, 2008, VACCINE, V26, pL16, DOI 10.1016/j.vaccine.2008.06.008
   Blossom DB, 2007, J MED VIROL, V79, P758, DOI 10.1002/jmv.20817
   Bollen LJM, 2006, SEX TRANSM DIS, V33, P259
   Bosch FX, 2007, DIS MARKERS, V23, P213, DOI 10.1155/2007/914823
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Calore EE, 2001, DIAGN CYTOPATHOL, V24, P117, DOI 10.1002/1097-0339(200102)24:2<117::AID-DC1021>3.0.CO;2-P
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   de Albuquerque KM, 2009, CAD SAUDE PUBLICA, V25, pS301, DOI 10.1590/S0102-311X2009001400012
   De Beaudrap P, 2009, AM J TROP MED HYG, V80, P1047, DOI 10.4269/ajtmh.2009.80.1047
   de Sanjose S, 2002, VIRUS RES, V89, P201, DOI 10.1016/S0168-1702(02)00189-2
   Fonseca Luiz Augusto Marcondes, 2004, Cad. Saúde Pública, V20, P136, DOI 10.1590/S0102-311X2004000100029
   Fonseca MGP, 2007, CAD SAUDE PUBLICA, V23, pS333, DOI 10.1590/S0102-311X2007001500002
   Franceschi S, 2007, CLIN INFECT DIS, V45, P510, DOI 10.1086/520022
   Franco EL, 2001, CAN MED ASSOC J, V164, P1017
   Gakidou E, 2008, PLOS MED, V5, P863, DOI 10.1371/journal.pmed.0050132
   Grinsztejn B, 2009, INT J INFECT DIS, V13, P72, DOI 10.1016/j.ijid.2008.03.031
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Hankins C, 1999, CAN MED ASSOC J, V160, P185
   Heard I, 2002, AIDS, V16, P1799, DOI 10.1097/00002030-200209060-00013
   Kalakun Luciane, 2005, Cad. Saúde Pública, V21, P299, DOI 10.1590/S0102-311X2005000100033
   de Araujo ACL, 2005, REV BRAS GINECOL OBS, V27, P106, DOI 10.1590/S0100-72032005000300002
   Leal Maria do Carmo, 2004, Cad Saude Publica, V20 Suppl 1, pS20
   Leal Maria do Carmo, 2005, Cad Saude Publica, V21 Suppl, P78
   Lehtovirta P, 2008, INT J STD AIDS, V19, P37, DOI 10.1258/ijsa.2007.005672
   Luque AE, 2006, J INFECT DIS, V194, P428, DOI 10.1086/505876
   Mangclaviraj S, 2008, INT J STD AIDS, V19, P529, DOI 10.1258/ijsa.2007.007222
   Massad LS, 1999, J ACQ IMMUN DEF SYND, V21, P33, DOI 10.1097/00126334-199905010-00005
   Ministry of Health, 2005, CANC EST YEAR 2006 B
   Nappi L, 2005, EUR J OBSTET GYN R B, V121, P226, DOI 10.1016/j.ejogrb.2004.12.003
   Palefsky JM, 2003, CURR OPIN ONCOL, V15, P382, DOI 10.1097/00001622-200309000-00007
   Paramsothy P, 2009, OBSTET GYNECOL, V113, P26, DOI 10.1097/AOG.0b013e31819225cb
   Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111
   Rama C, 2008, REV SAUDE PUBL, V42, P411, DOI 10.1590/S0034-89102008000300004
   Ronco G, 2007, LANCET, V370, P1740, DOI 10.1016/S0140-6736(07)61480-9
   Sahasrabuddhe VV, 2007, BRIT J CANCER, V96, P1480, DOI 10.1038/sj.bjc.6603737
   Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5
   Smith JS, 2003, LANCET, V361, P1159, DOI 10.1016/S0140-6736(03)12949-2
   Snijders PJF, 2006, J PATHOL, V208, P152, DOI 10.1002/path.1866
   Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073
   Wright TC, 2007, CLIN OBSTET GYNECOL, V50, P313, DOI 10.1097/GRF.0b013e31804a8285
   Xi LF, 2004, JNCI-J NATL CANCER I, V96, P1051, DOI 10.1093/jnci/djh223
   Zimmermmann JB, 2006, REV BRAS GINECOL OBS, V28, P345, DOI 10.1590/S0100-72032006000600005
NR 46
TC 10
Z9 10
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD JAN
PY 2012
VL 23
IS 1
BP 12
EP 17
DI 10.1258/ijsa.2009.009409
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 913UL
UT WOS:000301902800003
PM 22362681
DA 2020-11-24
ER

PT J
AU Eshleman, SH
   Hudelson, SE
   Redd, AD
   Wang, L
   Debes, R
   Chen, YQ
   Martens, CA
   Ricklefs, SM
   Selig, EJ
   Porcella, SF
   Munshaw, S
   Ray, SC
   Piwowar-Manning, E
   McCauley, M
   Hosseinipour, MC
   Kumwenda, J
   Hakim, JG
   Chariyalertsak, S
   de Bruyn, G
   Grinsztejn, B
   Kumarasamy, N
   Makhema, J
   Mayer, KH
   Pilotto, J
   Santos, BR
   Quinn, TC
   Cohen, MS
   Hughes, JP
AF Eshleman, Susan H.
   Hudelson, Sarah E.
   Redd, Andrew D.
   Wang, Lei
   Debes, Rachel
   Chen, Ying Q.
   Martens, Craig A.
   Ricklefs, Stacy M.
   Selig, Ethan J.
   Porcella, Stephen F.
   Munshaw, Supriya
   Ray, Stuart C.
   Piwowar-Manning, Estelle
   McCauley, Marybeth
   Hosseinipour, Mina C.
   Kumwenda, Johnstone
   Hakim, James G.
   Chariyalertsak, Suwat
   de Bruyn, Guy
   Grinsztejn, Beatriz
   Kumarasamy, Nagalingeswaran
   Makhema, Joseph
   Mayer, Kenneth H.
   Pilotto, Jose
   Santos, Breno R.
   Quinn, Thomas C.
   Cohen, Myron S.
   Hughes, James P.
TI Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV
   Prevention Trials Network 052 Trial
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID MOLECULAR EPIDEMIOLOGY; INFECTION; IDENTIFICATION; EVOLUTIONARY;
   TRANSMISSION
AB Methods. Linkage was assessed using phylogenetic analysis of HIV pol sequences and Bayesian analysis of genetic distances between pol sequences from index-partner pairs and controls. Selected samples were also analyzed using next-generation sequencing (env region).
   Results. In 29 of the 38 (76.3%) cases analyzed, the index was the likely source of the partner's HIV infection (linked). In 7 cases (18.4%), the partner was most likely infected from a source other than the index participant (unlinked). In 2 cases (5.3%), linkage status could not be definitively established.
   Conclusions. Nearly one-fifth of the seroconversion events in HPTN 052 were unlinked. The association of early ART and reduced HIV transmission was stronger when the analysis included only linked events. This underscores the importance of assessing the genetic linkage of HIV seroconversion events in HIV prevention studies involving serodiscordant couples.
C1 [Eshleman, Susan H.; Hudelson, Sarah E.; Piwowar-Manning, Estelle] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Redd, Andrew D.; Quinn, Thomas C.] NIAID, Immunoregulat Lab, Div Intramural Res, NIH, Baltimore, MD USA.
   [Wang, Lei; Chen, Ying Q.; Hughes, James P.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA.
   [Debes, Rachel; Hughes, James P.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Martens, Craig A.; Ricklefs, Stacy M.; Selig, Ethan J.; Porcella, Stephen F.] NIAID, Genom Unit, Res Technol Sect, Rocky Mt Labs,Div Intramural Res,NIH, Hamilton, MT USA.
   [Munshaw, Supriya; Ray, Stuart C.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [McCauley, Marybeth] FHI 360, Hlth & Dev Sci Div, Arlington, VA USA.
   [Hosseinipour, Mina C.] Kamuzu Cent Hosp, UNC Project, Lilongwe, Malawi.
   [Kumwenda, Johnstone] Coll Med, Blantyre, Malawi.
   [Hakim, James G.] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [de Bruyn, Guy] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Lab Pesquisa Clin DST AIDS, Rio De Janeiro, Brazil.
   [Kumarasamy, Nagalingeswaran] YRG CARE Med Ctr, Madras, Tamil Nadu, India.
   [Makhema, Joseph] Botswana Harvard Sch Publ Hlth AIDS Initiat Partn, Gaborone, Botswana.
   [Mayer, Kenneth H.] Fenway Hlth, Boston, MA USA.
   [Pilotto, Jose] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   [Pilotto, Jose] Lab AIDS & Imunol Mol IOC Fiocruz, Rio De Janeiro, Brazil.
   [Cohen, Myron S.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
   [Santos, Breno R.] Hosp Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil.
RP Eshleman, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Room 646,720 Rutland Ave, Baltimore, MD 21205 USA.
EM seshlem@jhmi.edu
RI Pilotto, Jose Henrique/AAD-9773-2019; Ray, Stuart C./B-7527-2008
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Ray, Stuart
   C./0000-0002-1051-7260
FU HIV Prevention Trials Network (HPTN); National Institute of Allergy and
   Infectious Diseases (NIAID)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); National Institute on Drug
   Abuse (NIDA)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA); National Institute of Mental Health (NIMH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH); Office of AIDS
   Research, of NIH; Department of Health and Human Services
   [U01AI068613/UM1AI068613, U01AI068617, U01AI068619]; Division of
   Intramural Research, NIAID, NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID); NIAID, NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI029168]; NIDA, NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [R01DA024565]; Abbott
   DiagnosticsAbbott Laboratories; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P30AI050410, P30AI050410,
   P30AI050410, U01AI068613, P30AI050410, P30AI050410, U01AI068617,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, ZIAAI000361,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   R01AI029168, P30AI050410, P30AI050410, UM1AI068613, P30AI050410,
   P30AI050410, P30AI050410, U01AI068619, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, R01AI029168, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, R01AI029168, ZICAI001052, P30AI050410,
   U01AI068617, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   UM1AI068613, P30AI050410, ZICAI001052, P30AI050410, R01AI029168,
   R01AI029168, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, ZICAI001052, ZIAAI000361, R01AI029168, U01AI068619,
   P30AI050410, R01AI029168, ZICAI001052, P30AI050410, P30AI050410,
   ZIAAI000361, U01AI068617, R01AI029168, P30AI050410, R01AI029168,
   P30AI050410, P30AI050410, P30AI050410, U01AI068619, ZICAI001052,
   UM1AI068613, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, R01AI029168, ZIAAI000361, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, R01AI029168, R01AI029168, UM1AI068613,
   P30AI050410, P30AI050410, P30AI050410, R01AI029168, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, R01AI029168, P30AI050410,
   ZIAAI000361, P30AI050410, P30AI050410, P30AI050410, UM1AI068613,
   P30AI050410, ZICAI001052, P30AI050410, P30AI050410, R01AI029168,
   R01AI029168, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, R01AI029168, ZICAI001052,
   UM1AI068613, R01AI029168, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, UM1AI068613, P30AI050410, P30AI050410,
   P30AI050410, U01AI068619, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, U01AI068613, P30AI050410, P30AI050410,
   U01AI068617, P30AI050410, U01AI068613, U01AI068617, ZIAAI000361,
   P30AI050410, ZIAAI000361, U01AI068613, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, ZIAAI000361, P30AI050410,
   ZIAAI000361, R37AI029168, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, U01AI068619, UM1AI068613, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, ZICAI001052, U01AI068613, R01AI029168, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, UM1AI068613,
   ZICAI001052, ZIAAI000361, UM1AI068613, P30AI050410, ZICAI001052,
   P30AI050410, P30AI050410, R01AI029168, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Drug Abuse (NIDA) [R01DA024565, R01DA024565, R01DA024565,
   R01DA024565, R01DA024565] Funding Source: NIH RePORTER
FX This work was supported by the HIV Prevention Trials Network (HPTN)
   sponsored by the National Institute of Allergy and Infectious Diseases
   (NIAID), the National Institute on Drug Abuse (NIDA), the National
   Institute of Mental Health (NIMH), and the Office of AIDS Research, of
   NIH, Department of Health and Human Services (U01AI068613/UM1AI068613 to
   HPTN Network Laboratory; U01AI068617 to HPTN Statistical and Data
   Management Center; and U01AI068619 to HPTN Core and Operations Center);
   the Division of Intramural Research, NIAID, NIH; NIAID,
   NIH(R01AI029168); and NIDA, NIH(R01DA024565).; S. H. E. has given
   presentations at meetings sponsored by Abbott Diagnostics (distributor
   of the ViroSeq HIV Genotyping System) and has collaborated with Celera
   (manufacturer of the ViroSeq HIV Genotyping System) and Abbott
   Diagnostics on evaluation of HIV-related assays. All other authors
   report no potential conflicts.
CR Apfalter P, 2005, J CLIN MICROBIOL, V43, P5835, DOI 10.1128/JCM.43.12.5835-5841.2005
   Campbell MS, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016986, 10.1371/journal.pone.0018283]
   Celum C, 2010, NEW ENGL J MED, V362, P427, DOI 10.1056/NEJMoa0904849
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Craig DW, 2008, NAT METHODS, V5, P887, DOI 10.1038/NMETH.1251
   Eshleman SH, 2004, J CLIN MICROBIOL, V42, P2711, DOI 10.1128/JCM.42.6.2711-2717.2004
   Eshleman SH, 2007, AIDS, V21, P1165, DOI 10.1097/QAD.0b013e32810fd72e
   KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115
   Lam TTY, 2010, CRIT REV CL LAB SCI, V47, P5, DOI 10.3109/10408361003633318
   LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H
   Pacold M, 2010, AIDS RES HUM RETROV, V26, P1291, DOI 10.1089/aid.2010.0042
   Perez-Losada M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016902
   Redd AD, 2011, J CLIN MICROBIOL, V49, P2859, DOI 10.1128/JCM.00804-11
   Scott D. W., 1992, MULTIVARIATE DENSITY
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Trask SA, 2002, J VIROL, V76, P397, DOI 10.1128/JVI.76.1.397-405.2002
   Zwickl D. J., 2006, THESIS U TEXAS AUSTI
NR 17
TC 76
Z9 79
U1 0
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 15
PY 2011
VL 204
IS 12
BP 1918
EP 1926
DI 10.1093/infdis/jir651
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 848QU
UT WOS:000297069100015
PM 21990420
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Firnhaber, C
   Evans, D
   Friedman-Khalili, R
   Willliams, S
   Michelow, P
   Matlhagela, K
   Wester, C
   Grinsztejn, B
   Lockman, S
AF Firnhaber, C.
   Evans, D.
   Friedman-Khalili, R.
   Willliams, S.
   Michelow, P.
   Matlhagela, K.
   Wester, C.
   Grinsztejn, B.
   Lockman, S.
TI Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected
   women from South Africa, Brazil and Botswana
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE HPV serology; HIV; Resource limited countries
ID HUMAN-PAPILLOMAVIRUS; CERVICAL DYSPLASIA; PARTICLE VACCINE; YOUNG-WOMEN;
   VIRUS; PREVALENCE; LESIONS; JOHANNESBURG; EFFICACY
AB Background: Many resource limited settings (RLS) suffer from high rates of both cervical cancer and HIV. Limited HPV serology data are available from RLS; such data could help describe local patterns of HPV infection and predict vaccine efficacy.
   Objectives: To determine seropositivity to HPV types 6, 11, 16 and 18 in HIV-infected women from South Africa (SA), Botswana and Brazil.
   Study design: HPV serotyping for high-risk types 6, 11, 16 and 18 was performed on samples collected from HIV-infected women from 2003-2010 using competitive Luminex Immuno Assay (HPV-4cLIA). We examined the association between seropositivity to these HPV types and country of enrollment, CD4, HIV-1 RNA level, and Pap smear.
   Results: HPV serology results were available for 487 HIV-infected women (157, 170 and 160 from SA, Botswana and Brazil respectively). Approximately 65% of women had serum antibodies to one of the 4 HPV types and less than 3% of women had antibodies all 4 serotypes. Approximately 30% women demonstrated antibodies to type 16 HPV. Rates of seropositivity to HPV 11, and HPV 16+18 varied significantly between countries. Statistical difference was also shown in women in different age categories in the different countries. There was no difference in serology results compared by CD4 count, HIV viral load or Pap smear results.
   Conclusions: These data suggest that the quadrivalent vaccine may be effective in preventing HPV infection in these countries. (C) 2011 Elsevier B. V. All rights reserved.
C1 [Firnhaber, C.; Evans, D.] Univ Witwatersrand, Clin HIV Res Unit, Fac Hlth Sci Ctr, Johannesburg, South Africa.
   [Firnhaber, C.; Willliams, S.] Right Care, Johannesburg, South Africa.
   [Friedman-Khalili, R.; Grinsztejn, B.] Inst Pesquisa Clin Evandro, Lab Pesquisa Clin DST AIDS, Chagas, Fiocruz, Brazil.
   [Michelow, P.] Univ Witwatersrand, Cytol Unit, Dept Anat Pathol, Fac Hlth Sci, Johannesburg, South Africa.
   [Michelow, P.] Natl Hlth Lab Serv, Johannesburg, South Africa.
   [Matlhagela, K.] Univ Botswana, Sch Med, Gaborone, Botswana.
   [Matlhagela, K.; Wester, C.; Lockman, S.] Botswana Harvard Sch Publ Hlth AIDS Initiat Partn, Gaborone, Botswana.
   [Lockman, S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Firnhaber, C (corresponding author), POB Postnet Suite 176,Private Bag X2600, ZA-2041 Houghton Johannesburg, South Africa.
EM cindy.firnhaber@righttocare.org
CR Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Cerqueira DM, 2007, ARCH VIROL, V152, P75, DOI 10.1007/s00705-006-0828-6
   Christensen ND, 1996, VIROLOGY, V224, P477, DOI 10.1006/viro.1996.0554
   Christensen ND, 1996, VIROLOGY, V223, P174, DOI 10.1006/viro.1996.0466
   Firnhaber C, 2010, CANCER CAUSE CONTROL, V21, P433, DOI 10.1007/s10552-009-9475-z
   Firnhaber C, 2009, ACTA CYTOL, V53, P10, DOI 10.1159/000325079
   Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4
   Marais DJ, 2009, J MED VIROL, V81, P203, DOI 10.1002/jmv.21343
   Mbwana J, 2007, SEX TRANSM INFECT, V83, P64, DOI 10.1136/sti.2006.021279
   Minkoff H, 2010, J INFECT DIS, V201, P681, DOI 10.1086/650467
   Omar T, 2011, AIDS, V25, P87, DOI 10.1097/QAD.0b013e328340fd99
   Sahasrabuddhe VV, 2007, BRIT J CANCER, V96, P1480, DOI 10.1038/sj.bjc.6603737
   Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527
   Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114
   Strickler HD, 2008, INT J CANCER, V123, P1224, DOI 10.1002/ijc.23630
   Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7
NR 16
TC 6
Z9 6
U1 2
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD NOV
PY 2011
VL 52
IS 3
BP 265
EP 268
DI 10.1016/j.jcv.2011.08.011
PG 4
WC Virology
SC Virology
GA 842AF
UT WOS:000296556800022
PM 21908233
DA 2020-11-24
ER

PT J
AU Cortes, F
   Bello, G
   Vorsatz, C
   Pilotto, J
   Grinsztejn, B
   Veloso, VG
   Cardoso, SW
   Morgado, MG
AF Cortes, F.
   Bello, G.
   Vorsatz, C.
   Pilotto, J.
   Grinsztejn, B.
   Veloso, V. G.
   Cardoso, S. W.
   Morgado, M. G.
TI Comparable Antigenicity Among Subtype B, Subtype F1 and Group M Nef
   Consensus Peptides in Brazilians HIV-1-Infected Subjects
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY SEP 12-15, 2011
CL Bangkok, THAILAND
C1 [Cortes, F.; Bello, G.; Pilotto, J.; Morgado, M. G.] Oswaldo Cruz Inst FIOCRUZ, Rio De Janeiro, Brazil.
   [Vorsatz, C.; Grinsztejn, B.; Veloso, V. G.; Cardoso, S. W.] Evandro Chagas Clin Res Inst FIOCRUZ, Rio De Janeiro, Brazil.
RI Veloso, Valdilea Goncalves/J-6189-2012; Pilotto, Jose
   Henrique/AAD-9773-2019; Cardoso, Sandra W/D-7965-2015; Cortes,
   Fernanda/AAF-9254-2020
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Cardoso, Sandra
   W/0000-0001-5230-0003; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2011
VL 27
IS 10
BP A113
EP A114
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 832GD
UT WOS:000295790500294
DA 2020-11-24
ER

PT J
AU Joao, EC
   Gouvea, MI
   Menezes, JA
   Matos, HJ
   Cruz, MLS
   Rodrigues, CAS
   De Souza, MJ
   Fracalanzza, SEL
   Botelho, ACN
   Calvet, GA
   Grinsztejn, BGJ
AF Joao, Esau C.
   Gouvea, Maria Isabel
   Menezes, Jacqueline A.
   Matos, Haroldo J.
   Cruz, Maria Leticia S.
   Rodrigues, Caio A. S.
   De Souza, Maria Jose
   Fracalanzza, Sergio E. L.
   Botelho, Ana Caroline N.
   Calvet, Guilherme A.
   Grinsztejn, Beatriz Gilda J.
TI Group B Streptococcus in a cohort of HIV-infected pregnant women:
   Prevalence of colonization, identification and antimicrobial
   susceptibility profile
SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Editorial Material
DE Group B Streptococcus (GBS); HIV-infected pregnant women; antibiotic
   prophylaxis; antibiotic susceptibility profile; serotype identification
ID CARRIAGE; DISEASE; AGALACTIAE; CARRIERS
AB Group B Streptococcus (GBS) is a leading cause of infectious morbidity in newborns. We describe the prevalence of GBS colonization and the serotypes and antibiotic susceptibility profiles of isolates obtained from a cohort of human immunodeficiency virus (HIV)-infected pregnant women. This was a cross-sectional study at a centre for the prevention of mother-to-child transmission of HIV. Vaginal and rectal swabs were collected at 35-37 weeks of gestation from 158 eligible women. GBS isolates were serotyped and antimicrobial susceptibility tests performed. Patient sociodemographic characteristics, CD4 counts and viral loads were abstracted from records. The overall anogenital prevalence of GBS colonization was 49/158 (31.0%): 40/158 (25.3%) for vagina, 19/158 (12.0%) for rectum and 10/158 (6.3%) for both. Predominant serotypes were Ib (34.9%) and Ia (25.6%). All were penicillin-susceptible. Two were resistant to erythromycin (4.0%) and one to clindamycin (2.0%). The colonization rate by GBS was high in this cohort. Serotype Ib was the most frequently identified.
C1 [Joao, Esau C.; Gouvea, Maria Isabel; Menezes, Jacqueline A.; Matos, Haroldo J.; Cruz, Maria Leticia S.] Hosp Servidores Estado, Dept Infect Dis, Pesquisa Clin Saude, BR-20221903 Rio De Janeiro, Brazil.
   [Gouvea, Maria Isabel; Calvet, Guilherme A.; Grinsztejn, Beatriz Gilda J.] Fdn Oswaldo Cruz Fiocruz, Dept Infect Dis, Inst Pesquisas Clin Evandro Chagas IPEC, Rio De Janeiro, Brazil.
   [Matos, Haroldo J.] Univ Estado Rio de Janeiro, BR-20550011 Rio De Janeiro, Brazil.
   [Rodrigues, Caio A. S.; De Souza, Maria Jose] Hosp Servidores Estado HSE, Dept Bacteriol, Rio De Janeiro, Brazil.
   [Fracalanzza, Sergio E. L.; Botelho, Ana Caroline N.] Univ Fed Rio de Janeiro, Inst Microbiol, BR-21941 Rio De Janeiro, Brazil.
RP Joao, EC (corresponding author), Hosp Servidores Estado, Dept Infect Dis, Pesquisa Clin Saude, Rua Sacadura Cabral,178,4 Andar,Anexo 4, BR-20221903 Rio De Janeiro, Brazil.
EM esau@uninet.com.br
RI Calvet, GA/G-6959-2013; Cruz, Maria Leticia/Y-5632-2019
OI Calvet, GA/0000-0002-3545-5238; Joao, Esau/0000-0002-2412-0627
CR [Anonymous], 2010, REC US ANT DRUGS PRE
   Baltimore RS, 2007, SEMIN PERINATOL, V31, P33, DOI 10.1053/j.semperi.2007.01.005
   Barcaite E, 2008, ACTA OBSTET GYN SCAN, V87, P260, DOI 10.1080/00016340801908759
   El Beitune P, 2006, EUR J OBSTET GYN R B, V128, P54, DOI 10.1016/j.ejogrb.2006.02.017
   BENCHETRIT LC, 1982, J CLIN MICROBIOL, V15, P787, DOI 10.1128/JCM.15.5.787-790.1982
   Campbell JR, 2000, OBSTET GYNECOL, V96, P498, DOI 10.1016/S0029-7844(00)00977-7
   Clinical and Laboratory Standards Institute, 2011, M100S21 CLIN LAB STA
   EDWARDS MS, 2010, PRINCIPLES PRACTICE, P2655
   EDWARDS MS, 2010, INFECT DIS FETUS NEW, P419
   El Beitune P, 2006, JAIDS-J ACQ IMM DEF, V43, P247
   Epalza C, 2010, PEDIATRICS, V126, pE631, DOI 10.1542/peds.2010-0183
   Gibbs RS, 2004, OBSTET GYNECOL, V104, P1062, DOI 10.1097/01.AOG.0000144128.03913.c2
   Hakansson S, 2008, ACTA OBSTET GYN SCAN, V87, P50, DOI 10.1080/00016340701802888
   Hardie J M, 1997, Soc Appl Bacteriol Symp Ser, V26, p1S
   Hong JS, 2010, J PERINAT MED, V38, P373, DOI [10.1515/JPM.2010.050, 10.1515/jpm.2010.050]
   Jeffery HE, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.1.e2
   Mavenyengwa RT, 2010, EUR J OBSTET GYN R B, V150, P34, DOI 10.1016/j.ejogrb.2010.02.021
   *MIN SAUD SECR VIG, 2010, REC PAR PROF TRANSM
   Panda B, 2009, J MATERN-FETAL NEO M, V22, P111, DOI 10.1080/14767050802488212
   Phares CR, 2008, JAMA-J AM MED ASSOC, V299, P2056, DOI 10.1001/jama.299.17.2056
   *ROY AUSTR NZ COLL, 2007, SCREEN TREATM GROUP
   *ROY COLL OBST GYN, 2007, PREV CARL ONS NEON G
   Shet A, 2004, INDIAN J MED RES, V120, P141
   Simoes JA, 2007, BRAZ J INFECT DIS, V11, P261, DOI 10.1590/S1413-86702007000200019
   Slotved HC, 2007, J CLIN MICROBIOL, V45, P2929, DOI 10.1128/JCM.00117-07
   Spellerberg B, 2007, MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED, P412
   Stoll BJ, 1998, PEDIATR INFECT DIS J, V17, P499, DOI 10.1097/00006454-199806000-00013
   Verani Jennifer R., 2010, Morbidity and Mortality Weekly Report, V59, P1
NR 28
TC 7
Z9 7
U1 0
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0036-5548
EI 1651-1980
J9 SCAND J INFECT DIS
JI Scand. J. Infect. Dis.
PD SEP
PY 2011
VL 43
IS 9
BP 742
EP 746
DI 10.3109/00365548.2011.585178
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 807QC
UT WOS:000293913800011
PM 21671824
DA 2020-11-24
ER

PT J
AU Guimaraes, MDC
   Grinsztejn, B
   Melo, VH
   Rocha, GM
   Campos, LN
   Pilotto, JH
   Carmo, RA
   Palefsky, JM
AF Crosland Guimaraes, Mark Drew
   Grinsztejn, Beatriz
   Melo, Victor Hugo
   Rocha, Gustavo Machado
   Campos, Lorenza Nogueira
   Pilotto, Jose Henrique
   Carmo, Ricardo Andrade
   Palefsky, Joel M.
TI Anal HPV Prevalence and Associated Factors Among HIV-Seropositive Men
   Under Antiretroviral Treatment in Brazil
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE anal HPV infection; HIV-seropositive men; urban Brazil
ID HUMAN-PAPILLOMAVIRUS INFECTION; HUMAN-IMMUNODEFICIENCY; RISK-FACTORS;
   INTRAEPITHELIAL NEOPLASIA; HOMOSEXUAL-MEN; CANCER; WOMEN; CYTOLOGY;
   THERAPY; LESIONS
AB Background: The incidence of anal cancer has increased in developed countries. There is evidence that high-grade anal intra-epithelial neoplasia and anal cancer are both linked to some human papillomavirus (HPV) infections. There are scarce data on anal cancer or male anal HPV infection in Brazil.
   Objective: The purpose of this study was to assess the prevalence of anal HPV infection and associated risk factors, stratified by oncogenic and nononcogenic types, in a sample of HIV-seropositive men in Brazil.
   Methods: Multicenter cross-sectional study of HIV-seropositive male patients attending public AIDS clinics in urban Brazil. Participants were interviewed for sociodemographic and behavioral characteristics. Anal HPV specimens were collected with a moistened Dacron swab inserted into the anal and stored in ThinPrep solution. HPV DNA-positive samples were typed by dot-blot hybridization. The prevalences of oncogenic and nononcogenic HPV types were calculated and multinomial logistic regression was used to assess independent predictors of HPV infection.
   Results: Among 445 men, 65.6% were positive for HPV DNA in the anal canal. Oncogenic types were detected in 40.7%. Logistic regression indicated that lifetime history of sexual intercourse only with men or with men and women; receptive anal intercourse in the last 12 months; and CD4(+) lymphocyte count below 200 cells per cubic millimeter were independently associated with the detection of anal HPV infection.
   Conclusions: The high prevalence of anal HPV infection in this cross-sectional study underscores the need for studying and implementing screening programs of high-risk groups in Brazil.
C1 [Crosland Guimaraes, Mark Drew] Univ Fed Minas Gerais, Dept Prevent & Social Med, Fac Med, BR-30130100 Belo Horizonte, MG, Brazil.
   [Grinsztejn, Beatriz] Fiocruz MS, Med Res Lab STD AIDS, Evandro Chagas Res Inst, BR-21045900 Rio De Janeiro, Brazil.
   [Rocha, Gustavo Machado] Univ Fed Sao Joao del Rei, Belo Horizonte, MG, Brazil.
   [Campos, Lorenza Nogueira; Carmo, Ricardo Andrade] Eduardo de Menezes Hosp, Belo Horizonte, MG, Brazil.
   [Pilotto, Jose Henrique] Fiocruz MS, AIDS & Mol Immunol Lab, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Nova Iguacu Hosp, Nova Iguacu, Brazil.
   [Palefsky, Joel M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Melo, Victor Hugo] Univ Fed Minas Gerais, Dept Obstet & Gynecol, Fac Med, BR-30130100 Belo Horizonte, MG, Brazil.
RP Guimaraes, MDC (corresponding author), Univ Fed Minas Gerais, Dept Prevent & Social Med, Fac Med, Av Prof Alfredo Balena 190, BR-30130100 Belo Horizonte, MG, Brazil.
EM drew@medicina.ufmg.br
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
FU Ministry of Health/Secretariat of Health Surveillance/Department of STD,
   AIDS and Viral Hepatitis through Brazilian Government [914/BRA/1101];
   Ministry of Health/Secretariat of Health Surveillance/Department of STD,
   AIDS and Viral Hepatitis through United Nations Educational, Scientific,
   and Cultural Organization-UNESCO [914/BRA/1101]
FX This work was carried out by the Federal University of Minas Gerais with
   technical and financial support of the Ministry of Health/Secretariat of
   Health Surveillance/Department of STD, AIDS and Viral Hepatitis through
   the Project of International Technical Cooperation 914/BRA/1101 between
   the Brazilian Government and the United Nations Educational, Scientific,
   and Cultural Organization-UNESCO.
CR Abramowitz L, 2007, AIDS, V21, P1457, DOI 10.1097/QAD.0b013e3281c61201
   Bower M, 2004, JAIDS-J ACQ IMM DEF, V37, P1563, DOI 10.1097/00126334-200412150-00004
   Chaturvedi AK, 2009, JNCI-J NATL CANCER I, V101, P1120, DOI 10.1093/jnci/djp205
   Chin-Hong PV, 2008, ANN INTERN MED, V149, P300, DOI 10.7326/0003-4819-149-5-200809020-00004
   Chin-Hong PV, 2002, CLIN INFECT DIS, V35, P1127, DOI 10.1086/344057
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   D'Souza G, 2008, JAIDS-J ACQ IMM DEF, V48, P491, DOI 10.1097/QAI.0b013e31817aebfe
   de Pokomandy A, 2009, J INFECT DIS, V199, P965, DOI 10.1086/597207
   de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5
   Grinsztejn B, 2009, INT J INFECT DIS, V13, P655, DOI 10.1016/j.ijid.2009.04.001
   Hoots BE, 2009, INT J CANCER, V124, P2375, DOI 10.1002/ijc.24215
   Mbulawa ZZA, 2009, J INFECT DIS, V199, P1514, DOI 10.1086/598220
   McCloskey JC, 2007, INT J STD AIDS, V18, P538, DOI 10.1258/095646207781439694
   Nielson CM, 2007, J INFECT DIS, V196, P1137, DOI 10.1086/521632
   Nielson CM, 2009, CANCER EPIDEM BIOMAR, V18, P1077, DOI 10.1158/1055-9965.EPI-08-0447
   Nyitray AG, 2010, J INFECT DIS, V201, P1498, DOI 10.1086/652187
   ORLANDO G, 2007, J ACQ IMMUN DEF SYND, V47, P129
   Palefsky JM, 1997, J ACQ IMMUN DEF SYND, V14, P415, DOI 10.1097/00042560-199704150-00004
   Palefsky JM, 1998, J INFECT DIS, V177, P361, DOI 10.1086/514194
   Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Piketty C, 2003, ANN INTERN MED, V138, P453, DOI 10.7326/0003-4819-138-6-200303180-00008
   Piketty C, 2008, AIDS, V22, P1203, DOI 10.1097/QAD.0b013e3283023f78
   Sirera G, 2006, AIDS, V20, P1201, DOI 10.1097/01.aids.0000226963.10342.f4
   Wilkin T, 2010, J INFECT DIS, V202, P1246, DOI 10.1086/656320
NR 25
TC 21
Z9 21
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 15
PY 2011
VL 57
SU 3
BP S217
EP S224
DI 10.1097/QAI.0b013e31821e9994
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 798TU
UT WOS:000293235900016
PM 21857322
DA 2020-11-24
ER

PT J
AU Moreira, RI
   Luz, PM
   Struchiner, CJ
   Morgado, M
   Veloso, VG
   Keruly, JC
   Grinsztejn, B
   Moore, RD
AF Moreira, Ronaldo I.
   Luz, Paula M.
   Struchiner, Claudio J.
   Morgado, Mariza
   Veloso, Valdilea G.
   Keruly, Jeanne C.
   Grinsztejn, Beatriz
   Moore, Richard D.
TI Immune Status at Presentation for HIV Clinical Care in Rio de Janeiro
   and Baltimore
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV/AIDS; late diagnosis/presentation; immunodeficiency care
ID CD4 CELL COUNT; ANTIRETROVIRAL THERAPY; UNITED-STATES; PERSONS AWARE;
   INFECTION; TRANSMISSION; INITIATION; DIAGNOSIS; SETTINGS; UNAWARE
AB Background: Late presentation to HIV clinical care increases individual risk for (multiple) clinical events and death, and decreases successful response to highly active antiretroviral therapy (HAART). In Brazil, provision of HAART free of charge to all individuals infected with HIV could lead to increased testing and linkage to care.
   Methods: We assessed the immune status of 2555 patients who newly presented for HIV clinical care between 1997 and 2009 at the Johns Hopkins Clinical Cohort, in Baltimore, Md, and at the Instituto de Pesquisa Clinica Evandro Chagas Clinical Cohort, in Rio de Janeiro, Brazil. The mean change in the CD4 cell count per year was estimated using multivariate linear regression models.
   Results: Overall, from 1997 to 2009, 56% and 54% of the patients presented for HIV clinical care with CD4 count <= 350 cells per cubic millimeter in Baltimore and Rio de Janeiro, respectively. On average, 75% of the patients presented with viral load >10,000 copies per millimeter. In Rio de Janeiro only, the overall adjusted per year increase in the mean CD4 cell count was statistically significant (5 cells/mm(3), 95% confidence interval: 1 to 10 cells/mm(3)).
   Conclusions : We found that, over years, the majority of patients presented late, that is, with a CD4 count <350 cells per cubic millimeter. Our findings indicate that, despite the availability of HAART for more than a decade, and mass media campaigns stimulating HIV testing in both countries, the proportion of patients who start therapy at an advanced stage of the disease is still high.
C1 [Moreira, Ronaldo I.; Luz, Paula M.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Lab Pesquisa Clin DST & AIDS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Morgado, Mariza] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Struchiner, Claudio J.] Fundacao Oswaldo Cruz, Programa Comp Cient, BR-21045900 Rio De Janeiro, Brazil.
   [Keruly, Jeanne C.; Moore, Richard D.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Lab Pesquisa Clin DST & AIDS, Inst Pesquisa Clin Evandro Chagas, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI Veloso, Valdilea Goncalves/J-6189-2012; Struchiner, Claudio
   J/M-9360-2013
OI Struchiner, Claudio J/0000-0003-2114-847X; Luz,
   Paula/0000-0001-9746-719X
FU National Counsel of Technological and Scientific DevelopmentNational
   Council for Scientific and Technological Development (CNPq); Research
   Funding Agency of the State of Rio de Janeiro; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [DA00432, DA11602, AA16893]; NATIONAL
   INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA016893,
   R01AA016893, R21AA015032, R01AA016893, R21AA015032, R01AA016893] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Drug Abuse (NIDA) [K24DA000432,
   R01DA011602, K24DA000432, R01DA011602, R01DA011602, R01DA011602,
   R01DA011602, R01DA011602, K24DA000432, R01DA011602, R01DA011602,
   K24DA000432, R01DA011602, K24DA000432, R01DA011602, K24DA000432,
   R01DA011602, K24DA000432, K24DA000432, K24DA000432, R01DA011602,
   R01DA011602, R01DA011602, K24DA000432, R01DA011602, R01DA011602] Funding
   Source: NIH RePORTER
FX Supported by the National Counsel of Technological and Scientific
   Development and the Research Funding Agency of the State of Rio de
   Janeiro (to B. G.) and by the National Institutes of Health (DA00432,
   DA11602, and AA16893 to R. D. M.).
CR Althoff KN, 2010, CLIN INFECT DIS, V50, P1512, DOI 10.1086/652650
   Antinori A, 2011, HIV MED, V12, P61, DOI 10.1111/j.1468-1293.2010.00857.x
   Beral V, 2004, AIDS, V18, P51, DOI 10.1097/01.aids.0000096908.73209.5d
   Brannstrom J, 2005, INT J STD AIDS, V16, P702, DOI 10.1258/095646205774357262
   Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1
   BRANSON BM, 2006, MMWR RECOMM REP, V55, pCE11
   Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2
   Girardi E, 2007, JAIDS-J ACQ IMM DEF, V46, pS3, DOI 10.1097/01.qai.0000286597.57066.2b
   Goicoechea M, 2007, CLIN INFECT DIS, V45, P1375, DOI 10.1086/522760
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Hader SL, 2001, JAMA-J AM MED ASSOC, V285, P1186, DOI 10.1001/jama.285.9.1186
   Keruly JC, 2007, CLIN INFECT DIS, V45, P1369, DOI 10.1086/522759
   Krentz HB, 2004, HIV MED, V5, P93, DOI 10.1111/j.1468-1293.2004.00193.x
   Lanoy E, 2009, AIDS, V23, P2199, DOI 10.1097/QAD.0b013e3283305a00
   Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79
   Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d
   Moore RD, 1998, J ACQ IMMUN DEF SYND, V17, pS38, DOI 10.1097/00042560-199801001-00011
   Qaseem A, 2009, ANN INTERN MED, V150, P125, DOI 10.7326/0003-4819-150-2-200901200-00300
   Souza PRB, 2007, CLINICS, V62, P579, DOI 10.1590/S1807-59322007000500008
   Spensley A, 2009, AM J PUBLIC HEALTH, V99, P631, DOI 10.2105/AJPH.2007.114421
   Wolbers M, 2008, HIV MED, V9, P397, DOI 10.1111/j.1468-1293.2008.00566.x
NR 21
TC 28
Z9 29
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 15
PY 2011
VL 57
SU 3
BP S171
EP S178
DI 10.1097/QAI.0b013e31821e9d59
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 798TU
UT WOS:000293235900008
PM 21857314
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Cohen, MS
   Chen, YQ
   McCauley, M
   Gamble, T
   Hosseinipour, MC
   Kumarasamy, N
   Hakim, JG
   Kumwenda, J
   Grinsztejn, B
   Pilotto, JHS
   Godbole, SV
   Mehendale, S
   Chariyalertsak, S
   Santos, BR
   Mayer, KH
   Hoffman, IF
   Eshleman, SH
   Piwowar-Manning, E
   Wang, L
   Makhema, J
   Mills, LA
   de Bruyn, G
   Sanne, I
   Eron, J
   Gallant, J
   Havlir, D
   Swindells, S
   Ribaudo, H
   Elharrar, V
   Burns, D
   Taha, ET
   Nielsen-Saines, K
   Celentano, D
   Essex, M
   Fleming, TR
AF Cohen, Myron S.
   Chen, Ying Q.
   McCauley, Marybeth
   Gamble, Theresa
   Hosseinipour, Mina C.
   Kumarasamy, Nagalingeswaran
   Hakim, James G.
   Kumwenda, Johnstone
   Grinsztejn, Beatriz
   Pilotto, Jose H. S.
   Godbole, Sheela V.
   Mehendale, Sanjay
   Chariyalertsak, Suwat
   Santos, Breno R.
   Mayer, Kenneth H.
   Hoffman, Irving F.
   Eshleman, Susan H.
   Piwowar-Manning, Estelle
   Wang, Lei
   Makhema, Joseph
   Mills, Lisa A.
   de Bruyn, Guy
   Sanne, Ian
   Eron, Joseph
   Gallant, Joel
   Havlir, Diane
   Swindells, Susan
   Ribaudo, Heather
   Elharrar, Vanessa
   Burns, David
   Taha, Taha E.
   Nielsen-Saines, Karin
   Celentano, David
   Essex, Max
   Fleming, Thomas R.
CA HPTN 052 Study Team
TI Prevention of HIV-1 Infection with Early Antiretroviral Therapy
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HETEROSEXUAL TRANSMISSION; HIV-1-INFECTED
   PATIENTS; MORTALITY; INITIATION; RETHINKING; RATES; RISK
AB Background
   Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples.
   Methods
   In nine countries, we enrolled 1763 couples in which one partner was HIV-1-positive and the other was HIV-1-negative; 54% of the subjects were from Africa, and 50% of infected partners were men. HIV-1-infected subjects with CD4 counts between 350 and 550 cells per cubic millimeter were randomly assigned in a 1: 1 ratio to receive antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 count or the onset of HIV-1-related symptoms (delayed therapy). The primary prevention end point was linked HIV-1 transmission in HIV-1-negative partners. The primary clinical end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a World Health Organization stage 4 event, or death.
   Results
   As of February 21, 2011, a total of 39 HIV-1 transmissions were observed (incidence rate, 1.2 per 100 person-years; 95% confidence interval [CI], 0.9 to 1.7); of these, 28 were virologically linked to the infected partner (incidence rate, 0.9 per 100 person-years, 95% CI, 0.6 to 1.3). Of the 28 linked transmissions, only 1 occurred in the early-therapy group (hazard ratio, 0.04; 95% CI, 0.01 to 0.27; P<0.001). Subjects receiving early therapy had fewer treatment end points (hazard ratio, 0.59; 95% CI, 0.40 to 0.88; P = 0.01).
   Conclusions
   The early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events, indicating both personal and public health benefits from such therapy.
C1 [Cohen, Myron S.] Univ N Carolina, Inst Global Hlth & Infect Dis, Sch Med, Chapel Hill, NC 27599 USA.
   [Chen, Ying Q.; Wang, Lei] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA.
   [Fleming, Thomas R.] Univ Washington, Seattle, WA 98195 USA.
   [McCauley, Marybeth] Family Hlth Int, Arlington, VA USA.
   [McCauley, Marybeth] Family Hlth Int, Durham, NC USA.
   UNC Project, Lilongwe, Malawi.
   [Kumwenda, Johnstone] Johns Hopkins Project, Coll Med, Blantyre, Malawi.
   [Kumarasamy, Nagalingeswaran] YR Gaitonade Ctr AIDS Res & Educ, Chennai, Tamil Nadu, India.
   [Godbole, Sheela V.; Mehendale, Sanjay] Natl AIDS Res Inst, Pune, Maharashtra, India.
   [Hakim, James G.] Univ Zimbabwe, Harare, Zimbabwe.
   [Grinsztejn, Beatriz] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, Jose H. S.] Fiocruz MS, Hosp Geral de Nova Iguacu, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, Jose H. S.] Lab AIDS & Imunol Mol IOC Fiocurz, BR-21045900 Rio De Janeiro, Brazil.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
   [Santos, Breno R.] Hosp Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil.
   [Mayer, Kenneth H.] Fenway Hlth, Boston, MA USA.
   [Ribaudo, Heather; Essex, Max] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Eshleman, Susan H.; Piwowar-Manning, Estelle; Gallant, Joel] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Taha, Taha E.; Celentano, David] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Makhema, Joseph] Botswana Harvard AIDS Inst, Gaborone, Botswana.
   [Mills, Lisa A.] Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Kenya Med Res Inst, CDC Res & Publ Hlth Collaborat HIV Res Branch, Kisumu, Kenya.
   [de Bruyn, Guy] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa.
   [Sanne, Ian] Univ Witwatersrand, Dept Med, ZA-2001 Johannesburg, South Africa.
   [Havlir, Diane] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Swindells, Susan] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Elharrar, Vanessa; Burns, David] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA.
   [Nielsen-Saines, Karin] David Geffen UCLA Sch Med, Los Angeles, CA USA.
RP Cohen, MS (corresponding author), Univ N Carolina, Inst Global Hlth & Infect Dis, Sch Med, Suite 2115,Bioinformat Bldg,130 Mason Farm Rd,CB, Chapel Hill, NC 27599 USA.
EM mscohen@med.unc.edu
RI Cardoso, Sandra W/D-7965-2015; Godbole, Sheela/K-4177-2017; Pilotto,
   Jose Henrique/AAD-9773-2019; Moyo, Sikhulile/E-1464-2015; Franzeck,
   Fabian C/B-5055-2011; Choobkar, Saeed/AAA-3212-2020; Hendrix,
   Craig/G-4182-2014; Azadbakht, Morteza/ABA-2569-2020
OI Cardoso, Sandra W/0000-0001-5230-0003; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Moyo, Sikhulile/0000-0003-3821-4592;
   Hendrix, Craig/0000-0002-5696-8665; Azadbakht,
   Morteza/0000-0001-8103-3506; Sahay, Seema/0000-0001-6064-827X; Taha,
   Taha/0000-0001-9814-4894; Nyirenda, Mulinda/0000-0003-2037-7449
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1-AI068619, U01-AI068619, UM1-AI068613, U01-AI068613, UM1-AI068617,
   U01-AI068617]; Abbott Virology; Roche Diagnostics; Monogram Biosciences;
   Sanofi Pasteur; MerckMerck & Company; Bristol-Myers SquibbBristol-Myers
   Squibb; GlaxoSmithKlineGlaxoSmithKline; ViiV Healthcare; Gilead Sciences
   and Tibotec; RocheRoche Holding; Tibotec Therapeutics; PfizerPfizer;
   Sangamo BioSciences; Koronis; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE
   OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Eunice
   Kennedy Shriver National Institute of Child Health & Human Development
   (NICHD) [R24HD042854, R24HD042854, R24HD042854, R24HD042854,
   R24HD042854, R24HD042854, R24HD042854, R24HD042854, R24HD042854,
   R24HD042854, R24HD042854, R24HD042854, R24HD042854, R24HD042854,
   R24HD042854, R24HD042854, R24HD042854, R24HD042854, R24HD042854,
   R24HD042854, R24HD042854, R24HD042854, R24HD042854, R24HD042854,
   R24HD042854, R24HD042854] Funding Source: NIH RePORTER; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [R24HD042854, R24HD042854,
   R24HD042854, R24HD042854, R24HD042854, R24HD042854, R24HD042854,
   R24HD042854, R24HD042854] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI050410, P30AI050410, P30AI027763, P30AI027763,
   P30AI050410, P30AI050410, P30AI050410, P30AI027763, UM1AI068619,
   P30AI050410, P30AI027763, UM1AI068619, P30AI027763, P30AI027763,
   P30AI027763, P30AI050410, U01AI068619, P30AI050410, P30AI050410,
   UM1AI068619, P30AI027763, P30AI027763, P30AI050410, U01AI068619,
   UM1AI068617, P30AI050410, P30AI050410, P30AI050410, UM1AI068613,
   UM1AI068617, P30AI050410, P30AI050410, P30AI027763, P30AI050410,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI050410,
   P30AI050410, P30AI027763, P30AI050410, P30AI027763, P30AI050410,
   UM1AI068613, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI050410, P30AI027763, K24AI051982, P30AI050410,
   P30AI050410, UM1AI068617, P30AI027763, P30AI027763, P30AI050410,
   P30AI027763, P30AI050410, UM1AI068613, P30AI050410, P30AI027763,
   P30AI027763, P30AI050410, P30AI050410, U01AI068619, P30AI027763,
   P30AI027763, P30AI050410, P30AI027763, P30AI027763, P30AI050410,
   P30AI027763, U01AI068619, P30AI050410, P30AI050410, P30AI050410,
   P30AI027763, P30AI027763, P30AI050410, UM1AI068619, P30AI050410,
   U01AI068617, P30AI027763, P30AI027763, P30AI050410, K24AI051982,
   P30AI027763, P30AI050410, P30AI027763, UM1AI068617, P30AI027763,
   U01AI068617, P30AI027763, U01AI068617, P30AI027763, P30AI050410,
   P30AI050410, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI050410, P30AI050410, UM1AI068613, P30AI027763,
   UM1AI068617, P30AI050410, P30AI027763, K24AI051982, P30AI050410,
   P30AI027763, UM1AI068619, P30AI050410, P30AI027763, P30AI050410,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI050410,
   P30AI050410, P30AI027763, P30AI050410, P30AI027763, P30AI027763,
   P30AI050410, UM1AI068619, P30AI050410, P30AI027763, P30AI027763,
   P30AI027763, P30AI050410, P30AI050410, P30AI027763, P30AI027763,
   P30AI027763, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI027763, P30AI050410, P30AI050410, P30AI050410, P30AI027763,
   P30AI027763, P30AI027763, UM1AI068613, P30AI027763, P30AI050410,
   U01AI068613, U01AI068613, P30AI027763, P30AI027763, P30AI027763,
   P30AI050410, P30AI050410, P30AI027763, P30AI027763, P30AI050410,
   P30AI050410, P30AI027763, P30AI050410, P30AI050410, UM1AI068619,
   P30AI050410, P30AI027763, K24AI051982, P30AI050410, P30AI027763,
   P30AI050410, P30AI027763, P30AI050410, P30AI027763, P30AI050410,
   P30AI050410, P30AI027763, P30AI050410, P30AI050410, UM1AI068619,
   U01AI068619, P30AI027763, P30AI050410, P30AI027763, U01AI068617,
   P30AI050410, P30AI027763, K24AI051982, P30AI027763, P30AI027763,
   K24AI051982, P30AI050410, K24AI051982, P30AI050410, P30AI050410,
   P30AI050410, P30AI027763, P30AI027763, UM1AI068613, P30AI050410,
   P30AI027763, P30AI050410, P30AI027763, P30AI050410, P30AI027763,
   P30AI050410, P30AI050410, P30AI027763, P30AI050410, UM1AI068613,
   P30AI050410, P30AI027763, P30AI027763, UM1AI068617, P30AI027763,
   UM1AI068613, P30AI050410, P30AI027763, P30AI050410, P30AI050410,
   P30AI050410, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI050410, P30AI050410, P30AI050410, K24AI051982, P30AI050410,
   P30AI027763, U01AI068613, UM1AI068619, P30AI027763, UM1AI068613,
   P30AI050410, P30AI050410, P30AI027763, P30AI050410, P30AI027763,
   P30AI050410, P30AI027763, P30AI050410, P30AI027763, UM1AI068613,
   P30AI027763, P30AI027763, U01AI068613, P30AI050410, P30AI050410,
   K24AI051982, P30AI050410, P30AI027763, P30AI027763, P30AI050410,
   P30AI027763, P30AI027763, P30AI027763, UM1AI068617, P30AI027763,
   P30AI050410, U01AI068613, P30AI050410, P30AI027763, P30AI050410,
   P30AI050410, P30AI027763, P30AI050410, P30AI027763, P30AI050410,
   P30AI027763, P30AI027763, P30AI050410, P30AI027763, P30AI027763,
   P30AI050410, P30AI027763, P30AI027763, P30AI050410, P30AI027763,
   P30AI027763, UM1AI068617, P30AI050410, P30AI050410, P30AI027763,
   P30AI027763, P30AI050410, P30AI027763, P30AI050410, P30AI027763,
   P30AI027763, P30AI027763, P30AI050410, P30AI027763, P30AI050410,
   P30AI050410, P30AI050410, P30AI027763, P30AI050410, P30AI027763,
   K24AI051982, P30AI027763, P30AI050410, K24AI051982, U01AI068617,
   P30AI027763, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI027763, P30AI050410, P30AI027763, P30AI050410, P30AI027763,
   P30AI050410, P30AI050410, P30AI050410, P30AI027763, P30AI050410,
   P30AI027763, P30AI027763, P30AI027763, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI027763, UM1AI068617] Funding
   Source: NIH RePORTER
FX Funded by the National Institute of Allergy and Infectious Diseases and
   others; HPTN 052 ClinicalTrials.gov number, NCT00074581.); Supported by
   the HIV Prevention Trials Network (HPTN) and by grants (UM1-AI068619 and
   U01-AI068619; UM1-AI068613 and U01-AI068613, to the HPTN Network
   Laboratory; and UM1-AI068617 and U01-AI068617, to the HPTN Statistical
   and Data Management Center) from the National Institute of Allergy and
   Infectious Diseases. Study drugs were donated by Abbott Laboratories,
   Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences,
   GlaxoSmithKline/ViiV Healthcare, and Merck.; Dr. Hosseinipour reports
   receiving lecture fees from Abbott Virology; Dr. Eshleman, consulting
   fees from Roche Diagnostics, lecture fees and samples or laboratory
   reagents from Abbott Diagnostics and Celera Diagnostics, and lecture
   fees from Monogram Biosciences; Dr. Mills, grant support from
   GlaxoSmithKline; Dr. de Bruyn, travel support from Sanofi Pasteur; Dr.
   Eron, consulting fees and grant support from Merck, Bristol-Myers
   Squibb, GlaxoSmithKline, and ViiV Healthcare, consulting fees from
   Gilead Sciences and Tibotec, and lecture fees from Bristol-Myers Squibb
   and Roche; Dr. Gallant, consulting fees from Abbott Laboratories,
   Bristol-Myers Squibb, Gilead Sciences, Merck, Tibotec Therapeutics, ViiV
   Healthcare, GlaxoSmithKline, Pfizer, Sangamo BioSciences, and Koronis,
   grant support and travel support from Gilead Sciences, and lecture fees
   from Monogram Biosciences; Dr. Havlir, study drug from Abbott; and Dr.
   Swindells, consulting fees from Gilead Sciences and Abbott Diagnostics
   and grant support from Pfizer, GlaxoSmithKline, and Bristol- Myers
   Squibb. No other potential conflict of interest relevant to this article
   was reported.
CR Baeten JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001888
   Baker JV, 2008, AIDS, V22, P841, DOI 10.1097/QAD.0b013e3282f7cb76
   Braitstein P, 2006, LANCET, V367, P817
   Bunnell R, 2006, AIDS, V20, P85, DOI 10.1097/01.aids.0000196566.40702.28
   Burns DN, 2010, CLIN INFECT DIS, V51, P725, DOI 10.1086/655889
   Cain LE, 2011, ANN INTERN MED, V154, P509, DOI 10.7326/0003-4819-154-8-201104190-00001
   Celum C, 2010, NEW ENGL J MED, V362, P427, DOI 10.1056/NEJMoa0904849
   Cohen MS, 2007, ANN INTERN MED, V146, P591, DOI 10.7326/0003-4819-146-8-200704170-00010
   Cohen MS, 2010, CLIN INFECT DIS, V50, pS85, DOI 10.1086/651478
   Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068
   Del Romero J, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2205
   DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308
   Dieffenbach CW, 2009, JAMA-J AM MED ASSOC, V301, P2380, DOI 10.1001/jama.2009.828
   Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2
   Dyer JR, 1998, J INFECT DIS, V177, P1742, DOI 10.1086/517436
   Eshleman SH, J INFECT DI IN PRESS
   Eyawo O, 2010, LANCET INFECT DIS, V10, P770, DOI 10.1016/S1473-3099(10)70189-4
   Graham SM, 2007, AIDS, V21, P501, DOI 10.1097/QAD.0b013e32801424bd
   Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9
   Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252
   Lowrance D, 2007, JAIDS-J ACQ IMM DEF, V46, P56
   Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1
   Novitsky V, 2011, AIDS            0418
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   Ping LH, 1999, J VIROL, V73, P6271, DOI 10.1128/JVI.73.8.6271-6281.1999
   Powers KA, 2008, LANCET INFECT DIS, V8, P553, DOI 10.1016/S1473-3099(08)70156-7
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Ray M, 2010, AIDS, V24, P123, DOI 10.1097/QAD.0b013e3283324283
   Reynolds SJ, 2011, AIDS, V25, P473, DOI 10.1097/QAD.0b013e3283437c2b
   Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370
   Smith K, 2011, CURR OPIN HIV AIDS, V6, P315, DOI 10.1097/COH.0b013e32834788e7
   Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7
   Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006
   Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411
   World Health Organization, 2011, GUID INT TUB CAS FIN
NR 35
TC 4491
Z9 4627
U1 33
U2 644
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD AUG 11
PY 2011
VL 365
IS 6
BP 493
EP 505
DI 10.1056/NEJMoa1105243
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 805MW
UT WOS:000293732100005
PM 21767103
OA Green Accepted, Green Published
DA 2020-11-24
ER

PT J
AU Molina, JM
   Cahn, P
   Grinsztejn, B
   Lazzarin, A
   Mills, A
   Saag, M
   Supparatpinyo, K
   Walmsley, S
   Crauwels, H
   Rimsky, LT
   Vanveggel, S
   Boven, K
AF Molina, Jean-Michel
   Cahn, Pedro
   Grinsztejn, Beatriz
   Lazzarin, Adriano
   Mills, Anthony
   Saag, Michael
   Supparatpinyo, Khuanchai
   Walmsley, Sharon
   Crauwels, Herta
   Rimsky, Laurence T.
   Vanveggel, Simon
   Boven, Katia
CA ECHO Study Grp
TI Rilpivirine versus efavirenz with tenofovir and emtricitabine in
   treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised
   double-blind active-controlled trial
SO LANCET
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; COMBINATION THERAPY; PROTEASE-INHIBITOR;
   GUIDELINES; NEVIRAPINE; LAMIVUDINE; REGIMENS; EFFICACY; SAFETY
AB Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non-nucleoside reverse transcriptase inhibitor, has shown similar antiviral efficacy to efavirenz in a phase 2b trial with two nucleoside/nucleotide reverse transcriptase inhibitors. We aimed to assess the efficacy, safety, and tolerability of rilpivirine versus efavirenz, each combined with tenofovir-disoproxil-fumarate and emtricitabine.
   Methods We did a phase 3, randomised, double-blind, double-dummy, active-controlled trial, in patients infected with HIV-1 who were treatment-naive. The patients were aged 18 years or older with a plasma viral load at screening of 5000 copies per mL or greater, and viral sensitivity to all study drugs. Our trial was done at 112 sites across 21 countries. Patients were randomly assigned by a computer-generated interactive web response system to receive either once-daily 25 mg rilpivirine or once-daily 600 mg efavirenz, each with tenofovir-disoproxil-fumarate and emtricitabine. Our primary objective was to show non-inferiority (12% margin) of rilpivirine to efavirenz in terms of the percentage of patients with confirmed response (viral load <50 copies per mL intention-to-treat time-to-loss-of-virological-response [ITT-TLOVR] algorithm) at week 48. Our primary analysis was by intention-to-treat. We also used logistic regression to adjust for baseline viral load. This trial is registered with ClinicalTrials.gov, number NCT00540449.
   Findings 346 patients were randomly assigned to receive rilpivirine and 344 to receive efavirenz and received at least one dose of study drug, with 287 (83%) and 285 (83%) in the respective groups having a confirmed response at week 48. The point estimate from a logistic regression model for the percentage difference in response was -0.4 (95% CI -5.9 to 5.2), confirming non-inferiority with a 12% margin (primary endpoint). The incidence of virological failures was 13% (rilpivirine) versus 6% (efavirenz; 11% vs 4% by ITT-TLOVR). Grade 2-4 adverse events (55 [16%] on rilpivirine vs 108 [31%] on efavirenz, p<0.0001), discontinuations due to adverse events (eight [2%] on rilpivirine vs 27 [8%] on efavirenz), rash, dizziness, and abnormal dreams or nightmares were more common with efavirenz. Increases in plasma lipids were significantly lower with rilpivirine.
   Interpretation Rilpivirine showed non-inferior efficacy compared with efavirenz, with a higher virological-failure rate, but a more favourable safety and tolerability profile.
C1 [Molina, Jean-Michel] St Louis Hosp, Dept Infect Dis, Paris 7, France.
   [Molina, Jean-Michel] Univ Paris Diderot, Paris, France.
   [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Lazzarin, Adriano] San Raffaele Univ, Milan, Italy.
   [Mills, Anthony] Anthony Mills MD Inc, Los Angeles, CA USA.
   [Saag, Michael] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA.
   [Supparatpinyo, Khuanchai] Chiang Mai Univ, Dept Med, Chiang Mai 50000, Thailand.
   [Walmsley, Sharon] Univ Hlth Network, Toronto, ON, Canada.
   [Crauwels, Herta; Rimsky, Laurence T.; Vanveggel, Simon] Tibotec BVBA, Beerse, Belgium.
   [Boven, Katia] Tibotec Inc, Titusville, NJ USA.
RP Molina, JM (corresponding author), St Louis Hosp, Dept Infect Dis, Paris 7, France.
EM jean-michel.molina@sls.aphp.fr
OI Mills, Anthony/0000-0002-6997-5581; Walmsley,
   Sharon/0000-0002-3959-5692; LAZZARIN, Adriano/0000-0003-2551-7754
FU AbbottAbbott Laboratories; Avexa; BI; GileadGilead Sciences; MSD;
   Tibotec; JanssenJohnson & Johnson USAJanssen Biotech Inc;
   GlaxoSmithKline (GSK)GlaxoSmithKline; ViiV Healthcare; PfizerPfizer;
   Pain Therapeutics; Tibotec/JJ; VertexVertex Pharmaceuticals
FX J-MM has acted as a consultant, participated in advisory boards, has
   received speaker fees and has been an investigator for clinical trials
   for Tibotec, ViiV Healthcare, Gilead, Bristol-Myers Squibb (BMS),
   Abbott, Boehringer Ingelheim (BI), and Merck, Sharp &, Dohme (MSD). PC
   has received grant research support, advisory and speaker fees from
   Abbott, Avexa, BI, Gilead, MSD, Tibotec, Janssen, GlaxoSmithKline (GSK),
   and ViiV Healthcare. BC has participated in advisory boards, has
   received speaker fees and has been an investigator for clinical trials
   for Tibotec, BMS, ViiV Healthcare, and MSD. AL has acted as a
   consultant, participated in advisory boards, speaker bureaus and has
   been an investigator in for clinical trials for Abbott, BM S, BI,
   Gilead, MSD, Tibotec, Pfizer, ViiV Healthcare, GSK, and Roche. AM has
   served on advisory boards and speaker bureaus for Tibotec, GSK, BMS,
   Gilead, BI, MSD, and ViiV Healthcare, and has received research funding
   from Tibotec. MS has received consulting fees, research support, or both
   from BMS, BI, GSK, MSD, Pfizer, Pain Therapeutics, Tibotec/J&J, Vertex,
   and ViiV Healthcare. SW has received consultancy fees or lecture
   sponsorships from Abbott, BI, Gilead, MSD, ViiV Healthcare, and Tibotec.
   HC, LTR, SV, and KB are all full-time employees of Tibotec. KS declares
   no conflicts of interest.
CR Adams J, 2010, ANN PHARMACOTHER, V44, P157, DOI 10.1345/aph.1M359
   *BRIST MYERS SQUIB, 2010, FDA LAB EF CAPS TABL
   Buelens A, 2009, 12 EUR AIDS C COL GE
   Clumeck N, 2008, HIV MED, V9, P65, DOI 10.1111/j.1468-1293.2007.00533.x
   Cohen CJ, 2011, LANCET, V378, P229, DOI 10.1016/S0140-6736(11)60983-5
   *CTR DRUG EV RES, 2002, GUID IND ANT DRUGS U
   DESMIDT M, 2009, 12 EUR AIDS C COL GE
   DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, 2011, GUID US ANT AG HIV 1
   Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871
   Gazzard BG, 2008, HIV MED, V9, P563, DOI 10.1111/j.1468-1293.2008.00636.x
   Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772
   HODDER S, 2010, 48 ANN M INF DIS SOC
   HOETELMANS R, 2005, 6 INT WORKSH CLIN PH
   Johnson Victoria A, 2009, Top HIV Med, V17, P138
   Laterza OF, 2002, CLIN CHEM, V48, P699
   Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   LOZANO IS, 2003, ANTIVIR THER S, V8, P337
   Manfredi R, 2004, JAIDS-J ACQ IMM DEF, V35, P492, DOI 10.1097/00126334-200404150-00007
   Margot NA, 2006, ANTIMICROB AGENTS CH, V50, P4087, DOI 10.1128/AAC.00816-06
   MATHIAS AA, 2010, 18 INT AIDS C VIENN
   Mbuagbaw LCE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004246.pub3
   NELSON M, 2010, J INT AIDS SOC S4, V13, pP210
   *NIAID, 2004, DIV AIDS TABL GRAD S
   PEREZMOLINA JA, 2002, TRIALS, V3, P279
   PICCHIO G, 2010, 18 INT AIDS C VIENN
   Pozniak AL, 2010, AIDS, V24, P55, DOI 10.1097/QAD.0b013e32833032ed
   Pulido F, 2004, JAIDS-J ACQ IMM DEF, V35, P343, DOI 10.1097/00126334-200404010-00003
   Rimsky L, 2010, 50 INT C ANT AG CHEM
   Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004
   *TIB, 2011, FDA LAB RILP TABL
   Tombuyzer L, 2009, ANTIVIR THER, V14, P103
   van Leeuwen R, 2003, AIDS, V17, P987, DOI 10.1097/00002030-200305020-00007
   van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7
   VANVEGGEL S, 2009, 47 ANN M INF DIS SOC
   Wilkin A, 2010, 19 ANN CAN C HIV AID
NR 36
TC 305
Z9 318
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUL 16
PY 2011
VL 378
IS 9787
BP 238
EP 246
DI 10.1016/S0140-6736(11)60936-7
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 798JD
UT WOS:000293201100031
PM 21763936
DA 2020-11-24
ER

PT J
AU Raposo, LM
   Velasque, L
   Luz, PM
   Friedman, RK
   Cytryn, A
   de Andrade, ACV
   Vanni, T
   Brasil, PEAA
   Russomano, F
   Veloso, VG
   Grinsztejn, B
   Struchiner, CJ
AF Raposo, Leticia Martins
   Velasque, Luciane
   Luz, Paula Mendes
   Friedman, Ruth Khalili
   Cytryn, Andrea
   Vasconcelos de Andrade, Angela Cristina
   Vanni, Tazio
   Brasil, Pedro E. A. A.
   Russomano, Fabio
   Veloso, Valdilea Goncalves
   Grinsztejn, Beatriz
   Struchiner, Claudio Jose
TI Performance by cytology and hybrid capture II in screening for
   high-grade squamous intraepithelial lesions in women with HIV
SO CADERNOS DE SAUDE PUBLICA
LA Portuguese
DT Article
DE Uterine Cervical Neoplasms; HIV; Women
ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-PAPILLOMAVIRUS INFECTION;
   HUMAN-IMMUNODEFICIENCY-VIRUS; RIO-DE-JANEIRO; CERVICAL-CANCER; POSITIVE
   WOMEN; METAANALYSIS; NEOPLASIA; ACCURACY; COHORT
AB HIV-infected women are at increased risk of developing high-grade squamous intraepithelial lesions (HSIL), the precursor lesions for cervical cancer. This study estimated and compared the performance of cytology and hybrid capture II in screening for precursor lesions of cervical cancer among HIV-infected women. The study population consisted of women from the open prospective cohort at the Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation (IPEC/Fiocruz). Colposcopy and histology were considered jointly in defining the gold standard. Cytology showed 31.8% sensitivity and 95.5% specificity, while hybrid capture II showed higher sensitivity (100%) and lower specificity (52%). The positive likelihood ratio was 7.1 for cytology and 2.1 for hybrid capture II, while the negative likelihood ratio was 0.7 for cytology and 0.0 for hybrid capture II.
C1 [Velasque, Luciane; Luz, Paula Mendes; Friedman, Ruth Khalili; Cytryn, Andrea; Vasconcelos de Andrade, Angela Cristina; Brasil, Pedro E. A. A.; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Raposo, Leticia Martins; Struchiner, Claudio Jose] Fundacao Oswaldo Cruz, Programa Computacao Cient, BR-21045900 Rio De Janeiro, Brazil.
   [Raposo, Leticia Martins; Velasque, Luciane] Univ Fed Estado Rio Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil.
   [Vanni, Tazio] London Sch Hyg & Trop Med, London WC1, England.
   [Russomano, Fabio] Fundacao Oswaldo Cruz, Inst Fernandes Figueira, BR-21045900 Rio De Janeiro, Brazil.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM paula.luz@ipec.fiocruz.br
RI Brasil, Pedro E A A/B-4357-2008; Raposo, Leticia/W-5253-2019; Veloso,
   Valdilea Goncalves/J-6189-2012; Vanni, Tazio P./B-7925-2018; Brasil,
   Pedro Emmanuel/AAG-2280-2019; Struchiner, Claudio J/M-9360-2013
OI Brasil, Pedro E A A/0000-0002-6700-2268; Brasil, Pedro
   Emmanuel/0000-0002-6700-2268; Struchiner, Claudio J/0000-0003-2114-847X;
   Luz, Paula/0000-0001-9746-719X
CR Anderson JR, 2006, CLIN INFECT DIS, V42, P562, DOI 10.1086/499357
   [Anonymous], 2008, REC TER ANT AD INF P
   Arbyn M, 2004, JNCI-J NATL CANCER I, V96, P280, DOI 10.1093/jnci/djh037
   Arbyn M, 2008, OBSTET GYNECOL, V111, P167, DOI 10.1097/01.AOG.0000296488.85807.b3
   Biggerstaff BJ, 2000, STAT MED, V19, P649, DOI 10.1002/(SICI)1097-0258(20000315)19:5&lt;649::AID-SIM371&gt;3.0.CO;2-H
   Bonnet F, 2008, CURR OPIN ONCOL, V20, P534, DOI 10.1097/CCO.0b013e32830a5080
   Bosch FX, 2007, DIS MARKERS, V23, P213, DOI 10.1155/2007/914823
   Brasil P., DIAGNOSISMED DIAGNOS
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Cong XY, 2007, GYNECOL ONCOL, V107, pS133, DOI 10.1016/j.ygyno.2007.08.080
   Cuzick J, 2006, INT J CANCER, V119, P1095, DOI 10.1002/ijc.21955
   Dillner J, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1754
   Fonseca MGP, 2007, CAD SAUDE PUBLICA, V23, pS333, DOI 10.1590/S0102-311X2007001500002
   Franceschi S, 2007, CLIN INFECT DIS, V45, P510, DOI 10.1086/520022
   Grinsztejn B, 2009, INT J INFECT DIS, V13, P72, DOI 10.1016/j.ijid.2008.03.031
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Heard I, 2002, AIDS, V16, P1799, DOI 10.1097/00002030-200209060-00013
   Heard I, 2009, CURR OPIN HIV AIDS, V4, P68, DOI 10.1097/COH.0b013e328319bcbe
   *I NAC CANC, 2006, J BRAS PATOL MED LAB, V42, P351
   Koliopoulos G, 2007, GYNECOL ONCOL, V104, P232, DOI 10.1016/j.ygyno.2006.08.053
   Longatto A, 2006, INT J GYNECOL CANCER, V16, P955, DOI 10.1111/j.1525-1438.2006.00582.x
   LUZ PM, INT J STD A IN PRESS
   Mangclaviraj S, 2008, INT J STD AIDS, V19, P529, DOI 10.1258/ijsa.2007.007222
   MEDRONHO R.A., 2002, EPIDEMIOLOGIA, P259
   Palefsky JM, 2003, CURR OPIN ONCOL, V15, P382, DOI 10.1097/00001622-200309000-00007
   Palefsky J, 2006, CURR OPIN ONCOL, V18, P463, DOI 10.1097/01.cco.0000239885.13537.36
   Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005
   Quinn TC, 2008, AIDS, V22, pS7, DOI 10.1097/01.aids.0000327510.68503.e8
   Santos André Luís Ferreira, 2003, Cad. Saúde Pública, V19, P1029, DOI 10.1590/S0102-311X2003000400025
   Sawaya GF, 2001, NEW ENGL J MED, V344, P1603, DOI 10.1056/NEJM200105243442107
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Snijders PJF, 2006, J PATHOL, V208, P152, DOI 10.1002/path.1866
   STEVENSON M, EPI R FUNCTIONS ANAL
   Stival CO, 2005, REV BRAS ANAL CLIN, V37, P215
   Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073
   TUON FELIPE FRANCISCO BONDAN, 2002, Rev. Assoc. Med. Bras., V48, P140, DOI 10.1590/S0104-42302002000200033
   Walker P, 2003, OBSTET GYNECOL, V101, P175, DOI 10.1016/S0029-7844(02)02581-4
   Wright TC, 2007, CLIN OBSTET GYNECOL, V50, P313, DOI 10.1097/GRF.0b013e31804a8285
   Xi LF, 2004, JNCI-J NATL CANCER I, V96, P1051, DOI 10.1093/jnci/djh223
   1989, JAMA, V262, P931
NR 41
TC 2
Z9 2
U1 0
U2 3
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PD JUL
PY 2011
VL 27
IS 7
BP 1281
EP 1291
DI 10.1590/S0102-311X2011000700004
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 801LZ
UT WOS:000293441700004
PM 21808813
OA DOAJ Gold, Green Accepted
DA 2020-11-24
ER

PT J
AU de Andrade, ACV
   Luz, PM
   Veloso, VG
   Cardoso, SW
   Moreira, RI
   Grinsztejn, B
   Friedman, RK
AF Vasconcelos de Andrade, Angela Cristina
   Luz, Paula Mendes
   Veloso, Valdilea Goncalves
   Cardoso, Sandra Wagner
   Moreira, Ronaldo Ismerio
   Grinsztejn, Beatriz
   Friedman, Ruth Khalili
TI Breast cancer in a cohort of human immunodeficiency virus (HIV)-infected
   women from Rio de Janeiro, Brazil: a cases series report and an
   incidence rate estimate
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; breast neoplasms; case reports; incidence
ID ACTIVE ANTIRETROVIRAL THERAPY; AIDS; HIV; RISK; ERA; INFECTION; TRENDS
AB Highly active antiretroviral therapy (HAART) has changed the morbidity pattern affecting HIV-infected individuals to include non-AIDS-defining cancers. We describe the breast cancer cases occurring in a cohort of 860 HIV-infected women followed in Rio de Janeiro, Brazil, and estimate the incidence rate of breast cancer for this population. Nine cases were identified; median age at diagnosis was 46 years. Median survival after breast cancer diagnosis was 12 months. Breast cancer diagnosis was made within 2 to 15 years of HIV-infection diagnosis. At breast cancer diagnosis, CD4 counts ranged from 135 to 782 cells/mm(3); six women were receiving HAART. Histological analysis indicated infiltrating ductal carcinoma in all cases. The incidence rate of breast cancer was 133 cases per 100,000 persons-year. Patients from our case series were late diagnosed with breast cancer and thus suffered from worse prognosis. Strategies targeting earlier diagnosis and prompt initiation of treatment are needed.
C1 [Vasconcelos de Andrade, Angela Cristina; Luz, Paula Mendes; Veloso, Valdilea Goncalves; Cardoso, Sandra Wagner; Moreira, Ronaldo Ismerio; Grinsztejn, Beatriz; Friedman, Ruth Khalili] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, RJ, Brazil.
RP Grinsztejn, B (corresponding author), Ave Brasil,4365 Manguinhos, BR-21040360 Rio De Janeiro, Brazil.
EM beatriz.grinsztejn@gmail.com
RI Veloso, Valdilea Goncalves/J-6189-2012; Cardoso, Sandra W/D-7965-2015
OI Cardoso, Sandra W/0000-0001-5230-0003; Luz, Paula/0000-0001-9746-719X
CR Amir H, 2000, J NATL MED ASSOC, V92, P301
   Anyanwu SNC, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-17
   Ashraff Zohreen, 2007, J HIV Ther, V12, P71
   Brito Claudia, 2009, Rev. Saúde Pública, V43, P481, DOI [10.1590/S0034-89102009000300012, 10.1590/s0034-89102009000300012]
   Chiao EY, 2003, CURR OPIN ONCOL, V15, P389, DOI 10.1097/00001622-200309000-00008
   Crum-Cianflone N, 2009, AIDS, V23, P41, DOI 10.1097/QAD.0b013e328317cc2d
   El-Rayes BF, 2002, BREAST CANCER RES TR, V76, P111, DOI 10.1023/A:1020587504186
   FRISCH M, JAMA, V285, P1736
   Gebrim LH, 2009, REV BRAS GINECOL OBS, V31, P216, DOI 10.1590/S0100-72032009000500002
   Goedert JJ, 2006, BRIT J CANCER, V95, P642, DOI 10.1038/sj.bjc.6603282
   Grinsztejn B, 2009, INT J INFECT DIS, V13, P72, DOI 10.1016/j.ijid.2008.03.031
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096
   Hessol NA, 2004, JAIDS-J ACQ IMM DEF, V36, P978, DOI 10.1097/00126334-200408010-00013
   Hurley I, 2001, CLIN BREAST CANCER, V2, P221
   Hurley J, 2001, Clin Breast Cancer, V2, P215, DOI 10.3816/CBC.2001.n.024
   Inca.gov.br, 2007, EST 2008 INC CANC BR
   Lester Joanne, 2007, Clin J Oncol Nurs, V11, P619
   LUZ PM, INT J STD A IN PRESS
   Marin B, 2009, AIDS, V23, P1743, DOI 10.1097/QAD.0b013e32832e9b78
   Mbulaiteye SM, 2003, JAIDS-J ACQ IMM DEF, V32, P527, DOI 10.1097/00126334-200304150-00010
   Mitsuyasu Ronald T, 2008, Top HIV Med, V16, P117
   Morgan J. W., 1998, BREAST J, V4(, P177, DOI DOI 10.1046/J.1524-4741.1998.430177.X
   Oluwole SF, 2005, J SURG ONCOL, V89, P23, DOI 10.1002/jso.20171
   Pantanowitz L, 2004, J CLIN ONCOL, V22, P1347, DOI 10.1200/JCO.2004.99.261
   Pantanowitz Liron, 2002, Breast J, V8, P234, DOI 10.1046/j.1524-4741.2002.08409.x
   Preston-Martin S, 2002, PREV MED, V34, P386, DOI 10.1006/pmed.2001.1003
   Richards MA, 1999, LANCET, V353, P1119, DOI 10.1016/S0140-6736(99)02143-1
   Rezende MCR, 2009, REV BRAS GINECOL OBS, V31, P75
   Sackoff JE, 2006, ANN INTERN MED, V145, P397, DOI 10.7326/0003-4819-145-6-200609190-00003
   Shiels MS, 2009, JAIDS-J ACQ IMM DEF, V52, P611, DOI 10.1097/QAI.0b013e3181b327ca
   Silverberg MJ, 2007, CURR OPIN ONCOL, V19, P446
   THULER LC, 2005, REV BRAS GINECOL OBS, V27, P650
   Voutsadakis IA, 2002, CANCER INVEST, V20, P452, DOI 10.1081/CNV-120002144
NR 34
TC 13
Z9 13
U1 0
U2 3
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUL-AUG
PY 2011
VL 15
IS 4
BP 387
EP 393
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 807AP
UT WOS:000293862800016
PM 21861013
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Nunes, EP
   de Oliveira, MS
   Grinsztejn, B
AF Nunes, Estevao Portela
   de Oliveira, Marilia Santini
   Grinsztejn, Beatriz
TI Lopinavir: the old champion
SO FUTURE VIROLOGY
LA English
DT Article
DE antiretroviral therapy; lopinavir; protease inhibitors
ID HIV-INFECTED PATIENTS; COMBINATION ANTIRETROVIRAL THERAPY; TWICE-DAILY
   LOPINAVIR/RITONAVIR; ONCE-DAILY ATAZANAVIR/RITONAVIR; NAIVE
   HIV-1-INFECTED PATIENTS; TO-CHILD TRANSMISSION; PROTEASE INHIBITOR;
   DARUNAVIR-RITONAVIR; NEVIRAPINE EXPOSURE; INITIAL TREATMENT
AB Lopinavir/ritonavir approval for use in antiretroviral treatment 10 years ago was very important for the recognition of boosted protease inhibitor (PI)-based therapy as an attractive option for first-line therapy. Being coformulated with ritonavir and having less toxicity than former PIs it allowed for effective and durable virologic suppression with less impact on quality of life. It soon became the standard of care for salvage therapy in its class. Since then, however, its central role has been challenged by new PIs with a more favorable impact on lipid profile, better gastrointestinal tolerability or that are more active in the setting of multidrug resistance. This article summarizes the main clinical studies with lopinavir and discusses its particular characteristics as well as its possible current role in antiretroviral therapy.
C1 [Nunes, Estevao Portela; de Oliveira, Marilia Santini; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, Brazil.
RP Nunes, EP (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Av Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM estevao.nunes@ipec.fiocruz.br
CR Aberg JA, 2009, JAIDS-J ACQ IMM DEF, V50, P54, DOI 10.1097/QAI.0b013e31818ceaa4
   Arribas JR, 2009, JAIDS-J ACQ IMM DEF, V51, P147, DOI 10.1097/QAI.0b013e3181a56de5
   Bierman WFW, 2009, AIDS, V23, P279, DOI 10.1097/QAD.0b013e32831c54e5
   Burger DM, 2001, J ACQ IMMUN DEF SYND, V26, P218, DOI 10.1097/00126334-200103010-00003
   Cadman J, 1998, GMHC Treat Issues, V12, P12
   Calmy A, 2009, AIDS, V23, P929, DOI 10.1097/QAD.0b013e32832995fa
   Casado JL, 1998, AIDS, V12, P335
   Chadwick EG, 2008, AIDS, V22, P249, DOI 10.1097/QAD.0b013e3282f2be1d
   Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8
   COOPER D, 2006, 8 INT C DRUG THER HI
   Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009
   Cressey TR, 2010, AIDS, V24, P2193, DOI 10.1097/QAD.0b013e32833ce57d
   Delfraissy JFO, 2008, AIDS, V22, P385, DOI 10.1097/QAD.0b013e3282f3f16d
   DEMEYER S, 2008, 15 C RETR OPP INF BO
   ELSTON R, 2004, 15 INT AIDS C BANGK
   Eron J, 2006, LANCET, V368, P1238, DOI 10.1016/S0140-6736(06)69155-1
   Fatkenheuer G, 1999, AIDS, V13, P1485, DOI 10.1097/00002030-199908200-00007
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   Gatell J, 2007, CLIN INFECT DIS, V44, P1484, DOI 10.1086/517497
   Gathe J, 2009, JAIDS-J ACQ IMM DEF, V50, P474, DOI 10.1097/QAI.0b013e31819c2937
   Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7
   Hitti J, 2004, JAIDS-J ACQ IMM DEF, V36, P772, DOI 10.1097/00126334-200407010-00002
   Johnson M, 2005, AIDS, V19, P153, DOI 10.1097/00002030-200501280-00007
   Katner HP, 2002, JAIDS, V31, P483, DOI 10.1097/00126334-200212150-00005
   Kempf DJ, 2004, J INFECT DIS, V189, P51, DOI 10.1086/380509
   KING M, 2001, 1 INT AIDS SOC C HIV
   Klein CE, 2007, JAIDS-J ACQ IMM DEF, V44, P401, DOI 10.1097/QAI.0b013e31803133c5
   Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72
   Lockman S, 2010, NEW ENGL J MED, V363, P1499, DOI 10.1056/NEJMoa0906626
   Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002
   Lundgren J., 2009, 16 C RETR OPP INF MO
   Lyons F, 2006, HIV MED, V7, P255, DOI 10.1111/j.1468-1293.2006.00369.x
   Lyons F, 2007, AIDS, V21, P1053, DOI 10.1097/QAD.0b013e3281053a1e
   Madruga JV, 2007, LANCET, V370, P49, DOI 10.1016/S0140-6736(07)61049-6
   MALLOLAS J, 2007, 4 IAS C HIV PATH TRE
   Marin B, 2009, AIDS, V23, P1743, DOI 10.1097/QAD.0b013e32832e9b78
   Mills AM, 2009, AIDS, V23, P1679, DOI 10.1097/QAD.0b013e32832d7350
   Molina JM, 2008, LANCET, V372, P646, DOI 10.1016/S0140-6736(08)61081-8
   Molina JM, 2010, JAIDS-J ACQ IMM DEF, V53, P323, DOI 10.1097/QAI.0b013e3181c990bf
   Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898
   Murphy RL, 2001, AIDS, V15, pF1, DOI 10.1097/00002030-200101050-00002
   Ndembi N, 2010, J INFECT DIS, V201, P106, DOI 10.1086/648590
   Nunes EP, 2009, HIV CLIN TRIALS, V10, P368, DOI 10.1310/hct1006-368
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Palumbo P, 2010, NEW ENGL J MED, V363, P1510, DOI 10.1056/NEJMoa1000931
   PEYTAVIN G, 2007, 14 C RETR OPP INF LO
   PULIDO F, 2007, 47 ICAAC CHIC IL US
   Qazi Nadeem A, 2002, Expert Opin Pharmacother, V3, P315, DOI 10.1517/14656566.3.3.315
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   Saez-Llorens X, 2003, PEDIATR INFECT DIS J, V22, P216, DOI 10.1097/00006454-200303000-00003
   Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501
   Stek AM, 2006, AIDS, V20, P1931, DOI 10.1097/01.aids.0000247114.43714.90
   Tebas P, 1999, AIDS, V13, pF23, DOI 10.1097/00002030-199902040-00002
   van Heeswijk RPG, 2000, AIDS, V14, pF103, DOI 10.1097/00002030-200006160-00003
   van Sighem A, 2010, AIDS, V24, P1527, DOI 10.1097/QAD.0b013e32833a3946
   Voigt E, 2002, HIV Med, V3, P277, DOI 10.1046/j.1468-1293.2002.00123.x
   Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354
   Walmsley S, 2009, JAIDS-J ACQ IMM DEF, V50, P367, DOI 10.1097/QAI.0b013e318198a815
   YOULE M, 2003, 2 INT AIDS SOC C HIV
   Zajdenverg R, 2010, JAIDS-J ACQ IMM DEF, V54, P143, DOI 10.1097/QAI.0b013e3181cbd21e
NR 60
TC 0
Z9 0
U1 0
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PD MAY
PY 2011
VL 6
IS 5
BP 561
EP 570
DI 10.2217/fvl.11.34
PG 10
WC Virology
SC Virology
GA 775DX
UT WOS:000291439800008
DA 2020-11-24
ER

PT J
AU Nunes, EP
   Grinsztejn, B
   Schechter, M
AF Nunes, Estevao Portela
   Grinsztejn, Beatriz
   Schechter, Mauro
TI The DART Trial: 'The Doctor's Dilemma' revisited
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
DE HIV; HAART; resource-limited countries; cost-effectiveness
ID HIV-INFECTED ADULTS; ANTIRETROVIRAL THERAPY; AFRICA; PREVALENCE
AB Treatment of HIV infection in developing countries, particularly those in Africa, is still a major challenge to healthcare systems with limited laboratory resources. While drug costs have fallen to levels where antiretroviral therapy is now possible in these countries, and results suggest that adherence is as good as in developed countries, questions remain regarding the effect of scarce laboratory resources on treatment monitoring and, hence, outcome. The DART trial aimed to measure the effect of laboratory monitoring. This randomized controlled trial evaluated the differences between routine laboratory monitoring and monitoring driven by clinical events, and was conducted between January 2003 and December 2008 at sites in Uganda and Zimbabwe. The results indicate that clinically driven monitoring is likely to be more cost-effective in this resource-limited situation.
C1 [Schechter, Mauro] Univ Fed Rio de Janeiro, Projeto Praca Onze, Hosp Escola Sao Francisco de Assis, Rio De Janeiro, Brazil.
   [Nunes, Estevao Portela; Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Lab Pesquisa Clin DST AIDS, Fiocruz, Brazil.
RP Schechter, M (corresponding author), Univ Fed Rio de Janeiro, Projeto Praca Onze, Hosp Escola Sao Francisco de Assis, Rio De Janeiro, Brazil.
EM mauro.schechter@gmail.com
RI Schechter, Mauro/AAG-7445-2020; Franzeck, Fabian C/B-5055-2011
CR CDC, 2010, GUID PREV TREATM OPP
   Fabiani M, 2003, JAIDS-J ACQ IMM DEF, V34, P62, DOI 10.1097/00126334-200309010-00009
   GILKS CJ, 2009, 5 INT AIDS SOC C HIV
   Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772
   Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9
   Hofer CB, 2004, JAIDS-J ACQ IMM DEF, V36, P967, DOI 10.1097/00126334-200408010-00011
   Hosseinipour Mina C, 2010, Curr HIV/AIDS Rep, V7, P168, DOI 10.1007/s11904-010-0046-4
   Lewis DK, 2003, T ROY SOC TROP MED H, V97, P91, DOI 10.1016/S0035-9203(03)90035-6
   Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5
   Munderi P, 2006, 16 INT AIDS C TOR
   Ndembi N, 2010, J INFECT DIS, V201, P106, DOI 10.1086/648590
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Reid A, 2009, 5 INT AIDS SOC C HIV
   Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155
   UNAIDS JUNPOH, 2009, AIDS EP UPD
   Walker AS, 2010, LANCET, V375, P1278, DOI 10.1016/S0140-6736(10)60057-8
NR 16
TC 3
Z9 4
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD MAY
PY 2011
VL 66
IS 5
BP 964
EP 967
DI 10.1093/jac/dkr020
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 750YK
UT WOS:000289584000002
PM 21393146
OA Bronze
DA 2020-11-24
ER

PT J
AU Cahn, P
   Fourie, J
   Grinsztejn, B
   Hodder, S
   Molina, JM
   Ruxrungtham, K
   Workman, C
   Van De Casteele, T
   De Doncker, P
   Lathouwers, E
   Tomaka, F
AF Cahn, Pedro
   Fourie, Jan
   Grinsztejn, Beatriz
   Hodder, Sally
   Molina, Jean-Michel
   Ruxrungtham, Kiat
   Workman, Cassy
   Van De Casteele, Tom
   De Doncker, Piet
   Lathouwers, Erkki
   Tomaka, Frank
TI Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in
   treatment-experienced HIV-1-infected patients
SO AIDS
LA English
DT Article
DE darunavir; efficacy; HIV; once-daily; safety; treatment-experienced;
   twice-daily
ID HIV-INFECTED PATIENTS; TREATMENT-NAIVE; EFFICACY; SAFETY;
   LOPINAVIR/RITONAVIR; DARUNAVIR; RITONAVIR; TMC114/RITONAVIR; REGIMENS
AB Objective: ODIN (Once-daily Darunavir In treatment-experieNced patients) was a phase III, 48-week, open-label study comparing once-daily vs. twice-daily darunavir/ritonavir (DRV/r) in treatment-experienced patients with no DRV resistance-associated mutations (RAMs) at screening.
   Methods: Patients with no DRV RAMs and receiving stable HAART for at least 12 weeks were stratified by HIV-1 RNA (<= or > 50 000 copies/ml) and randomized to once-daily DRV/r 800/100 mg or twice-daily DRV/r 600/100 mg and an optimized background regimen (>= 2 nucleoside reverse transcriptase inhibitors). Primary objective was to demonstrate noninferiority of once-daily vs. twice-daily DRV/r in confirmed virologic response (HIV-1 RNA < 50 copies/ml) at week 48.
   Results: Five hundred and ninety patients received once-daily (n = 294) or twice-daily (n = 296) DRV/r. Mean baseline HIV-1 RNA was 4.16 log(10) copies/ml; median CD4 cell count was 228 cells/mu l; and 53.9% had previously used at least one protease inhibitor. At week 48, 72.1% of once-daily and 70.9% of twice-daily patients achieved HIV-1 RNA less than 50 copies/ml (intent-to-treat/time-to-loss of virologic response). The difference in response between once-daily and twice-daily arms was 1.2% (95% confidence interval -6.1 to 8.5%; P < 0.001), establishing noninferiority of once-daily DRV/r versus twice-daily DRV/r. Median CD4 cell count increase was 100 (once-daily) and 94 cells/mu l (twice-daily). Virologic failure rate was low and similar for both arms; only one patient (once-daily arm) developed primary protease inhibitor mutations. Once-daily DRV/r had a lower incidence of grade 2-4 triglyceride increases (5.2 vs. 11.0%, P < 0.05).
   Conclusion: Once-daily DRV/r 800/100 mg was noninferior in virologic response to twice-daily DRV/r 600/100 mg at 48 weeks in treatment-experienced patients with no DRV RAMs, and with a more favorable lipid profile. These findings support use of once-daily DRV/r in this population. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Hodder, Sally] Univ Med & Dent New Jersey, Newark, NJ 07103 USA.
   [Molina, Jean-Michel] Hop St Louis, Paris, France.
   [Ruxrungtham, Kiat] Chulalongkorn Univ, Fac Med, Bangkok 10330, Thailand.
   [Ruxrungtham, Kiat] Chulalongkorn Univ, Thai Red Cross AIDS Res Ctr, HIVNAT, Bangkok, Thailand.
   [Workman, Cassy] AIDS Res Initiat, Darlinghurst, NSW, Australia.
   [Van De Casteele, Tom; De Doncker, Piet; Lathouwers, Erkki] Tibotec BVBA, Beerse, Belgium.
   [Tomaka, Frank] Tibotec Inc, Titusville, NJ USA.
RP Cahn, P (corresponding author), Fdn Huesped, Angel Peluffo 3932, Buenos Aires, DF, Argentina.
EM pcahn@huesped.org.ar
RI Rugina, Sorin/U-5168-2019
FU Tibotec BVBA; Tibotec; Merck Sharp DohmeMerck & Company; Janssen
   CilagJohnson & Johnson USAJanssen Biotech Inc; ViiV Healthcare;
   Bristol-Myers SquibbBristol-Myers Squibb; Tibotec Therapeutics;
   GileadGilead Sciences; AbbottAbbott Laboratories; Boehringer
   IngelheimBoehringer Ingelheim; Avexa; GlaxoSmithKlineGlaxoSmithKline;
   Gilead SciencesGilead Sciences; RocheRoche Holding; PfizerPfizer;
   Panacos
FX The authors would also like to thank Guy De La Rosa, Eric Lefebvre,
   Benny Baeten, Sarah Elkogali, Christiane Moecklinghoff, and Gaston
   Picchio from Tibotec for their important contributions to the
   manuscript. In addition, the authors would like to acknowledge Catherine
   Elliott (Medical Writer, Gardiner-Caldwell Communications) for
   assistance in drafting the manuscript and collating author
   contributions. Financial assistance to support this service was provided
   by Tibotec BVBA. The ODIN study was funded by Tibotec BVBA.; B.G. has
   received grants or research support from Tibotec and Merck Sharp & Dohme
   and received speaker fees from Janssen Cilag, Merck Sharp & Dohme, and
   ViiV Healthcare.; S.H. has received grants or research support from
   Bristol-Myers Squibb and Tibotec Therapeutics. She has served as a
   consultant for Bristol-Myers Squibb, Boehringer Ingelheim, Gilead
   Sciences, and Tibotec Therapeutics.; J-M.M. has received consulting fees
   and speaker fees from Tibotec, Gilead, Abbott, Bristol-Myers Squibb,
   ViiV healthcare, Merck Sharp & Dohme, and Boehringer Ingelheim.; K.R.
   has received grants or research support from Avexa, Bristol-Myers
   Squibb, Boehringer Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme,
   Gilead Sciences, Roche, and Tibotec. He has served as a consultant for
   Merck Sharp & Dohme, and Tibotec. He has also been a speaker for
   Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Janssen-Cilag,
   GlaxoSmithKline, and Tibotec.; C. W. has received grants or research
   support from Bristol-Myers Squibb, Boehringer Ingelheim,
   GlaxoSmithKline, Merck Sharp & Dohme, Gilead Sciences, Roche, Pfizer,
   Abbott, Panacos and Tibotec. She has served as a consultant for Merck
   Sharp & Dohme, Abbott, Gilead and Tibotec. She has been a speaker for
   Merck Sharp & Dohme, Roche, Janssen-Cilag, Abbott, GlaxoSmithKline, and
   Tibotec.
CR AIDS Clinical Trials Group, 2004, DIV AIDS TABL GRAD S
   Arasteh K, 2009, ANTIVIR THER, V14, P859, DOI 10.3851/IMP1301
   BOFFITO M, 2008, 9 INT WORKSH CLIN PH
   CAHN P, 2010, 18 INT AIDS C 18 23
   De Meyer S, 2008, 16 INT HIV DRUG RES
   De Meyer S, 2009, AIDS, V23, P1829, DOI 10.1097/QAD.0b013e32832cbcec
   De Meyer SMJ, 2008, JAIDS-J ACQ IMM DEF, V49, P179, DOI 10.1097/QAI.0b013e318183a959
   *EACS, 2009, GUID CLIN MAN TREATM
   Fontas E, 2004, J INFECT DIS, V189, P1056, DOI 10.1086/381783
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Haubrich R, 2007, AIDS, V21, pF11, DOI 10.1097/QAD.0b013e3280b07b47
   Hill A, 2009, HIV CLIN TRIALS, V10, P1, DOI [10.1310/hct1001-001, 10.1310/hct1001-1]
   Johnson Victoria A, 2009, Top HIV Med, V17, P138
   Johnson Victoria A, 2008, Top HIV Med, V16, P138
   Katlama C, 2007, AIDS, V21, P395, DOI 10.1097/QAD.0b013e328013d9d7
   Lathouwers E., 2008, 6 EUR HIV DRUG RES W
   Madruga JV, 2007, LANCET, V370, P49, DOI 10.1016/S0140-6736(07)61049-6
   Mills AM, 2009, AIDS, V23, P1679, DOI 10.1097/QAD.0b013e32832d7350
   Molina JM, 2008, DRUGS, V68, P567, DOI 10.2165/00003495-200868050-00001
   Moore D A, 2000, HIV Med, V1, P149, DOI 10.1046/j.1468-1293.2000.00019.x
   Ortiz R, 2008, AIDS, V22, P1389, DOI 10.1097/QAD.0b013e32830285fb
   *PAN ANT GUID AD A, 2009, GUID US ANT AG HIV 1, P1, DOI DOI 10.1111/J.1468-1293.2008.00636.X
   Parienti JJ, 2009, CLIN INFECT DIS, V48, P484, DOI 10.1086/596482
   RINEHART AR, 2007, 5 EUR HIV DRUG RES W
   Sekar V, 2008, 15 C RETR OPP INF 3
   Sekar V., 2007, 11 EUR AIDS C 24 27
   SPINOSAGUZMAN S, 2008, TMC114C214 TIB PHARM
   Tomaka F, 2009, HIV MED, V10, P318, DOI 10.1111/j.1468-1293.2008.00690.x
   Zajdenverg R, 2010, JAIDS-J ACQ IMM DEF, V54, P143, DOI 10.1097/QAI.0b013e3181cbd21e
NR 29
TC 91
Z9 91
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD APR 24
PY 2011
VL 25
IS 7
BP 929
EP 939
DI 10.1097/QAD.0b013e328345ee95
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 749IQ
UT WOS:000289458900006
PM 21346512
DA 2020-11-24
ER

PT J
AU Vitorino, RL
   Grinsztejn, BG
   de Andrade, CAF
   Hokerberg, YHM
   de Souza, CTV
   Friedman, RK
   Passos, SRL
AF Vitorino, Raquel Loja
   Grinsztejn, Beatriz Gilda
   Ferreira de Andrade, Carlos Augusto
   Marques Hoekerberg, Yara Hahr
   Vieira de Souza, Claudia Teresa
   Friedman, Ruth Khalili
   Lambert Passos, Sonia Regina
TI Systematic review of the effectiveness and safety of assisted
   reproduction techniques in couples serodiscordant for human
   immunodeficiency virus where the man is positive
SO FERTILITY AND STERILITY
LA English
DT Article
DE Artificial insemination; assisted reproduction; HIV infection;
   infertility; intracytoplasmic sperm injection (ICSI); in vitro
   fertilization; reproductive techniques; systematic review
ID INTRACYTOPLASMIC SPERM INJECTION; IN-VITRO FERTILIZATION; INFECTED MALE
   PARTNER; INTRAUTERINE INSEMINATION; HEPATITIS-C; HIV; ICSI; CYCLES;
   WOMEN; METAANALYSIS
AB Objective: To evaluate the effectiveness and safety of assisted reproduction techniques (ART) in human immunodeficiency virus (HIV) serodiscordant couples.
   Design: Systematic review of five databases of noncomparative open intervention and observational studies of serodiscordant couples undergoing ART, with study selection and data extraction performed independently and in duplicate.
   Setting: Tertiary fertility centers.
   Patient(s): HIV serodiscordant couples where the man is HIV positive.
   Intervention(s): Intrauterine insemination (IUI), in vitro fertilization (IVF), or intracytoplasmic injection (ICSI) performed after washed semen viral testing.
   Main Outcome Measure(s): Pregnancy rates per cycle, cumulative pregnancy, abortion rate, and HIV seroconversion in newborns or women.
   Result(s): Of the 658 abstracts retrieved, 41 were selected for review, and 17 full articles were included (3,900 IUI cycles in 1,184 couples in 11 aggregated studies and 738 ICSI/IVF cycles in 579 couples across 10 studies). The IUI and ICSI results were, respectively: pregnancy rates per cycle, 18% and 38.1%; cumulative pregnancy, 50% and 52.9%; and abortion rate, 15.6% and 20.6%. No seroconversions in women or newborns were detectable at birth or after 3 to 6 months.
   Conclusion(s): Cumulative evidence suggests that ART is safe and effective for avoiding horizontal and vertical transmission in HIV serodiscordant couples. (Fertil Steril (R) 2011;95:1684-90. (C)2011 by American Society for Reproductive Medicine.)
C1 [Vitorino, Raquel Loja; Ferreira de Andrade, Carlos Augusto; Marques Hoekerberg, Yara Hahr; Vieira de Souza, Claudia Teresa; Lambert Passos, Sonia Regina] Fundacao Oswaldo Cruz, Lab Clin Epidemiol, BR-21045900 Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz Gilda; Friedman, Ruth Khalili] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst IPEC, STD AIDS Clin Res Lab, BR-21045900 Rio De Janeiro, Brazil.
RP Passos, SRL (corresponding author), Fundacao Oswaldo Cruz, Lab Clin Epidemiol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM sonialambert@ipec.fiocruz.br
RI Passos, Sonia/C-5292-2013
OI Passos, Sonia/0000-0001-9947-2291
FU Oswaldo Cruz Foundation (Fiocruz)
FX Scholarship funding from the Oswaldo Cruz Foundation (Fiocruz) (to
   R.L.V.).
CR Andersen AN, 2009, HUM REPROD, V24, P1267, DOI 10.1093/humrep/dep035
   Barreiro P, 2007, HUM REPROD, V22, P2353, DOI 10.1093/humrep/dem226
   Bujan L, 2004, FERTIL STERIL, V82, P857, DOI 10.1016/j.fertnstert.2004.02.128
   Louis B, 2007, EUR J OBSTET GYN R B, V135, P76, DOI 10.1016/j.ejogrb.2007.04.011
   Chu MC, 2005, REPROD BIOMED ONLINE, V10, P130, DOI 10.1016/S1472-6483(10)60814-0
   Chu Micheline C., 2006, Archives of Gynecology and Obstetrics, V274, P155, DOI 10.1007/s00404-006-0164-9
   Dovey S, 2008, FERTIL STERIL, V90, P2281, DOI 10.1016/j.fertnstert.2007.10.057
   Egger M, 1998, BRIT MED J, V316, P140
   Egger M., 2008, SYSTEMATIC REV HLTH, P211, DOI [10.1002/9780470693926.ch12, DOI 10.1002/9780470693926.CH12]
   *ETH COMM AM SOC R, 2004, FERTIL STERIL S1, V82
   Farhi J, 2007, FERTIL STERIL, V88, P396, DOI 10.1016/j.fertnstert.2006.11.187
   Garrido N, 2004, HUM REPROD, V19, P2581, DOI 10.1093/humrep/deh460
   Kovacic B, 2010, FERTIL STERIL, V94, P511, DOI 10.1016/j.fertnstert.2009.03.077
   Kowalska A., 2005, HIV AIDS REV, V4, P7
   LEE S, 2001, J BRASIL REPROD ASSI, V5, P64
   Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Manigart Y, 2006, HUM REPROD, V21, P2935, DOI 10.1093/humrep/del277
   Marina S, 1998, FERTIL STERIL, V70, P35, DOI 10.1016/S0015-0282(98)00102-2
   Marina S, 2002, GINECOL OBSTET CLIN, V3, P146
   Melo MAB, 2008, FERTIL STERIL, V89, P141, DOI 10.1016/j.fertnstert.2007.02.004
   Mencaglia L, 2005, HUM REPROD, V20, P2242, DOI 10.1093/humrep/dei031
   Nicopoullos JDM, 2004, FERTIL STERIL, V81, P670, DOI 10.1016/j.fertnstert.2003.08.019
   Pena JE, 2003, FERTIL STERIL, V80, P356, DOI 10.1016/S0015-0282(03)00662-9
   Prisant N, 2010, FERTIL STERIL, V93, P1020, DOI 10.1016/j.fertnstert.2009.07.1663
   Queiroz P, 2008, REV BRAS GINECOL OBS, V30, P171, DOI 10.1590/S0100-72032008000400003
   Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507
   Sauer MV, 2002, AM J OBSTET GYNECOL, V186, P627, DOI 10.1067/mob.2002.122125
   Savasi V, 2007, HUM REPROD, V22, P772, DOI 10.1093/humrep/del422
   SEMPRINI AE, 1992, LANCET, V340, P1317, DOI 10.1016/0140-6736(92)92495-2
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tay Paul Y S, 2007, Med J Malaysia, V62, P286
   Terriou P, 2005, HUM REPROD, V20, P2838, DOI 10.1093/humrep/dei119
   van Leeuwen E, 2005, Ned Tijdschr Geneeskd, V149, P423
   Veiga A, 1999, PRENAT NEONAT MED, V4, P356
   World Health Organization United Nations International Children's Emergency Fund Joint United Nations Programme on HIV/AIDS, 2009, JOINT UN PROGR HIV A
   Zadehmodarres S, 2009, J ASSIST REPROD GEN, V26, P7, DOI 10.1007/s10815-008-9273-7
NR 36
TC 31
Z9 32
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD APR
PY 2011
VL 95
IS 5
BP 1684
EP 1690
DI 10.1016/j.fertnstert.2011.01.127
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 738OA
UT WOS:000288648000031
PM 21324449
DA 2020-11-24
ER

PT J
AU Friedman, RK
   Bastos, FI
   Leite, IC
   Veloso, VG
   Moreira, RI
   Cardoso, SW
   de Andrade, ACV
   Sampaio, MC
   Currier, J
   Grinsztejn, B
AF Friedman, Ruth Khalili
   Bastos, Francisco I.
   Leite, Iuri Costa
   Veloso, Valdilea G.
   Moreira, Ronaldo I.
   Cardoso, Sandra W.
   Vasconcelos de Andrade, Angela C.
   Sampaio, Michelle Cristina
   Currier, Judith
   Grinsztejn, Beatriz
TI Pregnancy rates and predictors in women with HIV/AIDS in Rio de Janeiro,
   Southeastern Brazil
SO REVISTA DE SAUDE PUBLICA
LA English
DT Article
DE HIV Infections; Pregnancy; Risk Factors; Cohort Studies
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-POSITIVE WOMEN; ANTIRETROVIRAL
   THERAPY; INFECTED WOMEN; AIDS PATIENTS; COHORT; FERTILITY; SURVIVAL;
   ABORTION; UGANDA
AB OBJECTIVE: To assess incidence and predictors of first pregnancy among women with HIV/AIDS.
   METHODS: Prospective cohort study was conducted in Rio de Janeiro, southeastern Brazil, between 1996 and 2003. This study comprised 225 women with HIV/AIDS followed up until their first pregnancy or first censored event (hysterectomy, tubal ligation, menopause, 50 years of age, loss to follow-up, death or the end of December 2003). Pregnancy and abortion rates were estimated, and Cox proportional hazards models were used to identify baseline characteristics associated with pregnancy risk.
   RESULTS: The women were followed up for 565 person/years with a median follow-up of 3 years per women. The mean age was 32 years (SD: 7), and 54.7% were white. There were 60 pregnancies in 39 women, and 18 were terminated (induced abortions), accounting for a rate of 6.9% and 2.1% women/year, respectively. Repeated pregnancies occurred in 33.3% of the women (13/39). Higher pregnancy risk was seen among younger women (HR= 3.42; 95% CI: 1.69; 6.95) and those living with their partners (HR= 1.89; 95% CI: 1.00; 3.57). Lower pregnancy risk was associated with higher education level (HR=0.43; 95% CI: 0.19; 0.99) and use of antiretroviral therapy (HR= 061; 95% CI: 0.31; 1.17).
   CONCLUSIONS: Lower pregnancy rates were found in our cohort than in the general population. Sociodemographic characteristics should be taken into consideration in the management of reproductive health in HIV-positive childbearing age women. Reproductive and family planning counseling must be incorporated into HIV/AIDS programs for women to help preventing HIV transmission to their partners and offspring.
C1 [Friedman, Ruth Khalili; Veloso, Valdilea G.; Moreira, Ronaldo I.; Cardoso, Sandra W.; Vasconcelos de Andrade, Angela C.; Sampaio, Michelle Cristina; Grinsztejn, Beatriz] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Lab Pesquisa DST Aids, BR-21040900 Rio De Janeiro, Brazil.
   [Bastos, Francisco I.] Fiocruz MS, Lab Informacao Saude, Inst Comunicacao & Informacao Cient & Tecnol Saud, BR-21040900 Rio De Janeiro, Brazil.
   [Leite, Iuri Costa] Fiocruz MS, Escola Nacl Saude Publ Sergio Arouca, Dept Epidemiol & Metodos Quantitat Saude, BR-21040900 Rio De Janeiro, Brazil.
   [Currier, Judith] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Clin AIDS Res & Educ, Los Angeles, CA 90095 USA.
RP Friedman, RK (corresponding author), Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Lab Pesquisa DST Aids, Av Brasil 4-365, BR-21040900 Rio De Janeiro, Brazil.
EM ruthkf@fiocruz.br
RI Veloso, Valdilea Goncalves/J-6189-2012; Cardoso, Sandra W/D-7965-2015
OI Cardoso, Sandra W/0000-0001-5230-0003; Bastos,
   Francisco/0000-0001-5970-8896
FU Ford Foundation, Brazil office; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [K24AI056933, K24AI056933,
   K24AI056933, K24AI056933, K24AI056933, K24AI056933, K24AI056933,
   K24AI056933, K24AI056933, K24AI056933] Funding Source: NIH RePORTER
FX This study is part of the research "Coorte de mulheres viviendo com
   HIV/AIDS: incidencia de co-infeccoes, saude sexual e reprodutiva",
   partially funded by the Ford Foundation, Brazil office.
CR Allison P.D., 1995, SURVIVAL ANAL USING
   Andia I, 2009, AM J PUBLIC HEALTH, V99, P340, DOI 10.2105/AJPH.2007.129528
   Barbosa RM, 2009, CIENC SAUDE COLETIVA, V14, P1085, DOI 10.1590/S1413-81232009000400015
   Bedimo AL, 1998, SOC SCI MED, V46, P171, DOI 10.1016/S0277-9536(97)00157-3
   Blair JM, 2004, OBSTET GYNECOL, V103, P663, DOI 10.1097/01.AOG.0000117083.33239.b5
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   Chu SY, 1996, OBSTET GYNECOL, V87, P195, DOI 10.1016/0029-7844(95)00399-1
   DeVincenzi I, 1997, AIDS, V11, P333, DOI 10.1097/00002030-199703110-00011
   Gray RH, 1998, LANCET, V351, P98, DOI 10.1016/S0140-6736(97)09381-1
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Kaida A, 2009, AIDS BEHAV, V13, pS72, DOI 10.1007/s10461-009-9553-y
   Levin L, 2001, J ADOLESCENT HEALTH, V29, P101, DOI 10.1016/S1054-139X(01)00281-6
   Maier M, 2009, AIDS BEHAV, V13, pS28, DOI 10.1007/s10461-008-9371-7
   Mannheimer SB, 2005, AIDS CARE, V17, P10, DOI 10.1080/09540120412331305098
   Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012
   Massad LS, 2004, AIDS, V18, P281, DOI 10.1097/00002030-200401230-00018
   Mofenson Lynne M, 2003, Semin Pediatr Infect Dis, V14, P295, DOI 10.1053/j.spid.2003.09.003
   Nebie Y, 2001, J ACQ IMMUN DEF SYND, V28, P367, DOI 10.1097/00126334-200112010-00010
   Olagbuji B, 2010, INT J GYNECOL OBSTET, V108, P101, DOI 10.1016/j.ijgo.2009.09.024
   Olinto Maria Teresa Anselmo, 2006, Cad. Saúde Pública, V22, P365, DOI 10.1590/S0102-311X2006000200014
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   *SAS I, SAS ONL DOC 9 1 3 US
   Thackway SV, 1997, AIDS, V11, P663, DOI 10.1097/00002030-199705000-00014
   van Benthem BHB, 2000, AIDS, V14, P2171, DOI 10.1097/00002030-200009290-00014
   Ventura Stephanie J, 2004, Natl Vital Stat Rep, V52, P1
NR 25
TC 14
Z9 15
U1 0
U2 1
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL
SN 0034-8910
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PD APR
PY 2011
VL 45
IS 2
BP 373
EP 381
DI 10.1590/S0034-89102011000200016
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 735AK
UT WOS:000288385500016
PM 21412574
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU de Andrade, ACV
   Luz, PM
   Velasque, L
   Veloso, VG
   Moreira, RI
   Russomano, F
   Chicarino-Coelho, J
   Pires, E
   Levi, JE
   Grinsztejn, B
   Friedman, RK
AF Vasconcelos de Andrade, Angela Cristina
   Luz, Paula Mendes
   Velasque, Luciane
   Veloso, Valdilea Goncalves
   Moreira, Ronaldo I.
   Russomano, Fabio
   Chicarino-Coelho, Janice
   Pires, Elaine
   Levi, Jose Eduardo
   Grinsztejn, Beatriz
   Friedman, Ruth Khalili
TI Factors Associated with Colposcopy-Histopathology Confirmed Cervical
   Intraepithelial Neoplasia among HIV-Infected Women from Rio De Janeiro,
   Brazil
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY;
   HUMAN-PAPILLOMAVIRUS; CANCER-RISK; AIDS; PREVALENCE; TERMINOLOGY;
   PREDICTORS; MANAGEMENT; PEOPLE
AB Introduction: Despite the availability of preventive strategies (screening tests and vaccines), cervical cancer continues to impose a significant health burden in low- and medium-resourced countries. HIV-infected women are at increased risk for infection with human papillomavirus (HPV) and thus development of cervical squamous intraepithelial neoplasia (CIN).
   Methods: Study participants included HIV-infected women enrolling the prospective open cohort of Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation (IPEC/FIOCRUZ). At cohort entry, women were subjected to conventional Papanicolaou test, HPV-DNA test and colposcopy; lesions suspicious for CIN were biopsied. Histopathology report was based on directed biopsy or on specimens obtained by excision of the transformation zone or cervical conization. Poisson regression modeling was used to assess factors associated with CIN2+ diagnosis.
   Results: The median age of the 366 HIV-infected women included in the study was 34 years (interquartile range: 28-41 years). The prevalence of CIN1, CIN2 and CIN3 were 20.0%, 3.5%, and 2.2%, respectively. One woman was found to have cervical cancer. The prevalence of CIN2+ was 6.0%. Factors associated with CIN2+ diagnosis in the multivariate model were age < years compared to >= 35 years (aPR = 3.22 95% CI 1.23-8.39), current tobacco use (aPR = 3.69 95% CI 1.54-8.78), nadir CD4 T-cell count < 350 cells/mm3 when compared to >= 350 cells/mm3 (aPR = 6.03 95% CI 1.50-24.3) and concomitant diagnosis of vulvar and/or vaginal intraepithelial lesion (aPR = 2.68 95% CI 0.99-7.24).
   Discussion: Increased survival through wide-spread use of highly active antiretroviral therapy might allow for the development of cervical cancer. In Brazil, limited cytology screening and gynecological care adds further complexity to the HIV-HPV co-infection problem. Integrated HIV care and cervical cancer prevention programs are needed for the prevention of cervical cancer mortality in this group of women.
C1 [Vasconcelos de Andrade, Angela Cristina; Luz, Paula Mendes; Velasque, Luciane; Veloso, Valdilea Goncalves; Moreira, Ronaldo I.; Chicarino-Coelho, Janice; Pires, Elaine; Grinsztejn, Beatriz; Friedman, Ruth Khalili] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil.
   [Russomano, Fabio] Fundacao Oswaldo Cruz, Inst Fernandes Figueira, Rio De Janeiro, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
RP de Andrade, ACV (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI Veloso, Valdilea Goncalves/J-6189-2012
OI Luz, Paula/0000-0001-9746-719X
CR Anastos K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013525
   Arrossi S, 2003, SALUD PUBLICA MEXICO, V45, pS306
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Behrens T, 2004, METHOD INFORM MED, V43, P505
   Bollen LJM, 2006, SEX TRANSM DIS, V33, P259
   Brasil. Ministerio da Saude (MS). Secretaria de Vigilancia em Saude. Programa Nacional de DST/Aids, 2006, MAN CONTR DOENC SEX
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Conley LJ, 2002, LANCET, V359, P108, DOI 10.1016/S0140-6736(02)07368-3
   Dexeus S, 2002, EUR J GYNAECOL ONCOL, V23, P269
   Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59
   Franceschi S, 2003, JAIDS-J ACQ IMM DEF, V34, P84, DOI 10.1097/00126334-200309010-00013
   Franceschi S, 2007, CLIN INFECT DIS, V45, P510, DOI 10.1086/520022
   Heard I, 2002, AIDS, V16, P1799, DOI 10.1097/00002030-200209060-00013
   *INCA, 2009, EST 2010 INC CANC BR
   INCA, 2006, NOM BRAS LAUD CERV C
   Jamieson DJ, 2006, OBSTET GYNECOL, V107, P1023, DOI 10.1097/01.AOG.0000210237.80211.ff
   Massad LS, 1999, J ACQ IMMUN DEF SYND, V21, P33, DOI 10.1097/00126334-199905010-00005
   Massad LS, 2004, AM J OBSTET GYNECOL, V190, P1241, DOI 10.1016/j.ajog.2003.12.037
   Orem J, 2004, CURR OPIN ONCOL, V16, P468, DOI 10.1097/00001622-200409000-00010
   Palefsky JM, 2003, CURR OPIN ONCOL, V15, P382, DOI 10.1097/00001622-200309000-00007
   Parham GP, 2006, GYNECOL ONCOL, V103, P1017, DOI 10.1016/j.ygyno.2006.06.015
   Petersen MR, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-9
   PRENDIVILLE W, 1989, BRIT J OBSTET GYNAEC, V96, P1054, DOI 10.1111/j.1471-0528.1989.tb03380.x
   RICHART RM, 1990, OBSTET GYNECOL, V75, P131
   Sahasrabuddhe VV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008634
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293
   Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073
   UNAIDS, 2010, AIDS EP UPD 2009
   Walker P, 2003, OBSTET GYNECOL, V101, P175, DOI 10.1016/S0029-7844(02)02581-4
   Yang BH, 2004, INT J CANCER, V109, P418, DOI 10.1002/ijc.11719
   Zimmermmann JB, 2006, REV BRAS GINECOL OBS, V28, P345, DOI 10.1590/S0100-72032006000600005
NR 33
TC 15
Z9 15
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 30
PY 2011
VL 6
IS 3
AR e18297
DI 10.1371/journal.pone.0018297
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 743YK
UT WOS:000289055700045
PM 21479179
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Pilotto, JH
   Velasque, LS
   Friedman, RK
   Moreira, RI
   Veloso, VG
   Grinsztejn, B
   Morgado, MG
   Watts, DH
   Currier, JS
   Hoffman, RM
AF Pilotto, Jose H.
   Velasque, Luciane S.
   Friedman, Ruth K.
   Moreira, Ronaldo I.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Morgado, Mariza G.
   Watts, D. Heather
   Currier, Judith S.
   Hoffman, Risa M.
TI Maternal outcomes after HAART for the prevention of mother-to-child
   transmission in HIV-infected women in Brazil
SO ANTIVIRAL THERAPY
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; VIRAL LOAD; HIV-1-INFECTED WOMEN;
   RANDOMIZED-TRIAL; CELL COUNTS; PREGNANCY; POSTPARTUM; PROGRESSION;
   MORTALITY; INTERRUPTION
AB Background: Information is lacking on outcomes in HIV-infected Brazilian women with CD4(+) T-cell counts >200 cells/mm(3) who initiate HAART for the prevention of mother-to-child transmission, and discontinue after delivery.
   Methods: Clinical event rates after postpartum HAART discontinuation were calculated for all WHO stage 2-3 events, as well as for HIV progression warranting HAART re-initiation, defined by a WHO stage 4 event and/or CD4(+) T-cell decrease to <= 200 cells/mm(3). Predictors of the WHO stage 2-3 events and HIV progression outcomes were evaluated with Cox's proportional hazards models.
   Results: A total of 120 women were followed for a mean of 1.5 years after delivery. Overall, 26 women had 30 events as follows: 20 developed WHO stage 2-3 events, yielding an incidence rate of 13/100 person-years (PY; 95% CI 8-20); 10 developed HIV progression requiring HAART re-initiation (incidence ratio 6/100 PY, 95% CI 3-11). Among progressors, a single woman developed a WHO stage 4 clinical event and the remainder had CD4(+) T-cell decreases. Women who had baseline CD4(+) T-cell counts between 200-500 cells/mm(3) had a hazard ratio for WHO stage 2-3 events of 2.5 compared to women with baseline >= 500 cells/mm(3) (95% CI 1.0-6.3; P=0.05). The only significant predictor of HIV progression was baseline CD4(+) T-cell count (hazard ratio 0.99, 95% CI 0.98-0.99; P=0.02).
   Conclusions: In this observational study, a baseline CD4(+) T-cell count <500 cells/mm(3) was associated with an increased risk of postpartum WHO stage 2-3 clinical events and HIV disease progression. Randomized studies are needed to further evaluate the effect of postpartum treatment discontinuation on maternal health.
C1 [Currier, Judith S.; Hoffman, Risa M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
   [Currier, Judith S.; Hoffman, Risa M.] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA 90095 USA.
   [Pilotto, Jose H.; Velasque, Luciane S.; Friedman, Ruth K.; Moreira, Ronaldo I.; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, Rio De Janeiro, Brazil.
   [Pilotto, Jose H.] Hosp Geral Nova Iguacu HGNI, HIV Family Care Clin HHFCC, Rio De Janeiro, Brazil.
   [Pilotto, Jose H.; Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, AIDS & Mol Immunol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Velasque, Luciane S.] Univ Fed Estado Rio de Janeiro UNIRIO, Dept Math & Stat, Rio De Janeiro, Brazil.
   [Watts, D. Heather] Eunice Kennedy Shriver Natl Inst Child Hlth & Dev, NICHD, NIH, Bethesda, MD USA.
RP Hoffman, RM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
EM rhoffman@mednet.ucla.edu
RI Pilotto, Jose Henrique/AAD-9773-2019; Veloso, Valdilea
   Goncalves/J-6189-2012
OI Pilotto, Jose Henrique/0000-0003-0521-8597; 
FU Ministry of HealthMinistry of Health - Turkey [CSV 086/06]; Merck and
   CompanyMerck & Company; Tibotec Therapeutics; Schering-PloughMerck &
   CompanySchering Plough Corporation; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [K24AI056933, K24AI056933,
   K24AI056933, K24AI056933, K24AI056933, K24AI056933, K24AI056933,
   K24AI056933, K24AI056933, K24AI056933] Funding Source: NIH RePORTER
FX Support was provided by the HIV/AIDS Brazilian National AIDS Program,
   Ministry of Health (Grant CSV 086/06). We gratefully acknowledge the
   clinical staff of the Hospital Geral de Nova Iguacu, Rio de Janeiro, for
   following-up the cohort of pregnant women, as well as the laboratory
   team of the AIDS and Molecular Immunology Laboratory/Instituto Oswaldo
   Cruz/FIOCRUZ, Rio de Janeiro, for their technical support in processing
   and analysing the blood samples.; JC has received research grant support
   to UCLA for clinical trials from Merck and Company, Tibotec Therapeutics
   and Schering-Plough in the past 48 months. In addition, she is involved
   in clinical trials in which drugs have been donated to NIH from Tibotec,
   Merck, Gilead, Abbott, GlaxoSmithKline and Bristol-Myers Squibb. All
   other authors declare no competing interests.
CR Alliegro MB, 1997, ARCH INTERN MED, V157, P2585, DOI 10.1001/archinte.157.22.2585
   Ananworanich J, 2006, LANCET, V368, P459, DOI 10.1016/S0140-6736(06)69153-8
   *BRAZ MIN HLTH, 2006, REC PROPH HIV VERT T
   Brown ER, 2009, J INFECT DIS, V199, P1292, DOI 10.1086/597617
   Burns DN, 1999, J REPROD IMMUNOL, V42, P147, DOI 10.1016/S0165-0378(98)00085-0
   Burns DN, 1998, AM J OBSTET GYNECOL, V178, P355, DOI 10.1016/S0002-9378(98)80025-2
   Cao YZ, 1997, NAT MED, V3, P549, DOI 10.1038/nm0597-549
   Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009
   Danel C, 2006, LANCET, V367, P1981, DOI 10.1016/S0140-6736(06)68887-9
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   Hargrove JW, 2010, AIDS, V24, pF11, DOI 10.1097/QAD.0b013e328335749d
   HOCKE C, 1995, OBSTET GYNECOL, V86, P886, DOI 10.1016/0029-7844(95)00257-R
   Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252
   Melekhin VV, 2010, AIDS PATIENT CARE ST, V24, P279, DOI 10.1089/apc.2009.0283
   Melvin AJ, 1997, J ACQ IMMUN DEF SYND, V14, P232, DOI 10.1097/00042560-199703010-00006
   Mikyas Y, 1997, J REPROD IMMUNOL, V33, P157, DOI 10.1016/S0165-0378(97)00018-1
   Palacios R, 2009, HIV MED, V10, P157, DOI 10.1111/j.1468-1293.2008.00665.x
   Tai JH, 2007, J INFECT DIS, V196, P1044, DOI 10.1086/520814
   TEMMERMAN M, 1994, OBSTET GYNECOL, V83, P495, DOI 10.1097/00006250-199404000-00002
   *UNAIDS, 2008, UNIAIDS JOINT UN PRO
   Watts DH, 2003, JAIDS-J ACQ IMM DEF, V33, P585, DOI 10.1097/00126334-200308150-00006
   Watts DH, 2009, INFECT DIS OBSTET GY, V2009
   World Health Organization, 2007, WHO CAS DEF HIV SURV
NR 23
TC 6
Z9 6
U1 0
U2 4
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2011
VL 16
IS 3
BP 349
EP 356
DI 10.3851/IMP1779
PG 8
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 813OA
UT WOS:000294375600008
PM 21555817
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Smeaton, L
   Barnett, R
   Klingman, K
   Hakim, J
   Flanigan, T
   Kumarasamy, N
   Campbell, T
   Currier, J
AF Grinsztejn, Beatriz
   Smeaton, Laura
   Barnett, Ronald
   Klingman, Karin
   Hakim, James
   Flanigan, Timothy
   Kumarasamy, N.
   Campbell, Thomas
   Currier, Judith
CA PEARLS Study Team ACTG
TI Sex-associated differences in pre-antiretroviral therapy plasma HIV-1
   RNA in diverse areas of the world vary by CD4(+) T-cell count
SO ANTIVIRAL THERAPY
LA English
DT Article
ID VIRAL LOAD; PROGRESSION; WOMEN; INDIVIDUALS; COHORT; MEN
AB Background: Sex differences in the natural history of HIV infection may vary between resource-rich and resource-limited settings.
   Methods: Baseline characteristics from a randomized clinical trial of treatment-naive subjects conducted at sites in Africa, Asia, the Caribbean, and North and South America were analysed to determine if there were significant differences by sex.
   Results: Of the 1,571 participants, 740 (47.1%) were women. Women had higher mean screening CD4(+) T-cell counts (mean 15 cells higher; P<0.001), lower mean haemoglobin and creatinine clearance, a lower mean baseline HIV-1 viral load (4.85 log(10) versus 5.05 log(10) copies/ml; P<0.001) and were less likely to have a prior AIDS diagnosis than men. The sex difference in viral load was related to CD4(+) T-cell count; however, it was independent of country and persisted within the strata with CD4(+) T-cell count <200 cells/mm(3).
   Conclusions: Women in resource-limited settings have lower levels of plasma HIV-1 RNA and appear to present for enrolment into clinical trials at an earlier stage of disease than men. The biological basis for lower viral load in women compared to men remains unexplained. It will be important to determine if the sex differences observed at baseline impact clinical outcomes once the PEARLS clinical trial is completed.
C1 [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Manguinho, Brazil.
   [Smeaton, Laura] Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA.
   [Barnett, Ronald] NIH, Off Biotechnol Act, Bethesda, MD 20892 USA.
   [Klingman, Karin] NIAID, HIV Res Branch, Div Aids, NIH, Bethesda, MD 20892 USA.
   [Hakim, James] Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe.
   [Flanigan, Timothy] Brown Univ, Sch Med, Miriam Hosp, Providence, RI 02912 USA.
   [Kumarasamy, N.] YRG Ctr AIDS Res & Educ, Chennai, Tamil Nadu, India.
   [Campbell, Thomas] Univ Colorado, Aurora, CO USA.
   [Currier, Judith] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Manguinho, Brazil.
EM gbeatriz@ipec.fiocruz.br
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01A1068636]; National Institute of Mental Health (NIMH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH); National Institute
   of Dental and Craniofacial Research (NIDCR)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Dental & Craniofacial Research (NIDCR); Boehringer
   Ingelheim Pharmaceuticals Inc.Boehringer Ingelheim; BristolMyers Squibb
   Inc.Bristol-Myers Squibb; Gilead Sciences Inc.Gilead Sciences;
   GlaxoSmithKlineGlaxoSmithKline; Merck Co. Inc.Merck & Company; 
   [AI69532];  [AI69424];  [AI69511];  [AI69428];  [AI27661];  [AI69484]; 
   [AI69495];  [AI69474];  [AI69513];  [AI69471];  [AI25915];  [AI46370]; 
   [AI69472];  [AI46381];  [AI69423];  [AI25868];  [AI69439];  [AI46376]; 
   [AI38858-09S1];  [AI34853];  [AI69450];  [AI69467];  [AI32782]; 
   [AI69419];  [AI69463];  [AI69426];  [AI69438];  [AI69399];  [AI69417]; 
   [AI69432];  [AI69518]; FOGARTY INTERNATIONAL CENTERUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Fogarty International Center (FIC) [D43TW000007, D43TW000007,
   D43TW000007, D43TW000007, D43TW000007, D43TW000007, D43TW000007,
   D43TW000007, D43TW000007, D43TW000007, D43TW000007, D43TW000007,
   D43TW000007, D43TW000007, D43TW000007, D43TW000007, D43TW000007,
   D43TW000007, D43TW000007, D43TW000007, D43TW000007, D43TW000007,
   D43TW000007, D43TW000007, D43TW000007, D43TW000007, D43TW000007,
   D43TW000007, D43TW000007, D43TW000007, D43TW000007, D43TW000007,
   D43TW000007, D43TW000007, D43TW000007, D43TW000007, D43TW000007,
   D43TW000007, D43TW000007, D43TW000007, D43TW008069, D43TW000007,
   D43TW000007, D43TW000007, D43TW000007, D43TW000007, D43TW000007,
   D43TW000007, D43TW008069, D43TW000007, D43TW000007, D43TW000007,
   D43TW000007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U01AI027661, U01AI034853,
   U01AI027661, U01AI038858, U01AI025915, K24AI056933, U01AI046381,
   UM1AI069463, UM1AI069472, UM1AI069421, U01AI034853, UM1AI069532,
   U01AI038858, U01AI069463, U01AI069421, UM1AI069518, U01AI025868,
   U01AI025868, UM1AI069423, U01AI046370, U01AI069401, U01AI069470,
   U01AI034853, U01AI025868, U01AI034853, U01AI025868, UM1AI069399,
   U01AI069484, UM1AI069423, U01AI025868, U01AI069495, U01AI068636,
   U01AI025915, U01AI034853, UM1AI069484, U19AI053218, U01AI069401,
   UM1AI069470, UM1AI069476, U01AI038858, U01AI034853, UM1AI069399,
   U01AI069426, U01AI025868, U01AI027661, U01AI034853, U01AI032782,
   U01AI027661, U01AI027661, U01AI069424, U01AI069428, K24AI051982,
   UM1AI069436, U01AI034853, U01AI032782, U01AI025915, U01AI025915,
   U01AI025868, K24AI051982, UM1AI069439, U01AI034853, UM1AI069432,
   U01AI069426, U01AI069471, U01AI038858, UM1AI069436, UM1AI069439,
   U01AI025868, U01AI025868, U01AI069495, U01AI025915, U01AI025915,
   U01AI034853, U01AI034853, U01AI025915, U01AI025868, U01AI025868,
   U01AI069484, U01AI032782, U01AI025868, UM1AI069511, U01AI046381,
   U01AI046376, U01AI069511, U01AI025915, U01AI025915, U01AI038858,
   U01AI025868, UM1AI069518, U01AI025868, U01AI025915, U01AI032782,
   U01AI027661, U01AI025915, U01AI025915, U01AI069439, UM1AI069471,
   UM1AI069495, U01AI038858, UM1AI069421, UM1AI069428, U19AI053218,
   U01AI025868, U19AI053218, U01AI032782, U01AI027661, UM1AI069484,
   UM1AI069439, U01AI025915, U01AI038858, U01AI025868, U01AI032782,
   U01AI034853, U01AI025868, U01AI034853, UM1AI069438, U01AI046376,
   U01AI027661, U01AI069421, UM1AI069424, U01AI069423, U01AI025915,
   U01AI027661, U01AI069463, U01AI025915, UM1AI069419, U01AI032782,
   U01AI025868, U01AI069470, U01AI025915, U01AI025915, K24AI051982,
   U01AI069424, U01AI069474, U01AI034853, U01AI032782, U01AI027661,
   U01AI027661, U01AI025868, U01AI025915, UM1AI069476, U01AI025868,
   UM1AI069419, UM1AI069470, U01AI069439, U01AI025868, U01AI032782,
   K24AI051982, U01AI027661, UM1AI069470, U01AI069423, U01AI025915,
   U01AI034853, UM1AI069424, U01AI025868, U01AI025915, U01AI027661,
   U01AI025915, UM1AI069417, UM1AI069511, U01AI038858, U01AI027661,
   U01AI027661, U01AI025868, U01AI025915, UM1AI069421, K24AI051982,
   U01AI069484, U01AI025915, U01AI032782, U01AI032782, U01AI027661,
   U01AI032782, U01AI032782, U01AI069472, U01AI069419, U01AI025868,
   U01AI032782, U01AI027661, U01AI027661, U01AI025868, U01AI027661,
   U19AI053218, U01AI034853, U01AI069421, U01AI046370, UM1AI069532,
   U01AI034853, U01AI032782, U01AI025868, U01AI025868, U01AI025915,
   U01AI032782, U01AI069428, K24AI056933, U01AI038858, UM1AI069471,
   U01AI069419, U01AI025868, U01AI034853, U01AI069532, U01AI069417,
   U01AI032782, U01AI069484, U01AI069401, U01AI027661, U01AI038858,
   U01AI038858, K24AI056933, U01AI032782, U01AI046370, U01AI025915,
   U01AI069513, U01AI025868, U01AI025915, U01AI038858, U01AI038858,
   U01AI069401, U01AI069399, U01AI034853, U01AI038858, UM1AI069467,
   U01AI032782, U01AI034853, U01AI038858, U01AI038858, U01AI046376,
   U01AI069436, U01AI025915, UM1AI069419, U01AI046376, U01AI025915,
   U01AI025915, U01AI038858, U01AI034853, U01AI032782, U01AI032782,
   U01AI025868, UM1AI069401, UM1AI069467, UM1AI069463, U01AI025868,
   U01AI027661, U01AI069436, U01AI025868, U01AI027661, U01AI038858,
   U01AI069476, U01AI025915, U01AI027661, U01AI027661, U01AI046381,
   U01AI032782, U01AI025915, U01AI069470, U01AI032782, U01AI025915,
   U01AI038858, U01AI025868, UM1AI069423, U01AI025868, U01AI046376,
   UM1AI069432, U01AI032782, U01AI069428, U01AI025915, U01AI025868,
   UM1AI069399, U01AI025868, UM1AI069476, UM1AI069518, U01AI032782,
   UM1AI069476, U01AI034853, UM1AI069518, UM1AI069436, UM1AI069432,
   U01AI034853, UM1AI069439, U01AI069518, U01AI027661, UM1AI069419,
   U01AI025868, U01AI069438, U01AI034853, U01AI069399, UM1AI069421,
   UM1AI069470, U01AI069532, U01AI038858, U01AI034853, U01AI032782,
   U01AI025915, U01AI034853, UM1AI069432, U01AI027661, U01AI069471,
   K24AI056933, UM1AI069432, U01AI025915, UM1AI069423, U01AI034853,
   K24AI051982, U01AI069476, U01AI034853, U01AI069518, U01AI025868,
   U01AI069450, U01AI025868, U01AI068636, UM1AI069436, U01AI027661,
   UM1AI069463, K24AI056933, U01AI038858, U01AI025868, U01AI025915,
   U01AI034853, UM1AI069476, U01AI034853, U01AI069484, UM1AI069471,
   UM1AI069474, U01AI025868, U01AI069438, U01AI038858, U01AI038858,
   U01AI025915, UM1AI069421, K24AI056933, UM1AI069438, U01AI025915,
   U01AI032782, U01AI027661, U01AI046376, UM1AI069471, U01AI032782,
   UM1AI069419, UM1AI069432, U01AI069471, U01AI027661, U01AI069511,
   U01AI069513, U01AI034853, U01AI025915, U01AI025915, U01AI034853,
   U01AI069472, U01AI069439, U01AI038858, U01AI034853, U01AI069399,
   U01AI032782, U01AI069476, U01AI069432, U01AI027661, UM1AI069426,
   UM1AI069484, U01AI027661, UM1AI069472, U01AI032782, U01AI032782,
   U01AI027661, U01AI025868, U01AI025868, U01AI069484, U01AI025868,
   U01AI025868, U01AI069471, U01AI025868, UM1AI069436, U01AI025915,
   U01AI027661, U01AI069484, U01AI069423, U01AI025915, U01AI038858,
   U01AI025868, U01AI069532, UM1AI069471, U01AI025868, U01AI068636,
   U01AI069511, U01AI046376, U01AI069511, U01AI038858, U01AI034853,
   U01AI032782, UM1AI069463, UM1AI069513, UM1AI069467, UM1AI069399,
   UM1AI069471, U01AI025915, U01AI032782, U01AI025868, U01AI069467,
   U01AI038858, U01AI027661, U01AI069450, U01AI032782, U01AI069495,
   K24AI056933, UM1AI069428, U01AI025915, U01AI069450, U01AI025915,
   U01AI034853, UM1AI069438, U01AI025915, U01AI069450, U01AI032782,
   U01AI038858, U01AI038858, U01AI069463, U01AI069463, U01AI034853,
   U01AI046370, UM1AI069417, U01AI025915, U01AI025915, U01AI046370,
   U01AI069438, K24AI056933, U01AI025868, U01AI069438, U01AI025915,
   U01AI069436, UM1AI069424, U01AI034853, U01AI025868, U01AI038858,
   U01AI032782, UM1AI069439, U01AI034853, UM1AI069423, U01AI025868,
   U01AI032782, U01AI025915, UM1AI069417, U01AI034853, U01AI069518,
   K24AI051982, U01AI046370, U01AI025915, U01AI027661, U01AI038858,
   UM1AI069419, U01AI046381, U01AI046381, UM1AI069419, U01AI025868,
   U01AI034853, U01AI032782, U01AI069472, U01AI046381, U01AI032782,
   UM1AI069401, UM1AI069439, U01AI025868, UM1AI069471, U01AI025868,
   UM1AI069438, U01AI027661, U01AI069423, U01AI069432, U01AI032782,
   U01AI069419, K24AI056933, U01AI025915, U01AI069424, U01AI069467,
   U01AI069417, U01AI038858, U01AI034853, U01AI069424, U01AI038858,
   UM1AI069423, U01AI025868, U01AI069467, U01AI025915, U01AI027661,
   U01AI034853, U01AI069417, U01AI027661, U01AI032782, U01AI025915,
   U01AI034853, U01AI025915, U01AI038858, U01AI034853, UM1AI069470,
   U01AI025915, U01AI032782, U01AI069417, U01AI032782, U01AI027661,
   U01AI027661, UM1AI069426, U01AI034853, U01AI038858, U01AI038858,
   U01AI069424, U01AI027661, U01AI038858, U01AI027661, U01AI034853,
   U01AI025915, U01AI069426, U01AI069419, U01AI027661, U01AI025868,
   U01AI027661, U01AI032782, U01AI025915, U01AI025915, UM1AI069470,
   U01AI025868, U01AI069399, UM1AI069511, UM1AI069511, U01AI032782,
   U01AI032782, U01AI068636, U01AI038858, U01AI032782, U01AI025868,
   U01AI034853, U01AI025868, U01AI069470, U01AI025868, U19AI053218,
   U01AI034853, U01AI025868, UM1AI069424, UM1AI069401, UM1AI069421,
   UM1AI069511, UM1AI069436, UM1AI069463, U01AI027661, U01AI069423,
   U01AI025868, UM1AI069476, U01AI032782, U01AI032782, U01AI025868,
   U01AI069532, U01AI025915, U01AI046376, UM1AI069518, U01AI025915,
   U01AI069463, UM1AI069450, U01AI025868, U01AI032782, U01AI027661,
   UM1AI069436, U01AI027661, U01AI025868, UM1AI069438, U01AI069426,
   U01AI027661, K24AI051982, U01AI069470, U01AI025915, U01AI025915,
   U01AI032782, UM1AI069463, U01AI069474, U01AI032782, U01AI069424,
   U01AI034853, UM1AI069463, U01AI032782, U01AI025868, U01AI069438,
   U01AI069439, U01AI025868, U01AI038858, U01AI069399, U01AI069518,
   U01AI025868, K24AI056933, U01AI069513, U01AI025868, U01AI069472,
   UM1AI069423, UM1AI069438, U01AI069426, UM1AI069476, U01AI069450,
   UM1AI069399, K24AI051982, U01AI069474, U01AI038858, U01AI027661,
   U01AI025915, UM1AI069438, U01AI025868, U01AI038858, UM1AI069518,
   U01AI032782, U01AI025868, UM1AI069424, U01AI069421, U01AI069511,
   UM1AI069511, U01AI034853, U19AI053218, U01AI025915, U01AI025915,
   U01AI068636, U01AI069428, U01AI025915, U01AI025915, U19AI053218,
   U01AI038858, U01AI069471, U01AI025915, U01AI034853, U01AI032782,
   U01AI069532, U01AI032782, U01AI025868, U01AI069423, UM1AI069421,
   U01AI038858, U01AI069476, U01AI068636, U01AI069463, U01AI025915,
   U01AI027661, UM1AI069424, U01AI069472, U01AI046381, U01AI069419,
   U01AI034853, U01AI046370, U01AI027661, U01AI025915, U01AI069401,
   U01AI069432, U01AI069439, U01AI025868, U01AI034853, U01AI034853,
   U01AI069513, U01AI069474, U01AI027661, UM1AI069421, K24AI051982,
   U01AI025868, UM1AI069474, U01AI069463, U01AI027661, U01AI069518,
   UM1AI069417, U01AI046370, UM1AI069432, UM1AI069399, U01AI038858,
   U01AI069436, U01AI034853, U01AI069471, U01AI025915, U01AI046376,
   U01AI027661, U01AI038858, U01AI034853, U01AI038858, UM1AI069518,
   UM1AI069450, UM1AI069399, U01AI038858, U01AI025915, UM1AI069424,
   U01AI025868, UM1AI069472, U01AI032782, U01AI069432, U01AI025915,
   UM1AI069511, U01AI034853, U01AI038858, U01AI034853, U01AI025868,
   U01AI025868, U01AI025868, U01AI032782, UM1AI069470, U01AI069424,
   U01AI069470, UM1AI069495, U01AI069436, U01AI069484, U01AI025868,
   U01AI069423, UM1AI069518, U01AI032782, U01AI069495, U01AI027661,
   K24AI051982, U01AI027661, U01AI034853, U01AI034853, U01AI025915,
   U01AI025868, U01AI032782, U19AI053218, U01AI069419, U01AI032782,
   UM1AI069439, U01AI069513, U01AI069467, U01AI027661, U01AI034853,
   U01AI038858, U01AI025915, U01AI025868, U01AI069432, U01AI025868,
   UM1AI069463, UM1AI069438, U01AI069401, U01AI069423, U01AI027661,
   U01AI069511, UM1AI069476, U01AI069436, U01AI032782, UM1AI069424,
   U01AI025868, UM1AI069532, U01AI025915, U01AI032782, U01AI034853,
   U01AI069495, U01AI032782, UM1AI069419, UM1AI069423, UM1AI069439,
   U01AI027661, U01AI025915, U01AI025915, U01AI027661, UM1AI069513,
   U01AI038858, UM1AI069436, U01AI025868, U01AI068636, U01AI069428,
   U01AI025868, U01AI038858, U01AI032782, U01AI032782, U01AI032782,
   U01AI025868, U01AI032782, UM1AI069439, U01AI046370, U01AI069438,
   UM1AI069511, U01AI046381, UM1AI069471, U01AI025915, U01AI069417,
   U01AI025915, U01AI025915, U01AI025868, UM1AI069470, U01AI069421,
   U19AI053218, U01AI034853, U01AI025915, UM1AI069511, U01AI025868,
   UM1AI069432, UM1AI069399, U01AI027661, U01AI069474, UM1AI069426,
   U01AI069467, U01AI025868, U01AI038858] Funding Source: NIH RePORTER
FX The project described was supported by Award Number U01A1068636 from the
   National Institute of Allergy and Infectious Diseases and supported by
   National Institute of Mental Health (NIMH), National Institute of Dental
   and Craniofacial Research (NIDCR). This work was supported by grants
   AI69532, AI69424, AI69511, AI69428, AI27661, AI69484, AI69495, AI69474,
   AI69513, AI69471, AI25915, AI46370, AI69472, AI46381, AI69423, Al25868,
   AI69439, AI46376, AI38858-09S1, AI34853, AI69450, AI69467, AI32782,
   AI69419, AI69463, AI69426, AI69438, AI69399, AI69417, AI69432, AI69518,
   AI69476, AI69401, AI69421, AI69518, AI69436 and AI69470.; The
   collaborating pharmaceutical supporters were Boehringer Ingelheim
   Pharmaceuticals Inc., BristolMyers Squibb Inc., Gilead Sciences Inc.,
   GlaxoSmithKline and Merck & Co. Inc. The authors declare no competing
   interests.
CR Deti EK, 2010, HIV MED, V11, P308, DOI 10.1111/j.1468-1293.2009.00780.x
   Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1
   Gandhi M, 2002, CLIN INFECT DIS, V35, P313, DOI 10.1086/341249
   Lucas GM, 2008, J INFECT DIS, V197, P1548, DOI 10.1086/587994
   MELLORS JW, 1991, J INFECT DIS, V163, P78, DOI 10.1093/infdis/163.1.78
   Moore AL, 2003, JAIDS-J ACQ IMM DEF, V32, P452, DOI 10.1097/00126334-200304010-00017
   Napravnik S, 2002, JAIDS-J ACQ IMM DEF, V31, P11, DOI 10.1097/00126334-200209010-00002
   Overton ET, 2009, HIV MED, V10, P343, DOI 10.1111/j.1468-1293.2009.00693.x
   Pitt J, 2001, 8 C RETR OPP INF 4 8
   Portales P, 2001, ANN INTERN MED, V134, P81, DOI 10.7326/0003-4819-134-1-200101020-00023
   Prins M, 2005, AIDS, V19, P357, DOI 10.1097/01.aids.0000161765.75663.27
   Reichelderfer PS, 2000, AIDS, V14, P2101, DOI 10.1097/00002030-200009290-00005
   Rezza G, 2000, J ACQ IMMUN DEF SYND, V25, P56, DOI 10.1097/00126334-200009010-00008
   RHODES K, 1969, ANN RHEUM DIS, V28, P104, DOI 10.1136/ard.28.2.104
   SHANKER G, 1994, LYMPHOKINE CYTOK RES, V13, P1
   Sterling TR, 2005, J INFECT DIS, V191, P881, DOI 10.1086/427827
   Sterling TR, 2001, NEW ENGL J MED, V344, P720, DOI 10.1056/NEJM200103083441003
   Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967
   Tordato F, 2011, HIV MED, V12, P4, DOI 10.1111/j.1468-1293.2010.00855.x
   Touloumi G, 2004, AIDS, V18, P1697, DOI 10.1097/01.aids.0000131395.14339.f5
   Trichavaroj R, 2001, J ACQ IMMUN DEF SYND, V26, P345, DOI 10.1097/00126334-200104010-00009
   World Health Organization, 2009, AIDS EP UPD DEC 2009
NR 22
TC 22
Z9 22
U1 0
U2 5
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2011
VL 16
IS 7
BP 1057
EP 1062
DI 10.3851/IMP1872
PG 6
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 846ZO
UT WOS:000296941900014
PM 22024521
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Santos-Oliveira, JR
   Giacoia-Gripp, CBW
   de Oliveira, PA
   Amato, VS
   Lindoso, JAL
   Goto, H
   Oliveira-Neto, MP
   Mattos, MS
   Grinsztejn, B
   Morgado, MG
   Da-Cruz, AM
AF Santos-Oliveira, Joanna R.
   Giacoia-Gripp, Carmem B. W.
   de Oliveira, Priscilla Alexandrino
   Amato, Valdir S.
   Lindoso, Jose Angelo L.
   Goto, Hiro
   Oliveira-Neto, Manoel P.
   Mattos, Marise S.
   Grinsztejn, Beatriz
   Morgado, Mariza G.
   Da-Cruz, Alda M.
TI High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected
   individuals despite low HIV viral load
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; AMERICAN CUTANEOUS LEISHMANIASIS; ACTIVE
   ANTIRETROVIRAL THERAPY; VISCERAL LEISHMANIASIS; IMMUNE-RESPONSES;
   CELL-ACTIVATION; CD38 EXPRESSION; AIDS; REPLICATION; PATHOGENESIS
AB Background: Concomitant infections may influence HIV progression by causing chronic activation leading to decline in T-cell function. In the Americas, visceral (AVL) and tegumentary leishmaniasis (ATL) have emerged as important opportunistic infections in HIV-AIDS patients and both of those diseases have been implicated as potentially important co-factors in disease progression. We investigated whether leishmaniasis increases lymphocyte activation in HIV-1 co-infected patients. This might contribute to impaired cellular immune function.
   Methods: To address this issue we analyzed CD4(+) T absolute counts and the proportion of CD8(+) T cells expressing CD38 in Leishmania/HIV co-infected patients that recovered after anti-leishmanial therapy.
   Results: We found that, despite clinical remission of leishmaniasis, AVL co-infected patients presented a more severe immunossupression as suggested by CD4(+) T cell counts under 200 cells/mm(3), differing from ATL/HIV-AIDS cases that tends to show higher lymphocytes levels (over 350 cells/mm(3)). Furthermore, five out of nine, AVL/HIV-AIDS presented low CD4(+) T cell counts in spite of low or undetectable viral load. Expression of CD38 on CD8(+) T lymphocytes was significantly higher in AVL or ATL/HIV-AIDS cases compared to HIV/AIDS patients without leishmaniasis or healthy subjects.
   Conclusions: Leishmania infection can increase the degree of immune system activation in individuals concomitantly infected with HIV. In addition, AVL/HIV-AIDS patients can present low CD4(+) T cell counts and higher proportion of activated T lymphocytes even when HIV viral load is suppressed under HAART. This fact can cause a misinterpretation of these laboratorial markers in co-infected patients.
C1 [Santos-Oliveira, Joanna R.; Da-Cruz, Alda M.] Fiocruz MS, Inst Oswaldo Cruz, Lab Interdisciplinar Pesquisas Med, BR-21040360 Rio De Janeiro, Brazil.
   [Giacoia-Gripp, Carmem B. W.; Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, BR-21040360 Rio De Janeiro, Brazil.
   [de Oliveira, Priscilla Alexandrino] Univ Fed Mato Grosso do Sul, Univ Hosp, Hosp Dia Profa Esterina Corsini, BR-79070900 Mato Grosso, Brazil.
   [Amato, Valdir S.] Univ Sao Paulo, Fac Med, Serv Doencas Infecciosas & Parasitarias, BR-05403010 Sao Paulo, Brazil.
   [Lindoso, Jose Angelo L.; Goto, Hiro] Univ Sao Paulo, Inst Med Trop Sao Paulo, BR-05403010 Sao Paulo, Brazil.
   [Oliveira-Neto, Manoel P.; Mattos, Marise S.; Grinsztejn, Beatriz] Fiocruz MS, IPEC, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, Brazil.
RP Da-Cruz, AM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Interdisciplinar Pesquisas Med, Av Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM alda@ioc.fiocruz.br
RI Goto, Hiro/B-5745-2009; Da-Cruz, Alda Maria/J-2152-2012; Lindoso, Jose
   Angelo Lauletta/E-9339-2012; Amato, Valdir S/L-6845-2017
OI Goto, Hiro/0000-0001-7048-562X; Lindoso, Jose Angelo
   Lauletta/0000-0002-4405-4401; 
FU Programa Nacional de DST/AIDS; Ministerio da Saude [ED00095/2007];
   Instituto Oswaldo Cruz; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)
FX We are very grateful to Dr. David Watkins for helpful discussions and
   for critical reviewing of this manuscript. To thanks Dr. Alvaro Bertho
   to assistance with flow cytometric analysis and helpful advices, to Dr.
   Jose Henrique Pilotto, to Dr. Sandra Wagner and to Ricardo Nogueira for
   helping with recruitment of HIV-1 patients and co-infected patients. To
   Dr. Filipe Carvalho-Costa for helpful assistance with statistical
   analysis. We would like to thank the following funding agencies for
   support of our work: Programa Nacional de DST/AIDS, Ministerio da Saude
   (grant ED00095/2007) and Instituto Oswaldo Cruz (internal funds). JRSO
   is a fellowship of CNPq. AMC is a researcher fellowship from CNPq and
   FAPERJ.
CR Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07
   Benito JM, 2004, AIDS RES HUM RETROV, V20, P227, DOI 10.1089/088922204773004950
   Benito JM, 2008, J INFECT DIS, V198, P1466, DOI 10.1086/592716
   BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7
   Bofill M, 1996, AIDS, V10, P827, DOI 10.1097/00002030-199607000-00005
   Cacopardo B, 1996, T ROY SOC TROP MED H, V90, P434, DOI 10.1016/S0035-9203(96)90538-6
   CARVALHO EM, 1989, J CLIN INVEST, V83, P860, DOI 10.1172/JCI113969
   Casado JL, 2001, EUR J CLIN MICROBIOL, V20, P202, DOI 10.1007/s10096-001-8082-z
   Couppie P, 2004, BRIT J DERMATOL, V151, P1165, DOI 10.1111/j.1365-2133.2004.06226.x
   COURA J R, 1987, Memorias do Instituto Oswaldo Cruz, V82, P581, DOI 10.1590/S0074-02761987000400019
   Da-Cruz AM, 2000, T ROY SOC TROP MED H, V94, P569, DOI 10.1016/S0035-9203(00)90090-7
   Da-Cruz AM, 2002, CLIN DIAGN LAB IMMUN, V9, P251, DOI 10.1128/CDLI.9.2.251-256.2002
   DAHER ED, 2008, J PARASITOL, V2, P1
   del Giudice P, 2002, J INFECT DIS, V186, P1366, DOI 10.1086/344325
   DESOUZA VB, 2006, J INFECT DIS, V194, P846
   Douek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549
   Gonzalez VD, 2009, J VIROL, V83, P11407, DOI 10.1128/JVI.01211-09
   Goto H, 2009, REV I MED TROP, V51, P241, DOI 10.1590/S0036-46652009000500002
   Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380
   Jacobson MA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005277
   Lindoso JAL, 2009, BRIT J DERMATOL, V160, P311, DOI 10.1111/j.1365-2133.2008.08908.x
   Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003
   Lopez-Velez R, 2001, CLIN MICROBIOL INFEC, V7, P394, DOI 10.1046/j.1198-743x.2001.00270.x
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Mattos M, 1998, J EUR ACAD DERMATOL, V10, P218, DOI 10.1016/S0926-9959(98)00012-9
   McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648
   Nigro L, 2007, MED MICROBIOL IMMUN, V196, P253, DOI 10.1007/s00430-007-0046-1
   Padovese V, 2009, T ROY SOC TROP MED H, V103, P707, DOI 10.1016/j.trstmh.2009.02.023
   Preiser W, 1996, INTERVIROLOGY, V39, P285, DOI 10.1159/000150531
   Rabello A, 2003, ANN TROP MED PARASIT, V97, P17, DOI 10.1179/000349803225002507
   Rodrigues Denise do Socorro S., 2003, Braz J Infect Dis, V7, P161, DOI 10.1590/S1413-86702003000200010
   Saha S, 2006, INDIAN J MED RES, V123, P245
   Schriefer A, 2008, CURR OPIN INFECT DIS, V21, P483, DOI 10.1097/QCO.0b013e32830d0ee8
   Wolday D, 1998, SCAND J INFECT DIS, V30, P29, DOI 10.1080/003655498750002268
   Zhao CQ, 2004, CLIN IMMUNOL, V113, P81, DOI 10.1016/j.clim.2004.06.003
NR 35
TC 25
Z9 25
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 20
PY 2010
VL 10
AR 358
DI 10.1186/1471-2334-10-358
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 706ZT
UT WOS:000286257000001
PM 21171992
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Tan, DHS
   Raboud, JM
   Kaul, R
   Grinsztejn, B
   Cahn, P
   Walmsley, SL
AF Tan, Darrell H. S.
   Raboud, Janet M.
   Kaul, Rupert
   Grinsztejn, Beatriz
   Cahn, Pedro
   Walmsley, Sharon L.
TI Can herpes simplex virus type 2 suppression slow HIV disease
   progression: a study protocol for the VALacyclovir In Delaying
   Antiretroviral Treatment Entry (VALIDATE) trial
SO TRIALS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SELF-REPORTED ADHERENCE; T-CELL DECLINE;
   LONG-TERM; GENITAL HERPES; SEX WORKERS; ACYCLOVIR-RESISTANT; INITIAL
   TREATMENT; DOSE ACYCLOVIR; NAIVE PATIENTS
AB Background: Although highly active antiretroviral therapy (HAART) has dramatically decreased HIV-related morbidity and mortality, the associated costs, toxicities, and resistance risks make the potential delay of HAART initiation an attractive goal. Suppression of herpes simplex virus type 2 (HSV-2) may be a novel strategy for achieving this goal because HSV-2 is associated with clinically significant increases in HIV viral load, the primary driver of HIV disease progression.
   Methods/Design: The VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial is a multicentre, randomized, fully blinded, clinical trial of twice daily valacyclovir 500 mg versus placebo for delaying the need for initiating HAART among HIV-1, HSV-2 co-infected HAART-naive adults. 480 participants from Canada, Brazil and Argentina will undergo quarterly clinical follow-up until reaching the composite primary endpoint of having a CD4 + T-cell count <= 350 cells/mm(3) or initiation of HAART for any reason, whichever occurs first. The primary analysis will use a proportional hazards model, stratified by site, to estimate the relative risk of progression to this endpoint associated with valacyclovir. Secondary analyses will compare the rates of change in CD4 count, median log(10) HIV viral load, drug-related adverse events, frequency of HSV reactivations, rate of acyclovir-resistant HSV, and quality of life between study arms.
   Discussion: Although HIV treatment guidelines continue to evolve, with some authorities recommending earlier HAART among asymptomatic individuals, the potential delay of HAART remains a clinically relevant goal for many. If shown to be of benefit, implementation of the VALIDATE intervention will require careful consideration of both individual patient-level and public health implications.
C1 [Tan, Darrell H. S.; Raboud, Janet M.; Kaul, Rupert; Walmsley, Sharon L.] Univ Hlth Network, Toronto, ON M5G 2N2, Canada.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, BR-21040900 Rio De Janeiro, Brazil.
   [Cahn, Pedro] Fdn Huesped, RA-3932 Buenos Aires, DF, Argentina.
RP Tan, DHS (corresponding author), Univ Hlth Network, 585 Univ Ave,13N-1323, Toronto, ON M5G 2N2, Canada.
EM darrell.tan@gmail.com
OI Kaul, Rupert/0000-0002-1586-4093; Walmsley, Sharon/0000-0002-3959-5692
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR); CIHR Canadian HIV Trials NetworkCanadian Institutes of
   Health Research (CIHR); Canada Research Chair ProgramCanada Research
   Chairs; Ontario HIV Treatment Network
FX This clinical trial is supported by a grant from the Canadian Institutes
   of Health Research and by the CIHR Canadian HIV Trials Network. DHST
   receives research fellowship support from the Canadian Institutes of
   Health Research. RK receives salary support from the Canada Research
   Chair Program. JMR and SLW receive salary support from the Ontario HIV
   Treatment Network. The funding agencies had no role in the design of the
   trial or writing of this manuscript.
CR Baeten JM, 2007, J INFECT DIS, V195, P1177, DOI 10.1086/512682
   Baggaley RF, 2009, AIDS, V23, P1005, DOI 10.1097/QAD.0b013e32832aadf2
   Balfour L, 2006, AIDS CARE, V18, P830, DOI 10.1080/09540120500466820
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Blower S, 2004, CLIN INFECT DIS, V39, pS240, DOI 10.1086/422361
   Brown EL, 2006, AM J EPIDEMIOL, V164, P733, DOI 10.1093/aje/kwj270
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   Celum C, 2010, NEW ENGL J MED, V362, P427, DOI 10.1056/NEJMoa0904849
   Celum C, 2008, LANCET, V371, P2109, DOI 10.1016/S0140-6736(08)60920-4
   Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891
   Chu K, 2006, INT J STD AIDS, V17, P681, DOI 10.1258/095646206780071108
   Coen Donald M., 1994, Trends in Microbiology, V2, P481, DOI 10.1016/0966-842X(94)90652-1
   COLLINS P, 1982, AM J MED, V73, P380, DOI 10.1016/0002-9343(82)90127-9
   Conant MA, 2002, INT J STD AIDS, V13, P12, DOI 10.1258/0956462021924550
   Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001
   Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144
   Cowan FF, 2006, AIDS, V20, P261, DOI 10.1097/01.aids.0000198086.39831.4a
   Cunningham WE, 2000, J ACQ IMMUN DEF SYND, V25, P115, DOI 10.1097/00126334-200010010-00005
   DeJesus E, 2003, J INFECT DIS, V188, P1009, DOI 10.1086/378416
   *DEP HLTH HUM SERV, 2009, PAN ANT GUID AD AD G, P1
   *DEP HLTH HUM SERV, 2008, GUID US ANT AG HIV 1
   Diaz JJ, 1996, NATURE, V379, P273, DOI 10.1038/379273a0
   Dunne EF, 2008, JAIDS-J ACQ IMM DEF, V49, P77, DOI 10.1097/QAI.0b013e3181831832
   DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   *EUR AIDS CLIN SOC, 2009, GUID CLIN MAN TREATM
   Fawzi W, 2005, J NUTR, V135, P938
   Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7
   Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871
   Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Gazzard BG, 2008, HIV MED, V9, P563, DOI 10.1111/j.1468-1293.2008.00636.x
   Gray RH, 1999, AIDS, V13, P2113, DOI 10.1097/00002030-199910220-00015
   Gray RH, 2004, J INFECT DIS, V189, P1209, DOI 10.1086/382750
   Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772
   Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555
   HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048
   Honda M, 2001, ANTIVIR CHEM CHEMOTH, V12, P233, DOI 10.1177/095632020101200404
   Ioannidis JPA, 1998, J INFECT DIS, V178, P349, DOI 10.1086/515621
   Kasiari M, 2008, J CHROMATOGR B, V864, P78, DOI 10.1016/j.jchromb.2008.01.046
   Kaul R, 2004, JAMA-J AM MED ASSOC, V291, P2555, DOI 10.1001/jama.291.21.2555
   Keller M, 2009, AIDS, V23, P731, DOI 10.1097/QAD.0b013e328326f77f
   KUCERA LS, 1990, AIDS RES HUM RETROV, V6, P641, DOI 10.1089/aid.1990.6.641
   Levin MJ, 2004, CLIN INFECT DIS, V39, pS248, DOI 10.1086/422364
   Lingappa JR, 2010, LANCET, V375, P824, DOI 10.1016/S0140-6736(09)62038-9
   Lisco A, 2008, CELL HOST MICROBE, V4, P260, DOI 10.1016/j.chom.2008.07.008
   MacArthur RD, 2006, LANCET, V368, P2125, DOI 10.1016/S0140-6736(06)69861-9
   MacDougall C, 2004, J ANTIMICROB CHEMOTH, V53, P899, DOI 10.1093/jac/dkh244
   MARGOLIS DM, 1992, VIROLOGY, V186, P788, DOI 10.1016/0042-6822(92)90048-T
   McFarland W, 1999, J INFECT DIS, V180, P1459, DOI 10.1086/315076
   McMahon MA, 2008, J BIOL CHEM, V283, P31289, DOI 10.1074/jbc.C800188200
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003
   Modjarrad K, 2010, LANCET INFECT DIS, V10, P455, DOI 10.1016/S1473-3099(10)70093-1
   Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297
   Moriuchi M, 2000, VIROLOGY, V278, P534, DOI 10.1006/viro.2000.0667
   MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0
   Nagot N, 2007, NEW ENGL J MED, V356, P790, DOI 10.1056/NEJMoa062607
   Nordqvist O, 2006, PATIENT EDUC COUNS, V62, P21, DOI 10.1016/j.pec.2005.09.014
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105
   PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402
   Patel R, 1997, GENITOURIN MED, V73, P105
   Ramaswamy M, 2006, SEX TRANSM DIS, V33, P96, DOI 10.1097/01.olq.0000187211.61052.c7
   Ramjee G, 2005, JAIDS-J ACQ IMM DEF, V39, P333, DOI 10.1097/01.qai.0000144445.44518.ea
   Reyes M, 2003, ARCH INTERN MED, V163, P76, DOI 10.1001/archinte.163.1.76
   Reynolds NR, 2007, JAIDS-J ACQ IMM DEF, V46, P402, DOI 10.1097/QAI.0b013e318158a44f
   Reynolds SJ, 2003, J INFECT DIS, V187, P1513, DOI 10.1086/368357
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498
   Rodriguez MDM, 2002, AIDS, V16, P451
   ROMANOWSKI B, 2008, SEX TRANSM DIS
   Santos FC, 2006, MEM I OSWALDO CRUZ, V101, P315, DOI 10.1590/S0074-02762006000300016
   Schacker T, 2002, J INFECT DIS, V186, P1718, DOI 10.1086/345771
   Schacker T, 1998, JAMA-J AM MED ASSOC, V280, P61, DOI 10.1001/jama.280.1.61
   Stebbing Justin, 2003, AIDS Rev, V5, P205
   STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352
   Strick LB, 2006, CLIN INFECT DIS, V43, P347, DOI 10.1086/505496
   Tan Darrell H S, 2009, Can J Infect Dis Med Microbiol, V20, pe1
   Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004
   Tyring SK, 2002, J INFECT DIS, V186, pS40, DOI 10.1086/342966
   VICENZI E, 1994, J LEUKOCYTE BIOL, V56, P328
   Wald A, 2003, J INFECT DIS, V187, P1509, DOI 10.1086/374976
   Watson-Jones D, 2008, NEW ENGL J MED, V358, P1560, DOI 10.1056/NEJMoa0800260
   Workowski Kimberly A., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Wu A. W., 1999, MOS HIV HLTH SURVEY
   Zhu J, 2009, NAT MED, V15, P886, DOI 10.1038/nm.2006
   Zuckerman RA, 2007, J INFECT DIS, V196, P1500, DOI 10.1086/522523
   2007, J ACQUIR IMMUNE DEFI, V46, P275
NR 89
TC 3
Z9 4
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD NOV 24
PY 2010
VL 11
AR 113
DI 10.1186/1745-6215-11-113
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 695MT
UT WOS:000285375400001
PM 21106086
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Belloso, WH
   Orellana, LC
   Grinsztejn, B
   Madero, JS
   La Rosa, A
   Veloso, VG
   Sanchez, J
   Moreira, RI
   Crabtree-Ramirez, B
   Messina, OG
   Lasala, MB
   Peinado, J
   Losso, MH
AF Belloso, W. H.
   Orellana, L. C.
   Grinsztejn, B.
   Madero, J. S.
   La Rosa, A.
   Veloso, V. G.
   Sanchez, J.
   Ismerio Moreira, R.
   Crabtree-Ramirez, B.
   Garcia Messina, O.
   Lasala, M. B.
   Peinado, J.
   Losso, M. H.
TI Analysis of serious non-AIDS events among HIV-infected adults at Latin
   American sites
SO HIV MEDICINE
LA English
DT Article
DE AIDS; cardiovascular disease; CD4 cell lymphocyte count; cohort studies;
   liver diseases; neoplasms
ID ACTIVE ANTIRETROVIRAL THERAPY; MORTALITY; RISK; DEATH; IMMUNODEFICIENCY;
   DISEASE; VIRUS; HAART; INDIVIDUALS; COUNTRIES
AB Objective
   Acquired immune deficiency appears to be associated with serious non-AIDS (SNA)-defining conditions such as cardiovascular disease, liver and renal insufficiency and non-AIDS-related malignancies. We analysed the incidence of, and factors associated with, several SNA events in the LATINA retrospective cohort.
   Materials and methods
   Cases of SNA events were recorded among cohort patients. Three controls were selected for each case from cohort members at risk. Conditional logistic models were fitted to estimate the effect of traditional risk factors as well as HIV-associated factors on non-AIDS-defining conditions.
   Results
   Among 6007 patients in follow-up, 130 had an SNA event (0.86 events/100 person-years of follow-up) and were defined as cases (40 with cardiovascular events, 54 with serious liver failure, 35 with non-AIDS-defining malignancies and two with renal insufficiency). Risk factors such as diabetes, hepatitis B and C virus coinfections and alcohol abuse showed an association with events, as expected. The last recorded CD4 T-cell count prior to index date (P=0.0056, with an average difference of more than 100 cells/mu L) and area under the CD4 cell curve in the year previous to index date (P=0.0081) were significantly lower in cases than in controls. CD4 cell count at index date was significantly associated with the outcome after adjusting for risk factors.
   Conclusions
   The incidence and type of SNA events found in this Latin American cohort are similar to those reported in other regions. We found a significant association between immune deficiency and the risk of SNA events, even in patients under antiretroviral treatment.
C1 [Belloso, W. H.] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina.
   [Belloso, W. H.; Losso, M. H.] CICAL, Buenos Aires, DF, Argentina.
   [Orellana, L. C.] Univ Buenos Aires, Inst Calculo, RA-1053 Buenos Aires, DF, Argentina.
   [Grinsztejn, B.; Veloso, V. G.; Ismerio Moreira, R.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Madero, J. S.; Crabtree-Ramirez, B.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [La Rosa, A.; Sanchez, J.; Peinado, J.] INMENSA, Lima, Peru.
   [Garcia Messina, O.] Hosp Parmenio Pinero, Buenos Aires, DF, Argentina.
   [Lasala, M. B.] Hosp Clin Jose San Martin, Buenos Aires, DF, Argentina.
   [Losso, M. H.] Hosp JM Ramos Mejia, Buenos Aires, DF, Argentina.
RP Belloso, WH (corresponding author), Hosp Italiano Buenos Aires, Riglos 177,1A,C1424AFC, Buenos Aires, DF, Argentina.
EM wbelloso@cical.org
RI Veloso, Valdilea Goncalves/J-6189-2012; Orellana, Liliana/I-5249-2013
OI Orellana, Liliana/0000-0003-3736-4337
CR Baker JV, 2008, JAIDS-J ACQ IMM DEF, V48, P541, DOI 10.1097/QAI.0b013e31817bebb3
   Baker JV, 2008, AIDS, V22, P841, DOI 10.1097/QAD.0b013e3282f7cb76
   Bastos FI, 2008, INT J EPIDEMIOL, V37, P729, DOI 10.1093/ije/dyn127
   Bautista-Arredondo S, 2008, AIDS, V22, pS67, DOI 10.1097/01.aids.0000327625.69974.08
   Beral V, 2004, AIDS, V18, P51, DOI 10.1097/01.aids.0000096908.73209.5d
   Bottecchia M, 2007, CURR OPIN INFECT DIS, V20, P621
   Chequer P, 2002, AIDS, V16, pS50, DOI 10.1097/00002030-200212003-00008
   CRABTREERAMIREZ B, BASELINE CHARACTERIS
   Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16
   Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   Emery S, 2008, J INFECT DIS, V197, P1133, DOI 10.1086/586713
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   *JOINT UN PROGR HI, 2008, TREATM CAR UNPR PROG, P129
   Knol MJ, 2008, AM J EPIDEMIOL, V168, P1073, DOI 10.1093/aje/kwn217
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lau B, 2007, JAIDS-J ACQ IMM DEF, V44, P179, DOI 10.1097/01.qai.0000247229.68246.c5
   LUNDGREN JD, 2006, J HIV THER, V2, P36
   McQueen MJ, 2008, LANCET, V372, P224, DOI 10.1016/S0140-6736(08)61076-4
   Mehta N, 2005, HIV CLIN TRIALS, V6, P5
   Mocroft A, 2004, ANN INTERN MED, V140, P578, DOI 10.7326/0003-4819-140-7-200404060-00024
   Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0
   Mocroft A, 2002, AIDS, V16, P1663, DOI 10.1097/00002030-200208160-00012
   Monforte AD, 2008, AIDS, V22, P2143, DOI 10.1097/QAD.0b013e3283112b77
   Moore RD, 2008, CLIN INFECT DIS, V47, P1102, DOI 10.1086/592115
   Mu H, 2007, WORLD J SURG, V31, P632, DOI 10.1007/s00268-006-0730-0
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Puoti M, 2006, J HEPATOL, V44, pS65, DOI 10.1016/j.jhep.2005.11.015
   ROBINS JM, 1986, BIOMETRICS, V42, P293, DOI 10.2307/2531050
   Rothman KJ, 2008, MODERN EPIDEMIOLOGY
   Sabin CA, 2008, LANCET, V371, P1417, DOI 10.1016/S0140-6736(08)60423-7
   Smit C, 2006, AIDS, V20, P741
   Stein JH, 2001, CIRCULATION, V104, P257
   Thein HH, 2008, AIDS, V22, P1979, DOI 10.1097/QAD.0b013e32830e6d51
   Weber R, 2006, ARCH INTERN MED, V166, P1632
NR 35
TC 25
Z9 26
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD OCT
PY 2010
VL 11
IS 9
BP 554
EP 564
DI 10.1111/j.1468-1293.2010.00824.x
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 647WU
UT WOS:000281652100002
PM 20345879
OA Bronze
DA 2020-11-24
ER

PT J
AU Veloso, VG
   Bastos, FI
   Portela, MC
   Grinsztejn, B
   Joao, EC
   Pilotto, JHD
   Araujo, ABB
   Santos, BR
   da Fonseca, RC
   Kreitchmann, R
   Derrico, M
   Friedman, RK
   Cunha, CB
   Morgado, MG
   Saines, KN
   Bryson, YJ
AF Veloso, Valdilea G.
   Bastos, Francisco I.
   Portela, Margareth Crisostomo
   Grinsztejn, Beatriz
   Joao, Esau Custodio
   da Silva Pilotto, Jose Henrique
   Busch Araujo, Ana Beatriz
   Santos, Breno Riegel
   da Fonseca, Rosana Campos
   Kreitchmann, Regis
   Derrico, Monica
   Friedman, Ruth Khalili
   Cunha, Cynthia B.
   Morgado, Mariza Goncalves
   Saines, Karin Nielsen
   Bryson, Yvonne J.
TI HIV rapid testing as a key strategy for prevention of mother-to-child
   transmission in Brazil
SO REVISTA DE SAUDE PUBLICA
LA English
DT Article
DE Pregnant Women; Prenatal Care; Breast Feeding; AIDS Serodiagnosis; HIV
   Infections, diagnosis; Infectious Disease Transmission, Vertical;
   Acquired Immunodeficiency Syndrome, prevention & control
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PREGNANT-WOMEN; ZIDOVUDINE; INTRAPARTUM;
   LABOR; COMBINATION; NEVIRAPINE
AB OBJECTIVE: To assess the feasibility of HIV rapid testing for pregnant women at maternity hospital admission and of subsequent interventions to reduce perinatal HIV transmission.
   METHODS: Study based on a convenience sample of women unaware of their HIV serostatus when they were admitted to delivery in public maternity hospitals in Rio de Janeiro and Porto Alegre, Brazil, between March 2000 and April 2002. Women were counseled and tested using the Determine HIV1/2 Rapid Test. HIV infection was confirmed using the Brazilian algorithm for HIV infection diagnosis. In utero transmission of HIV was determined using HIV-DNA-PCR. There were performed descriptive analyses of sociodemographic data, number of previous pregnancies and abortions, number of prenatal care visits, timing of HIV testing, HIV rapid test result, neonatal and mother-to-child transmission interventions, by city studied.
   RESULTS: HIV prevalence in women was 6.5% (N=1,439) in Porto Alegre and 1.3% (N=3.778) in Rio de Janeiro. In Porto Alegre most of women were tested during labor (88.7%), while in Rio de Janeiro most were tested in the postpartum (67.5%). One hundred and forty-four infants were born to 143 HIV-infected women. All newborns but one in each city received at least prophylaxis with oral zidovudine. It was possible to completely avoid newborn exposure to breast milk in 96.8% and 51.1% of the cases in Porto Alegre and Rio de Janeiro, respectively. Injectable intravenous zidovudine was administered during labor to 68.8% and 27.7% newborns in Porto Alegre and Rio de Janeiro, respectively. Among those from whom blood samples were collected within 48 hours of birth, in utero transmission of HIV was confirmed in 4 cases in Rio de Janeiro (4/47) and 6 cases in Porto Alegre (6/79).
   CONCLUSIONS: The strategy proved feasible in maternity hospitals in Rio de Janeiro and Porto Alegre. Efforts must be taken to maximize HIV testing during labor. There is a need of strong social support to provide this population access to health care services after hospital discharge.
C1 [Veloso, Valdilea G.; Grinsztejn, Beatriz; da Silva Pilotto, Jose Henrique; Derrico, Monica; Friedman, Ruth Khalili; Cunha, Cynthia B.] Fundacao Oswaldo Cruz Fiocruz, Lab Pesquisa DST AIDS, Inst Pesquisa Clin Evandro Chagas, BR-21040900 Rio De Janeiro, Brazil.
   [Bastos, Francisco I.] Fiocruz MS, Lab Informacao Saude, Inst Comunicacao & Informacao Cient & Tecnol Saud, BR-21045900 Rio De Janeiro, Brazil.
   [Portela, Margareth Crisostomo] Fiocruz MS, Escola Nacl Saude Publ, Dept Adm & Planejamento Saude, BR-21045900 Rio De Janeiro, Brazil.
   [Joao, Esau Custodio] Hosp Servidores Estado Rio de Janeiro, Serv Doencas Infecciosas & Parasitarias, Rio De Janeiro, Brazil.
   [Busch Araujo, Ana Beatriz] Secretaria Municipal Saude Rio de Janeiro, Rio De Janeiro, Brazil.
   [Santos, Breno Riegel] Hosp Nossa Senhora Conceicao, Dept Doencas Infecciosas, Grp Hosp Conceicao, Porto Alegre, RS, Brazil.
   [da Fonseca, Rosana Campos] Hosp Femina, Porto Alegre, RS, Brazil.
   [Kreitchmann, Regis] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Morgado, Mariza Goncalves] Fiocruz MS, Lab AIDS & Imunol Mol, Dept Imunol, BR-21045900 Rio De Janeiro, Brazil.
   [Saines, Karin Nielsen; Bryson, Yvonne J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA.
RP Veloso, VG (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Lab Pesquisa DST AIDS, Inst Pesquisa Clin Evandro Chagas, Av Brasil,4-365 Manguinhos, BR-21040900 Rio De Janeiro, Brazil.
EM vgveloso@ipec.fiocruz.br
RI Portela, Margareth C/G-6699-2012; Pilotto, Jose Henrique/AAD-9773-2019;
   Veloso, Valdilea Goncalves/J-6189-2012
OI Portela, Margareth C/0000-0002-9858-9276; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Kreitchmann, Regis/0000-0002-1146-0497;
   Joao, Esau/0000-0002-2412-0627; Bastos, Francisco/0000-0001-5970-8896
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI027550, U01AI027550, U01AI027550, U01AI027550, U01AI027550,
   U01AI027550, U01AI027550, U01AI027550, U01AI027550, U01AI027550,
   U01AI027550, U01AI027550, U01AI027550, U01AI027550, U01AI027550,
   U01AI027550, U01AI027550, U01AI027550, U01AI027550, U01AI027550,
   U01AI027550, U01AI027550, U01AI027550, U01AI027550, U01AI027550,
   U01AI027550, U01AI027550, U01AI027550, U01AI027550, U01AI027550] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01 AI275, U01
   AI027550] Funding Source: Medline
CR Barcellos C, 2006, REV SAUDE PUBL, V40, P928, DOI [10.1590/S0034-89102006005000007, 10.1590/S0034-89102006000600025]
   BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718
   Bulterys M, 2004, JAMA-J AM MED ASSOC, V292, P219, DOI 10.1001/jama.292.2.219
   Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009
   Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2
   Dao H, 2007, AM J OBSTET GYNECOL, V197, pS42, DOI 10.1016/j.ajog.2007.03.001
   de Brito AM, 2006, REV SAUDE PUBL, V40, P18, DOI 10.1590/S0034-89102006000800004
   de Souza PRB, 2004, REV SAUDE PUBL, V38, P764, DOI 10.1590/S0034-89102004000600003
   DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V
   Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7
   HATCH MC, 1991, AM J EPIDEMIOL, V133, P826, DOI 10.1093/oxfordjournals.aje.a115962
   KISSIN DM, 2008, AM J OBSTET GYNECOL, V198, pNIL59, DOI DOI 10.1016/J.AJ0G.2007.09.005
   Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898
   Nogueira SA, 2001, J HUMAN VIROL, V4, P278
   Pai NP, 2007, TROP MED INT HEALTH, V12, P162, DOI 10.1111/j.1365-3156.2006.01812.x
   Pai NP, 2008, PLOS MED, V5, P768, DOI 10.1371/journal.pmed.0050092
   Richardson BA, 2003, BIOMETRICS, V59, P179, DOI 10.1111/1541-0420.00021
   ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503
   Saba J, 2002, LANCET, V359, P1178
   VELOSO VG, 1999, B EPIDEMIOL AIDS, V12, P16
   Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001
   1994, ACTA PAEDIAT S, V400, P51
NR 22
TC 18
Z9 21
U1 0
U2 13
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL
SN 0034-8910
EI 1518-8787
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PD OCT
PY 2010
VL 44
IS 5
BP 803
EP 811
DI 10.1590/S0034-89102010005000034
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 675UQ
UT WOS:000283864700005
PM 20835495
OA DOAJ Gold, Green Accepted
DA 2020-11-24
ER

PT J
AU Cardoso, SW
   Grinsztejn, B
   Velasque, L
   Veloso, VG
   Luz, PM
   Friedman, RK
   Morgado, M
   Ribeiro, SR
   Moreira, RI
   Keruly, J
   Moore, RD
AF Cardoso, Sandra W.
   Grinsztejn, Beatriz
   Velasque, Luciane
   Veloso, Valdilea G.
   Luz, Paula M.
   Friedman, Ruth K.
   Morgado, Mariza
   Ribeiro, Sayonara R.
   Moreira, Ronaldo I.
   Keruly, Jeanne
   Moore, Richard D.
TI Incidence of Modifying or Discontinuing First HAART Regimen and Its
   Determinants in a Cohort of HIV-Infected Patients from Rio de Janeiro,
   Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; VIROLOGICAL FAILURE; NAIVE PATIENTS;
   CLINICAL PROGRESSION; PROTEASE INHIBITOR; INITIAL RESPONSE; AIDS;
   REASONS; ADULTS; PREDICTORS
AB Studies on the long-term safety and tolerability of HAART are scarce in developing countries. HAART has been universally available in Brazil since 1997, providing a unique opportunity to evaluate the incidence and risk factors for HAART discontinuation or modification. We analyzed retrospective data from 670 treatment-naive patients followed at the HIV cohort of Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation, in Rio de Janeiro, Brazil, who first received HAART between January 1996 and December 2006. Our four outcomes of interest were treatment failure (TF-MOD), short-term toxicity (ST-MOD), long-term toxicity (LT-MOD), and overall modification/discontinuation (MOD, composed of TF-MOD, ST-MOD, LT-MOD, and other reasons). Risk factors were assessed using Cox's proportional hazards regression. Incidences of MOD, ST-MOD, LT-MOD, and TF-MOD were 28.3, 24.0, 4.0, and 5.6 per 100 persons-years, respectively. MOD was observed in 69% of the patients; 40% of the MODs were toxicity related. The risk of MOD in the first year of treatment was 32% (95% CI: 28.3-35.5%); the median time from HAART initiation to MOD was 14 months (IQR: 3.0-29.5). The most frequent reasons for ST-MOD were gastrointestinal; women had a higher hazard for ST-MOD. Metabolic toxicity was the most frequent reason for LT-MOD, particularly dislipidemia and lipodystrophy. Increased hazard of TF-MOD was observed among those with lower CD4(+) lymphocyte counts (< 200 cells/mm(3)). Our results indicate that toxicities can compromise adherence and thus impact future treatment options. This is especially relevant in the context of limited access to second and third line treatment regimens.
C1 [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Lab Pesquisa Clin DST & AIDS, BR-21045900 Rio De Janeiro, Brazil.
   [Keruly, Jeanne; Moore, Richard D.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
   [Morgado, Mariza] Inst Oswaldo Cruz, BR-20001 Rio De Janeiro, Brazil.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Lab Pesquisa Clin DST & AIDS, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI Cardoso, Sandra W/D-7965-2015; Veloso, Valdilea Goncalves/J-6189-2012
OI Cardoso, Sandra W/0000-0001-5230-0003; Luz, Paula/0000-0001-9746-719X
FU National Counsel of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); State of Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)
FX B.G. acknowledges funding from the National Counsel of Technological and
   Scientific Development (CNPq) and the Research Funding Agency of the
   State of Rio de Janeiro (FAPERJ). Data were presented at the
   International AIDS Conference, Mexico City, August 2008. This study was
   funded by IPEC/FIOCRUZ.
CR Antinori A, 2009, INFECTION, V37, P270, DOI 10.1007/s15010-008-8134-8
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   Carr A, 2003, LANCET, V361, P726, DOI 10.1016/S0140-6736(03)12656-6
   Centers for Disease Control and Prevention, 1993, REV CLASS SYST HIV I
   Chen RY, 2003, CLIN INFECT DIS, V37, P714, DOI 10.1086/377271
   Chene G, 2003, LANCET, V362, P679
   Currier JS, 2000, J ACQ IMMUN DEF SYND, V24, P316
   DAYSE PC, BANCO DADOS INDIVIDU
   de Padua CAM, 2006, BRAZ J MED BIOL RES, V39, P495, DOI 10.1590/S0100-879X2006000400010
   DIAS J, 2000, ACCESS ANTIRETROVIRA
   Dragsted UB, 2004, J INFECT DIS, V190, P148, DOI 10.1086/420786
   Enanoria WTA, 2004, LANCET INFECT DIS, V4, P414, DOI 10.1016/S1473-3099(04)01057-6
   Fonseca MGP, 2007, CAD SAUDE PUBLICA, V23, pS333, DOI 10.1590/S0102-311X2007001500002
   Gay CL, 2006, AIDS, V20, P775, DOI 10.1097/01.aids.0000216380.30055.4a
   Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Hart E, 2007, HIV MED, V8, P186, DOI 10.1111/j.1468-1293.2007.00451.x
   Hofer CB, 2004, JAIDS-J ACQ IMM DEF, V36, P967, DOI 10.1097/00126334-200408010-00011
   IDOKO J, 2007, C RETR OPP INF CROI2
   Keiser O, 2008, TROP MED INT HEALTH, V13, P870, DOI 10.1111/j.1365-3156.2008.02078.x
   Kiguba R, 2007, JAIDS-J ACQ IMM DEF, V45, P218, DOI 10.1097/QAI.0b013e31805d8ae3
   Klein MB, 2004, AIDS, V18, P1895, DOI 10.1097/00002030-200409240-00005
   Kumarasamy N, 2004, JAIDS-J ACQ IMM DEF, V37, P1574, DOI 10.1097/00126334-200412150-00007
   Kumarasamy N, 2003, AIDS, V17, P2267, DOI 10.1097/00002030-200310170-00019
   Lampe FC, 2006, ARCH INTERN MED, V166, P521, DOI 10.1001/archinte.166.5.521
   Le Moing V, 2002, CLIN INFECT DIS, V34, P239, DOI 10.1086/324354
   Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8
   Loo VS, 2004, AIDS CARE, V16, P834, DOI 10.1080/09540120412331290121
   May SB, 2007, BRAZ J MED BIOL RES, V40, P551, DOI 10.1590/S0100-879X2007000400014
   Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011
   Mocroft A, 2001, AIDS, V15, P185, DOI 10.1097/00002030-200101260-00007
   Mocroft A, 2000, AIDS, V14, P1545, DOI 10.1097/00002030-200007280-00010
   Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005
   Moore RD, 2005, JAIDS-J ACQ IMM DEF, V39, P195
   O'Brien ME, 2003, JAIDS-J ACQ IMM DEF, V34, P407, DOI 10.1097/00126334-200312010-00008
   Sabin CA, 2009, HIV MED, V10, P35, DOI 10.1111/j.1468-1293.2008.00654.x
   Schneider MF, 2005, AIDS, V19, P2009, DOI 10.1097/01.aids.0000189864.90053.22
   Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908
   Smith CJ, 2004, J INFECT DIS, V190, P1860, DOI 10.1086/425075
   Spire B, 2002, SOC SCI MED, V54, P1481, DOI 10.1016/S0277-9536(01)00125-3
   Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501
   Sterne JAC, 2005, LANCET, V366, P378, DOI 10.1016/S0140-6736(05)67022-5
   van Roon EN, 1999, J ACQ IMMUN DEF SYND, V20, P290, DOI 10.1097/00042560-199903010-00012
   Vo TTN, 2008, J INFECT DIS, V197, P1685, DOI 10.1086/588141
   Wohl DA, 2006, CLIN INFECT DIS, V43, P645, DOI 10.1086/507333
   World Health Organization UNAIDS UNICEF, 2007, UN ACC SCAL PRIOR HI
   Young J, 2005, ANTIVIR THER, V10, P585
   Yuan Y, 2006, HIV MED, V7, P156, DOI 10.1111/j.1468-1293.2006.00355.x
NR 48
TC 23
Z9 25
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD AUG
PY 2010
VL 26
IS 8
BP 865
EP 874
DI 10.1089/aid.2009.0274
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 637YK
UT WOS:000280854400005
PM 20672997
DA 2020-11-24
ER

PT J
AU de Castro, CAV
   Grinsztejn, B
   Veloso, VG
   Bastos, FI
   Pilotto, JH
   Morgado, MG
AF Velasco de Castro, Carlos A.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Bastos, Francisco I.
   Pilotto, Jose H.
   Morgado, Mariza G.
TI Prevalence, estimated HIV-1 incidence and viral diversity among people
   seeking voluntary counseling and testing services in Rio de Janeiro,
   Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID CAPTURE ENZYME-IMMUNOASSAY; SEQUENCE ALIGNMENT; DRUG-RESISTANCE;
   BLOOD-DONORS; ASSAY; IDENTIFICATION; INFECTION; SEROCONVERSION;
   SOFTWARE; TRIALS
AB Background: BED-EIA HIV-1 Incidence Test (BED-CEIA) has been described as a tool to discriminate recent (RS) from long-term (LTS) seroconversion of HIV-1 infection, contributing to a better understanding of the dynamics of the HIV/AIDS epidemic over time. This study determined the prevalence, estimated incidence and HIV-1 subtype infection among individuals seeking testing in Voluntary Counseling and Testing centers (VCTs) from Rio de Janeiro, Brazil.
   Methods: Demographics and behavioral data were obtained from 434 individuals, diagnosed as HIV-positive among 9,008 volunteers screened from November 2004 to October 2005 in three VCTs located in the Rio de Janeiro Metropolitan area, Brazil. BED-CEIA protocol was performed to identify RS. DNA samples from RS and a subset of LTS (under a proportion of 1: 2) were selected for gp120 C2-V3 and pol (protease and reverse transcriptase) regions genomic sequencing.
   Results: Overall HIV-1 prevalence was 4.8%. Sixty-one of 434 seropositive individuals were classified as RS, corresponding to an incidence rate of 1.68%/year (95% CI 1.26% -2.10%). Estimated incidence between Men Who Have Sex with Men (MSM) was 11 times higher than among heterosexual men and 55% of the new cases were identified in volunteers aged 25-40 years. A similar distribution of different HIV-1 subtypes was found among RS and LTS.
   Conclusions: Our data suggest that prevention for MSM remains a challenge and efforts focusing on prevention targeting this population should be prioritized. No significant changes in HIV-1 subtypes were observed among the RS and LTS subgroups. One case of HIV-1 AUK (pol)/A (env) recombinant genome was detected for the first time in Brazil.
C1 [Velasco de Castro, Carlos A.; Pilotto, Jose H.; Morgado, Mariza G.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Velasco de Castro, Carlos A.; Grinsztejn, Beatriz; Veloso, Valdilea G.; Pilotto, Jose H.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Bastos, Francisco I.] Fundacao Oswaldo Cruz, Inst Comunicacao & Informacao Cient & Tecnol Saud, Rio De Janeiro, Brazil.
   [Pilotto, Jose H.] Hosp Geral de Nova Iguacu, Rio De Janeiro, Brazil.
   [Velasco de Castro, Carlos A.] Fundacao Oswaldo Cruz, Inst Fernandes Figueira, Dept Patol Clin, Virol Lab, Rio De Janeiro, Brazil.
RP Morgado, MG (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Pilotto, Jose Henrique/AAD-9773-2019; Veloso, Valdilea
   Goncalves/J-6189-2012
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Bastos,
   Francisco/0000-0001-5970-8896
FU PAPES IV CNPq/FIOCRUZNational Council for Scientific and Technological
   Development (CNPq); FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX The authors would like to thank Ms Margarete Paiva for logistical
   support in the VCTs. This study was partially supported by PAPES IV
   CNPq/FIOCRUZ and FAPERJ.
CR Alves K, 2003, JAIDS-J ACQ IMM DEF, V32, P551, DOI 10.1097/00126334-200304150-00014
   Barroso PF, 2004, JAIDS-J ACQ IMM DEF, V36, P880, DOI 10.1097/00126334-200407010-00019
   Bassichetto KC, 2009, BRAZ J INFECT DIS, V13, P9, DOI 10.1590/S1413-86702009000100004
   Bastos FI, 2005, MEM I OSWALDO CRUZ, V100, P91, DOI 10.1590/S0074-02762005000100017
   Bastos FI, 2008, INT J EPIDEMIOL, V37, P729, DOI 10.1093/ije/dyn127
   Brookmeyer R, 2009, AIDS, V23, P2066, DOI 10.1097/QAD.0b013e32832f3dbb
   Brookmeyer R, 2009, AIDS, V23, P485, DOI 10.1097/QAD.0b013e3283269e28
   Burland T G, 2000, Methods Mol Biol, V132, P71
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   de Sa DJ, 2009, AIDS RES HUM RETROV, V25, P925, DOI 10.1089/aid.2009.0073
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Dobbs T, 2004, J CLIN MICROBIOL, V42, P2623, DOI 10.1128/JCM.42.6.2623-2628.2004
   *DST AIDS MIN SAUD, 2008, PLAN NAC ENFR EP AID
   Ever-Silva WA, 2006, JAIDS-J ACQ IMM DEF, V41, P664, DOI 10.1097/01.qai.0000194736.66322.02
   Eyer-Silva WA, 2005, MEM I OSWALDO CRUZ, V100, P869, DOI 10.1590/S0074-02762005000800008
   Fl Bastos, 2008, PUBLIC HLTH ASPECTS, P629, DOI DOI 10.1007/978-0-387-72711-0_29
   Guimaraes ML, 2008, AIDS, V22, P433, DOI 10.1097/QAD.0b013e3282f47ad0
   Hall HI, 2008, JAMA-J AM MED ASSOC, V300, P520, DOI 10.1001/jama.300.5.520
   Hargrove JW, 2008, AIDS, V22, P511, DOI 10.1097/QAD.0b013e3282f2a960
   Hargrove JW, 2009, AIDS, V23, P2061, DOI 10.1097/QAD.0b013e32832f3d8b
   Hayashida T, 2008, AIDS RES HUM RETROV, V24, P495, DOI 10.1089/aid.2007.0150
   Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42
   *JOINT UN PROGR HI, 2009, AIDS EPI UPD, P100
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Laeyendecker O, 2008, JAIDS-J ACQ IMM DEF, V48, P211, DOI 10.1097/QAI.0b013e3181743980
   Loschen S, 2008, J CLIN MICROBIOL, V46, P341, DOI 10.1128/JCM.01055-07
   Malta M, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-317
   McDougal JS, 2006, AIDS RES HUM RETROV, V22, P945, DOI 10.1089/aid.2006.22.945
   McDougal JS, 2009, AIDS, V23, P2064, DOI 10.1097/QAD.0b013e32832eff6e
   MELLO M, 2008, ASSESSMENT RISK FACT, P1
   Morgado MG, 2002, MEM I OSWALDO CRUZ, V97, P143, DOI 10.1590/S0074-02762002000200001
   Murphy G., 2008, EUROSURVEILLANCE, V13, P314
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   Parekh BS, 2005, INDIAN J MED RES, V121, P510
   Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874
   *PN DST AIDS MIN S, 2008, CONTR TES COUNS CTR
   *PN DST AIDS MIN S, 2009, B EP AIDS DST
   Sa-Ferreira JA, 2007, TRANSFUSION, V47, P97, DOI 10.1111/j.1537-2995.2007.01069.x
   SAMBROOK J, 1989, COLD SPRING HARBOR L, P458
   Schechter M, 2000, J ACQ IMMUN DEF SYND, V24, P175
   Scuracchio PSP, 2007, TRANSFUSION MED, V17, P200, DOI 10.1111/j.1365-3148.2007.00748.x
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   *UNAIDS REF GROUP, 2006, WKLY EPIDEMIOL REC, V81, P40
   Welte A, 2009, AIDS, V23, P2062, DOI 10.1097/QAD.0b013e32832eff59
NR 44
TC 23
Z9 23
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUL 28
PY 2010
VL 10
AR 224
DI 10.1186/1471-2334-10-224
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 666SS
UT WOS:000283140500003
PM 20667113
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Di Perri, G
   Towner, W
   Woodfall, B
   De Smedt, G
   Peeters, M
AF Grinsztejn, Beatriz
   Di Perri, Giovanni
   Towner, William
   Woodfall, Brian
   De Smedt, Goedele
   Peeters, Monika
TI A Review of the Safety and Tolerability Profile of the Next-Generation
   NNRTI Etravirine
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Review
ID EXPERIENCED HIV-1-INFECTED PATIENTS; REVERSE-TRANSCRIPTASE INHIBITORS;
   1ST-LINE ANTIRETROVIRAL THERAPY; TMC125 ETRAVIRINE; NUCLEOSIDE ANALOGS;
   DOUBLE-BLIND; EFAVIRENZ; EFFICACY; NEVIRAPINE; RESISTANCE
AB The next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) etravirine (TMC125) has demonstrated durable virologic efficacy in clinical trials involving >1000 treatment-experienced, NNRTI-resistant, HIV-1-infected patients. In this clinical safety review, we show etravirine to be well tolerated with a proven safety record. The nature and magnitude of adverse events observed during treatment suggest that etravirine may offer improved tolerability over existing antiretrovirals, including NNRTIs. Notably, adverse events reported with etravirine treatment are generally mild to moderate in severity. Rash has been shown to occur with a higher incidence in etravirine-treated patients versus placebo, but cases are generally mild to moderate, occur within the first few weeks, and resolve with continued use. In addition, the rate of adverse event-related discontinuations is low with etravirine. In summary, the safety and tolerability profile of etravirine, combined with its virologic efficacy, suggest that the drug may be a valuable option for treatment-experienced patients with HIV-1 infection.
C1 [Grinsztejn, Beatriz] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Ave Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
   [Di Perri, Giovanni] Univ Turin, Turin, Italy.
   [Towner, William] Kaiser Permanente, Los Angeles, CA USA.
   [Woodfall, Brian; De Smedt, Goedele; Peeters, Monika] Tibotec BVBA, Mechelen, Belgium.
RP Grinsztejn, B (corresponding author), Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Ave Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI Di Perri, Giovanni/AAC-1882-2019
FU Tibotec BVBA, Mechelen, Belgium
FX We are grateful to the patients, investigators, study center staff, Data
   and Safety Monitoring Boards, and Tibotec study personnel involved in
   the etravirine clinical development program. We thank Benny Baeten,
   Andrew Clark, and James Witek from Tibotec for their important
   contributions to the manuscript. We also thank Louise Marks
   (Gardiner-Caldwell Communications, Macclesfield, UK) for her assistance
   in drafting the manuscript and collating author contributions. This
   service was funded by Tibotec BVBA, Mechelen, Belgium.
CR Anderson MS, 2008, ANTIMICROB AGENTS CH, V52, P4228, DOI 10.1128/AAC.00487-08
   Andries K, 2004, ANTIMICROB AGENTS CH, V48, P4680, DOI 10.1128/AAC.48.12.4680-4686.2004
   Anuurad E, 2008, ATHEROSCLEROSIS, V198, P192, DOI 10.1016/j.atherosclerosis.2007.09.042
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   *BOEHR ING PHARM I, 2008, VIR NEV US PRESCR IN
   *BRIST MYERS SQUIB, 2008, SUST EF US PRESCR IN
   Capparelli E, 2005, SEMIN FETAL NEONAT M, V10, P161, DOI 10.1016/j.siny.2004.10.001
   Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3
   Cespedes MS, 2006, DRUG SAFETY, V29, P865, DOI 10.2165/00002018-200629100-00004
   Clark R, 2005, DRUG SAFETY, V28, P1075, DOI 10.2165/00002018-200528120-00003
   Clevenbergh P, 2003, HIV CLIN TRIALS, V4, P330, DOI 10.1310/8TXF-P814-8JPF-7TRY
   Clifford DB, 2005, ANN INTERN MED, V143, P714, DOI 10.7326/0003-4819-143-10-200511150-00008
   CLOTET B, 2008, 9 INT C DRUG THER HI
   Cohen CJ, 2009, AIDS, V23, P423, DOI 10.1097/QAD.0b013e32831c5040
   Dao H, 2007, AM J OBSTET GYNECOL, V197, pS42, DOI 10.1016/j.ajog.2007.03.001
   Davis J., 2007, 11 EUR AIDS C MADR S
   De Luca A, 2006, ANTIVIR THER, V11, P609
   Delaugerre C, 2001, J MED VIROL, V65, P445, DOI 10.1002/jmv.2055
   Demeter LM, 2000, ANTIMICROB AGENTS CH, V44, P794, DOI 10.1128/AAC.44.3.794-797.2000
   DIPERRI G, 2007, 11 EUR AIDS C MADR S
   Dube MP, 2003, CLIN INFECT DIS, V37, P613, DOI 10.1086/378131
   *EMEA, 2009, INT 100 MG TABL SUMM
   Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   Furco A, 2009, AIDS, V23, P434, DOI 10.1097/QAD.0b013e32832027d6
   Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x
   Gazzard BG, 2008, HIV MED, V9, P563, DOI 10.1111/j.1468-1293.2008.00636.x
   Grover SA, 2005, AM J CARDIOL, V95, P586, DOI 10.1016/j.amjcard.2004.11.004
   Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555
   HAUBRICH R, 2007, 45 ANN M INF DIS SOC
   Hill A, 2009, HIV CLIN TRIALS, V10, P1, DOI [10.1310/hct1001-001, 10.1310/hct1001-1]
   *HOFFM LAR INC, 2008, FUZ ENF US PRESCR IN
   IZURIETA P, 12 EACS 2009
   KAKUDA TN, 2008, 17 INT AIDS C MEX CI
   KATLAMA C, 2008, 17 INT AIDS C MEX CI
   Katlama C, 2009, AIDS, V23, P2289, DOI 10.1097/QAD.0b013e3283316a5e
   Lazzarin A, 2007, LANCET, V370, P39, DOI 10.1016/S0140-6736(07)61048-4
   Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2
   Manfredi R, 2005, HIV CLIN TRIALS, V6, P302, DOI 10.1310/EWWC-YLJ6-8LHE-054A
   Manfredi R, 2005, JAIDS-J ACQ IMM DEF, V38, P236, DOI 10.1097/01.qai.0000143037.70120.fc
   MELLORS, 1992, MOL PHARMACOL, V42, P174
   MELLORS JW, 1992, MOL PHARMACOL, V41, P446
   *MERCK CO INC, 2009, IS RALT US PRESCR IN
   MILLS A, 2008, 17 INT AIDS C MEX CI
   Montaner J, 2008, CLIN INFECT DIS, V47, P969, DOI 10.1086/591705
   Nolan D, 2005, DRUG SAFETY, V28, P1069, DOI 10.2165/00002018-200528120-00002
   *PAN ANT GUID AD A, 2008, GUID US ANT AG HIV 1
   Panagopoulos P, 2006, CLIN MICROBIOL INFEC, V12, P486, DOI 10.1111/j.1469-0691.2006.01372.x
   Parienti JJ, 2007, CLIN INFECT DIS, V45, P263, DOI 10.1086/518973
   *PFIZ INC, 2008, SELZ MAR US PRESCR I
   Raoof A., 2008, 17 INT AIDS C MEX CI
   RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994
   Ruxrungtham K, 2008, HIV MED, V9, P883, DOI 10.1111/j.1468-1293.2008.00644.x
   Stern JO, 2003, JAIDS-J ACQ IMM DEF, V34, pS21, DOI 10.1097/00126334-200309011-00005
   Taiwo B, 2006, INT J STD AIDS, V17, P364, DOI 10.1258/095646206777323346
   *TIB INC, 2008, INT ETR US PRESCR IN
   Trottier B, 2009, 18 ANN CAN C HIV AID
   van Leth F, 2004, PLOS MED, V1, P64, DOI 10.1371/journal.pmed.0010019
   van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
   Vrouenraets SME, 2007, EXPERT OPIN PHARMACO, V8, P851, DOI 10.1517/14656566.8.6.851
   WHO, ANT DRUGS TREAT PREG
   Yazdanpanah Y, 2008, 17 INT AIDS C MEX CI
   Young J, 2005, ANTIVIR THER, V10, P585
   Zhou ML, 2006, JAIDS-J ACQ IMM DEF, V43, P501
NR 65
TC 2
Z9 2
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUL
PY 2010
VL 26
IS 7
BP 725
EP 733
DI 10.1089/aid.2009.0293
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 626PF
UT WOS:000279977200001
PM 20624073
DA 2020-11-24
ER

PT J
AU Lazzarin, A
   Cahn, P
   Fourie, J
   Grinsztejn, B
   Hodder, S
   Molina, JM
   Ruxrungtham, K
   Workman, C
   Garau, M
   De Doncker, P
AF Lazzarin, A.
   Cahn, P.
   Fourie, J.
   Grinsztejn, B.
   Hodder, S.
   Molina, J. -M.
   Ruxrungtham, K.
   Workman, C.
   Garau, M.
   De Doncker, P.
TI Efficacy and Safety at 48 weeks of Once-daily (qd) versus Twice-daily
   (bid) Darunavir/ritonavir (DRV/r) in Treatment-experienced
   HIV-1-infected Patients with no DRV Resistance-Associated Mutations
   (RAMs) in the ODIN trial
SO INFECTION
LA English
DT Meeting Abstract
C1 [Lazzarin, A.] Fondazione Centro San Raffaele Monte Tabor, Milan, Italy.
   [Cahn, P.] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Fourie, J.] MRC, Tygerberg, South Africa.
   [Grinsztejn, B.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Hodder, S.] Univ Med & Dent New Jersey, Newark, NJ 07103 USA.
   [Molina, J. -M.] Hop St Louis, Paris, France.
   [Ruxrungtham, K.] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand.
   [Ruxrungtham, K.] Chulalongkorn Univ, Bangkok, Thailand.
   [Workman, C.] Ground Zero Med Ctr, Darlinghurst, NSW, Australia.
   [De Doncker, P.] Tibotec BVBA, Mechelen, Belgium.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU URBAN & VOGEL
PI MUNICH
PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY
SN 0300-8126
J9 INFECTION
JI Infection
PD JUN 10
PY 2010
VL 38
SU 1
BP 61
EP 62
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 613UM
UT WOS:000279007400106
DA 2020-11-24
ER

PT J
AU Wilkin, A
   Pozniak, AL
   Morales-Ramirez, J
   Steyn, D
   Santoscoy, M
   Grinsztejn, B
   Ruxrungtham, K
   Vanveggel, S
   Termini, R
   Boven, K
AF Wilkin, A.
   Pozniak, A. L.
   Morales-Ramirez, J.
   Steyn, D.
   Santoscoy, M.
   Grinsztejn, B.
   Ruxrungtham, K.
   Vanveggel, S.
   Termini, R.
   Boven, K.
TI TMC278 shows favorable tolerability and non-inferior efficacy compared
   to efavirenz over 192 weeks in HIV-1-infected treatment-naive patients
SO INFECTION
LA English
DT Meeting Abstract
C1 [Wilkin, A.] Wake Forest Univ Hlth Sci, Med Ctr Boulevard, Winston Salem, NC USA.
   [Pozniak, A. L.] Chelsea & Westminster NHS Fdn Trust, London, England.
   [Pozniak, A. L.] PKR SSR, London, England.
   [Morales-Ramirez, J.] Clin Res Puerto Rico Inc, San Juan, PR USA.
   [Steyn, D.] Univ Free State, Bloemfontein, South Africa.
   [Santoscoy, M.] Hosp Carlos Mac Gregor IMSS, Mexico City, DF, Mexico.
   [Grinsztejn, B.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Ruxrungtham, K.] Chulalongkorn Univ, Fac Med, Thai Red Cross AIDS Res Ctr, HIV NAT, Bangkok, Thailand.
   [Vanveggel, S.] Tibotec BVBA, Mechelen, Belgium.
   [Termini, R.] Janssen Cilag Spa, Cologno Monzese, MI, Italy.
   [Boven, K.] Tibotec Inc, Titusville, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU URBAN & VOGEL
PI MUNICH
PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY
SN 0300-8126
J9 INFECTION
JI Infection
PD JUN 10
PY 2010
VL 38
SU 1
BP 63
EP 64
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 613UM
UT WOS:000279007400109
DA 2020-11-24
ER

PT J
AU Gatell, JM
   Katlama, C
   Grinsztejn, B
   Eron, JJ
   Lazzarin, A
   Vittecoq, D
   Gonzalez, CJ
   Danovich, RM
   Wan, H
   Zhao, J
   Meibohm, AR
   Strohmaier, KM
   Harvey, CM
   Isaacs, RD
   Nguyen, BYT
AF Gatell, Jose M.
   Katlama, Christine
   Grinsztejn, Beatriz
   Eron, Joseph J.
   Lazzarin, Adriano
   Vittecoq, Daniel
   Gonzalez, Charles J.
   Danovich, Robert M.
   Wan, Hong
   Zhao, Jing
   Meibohm, Anne R.
   Strohmaier, Kim M.
   Harvey, Charlotte M.
   Isaacs, Robin D.
   Nguyen, Bach-Yen T.
CA Protocol 005 Team
TI Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir
   in Patients With Limited Treatment Options in a Phase II Study
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT 49th Interscience Conference on Antimicrobial Agents and Chemotherapy
   (ICAAC)
CY SEP 12-15, 2009
CL San Francisco, CA
DE HIV; AIDS; antiretroviral therapy; integrase inhibitor; resistance;
   raltegravir
ID TREATMENT-EXPERIENCED PATIENTS; RESISTANT HIV-1; INFECTION; SUBGROUP;
   COMBINATION; ASSOCIATION; ENFUVIRTIDE; RITONAVIR; AMERICA; TRIALS
AB Background: Raltegravir in combination therapy has demonstrated potent suppression of HIV-1 with a favorable safety profile. This report provides 96-week efficacy and safety data from Protocol 005, a Phase II study.
   Methods: HIV-infected patients with very limited treatment options and failing antiretroviral therapy were randomized to raltegravir 200, 400, or 600 mg or placebo b.i.d., plus optimized background therapy for >= 24 weeks; all patients were then offered open-label raltegravir 400 mg b.i.d. Efficacy measurements included changes in viral load and CD4 count from baseline and percent of patients with HIV-1 RNA < 400 and < 50 copies/mL.
   Results: One hundred and thirty-three patients received raltegravir and 45 received placebo. No dose-dependent differentiation in the safety or antiviral activity of raltegravir was observed during the double-blind phase. For the combined raltegravir groups, mean change in viral load from baseline was -1.60 log(10) copies/mL at week 48 and -1.38 log(10) copies/mL at week 96 (observed failure approach). At week 48, HIV-1 RNA levels were < 400 copies/mL in 68% of raltegravir recipients and < 50 copies/mL in 55%; these levels were maintained in 55% and 48% of raltegravir recipients, respectively, at week 96 (noncompleter = failure). There were few discontinuations of raltegravir (4%) due to adverse events.
   Conclusions: In patients with limited treatment options, raltegravir with OBT had a potent and sustained antiretroviral effect and was generally well tolerated through 96 weeks.
C1 [Wan, Hong; Zhao, Jing; Meibohm, Anne R.; Strohmaier, Kim M.; Harvey, Charlotte M.; Isaacs, Robin D.; Nguyen, Bach-Yen T.] Merck Res Labs, N Wales, PA 19454 USA.
   [Gatell, Jose M.] Univ Barcelona, Barcelona, Spain.
   [Katlama, Christine] Hop La Pitie Salpetriere, Paris, France.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   [Eron, Joseph J.] Univ N Carolina, Chapel Hill, NC USA.
   [Lazzarin, Adriano] Ist Sci San Raffaele, I-20132 Milan, Italy.
   [Vittecoq, Daniel] Hop Paul Brousse, Villejuif, France.
   [Gonzalez, Charles J.] NYU, Sch Med, New York, NY USA.
   [Danovich, Robert M.] Percepticore LLC, Doylestown, PA USA.
RP Nguyen, BYT (corresponding author), Merck Res Labs, POB 1000, N Wales, PA 19454 USA.
EM bachyen_n-guyen@merck.com
RI Gatell, Jose M/ABC-3607-2020; Soriano, Vicente/O-5730-2018
OI Kozal, Michael/0000-0002-3100-8254; Soriano,
   Vicente/0000-0002-4624-5199; LAZZARIN, Adriano/0000-0003-2551-7754
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI074621, P01AI074621, P01AI074621, P01AI074621, P01AI074621,
   P01AI074621, P01AI074621, R24AI106039, R24AI106039, P01AI074621,
   P01AI074621, P01AI074621, P01AI074621, R24AI106039, P01AI074621,
   P01AI074621, P01AI074621, P01AI074621, R24AI106039, R24AI106039,
   P01AI074621, P01AI074621, P01AI074621, P01AI074621, P01AI074621,
   P01AI074621, P01AI074621, P01AI074621, P01AI074621, P01AI074621,
   R24AI106039, P01AI074621, R24AI106039, P01AI074621] Funding Source: NIH
   RePORTER; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R24 AI106039, P01 AI074621]
   Funding Source: Medline
CR Aberg JA, 2009, CLIN INFECT DIS, V49, P651, DOI 10.1086/605292
   Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   Dicenzo R, 2006, J ANTIMICROB CHEMOTH, V58, P393, DOI 10.1093/jac/dkl238
   Fatkenheuer G, 2008, NEW ENGL J MED, V359, P1442, DOI 10.1056/NEJMoa0803154
   GRINSZTEJN B, 2007, 47 INT C ANT AG CHEM
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Havlir DV, 2004, CLIN INFECT DIS, V38, P1599, DOI 10.1086/420932
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hicks CB, 2006, LANCET, V368, P466, DOI 10.1016/S0140-6736(06)69154-X
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026
   Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211
   Markowitz M, 2009, JAIDS-J ACQ IMM DEF, V52, P350, DOI 10.1097/QAI.0b013e3181b064b0
   MILLER M, 2008, 17 INT HIV DRUG RES
   Miller M., 2006, 16 INT AIDS C TOR CA
   STEIGBIGEL R, 2009, 16 C RETR OPP INF MO
NR 16
TC 46
Z9 48
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 1
PY 2010
VL 53
IS 4
BP 456
EP 463
DI 10.1097/QAI.0b013e3181c9c967
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 567YW
UT WOS:000275486600004
PM 20306554
DA 2020-11-24
ER

PT J
AU Pozniak, AL
   Morales-Ramirez, J
   Katabira, E
   Steyn, D
   Lupo, SH
   Santoscoy, M
   Grinsztejn, B
   Ruxrungtham, K
   Rimsky, LT
   Vanveggel, S
   Boven, K
AF Pozniak, Anton L.
   Morales-Ramirez, Javier
   Katabira, Elly
   Steyn, Dewald
   Lupo, Sergio H.
   Santoscoy, Mario
   Grinsztejn, Beatriz
   Ruxrungtham, Kiat
   Rimsky, Laurence T.
   Vanveggel, Simon
   Boven, Katia
CA TMC278-C204 Study Grp
TI Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients:
   week 96 results of a phase IIb randomized trial
SO AIDS
LA English
DT Article
DE antiretroviral therapy; HIV-1; nonnucleoside reverse transcriptase
   inhibitors; TMC278; treatment-naive
ID REVERSE-TRANSCRIPTASE INHIBITORS; RESISTANCE MUTATIONS;
   CROSS-RESISTANCE; THERAPY; NEVIRAPINE; EFAVIRENZ; REGIMENS; PROFILE;
   DRUGS
AB Objective: TMC278 is a next-generation nonnucleoside reverse transcriptase inhibitor highly active against wild-type and nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in vitro. The week 96 analysis of TMC278-C204, a large close-ranging study of TMC278 in treatment-naive HIV-1-infected patients, is presented.
   Design: Phase IIb randomized trial.
   Methods: Three hundred sixty-eight patients were randomized and treated with three blinded once-daily TMC278 doses 25, 75 or 150 mg, or an open-label, active control, efavirenz 600 mg once daily, all with two nucleoside reverse transcriptase inhibitors. The primary analysis was at week 48.
   Results: No TMC278 close-response relationship for efficacy and safety was observed. TMC278 demonstrated potent antiviral efficacy comparable with efavirenz over 48 weeks that was sustained to week 96 (76.9-80.0% and 71.4-76.3% of TMC278-treated patients with confirmed viral load <50 copies/ml, respectively; time-to-loss of virological-response algorithm). Median increases from baseline in CD4 cell Count with TMC278 at week 96 (138.0-149.0 cells/mu l) were higher than at week 48 (108.0-123.0 cells/mu l). All TMC278 closes were well tolerated. The incidences of the most commonly reported grade 2-4 adverse events at least possibly related to study medication, including nausea, dizziness, abnormal dreams/nightmare, dyspepsia, asthenia, rash, somnolence and vertigo, were low and lower with TMC278 than with efavirenz. Incidences of serious adverse events, grade 3 or 4 adverse events and discontinuations clue to adverse events were similar among groups.
   Conclusion: All TMC278 closes demonstrated potent and sustained efficacy comparable with efavirenz in treatment-naive patients over 96 weeks. TMC278 was well tolerated with lower incidences of neurological and psychiatric adverse events, rash and lower lipid elevations than those with efavirenz. TMC278 25 mg once daily was selected for further clinical development. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Pozniak, Anton L.] Chelsea & Westminster NHS Fdn Trust, London SW10 9NH, England.
   [Pozniak, Anton L.] PKR SSR, London, England.
   [Morales-Ramirez, Javier] Clin Res Puerto Rico Inc, San Juan, PR USA.
   [Katabira, Elly] Makerere Univ, Kampala, Uganda.
   [Steyn, Dewald] Univ Free State, Bloemfontein, South Africa.
   [Lupo, Sergio H.] Univ Nacl Rosario, RA-2000 Rosario, Santa Fe, Argentina.
   [Santoscoy, Mario] Hosp Carlos Mac Gregor IMSS, Mexico City, DF, Mexico.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Ruxrungtham, Kiat] Chulalongkorn Univ, HIV NAT, Thai Red Cross AIDS Res Ctr, Fac Med, Bangkok, Thailand.
   [Ruxrungtham, Kiat] Chulalongkorn Univ, Dept Med, Fac Med, Bangkok, Thailand.
   [Rimsky, Laurence T.; Vanveggel, Simon] Tibotec BVBA, Mechelen, Belgium.
   [Boven, Katia] Tibotec Inc, Yardley, PA USA.
RP Pozniak, AL (corresponding author), Chelsea & Westminster NHS Fdn Trust, 369 Fulham Rd, London SW10 9NH, England.
EM anton.pozniak@chelwest.nhs.uk
FU Tibotec; F Hoffmann-La RocheHoffmann-La Roche; MerckMerck & Company;
   Sharp and Dohme; Bristol-Myers SquibbBristol-Myers Squibb; GileadGilead
   Sciences; AbbottAbbott Laboratories; Glaxo SmithKlineGlaxoSmithKline
FX J.M.-R., D.S., S.L. and B.G. have no contractual obligations,
   restrictions or conflicts of interest that prevent their participation
   in this publication. E.K. is a member of the Tibotec Global Access
   Program Advisory Board, and as a result Of thiS membership, has received
   two honoraria for attending two meetings. K.R. and A.P. have received
   consultancy fees, and/or honoraria, travel grants, and/or research
   grants from Tibotec, F Hoffmann-La Roche, Merck, Sharp and Dohme,
   Bristol-Myers Squibb, Gilead, Abbott and Glaxo SmithKline. M.S. has
   attended advisory boards and/or received consultancy fees, and/or
   honoraria, and/or educational/travel rants from Abbott, Aventis, Bayer,
   Boehringer-Ingelheim/Promeco, Bristol-Myers Squibb, Gilead/Stendhal,
   Glaxo SmithKline, Merck Sharp & Dohme, Roche, Schering-Plough, Serono
   and Tibotec/Janssen-Cilag. L.T.R., S.V and K.B. are full-time employees
   of Tibotec.
CR [Anonymous], DHHS GUID
   Antinori A, 2002, AIDS RES HUM RETROV, V18, P835, DOI 10.1089/08892220260190308
   Basavapathruni A, 2004, J BIOL CHEM, V279, P6221, DOI 10.1074/jbc.C300523200
   *BOEHR ING, 2008, FDA LAB VIR NEV TABL
   *BRIST MYERS SQUIB, 2009, FDA LAB SUST EF CAPS
   *DAIDS, 2004, DIV ACQ IMM DEF SYND
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   DEBETHUNE MP, 2005, 12 C RETR OPP INF 22
   Delaugerre C, 2001, J MED VIROL, V65, P445, DOI 10.1002/jmv.2055
   *FDA GUID IND, 2002, ANT DRUGS US PLASM H
   Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Goebel F, 2006, AIDS, V20, P1721, DOI 10.1097/01.aids.0000242818.65215.bd
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   MELLORS JW, 1992, MOL PHARMACOL, V41, P446
   Moyle G, 2001, DRUGS, V61, P19, DOI 10.2165/00003495-200161010-00003
   Perez-Molina Jose A, 2002, HIV Clin Trials, V3, P279, DOI 10.1310/3Q91-YT2D-BUT4-8HN6
   POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712
   Pozniak AL, 2006, JAIDS-J ACQ IMM DEF, V43, P535
   RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994
   Richman DD, 2004, AIDS, V18, P1393, DOI 10.1097/01.aids.0000131310.52526.c7
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   TAMBUYZER L, 2007, 5 EUR HIV DRUG RES W
   *TIB INC, 2008, INT ETR CAN PRESCR I
   *TIB THER, 2008, FDA LAB INT ETR TABL
   van der Valk M, 2001, AIDS, V15, P2407, DOI 10.1097/00002030-200112070-00008
   van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7
   VANDAMME AM, 1994, AIDS RES HUM RETROV, V10, P39, DOI 10.1089/aid.1994.10.39
   Weiser SD, 2004, HIV CLIN TRIALS, V5, P278, DOI 10.1310/LNHD-K1R7-HQP5-HJCQ
NR 28
TC 93
Z9 96
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JAN 2
PY 2010
VL 24
IS 1
BP 55
EP 65
DI 10.1097/QAD.0b013e32833032ed
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 534SP
UT WOS:000272917900008
PM 19926964
DA 2020-11-24
ER

PT J
AU Katlama, C
   Clotet, B
   Mills, A
   Trottier, B
   Molina, JM
   Grinsztejn, B
   Towner, W
   Haubrich, R
   Nijs, S
   Vingerhoets, J
   Woodfall, B
   Witek, J
AF Katlama, Christine
   Clotet, Bonaventura
   Mills, Anthony
   Trottier, Benoit
   Molina, Jean-Michel
   Grinsztejn, Beatriz
   Towner, William
   Haubrich, Richard
   Nijs, Steven
   Vingerhoets, Johan
   Woodfall, Brian
   Witek, James
TI Efficacy and safety of etravirine at week 96 in treatment-experienced
   HIV type-1-infected patients in the DUET-1 and DUET-2 trials
SO ANTIVIRAL THERAPY
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; HIV-1-INFECTED PATIENTS; TMC125 ETRAVIRINE;
   DOUBLE-BLIND
AB Background: Durable efficacy and long-term safety of antiretroviral therapy are important goals in the management of treatment-experienced patients. The 96-week efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine were evaluated in the Phase Ill DUET trials.
   Methods: HIV type-1-infected treatment-experienced adults with viral loads >5,000 copies/ml and NNRTI and protease inhibitor resistance were randomized to receive etravirine 200 mg or placebo, each twice daily and in combination with a background regimen of darunavir/ritonavir twice daily, nucleoside/nucleotide reverse transcriptase inhibitors and optional enfuvirtide. The primary end point was the proportion of patients with viral load <50 copies/ml (intent-to-treat analysis, time-to-loss of virological response algorithm) at week 24. Results from both trials were combined in the pre-specified pooled 96-week analysis.
   Results: In total, 599 patients received etravirine and 604 received placebo. At week 96, 57% of patients in the etravirine group versus 36% in the placebo group had a viral load <50 copies/ml (P<0.0001); 91% and 88% of patients, respectively, had maintained this response from week 48. Mean increases in CD4(+) T-cell count from baseline at week 96 were 128 cells/mm(3) with etravirine versus 86 cells/mm3 with placebo (P<0.0001). With the exception of rash, which was reported more frequently with etravirine than placebo (21% versus 12%, respectively; P<0.0001), the safety and tolerability profile of etravirine was similar to placebo over the treatment period.
   Conclusions: Etravirine, in combination with an antiretroviral background regimen, provided durable virological and immunological responses with no new safety concerns in treatment-experienced patients over 96 weeks in the DUET trials.
C1 [Katlama, Christine] Univ Paris 06, Paris 6, France.
   [Katlama, Christine] Hop La Pitie Salpetriere, Serv Malad Infect & Trop, Paris, France.
   [Clotet, Bonaventura] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain.
   [Clotet, Bonaventura] IrsiCaixa Fdn, Barcelona, Spain.
   [Trottier, Benoit] Clin Med Actuel, Montreal, PQ, Canada.
   [Molina, Jean-Michel] Hop St Louis, Serv Malad Infect & Trop, Paris, France.
   [Molina, Jean-Michel] Univ Paris Diderot, Paris 7, France.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Towner, William] Kaiser Permanente, Los Angeles, CA USA.
   [Haubrich, Richard] Univ Calif San Diego, Div Infect Dis, San Diego, CA 92103 USA.
   [Nijs, Steven; Vingerhoets, Johan; Woodfall, Brian] Tibotec BVBA, Beerse, Belgium.
   [Witek, James] Tibotec Inc, Titusville, NJ USA.
RP Katlama, C (corresponding author), Univ Paris 06, Paris 6, France.
EM christine.katlama@psl.aphp.fr
OI Mills, Anthony/0000-0002-6997-5581
FU Tibotec Pharmaceuticals, Ltd.; Tibotec; Abbott LaboratoriesAbbott
   Laboratories; Boehringer IngelheimBoehringer Ingelheim; Gilead
   SciencesGilead Sciences; GlaxoSmithKlineGlaxoSmithKline;
   Janssen-CilagJohnson & Johnson USAJanssen Biotech Inc; MerckMerck &
   Company; Panacos; PfizerPfizer; RocheRoche Holding; Schering-PloughMerck
   & CompanySchering Plough Corporation; Progenics; Virco; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [K24AI064086, K24AI064086, K24AI064086, K24AI064086, K24AI064086,
   K24AI064086, K24AI064086, K24AI064086, K24AI064086, K24AI064086] Funding
   Source: NIH RePORTER
FX The authors thank the patients and their families, the study
   coordinators, the investigators who participated in the DUET clinical
   trials and Tibotec study personnel. They also acknowledge Benny Baeten,
   Stephan Marks and David Anderson for their important contributions to
   the manuscript. Assistance in drafting the manuscript and collating
   author contributions was provided by Emily de Looze (Medical Writer;
   Gardiner-Caldwell Communications, Macclesfield, UK). This service was
   funded by Tibotec Pharmaceuticals, Ltd.; All study investigators
   received research funding from Tibotec to support their patients'
   participation in this trial. CK has served on advisory boards for Abbott
   Laboratories, Boehringer Ingelheim, GlaxoSmithKline, Janssen-Cilag,
   Merck, Pfizer, Roche and Tibotec. BC has received research funding,
   consultancy fees, or lecture sponsorships from, or has served on
   advisory boards for Abbott Laboratories, Boehringer Ingelheim, Gilead
   Sciences, GlaxoSmithKline, Janssen-Cilag, Merck, Panacos, Pfizer, Roche
   and Tibotec. AM has received research support from Tibotec, Merck,
   Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Pfizer and
   Schering-Plough; he has served as a consultant for Tibotec, Merck,
   Gilead Sciences, Abbott Laboratories and Solvay, and has been on
   speakers' bureaus for Tibotec, Merck, Gilead Sciences, Serono,
   Bristol-Myers Squibb and Boehringer Ingelheim. BT has received honoraria
   for participation in advisory boards or as a speaker from Abbott
   Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead
   Sciences, GlaxoSmithKline, Merck, Pfizer, Roche and Tibotec. J-MM has
   received honoraria for participation in advisory boards and/or lectures
   for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Pfizer,
   GlaxoSmithKline and Tibotec. WT has received research support from
   Tibotec, Pfizer, Bristol-Myers Squibb, Schering-Plough, Merck and Gilead
   Sciences. On behalf of RH, the University of California San Diego has
   received research grants from Tibotec, GlaxoSmithKline and Abbott
   Laboratories; RH has received honoraria for consulting/lectures from
   Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences,
   GlaxoSmithKline, Merck, Pfizer, Progenics, Schering-Plough, Tibotec and
   Virco. SN, JV, BW and JW are full-time employees of Tibotec. BG declares
   no competing interests.
CR *EUR MED AG, INT ETR
   Johnson Victoria A, 2005, Top HIV Med, V13, P125
   Katlama C, 2009, AIDS, V23, P2289, DOI 10.1097/QAD.0b013e3283316a5e
   Lazzarin A, 2007, LANCET, V370, P39, DOI 10.1016/S0140-6736(07)61048-4
   Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2
   NOZZA S, 2008, 9 INT C DRUG THER HI
   Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG HIV 1
   TAMBUYZER L, 2007, 5 EUR HIV DRUG RES W
   TAMBUYZER L, 2010, AIDS RES HU IN PRESS
   Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004
   *TIB INC, INTELENCE ETR TABL F
   Towner W, 2010, JAIDS-J ACQ IMM DEF, V53, P614, DOI 10.1097/QAI.0b013e3181cdebb1
   Vingerhoets J, 2010, AIDS, V24, P503, DOI 10.1097/QAD.0b013e32833677ac
   Yazdanpanah Y, 2009, CLIN INFECT DIS, V49, P1441, DOI 10.1086/630210
NR 14
TC 87
Z9 92
U1 0
U2 4
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2010
VL 15
IS 7
BP 1045
EP 1052
DI 10.3851/IMP1662
PG 8
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 683XZ
UT WOS:000284512900014
PM 21041921
DA 2020-11-24
ER

PT J
AU Japiassu, AM
   Amancio, RT
   Mesquita, EC
   Medeiros, DM
   Bernal, HB
   Nunes, EP
   Luz, PM
   Grinsztejn, B
   Bozza, FA
AF Japiassu, Andre M.
   Amancio, Rodrigo T.
   Mesquita, Emerson C.
   Medeiros, Denise M.
   Bernal, Helena B.
   Nunes, Estevao P.
   Luz, Paula M.
   Grinsztejn, Beatriz
   Bozza, Fernando A.
TI Sepsis is a major determinant of outcome in critically ill HIV/AIDS
   patients
SO CRITICAL CARE
LA English
DT Article
ID HIV-INFECTED PATIENTS; ACTIVE ANTIRETROVIRAL THERAPY; RIO-DE-JANEIRO;
   INTENSIVE-CARE; SEPTIC SHOCK; UNITED-STATES; SURVIVING SEPSIS; ORGAN
   FAILURE; SAPS-II; EPIDEMIOLOGY
AB Introduction: New challenges have arisen for the management of critically ill HIV/AIDS patients. Severe sepsis has emerged as a common cause of intensive care unit (ICU) admission for those living with HIV/AIDS. Contrastingly, HIV/AIDS patients have been systematically excluded from sepsis studies, limiting the understanding of the impact of sepsis in this population. We prospectively followed up critically ill HIV/AIDS patients to evaluate the main risk factors for hospital mortality and the impact of severe sepsis on the short-and long-term survival.
   Methods: All consecutive HIV-infected patients admitted to the ICU of an infectious diseases research center, from June 2006 to May 2008, were included. Severity of illness, time since AIDS diagnosis, CD4 cell count, antiretroviral treatment, incidence of severe sepsis, and organ dysfunctions were registered. The 28-day, hospital, and 6-month outcomes were obtained for all patients. Cox proportional hazards regression analysis measured the effect of potential factors on 28-day and 6-month mortality.
   Results: During the 2-year study period, 88 HIV/AIDS critically ill patients were admitted to the ICU. Seventy percent of patients had opportunist infections, median CD4 count was 75 cells/mm(3), and 45% were receiving antiretroviral therapy. Location on a ward before ICU admission, cardiovascular and respiratory dysfunctions on the first day after admission, and the presence of severe sepsis/septic shock were associated with reduced 28-day and 6-month survival on a univariate analysis. After a multivariate analysis, severe sepsis determined the highest hazard ratio (HR) for 28-day (adjusted HR, 3.13; 95% CI, 1.21-8.07) and 6-month (adjusted HR, 3.35; 95% CI, 1.42-7.86) mortality. Severe sepsis occurred in 44 (50%) patients, mainly because of lower respiratory tract infections. The survival of septic and nonseptic patients was significantly different at 28-day and 6-month follow-up times (log-rank and Peto test, P < 0.001).
   Conclusions: Severe sepsis has emerged as a major cause of admission and mortality for hospitalized HIV/AIDS patients, significantly affecting short-and longer-term survival of critically ill HIV/AIDS patients.
C1 [Japiassu, Andre M.; Amancio, Rodrigo T.; Mesquita, Emerson C.; Medeiros, Denise M.; Bozza, Fernando A.] Fundacao Oswaldo Cruz, Intens Care Unit, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, Brazil.
   [Bernal, Helena B.; Nunes, Estevao P.; Luz, Paula M.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, HIV AIDS Res Ctr, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Intens Care Unit, Inst Pesquisa Clin Evandro Chagas, Av Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Mesquita,
   Emersom/0000-0002-5132-3315; Luz, Paula/0000-0001-9746-719X
CR Afessa B, 2000, CHEST, V118, P138, DOI 10.1378/chest.118.1.138
   Ballester JCA, 2008, INFECT CONT HOSP EP, V29, P630, DOI 10.1086/589583
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087
   Arthur G, 2001, CLIN INFECT DIS, V33, P248, DOI 10.1086/321820
   Beale R, 2009, INFECTION, V37, P222, DOI 10.1007/s15010-008-8203-z
   Becker JU, 2009, LANCET INFECT DIS, V9, P577, DOI 10.1016/S1473-3099(09)70135-5
   Blanco J, 2008, CRIT CARE, V12, DOI 10.1186/cc7157
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Bozza FA, 2010, LANCET INFECT DIS, V10, P290, DOI 10.1016/S1473-3099(10)70074-8
   Brun-Buisson C, 2004, INTENS CARE MED, V30, P580, DOI 10.1007/s00134-003-2121-4
   Casalino E, 2004, AIDS, V18, P1429, DOI 10.1097/01.aids.0000131301.55204.a7
   Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P308
   Cheng AC, 2008, PLOS MED, V5, P1173, DOI 10.1371/journal.pmed.0050175
   Croda J, 2009, CRIT CARE MED, V37, P1605, DOI 10.1097/CCM.0b013e31819da8c7
   Davaro Raul E, 2007, J Intensive Care Med, V22, P73, DOI 10.1177/0885066606297964
   Davis JL, 2008, THORAX, V63, P988, DOI 10.1136/thx.2008.095786
   Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41
   Grinsztejn B, 1997, ARCH INTERN MED, V157, P2359, DOI 10.1001/archinte.157.20.2359
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
   Huang L, 2006, NEW ENGL J MED, V355, P173, DOI 10.1056/NEJMra050836
   Hung CC, 1998, J FORMOS MED ASSOC, V97, P690
   Khouli Hassan, 2005, J Intensive Care Med, V20, P327
   Khwannimit B, 2009, EPIDEMIOL INFECT, V137, P1333, DOI 10.1017/S0950268809002027
   Le Gall JR, 2005, CRIT CARE, V9, pR645, DOI 10.1186/cc3821
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Morris A, 2002, AM J RESP CRIT CARE, V166, P262, DOI 10.1164/rccm.2111025
   Mrus JM, 2005, CRIT CARE, V9, pR623, DOI 10.1186/cc3811
   Narasimhan M, 2004, CHEST, V125, P1800, DOI 10.1378/chest.125.5.1800
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Palacios R, 2006, HIV MED, V7, P193, DOI 10.1111/j.1468-1293.2006.00353.x
   Petrosillo N, 2003, INFECTION, V31, P28, DOI 10.1007/s15010-003-8227-3
   Powell K, 2009, CHEST, V135, P11, DOI 10.1378/chest.08-0980
   Rosen MJ, 2006, CRIT CARE MED, V34, pS245, DOI 10.1097/01.CCM.0000232491.15369.AB
   Rosenberg AL, 2001, CRIT CARE MED, V29, P548, DOI 10.1097/00003246-200103000-00013
   Sales Júnior João Andrade L., 2006, Rev. bras. ter. intensiva, V18, P9, DOI 10.1590/S0103-507X2006000100003
   Silva E, 2004, CRIT CARE, V8, pR251, DOI 10.1186/cc2892
   Soares M, 2007, INTENS CARE MED, V33, P1014, DOI 10.1007/s00134-007-0623-1
   Schmaltz CAS, 2009, JAIDS-J ACQ IMM DEF, V52, P623, DOI 10.1097/QAI.0b013e3181b31e56
   Thyrault M, 1997, INTENS CARE MED, V23, P1018, DOI 10.1007/s001340050451
   Tumbarello M, 2000, J ACQ IMMUN DEF SYND, V23, P145
   *UNAIDS WHO, AIDS EP UPD 2009
   Vidal F, 1999, EUR J CLIN MICROBIOL, V18, P473, DOI 10.1007/s100960050326
   Vincent B, 2004, INTENS CARE MED, V30, P859, DOI 10.1007/s00134-004-2158-z
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156
   Waddell RD, 2001, AIDS, V15, P55, DOI 10.1097/00002030-200101050-00009
   Zubrod C.G, 1960, J CHRON DIS, V11, P7, DOI DOI 10.1016/0021-9681(60)90137-5
NR 51
TC 57
Z9 58
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PY 2010
VL 14
IS 4
AR R152
DI 10.1186/cc9221
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 680JJ
UT WOS:000284227900027
PM 20698966
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Silva, MTT
   Serpa, MJA
   Araujo, A
   Leite, AC
   Grinsztejn, B
   Campos, D
   Braga, E
   Neves, E
   Pilotto, JH
   Lima, MA
   Harab, R
   Santos, VV
AF Silva, M. T. T.
   Serpa, M. J. A.
   Araujo, A.
   Leite, A. C.
   Grinsztejn, B.
   Campos, D.
   Braga, E.
   Neves, E.
   Pilotto, J. H.
   Lima, M. A.
   Harab, R.
   Santos, V. V.
TI Neurological Manifestations in HIV/HTLV-Coinfected Patients
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 14th International Conference on Human Retrovirology HTLV and Related
   Retroviruses
CY JUL 01-04, 2009
CL Salvador, BRAZIL
C1 [Silva, M. T. T.; Serpa, M. J. A.; Araujo, A.; Leite, A. C.; Grinsztejn, B.; Campos, D.; Braga, E.; Neves, E.; Pilotto, J. H.; Lima, M. A.; Harab, R.; Santos, V. V.] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
RI Pilotto, Jose Henrique/AAD-9773-2019; Silva, Marcus Tulius/AAM-1077-2020
OI Pilotto, Jose Henrique/0000-0003-0521-8597; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2009
VL 25
IS 11
BP 1276
EP 1277
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 524ZF
UT WOS:000272182200207
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Veloso, VG
   Friedman, RK
   Moreira, RI
   Luz, PM
   Campos, DP
   Pilotto, JH
   Cardoso, SW
   Keruly, JC
   Moore, RD
AF Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Friedman, Ruth K.
   Moreira, Ronaldo I.
   Luz, Paula M.
   Campos, Dayse P.
   Pilotto, Jose H.
   Cardoso, Sandra W.
   Keruly, Jeanne C.
   Moore, Richard D.
TI Early mortality and cause of deaths in patients using HAART in Brazil
   and the United States
SO AIDS
LA English
DT Article
DE antiretroviral therapy; causes of death; cohort; early mortality;
   HIV/AIDS
ID ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE RECONSTITUTION DISEASE;
   RIO-DE-JANEIRO; SOUTH-AFRICA; HIV-1-INFECTED PATIENTS; TREATMENT
   PROGRAM; HIV-INFECTION; TUBERCULOSIS; ADULTS; AIDS
AB Objective: To compare the early mortality pattern and causes of death among patients starting HAART in Brazil and the United States.
   Methods: We analyzed the combined data from two clinical cohorts followed at the Johns Hopkins AIDS Service in Baltimore, United States, and the Evandro Chagas Clinical Research Institute AIDS Clinic in Rio de Janeiro, Brazil. Participants included those who entered either cohort between 1999 and 2007 and were antiretroviral naive. Follow-up was at 1 year since HAART initiation. Cox proportional hazards regression analysis was used to assess the role of the city on the risk of death.
   Results: A total of 859 and 915 participants from Baltimore and Rio de Janeiro, respectively, were included. In Rio de Janeiro, 64.7% of deaths occurred within 90 days of HAART initiation; in Baltimore, 48.9% occurred between 180 and 365 days. AIDS-defining illness (61.8%) and non-AIDS-defining illness (55.6%) predominated as causes of death in Rio de Janeiro and Baltimore, respectively. Risk of death was similar in both cities (hazard ratio 1.04; P value=0.95) after adjusting for CD4(+) T cell count, age, sex, HIV risk group, prior AIDS-defining illness, and Pneumocystis jirovecii pneumonia and Mycobacterium avium prophylaxis. Individuals with CD4+ T cell count less than or equal to 50cells/mu l (hazard ratio 4.36; P=0.001) or older (hazard ratio, 1.03; P=0.03) were more likely to die.
   Conclusion: Although late HIV diagnosis is a problem both in developed and developing countries, differences in the timing and causes of deaths clearly indicate that, besides interventions for early HIV diagnosis, different strategies to curb early mortality need to be tailored in each country. (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
C1 [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas, Fundacao Oswaldo Cruz, Lab Pesquisa Clin DST & AIDS, BR-21045900 Rio De Janeiro, Brazil.
   [Keruly, Jeanne C.; Moore, Richard D.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
RP Grinsztejn, B (corresponding author), Inst Pesquisa Clin Evandro Chagas, Fundacao Oswaldo Cruz, Lab Pesquisa Clin DST & AIDS, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM beatriz.grinsztejn@ipec.fiocruz.br
RI Cardoso, Sandra W/D-7965-2015; Veloso, Valdilea Goncalves/J-6189-2012;
   Pilotto, Jose Henrique/AAD-9773-2019
OI Cardoso, Sandra W/0000-0001-5230-0003; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Luz, Paula/0000-0001-9746-719X
FU National Counsel of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); National Institutes of Health (NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [R01 DA11602, R01 AA18693, K24 DA00432]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI094189, U01AI069918, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   U01AI069918, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, U01AI069918, P30AI094189,
   U01AI069918, P30AI094189, P30AI094189, U01AI069918, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, U01AI069918, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, U01AI069918, P30AI094189, P30AI094189, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   U01AI069918, U01AI069918, U01AI069918, P30AI094189, P30AI094189,
   P30AI094189, U01AI069918, P30AI094189, U01AI069918, P30AI094189,
   P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189,
   U01AI069918, P30AI094189, U01AI069918, P30AI094189, P30AI094189,
   P30AI094189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL
   ABUSE AND ALCOHOLISMUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Alcohol Abuse & Alcoholism (NIAAA) [R01AA016893, R01AA016893,
   R21AA015032, R01AA018693, R01AA018693, R01AA016893, R01AA018693,
   R01AA018693, R01AA016893, R01AA018693, R21AA015032, R01AA018693] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Drug Abuse (NIDA) [R01DA011602,
   R01DA011602, R01DA011602, K24DA000432, K24DA000432, R01DA011602,
   R01DA011602, R01DA011602, R01DA011602, R01DA011602, R01DA011602,
   R01DA011602, R01DA011602, K24DA000432, R01DA011602, R01DA011602,
   K24DA000432, R01DA011602, K24DA000432, K24DA000432, K24DA000432,
   K24DA000432, R01DA011602, K24DA000432, K24DA000432, R01DA011602] Funding
   Source: NIH RePORTER
FX B.G. acknowledges funding from the National Counsel of Technological and
   Scientific Development (CNPq) and the Research Funding Agency of the
   State of Rio de Janeiro (FAPERJ). R.M. acknowledges funding from
   National Institutes of Health (NIH): R01 DA11602, R01 AA18693, K24
   DA00432.
CR Allison P.D., 1995, SURVIVAL ANAL USING
   Braitstein P, 2006, LANCET, V367, P817
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   CAMPOS DP, 2006, 10 C INF HLTH FLOR
   Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200406003-00006
   Dore GJ, 2002, J ACQ IMMUN DEF SYND, V29, P388, DOI 10.1097/00126334-200204010-00010
   Dromer F, 2007, PLOS MED, V4, P297, DOI 10.1371/journal.pmed.0040021
   Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4
   Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01
   Getahun H, 2007, LANCET, V369, P2042, DOI 10.1016/S0140-6736(07)60284-0
   Girardi E, 2007, JAIDS-J ACQ IMM DEF, V46, pS3, DOI 10.1097/01.qai.0000286597.57066.2b
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568
   Jarvis JN, 2009, CLIN INFECT DIS, V48, P856, DOI 10.1086/597262
   KAMBUGU A, 2007, 4 IAS C HIV PATH TRE
   KARIM SA, 2009, 16 C RETR OPP INF MO
   Lawn SD, 2005, AIDS, V19, P2050, DOI 10.1097/01.aids.0000191232.16111.f9
   Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1
   Lawn SD, 2007, AIDS, V21, P335, DOI 10.1097/QAD.0b013e328011efac
   Lee LM, 2001, JAMA-J AM MED ASSOC, V285, P1308, DOI 10.1001/jama.285.10.1308
   Lucas GM, 2006, AM J EPIDEMIOL, V163, P412, DOI 10.1093/aje/kwj059
   Moh R, 2007, AIDS, V21, P2483, DOI 10.1097/QAD.0b013e3282f09876
   Moore D, 2007, AIDS, V21, P713, DOI 10.1097/QAD.0b013e328013f632
   Moore RD, 1998, J ACQ IMMUN DEF SYND, V17, pS38, DOI 10.1097/00042560-199801001-00011
   Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298
   Saraceni V, 2008, INT J TUBERC LUNG D, V12, P769
   SAS Institute Inc, 2002, SAS ONL DOC 9 1 3
   Souza PRB, 2007, CLINICS, V62, P579, DOI 10.1590/S1807-59322007000500008
   TUBOI SH, 2009, J ACQUIR IM IN PRESS
   Wester CW, 2005, JAIDS-J ACQ IMM DEF, V40, P336, DOI 10.1097/01.qai.0000159668.80207.5b
   Wood R, 2007, AM J RESP CRIT CARE, V175, P87, DOI 10.1164/rccm.200606-759OC
NR 31
TC 52
Z9 53
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD OCT 23
PY 2009
VL 23
IS 16
BP 2107
EP 2114
DI 10.1097/QAD.0b013e32832ec494
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 517FS
UT WOS:000271599200005
PM 19770698
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Sant'Anna, FM
   Velasque, L
   Costa, MJ
   Schmaltz, CA
   Morgado, MG
   Lourenco, MC
   Grinsztejn, B
   Rolla, VC
AF Sant'Anna, Flavia Marinho
   Velasque, Luciane
   Costa, Marli Jane
   Schmaltz, Carolina Arana
   Morgado, Mariza Goncalves
   Lourenco, Maria Cristina
   Grinsztejn, Beatriz
   Rolla, Valeria Cavalcanti
TI Effectiveness of Highly Active Antiretroviral Therapy (HAART) Used
   Concomitantly With Rifampicin in Patients with Tuberculosis and AIDS
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Tuberculosis; AIDS; HAART; rifampicin; effectiveness
ID HIV-INFECTED PATIENTS
AB This study evaluated the effectiveness of two HAART regimens concomitant to rifampicin based tuberculosis (TB) treatment. Patients with TB/HIV diagnosis followed at the TB program between June 2000 and March 2005 were prospectively evaluated. The different HAART regimens in antiretrovirals (ARV) treatment naive and ARV experienced patients were compared. The effectiveness of HAART was defined as a VL < 80 copies/mL from month 4 to month 10 after TB treatment. One hundred and forty-two patients were included. Among these, 68 (47%) were treatment naive and 76 (53%) previously exposed. Odds ratio (OR) in naive patients treated with efavirenz (EFV) based regimen (n=42) compared to ritonavir/saquinavir (RTV/SQV) based regimen (n=26) was 8.0 (CI=1.67-38.35, p=0.008). OR from ARV experienced patients treated with RTV/SQV based regimen compared to EFV was 3.08 (CI=0.65-14.6, p=0.15), although with no statistical significance. Better effectiveness and tolerability were observed in antiretrovirals treatment naive patients using EFV based regimens. Although not statistically significant, a favorable virologic response and a better tolerability were observed in the ARV experienced patients group who received a RTV/SQV based regimen.
C1 [Lourenco, Maria Cristina; Rolla, Valeria Cavalcanti] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Bacteriol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Morgado, Mariza Goncalves] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Dept Imunol, BR-21045900 Rio De Janeiro, Brazil.
RP Rolla, VC (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Bacteriol Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM valeria.rolla@ipec.fiocruz.br
FU CNPq (Millenio II - REDE TB)National Council for Scientific and
   Technological Development (CNPq); PDTSP-SUS (Fiocruz)
FX We thank to CNPq (Millenio II - REDE TB) and PDTSP-SUS (Fiocruz) for the
   financial support, to Dr. Carla Vorsatz for the English revision and to
   all patients who participated in this study.
CR Aaron L, 2004, CLIN MICROBIOL INFEC, V10, P388, DOI 10.1111/j.1469-0691.2004.00758.x
   Boesecke C, 2008, CURR OPIN HIV AIDS, V3, P653, DOI 10.1097/COH.0b013e328312c392
   *BRAS MIN SAUD, 2008, GUIA TRAT REC TER AN
   Campbell Michelle, 2005, Aust J Adv Nurs, V22, P26
   Collins Kalonji R., 2002, AIDS Reviews, V4, P165
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4
   KARIM SA, 2009, 16 C RETR OPP INF MO
   Lopez-Cortes LF, 2002, CLIN PHARMACOKINET, V41, P681, DOI 10.2165/00003088-200241090-00004
   Moreno S, 2006, AIDS REV, V8, P115
   Pedral-Sampaio Diana B., 2004, Braz J Infect Dis, V8, P211, DOI 10.1590/S1413-86702004000300004
   Pozniak AL, 1999, AIDS, V13, P435, DOI 10.1097/00002030-199903110-00001
   Rolla VC, 2006, CLIN DRUG INVEST, V26, P469, DOI 10.2165/00044011-200626080-00005
   Saraceni V, 2008, INT J TUBERC LUNG D, V12, P769
   Schmitt Christophe, 2009, Arch Drug Inf, V2, P8
   SUNGKANUPARPH S, 2005, J INFECTION, P1
   Torres TS, 2007, INT J TUBERC LUNG D, V11, P933
   *WHO, 2008, GLOB TUB CONTR SURV
NR 18
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD OCT
PY 2009
VL 13
IS 5
BP 362
EP 366
DI 10.1590/S1413-86702009000500010
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 594SX
UT WOS:000277559300010
PM 20428637
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Bello, G
   Velasco-de-Castro, CA
   Bongertz, V
   Rodrigues, CAS
   Giacoia-Gripp, CBW
   Pilotto, JH
   Grinsztejn, B
   Veloso, VG
   Morgado, MG
AF Bello, Gonzalo
   Velasco-de-Castro, Carlos A.
   Bongertz, Vera
   Santos Rodrigues, Caio A.
   Giacoia-Gripp, Carmem B. W.
   Pilotto, Jose H.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Morgado, Mariza G.
TI Immune Activation and Antibody Responses in Non-Progressing Elite
   Controller Individuals Infected With HIV-1
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HIV controllers; long-term non-progressors; chronic activation; binding
   antibodies; antibody avidity
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; LONG-TERM
   NONPROGRESSORS; T-CELL-ACTIVATION; VIRAL REPLICATION; DISEASE
   PROGRESSION; ENZYME-IMMUNOASSAY; TYPE-1 INFECTION; AVIDITY INDEX; RNA
   LEVELS
AB An extremely rare subset of patients infected with HIV-1 designated as "non-progressing elite controllers" appears to be able to maintain stable CD4 + T-cell counts and a median plasma viremia below the detection limit of current ultrasensitive assays (10 years in the absence of antiretroviral therapy. Lymphocyte subsets (CD4 +, CD8 +), immune activation markers (HLA-DR +, CD38 +, Beta-2-microglobulin), and HIV-specific antibody responses were longitudinally examined in four non-progressing elite controllers over more than 5 years. Two control groups of seronegative healthy individuals and untreated patients infected with HIV-1 presenting detectable viremia were also included. None of the non-progressing elite controllers displayed the high T-cell activation levels generally seen in the seropositive individuals, keeping them within the normal range. Three non-progressing elite controllers showed no significant immune system abnormalities when compared to seronegative individuals, displaying a low proportion of HIV-1-specific binding antibodies and low avidity index, similar to those observed for individuals infected recently with HIV-1. One non-progressing elite controller exhibited CD8 + T-cell counts and beta 2-M levels above normal ranges and developed a low but "mature" (high-avidity) HIV-1-specific antibody response. Thus, the non-progressing elite controllers are able to maintain normal T-cell activation levels, which may contribute to prevent, or greatly reduce,the damage of the immune system typically induced by the HIV-1 overtime. They are, however, immunologically heterogeneous and very low levels of antigen exposure seem to occur in these patients, sufficient for sustaining a low, but detectable, HIV-1-specific immunity. J. Med Virol. 81:1681-1690,2009. (C) 2009 Wiley-Liss, Inc.
C1 [Bello, Gonzalo; Velasco-de-Castro, Carlos A.; Bongertz, Vera; Santos Rodrigues, Caio A.; Giacoia-Gripp, Carmem B. W.; Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, Jose H.; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
RP Morgado, MG (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Pilotto, Jose
   Henrique/AAD-9773-2019; Bello, Gonzalo/E-6842-2013; Veloso, Valdilea
   Goncalves/J-6189-2012
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Pilotto, Jose
   Henrique/0000-0003-0521-8597; 
FU National Institute for Biological Standards Control, UK
FX We wish to thank Dr. David Watkins for helpful discussions and for
   critical review of the manuscript. We thank the National Institute for
   Biological Standards & Control, UK, for the kind donation of HIV-1 SF162
   and Dr. Eva-Maria Fenyo, Lund University, Sweden, for the kind donation
   of HIV-1 IIIB.
CR Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005
   Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   Babiker A, 2000, LANCET, V355, P1131
   Bailey JR, 2006, J VIROL, V80, P4758, DOI 10.1128/JVI.80.10.4758-4770.2006
   Barker E, 1998, BLOOD, V92, P3105, DOI 10.1182/blood.V92.9.3105.421k46_3105_3114
   Bello G, 2005, J GEN VIROL, V86, P355, DOI 10.1099/vir.0.80410-0
   Bello G, 2007, AIDS RES HUM RETROV, V23, P1242, DOI 10.1089/aid.2007.0074
   Binley JM, 2000, J INFECT DIS, V182, P945, DOI 10.1086/315774
   Bisset LR, 1998, AIDS, V12, P2115, DOI 10.1097/00002030-199816000-00006
   Bongertz V, 2007, MEM I OSWALDO CRUZ, V102, P817, DOI 10.1590/S0074-02762007005000119
   Bouscarat F, 1998, AIDS, V12, P1267, DOI 10.1097/00002030-199811000-00007
   Buchbinder S, 1999, MICROBES INFECT, V1, P1113, DOI 10.1016/S1286-4579(99)00204-X
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997
   FERBAS J, 1995, J INFECT DIS, V172, P329, DOI 10.1093/infdis/172.2.329
   Giorgi JV, 1998, AIDS, V12, P1833, DOI 10.1097/00002030-199814000-00015
   Greenough TC, 1999, NEW ENGL J MED, V340, P236, DOI 10.1056/NEJM199901213400314
   HAGERVORST E, 1995, J INFECT DIS, V171, P811
   Hare CB, 2006, CLIN INFECT DIS, V42, P700, DOI 10.1086/500215
   Hatano H, 2009, J VIROL, V83, P329, DOI 10.1128/JVI.01763-08
   Hayashida T, 2008, AIDS RES HUM RETROV, V24, P495, DOI 10.1089/aid.2007.0150
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Jin X, 2000, MOL MED, V6, P803, DOI 10.1007/BF03402195
   Kassutto S, 2005, CLIN INFECT DIS, V40, P868, DOI 10.1086/428127
   Killian MS, 2006, AIDS RES HUM RETROV, V22, P640, DOI 10.1089/aid.2006.22.640
   Laeyendecker O, 2008, JAIDS-J ACQ IMM DEF, V48, P211, DOI 10.1097/QAI.0b013e3181743980
   Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188
   Learmont JC, 1999, NEW ENGL J MED, V340, P1715, DOI 10.1056/NEJM199906033402203
   Lefrere JJ, 1999, J INFECT DIS, V180, P526, DOI 10.1086/314906
   Lefrere JJ, 1997, BLOOD, V90, P1133, DOI 10.1182/blood.V90.3.1133.1133_1133_1140
   LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959
   Loffredo JT, 2007, J VIROL, V81, P8827, DOI 10.1128/JVI.00895-07
   Madec Y, 2005, AIDS, V19, P2001, DOI 10.1097/01.aids.0000194134.28135.cd
   Madec Y, 2005, CLIN INFECT DIS, V40, P1350, DOI 10.1086/429318
   Markowitz M, 1999, J INFECT DIS, V179, P527, DOI 10.1086/314628
   MOOSTERBOER N, 2005, VIROLOGY, V339, P70
   Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233
   Parekh BS, 2005, INDIAN J MED RES, V121, P510
   Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786
   Rodes B, 2004, AIDS, V18, P1109, DOI [10.1097/01.aids.0000125962.16506.f9, 10.1097/00002030-200405210-00004]
   Sajadi MM, 2007, AIDS, V21, P517
   Selleri M, 2007, JAIDS-J ACQ IMM DEF, V46, P145, DOI 10.1097/QAI.0b013e318120039b
   SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002
   Shioda T, 1997, J VIROL, V71, P4871, DOI 10.1128/JVI.71.7.4871-4881.1997
   Suligoi B, 2003, JAIDS-J ACQ IMM DEF, V32, P424, DOI 10.1097/00126334-200304010-00012
   Suligoi B, 2002, J CLIN MICROBIOL, V40, P4015, DOI 10.1128/JCM.40.11.4015-4020.2002
   Verity EE, 2007, J VIROL, V81, P9268, DOI 10.1128/JVI.00650-07
   Wang B, 2003, VIROLOGY, V312, P135, DOI 10.1016/S0042-6822(03)00159-4
   Wang B, 2002, VIROLOGY, V304, P246, DOI 10.1006/viro.2002.1706
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
   Zaunders JJ, 1999, AIDS RES HUM RETROV, V15, P1519, DOI 10.1089/088922299309801
NR 51
TC 28
Z9 29
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2009
VL 81
IS 10
BP 1681
EP 1690
DI 10.1002/jmv.21565
PG 10
WC Virology
SC Virology
GA 489BV
UT WOS:000269395400001
PM 19697415
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Veloso, VG
   Levi, JE
   Velasque, L
   Luz, PM
   Friedman, RK
   Andrade, AC
   Moreira, RI
   Russomano, F
   Pilotto, JH
   Bastos, FI
   Palefsky, J
AF Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
   Levi, Jose Eduardo
   Velasque, Luciane
   Luz, Paula Mendes
   Friedman, Ruth Khalili
   Andrade, Angela Cristina
   Moreira, Ronaldo Ismerio
   Russomano, Fabio
   Pilotto, Jose Henrique
   Bastos, Francisco Inacio
   Palefsky, Joel
TI Factors associated with increased prevalence of human papillomavirus
   infection in a cohort of HIV-infected Brazilian women (vol 13, pg 72,
   2009)
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Correction
C1 [Grinsztejn, Beatriz; Veloso, Valdilea Goncalves; Velasque, Luciane; Luz, Paula Mendes; Friedman, Ruth Khalili; Andrade, Angela Cristina; Moreira, Ronaldo Ismerio; Pilotto, Jose Henrique] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, BR-21045900 Rio De Janeiro, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Russomano, Fabio] Fundacao Oswaldo Cruz, IFF, BR-21045900 Rio De Janeiro, Brazil.
   [Bastos, Francisco Inacio] Fundacao Oswaldo Cruz, ICICT, BR-21045900 Rio De Janeiro, Brazil.
   [Palefsky, Joel] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, Av Brasil,4365 Manguinhos, BR-21045900 Rio De Janeiro, Brazil.
RI Veloso, Valdilea Goncalves/J-6189-2012; Pilotto, Jose
   Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Bastos,
   Francisco/0000-0001-5970-8896
CR Grinsztejn B, 2009, INT J INFECT DIS, V13, P72, DOI 10.1016/j.ijid.2008.03.031
NR 1
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD SEP
PY 2009
VL 13
IS 5
BP 655
EP 656
DI 10.1016/j.ijid.2009.04.001
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 498HB
UT WOS:000270126900020
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Silva, MTT
   Wagner, S
   Grinsztejn, B
AF Silva, Marcus Tulius T.
   Wagner, Sandra
   Grinsztejn, Beatriz
TI Human Immunodeficiency Virus Encephalopathy Cognitive and Radiologic
   Improvement After Antiretroviral Therapy
SO ARCHIVES OF NEUROLOGY
LA English
DT Editorial Material
ID DEMENTIA; AIDS
C1 [Silva, Marcus Tulius T.] Fiocruz MS, Lab Pesquisa Clin Neuroinfeccao, Inst Pesquisa Clin Evandro Chagas IPEC, Fundacao Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
RP Silva, MTT (corresponding author), Fiocruz MS, Lab Pesquisa Clin Neuroinfeccao, Inst Pesquisa Clin Evandro Chagas IPEC, Fundacao Oswaldo Cruz, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM marcustulius@ipec.fiocruz.br
RI Silva, Marcus Tulius/AAM-1077-2020
CR Archibald SL, 2004, ARCH NEUROL-CHICAGO, V61, P369, DOI 10.1001/archneur.61.3.369
   OLSEN WL, 1988, RADIOLOGY, V169, P445, DOI 10.1148/radiology.169.2.3174991
   Sacktor NC, 2005, AIDS, V19, P1367
   Thurnher MM, 2000, AM J NEURORADIOL, V21, P670
   Wu DT, 2000, J NEUROVIROL, V6, pS82
NR 5
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD AUG
PY 2009
VL 66
IS 8
BP 1040
EP 1041
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 481YA
UT WOS:000268848100021
PM 19667231
DA 2020-11-24
ER

PT J
AU Sension, M
   Neto, JLD
   Grinsztejn, B
   Molina, JM
   Zavala, I
   Gonzalez-Garcia, J
   Donnelly, A
   Phiri, P
   Ledesma, E
   McGrath, D
AF Sension, Michael
   de Andrade Neto, Jose Luiz
   Grinsztejn, Beatriz
   Molina, Jean Michel
   Zavala, Isidro
   Gonzalez-Garcia, Juan
   Donnelly, Alice
   Phiri, Phillip
   Ledesma, Emilio
   McGrath, Donnie
CA 067 Study Grp
TI Improvement in Lipid Profiles in Antiretroviral-Experienced HIV-Positive
   Patients With Hyperlipidemia After a Switch to Unboosted Atazanavir
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT 12th Conference on Retroviruses and Opportunistic Infections
CY FEB 22-25, 2005
CL Boston, MA
DE antiretroviral therapy; atazanavir; cholesterol; lipids; protease
   inhibitor
ID PROTEASE INHIBITORS; INCREASED RISK; CARDIOVASCULAR-DISEASE;
   GLUCOSE-TOLERANCE; APOLIPOPROTEIN-B; CLINICAL-TRIAL; THERAPY;
   LAMIVUDINE; STAVUDINE; LIPODYSTROPHY
AB Objective: The primary objective was to compare the change in fasting low-density lipoprotein (LDL) cholesterol from baseline to week 12 between patients receiving an atazanavir-containing regimen and those receiving comparator protease inhibitor (PI) regimens.
   Design: AI424-067 was a 48-week, open-label, randomized, prospective study of 246 patients on PI-based regimens with hyperlipidemia [fasting LDL cholesterol > 130 mg/dL (>3.4 mmol/L)] and with HIV RNA <50 copies per milliliter. Patients were randomized to switch to atazanavir (400 mg once daily) on day 1 (immediate switch) or maintain current PI regimen for the first 24 weeks, then switch to atazanavir (delayed switch).
   Methods: Plasma lipid levels were compared with baseline values at weeks 12, 24, and 48. Safety, viral load, and CD4 profiles were also evaluated.
   Results: At week 12, the mean percent changes in LDL cholesterol from baseline for the immediate-switch and delayed-switch groups were -15% and +1%, respectively (P < 0.0001). Favorable LDL cholesterol levels in the immediate-switch group were sustained through week 48. Both groups maintained comparable virologic control. Switching to atazanavir did not produce a significant change in safety or tolerability.
   Conclusions: A switch-either immediate or delayed-from a boosted or unboosted PI to unboosted atazanavir in patients with hyperlipidemia was associated with improvements in plasma lipid parameters without loss of virological suppression.
C1 [Sension, Michael] N Broward Hosp Dist, HIV Clin Res, Ft Lauderdale, FL 33311 USA.
   [de Andrade Neto, Jose Luiz] Pontificia Univ Catolica Parana, Curitiba, Parana, Brazil.
   [Grinsztejn, Beatriz] Hosp Evandro Chagas, Rio De Janeiro, Brazil.
   [Molina, Jean Michel] Hosp St Louis, Paris, France.
   [Gonzalez-Garcia, Juan] Hosp La Paz, Madrid, Spain.
   [Donnelly, Alice; Phiri, Phillip; Ledesma, Emilio; McGrath, Donnie] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA.
RP Sension, M (corresponding author), N Broward Hosp Dist, HIV Clin Res, 1101 NW 1st St, Ft Lauderdale, FL 33311 USA.
EM msension@nbhd.org
CR Behrens G, 1999, AIDS, V13, pF63, DOI 10.1097/00002030-199907090-00001
   Boyle BA, 2004, AIDS REV, V6, P218
   CAHN PE, 2004, AIDS CARE, V3, P92
   Calza L, 2003, AIDS, V17, P851, DOI 10.1097/00002030-200304110-00010
   Calza L, 2004, J ANTIMICROB CHEMOTH, V53, P10, DOI 10.1093/jac/dkh013
   Carr A, 2003, AIDS, V17, pS141, DOI 10.1097/00002030-200304001-00017
   Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   *DHHS, 2008, PAN CLIN PRACT TREAT
   Dube MP, 2003, CLIN INFECT DIS, V37, P613, DOI 10.1086/378131
   FRIISMOLLER N, 2006, 13 C RETR OPP INF FE
   FRIISMOLLER N, 2007, 14 C RETR OPP INF FE
   Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450
   Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2
   Iloeje UH, 2005, HIV MED, V6, P37, DOI 10.1111/j.1468-1293.2005.00265.x
   Jemsek JG, 2006, CLIN INFECT DIS, V42, P273, DOI 10.1086/498505
   Johnson Victoria A, 2006, Top HIV Med, V14, P125
   KEISER P, 2006, 16 INT AIDS C AUG TO
   Keiser PH, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-2
   Koppel K, 2000, INT J STD AIDS, V11, P451, DOI 10.1258/0956462001916236
   Levy Adrian R, 2005, Lipids Health Dis, V4, P4
   Llibre JM, 2006, AIDS, V20, P1407, DOI 10.1097/01.aids.0000233574.49220.de
   MARTINEZ E, 2005, 12 C RETR OPP INF FE
   Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010
   Mobius U, 2005, JAIDS-J ACQ IMM DEF, V39, P174
   Murphy RL, 2003, AIDS, V17, P2603, DOI 10.1097/00002030-200312050-00007
   Negredo E, 2006, J ANTIMICROB CHEMOTH, V58, P235, DOI 10.1093/jac/dkl191
   Nolan D, 2003, DRUGS, V63, P2555, DOI 10.2165/00003495-200363230-00001
   Noor MA, 2004, AIDS, V18, P2137, DOI 10.1097/00002030-200411050-00005
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918
   Sanne I, 2003, JAIDS-J ACQ IMM DEF, V32, P18, DOI 10.1097/00126334-200301010-00004
   Schambelan M, 2002, JAIDS-J ACQ IMM DEF, V31, P257, DOI 10.1097/00126334-200211010-00001
   SENSION M, 2005, 12 C RETR OPP INF FE
   Squires K, 2004, JAIDS-J ACQ IMM DEF, V36, P1011, DOI 10.1097/00126334-200408150-00003
   Taburet AM, 2004, ANTIMICROB AGENTS CH, V48, P2091, DOI 10.1128/AAC.48.6.2091-2096.2004
   Tsiodras S, 2000, ARCH INTERN MED, V160, P2050, DOI 10.1001/archinte.160.13.2050
   Umpleby AM, 2005, ANTIVIR THER, V10, P663
   Walldius G, 2004, J INTERN MED, V255, P188, DOI 10.1046/j.1365-2796.2003.01276.x
   Walli R, 1998, AIDS, V12, pF167, DOI 10.1097/00002030-199815000-00001
   Wood R, 2004, JAIDS-J ACQ IMM DEF, V36, P684, DOI 10.1097/00126334-200406010-00005
NR 41
TC 24
Z9 25
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN 1
PY 2009
VL 51
IS 2
BP 153
EP 162
DI 10.1097/QAI.0b013e3181a5701c
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 451IJ
UT WOS:000266463600008
PM 19346966
DA 2020-11-24
ER

PT J
AU Rodrigues, J
   Grinsztejn, B
   Bastos, FI
   Velasque, L
   Luz, PM
   de Souza, CT
   Georg, I
   Pilotto, JH
   Veloso, VG
AF Rodrigues, Junia
   Grinsztejn, Beatriz
   Bastos, Francisco I.
   Velasque, Luciane
   Luz, Paula M.
   de Souza, Claudia Tv
   Georg, Ingebourg
   Pilotto, Jose H.
   Veloso, Valdilea G.
TI Seroprevalence and factors associated with herpes simplex virus type 2
   among HIV-negative high-risk men who have sex with men from Rio de
   Janeiro, Brazil: a cross-sectional study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED-DISEASES;
   LINKED-IMMUNOSORBENT-ASSAY; GENITAL HERPES; EPIDEMIOLOGIC SYNERGY; HSV-2
   INFECTION; CONDOM USE; ACQUISITION; WOMEN; TRANSMISSION
AB Background: Herpes simplex virus type 2 (HSV-2) is the leading cause of genital ulcer disease in developing countries, including Brazil, and is especially prevalent among men who have sex with men (MSM). HSV-2 infection represents a risk factor for the acquisition and transmission of other sexually transmitted diseases. The goal of the present cross-sectional study was to estimate HSV-2 seroprevalence and to determine the factors associated with HSV-2 seropositivity in HIV-negative high-risk MSM from Rio de Janeiro, Brazil.
   Methods: Stored sera were tested to estimate HSV-2 seroprevalence, while socio-demographic and sexual behavior data were used to measure associations between risk factors and HSV-2 seropositivity. Using the Poisson regression model with robust variance, prevalence ratios (PR) were used to estimate de degree of association between risk factors and HSV-2 seropositivity in bivariate and multivariate analyses.
   Results: Seroprevalence of HSV-2 was of 45.7% (184 out of 403). Factors independently associated with HSV-2 seroprevalence in the multivariate model were: older age (>= 26 years, PR: 1.41 95% Confidence Interval: 1.11-1.78), non- white race (PR: 1.32 95% CI: 1.06-1.64), positive serology for syphilis (PR: 1.65 95% CI: 1.33-2.05), positive serology for hepatitis B (PR: 1.25 95% CI: 0.99-1.57), stable male partner in the past 6 months (PR: 1.42 95% CI: 1.12-1.79), and unprotected anal sex with a stable female partner (PR: 1.46 95% CI: 1.05-2.04) in the 6 months preceding the cross-sectional assessment.
   Conclusion: The present study made evident a high prevalence of HSV-2 infection in a sample of HIV-negative high-risk MSM from Rio de Janeiro. This finding indicates the need and urgency for implementing integrated programs for the prevention of HSV-2 and other sexually transmitted diseases, and, in particular, programs targeting high-risk MSM.
C1 [Rodrigues, Junia; Grinsztejn, Beatriz; Velasque, Luciane; Luz, Paula M.; de Souza, Claudia Tv; Georg, Ingebourg; Pilotto, Jose H.; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Bastos, Francisco I.] Fundacao Oswaldo Cruz, Inst Comunicacao & Informacao Cient & Tecnol Saud, Rio De Janeiro, Brazil.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM junia.rodrigues@gmail.com; gbeatriz@ipec.fiocruz.br;
   chicao29@hotmail.com; velasque@fiocruz.br; paula.luz@ipec.fiocruz.br;
   clau@cpqhec.fiocruz.br; inge@ipec.fiocruz.br;
   jose.pilotto@ipec.fiocruz.br; vgveloso@ipec.fiocruz.br
RI ENYEGUE, ELISEE LIBERT EMBOLO/AAL-1654-2020; Veloso, Valdilea
   Goncalves/J-6189-2012; Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Bastos,
   Francisco/0000-0001-5970-8896; Luz, Paula/0000-0001-9746-719X
CR Ashley Rhoda L, 2002, Herpes, V9, P38
   Ballard RC, 2002, SEX TRANSM INFECT, V78, P274, DOI 10.1136/sti.78.4.274
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Brown EL, 2006, AM J EPIDEMIOL, V164, P733, DOI 10.1093/aje/kwj270
   Carvalho M, 1998, Int J Infect Dis, V3, P94
   Celum C, 2004, B WORLD HEALTH ORGAN, V82, P447
   COREY L, 1994, SEX TRANSM DIS, V21, pS38
   Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001
   Cusini M, 2000, SEX TRANSM DIS, V27, P292, DOI 10.1097/00007435-200005000-00011
   DaRosaSantos OL, 1996, INT J DERMATOL, V35, P794
   de Souza CTV, 1999, AIDS CARE, V11, P567, DOI 10.1080/09540129947721
   de Souza CTV, 2003, AIDS CARE, V15, P539, DOI 10.1080/0954012031000134773
   de Souza CTV, 2002, J ACQ IMMUN DEF SYND, V29, P95, DOI 10.1097/00126334-200201010-00013
   Donovan B, 2000, LANCET, V355, P1897, DOI 10.1016/S0140-6736(00)02302-3
   Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3
   Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7
   Golden MR, 2005, SEX TRANSM DIS, V32, P771, DOI 10.1097/01.olq.0000175377.88358.f3
   Gottlieb SL, 2002, J INFECT DIS, V186, P1381, DOI 10.1086/344317
   Konda KA, 2005, SEX TRANSM DIS, V32, P534, DOI 10.1097/01.olq.0000175413.89733.ae
   LAAR MJ, 1998, INT J EPIDEMIOL, V27, P127
   Laeyendecker O, 2004, J CLIN MICROBIOL, V42, P1794, DOI 10.1128/JCM.42.4.1794-1796.2004
   Lama JR, 2006, J INFECT DIS, V194, P1459, DOI 10.1086/508548
   LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882
   LOWHAGEN GB, 1990, ACTA DERM-VENEREOL, V70, P330
   Mark HD, 2005, SEX TRANSM DIS, V32, P691, DOI 10.1097/01.olq.0000175402.55952.d7
   Martinez MJ, 2005, REV MED CHILE, V133, P302, DOI 10.4067/S0034-98872005000300005
   MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007
   Mihret W, 2002, SEX TRANSM DIS, V29, P175, DOI 10.1097/00007435-200203000-00008
   Renzi C, 2003, J INFECT DIS, V187, P19, DOI 10.1086/345867
   Reynolds SJ, 2003, J INFECT DIS, V187, P1513, DOI 10.1086/368357
   Rodriguez AC, 2003, SEX TRANSM INFECT, V79, P460, DOI 10.1136/sti.79.6.460
   Sacks SL, 2004, ANTIVIR RES, V63, pS19, DOI 10.1016/j.antiviral.2004.06.004
   Sacks SL, 2004, ANTIVIR RES, V63, pS27, DOI 10.1016/j.antiviral.2004.06.005
   Santos FC, 2006, MEM I OSWALDO CRUZ, V101, P315, DOI 10.1590/S0074-02762006000300016
   Singh AE, 2005, SEX TRANSM DIS, V32, P95, DOI 10.1097/01.olq.0000151415.78210.85
   Smith JS, 2001, SEX TRANSM DIS, V28, P187, DOI 10.1097/00007435-200104000-00001
   Sutmoller F, 1997, MEM I OSWALDO CRUZ, V92, P39, DOI 10.1590/S0074-02761997000100009
   Sutmoller Frits, 2002, International Journal of Infectious Diseases, V6, P259, DOI 10.1016/S1201-9712(02)90158-X
   Svenson GR, 2002, AIDS EDUC PREV, V14, P515, DOI 10.1521/aeap.14.8.515.24111
   Wald A, 1997, SEX TRANSM DIS, V24, P149, DOI 10.1097/00007435-199703000-00005
   WALD A, 1993, ANNU REV PUBL HEALTH, V14, P19
   Wald A, 2003, J INFECT DIS, V187, P1509, DOI 10.1086/374976
   WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205
   Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231
   WASSERHEIT JN, 1994, P NATL ACAD SCI USA, V91, P2430, DOI 10.1073/pnas.91.7.2430
   WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001
   Weinhardt LS, 1998, ARCH SEX BEHAV, V27, P155, DOI 10.1023/A:1018682530519
   Weiss HA, 2001, AIDS, V15, pS97, DOI 10.1097/00002030-200108004-00011
   Williamson NE, 2006, REPROD HEALTH MATTER, V14, P89, DOI 10.1016/S0968-8080(06)28268-5
NR 50
TC 12
Z9 12
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD APR 1
PY 2009
VL 9
AR 39
DI 10.1186/1471-2334-9-39
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 442JU
UT WOS:000265838300001
PM 19335922
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Silva, MTT
   Andrada-Serpa, MJ
   Grinsztejn, BGJ
   Neves, ED
   Harab, RC
   Leite, ACCB
   Pilotto, JH
   Campos, DP
   Braga, EB
   dos Santos, VV
   Araujo, A
AF Teixeira Silva, Marcus Tulius
   Andrada-Serpa, Maria Jose
   Jegerhorn Grinsztejn, Beatriz Gilda
   Neves, Elizabeth De Souza
   Harab, Ramza Cabral
   Leite, Ana Claudia C. B.
   Pilotto, Jose Henrique
   Campos, Dayse Pereira
   Braga, Eliane Berinque
   dos Santos, Valdilea Veloso
   Araujo, Abelardo
TI Neurological Manifestations in HIV/HTLV-Coinfected Patients
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of American-Academy-of-Neurology
CY APR 28-29, 2009
CL Seattle, WA
SP Amer Acad Neurol
RI Pilotto, Jose Henrique/AAD-9773-2019; de Queiroz-Campos Araujo,
   Abelardo/N-3637-2013; Silva, Marcus Tulius/AAM-1077-2020
OI Pilotto, Jose Henrique/0000-0003-0521-8597; de Queiroz-Campos Araujo,
   Abelardo/0000-0001-7694-7223; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD MAR 17
PY 2009
VL 72
IS 11
BP A202
EP A202
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 423WT
UT WOS:000264527901187
DA 2020-11-24
ER

PT J
AU Luz, PM
   Grinsztejn, B
   Galvani, AP
AF Luz, P. M.
   Grinsztejn, B.
   Galvani, A. P.
TI Disability adjusted life years lost to dengue in Brazil
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Brazil; dengue; disability adjusted life years; disease burden; Rio de
   Janeiro
ID RIO-DE-JANEIRO; HEMORRHAGIC-FEVER; ECONOMIC-IMPACT; PUERTO-RICO;
   COST-EFFECTIVENESS; SHOCK SYNDROME; EPIDEMIC; STATE; SURVEILLANCE;
   INFECTION
AB To assess the dengue burden in Brazil, and to compare it over three spatial scales: in the city of Rio de Janeiro, the state of Rio de Janeiro, and in Brazil overall.
   We calculated disability adjusted life years (DALYs) lost to dengue per million individuals annually from 1986 through 2006. To calculate DALYs, we compiled data on the number of dengue cases by age, clinical syndrome and outcome. We evaluated the sensitivity of our results to multiplication factors used to adjust for inaccuracies in reporting using a Monte Carlo method.
   From 1986 through 2006, a mean of 56, 47 and 22 DALYs per million individuals annually were lost to dengue in the city of Rio de Janeiro, in the state of Rio de Janeiro and in Brazil, respectively. Over 80% of the dengue burden derived from dengue fever cases. The dengue burden was highest at the city-level with a maximum single-year estimate of 560 DALYs per million individuals for 2002.
   Assessment of dengue burden requires consideration of all clinical syndromes over multiple years. Our results indicate that the dengue burden is as high as the burden of other major infectious diseases that afflict the Brazilian population, including malaria. These results may prompt policy makers to elevate the prioritization of dengue control, and allocate resources needed to curtail the increasing dengue burden.
C1 [Luz, P. M.; Galvani, A. P.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA.
   [Grinsztejn, B.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
RP Luz, PM (corresponding author), Yale Univ, Sch Publ Hlth, 60 Coll St, New Haven, CT 06520 USA.
EM paula.luz@yale.edu
OI Luz, Paula/0000-0001-9746-719X
FU CAPES (Brazilian federal agency for post-graduate education),
   FulbrightCAPES; Garfield Weston Foundation; Notsew Orm Sands Foundation
FX We thank Claudia Torres Codeco for her interesting discussions and
   insights. We also thank Iuri da Costa Leite and Joaquim Goncalves
   Valente for their advice on the DALYs calculation, and for their
   enormous support in providing us with the methods and results from the
   Projeto Carga de Doenca (The Burden of Disease study conducted in
   Brazil). We thank Kristina Talbert-Slagle and Angie Hofmann for editing
   revision, and the two anonymous reviewers for suggestions which greatly
   improved the manuscript. P. M. Luz was funded by CAPES (Brazilian
   federal agency for post-graduate education), Fulbright, and the Garfield
   Weston Foundation. A. P. Galvani greatly acknowledges funding from
   Notsew Orm Sands Foundation and the Garfield Weston Foundation.
CR Anderson KB, 2007, LANCET, V369, P1452, DOI 10.1016/S0140-6736(07)60671-0
   Anez G, 2006, REV PANAM SALUD PUBL, V19, P314, DOI 10.1590/S1020-49892006000500004
   Balmaseda A, 2006, AM J TROP MED HYG, V74, P449, DOI 10.4269/ajtmh.2006.74.449
   Balmaseda A, 2006, TROP MED INT HEALTH, V11, P935, DOI 10.1111/j.1365-3156.2006.01641.x
   Casali Clarisse Guimarães, 2004, Rev. Soc. Bras. Med. Trop., V37, P296, DOI 10.1590/S0037-86822004000400002
   Clark DV, 2005, AM J TROP MED HYG, V72, P786, DOI 10.4269/ajtmh.2005.72.786
   Cunha Rivaldo Venancio Da, 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P517, DOI 10.1590/S0036-46651995000600008
   DIETZ VJ, 1990, AM J EPIDEMIOL, V131, P693
   Duarte HHP, 2006, REV SAUDE PUBL, V40, P134, DOI 10.1590/S0034-89102006000100021
   Farrar J, 2007, TROP MED INT HEALTH, V12, P695, DOI [10.1111/j.1365-3156.2007.01838, 10.1111/j.1365-3156.2007.01838.x]
   Figueiredo L T, 1990, Bull Pan Am Health Organ, V24, P217
   Gadelha AMJ, 2002, RELATORIO FINAL PROJ
   Gubler DJ, 1999, ADV VIRUS RES, V53, P35, DOI 10.1016/S0065-3527(08)60342-5
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Guzman MG, 2003, J CLIN VIROL, V27, P1, DOI 10.1016/S1386-6532(03)00010-6
   Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2
   Halstead SB, 2007, LANCET, V369, P1410, DOI 10.1016/S0140-6736(07)60645-X
   HOOD GM, 2008, POPTOOLS VERSION 3 0
   Kochel TJ, 2002, LANCET, V360, P310, DOI 10.1016/S0140-6736(02)09522-3
   KOURI GP, 1989, B WORLD HEALTH ORGAN, V67, P375
   Lum LCS, 2008, AM J TROP MED HYG, V78, P862, DOI 10.4269/ajtmh.2008.78.862
   MELTZER MI, 1988, AM J TROP MED HYG, V59, P265
   Miagostovich Mariz P., 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P149, DOI 10.1590/S0036-46651993000200006
   Murray CJ, 1996, GLOBAL BURDEN DIS
   MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429
   MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P481
   NOGUEIRA R M R, 1988, Memorias do Instituto Oswaldo Cruz, V83, P219, DOI 10.1590/S0074-02761988000200012
   Nogueira RMR, 1999, MEM I OSWALDO CRUZ, V94, P297, DOI 10.1590/S0074-02761999000300004
   NOGUEIRA RMR, 1993, EPIDEMIOL INFECT, V111, P163, DOI 10.1017/S0950268800056788
   NOGUEIRA RMR, 1991, MEM I OSWALDO CRUZ, V86, P269, DOI 10.1590/S0074-02761991000200018
   Oliveira SA, 2001, EPIDEMIOL INFECT, V127, P509, DOI 10.1017/S0950268801005908
   Nogueira RMR, 2007, REV PANAM SALUD PUBL, V22, P358, DOI 10.1590/S1020-49892007001000009
   Schramm Joyce Mendes de Andrade, 2004, Ciênc. saúde coletiva, V9, P897, DOI 10.1590/S1413-81232004000400011
   Shepard DS, 2004, VACCINE, V22, P1275, DOI 10.1016/j.vaccine.2003.09.019
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   SUAYA JA, 2006, REPORT SCI WORKING G, P35
   Suaya JA, 2007, TROP MED INT HEALTH, V12, P1026, DOI 10.1111/j.1365-3156.2007.01889.x
   Teixeira MD, 2002, TROP MED INT HEALTH, V7, P757, DOI 10.1046/j.1365-3156.2002.00930.x
   Toledo Ana Lucia Araujo de, 2006, Cad. Saúde Pública, V22, P933, DOI 10.1590/S0102-311X2006000500006
   Torralba JM, 2007, ADV MATER RES-SWITZ, V23, P1, DOI 10.4028/www.scientific.net/AMR.23.1
   Torres MI, 1997, HUM ORGAN, V56, P19, DOI 10.17730/humo.56.1.gw72125m546701wh
   Valdés G Luis, 2002, Rev Cubana Med Trop, V54, P220
   VONALLMEN SD, 1979, AM J TROP MED HYG, V28, P1040, DOI 10.4269/ajtmh.1979.28.1040
   *WHO, 2004, GLOB BURD DIS EST YE
   ZAGNE SMO, 1994, T ROY SOC TROP MED H, V88, P677, DOI 10.1016/0035-9203(94)90225-9
NR 46
TC 40
Z9 42
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD FEB
PY 2009
VL 14
IS 2
BP 237
EP 246
DI 10.1111/j.1365-3156.2008.02203.x
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 409HL
UT WOS:000263496700016
PM 19171013
DA 2020-11-24
ER

PT J
AU Arasteh, K
   Yeni, P
   Pozniak, A
   Grinsztejn, B
   Jayaweera, D
   Roberts, A
   Hoy, J
   De Meyer, S
   Vangeneugden, T
   Tomaka, F
AF Arasteh, Keikawus
   Yeni, Patrick
   Pozniak, Anton
   Grinsztejn, Beatriz
   Jayaweera, Dushyantha
   Roberts, Afsoon
   Hoy, Jennifer
   De Meyer, Sandra
   Vangeneugden, Tony
   Tomaka, Frank
TI Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV
   type-1 patients in the POWER 1, 2 and 3 trials at week 96
SO ANTIVIRAL THERAPY
LA English
DT Article
ID DARUNAVIR-RITONAVIR; TMC114/RITONAVIR
AB Background: Long-term (96-week) efficacy and safety of the protease inhibitor (PI) darunavir coadministered with low-dose ritonavir (DRV/r) was evaluated in HIV type-1 (HIV-1)-infected patients with extensive prior treatment experience in the POWER 1, 2 and 3 trials.
   Methods: Patients with HIV-1 RNA >= 1,000 copies/ml and >= 1 primary PI mutation were randomized to receive either DRV/r 600/100 mg twice daily plus an optimized background regimen (OBR), or an investigator-selected control PI (CPI) plus OBR (POWER 3 was a DRV/r 600/100 mg twice daily single-arm study). The proportion of patients with HIV-1 RNA<50 copies/ml at week 96 was assessed (intent-to-treat [ITT], time-to-loss of virological response algorithm).
   Results: In total, 467 patients received DRV/r 600/100 mg twice daily; 124 patients received CPI(s). At week 96, 39% of DRV/r patients in POWER 1 and 2 (pooled analysis) versus 9% of CPI patients achieved HIV-1 RNA<50 copies/ml (ITT, time-to-loss of virological response algorithm; P<0.001). A similar proportion of DRV/r patients (42%) in POWER 3 achieved HIV-1 RNA<50 copies/ml at week 96. Mean absolute CD4(+) T-cell count increase for DRV/r at 96 weeks was 133 cells/mm(3) in POWER 1 and 2 and 103 cells/mm(3) in POWER 3. Grade 2-4 treatment-emergent adverse events at least possibly related to DRV/r (>= 2% incidence, excluding laboratory abnormalities) were diarrhoea (3%), vomiting (3%), nausea (2%) and headache (2%).
   Conclusions: Treatment with DRV/r 600/100 mg twice daily was well tolerated and led to sustained virological and immunological responses in treatment-experienced HIV-1-infected patients over 96 weeks.
C1 [Arasteh, Keikawus] Vivantes Auguste Viktoria Klinikum, EPIMED, Berlin, Germany.
   [Yeni, Patrick] Hop Bichat Claude Bernard, F-75877 Paris, France.
   [Yeni, Patrick] Univ Paris, F-75252 Paris, France.
   [Pozniak, Anton] Chelsea & Westminster Hosp, London, England.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas FIOCRUZ, Rio De Janeiro, Brazil.
   [Jayaweera, Dushyantha] Univ Miami, Miami, FL USA.
   [Roberts, Afsoon] George Washington Univ, Med Ctr, Washington, DC 20037 USA.
   Alfred Hosp, Melbourne, Vic, Australia.
   [De Meyer, Sandra; Vangeneugden, Tony] Tibotec BVBA, Mechelen, Belgium.
   [Tomaka, Frank] Tibotec Inc, Yardley, PA USA.
RP Arasteh, K (corresponding author), Vivantes Auguste Viktoria Klinikum, EPIMED, Berlin, Germany.
EM keikawus.arasteh@vivantes.de
RI Hoy, Jennifer/AAK-7968-2020
OI Hoy, Jennifer/0000-0002-6948-7086
FU Tibotec
FX Financial assistance to support these services was provided by the study
   sponsor, Tibotec.
CR Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8
   Cooper D, 2008, 15 C RETR OPP INF 3
   D'Aquila Richard T, 2003, Top HIV Med, V11, P92
   Haubrich RH, 2008, 15 C RETR OPP INF 3
   Haubrich R, 2007, AIDS, V21, pF11, DOI 10.1097/QAD.0b013e3280b07b47
   Johnson M, 2008, 15 C RETR OPP INF 3
   Johnson Victoria A, 2004, Top HIV Med, V12, P119
   Katlama C, 2007, AIDS, V21, P395, DOI 10.1097/QAD.0b013e328013d9d7
   Madruga JV, 2007, LANCET, V370, P49, DOI 10.1016/S0140-6736(07)61049-6
   Molina JM, 2007, JAIDS-J ACQ IMM DEF, V46, P24
   Ortiz R, 2008, AIDS, V22, P1389, DOI 10.1097/QAD.0b013e32830285fb
   *PAN ANT GUID AD A, 2008, GUID US ANT AG HIV 1
   SAAG M, 2006, 44 ANN M INF DIS SOC
   Steigbigel R, 2008, 15 C RETR OPP INF 3
NR 14
TC 60
Z9 62
U1 0
U2 2
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2009
VL 14
IS 6
BP 859
EP 864
DI 10.3851/IMP1301
PG 6
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 507UH
UT WOS:000270880100015
PM 19812449
DA 2020-11-24
ER

PT J
AU Pilotto, JH
   Grinsztejn, B
   Veloso, V
   Couto-Fernandez, JC
   Rodrigues-Pedro, A
   Velasco-De-Castro, CA
   Ribeiro, JE
   Khalili, R
   Muri, S
   Ismerio, R
   Hoffman, R
   Currier, J
   Morgado, MG
AF Pilotto, J. H.
   Grinsztejn, B.
   Veloso, V.
   Couto-Fernandez, J. C.
   Rodrigues-Pedro, A.
   Velasco-de-Castro, C. A.
   Ribeiro, J. Eurico
   Khalili, R.
   Muri, S.
   Ismerio, R.
   Hoffman, R.
   Currier, J.
   Morgado, M. G.
TI HIV drug resistance after HAART discontinuation among treatment-naive
   women who initiate antiretroviral therapy for the prevention of
   mother-to-child transmission in Rio de Janeiro, Brazil
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT 18th International HIV Drug Resistance Workshop
CY JUN 09-13, 2009
CL Ft Myers, FL
C1 [Pilotto, J. H.; Grinsztejn, B.; Veloso, V.; Couto-Fernandez, J. C.; Rodrigues-Pedro, A.; Velasco-de-Castro, C. A.; Muri, S.; Ismerio, R.; Morgado, M. G.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Pilotto, J. H.; Ribeiro, J. Eurico] HGNI, Nova Iguacu, RJ, Brazil.
   [Hoffman, R.; Currier, J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RI Veloso, Valdilea Goncalves/J-6189-2012; Pilotto, Jose
   Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2009
VL 14
IS 4
MA 144
BP A167
EP A167
PG 1
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 471FA
UT WOS:000268039900161
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Veloso, VG
   Levi, JE
   Velasque, L
   Luz, PM
   Friedman, RK
   Andrade, AC
   Moreira, RI
   Russomano, F
   Pilotto, JH
   Bastos, FI
   Palefsky, J
AF Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
   Levi, Jose Eduardo
   Velasque, Luciane
   Luz, Paula Mendes
   Friedman, Ruth Khalili
   Andrade, Angela Cristina
   Moreira, Ronaldo Ismerio
   Russomano, Fabio
   Pilotto, Jose Henrique
   Bastos, Francisco Inacio
   Palefsky, Joel
TI Factors associated with increased prevalence of human papillomavirus
   infection in a cohort of HIV-Infected Brazilian women
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Human papillomavirus; Human immunodeficiency virus; Evandro Chagas
   Research Institute cohort; Prevalence ratio; Brazil
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA;
   RIO-DE-JANEIRO; RISK-FACTORS; GENITAL WARTS; HPV INFECTION; DNA
   DETECTION; CANCER; ABNORMALITIES; EPIDEMIOLOGY
AB Objectives: Human papillomavirus (HPV) infection is a major risk factor for cervical disease. Using baseline data from the HIV-infected cohort of Evandro Chagas Clinical Research Institute at Fiocruz, Rio de Janeiro, Brazil, factors associated with an increased prevalence of HPV were assessed.
   Methods: Samples from 634 HIV-infected women were tested for the presence of HPV infection using hybrid capture 11 and polymerase chain reaction. Prevalence ratios (PR) were estimated using Poisson regression analysis with robust variance.
   Results: The overall prevalence of HPV infection was 48%, of which 94% were infected with a high-risk HPV. In multivariate analysis, factors independently associated with infection with high-risk HPV type were: younger age (<30 years of age; PR 1.5, 95% confidence interval (CI) 1.1-2.1), current or prior drug use (PR 1.3, 95% CI 1.0-1.6), self-reported history of HPV infection (PR 1.2, 95% CI 0.96-1.6), condom use in the last sexual intercourse (PR 1.3, 95% CI 1.1-1.7), and nadir CD4+ T-cell count <100 cells/mm(3) (PR 1.6, 95% CI 1.2-2.1).
   Conclusions: The estimated prevalence of high-risk HPV-infection among HIV-infected women from Rio de Janeiro, Brazil, was high. Close monitoring of HPV-related effects is warranted in all HIV-infected women, in particular those of younger age and advanced immunosuppression. (C) 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Grinsztejn, Beatriz; Veloso, Valdilea Goncalves; Velasque, Luciane; Luz, Paula Mendes; Friedman, Ruth Khalili; Andrade, Angela Cristina; Moreira, Ronaldo Ismerio; Pilotto, Jose Henrique] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Russomano, Fabio] Fundacao Oswaldo Cruz, IFF, BR-21045900 Rio De Janeiro, Brazil.
   [Bastos, Francisco Inacio] Fundacao Oswaldo Cruz, ICICT, BR-21045900 Rio De Janeiro, Brazil.
   [Palefsky, Joel] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM gbeatriz@ipec.flocruz.br
RI Veloso, Valdilea Goncalves/J-6189-2012; Pilotto, Jose
   Henrique/AAD-9773-2019; Palefsky, Joel/A-7128-2009
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Luz,
   Paula/0000-0001-9746-719X; Bastos, Francisco/0000-0001-5970-8896
FU Digene Inc., Brazilian branch; Brazilian National AIDS Program
FX Thanks are due to Digene Inc., Brazilian branch, for partially
   supporting HPV testing and to the Brazilian National AIDS Program for
   financial support to the project.
CR Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Bower M, 2006, CURR OPIN INFECT DIS, V19, P14, DOI 10.1097/01.qco.0000200295.30285.13
   BROWN D, 2007, 24 INT PAP C CLIN WO
   Burk RD, 1996, J INFECT DIS, V174, P679, DOI 10.1093/infdis/174.4.679
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   CANTONI E, 2004, J STAT SOFTW, V10, P1
   Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5
   de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033
   Dolei A, 1999, J GEN VIROL, V80, P2937, DOI 10.1099/0022-1317-80-11-2937
   Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031
   Franco EL, 1999, J INFECT DIS, V180, P1415, DOI 10.1086/315086
   Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4
   Goncalves MAG, 1999, INT J STD AIDS, V10, P803, DOI 10.1258/0956462991913583
   Goncalves MAG, 2003, TUMORI, V89, P9
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Heard I, 2000, OBSTET GYNECOL, V96, P403, DOI 10.1016/S0029-7844(00)00948-0
   *INCA, 2006, EST 2006 CANC INC BR, P96
   Kjaer SK, 1997, CANCER EPIDEM BIOMAR, V6, P799
   Levi JE, 2002, J CLIN MICROBIOL, V40, P3341, DOI 10.1128/JCM.40.9.3341-3345.2002
   Levi JE, 2004, GYNECOL ONCOL, V92, P225, DOI 10.1016/j.ygyno.2003.10.004
   MAIMAN M, 1990, GYNECOL ONCOL, V38, P377, DOI 10.1016/0090-8258(90)90077-X
   Manhart LE, 2002, SEX TRANSM DIS, V29, P725, DOI 10.1097/00007435-200211000-00018
   Manhart LE, 2006, SEX TRANSM DIS, V33, P502, DOI 10.1097/01.olq.0000204545.89516.0a
   Massad LS, 1999, J ACQ IMMUN DEF SYND, V21, P33, DOI 10.1097/00126334-199905010-00005
   Minkoff H, 1998, AM J OBSTET GYNECOL, V178, P982, DOI 10.1016/S0002-9378(98)70535-6
   Miotti PG, 1996, J INFECT DIS, V173, P714, DOI 10.1093/infdis/173.3.714
   Munoz N, 1996, SEX TRANSM DIS, V23, P504, DOI 10.1097/00007435-199611000-00012
   Orem J, 2004, CURR OPIN ONCOL, V16, P468, DOI 10.1097/00001622-200409000-00010
   Palefsky JM, 1999, JNCI-J NATL CANCER I, V91, P226, DOI 10.1093/jnci/91.3.226
   Palefsky JM, 2003, CURR OPIN ONCOL, V15, P382, DOI 10.1097/00001622-200309000-00007
   Palefsky Joel M, 2003, J Natl Cancer Inst Monogr, P41
   REEVES WC, 1994, J INFECT DIS, V170, P753, DOI 10.1093/infdis/170.4.753
   Rezza G, 1998, EPIDEMIOL INFECT, V121, P173, DOI 10.1017/S0950268898008954
   Richardson H, 2000, SEX TRANSM DIS, V27, P79, DOI 10.1097/00007435-200002000-00005
   Serwadda D, 1999, J INFECT DIS, V180, P1316, DOI 10.1086/315026
   Shah KV, 1997, J CLIN MICROBIOL, V35, P517, DOI 10.1128/JCM.35.2.517-519.1997
   Sirera G, 2005, MED CLIN-BARCELONA, V125, P127, DOI 10.1157/13076944
   Skov T, 1998, INT J EPIDEMIOL, V27, P91, DOI 10.1093/ije/27.1.91
   Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527
   STONE KM, 1999, SEXUALLY TRANSMITTED, P1307
   Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073
   Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   VERNON SD, 1994, J INFECT DIS, V169, P1108, DOI 10.1093/infdis/169.5.1108
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Winer RL, 2006, NEW ENGL J MED, V354, P2645, DOI 10.1056/NEJMoa053284
   WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591
NR 49
TC 36
Z9 37
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JAN
PY 2009
VL 13
IS 1
BP 72
EP 80
DI 10.1016/j.ijid.2008.03.031
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 398CY
UT WOS:000262711400011
PM 18632296
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Araujo, NM
   Branco-Vieira, M
   Silva, ACM
   Pilotto, JH
   Grinsztejn, B
   de Almeida, AJ
   Trepo, C
   Gomes, SA
AF Araujo, Natalia M.
   Branco-Vieira, Monique
   Silva, Anita C. M.
   Pilotto, Jose H.
   Grinsztejn, Beatriz
   de Almeida, Adilson Jose
   Trepo, Christian
   Gomes, Selma A.
TI Occult hepatitis B virus infection in HIV-infected patients: Evaluation
   of biochemical, virological and molecular parameters
SO HEPATOLOGY RESEARCH
LA English
DT Article
DE hepatitis B virus; mutations; occult infection; surface antigen;
   transfection
ID HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE-CHAIN-REACTION;
   SURFACE-ANTIGEN; LAMIVUDINE THERAPY; VIRAL REPLICATION; ANTIRETROVIRAL
   THERAPY; POSITIVE POPULATION; HBV INFECTION; CHRONIC HCV; GENOTYPE-A
AB Aim: To determine the prevalence of occult hepatitis B virus (HBV) infection in a group of human immunodeficiency virus (HIV)-infected Brazilian patients and to investigate its association with biochemical, virological and molecular features.
   Methods: Sera from 43 patients positive for HBV core antibody and negative for HBV surface antigen (HBsAg) were tested for HBV DNA positivity by semi-nested PCR. HBV loads were assessed by real-time PCR. S gene was cloned and sequenced for HBV isolates from 3 patients. HBsAg expression of these cases was performed in HuH7 cells.
   Results: HBV DNA was found in 6/43 (14%) samples, all except one associated with low viral loads. Occult HBV infection was further correlated with anti-hepatitis C virus (anti-HCV) antibodies positivity, but not with alanine aminotransferase (ALT) elevated levels. S gene sequences derived from three patients were determined. Two of them displayed mutations that may explain HBsAg negativity. In the first one, a stop codon mutation was found at position 216 in the C-terminal end of HBsAg. In the second patient, E164D and I195M substitutions in HBsAg, associated with lamivudine-resistance mutations in the polymerase were identified. As expected, all clones showing those mutations displayed undetectable or very low levels of HBsAg.
   Conclusion: Occult HBV infection was frequent in HIV-infected patients, was not associated with ALT elevation but significantly correlated with HCV seropositivity. The low viremia and the detection of HBsAg mutants confirm that multifactorial mechanisms are involved in occult HBV infection. HBV molecular monitoring should be employed for an adequate management of HBV/HIV co-infected patients.
C1 [Araujo, Natalia M.; Branco-Vieira, Monique; Gomes, Selma A.] Fiocruz MS, Inst Oswaldo Cruz, Mol Virol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Silva, Anita C. M.; Pilotto, Jose H.; Grinsztejn, Beatriz] Fiocruz MS, Evandro Chagas Clin Res Inst, BR-21045900 Rio De Janeiro, Brazil.
   [de Almeida, Adilson Jose] Fed Univ State Rio de Janeiro UNIRIO, Sch Med & Surg, Univ Hosp Gaffree & Guinle, Rio De Janeiro, Brazil.
   [Trepo, Christian] INSERM, U871, F-69008 Lyon, France.
RP Araujo, NM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Mol Virol Lab, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM nmaraujo@ioc.fiocruz.br
RI Branco-Vieira, Monique/E-5737-2017; Pilotto, Jose
   Henrique/AAD-9773-2019; Araujo, Natalia M/B-6596-2013; gomes, selma
   A/D-2762-2015
OI Branco-Vieira, Monique/0000-0002-6251-2875; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Gomes, Selma/0000-0003-0233-3370
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ)
FX WE THANK DR. Jussara Arabe for collecting patients' data, Cleber
   Ferreira Genuino for performing the AxSYM immunoassays, Dr Christian
   Niel for manuscript revision and the Genomic Platform-DNA Sequencing
   PDTIS/FIOCRUZ. This work was supported by CNPq and FAPERJ grants.
CR Altfeld M, 1998, J HEPATOL, V29, P306, DOI 10.1016/S0168-8278(98)80017-2
   Araujo NM, 2004, ARCH VIROL, V149, P1383, DOI 10.1007/s00705-003-0269-4
   Besisik F, 2003, J HEPATOL, V38, P506, DOI 10.1016/S0168-8278(02)00457-9
   Carman WF, 1997, HEPATOLOGY, V26, P1658, DOI 10.1002/hep.510260640
   Chaudhuri V, 2004, GASTROENTEROLOGY, V127, P1356, DOI 10.1053/j.gastro.2004.08.003
   Chemin I, 2005, J CLIN VIROL, V34, pS15, DOI 10.1016/S1386-6532(05)80005-8
   Colin JF, 1999, HEPATOLOGY, V29, P1306, DOI 10.1002/hep.510290447
   COURSAGET P, 1991, FEMS MICROBIOL LETT, V83, P35
   Delaney WE, 2003, J VIROL, V77, P11833, DOI 10.1128/JVI.77.21.11833-11841.2003
   Filippini P, 2006, AIDS, V20, P1253, DOI 10.1097/01.aids.0000232232.41877.2a
   Gomes SA, 1996, ACTA VIROL, V40, P133
   Gutierrez C, 2004, J MED VIROL, V73, P200, DOI 10.1002/jmv.20076
   Hino K, 2002, DIGEST DIS SCI, V47, P415, DOI 10.1023/A:1013794711235
   Hofer M, 1998, EUR J CLIN MICROBIOL, V17, P6, DOI 10.1007/BF01584356
   Hu KQ, 2002, J VIRAL HEPATITIS, V9, P243, DOI 10.1046/j.1365-2893.2002.00344.x
   Jeantet D, 2004, J MED VIROL, V73, P508, DOI 10.1002/jmv.20119
   Jeantet D, 2002, HEPATOLOGY, V35, P1215, DOI 10.1053/jhep.2002.32710
   Jenna S, 1999, J VIROL, V73, P3351, DOI 10.1128/JVI.73.4.3351-3358.1999
   KOBLIN BA, 1992, HEPATOLOGY, V15, P590, DOI 10.1002/hep.1840150406
   Koibuchi T, 2001, J MED VIROL, V64, P435, DOI 10.1002/jmv.1069
   Locarnini SA, 1998, HEPATOLOGY, V27, P294, DOI 10.1002/hep.510270144
   Lok ASF, 2000, HEPATOLOGY, V32, P1145
   Marschenz S, 2006, GASTROENTEROLOGY, V131, P765, DOI 10.1053/j.gastro.2006.07.008
   Melegari M, 1998, HEPATOLOGY, V27, P628, DOI 10.1002/hep.510270243
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   MILLS CT, 1990, GASTROENTEROLOGY, V99, P519, DOI 10.1016/0016-5085(90)91035-5
   Montague M, 2004, J LEARN DISABIL-US, V37, P2, DOI 10.1177/00222194040370010101
   Moraes MTB, 1999, BRAZ J MED BIOL RES, V32, P45, DOI 10.1590/S0100-879X1999000100006
   Nebbia G, 2007, J MED VIROL, V79, P1464, DOI 10.1002/jmv.20954
   NIEL C, 1994, J MED VIROL, V44, P180, DOI 10.1002/jmv.1890440212
   Nunez M, 2002, AIDS, V16, P2099, DOI 10.1097/00002030-200210180-00024
   Nunez M, 2003, CLIN INFECT DIS, V37, P1678, DOI 10.1086/379774
   Ono SK, 2001, J CLIN INVEST, V107, P449, DOI 10.1172/JCI11100
   Pavan Maria Helena P., 2003, Braz J Infect Dis, V7, P253, DOI 10.1590/S1413-86702003000400005
   Pereira RARD, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-34
   Quarleri J, 2007, AIDS RES HUM RETROV, V23, P525, DOI 10.1089/aid.2006.0172
   Raimondo G, 2007, J HEPATOL, V46, P160, DOI 10.1016/j.jhep.2006.10.007
   Rodriguez-Inigo E, 2005, J VIROL, V79, P15578, DOI 10.1128/JVI.79.24.15578-15581.2005
   Santos EA, 2003, EUR J CLIN MICROBIOL, V22, P92, DOI 10.1007/s10096-002-0868-0
   Selabe SG, 2007, J MED VIROL, V79, P1650, DOI 10.1002/jmv.20974
   Shire NJ, 2004, JAIDS-J ACQ IMM DEF, V36, P869, DOI 10.1097/00126334-200407010-00015
   Souza Milta Gomes de, 2004, Rev. Soc. Bras. Med. Trop., V37, P391, DOI 10.1590/S0037-86822004000500004
   Stuyver LJ, 2001, HEPATOLOGY, V33, P751, DOI 10.1053/jhep.2001.22166
   Sucupira MVF, 2006, MEM I OSWALDO CRUZ, V101, P655, DOI 10.1590/S0074-02762006000600013
   Thibault V, 1999, J CLIN MICROBIOL, V37, P3013, DOI 10.1128/JCM.37.9.3013-3016.1999
   Thio CL, 2004, CLIN INFECT DIS, V38, P1024, DOI 10.1086/382534
   Torbenson M, 2002, LANCET INFECT DIS, V2, P479, DOI 10.1016/S1473-3099(02)00345-6
   Torresi J, 2002, VIROLOGY, V293, P305, DOI 10.1006/viro.2001.1246
   TREITINGER A, 1999, BRAZ J INFECT DIS, V3, P1
   TWU SJ, 1993, J INFECT DIS, V167, P299, DOI 10.1093/infdis/167.2.299
   VENTO S, 1989, LANCET, V1, P332
   VILLA E, 1995, DIGEST DIS SCI, V40, P8, DOI 10.1007/BF02063934
   YAMAMOTO K, 1994, J VIROL, V68, P2671, DOI 10.1128/JVI.68.4.2671-2676.1994
   Zuckerman JN, 2000, J INFECTION, V41, P130, DOI 10.1053/jinf.2000.0720
NR 54
TC 31
Z9 31
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1386-6346
EI 1872-034X
J9 HEPATOL RES
JI Hepatol. Res.
PD DEC
PY 2008
VL 38
IS 12
BP 1194
EP 1203
DI 10.1111/j.1872-034X.2008.00392.x
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 367FL
UT WOS:000260537800005
PM 18624719
DA 2020-11-24
ER

PT J
AU Nicol, AF
   Pires, ARC
   de Souza, SR
   Nuovo, GJ
   Grinsztejn, B
   Tristao, A
   Russomano, FB
   Velasque, L
   Silva, JRLE
   Pirmez, C
AF Nicol, Alcina F.
   Cordovil Pires, Andrea Rodrigues
   de Souza, Simone R.
   Nuovo, Gerard J.
   Grinsztejn, Beatriz
   Tristao, Aparecida
   Russomano, Fabio B.
   Velasque, Luciane
   Lapa e Silva, Jose R.
   Pirmez, Claude
TI Cell-cycle and suppressor proteins expression in uterine cervix in
   HIV/HPV co-infection: comparative study by tissue micro-array (TMA)
SO BMC CANCER
LA English
DT Article
ID HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; HIV-1 TAT; CARCINOMA;
   PATHOGENESIS; P16(INK4A); P27(KIP1); INFECTION; CANCER; GRADE
AB Background: The oncoproteins of human papillomavirus (HPVs) directly effect cell-cycle control. We hypothesize that regulatory and cell cycle protein expression might be additionally modified in the cervix of HIV/HPV co-infected women.
   Methods: We analyzed the expression of Rb, p27, VEGF and Elf-1 transcriptor factor by immunohistochemistry in 163 paraffin-embeded cervical samples using Tissue Micro-Array (TMA) and correlated this to HIV-1 and HPV infection.
   Results: HIV/HPV co-infection was associated with a significant increase in expression (p<0.001) of VEGF and p27 in both low and high grade CIN when compared to the cervices of women infected by HPV alone. Decreased Rb expression was evident with increased CIN grade in the cervices of women infected with HPV alone (p=0.003 average of cells/mm(2) in CIN I: 17.9, CIN II/III: 4.8, and tumor 3.9). Rb expression increased 3-fold for both low and high grade CIN with HPV/HIV-1 co-infection compared to HPV infection alone but did not reach statistical significance. There was a significant increase in Elf-1 expression in HPV+/HIV-women with CIN II/III and tumor (average of cells/mm(2) in CIN I:63.8; CIN II/III: 115.7 and tumor: 112.0, p = 0.005), in comparison to controls.
   Conclusion: Co-infection of HPV and HIV leads to significant increase in the VEGF and p27 expression when compared to HPV+/HIV-negative infection that could facilitate viral persistence and invasive tumor development.
C1 [Nicol, Alcina F.; Pirmez, Claude] Fiocruz MS, Inst Oswaldo Cruz, Immunopathol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Cordovil Pires, Andrea Rodrigues; de Souza, Simone R.] Fonte Med Diagnost Lab, Niteroi, RJ, Brazil.
   [Cordovil Pires, Andrea Rodrigues; de Souza, Simone R.] Univ Fed Fluminense, Niteroi, RJ, Brazil.
   [Nuovo, Gerard J.] Ohio State Univ Hosp, Dept Pathol, Columbus, OH 43210 USA.
   [Grinsztejn, Beatriz; Velasque, Luciane] Fiocruz MS, Dept Infect Dis, Evandro Chagas Clin Res Inst, BR-21045900 Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz; Velasque, Luciane] Univ Fed Rio de Janeiro, Dept Math & Stat, Rio De Janeiro, Brazil.
   [Tristao, Aparecida; Russomano, Fabio B.] Fiocruz MS, Fernandes Figueira Inst, BR-21045900 Rio De Janeiro, Brazil.
   [Lapa e Silva, Jose R.] Univ Fed Rio de Janeiro, Multidisciplinary Lab, Clementino Fraga Filho Univ Hosp, Rio De Janeiro, Brazil.
RP Nicol, AF (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Immunopathol Lab, BR-21045900 Rio De Janeiro, Brazil.
EM nicol@ioc.fiocruz.br; andreapires@fontemd.com.br; simone@fontemd.com.br;
   nuovo-1@medctr.osu.edu; gbeatriz@unisys.com.br;
   aptristao@iff.fiocruz.br; frussomano@superig.com.br;
   velasque@fiocruz.br; jrlapa.ntg@terra.com.br; pirmez@ioc.fiocruz.br
RI Pirmez, Claude/AAF-9977-2019; Lapa e Silva, Jose R./AAS-4793-2020;
   Pirmez, Claude/K-8579-2012
OI Pirmez, Claude/0000-0002-7443-0455; Lapa e Silva, Jose
   R./0000-0003-3116-0253; Pirmez, Claude/0000-0002-7443-0455
FU PN-DST/AIDS-MS-UNESCO; FAPERJ and IOC-FiocruzCarlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   Rio de Janeiro, Brazil
FX We would like to thank Max Thiago F. Xavier; Karine da Conceiao Pessanha
   and Rodrigo Mexas for the excellent technical assistance. This work was
   supported in part by grants from PN-DST/AIDS-MS-UNESCO; FAPERJ and
   IOC-Fiocruz, Rio de Janeiro, Brazil.
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
   Benevolo M, 2006, MODERN PATHOL, V19, P384, DOI 10.1038/modpathol.3800551
   Branca M, 2006, J CLIN PATHOL, V59, P40, DOI 10.1136/jcp.2005.026922
   Cho NH, 2002, YONSEI MED J, V43, P722, DOI 10.3349/ymj.2002.43.6.722
   Clarke B, 2001, GYNECOL ONCOL, V82, P238, DOI 10.1006/gyno.2001.6306
   Pires ARC, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-14
   De Falco G, 2003, ONCOGENE, V22, P6214, DOI 10.1038/sj.onc.1206637
   Estable MC, 1996, J VIROL, V70, P4053, DOI 10.1128/JVI.70.6.4053-4062.1996
   Gage JR, 2000, OBSTET GYNECOL, V96, P879, DOI 10.1016/S0029-7844(00)01057-7
   Goff BA, 2003, GYNECOL ONCOL, V88, P40, DOI 10.1006/gyno.2002.6858
   Huang XL, 2006, BLOOD, V107, P3153, DOI 10.1182/blood-2005-08-3206
   Moberg M, 2004, INT J CANCER, V112, P854, DOI 10.1002/ijc.20480
   Nam EJ, 2007, GYNECOL ONCOL, V104, P207, DOI 10.1016/j.ygyno.2006.07.043
   Nicol AF, 2008, J CLIN PATHOL, V61, P84, DOI 10.1136/jcp.2007.047290
   Nicol AF, 2006, EXP MOL PATHOL, V81, P42, DOI 10.1016/j.yexmp.2006.01.002
   Nicol AF, 2005, METHOD MICROBIOL, V34, P239, DOI 10.1016/S0580-9517(04)34009-2
   Nicol AF, 2005, DIAGN MOL PATHOL, V14, P39, DOI 10.1097/01.pas.0000143309.81183.6c
   Nyagol J, 2006, CANCER BIOL THER, V5, P684, DOI 10.4161/cbt.5.6.2907
   Shiozawa T, 2001, CANCER, V92, P3005, DOI 10.1002/1097-0142(20011215)92:12<3005::AID-CNCR10153>3.0.CO;2-6
   Stiegler P, 1998, J CELL BIOCHEM, P30
   Tjalma WAA, 2005, BEST PRACT RES CL OB, V19, P469, DOI 10.1016/j.bpobgyn.2005.02.002
   Tjalma WAA, 2004, INT J GYNECOL CANCER, V14, P751, DOI 10.1111/j.1048-891X.2004.014505.x
   Tringler B, 2004, HUM PATHOL, V35, P689, DOI 10.1016/j.humpath.2004.02.012
   Troncone G, 1999, J CLIN PATHOL, V52, P880, DOI 10.1136/jcp.52.12.880
   Wentzensen N, 2007, DIS MARKERS, V23, P315, DOI 10.1155/2007/678793
NR 25
TC 15
Z9 15
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 7
PY 2008
VL 8
AR 289
DI 10.1186/1471-2407-8-289
PG 10
WC Oncology
SC Oncology
GA 368OE
UT WOS:000260630700002
PM 18840277
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU de Castro, CV
   Grinsztejn, B
   Veloso, V
   Bastos, F
   Pilotto, J
   Morgado, M
AF Velasco de Castro, C.
   Grinsztejn, B.
   Veloso, V.
   Bastos, F.
   Pilotto, J.
   Morgado, M.
TI Serological Approaches to Access Recent HIV-1 Seroconvertion: Proposal
   of Criterion to Improve the Predictive Values in BEDCEIA and Avidity
   Index Assay
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Velasco de Castro, C.; Grinsztejn, B.; Veloso, V.; Bastos, F.; Pilotto, J.; Morgado, M.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RI Pilotto, Jose Henrique/AAD-9773-2019; Veloso, Valdilea
   Goncalves/J-6189-2012
OI Pilotto, Jose Henrique/0000-0003-0521-8597; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 36
EP 36
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800083
DA 2020-11-24
ER

PT J
AU Bongertz, V
   Almeida, DV
   Chequer-Fernandez, S
   Grinsztejn, B
   Veloso, V
   Pilotto, JH
   Morgado, MG
AF Bongertz, V.
   Almeida, D. V.
   Chequer-Fernandez, S.
   Grinsztejn, B.
   Veloso, V.
   Pilotto, J. H.
   Morgado, M. G.
TI High Neutralization Sensitivity of a Brazilian Subtype F HIV-1 Primary
   Isolate
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Bongertz, V.; Almeida, D. V.; Chequer-Fernandez, S.; Morgado, M. G.] Fiocruz MS, Fundacao Oswaldo Cruz IOC, BR-21045900 Rio De Janeiro, Brazil.
   [Grinsztejn, B.; Veloso, V.; Pilotto, J. H.] Fiocruz MS, Fundacao Oswaldo Cruz IPEC, BR-21045900 Rio De Janeiro, Brazil.
RI Veloso, Valdilea Goncalves/J-6189-2012; Pilotto, Jose
   Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 41
EP 42
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800099
DA 2020-11-24
ER

PT J
AU Bello, G
   de Castro, CAV
   Pilotto, JH
   Grinsztejn, B
   Veloso, VG
   Morgado, M
AF Bello, G.
   de Castro, C. A. Velasco
   Pilotto, J. H.
   Grinsztejn, B.
   Veloso, V. G.
   Morgado, M.
TI Proportional Level and Avidity of HIV-Specific Antibodies in
   HIV-1-Infected Non-Progressing Elite Controllers
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Bello, G.; de Castro, C. A. Velasco; Morgado, M.] Fiocruz MS, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, J. H.; Grinsztejn, B.; Veloso, V. G.] Fiocruz MS, Inst Pesquisas Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
RI Veloso, Valdilea Goncalves/J-6189-2012; Pilotto, Jose
   Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 53
EP 53
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800129
DA 2020-11-24
ER

PT J
AU Veloso, VG
   Portela, MC
   Vasconcellos, MTL
   Matzenbacher, LA
   de Vasconcelos, ALR
   Grinsztejn, B
   Bastos, FI
AF Veloso, Valdilea G.
   Portela, Margareth C.
   Vasconcellos, Mauricio T. L.
   Matzenbacher, Luiz A.
   de Vasconcelos, Ana Lucia R.
   Grinsztejn, Beatriz
   Bastos, Francisco I.
TI HIV testing among pregnant women in Brazil: rates and predictors
SO REVISTA DE SAUDE PUBLICA
LA English
DT Article
DE pregnant women; HIV infections, diagnosis; acquired immunodeficiency
   syndrome, prevention & control prenatal care; socioeconomic factors;
   cross-sectional studies
ID PRENATAL-CARE; HEALTH; BARRIERS
AB OBJECTIVE: To assess rates of offering and uptake of HIV testing and their predictors among women who attended prenatal care.
   METHODS: A population- based cross-sectional study was conducted among postpartum women (N = 2,234) who attended at least one prenatal care visit in 12 cities. Independent and probabilistic samples were selected in the cities studied. Sociodemographic data, information about prenatal care and access to HIV prevention interventions during the current pregnancy were collected. Bivariate and multivariate analyses were carried out to assess independent effects of the covariates on offering and uptake of HIV testing. Data collection took place between November 1999 and April 2000.
   RESULTS: Overall, 77.5% of the women reported undergoing HIV testing during the current pregnancy. Offering of HIV testing was positively associated with: previous knowledge about prevention of mother-to-child transmission of HIV; higher number of prenatal care visits; higher level of education and being white. HIV testing acceptance rate was 92.5%.
   CONCLUSIONS: The study results indicate that dissemination of information about prevention of mother-to-child transmission among women may contribute to increasing HIV testing coverage during pregnancy. Non-white women with lower level of education should be prioritized. Strategies to increase attendance of vulnerable women to prenatal care and to raise awareness among health care workers are of utmost importance.
C1 [Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21040900 Rio De Janeiro, Brazil.
   [Portela, Margareth C.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, BR-21040900 Rio De Janeiro, Brazil.
   [Vasconcellos, Mauricio T. L.] IBGE, Escola Nacl Ciencias Estat, Rio De Janeiro, Brazil.
   [Matzenbacher, Luiz A.] IBGE, Diretoria Pesquisas, Rio De Janeiro, Brazil.
   [de Vasconcelos, Ana Lucia R.] Fundacao Oswaldo Cruz, Inst Pesquisa Aggeu Magalhaes, Recife, PE, Brazil.
   [Bastos, Francisco I.] Fundacao Oswaldo Cruz, Inst Comunicacao & Informacao Cient & Tecnol, BR-21040900 Rio De Janeiro, Brazil.
RP Veloso, VG (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Av Brasil,4-365 Manguinhos, BR-21040900 Rio De Janeiro, Brazil.
EM vgveloso@ipec.fiocruz.br
RI Bastos, Francisco/AAV-4684-2020; Portela, Margareth C/G-6699-2012;
   Veloso, Valdilea Goncalves/J-6189-2012
OI Bastos, Francisco/0000-0001-5970-8896; Portela, Margareth
   C/0000-0002-9858-9276; 
CR Almeida C, 2000, INT J HEALTH SERV, V30, P129, DOI 10.2190/NDGW-C2DP-GNF8-HEW8
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   de Souza PRB, 2004, REV SAUDE PUBL, V38, P764, DOI 10.1590/S0034-89102004000600003
   Ethier KA, 2000, AM J PUBLIC HEALTH, V90, P1448, DOI 10.2105/AJPH.90.9.1448
   Fernandez MI, 2000, PUBLIC HEALTH REP, V115, P460, DOI 10.1093/phr/115.5.460
   FONSECA MG, 2000, CAD SAUDE PUBLICA S1, V16, pS77
   Goldani MZ, 2003, REV SAUDE PUBL, V37, P552, DOI 10.1590/s0034-89102003000500002
   *I BRAS GEOGR EST, 2006, CENS DEM
   MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735
   Rosa H, 2006, REV SAUDE PUBL, V40, P220, DOI 10.1590/S0034-89102006000200006
   Royce RA, 2001, AM J PUBLIC HEALTH, V91, P727, DOI 10.2105/AJPH.91.5.727
   Ruiz J D, 1998, Matern Child Health J, V2, P117, DOI 10.1023/A:1022944907256
   SANTOS VV, 2001, 8 C RETR OPP INF 200
   Schellenberg JA, 2003, LANCET, V361, P561, DOI 10.1016/S0140-6736(03)12515-9
   Segurado AC, 2003, AIDS PATIENT CARE ST, V17, P85, DOI 10.1089/108729103321150818
   *SUDAAN RES TRIANG, 2001, SUDAAN US MAN REL 8
   SZWARCWALD C, 2001, B EPIDEMIOL AIDS DST, V14
   Troccoli K, 2002, OBSTET GYNECOL, V100, P420, DOI 10.1016/S0029-7844(02)02120-8
   Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7
   Wood E, 2003, AIDS, V17, P2419, DOI 10.1097/00002030-200311210-00003
NR 20
TC 1
Z9 1
U1 0
U2 0
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL
SN 0034-8910
EI 1518-8787
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PD OCT
PY 2008
VL 42
IS 5
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 356AN
UT WOS:000259751200011
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Guimaraes, MDC
   Grinsztejn, B
   Chin-Hong, PV
   Campos, LN
   Gomes, VR
   Melo, VH
   Pilotto, JH
   Carmo, RA
   Palefsky, JM
AF Guimaraes, Mark D. C.
   Grinsztejn, Beatriz
   Chin-Hong, Peter V.
   Campos, Lorenza N.
   Gomes, Valeria R.
   Melo, Victor H.
   Pilotto, Jose Henrique
   Carmo, Ricardo A.
   Palefsky, Joel M.
TI Behavior surveillance: Prevalence and factors associated with high-risk
   sexual behavior among HIV-Infected men in brazil in the Post-HAART era
SO AIDS AND BEHAVIOR
LA English
DT Article
DE risk taking; sexual behavior; HIV-infected men; HAART; heterosexual
ID ACTIVE ANTIRETROVIRAL THERAPY
AB A cross-sectional analysis was conducted to describe unsafe sexual practices among HIV-infected men under care in two Brazilian urban areas. Data were collected by face-to-face interviews. Twenty-five percent practiced unprotected sex in the previous year, 16% were abstinent, 33% had sex with men only, 45% with women only, 48% had male/female stable partners, 84% were on HAART and 48% had AIDS. Illicit drug use, number of female partners, having stable partners, and STD diagnosis were associated with unsafe sex. Interventions to reduce risk taking behavior among HIV-positive men under care in these settings are urgent, especially among heterosexual stable couples.
C1 [Guimaraes, Mark D. C.; Campos, Lorenza N.; Melo, Victor H.] Univ Fed Minas Gerais, Fac Med, Dept Prevent & Social Med, BR-30130100 Belo Horizonte, MG, Brazil.
   [Guimaraes, Mark D. C.] Columbia Univ, HIV Ctr Clin & Behav Studies, New York, NY USA.
   [Grinsztejn, Beatriz] Evandro Chagas Res Inst Fiocruz, Rio De Janeiro, Brazil.
   [Chin-Hong, Peter V.; Palefsky, Joel M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Gomes, Valeria R.] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Carmo, Ricardo A.] Eduardo de Menezes Hosp, Nova Iguacu, MG, Brazil.
RP Guimaraes, MDC (corresponding author), Univ Fed Minas Gerais, Fac Med, Dept Prevent & Social Med, Av Prof Alfredo Balena 190-10 Andar, BR-30130100 Belo Horizonte, MG, Brazil.
EM drew@medicina.ufmg.br
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
CR Bouhnik AD, 2007, AIDS, V21, pS57, DOI 10.1097/01.aids.0000255086.54599.23
   *BRAS MIN SAUD, 2007, EPIDEMIOLOGIC B AIDS, V1, P1
   Chin-Hong PV, 2005, JAIDS-J ACQ IMM DEF, V40, P463, DOI 10.1097/01.qai.0000162238.93988.0c
   Guimaraes MDC, 2001, INT J STD AIDS, V12, P334, DOI 10.1258/0956462011923057
   Halperin DT, 1999, AIDS PATIENT CARE ST, V13, P717, DOI 10.1089/apc.1999.13.717
   Johnson BT, 2006, JAIDS-J ACQ IMM DEF, V41, P642, DOI 10.1097/01.qai.0000194495.15309.47
   Moatti JP, 2003, AIDS, V17, pS69, DOI 10.1097/00002030-200317003-00010
   Nemes MIB, 2004, AIDS, V18, pS15, DOI 10.1097/00002030-200406003-00004
   Ostrow DE, 2002, AIDS, V16, P775, DOI 10.1097/00002030-200203290-00013
   Souza PRB, 2007, CLINICS, V62, P579, DOI 10.1590/S1807-59322007000500008
   Stolte IG, 2004, AIDS, V18, P303, DOI 10.1097/00002030-200401230-00021
   Wolf K, 2003, JAIDS-J ACQ IMM DEF, V33, P494, DOI 10.1097/00126334-200308010-00010
NR 12
TC 11
Z9 11
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD SEP
PY 2008
VL 12
IS 5
BP 741
EP 747
DI 10.1007/s10461-008-9407-z
PG 7
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 339LD
UT WOS:000258578200008
PM 18491224
DA 2020-11-24
ER

PT J
AU Ferreira, VB
   Passos, SL
   Grinsztejn, BJ
AF Ferreira, V. B.
   Passos, S. L.
   Grinsztejn, B. J.
TI Biological variation and population-based reference values in
   interpretation of the changes in serial laboratory results of the
   AIDS/HIV patients in Evandro Chagas Clinical Research Institute(IPEC) -
   Oswaldo Cruz Foundation (FIOCRUZ)
SO CLINICAL CHEMISTRY
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-Association-for-Clinical-Chemistry
CY JUL 27-31, 2008
CL Washington, DC
SP Amer Assoc Clin Chem
C1 [Ferreira, V. B.; Passos, S. L.; Grinsztejn, B. J.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD JUN
PY 2008
VL 54
IS 6
SU S
MA E98
BP A224
EP A225
PG 2
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 307NN
UT WOS:000256325700691
DA 2020-11-24
ER

PT J
AU Russomano, F
   Reis, A
   Cornargo, MJ
   Grinsztejn, B
   Tristao, MA
AF Russomano, Fabio
   Reis, Aldo
   Cornargo, Maro Jose
   Grinsztejn, Beatriz
   Tristao, Maria Aparecida
TI Recurrence of cervical intraepithelial neoplasia grades 2 or 3 in
   HIV-infected women treated by large loop excision of the transformation
   zone (LLETZ)
SO SAO PAULO MEDICAL JOURNAL
LA English
DT Article
DE cervical intraepithelial neoplasia; prognosis; HIV seropositivity;
   recurrence; electrosurgery
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY;
   SEROPOSITIVE WOMEN; POSITIVE WOMEN; LESIONS
AB CONTEXT AND OBJECTIVE: Women infected by HIV are more likely to have cervical cancer and its precursors. Treatment of the precursor lesions can prevent this neoplasia. The aim of this study was to assess the likelihood of recurrent cervical intraepithelial neoplasia grades 2 or 3 (CIN 2-3) in HIV-infected women, compared with HIV-negative women, all treated by large loop excision of the transformation zone (LLETZ).
   DESIGN AND SETTING: A cohort study in Instituto Fernandes Figueira, Funcla ao Oswaldo Cruz (IFF-Fiocruz), Rio cle Janeiro.
   METHOD: 55 HIV-positive and 212 HIV-negative women were followed up after LLETZ for CIN 2-3 (range: 6-133 months).
   RESULTS: The incidence of recurrent CIN 2-3 was 30.06/10,000 woman-months in the HIV-positive group and 4.88/10,000 woman-months in the HIV-negative group (relative risk, RR = 6.16; 95% confidence interval, Cl: 2.07-18.34). The likelihood of recurrence reached 26% at the 62 d month of follow-up among the HIV-positive women, and remained stable at almost 0.6% at the 93,d month of follow-up among the HIV-negalive women. We were unable to demonstrate other prognostic factors relating to CIN recurrence, but the use of highly active antiretroviral therapy (HAART) may decrease the risk of this occurrence among HIV patients.
   CONCLUSION: After LLETZ there is a higher risk of recurrence of CIN 2-3 among HIV-positive women than among HIV-negative women. This higher risk was not influenced by margin status or grade of cervical disease treated. The use of HAART may decrease the risk of this occurrence in HIV patients.
C1 [Russomano, Fabio] Fundacao Oswaldo Cruz, IFF, Colposcopy Clin, BR-22250020 Rio De Janeiro, Brazil.
   [Reis, Aldo] FMC Corp, Rio De Janeiro, Brazil.
   [Grinsztejn, Beatriz] Fdn Oswaldo Cruz IPEC, IFF, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
RP Russomano, F (corresponding author), Fundacao Oswaldo Cruz, IFF, Colposcopy Clin, Ave Rui Barbosa,716 3 Andar Flamengo, BR-22250020 Rio De Janeiro, Brazil.
EM fabio@iff.fiacruz.br
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01 AI069476] Funding Source: Medline
CR Brito Ana Maria de, 2005, Braz J Infect Dis, V9, P9, DOI 10.1590/S1413-86702005000100004
   Chirenje Z M, 2003, J Low Genit Tract Dis, V7, P16, DOI 10.1097/00128360-200301000-00005
   DELPRIORE G, 1994, INT J GYNECOL OBSTET, V47, P273, DOI 10.1016/0020-7292(94)90573-8
   Frega A, 2006, ANTICANCER RES, V26, P3167
   Fruchter RG, 1996, OBSTET GYNECOL, V87, P338, DOI 10.1016/0029-7844(95)00408-4
   Gilles C, 2005, GYNECOL ONCOL, V96, P112, DOI 10.1016/j.ygyno.2004.10.003
   GRINSZTEJN B, 2001, THESIS U FEDERAL RIO
   Heard I, 2005, JAIDS-J ACQ IMM DEF, V39, P412, DOI 10.1097/01.qai.0000167157.83098.60
   Heard I, 2002, AIDS, V16, P1799, DOI 10.1097/00002030-200209060-00013
   Hluangdansakul Wiyada, 2006, Journal of the Medical Association of Thailand, V89, P289
   Holcomb K, 1999, GYNECOL ONCOL, V74, P428, DOI 10.1006/gyno.1999.5479
   Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P242
   Kuhn L, 1999, CURR OPIN OBSTET GYN, V11, P35, DOI 10.1097/00001703-199901000-00007
   MAIMAN M, 1993, OBSTET GYNECOL, V82, P170
   Massad L Stewart, 2007, J Low Genit Tract Dis, V11, P90, DOI 10.1097/01.lgt.0000245038.06977.a7
   Massad LS, 2001, J ACQ IMMUN DEF SYND, V27, P432, DOI 10.1097/00126334-200108150-00003
   Olaitan A, 1997, OBSTET GYNECOL, V89, P71, DOI 10.1016/S0029-7844(96)00377-8
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   PETRY KU, 1994, INT J CANCER, V57, P836, DOI 10.1002/ijc.2910570612
   PRENDIVILLE W, 1993, LARGE LOOP EXCISION, P36
   RINCON AES, 2003, GINECOLOGIA OBSTETRI, V71, P32
   Robinson W, 2000, SEMIN ONCOL, V27, P463
   Robinson WR, 2001, AM J OBSTET GYNECOL, V184, P538, DOI 10.1067/mob.2001.111103
   RUSSOMANO F, 2002, 14 INT AIDS C JUL 7
   SCHWARTZ LB, 1991, GYNECOL ONCOL, V41, P255, DOI 10.1016/0090-8258(91)90319-Z
   STRATTON P, 1994, CURR OPIN OBSTET GYN, V6, P86
   Tate DR, 2002, AM J OBSTET GYNECOL, V186, P880, DOI 10.1067/mob.2002.123607
   Tebeu PM, 2006, INT J STD AIDS, V17, P507, DOI 10.1258/095646206778145703
   UNAIDS/WHO, 2006, AIDS EP UPD, p[1, 53]
   WRIGHT TC, 1994, GYNECOL ONCOL, V55, P253, DOI 10.1006/gyno.1994.1286
NR 30
TC 8
Z9 9
U1 0
U2 4
PU ASSOCIACAO PAULISTA MEDICINA
PI SAO PAULO
PA AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL
SN 1516-3180
J9 SAO PAULO MED J
JI Sao Paulo Med. J.
PD JAN 3
PY 2008
VL 126
IS 1
BP 17
EP 22
DI 10.1590/S1516-31802008000100004
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 338MD
UT WOS:000258511100004
PM 18425282
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Kaida, A
   Gray, G
   Bastos, FI
   Andia, I
   Maier, M
   Mcintyre, J
   Grinsztejn, B
   Strathdee, SA
   Bangsberg, DR
   Hogg, R
AF Kaida, A.
   Gray, G.
   Bastos, F. I.
   Andia, I.
   Maier, M.
   Mcintyre, J.
   Grinsztejn, B.
   Strathdee, S. A.
   Bangsberg, D. R.
   Hogg, R.
TI The relationship between HAART use and sexual activity among
   HIV-positive women of reproductive age in Brazil, South Africa, and
   Uganda
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; HIGH-RISK; BEHAVIOR; OPTIMISM; INFECTION;
   SURVIVAL; HIV/AIDS; DIVOIRE; KAMPALA; STATES
AB The purpose of this study was to determine whether current HAART use is associated with recent sexual intercourse among HIV-infected women (18-49 years) from Brazil, South Africa and Uganda. We conducted an analysis of survey data from a cross-sectional study, which enrolled 179 HIV-infected women receiving regular care from the Mbarara Hospital HIV Clinic in Uganda (n = 85); the Perinatal HIV Research Unit in Soweto, South Africa (n = 50); and the IPEC-Fiocruz cohort in Rio de Janeiro, Brazil (n = 44). The primary outcome was sexual intercourse in the previous month. Secondary outcomes were protected sex and contraceptive use. We found that overall, 46% reported recent sexual intercourse. After adjusting for covariates, recent sexual intercourse was not associated with HAART use (AOR: 0.76; 95% CI: 0.34-1.72); however, it was significantly associated with being currently married, wanting to have more children and having higher HAART optimism. Among women reporting recent sexual intercourse (n = 83), HAART users were significantly more likely to practice protected sex (crude OR: 3.64; 95%CI: 1.41-9.38) and non-significantly more likely to use contraceptive methods (crude OR: 2.15; 95% Cl: 0.77-5.99). In summary, self-reported recent sexual intercourse is not more likely among women on HAART. Moreover, sexually active HAART users may be more likely to practice protected sex and use contraceptives.
C1 [Kaida, A.; Hogg, R.] BC Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.
   [Kaida, A.] Univ British Columbia, Fac Med, Dept Healthcare & Epidemiol, Vancouver, BC, Canada.
   [Gray, G.; Mcintyre, J.] Univ Witwatersrand, Perinatal HIV Res Unit, Soweto, South Africa.
   [Bastos, F. I.; Grinsztejn, B.] Fiocruz MS, Oswaldo Cruz Fdn, BR-21045900 Rio De Janeiro, Brazil.
   [Andia, I.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
   [Maier, M.; Bangsberg, D. R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Strathdee, S. A.] Univ Calif San Diego, Dept Family & Prevent Med, Div Int Hlth & Cross Cultural Med, San Diego, CA 92103 USA.
   [Hogg, R.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada.
RP Kaida, A (corresponding author), BC Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM akaida@interchange.ubc.ca
RI Strathdee, Steffanie A/B-9042-2009; McIntyre, James/V-7115-2019; Hogg,
   Robert S/B-2783-2012
OI Hogg, Robert S/0000-0003-3463-5488; Strathdee,
   Steffanie/0000-0002-7724-691X; Bastos, Francisco/0000-0001-5970-8896
FU NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [R01MH054907, R01MH054907,
   R01MH054907, R01MH054907, R01MH054907, R01MH054907, R01MH054907,
   R01MH054907, R01MH054907, R01MH054907, R01MH054907, R01MH054907,
   R01MH054907, R01MH054907, R01MH054907, R01MH054907, R01MH054907,
   R01MH054907, R01MH054907, R01MH054907, R01MH054907] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism
   (NIAAA) [K24AA015287, K24AA015287, K24AA015287, K24AA015287,
   K24AA015287, K24AA015287] Funding Source: NIH RePORTER; NIAAA NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse
   & Alcoholism (NIAAA) [AA015287] Funding Source: Medline; NIMH NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [MH54907, R01 MH054907] Funding Source: Medline
CR Abelson J, 2006, AIDS, V20, P1215, DOI 10.1097/01.aids.0000226972.42622.95
   Bateganya M, 2005, AIDS PATIENT CARE ST, V19, P760, DOI 10.1089/apc.2005.19.760
   Bongaarts J., 1983, FERTILITY BIOL BEHAV
   Bunnell R, 2006, AIDS, V20, P85, DOI 10.1097/01.aids.0000196566.40702.28
   Gray RH, 1998, LANCET, V351, P98, DOI 10.1016/S0140-6736(97)09381-1
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   Kaida A., 2006, Current HIV/AIDS Reports, V3, P177, DOI 10.1007/s11904-006-0015-0
   Kalichman SC, 2001, J ACQ IMMUN DEF SYND, V28, P303
   Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012
   Moatti JP, 2003, AIDS, V17, pS69, DOI 10.1097/00002030-200317003-00010
   RAO KV, 1995, J BIOSOC SCI, V27, P135, DOI 10.1017/S0021932000022653
   *SAS I, 2005, SAS COMP PROGR
   Seyler C, 2003, ANTIVIR THER, V8, P385
   Spacek LA, 2006, CLIN INFECT DIS, V42, P252, DOI 10.1086/499044
   Sullivan PS, 2007, AIDS BEHAV, V11, P123, DOI 10.1007/s10461-006-9100-z
   *UNAIDS, 2006, AIDS QP UPD DEC 2005
   Van de Ven P, 2000, AIDS CARE, V12, P171, DOI 10.1080/09540120050001841
   *WHO, 2004, 3 5 PROGR REP
   Wilson TE, 1999, AIDS, V13, P591, DOI 10.1097/00002030-199904010-00008
   Wools-Kaloustian K, 2006, AIDS, V20, P41, DOI 10.1097/01.aids.0000196177.65551.ea
NR 21
TC 42
Z9 44
U1 0
U2 7
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0954-0121
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PD JAN
PY 2008
VL 20
IS 1
BP 21
EP 25
DI 10.1080/09540120701426540
PG 5
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychology, Multidisciplinary; Respiratory System; Social Sciences,
   Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychology; Respiratory System; Biomedical Social Sciences
GA 253IK
UT WOS:000252511700003
PM 18278611
DA 2020-11-24
ER

PT J
AU Bongertz, V
   Ouverney, EP
   Fernandez, SC
   Grinsztejn, B
   Veloso, V
   Couto-Fernandez, JC
   Pilotto, JH
   Morgado, MG
AF Bongertz, Vera
   Ouverney, E. Priscilla
   Fernandez, Saada Chequer
   Grinsztejn, Beatriz
   Veloso, Valdilea
   Couto-Fernandez, Jose C.
   Pilotto, Jose H.
   Morgado, Mariza G.
TI Anti-human immunodeficiency virus type 1 humoral immune response and
   highly active antiretroviral treatment
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE antibodies; seroreactivity; neutralization; antiretroviral treatment;
   treatment failure
ID HIV-INFECTED PATIENTS; B-CELL RESPONSES; NEUTRALIZING ANTIBODY; VIRAL
   LOAD; HIV-1-INFECTED SUBJECTS; DRUG-RESISTANCE; THERAPY; RECONSTITUTION;
   VIREMIA; PLASMA
AB Highly active antiretroviral treatment (HAART) of human immunodeficiency type I (HIV-1) infection is very effective in controlling infection, but elimination of viral infection has not been achieved as yet, and upon treatment interruption an immediate rebound of viremia is observed. A combination of HAART with an immune stimulation might allow treatment interruption without this rebounding viremia, as the very low viremias observed with successful HAART may be insufficient to permit maintenance of a specific anti-HIV-1 immune response. The objective of this study was to compare the humoral immune response of individuals undergoing successful HAART (NF-no failure) with that of individuals with evidence of failure of therapy (FT) and to verify if the viremia peaks observed in individuals with therapy failure would act as a specific stimulus for the humoral anti-HIV-1 immune response. Antibodies binding to gp120 V3 genotype consensus peptides were more frequently observed for FT mainly against peptides corresponding to sequences of genotypes prevalent in the Rio de Janeiro city area, B and E HIV-1 neutralization of HIV-1 111B and of four primary isolates from Rio de Janeiro was less frequently observed for plasma from the NF than the FT group, but this difference was more expressive when plasma from individuals with detectable viremia were compared to that of individuals with undetectable viral loads in the year before sample collection. Although statistically significant differences were observed only in some specific comparisons, the study indicates that presence of detectable viremia may contribute to the maintenance of a specific anti-HIV-1 Immoral immune response.
C1 [Grinsztejn, Beatriz; Veloso, Valdilea; Pilotto, Jose H.] Inst Pesquisa Clin Evandro Chagas, FIOCRUZ, Rio De Janeiro, RJ, Brazil.
   [Bongertz, Vera] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
RP Bongertz, V (corresponding author), Inst Pesquisa Clin Evandro Chagas, FIOCRUZ, Rio De Janeiro, RJ, Brazil.
EM bongertz@ioc.fiocruz.br
RI Pilotto, Jose Henrique/AAD-9773-2019; Veloso, Valdilea
   Goncalves/J-6189-2012
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Couto-Fernandez, Jose
   Carlos/0000-0001-7091-9774
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1 AI069476] Funding Source: Medline
CR Amor A, 2006, AIDS, V20, P1460, DOI 10.1097/01.aids.0000233584.10209.43
   Bailey JR, 2006, J VIROL, V80, P4758, DOI 10.1128/JVI.80.10.4758-4770.2006
   Beniguel L, 2004, IMMUNOL LETT, V93, P57, DOI 10.1016/j.imlet.2004.02.004
   Benito JM, 2006, AIDS RES HUM RETROV, V22, P734, DOI 10.1089/aid.2006.22.734
   Binley JM, 2000, J INFECT DIS, V182, P945, DOI 10.1086/315774
   Bongertz V, 2005, MEM I OSWALDO CRUZ, V100, P85, DOI 10.1590/S0074-02762005000100016
   Bongertz V, 2003, MEM I OSWALDO CRUZ, V98, P209, DOI 10.1590/S0074-02762003000200007
   Bongertz V, 2001, SCAND J IMMUNOL, V53, P302, DOI 10.1046/j.1365-3083.2001.00866.x
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brigido L, 2004, AIDS PATIENT CARE ST, V18, P189, DOI 10.1089/108729104323038865
   Bucy RP, 2001, AIDS, V15, pS36, DOI 10.1097/00002030-200102002-00007
   Burns S, 2007, AIDS, V21, P1035
   Casseb J, 2002, BRAZ J MED BIOL RES, V35, P369, DOI 10.1590/S0100-879X2002000300013
   Chehimi J, 2007, J IMMUNOL, V179, P2642, DOI 10.4049/jimmunol.179.4.2642
   Cheonis Nicholas, 2005, BETA, V17, P12
   Cornelissen Marion, 2006, AIDS Res Ther, V3, P3, DOI 10.1186/1742-6405-3-3
   Dalod M, 1998, J INFECT DIS, V178, P61, DOI 10.1086/515587
   David D, 1999, AIDS RES HUM RETROV, V15, P315, DOI 10.1089/088922299311510
   Devito C, 2006, AIDS RES HUM RETROV, V22, P908, DOI 10.1089/aid.2006.22.908
   Dreyer K, 1999, AIDS RES HUM RETROV, V15, P1563, DOI 10.1089/088922299309856
   Ever-Silva WA, 2006, JAIDS-J ACQ IMM DEF, V41, P664, DOI 10.1097/01.qai.0000194736.66322.02
   Fournier AM, 2002, AIDS, V16, P1755, DOI 10.1097/00002030-200209060-00007
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Ioannidis JPA, 2000, AIDS, V14, P1481, DOI 10.1097/00002030-200007280-00003
   Jacobson JM, 2006, J INFECT DIS, V194, P623, DOI 10.1086/506364
   Karlsson AC, 2004, AIDS, V18, P981, DOI 10.1097/00002030-200404300-00005
   Killian MS, 2006, AIDS RES HUM RETROV, V22, P640, DOI 10.1089/aid.2006.22.640
   Kim JH, 2001, AIDS RES HUM RETROV, V17, P1021, DOI 10.1089/088922201300343708
   Kimura T, 2002, J INFECT DIS, V185, P53, DOI 10.1086/338099
   Kovacs A, 2005, J INFECT DIS, V192, P296, DOI 10.1086/430922
   Kumar M, 2001, HUM GENE THER, V12, P1893, DOI 10.1089/104303401753153947
   Macias J, 2005, J INFECTION, V51, P195, DOI 10.1016/j.jinf.2004.11.010
   Manzardo C, 2007, JAIDS-J ACQ IMM DEF, V46, pS9, DOI 10.1097/01.qai.0000286599.38431.ef
   Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0
   Montefiori DC, 2001, J VIROL, V75, P10200, DOI 10.1128/JVI.75.21.10200-10207.2001
   Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233
   Morris MK, 2001, J ACQ IMMUN DEF SYND, V28, P405, DOI 10.1097/00042560-200112150-00001
   Parren PWHI, 1997, NAT MED, V3, P366, DOI 10.1038/nm0497-366d
   Popovic M, 2005, P NATL ACAD SCI USA, V102, P14807, DOI 10.1073/pnas.0506857102
   Siddique MA, 2006, J INFECT DIS, V194, P661, DOI 10.1086/505913
   Soares MA, 2004, AIDS, V18, pS9, DOI 10.1097/00002030-200406003-00003
   Sullivan AK, 2003, SCAND J IMMUNOL, V57, P600, DOI 10.1046/j.1365-3083.2003.01276.x
   Vermund SH, 2006, J INFECT DIS, V194, P1, DOI 10.1086/505154
   Wang FX, 2002, J INFECT DIS, V185, P608, DOI 10.1086/339015
   Wang FX, 2002, J INFECT DIS, V186, P145
   *WHO, 2002, WHO MAN AN INFL DIAG, P40
NR 46
TC 4
Z9 6
U1 0
U2 0
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD NOV
PY 2007
VL 102
IS 7
BP 817
EP 825
DI 10.1590/S0074-02762007005000119
PG 9
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 243CD
UT WOS:000251771600006
PM 18060317
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Bello, G
   Casado, C
   Sandonis, V
   Alvaro-Cifuentes, T
   Dos Santos, CAR
   Garcia, S
   Rodriguez, C
   Del Romero, J
   Pilotto, JH
   Grinsztejn, B
   Veloso, VG
   Morgado, MG
   Lopez-Galindez, C
AF Bello, Gonzalo
   Casado, Concepcion
   Sandonis, Virginia
   Alvaro-Cifuentes, Tamara
   Dos Santos, Caio A. Rodrigues
   Garcia, Soledad
   Rodriguez, Carmen
   Del Romero, Jorge
   Pilotto, Jose H.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Morgado, Mariza G.
   Lopez-Galindez, Cecilio
TI Plasma viral load threshold for sustaining intrahost HIV type 1
   evolution
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; LONG-TERM
   NONPROGRESSORS; POTENT ANTIVIRAL THERAPY; CD4(+) T-CELLS; DISEASE
   PROGRESSION; LATENT RESERVOIR; DRUG-RESISTANCE; COMBINATION THERAPY;
   SEQUENCE ALIGNMENT
AB The objective of the present study was to determine if natural suppression of plasma viremia below the detection limit of commercial assays (50-80 copies HIV-1 RNA/ml) can contain the HIV-1 evolution. HIV-1 quasispecies complexity in PBMC DNA was assessed in the env gene at two time points in 14 long-term nonprogressors (LTNPs). Sequence changes consistent with viral evolution was found in all patients with a median plasma RNA viral load >100 copies/ml. Evidence of low-level viral evolution was detected in two of four patients with intermittent viremia and a median plasma HIV-1 RNA load of <80 copies/ml. No significant evolution was observed in the three LTNPs with persistent viral suppression below the detection limit. Overall, a significant positive correlation (p <0.001) was observed between viral evolution and plasma RNA viral load in the LTNPs analyzed. These results suggest that the detection limit of ultrasensitive viremia assays could represent an important threshold below which intrahost HIV-1 evolution does not occur.
C1 Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   Inst Salud Carlos III, Ctr Nacl Microbiol, Serv Microbiol Virol, Madrid 28220, Spain.
   IMSALUD, Ctr Sanitario Sandoval, Comunidad Autonoma Madrid, Madrid, Spain.
   Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
RP Lopez-Galindez, C (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Serv Microbiol Virol, Carretera Majadahonda Pozuelo,Km 2-200, Madrid 28220, Spain.
EM clopez@isciii.es
RI Sandonis, Virginia/K-2884-2014; Pilotto, Jose Henrique/AAD-9773-2019;
   Casado, Concepcion/F-3060-2016; Bello, Gonzalo/E-6842-2013;
   Lopez-Galindez, Cecilio/A-3603-2008; Veloso, Valdilea
   Goncalves/J-6189-2012; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Sandonis, Virginia/0000-0001-5762-7531; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Casado, Concepcion/0000-0003-3412-2877;
   Lopez-Galindez, Cecilio/0000-0002-2324-9584; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793
CR Bagnarelli P, 1999, J VIROL, V73, P3764, DOI 10.1128/JVI.73.5.3764-3777.1999
   Bello G, 2005, J GEN VIROL, V86, P355, DOI 10.1099/vir.0.80410-0
   Bello G, 2004, ARCH VIROL, V149, P1761, DOI 10.1007/s00705-004-0322-y
   Bello G, 2004, J GEN VIROL, V85, P399, DOI 10.1099/vir.0.19365-0
   Bello G, 2007, VIROLOGY, V362, P294, DOI 10.1016/j.virol.2006.11.039
   Birk M, 2000, HIV Med, V1, P205, DOI 10.1046/j.1468-1293.2000.00030.x
   Casado C, 2001, J GEN VIROL, V82, P2495, DOI 10.1099/0022-1317-82-10-2495
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997
   Finzi D, 1999, NAT MED, V5, P512
   Frenkel LM, 2003, J VIROL, V77, P5721, DOI 10.1128/JVI.77.10.5721-5730.2003
   Frost SDW, 2001, VIROLOGY, V284, P250, DOI 10.1006/viro.2000.0887
   Ganeshan S, 1997, J VIROL, V71, P663, DOI 10.1128/JVI.71.1.663-677.1997
   Goudsmit J, 2002, AIDS, V16, P791, DOI 10.1097/00002030-200203290-00016
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   Greub G, 2002, AIDS, V16, P1967, DOI 10.1097/00002030-200209270-00017
   Gunthard HF, 1999, J VIROL, V73, P9404
   Gunthard HF, 1998, J VIROL, V72, P2422
   Gunthard HF, 2001, J INFECT DIS, V183, P1318, DOI 10.1086/319864
   Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196
   Hubert JB, 2000, AIDS, V14, P123, DOI 10.1097/00002030-200001280-00007
   Karlsson AC, 2001, AIDS RES HUM RETROV, V17, P409, DOI 10.1089/088922201750102463
   Kieffer TL, 2004, J INFECT DIS, V189, P1452, DOI 10.1086/382488
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188
   Lefrere JJ, 1999, J INFECT DIS, V180, P526, DOI 10.1086/314906
   Lefrere JJ, 1997, BLOOD, V90, P1133, DOI 10.1182/blood.V90.3.1133.1133_1133_1140
   Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997
   LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995
   Madec Y, 2005, AIDS, V19, P2001, DOI 10.1097/01.aids.0000194134.28135.cd
   Madec Y, 2005, CLIN INFECT DIS, V40, P1350, DOI 10.1086/429318
   Mani I, 2002, J VIROL, V76, P10745, DOI 10.1128/JVI.76.21.10745-10755.2002
   Markham RB, 1998, P NATL ACAD SCI USA, V95, P12568, DOI 10.1073/pnas.95.21.12568
   Martinez-Picado J, 2000, P NATL ACAD SCI USA, V97, P10948, DOI 10.1073/pnas.97.20.10948
   Menzo S, 1998, AIDS, V12, P985, DOI 10.1097/00002030-199809000-00004
   Mikhail M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-41
   Nettles RE, 2005, JAMA-J AM MED ASSOC, V293, P817, DOI 10.1001/jama.293.7.817
   Persaud D, 2004, J VIROL, V78, P968, DOI 10.1128/JVI.78.2.968-979.2004
   Persaud D, 2000, J CLIN INVEST, V105, P995, DOI 10.1172/JCI9006
   Riva E, 2001, AIDS RES HUM RETROV, V17, P1599, DOI 10.1089/088922201753342004
   Rodrigo AG, 1997, AIDS RES HUM RETROV, V13, P737, DOI 10.1089/aid.1997.13.737
   Ruff CT, 2002, J VIROL, V76, P9481, DOI 10.1128/JVI.76.18.9481-9492.2002
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Shioda T, 1997, J VIROL, V71, P4871, DOI 10.1128/JVI.71.7.4871-4881.1997
   Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880
   STRUNNIKOVA N, 1995, J VIROL, V69, P7548, DOI 10.1128/JVI.69.12.7548-7558.1995
   Stuart JWTC, 2001, J ACQ IMMUN DEF SYND, V28, P105, DOI 10.1097/00042560-200110010-00001
   TANURI A, 1999, BRAZIL J ACQUIR IMMU, V20, P60
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005
   Wang B, 2003, VIROLOGY, V312, P135, DOI 10.1016/S0042-6822(03)00159-4
   Wang B, 2000, AIDS, V14, P213, DOI 10.1097/00002030-200002180-00002
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
   Zhang LQ, 1997, J VIROL, V71, P2555, DOI 10.1128/JVI.71.3.2555-2561.1997
   Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101
NR 55
TC 16
Z9 16
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2007
VL 23
IS 10
BP 1242
EP 1250
DI 10.1089/aid.2007.0074
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 228HO
UT WOS:000250720900013
PM 17961111
DA 2020-11-24
ER

PT J
AU Molina, JM
   Cohen, C
   Katlama, C
   Grinsztejn, B
   Timerman, A
   Pedro, RD
   Vangeneugden, T
   Miralles, D
   De Meyer, S
   Parys, W
   Lefebvre, E
AF Molina, Jean-Michel
   Cohen, Calvin
   Katlama, Christine
   Grinsztejn, Beatriz
   Timerman, Artur
   Pedro, Rogerio de Jesus
   Vangeneugden, Tony
   Miralles, Diego
   De Meyer, Sandra
   Parys, Wim
   Lefebvre, Eric
CA TMC114-C208 -C215 Study Grp
TI Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in
   treatment-experienced patients - 24-week results of POWER 3
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT 44th Annual Meeting of the Infectious-Diseases-Society-of-America
CY OCT 12-15, 2006
CL Toronto, CANADA
SP Infect Dis Soc Amer
DE darunavir; HIV RNA < 50 copies/mL; protease inhibitors; TMC114
ID OPTIMIZED BACKGROUND REGIMEN; HIV-1-INFECTED PATIENTS; DURABLE EFFICACY;
   HIV-INFECTION; TMC114/RITONAVIR; ENFUVIRTIDE; TRIALS; INHIBITOR
AB Objective: In POWER I and POWER 2, darunavir (TMC 114) with low-dose ritonavir (darunavir/r) demonstrated greater efficacy versus control protease inhibitors (PIs). To examine the efficacy and safety of the selected darunavir/r dose further, additional patients were analyzed.
   Methods: Treatment-experienced HIV-1-infected patients received darunavir/r at a dose of 600/100 mg twice daily plus an optimized background regimen. The primary intent-to-treat analysis was the proportion of patients with an HIV-1 RNA reduction >= 1 log(10) at week 24.
   Results: Three hundred twenty-seven patients were treated; the baseline mean HIV-1 RNA was 4.6 log(10) copies/mL, and the median CD4 count was 115 cells/mm(3) (median primary PI mutations = 3, PI resistance-associated mutations = 9). Two hundred forty-six patients reached week 24 by the cutoff date and were included in the efficacy analysis: 65% and 40% achieved HIV-1 RNA reductions of >= 1 log(10) and <50 copies/mL, respectively, at week 24. The mean CD4 count increase was 80 cells/mm(3). The most common adverse events (AEs) were diarrhea (14%), nasopharyngitis (11%), and nausea (10%). Nine (3%) patients discontinued treatment because of AEs or HIV-1-related events. Six treatment-unrelated deaths (2%) were reported.
   Conclusions: These results corroborate POWER I and POWER 2. In this larger set of treatment-experienced patients, darunavir/r at a dose of 600/100 mg twice daily provided substantial virologic and immunologic responses and was generally safe and well tolerated.
C1 Hop St Louis, AP HP, Dept Infect Dis, F-75010 Paris, France.
   Univ Paris 07, Paris, France.
   Community Res Initiat New England, Boston, MA USA.
   Hop La Pitie Salpetriere, Paris, France.
   Inst De Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   PAM Heliopolis, Sao Paulo, Brazil.
   Hosp Clin Unicamp, Campinas, Brazil.
   Tibotec BVBA, Mechelen, Belgium.
   Tibotec Inc, Yardley, PA USA.
RP Molina, JM (corresponding author), Hop St Louis, AP HP, Dept Infect Dis, 1 Ave Claude Vellefaux, F-75010 Paris, France.
EM jean-michel.molina@sls.aphp.fr
CR *AIDS CLIN TRIALS, 1992, DIV AIDS TABL GRAD S
   Arasteh K, 2005, AIDS, V19, P943, DOI 10.1097/01.aids.0000171408.38490.01
   Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8
   De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.6.2314-2321.2005
   DEMEYER S, 2006, INT HIV DRUG RES WOR
   *DEP HHS, 2006, GUID US ANT AG HICV
   ELSTON RC, 2004, 15 WORLD AIDS C
   Eron J, 2006, LANCET, V368, P1238, DOI 10.1016/S0140-6736(06)69155-1
   Food and Drug Administration Guidance for Industry, 2002, ANT DRUGS US PLASM H
   GATHE J, 2006, FRONT DRUG DEV ANT T
   GAZZARD B, 2005, BRIT HIV ASS GUIDELI
   Haubrich R, 2007, AIDS, V21, pF11, DOI 10.1097/QAD.0b013e3280b07b47
   Hicks CB, 2006, LANCET, V368, P466, DOI 10.1016/S0140-6736(06)69154-X
   HOETELMANS R, 2004, 5 INT WORKSH CLIN PA
   Johnson M, 2006, AIDS, V20, P711, DOI 10.1097/01.aids.0000216371.76689.63
   Johnson Victoria A, 2005, Top HIV Med, V13, P51
   Katlama C, 2007, AIDS, V21, P395, DOI 10.1097/QAD.0b013e328013d9d7
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026
   Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211
   Nelson M, 2005, JAIDS-J ACQ IMM DEF, V40, P404, DOI 10.1097/01.qai.0000185314.56556.c3
   PHILLIPS A, 2003, 9 EUR AIDS C
   Rockstroh J, 2006, 8 INT C DRUG THER HI
   Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354
NR 23
TC 81
Z9 82
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD SEP 1
PY 2007
VL 46
IS 1
BP 24
EP 31
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 206RZ
UT WOS:000249201900004
PM 17621237
DA 2020-11-24
ER

PT J
AU Madruga, JV
   Cahn, P
   Grinsztejn, B
   Haubrich, R
   Lalezari, J
   Mills, A
   Pialoux, G
   Wilkin, T
   Peeters, M
   Vingerhoets, J
   de Smedt, G
   Leopold, L
   Trefiglio, R
   Woodfall, B
AF Madruga, Jose Valdez
   Cahn, Pedro
   Grinsztejn, Beatriz
   Haubrich, Richard
   Lalezari, Jacob
   Mills, Anthony
   Pialoux, Gilles
   Wilkin, Timothy
   Peeters, Monika
   Vingerhoets, Johan
   de Smedt, Goedele
   Leopold, Lorant
   Trefiglio, Roberto
   Woodfall, Brion
CA DUET-1 Study Grp
TI Efficacy and safety of TMC125 (etravirine) in treatment-experienced
   HIV-1-infected patients in DUET-1: 24-week results from a randomised,
   double-blind, placebo-controlled trial
SO LANCET
LA English
DT Article; Proceedings Paper
CT 4th International-AIDS-Society Conference on HIV Pathogenesis, Treatment
   and Prevention
CY JUL 22-25, 2007
CL Sydney, AUSTRALIA
SP Int AIDS Soc
ID RESISTANCE; INFECTION; HIV-1
AB Background Antiretroviral agent; active against drug-resistant HIV-1 are needed for treatment-experienced patients. The aim of this trial was to assess the efficacy, safety; and tolerability of TMC125 (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI).
   Methods DUET-1 is a continuing, multinational randomised, double-blind, placebo-controlled, phase III trial. Treatment-experienced adult patients with virological failure on stable antiretroviral therapy, documented genotypic evidence of NNRTI resistance, Aral load over 5000 copies per mL, and three or more primary protease inhibitor mutations were randomly assigned to receive 200 mg TMC125 or placebo twice daily. All patients also received darunavir with low-dose ritonavir and investigator-selected nucleoside reverse transcriptase inhibitors. Enfuvirtide use was optional. The primary endpoint was a confirmed viral load below 50 copies per mL at week 24 (FDA time-to-loss of virological response algorithm). Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, with the number NCT00254046.
   Findings 612 patients were randomised and treated (304 in the TMC125 group, 308 in the placebo group). By week 24, 42 (14%) patients in the TMC125 group and 56 (18%) in the placebo group had discontinued, mainly due to virological failure. At week 24, 170 (56%) patients in the TMC125 group and 119 (39%) patients in the placebo group achieved a confirmed viral load of less than 50 copies per mL (difference in response rates 17%; 95% CI 9-25; p = 0.005). Most adverse events were mild or moderate in severity. The type and incidence of adverse events, including neuropsychiatric events, seen with TMC125 were generally comparable with placebo, with the exception of rash (61 [20%] patients on TMC125 vs 30 [10%] on placebo) and diarrhoea (36 [12%] patients on TMC125 vs 63 [20%] on placebo).
   Interpretation In treatment-experienced patients with NNRTI resistance, treatment with TMC125 achieved better virological suppression at week 24 than did placebo. The safety and tolerability profile of TMC125 was generally comparable with placebo.
C1 DST AIDS, Ctr Referencia & Treinamento, BR-04121000 Sao Paulo, Brazil.
   Hosp Juan A Fernandez & Fdn Huesped, Buenos Aires, DF, Argentina.
   Univ Calif San Diego, San Diego, CA 92103 USA.
   Quest Clin Res, San Francisco, CA USA.
   Hop Tenon, Serv Malad Infect, APHP, F-75970 Paris, France.
   Cornell Univ, Weill Med Coll, New York, NY USA.
   Tibotec BVBA, Mechelen, Belgium.
   Tibotec Inc, Yardley, PA USA.
RP Madruga, JV (corresponding author), DST AIDS, Ctr Referencia & Treinamento, Rua Santa Cruz 81,Vila Mariana, BR-04121000 Sao Paulo, Brazil.
EM vaidezmr@uol.com.br
OI Mills, Anthony/0000-0002-6997-5581
CR Andries K, 2004, ANTIMICROB AGENTS CH, V48, P4680, DOI 10.1128/AAC.48.12.4680-4686.2004
   Bacheler L, 2001, J VIROL, V75, P4999, DOI 10.1128/JVI.75.11.4999-5008.2001
   Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8
   COHEN C, 2006, 16 INT AIDS C TOR CA
   COOPER D, 2007, 14 C RETR OPP INF LO
   Delaugerre C, 2001, J MED VIROL, V65, P445, DOI 10.1002/jmv.2055
   DEMEYER S, 2006, 15 INT HIV DRUG RES
   DEMEYER S, 2006, 8 INT C DRUG THER HI
   Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x
   Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827
   Johnson Victoria A, 2005, Top HIV Med, V13, P125
   KATLAMA C, 2005, 12 C RETR OPP INF BO
   LALEZARI J, 2007, 14 C RETR OPP INF LO
   Lazzarin A, 2007, LANCET, V370, P39, DOI 10.1016/S0140-6736(07)61048-4
   MONTANER J, 2005, 10 EUR AIDS C DUBL I
   Nadler JP, 2007, AIDS, V21, pF1
   NELSON M, 2007, 14 C RETR OPP INF LO
   PISCITELLI S, 2002, 42 INT C ANT AG CHEM
   POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712
   SCHOLLER M, 2006, 13 C RETR OPP INF DE
   SCHOLLER M, 2005, 3 IAS C HIV PATH TRE
   STEIGBIGEL R, 2007, 14 C RETR OPP INF LO
   TAMBUYZER L, 2007, 5 EUR HIV DRUG RES W
   *US DEP HHS, 2006, GUID US ANT AG HIV 1
   *US DEP HHS FDA CD, 2002, GUID IND ANT DRUGS U
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
   VINGERHOETS J, 2007, 16 INT HIV DRUG RES
   Youle M, 2004, LANCET, V364, P1036, DOI 10.1016/S0140-6736(04)17055-4
NR 28
TC 353
Z9 370
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUL 7
PY 2007
VL 370
IS 9581
BP 29
EP 38
DI 10.1016/S0140-6736(07)61047-2
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 187QE
UT WOS:000247862300028
PM 17617270
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Nguyen, BY
   Katlama, C
   Gatell, JM
   Lazzarin, A
   Vittecoq, D
   Gonzalez, CJ
   Chen, J
   Harvey, CM
   Isaacs, RD
AF Grinsztejn, Beatriz
   Nguyen, Bach-Yen
   Katlama, Christine
   Gatell, Jose M.
   Lazzarin, Adriano
   Vittecoq, Daniel
   Gonzalez, Charles J.
   Chen, Joshua
   Harvey, Charlotte M.
   Isaacs, Robin D.
CA Protocol 005 Team
TI Safety and efficacy of the HIV-1 integrase inhibitor raltegravir
   (MK-0518) in treatment-experienced patients with multidrug-resistant
   virus: a phase II randomised controlled trial
SO LANCET
LA English
DT Article
ID DRUG-RESISTANCE; ANTIRETROVIRAL DRUGS; HIV-1-INFECTED INDIVIDUALS;
   THERAPY; ENFUVIRTIDE; PREVALENCE; INFECTION
AB Background Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in-vitro activity against HIV-1 strains including those resistant to currently available antiretroviral drugs. The aim of this study was to assess the safety and efficacy of raltegravir when added to optimised background regimens in HIV-infected patients.
   Methods HIV-infected patients with HIV-1 RNA viral load over 5000 copies per mL, CD4 cell counts over 50 cells per mu L, and documented genotypic and phenotypic resistance to at least one nucleoside reverse transcriptase inhibitor, one non-nucleoside reverse transcriptase inhibitor, and one protease inhibitor were randomly assigned to receive raltegravir (200 mg, 400 mg, or 600 mg) or placebo orally twice daily in this multicentre, triple-blind, dose-ranging, randomised study. The primary endpoints were change in viral load from baseline at week 24 and safety. Analyses were done on a modified intention-to-treat basis. This trial is registered with ClinicalTrials.gov, with the number NCT00105157.
   Findings 179 patients were eligible for randomisation. 44 patients were randomly assigned to receive 200 mg raltegravir, 45 to receive 400 mg raltegravir, and 45 to receive 600 mg raltegravir; 45 patients were randomly assigned to receive placebo. One patient in the 200 mg group did not receive treatment and was therefore excluded from the analyses. For all groups, the median duration of previous antiretroviral therapy was 9.9 years (range 0.4-17.3 years) and the mean baseline viral load was 4.7 (SD 0.5) log(10) copies per mL. Four patients discontinued due to adverse experiences, three (2%) of the 133 patients across all raltegravir groups and one (2%) of the 45 patients on placebo. 41 patients discontinued due to lack of efficacy: 14 (11%) of the 133 patients across all raltegravir groups and 27 (60%) of the 45 patients on placebo. At week 24, mean change in viral load from baseline was -1.80 (95% CI -2.10 to -1.50) log(10) copies per mL in the 200 mg group, -1.87 (-2.16 to -1.58) log(10) copies per mL in the 400 mg group, -1.84 (-2.10 to -1.58) log(10) copies per mL in the 600 mg group, and -0.35 (-0.61 to -0.09) log(10) copies per mL for the placebo group. Raltegravir at all doses showed a safety profile much the same as placebo; there were no dose-related toxicities.
   Interpretation In patients with few remaining treatment options, raltegravir at all doses studied provided better viral suppression than placebo when added to an optimised background regimen. The safety profile of raltegravir is comparable with that of placebo at all doses studied.
C1 Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   Merck Res Labs, West Point, PA USA.
   Hop La Pitie Salpetriere, Paris, France.
   Univ Barcelona, Barcelona, Spain.
   Ist Sci San Raffaele, I-20132 Milan, Italy.
   Hop Paul Brousse, Villejuif, France.
   NYU, Sch Med, New York, NY USA.
RP Nguyen, BY (corresponding author), Merck Res Labs, POB 1000, N Wales, PA 19454 USA.
EM bachyen-nguyen@merck.com
RI Gatell, Jose M/ABC-3607-2020
OI LAZZARIN, Adriano/0000-0003-2551-7754
CR Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   de Bethune MP, 2006, CURR MED RES OPIN, V22, P2603, DOI 10.1185/030079906X154114
   De Clercq Erik, 2005, Expert Opin Emerg Drugs, V10, P241, DOI 10.1517/14728214.10.2.241
   *DHHS PAN OFF AIDS, 2006, GUID US ANT AG HIV 1
   Gulick RM, 2003, CLIN MICROBIOL INFEC, V9, P186, DOI 10.1046/j.1469-0691.2003.00570.x
   Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hicks CB, 2006, LANCET, V368, P466, DOI 10.1016/S0140-6736(06)69154-X
   IWAMOTO M, 2006, 46 ANN INT C ANT AG
   KASSAHUN K, 2006, 46 ANN INT C ANT AG
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026
   Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211
   Machouf N, 2006, J MED VIROL, V78, P608, DOI 10.1002/jmv.20582
   MARKOWITZ M, 2006, 16 INT AIDS C TOR CA
   Markowitz M, 2006, JAIDS-J ACQ IMM DEF, V43, P509, DOI 10.1097/QAI.0b013e31802b4956
   Miller M., 2006, 16 INT AIDS C TOR CA
   MISTRY GC, 2006, 8 INT C DRUG THER HI
   Richman DD, 2004, AIDS, V18, P1393, DOI 10.1097/01.aids.0000131310.52526.c7
   Tozzi V, 2006, ANTIVIR THER, V11, P553
   WENNING LA, 2006, 46 ANN INT C ANT AG
   YOUNG B, 2006, JAAPA S, V1, P3
NR 21
TC 436
Z9 453
U1 0
U2 24
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 14
PY 2007
VL 369
IS 9569
BP 1261
EP 1269
DI 10.1016/S0140-6736(07)60597-2
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 164YA
UT WOS:000246269700028
PM 17434401
DA 2020-11-24
ER

PT J
AU Katlama, C
   Esposito, R
   Gatell, JM
   Goffard, JC
   Grinsztejn, B
   Pozniak, A
   Rockstroh, J
   Stoehr, A
   Vetter, N
   Yeni, P
   Parys, W
   Vangeneugdenk, T
AF Katlama, Christine
   Esposito, Roberto
   Gatell, Jose M.
   Goffard, Jean-Christophe
   Grinsztejn, Beatriz
   Pozniak, Anton
   Rockstroh, Jurgen
   Stoehr, Albrecht
   Vetter, Norbert
   Yeni, Patrick
   Parys, Wim
   Vangeneugdenk, Tony
CA POWER 1 study grp
TI Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV
   patients: 24-week results of POWER 1
SO AIDS
LA English
DT Article
DE HIV; TMC114; darunavir; protease inhibitor; treatment-experienced
   patients; efficacy; safety
ID TMC114
AB Background: The ongoing phase IIb POWER 1 (TMC114-C213) trial is designed to assess efficacy and safety of the protease inhibitor (PI) TMC114 (darunavir) in treatment-experienced HIV-1-infected patients.
   Design: This randomized, partially blinded, 24-week dose-finding study compared efficacy and safety of four doses of TMC114 plus low-dose ritonavir (TMC114/r) with investigator-selected control PI(s) (CPI[s]).
   Methods: Patients with one or more primary PI mutation and HIV RNA > 1000 copies/ml received optimized background therapy, plus TMC114/r 400/100 mg once daily, 800/100 mg once daily, 400/100 mg twice daily or 600/100 mg twice daily, or CPI(s). The primary endpoint (intent-to-treat) compared proportions of patients achieving viral load reduction >= 1.0log(10)copies/ml from baseline.
   Results: In total, 318 patients were treated. Baseline mean viral load was 4.48log(10) copies/ml; median CD4 cell count was 179 cells/mu l. In the CPI arm 62% of patients discontinued (virological failure: 54%); 10% of TMC114/r patients discontinued. More TMC114/r (69-77%) than CPI patients (25%) reached the primary endpoint (P < 0.001); 43-53% of TMC114/r patients and 18% of the CPI arm achieved viral load < 50 copies/ml (P < 0.001). TMC114/r demonstrated greater mean CD4 cell count increases versus CPI(s) (68-124 versus 20cells/mu l; P < 0.05). TMC114/r 600/100 mg twice daily demonstrated the highest virological and immunological responses. Adverse event incidence was similar between treatments; headache and diarrhoea were more common with CPI(s).
   Conclusions: TMC114/r demonstrated statistically higher 24-week virological response rates and CD4 cell count increases than CPI(s). TMC114/r 600/100 mg twice daily has received regulatory approval in treatment-experienced patients. (c) 2007 Lippincott Williams & Wilkins.
C1 Hop La Pitie Salpetriere, Serv Malad Infect & Trop, F-75651 Paris 13, France.
   Policlin Modena, Modena, Italy.
   Univ Barcelona, Hosp Clin, E-08007 Barcelona, Spain.
   Univ Brussels, Hop Erasme, Brussels, Belgium.
   Chelsea & Westminster Hosp, London, England.
   Univ Bonn, Mediz Klin Immunol Ambulanz, D-5300 Bonn, Germany.
   IFI, Inst AK St Georg, Hamburg, Germany.
   Otto Wagner Spital, Interne Lungenabt, Vienna, Austria.
   Hop Bichat, F-75877 Paris, France.
   Tibotec BVBA, Mechelen, Belgium.
RP Katlama, C (corresponding author), Hop La Pitie Salpetriere, Serv Malad Infect & Trop, 47-83 Blvd Hop, F-75651 Paris 13, France.
EM christine.katlama@psl.ap-hop-paris.fr
RI Gatell, Jose M/ABC-3607-2020
OI Goffard, Jean-Christophe/0000-0002-2730-7673
CR Arasteh K, 2005, AIDS, V19, P943, DOI 10.1097/01.aids.0000171408.38490.01
   BAUER P, 1991, STAT MED, V10, P871, DOI 10.1002/sim.4780100609
   D'Aquila Richard T, 2003, Top HIV Med, V11, P92
   De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.6.2314-2321.2005
   Gulick RM, 2003, CLIN MICROBIOL INFEC, V9, P186, DOI 10.1046/j.1469-0691.2003.00570.x
   Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827
   HAUBRICH R, 2006, UNPUB WEEK 24 EFFICA
   Johnson Victoria A, 2004, Top HIV Med, V12, P119
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
NR 9
TC 146
Z9 150
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD FEB 1
PY 2007
VL 21
IS 4
BP 395
EP 402
DI 10.1097/QAD.0b013e328013d9d7
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 146BR
UT WOS:000244910000001
PM 17301557
DA 2020-11-24
ER

PT J
AU Cahn, P
   Villacian, J
   Lazzarin, A
   Katlama, C
   Grinsztejn, B
   Arasteh, K
   Lopez, P
   Clumeck, N
   Gerstoft, J
   Stavrianeas, N
   Moreno, S
   Antunes, F
   Neubacher, D
   Mayers, D
AF Cahn, Pedro
   Villacian, Jorge
   Lazzarin, Adriano
   Katlama, Christine
   Grinsztejn, Beatriz
   Arasteh, Keikawus
   Lopez, Paulo
   Clumeck, Nathan
   Gerstoft, Jan
   Stavrianeas, Nikolas
   Moreno, Santiago
   Antunes, Francisco
   Neubacher, Dietmar
   Mayers, Douglas
TI Ritonavir-boosted tipranavir demonstrates superior efficacy to
   ritonavir-boosted protease inhibitors in treatment-experienced
   HIV-infected patients: 24-week results of the RESIST-2 trial
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; DRUG-RESISTANCE; HIV-1-INFECTED PATIENTS;
   HEALTHY-VOLUNTEERS; VIRUS; FAILURE; INDINAVIR; INDIVIDUALS; PREDICTORS;
   METABOLISM
AB Background. Tipranavir, a novel protease inhibitor, has demonstrated antiviral activity against protease inhibitor -resistant human immunodeficiency virus type 1 (HIV-1) isolates. The Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST-2) trial is an ongoing, open-label, phase III trial comparing ritonavir-boosted tipranavir (TPV/r) plus an optimized background regimen with an individually optimized, ritonavir-boosted protease inhibitor in treatment-experienced, HIV-1-infected patients.
   Methods. Patients at 171 sites in Europe and Latin America who had received >= 2 previous protease inhibitor regimens, had triple-antiretroviral class experience, had an HIV-1 RNA level >= 1000 copies/mL, and had genotypically demonstrated primary protease inhibitor resistance were eligible. After genotypic resistance tests were performed, a protease inhibitor and optimized background regimen were selected before randomization. Patients were randomized to receive either TPV/r or comparator protease inhibitor-ritonavir (CPI/r) and were stratified on the basis of preselected protease inhibitor and enfuvirtide use. Treatment response was defined as a confirmed HIV-1 load reduction >= 1log(10) less than the baseline value without a treatment change at week 24.
   Results. A total of 863 patients were randomized and treated. At baseline, the mean HIV-1 load was 4.73 log(10) copies/mL, and the mean CD4(+) cell count was 218 cells/mm(3). The preplanned 24-week efficacy analyses of 539 patients demonstrated treatment response rates of 41% in the TPV/r arm and 14.9% in the CPI/r arm (intent-to-treat analysis;). The mean CD4+ cell count increased by 51 cells/mm(3) in the TPV/r arm and by 18 P <.0001 cells/mm(3) in the CPI/r arm. The most common adverse events were mild-to-moderate diarrhea, nausea, and headache. Grade 3 or greater elevations in serum transaminase, cholesterol, and triglyceride levels were more frequent in the TPV/r arm.
   Conclusions. TPV/r had superior antiviral activity and increased immunologic benefits, compared with CPI/r, at week 24 among treatment-experienced patients infected with multidrug-resistant HIV-1.
C1 Fdn Huesped, Buenos Aires, DF, Argentina.
   Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   Hosp Juan I Menchaca, Inst Mexicano Seguro Social, Guadalajara, Jalisco, Mexico.
   Boehringer Ingelheim Pharmaceut, Ridgefield, CT USA.
   Boehringer Ingelheim GmbH & Co Kg, Ingelheim, Germany.
   Auguste Viktoria Klinikum, Berlin, Germany.
   Vila Salute San Raffaele Univ, Milan, Italy.
   Hop La Pitie Salpetriere, Paris, France.
   Hop Univ St Pierre, Brussels, Belgium.
   Rigshosp, DK-2100 Copenhagen, Denmark.
   Andreas Syngros Hosp, Athens, Greece.
   Hosp Ramon y Cajal, E-28034 Madrid, Spain.
   Hosp Santa Maria, Lisbon, Portugal.
RP Cahn, P (corresponding author), Fdn Huesped, Angel Peluffio 3932, Buenos Aires, DF, Argentina.
EM pcahn@huesped.org.ar
OI Antunes, Francisco/0000-0001-7932-1154; LAZZARIN,
   Adriano/0000-0003-2551-7754
CR Adams P F, 1999, Vital Health Stat 10, P1
   Back NKT, 2000, AIDS, V14, P101, DOI 10.1097/00002030-200001070-00019
   Barry M, 1997, CLIN PHARMACOKINET, V32, P194, DOI 10.2165/00003088-199732030-00003
   Boden D, 1999, JAMA-J AM MED ASSOC, V282, P1135, DOI 10.1001/jama.282.12.1135
   Chrusciel RA, 2004, CURR TOP MED CHEM, V4, P1097, DOI 10.2174/1568026043388312
   Cingolani A, 2002, AIDS, V16, P369, DOI 10.1097/00002030-200202150-00008
   Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996
   Condra JH, 2000, J INFECT DIS, V182, P758, DOI 10.1086/315782
   Deeks SG, 1999, ADV EXP MED BIOL, V458, P175
   Demeter LM, 2001, ANN INTERN MED, V135, P954, DOI 10.7326/0003-4819-135-11-200112040-00007
   FATKENHEUER G, 1997, AIDS, V11, P113
   GATHE J, 2003, 10 ANN C RETR OPP IN
   Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007
   Hertogs K, 2000, AIDS, V14, P1203, DOI 10.1097/00002030-200006160-00018
   HICKS C, 2004, 44 INT C ANT AG CHEM
   JOHSON VA, 2003, TOP HIV MED, V11, P215
   Khaliq Y, 2001, BRIT J CLIN PHARMACO, V51, P591, DOI 10.1046/j.1365-2125.2001.01393.x
   Koudriakova T, 1998, DRUG METAB DISPOS, V26, P552
   Kumar GN, 1999, DRUG METAB DISPOS, V27, P902
   Larder BA, 2000, AIDS, V14, P1943, DOI 10.1097/00002030-200009080-00009
   Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8
   MacGregor TR, 2004, HIV CLIN TRIALS, V5, P371, DOI 10.1310/RRX7-49ME-27V7-MWWV
   McCallister S, 2004, JAIDS-J ACQ IMM DEF, V35, P376, DOI 10.1097/00126334-200404010-00007
   Mehandru S, 2003, EXPERT OPIN INV DRUG, V12, P1821, DOI 10.1517/13543784.12.11.1821
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Moore N, 2003, PHARMACOEPIDEM DR S, V12, P271, DOI 10.1002/pds.848
   OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002
   Poppe SM, 1997, ANTIMICROB AGENTS CH, V41, P1058, DOI 10.1128/AAC.41.5.1058
   Randolph JT, 2004, CURR TOP MED CHEM, V4, P1079, DOI 10.2174/1568026043388330
   SABO JP, 2006, 7 INT WORKSH CLIN PH
   Selik RM, 1997, J INFECT DIS, V176, P632, DOI 10.1086/514083
   TREDGER JM, 2002, HOSP PHARM, V9, P167
   Wit FWNM, 1999, J INFECT DIS, V179, P790, DOI 10.1086/314675
NR 33
TC 67
Z9 69
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 15
PY 2006
VL 43
IS 10
BP 1347
EP 1356
DI 10.1086/508352
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 096UU
UT WOS:000241403100020
PM 17051504
OA Bronze
DA 2020-11-24
ER

PT J
AU Nicol, AF
   Nuovo, GJ
   Wang, Y
   Grinsztejn, B
   Tristao, A
   Russomano, F
   Perez, MA
   Lapa e Silva, JR
   Fernandes, ATG
   Gage, JR
   Martinez-Maza, O
   Bonecini-Almeida, MG
AF Nicol, A. F.
   Nuovo, G. J.
   Wang, Y.
   Grinsztejn, B.
   Tristao, A.
   Russomano, F.
   Perez, M. A.
   Lapa e Silva, J. R.
   Fernandes, A. T. G.
   Gage, J. R.
   Martinez-Maza, O.
   Bonecini-Almeida, M. G.
TI In situ detection of SOCS and cytokine expression in the uterine cervix
   from HIV/HPV coinfected women
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article
DE SSI/SOCS; uterine cervix; in situ RT-PCR; HIV-1/HPV coinfection
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NECROSIS FACTOR-ALPHA; HIV-1
   NUCLEIC-ACIDS; INFECTION; CELLS; DYSPLASIA; PCR; ACTIVATION; INDUCTION;
   NEOPLASIA
AB The purpose of this study was to look for associations between a newly described class of suppressors of cytokine signaling (SSI/SOCS) and cytokine expression in the uterine cervix from HIV/HPV coinfected women. We examined the pro-inflammatory cytokines TNF-alpha and IL-6 since their expressions are linked and responsible for many aspects of both localized and systemic inflammatory responses. Further, expression of SSI/SOCS has been implicated in the negative feedback regulation of cytokine receptor signaling. PCR-amplified HIV-1 cDNA was noted mainly in the stroma, showing a perivascular distribution, and most of the infected cells colabeled with the macrophage marker CD68. The distribution of IL-6 and TNF-alpha was in the same area to HIV-1 and much greater than normal cervices from women with no evidence of viral infection. SOCS/SSI-1 and -3 mRNA positive cells in the uterine cervix were commonly detected in these noninfected cervical tissues; however, very few cells that contained SOCS were evident in areas where HIV-1, TNF-alpha, and IL-6 expressing cells were found. This suggests that viral-related suppression of SOCS/SSI-1-3 expression may be a factor in the marked local enhancement of TNF-alpha and IL-6 production which, in turn, may help facilitate viral spread; however, further studies should be done in order to elucidate the exact mechanisms of SOCS in the cervix. (c) 2006 Elsevier Inc. All rights reserved.
C1 Fiocruz MS, IPEC, Immunol Serv Evandro Chagas, Clin Res Inst, BR-21045900 Rio De Janeiro, Brazil.
   Univ Hosp, Dept Pathol, Cleveland, OH 44106 USA.
   Fiocruz MS, IFF, Fernades Figueira Inst, BR-21045900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Fraga Filho Univ Hosp, Multidisciplinary Lab, BR-21941 Rio De Janeiro, Brazil.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Immunol, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol Genet, Los Angeles, CA 90095 USA.
RP Nicol, AF (corresponding author), Fiocruz MS, IPEC, Immunol Serv Evandro Chagas, Clin Res Inst, Ave Brazil 4365 Manguinhos, BR-21045900 Rio De Janeiro, Brazil.
EM nicol@ioc.fiocruz.br
RI Martinez-Maza, Otoniel/B-2667-2009; Lapa e Silva, Jose R./AAS-4793-2020;
   Bonecini-Almeida, Gloria Maria/C-7237-2012
OI Martinez-Maza, Otoniel/0000-0003-1364-0675; Lapa e Silva, Jose
   R./0000-0003-3116-0253; Bonecini-Almeida, Maria da
   Gloria/0000-0001-6030-5576
CR ALSALEH W, 1995, VIRCHOWS ARCH, V427, P41
   Arany I, 1996, J INTERF CYTOK RES, V16, P453, DOI 10.1089/jir.1996.16.453
   BELEC L, 1995, CYTOKINE, V7, P568, DOI 10.1006/cyto.1995.0077
   Breen EC, 2002, PHARMACOL THERAPEUT, V95, P295, DOI 10.1016/S0163-7258(02)00263-2
   Clarke B, 2002, J CLIN PATHOL-MOL PA, V55, P19, DOI 10.1136/mp.55.1.19
   de Gruijl TD, 1999, EUR J CANCER, V35, P490, DOI 10.1016/S0959-8049(98)00371-2
   Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9
   Dogusan Z, 2000, J NEUROIMMUNOL, V109, P34, DOI 10.1016/S0165-5728(00)00300-3
   Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213
   Gage JR, 2000, OBSTET GYNECOL, V96, P879, DOI 10.1016/S0029-7844(00)01057-7
   GARZETTI GG, 1995, GYNECOL OBSTET INVES, V40, P52, DOI 10.1159/000292302
   Imai K, 2003, FEMS IMMUNOL MED MIC, V39, P173, DOI 10.1016/S0928-8244(03)00231-1
   Kamio M, 2004, ONCOGENE, V23, P3107, DOI 10.1038/sj.onc.1207453
   Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263
   Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1
   Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219
   Nicol AF, 2005, METHOD MICROBIOL, V34, P239, DOI 10.1016/S0580-9517(04)34009-2
   Nicol AF, 2005, DIAGN MOL PATHOL, V14, P39, DOI 10.1097/01.pas.0000143309.81183.6c
   NUOVO GJ, 1993, AM J PATHOL, V143, P40
   NUOVO GJ, 1994, J ACQ IMMUN DEF SYND, V7, P916
   OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336
   POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151
   ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P
   Rosini S, 1996, HUM PATHOL, V27, P834, DOI 10.1016/S0046-8177(96)90458-X
   SCHAFER A, 1991, AM J OBSTET GYNECOL, V164, P593, DOI 10.1016/S0002-9378(11)80029-3
   TWEDDEL G, 1994, GYNECOL ONCOL, V52, P161, DOI 10.1006/gyno.1994.1024
   van der Meijden M, 1998, CELL IMMUNOL, V190, P156, DOI 10.1006/cimm.1998.1387
NR 27
TC 10
Z9 11
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
EI 1096-0945
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD AUG
PY 2006
VL 81
IS 1
BP 42
EP 47
DI 10.1016/j.yexmp.2006.01.002
PG 6
WC Pathology
SC Pathology
GA 065IX
UT WOS:000239154500006
PM 16878360
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Bastos, FI
   Veloso, VG
   Friedman, RK
   Pilotto, JH
   Schechter, M
   Derrico, M
   Andrade, A
   Lourenco, MC
   Moreira, RI
   Russomano, F
   Morgado, M
   Currier, JS
AF Grinsztejn, Beatriz
   Bastos, Francisco Inacio
   Veloso, Valdilea G.
   Friedman, Ruth Khalili
   Pilotto, Jose Henrique
   Schechter, Mauro
   Derrico, Monica
   Andrade, Angela
   Lourenco, Maria Cristina
   Moreira, Ronaldo Ismerio
   Russomano, Fabio
   Morgado, Mariza
   Currier, Judith S.
TI Assessing sexually transmitted infections in a cohort of women living
   with HIV/AIDS, in Rio de Janeiro, Brazil
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE HIV/AIDS; sexually transmitted infections (STIs); human papilloma virus
   (HPV); co-infection; Brazil
ID HUMAN-PAPILLOMAVIRUS INFECTION; GENITAL-TRACT INFECTIONS; INTERAGENCY
   HIV; VIRUS INFECTION; RISK; ASSOCIATION; PREVALENCE; ULCERATION;
   DISEASES
AB A cohort of 458 HIV-positive women under antiretroviral therapy has been followed at a reference hospital in Rio de Janeiro, Brazil. Most of them belong to impoverished social strata. Patients were screened for sexually transmitted infections (STIs) and gynaecologic conditions. Some STIs were found to be uncommon (e.g. chlamydial and gonococcal infections), while some conditions (bacterial vaginosis) and STIs, e.g. hepatitis B and human papilloma virus (HPV) infection, were found to be quite prevalent. The latter is of special concern, due to the high prevalence of HIV/HPV co-infection (similar to 51%) and its association with severe immunodeficiency, in a context of unacceptable high levels of uterine cancer and uneven gynaecological care. HIV-positive women are in need of comprehensive health services, including high-quality, regular, gynaecologic care in order to diagnose and treat lower genital tract infections and prevent the evolution of HPV-related lesions. Reproductive counselling should be a part of this approach.
C1 Fiocruz MS, Fdn Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, IPEC,HIV AIDS Clin Res Inst, BR-21045900 Rio De Janeiro, Brazil.
   Fiocruz MS, Ctr Sci & Technol Informat, BR-21045900 Rio De Janeiro, Brazil.
   Fed Univ Rio De Janeiro, Rio De Janeiro, Brazil.
   Fiocruz MS, Fernandes Figueira Inst, BR-21045900 Rio De Janeiro, Brazil.
   Fiocruz MS, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA 90024 USA.
RP Grinsztejn, B (corresponding author), Fiocruz MS, Fdn Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, IPEC,HIV AIDS Clin Res Inst, Av Brasil,4365 Manguinhos, BR-21045900 Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI Pilotto, Jose Henrique/AAD-9773-2019; Veloso, Valdilea
   Goncalves/J-6189-2012; Schechter, Mauro/AAG-7445-2020
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Bastos,
   Francisco/0000-0001-5970-8896
CR BAGDADES EK, 1992, AIDS, V6, P1317, DOI 10.1097/00002030-199211000-00012
   CARPENTER CCJ, 1991, MEDICINE, V70, P307, DOI 10.1097/00005792-199109000-00003
   Cohen M, 2000, AM J PUBLIC HEALTH, V90, P560, DOI 10.2105/AJPH.90.4.560
   Cook RL, 2004, SEX TRANSM DIS, V31, P67, DOI 10.1097/01.OLQ.0000105004.85419.17
   *COORD NAC DST AID, 2004, B EP AIDS
   Cu-Uvin S, 1999, CLIN INFECT DIS, V29, P1145, DOI 10.1086/313434
   Franco EL, 1999, J INFECT DIS, V180, P1415, DOI 10.1086/315086
   Greenblatt RM, 1999, SEX TRANSM DIS, V26, P143, DOI 10.1097/00007435-199903000-00004
   Levi José E., 2002, Braz J Infect Dis, V6, P129, DOI 10.1590/S1413-86702002000300005
   Moherdaui F, 1998, SEX TRANSM INFECT, V74, pS38
   Newmann S, 2000, INT J STD AIDS, V11, P250, DOI 10.1258/0956462001915796
   NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991
   Olaitan A, 1997, OBSTET GYNECOL, V89, P71, DOI 10.1016/S0029-7844(96)00377-8
   Palefsky JM, 1999, JNCI-J NATL CANCER I, V91, P226, DOI 10.1093/jnci/91.3.226
   Tien PC, 2004, CLIN INFECT DIS, V39, P1363, DOI 10.1086/424879
   van Benthem BHB, 2000, AIDS, V14, P595, DOI 10.1097/00002030-200003310-00014
   Wang CC, 2001, J INFECT DIS, V183, P1017, DOI 10.1086/319287
   WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P6177
   Wright TC, 2001, AM J OBSTET GYNECOL, V184, P279, DOI 10.1067/mob.2001.108999
NR 19
TC 27
Z9 26
U1 0
U2 1
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0956-4624
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD JUL
PY 2006
VL 17
IS 7
BP 473
EP 478
DI 10.1258/095646206777689071
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 066DI
UT WOS:000239209500009
PM 16820078
DA 2020-11-24
ER

PT J
AU Johnson, M
   Grinsztejn, B
   Rodriguez, C
   Coco, J
   DeJesus, E
   Lazzarin, A
   Lichtenstein, K
   Wirtz, V
   Righmire, A
   Odeshoo, L
   McLaren, C
AF Johnson, M
   Grinsztejn, B
   Rodriguez, C
   Coco, J
   DeJesus, E
   Lazzarin, A
   Lichtenstein, K
   Wirtz, V
   Righmire, A
   Odeshoo, L
   McLaren, C
TI 96-week comparison of once-daily atazanavir/ritonavir and twice-daily
   lopinavir/ritonavir in patients with multiple virologic failures
SO AIDS
LA English
DT Article
DE antiretroviral therapy; atazanavir; lipids; lopinavir; protease
   inhibitors; ritonavir
ID HIV-INFECTED MEN; PROTEASE INHIBITORS; MYOCARDIAL-INFARCTION; SALVAGE
   THERAPY; LIPODYSTROPHY; TENOFOVIR; HYPERLIPIDEMIA; DIDANOSINE;
   RITONAVIR; REGIMENS
AB Background: In BMS Study 045, once-daily (QD) atazanavir/ritonavir (ATV/RTV) demonstrated comparable efficacy and safety to twice-daily (BID) lopinavir/ritonavir (LPV/RTV) over 48 weeks in treatment-experienced patients. Results of extended follow-up to 96 weeks are presented.
   Methods: BMS Study 045 was an open-label, randomized, multi-national trial of HIV-infected patients with virologic failure on two or more prior HAART regimens designed to evaluate the efficacy and safety of ATV/RTV (300/100 mg) QD and LPV/RTV (400/ 100 mg) BID, each with tenofovir (300 mg) QD and one nucleoside reverse transcriptase inhibitor. The primary efficacy measure was the time-averaged difference (TAD) in reduction in HIV RNA from baseline. Secondary objectives included evaluation of safety and plasma lipid levels through week 96.
   Results: Over 96 weeks, the ATV/RTV regimen demonstrated similar virologic efficacy to the LPV/RTV regimen. Mean reductions from baseline in HIV RNA were -2.29 and -2.08 log(10) copies/ml, respectively ITAD (97.5% confidence interval): 0.14 log(10) copies/ml (-0.13, 0.41)]. The LPV/RTV regimen resulted in significant increases in total cholesterol (+9%) and fasting triglycerides (+30%) in comparison with the ATV/ RTV regimen, which demonstrated decreases in these parameters [-7 and -2%, respectively, (P < 0.0001)]. Grade 2-4 diarrhoea occurred less frequently in ATV/ RTV patients (3%) in comparison with LPV/RTV patients (13%) (P < 0.01). Grade 3-4 elevations in bilirubin were more common in ATV/RTV patients (53%) than LPV/RTV patients (<1%) (P < 0.0001), with no resulting discontinuations.
   Conclusions: Regimens containing once-daily ATV/RTV demonstrated comparable efficacy and safety, with significant reductions in total cholesterol and fasting triglycerides and improved gastrointestinal-tolerability in comparison with twice-daily regimens containing LPV/RTV over 96 weeks in treatment-experienced patients. (C) 2006 Lippincott Williams & Wilkins.
C1 Royal Free Hosp, London NW3 2QG, England.
   Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA.
   Univ Colorado Hlth Sci, Denver, CO USA.
   Hosp San Raffaele, I-20132 Milan, Italy.
   IDC Res Initiat, Altamonte Springs, FL USA.
   Pendleton Mem Methodist Hosp, New Orleans, LA USA.
   Hosp Argerich, Buenos Aires, DF, Argentina.
   Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
RP Johnson, M (corresponding author), Royal Free Hosp, Pond St, London NW3 2QG, England.
EM margaret.johnson@royalfree.nhs.uk
OI LAZZARIN, Adriano/0000-0003-2551-7754
CR AGARWALA S, 2005, 6 INT WORKSH CLIN PH
   Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2
   Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003
   Dragsted UB, 2003, J INFECT DIS, V188, P635, DOI 10.1086/377288
   Flynn TE, 1999, ANN INTERN MED, V131, P548, DOI 10.7326/0003-4819-131-7-199910050-00032
   Fulco PP, 2003, ANN PHARMACOTHER, V37, P1325, DOI 10.1345/aph.1C412
   Gallant Joel E, 2005, Curr HIV/AIDS Rep, V2, P83, DOI 10.1007/s11904-005-0023-5
   Gutierrez F, 2003, JAIDS-J ACQ IMM DEF, V33, P594, DOI 10.1097/00126334-200308150-00007
   Hadigan C, 2001, CLIN INFECT DIS, V32, P130, DOI 10.1086/317541
   Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2
   ILOEJE U, 2003, 10 C RETR OPP INF BO
   Johnson M, 2005, AIDS, V19, P685, DOI 10.1097/01.aids.0000166091.39317.99
   JUETTE A, 1999, 6 C RETR OPP INF CHI
   Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010
   Mellors J, 2000, LANCET, V355, P1435, DOI 10.1016/S0140-6736(05)74636-5
   Murphy RL, 2003, AIDS, V17, P2603, DOI 10.1097/00002030-200312050-00007
   Negredo E, 2004, AIDS, V18, P459, DOI 10.1097/00002030-200402200-00012
   *PAN CLIN PRACT TR, 2005, GUID US ANT AG HIV 1
   Periard D, 1999, CIRCULATION, V100, P700, DOI 10.1161/01.CIR.100.7.700
   SENSION M, 2005, 12 C RETR OPP INF BO
   Taburet AM, 2004, ANTIMICROB AGENTS CH, V48, P2091, DOI 10.1128/AAC.48.6.2091-2096.2004
   Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251
NR 22
TC 159
Z9 165
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAR 21
PY 2006
VL 20
IS 5
BP 711
EP 718
DI 10.1097/01.aids.0000216371.76689.63
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 027MZ
UT WOS:000236421000010
PM 16514301
DA 2020-11-24
ER

PT J
AU Couto-Fernandez, JC
   Eyer-Silva, WA
   Guimaraes, ML
   Chequer-Fernandez, SL
   Grinsztejn, B
   Delaporte, E
   Peeters, M
   Morgado, MG
AF Couto-Fernandez, JC
   Eyer-Silva, WA
   Guimaraes, ML
   Chequer-Fernandez, SL
   Grinsztejn, B
   Delaporte, E
   Peeters, M
   Morgado, MG
TI Phylogenetic analysis of Brazilian HIV type 1 subtype D strains: Tracing
   the origin of this subtype in Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SOUTH-AFRICA; GENETIC SUBTYPES;
   CAPE-TOWN; IDENTIFICATION; SEQUENCES; PREVALENCE; JANEIRO; UGANDA
AB HIV-1 Subtype D occurs mainly in East and Central African countries, especially Uganda, where the prevalence of HIV-1 infection is among the highest in the world. We present the phylogenetic analysis of one nonau-tochthonous and four autochthonous (including a near full-length genome) Brazilian HIV-1 subtype D strains identified in Rio de Janeiro State, where subtypes B, F1, and BF1 recombinants predominate. Phylogenetic inferences using maximum likelihood were applied on a near-full length genome and on concatenated gag, protease, reverse transcriptase, integrase, C2V3/env, gp41, and nef segments. Sequences from an Angolan immigrant showed close genetic similarity with a strain described in Finland, from an HIV patient of African origin, whereas all four autochthonous Brazilian sequences clustered with South African strains, where subtype D occurs only in isolated cases. Our results suggest the successful introduction and circulation in Brazil of closely related HIV-1 subtype D strains, possibly of South African origin.
C1 Fiocruz MS, Fdn Oswaldo Cruz, Dept Imunol, IOC,Lab Aids & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   Univ Fed Estado Rio de Janeiro, Hosp Univ Gaffree & Guinle, Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, IPEC, Inst Pesquisas Clin Evandro Chagas, Rio De Janeiro, Brazil.
   IRD, Retrovirus Lab, Montpellier, France.
RP Couto-Fernandez, JC (corresponding author), Fiocruz MS, Fdn Oswaldo Cruz, Dept Imunol, IOC,Lab Aids & Imunol Mol, Av Brasil 4365 Pavilhao Leonidas Deane 413-415, BR-21045900 Rio De Janeiro, Brazil.
EM coutofer@ioc.fiocruz.br
RI Delaporte, Eric/J-5397-2018; de Araujo Eyer-Silva, Walter/J-6264-2019
OI Delaporte, Eric/0000-0002-1822-9853; Couto-Fernandez, Jose
   Carlos/0000-0001-7091-9774; Eyer-Silva, Walter de
   Araujo/0000-0001-6386-666X
CR BECKER MLB, 1995, AIDS RES HUM RETROV, V11, P1265, DOI 10.1089/aid.1995.11.1265
   Bessong PO, 2005, AIDS RES HUM RETROV, V21, P103, DOI 10.1089/aid.2005.21.103
   Bikandou B, 2000, AIDS RES HUM RETROV, V16, P613, DOI 10.1089/088922200308837
   Bredell H, 2002, AIDS RES HUM RETROV, V18, P681, DOI 10.1089/088922202760019400
   Caride E, 2000, VIROLOGY, V275, P107, DOI 10.1006/viro.2000.0487
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Harris ME, 2002, AIDS RES HUM RETROV, V18, P1281, DOI 10.1089/088922202320886325
   LEITNER T, 2000, HIV SEQUENCE COMPEND
   Liitsola K, 2000, SCAND J INFECT DIS, V32, P475, DOI 10.1080/003655400458721
   Loxton AG, 2005, AIDS RES HUM RETROV, V21, P410, DOI 10.1089/aid.2005.21.410
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Rayfield MA, 1998, AIDS, V12, P521, DOI 10.1097/00002030-199805000-00014
   Toure-Kane C, 2000, AIDS RES HUM RETROV, V16, P603, DOI 10.1089/088922200309025
   Triques K, 2000, AIDS RES HUM RETROV, V16, P139, DOI 10.1089/088922200309485
   vanHarmelen J, 1997, AIDS, V11, P81, DOI 10.1097/00002030-199701000-00012
NR 17
TC 23
Z9 23
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD FEB
PY 2006
VL 22
IS 2
BP 207
EP 211
DI 10.1089/aid.2006.22.207
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 014ID
UT WOS:000235472200014
PM 16478405
DA 2020-11-24
ER

PT J
AU Campos, DP
   Ribeiro, SR
   Grinsztejn, B
   Veloso, VG
   Valente, JG
   Bastos, FI
   Morgado, MG
   Gadelha, AJ
AF Campos, DP
   Ribeiro, SR
   Grinsztejn, B
   Veloso, VG
   Valente, JG
   Bastos, FI
   Morgado, MG
   Gadelha, AJ
TI Survival of AIDS patients using two case definitions, Rio de Janeiro,
   Brazil, 1986-2003
SO AIDS
LA English
DT Article
DE AIDS; Brazil; case definition; highly active antiretroviral therapy;
   survival
ID ACTIVE ANTIRETROVIRAL THERAPY; UNITED-STATES; DIAGNOSIS; AUSTRALIA;
   ADULTS
AB Background: Recent studies have shown substantial increases in the survival of AIDS patients in developed countries and in Brazil as a result of antiretroviral therapy (ART) and prophylaxis for opportunistic infections. This study compares survival rates using the Brazilian Ministry of Health 2004 and Centers for Disease Control and Prevention (CDC) 1993 case definitions in a large HIV/AIDS referral centre in Rio de Janeiro.
   Methods: Survival after AIDS diagnosis was assessed in a clinic-based cohort of 1415 individuals using the Kaplan-Meier method and Cox proportional hazards models.
   Results: There were 393 (88%) deaths from AIDS-related causes and 52 (12%) from unrelated or unknown causes. A total of 205 patients (14%) were lost to follow-up and 765 patients (55%) remained alive until the end of the study. Three-quarters of patients (75%) were still alive 22 months [95% confidence interval (Cl) 19-26] after the AIDS diagnosis according to the CDC case definition and 31 months (95% Cl 26-36) according to the Ministry of Health case definition. Independent predictors of survival included AIDS defined by CD4 cell count and any use of highly active antiretroviral therapy, with either case definition, and initial stage of the case, with the Ministry of Health case definition.
   Conclusion: Survival observed in this reference centre is comparable or longer than other international studies, although the choice of case definition criterion influenced findings. Adoption of the Ministry of Health case definition may enhance the ability to track the use of and outcomes from ART among AIDS patients. (c) 2005 Lippincott Williams & Wilkins.
C1 Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   Natl Sch Publ Hlth, Rio De Janeiro, Brazil.
   Sci & Technol Informat Ctr, Rio De Janeiro, Brazil.
   Oswaldo Cruz Fdn, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   STD AIDS Program, Municipal Hlth Dept, Rio De Janeiro, Brazil.
RP Campos, DP (corresponding author), Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM dayse@fiocruz.br
RI Veloso, Valdilea Goncalves/J-6189-2012
CR Amundsen EJ, 2003, SCAND J PUBLIC HEALT, V31, P312, DOI 10.1080/14034940210165000
   *BRAZ MIN HLTH BRA, 2004, AIDS CAS DEF CRIT AD, V60
   Brockington A, 1997, SCOT MED J, V42, P114, DOI 10.1177/003693309704200405
   COX DR, 1972, J R STAT SOC B, V34, P187
   Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497
   Dore GJ, 2002, J ACQ IMMUN DEF SYND, V29, P388, DOI 10.1097/00126334-200204010-00010
   Dworkin MS, 2001, J INFECT DIS, V183, P1409, DOI 10.1086/319866
   Fonseca LAM, 1999, INT J EPIDEMIOL, V28, P1156, DOI 10.1093/ije/28.6.1156
   Guerreiro MF, 2002, REV SAUDE PUBL, V36, P278, DOI [10.1590/S0034-89102002000300004, 10.1590/s0034-89102002000300004]
   KLEINBAUM DG, 1997, STAT HLTH SCI
   Lee LM, 2001, JAMA-J AM MED ASSOC, V285, P1308, DOI 10.1001/jama.285.10.1308
   Li YM, 2000, AIDS, V14, P2349, DOI 10.1097/00002030-200010200-00016
   Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012
   *MIN HLTH BRAZ, 2003, BRAZ AIDS PROF GOV G, P3
   Santoro-Lopes G, 1998, J ACQ IMMUN DEF SYND, V19, P403, DOI 10.1097/00042560-199812010-00012
   *UNAIDS, 1999, UNAIDS 3 M LAT AM CA, P12
   *US DHHS, 1993, MMWR-MORBID MORTAL W, V16, P308
   Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008
   2000, BR HIV ASS HIV MED, V1, P224
NR 19
TC 30
Z9 31
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD OCT
PY 2005
VL 19
SU 4
BP S22
EP S26
DI 10.1097/01.aids.0000191486.92285.1c
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 988MG
UT WOS:000233604700004
PM 16249649
DA 2020-11-24
ER

PT J
AU Johnson, M
   Grinsztejn, B
   Rodriguez, C
   Coco, J
   DeJesus, E
   Lazzarin, A
   Lichtenstein, K
   Rightmire, A
   Sankoh, S
   Wilber, R
AF Johnson, M
   Grinsztejn, B
   Rodriguez, C
   Coco, J
   DeJesus, E
   Lazzarin, A
   Lichtenstein, K
   Rightmire, A
   Sankoh, S
   Wilber, R
TI Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in
   patients experiencing multiple virological failures
SO AIDS
LA English
DT Article
DE antiretroviral therapy; atazanavir; lipids; lopinavir; protease;
   inhibitors; ritonavir; saquinavir
ID ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR THERAPY;
   MYOCARDIAL-INFARCTION; SALVAGE THERAPY; CLINICAL-TRIAL; RISK-FACTORS;
   HYPERLIPIDEMIA; MORTALITY; LIPODYSTROPHY; COMBINATION
AB Objective: To evaluate atazanavir/ritonavir (ATV/RTV) (300/100mg) once daily, atazanavir/saquinavir (ATV/SQV) (400/1200 mg) once daily, and lopinavir/ritonavir (LPV/RTV) (400/100 mg) twice daily, each with tenofovir (300 mg) once daily and a nucleoside reverse transcriptase inhibitor in treatment-experienced HIV-infected patients.
   Methods: Randomized, open-label, 48-week multicenter trial of 358 randomized adult patients who had failed two or more prior HAART regimens with baseline HIV RNA >= 1000 copies/ml and CD4 cell count >= 50 x 106 cells/l.
   Results: The primary efficacy endpoint [plasma HIV RNA reduction assessed by time-averaged difference (TAD)] was similar for ATV/RTV and LPV/RTV [TAD 0.13; 97.5% confidence interval, -0.12 to 0.39] at 48 weeks. Mean reductions from baseline for ATV/RTV and LPV/RTV were comparable at 1.93 and 1.87 log(10) copies/ml, respectively. Mean CD4 cell count increases were 110 and 121 x 10(6) cells/l for ATV/RTV, and LPV/RTV, respectively. The efficacy of ATV/SQV was lower than LPV/RTV by both these parameters. Declines in total cholesterol and fasting triglycericles were greater with ATV/RTV and ATV/SQV than with LPV/RTV (P <= 0.005). Lipids in the LPV/RTV arm at week 48 generally increased from baseline. Lipid-lowering agents were used more frequently in the LPV/RTV arm than in the ATV arms (P < 0.05 versus ATV/RTV), as were antidiarrheal agents (P < 0.04 versus both ATV treatments). No new or unique safety findings emerged.
   Conclusions: ATV boosted with RTV is as effective and well tolerated as LPV/RTV in treatment-experienced patients, with a more favorable impact on serum lipids. Pharmacokinetically enhanced ATV provides a suitable choice for therapy of treatment-experienced HIV-infected patients. (c) 2005 Lippincott Williams & Wilkins.
C1 Royal Free Hosp, London NW3 2QG, England.
   Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   Hosp Argerich, Buenos Aires, DF, Argentina.
   Pendleton Mem Methodist Hosp, New Orleans, LA USA.
   IDC Res Initiat, Altamonte Springs, FL USA.
   Hosp San Raffaele, I-20132 Milan, Italy.
   Univ Colorado Hlth Sci, Denver, CO USA.
   Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA.
   Bristol Myers Squibb Co, Pharmaceut Res Inst, Hopewell Jct, NY USA.
RP Johnson, M (corresponding author), Royal Free Hosp, Pond St, London NW3 2QG, England.
EM margaret.johnson@royalfree.nhs.uk
OI LAZZARIN, Adriano/0000-0003-2551-7754
CR AGARWALA S, 2002, 42 INT C ANT AG CHEM
   Bartlett JA, 2002, J ACQ IMMUN DEF SYND, V29, pS2, DOI 10.1097/00126334-200202011-00002
   Calza L, 2003, INT J ANTIMICROB AG, V22, P54, DOI 10.1016/S0924-8579(03)00100-6
   Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2
   Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003
   Catz SL, 2000, HEALTH PSYCHOL, V19, P124, DOI 10.1037/0278-6133.19.2.124
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Colonno R, 2004, J INFECT DIS, V189, P1802, DOI 10.1086/386291
   Colonno RJ, 2003, ANTIMICROB AGENTS CH, V47, P1324, DOI 10.1128/AAC.47.4.1324-1333.2003
   Dragsted UB, 2003, J INFECT DIS, V188, P635, DOI 10.1086/377288
   *FDA, 2004, WHATS NEW HIV AIDS W
   Flynn TE, 1999, ANN INTERN MED, V131, P548, DOI 10.7326/0003-4819-131-7-199910050-00032
   Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157
   Gutierrez F, 2003, JAIDS-J ACQ IMM DEF, V33, P594, DOI 10.1097/00126334-200308150-00007
   Haas DW, 2003, AIDS, V17, P1339, DOI 10.1097/00002030-200306130-00008
   Hadigan C, 2001, CLIN INFECT DIS, V32, P130, DOI 10.1086/317541
   Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2
   ILOEJE U, 2003, 10 C RETR OPP INF BO
   JUETTE A, 1999, 6 C  RETR OPP INF CH
   Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010
   Mellors J, 2000, LANCET, V355, P1435, DOI 10.1016/S0140-6736(05)74636-5
   Miller V, 2001, J ACQ IMMUN DEF SYND, V26, pS34, DOI 10.1097/00126334-200103011-00005
   Murphy EL, 2001, ANN INTERN MED, V135, P17, DOI 10.7326/0003-4819-135-1-200107030-00005
   Murphy RL, 2003, AIDS, V17, P2603, DOI 10.1097/00002030-200312050-00007
   OMARA E, 2001, 8 C RETR OPP INF CHI
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Penzak SR, 2000, SCAND J INFECT DIS, V32, P111
   Periard D, 1999, CIRCULATION, V100, P700, DOI 10.1161/01.CIR.100.7.700
   Sanne I, 2003, JAIDS-J ACQ IMM DEF, V32, P18, DOI 10.1097/00126334-200301010-00004
   Stein JH, 2003, AM J CARDIOL, V92, P270, DOI 10.1016/S0002-9149(03)00622-2
   Svedhem V, 2002, J MED VIROL, V68, P473, DOI 10.1002/jmv.10246
   van Sighem AI, 2003, AIDS, V17, P2227, DOI 10.1097/00002030-200310170-00011
   Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354
   WALMSLEY S, 2004, 11 C RETR OPP INF SA
NR 35
TC 179
Z9 185
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD APR 29
PY 2005
VL 19
IS 7
BP 685
EP 694
DI 10.1097/01.aids.0000166091.39317.99
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 921BT
UT WOS:000228739900005
PM 15821394
DA 2020-11-24
ER

PT J
AU van Leth, F
   Andrews, S
   Grinsztejn, B
   Wilkins, E
   Lazanas, MK
   Lange, JMA
   Montaner, J
AF van Leth, F
   Andrews, S
   Grinsztejn, B
   Wilkins, E
   Lazanas, MK
   Lange, JMA
   Montaner, J
CA 2NN Study Grp
TI The effect of baseline CD4 cell count and HIV-1 viral load on the
   efficacy and safety of nevirapine or efavirenz-based first-line HAART
SO AIDS
LA English
DT Article
DE HIV-1; CD4; viral load; disease stage; 2NN
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-1-INFECTED PATIENTS; NAIVE PATIENTS;
   COMBINATION THERAPY; PROTEASE INHIBITOR; INFECTION; REGIMENS; TRIAL;
   INITIATION; LAMIVUDINE
AB Backgound: A substantial number of patients start their first-line antiretroviral therapy at an advanced stage of an HIV-1 infection. Potential differences between specific drug regimens in antiviral efficacy and safety in these patients are of major importance.
   Methods: A post-hoc analysis within the randomized controlled 2NN trial comparing efficacy between regimes containing nevirapine (NVP), efavirenz (EFV), or both, in addition to stavudine and lamivudine. Primary outcome: risk of virologic failure in different strata of baseline CD4 T-lymphocyte counts and plasma HIV-1 RNA concentrations (pVL). Virologic failure: never reaching a pVL < 400 copies/ml, or a rebound to two consecutive values > 400 copies/ml.
   Results: The risk of virologic failure was increased at very low CD4 counts (< 25 x 10(6) cells/l) compared to CD4 counts > 200 x 10(6) cells/l [hazard ratio (HR), 1.28; 95% confidence interval (CI), 0.93-1.77]. The same was seen for a pVL >= 100 000 copies/ml compared to a lower pVL (HR, 1.20; CI, 0.96-1.50). There were no statistically significant differences between NVP and EFV in risk of virologic failure within any of the CD4 or pVL strata, although EFV performed slightly better in the low CD4 stratum. The incidence of rash in the NVP group was significantly higher in female patients with higher CD4 cell counts, while adverse events in the EFV group were not associated with CD4 cell count.
   Conclusions: Initial antiretroviral therapy including NVP or EFV is effective in patients with an advanced HIV-1 infection. A high baseline CD4 cell count is associated with the occurrence of rash in female patients using NVP. (c) 2005 Lippincott Williams & Wilkins.
C1 Univ Amsterdam, Int Antiviral Therapy Evaluat Ctr, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands.
   Brooklyn Med Ctr, Cape Town, South Africa.
   Ctr Pesquisa Hosp Evandro Chagas, Rio De Janeiro, Brazil.
   N Manchester Grp Hosp, Manchester, Lancs, England.
   Hellen Red Cross Gen Hosp, Athens, Greece.
   Univ British Columbia, St Pauls Hosp, Vancouver, BC, Canada.
RP van Leth, F (corresponding author), Univ Amsterdam, Int Antiviral Therapy Evaluat Ctr, Acad Med Ctr, Dept Internal Med, Room T0-122,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM f.c.vanleth@amc.uva.nl
RI Montaner, Julio/K-7621-2012
OI van Leth, Frank/0000-0002-5490-8968
CR *AIDS CLIN TRIAL G, 1996, TABL GRAD SEV AD ADV
   Arribas JR, 2002, AIDS, V16, P1554, DOI 10.1097/00002030-200207260-00014
   Barreiro P, 2002, AIDS, V16, P245, DOI 10.1097/00002030-200201250-00014
   Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4
   Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568
   Kaplan JE, 2003, CLIN INFECT DIS, V37, P951, DOI 10.1086/377606
   Keiser Philip, 2002, HIV Clin Trials, V3, P296
   LANGE JM, J ACQUIR IMMUNE DEFI, V34, pS40
   Lepri AC, 2001, AIDS, V15, P983, DOI 10.1097/00002030-200105250-00006
   Maggiolo Franco, 2002, HIV Clin Trials, V3, P371, DOI 10.1310/98B3-PWG8-PMYW-W5BP
   Manosuthi W, 2004, HIV MED, V5, P105, DOI 10.1111/j.1468-1293.2004.00195.x
   Matthews GV, 2002, AIDS, V16, P53, DOI 10.1097/00002030-200201040-00008
   Moyle G, 2001, DRUGS, V61, P19, DOI 10.2165/00003495-200161010-00003
   Nunez Marina, 2002, HIV Clin Trials, V3, P186
   Opravil M, 2002, AIDS, V16, P1371, DOI 10.1097/00002030-200207050-00009
   Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007
   Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123
   Phillips AN, 2004, AIDS, V18, P365, DOI 10.1097/00002030-200402200-00001
   Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560
   Podzamczer D, 2002, ANTIVIR THER, V7, P81
   Pozniak A, 2003, HIV Med, V4 Suppl 1, P1
   Raffi F, 2001, HIV Clin Trials, V2, P317
   Raffi F, 2000, ANTIVIR THER, V5, P267
   Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264
   SHEPARD KV, CLARIFICATION RISK F
   Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501
   van Leeuwen R, 2003, AIDS, V17, P987, DOI 10.1097/00002030-200305020-00007
   van Leth F, 2004, HIV MED, V5, P74, DOI 10.1111/j.1468-1293.2004.00188.x
   van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7
   Wood E, 2003, AIDS, V17, P711, DOI 10.1097/00002030-200303280-00009
   Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251
   GUIDELINES USE ANTIR
NR 32
TC 110
Z9 114
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAR 25
PY 2005
VL 19
IS 5
BP 463
EP 471
DI 10.1097/01.aids.0000162334.12815.5b
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 912XQ
UT WOS:000228113600002
PM 15764851
DA 2020-11-24
ER

PT J
AU Nicol, AF
   Fernandes, ATG
   Grinsztejn, B
   Russomano, T
   Silva, JRLE
   Tristao, A
   Perez, MD
   Nuovo, GJ
   Martinez-Maza, O
   Bonecini-Almeida, MD
AF Nicol, AF
   Fernandes, ATG
   Grinsztejn, B
   Russomano, T
   Silva, JRLE
   Tristao, A
   Perez, MD
   Nuovo, GJ
   Martinez-Maza, O
   Bonecini-Almeida, MD
TI Distribution of immune cell subsets and cytokine-producing cells in the
   uterine cervix of human papillomavirus (HPV)-infected women - Influence
   of HIV-1 coinfection
SO DIAGNOSTIC MOLECULAR PATHOLOGY
LA English
DT Article
DE cytokine; HIV-1; in situ PCR; cervical immune response; HPV
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SQUAMOUS INTRAEPITHELIAL LESIONS; IN-SITU
   DETECTION; CERVICOVAGINAL SECRETIONS; PERIPHERAL-BLOOD; LANGERHANS
   CELLS; INFECTED WOMEN; NUCLEIC-ACIDS; GENITAL-TRACT; LYMPH-NODES
AB The aim of this study was to characterize the immune system profile in the uterine cervix of 17 human papillomavirus (HPV)-infected women, compared with 17 whom were coinfected with HIV-1. Five histologically normal cervices in immunocompetent women were used as controls. HPV infection was associated with a marked increase in cells expressing interleukin (IL)-6, interferon gamma (IFN-gamma), and tumor necrosis factor alpha (TNF-alpha). Coinfection by HPV and HIV-1 led to decreased expression of IL-6, TNF-alpha, and IFN-gamma. However, coinfection led to increased numbers of cells expressing IL-4, IL-10, and IL-8. Compared with the histologically normal cervices, increased numbers of macrophages (CD68, RFD7) and T lymphocytes (CD4, CD8) were seen in HPV-infected cervices- coinfection with HIV-1 was associated with a higher number of CD8 cells and lower number of CD68 cells. HPV DNA localized exclusively to the dysplastic squamous cells, whereas HIV-1 RNA was detected mainly in CD68-positive stromal cells. In conclusion, this study shows differential expression of various cytokines and classes of inflammatory cells, relative to HIV-1 infection and HPV coinfection, which may relate to the risk of transmission of HIV-1 and increased risk of cervical cancer in these women.
C1 Fundacao Oswaldo Cruz, Chagas Res Inst, Serv Immunol, Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, Evandro Chagas Res Inst, Dept Infect Dis, Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, Fernandes Figueira Inst, Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Multidisciplinary Lab, Clementino Fraga Filho Hosp, Rio De Janeiro, Brazil.
   Univ Hosp, Dept Pathol, Columbus, OH USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol, Los Angeles, CA USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Immunol & Mol Genet, Los Angeles, CA USA.
RP Bonecini-Almeida, MD (corresponding author), Fundacao Oswaldo Cruz, Lab Imunol, Dept Microbiol Imunol & Parasitol, Inst Pesquisa Clin Evandro Chagas, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM bonecini@ipec.fiocruz.br
RI Martinez-Maza, Otoniel/B-2667-2009; Bonecini-Almeida, Gloria
   Maria/C-7237-2012; Lapa e Silva, Jose R./AAS-4793-2020
OI Martinez-Maza, Otoniel/0000-0003-1364-0675; Lapa e Silva, Jose
   R./0000-0003-3116-0253
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [TW-000013-16S1] Funding Source: Medline
CR Al-Saleh W, 1998, J PATHOL, V184, P283, DOI 10.1002/(SICI)1096-9896(199803)184:3<283::AID-PATH25>3.0.CO;2-K
   Arany I, 1996, J INTERF CYTOK RES, V16, P453, DOI 10.1089/jir.1996.16.453
   Arany I, 2001, ANTICANCER RES, V21, P425
   BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277
   Barberis MC, 1998, TUMORI, V84, P489
   BELEC L, 1995, CYTOKINE, V7, P568, DOI 10.1006/cyto.1995.0077
   Bell MC, 2000, GYNECOL ONCOL, V76, P315, DOI 10.1006/gyno.1999.5716
   BREEN EC, 1990, J IMMUNOL, V144, P480
   Castrilli G, 1997, BRIT J CANCER, V75, P855, DOI 10.1038/bjc.1997.152
   Clarke B, 2002, J CLIN PATHOL-MOL PA, V55, P19, DOI 10.1136/mp.55.1.19
   Clerici M, 1997, J NATL CANCER I, V89, P245, DOI 10.1093/jnci/89.3.245
   COLEMAN N, 1994, AM J CLIN PATHOL, V102, P768, DOI 10.1093/ajcp/102.6.768
   Crowley-Nowick PA, 2000, J INFECT DIS, V181, P939, DOI 10.1086/315311
   Davidson B, 1997, PATHOL RES PRACT, V193, P491, DOI 10.1016/S0344-0338(97)80102-1
   de Gruijl TD, 1999, EUR J CANCER, V35, P490, DOI 10.1016/S0959-8049(98)00371-2
   Gage JR, 2000, OBSTET GYNECOL, V96, P879, DOI 10.1016/S0029-7844(00)01057-7
   GARZETTI GG, 1995, GYNECOL OBSTET INVES, V40, P52, DOI 10.1159/000292302
   Giannini SL, 2002, INT J CANCER, V97, P654, DOI 10.1002/ijc.10084
   HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233
   Hess S, 2000, J IMMUNOL, V165, P1939, DOI 10.4049/jimmunol.165.4.1939
   HOGG N, 1984, IMMUNOLOGY, V53, P753
   IARC, 1995, IARC MON EV CARC RIS, P64
   IGLESIAS M, 1995, AM J PATHOL, V146, P944
   Kleine-Lowinski K, 1999, INT J CANCER, V82, P6, DOI 10.1002/(SICI)1097-0215(19990702)82:1<6::AID-IJC2>3.0.CO;2-3
   Kobayashi A, 2002, AM J PATHOL, V160, P151, DOI 10.1016/S0002-9440(10)64359-3
   Lee BN, 1999, GYNECOL ONCOL, V75, P379, DOI 10.1006/gyno.1999.5587
   Lopez MC, 2000, J GEN VIROL, V81, P1175, DOI 10.1099/0022-1317-81-5-1175
   Manetti R, 1996, CHEM IMMUNOL, V63, P138
   MARTINEZMAZA O, 1987, J IMMUNOL, V138, P3720
   NUOVO GJ, 1993, AM J PATHOL, V143, P40
   NUOVO GJ, 1994, J ACQ IMMUN DEF SYND, V7, P916
   Nuovo GJ, 1996, PCR IN SITU HYBRIDIZ
   Olaitan A, 1996, AIDS, V10, P759, DOI 10.1097/00002030-199606001-00010
   Passmore JAS, 2002, J MED VIROL, V67, P234, DOI 10.1002/jmv.2212
   POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151
   RICHART RM, 1990, OBSTET GYNECOL, V75, P131
   Sander B, 1996, J UROLOGY, V156, P536, DOI 10.1016/S0022-5347(01)65921-4
   Santin AD, 2001, GYNECOL ONCOL, V81, P424, DOI 10.1006/gyno.2001.6200
   SCHAFER A, 1991, AM J OBSTET GYNECOL, V164, P593, DOI 10.1016/S0002-9378(11)80029-3
   SPITERI MA, 1992, EUR RESPIR J, V5, P394
   Tartour E, 1998, J NATL CANCER I, V90, P287, DOI 10.1093/jnci/90.4.287
   TAY SK, 1987, BRIT J OBSTET GYNAEC, V94, P16, DOI 10.1111/j.1471-0528.1987.tb02245.x
   Tjiong MY, 1999, GYNECOL ONCOL, V73, P285, DOI 10.1006/gyno.1999.5358
   Tsukui T, 1996, CANCER RES, V56, P3967
   TWEDDEL G, 1994, GYNECOL ONCOL, V52, P161, DOI 10.1006/gyno.1994.1024
   VIAC J, 1990, IMMUNOBIOLOGY, V180, P328, DOI 10.1016/S0171-2985(11)80296-2
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Wei LH, 2001, GYNECOL ONCOL, V82, P49, DOI 10.1006/gyno.2001.6235
   YARCHOAN R, 1986, J CLIN INVEST, V78, P439, DOI 10.1172/JCI112595
NR 49
TC 28
Z9 29
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1052-9551
EI 1533-4066
J9 DIAGN MOL PATHOL
JI Diagn. Mol. Pathol.
PD MAR
PY 2005
VL 14
IS 1
BP 39
EP 47
DI 10.1097/01.pas.0000143309.81183.6c
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Pathology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Pathology
GA 900RD
UT WOS:000227231100007
PM 15714063
DA 2020-11-24
ER

PT J
AU Johnson, M
   Grinsztejn, B
   Rodriguez, C
   Coco, J
   DeJesus, E
   Lazzarin, A
   Lichtenstein, K
   Rightmire, A
   Sankoh, S
   Wilber, R
AF Johnson, M
   Grinsztejn, B
   Rodriguez, C
   Coco, J
   DeJesus, E
   Lazzarin, A
   Lichtenstein, K
   Rightmire, A
   Sankoh, S
   Wilber, R
TI Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in
   patients experiencing multiple virological failures
SO AIDS
LA English
DT Article
OI LAZZARIN, Adriano/0000-0003-2551-7754
NR 0
TC 26
Z9 27
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JAN 28
PY 2005
VL 19
IS 2
BP 153
EP 162
DI 10.1097/00002030-200501280-00007
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 904EH
UT WOS:000227478400007
PM 15668540
DA 2020-11-24
ER

PT J
AU DeJesus, E
   McCarty, D
   Farthing, CF
   Shortino, DD
   Grinsztejn, B
   Thomas, DA
   Schrader, SR
   Castillo, SA
   Sension, MG
   Gough, K
   Madison, SJ
AF DeJesus, E
   McCarty, D
   Farthing, CF
   Shortino, DD
   Grinsztejn, B
   Thomas, DA
   Schrader, SR
   Castillo, SA
   Sension, MG
   Gough, K
   Madison, SJ
CA EPV20001 Int Study Team
TI Once-daily versus twice-daily lamivudine, in combination with zidovudine
   and efavirenz, for the treatment of antiretroviral-naive adults with HIV
   infection: A randomized equivalence trial
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy
CY SEP 26-30, 2002
CL SAN DIEGO, CA
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1-INFECTED ADULTS; THERAPY;
   PHARMACOKINETICS; DIDANOSINE; ADHERENCE; INDINAVIR; REGIMENS; EFFICACY;
   PLASMA
AB A randomized, double-blind, double-dummy controlled, multicenter trial was conducted that involved 554 antiretroviral-naive human immunodeficiency virus-infected adults (plasma HIV type 1 [ HIV-1] RNA level, greater than or equal to400 copies/mL; CD4(+) cell count, >100 cells/mm(3)) and compared a 300-mg once-daily (q.d.) regimen of lamivudine (3TC) versus a 150-mg twice-daily (b.i.d.) regimen of 3TC, combined with zidovudine (300 mg b.i.d.) and efavirenz (600 mg q.d.), during a 48-week period. Treatments were considered equivalent if the 95% confidence interval (CI) for the difference in proportions of patients achieving an HIV-1 RNA level of <400 copies/mL was within the bound of -12% to 12%. At week 48 of the study, an intent-to-treat analysis in which patients with missing data were considered to have experienced treatment failure showed that the 3TC q.d. and 3TC b.i.d. regimens were equivalent (HIV-1 RNA level <400 copies/mL, 178 [64%] of 278 vs. 174 [ 63%] of 276; treatment difference, 1% [ 95% CI, -7.1% to 8.9%]; HIV-1 RNA level ! 50 copies/ mL, 165 [59%] of 278 vs. 168 [61%] of 276; treatment difference, 1.7% [95% CI, -9.7% to 6.6%]). Median increase above baseline in CD4(+) cell count was similar (q.d. group, +144 cells/mm(3); b.i.d. group, +146 cells/mm(3)), and the incidences of adverse events, disease progression, and HIV-associated conditions were comparable.
C1 IDC Res Initiat, Altamonte Springs, FL 32701 USA.
   Ft Broward Hosp Dist, Ft Lauderdale, FL USA.
   GlaxoSmithKline, HIV Clin Dev & Med Affairs, Res Triangle Pk, NC USA.
   AHF Res Ctr, Los Angeles, CA USA.
   Montrose Clin, Houston, TX USA.
   Evandro Chagas Hosp, Rio De Janeiro, Brazil.
   St Michaels Hosp, Toronto, ON M5B 1W8, Canada.
RP DeJesus, E (corresponding author), IDC Res Initiat, 685 Palm Springs Dr,Suite 2C, Altamonte Springs, FL 32701 USA.
EM EdwinDeJesusMD@aol.com
CR Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008
   Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006
   BOYLE BA, 2002, AIDS READ, V12, P109
   Boyle Brian A, 2002, AIDS Read, V12, P90
   Bruno R, 2001, CLIN PHARMACOKINET, V40, P695, DOI 10.2165/00003088-200140090-00005
   CAHN P, 2000, 40 INT C ANT AG CHEM, P293
   Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149-2918(01)80109-0
   Committee for Proprietary Medicinal Products, POINTS CONS SWITCH S
   de Mendoza C, 2000, J HUMAN VIROL, V3, P335
   DEJESUS E, 2003, 43 INT C ANT AG CHEM, P305
   *DIV AIDS, 1996, DIV AIDS TABL GRAD S
   Hogg RS, 1999, CAN MED ASSOC J, V160, P659
   Landman R, 2003, AIDS, V17, P1017, DOI 10.1097/00002030-200305020-00010
   Maggiolo F, 2001, ANTIVIR THER, V6, P249
   Mole L, 2001, J ACQ IMMUN DEF SYND, V27, P260, DOI 10.1097/00126334-200107010-00007
   Moore KHP, 1999, AIDS, V13, P2239, DOI 10.1097/00002030-199911120-00006
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   PERNERSTORFERSC.H, 1998, 12 WORLD AIDS C JUN, P600
   Perry CM, 1997, DRUGS, V53, P657, DOI 10.2165/00003495-199753040-00008
   PROENCAL J, 2000, 13 IN AIDS C DURB
   Raboud J M, 2002, HIV Med, V3, P118, DOI 10.1046/j.1468-1293.2002.00109.x
   REIGER A, 1998, 5 C RETR OPP INF CHI, P209
   Rosenbach KA, 2002, CLIN INFECT DIS, V34, P686, DOI 10.1086/338255
   Ruane PJ, 2004, PHARMACOTHERAPY, V24, P307, DOI 10.1592/phco.24.4.307.33184
   Staszewski S, 1998, ANTIVIR THER, V3, P55
   Staszewski S, 2000, HIV Med, V1, P162, DOI 10.1046/j.1468-1293.2000.00020.x
   VAVRO C, 2002, 42 INT C ANT AG CHEM, P292
   WOODWARD WC, 1999, 37 ANN M INF DIS SOC, P104
   Yuen GJ, 2004, ANTIMICROB AGENTS CH, V48, P176, DOI 10.1128/AAC.48.1.176-182.2004
NR 30
TC 48
Z9 49
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2004
VL 39
IS 3
BP 411
EP 418
DI 10.1086/422143
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 839VR
UT WOS:000222813500018
PM 15307010
OA Bronze
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
AF Grinsztejn, Beatriz
TI The challenge to conduct clinical research in developing countries
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Meeting Abstract
C1 Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Infect Dis Serv, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1355-0284
J9 J NEUROVIROL
JI J. Neurovirol.
PY 2004
VL 10
SU 3
BP 8
EP 9
PG 2
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA V44GU
UT WOS:000202992000011
DA 2020-11-24
ER

PT J
AU Bongertz, V
   Costa, CI
   Veloso, VG
   Grinsztejn, B
   Filho, ECJ
   Calvet, G
   Pilotto, JH
AF Bongertz, V
   Costa, CI
   Veloso, VG
   Grinsztejn, B
   Filho, ECJ
   Calvet, G
   Pilotto, JH
TI Neutralization titres and vertical HIV-1 transmission
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIBODY; SERA
AB Replication of the human immunodeficiency virus type 1 (HIV-1) isolate MN in CEM cells was less neutralized by the plasma from the mothers of infected children (MIC) in comparison with the plasma from the mothers of uninfected children (MUC). Significantly higher neutralization titres were observed for the sera from MUCs compared with MICs, and only the sera from MUC showed 100% neutralization of the HIV-1 MN strain. We suggest that a simple neutralization assay as described here could be useful in prognostic analyses.
C1 Fiocruz MS, IOC, Dept Immunol, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   Fiocruz MS, Evandro Chagas Hosp Res Ctr, BR-21045900 Rio De Janeiro, Brazil.
   Nova Iguacu Gen Hosp, Rio De Janeiro, Brazil.
RP Bongertz, V (corresponding author), Fiocruz MS, IOC, Dept Immunol, Lab AIDS & Imunol Mol, Av Brazil 4365,Pav Leonidas Deane Sala 413, BR-21045900 Rio De Janeiro, Brazil.
RI Calvet, GA/G-6959-2013; Pilotto, Jose Henrique/AAD-9773-2019; Veloso,
   Valdilea Goncalves/J-6189-2012
OI Calvet, GA/0000-0002-3545-5238; Pilotto, Jose
   Henrique/0000-0003-0521-8597; 
CR Beirnaert E, 2000, J MED VIROL, V62, P14, DOI 10.1002/1096-9071(200009)62:1&lt;14::AID-JMV3&gt;3.0.CO;2-L
   Bongertz V, 2001, SCAND J IMMUNOL, V53, P302, DOI 10.1046/j.1365-3083.2001.00866.x
   Dreyer K, 1999, AIDS RES HUM RETROV, V15, P1563, DOI 10.1089/088922299309856
   Hengel RL, 1998, AIDS RES HUM RETROV, V14, P475, DOI 10.1089/aid.1998.14.475
   Lathey JL, 1999, J INFECT DIS, V180, P344, DOI 10.1086/314886
   Louisirirotchanakul S, 1999, J ACQ IMMUN DEF SYND, V21, P259, DOI 10.1097/00126334-199908010-00001
   MATTHEWS TJ, 1994, AIDS RES HUM RETROV, V10, P631, DOI 10.1089/aid.1994.10.631
   Moore JP, 1999, NAT MED, V5, P142, DOI 10.1038/5502
   Nyambi PN, 1996, J VIROL, V70, P6235, DOI 10.1128/JVI.70.9.6235-6243.1996
   SCARLATTI G, 1993, J INFECT DIS, V168, P207, DOI 10.1093/infdis/168.1.207
NR 10
TC 12
Z9 12
U1 0
U2 0
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0300-9475
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD DEC
PY 2002
VL 56
IS 6
BP 642
EP 644
DI 10.1046/j.1365-3083.2002.01174.x
PG 3
WC Immunology
SC Immunology
GA 622JV
UT WOS:000179644700013
PM 12472677
OA Bronze
DA 2020-11-24
ER

PT J
AU Oelemann, WMR
   Lowndes, CM
   da Costa, GCV
   Morgado, MG
   Castello-Branco, LRR
   Grinsztejn, B
   Alary, M
   Bastos, FI
AF Oelemann, WMR
   Lowndes, CM
   da Costa, GCV
   Morgado, MG
   Castello-Branco, LRR
   Grinsztejn, B
   Alary, M
   Bastos, FI
TI Diagnostic detection of human immunodeficiency virus type 1 antibodies
   in urine: a Brazilian study
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID RIO-DE-JANEIRO; HIV-1; INFECTION; ASSAYS; SALIVA; SERUM; SENSITIVITY;
   PREVALENCE; SPECIMENS
AB We evaluated, for the first time in Latin America, the performance of a commercial enzyme immunoassay (EIA) (Calypte Biomedical Corporation, Berkeley, Calif.) that detects human immunodeficiency virus type I (HIV-1)-specific antibodies in urine in comparison to standard serological assays (two commercial EIAs and a commercial Western blot [WB] assay). Paired serum and urine specimens were: collected from two different groups of Brazilian patients: 225 drug users with unknown HIV status who attended drug treatment centers in Rio de Janeiro, Brazil, and 135 subjects with known HIV status. Patients showing positive results in the serum EIAs and/or in the urine EIA were serologically confirmed by WB; assay. For 135 individuals with known HIV status, the urine EIA showed 100% sensitivity (74 positive samples) and 95.1% specificity (58 of 61 negative specimens). For 225 drug users, the test showed 100% sensitivity (2 positive samples) and 98.7% specificity (220 of 223 negative samples) compared to WB-confirmed serological EIA results. Thus, in a total of 360 samples, the urine EIA correctly identified all 76 HIV-positive samples and 278 of 284 negative samples (100% sensitivity and 97.9% specificity). Detailed analysis of the urine EIA results indicates that an increase of the recommended cutoff value might raise the specificity of the assay without affecting its sensitivity. Our results suggest that the HIV-1 urine EIA is a good screening test suitable for developing countries like Brazil. However, as for all other HIV screening tests on the market, it is not specific enough to be used as a one-step test and therefore requires confirmation.
C1 Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, CCS, BR-21941590 Rio De Janeiro, Brazil.
   IOC, Depto Imunol, BR-21045900 Rio De Janeiro, Brazil.
   Fiocruz MS, Depto Informacoes Saude, CICT, UNAIDS Collaborating Ctr, BR-21045900 Rio De Janeiro, Brazil.
   Univ Laval, Grp Rech Epidemiol, Hop St Sacrement CHA, Laval, PQ G1S 4L8, Canada.
RP Oelemann, WMR (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, CCS, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.
OI Verissimo da Costa, Giovani Carlo/0000-0003-2721-0238; Bastos,
   Francisco/0000-0001-5970-8896
CR Bastos FI, 2000, INT J STD AIDS, V11, P383, DOI 10.1258/0956462001916100
   Beck A, 1996, ZBL BAKT-INT J MED M, V283, P340, DOI 10.1016/S0934-8840(96)80069-7
   BERRIOS DC, 1995, ARCH PATHOL LAB MED, V119, P139
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Broutet N, 1996, INT J STD AIDS, V7, P365, DOI 10.1258/0956462961918103
   CONNELL JA, 1990, LANCET, V335, P1366, DOI 10.1016/0140-6736(90)91245-6
   DESAI S, 1991, LANCET, V337, P183, DOI 10.1016/0140-6736(91)90855-J
   Flaitz CM, 1998, J DENT CHILD, V65, P318
   FRERICHS RR, 1994, J ACQ IMMUN DEF SYND, V7, P522
   FRERICHS RR, 1994, AIDS, V8, P885, DOI 10.1097/00002030-199407000-00004
   GOTTFRIED TD, 1990, TRENDS BIOTECHNOL, V8, P35, DOI 10.1016/0167-7799(90)90130-P
   HENDRY RM, 1991, J ACQ IMMUN DEF SYND, V4, P623
   MARTIN DC, 1994, J AM ASSOC GYN LAP, V1, P17
   Meehan MP, 1999, SEX TRANSM DIS, V26, P590, DOI 10.1097/00007435-199911000-00009
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Pinho RT, 1999, ACTA TROP, V72, P31, DOI 10.1016/S0001-706X(98)00075-8
   SKOLNIK PR, 1989, J INFECT DIS, V160, P1056, DOI 10.1093/infdis/160.6.1056
   Tribble DR, 1997, CLIN DIAGN VIROL, V7, P127, DOI 10.1016/S0928-0197(96)00261-9
   Urnovitz HB, 1999, CLIN CHEM, V45, P1602
   URNOVITZ HB, 1993, LANCET, V342, P1458, DOI 10.1016/0140-6736(93)92934-L
   Urnovitz HB, 1997, NAT MED, V3, P1258, DOI 10.1038/nm1197-1258
   Watt G, 2000, CLIN INFECT DIS, V30, P819, DOI 10.1086/313777
NR 22
TC 9
Z9 11
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAR
PY 2002
VL 40
IS 3
BP 881
EP 885
DI 10.1128/JCM.40.3.881-885.2002
PG 5
WC Microbiology
SC Microbiology
GA 528HP
UT WOS:000174238600024
PM 11880409
OA Green Published, Bronze
DA 2020-11-24
ER

PT B
AU Nicol, A
   Fernandes, ATG
   Grinsztejn, BG
   Russomano, F
   Silva, JRLE
   Tristao, A
   Perez, M
   Maza, OM
   Bonecini-Almedia, MG
AF Nicol, A
   Fernandes, ATG
   Grinsztejn, BG
   Russomano, F
   Silva, JRLE
   Tristao, A
   Perez, M
   Maza, OM
   Bonecini-Almedia, MG
GP MONDUZZI EDITORE
   MONDUZZI EDITORE
   MONDUZZI EDITORE
TI Cervical immunity response induced by HPV and the influence of HIV-1
   co-infection
SO XIV INTERNATIONAL AIDS CONFERENCE: BASIC SCIENCES
LA English
DT Proceedings Paper
CT 14th International AIDS Conference
CY JUL 07-12, 2002
CL BARCELONA, SPAIN
SP Univ N Carolina, Gen Clin Res Ctr, UNC Ctr AIDS Res, Natl Inst Hlth, Swiss Natl AIDS Res Program, Bristol-Myers Squibb Co, Boehringer Ingelheim, GlaxoWellcome Res & Dev, HIV Antiviral Res
ID INTRAEPITHELIAL NEOPLASIA; CELLS; INTERLEUKIN-6; EXPRESSION; CARCINOMA
AB The women have assumed an important role in the epidemic of HIV-1 infection. Little is known about the immune system of the female genital tract. To characterize the cervical immune response, we analyzed inflammatory cells and cytokines in HIV/HPV infection. HIV-positive patients showed significantly decreased of IL-6, TNF-alpha, IL-10 and IFN-gamma production compared to HIV-negative individuals. Great number of macrophages and T cells were seen in both studied groups, although a marked number of CD8(+) T cells was seen in HIV-positive women. The majority of HIV positive patients harbor high risk HPV type and may lead to an increased risk to develop cervical cancer. HPV infection trigger the migration of HIV-1 reservoir cells contributing to HIV replication in co-infected women, even in the presence of low expressions of cytokines that enhance HIV replication. Others mechanisms could be probably involved and should be addressed on cervical lesion.
C1 Owaldo Cruz Fdn, Inst Clin Res Evandro Chagas, Rio De Janeiro, Brazil.
RP Nicol, A (corresponding author), Owaldo Cruz Fdn, Inst Clin Res Evandro Chagas, Rio De Janeiro, Brazil.
CR COLEMAN N, 1994, AM J CLIN PATHOL, V102, P768, DOI 10.1093/ajcp/102.6.768
   Davidson B, 1997, PATHOL RES PRACT, V193, P491, DOI 10.1016/S0344-0338(97)80102-1
   de Gruijl TD, 1999, EUR J CANCER, V35, P490, DOI 10.1016/S0959-8049(98)00371-2
   Fruchter RG, 1996, OBSTET GYNECOL, V87, P338, DOI 10.1016/0029-7844(95)00408-4
   Gage JR, 2000, OBSTET GYNECOL, V96, P879, DOI 10.1016/S0029-7844(00)01057-7
   Hess S, 2000, J IMMUNOL, V165, P1939, DOI 10.4049/jimmunol.165.4.1939
   IARC, 1995, MON EV CARC RISKS HU, V64
   MAIMAN M, 1993, OBSTET GYNECOL, V82, P170
   POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Wei LH, 2001, GYNECOL ONCOL, V82, P49, DOI 10.1006/gyno.2001.6235
NR 11
TC 1
Z9 1
U1 0
U2 0
PU MEDIMOND S R L
PI 40128 BOLOGNA
PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY
PY 2002
BP 117
EP 121
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA BV88Y
UT WOS:000180303800023
DA 2020-11-24
ER

PT J
AU Bongertz, V
   Costa, CI
   Veloso, VG
   Grinsztejn, B
   Joao, EC
   Calvet, G
   Pilotto, JH
   Guimaraes, ML
   Morgado, MG
AF Bongertz, V
   Costa, CI
   Veloso, VG
   Grinsztejn, B
   Joao, EC
   Calvet, G
   Pilotto, JH
   Guimaraes, ML
   Morgado, MG
TI Vertical HIV-1 transmission: Importance of neutralizing antibody titer
   and specificity
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MATERNAL-INFANT TRANSMISSION; TO-CHILD
   TRANSMISSION; PERINATAL TRANSMISSION; HUMORAL IMMUNITY; TYPE-1 HIV-1;
   RISK-FACTORS; VIRAL LOAD; INFECTION; SUSCEPTIBILITY
AB Neutralization analyses were carried out with plasma from 132 volunteer human immunodeficiency virus (HIV)-1 infected women (76% pregnant, 24% with infants suspected for HIV-1 infection) collected between 1994 and 1998, against autologous and heterologous primary- and the reference HIV-1 MN isolates. A significantly lower percentage of HIV-1 transmissions was observed after 1996, parallel to a more intense antiretroviral treatment of infected pregnant women. HIV-1 isolation was significantly more frequent from peripheral blood mononuclear cells of mothers of infected children than mothers of uninfected children (P = 0.0065). Neutralization of autologous HIV-1 isolates was comparable for HIV-1 transmitters and nontransmitters' plasma, whereas neutralization of the reference isolate HIV-1 MN was more frequent at high titers for pregnant women who did not transmit HIV to their offspring compared to pregnant women who did. Although neutralization of heterologous primary HIV-1 isolates from HIV transmitters and non transmitters by transmitter plasma occurred with similar frequency, neutralization of isolates from transmitters was much more frequent when heterologous plasma from nontransmitters were used. Macrophage-tropic heterologous HIV-1 isolates were neutralized more frequently at higher titers by plasma from nontransmitters than from transmitters. The results obtained indicate that antiretroviral treatment, lack of success of HIV-1 isolation and high titers of antibodies able to neutralize macrophage-tropic viruses appear to be of importance for protection against HIV-1 vertical transmission for the group of patients studied.
C1 Fiocruz MS, IOC, Dept Imunol, AIDS & Imunol Mol Lab, BR-21045900 Rio De Janeiro, Brazil.
   Fiocruz MS, Evandro Chagas Hosp Res Ctr, BR-21045900 Rio De Janeiro, Brazil.
   Serv Estado Hosp, Rio De Janeiro, Brazil.
   Nova Iguacu Gen Hosp, Rio De Janeiro, Brazil.
RP Bongertz, V (corresponding author), Fiocruz MS, IOC, Dept Imunol, AIDS & Imunol Mol Lab, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM bongertz@ioc.fiocruz.br
RI Veloso, Valdilea Goncalves/J-6189-2012; Calvet, GA/G-6959-2013; Pilotto,
   Jose Henrique/AAD-9773-2019
OI Calvet, GA/0000-0002-3545-5238; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Joao, Esau/0000-0002-2412-0627
CR ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002
   Aleixo LF, 1997, J PEDIATR-US, V130, P906, DOI 10.1016/S0022-3476(97)70276-2
   Asjo B, 1997, AIDS, V11, P17
   BABOONIAN C, 1983, BRIT J OBSTET GYNAEC, V90, P1168, DOI 10.1111/j.1471-0528.1983.tb06466.x
   Bongertz V, 1999, J CLIN VIROL, V12, P27, DOI 10.1016/S0928-0197(98)00068-3
   Bongertz V, 1997, AIDS, V11, P969, DOI 10.1097/00002030-199708000-00004
   Bongertz V, 1998, SCAND J IMMUNOL, V47, P603, DOI 10.1046/j.1365-3083.1998.00345.x
   BORKOWSKY W, 1994, J PEDIATR-US, V125, P345, DOI 10.1016/S0022-3476(05)83274-3
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445
   Dreyer K, 1999, AIDS RES HUM RETROV, V15, P1563, DOI 10.1089/088922299309856
   FENYO EM, 1988, J VIROL, V62, P4414
   Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602
   HEAGY W, 1991, J CLIN INVEST, V87, P1916, DOI 10.1172/JCI115217
   Hengel RL, 1998, AIDS RES HUM RETROV, V14, P475, DOI 10.1089/aid.1998.14.475
   LAMERS SL, 1994, J CLIN INVEST, V93, P380, DOI 10.1172/JCI116970
   Lathey JL, 1999, J INFECT DIS, V180, P344, DOI 10.1086/314886
   LJUNGGREN K, 1990, J INFECT DIS, V161, P198, DOI 10.1093/infdis/161.2.198
   Louisirirotchanakul S, 1999, J ACQ IMMUN DEF SYND, V21, P259, DOI 10.1097/00126334-199908010-00001
   Menu E, 1999, J INFECT DIS, V179, P44, DOI 10.1086/314542
   *MIN SAUD SECR POL, 1999, B EP AIDS, V12
   Mock PA, 1999, AIDS, V13, P407, DOI 10.1097/00002030-199902250-00014
   Moore JP, 1999, NAT MED, V5, P142, DOI 10.1038/5502
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Newell ML, 1998, AIDS, V12, P831, DOI 10.1097/00002030-199808000-00004
   OMETTO L, 1995, AIDS, V9, P427, DOI 10.1097/00002030-199509050-00003
   PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004
   Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508
   Pitt J, 1997, J INFECT DIS, V175, P567, DOI 10.1093/infdis/175.3.567
   Rogers MF, 1999, NEW ENGL J MED, V341, P441, DOI 10.1056/NEJM199908053410609
   RUBSAMENWAIGMANN H, 1994, AIDS RES HUM RETROV, V10, P1401, DOI 10.1089/aid.1994.10.1401
   SCARLATTI G, 1993, J INFECT DIS, V168, P207, DOI 10.1093/infdis/168.1.207
   SCARLATTI G, 1993, VIROLOGY, V197, P624, DOI 10.1006/viro.1993.1637
   SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002
   Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201
   Tscherning-Casper C, 1999, J VIROL, V73, P9673, DOI 10.1128/JVI.73.11.9673-9678.1999
NR 37
TC 20
Z9 21
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD MAR
PY 2001
VL 53
IS 3
BP 302
EP 309
DI 10.1046/j.1365-3083.2001.00866.x
PG 8
WC Immunology
SC Immunology
GA 413WK
UT WOS:000167634400014
PM 11251889
OA Bronze, Green Published
DA 2020-11-24
ER

PT J
AU Lourenco, MCS
   Grinsztejn, B
   Fandinho-Montes, FCO
   da Silva, MG
   Saad, MHF
   Fonseca, LS
AF Lourenco, MCS
   Grinsztejn, B
   Fandinho-Montes, FCO
   da Silva, MG
   Saad, MHF
   Fonseca, LS
TI Genotypic patterns of multiple isolates of M-tuberculosis from
   tuberculous HIV patients
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE tuberculosis; HIV coinfection; multiple isolates; genotypic patterns
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT MYCOBACTERIUM-TUBERCULOSIS;
   FRAGMENT-LENGTH-POLYMORPHISM; EXOGENOUS REINFECTION; PULMONARY
   TUBERCULOSIS; INFECTED PATIENTS; TRANSMISSION; EPIDEMIOLOGY; AIDS;
   MORTALITY
AB We investigated whether the recurrence of tuberculosis in HIV-infected patients is due to an exogenous reinfection or relapses after antituberculosis chemotherapy. We reviewed clinical information on 32 patients at a Rio de Janeiro hospital from whom multiple Mycobacterium tuberculosis isolates were taken. All isolates were analysed by DRE-PCR fingerprinting technique, and those with identical DRE-PCR patterns were analysed by the RFLP method. Twenty patients had M. tuberculosis simultaneously isolated from different organs. These patients and nine others with sequential positive cultures after 2 months of therapy showed stable DRE-PCR and RFLP patterns. One patient's isolate became resistant to isoniazid, but the molecular pattern remained unchanged despite the development of drug resistance. in three patients, the DRE-PCR patterns of the isolates changed dramatically. Clinical and microbiological evidence was consistent with active tuberculosis caused by a new strain of M. tuberculosis. The exogenous reinfection of the three patients was not due to an outbreak, but the isolates from each patient showed unique patterns.
C1 Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Microbiol, BR-21941590 Rio De Janeiro, Brazil.
   FIOCRUZ, Hosp Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   FIOCRUZ, Inst Desenvolvimento Tecnol & Prod Imunobiol, BR-21045900 Rio De Janeiro, Brazil.
   FIOCRUZ, Inst Oswaldo Cruz, Lab Hanseniase, BR-21045900 Rio De Janeiro, Brazil.
RP Fonseca, LS (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Microbiol, Bloco I,Ilha Fundao, BR-21941590 Rio De Janeiro, Brazil.
CR ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403
   Bishai WR, 1998, JAMA-J AM MED ASSOC, V280, P1679, DOI 10.1001/jama.280.19.1679
   CANETTI G, 1963, Rev Tuberc Pneumol (Paris), V27, P217
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213
   FRIEDMAN CR, 1995, J CLIN MICROBIOL, V33, P1383, DOI 10.1128/JCM.33.5.1383-1384.1995
   Grinsztejn B, 1997, ARCH INTERN MED, V157, P2359, DOI 10.1001/archinte.157.20.2359
   HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z
   HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540
   HORN DL, 1994, ANN INTERN MED, V121, P115, DOI 10.7326/0003-4819-121-2-199407150-00007
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607, DOI 10.1128/JCM.37.8.2607-2618.1999
   NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502
   PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204
   PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750
   PITCHENIK AE, 1990, ANN INTERN MED, V113, P89, DOI 10.7326/0003-4819-113-2-89
   Pulido F, 1997, ARCH INTERN MED, V157, P227, DOI 10.1001/archinte.157.2.227
   ROMEYN JA, 1970, AM REV RESPIR DIS, V101, P923
   Saad MHF, 1997, MEM I OSWALDO CRUZ, V92, P471, DOI 10.1590/S0074-02761997000400004
   SAHADEVAN R, 1995, J CLIN MICROBIOL, V33, P3037, DOI 10.1128/JCM.33.11.3037-3039.1995
   SCHAFER RW, 1995, TUBERCLE LUNG DIS, V76, P575
   SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601
   SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402
   STEAD WW, 1967, AM REV RESPIR DIS, V95, P729
   Torrea G, 1996, J CLIN MICROBIOL, V34, P1043, DOI 10.1128/JCM.34.5.1043-1049.1996
   TSANG AY, 1992, J CLIN MICROBIOL, V30, P479, DOI 10.1128/JCM.30.2.479-484.1992
   Turett GS, 1997, CLIN INFECT DIS, V24, P513, DOI 10.1093/clinids/24.3.513
   Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993
   YANG ZH, 1995, J CLIN MICROBIOL, V33, P2077, DOI 10.1128/JCM.33.8.2077-2081.1995
   YANG ZH, 1994, J CLIN MICROBIOL, V32, P3018, DOI 10.1128/JCM.32.12.3018-3025.1994
NR 31
TC 16
Z9 18
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUL
PY 2000
VL 5
IS 7
BP 488
EP 494
DI 10.1046/j.1365-3156.2000.00583.x
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 345GH
UT WOS:000088807900004
PM 10964271
OA Bronze
DA 2020-11-24
ER

PT J
AU Bongertz, V
   Costa, CI
   Guimaraes, ML
   Grinsztejn, B
   Joao, EC
   Galvao-Castro, B
   Morgado, MG
AF Bongertz, V
   Costa, CI
   Guimaraes, ML
   Grinsztejn, B
   Joao, EC
   Galvao-Castro, B
   Morgado, MG
CA HEC FIOCRUZ AIDS Clinical Res Grp
TI Neutralization susceptibility of B subtype variant B '' primary HIV-1
   isolates
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GENES; CROSS-CLADE; V3 REGION;
   TYPE-1; BRAZIL; ANTIBODIES; INFECTION; RESPONSES; SEROTYPES
AB Susceptibility to autologous and heterologous neutralization of primary human immunodeficiency virus (HIV)-1 isolates belonging to subtype B, to the B''-variant of subtype B or to subtype F from infected individuals residing in Rio de Janeiro was assayed. A lower infectivity of the B''- and F isolates when compared to the classical B-subtype HIV-1 isolates was observed. Comparisons of neutralization susceptibilities were carried out for 19 B-subtype, 11 B''-variant and two F-subtype HIV-1 isolates with plasma from autologous and heterologous samples. Frequency of autologous neutralization was slightly lower for B-subtype isolates in comparison to B''-variant isolates. Heterologous intra-subtype neutralization was significantly lower for B-subtype than for the B"-variant or the F-subtype isolates. While B-subtype isolates were neutralized by most anti-F-subtype plasma, F-subtype isolates, although most susceptible to F-subtype antibodies, were highly susceptible to neutralization by anti-B-subtype antibodies. Cross-neutralization for B''-variant and B-subtype isolates was not as extensive as observed for B- and F-subtype isolates. However, the results presented indicate a quite extensive cross-neutralization between Brazilian HIV-1 isolates.
C1 Evandro Chagas Hosp HEC, IOC, Oswaldo Cruz Fdn, Rio De Janeiro, RJ, Brazil.
   Oswaldo Cruz Fdn, Adv Lab Publ Hlth, CPqGM, Salvador, BA, Brazil.
RP Bongertz, V (corresponding author), FIOCRUZ, IOC, Dept Immunol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
OI Joao, Esau/0000-0002-2412-0627
CR ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002
   ALBERT J, 1993, AIDS RES HUM RETROV, V9, P501, DOI 10.1089/aid.1993.9.501
   ARENDRUP M, 1993, J GEN VIROL, V74, P855, DOI 10.1099/0022-1317-74-5-855
   BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160
   Bollinger R C, 1996, AIDS, V10 Suppl A, pS85, DOI 10.1097/00002030-199601001-00013
   Bongertz V, 1997, AIDS, V11, P969, DOI 10.1097/00002030-199708000-00004
   BONGERTZ V, 1998, IN PRESS MEM I O CRU, V93
   *CDC, 1986, ANN INTERN MED, V105, P234
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   GalvaoCastro B, 1996, MEM I OSWALDO CRUZ, V91, P335, DOI 10.1590/S0074-02761996000300014
   Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996
   HAMMER S, 1996, 11 INT C AIDS TRANSC
   Hendry RM, 1996, MEM I OSWALDO CRUZ, V91, P347
   Kostrikis LG, 1996, AIDS RES HUM RETROV, V12, P1667, DOI 10.1089/aid.1996.12.1667
   Lathey JL, 1997, J INFECT DIS, V175, P231, DOI 10.1093/infdis/175.1.231
   MONTEFIORI DC, 1991, VIROLOGY, V182, P635, DOI 10.1016/0042-6822(91)90604-A
   Moore J, 1997, AIDS RES HUM RETROV, V13, P733, DOI 10.1089/aid.1997.13.733
   Moore JP, 1996, J VIROL, V70, P427, DOI 10.1128/JVI.70.1.427-444.1996
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   MORGADO MG, 1998, IN PRESS MEM I O CRU, V93
   Nyambi PN, 1996, J VIROL, V70, P6235, DOI 10.1128/JVI.70.9.6235-6243.1996
   Nyambi PN, 1997, AIDS RES HUM RETROV, V13, P7, DOI 10.1089/aid.1997.13.7
   OSMANOV S, 1994, AIDS RES HUM RETROV, V10, P1327, DOI 10.1089/aid.1994.10.1327
   Poignard P, 1996, IMMUNOL TODAY, V17, P239, DOI 10.1016/0167-5699(96)10007-4
   POTTS KE, 1993, AIDS, V7, P1191, DOI 10.1097/00002030-199309000-00007
   RUEBSAMENWAIGMA.H, 1994, AIDS RES HUM RETROV, V10, P1401
   SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994
   Shibata R, 1996, J VIROL, V70, P4361, DOI 10.1128/JVI.70.7.4361-4369.1996
   TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995
   WainHobson S, 1997, NATURE, V387, P123, DOI 10.1038/387123a0
   Wang B, 1995, ANN NY ACAD SCI, V772, P186, DOI 10.1111/j.1749-6632.1995.tb44744.x
   Weber J, 1996, J VIROL, V70, P7827, DOI 10.1128/JVI.70.11.7827-7832.1996
NR 32
TC 8
Z9 8
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0300-9475
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD JUN
PY 1998
VL 47
IS 6
BP 603
EP 608
PG 6
WC Immunology
SC Immunology
GA ZV752
UT WOS:000074337600012
PM 9652830
OA Bronze
DA 2020-11-24
ER

PT J
AU Bongertz, V
   Costa, CI
   Guimaraes, ML
   Soares-da-Costa, MFG
   Grinsztejn, B
   Bastos, FI
   Pilotto, JH
   Joao, EC
   Loureiro, R
   Chequer, P
   Telles, PR
   Galvao-Castro, B
   Morgado, MG
AF Bongertz, V
   Costa, CI
   Guimaraes, ML
   Soares-da-Costa, MFG
   Grinsztejn, B
   Bastos, FI
   Pilotto, JH
   Joao, EC
   Loureiro, R
   Chequer, P
   Telles, PR
   Galvao-Castro, B
   Morgado, MG
CA HEC Fiocruz AIDS Clin Res Grp
TI HIV specific humoral immune response in Rio de Janeiro, Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article; Proceedings Paper
CT 2nd Brazilian Symposium on Basic Research in HIV/AIDS
CY SEP 07-11, 1997
CL ANGRA REIS, BRAZIL
SP IOC, Dept Imunol, CPGM, Avancado Saude Publ Lab, Fdn Oswaldo Cruz, Minist Saude, Program Nacl Doencas Sexualmente Transmiss & AIDS, Inst Oswaldo Cruz, Soc Brasileira Virol, CNPq, CAPES, FAPERJ, FINEP, EMBRATEL, XEROX, LABLASER, FURNAS, CER-MED, ORGANON
DE HIV-1; antibody specificity; neutralization; genotypes
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HETERODUPLEX MOBILITY ASSAY; INJECTING
   DRUG-USERS; V3 REGION; NEUTRALIZATION SEROTYPES; ENVELOPE GLYCOPROTEIN;
   TYPE-1; INFECTION; ANTIBODIES; DIVERSITY
AB Efforts to characterize HIV-1 polymorphism and anti-HIV immune response are being made in areas where anti-HIV/AIDS vaccines are to be employed. Anti-HIV-1 humoral immune response is being studied in infected individuals resident in Rio de Janeiro, in distinct cohorts involving recent seroconvertors, pregnant women or intravenous drug users (IDU). Comparative analyses of specificity of antibody response towards epitopes important for anti-HIV-1 immune response indicate quantitative differences between cohorts, with an exceptionally strong response in IDUs and weakest response in pregnant women. However, a comparative analysis between pregnant women cohorts from Rio de Janeiro and Rio Grande no Sul indicated an even lower response (with exception of the anti-V3-C clads peptide recognition) for the southern cohort. Studies analysing the immune function of the humoral response indicate a quite elevated occurrence of antibodies capable of neutralizing heterologous primary HIV-1 isolates from Rio de Janeiro. Attempts to correlate seroreactivity with HIV-1 neutralization with respect to HIV-1 polymorphism were not very successfull: while the Brazilian B clade B" variant could be recognized by binding assays, no significant distinction of HIV-1 clades/variants teas observed in viral neutralization assays.
C1 Inst Oswaldo Cruz, Dept Imunol, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   Inst Oswaldo Cruz, Hosp Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   FIOCRUZ, Ctr Informacoes Ciencia & Tecnol, BR-21045900 Rio De Janeiro, Brazil.
   Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
   Hosp Servidores Estado, Rio De Janeiro, Brazil.
   Secretaria Saude & Meio Ambiente, Porto Alegre, RS, Brazil.
   MS, Programa Nacl DST AIDS, Brasilia, DF, Brazil.
   Univ Estadual Rio de Janeiro, NEPAD, Rio De Janeiro, Brazil.
   FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Lab Avancado Saude Publ, Salvador, BA, Brazil.
RP Bongertz, V (corresponding author), Inst Oswaldo Cruz, Dept Imunol, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM bongertz@gene.dbbm.fiocruz.br
RI Dias, Paulo Roberto Telles Pires/ABB-9006-2020; Pilotto, Jose
   Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Joao,
   Esau/0000-0002-2412-0627; Bastos, Francisco/0000-0001-5970-8896
CR ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002
   ALBERT J, 1993, AIDS RES HUM RETROV, V9, P501, DOI 10.1089/aid.1993.9.501
   ARENDRUP M, 1993, J GEN VIROL, V74, P855, DOI 10.1099/0022-1317-74-5-855
   BASTOS FI, 1997, 2 S BRAS PESQ BAS HI, P11
   BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160
   Bloom BR, 1996, SCIENCE, V272, P1888, DOI 10.1126/science.272.5270.1888
   BONGERTZ V, 1994, BRAZ J MED BIOL RES, V27, P1225
   BONGERTZ V, 1997, AIDS, V11, P977
   CARROW EW, 1991, AIDS RES HUM RETROV, V7, P831, DOI 10.1089/aid.1991.7.831
   *CDC, 1986, ANN INTERN MED, V105, P234
   CHEINGSONGPOPOV R, 1992, J INFECT DIS, V165, P256, DOI 10.1093/infdis/165.2.256
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   DESJARLAIS DC, 1988, AIDS PRINCIPLES PRAC, P256
   Fenyo E M, 1996, AIDS, V10 Suppl A, pS97, DOI 10.1097/00002030-199601001-00014
   GADELHA AJ, 1997, THESIS U SAO PAULO S
   GalvaoCastro B, 1996, MEM I OSWALDO CRUZ, V91, P335, DOI 10.1590/S0074-02761996000300014
   Hendry RM, 1996, MEM I OSWALDO CRUZ, V91, P347
   Kostrikis LG, 1996, AIDS RES HUM RETROV, V12, P1667, DOI 10.1089/aid.1996.12.1667
   Lathey JL, 1997, J INFECT DIS, V175, P231, DOI 10.1093/infdis/175.1.231
   Louisirirotchanakul S, 1997, AIDS RES HUM RETROV, V13, P807, DOI 10.1089/aid.1997.13.807
   Manoff SB, 1996, EPIDEMIOLOGY, V7, P566, DOI 10.1097/00001648-199611000-00001
   Mikyas Y, 1997, J REPROD IMMUNOL, V33, P157, DOI 10.1016/S0165-0378(97)00018-1
   MONTEFIORI DC, 1991, VIROLOGY, V182, P635, DOI 10.1016/0042-6822(91)90604-A
   Moore J, 1997, AIDS RES HUM RETROV, V13, P733, DOI 10.1089/aid.1997.13.733
   Moore JP, 1996, J VIROL, V70, P427, DOI 10.1128/JVI.70.1.427-444.1996
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   MORGADO MG, 1996, HIV 1 DIVERSITY PATI
   Nyambi PN, 1996, J VIROL, V70, P6235, DOI 10.1128/JVI.70.9.6235-6243.1996
   Nyambi PN, 1997, AIDS RES HUM RETROV, V13, P7, DOI 10.1089/aid.1997.13.7
   PAU CP, 1994, AIDS RES HUM RETROV, V10, P1369, DOI 10.1089/aid.1994.10.1369
   Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508
   POTTS KE, 1993, AIDS, V7, P1191, DOI 10.1097/00002030-199309000-00007
   Simon F, 1996, AIDS RES HUM RETROV, V12, P1427, DOI 10.1089/aid.1996.12.1427
   STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532
   TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995
   vanHaastrecht HJA, 1996, INT J EPIDEMIOL, V25, P846, DOI 10.1093/ije/25.4.846
   WASI C, 1995, AIDS, V9, P843, DOI 10.1097/00002030-199508000-00003
   Weber J, 1996, J VIROL, V70, P7827, DOI 10.1128/JVI.70.11.7827-7832.1996
NR 38
TC 5
Z9 5
U1 0
U2 0
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAY-JUN
PY 1998
VL 93
IS 3
BP 391
EP 398
DI 10.1590/S0074-02761998000300022
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA ZP897
UT WOS:000073799600021
PM 9698875
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Grinsztejn, B
   Fandinho, FCO
   Veloso, VG
   Joao, EC
   Lourenco, MCS
   Nogueira, SA
   Fonseca, LS
   WerneckBarroso, E
AF Grinsztejn, B
   Fandinho, FCO
   Veloso, VG
   Joao, EC
   Lourenco, MCS
   Nogueira, SA
   Fonseca, LS
   WerneckBarroso, E
TI Mycobacteremia in patients with the acquired immunodeficiency syndrome
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID VIRUS-INFECTION; AIDS PATIENTS; TUBERCULOSIS BACTEREMIA; COMPLEX
   BACTEREMIA; DIAGNOSIS; BLOOD; AMPLIFICATION; CULTURE; IMPACT; YIELD
AB Background: Bacillemia is a key event in the pathogenesis of tuberculosis. Although current evidence indicates that Mycobacterium tuberculosis bacteremia is rare in patients seronegative for the human immunodeficiency virus, it has been increasingly reported in patients with the acquired immunodeficiency syndrome (AIDS).
   Objective: To determine clinical and laboratory characteristics of patients with AIDS and tuberculosis with and without bacillemia.
   Methods: Fifty patients with AIDS with clinical suspicion of disseminated mycobacterial disease were prospectively selected. Three consecutive blood samples were collected for culture using a standardized protocol.
   Results: Mycobacterium was isolated from any body site in 42 patients (84%). Bacillemia was detected in 30 (71.4%) of these 42 patients: 11 (28.2%) caused by Mycobacterium avium-intracellulare complex and 19 (71.8%) caused by M tuberculosis. Blood culture was the only method used to confirm the diagnosis in 5 (15%) of the 33 tuberculosis cases. Tuberculosis in patients with AIDS developed with nonspecific insidious symptoms, a remarkable elevated alkaline phosphatase level, and without the classic miliary radiological pattern. We could demonstrate 2 previously unrevealed clinical characteristics of bacteremic tuberculosis in patients with AIDS: a shift to the left in the white blood cell count and abdominal lymph node enlargement. In patients with tuberculosis, the in-hospital mortality rate was higher among patients with bacillemia, although the posttreatment survival rate was comparable.
   Conclusions: Blood culture is a valuable tool to confirm the clinical diagnosis of disseminated tuberculosis in patients with AIDS and can distinguish patients with characteristic clinical findings and outcome. Abdominal ultrasonography may be an additional helpful tool to identify these patients.
C1 HOSP EVANDRO CHAGAS,INST OSWALDO CRUZ,OSWALDO CRUZ FDN,BR-21045900 MANGUINHO,RJ,BRAZIL.
   INST OSWALDO CRUZ,OSWALDO CRUZ FDN,DEPT TECHNOL DEV IMMUNOBIOL PROD,RIO JANEIRO,BRAZIL.
   FED UNIV RIO DE JANEIRO,SERVIDORES ESTADO HOSP,NATL HLTH INST,INFECT DIS SERV,RIO JANEIRO,BRAZIL.
   FED UNIV RIO DE JANEIRO,CLEMENTINO FRAGA FILHO HOSP,INFECT DIS SERV,RIO JANEIRO,BRAZIL.
   FED UNIV RIO DE JANEIRO,INST MICROBIOL,MYCOBACTERIOL LAB,RIO JANEIRO,BRAZIL.
   FED UNIV RIO DE JANEIRO,MYCOBACTERIOL LAB,PHTHYSIOL & PNEUMOL INST,RIO JANEIRO,BRAZIL.
RI Veloso, Valdilea Goncalves/J-6189-2012
OI Joao, Esau/0000-0002-2412-0627
CR BARBER TW, 1990, MEDICINE, V69, P375, DOI 10.1097/00005792-199011000-00005
   BARNES PF, 1987, J INFECT DIS, V156, P377, DOI 10.1093/infdis/156.2.377
   BISHBURG E, 1986, J CLIN MICROBIOL, V24, P312, DOI 10.1128/JCM.24.2.312-314.1986
   BLOOM B, 1995, TUBERCULOSIS PATHOGE
   BOUZA E, 1993, ARCH INTERN MED, V153, P496, DOI 10.1001/archinte.153.4.496
   BOUZA E, 1988, EUR J CLIN MICROBIOL, V7, P785, DOI 10.1007/BF01975050
   BRISSONNOEL A, 1989, LANCET, V2, P1069
   Centers for Disease Control (CDC), 1987, MMWR-MORBID MORTAL W, V36, p1S
   CHIN DP, 1994, J INFECT DIS, V170, P578, DOI 10.1093/infdis/170.3.578
   Clough MC, 1917, AM REV TUBERCULOSIS, V1, P598
   DANNENBERG AM, 1989, REV INFECT DIS S, V2, P369
   ENG RHK, 1989, J CLIN MICROBIOL, V27, P768, DOI 10.1128/JCM.27.4.768-769.1989
   GACHOT B, 1990, INTENS CARE MED, V16, P491, DOI 10.1007/BF01709398
   GRIECO MH, 1974, AM REV RESPIR DIS, V109, P554
   HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540
   JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292
   KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N
   Lurie MB, 1964, RESISTANCE TUBERCULO
   MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201
   MUNT PW, 1972, MEDICINE, V51, P139, DOI 10.1097/00005792-197203000-00004
   NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082
   Nogales M C, 1994, Arch Bronconeumol, V30, P181
   PITCHENIK AE, 1983, ANN INTERN MED, V98, P112, DOI 10.7326/0003-4819-98-1-112_2
   PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393
   PREGO V, 1990, ARCH INTERN MED, V150, P333, DOI 10.1001/archinte.150.2.333
   Rich A.R., 1951, PATHOGENESIS TUBERCU
   ROM WN, 1995, TUBERCULOSIS
   RUF B, 1989, KLIN WOCHENSCHR, V67, P717, DOI 10.1007/BF01721290
   SALZMAN BR, 1986, JAMA-J AM MED ASSOC, V256, P390
   SCHLUGER NW, 1994, LANCET, V344, P232, DOI 10.1016/S0140-6736(94)92999-8
   SHAFER RW, 1989, AM REV RESPIR DIS, V140, P1611, DOI 10.1164/ajrccm/140.6.1611
   Shapiro L, 1932, AM REV TUBERCUL, V26, P418
   SLAVIN RE, 1980, MEDICINE, V59, P352, DOI 10.1097/00005792-198009000-00003
   STEAD WW, 1971, ANN INTERN MED, V74, P559, DOI 10.7326/0003-4819-74-4-559
   TRUFFOTPERNOT C, 1989, TUBERCLE, V70, P187, DOI 10.1016/0041-3879(89)90049-4
NR 35
TC 35
Z9 37
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD NOV 10
PY 1997
VL 157
IS 20
BP 2359
EP 2363
DI 10.1001/archinte.157.20.2359
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA YE938
UT WOS:A1997YE93800010
PM 9361577
DA 2020-11-24
ER

PT J
AU Bongertz, V
   Costa, CI
   Santos, VGV
   Joao, EC
   GalvaoCastro, B
   Morgado, MG
   Cavalcante, S
   Galhardo, MCG
   Guimaraes, MRC
   Grinsztejn, B
   Rolla, VC
AF Bongertz, V
   Costa, CI
   Santos, VGV
   Joao, EC
   GalvaoCastro, B
   Morgado, MG
   Cavalcante, S
   Galhardo, MCG
   Guimaraes, MRC
   Grinsztejn, B
   Rolla, VC
TI Correlation between susceptibility of primary HIV-1 isolates to
   autologous and heterologous neutralizing antibodies
SO AIDS
LA English
DT Article
DE primary HIV-1 isolates; autologous neutralization; heterologous
   neutralization
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1; AIDS; SERA; INDIVIDUALS;
   INFECTION; PLASMA; ESCAPE; GP120
AB Objective: To study the susceptibility of primary HIV-1 isolates towards autologous and heterologous neutralizing antibodies (NAb).
   Design: Blood was collected and primary HIV-1 isolated from individuals residing in Rio de Janeiro, Brazil, in all phases of disease.
   Methods: Primary HIV-1 isolates were incubated with autologous or heterologous plasma and neutralization of infection of freshly pre-stimulated normal human peripheral blood mononuclear cells was assayed in parallel to median infectious dose determinations in the absence of antibodies. Levels of HIV-1 p24 antigen were used for evaluation of viral neutralization.
   Results: Autologous neutralization (75%) was observed for 13 (52%) out of 25 of the primary HIV-1 isolates, and 15 (71%) out of 21 isolates were susceptible to 75% heterologous neutralization by at least one-half of the heterologous plasma tested. Primary HIV-1 isolates susceptible to autologous NAb showed a higher susceptibility towards neutralization by heterologous NAb than isolates that could not be neutralized by the autologous plasma (P = 0.049). The susceptibility of the primary HIV-1 isolates towards neutralization by heterologous NAb was significantly higher for isolates derived from men (P = 0.001), and for isolates obtained from individuals infected through homo/bisexual risk behaviour in comparison with those infected through heterosexual HIV-1 transmission (P = 0.03).
   Conclusions: Susceptibility of primary HIV-1 isolates to autologous and heterologous neutralization was significantly correlated, indicating that escape mutants may become resistant not only to autologous but also to heterologous NAb.
C1 INST OSWALDO CRUZ,OSWALDO CRUZ FDN,EVANDRO CHAGAS HOSP,BR-20001 RIO JANEIRO,BRAZIL.
   STATE EMPLOYEE HOSP,RIO JANEIRO,BRAZIL.
   OSWALDO CRUZ FDN,ADV PUBL HLTH LAB,GONCALO MONIZ RES CTR,SALVADOR,BA,BRAZIL.
RP Bongertz, V (corresponding author), FIOCRUZ MS,IOC,DEPT IMMUNOL,AIDS & MOL IMMUNOL LAB,AV BRASIL 4365,BR-21045900 RIO JANEIRO,BRAZIL.
OI Joao, Esau/0000-0002-2412-0627
CR ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002
   ALBERT J, 1993, AIDS RES HUM RETROV, V9, P501, DOI 10.1089/aid.1993.9.501
   ARENDRUP M, 1993, J GEN VIROL, V74, P855, DOI 10.1099/0022-1317-74-5-855
   ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303
   BJOERLING E, 1993, VIROLOGY, V193, P528
   BONGERTZ V, 1994, MEM I OSWALDO CRUZ, V89, P113, DOI 10.1590/S0074-02761994000100019
   BOUHABIB DC, 1994, J VIROL, V68, P6006, DOI 10.1128/JVI.68.9.6006-6013.1994
   CARROW EW, 1991, AIDS RES HUM RETROV, V7, P831, DOI 10.1089/aid.1991.7.831
   *CDC, 1986, ANN INTERN MED, V105, P234
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   GalvaoCastro B, 1996, MEM I OSWALDO CRUZ, V91, P335, DOI 10.1590/S0074-02761996000300014
   GORNY MK, 1994, J VIROL, V68, P8312, DOI 10.1128/JVI.68.12.8312-8320.1994
   HO DD, 1985, NEW ENGL J MED, V312, P649, DOI 10.1056/NEJM198503073121015
   MATTHEWS TJ, 1994, AIDS RES HUM RETROV, V10, P631, DOI 10.1089/aid.1994.10.631
   MONTEFIORI DC, 1991, VIROLOGY, V182, P635, DOI 10.1016/0042-6822(91)90604-A
   MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995
   RENCHER SD, 1995, AIDS RES HUM RETROV, V11, P1131, DOI 10.1089/aid.1995.11.1131
   ROBERTGUROFF M, 1985, NATURE, V316, P72, DOI 10.1038/316072a0
   RUEBSAMENWAIGMA.H, 1994, AIDS RES HUM RETROV, V10, P1401
   SAWYER LSW, 1994, J VIROL, V68, P1342, DOI 10.1128/JVI.68.3.1342-1349.1994
   SCARLATTI G, 1993, J INFECT DIS, V168, P207, DOI 10.1093/infdis/168.1.207
   TREMBLAY M, 1990, J INFECT DIS, V162, P735, DOI 10.1093/infdis/162.3.735
   VITTECOQ D, 1995, P NATL ACAD SCI USA, V92, P1195, DOI 10.1073/pnas.92.4.1195
   WATKINS BA, 1993, J VIROL, V67, P7493, DOI 10.1128/JVI.67.12.7493-7500.1993
   WEISS RA, 1985, NATURE, V316, P69, DOI 10.1038/316069a0
NR 25
TC 8
Z9 8
U1 0
U2 0
PU RAPID SCIENCE PUBLISHERS
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH
SN 0269-9370
J9 AIDS
JI Aids
PD JUL
PY 1997
VL 11
IS 8
BP 969
EP 975
DI 10.1097/00002030-199708000-00004
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA XH111
UT WOS:A1997XH11100004
PM 9223730
DA 2020-11-24
ER

PT J
AU Fandinho, FCO
   Grinsztejn, B
   Veloso, VG
   Lourenco, MCS
   WerneckBarroso, E
   Joao, E
   Nogueira, SA
   deFonseca, L
AF Fandinho, FCO
   Grinsztejn, B
   Veloso, VG
   Lourenco, MCS
   WerneckBarroso, E
   Joao, E
   Nogueira, SA
   deFonseca, L
TI Diagnosis of disseminated mycobacterial infection: testing a simple and
   inexpensive method for use in developing countries
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AVIUM COMPLEX; TUBERCULOSIS
   BACTEREMIA; AIDS PATIENTS; VIRUS INFECTION; BLOOD
AB With the development of the acquired immunodeficiency syndrome (AIDS) epidemic, the isolation of mycobacteria from blood has become a common problem for clinical laboratories, In this study two methods were used for the recovery of mycobacteria from blood specimens obtained from AIDS patients: (I) direct inoculation of a biphasic medium, and (2) a non-commercial lysis-centrifugation method A total of 3 consecutive blood samples were taken at 15-minute intervals from each of 50 AIDS patients with clinical suspicion of disseminated mycobacterial disease. Mycobacterium growth was noted in 70/138 blood specimens from 30 (60%) patients. These cultures yielded Mycobacterium tuberculosis in 19 (63%) and Mycobacterium avium complex organisms in 11 (37%) patients. Cultures using the lysis-centrifugation method were positive in 54% of the patients while cultures using biphasic medium were positive in 44% (P > 0.05). The positivity for M, avium complex was higher with lysis-centrifugation (91%) than with biphasic medium (45.4%) (P < 0.05). However, the positivities for M, tuberculosis with the lysis-centrifugation method (89.5%) and direct inoculation in biphasic medium (100%) were similar (P > 0.05), The use of a noncommercial lysis-centrifugation technique is inexpensive, reliable, and can be an alternative method for the diagnosis of mycobacteraemia in developing countries.
C1 FIOCRUZ MS, DEPT TECHNOL DEV, IMMUNOBIOL PROD INST, BR-21045900 RIO DE JANEIRO, BRAZIL.
   FIOCRUZ MS, EVANDRO CHAGAS HOSP, BACTERIOL LAB, BR-21045900 RIO DE JANEIRO, BRAZIL.
   UNIV FED RIO DE JANEIRO, PNEUMOL & PHYSIOL INST, RIO DE JANEIRO, BRAZIL.
   RIO DE JANEIRO HOSP, SERVIDORES ESTADO, RIO DE JANEIRO, BRAZIL.
   UNIV FED RIO DE JANEIRO, DEPT INFECT DIS, RIO DE JANEIRO, BRAZIL.
RP Fandinho, FCO (corresponding author), UNIV FED RIO DE JANEIRO, INST MICROBIOL,DEPT MED MICROBIOL,CTR HLTH SCI, BLOCO 1, ILHA FUNDAO, BR-21941590 RIO DE JANEIRO, BRAZIL.
RI Veloso, Valdilea Goncalves/J-6189-2012
OI Joao, Esau/0000-0002-2412-0627
CR BABER TW, 1990, MEDICINE, V69, P375
   BARRETO JA, 1993, J INFECT DIS, V168, P777, DOI 10.1093/infdis/168.3.777
   BOUZA E, 1988, EUR J CLIN MICROBIOL, V7, P785, DOI 10.1007/BF01975050
   CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770
   GILKS CF, 1995, J ACQ IMMUN DEF SYND, V8, P195
   HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906
   INDERLIED CB, 1993, CLIN MICROBIOL REV, V6, P266, DOI 10.1128/CMR.6.3.266-310.1993
   JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292
   KIEHN TE, 1985, J CLIN MICROBIOL, V21, P647, DOI 10.1128/JCM.21.4.647-648.1985
   MEYLAN PR, 1990, INFECT IMMUN, V58, P2564, DOI 10.1128/IAI.58.8.2564-2568.1990
   NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082
   PITCHENIK AE, 1992, MED CLIN N AM, V76, P121, DOI 10.1016/S0025-7125(16)30375-3
   SALFINGER M, 1988, J CLIN MICROBIOL, V26, P1225, DOI 10.1128/JCM.26.6.1225-1226.1988
   SALTZMAN B R, 1986, Journal of the American Medical Association, V256, P390, DOI 10.1001/jama.256.3.390
   SHAFER RW, 1989, AM REV RESPIR DIS, V140, P1611, DOI 10.1164/ajrccm/140.6.1611
   STONE BL, 1994, J CLIN MICROBIOL, V32, P814
   THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8
   TRUFFOTPERNOT C, 1989, TUBERCLE, V70, P187, DOI 10.1016/0041-3879(89)90049-4
NR 18
TC 15
Z9 19
U1 0
U2 1
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
EI 1564-0604
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PY 1997
VL 75
IS 4
BP 361
EP 366
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA XZ713
UT WOS:A1997XZ71300009
PM 9342895
DA 2020-11-24
ER

PT J
AU Bongertz, V
   Costa, CI
   Grinsztejn, B
   Pilotto, JHC
   Joao, EC
   Morgado, MG
AF Bongertz, V
   Costa, CI
   Grinsztejn, B
   Pilotto, JHC
   Joao, EC
   Morgado, MG
TI Neutralization of primary HIV-1 isolated from individuals residing in
   Rio de Janeiro
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE HIV-1; primary isolates; neutralization
C1 HOSP EVANDRO CHAGAS,RIO JANEIRO,BRAZIL.
   HOSP SERVIDORES ESTADO,RIO JANEIRO,BRAZIL.
   HOSP GERAL NOVA IGUACU,RIO JANEIRO,BRAZIL.
RP Bongertz, V (corresponding author), INST OSWALDO CRUZ,LAB AIDS & IMUNOL MOLEC,DEPT IMUNOL,AV BRASIL 4365,BR-21045900 RIO JANEIRO,BRAZIL.
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Joao,
   Esau/0000-0002-2412-0627
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MEM INST OSWALDO CRUZ
PI RIO DE JANEIRO
PA SECRETARY CAIXA POSTAL 926, 20001 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAY-JUN
PY 1996
VL 91
IS 3
BP 343
EP 345
DI 10.1590/S0074-02761996000300016
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA UL961
UT WOS:A1996UL96100016
PM 9040852
OA DOAJ Gold
DA 2020-11-24
ER

EF